PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Wang, CW; Kim, J; Huang, WP; Abeliovich, H; Stromhaug, PE; Dunn, WA; Klionsky, DJ				Wang, CW; Kim, J; Huang, WP; Abeliovich, H; Stromhaug, PE; Dunn, WA; Klionsky, DJ			Apg2 is a novel protein required for the cytoplasm to vacuole targeting, autophagy, and pexophagy pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST VACUOLE; PEROXISOME DEGRADATION; CONJUGATION SYSTEM; AMINOPEPTIDASE-I; MACROAUTOPHAGY; TRANSPORT; MUTANTS; COMPLEX; MACHINERY	To survive starvation conditions, eukaryotes have developed an evolutionarily conserved process, termed autophagy, by which the vacuole/lysosome mediates the turnover and recycling of non-essential intracellular material for re-use in critical biosynthetic reactions. Morphological and biochemical studies in Saccharomyces cerevisiae have elucidated the basic steps and mechanisms of the autophagy pathway. Although it is a degradative process, autophagy shows substantial overlap with the biosynthetic cytoplasm to vacuole targeting (Cvt) pathway that delivers resident hydrolases to the vacuole. Recent molecular genetics analyses of mutants defective in autophagy and the Cvt pathway, apg, aut, and cvt, have begun to identify the protein machinery and provide a molecular resolution of the sequestration and import mechanism that are characteristic of these pathways. In this study, we have identified a novel protein, termed Apg2, required for both the Cvt and autophagy pathways as well as the specific degradation of peroxisomes. Apg2 is required for the formation and/or completion of cytosolic, sequestering vesicles that are needed for vacuolar import through both the Cvt pathway and autophagy. Biochemical studies revealed that Apg2 is a peripheral membrane protein. Apg2 localizes to the previously identified perivacuolar compartment that contains Apg9, the only characterized integral membrane protein that, is required for autophagosome/Cvt vesicle formation.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	University of Michigan System; University of Michigan; State University System of Florida; University of Florida	Klionsky, DJ (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.		WANG, CHAO-WEN/HIR-2326-2022; Klionsky, Daniel J./ABD-5189-2021	WANG, CHAO-WEN/0000-0002-4073-299X; Klionsky, Daniel J./0000-0002-7828-8118; HUANG, WEI-PANG/0000-0001-8410-6555	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM053396-11, R01 GM053396, GM53396, R01 GM053396-12] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; George MD, 2000, MOL BIOL CELL, V11, P969, DOI 10.1091/mbc.11.3.969; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; HARLOW E, 1999, USING ANTIBODIES LAB, P61; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Hutchins MU, 1999, J CELL SCI, V112, P4079; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; Kim J, 2001, J CELL BIOL, V153, P381, DOI 10.1083/jcb.153.2.381; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 1997, J MEMBRANE BIOL, V157, P105, DOI 10.1007/s002329900220; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Klionsky DJ, 1998, J BIOL CHEM, V273, P10807, DOI 10.1074/jbc.273.18.10807; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Saiz JE, 1999, YEAST, V15, P155, DOI 10.1002/(SICI)1097-0061(19990130)15:2<155::AID-YEA342>3.0.CO;2-U; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Shintani T, 2001, J BIOL CHEM, V276, P30452, DOI 10.1074/jbc.M102346200; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; TUTTLE DL, 1995, J CELL SCI, V108, P25; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	38	117	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30442	30451		10.1074/jbc.M102342200	http://dx.doi.org/10.1074/jbc.M102342200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11382760	hybrid, Green Submitted, Green Accepted			2022-12-27	WOS:000170558000110
J	Hubbard, PA; Shen, AL; Paschke, R; Kasper, CB; Kim, JJP				Hubbard, PA; Shen, AL; Paschke, R; Kasper, CB; Kim, JJP			NADPH-cytochrome P450 oxidoreductase - Structural basis for hydride and electron transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE PHOSPHATE; REDUCTIVE HALF-REACTION; CRYSTAL-STRUCTURES; NADPH-CYTOCHROME-P-450 OXIDOREDUCTASE; 3-DIMENSIONAL STRUCTURE; P-450 REDUCTASE; BINDING-SITE; CATALYSIS; SYSTEM; NICOTINAMIDE	NADPH-cytochrome P450 oxidoreductase catalyzes transfer of electrons from NADPH, via two flavin cofactors, to various cytochrome P450s. The crystal structure of the rat reductase complexed with NADP(+) has revealed that nicotinamide access to FAD is blocked by an aromatic residue (Trp-677), which stacks against the reface of the isoalloxazine ring of the flavin. To investigate the nature of interactions between the nicotinamide, FAD, and Trp-677 during the catalytic cycle, three mutant proteins were studied by crystallography. The first mutant, W677X, has the last two C-terminal residues, Trp-677 and Ser-678, removed; the second mutant, W677G, retains the C-terminal serine residue. The third mutant has the following three catalytic residues substituted: S457A, C630A, and D675N. In the W677X and W677G structures, the nicotinamide moiety of NADP(+) lies against the FAD isoalloxazine ring with a tilt of similar to 30 degrees between the planes of the two rings. These results, together with the S457A/C630A/D675N structure, allow us to propose a mechanism for hydride transfer regulated by changes in hydrogen bonding and pi-pi interactions between the isoalloxazine ring and either the nicotinamide ring or Trp-677 indole ring. Superimposition of the mutant and wild-type structures shows significant mobility between the two flavin domains of the enzyme. This, together with the high degree of disorder observed in the FMN domain of all three mutant structures, suggests that conformational changes occur during catalysis.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison	Kim, JJP (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.	jjkim@mcw.edu			NATIONAL CANCER INSTITUTE [P01CA022484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052682] Funding Source: NIH RePORTER; NCI NIH HHS [CA 22484] Funding Source: Medline; NIGMS NIH HHS [GM 52682] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chipot C, 1996, J AM CHEM SOC, V118, P11217, DOI 10.1021/ja961379l; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Dohr O, 2001, P NATL ACAD SCI USA, V98, P81, DOI 10.1073/pnas.98.1.81; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; GASSNER GT, 1995, FASEB J, V9, P1411, DOI 10.1096/fasebj.9.14.7589982; Gruez A, 2000, J MOL BIOL, V299, P199, DOI 10.1006/jmbi.2000.3748; Gutierrez A, 2000, BIOCHEMISTRY-US, V39, P15990, DOI 10.1021/bi002135n; ILAN Z, 1981, J BIOL CHEM, V256, P66; IYANAGI T, 1981, BIOCHEMISTRY-US, V20, P1722, DOI 10.1021/bi00510a004; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; LI RB, 1995, P NATL ACAD SCI USA, V92, P8846, DOI 10.1073/pnas.92.19.8846; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; McPherson A, 1999, CRYSTALLIZATION BIOL, P159; Murataliev MB, 2000, BIOCHEMISTRY-US, V39, P5066, DOI 10.1021/bi992917k; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1988, BIOCHEMISTRY-US, V27, P4465, DOI 10.1021/bi00412a038; Paine MJI, 2000, J BIOL CHEM, V275, P1471, DOI 10.1074/jbc.275.2.1471; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; SEM DS, 1992, BIOCHEMISTRY-US, V31, P3391, DOI 10.1021/bi00128a013; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11548, DOI 10.1021/bi00094a011; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Shen A.L., 1993, HDB EXPT PHARM, P35; SHEN AL, 1991, J BIOL CHEM, V266, P19976; Shen AL, 1999, J BIOL CHEM, V274, P5391, DOI 10.1074/jbc.274.9.5391; Shen AL, 2000, J BIOL CHEM, V275, P41087, DOI 10.1074/jbc.M008380200; STEHLE T, 1993, EUR J BIOCHEM, V211, P221, DOI 10.1111/j.1432-1033.1993.tb19889.x; Strobel Henry W., 1995, P225; van den Akker F, 1999, ACTA CRYSTALLOGR D, V55, P206, DOI 10.1107/S0907444998007161; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Ziegler GA, 2000, BIOCHEMISTRY-US, V39, P10986, DOI 10.1021/bi000079k	40	182	192	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29163	29170		10.1074/jbc.M101731200	http://dx.doi.org/10.1074/jbc.M101731200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11371558	hybrid			2022-12-27	WOS:000170346000072
J	Iodice, L; Sarnataro, S; Bonatti, S				Iodice, L; Sarnataro, S; Bonatti, S			The carboxyl-terminal valine is required for transport of glycoprotein CD8 alpha from the endoplasmic reticulum to the intermediate compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CD8 GLYCOPROTEIN; SINGLE REPORTER PROTEIN; EARLY SECRETORY PATHWAY; AMINO-ACID PERMEASES; LUMINAL ER PROTEINS; TRANSMEMBRANE PROTEINS; CYTOPLASMIC DOMAINS; VIRUS GLYCOPROTEIN; MEMBRANE-PROTEINS; COATED VESICLES	There is evidence that a carboxyl-terminal valine residue is an anterograde transport signal for type I transmembrane proteins. Removal of the signal would either delay glycosylation in the Golgi complex of proteins destined to recycle to the endoplasmic reticulum or determine accumulation in the endoplasmic reticulum of newly synthesized proteins destined for the plasma membrane. We used the human CD8 alpha glycoprotein to investigate the role of the carboxyl-terminal valine in the exocytic pathway. Using immunofluorescence light microscopy, metabolic labeling, and cell fractionation, we demonstrate that removal of the carboxyl-terminal valine residue delays transport of CD8 alpha from the endoplasmic reticulum to the intermediate compartment. Removal of the residue did not affect the other steps of the exocytic pathway or the folding/dimerization and glycosylation processes. Therefore, it is likely that this signal plays a role in the transport of CD8 alpha from the endoplasmic reticulum. to the intermediate compartment either before or during the formation of the transport vesicles that drive the exit the protein from the endoplasmic reticulum.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy	University of Naples Federico II	Bonatti, S (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.							BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BONATTI S, 1989, J BIOL CHEM, V264, P12590; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Erra MC, 1999, CELL BIOL INT, V23, P571, DOI 10.1006/cbir.1999.0420; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FUNGLEUNG WP, 1993, EUR J IMMUNOL, V23, P2834, DOI 10.1002/eji.1830231117; Gilstring CF, 1999, MOL BIOL CELL, V10, P3549, DOI 10.1091/mbc.10.11.3549; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Herrmann JM, 1999, TRENDS CELL BIOL, V9, P5, DOI 10.1016/S0962-8924(98)01414-7; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Klumperman J, 2000, CURR OPIN CELL BIOL, V12, P445, DOI 10.1016/S0955-0674(00)00115-0; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; Lotti LV, 1999, J BIOL CHEM, V274, P10413, DOI 10.1074/jbc.274.15.10413; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Malide D, 2001, MOL BIOL CELL, V12, P101, DOI 10.1091/mbc.12.1.101; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; Martire G, 1996, J BIOL CHEM, V271, P3541; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; MIGLIACCIO G, 1989, EXP CELL RES, V185, P203, DOI 10.1016/0014-4827(89)90049-9; Mottola G, 2000, J BIOL CHEM, V275, P24070, DOI 10.1074/jbc.M910400199; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nakamura N, 1998, MOL BIOL CELL, V9, P3493, DOI 10.1091/mbc.9.12.3493; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nufer O, 2000, MOL BIOL CELL, V11, p208A; PASCALE MC, 1992, J BIOL CHEM, V267, P9940; PASCALE MC, 1992, J BIOL CHEM, V267, P25196; Pascale MC, 2000, FEBS LETT, V480, P226, DOI 10.1016/S0014-5793(00)01945-1; PELHAM HR, 1995, CURR OPIN CELL BIOL, V7, P539; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; Schneider S, 1999, NAT BIOTECHNOL, V17, P170, DOI 10.1038/6172; Sevier CS, 2000, MOL BIOL CELL, V11, P13, DOI 10.1091/mbc.11.1.13; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; Urena JM, 1999, J CELL SCI, V112, P773; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; VERDE C, 1995, EUR J CELL BIOL, V67, P267	48	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28920	28926		10.1074/jbc.M103558200	http://dx.doi.org/10.1074/jbc.M103558200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384990	hybrid			2022-12-27	WOS:000170346000039
J	Schuierer, M; Hilger-Eversheim, K; Dobner, T; Bosserhoff, AK; Moser, M; Turner, J; Crossley, M; Buettner, R				Schuierer, M; Hilger-Eversheim, K; Dobner, T; Bosserhoff, AK; Moser, M; Turner, J; Crossley, M; Buettner, R			Induction of AP-2 alpha expression by adenoviral infection involves inactivation of the AP-2rep transcriptional corepressor CtBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL BINDING-PROTEIN; REGION 1A PROTEINS; GENE-EXPRESSION; GENOMIC STRUCTURE; CELLS; E1A; REPRESSOR; AP-2-BETA; CLONING; DNA	AP-2 transcription factors execute important functions during embryonic development and malignant transformation. Recently, we have isolated a transcriptional repressor of AP-2 alpha expression, the novel Kruppel-related zinc finger protein AP-2rep (KIf12). Here, we show that repression of AP-2 alpha transcription by AP-2rep is dependent on an N-terminal PVDLS motif that interacts specifically with the corepressor CtBP1 both in vivo and in vitro. This interaction motif was previously identified in the C-terminal region of the adenoviral oncoprotein EIA. Infection of both HeLa and PA-1. cells with adenovirus type 5 strongly induced AP-2 alpha mRNA. Consistently, EIA was necessary and sufficient to mediate up-regulation of AP-2 alpha. Transiently transfected wild-type EIA protein activated an AP-2rep sensitive cis-regulatory element of the AP-2 alpha promoter, but E1A protein harboring a mutation in the PVDLS motif failed to activate. In summary, we conclude that the adenoviral oncoprotein EIA activates transcription from the endogenous AP-2 alpha gene, an effect that involves transcriptional derepression of the AP-2 alpha promoter by interaction of E1A with the AP-2rep corepressor CtBP1.	Univ Hosp RWTH Aachen, Inst Pathol, D-52074 Aachen, Germany; Univ Regensburg, Sch Med, Inst Microbiol, D-93042 Regensburg, Germany; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	RWTH Aachen University; RWTH Aachen University Hospital; University of Regensburg; University of Sydney	Buettner, R (corresponding author), Univ Hosp RWTH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.		Crossley, Merlin/D-7888-2011; Bosserhoff, Anja/GNH-4801-2022	Crossley, Merlin/0000-0003-2057-3642; Bosserhoff, Anja/0000-0001-8147-394X				Baskin F, 1997, NEUROSCIENCE, V76, P821; BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GretherBeck S, 1997, BIOL CHEM, V378, P1231; HARDY S, 1989, MOL CELL BIOL, V9, P4495, DOI 10.1128/MCB.9.10.4495; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Imhof A, 1999, MOL CELL BIOL, V19, P194; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Molloy DP, 1998, J BIOL CHEM, V273, P20867, DOI 10.1074/jbc.273.33.20867; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Moser M, 1997, DEV DYNAM, V208, P115, DOI 10.1002/(SICI)1097-0177(199701)208:1<115::AID-AJA11>3.0.CO;2-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; Pena P, 1999, MOL ENDOCRINOL, V13, P1402, DOI 10.1210/me.13.8.1402; Roth C, 2000, GENOMICS, V63, P384, DOI 10.1006/geno.1999.6084; Satoda M, 2000, NAT GENET, V25, P42, DOI 10.1038/75578; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sinha S, 2000, MOL CELL BIOL, V20, P2543, DOI 10.1128/MCB.20.7.2543-2555.2000; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Turner BC, 1998, CANCER RES, V58, P5466; Turner J, 1999, INT J BIOCHEM CELL B, V31, P1169, DOI 10.1016/S1357-2725(99)00067-9; West-Mays JA, 1999, DEV BIOL, V206, P46, DOI 10.1006/dbio.1998.9132; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	34	43	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27944	27949		10.1074/jbc.M100070200	http://dx.doi.org/10.1074/jbc.M100070200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373277	hybrid			2022-12-27	WOS:000170093400028
J	Fadel, MP; Szewczenko-Pawlikowski, M; Leclerc, P; Dziak, E; Symonds, JM; Blaschuk, O; Michalak, M; Opas, M				Fadel, MP; Szewczenko-Pawlikowski, M; Leclerc, P; Dziak, E; Symonds, JM; Blaschuk, O; Michalak, M; Opas, M			Calreticulin affects beta-catenin-associated pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; PROTEIN-TYROSINE-PHOSPHATASE; RETICULUM CA2+ STORE; ENDOPLASMIC-RETICULUM; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; E-CADHERIN; V-SRC; ENDOTHELIAL-CELLS; N-CADHERIN	Calreticulin, a Ca2+ storage protein and chaperone in the endoplasmic reticulum, also modulates cell adhesiveness. Overexpression of calreticulin correlates with (i) increased cell adhesiveness, (ii) increased expression of N-cadherin and vinculin, and (iii) decreased protein phosphorylation on tyrosine. Among proteins that are dephosphorylated in cells that overexpress calreticulin is beta -catenin, a structural component of cadherin-dependent adhesion complexes, a member of the armadillo family of proteins and a part of the Wnt signaling pathway. We postulate that the changes in cell adhesiveness may be due to calreticulin-mediated effects on a signaling pathway from the endoplasmic reticulum, which impinges on the Wnt signaling pathway via the cadherin/catenin protein system and involves changes in the activity of protein-tyrosine kinases and/or phosphatases.	Univ Toronto, Dept Anat & Cell Biol, Toronto, ON M5S 1A8, Canada; Univ Laval, Dept Obstet & Gynecol, Quebec City, PQ G1L 3L5, Canada; Royal Victoria Hosp, Urol Res Lab, Montreal, PQ H3A 1A1, Canada; Univ Alberta, Dept Biochem, Canadian Inst Hlth, Res Grp Mol Biol Membrane Prot, Edmonton, AB T6G 2H7, Canada	University of Toronto; Laval University; McGill University; Royal Victoria Hospital; University of Alberta	Opas, M (corresponding author), Univ Toronto, Dept Anat & Cell Biol, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	m.opas@utoronto.ca		Leclerc, Pierre/0000-0003-2053-3958				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Ayalon O, 1997, J CELL SCI, V110, P547; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Corbett EF, 2000, J BIOL CHEM, V275, P27177; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fadel MP, 1999, J BIOL CHEM, V274, P15085, DOI 10.1074/jbc.274.21.15085; Folsom TD, 1997, GLIA, V20, P348; GEIGER B, 1990, J CELL SCI, V97, P607; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; GUMBINER BM, 1993, J CELL SCI, P155; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Hazan RB, 1997, J BIOL CHEM, V272, P32448, DOI 10.1074/jbc.272.51.32448; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lampugnani MG, 1997, J CELL SCI, V110, P2065; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; Llewellyn DH, 1996, BIOCHEM J, V318, P555, DOI 10.1042/bj3180555; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCMILLAN A, 1994, CURR OPIN BIOTECH, V6, P540; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Michalak M, 1996, J BIOL CHEM, V271, P29436, DOI 10.1074/jbc.271.46.29436; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Nguyen TQ, 1996, MOL IMMUNOL, V33, P379, DOI 10.1016/0161-5890(95)00149-2; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; Opas M, 1996, J CELL BIOL, V135, P1913, DOI 10.1083/jcb.135.6.1913; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Pahl HL, 1997, TRENDS CELL BIOL, V7, P50, DOI 10.1016/S0962-8924(96)10050-7; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Papkoff J, 1997, J BIOL CHEM, V272, P4536; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Waser M, 1997, J CELL BIOL, V138, P547, DOI 10.1083/jcb.138.3.547	64	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27083	27089		10.1074/jbc.M101676200	http://dx.doi.org/10.1074/jbc.M101676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369768	hybrid			2022-12-27	WOS:000169966900048
J	Fukuda, M; Mikoshiba, K				Fukuda, M; Mikoshiba, K			Mechanism of the calcium-dependent multimerization of synaptotagmin VII mediated by its first and second C2 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-POLYPHOSPHATE BINDING; SQUID GIANT SYNAPSE; CRYSTAL-STRUCTURE; ANTIBODY INJECTION; OLIGOMERIZATION; EXOCYTOSIS; VESICLE; DROSOPHILA; PROTEINS; ISOFORMS	The Ca2+-dependent oligomerization activity of the second C2 (C2B) domain of synaptotagmin I (Syt I) has been hypothesized to regulate neurotransmitter release. We previously showed that the cytoplasmic domains of several other Syt isoforms also show Ca2+ dependent oligomerization activity (Fukuda, M., and Mikoshiba, K. (2000) J. Biol. Chem. 275, 28180-28185), but little is known, about the involvement of their C2 domains in Ca2+-dependent oligomerization, In this study, we, analyzed the Ca2+-dependent oligomerization properties of the first (C2A) and the second C2 (C2B) domains of Syt VII. Unlike Syt I, both C2 domains of Syt VII contribute to Ca2+-dependent homo- and hetero-oligomerization with other isoforms. For instance, the Syt VII C2A domain Ca2+-dependently binds itself and the C2A domain of Syt VI but not its C2B domain, whereas the Syt VII C2B domain Ca2+-dependently binds itself and the C2B domain of Syt II but not its C2A domain. In addition, we showed by gel filtration that a single Syt VII C2 domain is sufficient to form a Ca2+-dependent multimer of very high molecular weight. Because of this "two handed" structure, the Syt VII cytoplasmic domain has been found to show the strongest Ca2+-dependent multimerization activity in the Syt family. We also identified Asn-328 in the C2B domain as a crucial residue for the efficient Ca2+-dependent switch for multimerization by site-directed mutagenesis. Our results suggest that Syt VII is a specific isoform that can cluster different Syt isoforms with two hands in response to Ca2+.	RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan	RIKEN; University of Tokyo	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015; Mikoshiba, Katsuhiko/N-7943-2015	Fukuda, MItsunori/0000-0002-8620-5853; 				BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Damer CK, 1996, J NEUROCHEM, V67, P1661; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fukuda M, 2000, BIOCHEM BIOPH RES CO, V276, P626, DOI 10.1006/bbrc.2000.3520; Fukuda M, 2000, FEBS LETT, V482, P269, DOI 10.1016/S0014-5793(00)02064-0; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Fukuda M, 2001, BIOCHEM J, V354, P249, DOI 10.1042/0264-6021:3540249; Fukuda M, 2000, P NATL ACAD SCI USA, V97, P14715, DOI 10.1073/pnas.260491197; Fukuda M, 2000, J BIOCHEM, V128, P637, DOI 10.1093/oxfordjournals.jbchem.a022796; Gao ZY, 2000, J BIOL CHEM, V275, P36079, DOI 10.1074/jbc.M004284200; Haucke V, 2000, EMBO J, V19, P6011, DOI 10.1093/emboj/19.22.6011; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Lloyd TE, 2000, NEURON, V26, P45, DOI 10.1016/S0896-6273(00)81136-8; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mizutani A, 1997, BIOCHEM BIOPH RES CO, V240, P128, DOI 10.1006/bbrc.1997.7578; Mochida S, 1997, NEUROSCIENCE, V77, P937; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Phillips AM, 2000, J NEUROSCI, V20, P8254, DOI 10.1523/JNEUROSCI.20-22-08254.2000; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; von Poser C, 2000, J BIOL CHEM, V275, P30916, DOI 10.1074/jbc.M005559200; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	45	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27670	27676		10.1074/jbc.M100851200	http://dx.doi.org/10.1074/jbc.M100851200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11373279	hybrid			2022-12-27	WOS:000169966900123
J	Kim, SJ; Rahbar, R; Hegde, RS				Kim, SJ; Rahbar, R; Hegde, RS			Combinatorial control of prion protein biogenesis by the signal sequence and transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES; HUMAN P-GLYCOPROTEIN; CHARGED RESIDUES; HYDROPHOBIC DOMAIN; TERMINAL DOMAIN; ANCHOR PROTEINS; STOP-TRANSFER; ER MEMBRANE; ORIENTATION	The prion protein (PrP) is synthesized in three topologic forms at the endoplasmic reticulum, (PrP)-Pr-sec is fully translocated into the endoplasmic reticulum lumen, whereas (NPrP)-Pr-tm and (PrP)-Pr-Ctm are single-spanning membrane proteins of opposite orientation. Increased generation of (PrP)-Pr-Ctm in either transgenic mice or humans is associated with the development of neurodegenerative disease, To study the mechanisms by which PrP can achieve three topologic outcomes, we analyzed the translocation of proteins containing mutations introduced into either the N-terminal signal sequence or potential transmembrane domain (TMD) of PrP, Although mutations in either domain were found to affect PrP topogenesis, they did so in qualitatively different ways. In addition to its traditional role in mediating protein targeting, the signal was found to play a surprising role in determining orientation of the PrP N terminus. By contrast, the TMD was found to influence membrane integration. Analysis of various signal and TMD double mutants demonstrated that the topologic consequence of TMD action was directly dependent on the previous, signal-mediated step. Together, these results reveal that PrP topogenesis is controlled at two discrete steps during its translocation and provide a framework for understanding how these steps act coordinately to determine the final topology achieved by PrP.	NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hegde, RS (corresponding author), NCI, Cellular Oncol Lab, NIH, Bldg 36,Rm 1D32,9000 Rockville Pike, Bethesda, MD 20892 USA.			Hegde, Ramanujan/0000-0001-8338-852X				BELTZER JP, 1991, J BIOL CHEM, V266, P973; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DEFEA KA, 1994, J BIOL CHEM, V269, P16810; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Eusebio A, 1998, EXP CELL RES, V241, P181, DOI 10.1006/excr.1998.4042; Falcone D, 1999, J BIOL CHEM, V274, P33661, DOI 10.1074/jbc.274.47.33661; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Harley CA, 1998, J BIOL CHEM, V273, P24963, DOI 10.1074/jbc.273.38.24963; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Heinrich SU, 2000, CELL, V102, P233, DOI 10.1016/S0092-8674(00)00028-3; HSIAO KK, 1991, NEUROLOGY, V41, P681, DOI 10.1212/WNL.41.5.681; Johnson RT, 1998, NEW ENGL J MED, V339, P1994, DOI 10.1056/NEJM199812313392707; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Mallucci GR, 1999, BRAIN, V122, P1823, DOI 10.1093/brain/122.10.1823; MASTRIANNI JA, 1995, NEUROLOGY, V45, P2042, DOI 10.1212/WNL.45.11.2042; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; SILHAVY TJ, 1983, MICROBIOL REV, V47, P313, DOI 10.1128/MMBR.47.3.313-344.1983; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; Tector M, 1999, EMBO J, V18, P6290, DOI 10.1093/emboj/18.22.6290; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRANCHANT C, 1992, J NEUROL NEUROSUR PS, V55, P185, DOI 10.1136/jnnp.55.3.185; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0	48	84	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26132	26140		10.1074/jbc.M101638200	http://dx.doi.org/10.1074/jbc.M101638200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11359769	hybrid			2022-12-27	WOS:000169823300067
J	Wilce, JA; Love, SG; Richardson, SJ; Alewood, PF; Craik, DJ				Wilce, JA; Love, SG; Richardson, SJ; Alewood, PF; Craik, DJ			Synthesis of an analog of the thyroid hormone-binding protein transthyretin via regioselective chemical ligation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID FIBRIL FORMATION; PHASE PEPTIDE-SYNTHESIS; RAY CRYSTAL-STRUCTURE; THYROXINE-BINDING; PLASMA-PROTEINS; ALTERNATIVE CONFORMATIONS; HIV-1 PROTEASE; PRE-ALBUMIN; RESOLUTION; EVOLUTION	Transthyretin is an essential protein responsible for the transport of thyroid hormones and retinol in human serum and is also implicated in the amyloid diseases familial amyloidotic polyneuropathy and senile systemic amyloidosis. Its folding properties and stabilization by ligands are of current interest due to their importance in understanding and combating these diseases, Here we report the solid phase synthesis of the monomeric unit of a transthyretin analog (equivalent to 127 amino acids) using t-Boc chemistry and peptide ligation and its folding to form a functional 54-kDa tetramer, The monomeric unit of the protein was chemically synthesized in three parts (positions 1-51, 54-99, and 102-127) and ligated using a chemoselective thioether ligation chemistry. The synthetic protein was folded and assembled to a tetrameric structure in the presence of transthyretin's native ligand, thyroxine, as shown by gel filtration chromatography, native gel electrophoresis, transthyretin antibody recognition, and thyroid hormone binding. Other folding products included a high molecular weight aggregate as well as a transient dimeric species. This represents one of the largest macromolecules chemically synthesized to date and demonstrates the potential of protein chemical synthesis for investigations of protein-ligand interactions.	Univ Western Australia, Dept Biochem Chem, Nedlands, WA 6907, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia	University of Western Australia; University of Queensland; University of Melbourne	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@imb.uq.edu.au	Wilce, Jacqueline/N-5018-2017; Craik, David/B-1695-2010	Wilce, Jacqueline/0000-0002-8344-2626; Craik, David/0000-0003-0007-6796; Richardson, Samantha/0000-0002-1708-9430				Alewood P, 1997, METHOD ENZYMOL, V289, P14; Ball H L, 1994, Biomed Pept Proteins Nucleic Acids, V1, P39; Benson MD, 1996, AMYLOID, V3, P44, DOI 10.3109/13506129609014354; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BRANCH WT, 1972, ARCH BIOCHEM BIOPHYS, V152, P144, DOI 10.1016/0003-9861(72)90202-0; CANNE LE, 1995, J AM CHEM SOC, V117, P2998, DOI 10.1021/ja00116a005; Chang L, 1999, EUR J BIOCHEM, V259, P534, DOI 10.1046/j.1432-1327.1999.00076.x; CISZAK E, 1992, P NATL ACAD SCI USA, V89, P6644, DOI 10.1073/pnas.89.14.6644; Damas AM, 1996, ACTA CRYSTALLOGR D, V52, P966, DOI 10.1107/S0907444996003307; Dawson PE, 1997, J AM CHEM SOC, V119, P4325, DOI 10.1021/ja962656r; DWULET FE, 1983, BIOCHEM BIOPH RES CO, V114, P657, DOI 10.1016/0006-291X(83)90831-8; ENGLEBRETSEN DR, 1995, TETRAHEDRON LETT, V36, P8871, DOI 10.1016/0040-4039(95)01843-7; Hackeng TM, 1997, P NATL ACAD SCI USA, V94, P7845, DOI 10.1073/pnas.94.15.7845; HAMILTON JA, 1993, J BIOL CHEM, V268, P2416; Jacobson D R, 1991, Adv Hum Genet, V20, P69; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Klabunde T, 2000, NAT STRUCT BIOL, V7, P312; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Lai ZH, 1997, BIOCHEMISTRY-US, V36, P10230, DOI 10.1021/bi963195p; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Lu WY, 1996, J AM CHEM SOC, V118, P8518, DOI 10.1021/ja960812o; Lu WY, 1998, FEBS LETT, V429, P31, DOI 10.1016/S0014-5793(98)00547-X; Lu WY, 1997, BIOCHEMISTRY-US, V36, P673, DOI 10.1021/bi9625612; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; MENDEL CM, 1989, J CLIN INVEST, V83, P143, DOI 10.1172/JCI113851; Miroy GJ, 1996, P NATL ACAD SCI USA, V93, P15051, DOI 10.1073/pnas.93.26.15051; MONACO HL, 1995, SCIENCE, V268, P1039, DOI 10.1126/science.7754382; MUNRO SL, 1989, J CLIN ENDOCR METAB, V68, P1141, DOI 10.1210/jcem-68-6-1141; NILSSON SF, 1975, J BIOL CHEM, V250, P8554; PARDRIDGE WM, 1980, J CLIN INVEST, V66, P367, DOI 10.1172/JCI109865; Peterson SA, 1998, P NATL ACAD SCI USA, V95, P12956, DOI 10.1073/pnas.95.22.12956; Rajarathnam K, 1997, METHOD ENZYMOL, V287, P89; Richardson SJ, 1996, ENDOCRINOLOGY, V137, P3507, DOI 10.1210/en.137.8.3507; RICHARDSON SJ, 1994, AM J PHYSIOL, V266, pR1359, DOI 10.1152/ajpregu.1994.266.4.R1359; Saraiva M J, 1996, J Peripher Nerv Syst, V1, P179; SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; STEINRAUF LK, 1993, J BIOL CHEM, V268, P2425; Wilken J, 1998, CURR OPIN BIOTECH, V9, P412, DOI 10.1016/S0958-1669(98)80016-5; Wojtczak A, 1996, ACTA CRYSTALLOGR D, V52, P758, DOI 10.1107/S0907444996003046; WOJTCZAK A, 1992, J BIOL CHEM, V267, P353; Xu R, 1999, P NATL ACAD SCI USA, V96, P388, DOI 10.1073/pnas.96.2.388	45	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25997	26003		10.1074/jbc.M101228200	http://dx.doi.org/10.1074/jbc.M101228200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352912	hybrid			2022-12-27	WOS:000169823300049
J	Awata, H; Huang, CF; Handlogten, ME; Miller, RT				Awata, H; Huang, CF; Handlogten, ME; Miller, RT			Interaction of the calcium-sensing receptor and filamin, a potential scaffolding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN-280; CA2+-SENSING RECEPTOR; SIGNAL-TRANSDUCTION; MEMBRANE DOMAINS; IDENTIFICATION; LOCALIZATION; ORGANIZATION; MUTATIONS; LIGAND; CA2+	In many cases, the biologic responses of cells to extracellular signals and the specificity of the responses cannot be explained solely on the basis of the interactions of known signaling proteins. Recently, scaffolding and adaptor proteins have been identified that organize signaling proteins in cells and that contribute to the nature and specificity of signaling pathways. In an effort to identify proteins that might organize the signaling system(s) activated by the extracellular Ca2+ receptor (CaR), we used a bait construct representing the intracellular C terminus of the human Call and the yeast two hybrid system to screen a human kidney cDNA library. We identified a clone representing the C-terminal 1042 amino acids (aa) of the cytoskeletal protein filamin (ABP-280). Analysis of truncation and deletion constructs of the CaR C terminus and the filamin cDNA clone demonstrated that the CaR and filamin interact via regions containing aa 907-997 of the CaR C terminus and aa 1566-1875 of filamin. Interaction of the two proteins in mammalian REK-293 cells was demonstrated by co-immunoprecipitation and colocalization of them using immunofluorescence microscopy. The functional importance of their interaction was documented by transiently expressing the CaR in M2 melanoma cells that lack filamin, or in A7 melanoma cells that stably express filamin, and demonstrating that the CaR activated ERK only in the presence of filamin. Co-expression of the CaR with a peptide derived from the region of the CaR C terminus that interacts with filamin reduced the ability of the CaR to activate p42ERK in a dose-dependent manner, but did not inhibit the ability of the ETA receptor to activate ERK. The fact that filamin interacts with the CaR and other cell signaling proteins including mitogen-activated protein kinases and small GTPases, indicates that it may act as a scaffolding protein to organize cell signaling systems involving the CaR.	Case Western Reserve Univ, Louis Stokes Vet Affairs Med Ctr, Dept Med, Div Nephrol, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Miller, RT (corresponding author), Case Western Reserve Univ, Louis Stokes Vet Affairs Med Ctr, Dept Med, Div Nephrol, 10701 E Blvd, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041726, R01DK041726] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41726] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bai M, 1998, J BIOL CHEM, V273, P21267, DOI 10.1074/jbc.273.33.21267; Becker M, 2000, J CELL BIOL, V149, P255, DOI 10.1083/jcb.149.2.255; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BRASS LF, 1988, J BIOL CHEM, V263, P5348; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; Brown EM, 1998, ANNU REV MED, V49, P15, DOI 10.1146/annurev.med.49.1.15; BROWN EM, 2001, PHYSIOL REV, V81, P289; Chattopadhyay N, 1997, BIOL CHEM, V378, P759; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Gama L, 1998, J BIOL CHEM, V273, P29712, DOI 10.1074/jbc.273.45.29712; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Handlogten ME, 2001, J BIOL CHEM, V276, P13941, DOI 10.1074/jbc.M007306200; Hastie LE, 1997, FREE RADICAL BIO MED, V22, P955, DOI 10.1016/S0891-5849(96)00482-0; Hofer AM, 2000, NAT CELL BIOL, V2, P392, DOI 10.1038/35017020; James P, 1996, GENETICS, V144, P1425; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Muller M, 1999, EXP CELL RES, V248, P136, DOI 10.1006/excr.1999.4395; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; PATROSSO MC, 1994, GENOMICS, V21, P71, DOI 10.1006/geno.1994.1226; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; PORTER RM, 1993, J PATHOL, V170, P435, DOI 10.1002/path.1711700406; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sasaki A, 2001, J BIOL CHEM, V276, P17871, DOI 10.1074/jbc.M008422200; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Thomas AP, 2000, NAT CELL BIOL, V2, pE126, DOI 10.1038/35017143; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Zuker CS, 1999, SCIENCE, V283, P650, DOI 10.1126/science.283.5402.650	50	138	142	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34871	34879		10.1074/jbc.M100775200	http://dx.doi.org/10.1074/jbc.M100775200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11390379	hybrid			2022-12-27	WOS:000171024600071
J	Shiina, T; Arai, K; Tanabe, S; Yoshida, N; Haga, T; Nagao, T; Kurose, H				Shiina, T; Arai, K; Tanabe, S; Yoshida, N; Haga, T; Nagao, T; Kurose, H			Clathrin box in G protein-coupled receptor kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; BETA-ARRESTIN; ARRESTIN/CLATHRIN INTERACTION; DOWN-REGULATION; SEQUESTRATION; INTERNALIZATION; BINDING; DOMAIN; RESENSITIZATION	beta (1)-Adrenergic receptor (beta (1)AR) shows the resistance to agonist-induced internalization. However, beta (1)AR can internalize as G protein-coupled receptor kinase 2 (GRK2) is fused to its carboxyl terminus. Internalization of the beta (1)AR and GRK2 fusion protein (beta (1)AR/GRK2) is dependent on dynamin but independent of beta -arrestin and phosphorylation. The beta (1)AR/GRK2 fusion protein internalizes via clathrin-coated pits and is found to co-localize with the endosome that contains transferrin. The fusion proteins consisting of beta (1)AR and various portions of GRK2 reveal that the residues 498-502 in the carboxyl-terminal domain of GRK2 are critical to promote internalization of the fusion proteins. This domain contains a consensus sequence of a clathrin-binding motif defined as a clathrin box. In vitro binding assays show that the residues 498-502 of GRK2 bind the amino-terminal domain of clathrin heavy chain to almost the same extent as beta -arrestin1. The mutation of the clathrin box in the carboxyl-terminal domain of GRK2 results in the loss of the ability to promote internalization of the fusion protein. GRK2 activity increases and then decreases as the concentration of clathrin heavy chain increases. Taken together, these results imply that GRK2 contains a functional clathrin box and directly interacts with clathrin to modulate its function.	Univ Tokyo, Lab Pharmacol & Toxicol, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Neurochem, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Kurose, H (corresponding author), Univ Tokyo, Lab Pharmacol & Toxicol, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Tanabe, Shihori/AAH-6584-2019	Tanabe, Shihori/0000-0003-3706-0616				Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Bohm SK, 1997, BIOCHEM J, V322, P1; Brodsky FM, 1997, TRENDS CELL BIOL, V7, P175, DOI 10.1016/S0962-8924(97)01038-6; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Damke H, 1996, FEBS LETT, V389, P48, DOI 10.1016/0014-5793(96)00517-0; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Furukawa H, 2000, J BIOCHEM-TOKYO, V127, P151, DOI 10.1093/oxfordjournals.jbchem.a022577; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GREEN SA, 1994, J BIOL CHEM, V269, P26215; Haga K, 1997, BIOCHEMISTRY-US, V36, P1315, DOI 10.1021/bi961613k; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; KUROSE H, 1994, J BIOL CHEM, V269, P10093; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LAW PY, 1984, J BIOL CHEM, V259, P4096; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sato Y, 1996, EUR J PHARMACOL, V315, P363, DOI 10.1016/S0014-2999(96)00648-6; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shiina T, 2000, J BIOL CHEM, V275, P29082, DOI 10.1074/jbc.M909757199; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; TSUGA H, 1994, J BIOL CHEM, V269, P32522; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; YU SS, 1993, J BIOL CHEM, V268, P337	39	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33019	33026		10.1074/jbc.M100140200	http://dx.doi.org/10.1074/jbc.M100140200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11389137	hybrid			2022-12-27	WOS:000170746000086
J	Huberman, T; Eisenberg-Domovich, Y; Gitlin, G; Kulik, T; Bayer, EA; Wilchek, M; Livnah, O				Huberman, T; Eisenberg-Domovich, Y; Gitlin, G; Kulik, T; Bayer, EA; Wilchek, M; Livnah, O			Chicken avidin exhibits pseudo-catalytic properties - Biochemical, structural, and electrostatic consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTAVIDIN-BIOTIN COMPLEX; X-RAY-DIFFRACTION; EGG-WHITE AVIDIN; PEPTIDE LIBRARIES; BINDING; TRYPTOPHAN; ANTIBODY; SYSTEM; SITE; TRANSPORT	Avidin and its bacterial analogue streptavidin exhibit similarly high affinities toward the vitamin biotin. The extremely high affinity of these two proteins has been utilized as a powerful tool in many biotechnological applications. Although avidin and streptavidin have similar tertiary and quaternary structures, they differ in many of their properties. Here we show that avidin enhances the alkaline hydrolysis of biotinyl p-nitrophenyl ester, whereas streptavidin protects this reaction even under extreme alkaline conditions (pH > 12). Unlike normal enzymatic catalysis, the hydrolysis reaction proceeds as a single cycle with no turnover because of the extremely high affinity of the protein for one of the reaction products (i.e. free biotin). The three-dimensional crystal structures of avidin (2 Angstrom) and streptavidin (2.4 Angstrom) complexed with the amide analogue, biotinyl p-nitroanilide, as a model for the p-nitrophenyl ester, revealed structural insights into the factors that enhance or protect the hydrolysis reaction. The data demonstrate that several molecular features of avidin are responsible for the enhanced hydrolysis of biotinyl p-nitrophenyl ester. These include the nature of a decisive flexible loop, the presence of an obtrusive arginine 114, and a newly formed critical interaction between lysine III and the nitro group of the substrate. The open conformation of the loop serves to expose the substrate to the solvent, and the arginine shifts the p-nitroanilide moiety toward the interacting lysine, which increases the electron withdrawing characteristics and consequent electrophilicity of the carbonyl group of the substrate. Streptavidin lacked such molecular properties, and analogous interactions with the substrate were consequently absent. The information derived from these structures may provide insight into the action of artificial protein catalysts and the evolution of catalytic sites in general.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, Wolfson Ctr Appl Struct Biol, IL-91904 Jerusalem, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Weizmann Institute of Science	Livnah, O (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, Wolfson Ctr Appl Struct Biol, IL-91904 Jerusalem, Israel.	oded.livnah@huji.ac.il						[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAYER EA, 1995, APPL BIOCHEM BIOTECH, V53, P1, DOI 10.1007/BF02783477; Bayer EA, 1996, ELECTROPHORESIS, V17, P1319, DOI 10.1002/elps.1150170808; BAYER EA, 1989, BIOCHEM J, V259, P369, DOI 10.1042/bj2590369; BAYER EA, 1975, FEBS LETT, V60, P309, DOI 10.1016/0014-5793(75)80737-X; BECKER JM, 1971, P NATL ACAD SCI USA, V68, P2604, DOI 10.1073/pnas.68.10.2604; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Freitag S, 1998, J MOL BIOL, V279, P211, DOI 10.1006/jmbi.1998.1735; Gigant B, 1997, P NATL ACAD SCI USA, V94, P7857, DOI 10.1073/pnas.94.15.7857; Gissel B, 1995, J Pept Sci, V1, P217, DOI 10.1002/psc.310010402; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; GREEN NM, 1965, BIOCHEM J, V94, P23; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Katz BA, 1997, J MOL BIOL, V274, P776, DOI 10.1006/jmbi.1997.1444; Laitinen OH, 1999, FEBS LETT, V461, P52, DOI 10.1016/S0014-5793(99)01423-4; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; LIVNAH O, 1993, FEBS LETT, V328, P165, DOI 10.1016/0014-5793(93)80986-5; MCCORMICK D. B., 1970, Methods in Enzymology, V18A, P383, DOI 10.1016/0076-6879(71)18331-0; Miles E W, 1977, Methods Enzymol, V47, P431; MINOR W, 1996, P MACR CRYST COMP SC; Morag E, 1996, BIOCHEM J, V316, P193, DOI 10.1042/bj3160193; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OSTERGAARD S, 1995, FEBS LETT, V362, P306, DOI 10.1016/0014-5793(95)00262-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PUGLIESE L, 1993, J MOL BIOL, V231, P698, DOI 10.1006/jmbi.1993.1321; SANO T, 1995, P NATL ACAD SCI USA, V92, P3180, DOI 10.1073/pnas.92.8.3180; Schechter B, 1996, J DRUG TARGET, V4, P171, DOI 10.3109/10611869609015974; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; Thayer MM, 1999, J MOL BIOL, V291, P329, DOI 10.1006/jmbi.1999.2960; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; WILCHEK M, 1967, BIOCHEMISTRY-US, V6, P247, DOI 10.1021/bi00853a038; WILCHEK M, 1988, ANAL BIOCHEM, V171, P1, DOI 10.1016/0003-2697(88)90120-0; WILCHEK M, 1990, METHOD ENZYMOL, V184, P14	42	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32031	32039		10.1074/jbc.M102018200	http://dx.doi.org/10.1074/jbc.M102018200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11395489	hybrid			2022-12-27	WOS:000170613500077
J	Krylov, DM; Hurley, JB				Krylov, DM; Hurley, JB			Identification of proximate regions in a complex of retinal guanylyl cyclase 1 and guanylyl cyclase-activating protein-1 by a novel mass spectrometry-based method	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM; DOMAIN; CLONING; EXPRESSION; REGULATOR; AFFINITY; ADENYLYL; MUTANT; GCAP-1; RETGC	A key challenge in studying protein/protein interactions is to accurately identify contact surfaces, i.e. regions of two proteins that are in direct physical contact. Aside from x-ray crystallography and NMR spectroscopy few methods are available that address this problem. Although x-ray crystallography often provides detailed information about contact surfaces, it is limited to situations when a co-crystal of proteins is available. NMR circumvents this requirement but is limited to small protein complexes. Other methods, for instance protection from proteolysis, are less direct and therefore less informative. Here we describe a new method that identifies candidate contact surfaces in protein complexes. The complexes are first stabilized by cross-linking. They are then digested with a protease, and the cross-linked fragments are analyzed by mass spectrometry. We applied this method, referred to as COSUMAS (contact surfaces by mass spectrometry), to two proteins, retinal guanylyl cyclase 1 (RetGC1) and guanylyl cyclase-activating protein-1 (GCAP-1), that regulate cGMP synthesis in photoreceptors. Two regions in GCAP-1 and three in RetGC1 were identified as possible contact sites. The two regions of RetGC1 that are in the vicinities of Cys(741) and Cys(780) map to a kinase homology domain in RetGC1. Their identities as contact sites were independently evaluated by peptide inhibition analysis. Peptides with sequences from these regions block GCAP-1-mediated regulation of guanylyl cyclase at both high and low Ca2+ concentrations. The two regions of GCAP-1 cross-linked to these peptides were in the vicinities of Cys(17) and Cys(105) of GCAP-1. Peptides with sequences derived from these regions inhibit guanylyl cyclase activity directly. These results support a model in which GCAP-1 binds constitutively to RetGC1 and regulates cyclase activity by structural changes caused by the binding or dissociation of Ca2+.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Hurley, JB (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.				NEI NIH HHS [EY06641] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; CHEN LL, 1991, J BIOL CHEM, V266, P18237; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; Duda T, 1996, BIOCHEMISTRY-US, V35, P8478, DOI 10.1021/bi960752z; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; JOHNSON RS, 1987, BIOCHEMISTRY-US, V26, P1209, DOI 10.1021/bi00379a001; Kachi S, 1999, EXP EYE RES, V68, P465, DOI 10.1006/exer.1998.0629; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; Krylov DM, 1999, J BIOL CHEM, V274, P10833, DOI 10.1074/jbc.274.16.10833; Lange C, 1999, FEBS LETT, V460, P27, DOI 10.1016/S0014-5793(99)01312-5; Laura RP, 1996, J BIOL CHEM, V271, P11646, DOI 10.1074/jbc.271.20.11646; Laura RP, 1998, BIOCHEMISTRY-US, V37, P11264, DOI 10.1021/bi9809674; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; Olshevskaya EV, 1999, J BIOL CHEM, V274, P10823, DOI 10.1074/jbc.274.16.10823; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; Sokal I, 1998, MOL CELL, V2, P129, DOI 10.1016/S1097-2765(00)80121-5; Sokal I, 1999, BIOCHEMISTRY-US, V38, P1387, DOI 10.1021/bi982512k; Sokal I, 1999, J BIOL CHEM, V274, P19829, DOI 10.1074/jbc.274.28.19829; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8626; TOMER KB, 1984, ANAL CHEM, V56, P880, DOI 10.1021/ac00270a006; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; Tucker CL, 1997, BIOCHEMISTRY-US, V36, P11995, DOI 10.1021/bi971212k; Wedel BJ, 2001, ANNU REV PHYSIOL, V63, P215, DOI 10.1146/annurev.physiol.63.1.215	32	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30648	30654		10.1074/jbc.M104121200	http://dx.doi.org/10.1074/jbc.M104121200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11387342	hybrid			2022-12-27	WOS:000170472900010
J	Ogushi, K; Wada, A; Niidome, T; Mori, N; Oishi, K; Nagatake, T; Takahashi, A; Asakura, H; Makino, S; Hojo, H; Nakahara, Y; Ohsaki, M; Hatakeyama, T; Aoyagi, H; Kurazono, H; Moss, J; Hirayama, T				Ogushi, K; Wada, A; Niidome, T; Mori, N; Oishi, K; Nagatake, T; Takahashi, A; Asakura, H; Makino, S; Hojo, H; Nakahara, Y; Ohsaki, M; Hatakeyama, T; Aoyagi, H; Kurazono, H; Moss, J; Hirayama, T			Salmonella enteritidis FliC (flagella filament protein) induces human beta-defensin-2 mRNA production by Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PSEUDOMONAS-AERUGINOSA; TYPHI FLAGELLA; BETA-DEFENSINS; EXPRESSION; ACTIVATION; INDUCTION; ALPHA; HBD-1	Antimicrobial peptides are crucial for host defense at mucosal surfaces. Bacterial factors responsible for induction of human beta -defensin-2 (hBD-2) mRNA expression in Caco-2 human carcinoma cells were determined. Salmonella enteritidis, Salmonella typhimurium, Salmonella typhi, Salmonella dublin, and culture supernatants of these strains induced hBD-2 mRNA expression in Caco-2 human carcinoma cells. Using luciferase as a reporter gene for a similar to2.1-kilobase pair hBD-2 promoter, the hBD-2-inducing factor in culture supernatant of S. enteritidis was isolated. The supernatant factor was heat-stable and proteinase-sensitive. After purification by anion exchange and gel filtration chromatography, the hBD-2-inducing factor was identified as a 53-kDa monomeric protein with the amino-terminal sequence AQVINTNSLSLLTQNNLNK, which is identical to that of the flagella filament structural protein (FliC) of S. enteritidis. Consistent with this finding, the 53-kDa protein reacted with anti-FliC antibody, which prevented its induction of hBD-2 mRNA in Caco-2 cells. In agreement, the hBD-2-inducing activity in culture supernatant was completely neutralized by anti-FliC antibody. In gel retardation analyses, FliC increased binding of NF-kappaB (p65 homodimer) to hBD-2 gene promoter sequences. We conclude that S. enteritidis FliC induces hBD-2 expression in Caco-2 cells via NF-kappaB activation and thus plays an important role in up-regulation of the innate immune response.	Nagasaki Univ, Dept Bacteriol, Nagasaki 8528523, Japan; Nagasaki Univ, Dept Prevent Med & AIDS Res, Nagasaki 8528523, Japan; Nagasaki Univ, Inst Trop Med, Dept Internal Med, Nagasaki 8528523, Japan; Nagasaki Univ, Dept Appl Chem, Fac Engn, Nagasaki 8528523, Japan; Univ Tokushima, Sch Med, Dept Nutr, Tokushima 7708503, Japan; Obihiro Univ Agr & Vet Med, Dept Vet Microbiol, Obihiro, Hokkaido 0808555, Japan; Tokai Univ, Dept Ind Chem, Hiratsuka, Kanagawa 2591292, Japan; Okayama Univ, Sch Med, Fac Hlth Sci, Okayama 7008558, Japan; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University; Tokushima University; Obihiro University of Agriculture & Veterinary Medicine; Tokai University; Okayama University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hirayama, T (corresponding author), Nagasaki Univ, Dept Bacteriol, Sakamoto, Nagasaki 8528523, Japan.	hirayama@net.nagasaki-u.ac.jp	Niidome, Takuro/F-1508-2010	Niidome, Takuro/0000-0002-8070-8708; Hatakeyama, Tomomitsu/0000-0002-9505-1980	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000659, ZIAHL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; Baumler AJ, 2000, SCIENCE, V287, P50, DOI 10.1126/science.287.5450.50; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Ciacci-Wooline F, 1999, INFECT IMMUN, V67, P5176, DOI 10.1128/IAI.67.10.5176-5185.1999; Ciacci-Woolwine F, 1998, INFECT IMMUN, V66, P1127, DOI 10.1128/IAI.66.3.1127-1134.1998; Eaves-Pyles T, 1999, INFECT IMMUN, V67, P800, DOI 10.1128/IAI.67.2.800-804.1999; Feldman M, 1998, INFECT IMMUN, V66, P43, DOI 10.1128/IAI.66.1.43-51.1998; Gewirtz AT, 2000, J CLIN INVEST, V105, P79, DOI 10.1172/JCI8066; Harder J, 2000, AM J RESP CELL MOL, V22, P714, DOI 10.1165/ajrcmb.22.6.4023; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; IBRAHIM GF, 1985, J CLIN MICROBIOL, V22, P1040, DOI 10.1128/JCM.22.6.1040-1044.1985; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; O'Neil DA, 1999, J IMMUNOL, V163, P6718; OHSAKI M, 1998, PEPT SCI, P453; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Steiner TS, 2000, J CLIN INVEST, V105, P1769, DOI 10.1172/JCI8892; Svinarich DM, 1997, AM J OBSTET GYNECOL, V176, P470, DOI 10.1016/S0002-9378(97)70517-9; VORDERVISZT F, 1989, J MOL BIOL, V209, P127; Wada A, 1999, BIOCHEM BIOPH RES CO, V263, P770, DOI 10.1006/bbrc.1999.1452; Wada A, 2001, CELL MICROBIOL, V3, P115, DOI 10.1046/j.1462-5822.2001.00096.x; Ward LR, 2000, SCIENCE, V287, P1753, DOI 10.1126/science.287.5459.1753c; Wyant TL, 1999, INFECT IMMUN, V67, P3619, DOI 10.1128/IAI.67.7.3619-3624.1999; Wyant TL, 1999, INFECT IMMUN, V67, P1338, DOI 10.1128/IAI.67.3.1338-1346.1999; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4	27	119	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30521	30526		10.1074/jbc.M011618200	http://dx.doi.org/10.1074/jbc.M011618200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11387317	hybrid			2022-12-27	WOS:000170558000120
J	Wrenger, C; Luersen, K; Krause, T; Muller, S; Walter, RD				Wrenger, C; Luersen, K; Krause, T; Muller, S; Walter, RD			The Plasmodium falciparum bifunctional ornithine decarboxylase, S-adenosyl-L-methionine decarboxylase, enables a well balanced polyamine synthesis without domain-domain interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYLMETHIONINE DECARBOXYLASE; DIHYDROFOLATE-REDUCTASE; THYMIDYLATE SYNTHASE; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; PUTRESCINE; SEQUENCES; ANALOGS; DIFLUOROMETHYLORNITHINE; DEGRADATION	In the human malaria parasite Plasmodium falciparum (Pf), polyamines are synthesized by a bifunctional enzyme that possesses both ornithine decarboxylase (ODC) and S-adenosyl-L-methionine decarboxylase (AdoMetDC) activities. The mature enzyme consists of the heterotetrameric N-terminal AdoMetDC and the C-terminal dimeric ODC, which results in the formation of a heterotetrameric complex. For the native bifunctional protein a half-life longer than 2 h was determined, which is in contrast to the extreme short half-life of its mammalian monofunctional counterparts. The biological advantage of the plasmodial bifunctional ODC/ AdoMetDC might be that the control of polyamine synthesis is achieved by only having to regulate the abundance and activity of one protein. An interesting feature in the regulation of the bifunctional protein is that putrescine inhibits PfODC activity similar to 10-fold more efficiently than the mammalian ODC activity, and in contrast to the mammalian AdoMetDC the activity of the PfAdoMetDC domain is not stimulated by the diamine. To analyze post-translational processing, polymerization, and domain-domain interactions, several mutant proteins were generated that have single mutations in either the PfODC or PfAdoMetDC domains. The exchange of amino acids essential for the activity of one domain had no effect on the enzyme activity of the other domain. Even prevention of the post-translational cleavage of the AdoMetDC domain or ODC dimerization and thus the interference with the folding of the protein hardly affected the activity of the partner domain. In addition, inhibition of the activity of the PfODC domain had no effect on the activity of the PfAdoMetDC domain and vice versa. These results demonstrate that no domain-domain interactions occur between the two enzymes of the bifunctional PfODC/AdoMetDC and that both enzymatic activities are operating as independent catalytic sites that do not affect each other.	Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany; Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland	Bernhard Nocht Institut fur Tropenmedizin; University of Dundee	Walter, RD (corresponding author), Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	walter@bni.uni-hamburg.de	Wrenger, Carsten/E-4110-2013	Wrenger, Carsten/0000-0001-5987-1749				BITONTI AJ, 1987, EXP PARASITOL, V64, P237, DOI 10.1016/0014-4894(87)90148-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETON CB, 1990, RES IMMUNOL, V141, P743, DOI 10.1016/0923-2494(90)90005-J; CHRISTOPHERS S. RICKARD, 1939, ANN TROP MED AND PARASITOL, V33, P161; COLEMAN CS, 1994, J BIOL CHEM, V269, P3155; Da'Dara AA, 1998, BIOCHEM J, V336, P545, DOI 10.1042/bj3360545; DEZEURE F, 1989, INT J BIOCHEM, V21, P889, DOI 10.1016/0020-711X(89)90288-7; Ekstrom JL, 1999, STRUCTURE, V7, P583, DOI 10.1016/S0969-2126(99)80074-4; GHODA L, 1990, J BIOL CHEM, V265, P11823; GUATTARI B, 1991, J CHROMATOGR-BIOMED, V567, P254, DOI 10.1016/0378-4347(91)80329-B; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HEBY O, 1985, ADV ENZYME REGUL, V24, P103, DOI 10.1016/0065-2571(85)90072-X; INSELBURG J, 1988, AM J TROP MED HYG, V39, P328, DOI 10.4269/ajtmh.1988.39.328; KANAANI J, 1989, J BIOL CHEM, V264, P3194; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; KITANI T, 1983, J BIOL CHEM, V258, P235; Krause T, 2000, BIOCHEM J, V352, P287, DOI 10.1042/0264-6021:3520287; Liang PH, 1998, BIOCHEMISTRY-US, V37, P12195, DOI 10.1021/bi9803168; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MCCANN PP, 1981, MED BIOL, V59, P434; METT H, 1993, CANCER CHEMOTH PHARM, V32, P39, DOI 10.1007/BF00685874; Muller S, 2000, J BIOL CHEM, V275, P8097, DOI 10.1074/jbc.275.11.8097; Muller S, 2001, TRENDS PARASITOL, V17, P242, DOI 10.1016/S1471-4922(01)01908-0; Niemann G, 1996, BIOCHEM J, V317, P135, DOI 10.1042/bj3170135; OSTERMAN A, 1994, BIOCHEMISTRY-US, V33, P13662, DOI 10.1021/bi00250a016; PASVOL G, 1978, ANN TROP MED PARASIT, V72, P87, DOI 10.1080/00034983.1978.11719283; PATCHETT ML, 1988, J CHROMATOGR-BIOMED, V425, P269, DOI 10.1016/0378-4347(88)80031-8; PEGG AE, 1969, J BIOL CHEM, V244, P682; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; Pegg AE, 1998, BIOCHEM SOC T, V26, P580, DOI 10.1042/bst0260580; PEGG AE, 1989, ENZYMES AS TARGETS FOR DRUG DESIGN, P157; PORTER CW, 1986, ANTICANCER RES, V6, P525; POULIN R, 1992, J BIOL CHEM, V267, P150; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUSSELL DH, 1969, MOL PHARMACOL, V5, P253; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shallom S, 1999, J BIOL CHEM, V274, P37781, DOI 10.1074/jbc.274.53.37781; STANEK J, 1993, J MED CHEM, V36, P46, DOI 10.1021/jm00053a007; STANLEY BA, 1989, J BIOL CHEM, V264, P21073; STANLEY BA, 1994, J BIOL CHEM, V269, P7901; Svensson F, 1997, P NATL ACAD SCI USA, V94, P397, DOI 10.1073/pnas.94.2.397; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; TABOR H, 1964, PHARMACOL REV, V16, P245; TOBIAS KE, 1993, EUR J BIOCHEM, V218, P245, DOI 10.1111/j.1432-1033.1993.tb18371.x; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; YAYON A, 1983, J PROTOZOOL, V30, P642, DOI 10.1111/j.1550-7408.1983.tb05336.x	48	46	48	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29651	29656		10.1074/jbc.M100578200	http://dx.doi.org/10.1074/jbc.M100578200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390378	hybrid			2022-12-27	WOS:000170558000009
J	Hay, E; Lemonnier, J; Fromigue, O; Marie, PJ				Hay, E; Lemonnier, J; Fromigue, O; Marie, PJ			Bone morphogenetic protein-2 promotes osteoblast apoptosis through a Smad-independent, protein kinase C-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; INHIBITS MYOGENIC DIFFERENTIATION; GROWTH-FACTOR-BETA; ALKALINE-PHOSPHATASE; MEDIATED APOPTOSIS; UP-REGULATION; MAP KINASES; ACTIVATION; EXPRESSION; PROLIFERATION	Bone morphogenetic protein-2 (BMP-2), a member of the transforming growth factor-beta (TGF-beta) family, regulates osteoblast differentiation and bone formation. Here we show a novel function of BMP-2 in human osteoblasts and identify a signaling pathway involved in this function. BMP-2 promotes apoptosis in primary human calvaria osteoblasts and in immortalized human neonatal calvaria osteoblasts, as shown by terminal deoxynucleotidyl transferase-mediated nick end labeling analysis. In contrast, TGF-beta2 inhibits apoptosis in human osteoblasts. Studies of the mechanisms of action showed that BMP-2 increases the Bax/Bcl-2 ratio, whereas TG beta -2 has a negative effect. Moreover, BMP-2 increases the release of mitochondrial cytochrome c to the cytosol. Consistent with these results, BMP-2 increases caspase-9 and caspase-3, -6, and -7 activity, and an anti-caspase-9 agent suppresses BMP-2-induced apoptosis. Overexpression of dominant-negative Smad1 effectively blocks BMP-2-induced expression of the osteoblast transcription factor Runx2 but not the activation of caspases or apoptosis induced by BMP-2, indicating that the Smad1 signaling pathway is not involved in the BMP-2-induced apoptosis. The proapoptotic effect of BMP-2 is PKC-dependent, because BMP-2 increases PKC activity, and the selective PKC inhibitor calphostin C blocks the BMP-2-induced increased Bax/Bcl-2, caspase activity, and apoptosis. In contrast, the cAMP-dependent protein kinase A inhibitor H89, the p38 MAPK inhibitor SB203580, and the MEK inhibitor PD-98059 have no effect. The results show that BMP-2 uses a Smad-independent, PKC-dependent pathway to promote apoptosis via a Bax/Bcl-2 and cytochrome c-caspase-9-caspase-3,-6,-7 cascade in human osteoblasts.	Hop Lariboisiere, CNRS, INSERM, U 349,Lab Osteoblast Biol & Pathol, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Marie, PJ (corresponding author), Hop Lariboisiere, CNRS, INSERM, U 349,Lab Osteoblast Biol & Pathol, F-75475 Paris 10, France.	pierre.marie@inserm.Irb.ap-hop-paris.fr	Fromigue, Olivia/B-8225-2013	Fromigue, Olivia/0000-0002-3050-6155; Hay, Eric/0000-0002-0131-9983				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Aubin Jane E., 1996, P51; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Bourez RLJH, 1997, J CRANIOFAC SURG, V8, P441, DOI 10.1097/00001665-199711000-00002; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Buckland RA, 1998, MECH DEVELOP, V71, P143, DOI 10.1016/S0925-4773(98)00008-2; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Debiais F, 2001, J CELL BIOCHEM, V81, P68, DOI 10.1002/1097-4644(20010401)81:1<68::AID-JCB1024>3.0.CO;2-S; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ducy P, 1998, CURR OPIN CELL BIOL, V10, P614, DOI 10.1016/S0955-0674(98)80037-9; Ferrari D, 1998, DEV BIOL, V197, P12, DOI 10.1006/dbio.1998.8880; Fromigue O, 1998, J CELL BIOCHEM, V68, P411, DOI 10.1002/(SICI)1097-4644(19980315)68:4<411::AID-JCB2>3.3.CO;2-C; FURTWANGLER JA, 1985, ACTA ANAT, V124, P74; GARCIAMARTINEZ V, 1993, J CELL SCI, V106, P201; GOMEZ J, 1994, EXP CELL RES, V213, P178, DOI 10.1006/excr.1994.1188; HARRIS SE, 1994, J BONE MINER RES, V9, P855; Hay E, 1999, J CELL BIOCHEM, V72, P81, DOI 10.1002/(SICI)1097-4644(19990101)72:1<81::AID-JCB9>3.0.CO;2-N; Hay E, 2000, J CELL PHYSIOL, V183, P117, DOI 10.1002/(SICI)1097-4652(200004)183:1<117::AID-JCP14>3.0.CO;2-#; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hill PA, 1997, ENDOCRINOLOGY, V138, P3849, DOI 10.1210/en.138.9.3849; Iantosca MR, 1999, J NEUROSCI RES, V56, P248; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Israels LG, 1999, STEM CELLS, V17, P306, DOI 10.1002/stem.170306; Jernvall J, 1998, DEVELOPMENT, V125, P161; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Ju WJ, 2000, J BONE MINER RES, V15, P1889, DOI 10.1359/jbmr.2000.15.10.1889; Kim HJ, 1998, DEVELOPMENT, V125, P1241; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lee YS, 1997, J CELL PHYSIOL, V170, P153, DOI 10.1002/(SICI)1097-4652(199702)170:2<153::AID-JCP7>3.0.CO;2-N; Lemonnier J, 2001, AM J PATHOL, V158, P1833, DOI 10.1016/S0002-9440(10)64139-9; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; Marazzi G, 1997, DEV BIOL, V186, P127, DOI 10.1006/dbio.1997.8576; MARIE PJ, 1998, ADV ORG BIO A-C, V5, P445; MARIE PJ, 1997, J CELL ENG, V2, P92; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151; Merino R, 1999, ANN NY ACAD SCI, V887, P120, DOI 10.1111/j.1749-6632.1999.tb07927.x; Mohan RR, 1998, INVEST OPHTH VIS SCI, V39, P2626; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Ozaki I, 1999, J BIOL CHEM, V274, P5310, DOI 10.1074/jbc.274.9.5310; Palcy S, 1999, BIOCHEM J, V343, P21, DOI 10.1042/0264-6021:3430021; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RITKE MK, 1994, MOL PHARMACOL, V46, P605; Rodriguez-Leon J, 1999, NAT CELL BIOL, V1, P125, DOI 10.1038/10098; Sanders JL, 1996, J BONE MINER RES, V11, P1862; Savickiene J, 1999, CELL DEATH DIFFER, V6, P698, DOI 10.1038/sj.cdd.4400541; Schmidt C, 1998, DEV BIOL, V202, P253, DOI 10.1006/dbio.1998.9011; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Song QB, 1998, DEV BIOL, V196, P119, DOI 10.1006/dbio.1998.8847; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; Suzuki A, 1999, ENDOCRINOLOGY, V140, P3177, DOI 10.1210/en.140.7.3177; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; Tsuboi M, 1999, J LAB CLIN MED, V134, P222, DOI 10.1016/S0022-2143(99)90201-9; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; YAMAGUCHI A, 1995, SEMIN CELL BIOL, V6, P165, DOI 10.1006/scel.1995.0023; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	78	148	154	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29028	29036		10.1074/jbc.M011265200	http://dx.doi.org/10.1074/jbc.M011265200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11395480	hybrid			2022-12-27	WOS:000170346000054
J	Kimple, RJ; De Vries, L; Tronchere, H; Behe, CI; Morris, RA; Farquhar, MG; Siderovski, DP				Kimple, RJ; De Vries, L; Tronchere, H; Behe, CI; Morris, RA; Farquhar, MG; Siderovski, DP			RGS12 and RGS14 GoLoco motifs are G alpha(i) interaction sites with guanine nucleotide dissociation inhibitor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; BETA-GAMMA-SUBUNITS; EXCHANGE FACTOR; INTRINSIC FLUORESCENCE; SIGNALING PATHWAYS; GTPASE ACTIVITY; ALPHA-SUBUNIT; BINDING; DOMAIN; STABILIZATION	The regulators of G-protein signaling (RGS) proteins accelerate the intrinsic guanosine triphosphatase activity of heterotrimeric G-protein a subunits and are thus recognized as key modulators of G-protein-coupled receptor signaling. RGS12 and RGS14 contain not only the hallmark RGS box responsible for GTPase-accelerating activity but also a single G alpha (i/o)-Loco (GoLoco) motif predicted to represent a second G alpha interaction site. Here, we describe functional characterization of the GoLoco motif regions of RGS12 and RGS14. Both regions interact exclusively with G alpha (i1), G alpha (i2), and G alpha (i3) in their GDP-bound forms. In GTP gammaS binding assays, both regions exhibit guanine nucleotide dissociation inhibitor (GDI) activity, inhibiting the rate of exchange of GDP for GTP by G alpha (i1). Both regions also stabilize G alpha (i1) in its GDP-bound form, inhibiting the increase in intrinsic tryptophan fluorescence stimulated by AlF4-. Our results indicate that both RGS12 and RGS14 harbor two distinctly different G alpha interaction sites: a previously recognized N-terminal RGS box possessing G alpha (i). GAP activity and a C-terminal GoLoco region exhibiting G alpha (i) GDI activity. The presence of two, independent G alpha interaction sites suggests that RGS12 and RGS14 participate in a complex coordination of G-protein signaling beyond simple G alpha GAP activity.	Univ N Carolina, Sch Med, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; INSERM, U326, F-31059 Toulouse 3, France	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Diego; Institut National de la Sante et de la Recherche Medicale (Inserm)	Siderovski, DP (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Lineberger Comprehens Canc Ctr, CB 7365,Mary Ellen Jones Bldg,Rm 1106, Chapel Hill, NC 27599 USA.		Kimple, Randall/L-6460-2019; Siderovski, David Peter/AAA-9603-2019; TRONCHERE, Helene/M-5631-2014	Kimple, Randall/0000-0001-8336-8000; Siderovski, David Peter/0000-0002-0688-8210; 	NCI NIH HHS [CA58689] Funding Source: Medline; NIDDK NIH HHS [DK07386, DK17780] Funding Source: Medline; NIGMS NIH HHS [GM07040, GM62338] Funding Source: Medline; NIMH NIH HHS [F30 MH064319, F30 MH064319-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017780, R37DK017780, T35DK007386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062338, T32GM007040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH064319] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BRANDT DR, 1985, J BIOL CHEM, V260, P266; Cho H, 2000, MOL PHARMACOL, V58, P569, DOI 10.1124/mol.58.3.569; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; McEwen DP, 2001, ANAL BIOCHEM, V291, P109, DOI 10.1006/abio.2001.5011; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; Ponting CP, 1999, J MOL MED, V77, P695, DOI 10.1007/s001099900054; Schiff ML, 2000, NATURE, V408, P723, DOI 10.1038/35047093; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Traver S, 2000, BIOCHEM J, V350, P19, DOI 10.1042/0264-6021:3500019; Wall MA, 1998, STRUCTURE, V6, P1169, DOI 10.1016/S0969-2126(98)00117-8	38	188	196	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29275	29281		10.1074/jbc.M103208200	http://dx.doi.org/10.1074/jbc.M103208200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387333	Green Published, hybrid			2022-12-27	WOS:000170346000086
J	Liu, CX; Li, YH; Obermoeller-McCormick, LM; Schwartz, AL; Bu, GJ				Liu, CX; Li, YH; Obermoeller-McCormick, LM; Schwartz, AL; Bu, GJ			The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROKINASE RECEPTOR; BINDING-PROTEIN; CELL-SURFACE; GENE FAMILY; COMPLEXES; CHAPERONE; PATHWAY; SYSTEM; SIGNAL; ROLES	The low density lipoprotein receptor-related protein. deleted in tumor (LRP1B, initially referred to as LRP-DIT) was cloned and characterized as a candidate tumor suppressor. It is a new member of the low density lipoprotein receptor gene family. Its overall domain structure and large size (similar to 600 kDa) are similar to LRP and suggest that it is a multifunctional cell surface receptor. Herein, we characterize a series of ligands for the receptor using cell lines that stably express it as a domain IV minireceptor (mLRP1B4). Ligands of LRP including receptor-associated protein, urokinase plasminogen activator, tissue-type plasminogen activator, and plasminogen activator inhibitor type-1 each demon. strate binding, internalization, and degradation via mLRP1B4. Interestingly, the kinetics of ligand endocytosis is distinctly different from that of LRP, with LRP1B exhibiting a markedly diminished internalization rate. In addition, tissue expression analysis reveals that the LRP1B gene is expressed in brain, thyroid, and salivary gland. These studies thus extend the physiological roles of members of the LDL receptor family.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Physiol & Cell Biol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Bu, GJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, CB 8208,660 S Euclid Ave, St Louis, MO 63110 USA.				NHLBI NIH HHS [HL59150, HL53280] Funding Source: Medline; NIDDK NIH HHS [DK56783] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059150, R01HL053280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056783] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BU GJ, 1992, J BIOL CHEM, V267, P15595; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BU GJ, 1993, J BIOL CHEM, V268, P13002; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Grimme S, 2000, J BIOL CHEM, V275, P33697, DOI 10.1074/jbc.M003789200; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Howell BW, 2001, CURR OPIN NEUROBIOL, V11, P74, DOI 10.1016/S0959-4388(00)00176-8; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; Li YH, 2001, MOL CELL BIOL, V21, P1185, DOI 10.1128/MCB.21.4.1185-1195.2001; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; LISITSYN NA, 1995, P NATL ACAD SCI USA, V92, P151, DOI 10.1073/pnas.92.1.151; Liu CX, 2000, GENOMICS, V69, P271, DOI 10.1006/geno.2000.6331; Liu CX, 2000, CANCER RES, V60, P1961; Mignatti P, 2000, ADV CANCER RES, V78, P103; MORTON PA, 1990, J BIOL CHEM, V265, P14093; Narita M, 1997, J NEUROCHEM, V68, P587; Neels JG, 1999, J BIOL CHEM, V274, P31305, DOI 10.1074/jbc.274.44.31305; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Ulery PG, 2000, J CLIN INVEST, V106, P1077, DOI 10.1172/JCI11455; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Webb DJ, 2000, J CELL SCI, V113, P123; Willnow TE, 1999, J MOL MED-JMM, V77, P306, DOI 10.1007/s001090050356; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Zhang JC, 1998, J BIOL CHEM, V273, P32273, DOI 10.1074/jbc.273.48.32273; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	42	105	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28889	28896		10.1074/jbc.M102727200	http://dx.doi.org/10.1074/jbc.M102727200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384978	hybrid			2022-12-27	WOS:000170346000035
J	Samuel, BU; Mohandas, N; Harrison, T; McManus, H; Rosse, W; Reid, M; Haldar, K				Samuel, BU; Mohandas, N; Harrison, T; McManus, H; Rosse, W; Reid, M; Haldar, K			The role of cholesterol and glycosylphosphatidylinositol-anchored proteins of erythrocyte rafts in regulating raft protein content and malarial infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE CHOLESTEROL; BETA-CYCLODEXTRIN; CELLS; COMPLEMENT; INVASION; RECEPTOR; CAVEOLAE; MICRODOMAINS; ACTIVATION; TRANSPORT	Human erythrocytes are terminally differentiated, non-endocytic cells that lack all intracellular organelles. Here we show that their plasma membranes contain detergent-resistant membrane rafts that constitute a small fraction (4%) of the total membrane protein, with a complex mixture of proteins that differentially associate with rafts. Depletion of raft-cholesterol abrogates association of all proteins with no significant effect on cholesterol:protein ratios in the rest of the membrane, lipid asymmetry, deformability, or transport properties of the bilayer, indicating that cholesterol is critical for protein assembly into rafts and suggesting that rafts have little influence on several erythrocyte functions. Erythrocytes from patients with paroxysmal nocturnal hemoglobinuria, which lack glycosylphosphatidylinositol-anchored proteins, show significant elevation in raft-cholesterol but no increase in raft protein association, suggesting that raft assembly does not require glycosylphosphatidylinositol-anchored proteins, raft proteins do not bind directly to cholesterol, and only threshold levels of raft-cholesterol are critical for protein recruitment. Loss of glycosylphosphatidylinositol-anchored proteins had no effect on erythrocytic infection by malarial parasite or movement of raft markers into the parasite's vacuole. However, infection is blocked following raft-cholesterol disruption, suggesting that erythrocyte rafts can be functionally exploited and providing the first evidence for the involvement of host rafts in an apicomplexan infection.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Duke Univ, Med Ctr, Dept Med, Div Hematol, Durham, NC 27710 USA; New York Blood Ctr, New York, NY 10021 USA	Northwestern University; Northwestern University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Duke University; New York Blood Center	Haldar, K (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave,Ward 3210, Chicago, IL 60611 USA.	k-haldar@nwu.edu	Haldar, Kasturi/C-6685-2014		NIAID NIH HHS [AI39071] Funding Source: Medline; NIDDK NIH HHS [DK 32094] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; CHASIS JA, 1989, BLOOD, V74, P1112, DOI 10.1182/blood.V74.3.1112.1112; Civenni G, 1998, BLOOD, V91, P1784, DOI 10.1182/blood.V91.5.1784.1784_1784_1792; CLARK MR, 1983, BLOOD, V61, P899, DOI 10.1182/blood.V61.5.899.899; DLUZEWSKI AR, 1985, PARASITOLOGY, V91, P273, DOI 10.1017/S003118200005736X; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; GOCKERMAN JP, 1978, AM J HEMATOL, V5, P323, DOI 10.1002/ajh.2830050407; HADLEY TJ, 1987, J CLIN INVEST, V80, P1190, DOI 10.1172/JCI113178; HALDAR K, 1994, METHOD CELL BIOL, V45, P221; HALDAR K, 1989, J CELL BIOL, V108, P2183, DOI 10.1083/jcb.108.6.2183; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; Holowka D, 2000, J CELL SCI, V113, P1009; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Lauer S, 2000, EMBO J, V19, P3556, DOI 10.1093/emboj/19.14.3556; Lauer SA, 1997, SCIENCE, V276, P1122, DOI 10.1126/science.276.5315.1122; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; MAYER MM, 1972, P NATL ACAD SCI USA, V69, P2954, DOI 10.1073/pnas.69.10.2954; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MOHANDAS N, 1980, BLOOD CELLS, V6, P329; Niculescu F, 1999, IMMUNOPHARMACOLOGY, V42, P187, DOI 10.1016/S0162-3109(99)00014-4; NICULESCU F, 1994, J BIOL CHEM, V269, P4417; Niculescu F, 1997, J IMMUNOL, V158, P4405; Okoyeh JN, 1999, INFECT IMMUN, V67, P5784, DOI 10.1128/IAI.67.11.5784-5791.1999; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; Page E, 1998, AM J PHYSIOL-HEART C, V274, pH1988, DOI 10.1152/ajpheart.1998.274.6.H1988; PASVOL G, 1983, CIBA F SYMP, V94, P174; Rosse WF, 1997, MEDICINE, V76, P63, DOI 10.1097/00005792-199703000-00001; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Schnitzer JE, 1996, AM J PHYSIOL-HEART C, V270, pH416, DOI 10.1152/ajpheart.1996.270.1.H416; SHIN ML, 1978, J IMMUNOL, V120, P1996; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Soubes SC, 1999, VOX SANG, V76, P107, DOI 10.1159/000031029; Stewart GW, 1997, INT J BIOCHEM CELL B, V29, P271, DOI 10.1016/S1357-2725(96)00072-6; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANVIANEN PH, 1993, CYTOMETRY, V14, P276, DOI 10.1002/cyto.990140307; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Verkade P, 1997, HISTOCHEM CELL BIOL, V108, P211, DOI 10.1007/s004180050161; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Wiesner J, 1997, EUR J IMMUNOL, V27, P2708, DOI 10.1002/eji.1830271034; Zager RA, 2000, KIDNEY INT, V58, P193, DOI 10.1046/j.1523-1755.2000.00154.x	49	150	155	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29319	29329		10.1074/jbc.M101268200	http://dx.doi.org/10.1074/jbc.M101268200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11352913	hybrid			2022-12-27	WOS:000170346000092
J	Danishpajooh, IO; Gudi, T; Chen, YC; Kharitonov, VG; Sharma, VS; Boss, GR				Danishpajooh, IO; Gudi, T; Chen, YC; Kharitonov, VG; Sharma, VS; Boss, GR			Nitric oxide inhibits methionine synthase activity in vivo and disrupts carbon flow through the folate pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LYMPHOBLASTS; PURINE SYNTHESIS; COBALAMIN; CELLS; INACTIVATION; REDUCTASE; RAT; NO; HOMOCYSTEINE; DEGRADATION	Many of nitric oxide's biological effects are mediated via NO binding to the iron in heme-containing proteins. Cobalamin (vitamin B-12) is structurally similar to heme and is a cofactor for methionine synthase, a key enzyme in folate metabolism, NO inhibits methionine synthase activity in vitro, but data concerning NO binding to cobalamin are controversial. We now show spectroscopically that NO reacts with all three valency states of cobalamin and that NO's inhibition of methionine synthase activity most likely involves its reaction with monovalent cobalamin, By following incorporation of the methyl moiety of [C-14]methyltetrahydrofolic acid into protein, we show that NO inhibits methionine synthase activity in vivo, in cultured mammalian cells. The inhibition of methionine synthase activity disrupted carbon flow through the folate pathway as measured by decreased incorporation of [C-14]formate into methionine, serine, and purine nucleotides, Homocysteine, but not cysteine, attenuated NO's inhibition of purine synthesis, providing further evidence that NO was acting through methionine synthase inhibition. NO's effect was observed both when NO donors were added to cells and when NO was produced physiologically in co-culture experiments. Treating cells with an MO synthase inhibitor increased formate incorporation into methionine, serine, and purines and methyl-tetrahydrofolate incorporation into protein. Thus, physiological concentrations of NO appear to regulate carbon flaw through the folate pathway.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; SkyePharma Inc, San Diego, CA 92121 USA	University of California System; University of California San Diego	Boss, GR (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32DK07233-24] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABIOR BM, 1995, WILLIAMS HEMATOLOGY; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; Bauer JA, 1998, ANTI-CANCER DRUG, V9, P239, DOI 10.1097/00001813-199803000-00006; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BOSS GR, 1981, J CLIN INVEST, V67, P1659, DOI 10.1172/JCI110202; BOSS GR, 1985, J CLIN INVEST, V76, P213, DOI 10.1172/JCI111948; BOSS GR, 1985, J BIOL CHEM, V260, P6054; BOSS GR, 1984, J CLIN INVEST, V74, P1262, DOI 10.1172/JCI111536; BOSS GR, 1982, J BIOL CHEM, V257, P4242; Brouwer M, 1996, BLOOD, V88, P1857; DEACON R, 1990, BRIT J HAEMATOL, V74, P354, DOI 10.1111/j.1365-2141.1990.tb02595.x; DRUMMOND JT, 1994, BIOCHEMISTRY-US, V33, P3732, DOI 10.1021/bi00178a033; Feinstein DL, 1997, NITRIC OXIDE-BIOL CH, V1, P167, DOI 10.1006/niox.1997.0117; FIRTH RA, 1969, J CHEM SOC A, P381, DOI 10.1039/j19690000381; Fukuyama Y, 1997, BRIT J CANCER, V75, P1125, DOI 10.1038/bjc.1997.194; GIULIDORI P, 1984, J BIOL CHEM, V259, P4205; HALPERN J, 1985, SCIENCE, V227, P869, DOI 10.1126/science.2857503; HERSHFIELD MS, 1977, J BIOL CHEM, V252, P6002; HERSHFIELD MS, 1976, J BIOL CHEM, V251, P7348; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; Ignarro L., 1995, NITRIC OXIDE BIOCH M; KHARITONOV VG, 1996, METHODS NITRIC OXIDE, P40; Kruszyna H, 1998, J PHARMACOL EXP THER, V285, P665; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; LEPOIVRE M, 1992, J BIOL CHEM, V267, P22994; LloydJones DM, 1996, ANNU REV MED, V47, P365; Ludwig ML, 1997, ANNU REV BIOCHEM, V66, P269, DOI 10.1146/annurev.biochem.66.1.269; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Moro MA, 1996, P NATL ACAD SCI USA, V93, P1480, DOI 10.1073/pnas.93.4.1480; Nicolaou A, 1997, EUR J BIOCHEM, V244, P876, DOI 10.1111/j.1432-1033.1997.00876.x; Nicolaou A, 1996, EUR J CLIN INVEST, V26, P167, DOI 10.1046/j.1365-2362.1996.122254.x; PILZ RB, 1984, J BIOL CHEM, V259, P2927; Pollman MJ, 1996, CIRC RES, V79, P748, DOI 10.1161/01.RES.79.4.748; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; ROCHELLE LG, 1995, J PHARMACOL EXP THER, V275, P48; ROSENBLATT DS, 1979, J CLIN INVEST, V63, P1019, DOI 10.1172/JCI109370; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; Scheele JS, 1998, ONCOGENE, V17, P2211, DOI 10.1038/sj.onc.1202137; SCHRAUZER GN, 1971, J AM CHEM SOC, V93, P4060, DOI 10.1021/ja00745a048; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; TRAYLOR TG, 1999, WINTROBES CLIN HEMAT; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507	43	83	85	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27296	27303		10.1074/jbc.M104043200	http://dx.doi.org/10.1074/jbc.M104043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11371572	hybrid			2022-12-27	WOS:000169966900076
J	Lee, S; Russo, DCW; Reiner, AP; Lee, JH; Sy, MY; Telen, MJ; Judd, WJ; Simon, P; Rodrigues, MJ; Chabert, T; Poole, J; Jovanovic-Srzentic, S; Levene, C; Yahalom, V; Redman, CM				Lee, S; Russo, DCW; Reiner, AP; Lee, JH; Sy, MY; Telen, MJ; Judd, WJ; Simon, P; Rodrigues, MJ; Chabert, T; Poole, J; Jovanovic-Srzentic, S; Levene, C; Yahalom, V; Redman, CM			Molecular defects underlying the Kell null phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MCLEOD-SYNDROME GENE; BLOOD-GROUP SYSTEM; ENDOTHELIN-B RECEPTOR; MICE DEFICIENT; MUTATION; XK; ENDOPEPTIDASE-24.11; METALLOPROTEASE; ANTIGENS; PROTEIN	Expression of the Kell blood group system is dependent on two proteins; Kell and XK, that are linked by a single disulfide bond. Kell, a type II membrane glycoprotein, is a zinc endopeptidase, while XX, which has 10 transmembrane domains, is a putative membrane transporter. A rare phenotype termed Kell null (Ko) is characterized by the absence of Kell protein and Kell antigens from the red cell membrane and diminished amounts of XK protein. We determined the molecular basis of eight unrelated persons with Ko phenotypes by sequencing the coding and the intron-exon splice regions of KEL and, in some cases, analysis of mRNA transcripts and expression of mutants on the cell surface of transfected cells. Six subjects were homozygous: four with premature stop codons, one with a 5' splice site mutation, G to A, in intron 3, and one with an amino acid substitution (S676N) in exon 18. Two Ko persons with premature stop codons had identical mutations in exon 4 (R128Stop), another had a different mutation in exon 4 (C83Stop), and the fourth had a stop codon in exon 9 (Q348Stop). Two Ko persons were heterozygous for two mutations. One had a 5' splice site mutation (G to A) in intron 3 of one allele that caused aberrant splicing and exon skipping, and the other allele had an amino acid substitution in exon 10 (S363N). The other heterozygote had the same amino acid substitution in exon 10 (S363N) in one allele and a premature stop codon in exon 6 (R192Stop) in the other allele. The S363N and S676N mutants, expressed in 293T cells, were retained in a pre-Golgi compartment and were not transported to the cell surface, indicating that these mutations inhibit trafficking. We conclude that several different molecular defects cause the Kell null phenotype.	New York Blood Ctr, Lindsley F Kimball Res Inst, 310 E 67th St, New York, NY 10021 USA; Univ Washington, Seattle, WA 98195 USA; Duke Univ, Med Ctr, Durham, NC 27710 USA; Univ Michigan, Med Ctr, Ann Arbor, MI 48109 USA; EFS, St Pierre 97448, Reunion, France; Lisbon Blood Reg Ctr, P-1700 Lisbon, Portugal; Int Blood Grp Reference Lab, Bristol B510 5ND, Avon, England; Natl Blood Transfus Inst, YU-11000 Belgrade, Yugoslavia; Blood Serv Ctr, Ramat Gan, Israel	New York Blood Center; University of Washington; University of Washington Seattle; Duke University; University of Michigan System; University of Michigan	Redman, CM (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, 310 E 67th St, New York, NY 10021 USA.	credman@nybc.org		Telen, Marilyn/0000-0003-3809-1780	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054459] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Carbonnet F, 1997, BRIT J HAEMATOL, V96, P857, DOI 10.1046/j.1365-2141.1997.d01-2110.x; CHABERT T, 2000, VOX SANG S1, V78, P121; Clouthier DE, 1998, DEVELOPMENT, V125, P813; DYALL L, 1999, 6 EUR C INT SOC BLOO, P64; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; GIBLETT ER, 1958, NATURE, V181, P1221, DOI 10.1038/1811221a0; Hanaoka N, 1999, J NEUROL SCI, V165, P6, DOI 10.1016/S0022-510X(99)00028-3; HARDIE RJ, 1989, Q J MED, V71, P291; HO MF, 1994, CELL, V77, P869, DOI 10.1016/0092-8674(94)90136-8; Ho MF, 1996, ANN NEUROL, V39, P672, DOI 10.1002/ana.410390518; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; Jung HH, 2001, ANN NEUROL, V49, P384, DOI 10.1002/ana.76; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; KURIHARA Y, 1995, J CLIN INVEST, V96, P293, DOI 10.1172/JCI118033; LEE S, 1995, BLOOD, V85, P1364, DOI 10.1182/blood.V85.5.1364.bloodjournal8551364; Lee S, 2000, SEMIN HEMATOL, V37, P113, DOI 10.1016/S0037-1963(00)90036-2; Lee S, 1999, BLOOD, V94, P1440, DOI 10.1182/blood.V94.4.1440.416k01_1440_1450; Lee S, 1997, TRANSFUSION, V37, P1117, DOI 10.1046/j.1537-2995.1997.37111298088039.x; Lee S, 1997, VOX SANG, V73, P1, DOI 10.1046/j.1423-0410.1997.7310001.x; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; Lee S, 2000, TRANSFUS MED REV, V14, P93, DOI 10.1016/S0887-7963(00)80001-2; LEE SH, 1995, BLOOD, V85, P912, DOI 10.1182/blood.V85.4.912.bloodjournal854912; MARSH WL, 1990, TRANSFUSION, V30, P158, DOI 10.1046/j.1537-2995.1990.30290162904.x; MASAKI T, 1995, ANNU REV PHARMACOL, V35, P235, DOI 10.1146/annurev.pharmtox.35.1.235; REDMAN CM, 1986, J BIOL CHEM, V261, P9521; REDMAN CM, 1993, SEMIN HEMATOL, V30, P209; Redman CM, 1999, BEST PRACT RES CL HA, V12, P621, DOI 10.1053/beha.1999.0045; ROBBINS PW, 1984, J BIOL CHEM, V259, P7577; ROQUES BP, 1993, PHARMACOL REV, V45, P87; Russo D, 2000, BLOOD, V96, P340, DOI 10.1182/blood.V96.1.340.013k45_340_346; Russo D, 1999, BBA-BIOMEMBRANES, V1461, P10, DOI 10.1016/S0005-2736(99)00148-0; Russo D, 1998, J BIOL CHEM, V273, P13950, DOI 10.1074/jbc.273.22.13950; SHIPP MA, 1991, P NATL ACAD SCI USA, V88, P10662, DOI 10.1073/pnas.88.23.10662; Stanfield GM, 2000, MOL CELL, V5, P423, DOI 10.1016/S1097-2765(00)80437-2; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; Turner AJ, 2000, ADV EXP MED BIOL, V477, P229; Ueyama H, 2000, J NEUROL SCI, V176, P151, DOI 10.1016/S0022-510X(00)00307-5; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; Yanagisawa H, 1998, J CLIN INVEST, V102, P22, DOI 10.1172/JCI2698; Yazdanbakhsh K, 1999, BLOOD, V94, P310, DOI 10.1182/blood.V94.1.310.413k12_310_318; Yu LC, 2001, J BIOL CHEM, V276, P10247, DOI 10.1074/jbc.M009879200	45	57	58	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27281	27289		10.1074/jbc.M103433200	http://dx.doi.org/10.1074/jbc.M103433200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375401	hybrid			2022-12-27	WOS:000169966900074
J	Banerjee, RR; Lazar, MA				Banerjee, RR; Lazar, MA			Dimerization of resistin and resistin-like molecules is determined by a single cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL TREFOIL FACTOR; ACTIVIN-A; GENE	Resistin is a peptide hormone secreted by adipocytes, Cysteine residues comprise 11 of 94 (12%) amino acids in resistin, The arrangement of these cysteines is unique to resistin and its recently discovered family of tissue-specific secreted proteins, which have been independently termed resistin-like molecules (RELMs) and the FIZZ (found in inflammatory zone) family. Here we show that resistin is a disulfide-linked homodimer that can be converted to a monomer by reducing conditions. The intestine-specific RELM beta has similar characteristics. Remarkably, however, the adipose-enriched RELM alpha is a monomer under non-reducing conditions. We note that RELM alpha lacks a cysteine residue, closest to the cleaved N terminus, that is present in resistin and RELM beta in multiple species. Conversion of this cysteine to alanine abolishes dimerization of resistin, Thus, a single disulfide bond is necessary to connect two resistin subunits in a homodimer. The additional 10 cysteines most likely participate in intramolecular disulfide bonds that define the conserved structure of the family members. The monomeric nature of RELM alpha suggests structural and potentially functional divergence between resistin and this close family member.	Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Dept Med, 611 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.		Lazar, Mitchell A/AAF-3738-2019; Banerjee, Ronadip/U-6649-2019		NIDDK NIH HHS [DK50306, DK49780, DK49210, DK19525] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK049210, P30DK019525, R01DK049780, P30DK050306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAWLA A, 1993, J BIOL CHEM, V268, P16265; CHINERY R, 1995, FEBS LETT, V357, P50, DOI 10.1016/0014-5793(94)01297-E; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; Huang EY, 2000, GENE DEV, V14, P45; HUSKENHINDI P, 1994, J BIOL CHEM, V269, P19380; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; Kinoshita K, 2000, MOL CELL BIOL, V20, P4680, DOI 10.1128/MCB.20.13.4680-4690.2000; MASON AJ, 1994, MOL ENDOCRINOL, V8, P325, DOI 10.1210/me.8.3.325; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o; Wittrup K. Dane, 1995, Current Opinion in Biotechnology, V6, P203, DOI 10.1016/0958-1669(95)80033-6	13	110	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25970	25973		10.1074/jbc.M103109200	http://dx.doi.org/10.1074/jbc.M103109200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11358969	hybrid			2022-12-27	WOS:000169823300045
J	Descamps, S; Toillon, RA; Adriaenssens, E; Pawlowski, V; Cool, SM; Nurcombe, V; Le Bourhis, XF; Boilly, B; Peyrat, JP; Hondermarck, H				Descamps, S; Toillon, RA; Adriaenssens, E; Pawlowski, V; Cool, SM; Nurcombe, V; Le Bourhis, XF; Boilly, B; Peyrat, JP; Hondermarck, H			Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FACTOR-LIKE PROTEIN; HUMAN PROSTATE; P75 RECEPTOR; PC12 CELLS; ACTIVATION; NGF; AFFINITY; DEATH; APOPTOSIS	We show here that the neurotrophin nerve growth factor (NGF), which has been shown to be a mitogen for breast cancer cells, also stimulates cell survival through a distinct signaling pathway. Breast cancer cell lines (MCF-7, T47-D, BT-20, and MDA-MB-231) were found to express both types of NGF receptors: p140(trkA) and p75(NTR). The two other tyrosine kinase receptors for neurotrophins, TrkB and TrkC, were not expressed. The mitogenic effect of NGF on breast cancer cells required the tyrosine kinase activity of p140(trkA) as well as the mitogen-activated protein kinase (MAPK) cascade, but was independent of p75(NTR). I, contrast, the anti-apoptotic effect of NGF (studied using the ceramide analogue C2) required p75(NTR) as well as the activation of the transcription factor NF-kB, but neither p140(trkA) nor MAPK was necessary. Other neurotrophins (BDNF, NT-3, NT-4/5) also induced cell survival, although not proliferation, emphasizing the importance of p75(NTR) in NGF-mediated survival. Both the pharmacological NF-KB inhibitor SN50, and cell transfection with IkBm, resulted in a diminution of NGF anti-apoptotic effect. These data show that two distinct signaling pathways are required for NGF activity and confirm the roles played by p75(NTR) and NF-kappaB in the activation of the survival pathway in breast cancer cells.	Univ Sci & Technol Lille, Equipe facteurs Croissance, UPRES EA Biol Dev 1033, F-59655 Villeneuve Dascq, France; Inst Biol, CNRS, UMR 8527, F-59000 Lille, France; Univ Queensland, Dept Anat Sci, St Lucia, Qld 4072, Australia; Ctr Oscar Lambret, Lab Oncol Mol Humaine, F-59020 Lille, France	Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); University of Queensland; UNICANCER; Centre Oscar Lambret	Hondermarck, H (corresponding author), Univ Sci & Technol Lille, Equipe facteurs Croissance, UPRES EA Biol Dev 1033, F-59655 Villeneuve Dascq, France.		Cool, Simon/W-1257-2018; Cool, Simon McKenzie/AAG-4346-2021; Toillon, Robert-Alain/Q-2286-2018; Le+Bourhis, Xuefen/AAL-5141-2021	Cool, Simon/0000-0001-8543-3056; Toillon, Robert-Alain/0000-0001-5483-2118; 				ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; Bhakar AL, 1999, J BIOL CHEM, V274, P21443, DOI 10.1074/jbc.274.30.21443; Carter BD, 1997, NEURON, V18, P187, DOI 10.1016/S0896-6273(00)80259-7; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Casaccia-Bonnefil P, 1998, CELL DEATH DIFFER, V5, P357, DOI 10.1038/sj.cdd.4400377; Chou TT, 2000, J BIOL CHEM, V275, P565, DOI 10.1074/jbc.275.1.565; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; DIMARCO E, 1993, J BIOL CHEM, V268, P22838; DJAKIEW D, 1993, CANCER RES, V53, P1416; DJAKIEW D, 1991, CANCER RES, V51, P3304; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; Foehr ED, 2000, J NEUROSCI, V20, P7556; Frade JM, 1996, NATURE, V383, P166; Friedman WJ, 1999, EXP CELL RES, V253, P131, DOI 10.1006/excr.1999.4705; Gentry JJ, 2000, J BIOL CHEM, V275, P7558, DOI 10.1074/jbc.275.11.7558; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; GRUETERS A, 1985, PEDIATR RES, V19, P934, DOI 10.1203/00006450-198509000-00014; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Le Bourhis X, 2000, BREAST CANCER RES TR, V60, P251, DOI 10.1023/A:1006461621905; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Lievremont JP, 1999, J BIOL CHEM, V274, P15466, DOI 10.1074/jbc.274.22.15466; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; Longo FM, 1997, J NEUROSCI RES, V48, P1, DOI 10.1002/(SICI)1097-4547(19970401)48:1<1::AID-JNR1>3.0.CO;2-K; LOSSING C, 1993, PLAST RECONSTR SURG, V91, P1277, DOI 10.1097/00006534-199306000-00014; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; Pflug B, 1998, MOL CARCINOGEN, V23, P106, DOI 10.1002/(SICI)1098-2744(199810)23:2<106::AID-MC7>3.0.CO;2-W; Pirianov G, 1999, CELL DEATH DIFFER, V6, P890, DOI 10.1038/sj.cdd.4400563; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Rabizadeh S, 1999, CELL DEATH DIFFER, V6, P1222, DOI 10.1038/sj.cdd.4400614; RAKOWICZSZULCZYNSKA EM, 1993, J CELL PHYSIOL, V154, P64, DOI 10.1002/jcp.1041540109; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; Sortino MA, 2000, MOL ENDOCRINOL, V14, P124, DOI 10.1210/me.14.1.124; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821; YAOZHONG L, 1995, J BIOL CHEM, V270, P14255	42	178	191	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17864	17870		10.1074/jbc.M010499200	http://dx.doi.org/10.1074/jbc.M010499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359788	Green Published, hybrid			2022-12-27	WOS:000168866500035
J	Toney, JH; Hammond, GG; Fitzgerald, PMD; Sharma, N; Balkovec, JM; Rouen, GP; Olson, SH; Hammond, ML; Greenlee, ML; Gao, YD				Toney, JH; Hammond, GG; Fitzgerald, PMD; Sharma, N; Balkovec, JM; Rouen, GP; Olson, SH; Hammond, ML; Greenlee, ML; Gao, YD			Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo-beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTEROIDES-FRAGILIS; CRYSTAL-STRUCTURE; PSEUDOMONAS-AERUGINOSA; BIPHENYL TETRAZOLES; SERRATIA-MARCESCENS; CARBOXYPEPTIDASE; DERIVATIVES; RESISTANCE; SERIES; L1	IMP-1 metallo-beta -lactamase (class B) is a plasmid-borne zinc metalloenzyme that efficiently hydrolyzes beta -lactam antibiotics, including carbapenems, rendering them ineffective. Because IMP-1 has been found in several clinically important carbapenem-resistant pathogens, there is a need for inhibitors of this enzyme that could protect broad spectrum antibiotics such as imipenem from hydrolysis and thus extend their utility. We have identified a series of 2,3-(S,S)-disubstituted succinic acids that are potent inhibitors of IMP-1. Determination of high resolution crystal structures and molecular modeling of succinic acid inhibitor complexes with IMP-1 has allowed an understanding of the potency, stereochemistry, and structure-activity relationships of these inhibitors.	Merck Res Labs, Dept Biochem, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA; Merck Res Labs, Dept Mol Syst, Rahway, NJ 07065 USA	Merck & Company; Merck & Company; Merck & Company	Toney, JH (corresponding author), Merck Res Labs, Dept Biochem, Rahway, NJ 07065 USA.	jeff_toney@merck.com	ID, IMCACAT/D-5867-2014					AsanteAppiah E, 1997, BIOCHEMISTRY-US, V36, P8710, DOI 10.1021/bi970354b; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Bush K, 1998, CLIN INFECT DIS, V27, pS48, DOI 10.1086/514922; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P47, DOI 10.1107/S090744499700927X; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P313, DOI 10.1107/S0907444997010627; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; CLISSOLD SP, 1987, DRUGS, V33, P183, DOI 10.2165/00003495-198733030-00001; Concha NO, 1997, PROTEIN SCI, V6, P2671; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Cornaglia G, 1999, LANCET, V353, P899, DOI 10.1016/S0140-6736(98)05954-6; Creighton T.E., 1984, PROTEINS STRUCTURE M; Cricco JA, 1999, COORDIN CHEM REV, V190, P519, DOI 10.1016/S0010-8545(99)00113-7; DELENCASTRE H, 1994, J ANTIMICROB CHEMOTH, V33, P7, DOI 10.1093/jac/33.1.7; DIMODUGNO E, 1999, CURR OPIN ANTIINFECT, V1, P26; Feuston BP, 2001, J CHEM INF COMP SCI, V41, P754, DOI 10.1021/ci000464g; Fitzgerald PMD, 1998, BIOCHEMISTRY-US, V37, P6791, DOI 10.1021/bi9730339; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GILPIN ML, 1995, J ANTIBIOT, V48, P1081, DOI 10.7164/antibiotics.48.1081; Goto M, 1997, BIOL PHARM BULL, V20, P1136, DOI 10.1248/bpb.20.1136; Greenlee ML, 1999, BIOORG MED CHEM LETT, V9, P2549, DOI 10.1016/S0960-894X(99)00425-4; Halgren TA, 1999, J COMPUT CHEM, V20, P730, DOI 10.1002/(SICI)1096-987X(199905)20:7<730::AID-JCC8>3.0.CO;2-T; Hammond GG, 1999, FEMS MICROBIOL LETT, V179, P289, DOI 10.1111/j.1574-6968.1999.tb08740.x; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; Kaminskaia NV, 2000, J AM CHEM SOC, V122, P6411, DOI 10.1021/ja993704l; Koh TH, 1999, LANCET, V353, P2162, DOI 10.1016/S0140-6736(05)75604-X; KROPP H, 1985, REV INFECT DIS, V7, pS389; Laraki N, 1999, ANTIMICROB AGENTS CH, V43, P902, DOI 10.1128/AAC.43.4.902; Lee M, 1999, BIOORGAN MED CHEM, V7, P1755, DOI 10.1016/S0968-0896(99)00110-8; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P262; LIVERMORE DM, 1992, ANTIMICROB AGENTS CH, V36, P2046, DOI 10.1128/AAC.36.9.2046; Livermore DM, 1997, J ANTIMICROB CHEMOTH, V39, P673, DOI 10.1093/jac/39.6.673; Livermore DM, 1998, J ANTIMICROB CHEMOTH, V41, P25, DOI 10.1093/jac/41.suppl_4.25; Livermore DM, 2000, CURR OPIN MICROBIOL, V3, P489, DOI 10.1016/S1369-5274(00)00128-4; Miller MD, 1999, J MED CHEM, V42, P1505, DOI 10.1021/jm9806143; Nagano R, 1999, ANTIMICROB AGENTS CH, V43, P2497, DOI 10.1128/AAC.43.10.2497; OSANO E, 1994, ANTIMICROB AGENTS CH, V38, P71, DOI 10.1128/AAC.38.1.71; Page MI, 1998, CHEM COMMUN, P1609, DOI 10.1039/a803578d; Payne DJ, 1997, FEMS MICROBIOL LETT, V157, P171, DOI 10.1016/S0378-1097(97)00472-2; Payne DJ, 1997, ANTIMICROB AGENTS CH, V41, P135, DOI 10.1128/AAC.41.1.135; Payne DJ, 2000, EXPERT OPIN INV DRUG, V9, P247, DOI 10.1517/13543784.9.2.247; Rasmussen BA, 1997, ANTIMICROB AGENTS CH, V41, P223, DOI 10.1128/AAC.41.2.223; Scrofani SDB, 1999, BIOCHEMISTRY-US, V38, P14507, DOI 10.1021/bi990986t; Senda K, 1996, J CLIN MICROBIOL, V34, P2909, DOI 10.1128/JCM.34.12.2909-2913.1996; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Toney JH, 1998, CHEM BIOL, V5, P185, DOI 10.1016/S1074-5521(98)90632-9; Toney JH, 1999, BIOORG MED CHEM LETT, V9, P2741, DOI 10.1016/S0960-894X(99)00458-8; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Walter MW, 1999, BIOORG CHEM, V27, P35, DOI 10.1006/bioo.1998.1111; Walter MW, 1996, BIOORG MED CHEM LETT, V6, P2455, DOI 10.1016/0960-894X(96)00453-2; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; WATANABE M, 1991, ANTIMICROB AGENTS CH, V35, P147, DOI 10.1128/AAC.35.1.147; Wong KK, 1998, ADV EXP MED BIOL, V456, P197; Yang KW, 1999, ARCH BIOCHEM BIOPHYS, V368, P1, DOI 10.1006/abbi.1999.1293	57	167	174	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31913	31918		10.1074/jbc.M104742200	http://dx.doi.org/10.1074/jbc.M104742200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11390410	hybrid			2022-12-27	WOS:000170613500062
J	De Crescenzo, G; Grothe, S; Zwaagstra, J; Tsang, M; O'Connor-McCourt, MD				De Crescenzo, G; Grothe, S; Zwaagstra, J; Tsang, M; O'Connor-McCourt, MD			Real-time monitoring of the interactions of transforming growth factor-beta (TGF-beta) isoforms with latency-associated protein and the ectodomains of the TGF-beta type II and III receptors reveals different kinetic models and stoichiometries of binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; FACTOR (TGF)-BETA RECEPTOR; LIGAND-BINDING; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; CONFORMATIONAL CHANGE; COMPLEX; GROWTH-FACTOR-BETA-1; BETAGLYCAN; MEMBRANE	Mature transforming growth factor-beta (TGF-beta) is proteolytically derived from the C terminus of a precursor protein. Latency-associated protein (LAP), the N-terminal remnant of the TGF-beta precursor, is able to bind and neutralize TGF-beta. Mature TGF-beta exerts its activity by binding and complexing members of two subfamilies of receptors, the type I and II receptors. In addition to these signaling receptors, TGF-beta can also interact with an accessory receptor termed the type III receptor. Using a surface plasmon resonance-based biosensor (BIAcore), we determined the mechanisms of interaction of four binding proteins (LAP, the type II and III receptor ectodomains (EDs), and a type II receptor ED/Fc chimera) with three TGF-beta isoforms, and we quantified their related kinetic parameters. Using global fitting based on a numerical integration data analysis method, we demonstrated that LAP and the type II receptor/Fc chimera interacted with the TGF-beta isoforms with a 1:1 stoichiometry. In contrast, the type II ED interactions with TGF-beta were best fit by a kinetic model assuming the presence of two independent binding sites on the ligand molecule. We also showed that the type III ED bound two TGF-beta molecules. Further experiments revealed that LAP was able to block the interactions of TGF-beta with the two EDs, but that the two EDs did not compete or cooperate with each other. Together, these results strongly support the existence of a cell-surface complex consisting of one type III receptor, two TGF-beta molecules, and four type II receptors, prior to the recruitment of the type I receptor for signal transduction. Additionally, our results indicate that the apparent dissociation rate constants are more predictive of the neutralizing potency of these TGF-beta -binding proteins (LAP, the type II and III receptor EDs, and the type II receptor/Fc chimera) than the apparent equilibrium constants.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; R&D Syst, Minneapolis, MN USA	National Research Council Canada	O'Connor-McCourt, MD (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 RoyalMount Ave, Montreal, PQ H4P 2R2, Canada.							ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Bailly S, 1997, J BIOL CHEM, V272, P16329, DOI 10.1074/jbc.272.26.16329; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; BRADLEY JV, 1968, DISTRIBUTION FREE ST, P251; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; De Crescenzo G, 2000, BIOCHEMISTRY-US, V39, P9466, DOI 10.1021/bi992987r; Deng XB, 1999, CELL GROWTH DIFFER, V10, P11; Fisher Robert J., 1994, Current Opinion in Biotechnology, V5, P389, DOI 10.1016/0958-1669(94)90047-7; Fivash M, 1998, CURR OPIN BIOTECH, V9, P97, DOI 10.1016/S0958-1669(98)80091-8; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Kaname S, 1996, BIOCHEM J, V315, P815, DOI 10.1042/bj3150815; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Komesli S, 1998, EUR J BIOCHEM, V254, P505, DOI 10.1046/j.1432-1327.1998.2540505.x; Letourneur O, 1996, BIOCHEM BIOPH RES CO, V224, P709, DOI 10.1006/bbrc.1996.1088; LIN HY, 1995, J BIOL CHEM, V270, P2747, DOI 10.1074/jbc.270.6.2747; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Matsuzaki K, 1996, IN VITRO CELL DEV-AN, V32, P345, DOI 10.1007/BF02722961; McMahon GA, 1996, BIOCHEM J, V313, P343, DOI 10.1042/bj3130343; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; MORTON TA, 1995, ANAL BIOCHEM, V227, P176, DOI 10.1006/abio.1995.1268; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; Muller KM, 1998, ANAL BIOCHEM, V261, P149, DOI 10.1006/abio.1998.2725; O'Connor-McCourt M., 1998, QUANTITATIVE ANAL BI, P175; OConnorMcCourt MD, 1995, ANN NY ACAD SCI, V766, P300, DOI 10.1111/j.1749-6632.1995.tb26682.x; OShannessy DJ, 1996, ANAL BIOCHEM, V236, P275, DOI 10.1006/abio.1996.0167; Padgett RW, 1998, BIOESSAYS, V20, P382, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;382::AID-BIES5&gt;3.0.CO;2-Q; Pepin MC, 1995, FEBS LETT, V377, P368, DOI 10.1016/0014-5793(95)01378-4; PEPIN MC, 1994, P NATL ACAD SCI USA, V91, P6997, DOI 10.1073/pnas.91.15.6997; Philip A, 1999, EUR J BIOCHEM, V261, P618, DOI 10.1046/j.1432-1327.1999.00298.x; PRESS WH, 1986, NUMERICAL RECIPES AR; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; Taniguchi A, 1998, IN VITRO CELL DEV-AN, V34, P232; TSANG MLS, 1995, CYTOKINE, V7, P389, DOI 10.1006/cyto.1995.0054; WAHL SM, 1989, IMMUNOL TODAY, V10, P258, DOI 10.1016/0167-5699(89)90136-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zwaagstra JC, 1999, EXP CELL RES, V252, P352, DOI 10.1006/excr.1999.4640	45	79	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29632	29643		10.1074/jbc.M009765200	http://dx.doi.org/10.1074/jbc.M009765200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11382746	hybrid			2022-12-27	WOS:000170558000007
J	Kamura, T; Burian, D; Yan, Q; Schmidt, SL; Lane, WS; Querido, E; Branton, PE; Shilatifard, A; Conaway, RC; Conaway, JW				Kamura, T; Burian, D; Yan, Q; Schmidt, SL; Lane, WS; Querido, E; Branton, PE; Shilatifard, A; Conaway, RC; Conaway, JW			MUF1, a novel Elongin BC-interacting leucine-rich repeat protein that can assemble with Cul5 and Rbx1 to reconstitute a ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; RNA-POLYMERASE-II; SOCS-BOX MOTIF; DEPENDENT PROTEOLYSIS; GENE FAMILY; COMPLEX; ELONGATION; BINDING; DOMAIN; SCF	The heterodimeric. Elongin BC complex has been shown to interact in vitro and in mammalian cells with a conserved BC-box motif found in a growing number of proteins including RNA polymerase Il elongation factor Elongin A, SOCS-box proteins, and the von Hippel-Lindau (VHL) tumor suppressor protein. Recently, the VHL-EIongin BC complex was found to interact with a module composed of Cullin family member Cul2 and RING-H2 finger protein Rbx1 to reconstitute a novel E3 ubiquitin ligase that activates ubiquitylation by the E2 ubiquitin-conjugating enzymes Ubc5 and Cdc34. In the context of: the VEL ubiquitin ligase, Elongin BC functions as an adaptor that links the VHL protein to the CuI2/Rbx1 module, raising the possibility that the Elongin BC complex could function as an integral component of a larger family of E3 ubiquitin ligases by linking alternative BC-box proteins to Cullin/Rbx1 modules. In this report, we describe identification and purification from rat liver of a novel leucine-rich repeat-containing BO-box protein, MUF1, which we demonstrate is capable of assembling, with a Cullin/Rbx1 module containing the Cullin family member Cul5 to reconstitute ubiquitin ligase activity. In addition, we show that the additional BC-box, proteins Elongin A, SOCS1, and WSB1 are also capable of assembling with the Cul5/Rbx1. module to reconstitute potential ubiquitin ligases. Taken together, our findings identify MUF1 as a new member of the BO-box family of proteins, and they predict the existence of a larger family of Elongin BC-based E3 ubiquitin ligases.	Oklahoma Med Res Fdn, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem, St Louis, MO 63104 USA; Harvard Univ, Harvard Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Saint Louis University; Harvard University; McGill University; McGill University	Conaway, JW (corresponding author), Oklahoma Med Res Fdn, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA.	jlc@stowers-institute.org	Yan, Qin/E-8893-2012	Yan, Qin/0000-0003-4077-453X; Querido, Emmanuelle/0000-0002-8027-3732; Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [R37GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; Burnatowska-Hledin M, 2000, AM J PHYSIOL-CELL PH, V279, pC266, DOI 10.1152/ajpcell.2000.279.1.C266; BURNATOWSKAHLEDIN MA, 1995, AM J PHYSIOL-RENAL, V268, pF1198, DOI 10.1152/ajprenal.1995.268.6.F1198; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Conaway RC, 1996, METHOD ENZYMOL, V273, P194; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P16528, DOI 10.1074/jbc.M010142200; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	38	125	142	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29748	29753		10.1074/jbc.M103093200	http://dx.doi.org/10.1074/jbc.M103093200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11384984	hybrid			2022-12-27	WOS:000170558000021
J	Makiniemi, M; Hillukkala, T; Tuusa, J; Reini, K; Vaara, M; Huang, DQ; Pospiech, H; Majuri, I; Westerling, T; Makela, TP; Syvaoja, JE				Makiniemi, M; Hillukkala, T; Tuusa, J; Reini, K; Vaara, M; Huang, DQ; Pospiech, H; Majuri, I; Westerling, T; Makela, TP; Syvaoja, JE			BRCT domain-containing protein TopBP1 functions in DNA replication and damage response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; S-PHASE CHECKPOINT; CELL-CYCLE CHECKPOINT; POLYMERASE-EPSILON; FISSION YEAST; DROSOPHILA-MELANOGASTER; CHROMOSOMAL REPLICATION; CONSERVED DOMAINS; MOLECULAR-CLONING; CATALYTIC SUBUNIT	Topoisomerase II beta -binding protein (TopBP1), a human protein with eight BRCT domains, is similar to Saccharomyces cerevisiae Dpb11 and Schizosaccharomyces pombe Cut5 checkpoint proteins and closely related to Drosophila Mus101. We show that human TopBP1 is required for DNA replication and that it interacts with DNA polymerase epsilon. In S phase TopBP1 colocalizes with Brca1 to foci that do not represent sites of ongoing DNA replication. Inhibition of DNA synthesis leads to relocalization of TopBP1 together with Brca1 to replication forks, suggesting a role in rescue of stalled forks. DNA damage induces formation of distinct TopBP1 foci that colocalize with Brca1 in S phase, but not in Gi phase. We also show that TopBP1 interacts with the checkpoint protein hRad9. Thus, these results implicate TopBP1 in replication and checkpoint functions.	Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Univ Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Diagnost Lab, FIN-00014 Helsinki, Finland; Univ Joensuu, Dept Biol, FIN-80101 Joensuu, Finland	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Eastern Finland	Syvaoja, JE (corresponding author), Univ Oulu, Bioctr Oulu, POB 3000, FIN-90014 Oulu, Finland.	Juhani.Syvaoja@oulu.fi	Pospiech, Helmut/J-8598-2015; makela, tomi/B-3734-2009	makela, tomi/0000-0002-4869-8044; Westerling, Thomas/0000-0001-8537-6493; Reini, Kaarina/0000-0003-1039-8289				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; BOYD JB, 1976, GENETICS, V84, P507; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURKE JD, 1994, MOL GEN GENET, V242, P169, DOI 10.1007/BF00391010; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DUrso G, 1997, P NATL ACAD SCI USA, V94, P12491, DOI 10.1073/pnas.94.23.12491; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GATTI M, 1983, SCIENCE, V221, P83, DOI 10.1126/science.6407113; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; Henderson DS, 1999, METHODS, V18, P377, DOI 10.1006/meth.1999.0797; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Jokela M, 1998, NUCLEIC ACIDS RES, V26, P730, DOI 10.1093/nar/26.3.730; Kamimura Y, 1998, MOL CELL BIOL, V18, P6102, DOI 10.1128/MCB.18.10.6102; KESTI T, 1993, J BIOL CHEM, V268, P10238; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li Y, 1997, J BIOL CHEM, V272, P32337, DOI 10.1074/jbc.272.51.32337; Li Y, 2000, J BIOL CHEM, V275, P23247, DOI 10.1074/jbc.M002548200; Masumoto H, 2000, MOL CELL BIOL, V20, P2809, DOI 10.1128/MCB.20.8.2809-2817.2000; McFarlane RJ, 1997, MOL GEN GENET, V255, P332, DOI 10.1007/s004380050504; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Pospiech H, 1999, NUCLEIC ACIDS RES, V27, P3799, DOI 10.1093/nar/27.19.3799; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; SAKA Y, 1994, EMBO J, V13, P5319, DOI 10.1002/j.1460-2075.1994.tb06866.x; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SMITH DA, 1985, GENETICS, V110, P647; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; TANAKA S, 1982, J BIOL CHEM, V257, P8386; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; TUUSA J, 1995, NUCLEIC ACIDS RES, V23, P2178, DOI 10.1093/nar/23.12.2178; UITTO L, 1995, NUCLEIC ACIDS RES, V23, P244, DOI 10.1093/nar/23.2.244; Verkade HM, 1998, MOL GEN GENET, V260, P426, DOI 10.1007/s004380050913; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wang H, 1999, P NATL ACAD SCI USA, V96, P3824, DOI 10.1073/pnas.96.7.3824; Wang Y, 2000, GENE DEV, V14, P927; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; XU HP, 1990, CELL REGUL, V1, P763, DOI 10.1091/mbc.1.10.763; Yamamoto RR, 2000, GENETICS, V156, P711; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x; Yamane K, 1999, ONCOGENE, V18, P5194, DOI 10.1038/sj.onc.1202922; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	59	176	180	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30399	30406		10.1074/jbc.M102245200	http://dx.doi.org/10.1074/jbc.M102245200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395493	hybrid			2022-12-27	WOS:000170558000104
J	Arnaudeau, S; Kelley, WL; Walsh, JV; Demaurex, N				Arnaudeau, S; Kelley, WL; Walsh, JV; Demaurex, N			Mitochondria recycle Ca2+ to the endoplasmic reticulum and prevent the depletion of neighboring endoplasmic reticulum regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTACT HELA-CELLS; CALCIUM OSCILLATIONS; GENE-EXPRESSION; INOSITOL TRISPHOSPHATE; RECOMBINANT AEQUORIN; TARGETED AEQUORIN; RELEASE; STORES; HOMEOSTASIS; WAVES	To study Ca2+ fluxes between mitochondria and the endoplasmic reticulum (ER), we used "cameleon" indicators targeted to the cytosol, the ER lumen, and the mitochondrial matrix. High affinity mitochondrial probes saturated in similar to 20% of mitochondria during histamine stimulation of HeLa cells, whereas a low affinity probe reported averaged peak values of 106 +/- 5 muM, indicating that Ca2+ transients reach high levels in a fraction of mitochondria. In concurrent ER measurements, [Ca2+](ER) averaged 371 +/- 21 muM: at rest and decreased to 133 +/- 14 muM and 59 +/- 5 muM upon stimulation with histamine and thapsigargin, respectively, indicating that substantial ER refilling occur during agonist stimulation. A larger ER depletion was observed when mitochondrial Ca2+ uptake was prevented by oligomycin and rotenone or when Ca2+ efflux from mitochondria was blocked by CGP 37157, indicating that some of the Ca2+ taken up by mitochondria is re-used for ER refilling. Accordingly, ER regions close to mitochondria released less Ca2+ than ER regions lacking mitochondria. The ER heterogeneity was abolished by thapsigargin, oligomycin/rotenone, or CGP 37157, indicating that mitochondrial Ca2+ uptake locally modulate ER refilling. These observations indicate that some mitochondria are very close to the sites of Ca2+ release and recycle a substantial portion of the captured Ca2+ back to vicinal ER domains. The distance between the two organelles thus determines both the amplitude of mitochondrial Ca2+ signals and the filling state of neighboring ER regions.	Univ Geneva, Dept Physiol, CH-1211 Geneva 4, Switzerland; Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva, Switzerland; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01605 USA	University of Geneva; University of Geneva; University of Massachusetts System; University of Massachusetts Worcester				Demaurex, Nicolas/0000-0002-9933-6772	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061297] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61297] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alonso MT, 1999, J CELL BIOL, V144, P241, DOI 10.1083/jcb.144.2.241; Babcock DF, 1998, CURR OPIN NEUROBIOL, V8, P398, DOI 10.1016/S0959-4388(98)80067-6; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; Berridge M, 1999, CURR BIOL, V9, pR157, DOI 10.1016/S0960-9822(99)80101-8; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; Button D, 1996, MOL BIOL CELL, V7, P419, DOI 10.1091/mbc.7.3.419; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Emmanouilidou E, 1999, CURR BIOL, V9, P915, DOI 10.1016/S0960-9822(99)80398-4; Fan GY, 1999, BIOPHYS J, V76, P2412, DOI 10.1016/S0006-3495(99)77396-0; FULCERI R, 1991, CELL CALCIUM, V12, P431, DOI 10.1016/0143-4160(91)90069-Q; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Gurney AM, 2000, CELL CALCIUM, V27, P339, DOI 10.1054/ceca.2000.0124; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HIROSE K, 1994, NATURE, V372, P791; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Kaftan EJ, 2000, J BIOL CHEM, V275, P25465, DOI 10.1074/jbc.M000903200; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MOHR FC, 1990, AM J PHYSIOL, V258, pC217, DOI 10.1152/ajpcell.1990.258.2.C217; Montero M, 1997, FASEB J, V11, P881, DOI 10.1096/fasebj.11.11.9285486; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Park MK, 2000, EMBO J, V19, P5729, DOI 10.1093/emboj/19.21.5729; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, CYTOTECHNOLOGY, V11, P44; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RIZZUTO R, 1994, METHOD CELL BIOL, V40, P339; Rutter GA, 2000, TRENDS BIOCHEM SCI, V25, P215, DOI 10.1016/S0968-0004(00)01585-1; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; Simpson PB, 1996, J BIOL CHEM, V271, P33493, DOI 10.1074/jbc.271.52.33493; Simpson PB, 1997, J BIOL CHEM, V272, P22654, DOI 10.1074/jbc.272.36.22654; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; TSE A, 1994, J PHYSIOL-LONDON, V477, P511, DOI 10.1113/jphysiol.1994.sp020212; Wu MM, 2000, CHEM BIOL, V7, P197, DOI 10.1016/S1074-5521(00)00088-0; Yu R, 2000, J BIOL CHEM, V275, P23648, DOI 10.1074/jbc.M002684200	58	215	217	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29430	29439		10.1074/jbc.M103274200	http://dx.doi.org/10.1074/jbc.M103274200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11358971	Green Published, hybrid			2022-12-27	WOS:000170346000105
J	Hsu, HY; Chiu, SL; Wen, MH; Chen, KY; Hua, KF				Hsu, HY; Chiu, SL; Wen, MH; Chen, KY; Hua, KF			Ligands of macrophage scavenger receptor induce cytokine expression via differential modulation of protein kinase signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TUMOR-NECROSIS-FACTOR; C-JUN; FACTOR-ALPHA; ATHEROSCLEROTIC LESIONS; CHOLESTEROL DEPOSITION; MOLECULAR-CLONING; ACTIVATION DOMAIN; COMPLEX-FORMATION; GENE-EXPRESSION	Our previous works demonstrated that ligands of macrophage scavenger receptor (MSR) induce protein kinases (PKs) including protein-tyrosine kinase (PTK) and up-regulate urokinase-type plasminogen activator expression (Hsu, H. Y., Hajjar, D. P., Khan, K. M., and Falcone, D. J. (1998) J. Biol. Chem. 273, 1240-1246). To continue to investigate MSR ligand-mediated signal transductions, we focus on ligands, oxidized low density lipoprotein (OxLDL), and fucoidan induction of the cytokines tumor necrosis factor-a (TNF) and interleukin 1 beta (IL-1). In brief, in murine macrophages J774A.1, OxLDL and fucoidan up-regulate TNF production; additionally, fucoidan but not OxLDL induces IL-1 secretion, prointerleukin 1 (proIL-1, precursor of IL-1) protein, and proIL-1 message. Simultaneously, fucoidan stimulates activity of interleukin 1-converting enzyme. We further investigate the molecular mechanism by which ligand binding-induced PK-mediated mitogen-activated protein kinase (MAPK) in regulation of expression of proIL-1 and IL-1. Specifically, fucoidan stimulates activity of p21-activated kinase (PAK) and of the MAPKs extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38. Combined with PK inhibitors and genetic mutants of Rac1 and JNK in PK activity assays, Western blotting analyses, and IL-1 enzyme-linked immunosorbent assay, the role of individual PKs in the regulation of proIL-1/IL-1 was extensively dissected. Moreover, tyrosine phosphorylation of pp60Src as well as association between pp60Src and Hsp90 play important roles in fucoidan-induced prolL-1 expression. We are the first to establish two fucoidanmediated signaling pathways: PTK(Src)/Rac1/PAK/JNK and PTK(Src)/Rac1/PAK/p38, but not PTK/phospholipase C-gamma1/PKC/MEK1/ERK, playing critical roles in proIL-1/IL-1 regulation. Our current results indicate and suggest a model for MSR ligands differentially modulating specific PK signal transduction pathways, which regulate atherogenesis-related inflammatory cytokines TNF and IL-1.	Natl Yang Ming Univ, Inst Biotechnol Med, Fac Med Technol, Taipei 112, Taiwan; Natl Hlth Adm, Natl Lab Foods & Drugs, Taipei 115, Taiwan	National Yang Ming Chiao Tung University	Hsu, HY (corresponding author), Natl Yang Ming Univ, Inst Biotechnol Med, Fac Med Technol, 155 Li Nong St, Taipei 112, Taiwan.	hyhsu@ym.edu.tw						ACTON S, 1993, J BIOL CHEM, V268, P3530; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ASHKENAS J, 1993, J LIPID RES, V34, P983; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chan ED, 1999, J IMMUNOL, V162, P415; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOI T, 1993, J BIOL CHEM, V268, P2126; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FALCONE DJ, 1988, J CELL PHYSIOL, V135, P387, DOI 10.1002/jcp.1041350305; FALCONE DJ, 1991, J BIOL CHEM, V266, P22726; Fong LG, 1999, J BIOL CHEM, V274, P36808, DOI 10.1074/jbc.274.51.36808; Fong LG, 1996, J LIPID RES, V37, P574; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; GENG YJ, 1995, AM J PATHOL, V147, P251; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAMILTON TA, 1995, J CLIN INVEST, V95, P2020, DOI 10.1172/JCI117887; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Hsu HY, 1998, J BIOL CHEM, V273, P1240, DOI 10.1074/jbc.273.2.1240; Hsu HY, 1996, J BIOL CHEM, V271, P7767, DOI 10.1074/jbc.271.13.7767; Hsu HY, 2000, J BIOL CHEM, V275, P41035, DOI 10.1074/jbc.M003464200; Jovinge S, 1996, ARTERIOSCL THROM VAS, V16, P1573, DOI 10.1161/01.ATV.16.12.1573; KAKAR SS, 1994, CANCER LETT, V87, P85, DOI 10.1016/0304-3835(94)90413-8; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Li YS, 1996, MOL CELL BIOL, V16, P5947; Lin JK, 1997, J CELL BIOCHEM, P39; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Mallat Z, 1997, CIRCULATION, V96, P424; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOULTON KS, 1992, P NATL ACAD SCI USA, V89, P8102, DOI 10.1073/pnas.89.17.8102; NAITO M, 1992, AM J PATHOL, V141, P591; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; OKADA T, 1994, J BIOL CHEM, V269, P3563; OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391; PALKAMA T, 1991, IMMUNOLOGY, V74, P432; PARTHASARATHY S, 1987, P NATL ACAD SCI USA, V84, P537, DOI 10.1073/pnas.84.2.537; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; RESNICK D, 1993, J BIOL CHEM, V268, P3538; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sakaguchi H, 1998, LAB INVEST, V78, P423; Sano H, 1999, MECH AGEING DEV, V107, P333, DOI 10.1016/S0047-6374(99)00011-1; Schreyer SA, 1996, J BIOL CHEM, V271, P26174, DOI 10.1074/jbc.271.42.26174; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TIPPING PG, 1993, AM J PATHOL, V142, P1721; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831	66	146	156	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28719	28730		10.1074/jbc.M011117200	http://dx.doi.org/10.1074/jbc.M011117200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390374	hybrid			2022-12-27	WOS:000170346000012
J	Ketchum, CJ; Schmidt, WK; Rajendrakumar, GV; Michaelis, S; Maloney, PC				Ketchum, CJ; Schmidt, WK; Rajendrakumar, GV; Michaelis, S; Maloney, PC			The yeast a-factor transporter Ste6p, a member of the ABC superfamily, couples ATP hydrolysis to pheromone export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; CYSTIC-FIBROSIS GENE; SACCHAROMYCES-CEREVISIAE; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; ESCHERICHIA-COLI; MALTOSE TRANSPORT; STIMULATED ATPASE; BINDING PROTEINS; DRUG	ATP-binding cassette (ABC) proteins transport a diverse collection of substrates. It is presumed that these proteins couple ATP hydrolysis to substrate transport, yet ATPase activity has been demonstrated for only a few. To provide direct evidence for such activity in Ste6p, the yeast ABC protein required for the export of a-factor mating pheromone, we established conditions for purification of Ste6p in biochemical quantities from both yeast and Sf9 insect cells. The basal ATPase activity of purified and reconstituted Ste6p (V-max = 18 nmol/ mg/min; K-m for MgATP = 0.2 mm) compares favorably with several other ABC proteins and was inhibited by orthovanadate in a profile diagnostic of ABC transporters (apparent K-I = 12 mum). Modest stimulation (similar to 40%) was observed upon the addition of a-factor either synthetic or in native form. We also used an S-azido[alpha- P-32]ATP binding and vanadate-trapping assay to examine the behavior of wild-type Ste6p and two different double mutants (G392V/G1087V and G509D/G11931)) shown previously to be mating-deficient in vivo. Both mutants displayed a diminished ability to hydrolyze ATP, with the latter uncoupled from pheromone transport. We conclude that Ste6p catalyzes ATP hydrolysis coupled to a-factor transport, which in turn promotes mating.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Maloney, PC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009995, R01DK058029, P50DK048977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051508] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 F32 DK09995-01, DK58029, DK48977] Funding Source: Medline; NIGMS NIH HHS [GM51508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P9083; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; BERKOWER C, 1996, MEMBRANE PROTEIN TRA, P231; BERKOWER C, 1993, MOL BIOL FUNCTION CA, P130; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BOEKE JD, 1987, METHOD ENZYMOL, V152, P481; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; DEAN DA, 1989, P NATL ACAD SCI USA, V86, P9134, DOI 10.1073/pnas.86.23.9134; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Fann MC, 1998, J BIOL CHEM, V273, P33735, DOI 10.1074/jbc.273.50.33735; Fu DX, 2001, J BIOL CHEM, V276, P8753, DOI 10.1074/jbc.M008417200; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Hagmann W, 1999, EUR J BIOCHEM, V265, P281, DOI 10.1046/j.1432-1327.1999.00735.x; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KIOKA N, 1989, BIOCHEM BIOPH RES CO, V162, P224, DOI 10.1016/0006-291X(89)91985-2; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Loayza D, 1998, MOL CELL BIOL, V18, P779, DOI 10.1128/MCB.18.2.779; Loayza D, 1998, MOL BIOL CELL, V9, P2767, DOI 10.1091/mbc.9.10.2767; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; Mao QC, 1999, BBA-BIOMEMBRANES, V1461, P69, DOI 10.1016/S0005-2736(99)00150-9; Mao QC, 1997, BBA-BIOMEMBRANES, V1327, P107, DOI 10.1016/S0005-2736(97)00050-3; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Rao US, 1998, BIOCHEMISTRY-US, V37, P14981, DOI 10.1021/bi980072r; RIORDAN JR, 1989, SCIENCE, V245, P1066; Romano JD, 1998, MOL BIOL CELL, V9, P2231, DOI 10.1091/mbc.9.8.2231; Sambrook J., 2002, MOL CLONING LAB MANU; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	53	33	34	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29007	29011		10.1074/jbc.M100810200	http://dx.doi.org/10.1074/jbc.M100810200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11389139	hybrid			2022-12-27	WOS:000170346000051
J	Li, LT; Chen, OS; Ward, DM; Kaplan, J				Li, LT; Chen, OS; Ward, DM; Kaplan, J			CCC1 is a transporter that mediates vacuolar iron storage in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE ENCODES; MITOCHONDRIAL; MEMBRANE; OXIDASE; MUTANTS; ACCUMULATION; ENDOCYTOSIS; DISRUPTION; EXPRESSION	The budding yeast Saccharomyces cerevisiae can grow for generations in the absence of exogenous iron, indicating a capacity to store intracellular iron. As cells can accumulate iron by endocytosis we studied iron metabolism in yeast that were defective in endocytosis. We demonstrated that endocytosis-defective yeast (Delta end4) can store iron in the vacuole, indicating a transfer of iron from the cytosol to the vacuole. Using several different criteria we demonstrated that CCC1 encodes a transporter that effects the accumulation of iron and Mn2+ in vacuoles. Overexpression of CCC1, which is localized to the vacuole, lowers cytosolic iron and increases vacuolar iron content. Conversely, deletion of CCC1 results in decreased vacuolar iron content and decreased iron stores, which affect cytosolic iron levels and cell growth. Furthermore Delta ccc1 cells show increased sensitivity to external iron. The sensitivity to iron is exacerbated by ectopic expression of the iron transporter FET4. These results indicate that yeast can store iron in the vacuole and that CCC1 is involved in the transfer of iron from the cytosol to the vacuole.	Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030534, R01DK030534] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-5238, DK-30534] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBERG DC, 1995, YEAST, V11, P1275, DOI 10.1002/yea.320111307; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BODE HP, 1995, EUR J BIOCHEM, V228, P337; Chen OS, 2000, J BIOL CHEM, V275, P7626, DOI 10.1074/jbc.275.11.7626; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; DIX DR, 1994, J BIOL CHEM, V269, P26092; EIDE D, 1992, J BIOL CHEM, V267, P20774; FU DD, 1994, YEAST, V10, P515, DOI 10.1002/yea.320100411; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Lapinskas PJ, 1996, MOL MICROBIOL, V21, P519, DOI 10.1111/j.1365-2958.1996.tb02561.x; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Li LT, 2001, J BIOL CHEM, V276, P5036, DOI 10.1074/jbc.M008969200; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; Sambrook J., 2002, MOL CLONING LAB MANU; SHERMAN F, 1989, METHODS YEAST GENETI; Spizzo T, 1997, MOL GEN GENET, V256, P547; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Szczypka MS, 1997, YEAST, V13, P1423, DOI 10.1002/(SICI)1097-0061(199712)13:15<1423::AID-YEA190>3.3.CO;2-3; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x	26	253	269	5	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29515	29519		10.1074/jbc.M103944200	http://dx.doi.org/10.1074/jbc.M103944200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390404	hybrid			2022-12-27	WOS:000170346000115
J	Li, WG; Miller, FJ; Zhang, HJ; Spitz, DR; Oberley, LW; Weintraub, NL				Li, WG; Miller, FJ; Zhang, HJ; Spitz, DR; Oberley, LW; Weintraub, NL			H2O2-induced O-2(radical anion) production by a non-phagocytic NAD(P)H oxidase causes oxidant injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SUPEROXIDE-DISMUTASE; CRITICAL COMPONENT; ANGIOTENSIN-II; APOPTOSIS; H2O2; LUCIGENIN; TOXICITY; RELEASE	Non-phagocytic NAD(P)H oxidases have been implicated as major sources of reactive oxygen species in blood vessels. These oxidases can be activated by cytokines, thereby generating O-2(radical anion), which is subsequently converted to H2O2 and other oxidant species. The oxidants, in turn, act as important second messengers in cell signaling cascades. We hypothesized that reactive oxygen species, themselves, can activate the non-phagocytic NAD(P)H oxidases in vascular cells to induce oxidant production and, consequently, cellular injury. The current report demonstrates that exogenous exposure of non-phagocytic cell types of vascular origin (smooth muscle cells and fibroblasts) to H2O2 activates these cell types to produce O-2* via an NAD(P)H oxidase. The ensuing endogenous production of O-2* contributes significantly to vascular cell injury following exposure to H2O2. These results suggest the existence of a feed-forward mechanism, whereby reactive oxygen species such as H2O2 can activate NAD(P)H oxidases in non-phagocytic cells to produce additional oxidant species, thereby amplifying the vascular injury process. Moreover, these findings implicate the non-phagocytic NAD(P)H oxidase as a novel therapeutic target for the amelioration of the biological effects of chronic oxidant stress.	Univ Iowa, Dept Internal Med, Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Free Rad & Radiat Biol Program, Coll Med, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Weintraub, NL (corresponding author), Univ Iowa, Dept Internal Med, Coll Med, 200 Hawkins Dr,E329-GH, Iowa City, IA 52242 USA.	Neal-weintraub@uiowa.edu	Miller Jr, Francis/N-7312-2015; Miller, Francis J/F-3801-2017	Miller Jr, Francis/0000-0001-5822-0549; Miller, Francis J/0000-0001-5822-0549; Weintraub, Neal/0000-0002-5138-3705; Spitz, Douglas/0000-0002-1254-8765	NCI NIH HHS [P01 CA066081, CA66081] Funding Source: Medline; NHLBI NIH HHS [R01 HL51469, K08 HL003669-05, HL49264, P01 HL062984, R01 HL051469, K08 HL003669-03, K08 HL003669-04, HL62984] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066081] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264, R01HL051469, P01HL062984, K08HL003669] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; Brown MR, 1999, CIRC RES, V85, P524, DOI 10.1161/01.RES.85.6.524; Cane A, 1998, AM J PHYSIOL-CELL PH, V274, pC1040, DOI 10.1152/ajpcell.1998.274.4.C1040; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; Carlsson LM, 1996, P NATL ACAD SCI USA, V93, P5219, DOI 10.1073/pnas.93.11.5219; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P479, DOI 10.1016/0891-5849(94)00166-H; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Fridovich I, 1998, J EXP BIOL, V201, P1203; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HIRAISHI H, 1992, J BIOL CHEM, V267, P14812; Hoyt KR, 1997, NEUROCHEM RES, V22, P333, DOI 10.1023/A:1022403224901; Hu QH, 1998, CIRCULATION, V97, P268, DOI 10.1161/01.CIR.97.3.268; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; Li PF, 1997, FEBS LETT, V404, P249, DOI 10.1016/S0014-5793(97)00093-8; Li WG, 2000, ARTERIOSCL THROM VAS, V20, P1473, DOI 10.1161/01.ATV.20.6.1473; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; Lynn S, 2000, CIRC RES, V86, P514, DOI 10.1161/01.RES.86.5.514; Marumo T, 1997, CIRCULATION, V96, P2361; Miller FJ, 1998, CIRC RES, V82, P1298, DOI 10.1161/01.RES.82.12.1298; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tarpey MM, 1999, CIRC RES, V84, P1203, DOI 10.1161/01.RES.84.10.1203; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Zhang HJ, 1999, CANCER RES, V59, P6276	31	219	239	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29251	29256		10.1074/jbc.M102124200	http://dx.doi.org/10.1074/jbc.M102124200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11358965	Green Accepted, hybrid			2022-12-27	WOS:000170346000083
J	Muir, AI; Chamberlain, L; Elshourbagy, NA; Michalovich, D; Moore, DJ; Calamari, A; Szekeres, PG; Sarau, HM; Chambers, JK; Murdock, P; Steplewski, K; Shabon, U; Miller, JE; Middleton, SE; Darker, JG; Larminie, CGC; Wilson, S; Bergsma, DJ; Emson, P; Faull, R; Philpott, KL; Harrison, DC				Muir, AI; Chamberlain, L; Elshourbagy, NA; Michalovich, D; Moore, DJ; Calamari, A; Szekeres, PG; Sarau, HM; Chambers, JK; Murdock, P; Steplewski, K; Shabon, U; Miller, JE; Middleton, SE; Darker, JG; Larminie, CGC; Wilson, S; Bergsma, DJ; Emson, P; Faull, R; Philpott, KL; Harrison, DC			AXOR12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; NEUROPEPTIDES; METASTASIS; IDENTIFICATION; EXPRESSION; CLEAVAGE; GALANIN; FAMILY; BRAIN	A novel human G protein-coupled receptor named AXOR12, exhibiting 81% homology to the rat orphan receptor GPR54, was cloned from a human brain cDNA library. Heterologous expression of AXOR12 in mammalian cells permitted the identification of three surrogate agonist peptides, all with a common C-terminal amidated motif. High potency agonism, indicative of a cognate ligand, was evident from peptides derived from the gene KiSS-1, the expression of which prevents metastasis in melanoma cells. Quantitative reverse transcriptase-polymerase chain reaction was used to study the expression of AXOR12 and KiSS-1 in a variety of tissues. The highest levels of expression of AXOR12 mRNA were observed in brain, pituitary gland, and placenta. The highest levels of KiSS-1 gene expression were observed in placenta and brain. A polyclonal antibody raised to the C. terminus of AXOR12 was generated and used to show localization of the receptor to neurons in the cerebellum, cerebral cortex, and brainstem. The biological significance of these expression patterns and the nature of the putative cognate ligand for AXOR12 are discussed.	GlaxoSmithKline, Dept Neurol, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Discovery Biol, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Biotechnol & Genet, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Discovery Chem, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Bioinformat, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Biotechnol & Genet, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Pulm Biol, King Of Prussia, PA 19406 USA; Babraham Inst, Neurobiol Programme, Cambridge CB2 4AT, England; Univ Auckland, Dept Anat & Radiol, Auckland 1, New Zealand	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Auckland	Harrison, DC (corresponding author), GlaxoSmithKline, Dept Neurol, New Frontiers Sci Pk, Harlow CM19 5AW, Essex, England.	David-C-Harrison@gsk.com	Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Michalovich, David/0000-0003-4452-5776; Faull, Richard/0000-0003-3385-9498				Aiyar N, 1999, MOL CELL BIOCHEM, V197, P179, DOI 10.1023/A:1006962221332; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Chan WC, 2000, FMOC SOLID PHASE PEP; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Elshourbagy NA, 2000, J BIOL CHEM, V275, P25965, DOI 10.1074/jbc.M004515200; GRAFF D, 1988, FEBS LETT, V239, P137, DOI 10.1016/0014-5793(88)80560-X; GRAFF D, 1988, BRAIN RES, V442, P354, DOI 10.1016/0006-8993(88)91525-9; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Hinuma S, 2000, NAT CELL BIOL, V2, P703, DOI 10.1038/35036326; Johnson EW, 1998, HUM MOL GENET, V7, P63, DOI 10.1093/hmg/7.1.63; Kapfhamer D, 1996, GENOMICS, V35, P533, DOI 10.1006/geno.1996.0394; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee DK, 1999, FEBS LETT, V446, P103, DOI 10.1016/S0014-5793(99)00009-5; Lee JH, 1997, CANCER RES, V57, P2384; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; Li C, 1999, BRAIN RES, V848, P26, DOI 10.1016/S0006-8993(99)01972-1; Moore D, 2000, J COMP NEUROL, V421, P374, DOI 10.1002/(SICI)1096-9861(20000605)421:3<374::AID-CNE6>3.0.CO;2-Z; Murray MJ, 1999, SEMIN REPROD ENDOCR, V17, P275, DOI 10.1055/s-2007-1016235; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nystuen A, 1996, HUM MOL GENET, V5, P525, DOI 10.1093/hmg/5.4.525; Ormandy CJ, 1998, CANCER RES, V58, P1353; Perry SJ, 1997, FEBS LETT, V409, P426, DOI 10.1016/S0014-5793(97)00557-7; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Servidei S, 1999, NEUROLOGY, V53, P830, DOI 10.1212/WNL.53.4.830; Seufferlein T, 1996, CANCER RES, V56, P5758; Shepard AR, 1997, NUCLEIC ACIDS RES, V25, P3183, DOI 10.1093/nar/25.15.3183; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; Szekeres PG, 2000, J BIOL CHEM, V275, P20247, DOI 10.1074/jbc.C000244200; TRILL JJ, 1995, CURR OPIN BIOTECH, V6, P553, DOI 10.1016/0958-1669(95)80092-1; TRIMMER BA, 1987, J COMP NEUROL, V266, P16, DOI 10.1002/cne.902660103; Wilson S, 1998, BRIT J PHARMACOL, V125, P1387, DOI 10.1038/sj.bjp.0702238; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757	34	720	771	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28969	28975		10.1074/jbc.M102743200	http://dx.doi.org/10.1074/jbc.M102743200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387329	hybrid			2022-12-27	WOS:000170346000046
J	Nakayama, A; Yamamoto, K; Tabata, S				Nakayama, A; Yamamoto, K; Tabata, S			Identification of the catalytic residues of bifunctional glycogen debranching enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RABBIT SKELETAL-MUSCLE; ALPHA-AMYLASE FAMILY; CYCLODEXTRIN GLYCOSYLTRANSFERASE; ASPERGILLUS-AWAMORI; MOLECULAR-CLONING; GLUCOAMYLASE; 1-CYCLOHEXYL-3-(2-MORPHOLINYL-(4)-ETHYL)CARBODIIMIDE; RESOLUTION; MECHANISM	Eukaryotic glycogen debranching enzyme (GDE) possesses two different catalytic activities (oligo-1,4 --> 1,4-glucantransferase/amylo-1,6-glucosidase) on a single polypeptide chain. To elucidate the structure-function relationship of GDE, the catalytic residues of yeast GDE were determined by site-directed mutagenesis. Asp-535, Glu-564, and Asp-670 on the N-terminal half and Asp1086 and Asp-1147 on the C-terminal half were chosen by the multiple sequence alignment or the comparison of hydrophobic cluster architectures among related enzymes. The five mutant enzymes, D535N, E564Q, D670N, D1086N, and D1147N were constructed. The mutant enzymes showed the same purification profiles as that of wild-type enzyme on beta -CD-Sepharose-6B affinity chromatography. All the mutant enzymes possessed either transferase activity or glucosidase activity. Three mutants, D535N, E564Q, and D670N, lost transferase activity but retained glucosidase activity. In contrast, D1086N and D1147N lost glucosidase activity but retained transferase activity. Furthermore, the kinetic parameters of each mutant enzyme exhibiting either the glucosidase activity or transferase activity did not vary markedly from the activities exhibited by the wild-type enzyme. These results strongly indicate that the two activities of GDE, transferase and glucosidase, are independent and located at different sites on the polypeptide chain.	Nara Med Univ, Dept Chem, Nara 6348521, Japan; Nara Prefectural Hosp, Nara 6310846, Japan	Nara Medical University	Tabata, S (corresponding author), Nara Med Univ, Dept Chem, Nara 6348521, Japan.							BATES EJ, 1975, FEBS LETT, V58, P181, DOI 10.1016/0014-5793(75)80254-7; Braun C, 1996, BIOCHEMISTRY-US, V35, P5458, DOI 10.1021/bi9526488; Chen Y-T, 1995, METABOLIC MOL BASES, P935; GILLARD BK, 1977, BIOCHEMISTRY-US, V16, P3978, DOI 10.1021/bi00637a007; HARRIS EMS, 1993, BIOCHEMISTRY-US, V32, P1618, DOI 10.1021/bi00057a028; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; INOKUCHI N, 1982, J BIOCHEM-TOKYO, V91, P125, DOI 10.1093/oxfordjournals.jbchem.a133669; IWAMA M, 1984, J BIOCHEM-TOKYO, V96, P329, DOI 10.1093/oxfordjournals.jbchem.a134842; JESPERSEN HM, 1993, J PROTEIN CHEM, V12, P791, DOI 10.1007/BF01024938; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; KLEIN C, 1992, BIOCHEMISTRY-US, V31, P8740, DOI 10.1021/bi00152a009; KOYAMA T, 1985, J BIOCHEM-TOKYO, V97, P633, DOI 10.1093/oxfordjournals.jbchem.a135099; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; Lee E. Y. C., 1971, ENZYMES, V5, P191; LEE EYC, 1970, BIOCHEMISTRY-US, V9, P2347, DOI 10.1021/bi00813a019; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; LIU W, 1991, BIOCHEMISTRY-US, V30, P1419, DOI 10.1021/bi00219a036; LIU W, 1993, ARCH BIOCHEM BIOPHYS, V306, P232, DOI 10.1006/abbi.1993.1505; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; Mosi R, 1997, BIOCHEMISTRY-US, V36, P9927, DOI 10.1021/bi970618u; NAKAMURA A, 1992, FEBS LETT, V296, P37, DOI 10.1016/0014-5793(92)80398-Z; Nakayama A, 2000, PROTEIN EXPRES PURIF, V19, P298, DOI 10.1006/prep.2000.1252; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIERKS MR, 1990, PROTEIN ENG, V3, P193, DOI 10.1093/protein/3.3.193; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; SVENSSON B, 1990, EUR J BIOCHEM, V188, P29, DOI 10.1111/j.1432-1033.1990.tb15367.x; TABATA S, 1992, CARBOHYD RES, V230, P179, DOI 10.1016/S0008-6215(00)90520-2; TABATA S, 1992, EUR J BIOCHEM, V206, P345, DOI 10.1111/j.1432-1033.1992.tb16933.x; TAYLOR C, 1975, EUR J BIOCHEM, V51, P105, DOI 10.1111/j.1432-1033.1975.tb03911.x; Teste MA, 2000, FEMS MICROBIOL LETT, V193, P105, DOI 10.1111/j.1574-6968.2000.tb09410.x; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; VANHOOF F, 1967, EUR J BIOCHEM, V2, P265; Watanabe K, 1997, J MOL BIOL, V269, P142, DOI 10.1006/jmbi.1997.1018; YANG BZ, 1992, J BIOL CHEM, V267, P9294	36	58	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28824	28828		10.1074/jbc.M102192200	http://dx.doi.org/10.1074/jbc.M102192200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11375985	hybrid			2022-12-27	WOS:000170346000026
J	Campos, F; Garcia-Gomez, BI; Solorzano, RM; Salazar, E; Estevez, J; Leon, P; Alvarez-Buylla, ER; Covarrubias, AJ				Campos, F; Garcia-Gomez, BI; Solorzano, RM; Salazar, E; Estevez, J; Leon, P; Alvarez-Buylla, ER; Covarrubias, AJ			A cDNA for nuclear-encoded chloroplast translational initiation factor 2 from a higher plant is able to complement an infB Escherichia coli null mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASEOLUS-VULGARIS L; EUGLENA-GRACILIS; GENE-EXPRESSION; FACTOR-II; TRANSIT PEPTIDES; GENOME SEQUENCE; FACTOR IF2; EVOLUTION; PROTEIN; ORIGIN	Formation of the initiation translation complex containing the three initiation factors, IF1, IF2, and IF3, tRNA(fMet), and GTP constitutes the earliest event in the protein synthesis. IF2, a GTP-binding protein, is the principal factor involved in selecting and binding fMet-tRNA(fMet) the 30 S ribosomal subunit. Although some chloroplast initiation translational factors have been identified and purified from algae, none of these factors have been characterized from plants. In this work, we report the molecular characterization of a nuclear-encoded chloroplastic IF2 gene from common bean (PvIF2cp). We show that the PvIF2cp gene encodes a protein containing a chloroplast translocation signal peptide, able to target a green fluorescent protein fusion protein to chloroplasts. A high accumulation of PvIF2cp transcript was found in photosynthetic tissues, whereas low mRNA levels were detected in etiolated plants and in nonphotosynthetic organs. Additional data indicate that the PvIF2cp transcript accumulation is modulated by light. The PvIF2cp gene encodes a functional factor, since the PvIF2cp conserved region, containing the G-domain and the C-terminal end, complements an Escherichia coli infB null mutation. Phylogenetic analysis using the PvIF2cp conserved region suggests that the PvIF2cp gene originated via endosymbiotic gene transfer to the nucleus and that it may be a useful marker for phylogeny reconstruction.	Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Biol Mol Plantas, Cuernavaca 62250, Morelos, Mexico; Univ Nacl Autonoma Mexico, Inst Ecol, Lab Genet Mol & Evoluc Plantas, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Covarrubias, AJ (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Biol Mol Plantas, AP 510-3, Cuernavaca 62250, Morelos, Mexico.	crobles@ibt.unam.mx		Alvarez-Buylla Roces, Maria Elena/0000-0002-7938-6473				ABEL S, 1994, PLANT J, V5, P421, DOI 10.1111/j.1365-313X.1994.00421.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; Bhattacharya D, 1998, PLANT PHYSIOL, V116, P9, DOI 10.1104/pp.116.1.9; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Bray E. A, 1991, ABSCISIC ACID PHYSL, P81; Bremaud L, 1997, J BACTERIOL, V179, P2348, DOI 10.1128/jb.179.7.2348-2355.1997; Bruce BD, 2000, TRENDS CELL BIOL, V10, P440, DOI 10.1016/S0962-8924(00)01833-X; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; ColmeneroFlores JM, 1997, PLANT MOL BIOL, V35, P393, DOI 10.1023/A:1005802505731; COVARRUBIAS AA, 1994, P 2 INT SCI M PHAS B; Danon A, 1997, PLANT PHYSIOL, V115, P1293, DOI 10.1104/pp.115.4.1293; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; GILLHAM NW, 1994, ANNU REV GENET, V28, P71, DOI 10.1146/annurev.ge.28.120194.000443; HARRIS EH, 1994, MICROBIOL REV, V58, P700, DOI 10.1128/MMBR.58.4.700-754.1994; Hirose T, 1999, FEBS LETT, V445, P169, DOI 10.1016/S0014-5793(99)00123-4; HOWE CJ, 1992, TRENDS ECOL EVOL, V7, P378, DOI 10.1016/0169-5347(92)90008-Y; HSIAO TC, 1973, ANNU REV PLANT PHYS, V24, P519, DOI 10.1146/annurev.pp.24.060173.002511; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KRAUS BL, 1988, PLANT PHYSIOL, V88, P993, DOI 10.1104/pp.88.4.993; LAALAMI S, 1991, BIOCHIMIE, V73, P1557, DOI 10.1016/0300-9084(91)90191-3; LAALAMI S, 1991, J MOL BIOL, V220, P335, DOI 10.1016/0022-2836(91)90017-Z; LARA M, 1984, PLANT PHYSIOL, V76, P1019, DOI 10.1104/pp.76.4.1019; LIN Q, 1994, J BIOL CHEM, V269, P9436; MA L, 1995, J BIOL CHEM, V270, P1859, DOI 10.1074/jbc.270.4.1859; Ma L, 1996, J BIOL CHEM, V271, P10528, DOI 10.1074/jbc.271.18.10528; MA L, 1992, J BIOL CHEM, V267, P18356; MA L, 1990, J BIOL CHEM, V265, P13560; Margulis L, 1970, ORIGIN EUKARYOTIC CE; Martin W, 1998, PLANT PHYSIOL, V118, P9, DOI 10.1104/pp.118.1.9; Moreira D, 2000, NATURE, V405, P69, DOI 10.1038/35011054; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEVERINI M, 1991, J BIOL CHEM, V266, P22800; SHEEN J, 1995, PLANT J, V8, P777, DOI 10.1046/j.1365-313X.1995.08050777.x; Shilperoort, 1994, PLANT MOL BIOL MAN D, P1, DOI 10.1007/978-94-011-0511-8_16; SHIMADA H, 1991, NUCLEIC ACIDS RES, V19, P983, DOI 10.1093/nar/19.5.983; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spurio R, 2000, J BIOL CHEM, V275, P2447, DOI 10.1074/jbc.275.4.2447; Stern DB, 1997, TRENDS PLANT SCI, V2, P308, DOI 10.1016/S1360-1385(97)89953-0; Sugiura M, 1998, ANNU REV GENET, V32, P437, DOI 10.1146/annurev.genet.32.1.437; SUGIURA M, 1992, PLANT MOL BIOL, V19, P149, DOI 10.1007/BF00015612; Swofford D. L., 2011, PAUP PHYLOGENETIC AN; TOBIN EM, 1985, ANNU REV PLANT PHYS, V36, P569, DOI 10.1146/annurev.pp.36.060185.003033; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAMBUTAS SH, 1991, EUR J BIOCHEM, V201, P543; Villanueva MA, 1999, PLANTA, V207, P582, DOI 10.1007/s004250050521; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535	52	8	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28388	28394		10.1074/jbc.M100605200	http://dx.doi.org/10.1074/jbc.M100605200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11356831	hybrid			2022-12-27	WOS:000170093400086
J	Stein, U; Jurchott, K; Walther, W; Bergmann, S; Schlag, PM; Royer, HD				Stein, U; Jurchott, K; Walther, W; Bergmann, S; Schlag, PM; Royer, HD			Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEIN; HEAT-SHOCK; MDR1 GENE; Y-BOX; P-GLYCOPROTEIN; NF-Y; CARCINOMA CELLS; MRP GENE; ACTIVATION; INVOLVEMENT	Genotoxic stress leads to nuclear translocation of the Y-box transcription factor YB-1 and enhanced expression of the multidrug resistance gene MDR1. Because hyperthermia is used for the treatment of colon cancer in combination with chemoradiotherapy, we investigated the influence of hyperthermia on YB-1 activity and the expression of multidrug resistance-related genes. Here we report that hyperthermia causes YB-1 translocation from the cytoplasm into the nucleus of human colon carcinoma cells HCT15 and HCT116. Nuclear translocation of YB-1 was associated with increased MDR1 and MRP1 gene activity, which is reflected in strong efflux pump activity. However, a combination of hyperthermia and drug treatment effectively reduced cell survival of the HCT15 and HCT116 cells. These results demonstrate that activation of MDR1 and MRP1 gene expression and increased efflux pump activity after hyperthermia were insufficient to cause an increase in drug resistance in colon cancer cell lines. The ability of hyperthermia to abrogate drug resistance in the presence of an increase in functional MDR proteins may provide an explanation for the efficacious results seen in the clinic in colon cancer patients treated with a combination of hyperthermia and chemotherapy.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Humboldt Univ, Charite, D-13122 Berlin, Germany; Univ Dusseldorf, Inst Transplantat Diagnost & Cell Therapy, D-40225 Dusseldorf, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Stein, U (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	ustein@mdc-berlin.de	Royer, Hans-dieter/AAH-6293-2019	Walther, Wolfgang/0000-0003-2360-1370; Jurchott, Karsten/0000-0003-1589-0037; Stein, Ulrike/0000-0001-7006-282X				Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; CHIN KV, 1990, J BIOL CHEM, V265, P221; Chuman Y, 1996, INT J CANCER, V66, P274, DOI 10.1002/(SICI)1097-0215(19960410)66:2<274::AID-IJC23>3.0.CO;2-B; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Dumontet C, 1998, CLIN CANCER RES, V4, P1563; Efferth Thomas, 2001, Current Molecular Medicine (Hilversum), V1, P45, DOI 10.2174/1566524013364194; FINKE J, 1993, BIOTECHNIQUES, V14, P448; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GRITTI A, 1993, INT J HYPERTHER, V9, P393, DOI 10.3109/02656739309005039; Hever-Szabo A, 1998, ANTICANCER RES, V18, P3045; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Izquierdo MA, 1996, INT J CANCER, V65, P230; Izumi H, 2001, NUCLEIC ACIDS RES, V29, P1200, DOI 10.1093/nar/29.5.1200; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kim SH, 1997, CANCER LETT, V115, P9, DOI 10.1016/S0304-3835(97)04725-3; KIOKA N, 1992, FEBS LETT, V301, P37, DOI 10.1016/0014-5793(92)80205-U; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; Lee PD, 1996, BRIT J CANCER, V74, P1046, DOI 10.1038/bjc.1996.487; LINN SC, 1995, EUR J CANCER, V31A, P1291, DOI 10.1016/0959-8049(95)00278-Q; Meijer GA, 1999, J CLIN PATHOL, V52, P450, DOI 10.1136/jcp.52.6.450; MIYAZAKI M, 1992, BIOCHEM BIOPH RES CO, V187, P677, DOI 10.1016/0006-291X(92)91248-O; MOSELEY PL, 1994, AM J PHYSIOL, V267, pC425, DOI 10.1152/ajpcell.1994.267.2.C425; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Rau B, 1998, ANN SURG, V227, P380, DOI 10.1097/00000658-199803000-00010; ROYER HD, 1991, NUCLEIC ACIDS RES, V19, P2363, DOI 10.1093/nar/19.9.2363; Shibao K, 1999, INT J CANCER, V83, P732; SPITKOVSKY DD, 1992, NUCLEIC ACIDS RES, V20, P797, DOI 10.1093/nar/20.4.797; Stein U, 1996, J CANCER RES CLIN, V122, P275, DOI 10.1007/BF01261403; Stein U, 1997, JNCI-J NATL CANCER I, V89, P807, DOI 10.1093/jnci/89.11.807; Stein U, 1996, JNCI-J NATL CANCER I, V88, P1383, DOI 10.1093/jnci/88.19.1383; Stein U, 1999, INT J CANCER, V80, P5, DOI 10.1002/(SICI)1097-0215(19990105)80:1<5::AID-IJC2>3.3.CO;2-6; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; Tanabe M, 1997, J BIOL CHEM, V272, P15389, DOI 10.1074/jbc.272.24.15389; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; YANG JM, 1995, BIOCHEM BIOPH RES CO, V210, P21, DOI 10.1006/bbrc.1995.1622; ZHANG JT, 1995, BIOCHEMISTRY-US, V34, P9159, DOI 10.1021/bi00028a027; ZHU QC, 1994, CANCER RES, V54, P4488	44	111	130	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28562	28569		10.1074/jbc.M100311200	http://dx.doi.org/10.1074/jbc.M100311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369762	hybrid			2022-12-27	WOS:000170093400109
J	Yang, J; Duerksen-Hughes, PJ				Yang, J; Duerksen-Hughes, PJ			Activation of a p53-independent, sphingolipid-mediated cytolytic pathway in p53-negative mouse fibroblast cells treated with N-methyl-N-nitro-N-nitrosoguanidine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CERAMIDE-INDUCED APOPTOSIS; DNA-DAMAGE; PROTEIN-KINASES; SPHINGOMYELIN PATHWAY; SIGNAL-TRANSDUCTION; DEPENDENT PATHWAY; FREE SPHINGOSINE; TERMINAL KINASE; STRESS-RESPONSE	Sphingolipids such as ceramide are important mediators of apoptosis and growth arrest triggered by ligands such as tumor necrosis factor and Fas-L binding to their receptors, When LM (expressing p53) and LME6 (lacking p53) cells were exposed to the genotoxin N-methyl-N-nitro-N-nitrosoguanidine (MNNG), both cell lines underwent cytolysis in a very similar manner, suggesting the presence of a p53-independent apoptotic response to this genotoxic stress. To determine whether sphingolipids such as ceramide might serve as mediators in this system, the responses of these cells to exogenous sphingolipids as well as their changes in endogenous sphingolipid levels after DNA damage were examined. Treatment with exogenous Ca-ceramide and sphingosine led to cell death in both LM and LME6, and treatment of the LME6 cells with MNNG resulted in a transient increase in intracellular ceramide of similar to 50% over a period of 3 h, Finally, treatment with the de novo inhibitor of ceramide synthesis ISP-1 protected LME6 cells from MNNG-triggered cell death. This MNNG-triggered induction of ceramide was not observed in the p53-expressing LM cells, suggesting that it may be down-regulated by p53, Although ceramide-mediated cell death can proceed in the absence of p53, exogenously added C2-ceramide increased the cellular p53 level in LM cells, suggesting that the two pathways do interact.	Loma Linda Univ, Ctr Mol Biol & Gene Therapy, Sch Med, Loma Linda, CA 92354 USA	Loma Linda University	Duerksen-Hughes, PJ (corresponding author), Loma Linda Univ, Ctr Mol Biol & Gene Therapy, Sch Med, 11085 Campus St,105 Mortensen Hall, Loma Linda, CA 92354 USA.	pdhughes@som.llu.edu	Duerksen-Hughes, Penelope/A-3488-2008	Duerksen-Hughes, Penelope/0000-0002-0998-2157				BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Chiarugi V, 1998, ONCOL RES, V10, P55; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Coroneos E, 1996, BIOCHEM J, V316, P13, DOI 10.1042/bj3160013; DBAIBO GS, 1995, BIOCHEM J, V310, P453, DOI 10.1042/bj3100453; Dbaibo GS, 1997, BIOCHEM SOC T, V25, P557, DOI 10.1042/bst0250557; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Duerksen-Hughes PJ, 1999, VIROLOGY, V264, P55, DOI 10.1006/viro.1999.9977; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1991, METHOD ENZYMOL, V201, P316; Hour TC, 1999, TOXICOL LETT, V110, P191, DOI 10.1016/S0378-4274(99)00158-7; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Hung WC, 1996, BIOCHEM BIOPH RES CO, V229, P11, DOI 10.1006/bbrc.1996.1750; Jarvis WD, 1997, MOL PHARMACOL, V52, P935, DOI 10.1124/mol.52.6.935; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; KASTAN MB, 1991, CANCER RES, V51, P6304; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Meek DW, 1997, BIOCHEM SOC T, V25, P416, DOI 10.1042/bst0250416; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; Milner J, 1997, PATHOL BIOL, V45, P797; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nakamura S, 1996, J BIOL CHEM, V271, P1255, DOI 10.1074/jbc.271.3.1255; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; SMART RC, 1994, CARCINOGENESIS; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; Spiegel S, 1998, BIOCHEMISTRY-MOSCOW+, V63, P69; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Vento R, 1998, MOL CELL BIOCHEM, V185, P7, DOI 10.1023/A:1006836428202; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XJ, 1997, J RADIAT RES, V38, P179, DOI 10.1269/jrr.38.179; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Yang J, 1998, CARCINOGENESIS, V19, P1117, DOI 10.1093/carcin/19.6.1117	61	29	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27129	27135		10.1074/jbc.M100729200	http://dx.doi.org/10.1074/jbc.M100729200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369765	hybrid			2022-12-27	WOS:000169966900054
J	Zhao, YG; Li, SC; Childs, EE; Kuharsky, DK; Yin, XM				Zhao, YG; Li, SC; Childs, EE; Kuharsky, DK; Yin, XM			Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis pathway in tumor necrosis factor-alpha-induced liver injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; HEPATOCYTE APOPTOSIS; CONFORMATIONAL-CHANGE; INTERACTING PROTEIN; CASPASE ACTIVATION; BAX TRANSLOCATION; FACTOR RECEPTOR; DEFICIENT MICE; ORGAN FAILURE	Tumor-necrosis factor-alpha (TNF alpha)-induced cytotoxicity contributes to the pathogenesis in inflammatory and immune responses. Here, we studied the role of prodeath Bcl-2 family proteins and the mitochondria apoptosis pathway in the development of TNF alpha -induced hepatic injury during endotoxemia, after treating mice with lipopolysaccharide or TNF alpha in the presence of D-galactosamine, Bid was cleaved and translocated to mitochondria in hepatocytes. Independently, Bax was also activated by the death receptor engagement and translocated to mitochondria. However, its subsequent insertion into the mitochondrial membrane depends on Bid. Nevertheless, Bid was required, but fax could be dispensed for the mitochondrial release of cytochrome c from mitochondria, suggesting that Bid could activate additional downstream molecules other than Bax. The lack of this Bid-dependent mitochondria activation and cytochrome c release in the bid-deficient mice was responsible for the significantly delayed effector caspase activation and hepatocyte injury upon endotoxin treatment, culminating in a prolonged survival of the bid-deficient mice. Additional genetic factor(s) could further modify the dependence of TNF alpha toxicity on the mitochondria pathway as the bid-deficient 129/SvJ mice manifested an even higher resistance than the same type of mice in C57BL/6 background. The functional significance of the mitochondria apoptosis pathway was thus elucidated in the TNF alpha -mediated pathogenesis in vivo.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yin, XM (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, 7th Floor,Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	xmyin@pitt.edu			NATIONAL CANCER INSTITUTE [K01CA074885, R01CA083817] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA74885, R01 CA83817] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ahmad M, 1997, CANCER RES, V57, P615; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CARLSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FREUDENBERG MA, 1986, INFECT IMMUN, V51, P891, DOI 10.1128/IAI.51.3.891-895.1986; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Goossens V, 1999, BIOFACTORS, V10, P145, DOI 10.1002/biof.5520100210; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jaeschke H, 1998, J IMMUNOL, V160, P3480; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kunstle G, 1999, HEPATOLOGY, V30, P1241, DOI 10.1002/hep.510300517; Kunstle G, 1997, IMMUNOL LETT, V55, P5, DOI 10.1016/S0165-2478(96)02642-9; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LEIST M, 1994, J IMMUNOL, V153, P1778; LEIST M, 1995, AM J PATHOL, V146, P1220; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; Moore FA, 1996, J TRAUMA, V40, P501, DOI 10.1097/00005373-199604000-00001; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Rouquet N, 1996, CURR BIOL, V6, P1192, DOI 10.1016/S0960-9822(02)70688-X; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; SCHIRMER WJ, 1989, ARCH SURG-CHICAGO, V124, P445; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Streetz K, 2000, GASTROENTEROLOGY, V119, P446, DOI 10.1053/gast.2000.9364; Tafani M, 2000, AM J PATHOL, V156, P2111, DOI 10.1016/S0002-9440(10)65082-1; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TIEGS G, 1989, BIOCHEM PHARMACOL, V38, P627, DOI 10.1016/0006-2952(89)90208-6; TRACEY KJ, 1993, CRIT CARE MED, V21, pS415; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2000, GENE DEV, V14, P2060; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	62	108	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27432	27440		10.1074/jbc.M102465200	http://dx.doi.org/10.1074/jbc.M102465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369777	hybrid			2022-12-27	WOS:000169966900093
J	Aprelikova, O; Pace, AJ; Fang, B; Koller, BH; Liu, ET				Aprelikova, O; Pace, AJ; Fang, B; Koller, BH; Liu, ET			BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETRACTED ARTICLE. SEE; DNA-DAMAGE RESPONSE; EXPRESSION; PHOSPHORYLATION; ASSOCIATION; FREQUENCY; PROTEIN; REPAIR; CYCLE; LEADS	BRCA1 gene is a tumor suppressor for breast and ovarian cancers with the putative role in DNA repair and transcription. To characterize the role of BRCA1 in transcriptional regulation, we analyzed gene expression profiles of mouse embryonic stem cells deficient in BRCA1 using microarray technology. We found that loss of BRCA1 correlated with decreased expression of several groups of genes including stress response genes, cytoskeleton genes, and genes involved in protein synthesis and degradation. Previous study showed that BRCA1 is a transcriptional co-activator of p53 protein; however the majority of p53 target genes remained at the same expression levels in BRCA1 knockout cells as in the wild type cells, The only p53 target gene downregulated with the loss of BRCA1 was 14-3-3 sigma, a major G(2)/M checkpoint control gene. Similar to cells with decreased 14-3-3 sigma activity, BRCA1-deficient cells were unable to sustain G(2)/M growth arrest after exposure to ionizing radiation. We find that BRCA1 induction of 14-3-3 sigma requires the presence of wild type p53 and can be regulated by a minimal p53 response element.	NCI, Div Clin Sci, Sect Mol Signaling & Oncogenesis, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Liu, ET (corresponding author), ATC Bldg,Rm 121,8717 Grovemont Cr, Gaithersburg, MD 20878 USA.	apreliko@mail.nih.gov	Liu, Edison/C-4141-2008		NATIONAL CANCER INSTITUTE [R01CA082423] Funding Source: NIH RePORTER; NCI NIH HHS [CA82423] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Liu QH, 2000, GENE DEV, V14, P1448; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhao RB, 2000, GENE DEV, V14, P981; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	30	88	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25647	25650		10.1074/jbc.C100265200	http://dx.doi.org/10.1074/jbc.C100265200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11384963	hybrid			2022-12-27	WOS:000169823300003
J	Nirodi, C; Hart, J; Dhawan, P; Moon, NS; Nepveu, A; Richmond, A				Nirodi, C; Hart, J; Dhawan, P; Moon, NS; Nepveu, A; Richmond, A			The role of CDP in the negative regulation of CXCL1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; CUT HOMEODOMAIN PROTEIN; HS294T MELANOMA-CELLS; DNA-BINDING DOMAINS; NF-KAPPA-B; ALPHA GENE; MGSA GRO; PROMOTER; TRANSCRIPTION; DROSOPHILA	The CXC chemokine, melanoma growth stimulatory activity/growth-regulated protein, CXCL1 is an important modulator of inflammation, wound healing, angiogenesis, and tumorigenesis, Transcription of CXCL1 is regulated through several cia-acting elements including Spl, NF-kappaB, and an element that lies immediately upstream of the NF-kappaB element, the immediate upstream region (IUR), A transcription element data base search indicated that the IUR element contains a binding site for the transcriptional repressor, human CUT homeodomain protein/CCAAT displacement protein (CDP), It is shown here that in electrophoretic mobility shift assays, complexes obtained with the IUR oligonucleotide probe are supershifted by anti-CDP antibodies and that a CDP polypeptide containing a high affinity DNA binding domain binds to the sequence GGGATCGATC in the IUR element. In Southwestern blot analyses, oligonucleotides containing the wild-type IUR sequence, but not a mutant oligonucleotide with substitutions in the GGGATCGATC sequence, bind a 170-180-kDa protein. Furthermore, overexpression of the CDP protein blocks CXCL1 promoter activity in reporter gene assays, whereas overexpression of an antisense CDP construct leads to a significant increase in CXCL1 promoter activity. Mutations in the IUR element, which map in the putative CUP-binding site, inhibit the binding of CDP to the IUR element and favor increased transcription from the CXCL1 promoter. Based on these results, we propose that transcriptional regulation of the CXCL1 gene is mediated in part by CDP, which could play an important role in inflammatory processes and tumorigenesis.	Dept Vet Affairs, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; McGill Univ, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	Vanderbilt University; McGill University	Richmond, A (corresponding author), Dept Vet Affairs, Nashville, TN 37212 USA.		Richmond, Ann/A-3048-2014; /AAB-8315-2020	Moon, Nam-Sung/0000-0002-0455-927X; RICHMOND, ANN/0000-0002-9580-900X	NCI NIH HHS [P30 CA068485, CA 68485, R01 CA056704-08, CA 56704, R01 CA056704-09, R01 CA056704-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056704, P30CA068485] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; BALENTIEN E, 1991, ONCOGENE, V6, P1115; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; Coqueret O, 1996, J BIOL CHEM, V271, P24862, DOI 10.1074/jbc.271.40.24862; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Devalaraja MN, 1999, CANCER RES, V59, P1372; ENGELAND K, 1995, J BIOL CHEM, V270, P24572, DOI 10.1074/jbc.270.41.24572; FONG CLW, 1994, NUCLEIC ACIDS RES, V22, P1108, DOI 10.1093/nar/22.6.1108; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; HARADA R, 1994, J BIOL CHEM, V269, P2062; HOSAKA S, 1994, CLIN EXP IMMUNOL, V97, P451; JAFFE GJ, 1993, INVEST OPHTH VIS SCI, V34, P2776; Johnston LA, 1998, GENETICS, V149, P131; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; Li SD, 2000, P NATL ACAD SCI USA, V97, P7166, DOI 10.1073/pnas.130028697; Lievens PMJ, 1997, GENE, V197, P73; LIWEBER M, 1994, J IMMUNOL, V153, P4122; LIWEBER M, 1993, J IMMUNOL, V151, P1371; Lopez S, 1997, J BIOL CHEM, V272, P22788, DOI 10.1074/jbc.272.36.22788; Luan J, 1997, J LEUKOCYTE BIOL, V62, P588, DOI 10.1002/jlb.62.5.588; Ludlow C, 1996, DEV BIOL, V178, P149, DOI 10.1006/dbio.1996.0205; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Mailly F, 1996, MOL CELL BIOL, V16, P5346; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; Moon NS, 2000, J BIOL CHEM, V275, P31325, DOI 10.1074/jbc.M002912200; Murphy PM, 2000, PHARMACOL REV, V52, P145; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Nourbakhsh M, 2001, J BIOL CHEM, V276, P4501, DOI 10.1074/jbc.M007532200; Rennekampff HO, 2000, J SURG RES, V93, P41, DOI 10.1006/jsre.2000.5892; ROMANOSPICA V, 1995, J IMMUNOL, V154, P2724; Schug J., 1997, CBILTR19971001V00 U; SHATTUCK RL, 1994, MOL CELL BIOL, V14, P791, DOI 10.1128/MCB.14.1.791; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; THANOS D, 1993, NUCLEIC ACIDS RES, V21, P6010, DOI 10.1093/nar/21.25.6010; van Gurp MF, 1999, CANCER RES, V59, P5980; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; vanWijnen AJ, 1997, J CELL BIOCHEM, V66, P512, DOI 10.1002/(SICI)1097-4644(19970915)66:4<512::AID-JCB10>3.0.CO;2-D; Wang ZY, 1999, MOL CELL BIOL, V19, P284; Webster MA, 1998, ONCOGENE, V16, P1963, DOI 10.1038/sj.onc.1201707; Wood LD, 1995, J BIOL CHEM, V270, P30619, DOI 10.1074/jbc.270.51.30619; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210	44	31	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26122	26131		10.1074/jbc.M102872200	http://dx.doi.org/10.1074/jbc.M102872200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11371564	Green Accepted, hybrid			2022-12-27	WOS:000169823300066
J	Mat-Arip, Y; Garver, K; Chen, CP; Sheng, S; Shao, ZF; Guo, PX				Mat-Arip, Y; Garver, K; Chen, CP; Sheng, S; Shao, ZF; Guo, PX			Three-dimensional interaction of phi29 pRNA dimer probed by chemical modification interference, cryo-AFM, and cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RIBONUCLEASE-P RNA; PERMUTED TRANSFER-RNAS; PHAGE PHI-29; BACTERIOPHAGE-PHI-29 DNA; IN-VITRO; RIBOSOMAL-RNA; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; TRANSCRIPTION TERMINATION	Six pRNAs (p for packaging) of bacterial virus phi29 form a hexamer complex that is an essential component of the viral DNA translocating motor. Dimers, the building block of pRNA hexamer, assemble in the order of dimer --> tetramer --> hexamer. The two-dimensional structure of the pRNA monomer has been investigated extensively; however, the three-dimensional structure concerning the distance constraints of the three stems and loops are unknown. In this report, we probed the three-dimensional structure of pRNA monomer and dimer by photo affinity cross-linking with azidophenacyl. Bases 75-81 of the left stem were found to be oriented toward the head loop and proximate to bases 26-31 in a parallel orientation. Chemical modification interference indicates the involvement of bases 45-71 and 82-91 in dimer formation. Dimer was formed via hand-in-hand contact, a novel RNA dimerization that in some aspects is similar to the kissing loops of the human immunodeficiency virus. The covalently linked dimers were found to be biologically active. Both the native dimer and the covalently linked dimer were found by cryo-atomic force microscopy to be similar in global conformation and size.	Purdue Univ, Purdue Canc Res Ctr, Dept Pathobiol, W Lafayette, IN 47907 USA; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Virginia	Guo, PX (corresponding author), Purdue Univ, Purdue Canc Res Ctr, Dept Pathobiol, B-36 Hansen Life Sci Res Bldg, W Lafayette, IN 47907 USA.	guo@vet.purdue.edu	Guo, Peixuan/AAE-2573-2022; Guo, Peixuan/I-7184-2015; Mat-Arip, Yahya/I-1980-2012; Shao, Zhifeng/B-6075-2013	Guo, Peixuan/0000-0001-5706-2833; Mat-Arip, Yahya/0000-0002-1570-5308; 	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR007720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060529, R01GM059944] Funding Source: NIH RePORTER; NCRR NIH HHS [RR07720] Funding Source: Medline; NIGMS NIH HHS [GM60529, GM59944] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAER MF, 1988, J BIOL CHEM, V263, P2344; BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; BENDER W, 1976, CELL, V7, P595, DOI 10.1016/0092-8674(76)90210-5; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; Chang KY, 1997, J MOL BIOL, V269, P52, DOI 10.1006/jmbi.1997.1021; Chen CP, 1997, J VIROL, V71, P3864, DOI 10.1128/JVI.71.5.3864-3871.1997; Chen CP, 2000, J BIOL CHEM, V275, P17510, DOI 10.1074/jbc.M909662199; Chen CP, 1999, RNA, V5, P805, DOI 10.1017/S1355838299990350; Chen T, 1997, J BIOMED MATER RES, V36, P190, DOI 10.1002/(SICI)1097-4636(199708)36:2<190::AID-JBM7>3.3.CO;2-7; Clever JL, 1996, J VIROL, V70, P5902, DOI 10.1128/JVI.70.9.5902-5908.1996; Doering C, 1995, BIOPHYS J, V69, P2256, DOI 10.1016/S0006-3495(95)80096-2; Egelman EH, 1996, STRUCTURE, V4, P759, DOI 10.1016/S0969-2126(96)00081-0; EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X; Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751; Garver K, 1997, RNA, V3, P1068; Garver K, 2000, J BIOL CHEM, V275, P2817, DOI 10.1074/jbc.275.4.2817; GEIDUSCHEK EP, 1995, CHEM BIOL, V2, P123, DOI 10.1016/1074-5521(95)90065-9; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; Greatorex JS, 1996, NUCLEIC ACIDS RES, V24, P2919, DOI 10.1093/nar/24.15.2919; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUO PX, 1994, SEMIN VIROL, V5, P27, DOI 10.1006/smvy.1994.1004; GUO PX, 1987, NUCLEIC ACIDS RES, V15, P7081, DOI 10.1093/nar/15.17.7081; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; GUO PX, 1991, VIROLOGY, V185, P395, DOI 10.1016/0042-6822(91)90787-C; GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124; Guo PX, 1998, MOL CELL, V2, P149, DOI 10.1016/S1097-2765(00)80124-0; GUO PX, 1991, VIROLOGY, V183, P366, DOI 10.1016/0042-6822(91)90149-6; GUO PX, 1986, P NATL ACAD SCI USA, V83, P3505, DOI 10.1073/pnas.83.10.3505; HAGENBUCHLE O, 1978, CELL, V13, P551, DOI 10.1016/0092-8674(78)90328-8; HAN WH, 1995, BIOCHEMISTRY-US, V34, P8215, DOI 10.1021/bi00026a001; Hendrix RW, 1998, CELL, V94, P147, DOI 10.1016/S0092-8674(00)81413-0; Henkin TM, 1996, ANNU REV GENET, V30, P35, DOI 10.1146/annurev.genet.30.1.35; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; HOMANN M, 1993, J MOL BIOL, V233, P7, DOI 10.1006/jmbi.1993.1480; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Laughrea M, 1997, J VIROL, V71, P3397, DOI 10.1128/JVI.71.5.3397-3406.1997; Lease RA, 1998, P NATL ACAD SCI USA, V95, P12456, DOI 10.1073/pnas.95.21.12456; LEE CS, 1995, J VIROL, V69, P5018, DOI 10.1128/JVI.69.8.5018-5023.1995; LEE CS, 1994, VIROLOGY, V202, P1039, DOI 10.1006/viro.1994.1434; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; NOLAN JM, 1993, SCIENCE, V261, P762, DOI 10.1126/science.7688143; OH BK, 1994, NUCLEIC ACIDS RES, V22, P4087, DOI 10.1093/nar/22.20.4087; Paillart JC, 1996, P NATL ACAD SCI USA, V93, P5572, DOI 10.1073/pnas.93.11.5572; PAN T, 1991, SCIENCE, V254, P1361, DOI 10.1126/science.1720569; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; PLEIJ CWA, 1989, METHOD ENZYMOL, V180, P289; PRATS AC, 1990, J VIROL, V64, P774, DOI 10.1128/JVI.64.2.774-783.1990; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SanMartin MC, 1997, J MOL BIOL, V268, P15, DOI 10.1006/jmbi.1997.0952; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STUDNICKA GM, 1978, NUCLEIC ACIDS RES, V5, P3365, DOI 10.1093/nar/5.9.3365; Trottier M, 2000, RNA, V6, P1257, DOI 10.1017/S1355838200992501; Trottier M, 1997, J VIROL, V71, P487, DOI 10.1128/JVI.71.1.487-494.1997; Trottier M, 1996, J VIROL, V70, P55, DOI 10.1128/JVI.70.1.55-61.1996; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; Verma M, 1997, CANCER BIOCHEM BIOPH, V15, P211; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; WICHITWECHKARN J, 1989, NUCLEIC ACIDS RES, V17, P3459, DOI 10.1093/nar/17.9.3459; YOUNG MC, 1994, J MOL BIOL, V235, P1436, DOI 10.1006/jmbi.1994.1099; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100; YOUVAN DC, 1982, ANAL BIOCHEM, V119, P86, DOI 10.1016/0003-2697(82)90669-8; ZHANG CL, 1995, VIROLOGY, V207, P442, DOI 10.1006/viro.1995.1103; ZHANG CL, 1994, VIROLOGY, V201, P77, DOI 10.1006/viro.1994.1267; Zhang CL, 1997, RNA, V3, P315; Zhang F, 1998, MOL CELL, V2, P141, DOI 10.1016/S1097-2765(00)80123-9; Zhang YY, 1996, BIOPHYS J, V71, P2168, DOI 10.1016/S0006-3495(96)79418-3; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	72	30	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32575	32584		10.1074/jbc.M100045200	http://dx.doi.org/10.1074/jbc.M100045200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11371551	hybrid			2022-12-27	WOS:000170746000028
J	Feng, Y; Huang, HJ; Liao, J; Cohen, SN				Feng, Y; Huang, HJ; Liao, J; Cohen, SN			Escherichia coli poly(A)-binding proteins that interact with components of degradosomes or impede RNA decay mediated by polynucleotide phosphorylase and RNase E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) BINDING-PROTEIN; RPSO MESSENGER-RNA; TRANSLATION INITIATION; ANTISENSE RNAI; DEGRADATION; GENE; CSPA; SEQUENCE; POLYADENYLATION; TRANSCRIPTION	The multifunctional ribonuclease RNase E and the 3 ' -exonuclease polynucleotide phosphorylase (PNPase) are major components of an Escherichia coli ribonucleolytic "machine" that has been termed the RNA degradosome. Previous work has shown that poly(A) additions to the 3 ' ends of RNA substrates affect RNA degradation by both of these enzymes. To better understand the mechanism(s) by which poly(A) tails can modulate ribonuclease action, we used selective binding in 1 M salt to identify E. coli proteins that interact at high affinity with poly(A) tracts. We report here that CspE, a member of a family of RNA-binding "cold shock" proteins, and S1, an essential component of the 30 S ribosomal subunit, are poly(A)-binding proteins that interact functionally and physically, respectively, with degradosome ribonucleases. We show that purified CspE impedes poly(A)mediated 3 ' to 5 ' exonucleolytic decay by PNPase by interfering with its digestion through the poly(A) tail and also inhibits both internal cleavage and poly(A) tail removal by RNase E. The ribosomal protein S1, which is known to interact with sequences at the 5 ' ends of mRNA molecules during the initiation of translation, can bind to both RNase E and PNPase, but in contrast to CspE, did not affect the ribonucleolytic actions of these enzymes. Our findings raise the prospect that E. coli proteins that bind to poly(A) tails may link the functions of degradosomes and ribosomes.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Program Canc Biol, Stanford, CA 94305 USA; CLONTECH Labs Inc, Palo Alto, CA 94303 USA	Stanford University; Stanford University	Cohen, SN (corresponding author), Stanford Univ, Med Ctr, Dept Genet, Rm M322, Stanford, CA 94305 USA.	ancohen@stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054158] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae WH, 1999, MOL MICROBIOL, V31, P1429, DOI 10.1046/j.1365-2958.1999.01284.x; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; Blum E, 1999, J BIOL CHEM, V274, P4009, DOI 10.1074/jbc.274.7.4009; BONI IV, 1991, NUCLEIC ACIDS RES, V19, P155, DOI 10.1093/nar/19.1.155; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Coburn GA, 1998, J MOL BIOL, V279, P1061, DOI 10.1006/jmbi.1998.1842; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; Cohen SN, 1997, MOL MICROBIOL, V23, P1099, DOI 10.1111/j.1365-2958.1997.tb02593.x; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; Etchegaray JP, 1996, GENES CELLS, V1, P171, DOI 10.1046/j.1365-2443.1996.d01-231.x; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; Hajnsdorf E, 1999, J MOL BIOL, V286, P1033, DOI 10.1006/jmbi.1999.2547; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; Hanna MM, 1998, J MOL BIOL, V282, P227, DOI 10.1006/jmbi.1998.2005; Huang HJ, 1998, NATURE, V391, P99, DOI 10.1038/34219; Ingle CA, 1996, P NATL ACAD SCI USA, V93, P12926, DOI 10.1073/pnas.93.23.12926; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jiang WN, 1997, J BIOL CHEM, V272, P196; Kalapos MP, 1997, BIOCHIMIE, V79, P493, DOI 10.1016/S0300-9084(97)82741-1; Keller W, 1997, CURR OPIN CELL BIOL, V9, P329, DOI 10.1016/S0955-0674(97)80004-X; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; McDowall KJ, 1996, J MOL BIOL, V255, P349, DOI 10.1006/jmbi.1996.0027; MCMURRY LM, 1987, J BACTERIOL, V169, P1321, DOI 10.1128/jb.169.3.1321-1324.1987; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; Phadtare S, 1999, MOL MICROBIOL, V33, P1004, DOI 10.1046/j.1365-2958.1999.01541.x; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sarkar N, 1997, ANNU REV BIOCHEM, V66, P173, DOI 10.1146/annurev.biochem.66.1.173; Steege DA, 2000, RNA, V6, P1079, DOI 10.1017/S1355838200001023; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; Vanzo NF, 1998, GENE DEV, V12, P2770, DOI 10.1101/gad.12.17.2770; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; WOLFFE AP, 1992, NEW BIOL, V4, P290; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756; YAMANAKA K, 1994, MOL MICROBIOL, V13, P301, DOI 10.1111/j.1365-2958.1994.tb00424.x	50	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31651	31656		10.1074/jbc.M102855200	http://dx.doi.org/10.1074/jbc.M102855200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11390393	hybrid			2022-12-27	WOS:000170613500026
J	Mourey, L; Da Re, S; Pedelacq, JD; Tolstykh, T; Faurie, C; Guillet, V; Stock, JB; Samama, JP				Mourey, L; Da Re, S; Pedelacq, JD; Tolstykh, T; Faurie, C; Guillet, V; Stock, JB; Samama, JP			Crystal structure of the CheA histidine phosphotransfer domain that mediates response regulator phosphorylation in bacterial chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; KINASE CHEA; KINETIC CHARACTERIZATION; MULTISTEP PHOSPHORELAY; MOLECULAR RECOGNITION; SECONDARY STRUCTURE; 4-HELIX BUNDLE; PROTEIN; ARCB	The x-ray crystal structure of the P1 or H domain of the Salmonella CheA protein has been solved at 2.1-Angstrom resolution. The structure is composed of an up-down up-down four-helix bundle that is typical of histidine phosphotransfer or HPt domains such as Escherichia coli ArcB(C) and Saccharomyces cerevisiae Ypd1. Loop regions and additional structural features distinguish all three proteins. The CheA domain has an additional C-terminal helix that lies over the surface formed by the C and D helices. The phosphoaccepting His-48 is located at a solvent-exposed position in the middle of the B helix where it is surrounded by several residues that are characteristic of other HPt domains. Mutagenesis studies indicate that conserved glutamate and lysine residues that are part of a hydrogen-bond network with His-48 are essential for the ATP-dependent phosphorylation reaction but not for the phosphotransfer reaction with CheY. These results suggest that the CheA-P1 domain may serve as a good model for understanding the general function of HPt domains in complex two-component phosphorelay systems.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; CNRS, Inst Pharmacol & Biol Struct, Grp Cristallog Biol, F-31077 Toulouse, France	Princeton University; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Stock, JB (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	jstock@princeton.edu; samama@ipbs.fr	Pedelacq, Jean-Denis/C-6053-2011; Da Re, Sandra/F-6383-2011; Mourey, Lionel/B-5662-2009; Guillet, Valérie/C-6058-2011	Da Re, Sandra/0000-0003-3579-9185; Mourey, Lionel/0000-0002-8259-1259; PEDELACQ, Jean-Denis/0000-0002-3202-2517	NIGMS NIH HHS [R01 GM57773] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057773] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Aizawa S, 2000, J BACTERIOL, V182, P1459, DOI 10.1128/JB.182.6.1459-1471.2000; Armitage JP, 1999, ADV MICROB PHYSIOL, V41, P229, DOI 10.1016/S0065-2911(08)60168-X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; Boissy G, 1996, STRUCTURE, V4, P1429, DOI 10.1016/S0969-2126(96)00150-5; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOU KC, 1988, P NATL ACAD SCI USA, V85, P4295, DOI 10.1073/pnas.85.12.4295; CHOU KC, 1992, P NATL ACAD SCI USA, V89, P7315, DOI 10.1073/pnas.89.16.7315; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; Dutta R, 1999, MOL MICROBIOL, V34, P633, DOI 10.1046/j.1365-2958.1999.01646.x; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Evans G, 2001, J APPL CRYSTALLOGR, V34, P82, DOI 10.1107/S0021889800014655; Fraser ME, 2000, J MOL BIOL, V299, P1325, DOI 10.1006/jmbi.2000.3807; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Grebe TW, 1999, ADV MICROB PHYSIOL, V41, P139, DOI 10.1016/S0065-2911(08)60167-8; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; ISHIGE K, 1994, EMBO J, V13, P5195, DOI 10.1002/j.1460-2075.1994.tb06850.x; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Janiak-Spens F, 2000, MOL MICROBIOL, V37, P136, DOI 10.1046/j.1365-2958.2000.01973.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kato M, 1997, CELL, V88, P717, DOI 10.1016/S0092-8674(00)81914-5; Koretke KK, 2000, MOL BIOL EVOL, V17, P1956, DOI 10.1093/oxfordjournals.molbev.a026297; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; Levit M, 1996, J BIOL CHEM, V271, P32057, DOI 10.1074/jbc.271.50.32057; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; Matsubara M, 2000, GENES CELLS, V5, P555, DOI 10.1046/j.1365-2443.2000.00347.x; Matsushika A, 1998, BIOSCI BIOTECH BIOCH, V62, P2236, DOI 10.1271/bbb.62.2236; McEvoy MM, 1998, P NATL ACAD SCI USA, V95, P7333, DOI 10.1073/pnas.95.13.7333; McEvoy MM, 1997, CURR OPIN STRUC BIOL, V7, P793, DOI 10.1016/S0959-440X(97)80148-0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NINFA AJ, 1988, P NATL ACAD SCI USA, V85, P5492, DOI 10.1073/pnas.85.15.5492; OLMEDO G, 1990, J MOL BIOL, V215, P359, DOI 10.1016/S0022-2836(05)80357-2; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROUSSEL A, 1989, SILICON GRAPHIC GEOM, P71; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; Sasaki S., 1989, Numerical tables of anomalous scattering factors calculated by the Cromer and Liberman's method; Silversmith RE, 1997, BIOCHEMISTRY-US, V36, P14965, DOI 10.1021/bi9715573; Song HK, 1999, J MOL BIOL, V293, P753, DOI 10.1006/jmbi.1999.3215; Sourjik V, 1998, BIOCHEMISTRY-US, V37, P2327, DOI 10.1021/bi972330a; Stewart RC, 2000, BIOCHEMISTRY-US, V39, P13157, DOI 10.1021/bi001100k; Stewart RC, 1997, BIOCHEMISTRY-US, V36, P2030, DOI 10.1021/bi962261k; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; Thomason PA, 1999, J BIOL CHEM, V274, P27379, DOI 10.1074/jbc.274.39.27379; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; Tsuzuki M, 1995, MOL MICROBIOL, V18, P953, DOI 10.1111/j.1365-2958.1995.18050953.x; Varughese KI, 1998, MOL CELL, V2, P485, DOI 10.1016/S1097-2765(00)80148-3; Welch M, 1998, NAT STRUCT BIOL, V5, P25, DOI 10.1038/nsb0198-25; Xu QP, 1999, J MOL BIOL, V292, P1039, DOI 10.1006/jmbi.1999.3143; Zapf J, 2000, STRUCTURE, V8, P851, DOI 10.1016/S0969-2126(00)00174-X; ZHOU HJ, 1995, BIOCHEMISTRY-US, V34, P13858, DOI 10.1021/bi00042a018; Zhou HJ, 1997, BIOCHEMISTRY-US, V36, P699, DOI 10.1021/bi961663p	63	70	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31074	31082		10.1074/jbc.M101943200	http://dx.doi.org/10.1074/jbc.M101943200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11387324	Green Published, hybrid			2022-12-27	WOS:000170472900065
J	Pillai, B; Sampath, V; Sharma, N; Sadhale, P				Pillai, B; Sampath, V; Sharma, N; Sadhale, P			Rpb4, a non-essential subunit of core RNA polymerase II of Saccharomyces cerevisiae is important for activated transcription of a subset of genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; HIGH-TEMPERATURE; YEAST; PROTEIN; PROMOTER; TBP; HOLOENZYME; INVITRO; BINDING; DOMAIN	A major role in the regulation of eukaryotic protein-coding genes is played by the gene-specific transcriptional regulators, which recruit the RNA polymerase II holoenzyme to the specific promoter. Several components of the mediator complex within the holoenzyme also have been shown to affect activation of different subsets of genes. Only recently has it been suggested that besides the largest subunit of RNA polymerase Il, smaller subunits like Rpb3 and Rpb5 may have regulatory roles in expression of specific sets of genes. We report here, the role of Rpb4, a non-essential subunit of core RNA polymerase II, in activation of a subset of genes in Saccharomyces cerevisiae. We have shown below that whereas constitutive transcription is largely unaffected, activation from various promoters tested is severely compromised in the absence of RPB4. This activation defect can be rescued by the overexpression of cognate activators. We have localized the region of Rpb4 involved in activation to the C-terminal 24 amino acids. We have also shown here that transcriptional activation by artificial recruitment of the TATA-binding protein (TBP) to the promoter is also defective in the absence of RPB4. Surprisingly, the overexpression of RPB7 (the interacting partner of Rpb4) does not rescue the activation defect of all the promoters tested, although it rescues the activation defect of the heat shock element-containing promoter and the temperature sensitivity associated with RPB4 deletion. Overall, our results indicate that Rpb4 and Rpb7 play independent roles in transcriptional regulation of genes.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Sadhale, P (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.		Sadhale, PArag/A-7799-2009	Pillai, Beena/0000-0002-9302-9878				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Boscheinen O, 1997, MOL GEN GENET, V255, P322, DOI 10.1007/s004380050503; BRENDEL V, 1994, COMPUT CHEM, V18, P251, DOI 10.1016/0097-8485(94)85020-8; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; Corpet F, 1999, NUCLEIC ACIDS RES, V27, P263, DOI 10.1093/nar/27.1.263; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Jensen GJ, 1998, EMBO J, V17, P2353, DOI 10.1017/S1431927600024983; Kabir MA, 2000, MOL GEN GENET, V262, P1113, DOI 10.1007/PL00008654; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Lee D, 1998, NATURE, V393, P389, DOI 10.1038/30770; LESSER CF, 1993, GENETICS, V133, P851; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Maillet I, 1999, J BIOL CHEM, V274, P22586, DOI 10.1074/jbc.274.32.22586; McNeil JB, 1998, GENE DEV, V12, P2510, DOI 10.1101/gad.12.16.2510; Miyao T, 1998, P NATL ACAD SCI USA, V95, P15281, DOI 10.1073/pnas.95.26.15281; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Piruat JI, 1997, GENETICS, V147, P1585; Ranish JA, 1996, CURR OPIN GENET DEV, V6, P151, DOI 10.1016/S0959-437X(96)80044-X; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Rosenheck S, 1998, J BACTERIOL, V180, P6187; RUET A, 1980, J BIOL CHEM, V255, P6450; RUSSNAK R, 1995, MOL CELL BIOL, V15, P1689; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Sharma N, 1999, J GENET, V78, P149, DOI 10.1007/BF02934460; Sheffer A, 1999, MOL CELL BIOL, V19, P2672; SHERMAN F, 1986, LABORATORY COURSE MA, P121; Tan Q, 2000, MOL CELL BIOL, V20, P8124, DOI 10.1128/MCB.20.21.8124-8133.2000; Tan Q, 2000, GENE DEV, V14, P339; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985	43	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30641	30647		10.1074/jbc.M010952200	http://dx.doi.org/10.1074/jbc.M010952200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11382749	hybrid			2022-12-27	WOS:000170472900009
J	Ben-Menahem, D; Jablonka-Shariff, A; Hyde, RK; Pixley, MR; Srivastava, S; Berger, P; Boime, I				Ben-Menahem, D; Jablonka-Shariff, A; Hyde, RK; Pixley, MR; Srivastava, S; Berger, P; Boime, I			The position of the alpha and beta subunits in a single chain variant of human chorionic gonadotropin affects the heterodimeric interaction of the subunits and receptor-binding epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; INDIVIDUAL DISULFIDE BONDS; HUMAN CHORIOGONADOTROPIN; GLYCOPROTEIN HORMONES; TERMINAL REGION; EXPRESSION; COMMON; FOLLITROPIN; SEQUENCE; PROTEIN	The glycoprotein hormone family represents a class of heterodimers, which include the placental hormone human chorionic gonadotropin (CG) and the anterior pituitary hormones follitropin, lutropin, and thyrotropin. They are composed of common alpha subunit and a hormone-specific beta subunit. Based on the CG crystal structure, it was suggested that the quaternary subunit interactions are crucial for biological activity. However, recent observations using single chain glycoprotein hormone analogs, where the beta and alpha subunits are linked (NH2-CG beta-alpha; CG beta alpha orientation), implied that the heterodimeric-like quaternary configuration is not a prerequisite for receptor binding/signal transduction. To study the heterodimeric alignment of the two subunit domains in a single chain and its role in the intracellular behavior and biological action of the hormone, a single chain CG variant was constructed in which the carboxyl terminus of a was fused to the CG beta amino terminus (NH2-alpha -CG beta; alpha CG beta orientation). The secretion rate of alpha CG beta from transfected Chinese hamster ovary cells was less than that seen for CG beta alpha. The alpha CG beta tether was not recognized by dimer-specific monoclonal antibodies and did not bind to lutropin/CG receptor. To define if one or both subunit domains were modified in alpha CG beta, it was co-transfected with a monomeric a or CGP gene. In each case, alpha CG beta/alpha and alpha CG beta /CG beta complexes were formed indicating that CG dimer-specific epitopes were established. The alpha CG beta/alpha complex bound to receptor indicating that the beta domain in the alpha CG/beta tether was still functional. In contrast, no significant receptor binding of alpha CG beta /CG beta was observed indicating a major perturbation in the alpha domain. These results suggest that although dimeric-like determinants are present in both alpha CG beta/alpha and alpha CG beta /CG beta complexes, the receptor binding determinants in the alpha domain of the tether are absent. These results show that generating heterodimeric determinants do not necessarily result in a bioactive molecule. Our data also indicate that the determinants for biological activity are distinct from those associated with intracellular behavior.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Austrian Acad Sci, Inst Biomed Aging Res, A-6020 Innsbruck, Austria	Washington University (WUSTL); Austrian Academy of Sciences	Boime, I (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, 660 S Euclin Ave, St Louis, MO 63110 USA.		hyde, kate/S-3235-2019	Ben-Menahem, David/0000-0002-8985-0591				Ben-Menahem D, 1999, BIOCHEMISTRY-US, V38, P15070, DOI 10.1021/bi991510c; BenMenahem D, 1996, TRENDS ENDOCRIN MET, V7, P100, DOI 10.1016/1043-2760(96)88667-X; BenMenahem D, 1997, J BIOL CHEM, V272, P6827, DOI 10.1074/jbc.272.11.6827; BIELINSKA M, 1990, J CELL BIOL, V111, P330; Birken S, 1996, ENDOCRINOLOGY, V137, P1402, DOI 10.1210/en.137.4.1402; BIRKEN S, 1977, J BIOL CHEM, V252, P5386; CHARLESWORTH MC, 1987, J BIOL CHEM, V262, P13409; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; Falcon CM, 1999, J BIOL CHEM, V274, P30849, DOI 10.1074/jbc.274.43.30849; FARES FA, 1992, P NATL ACAD SCI USA, V89, P4304, DOI 10.1073/pnas.89.10.4304; Fares FA, 1998, ENDOCRINOLOGY, V139, P2459, DOI 10.1210/en.139.5.2459; FURUHASHI M, 1994, J BIOL CHEM, V269, P25543; FURUHASHI M, 1995, MOL ENDOCRINOL, V9, P54, DOI 10.1210/me.9.1.54; Grossmann M, 1997, J BIOL CHEM, V272, P21312, DOI 10.1074/jbc.272.34.21312; Gupta C. Sen, 2000, Journal of Molecular Endocrinology, V24, P157; Jackson AM, 1999, MOL ENDOCRINOL, V13, P2175, DOI 10.1210/me.13.12.2175; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kanda M, 1999, MOL ENDOCRINOL, V13, P1873, DOI 10.1210/me.13.11.1873; KEENE JL, 1989, J BIOL CHEM, V264, P4769; LUSTBADER J, 1987, J BIOL CHEM, V262, P14204; MERZ WE, 1979, EUR J BIOCHEM, V101, P541, DOI 10.1111/j.1432-1033.1979.tb19749.x; NARAYAN P, 1995, MOL ENDOCRINOL, V9, P1720, DOI 10.1210/me.9.12.1720; Narayan P, 2000, ENDOCRINOLOGY, V141, P67, DOI 10.1210/en.141.1.67; PARSONS TF, 1979, J BIOL CHEM, V254, P6010; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SALESSE R, 1990, MOL CELL ENDOCRINOL, V68, P113, DOI 10.1016/0303-7207(90)90183-9; Sato A, 1997, J BIOL CHEM, V272, P18098, DOI 10.1074/jbc.272.29.18098; Sugahara T, 1996, J BIOL CHEM, V271, P10445, DOI 10.1074/jbc.271.18.10445; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; WEISS J, 1992, NEW ENGL J MED, V326, P179, DOI 10.1056/NEJM199201163260306; XIA H, 1993, J MOL ENDOCRINOL, V10, P337, DOI 10.1677/jme.0.0100337; YOO JK, 1993, J BIOL CHEM, V268, P13034	33	13	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29871	29879		10.1074/jbc.M104687200	http://dx.doi.org/10.1074/jbc.M104687200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390409	hybrid			2022-12-27	WOS:000170558000037
J	Mullally, JE; Moos, PJ; Edes, K; Fitzpatrick, FA				Mullally, JE; Moos, PJ; Edes, K; Fitzpatrick, FA			Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MALIGNANT-MELANOMA CELLS; CROSS-LINKED PROTEIN; P53 TUMOR-SUPPRESSOR; HUMAN GLIOMA-CELLS; MULTICATALYTIC PROTEASE; GROWTH-INHIBITION; OXIDATIVE STRESS; CANCER-CELLS; MUTANT P53	Electrophilic eicosanoids of the J series, with their distinctive cross-conjugated alpha,beta -unsaturated ketone, inactivate genetically wild type tumor suppressor p53 in a manner analogous to prostaglandins of the A series. Like the prostaglandins of the A series, prostaglandins of the J series have a structural determinant (endocyclic cyclopentenone) that confers the ability to impair the conformation, the phosphorylation, and the transcriptional activity of the p53 tumor suppressor with equivalent potency and efficacy. However, J series prostaglandins have a unique structural determinant (exocyclic alpha,beta -unsaturated ketone) that confers unique efficacy as an apoptotic agonist. In seeking to understand how J series prostaglandins cause apoptosis despite their inactivation of p53, we discovered that they inhibit the ubiquitin isopeptidase activity of the proteasome pathway. In this regard, J series prostaglandins were more efficacious inhibitors than representative members of the A, B, or E series prostaglandins. Disruption of the proteasome pathway with proteasome inhibitors can cause apoptosis independently of p53. Therefore, this finding helps reconcile the p53 transcriptional independence of apoptosis caused by Delta 12-prostaglandin J(2). This. discovery represents a novel mechanism for proteasome pathway inhibition in intact cells. Furthermore, it identifies isopeptidases as novel targets for the development of antineoplastic agents.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84108 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Fitzpatrick, FA (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84108 USA.			Moos, Philip/0000-0002-8223-442X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026730] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 26730] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams J, 1999, CANCER RES, V59, P2615; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTEK J, 1991, ONCOGENE, V6, P1699; BARTEK J, 1990, ONCOGENE, V5, P893; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CHARD PS, 1995, NEUROSCIENCE, V65, P1099, DOI 10.1016/0306-4522(94)00548-J; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Clay CE, 1999, CARCINOGENESIS, V20, P1905, DOI 10.1093/carcin/20.10.1905; Dang LC, 1998, BIOCHEMISTRY-US, V37, P1868, DOI 10.1021/bi9723360; Desterro JMP, 2000, CELL MOL LIFE SCI, V57, P1207, DOI 10.1007/PL00000760; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FITZPATRICK FA, 1979, P NATL ACAD SCI USA, V76, P1765, DOI 10.1073/pnas.76.4.1765; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Glockzin S, 1999, J BIOL CHEM, V274, P19581, DOI 10.1074/jbc.274.28.19581; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HONN KV, 1985, BIOCHEM BIOPH RES CO, V129, P34, DOI 10.1016/0006-291X(85)91398-1; HOUGH R, 1986, J BIOL CHEM, V261, P2391; Keller JN, 2000, J CEREBR BLOOD F MET, V20, P1467, DOI 10.1097/00004647-200010000-00008; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kitagawa H, 1999, FEBS LETT, V443, P181, DOI 10.1016/S0014-5793(98)01709-8; LEGROS Y, 1994, ONCOGENE, V9, P3689; Liu H, 1996, J BIOL CHEM, V271, P4805; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; Meng LH, 1999, CANCER RES, V59, P2798; Moos PJ, 1998, CELL GROWTH DIFFER, V9, P687; Moos PJ, 2000, P NATL ACAD SCI USA, V97, P9215, DOI 10.1073/pnas.160241897; Mueller H, 1996, ANTICANCER RES, V16, P3845; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; NARUMIYA S, 1985, BIOCHEM BIOPH RES CO, V127, P739, DOI 10.1016/S0006-291X(85)80005-X; OConnor PM, 1997, CANCER RES, V57, P4285; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; Pich A, 1998, CANCER J - FRANCE, V11, P223; Prives C, 1999, J PATHOL, V187, P112; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; SASAKI H, 1991, GYNECOL ONCOL, V41, P36, DOI 10.1016/0090-8258(91)90251-Y; SCHAEFFER JR, 1996, BIOCHEMISTRY-US, V35, P10886; Shringarpure R, 2000, CELL MOL LIFE SCI, V57, P1802, DOI 10.1007/PL00000660; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; STRINGFELLOW DA, 1979, NATURE, V282, P76, DOI 10.1038/282076a0; Wagenknecht B, 1999, CELL PHYSIOL BIOCHEM, V9, P117, DOI 10.1159/000016308; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Yin LM, 2000, BIOCHEMISTRY-US, V39, P10001, DOI 10.1021/bi0007019	56	113	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30366	30373		10.1074/jbc.M102198200	http://dx.doi.org/10.1074/jbc.M102198200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390388	hybrid			2022-12-27	WOS:000170558000100
J	Zhang, J; Kabra, NH; Cado, D; Kang, C; Winoto, A				Zhang, J; Kabra, NH; Cado, D; Kang, C; Winoto, A			FADD-deficient T cells exhibit a disaccord in regulation of the cell cycle machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH DOMAIN; INHIBITS PROLIFERATION; MEDIATED APOPTOSIS; TRAIL RECEPTOR-2; PROTEIN; FAS; FADD/MORT1; LYMPHOCYTES; PROGRESSION; CASPASE-8	FADD is an adapter protein that was originally isolated as a transducer of apoptotic signals for death domain-containing receptors. However, FADD-deficient mice are embryonic lethal and FADD(-/-) T cells developed from FADD(-/-) embryonic stem cells in the RAG-1(-/-) hosts lack the full potential to proliferate when stimulated through their T-cell receptor complex, suggesting that FADD protein might play a dualistic role in mediating not only cell death signaling but other non-apoptotic cellular pathways as well. Here we show that a substantial number of freshly isolated FADD(-/-) peripheral T cells are cycling but are defective in their co-stimulatory response when stimulated. Analysis of several cell cycle proteins shows normal down-regulation of p27 inhibitor but increased levels of p21, decreased levels of cyclin D2, and constitutive activation of several cyclin-dependent kinases in activated T cells. These data suggest that FADD is involved in the regulation of cell cycle machinery in T lymphocytes.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Winoto, A (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA.			Zhang, Jianke/0000-0002-5822-2226	NCI NIH HHS [CA75162] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075162] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Hueber AO, 2000, J BIOL CHEM, V275, P10453, DOI 10.1074/jbc.275.14.10453; KAHRA NH, 2001, P NATL ACAD SCI USA, V98, P6307; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; LUCAS JJ, 1995, J IMMUNOL, V154, P6275; Morgan DO, 1996, CURR OPIN CELL BIOL, V8, P767, DOI 10.1016/S0955-0674(96)80076-7; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Song KM, 2000, J EXP MED, V191, P1095, DOI 10.1084/jem.191.7.1095; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Surh CD, 2000, J EXP MED, V192, pF9, DOI 10.1084/jem.192.4.F9; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang J, 1999, COLD SPRING HARB SYM, V64, P363, DOI 10.1101/sqb.1999.64.363; Zhang J, 1996, MOL CELL BIOL, V16, P2756; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhou T, 1996, J IMMUNOL, V156, P2661; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	36	78	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29815	29818		10.1074/jbc.M103838200	http://dx.doi.org/10.1074/jbc.M103838200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390402	hybrid			2022-12-27	WOS:000170558000029
J	Bender, K; Wellner-Kienitz, MC; Inanobe, A; Meyer, T; Kurachi, Y; Pott, L				Bender, K; Wellner-Kienitz, MC; Inanobe, A; Meyer, T; Kurachi, Y; Pott, L			Overexpression of monomeric and multimeric GIRK4 subunits in rat atrial myocytes removes fast desensitization and reduces inward rectification of muscarinic K(+) current (I(K(ACh))) - Evidence for functional homomeric GIRK4 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN REGULATION; RECTIFYING POTASSIUM CHANNELS; BETA-GAMMA-SUBUNITS; I-KACH; COUPLED RECEPTORS; PLASMA-MEMBRANE; DOWN-REGULATION; M-2 RECEPTORS; ACTIVATION; BINDING	K(+) channels composed of G-protein-coupled inwardly rectifying K(+) channel (GIRK) (Kir3.0) subunits are ex. pressed in cardiac, neuronal, and various endocrine tissues. They are involved in inhibiting excitability and contribute to regulating important physiological functions such as cardiac frequency and secretion of hormones. The functional cardiac (K((ACh))) channel activated by G(i)/G(o)-coupled receptors such as muscarinic M(2) or purinergic A., receptors is supposed to be composed of the subunits GIRK1 and GIRK4 in a heterotetrameric (2:2) fashion. In the present study, we have manipulated the subunit composition of the K(ACh) channels in cultured atrial myocytes from hearts of adult rats by transient transfection of vectors encoding for GIRK1 or GIRK4 subunits or GIRK4 concatemeric constructs and investigated the effects on properties of macroscopic IK(Ach). Transfection with a GIRK1 vector did not cause any measurable effect on properties Of IK(ACh), whereas transfection with a GIRK4 vector resulted in a complete loss in desensitization, a reduction of inward rectification, and a slowing of activation. Transfection of myocytes with a construct encoding for a concatemeric GIRK4(2) subunit had similar effects on desensitization and inward rectification. Following transfection of a tetrameric construct (GIRK4,), these changes in properties Of IK(ACh) were still observed but were less pronounced. Heterologous expression in Chinese hamster ovary cells and human embryonic kidney 293 cells of monomeric, dimeric, and tetrameric GIRK4 resulted in robust currents activated by co-expressed A(1) and M(2) receptors, respectively. These data provide strong evidence that homomeric GIRK4 complexes form functional G(beta gamma) gated ion channels and that kinetic properties of GIRK channels, such as activation rate, desensitization, and inward rectification, depend on subunit composition.	Ruhr Univ Bochum, Inst Physiol, D-4480 Bochum, Germany; Osaka Univ, Grad Sch, Dept Pharmacol 2, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Med, Suita, Osaka 5650871, Japan	Ruhr University Bochum; Osaka University; Osaka University	Pott, L (corresponding author), Ruhr Univ Bochum, Inst Physiol, D-4480 Bochum, Germany.	lutz.pott@ruhr-uni-bochum.de	Pott, Lutz/E-5304-2011	Pott, Lutz/0000-0002-4000-4132				Brandts B, 1997, BRIT J PHARMACOL, V121, P1217, DOI 10.1038/sj.bjp.0701254; Bunemann M, 2000, J BIOL CHEM, V275, P12537, DOI 10.1074/jbc.275.17.12537; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; Bunemann M, 1997, J PHYSIOL-LONDON, V501, P549, DOI 10.1111/j.1469-7793.1997.549bm.x; BUNEMANN M, 1996, J PHYSIOL-LONDON, V492, P351; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; Corey S, 2001, J BIOL CHEM, V276, P11409, DOI 10.1074/jbc.M100058200; Corey S, 1998, J BIOL CHEM, V273, P27499, DOI 10.1074/jbc.273.42.27499; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; Guo DL, 2000, J GEN PHYSIOL, V116, P561, DOI 10.1085/jgp.116.4.561; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; Inanobe A, 1999, J NEUROSCI, V19, P1006; Jan LY, 1997, J PHYSIOL-LONDON, V505, P267, DOI 10.1111/j.1469-7793.1997.267bb.x; Jelacic TM, 2000, J BIOL CHEM, V275, P36211, DOI 10.1074/jbc.M007087200; Ji S, 1998, J BIOL CHEM, V273, P1324, DOI 10.1074/jbc.273.3.1324; Karschin A, 1999, NEWS PHYSIOL SCI, V14, P215; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; KIM DH, 1993, CIRC RES, V73, P89, DOI 10.1161/01.RES.73.1.89; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Koumi S, 1997, J MEMBRANE BIOL, V157, P71, DOI 10.1007/s002329900217; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KURACHI Y, 1987, PFLUG ARCH EUR J PHY, V410, P227, DOI 10.1007/BF00580270; Meyer T, 2001, J BIOL CHEM, V276, P5650, DOI 10.1074/jbc.M009179200; Morishige K, 1999, J BIOL CHEM, V274, P7969, DOI 10.1074/jbc.274.12.7969; Oliver D, 2000, EUR J BIOCHEM, V267, P5824, DOI 10.1046/j.1432-1327.2000.01669.x; Shui Z, 1997, J PHYSIOL-LONDON, V505, P77, DOI 10.1111/j.1469-7793.1997.077bc.x; Silverman SK, 1996, J BIOL CHEM, V271, P30524, DOI 10.1074/jbc.271.48.30524; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; TAKAO K, 1994, NEURON, V13, P747, DOI 10.1016/0896-6273(94)90041-8; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9; Tucker SJ, 1996, AM J PHYSIOL-HEART C, V271, pH379, DOI 10.1152/ajpheart.1996.271.1.H379; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Wellner-Kienitz MC, 1999, FEBS LETT, V451, P279, DOI 10.1016/S0014-5793(99)00594-3; Wellner-Kienitz MC, 2000, CIRC RES, V86, P643, DOI 10.1161/01.RES.86.6.643; Wickman K, 2000, J NEUROSCI, V20, P5608, DOI 10.1523/JNEUROSCI.20-15-05608.2000; YAMADA M, 1995, J BIOL CHEM, V270, P9289, DOI 10.1074/jbc.270.16.9289; Yamada M, 1998, PHARMACOL REV, V50, P723	45	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28873	28880		10.1074/jbc.M102328200	http://dx.doi.org/10.1074/jbc.M102328200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384974	hybrid			2022-12-27	WOS:000170346000033
J	Koutsodontis, G; Tentes, I; Papakosta, P; Moustakas, A; Kardassis, D				Koutsodontis, G; Tentes, I; Papakosta, P; Moustakas, A; Kardassis, D			Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CELL-CYCLE; WAF1/CIP1 GENE; P53-INDEPENDENT PATHWAY; FUNCTIONAL INTERACTIONS; SYNERGISTIC ACTIVATION; P53-INDUCED APOPTOSIS; EMBRYONIC-DEVELOPMENT; POTENTIAL MEDIATOR; CARCINOMA-CELLS	In the present study we present evidence for the critical role of Spl in the mechanism of transactivation of the human cell cycle inhibitor p21(WAF1/Cip1) (p21) gene promoter by the tumor suppressor p53 protein. We found that the distal p53-binding site of the p21 promoter acts as an enhancer on the homologous or heterologous promoters in hepatoma HepG2 cells. In transfection experiments, p53 transactivated the p21 promoter in HaCaT cells that express Spl but have a mutated p53 form. In contrast, p53 could not transactivate the p21 promoter in the Drosophila embryo-derived Schneider's SL2 cells that lack endogenous Spl or related factors. Cotransfection of SL2 cells with p53 and Spl resulted in a synergistic transactivation of the p21 promoter. Synergistic transactivation was greatly decreased in SL2 cells and HaCaT cells by mutations in either the p53-binding site or in the -82/-77 Spl-binding site indicating functional cooperation between Spl and p53 in the transactivation of the p21 promoter. Synergistic transactivation was also decreased by mutations in the transactivation domain of p53. Physical interactions between Spl and p53 proteins were established by glutathione S-transferase pull-down and coimmunoprecipitation assays. By using deletion mutants we found that the DNA binding domain of Spl is required for its physical interaction with p53. In conclusion, Spl must play a critical role in regulating important biological processes controlled by p53 via p21 gene activation such as DNA repair, cell growth, differentiation, and apoptosis.	Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Greece; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Democritus Univ Thrace, Sch Med, Dept Biochem, GR-68100 Alexandroupolis, Greece	University of Crete; Foundation for Research & Technology - Hellas (FORTH); Ludwig Institute for Cancer Research; Democritus University of Thrace	Kardassis, D (corresponding author), Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece.	kardasis@imbb.forth.gr						AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Bist A, 2000, BIOCHEMISTRY-US, V39, P1966, DOI 10.1021/bi991721h; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Hunt KK, 1998, CANCER RES, V58, P5656; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; Jaiswal AS, 2001, J BIOL CHEM, V276, P18193, DOI 10.1074/jbc.M101298200; JIANG HP, 1994, ONCOGENE, V9, P3397; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KARDASSIS D, 1992, J BIOL CHEM, V267, P7956; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kolli S, 2001, P NATL ACAD SCI USA, V98, P4646, DOI 10.1073/pnas.081141998; Lange C, 2000, BIOCHEM BIOPH RES CO, V278, P125, DOI 10.1006/bbrc.2000.3782; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MICHIELI P, 1994, CANCER RES, V54, P3391; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; Yan GZ, 1997, J NEUROSCI, V17, P6122; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zauberman A, 1997, ONCOGENE, V15, P1705, DOI 10.1038/sj.onc.1201348; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; ZHANG H, 1994, COLD SPRING HARB SYM, V59, P21, DOI 10.1101/SQB.1994.059.01.005; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhang LL, 2000, CANCER RES, V60, P3655; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhao RB, 2000, GENE DEV, V14, P981	81	141	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29116	29125		10.1074/jbc.M104130200	http://dx.doi.org/10.1074/jbc.M104130200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384995	hybrid			2022-12-27	WOS:000170346000066
J	Leber, R; Silles, E; Sandoval, IV; Mazon, MJ				Leber, R; Silles, E; Sandoval, IV; Mazon, MJ			Yo1082p, a novel CVT protein involved in the selective targeting of aminopeptidase I to the yeast vacuole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE DELETION; CYTOPLASM; AUTOPHAGY; PATHWAYS; TRANSPORT; MACROAUTOPHAGY; MECHANISM; CELLS	The yeast vacuolar enzyme aminopeptidase I (API) is synthesized in the cytoplasm as a precursor (pAPI). Upon its assembly into dodecamers, pAPI is wrapped by double-membrane saccular structures for its further transport within vesicles that fuse with the vacuolar membrane and release their content in the vacuolar lumen. Targeting of API to the vacuole occurs by two alternative transport routes, the cvt and the autophagy pathways, which although mechanistically similar specifically operate under vegetative growth or nitrogen starvation conditions, respectively. We have studied the role of Yol082p, a protein identified by its ability to interact with API, in the transport of its precursor to the vacuole. We show that Yol082p, interacts with mature API, an interaction that is strengthened by the amino extension of the API protein. Yol082p is required for targeting of pAPI to the vacuole, both under growing and short term nitrogen starvation conditions. Absence of Yol082p does not impede the assembly of pAPI into dodecamers, but precludes the enclosure of pAPI within transport vesicles. Microscopy studies show that during vegetative growth Yol082p is distributed between a cytoplasmic pool and a variable number of 0.13-0.27-mum round, mobile structures, which are no longer observed under conditions of nitrogen starvation, and become larger in cells expressing the inactive Yol082 Delta C32p, or lacking Apg12p. In contrast to the autophagy mutants involved in API transport, a Delta yol082 strain does not lose viability under nitrogen starvation conditions, indicating normal function of the autophagy pathway. The data are consistent with a role of Yol082p in an early step of the API transport, after its assembly into dodecamers. Because Yo1082p fulfills the functional requisites that define the CVT proteins, we propose to name it Cvt19.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Mazon, MJ (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain.		Calpena, María Jesús Mazón/E-9168-2016	Calpena, María Jesús Mazón/0000-0003-4151-4051; Leber, Regina/0000-0001-5306-5834				Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Adams Alison, 1997, P123; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; George MD, 2000, MOL BIOL CELL, V11, P969, DOI 10.1091/mbc.11.3.969; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; James P, 1996, GENETICS, V144, P1425; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Martinez E, 1999, MOL MICROBIOL, V33, P52, DOI 10.1046/j.1365-2958.1999.01446.x; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Oda MN, 1996, J CELL BIOL, V132, P999, DOI 10.1083/jcb.132.6.999; Satyanarayana C, 2000, FEBS LETT, V470, P232, DOI 10.1016/S0014-5793(00)01324-7; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Scott SV, 1995, J CELL BIOL, V131, P1727, DOI 10.1083/jcb.131.6.1727; SEGUIREAL B, 1995, EMBO J, V14, P5476, DOI 10.1002/j.1460-2075.1995.tb00234.x; Silles E, 2000, J BIOL CHEM, V275, P34054, DOI 10.1074/jbc.M003514200; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	29	59	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29210	29217		10.1074/jbc.M101438200	http://dx.doi.org/10.1074/jbc.M101438200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382752	hybrid			2022-12-27	WOS:000170346000078
J	Ng, DCH; Long, CS; Bogoyevitch, MA				Ng, DCH; Long, CS; Bogoyevitch, MA			A role for the extracellular signal-regulated kinase and p38 mitogen-activated protein kinases in interleukin-1 beta-stimulated delayed signal tranducer and activator of transcription 3 activation, atrial natriuretic factor expression, and cardiac myocyte morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-INFLAMMATORY CYTOKINES; LEUKEMIA INHIBITORY FACTOR; GENE-EXPRESSION; C-JUN; HYPERTROPHIC RESPONSE; INTERLEUKIN-6 FAMILY; CELLULAR STRESSES; STAT3 ACTIVATION; PATHWAY; GP130	We have demonstrated that two hypertrophic agents, interleukin-1 (IL-1 beta) and leukemic inhibitory factor (LIF), altered cardiac myocyte morphology with striking similarity and prompted us to investigate the common actions of these cytokines. We compared the phosphorylation/activation of signal tranducer and activator of transcription 3 (STAT3), extracellular signal-regulated kinase (ERK), p38(MAPK), and c-Jun N-terminal kinase mitogen-activated protein kinases (MAPKs). The phosphorylation of STAT3 by IL-1 beta was delayed (> 60 min), whereas the response to LIF was rapid (< 10 min) and transient. We confirmed that IL-1 beta potently stimulated all three MAPK subfamilies. In contrast, LIF promoted strong activation of ERKs, marginal activation of p38(MAPK), and no c-Jun N-terminal kinase activation. To test the roles of ERKs and p38(MAPK), myocytes were pretreated with PD98059 and SB203580. Either inhibitor alone prevented STAT3 phosphorylation, implicating ERKs and p38MAPK in the delayed STAT3 response to IL-1 beta. The interplay of MAPKs and STAT3 phosphorylation in regulating IL-lp-stimulated hypertrophy was investigated by evaluating the effect of MAPK inhibitors on atrial natriuretic factor (ANF) expression and myocyte morphology. The specific inhibition of either ERK or p38(MAPK) attenuated the IL-1 beta- or LIF-stimulated ANF expression by up to 70%. Inhibition was not further increased in the presence of both inhibitors. Furthermore, although individual inhibition of ERK or p38(MAPK) did not affect morphology, co-treatment with both inhibitors abrogated the hypertrophic morphology stimulated by IL-1 beta but not by LIF. Taken together, our data indicate that the activation of ERK and p38(MAPK) is essential in regulating a delayed STAT3 phosphorylation as well as changes in ANF expression and morphology that follow IL-1 beta treatment. Thus, the role of MAPKs in the hypertrophic response can be dictated at least partly by the nature of the hypertrophic agent employed.	Univ Western Australia, Dept Biochem, Cell Signaling Lab, Crawley, WA 6009, Australia; Denver Hlth Med Ctr, Cardiol Sect, Denver, CO 80204 USA; Univ Colorado, Denver, CO 80204 USA; Western Australian Inst Med Res, Perth, WA 6000, Australia	University of Western Australia; Denver Health Medical Center; University of Colorado System; University of Colorado Denver; University of Western Australia	Bogoyevitch, MA (corresponding author), Univ Western Australia, Dept Biochem, Cell Signaling Lab, 35 Stirling Hwy, Crawley, WA 6009, Australia.	marieb@cyllene.uwa.edu.au	Ng, Dominic/C-7291-2015	Ng, Dominic/0000-0003-4657-159X; Bogoyevitch, Marie/0000-0001-9745-3716; Long, Carlin/0000-0001-7251-2847				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aoki H, 2000, BIOCHEM J, V347, P275, DOI 10.1042/0264-6021:3470275; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Bogoyevitch MA, 2000, CARDIOVASC RES, V45, P826, DOI 10.1016/S0008-6363(99)00386-7; Bueno OF, 2001, CIRC RES, V88, P88, DOI 10.1161/01.RES.88.1.88; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; CANO E, 1995, J CELL SCI, V108, P3599; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Clerk A, 1999, J MOL CELL CARDIOL, V31, P2087, DOI 10.1006/jmcc.1999.1040; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; De Windt LJ, 2001, P NATL ACAD SCI USA, V98, P3322, DOI 10.1073/pnas.031371998; Fukada T, 1999, GROWTH FACTORS, V17, P81, DOI 10.3109/08977199909103518; GERDES AM, 1988, LAB INVEST, V59, P857; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Harada E, 1999, J MOL CELL CARDIOL, V31, P1997, DOI 10.1006/jmcc.1999.1030; Hefti MA, 1997, J MOL CELL CARDIOL, V29, P2873, DOI 10.1006/jmcc.1997.0523; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Kunisada K, 2000, P NATL ACAD SCI USA, V97, P315, DOI 10.1073/pnas.97.1.315; Kunisada K, 1996, CIRCULATION, V94, P2626, DOI 10.1161/01.CIR.94.10.2626; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Legrand-Poels S, 2000, BIOCHEM J, V349, P765, DOI 10.1042/bj3490765; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Nguyen VAT, 1999, J BIOL CHEM, V274, P35492, DOI 10.1074/jbc.274.50.35492; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; O'Neill LA, 2000, SCI STKE; Olivetti G, 2000, CARDIOVASC RES, V45, P68, DOI 10.1016/S0008-6363(99)00298-9; PALMER JN, 1995, J CLIN INVEST, V95, P2555, DOI 10.1172/JCI117956; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Ross RS, 1998, CIRC RES, V82, P1160, DOI 10.1161/01.RES.82.11.1160; Saito S, 1999, FEBS LETT, V456, P103, DOI 10.1016/S0014-5793(99)00936-9; Saklatvala J, 1999, BIOCHEM SOC SYMP, P63; Sano M, 2000, BIOCHEM BIOPH RES CO, V269, P798, DOI 10.1006/bbrc.2000.2364; Sano M, 2000, J BIOL CHEM, V275, P29717, DOI 10.1074/jbc.M003128200; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Shioi T, 1997, CIRC RES, V81, P664; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; Taylor JM, 2000, J BIOL CHEM, V275, P19250, DOI 10.1074/jbc.M909099199; THAIK CM, 1995, J CLIN INVEST, V96, P1093, DOI 10.1172/JCI118095; THORBURN J, 1994, J BIOL CHEM, V269, P30580; Ueyama T, 2000, J MOL CELL CARDIOL, V32, P947, DOI 10.1006/jmcc.2000.1135; Uozumi H, 2001, J BIOL CHEM, V276, P23115, DOI 10.1074/jbc.M100814200; Vikstrom KL, 1998, CIRC RES, V82, P773, DOI 10.1161/01.RES.82.7.773; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; Yamauchi-Takihara K, 2000, INT J EXP PATHOL, V81, P1; YOKOTA N, 1995, AM J HYPERTENS, V8, P301, DOI 10.1016/0895-7061(94)00210-3; Yue P, 1998, AM J PHYSIOL-HEART C, V275, pH250, DOI 10.1152/ajpheart.1998.275.1.H250; Yue TL, 2000, J BIOL CHEM, V275, P37895, DOI 10.1074/jbc.M007037200	55	67	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29490	29498		10.1074/jbc.M100699200	http://dx.doi.org/10.1074/jbc.M100699200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382751	hybrid			2022-12-27	WOS:000170346000112
J	Persson, E; Bak, H; Olsen, OH				Persson, E; Bak, H; Olsen, OH			Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR VIIA; TISSUE FACTOR-BINDING; DOSE FACTOR-VIIA; BLOOD-COAGULATION; EXTRINSIC PATHWAY; CRYSTAL-STRUCTURE; ANTITHROMBIN-III; FACTOR-X; DOMAIN; ACTIVATION	Factor VII requires the cleavage of an internal peptide bond and the association with tissue factor (TF) to attain its fully active factor VIIa (FVIIa) conformation. The former event alone leaves FVIIa in a zymogen-like state of relatively low specific activity. We have designed a number of FVIIa mutants with the aim of mimicking the effect of TF, that is, creating molecules with increased intrinsic (TF-independent) enzymatic activity. Based on a possible structural difference between free and TF-bound FVIIa (Pike, A. C. W., Brzozowski, A. M., Roberts, S. M., Olsen, O. H., and Persson, E. (1999) Proc. Natl. Acad. Sci. U.S.A. 96, 8925-8930), we focused on the helical region encompassing residues 307-312 and residues in its spatial vicinity. For instance, FVIIa contains Phe-374 and Leu-305, whereas a Phe/Tyr residue in the position corresponding to 374 in homologous coagulation serine proteases is accompanied by Val in the position corresponding to 305. This conceivably results in a unique orientation of this helix in FVIIa. Substitution of Val for Leu-305 in FVIIa resulted in a 3-4-fold increase in the intrinsic amidolytic and proteolytic activity as compared with wild-type FVIIa, whereas the activity in complex with soluble TF remained the same. In accordance with this, L305V-FVIIa exhibited an increased rate of inhibition as compared with wild-type FVIIa, both by D-Phe-Phe-Arg-chloromethyl ketone and antithrombin III in the presence of heparin. The increased FVIIa activity upon replacement of Leu-305 by Val may be mediated by a movement of the 307-312 helix into an orientation resembling that found in factors IXa and Xa and thrombin. The corresponding shortening of the side chain of residue 374 (Phe --> Pro) had a smaller effect (about 1.5-fold increase) on the intrinsic activity of FVIIa. Attempts to increase FVIIa activity by introducing single or multiple mutations at positions 306, 309, and 312 to stabilize the 307-312 helix failed.	Novo Nordisk AS, Vasc Biochem, DK-2760 Malov, Denmark; Novo Nordisk AS, Med Chem Res 4, DK-2760 Malov, Denmark	Novo Nordisk; Novo Nordisk	Persson, E (corresponding author), Novo Nordisk AS, Vasc Biochem, Novo Nordisk Pk, DK-2760 Malov, Denmark.			Persson, Egon/0000-0003-3005-4926				Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; Dickinson CD, 1997, J BIOL CHEM, V272, P19875, DOI 10.1074/jbc.272.32.19875; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Freskgard PO, 1996, PROTEIN SCI, V5, P1531, DOI 10.1002/pro.5560050809; HOFFMAN M, 1994, BLOOD, V83, P38; Kemball-Cook G, 1999, J STRUCT BIOL, V127, P213, DOI 10.1006/jsbi.1999.4158; Kornfelt T, 1999, ARCH BIOCHEM BIOPHYS, V363, P43, DOI 10.1006/abbi.1998.1071; LAWSON JH, 1993, J BIOL CHEM, V268, P767; Monroe DM, 1997, BRIT J HAEMATOL, V99, P542, DOI 10.1046/j.1365-2141.1997.4463256.x; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; Persson E, 1996, HAEMOSTASIS, V26, P31; Persson E, 1997, J BIOL CHEM, V272, P19919, DOI 10.1074/jbc.272.32.19919; Persson E, 2001, BIOCHEMISTRY-US, V40, P3251, DOI 10.1021/bi001612z; Persson E, 1996, FEBS LETT, V385, P241, DOI 10.1016/0014-5793(96)00400-0; Peterson RW, 1999, J MOL BIOL, V286, P1609, DOI 10.1006/jmbi.1999.2574; Petrovan RJ, 2000, BIOCHEMISTRY-US, V39, P14457, DOI 10.1021/bi0009486; Pike ACW, 1999, P NATL ACAD SCI USA, V96, P8925, DOI 10.1073/pnas.96.16.8925; RAO LVM, 1993, BLOOD, V81, P2600; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; Stapley BJ, 1997, J MOL BIOL, V272, P465, DOI 10.1006/jmbi.1997.1262; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; Zhang E, 1999, J MOL BIOL, V285, P2089, DOI 10.1006/jmbi.1998.2452	25	38	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29195	29199		10.1074/jbc.M102187200	http://dx.doi.org/10.1074/jbc.M102187200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11389142	hybrid			2022-12-27	WOS:000170346000076
J	Ratnaparkhi, GS; Varadarajan, R				Ratnaparkhi, GS; Varadarajan, R			Osmolytes stabilize ribonuclease S by stabilizing its fragments S protein and S peptide to compact folding-competent states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VAPOR-PRESSURE OSMOMETRY; THERMODYNAMIC CHARACTERIZATION; PREFERENTIAL HYDRATION; KINETIC MECHANISM; NATIVE-STATE; PACKING; UREA; DENATURATION; RECEPTOR; EXCHANGE	Osmolytes stabilize proteins to thermal and chemical denaturation. We have studied the effects of the osmolytes sarcosine, betaine, trimethylamine-N-oxide, and taurine on the structure and stability of the protein-peptide complex RNase S using x-ray crystallography and titration calorimetry, respectively. The largest degree of stabilization is achieved with 6 M sarcosine, which increases the denaturation temperatures of RNase S and S pro by 24.6 and 17.4 degreesC, respectively, at pH 5 and protects both proteins against tryptic cleavage. Four crystal structures of RNase S in the presence of different osmolytes do not offer any evidence for osmolyte binding to the folded state of the protein or any perturbation in the water structure surrounding the protein. The degree of stabilization in 6 M sarcosine increases with temperature, ranging from -0.52 kcal mol(-1) at 20 degreesC to -5.4 kcal mol(-1) at 60 degreesC. The data support the thesis that osmolytes that stabilize proteins, do so by perturbing unfolded states, which change conformation to a compact, folding competent state in the presence of osmolyte. The increased stabilization thus results from a decrease in conformational entropy of the unfolded state.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Chem Biol Unit, Bangalore 560064, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS); Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Varadarajan, R (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.	varadar@mbu.iisc.ernet.in	Ratnaparkhi, Girish/ABC-4128-2020; Ratnaparkhi, Girish S/K-6584-2012	Ratnaparkhi, Girish/0000-0001-7615-3140; Ratnaparkhi, Girish S/0000-0001-7615-3140				ALLENDE JE, 1962, BIOCHEMISTRY-US, V1, P295, DOI 10.1021/bi00908a017; Anjum F, 2000, BBA-PROTEIN STRUCT M, V1476, P75, DOI 10.1016/S0167-4838(99)00215-0; ARAKAWA T, 1990, BIOCHEMISTRY-US, V29, P1924, DOI 10.1021/bi00459a037; ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; Baskakov IV, 1999, J BIOL CHEM, V274, P10693, DOI 10.1074/jbc.274.16.10693; Burton RE, 2000, PROTEIN SCI, V9, P776; Catanzano F, 1996, BIOCHEMISTRY-US, V35, P13378, DOI 10.1021/bi960855h; Chakravarty S, 1999, STRUCT FOLD DES, V7, P723, DOI 10.1016/S0969-2126(99)80097-5; Chakravarty S, 2000, FEBS LETT, V476, P296, DOI 10.1016/S0014-5793(00)01725-7; Chakshusmathi G, 1999, P NATL ACAD SCI USA, V96, P7899, DOI 10.1073/pnas.96.14.7899; CONNELLY PR, 1990, BIOCHEMISTRY-US, V29, P6108, DOI 10.1021/bi00477a031; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Courtenay ES, 2000, BIOCHEMISTRY-US, V39, P4455, DOI 10.1021/bi992887l; DELPINO IMP, 1995, BIOCHEMISTRY-US, V34, P8621, DOI 10.1021/bi00027a011; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOIG AJ, 1991, J MOL BIOL, V217, P389, DOI 10.1016/0022-2836(91)90551-G; Foord RL, 1998, BIOCHEMISTRY-US, V37, P2969, DOI 10.1021/bi9712798; Frye KJ, 1997, PROTEIN SCI, V6, P789; Ganesh C, 1997, BIOCHEMISTRY-US, V36, P5020, DOI 10.1021/bi961967b; Goldberg JM, 1998, BIOCHEMISTRY-US, V37, P2556, DOI 10.1021/bi972403q; Goldberg JM, 1998, BIOCHEMISTRY-US, V37, P2546, DOI 10.1021/bi972402y; Kendrick BS, 1997, P NATL ACAD SCI USA, V94, P11917, DOI 10.1073/pnas.94.22.11917; KIM EE, 1992, BIOCHEMISTRY-US, V31, P12304, DOI 10.1021/bi00164a004; KIM PS, 1984, NATURE, V307, P329, DOI 10.1038/307329a0; Knapp S, 1999, EXTREMOPHILES, V3, P191, DOI 10.1007/s007920050116; Knubovets T, 1999, P NATL ACAD SCI USA, V96, P1262, DOI 10.1073/pnas.96.4.1262; Kurapkat G, 1997, BIOPOLYMERS, V41, P267, DOI 10.1002/(SICI)1097-0282(199703)41:3<267::AID-BIP3>3.0.CO;2-Q; LIN TY, 1994, BIOCHEMISTRY-US, V33, P12695, DOI 10.1021/bi00208a021; LIU YF, 1995, BIOCHEMISTRY-US, V34, P12884, DOI 10.1021/bi00039a051; MANIKEN MW, 1977, ANNU REV BIOPHYS BIO, V6, P301; MITCHINSON C, 1986, Proteins Structure Function and Genetics, V1, P23, DOI 10.1002/prot.340010106; Nadig G, 1996, PROTEIN SCI, V5, P2104, DOI 10.1002/pro.5560051017; OOI T, 1963, BIOCHEMISTRY-US, V2, P432, DOI 10.1021/bi00903a006; Ozer I, 1998, ANAL BIOCHEM, V264, P199, DOI 10.1006/abio.1998.2855; Pattabiraman N, 1995, J MOL RECOGNIT, V8, P334, DOI 10.1002/jmr.300080603; PERSICHETTI RA, 1995, J AM CHEM SOC, V117, P2732, DOI 10.1021/ja00115a008; PFLUMM MN, 1969, J BIOL CHEM, V244, P3973; Qu YX, 1998, P NATL ACAD SCI USA, V95, P9268, DOI 10.1073/pnas.95.16.9268; Ratnaparkhi GS, 1999, PROTEINS, V36, P282, DOI 10.1002/(SICI)1097-0134(19990815)36:3<282::AID-PROT3>3.3.CO;2-6; Ratnaparkhi GS, 2000, BIOCHEMISTRY-US, V39, P12365, DOI 10.1021/bi000775k; Ratnaparkhi GS, 1998, BIOCHEMISTRY-US, V37, P6958, DOI 10.1021/bi972857n; Ratnaparkhi GS, 2000, PROTEIN ENG, V13, P697, DOI 10.1093/protein/13.10.697; RICHARDS FM, 1971, ENZYMES, V4, P647; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P5278, DOI 10.1021/bi00138a006; THOMSON J, 1994, BIOCHEMISTRY-US, V33, P8587, DOI 10.1021/bi00194a025; Timasheff S N, 1995, Methods Mol Biol, V40, P253; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P1421, DOI 10.1021/bi00120a019; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P12315, DOI 10.1021/bi00164a005; WANG A, 1995, BIOCHEMISTRY-US, V34, P15096, DOI 10.1021/bi00046a016; Xie GF, 1997, PROTEIN SCI, V6, P211; Xie GF, 1997, PROTEIN SCI, V6, P222; YANCEY PH, 1979, BIOCHEM J, V183, P317, DOI 10.1042/bj1830317; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Yang DS, 1999, J BIOL CHEM, V274, P32970, DOI 10.1074/jbc.274.46.32970; Zelinski T, 1997, ANGEW CHEM INT EDIT, V36, P722, DOI 10.1002/anie.199707221; Zhang WT, 1996, BIOCHEMISTRY-US, V35, P10506, DOI 10.1021/bi960795f; [No title captured]	58	60	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28789	28798		10.1074/jbc.M101906200	http://dx.doi.org/10.1074/jbc.M101906200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11373282	hybrid			2022-12-27	WOS:000170346000021
J	Walter, W; Studitsky, VM				Walter, W; Studitsky, VM			Facilitated transcription through the nucleosome at high ionic strength occurs via a histone octamer transfer mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ACTIVE TRANSCRIPTION; CHROMATIN TEMPLATES; SWI/SNF COMPLEX; HEAT-SHOCK; IN-VITRO; ELONGATION; SPT5; DNA; INVITRO	The rate of transcription through the nucleosome, the fine structure of the nucleosomal barrier, and the fate of the nucleosome during transcription at different salt concentrations were analyzed using linear 227-base pair mononucleosomal templates containing a uniquely positioned nucleosome core. At lower ionic strength (30 mm NaCl), the nucleosome constitutes a strong barrier for SP6 RNA polymerase. At higher ionic strength (330 mm NaCl), the rates of transcription on nucleosomal and histone-free DNA templates are very similar. At both higher and lower ionic strengths, the complete histone octamer is transferred over the same distance by fundamentally similar mechanisms. The data indicate that even at the rate of transcription characteristic of histone-free DNA, the transfer intermediates can be formed quite efficiently. This suggests possible mechanisms that could facilitate transcription through the nucleosome at physiological ionic strength.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Studitsky, VM (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave,Rm 5123, Detroit, MI 48201 USA.		Studitsky, Vasily/A-9382-2014		NIGMS NIH HHS [GM58650] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058650] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BASHKIN J, 1993, BIOCHEMISTRY-US, V32, P1895, DOI 10.1021/bi00059a002; Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; Bednar J, 1999, MOL CELL, V4, P377, DOI 10.1016/S1097-2765(00)80339-1; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Chang CH, 1997, J BIOL CHEM, V272, P23427, DOI 10.1074/jbc.272.37.23427; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; FOE VE, 1976, CELL, V9, P131, DOI 10.1016/0092-8674(76)90059-3; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JORGENSEN ED, 1991, J BIOL CHEM, V266, P645; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MATHIS DJ, 1978, NUCLEIC ACIDS RES, V5, P3523, DOI 10.1093/nar/5.10.3523; MCKNIGHT SL, 1979, CELL, V17, P551; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; OBRIEN T, 1993, MOL CELL BIOL, V13, P3456, DOI 10.1128/MCB.13.6.3456; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; POSTNIKOV YV, 1991, NUCLEIC ACIDS RES, V19, P717, DOI 10.1093/nar/19.4.717; Protacio RU, 2000, MOL CELL BIOL, V20, P8866, DOI 10.1128/MCB.20.23.8866-8878.2000; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; UCKER DS, 1984, J BIOL CHEM, V259, P7416; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WASYLYK B, 1979, J MOL BIOL, V128, P411, DOI 10.1016/0022-2836(79)90095-0; WASYLYK B, 1980, EUR J BIOCHEM, V103, P219, DOI 10.1111/j.1432-1033.1980.tb04306.x; WASYLYK B, 1979, EUR J BIOCHEM, V98, P317, DOI 10.1111/j.1432-1033.1979.tb13191.x; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; WILLIAMSON P, 1978, BIOCHEMISTRY-US, V17, P5695, DOI 10.1021/bi00619a015; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Zhou YB, 1998, NATURE, V395, P402, DOI 10.1038/26521	42	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29104	29110		10.1074/jbc.M103704200	http://dx.doi.org/10.1074/jbc.M103704200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390400	hybrid			2022-12-27	WOS:000170346000064
J	Chen, YA; Scales, SJ; Jagath, JR; Scheller, RH				Chen, YA; Scales, SJ; Jagath, JR; Scheller, RH			A discontinuous SNAP-25 C-terminal coil supports exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; SNARE COMPLEX; NEUROTRANSMITTER RELEASE; SYNAPTIC EXOCYTOSIS; ALPHA-SNAP; BOTULINAL NEUROTOXINS; CYTOSOLIC PROTEINS; KINETIC COMPONENTS; NSF; SPECIFICITY	Membrane fusion requires the formation of four-helical bundles comprised of the SNARE proteins syntaxin, vesicle-associated membrane protein (VAMP), and the synaptosomal-associated protein of 25 kDa (SNAP-25). Botulinum. neurotoxin E cleaves the C-terminal coil of SNAP-25, inhibiting exocytosis of norepinephrine from permeabilized PC12 cells. Addition of a 26-mer peptide comprising the C terminus of SNAP-25 that is cleaved by the toxin restores exocytosis, demonstrating that continuity of the SNAP-25 C-terminal helix is not critical for its function. By contrast, vesicle-associated membrane protein peptides could not rescue botulinum neurotoxin D-treated cells, suggesting that helix continuity is critical for VAMP function. Much higher concentrations of the SNAP-25 C-terminal peptide are required for rescuing exocytosis (K-assembly = similar to 460 mum) than for binding to other SNARES in vitro (K-d < 5 <mu>m). Each residue of the peptide was mutated to alanine to assess its functional importance. Whereas most mutants rescue exocytosis with lower efficiency than the wild type peptide, D186A rescues with higher efficiency, and kinetic analysis suggests this is because of higher affinity for the cellular binding site. This is consistent with Asp-186 contributing to negative regulation of the fusion process.	Stanford Univ, Howard Hughes Med Inst, Dept Cellular & Mol Physiol, Sch Med, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Scheller, RH (corresponding author), Stanford Univ, Howard Hughes Med Inst, Dept Cellular & Mol Physiol, Sch Med, Stanford, CA 94305 USA.		Junutula, Jagath Reddy/ABD-4753-2020; Scales, Suzie J./H-4507-2019	Junutula, Jagath Reddy/0000-0002-5942-4428; Scales, Suzie J./0000-0003-2544-0283				BINZ T, 1994, J BIOL CHEM, V269, P1617; Bock JB, 1999, P NATL ACAD SCI USA, V96, P12227, DOI 10.1073/pnas.96.22.12227; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fernandez-Chacon R, 2001, NATURE, V410, P41; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hua SY, 1999, NAT NEUROSCI, V2, P1078, DOI 10.1038/16005; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; Lonart G, 2000, J BIOL CHEM, V275, P27703; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; McNew JA, 1999, MOL CELL, V4, P415, DOI 10.1016/S1097-2765(00)80343-3; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Weber T, 2000, J CELL BIOL, V149, P1063, DOI 10.1083/jcb.149.5.1063; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Xu T, 1999, EMBO J, V18, P3293, DOI 10.1093/emboj/18.12.3293; YAMASAKI S, 1994, J BIOL CHEM, V269, P12764; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	35	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28503	28508		10.1074/jbc.M103009200	http://dx.doi.org/10.1074/jbc.M103009200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373287	hybrid			2022-12-27	WOS:000170093400101
J	Xiong, YM; Tanaka, H; Richardson, JA; Williams, SC; Slaughter, CA; Nakamura, M; Chen, JL; Yanagisawa, M				Xiong, YM; Tanaka, H; Richardson, JA; Williams, SC; Slaughter, CA; Nakamura, M; Chen, JL; Yanagisawa, M			Endothelin-1 stimulates leptin production in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBESE GENE-EXPRESSION; OB MESSENGER-RNA; GLUCOSE-UPTAKE; PHOSPHATIDYLINOSITOL 3-KINASE; GLUT4 TRANSLOCATION; PROTEIN EXPRESSION; RECEPTOR GENE; FEMALE MICE; FOOD-INTAKE; EARLY-ONSET	Leptin is an adipocyte-derived hormone that regulates body fat stores and feeding behavior. In an effort to identify endogenous diffusible modulators of leptin production, we found that endothelin-1 (ET-1) up-regulates leptin expression in adipocytes. ET-1 is as potent and efficacious as insulin in stimulating leptin production in two different adipocyte cell lines. Endothelins stimulate leptin production via the endothelin-A receptor (ETA), as judged by a potency rank order of ET-1 >> ET-3. We detected expression of ETA but not ETB in both cell lines by Northern blot analysis. In addition, the ETA-selective antagonist FR139317 inhibited ET-1-induced leptin expression more potently than did the ETB-selective antagonist BQ788. ET-1 and insulin positively interact with each other in increasing leptin production in adipocytes. In primary mouse white fat cells, we detected expression of both ETA and ETB by Northern blot and in situ hybridization analyses. We conclude that ET-1 stimulates leptin production via the ETA receptor in cultured adipocytes.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Donald W Reynolds Cardiovasc Clin Res Ctr, Dallas, TX 75390 USA; Tularik Inc, San Francisco, CA 94040 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yanagisawa, M (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd,Rm Y5-224, Dallas, TX 75390 USA.	myanagisawa@aol.com						Aizawa-Abe M, 2000, J CLIN INVEST, V105, P1243, DOI 10.1172/JCI8341; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Benjamin IJ, 1997, DEV DYNAM, V208, P75; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHOU YC, 1994, BIOCHEM BIOPH RES CO, V202, P688, DOI 10.1006/bbrc.1994.1985; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; DELABROUSSE FC, 1998, Patent No. 5780258; Dupuis J, 1998, AM HEART J, V135, P614, DOI 10.1016/S0002-8703(98)70276-5; FERRI C, 1995, J CLIN ENDOCR METAB, V80, P829, DOI 10.1210/jc.80.3.829; FRANK HJL, 1993, ENDOCRINOLOGY, V133, P1092, DOI 10.1210/en.133.3.1092; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; HAUNER H, 1994, METABOLISM, V43, P227, DOI 10.1016/0026-0495(94)90250-X; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; Hocher B, 1997, EUR J CLIN CHEM CLIN, V35, P175; Hoggard N, 1997, P NATL ACAD SCI USA, V94, P11073, DOI 10.1073/pnas.94.20.11073; Hu J, 1998, BIOCHEM BIOPH RES CO, V245, P894, DOI 10.1006/bbrc.1998.8543; HU RM, 1993, DIABETES, V42, P351, DOI 10.2337/diabetes.42.2.351; IMAI T, 1992, HYPERTENSION, V19, P753, DOI 10.1161/01.HYP.19.6.753; Imamura T, 1999, J BIOL CHEM, V274, P33691, DOI 10.1074/jbc.274.47.33691; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Jiang ZY, 1999, DIABETES, V48, P1120, DOI 10.2337/diabetes.48.5.1120; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Kolaczynski JW, 1996, DIABETES, V45, P699, DOI 10.2337/diabetes.45.5.699; KURIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P1435, DOI 10.1016/0006-291X(89)92270-5; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lee YC, 1998, METABOLISM, V47, P1468, DOI 10.1016/S0026-0495(98)90071-3; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; MALEK AM, 1993, P NATL ACAD SCI USA, V90, P5999, DOI 10.1073/pnas.90.13.5999; Mandrup S, 1997, P NATL ACAD SCI USA, V94, P4300, DOI 10.1073/pnas.94.9.4300; Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909; Mark AL, 1999, HYPERTENSION, V33, P537, DOI 10.1161/01.HYP.33.1.537; MARSDEN PA, 1992, AM J PHYSIOL, V262, pC854, DOI 10.1152/ajpcell.1992.262.4.C854; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MOORE K, 1992, NEW ENGL J MED, V327, P1774, DOI 10.1056/NEJM199212173272502; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V214, P1260, DOI 10.1006/bbrc.1995.2422; RODBELL M, 1964, J BIOL CHEM, V239, P375; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Satoh H, 1999, BIOCHEM BIOPH RES CO, V254, P757, DOI 10.1006/bbrc.1998.0126; Shih KC, 2000, J CELL BIOCHEM, V78, P231, DOI 10.1002/(SICI)1097-4644(20000801)78:2<231::AID-JCB6>3.0.CO;2-O; SHINOHARA O, 1992, ENDOCRINOLOGY, V130, P2031, DOI 10.1210/en.130.4.2031; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Slieker LJ, 1996, J BIOL CHEM, V271, P5301, DOI 10.1074/jbc.271.10.5301; TAKAHASHI K, 1990, DIABETOLOGIA, V33, P306, DOI 10.1007/BF00403325; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TOMITA K, 1989, NEW ENGL J MED, V321, P1127; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103; Yamada H, 1998, J CARDIOVASC PHARM, V31, pS215, DOI 10.1097/00005344-199800001-00060; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320; Zhang B, 1996, J BIOL CHEM, V271, P9455, DOI 10.1074/jbc.271.16.9455	64	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28471	28477		10.1074/jbc.M103478200	http://dx.doi.org/10.1074/jbc.M103478200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11359784	hybrid			2022-12-27	WOS:000170093400097
J	Allan, AL; Albanese, C; Pestell, RG; LaMarre, J				Allan, AL; Albanese, C; Pestell, RG; LaMarre, J			Activating transcription factor 3 induces DNA synthesis and expression of cyclin D1 in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-REGENERATION FACTOR; ELEMENT-BINDING PROTEIN; BREAST-CANCER CELLS; C-JUN; MESSENGER-RNA; GROWTH-FACTOR; HEPATOCELLULAR-CARCINOMA; RETINOBLASTOMA GENE; RAT HEPATOCYTES; DOWN-REGULATION	Activating transcription factor 3 (ATF3) is an early response gene that is induced rapidly during in vivosituations of cellular growth such as liver regeneration. However, neither the physiological function nor the potential target genes of this transcription factor related to cellular proliferation have been identified in the liver or other tissues. We demonstrate here that endogenous ATF3 mRNA expression is rapidly induced up to 4-fold upon mitogenic stimulation of quiescent Hepa 1-6 mouse hepatoma cells. Overexpression of exogenous ATF3 results in a significant, dose-dependent increase in DNA synthesis of up to 140% over control cells. ATF3; transfected cells also display significantly higher rates of [H-3]thymidine incorporation in comparison with nontransfected controls in the presence of serum, Northern blot analysis and co transfection experiments demonstrate that overexpression of ATF3 enhances cyclin D1 mRNA expression and activates the cyclin D1 promoter 2.5-fold when activating protein-1 (AP-1) and cyclic AMP response element (CRE) sites within the promoter are intact. ATF3-mediated promoter activation is reduced to 1.3-fold and 1.6-fold respectively when the AP-1 or CRE sites are mutated, and mutation of both sites simultaneously leads to the complete abrogation of promoter activation. Furthermore, DNA-binding studies demonstrate that ATF3 binds directly to the AP-I site within the cyclin DI promoter. These results indicate that ATF3 expression stimulates hepatocellular proliferation, suggesting that this effect is mediated, at least in part, by the ATF3-dependent activation of cyclin D1 transcription.	Univ Guelph, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Div Hormone Depdendent Tumor Biol, Bronx, NY 10461 USA	University of Guelph; Yeshiva University; Albert Einstein College of Medicine	LaMarre, J (corresponding author), Univ Guelph, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada.				NATIONAL CANCER INSTITUTE [R01CA086072, R01CA075503, R01CA070896] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA75503, R01CA86072, R01CA70896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALBRECHT JH, 1993, AM J PHYSIOL, V265, pG857, DOI 10.1152/ajpgi.1993.265.5.G857; Arnold A, 1995, J INVEST MED, V43, P543; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Barnabas S, 1997, J BIOL CHEM, V272, P20684, DOI 10.1074/jbc.272.33.20684; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; CHU HM, 1994, MOL ENDOCRINOL, V8, P59, DOI 10.1210/me.8.1.59; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Darlington G J, 1987, Methods Enzymol, V151, P19, DOI 10.1016/S0076-6879(87)51006-0; Della Ragione F, 1999, ADV EXP MED BIOL, V472, P73; Drysdale BE, 1996, MOL IMMUNOL, V33, P989, DOI 10.1016/S0161-5890(96)00043-0; Feitelson MA, 1997, AM J PATHOL, V150, P1141; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Hai T, 1999, GENE EXPRESSION, V7, P321; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HERBER B, 1994, ONCOGENE, V9, P1295; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; Ishiguro T, 1996, CANCER RES, V56, P875; Ishiguro T, 1998, CLIN EXP METASTAS, V16, P179; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Liao DZ, 1996, CANCER LETT, V100, P215, DOI 10.1016/0304-3835(95)04088-9; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; LINARDOPOULOS S, 1993, ANTICANCER RES, V13, P257; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; LU XP, 1992, J BIOL CHEM, V267, P2841; LUKAS J, 1994, ONCOGENE, V9, P707; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Nishida N, 1997, HISTOL HISTOPATHOL, V12, P1019; Palmero I, 1996, CANCER SURV, V27, P351; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; PETERS G, 1994, J CELL SCI S, V18, P89; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; Sambrook J., 2002, MOL CLONING LAB MANU; Scotto C, 1999, MOL CELL BIOL, V19, P7168; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; Takeda M, 2000, INVEST OPHTH VIS SCI, V41, P2412; Tarn C, 1999, J BIOL CHEM, V274, P2327, DOI 10.1074/jbc.274.4.2327; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; THOMPSON NL, 1986, CANCER RES, V46, P3111; Tsujino H, 2000, MOL CELL NEUROSCI, V15, P170, DOI 10.1006/mcne.1999.0814; Wang ZY, 1996, GENOMICS, V35, P156, DOI 10.1006/geno.1996.0334; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Weinberg RA, 1996, CYTOKINES MOL THER, V2, P105; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEIR E, 1994, HEPATOLOGY, V20, P955, DOI 10.1002/hep.1840200426; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	60	94	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27272	27280		10.1074/jbc.M103196200	http://dx.doi.org/10.1074/jbc.M103196200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375399	hybrid			2022-12-27	WOS:000169966900073
J	Ameloot, P; Declercq, W; Fiers, W; Vandenabeele, P; Brouckaert, P				Ameloot, P; Declercq, W; Fiers, W; Vandenabeele, P; Brouckaert, P			Heterotrimers formed by tumor necrosis factors of different species or muteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TNF-ALPHA; MONOCLONAL-ANTIBODIES; RECEPTOR-BINDING; INTERFERON-GAMMA; MUTANTS; RESOLUTION; GENERATION; MECHANISM; INDUCTION; TOXICITY	Incubation of murine tumor necrosis factor (mTNF) at subnanomolar concentrations results in partial dissociation of the trimers, coinciding with a decrease in bioactivity. Using size-exclusion chromatography, we observed that the conversion of labeled mTNF to monomers is not only prevented by coincubation with an excess of unlabeled mTNF but also with unlabeled human TNF (hTNF). Moreover, after coincubation of mTNF and hTNF four different TNF complexes were revealed by native polyacrylamide gel electrophoresis, viz. homotrimeric mTNF and hTNF, as well as two complexes with an intermediate migration pattern. Analytical gel filtration in combination with native polyacrylamide gel electrophoresis and Western blot immunodetection indicated that these new complexes consisted of heterotrimeric TNF molecules. We conclude that an exchange of monomers takes place during coincubation of two different species of TNF, which results in homotrimeric and heterotrimeric TNF. To assess receptor interaction in vitro, TNF heterotrimeric molecules were used as obtained after incubation of mTNF with labeled hTNF (which only binds to mTNF receptor I) or with labeled mutein mTNF75 (specific for mTNF receptor II). These heterotrimers were retained by both mTNF receptors, which means that the mTNF subunits incorporated in heterotrimeric complexes still can bind to both types of TNF receptor. In addition, the gradual decrease in mTNF bioactivity during preincubation at subnanomolar concentrations was prevented by the presence of mutein mTNF75, which is inactive in an L929 cytotoxicity assay, indicating that heterotrimerization can influence the overall bioactivity.	Flanders Interuniv Inst Biotechnol, Dept Mol Biol, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, Unit Mol Pathophysiol & Expt Therapy, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, Unit Mol Signaling & Cell Death, B-9000 Ghent, Belgium; Ghent Univ, B-9000 Ghent, Belgium	Ghent University	Brouckaert, P (corresponding author), Flanders Interuniv Inst Biotechnol, Dept Mol Biol, KL Ledeganckst 35, B-9000 Ghent, Belgium.		Vandenabeele, Peter/AAD-5793-2022; Vandenabeele, Peter/C-8597-2009	Vandenabeele, Peter/0000-0002-6669-8822; 				ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; ALZANI R, 1995, BIOCHEMISTRY-US, V34, P6344, DOI 10.1021/bi00019a012; Baeyens KJ, 1999, ACTA CRYSTALLOGR D, V55, P772, DOI 10.1107/S0907444998018435; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAZZONI F, 1995, P NATL ACAD SCI USA, V92, P5376, DOI 10.1073/pnas.92.12.5376; Beutler B, 1998, BLOOD CELL MOL DIS, V24, P216, DOI 10.1006/bcmd.1998.0187; CORTI A, 1992, BIOCHEM J, V284, P905, DOI 10.1042/bj2840905; DECLERCQ W, 1995, CYTOKINE, V7, P701, DOI 10.1006/cyto.1995.0082; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Fiers W, 1995, BIOL THERAPY CANC, P295; HLODAN R, 1995, EUR J BIOCHEM, V231, P381, DOI 10.1111/j.1432-1033.1995.tb20710.x; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; LUCAS R, 1990, IMMUNOLOGY, V71, P218; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; STEVENS HPJD, 1990, TRANSPLANTATION, V50, P856, DOI 10.1097/00007890-199011000-00022; TAKAHASHI N, 1994, CYTOKINE, V6, P235, DOI 10.1016/1043-4666(94)90018-3; Takahashi N, 1995, INT J CANCER, V63, P846, DOI 10.1002/ijc.2910630616; TAVERNIER J, 1990, J MOL BIOL, V211, P493, DOI 10.1016/0022-2836(90)90367-U; VANOSTADE X, 1993, NATURE, V361, P266; VANOSTADE X, 1994, EUR J BIOCHEM, V220, P771; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; VANZEE KJ, 1994, J EXP MED, V179, P1185, DOI 10.1084/jem.179.4.1185; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X	26	24	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27098	27103		10.1074/jbc.M104486200	http://dx.doi.org/10.1074/jbc.M104486200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11371574	hybrid			2022-12-27	WOS:000169966900050
J	Gu, JG; Sumida, Y; Sanzen, N; Sekiguchi, K				Gu, JG; Sumida, Y; Sanzen, N; Sekiguchi, K			Laminin-10/11 and fibronectin differentially regulate integrin-dependent rho and rac activation via p130(Cas)-CrkII-DOCK180 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SRC FAMILY KINASES; CELL-MIGRATION; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; ALPHA-5 CHAIN; P120 CATENIN; ALPHA-3-BETA-1; EXPRESSION; MOTILITY	The alpha (5) chain-containing laminin isoforms, laminins-10 and -11 (laminin-10/11), are the major components of the basement membrane, having potent cell-adhesive activity. Ne examined the cell-adhesive and integrin-mediated signaling activities of laminin-10/11 in comparison to fibronectin, the best characterized extracellular adhesive ligand. We found that laminin-10/11 are more active than fibronectin in promoting cell migration and preferentially activate Rac, not Rho, via the p130(Cas)- CrkII-DOCK180 pathway. Cells adhering to fibronectin develop stress fibers and focal contacts, whereas cells adhering to laminin-10/11 do not, consistent with the high cell migration-promoting activity of laminin-10/11. Pull-down assays of GTP-loaded Rac and Rho demonstrated the preferential activation of Rac on laminin-10/11, in contrast to the activation of Rho on fibronectin. Activation of Rac by laminin-10/11 was associated with the phosphorylation of p130(Cas) and an increased formation of a p130(Cas)-CrkII-DOCK180 complex. Cell migration on laminin-10/11 was suppressed by the expression of either a dominant-negative Rac or CrkII mutants defective in p130(Cas) or DOCK180 binding This is the first report demonstrating a distinct activation of Rho family GTPases resulting from adhesion to different extracellular ligands.	Osaka Univ, Inst Prot Res, Div Prot Chem, Osaka 5650871, Japan	Osaka University	Sekiguchi, K (corresponding author), Osaka Univ, Inst Prot Res, Div Prot Chem, 3-2 Yamadaoka, Osaka 5650871, Japan.	sekiguchi@protein.osaka-u.ac.jp	Gu, Jianguo/ABC-9257-2020	Sanzen, Noriko/0000-0001-6518-403X				Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Aumailley M, 1998, J ANAT, V193, P1, DOI 10.1046/j.1469-7580.1998.19310001.x; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; Fukushima Y, 1998, INT J CANCER, V76, P63, DOI 10.1002/(SICI)1097-0215(19980330)76:1<63::AID-IJC11>3.0.CO;2-H; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Kikkawa Y, 1998, J BIOL CHEM, V273, P15854, DOI 10.1074/jbc.273.25.15854; Kikkawa Y, 2000, J CELL SCI, V113, P869; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Lampe PD, 1998, J CELL BIOL, V143, P1735, DOI 10.1083/jcb.143.6.1735; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Testa JE, 1999, CANCER RES, V59, P3812; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang ZM, 1999, J CELL SCI, V112, P2925; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wenk MB, 2000, J CELL BIOL, V150, P913, DOI 10.1083/jcb.150.4.913; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751	51	136	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27090	27097		10.1074/jbc.M102284200	http://dx.doi.org/10.1074/jbc.M102284200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369773	hybrid, Green Published			2022-12-27	WOS:000169966900049
J	Hernandez, N				Hernandez, N			Small nuclear RNA genes: a model system to study fundamental mechanisms of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							POLYMERASE-III TRANSCRIPTION; SELENOCYSTEINE TRANSFER-RNA; U6 SNRNA GENE; SPH-BINDING-FACTOR; OCT-1 POU DOMAIN; MOLECULAR-CLONING; ACTIVITY REQUIRES; PROMOTER ELEMENT; BASAL PROMOTER; FACTOR-TFIIIB		Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	Hernandez, N (corresponding author), Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA.			Hernandez, Nouria/0000-0003-1465-4585	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038810] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38810] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi K, 1998, J BIOL CHEM, V273, P8598, DOI 10.1074/jbc.273.15.8598; Boyd DC, 2000, GENE, V247, P33, DOI 10.1016/S0378-1119(00)00134-7; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; Chong SS, 2001, J BIOL CHEM, V276, P20727, DOI 10.1074/jbc.M100088200; DANZEISER DA, 1993, MOL CELL BIOL, V13, P4670, DOI 10.1128/MCB.13.8.4670; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; ESCHENLAUER JB, 1993, MOL CELL BIOL, V13, P3015, DOI 10.1128/MCB.13.5.3015; Ford E, 1998, GENE DEV, V12, P3528, DOI 10.1101/gad.12.22.3528; Henry RW, 1998, COLD SPRING HARB SYM, V63, P111, DOI 10.1101/sqb.1998.63.111; Henry RW, 1998, GENE DEV, V12, P2664, DOI 10.1101/gad.12.17.2664; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; Jensen RC, 1998, NUCLEIC ACIDS RES, V26, P616, DOI 10.1093/nar/26.2.616; JOAZEIRO CAP, 1994, MOL CELL BIOL, V14, P2798, DOI 10.1128/MCB.14.4.2798; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; Kuhlman TC, 1999, MOL CELL BIOL, V19, P2130; Kunkel GR, 1998, NUCLEIC ACIDS RES, V26, P1536, DOI 10.1093/nar/26.6.1536; Kunkel GR, 1996, GENE EXPRESSION, V6, P59; Li JM, 1996, MOL CELL BIOL, V16, P1275; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; Ma B, 2001, J BIOL CHEM, V276, P5027, DOI 10.1074/jbc.M009301200; McCulloch V, 2000, EMBO J, V19, P4134, DOI 10.1093/emboj/19.15.4134; Mital R, 1996, MOL CELL BIOL, V16, P7031; Mittal V, 1999, GENE DEV, V13, P1807, DOI 10.1101/gad.13.14.1807; Mittal V, 1997, SCIENCE, V275, P1136, DOI 10.1126/science.275.5303.1136; MYSLINSKI E, 1993, J MOL BIOL, V234, P311, DOI 10.1006/jmbi.1993.1588; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; MYSLINSKI E, 1992, NUCLEIC ACIDS RES, V20, P203, DOI 10.1093/nar/20.2.203; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Rincon JC, 1998, NUCLEIC ACIDS RES, V26, P4846, DOI 10.1093/nar/26.21.4846; ROEBUCK KA, 1990, MOL CELL BIOL, V10, P341, DOI 10.1128/MCB.10.1.341; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Schaub M, 1999, J BIOL CHEM, V274, P25042, DOI 10.1074/jbc.274.35.25042; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; Schuster C, 1998, MOL CELL BIOL, V18, P2650, DOI 10.1128/MCB.18.5.2650; SCHUSTER C, 1995, EMBO J, V14, P3777, DOI 10.1002/j.1460-2075.1995.tb00047.x; Stunkel W, 1997, MOL CELL BIOL, V17, P4397; Teichmann M, 2000, P NATL ACAD SCI USA, V97, P14200, DOI 10.1073/pnas.97.26.14200; WAIBEL F, 1990, NATURE, V346, P199, DOI 10.1038/346199a0; Wang Y, 1998, MOL CELL BIOL, V18, P1570, DOI 10.1128/MCB.18.3.1570; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; ZAMROD Z, 1990, NUCLEIC ACIDS RES, V18, P7323, DOI 10.1093/nar/18.24.7323; Zhao XY, 2001, MOL CELL, V7, P539, DOI 10.1016/S1097-2765(01)00201-5	45	170	185	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26733	26736		10.1074/jbc.R100032200	http://dx.doi.org/10.1074/jbc.R100032200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11390411	hybrid			2022-12-27	WOS:000169966900001
J	Shu, WG; Yang, HH; Zhang, LL; Lu, MM; Morrisey, EE				Shu, WG; Yang, HH; Zhang, LL; Lu, MM; Morrisey, EE			Characterization of a new subfamily of winged-helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-B; HEPATOCYTE NUCLEAR FACTOR-3-BETA; GATA-6 ACTIVATES TRANSCRIPTION; DEVELOPING MOUSE LUNG; FACTOR-I; RESPIRATORY EPITHELIUM; TRANSGENIC MICE; CELL LINEAGES; SPINAL-CORD; FORK HEAD	Epithelial gene expression in the lungis thought to be regulated by the coordinate activity of several different families of transcription factors including the Fox family of winged-helix/forkhead DNA-binding proteins. In this report, we have identified and characterized two members of this Fox gene family Foxp1 and Foxp2, and show that they comprise a new subfamily of Fox genes expressed in the lung, Foxp1 and Foxp2 are expressed at high levels in the lung as early as E12.5 of mouse development with Foxp2 expression restricted to the airway epithelium. In addition, Foxp1 and Foxp2 are expressed at lower levels in neural, intestinal, and cardiovascular tissues during development. Upon differentiation of the airway epithelium along the proximal-distal axis, Foxp2 expression becomes restricted to the distal alveolar epithelium whereas Foxp1 expression is observed in the distal epithelium and mesenchyme. Foxp1 and Foxp2 can regulate epithelial lung gene transcription as was demonstrated by their ability to dramatically repress the mouse CC10 promoter and, to a lesser extent, the human surfactant protein C promoter. In addition, GAL4 fusion proteins encoding subdomains of Foxp1 and Foxp2 demonstrate that an independent and homologous transcriptional repression domain lies within the N-terminal end of the proteins. Together, these studies suggest that Foxp1 and Foxp2 are important regulators of lung epithelial gene transcription.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Morrisey, EE (corresponding author), Univ Penn, Dept Med, 953 BRB II-III,421 Curie Blvd, Philadelphia, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064632] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL64632] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aitola M, 2000, DEV DYNAM, V218, P136, DOI 10.1002/(SICI)1097-0177(200005)218:1<136::AID-DVDY12>3.0.CO;2-U; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Bruno MD, 2000, J BIOL CHEM, V275, P1043, DOI 10.1074/jbc.275.2.1043; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; Chen JC, 1998, J CLIN INVEST, V102, P1077, DOI 10.1172/JCI4786; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; Hao ZL, 1999, DEV DYNAM, V216, P201, DOI 10.1002/(SICI)1097-0177(199910)216:2<201::AID-DVDY10>3.0.CO;2-6; He GP, 1999, J BIOL CHEM, V274, P14678, DOI 10.1074/jbc.274.21.14678; Hellqvist M, 1996, J BIOL CHEM, V271, P4482; Hoch M, 1996, MECH DEVELOP, V58, P3, DOI 10.1016/S0925-4773(96)00541-2; Iida K, 1997, DEVELOPMENT, V124, P4627; Ikeda K, 1996, MOL CELL BIOL, V16, P3626; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; MADDEN SL, 1993, ONCOGENE, V8, P1713; Margana RK, 1997, J BIOL CHEM, V272, P3083, DOI 10.1074/jbc.272.5.3083; Matise MP, 1997, J NEUROSCI, V17, P7805; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, J BIOL CHEM, V272, P8515, DOI 10.1074/jbc.272.13.8515; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Perrone L, 2000, BIOCHEM BIOPH RES CO, V275, P203, DOI 10.1006/bbrc.2000.3232; RAY MK, 1993, BIOCHEM BIOPH RES CO, V197, P163, DOI 10.1006/bbrc.1993.2455; RAY MK, 1995, J BIOL CHEM, V270, P2689, DOI 10.1074/jbc.270.6.2689; Ray MK, 1996, MOL CELL BIOL, V16, P2056; SAWAYA PL, 1993, MOL CELL BIOL, V13, P3860, DOI 10.1128/MCB.13.7.3860; Shaw-White JR, 1999, J BIOL CHEM, V274, P2658, DOI 10.1074/jbc.274.5.2658; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; Sutton J, 1996, J BIOL CHEM, V271, P23126, DOI 10.1074/jbc.271.38.23126; Svensson EC, 2000, J BIOL CHEM, V275, P20762, DOI 10.1074/jbc.M001522200; Tichelaar JW, 1999, J HISTOCHEM CYTOCHEM, V47, P823, DOI 10.1177/002215549904700612; Tichelaar JW, 1999, DEV BIOL, V213, P405, DOI 10.1006/dbio.1999.9380; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; Warburton D, 1998, BIOCHEM CELL BIOL, V76, P971, DOI 10.1139/bcb-76-6-971; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Winnier GE, 1999, DEV BIOL, V213, P418, DOI 10.1006/dbio.1999.9382; Xiao H, 1998, J BIOL CHEM, V273, P22873, DOI 10.1074/jbc.273.36.22873; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Zhou L, 1997, DEV DYNAM, V210, P305, DOI 10.1002/(SICI)1097-0177(199711)210:3<305::AID-AJA10>3.0.CO;2-9; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	47	270	284	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27488	27497		10.1074/jbc.M100636200	http://dx.doi.org/10.1074/jbc.M100636200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11358962	hybrid			2022-12-27	WOS:000169966900100
J	Hogan, A; Shepherd, L; Chabot, J; Quenneville, S; Prescott, SM; Topham, MK; Gee, SH				Hogan, A; Shepherd, L; Chabot, J; Quenneville, S; Prescott, SM; Topham, MK; Gee, SH			Interaction of gamma 1-syntrophin with diacylglycerol kinase-zeta - Regulation of nuclear localization by PDZ interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-ASSOCIATED PROTEIN; CENTRAL-NERVOUS-SYSTEM; NEUROMUSCULAR-JUNCTION; SODIUM-CHANNELS; SYNTROPHIN; DOMAIN; FAMILY; CLONING; MUSCLE; ALPHA-1-SYNTROPHIN	Syntrophins are modular adapter proteins that link ion channels and signaling proteins to dystrophin and its homologues, A yeast two-hybrid screen of a human brain cDNA library using the PDZ domain of gamma1-syntrophin, a recently identified brain-specific isoform, yielded overlapping clones encoding the C terminus of diacylglycerol kinase-zeta (DGK-zeta), an enzyme that converts diacylglycerol into phosphatidic acid, In biochemical assays, the C terminus of DGK-zeta, which contains a consensus PDZ-binding motif, was found to be necessary and sufficient for association with gamma1-syntrophin, When coexpressed in HeLa cells. DGK-zeta and gamma1-syntrophin formed a stable complex that partitioned between the cytoplasm and nucleus. DGK-zeta translocates from the cytosol to the nucleus, a process negatively regulated by protein kinase C phosphorylation, We found that DGK-zeta recruits gamma1-syntrophin into the nucleus and that the PDZ-binding motif is required. Disrupting the interaction altered the intracellular localization of both proteins; DGK-zeta accumulated in the nucleus, whereas gamma1-syntrophin remained in the cytoplasm, The level of endogenous syntrophins in the nucleus of HeLa cells also reflected the amount of nuclear DGK-zeta, In the brain, DGK-zeta and gamma1-syntrophin were colocalized in cell bodies and dendrites of cerebellar Purkinjie neurons and other neuronal cell types, suggesting that their interaction is physiologically relevant. Moreover, coimmunoprecipitation and pull-down experiments from brain extracts and cells suggest that DGK-zeta, gamma1-syntrophin, and dystrophin form a ternary complex. Collectively, our results suggest that gamma1-syntrophin participates in regulating the subcellular localization of DGK-zeta to ensure correct termination of diacylglycerol signaling.	Univ Ottawa, Dept Cellular & Mol Med, Ctr Neuromusc Dis, Ottawa, ON K1H 8M5, Canada; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA	University of Ottawa; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Gee, SH (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Ctr Neuromusc Dis, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.							Adams ME, 2000, J CELL BIOL, V150, P1385, DOI 10.1083/jcb.150.6.1385; ADAMS ME, 1995, J BIOL CHEM, V270, P25859, DOI 10.1074/jbc.270.43.25859; ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; Blake DJ, 2000, TRENDS NEUROSCI, V23, P92, DOI 10.1016/S0166-2236(99)01510-6; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Ding L, 1998, FEBS LETT, V429, P109, DOI 10.1016/S0014-5793(98)00490-6; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Froehner SC, 1997, SOC GEN PHY, V52, P197; Gee SH, 2000, BIOCHEMISTRY-US, V39, P14638, DOI 10.1021/bi001633t; Gee SH, 1998, J BIOL CHEM, V273, P21980, DOI 10.1074/jbc.273.34.21980; Gee SH, 1998, J NEUROSCI, V18, P128; Gorecki DC, 1997, EUR J NEUROSCI, V9, P965, DOI 10.1111/j.1460-9568.1997.tb01447.x; Goto K, 1996, P NATL ACAD SCI USA, V93, P11196, DOI 10.1073/pnas.93.20.11196; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; HARLOW E, 1988, ANTIBODIES LAB MANUA, P314; Hasegawa M, 1999, J BIOL CHEM, V274, P12626, DOI 10.1074/jbc.274.18.12626; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Kachinsky AM, 1999, J CELL BIOL, V145, P391, DOI 10.1083/jcb.145.2.391; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; Kramarcy NR, 2000, MOL CELL NEUROSCI, V15, P262, DOI 10.1006/mcne.1999.0823; Lee SH, 2000, CURR OPIN NEUROBIOL, V10, P125, DOI 10.1016/S0959-4388(99)00046-X; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; LIDOV HGW, 1993, NEUROSCIENCE, V54, P167, DOI 10.1016/0306-4522(93)90392-S; Lumeng C, 1999, NAT NEUROSCI, V2, P611, DOI 10.1038/10165; Miller KG, 2000, NEURON, V27, P289, DOI 10.1016/S0896-6273(00)00037-4; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Nurrish S, 1999, NEURON, V24, P231, DOI 10.1016/S0896-6273(00)80835-1; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Piluso G, 2000, J BIOL CHEM, V275, P15851, DOI 10.1074/jbc.M000439200; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; YANG B, 1994, J BIOL CHEM, V269, P6040; Zhang YJ, 2001, J BIOL CHEM, V276, P1299, DOI 10.1074/jbc.M008513200	51	87	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26526	26533		10.1074/jbc.M104156200	http://dx.doi.org/10.1074/jbc.M104156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352924	hybrid			2022-12-27	WOS:000169823300116
J	Livneh, Z				Livneh, Z			DNA damage control by novel DNA polymerases: Translesion replication and mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SINGLE-STRANDED-DNA; THYMINE-THYMINE DIMER; PRONE LESION BYPASS; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; XERODERMA-PIGMENTOSUM; EMBRYONIC LETHALITY; CATALYTIC SUBUNIT; RECA PROTEIN; GENE ENCODES		Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Livneh, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; Bemark M, 2000, CURR BIOL, V10, P1213, DOI 10.1016/S0960-9822(00)00724-7; BROTCORNELANNOYE A, 1986, P NATL ACAD SCI USA, V83, P3904, DOI 10.1073/pnas.83.11.3904; Bruck I, 1996, J BIOL CHEM, V271, P10767, DOI 10.1074/jbc.271.18.10767; CAILLETFAUQUET P, 1984, EMBO J, V3, P707, DOI 10.1002/j.1460-2075.1984.tb01873.x; Cordonnier AM, 1999, MUTAT RES-DNA REPAIR, V435, P111, DOI 10.1016/S0921-8777(99)00047-6; Cox MM, 2000, PROG NUCLEIC ACID RE, V63, P311, DOI 10.1016/S0079-6603(08)60726-6; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ECHOLS H, 1981, CELL, V25, P1, DOI 10.1016/0092-8674(81)90223-3; Esposito G, 2000, CURR BIOL, V10, P1221, DOI 10.1016/S0960-9822(00)00726-0; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Fijalkowska IJ, 1997, J BACTERIOL, V179, P7435, DOI 10.1128/jb.179.23.7435-7445.1997; FRANK EG, 1993, P NATL ACAD SCI USA, V90, P8169, DOI 10.1073/pnas.90.17.8169; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Goldsmith M, 2000, P NATL ACAD SCI USA, V97, P11227, DOI 10.1073/pnas.200361997; Goodman MF, 2000, TRENDS BIOCHEM SCI, V25, P189, DOI 10.1016/S0968-0004(00)01564-4; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; KoffelSchwartz N, 1996, P NATL ACAD SCI USA, V93, P7805, DOI 10.1073/pnas.93.15.7805; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Lawrence CW, 1996, CANCER SURV, V28, P21; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Maor-Shoshani A, 2000, P NATL ACAD SCI USA, V97, P565, DOI 10.1073/pnas.97.2.565; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; MCCANN J, 1975, P NATL ACAD SCI USA, V72, P979, DOI 10.1073/pnas.72.3.979; MORIYA M, 1994, P NATL ACAD SCI USA, V91, P11899, DOI 10.1073/pnas.91.25.11899; Murakumo Y, 2000, J BIOL CHEM, V275, P4391, DOI 10.1074/jbc.275.6.4391; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; NETO JBC, 1994, J MOL BIOL, V240, P416, DOI 10.1006/jmbi.1994.1457; Ni TT, 1999, MOL CELL, V4, P439, DOI 10.1016/S1097-2765(00)80346-9; Nikolaishvili-Feinberg N, 2000, J BIOL CHEM, V275, P30943, DOI 10.1074/jbc.M005225200; Ohashi E, 2000, GENE DEV, V14, P1589; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Pham P, 2001, NATURE, V409, P366, DOI 10.1038/35053116; Radman M., 1975, MOL MECHANISMS REPAI, P355; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; Reuven NB, 2001, J BIOL CHEM, V276, P5511, DOI 10.1074/jbc.M006828200; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Sarov-Blat L, 1998, J BIOL CHEM, V273, P5520, DOI 10.1074/jbc.273.10.5520; Sharief FS, 1999, GENOMICS, V59, P90, DOI 10.1006/geno.1999.5843; Strauss BS, 2000, J BACTERIOL, V182, P6742, DOI 10.1128/JB.182.23.6742-6750.2000; STRAUSS BS, 1985, CANCER SURV, V4, P493; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Tissier A, 2000, GENE DEV, V14, P1642; Vaisman A, 2000, BIOCHEMISTRY-US, V39, P4575, DOI 10.1021/bi000130k; Wagner J, 2000, J BACTERIOL, V182, P4587, DOI 10.1128/JB.182.16.4587-4595.2000; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X; Wang ZH, 2000, SCIENCE, V289, P774, DOI 10.1126/science.289.5480.774; WITKIN EM, 1979, COLD SPRING HARB SYM, V43, P881, DOI 10.1101/SQB.1979.043.01.095; Wittschieben J, 2000, CURR BIOL, V10, P1217, DOI 10.1016/S0960-9822(00)00725-9; WOOD RD, 1984, J MOL BIOL, V173, P293, DOI 10.1016/0022-2836(84)90122-0; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; WOODGATE R, 1992, MOL MICROBIOL, V6, P2213, DOI 10.1111/j.1365-2958.1992.tb01397.x; WOODGATE R, 1989, P NATL ACAD SCI USA, V86, P7301, DOI 10.1073/pnas.86.19.7301; Yuan FH, 2000, J BIOL CHEM, V275, P8233, DOI 10.1074/jbc.275.11.8233; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4717, DOI 10.1093/nar/28.23.4717; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4147, DOI 10.1093/nar/28.21.4147; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000	87	102	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25639	25642		10.1074/jbc.R100019200	http://dx.doi.org/10.1074/jbc.R100019200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11371576	hybrid			2022-12-27	WOS:000169823300001
J	Byun, T; Tang, M; Sloma, A; Brown, KM; Marumoto, C; Fujii, M; Blinkovsky, AM				Byun, T; Tang, M; Sloma, A; Brown, KM; Marumoto, C; Fujii, M; Blinkovsky, AM			Aminopeptidase from Sphingomonas capsulata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIFICITY	A novel aminopeptidase with unique substrate specificity was purified from a culture broth of Sphingomonas capsulata, This is the first reported aminopeptidase to demonstrate broad substrate specificity and yet release glycine and alanine with the highest efficacy. On a series of pentapeptide amides with different N-terminal amino acids, this enzyme efficiently releases glycine, alanine, leucine, proline, and glutamate with the lowest turnover value of 370 min(-1) for glutamate, At pH 7.5 (pH optimum) and 25 degreesC, the kinetic parameters for alanine para-nitroanilide were found to be k(cat) = 7600 min(-1) and K-m = 14 mM. For alanine beta -naphthylamide, they were k(cat) = 860 min(-1) and K-m = 6.7 mm, Polymerase chain reaction primers were designed based upon obtained internal sequences of the wild type enzyme. The subsequent product was then used to acquire the full-length gene from an S, capsulata genomic library. An open reading frame encoding a protein of 670 amino acids was obtained. The translated protein has a putative signal peptide that directs the enzyme into the supernatant, A search of the amino acid sequence revealed no significant homology to any known aminopeptidases in the available data bases.	Novozymes Biotech Inc, Davis, CA 95616 USA; Japan Tobacco Inc, Foods Technol Ctr, Ohito, Shizuoka 4102318, Japan	Novozymes; Japan Tobacco Inc.	Blinkovsky, AM (corresponding author), Novozymes Biotech Inc, 1445 Drew Ave, Davis, CA 95616 USA.							Adler-Nissen J, 1985, ENZYMIC HYDROLYSIS F; Alan Sloma, 1999, US Patent, Patent No. 5958728; Blinkovsky AM, 2000, BBA-PROTEIN STRUCT M, V1480, P171, DOI 10.1016/S0167-4838(00)00064-9; CHAPPELETTORDO D, 1977, EUR J BIOCHEM, V81, P299, DOI 10.1111/j.1432-1033.1977.tb11952.x; Cunningham DF, 1997, BBA-PROTEIN STRUCT M, V1343, P160, DOI 10.1016/S0167-4838(97)00134-9; FERSHT A, 1985, ENZYME STRUCTURE MEC, P405; Gonzales T, 1996, FEMS MICROBIOL REV, V18, P319, DOI 10.1111/j.1574-6976.1996.tb00247.x; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; NISHIMURA T, 1988, Food Reviews International, V4, P175; OSADA H, 1986, BIOCHEM J, V233, P459, DOI 10.1042/bj2330459; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOMBURG D, 1991, ENZYME HDB CLASS 3 H, V5; SLOMA AP, 1997, Patent No. 5622850; TAN PST, 1993, J DAIRY RES, V60, P69; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WATSON RR, 1976, METHOD MICROBIOL, V9, P1	18	6	6	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17902	17907		10.1074/jbc.M010608200	http://dx.doi.org/10.1074/jbc.M010608200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359790	hybrid			2022-12-27	WOS:000168866500040
J	Coe, APF; Askari, JA; Kline, AD; Robinson, MK; Kirby, H; Stephens, PE; Humphries, MJ				Coe, APF; Askari, JA; Kline, AD; Robinson, MK; Kirby, H; Stephens, PE; Humphries, MJ			Generation of a minimal alpha(5)beta(1) integrin-Fc fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIB; BETA-PROPELLER DOMAIN; DEPENDENT ADHESION SITE; FUNCTION-ASSOCIATED ANTIGEN-1; LIGAND-BINDING REGION; AMINO-ACID-RESIDUES; I-DOMAIN; HUMAN FIBRONECTIN; CELL-ADHESION; CRYSTAL-STRUCTURE	The tertiary structure of the integrin heterodimer is currently unknown, although several predictive models have been generated. Detailed structural studies of integrins have been consistently hampered for several reasons, including the small amounts of purified protein available, the large size and conformational flexibility of integrins, and the presence of transmembrane domains and N-linked glycosylation sites in both receptor subunits. As a first step toward obtaining crystals of an integrin receptor, we have expressed a minimized dimer. By using the Fc dimerization and mammalian cell expression system designed and optimized by Stephens et al. (Stephens, P. E., Ortlepp, S., Perkins, V. C., Robinson, M. K., and Kirby, H. (2000) Cell. Adhes. Commun. 7, 377-390), a series of recombinant soluble human alpha (5)beta (1) integrin truncations have been expressed as Fc fusion proteins. These proteins were examined for their ligand-binding properties and for their expression of anti-integrin antibody epitopes. The shortest functional alpha (5)-subunit truncation contained the N-terminal 613 residues, whereas the shortest beta (1)-subunit was a fragment containing residues 121-455. Each of these minimally truncated integrins displayed the antibody binding characteristics of alpha (5)beta (1) purified from human placenta and bound ligand with the same apparent affinity as the native receptor.	Univ Manchester, Sch Biol Sci, Wellcome Trust, Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Celltech Ltd, Slough SL1 4EN, Berks, England	University of Manchester; Celltech Group Ltd	Humphries, MJ (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust, Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.			Humphries, Martin/0000-0002-4331-6967				AOTA S, 1994, J BIOL CHEM, V269, P24756; BAJT ML, 1994, J BIOL CHEM, V269, P20913; Baneres JL, 2000, J BIOL CHEM, V275, P5888, DOI 10.1074/jbc.275.8.5888; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BEBBINGTON C, 1995, DNA CLONING, V4, P85; BENNETT JS, 1993, J BIOL CHEM, V268, P3580; BERMAN PW, 1993, J CELL BIOCHEM, V52, P183, DOI 10.1002/jcb.240520210; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; BRIESEWITZ R, 1993, MOL BIOL CELL, V4, P593, DOI 10.1091/mbc.4.6.593; Burrows L, 1999, BIOCHEM J, V344, P527, DOI 10.1042/0264-6021:3440527; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CALVETE JJ, 1989, BIOCHEM J, V261, P561, DOI 10.1042/bj2610561; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; Chen J, 1996, CELL ADHES COMMUN, V4, P237, DOI 10.3109/15419069609010769; Clark K, 2000, FEBS LETT, V471, P182, DOI 10.1016/S0014-5793(00)01391-0; COCKETT MI, 1991, NUCLEIC ACIDS RES, V19, P319, DOI 10.1093/nar/19.2.319; Curley GP, 1999, CELL MOL LIFE SCI, V56, P427, DOI 10.1007/s000180050443; DANA N, 1991, P NATL ACAD SCI USA, V88, P3106, DOI 10.1073/pnas.88.8.3106; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DeMelker AA, 1996, EUR J BIOCHEM, V241, P254; Denda S, 1998, BIOCHEMISTRY-US, V37, P5464, DOI 10.1021/bi9727489; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; Edwards CP, 1998, J BIOL CHEM, V273, P28937, DOI 10.1074/jbc.273.44.28937; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; Goodman TG, 1998, J LEUKOCYTE BIOL, V64, P767, DOI 10.1002/jlb.64.6.767; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; GULINO D, 1995, EUR J BIOCHEM, V227, P108, DOI 10.1111/j.1432-1033.1995.tb20365.x; Henderson WR, 1997, J CLIN INVEST, V100, P3083, DOI 10.1172/JCI119863; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3156, DOI 10.1073/pnas.94.7.3156; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3162, DOI 10.1073/pnas.94.7.3162; Humphries JD, 2000, J BIOL CHEM, V275, P20337, DOI 10.1074/jbc.M000568200; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; Humphries MJ, 1998, TRENDS CELL BIOL, V8, P78, DOI 10.1016/S0962-8924(98)80016-0; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; Kamata T, 1999, J BIOL CHEM, V274, P32108, DOI 10.1074/jbc.274.45.32108; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; Krukonis ES, 1998, J BIOL CHEM, V273, P31837, DOI 10.1074/jbc.273.48.31837; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; Loftus JC, 1996, J BIOL CHEM, V271, P2033, DOI 10.1074/jbc.271.4.2033; Lu CF, 1998, J BIOL CHEM, V273, P15138, DOI 10.1074/jbc.273.24.15138; Mathias P, 1998, J VIROL, V72, P8669, DOI 10.1128/JVI.72.11.8669-8675.1998; McKay BS, 1996, J BIOL CHEM, V271, P30544, DOI 10.1074/jbc.271.48.30544; Mehta RJ, 1998, BIOCHEM J, V330, P861; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; Mould AP, 1998, J BIOL CHEM, V273, P25664, DOI 10.1074/jbc.273.40.25664; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; MOULD AP, 1997, J BIOL CHEM, V272, P17288; Munoz M, 1997, BIOCHEM J, V327, P727, DOI 10.1042/bj3270727; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; Oxvig C, 1998, P NATL ACAD SCI USA, V95, P4870, DOI 10.1073/pnas.95.9.4870; PARDI R, 1995, J IMMUNOL, V155, P1252; Peterson JA, 1998, BLOOD, V92, P2053, DOI 10.1182/blood.V92.6.2053.418k14_2053_2063; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; SCHIFFER SG, 1995, J BIOL CHEM, V270, P14270, DOI 10.1074/jbc.270.24.14270; Sonnenberg A, 1993, Curr Top Microbiol Immunol, V184, P7; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Stephens PE, 2000, CELL ADHES COMMUN, V7, P377, DOI 10.3109/15419060009109020; Takada Y, 1997, MATRIX BIOL, V16, P143, DOI 10.1016/S0945-053X(97)90002-0; TAKAHASHI N, 1982, CELL, V29, P671, DOI 10.1016/0092-8674(82)90183-0; Tan SM, 2000, J IMMUNOL, V165, P2574, DOI 10.4049/jimmunol.165.5.2574; Tominaga Y, 1998, J IMMUNOL METHODS, V212, P61, DOI 10.1016/S0022-1759(97)00207-X; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Wang AZ, 1997, ARTHRITIS RHEUM, V40, P1298, DOI 10.1002/art.1780400715; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558; Zhang XP, 1999, BIOCHEMISTRY-US, V38, P14424, DOI 10.1021/bi990323b	86	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35854	35866		10.1074/jbc.M103639200	http://dx.doi.org/10.1074/jbc.M103639200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11389148	hybrid			2022-12-27	WOS:000171109300085
J	Kim, SH; Goto, M; Akaike, T				Kim, SH; Goto, M; Akaike, T			Specific binding of glucose-derivatized polymers to the asialoglycoprotein receptor of mouse primary hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTES; LECTIN; CARBOHYDRATE; RECOGNITION; LIVER; GALACTOSE; ADHESION; EXPRESSION; LIGAND; SUGARS	In this study, we designed a novel amphiphilic poly-(p-N-vinylbenzyl-D-glucuronamide) (PV6Gna) modified at the 6-OH position of glucose for hepatocyte recognition to address the mechanism of the interaction between mouse primary hepatocytes and the PV6Gna. PV6Gna bound to lectins specific for glucose but not galactose as did other glucose-derivatized polymers. However, hepatocyte adhesion onto the PV6Gna surface was inhibited in the presence of galactose and its analogues but not in the presence of glucose and its analogues. We also showed that hepatocyte adhesion to the PV6Gna surface was inhibited dose dependently by asialofetuin (ASF). Interactions between soluble PV6Gna and hepatocytes were inhibited by GalNAc, ASF, and EGTA in flow cytometry analysis using fluorescein isothiocyanate-conjugated PV6Gna. Hepatocyte adhesion to the PV6Gna surface was inhibited more effectively by GalNAc than by methyl beta -D-galactose. In flow cytometry analysis and cell adhesion assay, ASF competed for the inhibition of interaction between PV6Gna and hepatocytes 0.5-4 x 10(5)-fold more effectively than did GalNAc. These results demonstrate involvement of asialoglycoprotein receptors (ASGPRs) in the interaction between PV6Gna and hepatocytes. Furthermore, to clarify the mechanism of the interaction between glycopolymers modified at the 6-OH position of glucose and the hepatocyte, we prepared a gel particle containing 6-O-methacryloyl-D-glucose (PMglc) synthesized by an enzymatic method. ASGPRs could be detected using Western blot analysis following precipitation with PMglc in hepatocyte cell lysate. The precipitation of ASGPRs was inhibited in the presence of galactose, ASF, PV6Gna, and EGTA. The precipitation was inhibited more effectively by GalNAc than by methyl beta -D-galactose. ASGPRs were rarely precipitated by PMglc in the cell lysate that had been treated with ASF-conjugated Sepharose. Taken together, we suggest that mouse primary hepatocytes adhere to the PV6Gna surface mediated by ASGPRs, which specifically interacted with the glycopolymers modified at the C-6 position of glucose.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biomol Engn, Midori Ku, Yokohama, Kanagawa 2268501, Japan; BioQuest Res Ltd, Tokyo 1070062, Japan	Tokyo Institute of Technology	Akaike, T (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biomol Engn, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.							ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; CHEN XM, 1995, MACROMOLECULES, V28, P6014, DOI 10.1021/ma00122a005; Eto T, 1999, NAT MED, V5, P577, DOI 10.1038/8462; Gordon EJ, 1998, NATURE, V392, P30, DOI 10.1038/32073; Griffith LG, 1998, BIOMATERIALS, V19, P979, DOI 10.1016/S0142-9612(97)00185-3; GUARNACCIA SP, 1982, J BIOL CHEM, V257, P4288; HONG WJ, 1988, HEPATOLOGY, V8, P553, DOI 10.1002/hep.1840080320; ICHIKAWA Y, 1990, J CARBOHYD CHEM, V9, P797; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; Julyan PJ, 1999, J CONTROL RELEASE, V57, P281, DOI 10.1016/S0168-3659(98)00124-2; KALINOWSKI HO, 1988, CARBON 13 NMR SPECTR, P441; Kim SH, 2000, BIOTECHNOL LETT, V22, P1049, DOI 10.1023/A:1005641928736; KOBAYASHI A, 1992, J BIOMAT SCI-POLYM E, V3, P499, DOI 10.1163/156856292X00466; KOHGO Y, 1993, HYBRIDOMA, V12, P591, DOI 10.1089/hyb.1993.12.591; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; Kolatkar AR, 1998, J BIOL CHEM, V273, P19502, DOI 10.1074/jbc.273.31.19502; LEE RT, 1982, BIOCHEMISTRY-US, V21, P6292, DOI 10.1021/bi00267a039; Lee Y. C., 1994, NEOGLYCOCONJUGATES P; LEE YC, 1992, FASEB J, V6, P3193, DOI 10.1096/fasebj.6.13.1397841; LEE YC, 1983, J BIOL CHEM, V258, P199; Li TL, 1998, J BIOMAT SCI-POLYM E, V9, P327, DOI 10.1080/09205063.1998.9753059; LOGANATHAN D, 1992, ARCH BIOCHEM BIOPHYS, V299, P268, DOI 10.1016/0003-9861(92)90274-Z; MATSUSHITA N, 1994, BIOSCI BIOTECH BIOCH, V58, P1514, DOI 10.1271/bbb.58.1514; MERWIN JR, 1994, BIOCONJUGATE CHEM, V5, P612, DOI 10.1021/bc00030a017; MORELL AG, 1968, J BIOL CHEM, V243, P155; MORITA M, 1995, HEPATOLOGY, V21, P1585, DOI 10.1016/0270-9139(95)90463-8; NAGAKI M, 1995, BIOCHEM BIOPH RES CO, V210, P38, DOI 10.1006/bbrc.1995.1624; OKA JA, 1986, J CELL BIOL, V103, P1055, DOI 10.1083/jcb.103.3.1055; ORA A, 1991, J CELL BIOL, V115, P495; RICE KG, 1990, J BIOL CHEM, V265, P18429; RIVA S, 1988, J AM CHEM SOC, V110, P584, DOI 10.1021/ja00210a045; Sanders WJ, 1999, J BIOL CHEM, V274, P5271, DOI 10.1074/jbc.274.9.5271; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; SATO Y, 1994, HEPATOLOGY, V19, P1023, DOI 10.1002/hep.1840190430; SCHLEPPERSCHAFER J, 1980, BIOCHEM J, V186, P827, DOI 10.1042/bj1860827; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Sharma V, 1996, J BIOL CHEM, V271, P21209, DOI 10.1074/jbc.271.35.21209; Shibatani S, 1997, BIOTECHNOL LETT, V19, P511; SONNAAR RL, 1978, J BIOL CHEM, V253, P7940; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; TAKADA A, 1993, CANCER RES, V53, P354; Taketa K, 1996, ELECTROPHORESIS, V17, P483, DOI 10.1002/elps.1150170309; TIEMEYER M, 1992, J BIOL CHEM, V267, P12252; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; WALL DA, 1980, CELL, V21, P79, DOI 10.1016/0092-8674(80)90116-6; WATANABE T, 1995, CARBOHYD RES, V275, P215, DOI 10.1016/0008-6215(95)00151-I; WEIGEL PH, 1979, J BIOL CHEM, V254, P830; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; WEIS WI, 1996, ANNU REV BIOCHEM, V6, P441; YOSHIMOTO K, 1980, CHEM PHARM BULL, V28, P2065	52	51	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35312	35319		10.1074/jbc.M009749200	http://dx.doi.org/10.1074/jbc.M009749200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11390372	hybrid			2022-12-27	WOS:000171109300016
J	Nakagawa, T; Flores-Rozas, H; Kolodner, RD				Nakagawa, T; Flores-Rozas, H; Kolodner, RD			The MER3 helicase involved in meiotic crossing over is stimulated by single-stranded DNA-binding proteins and unwinds DNA in the 3 ' to 5 ' direction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; BLOOMS-SYNDROME PROTEIN; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SYNAPSIS; MISMATCH CORRECTION; RAD51 PROTEIN; MUTS HOMOLOG; RECOMBINATION; MEIOSIS; YEAST	The meiosis-specific MER3 protein of Saccharomyces cerevisiae is required for crossing over, which ensures faithful segregation of homologous chromosomes at the first meiotic division. The predicted sequence of the MER3 protein contains the seven motifs characteristic of the DExH-box type of DNA/RNA helicases. The purified MER3 protein is a DNA helicase, which can displace a 50-nucleotide fragment annealed to a single-stranded circular DNA. MER3 was found to have ATPase activity, which was stimulated either by single- or double-stranded DNA. The turnover rate, k(cat), of ATP hydrolysis was similar to 500/min in the presence of either DNA. MER3 was able to efficiently displace relatively long 631-nucleotide fragments from single-stranded circular DNA only in the presence of the S. cerevisiae single-stranded DNA-binding protein, RPA (replication protein A). It appears that RPA inhibits re-annealing of the single-stranded products of the MER3 helicase. The MER3 helicase was found to unwind DNA in the 3 ' to 5 ' direction relative to single-stranded regions in the DNA substrates. Possible roles for the MER3 helicase in meiotic crossing over are discussed.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ctr Canc, Dept Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, CMME 3080,9500 Gilman Dr, La Jolla, CA 92093 USA.		Nakagawa, Takuro/A-1367-2017	Nakagawa, Takuro/0000-0003-3455-8224	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026017, R37GM026017] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM026017, GM26017, R37 GM026017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Bennett RJ, 1999, J MOL BIOL, V289, P235, DOI 10.1006/jmbi.1999.2739; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Chua PR, 1998, CELL, V93, P349, DOI 10.1016/S0092-8674(00)81164-2; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Frei C, 2000, GENE DEV, V14, P81; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P407; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; Hunter N, 1997, GENE DEV, V11, P1573, DOI 10.1101/gad.11.12.1573; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kirkpatrick DT, 2000, GENETICS, V156, P1549; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; Liao SR, 2000, GENE DEV, V14, P2570, DOI 10.1101/gad.822400; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; Nakagawa T, 1997, GENES CELLS, V2, P65, DOI 10.1046/j.1365-2443.1997.d01-283.x; Nakagawa T, 1999, EMBO J, V18, P5714, DOI 10.1093/emboj/18.20.5714; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Storlazzi A, 1996, P NATL ACAD SCI USA, V93, P9043, DOI 10.1073/pnas.93.17.9043; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Tsubouchi H, 2000, MOL BIOL CELL, V11, P2221, DOI 10.1091/mbc.11.7.2221; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Watt PM, 1996, GENETICS, V144, P935	47	45	47	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31487	31493		10.1074/jbc.M104003200	http://dx.doi.org/10.1074/jbc.M104003200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11376001	Green Accepted, hybrid			2022-12-27	WOS:000170613500004
J	Kaneto, H; Xu, G; Song, KH; Suzuma, K; Bonner-Weir, S; Sharma, A; Weir, GC				Kaneto, H; Xu, G; Song, KH; Suzuma, K; Bonner-Weir, S; Sharma, A; Weir, GC			Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-TRANSCRIPTION; O-LINKED GLYCOSYLATION; GLUCOSE TOXICITY; TRANSGENIC MICE; IN-VIVO; GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; SKELETAL-MUSCLE; HOMEOBOX FACTOR; HIT-T15 CELLS; GROWTH-FACTOR	It is known well that activation of the hexosamine pathway causes insulin resistance, but how this activation influences pancreatic beta -cell function remains unclear. In this study, we found that in isolated rat islets adenovirus-mediated overexpression of glutamine:fructose-6-phosphate amidotransferase (GFAT), the first and rate-limiting enzyme of the hexosamine pathway, leads to deterioration of beta -cell function, which is similar to that found in diabetes. Overexpression of GFAT or treatment with glucosamine results in impaired glucose-stimulated insulin secretion and reduction irk the expression levels of several beta -cell specific genes (insulin, GLUT2, and glucokinase). Additionally, the DNA binding activity of PDX-1, an important transcription factor for these three genes, was markedly reduced. These phenomena were not mimicked by the induction of O-linked glycosylation with an inhibitor of O-GlcNAcase, PUG-NAc. It was also found that glucosamine increases hydrogen peroxide levels and that several hexosamine pathway-mediated changes were suppressed by treatment with the antioxidant N-acetyl-L-cysteine. In conclusion, activation of the hexosamine pathway leads to deterioration of beta -cell function through the induction of oxidative stress rather than O-linked glycosylation. Thus, the hexosamine pathway may contribute to the deterioration of beta -cell function found in diabetes.	Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.	Weir, GC (corresponding author), Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, 1 Joslin Pl, Boston, MA 02215 USA.			Bonner-Weir, Susan/0000-0003-4682-0656	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035449] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35449] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Akimoto Y, 1999, DIABETES, V48, P2407, DOI 10.2337/diabetes.48.12.2407; Akimoto Y, 2000, DIABETOLOGIA, V43, P1239, DOI 10.1007/s001250051519; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BONNERWEIR S, 1983, J CLIN INVEST, V71, P1544, DOI 10.1172/JCI110910; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Dutta S, 1998, NATURE, V392, P560, DOI 10.1038/33311; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; Ihara Y, 1999, DIABETES, V48, P927, DOI 10.2337/diabetes.48.4.927; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Kaneto H, 1997, J BIOL CHEM, V272, P29137, DOI 10.1074/jbc.272.46.29137; Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398; Kaneto H, 1996, BIOCHEM J, V320, P855, DOI 10.1042/bj3200855; KELLY WG, 1993, J BIOL CHEM, V268, P10416; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; Maechler P, 1999, J BIOL CHEM, V274, P27905, DOI 10.1074/jbc.274.39.27905; Matsuoka T, 1997, J CLIN INVEST, V99, P144, DOI 10.1172/JCI119126; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OLSON LK, 1993, J CLIN INVEST, V92, P514, DOI 10.1172/JCI116596; Patti ME, 1999, DIABETES, V48, P1562, DOI 10.2337/diabetes.48.8.1562; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; SUTTON R, 1986, TRANSPLANTATION, V42, P689, DOI 10.1097/00007890-198612000-00022; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; Tang JP, 2000, DIABETES, V49, P1492, DOI 10.2337/diabetes.49.9.1492; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; Veerababu G, 2000, DIABETES, V49, P2070, DOI 10.2337/diabetes.49.12.2070; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; XIA MH, 1993, DIABETES, V42, P1392, DOI 10.2337/diabetes.42.10.1392; Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258	44	240	255	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31099	31104		10.1074/jbc.M104115200	http://dx.doi.org/10.1074/jbc.M104115200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11390407	hybrid			2022-12-27	WOS:000170472900068
J	Khandekar, SS; Gentry, DR; Van Aller, GS; Warren, P; Xiang, H; Silverman, C; Doyle, ML; Chambers, PA; Konstantinidis, AK; Brandt, M; Daines, RA; Lonsdale, JT				Khandekar, SS; Gentry, DR; Van Aller, GS; Warren, P; Xiang, H; Silverman, C; Doyle, ML; Chambers, PA; Konstantinidis, AK; Brandt, M; Daines, RA; Lonsdale, JT			Identification, substrate specificity, and inhibition of the Streptococcus pneumoniae beta-ketoacyl-acyl carrier protein synthase III (FabH)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; ESCHERICHIA-COLI K-12; MYCOBACTERIUM-TUBERCULOSIS; CRYSTAL-STRUCTURE; ANTIBIOTIC THIOLACTOMYCIN; ACTIVE-SITE; TARGET; EXPRESSION; CLONING; GENE	In the bacterial type II fatty acid synthase system, beta -ketoacyl-acyl carrier protein (ACP) synthase IH (FabH) catalyzes the condensation of acetyl-CoA with malonyl-ACP. We have identified, expressed, and characterized the Streptococcus pneumoniae homologue of Escherichia coli FabH. S. pneumoniae FabH is similar to 41, 39, and 38% identical in amino acid sequence to Bacillus subtilis, E. coli and Hemophilus influenzae FabH, respectively. The His-Asn-Cys catalytic triad present in other FabH molecules is conserved in S. pneumoniae FabH. The apparent K-m values for acetyl-CoA and malonyl-ACP were determined to be 40.3 and 18.6 muM, respectively. Purified S. pneumoniae FabH preferentially utilized straight short-chain CoA primers. Similar to E. coli FabH, S. pneumoniae FabH was weakly inhibited by thiolactomycin. In contrast, inhibition of S. pneumoniae FabH by the newly developed compound SB418011 was very potent, with an IC50 value of 0.016 muM. SB418011 also inhibited E. coli and H. influenzae FabH with IC50 values of 1.2 and. 0.59 muM, respectively. The availability of purified and characterized S. pneumoniae FabH will greatly aid in structural studies of this class of essential bacterial enzymes and. facilitate the identification of small molecule inhibitors of type II fatty acid synthase with the potential to be novel and potent antibacterial agents active against pathogenic bacteria.	Glaxo SmithKline, Dept Prot Biochem, King Of Prussia, PA 19406 USA; Glaxo SmithKline, Dept Prot Biochem, King Of Prussia, PA 19406 USA; Glaxo SmithKline, Dept Biol Struct, King Of Prussia, PA 19406 USA; Glaxo SmithKline, Dept Bioinformat, King Of Prussia, PA 19406 USA; Glaxo SmithKline, Dept Mechanist Enzymol, King Of Prussia, PA 19406 USA; Glaxo SmithKline, Dept Med Chem, King Of Prussia, PA 19406 USA; Glaxo SmithKline, Dept Microbial Biochem, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Khandekar, SS (corresponding author), Glaxo SmithKline, Dept Prot Biochem, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.			Doyle, Michael/0000-0003-4569-6315				BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Besra GS, 1998, METH MOL B, V101, P91, DOI 10.1385/0-89603-471-2:91; BRICE JL, 1979, J INFECT DIS, V140, P443, DOI 10.1093/infdis/140.4.443; Chirala SS, 1997, P NATL ACAD SCI USA, V94, P5588, DOI 10.1073/pnas.94.11.5588; Choi KH, 2000, J BIOL CHEM, V275, P28201; Choi KH, 2000, J BACTERIOL, V182, P365, DOI 10.1128/JB.182.2.365-370.2000; CLOUGH RC, 1992, J BIOL CHEM, V267, P20992; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; Edwards P, 1997, FEBS LETT, V402, P62, DOI 10.1016/S0014-5793(96)01437-8; GARLAND PB, 1964, BIOCHEM J, V92, pC10, DOI 10.1042/bj0920010C; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; Han L, 1998, J BACTERIOL, V180, P4481, DOI 10.1128/JB.180.17.4481-4486.1998; HAYASHI T, 1983, BIOCHEM BIOPH RES CO, V115, P1108, DOI 10.1016/S0006-291X(83)80050-3; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Huang WJ, 1998, EMBO J, V17, P1183, DOI 10.1093/emboj/17.5.1183; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7624; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; JAYAKUMAR A, 1995, P NATL ACAD SCI USA, V92, P8695, DOI 10.1073/pnas.92.19.8695; KANEDA T, 1991, MICROBIOL REV, V55, P288, DOI 10.1128/MMBR.55.2.288-302.1991; Khandekar SS, 2000, BIOCHEM BIOPH RES CO, V270, P100, DOI 10.1006/bbrc.2000.2380; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MATHIEU M, 1994, STRUCTURE, V2, P797, DOI 10.1016/S0969-2126(94)00081-6; McMurry LM, 1998, FEMS MICROBIOL LETT, V166, P305, DOI 10.1016/S0378-1097(98)00347-4; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; Qiu XY, 1999, J BIOL CHEM, V274, P36465, DOI 10.1074/jbc.274.51.36465; Qiu XY, 2001, J MOL BIOL, V307, P341, DOI 10.1006/jmbi.2000.4457; Qiu XY, 1999, PROTEIN SCI, V8, P2529, DOI 10.1110/ps.8.11.2529; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; TSAY JT, 1992, J BIOL CHEM, V267, P6807; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; WOODY RW, 1995, METHOD ENZYMOL, V246, P34	36	87	100	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30024	30030		10.1074/jbc.M101769200	http://dx.doi.org/10.1074/jbc.M101769200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11375394	hybrid			2022-12-27	WOS:000170558000056
J	Aikawa, T; Segre, GV; Lee, K				Aikawa, T; Segre, GV; Lee, K			Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-Cdk2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; FACTOR RECEPTOR-3; BONE-DEVELOPMENT; TRANSGENIC MICE; INDIAN HEDGEHOG; DIFFERENTIATION; PROLIFERATION; EXPRESSION; ACTIVATION; ARREST	Fibroblast growth factor (FGF) and its receptor (FGFR) are thought to be negative regulators of chondrocytic growth, as exemplified by achondroplasia and related chondrodysplasias, which are caused by constitutively active mutations in FGFR3. To understand the growth-inhibitory mechanisms of FGF, we analyzed the effects of FGF2 on cell cycle-regulating molecules in chondrocytes. FGF2 dramatically inhibited proliferation of rat chondrosarcoma (RCS) cells and arrested their cell cycle at the G(1) phase. FGF2 increased p21 expression in RCS cells, which assembled with the cyclin E-Cdk2 complexes, although the expression of neither cyclin E nor Cdk2 increased. In addition, the kinase activity of immunoprecipitated cyclin E or Cdk2, assessed with retinoblastoma protein (pRb) as substrate, was dramatically reduced by FGF-2. Moreover, FGF2 shifted pRb to its underphosphorylated, active form in RCS cells. FGF2 not only induced p21 protein expression in proliferating chondrocytes in mouse fetal limbs cultured in vitro but also decreased their proliferation as assessed by the expression of histone H4 mRNA, a marker for cells in S phase. Furthermore, inhibitory effects of FGF2 on chondrocytic proliferation were partially reduced in p21-null limbs, compared with those in wild-type limbs in vitro. Taken together, FGF's growth inhibitory effects of chondrocytes appear to be mediated at least partially through p21 induction and the subsequent inactivation of cyclin E-Cdk2 and activation of pRb.	Harvard Univ, Endocrine Unit, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School	Lee, K (corresponding author), Harvard Univ, Endocrine Unit, Massachusetts Gen Hosp, Sch Med, 50 Blossom St,Wellman 501, Boston, MA 02114 USA.			Aikawa, Tomonao/0000-0001-6906-6874	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053343] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53343] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen L, 1999, J CLIN INVEST, V104, P1517, DOI 10.1172/JCI6690; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Garofalo S, 1999, J BONE MINER RES, V14, P1909, DOI 10.1359/jbmr.1999.14.11.1909; Gius DR, 1999, CANCER RES, V59, P2577; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Iwata T, 2000, HUM MOL GENET, V9, P1603, DOI 10.1093/hmg/9.11.1603; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; Karp SJ, 2000, DEVELOPMENT, V127, P543; KATO J, 1993, GENE DEV, V7, P331; Lee K, 1996, ENDOCRINOLOGY, V137, P5109, DOI 10.1210/en.137.11.5109; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Naski MC, 1998, DEVELOPMENT, V125, P4977; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Segev O, 2000, HUM MOL GENET, V9, P249, DOI 10.1093/hmg/9.2.249; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SIERRA F, 1983, NUCLEIC ACIDS RES, V11, P7069, DOI 10.1093/nar/11.20.7069; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Szebenyi G, 1999, INT REV CYTOL, V185, P45; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Wang HS, 1997, CANCER RES, V57, P1750; Wang YC, 1999, P NATL ACAD SCI USA, V96, P4455, DOI 10.1073/pnas.96.8.4455; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xu XL, 1999, CELL TISSUE RES, V296, P33, DOI 10.1007/s004410051264	36	84	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29347	29352		10.1074/jbc.M101859200	http://dx.doi.org/10.1074/jbc.M101859200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384971	hybrid			2022-12-27	WOS:000170346000095
J	Saito, H; Papaconstantinou, J				Saito, H; Papaconstantinou, J			Age-associated differences in cardiovascular inflammatory gene induction during endotoxic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; HUMAN-FIBROBLASTS; CARDIAC MYOCYTES; TRANSGENIC MICE; SEVERE SEPSIS; NITRIC-OXIDE; INTERLEUKIN-6; IL-6	Upon physiological stress, families of stress response genes are activated as natural defense mechanisms. Here, we show that induction of specific inflammatory genes is significantly dysregulated and altered in the heart of aged (24-26-month-old) versus young (4-month-old) mice experimentally challenged with a bacterial endotoxin, lipopolysaccharide (LPS, 1.5 mg/kg of body mass). Whereas the LPS-mediated induction of cardiac mRNA for tumor necrosis factor a or inducible nitric-oxide synthase showed no age-associated differences, the induction of interleukin-1 beta (IL-1 beta) and intracellular adhesion molecule-1 was modestly extended with aging, and the induction of IL-6 was significantly prolonged with aging. This age-associated phenomenon occurred gradually from 4 to 17 months of age and became more evident after 23 months of age. The age-associated augmentation of the cardiac IL-6 induction was also dramatic at the protein level. Immunohistochemically, the LPS-induced cardiac IL-6 was localized mainly in the microvascular walls. Aged but not young mice showed a high mortality rate during these experiments. These results demonstrate that endotoxin-mediated induction of specific inflammatory genes in cardiovascular tissues is altered with aging, which may be causally related to the increased susceptibility of aged animals to endotoxic stress.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Papaconstantinou, J (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 301 Univ Blvd, Galveston, TX 77555 USA.		Papaconstantinou, John/E-3312-2010		NIA NIH HHS [2-P01-AG10514, P30 AG024832] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG024832, P01AG010514] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKASHI M, 1990, J CLIN INVEST, V85, P121, DOI 10.1172/JCI114401; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BALDWIN KM, 1998, PATHOPHYSIOLOGY BIOL, P1570; BELMIN J, 1995, AM J PHYSIOL-HEART C, V268, pH2288, DOI 10.1152/ajpheart.1995.268.6.H2288; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; Chorinchath BB, 1996, J IMMUNOL, V156, P1525; DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009; DeBenedetti F, 1997, J CLIN INVEST, V99, P643, DOI 10.1172/JCI119207; Delpedro AD, 1998, J INTERF CYTOK RES, V18, P429, DOI 10.1089/jir.1998.18.429; FINKEL MS, 1993, AM J CARDIOL, V71, P1231, DOI 10.1016/0002-9149(93)90654-U; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; FOSTER KD, 1992, AM J PHYSIOL, V262, pR211, DOI 10.1152/ajpregu.1992.262.2.R211; Fujita J, 1996, EUR SURG RES, V28, P361, DOI 10.1159/000129477; Grocott-Mason RM, 1998, INTENS CARE MED, V24, P286, DOI 10.1007/s001340050570; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Helenius M, 1996, J MOL CELL CARDIOL, V28, P487, DOI 10.1006/jmcc.1996.0045; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; Hsieh CC, 1998, MOL BIOL CELL, V9, P1479, DOI 10.1091/mbc.9.6.1479; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kumar A, 1996, J EXP MED, V183, P949, DOI 10.1084/jem.183.3.949; KUMAR S, 1992, P NATL ACAD SCI USA, V89, P4683, DOI 10.1073/pnas.89.10.4683; LAKATTA EG, 1990, HDB BIOL AGING, P181; LAMY M, 1995, INTENS CARE MED, V21, P250; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; Miller Richard A., 1996, P355; Papaconstantinou John, 1996, P150; Raber J, 1997, J NEUROSCI, V17, P9473; Saito H, 2000, AM J PHYSIOL-HEART C, V279, pH2241, DOI 10.1152/ajpheart.2000.279.5.H2241; Simpson AJH, 2000, J INFECT DIS, V181, P621, DOI 10.1086/315271; SIRONI M, 1989, J IMMUNOL, V142, P549; SMITH CW, 1991, J CLIN INVEST, V88, P1216, DOI 10.1172/JCI115424; STARNES HF, 1990, J IMMUNOL, V145, P4185; Stengle J, 1994, Crit Care Nurs Clin North Am, V6, P421; Streat SJ, 2000, WORLD J SURG, V24, P655, DOI 10.1007/s002689910107; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; TANABE O, 1988, J IMMUNOL, V141, P3875; Tateda K, 1996, INFECT IMMUN, V64, P769, DOI 10.1128/IAI.64.3.769-774.1996; THIJS LG, 1995, INTENS CARE MED, V21, P258; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; YAMAUCHITAKIHARA K, 1995, CIRCULATION, V91, P1520, DOI 10.1161/01.CIR.91.5.1520; YOUKER K, 1992, J CLIN INVEST, V89, P602, DOI 10.1172/JCI115626; YUAN L, 1993, EXP CELL RES, V209, P375, DOI 10.1006/excr.1993.1323	42	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29307	29312		10.1074/jbc.M103740200	http://dx.doi.org/10.1074/jbc.M103740200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382779	hybrid			2022-12-27	WOS:000170346000090
J	Lepesheva, GI; Podust, LM; Bellamine, A; Waterman, MR				Lepesheva, GI; Podust, LM; Bellamine, A; Waterman, MR			Folding requirements are different between sterol 14 alpha-demethylase (CYP51) from Mycobacterium tuberculosis and human or fungal orthologs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							14-DEMETHYLASE P450 CYP51; CIRCULAR-DICHROISM; PROTEIN; CYTOCHROME-P450; GENE; SEQUENCES; EVOLUTION; NUCLEUS; FLUORESCENCE; SUPERFAMILY	Upon sequence alignment of CYP51 sterol 14 alpha -demethylase from animals, plants, fungi, and bacteria, arginine corresponding to Arg-448 of CYP51 in Mycobacterium tuberculosis (MT) is conserved near the C terminus of all family members. In MTCYP51 Arg-448 forms a salt bridge with Asp-287, connecting beta -strand 3-2 with helix J. Deletion of the three C-terminal residues of MTCYP51 has little effect on expression of P450 in Escherichia coli. However, truncation of the fourth amino acid (Arg-448) completely abolishes P450 expression. We have investigated whether Arg-448 has other structural or functional roles in addition to folding and whether its conservation reflects conservation of a common folding pathway in the CYP51 family. Characterization of wild type protein and three mutants, R448K, R4481, and R448A, including examination of catalytic activity, secondary and tertiary structure analysis by circular dichroism and tryptophan fluorescence, and studies of both equilibrium and temporal MTCYP51 unfolding behavior, shows that Arg-448 does not play any role in P450 function or maintenance of the native structure. C-terminal truncation of Candida albicans and human CYP51 orthologs reveals that, despite conservation in sequence, the requirement for arginine at the homologous C-terminal position in folding in E. coli is not conserved. Thus, despite similar spatial folds, functionally related but evolutionarily distinct P450s can follow different folding pathways.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Waterman, MR (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA.	lepesh@ns.iboch.ac.by; waterman@mcmail.vanderbilt.edu	Podust, Larissa/ABB-7940-2020	Podust, Larissa/0000-0002-8537-8760	NIEHS NIH HHS [ES00267-32] Funding Source: Medline; NIGMS NIH HHS [GM37942] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037942, R01GM037942] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama S, 2000, NAT STRUCT BIOL, V7, P514; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Aoyama Y, 1998, J BIOCHEM-TOKYO, V124, P694; Aoyama Y, 1996, J BIOCHEM-TOKYO, V119, P926; Auchus RJ, 1999, MOL ENDOCRINOL, V13, P1169, DOI 10.1210/me.13.7.1169; Aurora R, 1997, J BIOL CHEM, V272, P1413, DOI 10.1074/jbc.272.3.1413; Bellamine A, 1999, P NATL ACAD SCI USA, V96, P8937, DOI 10.1073/pnas.96.16.8937; Belpaire FM, 1996, ACTA CLIN BELG, V51, P254, DOI 10.1080/22953337.1996.11718518; Bera AK, 1999, ARCH BIOCHEM BIOPHYS, V361, P315, DOI 10.1006/abbi.1998.1005; CHELVANAYAGAM G, 1992, J MOL BIOL, V227, P901, DOI 10.1016/0022-2836(92)90230-H; Chen CD, 1996, J BIOL CHEM, V271, P28607, DOI 10.1074/jbc.271.45.28607; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; Dai R, 2000, CELL MOL LIFE SCI, V57, P487, DOI 10.1007/PL00000709; Dokholyan NV, 2000, J MOL BIOL, V296, P1183, DOI 10.1006/jmbi.1999.3534; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; FISCHER RT, 1989, J LIPID RES, V30, P1621; GOTOH O, 1992, J BIOL CHEM, V267, P83; Graham SE, 1999, ARCH BIOCHEM BIOPHYS, V369, P24, DOI 10.1006/abbi.1999.1350; GRIKO YV, 1994, J MOL BIOL, V243, P93, DOI 10.1006/jmbi.1994.1632; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harlow GR, 1997, BBA-PROTEIN STRUCT M, V1338, P259, DOI 10.1016/S0167-4838(96)00209-9; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; Jenkins CM, 1998, BIOCHEMISTRY-US, V37, P6106, DOI 10.1021/bi973076p; Leeson DT, 2000, P NATL ACAD SCI USA, V97, P2527, DOI 10.1073/pnas.040580397; Li L, 2000, NAT STRUCT BIOL, V7, P336; Manyusa S, 1999, BIOCHEMISTRY-US, V38, P14352, DOI 10.1021/bi991413j; MARDEN MC, 1986, BIOPHYS J, V49, P619, DOI 10.1016/S0006-3495(86)83689-X; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Nishimura C, 2000, NAT STRUCT BIOL, V7, P679, DOI 10.1038/77985; Okamoto N, 1998, BIOCHEMISTRY-US, V37, P8839, DOI 10.1021/bi980469v; Omura T., 1993, CYTOCHROME P450; Plotkin SS, 2000, P NATL ACAD SCI USA, V97, P6509, DOI 10.1073/pnas.97.12.6509; Podust LM, 2001, P NATL ACAD SCI USA, V98, P3068, DOI 10.1073/pnas.061562898; Ptitsyn OB, 1998, J MOL BIOL, V278, P655, DOI 10.1006/jmbi.1997.1620; Schulze J, 2000, BIOCHEM BIOPH RES CO, V270, P777, DOI 10.1006/bbrc.2000.2495; Shyadehi AZ, 1996, J BIOL CHEM, V271, P12445, DOI 10.1074/jbc.271.21.12445; Stromstedt M, 1996, ARCH BIOCHEM BIOPHYS, V329, P73, DOI 10.1006/abbi.1996.0193; TRETIAKOV VE, 1989, ARCH BIOCHEM BIOPHYS, V275, P429, DOI 10.1016/0003-9861(89)90389-5; UCHIDA K, 1983, J BIOL CHEM, V258, P2519; van Mierlo CPM, 2000, J BIOTECHNOL, V79, P281, DOI 10.1016/S0168-1656(00)00244-3; YANASE T, 1992, BIOCHIM BIOPHYS ACTA, V1139, P275, DOI 10.1016/0925-4439(92)90100-2; Yon JM, 1997, CELL MOL LIFE SCI, V53, P557, DOI 10.1007/s000180050072; Yoshida Y, 1997, J BIOCHEM-TOKYO, V122, P1122; Yoshida Y, 2000, BIOCHEM BIOPH RES CO, V273, P799, DOI 10.1006/bbrc.2000.3030	45	43	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28413	28420		10.1074/jbc.M102767200	http://dx.doi.org/10.1074/jbc.M102767200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373285	hybrid			2022-12-27	WOS:000170093400089
J	Svingor, A; Kardos, J; Hajdu, I; Nemeth, A; Zavodszky, P				Svingor, A; Kardos, J; Hajdu, I; Nemeth, A; Zavodszky, P			A better enzyme to cope with cold - Comparative flexibility studies on psychrotrophic, mesophilic, and thermophilic IPMDHS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMUS-THERMOPHILUS; 3-ISOPROPYLMALATE DEHYDROGENASE; EXTREME THERMOPHILE; ISOPROPYLMALATE DEHYDROGENASE; ESCHERICHIA-COLI; D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; PSYCHROPHILIC ENZYMES; CATALYTIC-PROPERTIES; CRYSTAL-STRUCTURES; MOLECULAR-BASIS	3-Isopropylmalate dehydrogenase (IPMDH) from the psychrotrophic bacterium Vibrio sp. 15 has been expressed in Escherichia coli and purified. This cold-adapted enzyme is highly homologous with IPMDHs from other organisms, including mesophilic E. coli and thermophilic Thermus thermophilus bacteria. Its molecular properties are similar to these counterparts. Whereas the E. coli and T. thermophilus enzymes are hardly active at room temperature, the Vibrio IPMDH has reasonable activity below room temperature. The thermal stabilities, conformational flexibilities (hydrogen-deuterium exchange), and kinetic parameters of these enzymes were compared. The temperature dependence of the catalytic parameters of the three enzymes show similar but shifted profiles. The Vibrio IPMDH is a much better enzyme at 25 degreesC than its counterparts. With decreasing temperature i.e. with decreasing conformational flexibility, the specific activity reduces, as well; however, in the case of the Vibrio enzyme, the residual activity is still high enough for normal physiological operation of the organism. The cold-adaptation strategy in this case is achieved by creation of an extremely efficient enzyme, which has reduced but still sufficient activity at low temperature.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1113 Budapest, Hungary; Eotvos Lorand Univ, Dept Biochem, H-1088 Budapest, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University	Zavodszky, P (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, Karolina Ut 29, H-1113 Budapest, Hungary.	zxp@enzim.hu	Zavodszky, Peter/C-1214-2008; Kardos, József/J-1035-2017; Hajdu, Istvan/B-8345-2008	Kardos, József/0000-0002-2135-2932; 				Aghajari N, 1998, PROTEIN SCI, V7, P564, DOI 10.1002/pro.5560070304; Aittaleb M, 1997, PROTEIN ENG, V10, P475, DOI 10.1093/protein/10.5.475; Alvarez M, 1998, J BIOL CHEM, V273, P2199, DOI 10.1074/jbc.273.4.2199; ASGEIRSSON B, 1993, BIOCHIM BIOPHYS ACTA, V1164, P91, DOI 10.1016/0167-4838(93)90116-9; DEAN AM, 1995, PROTEIN SCI, V4, P2156, DOI 10.1002/pro.5560041022; Feller G, 1997, CELL MOL LIFE SCI, V53, P830, DOI 10.1007/s000180050103; FELLER G, 1994, EUR J BIOCHEM, V222, P441, DOI 10.1111/j.1432-1033.1994.tb18883.x; Genicot S, 1996, BBA-PROTEIN STRUCT M, V1298, P45, DOI 10.1016/S0167-4838(96)00095-7; Gerday C, 1997, BBA-PROTEIN STRUCT M, V1342, P119, DOI 10.1016/S0167-4838(97)00093-9; Hayashi-Iwasaki Y, 2000, METHOD ENZYMOL, V324, P301; IMADA K, 1991, J MOL BIOL, V222, P725, DOI 10.1016/0022-2836(91)90508-4; JAENICKE R, 1990, FEBS LETT, V268, P344, DOI 10.1016/0014-5793(90)81283-T; Jaenicke R, 1996, FASEB J, V10, P84, DOI 10.1096/fasebj.10.1.8566552; KAGAWA Y, 1984, J BIOL CHEM, V259, P2956; KIRINO H, 1994, EUR J BIOCHEM, V220, P275, DOI 10.1111/j.1432-1033.1994.tb18623.x; KOHLHAW GB, 1988, METHOD ENZYMOL, V166, P429; Kotsuka T, 1996, J BACTERIOL, V178, P723, DOI 10.1128/jb.178.3.723-727.1996; LUISIDELUCA C, 1989, GENETICS, V122, P269; Narinx E, 1997, PROTEIN ENG, V10, P1271, DOI 10.1093/protein/10.11.1271; PARSONS SJ, 1969, J BIOL CHEM, V244, P996; RICHARD C, 1984, BERGEYS MANUAL SYSTE, V1, P465; RUSSELL RJM, 1995, CURR OPIN BIOTECH, V6, P370, DOI 10.1016/0958-1669(95)80064-6; SMALAS AO, 1994, PROTEINS, V20, P149, DOI 10.1002/prot.340200205; Szilagyi A, 2000, STRUCTURE, V8, P493, DOI 10.1016/S0969-2126(00)00133-7; SZILAGYI A, 1995, PROTEIN ENG, V8, P779, DOI 10.1093/protein/8.8.779; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P2597, DOI 10.1021/bi951988q; VARLEY PG, 1991, J MOL BIOL, V220, P531, DOI 10.1016/0022-2836(91)90028-5; Villeret V, 1997, PROTEIN SCI, V6, P2462; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042; Wallon G, 1997, BBA-PROTEIN STRUCT M, V1337, P105, DOI 10.1016/S0167-4838(96)00157-4; Wallon G, 1997, J MOL BIOL, V266, P1016, DOI 10.1006/jmbi.1996.0797; Wallon G, 1997, PROTEIN ENG, V10, P665, DOI 10.1093/protein/10.6.665; WIEBE WJ, 1992, APPL ENVIRON MICROB, V58, P359, DOI 10.1128/AEM.58.1.359-364.1992; YAMADA T, 1990, J BIOCHEM-TOKYO, V108, P449, DOI 10.1093/oxfordjournals.jbchem.a123220; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406	36	54	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28121	28125		10.1074/jbc.M104432200	http://dx.doi.org/10.1074/jbc.M104432200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369782	hybrid			2022-12-27	WOS:000170093400051
J	Furukawa, K; Shirai, H; Azuma, T; Nakamura, H				Furukawa, K; Shirai, H; Azuma, T; Nakamura, H			A role of the third complementarity-determining region in the affinity maturation of an antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATIC HYPERMUTATION; JUNCTIONAL DIVERSITY; GERMINAL-CENTERS; N-REGIONS; IMMUNOGLOBULIN; GENERATION; MUTATION; PROGRAM; CDR-H3; FETAL	We recently found that there are two distinct antibody maturation pathways for the immune response of C57BL/6 mice to (4-hydroxy-3-nitrophenyl) acetyl and that a junctional amino acid introduced at a point far in advance of somatic hypermutation determined which pathway of affinity maturation was used. We describe here the structural basis for this aspect of maturation using recently developed H3 rules, which allow for reliable identification of the conformation of the third complementarity-determining region of the heavy chain (CDR-H3) from the primary amino acid sequences only. By the application of these rules, the anti-(4-hydroxy-3-nitrophenyl) acetyl antibodies examined here were classified into two major groups on the basis of their CDR-H3 structure, and these groups were found to be consistent with the maturation pathways. In addition, circular dichroism measurements revealed that the versatile nature-of the antigen binding of the antibodies was significantly influenced by the pathway employed. We postulated in this study that flexibility in the CDR-H3 structure in the antigen-combining site could facilitate efficient antibody maturation supported by a plurality of possible antigen binding modes.	Tokyo Univ Sci, Res Inst Biol Sci, Chiba 2780022, Japan; Tokyo Med & Dent Univ, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Tokyo University of Science; Tokyo Medical & Dental University (TMDU); University of Cambridge; Osaka University	Furukawa, K (corresponding author), Tokyo Univ Sci, Res Inst Biol Sci, 2669 Yamazaki, Chiba 2780022, Japan.	furukama@rs.noda.sut.ac.jp	Furukawa, Koji/L-6909-2018	Furukawa, Koji/0000-0002-5701-2497				ALLEN D, 1988, EMBO J, V7, P1995, DOI 10.1002/j.1460-2075.1988.tb03038.x; Benedict CL, 1999, IMMUNITY, V10, P607, DOI 10.1016/S1074-7613(00)80060-6; BEREK C, 1993, CURR OPIN IMMUNOL, V5, P218, DOI 10.1016/0952-7915(93)90007-F; BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; CUMANO A, 1985, EUR J IMMUNOL, V15, P512, DOI 10.1002/eji.1830150517; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; FRENCH DL, 1989, SCIENCE, V244, P1152, DOI 10.1126/science.2658060; Furukawa K, 1999, IMMUNITY, V11, P329, DOI 10.1016/S1074-7613(00)80108-9; Joyce GF, 1997, SCIENCE, V276, P1658, DOI 10.1126/science.276.5319.1658; Kelsoe G, 1996, IMMUNITY, V4, P107, DOI 10.1016/S1074-7613(00)80675-5; Kim ST, 1999, PROTEINS, V37, P683, DOI 10.1002/(SICI)1097-0134(19991201)37:4<683::AID-PROT17>3.0.CO;2-D; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; MACLENNAN ICM, 1992, IMMUNOL REV, V126, P143, DOI 10.1111/j.1600-065X.1992.tb00635.x; MEEK K, 1990, SCIENCE, V250, P820, DOI 10.1126/science.2237433; MIZUTANI R, 1995, J MOL BIOL, V254, P208, DOI 10.1006/jmbi.1995.0612; MORIKAMI K, 1992, COMPUT CHEM, V16, P243, DOI 10.1016/0097-8485(92)80010-W; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; Shirai H, 1999, FEBS LETT, V455, P188, DOI 10.1016/S0014-5793(99)00821-2; Shirai H, 1996, FEBS LETT, V399, P1, DOI 10.1016/S0014-5793(96)01252-5; Smith DK, 1997, J MOL BIOL, V274, P530, DOI 10.1006/jmbi.1997.1432; TANIMURA R, 1994, PROTEIN SCI, V3, P2358, DOI 10.1002/pro.5560031220; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VARGASMADRAZO E, 1995, J MOL BIOL, V254, P497, DOI 10.1006/jmbi.1995.0633; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665	28	28	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27622	27628		10.1074/jbc.M102714200	http://dx.doi.org/10.1074/jbc.M102714200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375987	hybrid			2022-12-27	WOS:000169966900117
J	Yamashita, A; Kawagishi, N; Miyashita, T; Nagatsuka, T; Sugiura, T; Kume, K; Shimizu, T; Waku, K				Yamashita, A; Kawagishi, N; Miyashita, T; Nagatsuka, T; Sugiura, T; Kume, K; Shimizu, T; Waku, K			ATP-independent fatty acyl-coenzyme A synthesis from phospholipid - Coenzyme A-dependent transacylation activity toward lysophosphatidic acid catalyzed by acyl-coenzyme A : lysophosphatidic acid acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; ARACHIDONIC-ACID; RAT-LIVER; MEMBRANE PHOSPHOLIPIDS; CDNA CLONING; COA; METABOLISM; LYSOPHOSPHOLIPIDS; EXPRESSION; ACYLATION	CoA-dependent transacylation activity in microsomes is known to catalyze the transfer of fatty acids between phospholipids and lysophospholipids in the presence of CoA without the generation of free fatty acids. We previously found a novel acyl-CoA synthetic pathway, ATP-independent acyl-CoA synthesis from phospholipids. We proposed that: 1) the ATP-independent acyl-CoA synthesis is due to the reverse reaction of acyl-CoA:lysophospholipid acyltransferases and 2) the reverse and forward reactions of acyltransferases can combine to form a CoA-dependent transacylation system. To test these proposals, we examined whether or not recombinant mouse acyl-CoA:1-acyl-sn-glycero-3-phosphate (lysophosphatidic acid, LPA) acyltransferase (LPAAT) could catalyze ATP-independent acyl-CoA synthetic activity and CoA-dependent transacylation activity. ATP-independent acyl-CoA synthesis was indeed found in the membrane fraction from Escherichia coli cells expressing mouse LPAAT, whereas negligible activity was observed in mock-transfected cells. Phosphatidic acid (PA), but not free fatty acids, served as an acyl donor for the reaction, and LPA was formed from PA in a CoA-dependent manner during acyl-CoA synthesis. These results indicate that the ATP-independent acyl-CoA synthesis was due to the reverse reaction of LPAAT, In addition, bacterial membranes containing LPAAT catalyzed CoA-dependent acylation of LPA; PA but not free fatty acid served as an acyl donor. These results indicate that the CoA-dependent transacylation of LPA consists of 1) acyl-CoA synthesis hom PA through the reverse action of LPAAT and 2) the transfer of the fatty acyl moiety of the newly formed acyl-CoA to LPA through the forward reaction of LPAAT.	Teikyo Univ, Fac Pharmaceut Sci, Kanagawa 1990195, Japan; Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Hongo, Japan; Japan Sci & Technol Corp, CREST, Bunkyo Ku, Tokyo 1130033, Japan	Teikyo University; University of Tokyo; Japan Science & Technology Agency (JST)	Yamashita, A (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Kanagawa 1990195, Japan.	ayamashi@pharm.teikyo-u.ac.jp		Kume, Kazuhiko/0000-0003-4232-1657; Yamashita, Atsushi/0000-0002-2544-2134				Aguado B, 1998, J BIOL CHEM, V273, P4096, DOI 10.1074/jbc.273.7.4096; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRONFMAN M, 1988, BIOCHEM BIOPH RES CO, V152, P987, DOI 10.1016/S0006-291X(88)80381-4; BURSTEN S, 1994, CIRC SHOCK, V44, P14; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; COLARD O, 1984, BIOCHIM BIOPHYS ACTA, V793, P42, DOI 10.1016/0005-2760(84)90051-1; COLEMAN J, 1990, J BIOL CHEM, V265, P17215; COLEMAN J, 1992, MOL GEN GENET, V232, P295, DOI 10.1007/BF00280009; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; Eberhardt C, 1997, J BIOL CHEM, V272, P20299, DOI 10.1074/jbc.272.32.20299; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Holub B J, 1978, Adv Lipid Res, V16, P1; HUANG WH, 1989, J BIOL CHEM, V264, P2605; IRVINE RF, 1979, BIOCHEM BIOPH RES CO, V91, P1399, DOI 10.1016/0006-291X(79)91222-1; KRAMER RM, 1984, J BIOL CHEM, V259, P2403; KRAMER RM, 1984, J BIOL CHEM, V259, P3316; KRAMER RM, 1983, J BIOL CHEM, V258, P3806; Kume K, 1997, BIOCHEM BIOPH RES CO, V237, P663, DOI 10.1006/bbrc.1997.7214; Lands W., 1976, ENZYMES BIOL MEMBRAN, V2, P3; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; LANDS WEM, 1965, J BIOL CHEM, V240, P1905; LI QL, 1990, J BIOCHEM-TOKYO, V107, P699, DOI 10.1093/oxfordjournals.jbchem.a123111; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; NAKAGAWA Y, 1989, PROG LIPID RES, V28, P205, DOI 10.1016/0163-7827(89)90013-1; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; ROBINSON M, 1985, J BIOL CHEM, V260, P7889; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SEUBERT W, 1960, BIOCHEM PREP, V7, P80; Singer J. W., 1994, EXPERT OPIN INV DRUG, V3, P631; SNYDER F, 1992, PROG LIPID RES, V31, P65, DOI 10.1016/0163-7827(92)90016-C; Stamps AC, 1997, BIOCHEM J, V326, P455, DOI 10.1042/bj3260455; STEINMAN HM, 1973, J BIOL CHEM, V248, P892; STYMNE S, 1985, BIOCHIM BIOPHYS ACTA, V837, P239, DOI 10.1016/0005-2760(85)90047-5; SUGIURA T, 1995, J LIPID RES, V36, P440; SUGIURA T, 1995, BBA-LIPID LIPID MET, V1255, P167, DOI 10.1016/0005-2760(94)00237-S; SUGIURA T, 1987, J BIOL CHEM, V262, P1199; SUGIURA T, 1988, J BIOL CHEM, V263, P17490; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TOKUMURA A, 1995, PROG LIPID RES, V34, P151, DOI 10.1016/0163-7827(95)00001-G; TROTTER J, 1982, J BIOL CHEM, V257, P1816; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; WAKU K, 1992, BIOCHIM BIOPHYS ACTA, V1124, P101, DOI 10.1016/0005-2760(92)90085-A; West J, 1997, DNA CELL BIOL, V16, P691, DOI 10.1089/dna.1997.16.691; YAMASHITA A, 1995, BIOCHEM J, V312, P301, DOI 10.1042/bj3120301; Yamashita A, 1997, J BIOCHEM-TOKYO, V122, P1	48	23	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26745	26752		10.1074/jbc.M101795200	http://dx.doi.org/10.1074/jbc.M101795200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11352914	hybrid			2022-12-27	WOS:000169966900004
J	Millman, JS; Qi, HY; Vulcu, F; Bernstein, HD; Andrews, DW				Millman, JS; Qi, HY; Vulcu, F; Bernstein, HD; Andrews, DW			FtsY binds to the Escherichia coli inner membrane via interactions with phosphatidylethanolamine and membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; SEQUENCE RECOGNITION; ACIDIC PHOSPHOLIPIDS; TARGETING PATHWAYS; NONBILAYER LIPIDS; PLASMA-MEMBRANE; ALPHA-SUBUNIT; BETA-SUBUNIT; NG DOMAIN; RECEPTOR	Targeting of many polytopic proteins to the inner membrane of prokaryotes occurs via an essential signal recognition particle-like pathway. FtsY, the Escherichia coli homolog of the eukaryotic signal recognition particle receptor alpha -subunit, binds to membranes via its amino-terminal AN domain. We demonstrate that FtsY assembles on membranes via interactions with phosphatidylethanolamine and with a trypsin-sensitive component. Both interactions are mediated by the AN domain of FtsY, In the absence of phosphatidylethanolamine, the trypsin-sensitive component is sufficient for binding and function of FtsY in the targeting of membrane proteins. We propose a two-step mechanism for the assembly of FtsY on the membrane similar to that of SecA on the E, coli inner membrane.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	McMaster University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			Millman, Jonathan/0000-0002-1766-2348; Andrews, David/0000-0002-9266-7157; Vulcu, Felicia/0000-0002-6426-6823				ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; de Leeuw E, 2000, EMBO J, V19, P531, DOI 10.1093/emboj/19.4.531; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; DUZGUNES N, 1981, BIOCHIM BIOPHYS ACTA, V642, P182, DOI 10.1016/0005-2736(81)90148-6; GILL DR, 1990, MOL MICROBIOL, V4, P575; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; HUGHES MJ, 1996, BIOTECHNIQUES, V20, P192; Jander G, 1996, J BACTERIOL, V178, P3049, DOI 10.1128/jb.178.11.3049-3058.1996; Kholodenko BN, 2000, TRENDS CELL BIOL, V10, P173, DOI 10.1016/S0962-8924(00)01741-4; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; Legate KR, 2000, J BIOL CHEM, V275, P27439; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; Mac Millan SV, 2000, EUR J CELL BIOL, V79, P327, DOI 10.1078/S0171-9335(04)70036-9; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; Millman JS, 1999, J BIOL CHEM, V274, P33227, DOI 10.1074/jbc.274.47.33227; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; OHTA A, 1977, J BACTERIOL, V132, P434, DOI 10.1128/JB.132.2.434-443.1977; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; Powers T, 1997, EMBO J, V16, P4880, DOI 10.1093/emboj/16.16.4880; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; RIETVELD AG, 1995, EMBO J, V14, P5506, DOI 10.1002/j.1460-2075.1995.tb00237.x; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Scotti PA, 1999, J BIOL CHEM, V274, P29883, DOI 10.1074/jbc.274.42.29883; Seluanov A, 1997, J BIOL CHEM, V272, P2053; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P7740, DOI 10.1093/nar/16.15.7740; Tian HP, 2000, P NATL ACAD SCI USA, V97, P4730, DOI 10.1073/pnas.090087297; TRAXLER B, 1992, J BIOL CHEM, V267, P5339; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472; YOUNG JC, 1995, J BIOL CHEM, V270, P15650, DOI 10.1074/jbc.270.26.15650; Zelazny A, 1997, P NATL ACAD SCI USA, V94, P6025, DOI 10.1073/pnas.94.12.6025	40	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25982	25989		10.1074/jbc.M011331200	http://dx.doi.org/10.1074/jbc.M011331200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11353766	hybrid			2022-12-27	WOS:000169823300047
J	Vilardaga, JP; Frank, M; Krasel, C; Dees, C; Nissenson, RA; Lohse, MJ				Vilardaga, JP; Frank, M; Krasel, C; Dees, C; Nissenson, RA; Lohse, MJ			Differential conformational requirements for activation of G proteins and the regulatory proteins arrestin and G protein-coupled receptor kinase in the G protein-coupled receptor for parathyroid hormone (PTH)/PTH-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEIN; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; TRANSMEMBRANE HELICES; VISUAL ARRESTIN; PHOSPHORYLATION; ENDOCYTOSIS; MUTANTS; INTERNALIZATION; MODEL	After stimulation with agonist, G protein-coupled receptors (GPCRs) activate G proteins and become phosphorylated by G protein-coupled receptor kinases (GRKs), and most of them translocate cytosolic arrestin proteins to the cytoplasmic membrane. Agonist-activated GPCRs are specifically phosphorylated by GRKs and are targeted for endocytosis by arrestin proteins, suggesting a connection between GPCR conformational changes and interaction with GRKs and arrestins. Previously, we showed that by substitution of histidine for residues at the cytoplasmic side of helix 3 (H3) and helix 6 (H6) of the parathyroid hormone (PTH) receptor (PTHR), a zinc metal ion-binding site is engineered that prevents PTH-stimulated G(5) activation (Sheikh, S. P., Vilardaga, J.-P., Baranski, T. J., Lichtarge, O., liri, T., Meng, E. C., Nissenson, R. A., and Bourne, H. R. (1999) J. Biol. Chem. 274,17033-17041). These data suggest that relative movements between H3 and H6 are critical for G. activation. Does this molecular event play a similar role in activation of GRKs and arrestin and in PTHR-mediated G(q) activation? To answer this question, we utilized the two previously described mutant forms of PTHR, H401 and H402, which contain a naturally present histidine residue at position 301 in H3 and a second substituted histidine residue at positions 401 and 402 in H6, respectively. Both mutant receptors showed inhibition of PTH-stimulated inositol phosphate and cAMP generation in the presence of increasing concentrations of Zn(Pi). However, the mutants showed no Zn(Pi)-dependent impairment of phosphorylation by GRK-2. Likewise, the mutants were indistinguishable from wild-type PTHR in the ability to translocate beta-arrestins/green fluorescent protein to the cell membrane and were also not affected by sensitivity to Zn(Il). These results suggest that agonist-mediated phosphorylation and internalization of PTHR require conformational switches of the receptor distinct from the cAMP and inositol phosphate signaling state. Furthermore, PTHR sequestration does not appear to require G protein activation.	Univ Wurzburg, Inst Pharmacol & Toxicol, Dept Pharmacol, D-97078 Wurzburg, Germany; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Endocrine Res Unit, San Francisco, CA 94121 USA	University of Wurzburg; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Lohse, MJ (corresponding author), Univ Wurzburg, Inst Pharmacol & Toxicol, Dept Pharmacol, Versbacher Str 9, D-97078 Wurzburg, Germany.	lohse@toxi.uni-wuerzburg.de	Lohse, Martin J/A-7160-2012; Krasel, Cornelius/AAH-7074-2019	Lohse, Martin J/0000-0002-0599-3510; Vilardaga, Jean-Pierre/0000-0002-1217-1435; Krasel, Cornelius/0000-0001-8309-8696	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035323] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; BENOVIC JL, 1988, J BIOL CHEM, V263, P3893; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; Dhanwada KR, 1996, MOL ENDOCRINOL, V10, P544, DOI 10.1210/me.10.5.544; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Groarke DA, 1999, J BIOL CHEM, V274, P23263, DOI 10.1074/jbc.274.33.23263; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUVERICH VV, 1993, J BIOL CHEM, V268, P11628; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; HOESLSHER SR, 1991, ENDOCRINOLOGY, V128, P2837; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; January B, 1997, J BIOL CHEM, V272, P23871, DOI 10.1074/jbc.272.38.23871; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KIM CM, 1993, RECEPTOR, V3, P39; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LUND KA, 1990, J BIOL CHEM, V265, P15713; Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846; Mhaouty-Kodja S, 1999, MOL PHARMACOL, V55, P339, DOI 10.1124/mol.55.2.339; NUSSENZVEIG DR, 1993, MOL ENDOCRINOL, V7, P1105, DOI 10.1210/me.7.9.1105; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pulvermuller A, 2000, J BIOL CHEM, V275, P37679, DOI 10.1074/jbc.M006776200; REN Q, 1993, J BIOL CHEM, V268, P16483; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; SZEKERS PG, 1997, MOL PHARMACOL, V53, P769; Thomas WG, 2000, J BIOL CHEM, V275, P2893, DOI 10.1074/jbc.275.4.2893; Vilardaga JP, 2000, J BONE MINER RES, V15, pS175; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451	41	85	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33435	33443		10.1074/jbc.M011495200	http://dx.doi.org/10.1074/jbc.M011495200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11387315	hybrid			2022-12-27	WOS:000170910200021
J	Morais, F; Kuhn, K; Stewart, DH; Barber, J; Brudvig, GW; Nixon, PJ				Morais, F; Kuhn, K; Stewart, DH; Barber, J; Brudvig, GW; Nixon, PJ			Photosynthetic water oxidation in cytochrome b(559) mutants containing a disrupted heme-binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PHOTOSYSTEM-II COMPLEXES; CYCLIC ELECTRON FLOW; CHLAMYDOMONAS-REINHARDTII; SYNECHOCOCCUS-ELONGATUS; AXIAL LIGANDS; CHLOROPLAST; B-559; PHOTOINHIBITION; POLYPEPTIDE	The role of cytochrome b(559) in photosynthetic oxygen evolution has been investigated in three chloroplast mutants of Chlamydomonas reinhardtii, in which one of the two histidine axial ligands to the heme, provided by the a subunit, has been replaced by the residues methionine, tyrosine, and glutamine. Photosystem two complexes functional for oxygen evolution could be assembled in the methionine and tyrosine mutants up to similar to 15% of wild type levels, whereas no complexes with oxygen evolution activity could be detected in the glutamine mutant. PSII supercomplexes isolated from the tyrosine and methionine mutants were as active as wild type in terms of light-saturated rates of oxygen evolution but in contrast to wild type contained no bound heme despite the presence of the alpha subunit. Oxygen evolution in the tyrosine and methionine mutants was, however, more sensitive to photoinactivation than the WT. Overall, these data establish unambiguously that a redox role for the heme of cytochrome b(559) is not required for photosynthetic oxygen evolution. Instead, our data provide new evidence of a role for cytochrome b(559) in the protection. of the photosystem two complex in vivo.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Imperial College London; Yale University	Nixon, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England.	p.nixon@ic.ac.uk	Kühn, Kristina/F-4918-2012	Kühn, Kristina/0000-0001-6747-783X; Nixon, Peter/0000-0003-1952-6937	NIGMS NIH HHS [GM32715] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032715] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIZADEH S, 1994, BBA-BIOENERGETICS, V1188, P439, DOI 10.1016/0005-2728(94)90067-1; ALLEN KD, 1994, PLANTA, V194, P42; ANANYEV G, 1994, PHOTOSYNTH RES, V41, P327, DOI 10.1007/BF00019410; Andronis C, 1998, PLANT PHYSIOL, V117, P515, DOI 10.1104/pp.117.2.515; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BABCOCK GT, 1985, BIOCHEMISTRY-US, V24, P3638, DOI 10.1021/bi00335a036; BARBER J, 1993, P NATL ACAD SCI USA, V90, P10942, DOI 10.1073/pnas.90.23.10942; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BOYNTON JE, 1993, METHOD ENZYMOL, V217, P510; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; DINER BA, 1980, EUR J BIOCHEM, V110, P521, DOI 10.1111/j.1432-1033.1980.tb04894.x; DINER BA, 1996, OXYGENIC PHOTOSYNTHE, P213; DOLLA A, 1995, BIOCHEM BIOPH RES CO, V211, P742, DOI 10.1006/bbrc.1995.1875; Eshaghi S, 1999, FEBS LETT, V446, P23, DOI 10.1016/S0014-5793(99)00149-0; FALKOWSKI PG, 1986, PLANT PHYSIOL, V81, P310, DOI 10.1104/pp.81.1.310; Fiege R, 1996, FEBS LETT, V387, P33, DOI 10.1016/0014-5793(96)00458-9; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; Hanley J, 1999, BIOCHEMISTRY-US, V38, P8189, DOI 10.1021/bi990633u; HEBER U, 1979, BIOCHIM BIOPHYS ACTA, V546, P292, DOI 10.1016/0005-2728(79)90047-1; Hippler M, 1998, BBA-BIOENERGETICS, V1367, P1, DOI 10.1016/S0005-2728(98)00136-4; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; KOMENDA J, 1995, BIOCHEMISTRY-US, V34, P9625, DOI 10.1021/bi00029a040; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; Kruk J, 1999, PHOTOSYNTH RES, V62, P273, DOI 10.1023/A:1006374319191; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Magnuson A, 1999, BBA-BIOENERGETICS, V1411, P180, DOI 10.1016/S0005-2728(99)00044-4; Matsson M, 2000, BIOCHEMISTRY-US, V39, P8617, DOI 10.1021/bi000271m; Melis A, 1999, TRENDS PLANT SCI, V4, P130, DOI 10.1016/S1360-1385(99)01387-4; MIYAZAKI A, 1989, BIOCHIM BIOPHYS ACTA, V975, P142, DOI 10.1016/S0005-2728(89)80212-9; Morais F, 1998, J BIOL CHEM, V273, P29315, DOI 10.1074/jbc.273.45.29315; Muller B, 1999, PLANT CELL, V11, P2365, DOI 10.1105/tpc.11.12.2365; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; Nield J, 2000, J BIOL CHEM, V275, P27940; OHNISHI N, 2000, 9 INT C CELL MOL BIO, P71; PAKRASI HB, 1991, EMBO J, V10, P1619, DOI 10.1002/j.1460-2075.1991.tb07684.x; POULSON M, 1995, BIOCHEMISTRY-US, V34, P10932, DOI 10.1021/bi00034a027; Rova EM, 1996, J BIOL CHEM, V271, P28918, DOI 10.1074/jbc.271.46.28918; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schweitzer RH, 1997, BIOCHEMISTRY-US, V36, P11351, DOI 10.1021/bi9709203; SHAPLEIGH JP, 1992, P NATL ACAD SCI USA, V89, P4786, DOI 10.1073/pnas.89.11.4786; Stewart DH, 1998, BBA-BIOENERGETICS, V1367, P63, DOI 10.1016/S0005-2728(98)00139-X; Stewart DH, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1113; TAE GS, 1992, BIOCHEMISTRY-US, V31, P4066, DOI 10.1021/bi00131a024; THOMPSON LK, 1988, BIOCHEMISTRY-US, V27, P6653, DOI 10.1021/bi00418a002; Tracewell CA, 2001, BIOCHEMISTRY-US, V40, P193, DOI 10.1021/bi001992o; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	52	23	25	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31986	31993		10.1074/jbc.M103935200	http://dx.doi.org/10.1074/jbc.M103935200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11390403	hybrid			2022-12-27	WOS:000170613500071
J	Levy, Y; Arbel-Goren, R; Hadari, YR; Eshhar, S; Ronen, D; Elhanany, E; Geiger, B; Zick, Y				Levy, Y; Arbel-Goren, R; Hadari, YR; Eshhar, S; Ronen, D; Elhanany, E; Geiger, B; Zick, Y			Galectin-8 functions as a matricellular modulator of cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; T-CELLS; BINDING; FIBRONECTIN; PROTEINS; LECTIN; DOMAIN; ACTIVATION; EXPRESSION; INTEGRINS	The interaction of cells with the extracellular matrix regulates cell adhesion and motility. Here we demonstrate that different cell types adhere and spread when cultured in serum-free medium on immobilized galectin-8, a mammalian 13-galactoside-binding protein. At maximal doses, galectin-8 is equipotent to fibronectin in promoting cen adhesion and spreading. Cell adhesion to immobilized galectin-8 is mediated by sugar-protein interactions with integrins, and galectin-8 triggers integrin-mediated signaling cascades including Tyr phosphorylation of focal adhesion kinase and paxillin. Cell adhesion is potentiated in the presence of Mn2+, whereas it is interrupted in the presence of soluble galectin-8, integrin beta (1), inhibitory antibodies, EDTA, or thiodigalactoside but not by RGD peptides. Furthermore, cells readily adhere onto immobilized monoclonal galectin-8 antibodies, which are equipotent to integrin antibodies in promoting cell adhesion. Cell adhesion to immobilized galectin-8 is partially inhibited by serum proteins, suggesting that complex formation between immobilized galectin-8 and serum components generates a matrix that is less supportive of cell adhesion. Accordingly, cell motility on immobilized galectin-8 readily takes place in the presence of serum. Truncation of the C-terminal half of galectin-8, including one of its two carbohydrate recognition domains, largely abolishes its ability to modulate cell adhesion, indicating that both carbohydrate recognition domains are required to maintain a functional form of galectin-8. Collectively, our findings implicate galectin-8 as a physiological modulator of cell adhesion. When immobilized, it functions as a matrix protein equipotent to fibronectin in promoting cell adhesion by ligation and clustering of cell surface integrin receptors. In contrast, when present in excess as a soluble ligand, galectin-8 (like fibronectin) forms a complex with integrins that negatively regulates cell adhesion. Because of its dual effects on the adhesive properties of the cells and its association with fibronectin, galectin-8 might be considered a novel type of matricellular protein.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Israel Inst Biol Res, Dept Biochem & Mol Biol, IL-70450 Ness Ziona, Israel	Weizmann Institute of Science	Zick, Y (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	yehiel.zick@weizmann.ac.il	Zick, Yehiel/K-1479-2012					AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Aplin AE, 1998, PHARMACOL REV, V50, P197; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; CALOF AL, 1994, NEURON, V13, P117, DOI 10.1016/0896-6273(94)90463-4; Camby I, 2001, BRAIN PATHOL, V11, P12; CHIQUETEHRISMANN R, 1995, CURR OPIN CELL BIOL, V7, P715, DOI 10.1016/0955-0674(95)80114-6; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; Eshhar Z, 1985, HYBRIDOMA TECHNOLOGY, P1; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; Feizi T, 1999, TRENDS BIOCHEM SCI, V24, P369, DOI 10.1016/S0968-0004(99)01458-9; FENSELAU C, 1997, ANAL CHEM NEWS FEATU, V1, P661; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Girard JP, 1996, J BIOL CHEM, V271, P4511; Hadari YR, 2000, J CELL SCI, V113, P2385; Hadari YR, 1997, TRENDS GLYCOSCI GLYC, V9, P103, DOI 10.4052/tigg.9.103; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; Jui HY, 1996, BIOCHEMISTRY-US, V35, P14326, DOI 10.1021/bi9613032; Kim JH, 2000, EXP CELL RES, V256, P445, DOI 10.1006/excr.2000.4852; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; Kuwabara I, 1996, J IMMUNOL, V156, P3939; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; Lyman S, 1997, J BIOL CHEM, V272, P22538, DOI 10.1074/jbc.272.36.22538; MAHANTHAPPA NK, 1994, DEVELOPMENT, V120, P1373; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; Miyamoto S, 1998, ANN NY ACAD SCI, V857, P119, DOI 10.1111/j.1749-6632.1998.tb10112.x; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; Retta SF, 1999, METH MOL B, V96, P125; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SATO S, 1992, J BIOL CHEM, V267, P6983; SAVAGE B, 1990, J BIOL CHEM, V265, P11766; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sharon N, 1995, ESSAYS BIOCHEM, V30, P59; Shih DT, 1997, J CELL SCI, V110, P2619; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Woods ML, 2000, EUR J IMMUNOL, V30, P38, DOI 10.1002/1521-4141(200001)30:1<38::AID-IMMU38>3.3.CO;2-2; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607	54	145	152	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31285	31295		10.1074/jbc.M100340200	http://dx.doi.org/10.1074/jbc.M100340200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11371555	hybrid			2022-12-27	WOS:000170472900092
J	Tang, CL; Klinman, JP				Tang, CL; Klinman, JP			The catalytic function of bovine lysyl oxidase in the absence of copper	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINE OXIDASE; CROSS-LINKING; COLLAGEN; ELASTIN	Bovine lysyl oxidase (BLO) contains two different co- factors, copper (Kagan, H. M. (1986) in Biology of Fxtra-cellular Matrix (Mecham, R. P., ed) Vol. 1, pp. 321-398, Academic Press, Orlando, FL) and lysine tyrosyl quinone (LTQ) (Wang, S. YL, Mure, M., Medzihradszky, K. F., Burlingame, A. L., Brown, D. E., Dooley, D. M., Smith, A. J., Kagan, H. M., and Klinman, J. P. (1996) Science 273, 1078-1084). By a combination of UV-visible spectroscopy, metal content analysis, and activity measurements, we find that copper-depleted BLO reacts in an irreversible manner with phenylhydrazine, an amine substrate analog, and catalyzes multiple turnovers of the substrate benzylamine. After removal of the majority of enzyme-bound copper, apoBLO exhibits a decrease in the LTQ content, as evidenced by the drop of the 510-520-nm absorbance, suggesting that the copper may play a structural role in stabilizing the LTQ. The remaining intact LTQ in the apoBLO reacted with phenylhydrazine, both in the presence and absence of the chelator, 10 nim 2,2 ' -dipyridyl. When benzylamine was used as the substrate, the apoBLO turned over at a rate of 50-60% of the native BLO (after correction for the residual copper and the change of LTQ content). Copper contamination from the assay buffer was ruled out by comparison of enzyme activity using different apoBLO concentrations. These studies demonstrate that the mature form of lysyl oxidase retains many of its functions in the absence of copper.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Klinman, JP (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	klinman@socrates.berkeley.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039296] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 39296] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRONSHAW AD, 1993, MATRIX, V13, P255, DOI 10.1016/S0934-8832(11)80009-0; GACHERU SN, 1990, J BIOL CHEM, V265, P19022; HARRIS ED, 1974, BIOCHIM BIOPHYS ACTA, V341, P332, DOI 10.1016/0005-2744(74)90226-5; KAGAN HM, 1995, METHOD ENZYMOL, V258, P122; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KUIVANIEMI H, 1982, J CLIN INVEST, V69, P730, DOI 10.1172/JCI110503; Liu GM, 1997, J BIOL CHEM, V272, P32370, DOI 10.1074/jbc.272.51.32370; Mills SA, 2000, J AM CHEM SOC, V122, P9897, DOI 10.1021/ja000325f; PAZ MA, 1991, J BIOL CHEM, V266, P689; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; SIEGEL RC, 1970, BIOCHEMISTRY-US, V9, P4486, DOI 10.1021/bi00825a004; Su QJ, 1998, BIOCHEMISTRY-US, V37, P12513, DOI 10.1021/bi981103l; TANG SS, 1983, J BIOL CHEM, V258, P4331; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; WILLIAMSON PR, 1987, J BIOL CHEM, V262, P8196; WILLIAMSON PR, 1986, J BIOL CHEM, V261, P9477; Zhu ZY, 1998, BBA-BIOENERGETICS, V1364, P297, DOI 10.1016/S0005-2728(98)00035-8	17	37	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30575	30578		10.1074/jbc.C100138200	http://dx.doi.org/10.1074/jbc.C100138200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11395477	hybrid			2022-12-27	WOS:000170472900001
J	Zhao, LC; Shey, M; Farnsworth, M; Dailey, MO				Zhao, LC; Shey, M; Farnsworth, M; Dailey, MO			Regulation of membrane metalloproteolytic cleavage of L-selectin (CD62L) by the epidermal growth factor domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; AMYLOID PRECURSOR PROTEIN; NODE HOMING RECEPTOR; CONVERTING ENZYME SECRETASE; CELL-SURFACE; TNF RECEPTOR; HUMAN NEUTROPHILS; KINASE-C; DISINTEGRIN-METALLOPROTEASE; STRUCTURAL REQUIREMENTS	The adhesion molecule L-selectin is cleaved rapidly from the surface of activated leukocytes by tumor necrosis factor-a converting enzyme, a cell surface metalloprotease, and also undergoes slower constitutive shedding in unactivated cells. The structural features that render it susceptible to shedding are poorly understood. We therefore analyzed the shedding of a series of mutant and chimeric L-selectin molecules. Although murine L-selectin is cleaved at a specific location in the juxtamembrane region 11 amino acids distal to the cell membrane, this cleavage has little sequence specificity. However, proline substitution at the P2 ' or P3 ' position or deletion of the epidermal growth factor (EGF) domain completely blocks the rapid phorbol ester-induced cleavage, but does not affect the slower basal proteolytic shedding. Insertion of the 15-residue membrane-proximal region (MPR) of L-selectin into the heterologous protein B7.2 results in a molecule that undergoes constitutive proteolytic turnover. In contrast, insertion of both the EGF domain and the MPR confers susceptibility to both slow constitutive shedding and the rapid proteolytic cleavage induced by phorbol 12-myristate 13-acetate. These results demonstrate that constitutive and induced L-selectin cleavage are separable processes and that the rapid phorbol ester-induced shedding requires the presence of the EGF domain, a sequence that is remote from the cleavage site.	Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Interdisciplinary Grad Program, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Dailey, MO (corresponding author), Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022730] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22730] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGER A, 1994, LYMPHOLOGY, V27, P187; Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bennett TA, 1996, J IMMUNOL, V156, P3093; Bennett TA, 2000, J IMMUNOL, V164, P4120, DOI 10.4049/jimmunol.164.8.4120; BERG M, 1990, BLOOD, V76, P2381; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CAPPELLUTI E, 1993, BIOCHEMISTRY-US, V32, P551, DOI 10.1021/bi00053a021; Chao CC, 1997, J IMMUNOL, V159, P1686; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DAILEY MO, 1993, LYMPHOCYTE ADHESION, P75; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Giblin PA, 1997, J IMMUNOL, V159, P3498; Gopalan PK, 1997, J IMMUNOL, V158, P367; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; Herman C, 1998, J IMMUNOL, V160, P2478; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hwang ST, 1996, J EXP MED, V184, P1343, DOI 10.1084/jem.184.4.1343; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; JUNG TM, 1990, J IMMUNOL, V144, P3130; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KALDJIAN EP, 1995, J IMMUNOL, V154, P4351; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; Martinez-Pomares L, 1998, J BIOL CHEM, V273, P23376, DOI 10.1074/jbc.273.36.23376; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Middelhoven PJ, 1997, FEBS LETT, V414, P14, DOI 10.1016/S0014-5793(97)00959-9; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Morrison M, 1980, Methods Enzymol, V70, P214; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; MURAKAWA Y, 1992, J IMMUNOL, V148, P1771; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; Parvathy S, 1997, BIOCHEM J, V327, P37, DOI 10.1042/bj3270037; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SIMON SI, 1995, J IMMUNOL, V155, P1502; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Solomon KA, 1999, J IMMUNOL, V163, P4105; Steeber DA, 1997, J IMMUNOL, V159, P952; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; Yamamoto S, 1999, IMMUNOL TODAY, V20, P278, DOI 10.1016/S0167-5699(99)01464-4; ZHAO LC, 2001, IN PRESS DEV IMMUNOL	83	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30631	30640		10.1074/jbc.M103748200	http://dx.doi.org/10.1074/jbc.M103748200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11375402	hybrid			2022-12-27	WOS:000170472900008
J	Jin, YJ; Atkinson, SJ; Marrs, JA; Gallagher, PJ				Jin, YJ; Atkinson, SJ; Marrs, JA; Gallagher, PJ			Myosin II light chain phosphorylation regulates membrane localization and apoptotic signaling of tumor necrosis factor receptor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI-DERIVED VESICLES; ESCHERICHIA-COLI; PROTEIN-KINASE; SMOOTH-MUSCLE; DEATH DOMAIN; CELL-DEATH; ACTIVATION; TNF; FADD; CASPASES	Activation of myosin II by myosin light chain kinase (MLCK) produces the force for many cellular processes including muscle contraction, mitosis, migration, and other cellular shape changes. The results of this study show that inhibition or potentiation of myosin II activation via over-expression of a dominant negative or wild type MLCK can delay or accelerate tumor necrosis factor-alpha (TNF)-induced apoptotic cell death in cells. Changes in the activation of caspase-8 that parallel changes in regulatory light chain phosphorylation levels reveal that myosin Il motor activities regulate TNF receptor-1 (TNFR-1) signaling at an early step in the TNF death signaling pathway. Treatment of cells with either ionomycin or endotoxin (lipopolysaccharide) leads to activation of myosin II and increased translocation of TNFR-1 to the plasma membrane independent of TNF signaling. The results of these studies establish a new role for myosin II motor activity in regulating TNFR-1-mediated apoptosis through the translocation of TNFR-1 to or within the plasma membrane.	Indiana Univ, Sch Med, Dept Cellular & Integrav Physiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Gallagher, PJ (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrav Physiol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	pgallag@iupui.edu			NHLBI NIH HHS [R01 HL054118-03, R01 HL054118, HL54118] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054118] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BALDWIN TJ, 1991, INFECT IMMUN, V59, P1599, DOI 10.1128/IAI.59.5.1599-1604.1991; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; ESSER C, 1995, CYTOMETRY, V21, P382, DOI 10.1002/cyto.990210411; Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543; GALLAGHER PJ, 1995, J BIOL CHEM, V270, P29090, DOI 10.1074/jbc.270.49.29090; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GAUSH CR, 1966, P SOC EXP BIOL MED, V122, P931; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Goeckeler ZM, 2000, J BIOL CHEM, V275, P18366, DOI 10.1074/jbc.M001339200; GUEDDEL DV, 1999, CHEST, V116, pS73S; Heimann K, 1999, J BIOL CHEM, V274, P10743, DOI 10.1074/jbc.274.16.10743; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ikonen E, 1997, J CELL SCI, V110, P2155; ITOH N, 1993, J BIOL CHEM, V268, P10932; Jones SJ, 1999, J IMMUNOL, V162, P1042; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kumar S, 1999, TRENDS BIOCHEM SCI, V24, P1, DOI 10.1016/S0968-0004(98)01332-2; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Musch A, 1997, J CELL BIOL, V138, P291, DOI 10.1083/jcb.138.2.291; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; PORTOLES MT, 1991, BIOCHIM BIOPHYS ACTA, V1092, P1; SAYEED MM, 1987, AM J PHYSIOL, V253, pR549, DOI 10.1152/ajpregu.1987.253.4.R549; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; SONG SK, 1993, P NATL ACAD SCI USA, V90, P3933, DOI 10.1073/pnas.90.9.3933; Stow JL, 1998, TRENDS CELL BIOL, V8, P138, DOI 10.1016/S0962-8924(98)01238-0; Stow JL, 1998, BBA-MOL CELL RES, V1404, P161, DOI 10.1016/S0167-4889(98)00055-X; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, CHEM BIOL, V5, pR97, DOI 10.1016/S1074-5521(98)90615-9; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Valderrama F, 2000, P NATL ACAD SCI USA, V97, P1560, DOI 10.1073/pnas.97.4.1560; Van Eyk JE, 1998, J BIOL CHEM, V273, P23433, DOI 10.1074/jbc.273.36.23433; WRIGHT SC, 1993, J CELL BIOCHEM, V53, P222, DOI 10.1002/jcb.240530307	48	40	40	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30342	30349		10.1074/jbc.M102404200	http://dx.doi.org/10.1074/jbc.M102404200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11384975	hybrid, Green Accepted, Green Published			2022-12-27	WOS:000170558000097
J	Jiang, N; Levavasseur, F; McCright, B; Shoubridge, EA; Hekimi, S				Jiang, N; Levavasseur, F; McCright, B; Shoubridge, EA; Hekimi, S			Mouse CLK-1 is imported into mitochondria by an unusual process that requires a leader sequence but no membrane potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; SACCHAROMYCES-CEREVISIAE; PROTEIN IMPORT; GENE CLK-1; LIFE-SPAN; COQ7 GENE; MUTATIONS; RECEPTOR; TIM23; INNER	clk-1 has been identified and characterized in the nematode Caenorhabditis elegans as a gene that affects the rates, regularity, and synchrony of physiological processes. The CLK-1 protein is mitochondrial and is required for ubiquinone biosynthesis in yeast and in worms, but its biochemical function remains unclear. We have studied the expression of murine mclk1 in a variety of tissues, and we find that the pattern of mclk1 m-RNA accumulation closely resembles that of mitochondrial genes involved in oxidative phosphorylation. The pattern of protein accumulation, however, is sharply distinct in some tissues; mCLK1 appears relatively enriched in the gut and depleted in the nervous tissue. We also show that mCLK1 is synthesized as a preprotein that is imported into the mitochondrial matrix, where a leader sequence is cleaved off and the protein becomes loosely associated with the inner membrane. However, in contrast to all known mitochondrial proteins that contain a cleavable pre-sequence, the import of mCLK1 does not require a mitochondrial membrane potential.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University; McGill University	Hekimi, S (corresponding author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.							Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Asaumi S, 1999, GENOMICS, V58, P293, DOI 10.1006/geno.1999.5838; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Braeckman BP, 1999, CURR BIOL, V9, P493, DOI 10.1016/S0960-9822(99)80216-4; Branicky R, 2000, BIOESSAYS, V22, P48, DOI 10.1002/(SICI)1521-1878(200001)22:1&lt;48::AID-BIES9&gt;3.0.CO;2-F; Casas F, 1999, MOL CELL BIOL, V19, P7913; DIRCKS LK, 1990, MOL CELL BIOL, V10, P4984, DOI 10.1128/MCB.10.9.4984; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Greenawalt J W, 1974, Methods Enzymol, V31, P310; HEKIMI S, 1995, GENETICS, V141, P1351; Hekimi S, 2000, RES PRO CEL, V29, P81; Hekimi S, 1998, TRENDS GENET, V14, P14, DOI 10.1016/S0168-9525(97)01299-7; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Jonassen T, 1996, ARCH BIOCHEM BIOPHYS, V330, P285, DOI 10.1006/abbi.1996.0255; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; MARTIN J, 1991, J BIOL CHEM, V266, P18051; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; Proft M, 1995, EMBO J, V14, P6116, DOI 10.1002/j.1460-2075.1995.tb00302.x; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; SANYAL A, 1995, J BIOL CHEM, V270, P11970, DOI 10.1074/jbc.270.20.11970; Steenaart NAE, 1997, FEBS LETT, V415, P294, DOI 10.1016/S0014-5793(97)01145-9; WONG A, 1995, GENETICS, V139, P1247	32	31	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29218	29225		10.1074/jbc.M103686200	http://dx.doi.org/10.1074/jbc.M103686200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387338	hybrid			2022-12-27	WOS:000170346000079
J	Agnihotri, R; Crawford, HC; Haro, H; Matrisian, LM; Havrda, MC; Liaw, L				Agnihotri, R; Crawford, HC; Haro, H; Matrisian, LM; Havrda, MC; Liaw, L			Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL APOPTOSIS; HERNIATED DISC RESORPTION; MICE LACKING OSTEOPONTIN; GROWTH-FACTOR; IN-VITRO; TUMOR PROGRESSION; THROMBIN-CLEAVAGE; TERMINAL FRAGMENT; DEFICIENT MICE; MIGRATION	Osteopontin (OPN) is a secreted phosphoprotein shown to function in wound healing, inflammation, and tumor progression. Expression of OPN is often co-localized with members of the matrix metalloproteinase (MMP) family. We report that OPN is a novel substrate for two MMPs, MMP-3 (stromelysin-1) and MMP-7 (matrilysin). Three cleavage sites were identified for MMP-3 in human OPN, and two of those sites were also cleaved by MMP-7. These include hydrolysis of the human Gly(166)-Leu(167), Ala(201)-Tyr(202) (MMP-3 only), and Asp(210)-Leu(211) peptide bonds. Only the N-terminal Gly-Leu cleavage site is conserved in rat OPN (Gly(151)-Leu(152)). These sites are distinct from previously reported cleavage sites in OPN for the proteases thrombin or enterokinase. We found evidence for the predicted MMP cleavage fragments of OPN in vitro in tumor cell lines, and in vivo in remodeling tissues such as the postpartum uterus, where OPN and MMPs are co-expressed. Furthermore, cleavage of OPN by MMP-3 or MMP-7 potentiated the function of OPN as an adhesive and migratory stimulus in vitro through cell surface integrins. We predict that interaction of MMPs with OPN at tumor and wound healing sites in vivo may be a mechanism of regulation of OPN bioactivity.	Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA; Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA	Maine Medical Center; Vanderbilt University	Liaw, L (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA.		Crawford, Howard/A-2874-2008		NATIONAL CANCER INSTITUTE [R01CA060867] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA60867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Attiga FA, 2000, CANCER RES, V60, P4629; Bayless KJ, 2001, J BIOL CHEM, V276, P13483, DOI 10.1074/jbc.M011392200; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; Crawford HC, 1998, CANCER RES, V58, P5206; DENHARDT DT, 1995, ANN NY ACAD SCI, V760, P127, DOI 10.1111/j.1749-6632.1995.tb44625.x; DENHARDT DT, 1994, J CELL BIOCHEM, V56, P48, DOI 10.1002/jcb.240560109; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GIACHELLI CM, 1995, ANN NY ACAD SCI, V760, P109, DOI 10.1111/j.1749-6632.1995.tb44624.x; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Grant MB, 1998, DIABETES, V47, P1335, DOI 10.2337/diabetes.47.8.1335; Haro H, 2000, J CLIN INVEST, V105, P133, DOI 10.1172/JCI7090; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Imai K, 1997, BIOCHEM J, V322, P809, DOI 10.1042/bj3220809; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; Liaw L, 1998, J CLIN INVEST, V101, P1468; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; Meyer-Siegler K, 2000, CYTOKINE, V12, P914, DOI 10.1006/cyto.2000.0682; Mudgett JS, 1998, ARTHRITIS RHEUM-US, V41, P110, DOI 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.0.CO;2-G; MUKHERJEE BB, 1995, ANN NY ACAD SCI, V760, P201, DOI 10.1111/j.1749-6632.1995.tb44631.x; Nagakawa O, 2000, CANCER LETT, V155, P173, DOI 10.1016/S0304-3835(00)00425-0; Nau GJ, 1999, INFECT IMMUN, V67, P4223, DOI 10.1128/IAI.67.8.4223-4230.1999; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Noiri E, 1999, KIDNEY INT, V56, P74, DOI 10.1046/j.1523-1755.1999.00526.x; O'Regan AW, 1999, J IMMUNOL, V162, P1024; Ohnami S, 1999, CANCER RES, V59, P5565; Ophascharoensuk V, 1999, KIDNEY INT, V56, P571, DOI 10.1046/j.1523-1755.1999.00580.x; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Rittling SR, 1999, EXP NEPHROL, V7, P103; Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101; Senger DR, 1996, BBA-MOL CELL RES, V1314, P13, DOI 10.1016/S0167-4889(96)00067-5; SENGER DR, 1994, MOL BIOL CELL, V5, P565, DOI 10.1091/mbc.5.5.565; Senger DR, 1996, AM J PATHOL, V149, P293; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; Sodek J, 2000, CRIT REV ORAL BIOL M, V11, P279, DOI 10.1177/10454411000110030101; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Takahashi K, 1998, BIOCHEM MOL BIOL INT, V46, P1081; Uede T, 1997, MICROBIOL IMMUNOL, V41, P641, DOI 10.1111/j.1348-0421.1997.tb01906.x; Weber Georg F., 1996, Cytokine and Growth Factor Reviews, V7, P241, DOI 10.1016/S1359-6101(96)00030-5; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; WRIGHT JH, 1994, MOL CARCINOGEN, V10, P207, DOI 10.1002/mc.2940100405; Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328; Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156	48	310	330	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28261	28267		10.1074/jbc.M103608200	http://dx.doi.org/10.1074/jbc.M103608200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375993	hybrid			2022-12-27	WOS:000170093400070
J	Zhou, J; Hsieh, JT				Zhou, J; Hsieh, JT			The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade - DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; AP-1 ACTIVITY; DOMAIN; CLONING	DOC-2/DAB2 ((d) under bar ifferentially expressed in (o) under bar varian (c) under bar arcinoma-(2) under bar/(d) under bar is (a) under bar(b) under bar led (2) under bar) appears to be a potential tumor suppressor gene with a growth inhibitory effect on several cancer types. Previously, we have shown that DOC2/DAB2 suppresses protein kinase C-induced AP-1 activation, which is modulated by serine 24 phosphorylation in the N terminus of DOC-2/DAB2. However, the functional impact of the C terminus of DOC-2/DAB2, containing three proline-rich domains, has not been explored. In this study, we examined this functional role in modulating signaling mediated by peptide growth factor receptor tyrosine kinase, particularly because it involves the interaction with Grb2. Using sequence-specific peptides, we found that the second proline-rich domain of DOC-2/DAB2 is the key binding site to Grb2 in the presence of growth factors. Such elevated binding interrupts the binding between SOS and Grb2, which consequently suppresses downstream ERK phosphorylation. Reduced ERK phosphorylation was restored when the binding between DOC-2/DAB2 and Grb2 was interrupted by a specific peptide or by increasing the expression of Grb2. Furthermore, the C terminus of the DOC-2/DAB2 construct can inhibit the AP-1 activity elicited by growth factors. We conclude that DOC-2/DAB2, a potent negative regulator, can suppress ERK activation by interrupting the binding between Grb2 and SOS that is elicited by peptide growth factors. This study further illustrates that DOC-2/DAB2 has multiple effects on the RAS-mediated signal cascades active in cancer cells.	Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hsieh, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Urol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	JT.Hsieh@UTSouthwestern.edu			NCI NIH HHS [CA 59939] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA059939] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Fulop V, 1998, ONCOGENE, V17, P419, DOI 10.1038/sj.onc.1201955; Gutacker C, 1999, BIOCHEM J, V339, P759, DOI 10.1042/0264-6021:3390759; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCarty MF, 1998, MED HYPOTHESES, V50, P511, DOI 10.1016/S0306-9877(98)90273-0; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Schwahn DJ, 1998, ONCOGENE, V17, P1173, DOI 10.1038/sj.onc.1202038; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; Ware JL, 1998, CANCER METAST REV, V17, P443, DOI 10.1023/A:1006114527274; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	24	87	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27793	27798		10.1074/jbc.M102803200	http://dx.doi.org/10.1074/jbc.M102803200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11371563	hybrid			2022-12-27	WOS:000170093400009
J	Tanoue, T; Yamamoto, T; Maeda, R; Nishida, E				Tanoue, T; Yamamoto, T; Maeda, R; Nishida, E			A novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 alpha and beta MAPKs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; DUAL-SPECIFICITY PHOSPHATASE; IMMEDIATE-EARLY GENE; KINASE PHOSPHATASE; PTP-SL; SELECTIVELY DEPHOSPHORYLATES; SUBSTRATE-SPECIFICITY; CATALYTIC ACTIVATION; SIGNAL-TRANSDUCTION; CELLULAR STRESSES	Mitogen-activated protein kinases (MAPKs) are inactivated via dephosphorylation of either the threonine or tyrosine residue or both in the P-loop catalyzed by protein phosphatases which include serine/threonine phosphatases, tyrosine phosphatases, and dual specificity phosphatases. Nine members of the dual specificity phosphatases specific for MAPKs, termed MKPs, have been reported. Each member has its own substrate specificity, tissue distribution, and subcellular localization. In this study, we have cloned and characterized a novel MKP, designated MKP-7. MKP-7 is most similar to hVH5, a member of previously known MKPs, in the primary structure. MKP-7 is predominantly localized in the cytoplasm when expressed in cultured cells, whereas hVH5 is both in the nucleus and the cytoplasm, MKP-7 binds to and inactivates p38 MAPK and JNK/SAPK, but not ERK, Furthermore, we have found that MKPs have the substrate specificity toward the isoforms of the p38 family (alpha, beta, gamma, and delta). MKP-7 binds to and inactivates p38 alpha and -beta, but not gamma or delta. MKP-5 and CL100/MKP-1 also bind to p38 alpha and -beta, but not gamma or delta. Finally, we propose a tentative classification of MKPs based on the sequence characteristics of their MAPK-docking site.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University; Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan.	L50174@sakura.kudpc.kyoto-u.ac.jp	Yamamoto, Takuya/H-2792-2017	Yamamoto, Takuya/0000-0002-0022-3947; Maeda, Ryota/0000-0002-1514-1071				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1993, ONCOGENE, V8, P2015; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CHARLES CH, 1992, ONCOGENE, V7, P187; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Dowd S, 1998, J CELL SCI, V111, P3389; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Hasegawa M, 1999, J BIOL CHEM, V274, P12626, DOI 10.1074/jbc.274.18.12626; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	58	127	138	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26629	26639		10.1074/jbc.M101981200	http://dx.doi.org/10.1074/jbc.M101981200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11359773	hybrid			2022-12-27	WOS:000169823300128
J	Ren, Q; Thony-Meyer, L				Ren, Q; Thony-Meyer, L			Physical interaction of CcmC with heme and the heme chaperone CcmE during cytochrome c maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; PARACOCCUS-DENITRIFICANS; MUTATIONAL ANALYSIS; BIOGENESIS; PROTEIN; PATHWAY; PERIPLASM; BACTERIA; CHLOROPLASTS; RECEPTOR	Biogenesis of c-type cytochromes requires the covalent attachment of heme to the apoprotein. In Escherichia coli, this process involves eight membrane proteins encoded by the cemABCDEFGH operon. CcmE binds heme covalently and transfers it to apocytochromes c in the presence of other Cem proteins. CcmC is necessary and sufficient to incorporate heme into CcmE. Here, we report that the CcmC protein directly interacts with heme. We further show that CcmC coimmunoprecipitates with CcmE. CcmC contains two conserved histidines and a signature sequence, the so-called tryptophan-rich motif, which is the only element common to cytochrome c maturation proteins of bacteria, archae, plant mitochondria, and chloroplasts. We report that mutational changes of these motifs affecting the function of CcmC in cytochrome c maturation do not influence heme binding of CcmC. However, the mutants are defective in the CcmC-CcmE interaction, suggesting that these motifs are involved in the formation of a CcmC-CcmE complex. We propose that CcmC, CcmE, and heme interact directly with each other, establishing a periplasmic heme delivery pathway for cytochrome c maturation.	ETH, Inst Mikrobiol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Thony-Meyer, L (corresponding author), ETH, Inst Mikrobiol, Schmelzbergstr 7, CH-8092 Zurich, Switzerland.		Ren, Qun/A-3532-2016	Ren, Qun/0000-0003-0627-761X				Bracken CS, 1999, J BACTERIOL, V181, P6063, DOI 10.1128/JB.181.19.6063-6072.1999; Cook GM, 2000, MICROBIOL-SGM, V146, P527, DOI 10.1099/00221287-146-2-527; Dickerson R E., 1983, HEMOGLOBIN STRUCTURE, P19; Fabianek RA, 1999, ARCH MICROBIOL, V171, P92, DOI 10.1007/s002030050683; Fabianek RA, 1998, J BACTERIOL, V180, P1947, DOI 10.1128/JB.180.7.1947-1950.1998; Gaballa A, 1998, MOL MICROBIOL, V30, P547, DOI 10.1046/j.1365-2958.1998.01085.x; Gaballa A, 1996, MOL MICROBIOL, V21, P777, DOI 10.1046/j.1365-2958.1996.391399.x; Ghigo JM, 1997, J BACTERIOL, V179, P3572, DOI 10.1128/jb.179.11.3572-3579.1997; Goldman BS, 1998, P NATL ACAD SCI USA, V95, P5003, DOI 10.1073/pnas.95.9.5003; Grove J, 1996, MOL MICROBIOL, V19, P467, DOI 10.1046/j.1365-2958.1996.383914.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; IOBBINIVOL C, 1994, FEMS MICROBIOL LETT, V119, P89, DOI 10.1016/0378-1097(94)90397-2; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; Letoffe S, 1999, MOL MICROBIOL, V33, P546, DOI 10.1046/j.1365-2958.1999.01499.x; Miller J. H., 1992, LAB MANUAL HDB ESCHE; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; Page MD, 1997, MICROBIOL-SGM, V143, P563, DOI 10.1099/00221287-143-2-563; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; PAGE MD, 1990, MOL MICROBIOL, V4, P1181, DOI 10.1111/j.1365-2958.1990.tb00693.x; Page MD, 1999, MICROBIOL-UK, V145, P3047, DOI 10.1099/00221287-145-11-3047; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; Schulz H, 1999, P NATL ACAD SCI USA, V96, P6462, DOI 10.1073/pnas.96.11.6462; Schulz H, 2000, MOL MICROBIOL, V37, P1379, DOI 10.1046/j.1365-2958.2000.02083.x; Thony-Meyer L, 2000, BBA-BIOENERGETICS, V1459, P316, DOI 10.1016/S0005-2728(00)00167-5; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; THONYMEYER L, 1994, MOL MICROBIOL, V12, P1, DOI 10.1111/j.1365-2958.1994.tb00988.x; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; ThroneHolst M, 1997, FEBS LETT, V410, P351, DOI 10.1016/S0014-5793(97)00656-X; Xie ZY, 1998, BBA-BIOENERGETICS, V1365, P309, DOI 10.1016/S0005-2728(98)00085-1	30	59	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32591	32596		10.1074/jbc.M103058200	http://dx.doi.org/10.1074/jbc.M103058200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11384983	hybrid			2022-12-27	WOS:000170746000030
J	Murata, M; Kaji, H; Iida, K; Okimura, Y; Chihara, K				Murata, M; Kaji, H; Iida, K; Okimura, Y; Chihara, K			Dual action of eicosapentaenoic acid in hepatoma cells - Up-regulation of metabolic action of insulin and inhibition of cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTES; DIABETES-MELLITUS; GENE-EXPRESSION; DIETARY-FAT; PEPCK GENE; RESISTANCE; LEPTIN; PROTEIN; RATS; LOCALIZATION	Exogenous administration of eicosapentaenoic acid (EPA) improves insulin sensitivity, but its precise mechanism remains unknown. Here we show that EPA stimulates the intracellular insulin signaling pathway in hepatoma cells. Exposure of these cells to EPA caused up-regulation of several insulin-induced activities including tyrosine phosphorylation of insulin receptor substrate-1, insulin receptor substrate-l-associated phosphatidylinositol 3-kinase, and its downstream target Akt kinase activity as well as down-regulation of gluconeogenesis. In contrast, EPA decreased mitogenactivated protein kinase activity and inhibited cell proliferation. These findings raise the possibility that EPA up-regulates metabolic action of insulin and inhibits cell growth in humans.	Kobe Univ, Sch Med, Dept Med, Div 3, Kobe, Hyogo 650017, Japan; Kobe Univ, Sch Med, Dept Basic Allied Med, Kobe, Hyogo 650017, Japan; Coll Nursing Art & Sci, Akashi, Hyogo 6738588, Japan	Kobe University; Kobe University	Murata, M (corresponding author), Kobe Univ, Sch Med, Dept Med, Div 3, 7-5-1 Kusunoki Cho, Kobe, Hyogo 650017, Japan.		Iida, Keiji/ABB-5126-2021	Iida, Keiji/0000-0002-1516-7757				ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; CARROLL KK, 1986, CANCER, V58, P1818, DOI 10.1002/1097-0142(19861015)58:8+<1818::AID-CNCR2820581406>3.0.CO;2-4; Carroll KK, 1997, CURR OPIN LIPIDOL, V8, P53, DOI 10.1097/00041433-199702000-00011; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; Hawkins M, 1997, J BIOL CHEM, V272, P4889, DOI 10.1074/jbc.272.8.4889; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Mori Y, 1997, METABOLISM, V46, P1458, DOI 10.1016/S0026-0495(97)90148-7; Murata M, 2000, BIOCHEM BIOPH RES CO, V270, P343, DOI 10.1006/bbrc.2000.2424; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; POPPSNIJDERS C, 1987, DIABETES RES CLIN EX, V4, P141; Rajas F, 2000, DIABETES, V49, P1165, DOI 10.2337/diabetes.49.7.1165; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; SKOINIK EY, 1993, EMBO J, V12, P1929; STORLIEN LH, 1987, SCIENCE, V237, P885, DOI 10.1126/science.3303333; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011; Willson TM, 1997, CURR OPIN CHEM BIOL, V1, P235, DOI 10.1016/S1367-5931(97)80015-4; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; [No title captured]	32	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31422	31428		10.1074/jbc.M010497200	http://dx.doi.org/10.1074/jbc.M010497200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11390373	hybrid			2022-12-27	WOS:000170472900108
J	Komlosh, A; Momburg, F; Weinschenk, T; Emmerich, N; Schild, H; Nadav, E; Shaked, I; Reiss, Y				Komlosh, A; Momburg, F; Weinschenk, T; Emmerich, N; Schild, H; Nadav, E; Shaked, I; Reiss, Y			A role for a novel luminal endoplasmic reticulum aminopeptidase in final trimming of 26 S proteasome-generated major histocompatability complex class I antigenic peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC-CLASS-I; HISTOCOMPATIBILITY CLASS-I; DISTINCT PROTEOLYTIC PROCESSES; BINDING PEPTIDES; T-CELLS; ORNITHINE DECARBOXYLASE; INHIBITOR LACTACYSTIN; RESTRICTED EPITOPE; PROTEIN SUBSTRATE; SECRETORY PATHWAY	Peptides presented to cytotoxic, T lymphocytes by the class I major histocompatability complex are 8-11 residues long. Although proteasomal activity generates the precise G termini of antigenic epitopes, the mechanism(s) involved in generation of the precise N termini is largely unknown. To investigate the mechanism of N-terminal. peptide processing, we used a cell-free system in which two recombinant ornithine decarboxylase (ODC) constructs, one expressing the native H2-K-b-restricted ovalbumin (ova)-derived epitope SIINFEKL (ODC-ova) and the other expressing the extended epitope LESIINFEKL (ODC-LEova), were targeted to degradation by 26 S proteasomes followed by import into microsomes. We found that the cleavage specificity of the 26 S proteasome was influenced by the N-terminal flank ng amino acids leading to significantly different yields of the final epitope SIINFEKL. Following incubation in the presence of purified 26 S proteasome, ODC-LEova generated largely ESIINFEKL that was efficiently converted to the final epitope SIINFEKL following translocation into microsomes. The conversion of ESIINFEKL to SIINFEKL was strictly dependent on the presence of H2-K-b and was completely inhibited by the metalloaminopeptidase inhibitor 1,10-phenanthroline. Importantly, the converting activity was resistant, to a stringent salt/EDTA wash of the microsomes and was only apparent when transport of TAP, the transporter associated with antigen processing, was facilitated. These results strongly suggest a crucial role for a luminal endoplasmic reticulum-resident metalloaminopeptidase in the N-terminal trimming of major histocompatability complex class I-associated peptides.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; German Canc Res Ctr, DKFZ, Div Mol Immunol, D-69120 Heidelberg, Germany; Univ Tubingen, Inst Cell Biol, Dept Immunol, D-72076 Tubingen, Germany	Tel Aviv University; Helmholtz Association; German Cancer Research Center (DKFZ); Eberhard Karls University of Tubingen	Reiss, Y (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.							ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; Anton LC, 1998, J IMMUNOL, V160, P4859; BACIK I, 1994, J IMMUNOL, V152, P381; Bai AL, 1997, J IMMUNOL, V159, P2139; Ben-Shahar S, 1999, J BIOL CHEM, V274, P21963, DOI 10.1074/jbc.274.31.21963; Benham AM, 1997, J IMMUNOL, V159, P5896; Benham AM, 1998, J IMMUNOL, V161, P83; Beninga J, 1998, J BIOL CHEM, V273, P18734, DOI 10.1074/jbc.273.30.18734; BenShahar S, 1997, J BIOL CHEM, V272, P21060, DOI 10.1074/jbc.272.34.21060; Cerundolo V, 1997, EUR J IMMUNOL, V27, P336, DOI 10.1002/eji.1830270148; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; EISENLOHR LC, 1992, CELL, V71, P963, DOI 10.1016/0092-8674(92)90392-P; ELLIOTT T, 1995, J EXP MED, V181, P1481, DOI 10.1084/jem.181.4.1481; Emmerich NPN, 2000, J BIOL CHEM, V275, P21140, DOI 10.1074/jbc.M000740200; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Gil-Torregrosa BC, 1998, J EXP MED, V188, P1105, DOI 10.1084/jem.188.6.1105; GRANT EP, 1995, J IMMUNOL, V155, P3750; GRIEM P, 1991, CELL, V65, P633, DOI 10.1016/0092-8674(91)90095-G; HAMMOND SA, 1993, NATURE, V364, P158, DOI 10.1038/364158a0; HARDING CV, 1995, J IMMUNOL, V155, P1767; HENDERSON RA, 1993, P NATL ACAD SCI USA, V90, P10275, DOI 10.1073/pnas.90.21.10275; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; KARTTUNEN J, 1992, P NATL ACAD SCI USA, V89, P6020, DOI 10.1073/pnas.89.13.6020; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Koopmann JO, 2000, IMMUNITY, V13, P117, DOI 10.1016/S1074-7613(00)00013-3; Koopmann JO, 1996, EUR J IMMUNOL, V26, P1720, DOI 10.1002/eji.1830260809; Lauvau G, 1999, J EXP MED, V190, P1227, DOI 10.1084/jem.190.9.1227; Lobigs M, 2000, EUR J IMMUNOL, V30, P1496, DOI 10.1002/(SICI)1521-4141(200005)30:5<1496::AID-IMMU1496>3.0.CO;2-6; Lopez D, 1997, J IMMUNOL, V159, P5769; Lopez D, 2000, J IMMUNOL, V164, P5070, DOI 10.4049/jimmunol.164.10.5070; Luckey CJ, 1998, J IMMUNOL, V161, P112; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; Mo XY, 1999, J IMMUNOL, V163, P5851; Momburg F, 1998, ADV IMMUNOL, V68, P191, DOI 10.1016/S0065-2776(08)60560-X; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NEEFJES J, 1995, EUR J IMMUNOL, V25, P1133, DOI 10.1002/eji.1830250444; NEISIG A, 1995, J IMMUNOL, V154, P1273; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; Niedermann G, 1999, IMMUNOL REV, V172, P29, DOI 10.1111/j.1600-065X.1999.tb01354.x; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; Perarnau B, 1999, EUR J IMMUNOL, V29, P1243, DOI 10.1002/(SICI)1521-4141(199904)29:04<1243::AID-IMMU1243>3.0.CO;2-A; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Powers J.C., 1986, PROTEINASE INHIBITOR, P219; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; ROELSE J, 1994, J EXP MED, V180, P1591, DOI 10.1084/jem.180.5.1591; SCHUMACHER TNM, 1994, J EXP MED, V179, P533, DOI 10.1084/jem.179.2.533; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SNYDER HL, 1994, J EXP MED, V180, P2389, DOI 10.1084/jem.180.6.2389; Snyder HL, 1998, EUR J IMMUNOL, V28, P1339; Stoltze L, 2000, NAT IMMUNOL, V1, P413, DOI 10.1038/80852; Stoltze L, 1998, EUR J IMMUNOL, V28, P4029, DOI 10.1002/(SICI)1521-4141(199812)28:12<4029::AID-IMMU4029>3.0.CO;2-N; TOKUNAGA F, 1994, J BIOL CHEM, V269, P17382; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; UMEZAWA H, 1982, ANNU REV MICROBIOL, V36, P75, DOI 10.1146/annurev.mi.36.100182.000451; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Vinitsky A, 1997, J IMMUNOL, V159, P554; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang Y, 1998, MELANOMA RES, V8, P345, DOI 10.1097/00008390-199808000-00008; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; Yang B, 1996, J EXP MED, V183, P1545, DOI 10.1084/jem.183.4.1545	66	32	32	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30050	30056		10.1074/jbc.M103177200	http://dx.doi.org/10.1074/jbc.M103177200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11373290	hybrid			2022-12-27	WOS:000170558000060
J	Seet, BT; Barrett, J; Robichaud, J; Shilton, B; Singh, R; McFadden, G				Seet, BT; Barrett, J; Robichaud, J; Shilton, B; Singh, R; McFadden, G			Glycosaminoglycan binding properties of the myxoma virus CC-chemokine inhibitor, M-T1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; HERPES-SIMPLEX VIRUS; T-CELL ADHESION; VACCINIA VIRUS; PROTEIN INTERACTIONS; CHONDROITIN SULFATE; ENDOTHELIAL-CELLS; T1/35KDA FAMILY; RECEPTOR; HOMOLOG	Poxviruses encode a number of secreted virulence factors that function to mitigate or modulate the host immune response. M-T1 is a secreted 43-kDa glycoprotein produced by the myxoma virus, a poxvirus pathogen of rabbits, that binds CC-chemokines with high affinity, blocks binding to their cognate G-protein coupled receptors, and thereby inhibits chemokine-induced leukocyte chemotaxis. The present study indicates that H-TI, but not the related vaccinia virus 35-kDa CC-chemokine-binding protein, can localize to cell surfaces through an interaction with, glycosaminoglycan molecules. In addition to biochemically characterizing the nature of this interaction, we demonstrate that M-TI can also simultaneously interact with CC-chemokines while bound to heparin, suggesting that the binding sites on M-TI for chemokines and heparin are distinct. Furthermore, Using recombinant baculovirus-expressed M-TI truncation and internal deletion mutants, we localize the heparin-binding region of M-TI to the C terminus of the protein, a region that contains a high abundance of basic residues and includes two clusters of basic amino acid residues that. resemble Cardin and Weintraub heparin-binding consensus sequences. The ability of AI-Ti to simultaneously interact with chemokines and glycosaminoglycans may enable M-TI to tether to endothelial. surfaces or extracellular matrix and capture host chemokines that are expressed close to sites of virus infection.	John P Robarts Res Inst, Viral Immunol & Pathogenesis Labs, London, ON N6G 2V4, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	McFadden, G (corresponding author), John P Robarts Res Inst, Viral Immunol & Pathogenesis Labs, 1400 Western Rd,SDRT Rm 133, London, ON N6G 2V4, Canada.		Shilton, Brian H/A-6667-2011					Alcami A, 1998, J IMMUNOL, V160, P624; Ali S, 2000, J BIOL CHEM, V275, P11721, DOI 10.1074/jbc.275.16.11721; BANFIELD BW, 1995, J VIROL, V69, P3290, DOI 10.1128/JVI.69.6.3290-3298.1995; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Carfi A, 1999, P NATL ACAD SCI USA, V96, P12379, DOI 10.1073/pnas.96.22.12379; CHRISTOPHER JA, 1998, STRUCTURAL PROPERTIE; Dabbagh K, 2000, J IMMUNOL, V165, P3418, DOI 10.4049/jimmunol.165.6.3418; Damon I, 1998, P NATL ACAD SCI USA, V95, P6403, DOI 10.1073/pnas.95.11.6403; FENNER F, 1965, MYXOMATOSIS; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; Graham KA, 1997, VIROLOGY, V229, P12, DOI 10.1006/viro.1996.8423; GRUENHEID S, 1993, J VIROL, V67, P93, DOI 10.1128/JVI.67.1.93-100.1993; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Hsiao JC, 1999, J VIROL, V73, P8750, DOI 10.1128/JVI.73.10.8750-8761.1999; Hsiao JC, 1998, J VIROL, V72, P8374, DOI 10.1128/JVI.72.10.8374-8379.1998; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim CH, 1999, J LEUKOCYTE BIOL, V65, P6, DOI 10.1002/jlb.65.1.6; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lalani AS, 1999, CYTOKINE GROWTH F R, V10, P219, DOI 10.1016/S1359-6101(99)00018-0; Lalani AS, 1999, VIROLOGY, V256, P233, DOI 10.1006/viro.1999.9617; Lalani AS, 1998, VIROLOGY, V250, P173, DOI 10.1006/viro.1998.9340; Lalani AS, 1997, J VIROL, V71, P4356, DOI 10.1128/JVI.71.6.4356-4363.1997; Lin CL, 2000, J VIROL, V74, P3353, DOI 10.1128/JVI.74.7.3353-3365.2000; Liu LY, 2000, J CLIN INVEST, V105, P1613, DOI 10.1172/JCI8934; Lusso P, 2000, VIROLOGY, V273, P228, DOI 10.1006/viro.2000.0443; MANN DM, 1994, J BIOL CHEM, V269, P23661; McFadden G, 1997, BIOCHEM PHARMACOL, V54, P1271, DOI 10.1016/S0006-2952(97)00182-2; Mummery RS, 2000, J IMMUNOL, V165, P5671, DOI 10.4049/jimmunol.165.10.5671; Nash P, 1999, IMMUNOL REV, V168, P103, DOI 10.1111/j.1600-065X.1999.tb01286.x; OPGENORTH A, 1992, J VIROL, V66, P4720, DOI 10.1128/JVI.66.8.4720-4731.1992; PATEL AH, 1990, J GEN VIROL, V71, P2013, DOI 10.1099/0022-1317-71-9-2013; Petersen F, 1998, J IMMUNOL, V161, P4347; Rajarathnam K, 2001, J BIOL CHEM, V276, P4909, DOI 10.1074/jbc.M005085200; REYNOLDS D, 1999, ADV ANIMAL VIROLOGY, P397; RICH RL, 2000, CURR OPIN BIOTECHNOL, V11; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; Smith CA, 1997, VIROLOGY, V236, P316, DOI 10.1006/viro.1997.8730; Smith SA, 2000, J VIROL, V74, P5659, DOI 10.1128/JVI.74.12.5659-5666.2000; Smith VP, 2000, J VIROL, V74, P8460, DOI 10.1128/JVI.74.18.8460-8471.2000; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Tanaka Y, 1996, J EXP MED, V184, P1987, DOI 10.1084/jem.184.5.1987; Tanaka Y, 1998, ARTHRITIS RHEUM-US, V41, P1365, DOI 10.1002/1529-0131(199808)41:8<1365::AID-ART5>3.0.CO;2-W; UPTON C, 1992, SCIENCE, V258, P1369, DOI 10.1126/science.1455233; Ward SG, 1998, BIOCHEM J, V333, P457, DOI 10.1042/bj3330457; Weber KSC, 1999, EUR J IMMUNOL, V29, P700, DOI 10.1002/(SICI)1521-4141(199902)29:02<700::AID-IMMU700>3.0.CO;2-1; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9	55	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30504	30513		10.1074/jbc.M011401200	http://dx.doi.org/10.1074/jbc.M011401200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11369757	hybrid			2022-12-27	WOS:000170558000118
J	Camacho, A; Salas, M				Camacho, A; Salas, M			Repression of bacteriophage phi 29 early promoter C2 by viral protein P6 is due to impairment of closed complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILIS PHAGE PHI-29; HISTONE-LIKE PROTEIN; RNA-POLYMERASE; ESCHERICHIA-COLI; DNA-REPLICATION; TRANSCRIPTION REGULATION; NUCLEOPROTEIN COMPLEX; INITIATION; SUBUNIT; BINDING	Bacillus subtilis phage phi 29 encodes a very abundant protein, p6, which is a non sequence-specific DNA-binding protein. Protein p6 has the potential to bind cooperatively to the phage genome, forming a nucleoprotein complex in which the DNA adopts a right-handed toroidal conformation winding around a protein core. The formation of this complex at the right end of the phage genome where the early promoter C2 is located affects local topology, which may contribute to the promoter repression, although the underlying molecular mechanism of this repression is not presently known. In this study, we analyzed the effect of the p6 nucleoprotein complex on the formation of transcription complexes at the C2 promoter. The results obtained indicate that the nucleoprotein complex does not occlude promoter C2 to RNA polymerase because both proteins can bind to the same DNA molecule. Protein p6 binds along the fragment including the sequence adjacent to the bound polymerase, altering the structure of the transcriptional complex and affecting specifically the stability of the closed complex. The findings presented might help to answer some of the open questions about the concerted molecular mechanisms of histone-like proteins as transcriptional silencers.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Salas, Margarita/J-9873-2014	Salas, Margarita/0000-0001-5939-3441	NIGMS NIH HHS [2R01 GM27242-21] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adhya S, 1998, COLD SPRING HARB SYM, V63, P1, DOI 10.1101/sqb.1998.63.1; Aki T, 1996, GENES CELLS, V1, P179, DOI 10.1046/j.1365-2443.1996.d01-236.x; BARTHELEMY I, 1989, J VIROL, V63, P460, DOI 10.1128/JVI.63.1.460-462.1989; Buckle M, 1999, J MOL BIOL, V285, P955, DOI 10.1006/jmbi.1998.2391; Camacho A, 2000, J BACTERIOL, V182, P6927, DOI 10.1128/JB.182.24.6927-6932.2000; DERLICA K, 1987, MICROBIOL REV, V51, P301; Elias-Arnanz M, 1999, GENE DEV, V13, P2502, DOI 10.1101/gad.13.19.2502; GUTIERREZ C, 1994, EMBO J, V13, P169; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; MONSALVE M, 1995, VIROLOGY, V207, P23, DOI 10.1006/viro.1995.1048; PASTRANA R, 1985, NUCLEIC ACIDS RES, V13, P3083, DOI 10.1093/nar/13.9.3083; PRIETO I, 1988, P NATL ACAD SCI USA, V85, P314, DOI 10.1073/pnas.85.2.314; Rine J, 1999, P NATL ACAD SCI USA, V96, P8309, DOI 10.1073/pnas.96.15.8309; Rojo F, 1998, PROG NUCLEIC ACID RE, V60, P29, DOI 10.1016/S0079-6603(08)60888-0; SCHRODER O, 2000, J MOL BIOL, V296, P248; SERRANO M, 1993, J MOL BIOL, V230, P248, DOI 10.1006/jmbi.1993.1140; SERRANO M, 1990, SCIENCE, V248, P1012, DOI 10.1126/science.2111580; SERRANO M, 1989, EMBO J, V8, P1879, DOI 10.1002/j.1460-2075.1989.tb03584.x; SOGO JM, 1979, J MOL BIOL, V127, P411; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x	20	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28927	28932		10.1074/jbc.M103738200	http://dx.doi.org/10.1074/jbc.M103738200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384991	hybrid			2022-12-27	WOS:000170346000040
J	Gensure, RC; Gardella, TJ; Juppner, H				Gensure, RC; Gardella, TJ; Juppner, H			Multiple sites of contact between the carboxyl-terminal binding domain of PTHrP-(1-36) analogs and the amino-terminal extracellular domain of the PTH/PTHrP receptor identified by photoaffinity cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PARATHYROID-HORMONE; PTH-RELATED PEPTIDE; PROTEIN-RECEPTOR; REGION; LIGAND; LOOP; MUTAGENESIS; FRAGMENTS; RESIDUES; COMPLEX	The carboxyl-terminal portions of parathyroid hormone (PTH)-(1-34) and PTH-related peptide (PTHrP)-(1-36) are critical for high affinity binding to the PTH/ PTHrP receptor (P1R), but the mechanism of receptor interaction for this domain is largely unknown. To identify interaction sites between the carboxyl-terminal region of PTHrP-(1-36) and the P1R, we prepared analogs of [I-5,W-23,Y-36]PTHrP-(1-36)-amide with individual p-benzoyl-L-phenylalanine (Bpa) substitutions at positions 22-35. When tested with LLC-PK1 cells stably transfected with human P1R (hP1R), the apparent binding affinity and the EC50 of agonist-stimulated cAMP accumulation for each analog was, with the exception of the Bpa(24)-substituted analog, similar to that of the parent compound. The radiolabeled Bpa(23)-, Bpa(27)-, Bpa (28)-, and Bpa(33)-substituted compounds affinity-labeled the hP1R sufficiently well to permit subsequent mapping of the cross-linked receptor region. Each of these peptides cross-linked to the amino-terminal extracellular domain of the P1R: [I-5,Bpa(23),Y-36]PTHrP-(1-36)-amide crosslinked to the extreme end of this domain (residues 33-63); [I-5,W-23 Bpa(27),Y-36]PTHrP-(1-36)-amide cross-linked to residues 96-102; [1(5),W-23 Bpa (28),Y-36] PTHrP-(1-36). amide cross-linked to residues 64-95; and [15,W23, Bpa(33),Y-36]PTHrP-(1-36)-amide cross-linked to residues 151-172. These data thus predict that residues 23, 279 28, and 33 of native PTHrP are each near to different regions of the amino-terminal extracellular receptor domain of the P1R. This information helps define sites of proximity between several ligand residues and this large receptor domain, which so far has been largely excluded from models of the hormone-receptor complex.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Pediat Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Juppner, H (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.				NIDDK NIH HHS [DK11794, 1F32DK10034-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794, F32DK010034] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams AE, 1998, MOL ENDOCRINOL, V12, P1673, DOI 10.1210/me.12.11.1673; Barbier JR, 1997, J MED CHEM, V40, P1373, DOI 10.1021/jm960743o; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Bergwitz C, 1998, ENDOCRINOLOGY, V139, P723, DOI 10.1210/en.139.2.723; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Carter PH, 1999, ENDOCRINOLOGY, V140, P4972, DOI 10.1210/en.140.11.4972; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; EPAND RM, 1985, INT J PEPT PROT RES, V25, P594; Gardella T J, 2000, Rev Endocr Metab Disord, V1, P317, DOI 10.1023/A:1026522619828; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; GARDELLA TJ, 1993, ENDOCRINOLOGY, V132, P2024, DOI 10.1210/en.132.5.2024; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Greenberg Z, 2000, BIOCHEMISTRY-US, V39, P8142, DOI 10.1021/bi000195n; GREMLICH HU, 1983, BIOCHEMISTRY-US, V22, P4257, DOI 10.1021/bi00287a015; Hoare SRJ, 2000, J BIOL CHEM, V275, P27274; Jin L, 2000, J BIOL CHEM, V275, P27238; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; Juppner H., 2000, ENDOCRINOLOGY, P969; KEMP BE, 1987, SCIENCE, V238, P1568, DOI 10.1126/science.3685995; KONG XF, 1994, BIOCHEM BIOPH RES CO, V200, P1290, DOI 10.1006/bbrc.1994.1591; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420; Piserchio A, 2000, BIOCHEMISTRY-US, V39, P8153, DOI 10.1021/bi000196f; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; Rubin DA, 1999, J BIOL CHEM, V274, P28185, DOI 10.1074/jbc.274.40.28185; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIPANI E, 1995, J CLIN ENDOCR METAB, V80, P1611, DOI 10.1210/jc.80.5.1611; Shimizu M, 2000, J BIOL CHEM, V275, P21836, DOI 10.1074/jbc.M909861199; Shimizu M, 2000, J BIOL CHEM, V275, P19456, DOI 10.1074/jbc.M001596200; Takasu H, 1999, BIOCHEMISTRY-US, V38, P13453, DOI 10.1021/bi990437n; Turner PR, 1998, J BIOL CHEM, V273, P3830, DOI 10.1074/jbc.273.7.3830; Zhou AT, 2000, BIOCHEMISTRY-US, V39, P6514, DOI 10.1021/bi992706f	39	55	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28650	28658		10.1074/jbc.M100717200	http://dx.doi.org/10.1074/jbc.M100717200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11356832	hybrid			2022-12-27	WOS:000170346000004
J	Kishi, S; Zhou, XZ; Ziv, Y; Khoo, C; Hill, DE; Shiloh, Y; Lu, KP				Kishi, S; Zhou, XZ; Ziv, Y; Khoo, C; Hill, DE; Shiloh, Y; Lu, KP			Telomeric protein Pin2/TRF1 as an important ATM target in response to double strand DNA breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA CELLS; IONIZING-RADIATION; CHROMOSOMAL LOCALIZATION; SACCHAROMYCES-CEREVISIAE; PROLYL ISOMERIZATION; REGULATORY MECHANISM; CYCLE REGULATION; MAMMALIAN-CELLS; DAMAGE RESPONSE; DEFICIENT MICE	ATM mutations are responsible for the genetic disease ataxia-telangiectasia (A-T). ATM encodes a protein kinase that is activated by ionizing radiation-induced double strand DNA breaks. Cells derived from A-T patients show many abnormalities, including accelerated telomere loss and hypersensitivity to ionizing radiation; they enter into mitosis and apoptosis after DNA damage. Pin2 was originally identified as a protein involved in G(2)/M regulation and is almost identical to TRF1, a telomeric protein that negatively regulates telomere elongation. Pin2 and TRF1, probably encoded by the same gene, PIN2/TRF1, are regulated during the cell cycle. Furthermore, up-regulation of Pin2 or TRF1 induces mitotic entry and apoptosis, a phenotype similar to that of A-T cells after DNA damage. These results suggest that ATM may regulate the function of Pin2/TRF1, but their exact relationship remains unknown. Here we show that Pin2/TRF1 coimmunoprecipitated with ATM, and its phosphorylation was increased in an ATM-dependent manner by ionizing DNA damage. Furthermore, activated ATM directly phosphorylated Pin2/TRF1 preferentially on the conserved Ser(219)-Gln site in vitro and in vivo. The biological significance of this phosphorylation is substantiated by functional analyses of the phosphorylation site mutants. Although expression of Pin2 and its mutants has no detectable effect on telomere length in transient transfection, a Pin2 mutant refractory to ATM phosphorylation on Ser(219) potently induces mitotic entry and apoptosis and increases radiation hypersensitivity of A-T cells. In contrast, Pin2 mutants mimicking ATM phosphorylation on Ser(219) completely fail to induce apoptosis and also reduce radiation hypersensitivity of A-T cells. Interestingly, the phenotype of the phosphorylation-mimicking mutants is the same as that which resulted from inhibition of endogenous Pin2/TRF1 in A-T cells by its dominant-negative mutants. These results demonstrate for the first time that ATM interacts with and phosphorylates Pin2/TRF1 and suggest that Pin2/TRF1 may be involved in the cellular response to double strand DNA breaks.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel; Oncogene Res Prod, Cambridge, MA 02142 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Tel Aviv University; Sackler Faculty of Medicine	Lu, KP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, HIM 1047,330 Brookline Ave, Boston, MA 02215 USA.	klu@Caregroup.Harvard.edu	Hill, David E/B-6617-2011		NIGMS NIH HHS [GM58556, GM56230] Funding Source: Medline; NINDS NIH HHS [NS31763] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056230, R01GM058556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Broccoli D, 1997, HUM MOL GENET, V6, P69, DOI 10.1093/hmg/6.1.69; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; ELDREDGE ER, 1995, METHOD ENZYMOL, V254, P481; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Fritz E, 2000, MOL BIOL CELL, V11, P2605, DOI 10.1091/mbc.11.8.2605; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Greider CW, 1996, SCI AM, V274, P92, DOI 10.1038/scientificamerican0296-92; Henderson S, 1996, J CELL BIOL, V134, P1, DOI 10.1083/jcb.134.1.1; Hultdin M, 1998, NUCLEIC ACIDS RES, V26, P3651, DOI 10.1093/nar/26.16.3651; Ishibashi T, 1998, P NATL ACAD SCI USA, V95, P4219, DOI 10.1073/pnas.95.8.4219; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kishi S, 2001, ONCOGENE, V20, P1497, DOI 10.1038/sj.onc.1204229; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; Lakin ND, 1996, ONCOGENE, V13, P2707; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Lu K P, 2000, Prog Cell Cycle Res, V4, P83; Lu KP, 1996, NATURE, V380, P544; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Lundblad V, 2000, MUTAT RES-FUND MOL M, V451, P227, DOI 10.1016/S0027-5107(00)00052-X; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PAULES RS, 1995, CANCER RES, V55, P1763; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1998, CANCER RES, V58, P4375; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scherthan H, 1996, J CELL BIOL, V134, P1109, DOI 10.1083/jcb.134.5.1109; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Smilenov LB, 1998, ONCOGENE, V17, P2137, DOI 10.1038/sj.onc.1202138; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xia SJJ, 1996, MUTAT RES-DNA REPAIR, V364, P1, DOI 10.1016/0921-8777(96)00015-8; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Young AC, 1997, SOMAT CELL MOLEC GEN, V23, P275, DOI 10.1007/BF02674418; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; ZIV Y, 1989, CANCER RES, V49, P2495; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	78	99	105	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29282	29291		10.1074/jbc.M011534200	http://dx.doi.org/10.1074/jbc.M011534200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11375976	Green Published, hybrid			2022-12-27	WOS:000170346000087
J	van der Merwe, GK; Cooper, TG; van Vuuren, HJJ				van der Merwe, GK; Cooper, TG; van Vuuren, HJJ			Ammonia regulates VID30 expression and Vid30p function shifts nitrogen metabolism toward glutamate formation especially when Saccharomyces cerevisiae is grown in low concentrations of ammonia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL KINASE HOMOLOG; CATABOLIC GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; TOR; RAPAMYCIN; REPRESSION; PRODUCT; GLN3P; PROTEIN; URE2P	The GATA family proteins Gln3p and Gat1p mediate nitrogen catabolite repression (NCR)-sensitive transcription in Saccharomyces cerevisiae. When cells are cultured with a good nitrogen source (glutamine, ammonia), Gln3p and Gat1p are restricted to the cytoplasm, whereas with a poor nitrogen source (proline), they localize to the nucleus, bind to the GATA sequences of NCR-sensitive gene promoters, and activate transcription. The target of rapamycin-signaling cascade and Ure2p participate in regulating the cellular localization of Gln3p and Gat1p. Rapamycin, a Tor protein inhibitor, like growth with a poor nitrogen source, promotes nuclear localization of Gln3p and Gat1p. gln3 Delta and ure2 Delta mutants are partially resistant and hypersensitive to growth inhibition by rapamycin, respectively. We show that a vid30 Delta is more rapamycin-sensitive than wild type but less so than a ure2 Delta. VID30 expression is modestly NCR-sensitive, responsive to deletion of URE2, and greatly increases in low ammonia medium. Patterns of gene expression in a vid30 Delta suggest that the Vid30p function shifts the balance of nitrogen metabolism toward the production of glutamate, especially when cells are grown in low ammonia. CAN1, DAL4, DAL5, MEP2, DAL1, DAL80, and GDH3 transcription is down-regulated by Vid30p function with proline as the nitrogen source. An effect, however, that could easily be indirect.	Univ British Columbia, Fac Agr Sci, Wine Res Ctr, Vancouver, BC V6T 1Z4, Canada; Univ Tennessee, Ctr Hlth Sci, Dept Microbiol & Immunol, Memphis, TN 38163 USA	University of British Columbia; University of Tennessee System; University of Tennessee Health Science Center	van Vuuren, HJJ (corresponding author), Univ British Columbia, Fac Agr Sci, Wine Res Ctr, Vancouver, BC V6T 1Z4, Canada.	hjjvv@interchange.ubc.ca		Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM035642, GM-35642-14] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1995, CURRENT PROTOCOLS MO, P241; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; BLINDER D, 1995, J BACTERIOL, V177, P4190, DOI 10.1128/jb.177.14.4190-4193.1995; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Chan TF, 2001, J BIOL CHEM, V276, P6463, DOI 10.1074/jbc.M008162200; Choi JH, 2000, CURR BIOL, V10, P861, DOI 10.1016/S0960-9822(00)00599-6; Coffman JA, 1996, MOL CELL BIOL, V16, P847; COFFMAN JA, 1994, J BACTERIOL, V176, P7476, DOI 10.1128/JB.176.24.7476-7483.1994; COGONI C, 1995, J BACTERIOL, V177, P792, DOI 10.1128/jb.177.3.792-798.1995; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; COOPER TG, 1990, J BACTERIOL, V172, P1014, DOI 10.1128/jb.172.2.1014-1018.1990; Cooper TG, 1996, MYCOTA, V3, P139; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P4455, DOI 10.1128/MCB.11.9.4455; COURCHESNE WE, 1988, J BACTERIOL, V170, P708, DOI 10.1128/jb.170.2.708-713.1988; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; Cunningham TS, 1996, J BACTERIOL, V178, P3470, DOI 10.1128/jb.178.12.3470-3479.1996; Cunningham TS, 2000, J BIOL CHEM, V275, P14408, DOI 10.1074/jbc.275.19.14408; DAUGHERTY JR, 1993, J BACTERIOL, V175, P64, DOI 10.1128/JB.175.1.64-73.1993; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LAW DTS, 1988, MOL CELL BIOL, V8, P912, DOI 10.1128/MCB.8.2.912; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; REITZER LJ, 1987, ESCHERICHIA COLI SAL, P301; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; STANBROUGH M, 1995, J BACTERIOL, V177, P94, DOI 10.1128/jb.177.1.94-102.1995; Stanbrough M, 1996, J BACTERIOL, V178, P2465, DOI 10.1128/jb.178.8.2465-2468.1996; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3	34	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28659	28666		10.1074/jbc.M102280200	http://dx.doi.org/10.1074/jbc.M102280200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11356843	Green Accepted, hybrid			2022-12-27	WOS:000170346000005
J	Zhou, HJ; Wong, CM; Chen, JH; Qiang, BQ; Yuan, JG; Jin, DY				Zhou, HJ; Wong, CM; Chen, JH; Qiang, BQ; Yuan, JG; Jin, DY			Inhibition of LZIP-mediated transcription through direct interaction with a novel host cell factor-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; ACCESSORY FACTOR HCF; HTLV-I TAX; COMPLEX-FORMATION; C1 FACTOR; VP16; FAMILY; ACTIVATION; BINDING; ASSOCIATION	Host cell factor 1 (HCF-1) is a cellular transcriptional coactivator which coordinates the assembly of enhancer complex through direct interactions with viral and cellular trans-activators such as VP16, Oct-1, LZIP, and GA-binding protein. These interactions are mediated by the P-propeller domain comprising the first 380 residues of HCF-1 with six kelch repeats. Here we describe the identification and characterization of a novel HCF-like kelch repeat protein, designated HCLP-1. HCLP-1 is a ubiquitously expressed nuclear protein which is composed almost entirely of a six-bladed P-propeller. HCLP-1 selectively interacts with LZIP but not with VP16. The physical interaction between HCLP-1 and LZIP leads to the repression of the LZIP-dependent transcription. The HCLP-1-binding domain of LZIP maps to residues 109-315, which contain the bZIP DNA-binding motif. Electrophoretic mobility shift assay demonstrates that HCLP-1 indeed interferes with the binding of LZIP to its DNA target. Thus, HCLP-1 serves a transcriptional co-repressor function mediated through its inhibitory interaction with the LZIP transcription factor. Our findings suggest a new mechanism for transcriptional regulation by HCF-like proteins.	Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; Peking Union, Coll Med, Chinese Natl Human Genome Ctr, Beijing 100005, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; University of Hong Kong	Yuan, JG (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China.		Wong, Chi-Ming/A-7627-2013; Zhou, Houjiang/AFU-3540-2022	Wong, Chi-Ming/0000-0002-0025-7135; 				ABEL T, 1992, GENE DEV, V6, P466, DOI 10.1101/gad.6.3.466; Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; BURBELO PD, 1994, GENE, V139, P241, DOI 10.1016/0378-1119(94)90763-3; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Grapes M, 2000, J VIROL, V74, P10112, DOI 10.1128/JVI.74.21.10112-10121.2000; Hughes TA, 1999, J BIOL CHEM, V274, P16437, DOI 10.1074/jbc.274.23.16437; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson KM, 1999, J VIROL, V73, P3930, DOI 10.1128/JVI.73.5.3930-3940.1999; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; Kristie TM, 1999, P NATL ACAD SCI USA, V96, P1229, DOI 10.1073/pnas.96.4.1229; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; La Boissiere S, 1999, EMBO J, V18, P480; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Liu Y, 1999, MOL CELL BIOL, V19, P909; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 2000, NUCLEIC ACIDS RES, V28, P2446, DOI 10.1093/nar/28.12.2446; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Luciano RL, 2000, P NATL ACAD SCI USA, V97, P10757, DOI 10.1073/pnas.190062797; Mahajan SS, 2000, MOL CELL BIOL, V20, P919, DOI 10.1128/MCB.20.3.919-928.2000; Neuveut C, 1997, J BIOMED SCI, V4, P229, DOI 10.1007/BF02253422; Scarr RB, 2000, MOL CELL BIOL, V20, P3568, DOI 10.1128/MCB.20.10.3568-3575.2000; SMOLIK SM, 1992, MOL CELL BIOL, V12, P4123, DOI 10.1128/MCB.12.9.4123; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Vogel JL, 2000, EMBO J, V19, P683, DOI 10.1093/emboj/19.4.683; Wilson AC, 2000, MOL CELL BIOL, V20, P6721, DOI 10.1128/MCB.20.18.6721-6730.2000; WILSON AC, 1995, GENOMICS, V25, P462, DOI 10.1016/0888-7543(95)80046-O; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	34	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28933	28938		10.1074/jbc.M103893200	http://dx.doi.org/10.1074/jbc.M103893200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384994	hybrid			2022-12-27	WOS:000170346000041
J	Davis, SL; Gurusiddappa, S; McCrea, KW; Perkins, S; Hook, M				Davis, SL; Gurusiddappa, S; McCrea, KW; Perkins, S; Hook, M			SdrG, a fibrinogen-binding bacterial adhesin of the microbial surface components recognizing adhesive matrix molecules subfamily from Staphylococcus epidermidis, targets the thrombin cleavage site in the B beta chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLUMPING FACTOR; ICA LOCUS; AUREUS; PROTEIN; FIBRONECTIN; IDENTIFICATION; PATHOGENESIS; EXPRESSION; RECEPTOR; PLASMA	Staphylococcus epidermidis is an important opportunistic pathogen and is a major cause of foreign body infections. We have characterized the ligand binding activity of SdrG, a fibrinogen-binding microbial surface component recognizing adhesive matrix molecules from S. epidermidis. Western ligand blot analysis showed that a recombinant form of the N-terminal A region of SdrG bound to the native B beta chain of fibrinogen (Fg) and to a recombinant form of the B beta chain expressed in Escherichia coli. By analyzing recombinant truncates and synthetic peptide mimetics of the Fg B beta chain, the binding site for SdrG was localized to residues 6-20 of this polypeptide. Recombinant SdrG bound to a synthetic 25-amino acid peptide (beta1-25) representing the N terminus of the Fg B beta chain with a K-D of 1.4 x 10(-7) M as determined by fluorescence polarization experiments. This was similar to the apparent K-D (0.9 x 10(-7) M) calculated from an enzyme-linked immunosorbent assay where SdrG bound immobilized Fg in a concentration-dependent manner. SdrG could recognize fibrinopeptide B (residues 1-14), but with a substantially lower affinity than that observed for SdrG binding to synthetic peptides beta1-25 and beta6-20. However, SdrG does not bind to thrombin-digested Fg. Thus, SdrG appears to target the thrombin cleavage site in the Fg B beta chain. In fact, SdrG was found to inhibit thrombin-induced fibrinogen clotting by interfering with fibrinopeptide B release.	Univ Texas, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Texas A&M University System; Texas A&M University College Station	Hook, M (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mhook@ibt.tamu.edu			NIAID NIH HHS [AI20624] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cramton SE, 1999, INFECT IMMUN, V67, P5427, DOI 10.1128/IAI.67.10.5427-5433.1999; Eidhin DN, 1998, MOL MICROBIOL, V30, P245; Entenza JM, 2000, INFECT IMMUN, V68, P5443, DOI 10.1128/IAI.68.9.5443-5446.2000; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FLOCK JI, 1987, EMBO J, V6, P2351, DOI 10.1002/j.1460-2075.1987.tb02511.x; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; FROMAN G, 1987, J BIOL CHEM, V262, P6564; GALLIANI S, 1994, J LAB CLIN MED, V123, P685; Garrett DO, 1999, INFECT CONT HOSP EP, V20, P167, DOI 10.1086/501605; HAVERKATE F, 1986, THROMB HAEMOSTASIS, V55, P131; Herrick S, 1999, INT J BIOCHEM CELL B, V31, P741, DOI 10.1016/S1357-2725(99)00032-1; KAY AB, 1974, BRIT J HAEMATOL, V27, P669, DOI 10.1111/j.1365-2141.1974.tb06633.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McCrea KW, 2000, MICROBIOL-SGM, V146, P1535, DOI 10.1099/00221287-146-7-1535; McDevitt D, 1997, EUR J BIOCHEM, V247, P416, DOI 10.1111/j.1432-1033.1997.00416.x; MCDEVITT D, 1995, MOL MICROBIOL, V16, P895, DOI 10.1111/j.1365-2958.1995.tb02316.x; McKenney D, 1998, INFECT IMMUN, V66, P4711, DOI 10.1128/IAI.66.10.4711-4720.1998; Meier PS, 2001, INFECT IMMUN, V69, P657; MOREILLON P, 1995, INFECT IMMUN, V63, P4738, DOI 10.1128/IAI.63.12.4738-4743.1995; Mullin JL, 2000, J BIOL CHEM, V275, P25239, DOI 10.1074/jbc.M004142200; NG AS, 1993, METHOD ENZYMOL, V222, P341; Nilsson M, 1998, INFECT IMMUN, V66, P2666, DOI 10.1128/IAI.66.6.2666-2673.1998; O'Connell DP, 1998, J BIOL CHEM, V273, P6821, DOI 10.1074/jbc.273.12.6821; PATTI JM, 1994, CURR OPIN CELL BIOL, V6, P752, DOI 10.1016/0955-0674(94)90104-X; Pei L, 1999, INFECT IMMUN, V67, P4525, DOI 10.1128/IAI.67.9.4525-4530.1999; RICHARDSON DL, 1976, BRIT J HAEMATOL, V32, P507, DOI 10.1111/j.1365-2141.1976.tb00953.x; SENIOR RM, 1986, J CLIN INVEST, V77, P1014, DOI 10.1172/JCI112353; VAUDAUX P, 1989, J INFECT DIS, V160, P865, DOI 10.1093/infdis/160.5.865; VAUDAUX PE, 1995, INFECT IMMUN, V63, P585, DOI 10.1128/IAI.63.2.585-590.1995; Wann ER, 2000, J BIOL CHEM, V275, P13863, DOI 10.1074/jbc.275.18.13863	30	99	102	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27799	27805		10.1074/jbc.M103873200	http://dx.doi.org/10.1074/jbc.M103873200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11371571	hybrid			2022-12-27	WOS:000170093400010
J	Guertin, DA; McCollum, D				Guertin, DA; McCollum, D			Interaction between the noncatalytic region of Sid1p kinase and Cdc14p is required for full catalytic activity and localization of Sid1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STE20-LIKE PROTEIN-KINASE; FISSION YEAST; CYTOKINESIS; THIAMINE; CLONING; FAMILY; GENE	Sid1p is a group II p21-activated kinase/germinal center kinase family member that is part of a signaling network required for cytokinesis in fission yeast. Germinal center kinases are characterized by well conserved amino-terminal catalytic domains followed by less conserved carboxyl termini. The carboxyl termini among group I germinal center kinases are moderately conserved and thought to be regulatory regions. Little is known about the carboxyl termini of group II family members. Sid1p has been shown to bind the novel protein Cdc14p; however, the functional significance of this interaction is unknown. Here we report that the carboxyl terminus of Sid1p is an essential regulatory region. Our results indicate that this region contains the binding domain for Cdc14p, and this association is required for full Sid1p catalytic activity as well as intracellular localization. Furthermore, overexpression of the carboxyl terminus of Sid1p alone compromises the signaling of cytokinesis. We conclude that Cdc14p positively regulates the Sid1p kinase by binding the noncatalytic carboxyl-terminal region of the protein.	Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	McCollum, D (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, 377 Plantat St, Worcester, MA 01605 USA.				NIGMS NIH HHS [GM58406] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058406] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balasubramanian MK, 2000, J CELL SCI, V113, P1503; Balasubramanian MK, 1998, GENETICS, V149, P1265; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; Eichinger L, 1998, J BIOL CHEM, V273, P12952, DOI 10.1074/jbc.273.21.12952; FANKHAUSER C, 1993, MOL BIOL CELL, V4, P531, DOI 10.1091/mbc.4.5.531; Guertin DA, 2000, EMBO J, V19, P1803, DOI 10.1093/emboj/19.8.1803; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; POMBO CM, 1996, EMBO J, V15, P537; Sawin KE, 2000, CURR BIOL, V10, pR547, DOI 10.1016/S0960-9822(00)00613-8; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9	13	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28185	28189		10.1074/jbc.M103802200	http://dx.doi.org/10.1074/jbc.M103802200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11384993	hybrid			2022-12-27	WOS:000170093400060
J	Ma, H; Fukiage, C; Kim, YH; Duncan, MK; Reed, NA; Shih, M; Azuma, M; Shearer, TR				Ma, H; Fukiage, C; Kim, YH; Duncan, MK; Reed, NA; Shih, M; Azuma, M; Shearer, TR			Characterization and expression of calpain 10 - A novel ubiquitous calpain with nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PROTEASE; ELEGANS SEX DETERMINATION; MESSENGER-RNA; DETERMINATION GENE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; RAT LENS; IDENTIFICATION; PROTEOLYSIS; ACTIVATION	Calpains are calcium-dependent intracellular nonlysosomal proteases that are believed to hydrolyze specific substrates important in calcium-regulated signaling pathways. Recently, an atypical member of the calpain family, calpain 10, was described, and genetic variation in this gene was associated with an increased risk of type II diabetes mellitus in humans. In the present report, a polyclonal antibody directed against rat calpain 10 was developed. This antibody was used to monitor the expression of calpain 10 protein in tissues from rats, mice, and humans. Calpain 10 protein was found to be present in all tissues examined by Western blotting including the lens, retina, brain, heart, and skeletal muscle. Although some calpain 10 was detectable in the water-soluble protein fraction of these tissues, it was preferentially found in the water-insoluble fraction. In the lens, immunohistochemistry revealed that calpain 10 was predominately located in the cytoplasm of epithelial and newly differentiating lens fibers at the transition zone. However, calpain 10 was found to be associated with the plasma membrane of differentiated lens fiber cells and the sarcolemma of skeletal muscle. In the lens epithelium-derived cell line, alpha TN4-1, the calpain 10 protein was found in a punctate distribution in the cell nucleus as well as the cytoplasm. After the elevation of intracellular calcium levels with ionomycin, calpain 10 protein levels in the nucleus of alpha TN4-1 cells increased markedly, whereas those in the cytoplasm decreased. In the lens, the elevation of intracellular calcium levels after selenite administration resulted in increased levels of calpain 10 RNA within I day and a loss of calpain 10 protein from the lens nucleus coincident with the onset of selenite cataract. In conclusion, calpain 10 seems to be a ubiquitous calpain, the expression level and subcellular distribution of which are dynamically influenced by calcium.	Oregon Hlth & Sci Univ, Dept Oral Mol Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA; Senju Pharmaceut Co Ltd, Biol Lab, Nishi Ku, Kobe, Hyogo 65122, Japan; Oregon State Univ, Dept Anim Sci, Corvallis, OR 97331 USA; Univ Delaware, Dept Biol Sci, Div Mol Biol & Genet, Newark, DE 19716 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Senju Pharmaceutical Co. Ltd.; Oregon State University; University of Delaware	Shearer, TR (corresponding author), Oregon Hlth & Sci Univ, Dept Oral Mol Biol, 611 SW Campus Dr, Portland, OR 97201 USA.	shearert@ohsu.edu		Kim, Yung Hae/0000-0002-2932-8689; Duncan, Melinda/0000-0003-1570-322X	NEI NIH HHS [EY05786, EY12221] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012221] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Azuma M, 2000, CURR EYE RES, V21, P710, DOI 10.1076/0271-3683(200009)21:3;1-R;FT710; Baghdiguian S, 1999, NAT MED, V5, P503, DOI 10.1038/8385; Baier LJ, 2000, J CLIN INVEST, V106, pR69, DOI 10.1172/JCI10665; Barnes TM, 1996, EMBO J, V15, P4477, DOI 10.1002/j.1460-2075.1996.tb00825.x; Braun C, 1999, BIOCHEM BIOPH RES CO, V260, P671, DOI 10.1006/bbrc.1999.0948; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DAVID LL, 1984, INVEST OPHTH VIS SCI, V25, P1275; Dear N, 1997, GENOMICS, V45, P175, DOI 10.1006/geno.1997.4870; DELUCA CI, 1993, BIOCHIM BIOPHYS ACTA, V1216, P81, DOI 10.1016/0167-4781(93)90040-K; EMORI Y, 1986, J BIOL CHEM, V261, P9465; HARDING J, 1991, CATARACT BIOCH EPIDE, P21; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Ma H, 2000, CURR EYE RES, V20, P183, DOI 10.1076/0271-3683(200003)20:3;1-9;FT183; Ma H, 1998, INVEST OPHTH VIS SCI, V39, P454; Ma H, 1997, EXP EYE RES, V64, P437, DOI 10.1006/exer.1996.0229; Ma H, 2000, INVEST OPHTH VIS SCI, V41, P4232; Mugita N, 1997, BIOCHEM BIOPH RES CO, V239, P845, DOI 10.1006/bbrc.1997.7571; *NIH, 1985, DHEW PUBL, V8623; Permutt MA, 2000, J CLIN INVEST, V106, P819, DOI 10.1172/JCI11228; Reed NA, 2001, J IMMUNOL METHODS, V253, P243, DOI 10.1016/S0022-1759(01)00374-X; Shearer T R, 1997, Mol Vis, V3, P8; SHEARER TR, 1992, CURR EYE RES, V11, P357, DOI 10.3109/02713689209001789; Sokol SB, 2000, GENE DEV, V14, P901; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; TANAKA Y, 2000, BIOCHEM BIOPH RES CO, V275, P300	28	98	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28525	28531		10.1074/jbc.M100603200	http://dx.doi.org/10.1074/jbc.M100603200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375982	hybrid			2022-12-27	WOS:000170093400104
J	Mazzorana, M; Cogne, S; Goldschmidt, D; Aubert-Foucher, E				Mazzorana, M; Cogne, S; Goldschmidt, D; Aubert-Foucher, E			Collagenous sequence governs the trimeric assembly of collagen XII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; TRIPLE-HELIX; MOLECULAR RECOGNITION; PROLYL 4-HYDROXYLASE; BINDING-PROPERTIES; III PROCOLLAGEN; C-PROPEPTIDE; IN-VITRO; DOMAIN; CHAIN	A minicollagen containing the COLT and NCI domains of chicken collagen XII has been produced in insect cells. Significant amounts of trimers contain a triple-helical domain in which the cysteines are not involved in inter- but in intrachain bonds. In reducing conditions, providing that the triple-helix is maintained, disulfide exchange between intra- and interchain bonding is observed, suggesting that the triple-helix forms first and that in favorable redox conditions interchain bonding occurs to stabilize the molecule. This hypothesis is verified by in vitro reassociation studies performed in the presence of reducing agents, demonstrating that the formation of interchain disulfide bonds is not a prerequisite to the trimeric association and triple-helical folding of the collagen XII molecule. Shortening the COLI domain of minicollagen XII to its five C-terminal GXY triplets results in an absence of trimers. This can be explained by the presence of a collagenous domain that is too short to form a stable triple-helix. In contrast, the presence of five additional C-terminal triplets in COLT allows the formation of triple-helical disulfide-bonded trimers, suggesting that the presence of a triple-helix is essential for the assembly of collagen XII.	Univ Lyon 1, Inst Biol & Chim Prot, CNRS, UMR 5086, F-69367 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Aubert-Foucher, E (corresponding author), Univ Lyon 1, Inst Biol & Chim Prot, CNRS, UMR 5086, 7 Passage Vercors, F-69367 Lyon 07, France.			MAZZORANA, Marlene/0000-0002-3956-4319				Alvares K, 1999, BIOCHEMISTRY-US, V38, P5401, DOI 10.1021/bi9821824; BACHINGER HP, 1991, INT J BIOL MACROMOL, V13, P152, DOI 10.1016/0141-8130(91)90040-2; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Bulleid NJ, 1996, BIOCHEM J, V317, P195, DOI 10.1042/bj3170195; Chiquet M, 1996, BIOCHEM CELL BIOL, V74, P737, DOI 10.1139/o96-080; CHOPRA RK, 1982, P NATL ACAD SCI-BIOL, V79, P7180, DOI 10.1073/pnas.79.23.7180; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; Ehnis T, 1996, EXP CELL RES, V229, P388, DOI 10.1006/excr.1996.0384; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FONT B, 1993, J BIOL CHEM, V268, P25015; Font B, 1996, MATRIX BIOL, V15, P341, DOI 10.1016/S0945-053X(96)90137-7; Garrone R, 1997, MICROSC RES TECHNIQ, V38, P407, DOI 10.1002/(SICI)1097-0029(19970815)38:4<407::AID-JEMT8>3.0.CO;2-F; INOUYE K, 1976, BIOCHIM BIOPHYS ACTA, V420, P133, DOI 10.1016/0005-2795(76)90352-4; Kania AM, 1999, J BIOL CHEM, V274, P22053, DOI 10.1074/jbc.274.31.22053; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; Klein G, 1998, MATRIX BIOL, V16, P307, DOI 10.1016/S0945-053X(98)90002-6; KRIEGIER M, 1990, GENE TRANSFER EXPRES; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Lesage A, 1996, BIOCHEMISTRY-US, V35, P9647, DOI 10.1021/bi952666p; Lim AL, 1998, J CELL BIOCHEM, V71, P216, DOI 10.1002/(SICI)1097-4644(19981101)71:2<216::AID-JCB7>3.3.CO;2-K; LUNSTRUM GP, 1992, J BIOL CHEM, V267, P20087; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; Mayne R, 1993, CURR OPIN CELL BIOL, V5, P883, DOI 10.1016/0955-0674(93)90039-S; MAZZORANA M, 1993, J BIOL CHEM, V268, P3029; Mazzorana M, 1996, J BIOL CHEM, V271, P29003, DOI 10.1074/jbc.271.46.29003; MAZZORANA M, 1995, MATRIX BIOL, V14, P583, DOI 10.1016/S0945-053X(05)80007-1; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Mechling DE, 1996, J BIOL CHEM, V271, P13781, DOI 10.1074/jbc.271.23.13781; NISHIYAMA T, 1994, J BIOL CHEM, V269, P28193; Niyibizi C, 1995, MATRIX BIOL, V14, P743, DOI 10.1016/S0945-053X(05)80017-4; Persikov AV, 2000, BIOCHEMISTRY-US, V39, P14960, DOI 10.1021/bi001560d; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ricard-Blum S, 2000, UNCONVENTIONAL COLLA; ROTH W, 1981, INT J PEPT PROT RES, V17, P527; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; SIES H, 1975, EUR J BIOCHEM, V57, P503, DOI 10.1111/j.1432-1033.1975.tb02325.x; SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; Trachslin J, 1999, EXP CELL RES, V247, P320, DOI 10.1006/excr.1998.4363; VANDERPLAATS GN, 1993, STRUCT OPTIMIZATION, V6, P1, DOI 10.1007/BF01743168; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Yang W, 1997, J BIOL CHEM, V272, P28837, DOI 10.1074/jbc.272.46.28837; Zafarullah K, 1997, MATRIX BIOL, V16, P201, DOI 10.1016/S0945-053X(97)90009-3	50	17	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27989	27998		10.1074/jbc.M101633200	http://dx.doi.org/10.1074/jbc.M101633200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375984	hybrid			2022-12-27	WOS:000170093400034
J	Rodrigues, RG; Guo, NH; Zhou, LG; Sipes, JM; Williams, SB; Templeton, NS; Gralnick, HR; Roberts, DD				Rodrigues, RG; Guo, NH; Zhou, LG; Sipes, JM; Williams, SB; Templeton, NS; Gralnick, HR; Roberts, DD			Conformational regulation of the fibronectin binding and alpha(3)beta(1) integrin-mediated adhesive activities of thrombospondin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; CELL LUNG-CARCINOMA; GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; PLATELET THROMBOSPONDIN; PLASMA FIBRONECTIN; ENDOTHELIAL-CELLS; TUMOR-GROWTH; GPIIB-IIIA; I REPEAT	The recognition of extracellular matrix components can be regulated by conformational changes that alter the activity of cell surface integrins. We now demonstrate that conformational regulation of the matrix glycoprotein thrombospondin-1 (TSP1) can also modulate its binding to an integrin receptor. F18 1G8 is a conformation-sensitive TSP1 antibody that binds weakly to soluble TSP1 in the presence of divalent cations. However, binding of the antibody to melanoma cells was strongly stimulated by adding exogenous TSP1 in the presence of calcium, suggesting that TSP1 undergoes a conformational change following its binding to the cell surface. This conformation was not induced by known cell surface TSP1 receptors, whereas binding of F18 was stimulated when TSP1 bound to fibronectin but not to heparin or fibrinogen. Conversely, binding of F18 to TSP1 enhanced TSP1 binding to fibronectin. Exogenous fibronectin also stimulated TSP1-dependent binding of F18 to melanoma cells. Binding of the fibronectin-TSP1 complex to melanoma cells was mediated by alpha (4)beta (1) and alpha (5)beta (1) integrins. Furthermore, binding to F18 or fibronectin strongly enhanced the adhesive activity of immobilized TSP1 for some cell types. This enhancement of adhesion was mediated by alpha (3)beta (1) integrin and required that the alpha (3)beta (1) integrin be in an active state. Fibronectin also enhanced TSP1 binding to purified alpha (3)beta (1) integrin. Therefore, both fibronectin and the F18 antibody induce conformational changes in TSP1 that enhance the ability of TSP1 to be recognized by alpha (3)beta (1) integrin. The conformational and functional regulation of TSP1 activity by fibronectin represents a novel mechanism for extracellular signal transduction.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; NIH, Hematol Serv, Ctr Clin, Bethesda, MD 20892 USA; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Baylor College of Medicine; Baylor College of Medicine	Roberts, DD (corresponding author), NCI, Pathol Lab, NIH, Bldg 10,Rm 2A33,10 Ctr DR,MSC 1500, Bethesda, MD 20892 USA.		Templeton, Nancy S/C-9565-2011; Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981				Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; AIKEN ML, 1986, J CLIN INVEST, V78, P1713, DOI 10.1172/JCI112767; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; BENEZRA D, 1993, INVEST OPHTH VIS SCI, V34, P3601; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BUEE L, 1992, AM J PATHOL, V141, P783; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; Castle VP, 1997, LAB INVEST, V77, P51; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DARDIK R, 1989, EUR J BIOCHEM, V185, P581, DOI 10.1111/j.1432-1033.1989.tb15153.x; Dardik R, 1999, EXP CELL RES, V248, P407, DOI 10.1006/excr.1999.4415; DEFREITAS MF, 1995, NEURON, V15, P333, DOI 10.1016/0896-6273(95)90038-1; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; GINSBERG MH, 1983, J CELL BIOL, V97, P571, DOI 10.1083/jcb.97.2.571; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOODWIN G, 1982, CANCER RES, V42, P1361; GRALNICK HR, 1992, BRIT J HAEMATOL, V80, P347, DOI 10.1111/j.1365-2141.1992.tb08144.x; Guo NH, 2000, CANCER RES, V60, P457; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; Guo NH, 1997, CANCER RES, V57, P1735; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HOMANDBERG GA, 1987, THROMB RES, V48, P329, DOI 10.1016/0049-3848(87)90445-2; Hotchkiss KA, 1996, BIOCHEMISTRY-US, V35, P9761, DOI 10.1021/bi9603938; Hotchkiss KA, 1998, BBA-PROTEIN STRUCT M, V1388, P478, DOI 10.1016/S0167-4838(98)00211-8; Huang EM, 1997, BLOOD, V89, P3205, DOI 10.1182/blood.V89.9.3205; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; KARCZEWSKI J, 1989, J BIOL CHEM, V264, P21322; Keenan RM, 1997, J MED CHEM, V40, P2289, DOI 10.1021/jm970205r; Krutzsch HC, 1999, J BIOL CHEM, V274, P24080, DOI 10.1074/jbc.274.34.24080; LAHAV J, 1984, EUR J BIOCHEM, V145, P151, DOI 10.1111/j.1432-1033.1984.tb08534.x; LAHAV J, 1982, CELL, V31, P253, DOI 10.1016/0092-8674(82)90425-1; LAWLER J, 1989, BLOOD, V74, P2022; LAWLER J, 1982, J BIOL CHEM, V257, P2257; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; Matthias LJ, 1996, BBA-PROTEIN STRUCT M, V1296, P138, DOI 10.1016/0167-4838(96)00060-X; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; Pijuan-Thompson V, 1999, EXP CELL RES, V249, P86, DOI 10.1006/excr.1999.4458; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; Roberts David D., 1994, Journal of Tissue Culture Methods, V16, P217, DOI 10.1007/BF01540654; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Shi SR, 1999, J HISTOCHEM CYTOCHEM, V47, P463, DOI 10.1177/002215549904700404; SIPES JM, 1993, J CELL BIOL, V121, P469, DOI 10.1083/jcb.121.2.469; SLANE JMK, 1988, FEBS LETT, V229, P363, DOI 10.1016/0014-5793(88)81157-8; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; TUSZYNSKI GP, 1987, CANCER RES, V47, P4130; VOLPERT OV, 1995, BREAST CANCER RES TR, V36, P119, DOI 10.1007/BF00666034; Watanabe K, 2000, BIOCHEMISTRY-US, V39, P7138, DOI 10.1021/bi992670r; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; YABKOWITZ R, 1993, J IMMUNOL, V151, P149; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209; ZAFAR RS, 1992, ARCH BIOCHEM BIOPHYS, V297, P271, DOI 10.1016/0003-9861(92)90672-J	65	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27913	27922		10.1074/jbc.M009518200	http://dx.doi.org/10.1074/jbc.M009518200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11358957	hybrid			2022-12-27	WOS:000170093400024
J	Shimizu, A; Persson, C; Heldin, CH; Ostman, A				Shimizu, A; Persson, C; Heldin, CH; Ostman, A			Ligand stimulation reduces platelet-derived growth factor beta-receptor susceptibility to tyrosine dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR; PHOSPHATASE LAR; SENSITIVITY; GENERATION; H2O2	Ligand binding to the platelet-derived growth factor (PDGF) beta -receptor leads to increased receptor tyrosine phosphorylation as a consequence of dimerization-induced activation of the intrinsic receptor tyrosine kinase activity. In this study we asked whether ligand-stimulated PDGF -receptor tyrosine phosphorylation, to some extent, also involved reduced susceptibility to tyrosine dephosphorylation. To investigate this possibility we compared the sensitivity of ligand-stimulated and nonstimulated forms of tyrosine-phosphorylated PDGF beta -receptors to dephosphorylation using various preparations containing protein-tyrosine phosphatase activity. Ligand-stimulated or unstimulated tyrosine-phosphorylated receptors were obtained after incubation of cells with pervanadate only or pervanadate, together with PDGF-BB, respectively. Dephosphorylation of receptors immobilized on wheat germ agglutinin-Sepharose, as well as of receptors in intact cell membranes, was investigated under conditions when rephosphorylation did not occur. As compared with unstimulated receptors the ligand-stimulated PDGF beta -receptors showed about 10-fold reduced sensitivity to dephosphorylation by cell membranes, a recombinant form of the catalytic domain of density-enhanced phosphatase-1, or recombinant protein-tyrosine phosphatase 1B. We conclude that ligand-stimulated forms of the PDGF beta -receptor display a reduced susceptibility to dephosphorylation. Our findings suggest a novel mechanism whereby ligand stimulation of PDGF beta -receptor, and possibly other tyrosine kinase receptors, leads to a net increase in receptor tyrosine phosphorylation.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ostman, A (corresponding author), Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.	arne.ostman@licr.uu.se						Ahmad F, 1997, J BIOL CHEM, V272, P448; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kokel M, 1998, GENE DEV, V12, P1425, DOI 10.1101/gad.12.10.1425; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; KOVALENKO M, 1994, CANCER RES, V54, P6106; Kulas DT, 1996, J BIOL CHEM, V271, P755, DOI 10.1074/jbc.271.2.755; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296	22	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27749	27752		10.1074/jbc.C100286200	http://dx.doi.org/10.1074/jbc.C100286200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11390370	hybrid			2022-12-27	WOS:000170093400002
J	Tomura, A; Goto, K; Morinaga, H; Nomura, M; Okabe, T; Yanase, T; Takayanagi, R; Nawata, H				Tomura, A; Goto, K; Morinaga, H; Nomura, M; Okabe, T; Yanase, T; Takayanagi, R; Nawata, H			The subnuclear three-dimensional image analysis of androgen receptor fused to green fluorescence protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROSTATIC-CARCINOMA; ANTIANDROGEN WITHDRAWAL SYNDROME; BINDING DOMAIN; LIVING CELLS; GLUCOCORTICOID RECEPTOR; INSENSITIVITY SYNDROME; NUCLEAR MATRIX; ANTI-ANDROGENS; LNCAP CELLS; LIGAND	To establish the novel approach in order to distinguish the transcriptionally active androgen receptor (AR) from the transcriptionally inactive A-R, we performed the three-dimensional construction of confocal microscopic images of intranuclear AR. This method clearly distinguished the subnuclear localization of transcriptionally active AR tagged with green fluorescent protein (AR-GFP) from the transcriptionally inactive AR-GFP. Transcriptionally active AR-GFP mainly produced 250-400 fluorescence foci in the boundary region between euchromatin and heterochromatin. Although the AR-GFP bound to such antiandrogens as hydroxyflutamide or bicalutamide translocated to the nucleus, they homogeneously spread throughout the nucleus without producing any fluorescence foci. Antiandrogenic environmental disrupting chemicals, such as 1,1-dichloro-2,2-bis (p-chlorophenyl) ethylene, vinclozolin, or nitrofen, also disrupted the intranuclear fluorescence foci. A point mutation (T877A) resulted in the loss of ligand specificity in AR-GFP. Even in this mutant receptor, agonists, such as dihydrotestosterone, hydroxyflutamide, or progesterone, produced the fluorescence foci in the nucleus, whereas the transcriptionally inactive mutant binding bicalutamide was observed to be spread homogeneously in the nucleus. Taken together, our findings suggest that, after nuclear translocation, AR is possibly located in the specific region in the nucleus while demonstrating clustering tightly depending on the agonist-induced transactivation competence.	Kyushu Univ, Grad Sch Med Sci, Dept Internal Med 3,Dept Med & Bioregulatory sci, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol, CREST, Tsukuba, Ibaraki, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Nawata, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Internal Med 3,Dept Med & Bioregulatory sci, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.							Adachi M, 2000, NEW ENGL J MED, V343, P856, DOI 10.1056/NEJM200009213431205; Breul J, 1998, UROLOGE A, V37, P156, DOI 10.1007/s001200050165; Cude KJ, 1999, J MOL MED, V77, P419, DOI 10.1007/s001090050372; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; FURR BJA, 1989, HORM RES, V32, P69, DOI 10.1159/000181315; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; Greer JJ, 2000, PEDIATR PULM, V29, P394, DOI 10.1002/(SICI)1099-0496(200005)29:5<394::AID-PPUL9>3.0.CO;2-2; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; HURT SSB, 1983, TOXICOLOGY, V29, P1; IMASAKI K, 1994, EUR J ENDOCRINOL, V130, P569, DOI 10.1530/eje.0.1300569; Jenster G, 1999, SEMIN ONCOL, V26, P407; KAIGHN ME, 1979, INVEST UROL, V17, P16; KAUFMANN SH, 1986, J BIOL CHEM, V261, P1962; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; Kelce WR, 1998, REPROD FERT DEVELOP, V10, P105, DOI 10.1071/R98051; Kelce WR, 1997, J MOL MED, V75, P198, DOI 10.1007/s001090050104; Kemppainen JA, 1996, UROLOGY, V48, P157, DOI 10.1016/S0090-4295(96)00117-3; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Llopis J, 2000, P NATL ACAD SCI USA, V97, P4363, DOI 10.1073/pnas.97.8.4363; Losada A, 1999, PEDIATR SURG INT, V15, P188, DOI 10.1007/s003830050551; McPhaul MJ, 1999, J STEROID BIOCHEM, V69, P315, DOI 10.1016/S0960-0760(99)00050-3; MICKEY DD, 1977, CANCER RES, V37, P4049; NAKAO R, 1992, J CLIN ENDOCR METAB, V74, P1152, DOI 10.1210/jc.74.5.1152; NERI R, 1972, ENDOCRINOLOGY, V91, P427, DOI 10.1210/endo-91-2-427; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; PLYMATE SR, 1991, J STEROID BIOCHEM, V40, P833, DOI 10.1016/0960-0760(91)90309-S; Racz A, 1999, J BIOL CHEM, V274, P19352, DOI 10.1074/jbc.274.27.19352; Remboutsika E, 1999, J CELL SCI, V112, P1671; Scher HI, 1997, EUR UROL, V31, P3; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Tang YT, 1996, MOL CELL BIOL, V16, P1989; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; VANSTEENSEL B, 1995, J CELL SCI, V108, P3003; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; WONG CI, 1995, J BIOL CHEM, V270, P19998, DOI 10.1074/jbc.270.34.19998; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	41	116	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28395	28401		10.1074/jbc.M101755200	http://dx.doi.org/10.1074/jbc.M101755200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369770	hybrid			2022-12-27	WOS:000170093400087
J	Grewal, JS; Luttrell, LM; Raymond, JR				Grewal, JS; Luttrell, LM; Raymond, JR			G protein-coupled receptors desensitize and down-regulate epidermal growth factor receptors in renal mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGENIC SIGNAL TRANSDUCTION; TYROSINE KINASE-ACTIVITY; FLUID-PHASE ENDOCYTOSIS; SMOOTH-MUSCLE CELLS; EGF RECEPTOR; ANGIOTENSIN-II; BETA(2)-ADRENERGIC RECEPTOR; MEDIATED ENDOCYTOSIS; PHOSPHOLIPASE-C; PHORBOL ESTER	Different types of plasma membrane receptors engage in various forms of cross-talk. We used cultures of rat renal mesangial cells to study the regulation of EGF receptors (EGFRs) by various endogenous G protein-coupled receptors (GPCRs). GPCRs (5-hydroxytryptamine(2A) lysophosphatidic acid, angiotensin AT(1), bradykinin B-2) were shown to transactivate EGFRs through a protein kinase C-dependent pathway. This transactivation resulted in the initiation of multiple cellular signals (phosphorylation of the EGFRs and ERK and activation of cAMP-responsive element-binding protein (CREB), NF-kappaB, and E2F), as well as subsequent rapid down-regulation of cell-surface EGFRs and internalization and desensitization of the EGFRs without change in the total cellular complement of EGFRs. Internalization of the EGFRs and the down-regulation of cell-surface receptors in mesangial cells were blocked by pharmacological inhibitors of clathrin-mediated endocytosis and in HEK293 cells by transfection of cDNA constructs that encode dominant negative beta -arrestin-1 or dynamin. Whereas all of the effects of GPCRs on EGFRs were dependent to a great extent on protein kinase C, those initiated by EGF were not. These studies demonstrate that GPCRs can induce multiple signals through protein kinase C-dependent transactivation of EGFRs. Moreover, GPCRs induce profound desensitization of EGFRs by a process associated with the loss of cell-surface EGFRs through clathrin-mediated endocytosis.	Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA; Ralph H Johnson Vet Affairs Med Ctr, Med Specialty Serv, Charleston, SC 29401 USA; Duke Univ, Med Ctr, Div Endocrinol, Dept Med, Durham, NC 27710 USA; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27710 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Raymond, JR (corresponding author), Med Univ S Carolina, Dept Med, Div Nephrol, Rm 829,Clin Sci Bldg,171 Ashley Ave, Charleston, SC 29425 USA.	raymondj@musc.edu		Luttrell, Louis/0000-0003-2805-6949	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK055524, R01DK055524, R01DK052448, R56DK052448, R01DK054720] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52448, DK55524, DK54720] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Arimura S, 1998, LIFE SCI, V63, P1563, DOI 10.1016/S0024-3205(98)00423-8; Baker VL, 1998, PLACENTA, V19, P475, DOI 10.1016/S0143-4004(98)91040-2; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BOWEN S, 1991, J BIOL CHEM, V266, P1162; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Choudhury GG, 1999, BIOCHEM BIOPH RES CO, V258, P490, DOI 10.1006/bbrc.1999.0599; Dajani OF, 1999, J CELL PHYSIOL, V180, P203, DOI 10.1002/(SICI)1097-4652(199908)180:2<203::AID-JCP8>3.3.CO;2-K; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; El-Dahr SS, 1998, AM J PHYSIOL-RENAL, V275, pF343, DOI 10.1152/ajprenal.1998.275.3.F343; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FLOEGE J, 1993, KIDNEY INT, V43, pS47; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Gaits F, 1997, KIDNEY INT, V51, P1022, DOI 10.1038/ki.1997.143; GANZ MB, 1994, AM J PHYSIOL, V266, pF576, DOI 10.1152/ajprenal.1994.266.4.F576; Garnovskaya MN, 1998, BIOCHEM J, V330, P489; Goppelt-Struebe M, 2000, BIOCHEM J, V345, P217, DOI 10.1042/0264-6021:3450217; GRAY GM, 1989, J CELL BIOCHEM, V40, P271, DOI 10.1002/jcb.240400303; Grewal JS, 1996, FEBS LETT, V383, P267, DOI 10.1016/0014-5793(96)00247-5; Grewal JS, 1999, AM J PHYSIOL-RENAL, V276, pF922, DOI 10.1152/ajprenal.1999.276.6.F922; Gulliford T, 1999, CELL SIGNAL, V11, P245, DOI 10.1016/S0898-6568(98)00058-8; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; HARADA H, 1993, AM J PHYSIOL, V264, pC956, DOI 10.1152/ajpcell.1993.264.4.C956; HAZAN R, 1995, J CELL PHYSIOL, V162, P74, DOI 10.1002/jcp.1041620110; HENIS YI, 1981, EXP CELL RES, V136, P189, DOI 10.1016/0014-4827(81)90050-1; HOFFMAN BL, 1993, J CELL PHYSIOL, V157, P535, DOI 10.1002/jcp.1041570313; HSUAN JJ, 1908, PROG GROWTH FACTOR R, V1, P23; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jaffa AA, 1997, AM J PHYSIOL-RENAL, V273, pF916, DOI 10.1152/ajprenal.1997.273.6.F916; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; KAJI H, 1988, J BIOL CHEM, V263, P13588; Kallal L, 2000, TRENDS PHARMACOL SCI, V21, P175, DOI 10.1016/S0165-6147(00)01477-2; KAPLOWITZ PB, 1988, J CELL PHYSIOL, V136, P13, DOI 10.1002/jcp.1041360103; Kasho M, 1998, KIDNEY INT, V54, P1083, DOI 10.1046/j.1523-1755.1998.00114.x; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; KramerGuth A, 1997, AM J PHYSIOL-CELL PH, V273, pC1409, DOI 10.1152/ajpcell.1997.273.4.C1409; Lamm MLG, 1999, ENDOCRINOLOGY, V140, P29, DOI 10.1210/en.140.1.29; LANGGUT W, 1995, FEBS LETT, V372, P173, DOI 10.1016/0014-5793(95)00971-B; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Lee CSL, 1996, J STEROID BIOCHEM, V58, P267, DOI 10.1016/0960-0760(96)00039-8; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Liebmann C, 1996, J BIOL CHEM, V271, P31098, DOI 10.1074/jbc.271.49.31098; LUND KA, 1990, J BIOL CHEM, V265, P20517; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Moriguchi Y, 1999, CIRC RES, V84, P1073, DOI 10.1161/01.RES.84.9.1073; MORRISON P, 1993, J BIOL CHEM, V268, P15536; Morrison P, 1996, J BIOL CHEM, V271, P12891, DOI 10.1074/jbc.271.22.12891; MOSS AL, 1991, J CELL PHYSIOL, V149, P319, DOI 10.1002/jcp.1041490220; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; NEBIGIL CG, 1995, AM J PHYSIOL-RENAL, V268, pF122, DOI 10.1152/ajprenal.1995.268.1.F122; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PHONPHOK Y, 1991, FEBS LETT, V281, P188, DOI 10.1016/0014-5793(91)80390-O; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Piiper A, 1997, AM J PHYSIOL-GASTR L, V272, pG1276, DOI 10.1152/ajpgi.1997.272.5.G1276; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAMIREZ I, 1995, CELL SIGNAL, V7, P303, DOI 10.1016/0898-6568(95)00001-6; Ranieri E, 1996, KIDNEY INT, V50, P1990, DOI 10.1038/ki.1996.521; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; RUPPRECHT HD, 1992, AM J PHYSIOL, V263, pF623, DOI 10.1152/ajprenal.1992.263.4.F623; SCHLONDORFF D, 1987, AM J PHYSIOL, V253, pC113, DOI 10.1152/ajpcell.1987.253.1.C113; SEEDORF K, 1995, J BIOL CHEM, V270, P18953, DOI 10.1074/jbc.270.32.18953; SERRERO G, 1995, BIOCHEM BIOPH RES CO, V212, P1125, DOI 10.1006/bbrc.1995.2085; Takata Y, 1996, BBA-MOL CELL RES, V1312, P68, DOI 10.1016/0167-4889(96)00017-1; Takemura T, 1999, J PATHOL, V189, P431; TAKUWA N, 1989, AM J PHYSIOL, V257, pF431, DOI 10.1152/ajprenal.1989.257.3.F431; Tang H, 2000, J BIOL CHEM, V275, P13420, DOI 10.1074/jbc.275.18.13420; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VERHEIJDEN GF, 1990, BIOCHEM J, V271, P215, DOI 10.1042/bj2710215; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	81	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27335	27344		10.1074/jbc.M103578200	http://dx.doi.org/10.1074/jbc.M103578200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11371570	hybrid			2022-12-27	WOS:000169966900081
J	Matza, D; Wolstein, O; Dikstein, R; Shachar, I				Matza, D; Wolstein, O; Dikstein, R; Shachar, I			Invariant chain induces B cell maturation by activating a TAF(II)105-NF-kappa B-dependent transcription program	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HEAT-STABLE ANTIGEN(HI); PHOSPHORYLATION; EXPRESSION; TAF(II)105; PROTEINS; MARROW; MOUSE; GENES; P65	Early stages of B cell development occur in the bone marrow, resulting in formation of immature B cells. From there these immature cells migrate to the spleen where they differentiate to mature cells. This final maturation step is crucial for the B cells to become responsive to antigens and to participate in the immune response. Recently, invariant chain (Ii), a major histocompatibility complex class II chaperone, as well as the transcription factors c-Rel and 65/RelA, were found to play a role in the final antigen-independent differentiation stage of B cells in the spleen. In this study, we investigated a possible link between Ii-dependent B cell maturation and the NF-kappaB pathway, Our studies indicate that Ii-induced B cell maturation involves activation of transcription mediated by the NF-kappaB p65/RelA homodimer and requires the B cell-enriched coactivator TBP-associated factor (II)105.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, Martha S Sagon Career Dev Chair, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, Alvin & Gertruder Levine Career Dev Chair Canc Re, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science	Shachar, I (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	shachar@weizmann.ac.il						ALLMAN DM, 1992, J IMMUNOL, V149, P2533; ALLMAN DM, 1993, J IMMUNOL, V151, P4431; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bendall HH, 1999, MOL IMMUNOL, V36, P187, DOI 10.1016/S0161-5890(99)00031-0; BOEKEL ET, 1995, INT IMMUNOL, V7, P1013; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; EHLICH A, 1994, CURR BIOL, V4, P573, DOI 10.1016/S0960-9822(00)00129-9; ELLIOTT EA, 1994, J EXP MED, V179, P681, DOI 10.1084/jem.179.2.681; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Henderson A, 1998, ANNU REV IMMUNOL, V16, P163, DOI 10.1146/annurev.immunol.16.1.163; Kenty G, 1998, J IMMUNOL, V160, P606; Kenty G, 1999, J IMMUNOL, V163, P232; MCMAHON SB, 1995, J IMMUNOL METHODS, V179, P251, DOI 10.1016/0022-1759(94)00292-5; RAJEWSKY K, 1993, IMMUNOL TODAY, V14, P40, DOI 10.1016/0167-5699(93)90324-E; Rolink AG, 1998, EUR J IMMUNOL, V28, P3738, DOI 10.1002/(SICI)1521-4141(199811)28:11<3738::AID-IMMU3738>3.0.CO;2-Q; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHACHAR I, 1995, IMMUNITY, V3, P373, DOI 10.1016/1074-7613(95)90121-3; Shachar I, 1996, SCIENCE, V274, P106, DOI 10.1126/science.274.5284.106; Thomas-Vaslin V, 1989, Int Immunol, V1, P237, DOI 10.1093/intimm/1.3.237; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	27	88	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27203	27206		10.1074/jbc.M104684200	http://dx.doi.org/10.1074/jbc.M104684200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11371575	hybrid			2022-12-27	WOS:000169966900064
J	Mou, HM; Cote, RH				Mou, HM; Cote, RH			The catalytic and GAF domains of the rod cGMP phosphodiesterase (PDE6) heterodimer are regulated by distinct regions of its inhibitory gamma subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; TRANSDUCIN ALPHA-SUBUNIT; SITE-DIRECTED MUTAGENESIS; DEPENDENT PROTEIN-KINASE; PHOTORECEPTOR G-PROTEIN; BINDING-SITES; OUTER SEGMENTS; RETINAL RODS; NUCLEOTIDE PHOSPHODIESTERASE; TARGET ENZYME	The central effector of visual transduction in retinal rod photoreceptors, cGMP phosphodiesterase (PDE6), is a catalytic heterodimer (alpha beta) to which low molecular weight inhibitory gamma subunits bind to form the nonactivated PDE holoenzyme (alpha beta gamma (2)). Although it is known that gamma binds tightly to alpha beta, the binding affinity for each gamma subunit to alpha beta, the domains on gamma that interact with alpha beta, and the allosteric interactions between gamma and the regulatory and catalytic regions on alpha beta are not well understood. We show here that the gamma subunit binds to two distinct sites on the catalytic alpha beta dimer (K-D1 < 1 pM, K-D2 = 3 pM) when the regulatory GAF domains of bovine rod PDE6 are occupied by cGMP. Binding heterogeneity of <gamma> to alpha beta is absent when cAMP occupies the noncatalytic sites. Two major domains on gamma can interact independently with alpha beta with the N-terminal half of gamma binding with 50-fold greater affinity than its C-terminal, inhibitory region. The N-terminal half of gamma is responsible for the positive cooperativity between gamma and cGMP binding sites on alpha beta but has no effect on catalytic activity. Using synthetic peptides, we identified regions of the amino acid sequence of gamma that bind to alpha beta, restore high affinity cGMP binding to low affinity noncatalytic sites, and retard cGMP exchange with both noncatalytic sites. Subunit heterogeneity, multiple sites of gamma interaction with alpha beta, and positive cooperativity of gamma with the GAF domains are all likely to contribute to precisely controlling the activation and inactivation kinetics of PDE6 during visual transduction in rod photoreceptors.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	Cote, RH (corresponding author), Univ New Hampshire, Dept Biochem & Mol Biol, 46 Coll Rd, Durham, NH 03824 USA.		Cote, Rick H/G-3363-2013	Cote, Rick H/0000-0002-1573-6526	NEI NIH HHS [EY-05798, R01 EY005798] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005798] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; Artemyev NO, 1998, METHODS, V14, P93, DOI 10.1006/meth.1997.0568; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; Berger AL, 1999, BIOCHEMISTRY-US, V38, P1293, DOI 10.1021/bi981683m; Bondarenko VA, 1997, J BIOL CHEM, V272, P15856, DOI 10.1074/jbc.272.25.15856; BOWNDS MD, 1995, BEHAV BRAIN SCI, V18, P415, DOI 10.1017/S0140525X00039170; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BRUCKERT F, 1994, BIOCHEMISTRY-US, V33, P12625, DOI 10.1021/bi00208a013; BURNS F, 1992, BIOCHEM J, V283, P487, DOI 10.1042/bj2830487; Calvert PD, 1998, J GEN PHYSIOL, V111, P39, DOI 10.1085/jgp.111.1.39; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLERC A, 1992, J BIOL CHEM, V267, P6620; Conti M, 2000, MOL ENDOCRINOL, V14, P1317, DOI 10.1210/me.14.9.1317; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; COTE RH, 1993, J BIOL CHEM, V268, P17190; Cote RH, 2000, METHOD ENZYMOL, V315, P646; D'Amours MR, 1999, BIOCHEM J, V340, P863, DOI 10.1042/0264-6021:3400863; Dryja TP, 1999, INVEST OPHTH VIS SCI, V40, P1859; GAL A, 1994, NAT GENET, V7, P64, DOI 10.1038/ng0594-64; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; Granovsky AE, 1997, J BIOL CHEM, V272, P11686, DOI 10.1074/jbc.272.18.11686; Granovsky AE, 2000, J BIOL CHEM, V275, P41258, DOI 10.1074/jbc.M008094200; HAMILTON SE, 1993, FEBS LETT, V318, P157, DOI 10.1016/0014-5793(93)80012-J; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hebert MC, 1998, J BIOL CHEM, V273, P5557, DOI 10.1074/jbc.273.10.5557; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; LIPKIN VM, 1993, BIOCHIM BIOPHYS ACTA, V1176, P250, DOI 10.1016/0167-4889(93)90052-Q; Malinski JA, 1996, J BIOL CHEM, V271, P12919, DOI 10.1074/jbc.271.22.12919; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; Matsuura I, 2000, J BIOL CHEM, V275, P32950, DOI 10.1074/jbc.M000702200; Melia TJ, 2000, J BIOL CHEM, V275, P3535, DOI 10.1074/jbc.275.5.3535; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; Natochin M, 1996, J BIOL CHEM, V271, P19964, DOI 10.1074/jbc.271.33.19964; Norton AW, 2000, J BIOL CHEM, V275, P38611, DOI 10.1074/jbc.M004606200; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; PFISTER C, 1993, CELL SIGNAL, V5, P235, DOI 10.1016/0898-6568(93)90015-E; PIRIEV NI, 1993, P NATL ACAD SCI USA, V90, P9340, DOI 10.1073/pnas.90.20.9340; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; QIN N, 1994, J BIOL CHEM, V269, P3265; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; Tsang SH, 1996, SCIENCE, V272, P1026, DOI 10.1126/science.272.5264.1026; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; Xu LX, 1998, BIOCHEMISTRY-US, V37, P6205, DOI 10.1021/bi973087i; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; YAMAMOTO T, 1983, J BIOL CHEM, V258, P2526; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495; Yamazaki A, 1996, BIOCHEM BIOPH RES CO, V222, P488, DOI 10.1006/bbrc.1996.0771	59	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27527	27534		10.1074/jbc.M103316200	http://dx.doi.org/10.1074/jbc.M103316200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375400	hybrid			2022-12-27	WOS:000169966900104
J	Tang, L; Ammann, R; Gao, T; Gomer, RH				Tang, L; Ammann, R; Gao, T; Gomer, RH			A cell number-counting factor regulates group size in Dictyostelium by differentially modulating cAMP-induced cAMP and cGMP pulse sizes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-MEDIATED ACTIVATION; SIGNAL-TRANSDUCTION; ADENYLYL-CYCLASE; CYTOSOLIC REGULATOR; GUANINE-NUCLEOTIDES; CHEMOATTRACTANT RECEPTOR; GENE-EXPRESSION; DISCOIDEUM; MUTANTS; CHEMOTAXIS	A secreted counting factor (CF), regulates the size of Dictyostelium discoideum fruiting bodies in part by regulating cell-cell adhesion. Aggregation and the expression of adhesion molecules are mediated by relayed pulses of cAMP. Cells also respond to cAMP with a short cGMP pulse. We find that CF slowly down-regulates the cAMP-induced cGMP pulse by inhibiting guanylyl cyclase activity. A 1-min exposure of cells to purified CF increases the cAMP-induced cAMP pulse. CF does not affect the cAMP receptor or its interaction with its associated G proteins or the translocation of the cytosolic regulator of adenylyl cyclase to the membrane in response to cAMP. Pulsing streaming wild-type cells with a high concentration of cAMP results in the formation of small groups, whereas reducing cAMP pulse size with exogenous cAMP phosphodiesterase during stream formation causes cells to form large groups. Altering the extracellular cAMP pulse size does not phenocopy the effects of CF on the cAMP-induced cGMP pulse size or cell-cell adhesion, indicating that CF does not regulate cGMP pulses and adhesion via CF's effects on cAMP pulses. The results suggest that regulating cell-cell adhesion, the cGMP pulse size, or the cAMP pulse size can control group size and that CF regulates all three of these independently.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, Howard Hughes Med Inst, Houston, TX 77005 USA	Rice University; Howard Hughes Medical Institute; Rice University	Gomer, RH (corresponding author), Rice Univ, Dept Biochem & Cell Biol, MS-140,6100 S Main St, Houston, TX 77005 USA.			Gomer, Richard/0000-0003-2361-4307				BONNER JT, 1963, J EMBRYOL EXP MORPH, V11, P571; BONNER JT, 1969, DEV BIOL, V20, P72, DOI 10.1016/0012-1606(69)90005-0; Brazill DT, 1997, FEBS LETT, V404, P100, DOI 10.1016/S0014-5793(97)00104-X; Brazill DT, 1998, J BIOL CHEM, V273, P8161, DOI 10.1074/jbc.273.14.8161; Brock DA, 1996, DEVELOPMENT, V122, P2569; Brock DA, 1999, GENE DEV, V13, P1960, DOI 10.1101/gad.13.15.1960; Chen MY, 1997, GENE DEV, V11, P3218, DOI 10.1101/gad.11.23.3218; Chen MY, 1996, TRENDS GENET, V12, P52, DOI 10.1016/0168-9525(96)81400-4; COUKELL MB, 1984, DEV BIOL, V103, P246, DOI 10.1016/0012-1606(84)90026-5; COUKELL MB, 1986, DEV GENET, V6, P163; Deery WJ, 1999, J BIOL CHEM, V274, P34476, DOI 10.1074/jbc.274.48.34476; FAURE M, 1988, P NATL ACAD SCI USA, V85, P8076, DOI 10.1073/pnas.85.21.8076; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; Firtel RA, 2000, CURR OPIN GENET DEV, V10, P421, DOI 10.1016/S0959-437X(00)00107-6; Gerisch G, 1968, Curr Top Dev Biol, V3, P157; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMER RH, 1991, DEVELOPMENT, V112, P269; Gomer RH, 2001, NAT REV MOL CELL BIO, V2, P48, DOI 10.1038/35048058; HARWOOD AJ, 1992, DEV BIOL, V149, P90, DOI 10.1016/0012-1606(92)90266-J; HOHL HR, 1964, DEV BIOL, V9, P137, DOI 10.1016/0012-1606(64)90018-1; INSALL R, 1994, J CELL BIOL, V126, P1537, DOI 10.1083/jcb.126.6.1537; JAIN R, 1992, GENE DEV, V6, P390, DOI 10.1101/gad.6.3.390; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; KESBEKE F, 1988, DEV BIOL, V130, P464, DOI 10.1016/0012-1606(88)90342-9; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUWAYAMA H, 1993, J CELL BIOL, V123, P1453, DOI 10.1083/jcb.123.6.1453; Lee S, 1999, MOL BIOL CELL, V10, P2829, DOI 10.1091/mbc.10.9.2829; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LILLY PJ, 1994, J BIOL CHEM, V269, P14123; Loomis WF., 1975, DICTYOSTELIUM DISCOI; Ma H, 1997, EMBO J, V16, P4317, DOI 10.1093/emboj/16.14.4317; MAEDA R, 1997, FRONTIERS SCI SERIES, V21; Mann SKO, 1997, DEV BIOL, V183, P208, DOI 10.1006/dbio.1996.8499; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; NEWELL PC, 1992, BIOESSAYS, V14, P473, DOI 10.1002/bies.950140708; NEWELL PC, 1988, J CELL SCI, V89, P123; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; PETERS DJM, 1991, DEV GENET, V12, P25, DOI 10.1002/dvg.1020120107; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; RIEDEL V, 1973, J MOL BIOL, V74, P573, DOI 10.1016/0022-2836(73)90048-X; Roisin-Bouffay C, 2000, MOL CELL, V6, P953, DOI 10.1016/S1097-2765(05)00082-1; ROSS FM, 1981, J GEN MICROBIOL, V127, P339; SHAFFER BM, 1957, Q J MICROSC SCI, V98, P393; SNAARJAGALSKA BE, 1988, J CELL SCI, V91, P287; SNAARJAGALSKA BE, 1994, METHOD ENZYMOL, V237, P387; Spann TP, 1996, P NATL ACAD SCI USA, V93, P5003, DOI 10.1073/pnas.93.10.5003; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; SUSSMAN RR, 1953, ANN NY ACAD SCI, V56, P949, DOI 10.1111/j.1749-6632.1953.tb30274.x; THADANI V, 1977, EXP CELL RES, V108, P75, DOI 10.1016/S0014-4827(77)80011-6; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; vanHaastert PJM, 1997, FEBS LETT, V410, P25, DOI 10.1016/S0014-5793(97)00416-X; VANHAASTERT PJM, 1989, BIOCHEM J, V258, P577, DOI 10.1042/bj2580577; VANHAASTERT PJM, 1982, MOL CELL ENDOCRINOL, V25, P171, DOI 10.1016/0303-7207(82)90050-8; VANHAASTERT PJM, 1987, EUR J BIOCHEM, V162, P251; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; Wang B, 1999, DEV BIOL, V208, P1, DOI 10.1006/dbio.1998.9193; WU L, 1995, DEV BIOL, V171, P149, DOI 10.1006/dbio.1995.1267	60	34	35	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27663	27669		10.1074/jbc.M102205200	http://dx.doi.org/10.1074/jbc.M102205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11371560	hybrid			2022-12-27	WOS:000169966900122
J	Dunn, R; Hicke, L				Dunn, R; Hicke, L			Multiple roles for Rsp5p-dependent ubiquitination at the internalization step of endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; LIGAND-INDUCED INTERNALIZATION; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; ALPHA-FACTOR; WW DOMAINS; DEUBIQUITINATING ENZYME; MULTIUBIQUITIN CHAIN; TRANSCRIPTION FACTOR; PHEROMONE RECEPTOR	Ubiquitination of integral plasma membrane proteins triggers their rapid internalization into the endocytic pathway. The yeast ubiquitin ligase Rsp5p, a homologue of mammalian Nedd4 and Itch, is required for the ubiquitination and subsequent internalization of multiple plasma membrane proteins, including the cu-factor receptor (Ste2p), Here we demonstrate that Rsp5p plays multiple roles at the internalization step of endocytosis, Temperature-sensitive rsp5 mutant cells were defective in the internalization of a-factor by a Ste2p-ubiquitin chimera, a receptor that does not require post-translational ubiquitination, Similarly, a modified version of Ste2p bearing a NPFXD linear peptide sequence as its only internalization signal was not internalized in rsp5 cells, Internalization of these variant receptors was dependent on the catalytic cysteine residue of Rsp5p and on ubiquitin-conjugating enzymes that bind Rsp5p, Thus, a Rsp5p-dependent ubiquitination event is required for internalization mediated by ubiquitin-dependent and -independent endocytosis signals, Constitutive Ste2p-ubiquitin internalization and fluid-phase endocytosis also required active ubiquitination machinery, including Rsp5p, These observations indicate that Rsp5p-dependent ubiquitination of a transacting protein component of the endocytosis machinery is required for the internalization step of endocytosis.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Hicke, L (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	l-hicke@northwestern.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 53257] Funding Source: Medline; NIGMS NIH HHS [T32GM08061] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Chang A, 2000, J BIOL CHEM, V275, P20562, DOI 10.1074/jbc.M002479200; CHANG A, 1995, J CELL BIOL, V128, P39, DOI 10.1083/jcb.128.1.39; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; D'Hondt K, 2000, ANNU REV GENET, V34, P255, DOI 10.1146/annurev.genet.34.1.255; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DULIC V, 1991, METHOD ENZYMOL, V194, P697; Dunn R, 2001, MOL BIOL CELL, V12, P421, DOI 10.1091/mbc.12.2.421; Gajewska B, 2001, GENETICS, V157, P91; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Horak J, 2001, J BACTERIOL, V183, P3083, DOI 10.1128/JB.183.10.3083-3088.2001; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lucero P, 2000, J BACTERIOL, V182, P241, DOI 10.1128/JB.182.1.241-243.2000; Medintz I, 1998, J BIOL CHEM, V273, P34454, DOI 10.1074/jbc.273.51.34454; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; NICKEL BE, 1989, BIOCHEMISTRY-US, V28, P958, DOI 10.1021/bi00429a006; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Springael JY, 1999, BIOCHEM BIOPH RES CO, V257, P561, DOI 10.1006/bbrc.1999.0505; Springael JY, 1999, J CELL SCI, V112, P1375; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Strous GJ, 1999, J CELL SCI, V112, P1417; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Tan PK, 1996, J CELL BIOL, V135, P1789, DOI 10.1083/jcb.135.6.1789; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; Wang GL, 1999, MOL CELL BIOL, V19, P342; Wang GL, 2001, MOL CELL BIOL, V21, P3564, DOI 10.1128/MCB.21.10.3564-3575.2001; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Zoladek T, 1997, GENETICS, V145, P595	63	122	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25974	25981		10.1074/jbc.M104113200	http://dx.doi.org/10.1074/jbc.M104113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11356856	hybrid			2022-12-27	WOS:000169823300046
J	Overmeyer, JH; Wilson, AL; Maltese, WA				Overmeyer, JH; Wilson, AL; Maltese, WA			Membrane targeting of a Rab GTPase that fails to associate with Rab escort protein (REP) or guanine nucleotide dissociation inhibitor (GDI)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY LIPOPROTEIN RECEPTOR; ENDOPLASMIC-RETICULUM; GERANYLGERANYL TRANSFERASE; POSTTRANSLATIONAL MODIFICATION; VESICULAR TRANSPORT; GOLGI COMPARTMENTS; IN-VITRO; BINDING; COMPLEX; FUSION	The targeting of various Rab proteins to different subcellular compartments appears to be determined by variable amino acid sequences located upstream from geranylgeranylated cysteine residues in the C-terminal tail. All nascent Rab proteins are prenylated by geranylgeranyltransferase II, which recognizes the Rab substrate only when it is bound to Rab escort protein (REP), After prenylation, REP remains associated with the modified Rab until it is delivered to the appropriate subcellular membrane. It remains unclear whether docking of the Rab with the correct membrane is solely a function of features contained within the prenylated Rab itself (with REP serving as a "passive" carrier) or whether REP actively participates in the targeting process. To address this issue, we took advantage of a mutation in the alpha2 helix of Rab1B (i.e. Y78D) that abolishes REP and GDI interaction without disrupting nucleotide binding or hydrolysis. These studies demonstrate that replacing the C-terminal GGCC residues of Rab1B(Y78D) with a CLLL motif permits this protein to be prenylated by geranylgeranyltransferase I but not II both in cell-free enzyme assays and in transfected cells. Subcellular fractionation and immunofluorescence studies reveal that the prenylated Rab1B(Y78D)CLLL, which remains deficient in REP and GDI association is, nonetheless, delivered to the Golgi and endoplasmic reticulum (ER) membranes. When the dominant-negative S22N mutation was inserted into Rab1B-CLLL, the resulting monoprenylated construct suppressed ER --> Golgi protein transport. However, when the Y78D mutation was added to the latter construct, its inhibitory effect on protein trafficking was lost despite the fact that it was localized to the ER/Golgi membrane. Therefore, protein interactions mediated by the alpha2 helical domain of Rab1B(S22N) appear to be essential for its functional interaction with components of the ER --> Golgi transport machinery.	Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University	Maltese, WA (corresponding author), Med Coll Ohio, Dept Biochem & Mol Biol, 3035 Arlington Ave, Toledo, OH 43614 USA.				NATIONAL CANCER INSTITUTE [R01CA034569] Funding Source: NIH RePORTER; NCI NIH HHS [CA34569] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; Alexandrov K, 1999, EUR J BIOCHEM, V265, P160, DOI 10.1046/j.1432-1327.1999.00699.x; Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ANTONY C, 1992, J CELL SCI, V103, P785; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CASTELLANO FC, 1995, J RECEPT SIGNAL TR R, V5, P847; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Danilczyk UG, 2000, J BIOL CHEM, V275, P13089, DOI 10.1074/jbc.275.17.13089; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; Erdman RA, 2000, J BIOL CHEM, V275, P3848, DOI 10.1074/jbc.275.6.3848; JANG GF, 1993, BIOCHEMISTRY-US, V32, P9500, DOI 10.1021/bi00087a031; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; Miaczynska M, 1997, J BIOL CHEM, V272, P16972, DOI 10.1074/jbc.272.27.16972; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MUSHA T, 1992, J BIOL CHEM, V267, P9821; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NEWMAN CMH, 1992, J BIOL CHEM, V267, P11329; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OVERMEYER JH, 1992, J BIOL CHEM, V267, P22686; Overmeyer JH, 1998, MOL BIOL CELL, V9, P223, DOI 10.1091/mbc.9.1.223; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SARASTE J, 1995, J CELL SCI, V108, P1541; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Shen F, 1996, J BIOL CHEM, V271, P3692; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TOLLESHAUG H, 1982, CELL, V30, P715, DOI 10.1016/0092-8674(82)90276-8; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; Vogt A, 1996, ONCOGENE, V13, P1991; WEI C, 1992, ONCOGENE, V7, P467; Wilson AL, 1996, J BIOL CHEM, V271, P10932, DOI 10.1074/jbc.271.18.10932; Wilson AL, 1996, BIOCHEM J, V318, P1007, DOI 10.1042/bj3181007; Wilson AL, 1998, BIOCHEM J, V333, P497, DOI 10.1042/bj3330497; Wu SK, 1998, J BIOL CHEM, V273, P26931, DOI 10.1074/jbc.273.41.26931	60	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20379	20386		10.1074/jbc.M101511200	http://dx.doi.org/10.1074/jbc.M101511200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11389151	hybrid			2022-12-27	WOS:000169135100096
J	Horswill, AR; Dudding, AR; Escalante-Semerena, JC				Horswill, AR; Dudding, AR; Escalante-Semerena, JC			Studies of propionate toxicity in Salmonella enterica identify 2-methylcitrate as a potent inhibitor of cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CITRATE SYNTHASE REACTION; CHAIN FATTY-ACIDS; ESCHERICHIA-COLI; METHYLCITRATE SYNTHASE; PRP LOCUS; TYPHIMURIUM; TRANSFORMATION; IDENTIFICATION; METABOLISM; MUTANTS	Salmonella enterica serovar Typhimurium LT2 showed increased sensitivity to propionate when the 2-methylcitric acid cycle was blocked. A derivative of a prpC mutant (which lacked 2-methylcitrate synthase activity) resistant to propionate was isolated, and the mutation responsible for the newly acquired resistance to propionate was mapped to the citrate synthase (gltA) gene. These results suggested that citrate synthase activity was the source of the increased sensitivity to propionate observed in the absence of the 2-methylcitric acid cycle. DNA sequencing of the wild-type and mutant gltA alleles revealed that the ATG start codon of the wild-type gene was converted to the rare GTG start codon in the revertant strain. This result suggested that lower levels of this enzyme were present in the mutant. Consistent with this change, cell-free extracts of the propionate-resistant strain contained 12-fold less citrate synthase activity. This was interpreted to mean that, in the wild-type strain, high levels of citrate synthase activity were the source of a toxic metabolite. In vitro experiments performed with homogeneous citrate synthase enzyme indicated that this enzyme was capable of synthesizing 2-methylcitrate from propionyl-CoA and oxaloacetate, This result lent further support to the in vivo data, which suggested that citrate synthase was the source of a toxic metabolite.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Escalante-Semerena, JC (corresponding author), Univ Wisconsin, Dept Bacteriol, 1550 Linden Dr, Madison, WI 53706 USA.	jcescala@facstaff.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062203] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062203, GM62203, GM08349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES EM, 1979, J HYG-CAMBRIDGE, V82, P263, DOI 10.1017/S0022172400025687; BEACH RL, 1977, J BIOL CHEM, V252, P2702; BERKOWIT.D, 1968, J BACTERIOL, V96, P215, DOI 10.1128/JB.96.1.215-220.1968; Blankenhorn D, 1999, J BACTERIOL, V181, P2209, DOI 10.1128/JB.181.7.2209-2216.1999; Bobik TA, 1999, J BACTERIOL, V181, P5967, DOI 10.1128/JB.181.19.5967-5975.1999; BOHNHOFF M, 1962, J INFECT DIS, V111, P117, DOI 10.1093/infdis/111.2.117; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDANGE S, 1977, ACTA CHEM SCAND B, V31, P628, DOI 10.3891/acta.chem.scand.31b-0628; BRANDANGE S, 1984, ACTA CHEM SCAND B, V38, P695, DOI 10.3891/acta.chem.scand.38b-0695; Brock M, 2000, MOL MICROBIOL, V35, P961, DOI 10.1046/j.1365-2958.2000.01737.x; BYRNE BM, 1979, INFECT IMMUN, V23, P559, DOI 10.1128/IAI.23.3.559-563.1979; CHAN RK, 1972, VIROLOGY, V50, P883, DOI 10.1016/0042-6822(72)90442-4; CHANG KH, 1992, BIOCHEMISTRY-US, V31, P5605, DOI 10.1021/bi00139a025; CHEEMADHADLI S, 1975, PEDIATR RES, V9, P905, DOI 10.1203/00006450-197512000-00008; CHERRINGTON CA, 1991, ADV MICROB PHYSIOL, V32, P87; Clark D. P., 1996, ESCHERICHIA COLI SAL, P343; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; DAVIS RW, 1980, MANUAL GENETIC ENG A, P78; DAWSON RMC, 1986, DATA BIOCH RES, P388; EnosBerlage JL, 1997, J BACTERIOL, V179, P3989, DOI 10.1128/jb.179.12.3989-3996.1997; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hammelman TA, 1996, FEMS MICROBIOL LETT, V137, P233; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARTZ D, 1991, J MOL BIOL, V218, P83, DOI 10.1016/0022-2836(91)90875-7; Hesslinger C, 1998, MOL MICROBIOL, V27, P477, DOI 10.1046/j.1365-2958.1998.00696.x; Hinton A, 1996, J APPL BACTERIOL, V81, P188, DOI 10.1111/j.1365-2672.1996.tb04498.x; Horswill AR, 1999, J BACTERIOL, V181, P5615, DOI 10.1128/JB.181.18.5615-5623.1999; Horswill AR, 1999, MICROBIOL-UK, V145, P1381, DOI 10.1099/13500872-145-6-1381; Horswill AR, 1997, J BACTERIOL, V179, P928, DOI 10.1128/jb.179.3.928-940.1997; HUME ME, 1993, AVIAN DIS, V37, P1051, DOI 10.2307/1591912; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; KABARA JJ, 1991, FOOD PRESERVATIVES, P45; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSHMI TM, 1976, J BACTERIOL, V127, P76, DOI 10.1128/JB.127.1.76-83.1976; LUCK E, 1997, ANTIMICROBIAL FOOD A, P145; Macfarlane GT, 1997, SCAND J GASTROENTERO, V32, P3, DOI 10.1080/00365521.1997.11720708; MAN WJ, 1995, BBA-PROTEIN STRUCT M, V1250, P69, DOI 10.1016/0167-4838(95)00044-U; MARUYAMA K, 1985, J BIOCHEM, V98, P819, DOI 10.1093/oxfordjournals.jbchem.a135340; Matlho G, 1997, AVIAN DIS, V41, P58, DOI 10.2307/1592443; MCHAN F, 1992, AVIAN DIS, V36, P139, DOI 10.2307/1591728; MEYNELL GG, 1963, BRIT J EXP PATHOL, V44, P197; MEYNELL GG, 1963, BRIT J EXP PATHOL, V44, P209; O'Toole GA, 1998, MOL MICROBIOL, V28, P449, DOI 10.1046/j.1365-2958.1998.00797.x; OBRADORS N, 1988, J BACTERIOL, V170, P2159, DOI 10.1128/jb.170.5.2159-2162.1988; PARKER JD, 1991, NUCLEIC ACIDS RES, V19, P3055, DOI 10.1093/nar/19.11.3055; RUSSELL JB, 1992, J APPL BACTERIOL, V73, P363, DOI 10.1111/j.1365-2672.1992.tb04990.x; RYU J, 1990, BIOTECHNIQUES, V8, P43; SALMOND CV, 1984, J GEN MICROBIOL, V130, P2845; SASSE J, 1991, CURRENT PROTOCOLS MO, V1, DOI DOI 10.6.1-10.6.8; SCHMIEGER H, 1973, MOL GEN GENET, V120, P181, DOI 10.1007/BF00267246; SCHMIEGER H, 1971, MOL GEN GENET, V110, P378, DOI 10.1007/BF00438281; Sealy-Lewis HM, 1998, MICROBIOL-UK, V144, P1895, DOI 10.1099/00221287-144-7-1895; SEIDMAN CG, 1997, CURRENT PROTOCOLS MO, V1; SRERE PA, 1963, ACTA CHEM SCAND, V17, P129, DOI 10.3891/acta.chem.scand.17s-0129; TABUCHI T, 1974, AGR BIOL CHEM TOKYO, V38, P1105, DOI 10.1080/00021369.1974.10861293; Textor S, 1997, ARCH MICROBIOL, V168, P428, DOI 10.1007/s002030050518; Thompson JL, 1997, BRIT POULTRY SCI, V38, P59, DOI 10.1080/00071669708417941; TSAI SP, 1989, J GEN MICROBIOL, V135, P2561; VANROOYEN JPG, 1994, J INHERIT METAB DIS, V17, P738, DOI 10.1007/BF00712017; VOYTAS D, 2000, CURRENT PROTOCOLS MO, V1; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; WEIDMAN SW, 1979, BIOCHEM J, V177, P169, DOI 10.1042/bj1770169	62	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19094	19101		10.1074/jbc.m100244200	http://dx.doi.org/10.1074/jbc.m100244200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376009	hybrid			2022-12-27	WOS:000169091000063
J	Nakamura, M; Nishida, W; Mori, S; Hiwada, K; Hayashi, K; Sobue, K				Nakamura, M; Nishida, W; Mori, S; Hiwada, K; Hayashi, K; Sobue, K			Transcriptional activation of beta-tropomyosin mediated by serum response factor and a novel barx homologue, Barx1b, in smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN GENE-TRANSCRIPTION; HOMEO BOX GENES; HOMEODOMAIN PROTEINS; MOLECULAR-CLONING; DEVELOPING HEART; CALDESMON GENE; EXPRESSION; SKELETAL; DROSOPHILA; MESODERM	Tropomyosin (TM) is a regulatory protein of actomyosin system. Muscle type-specific expression of TM isoforms is generated from different genes and by alternative splicing. beta -TM isoforms in chicken skeletal and smooth muscles are encoded by a single gene and transcribed from the same promoter. We previously reported a smooth muscle cell (SMC) phenotype-dependent change in beta -TM expression (Kashiwada, K., Nishida, W,, Hayashi, K,, Ozawa, K., Yamanaka, Y,, Saga, H,, Yamashita, T,, Tohyama, M,, Shimada, S,, Sate, K,, and Sobue, K, (1997) J. Biol. Chem. 272, 15396-15404), and identified beta -TM as an SMC-differentiation marker. Here, we characterized the transcriptional machinery of the beta -TM gene in SMCs. Promoter and gel mobility shift analyses revealed an obligatory role for serum response factor and its interaction with the CArG box sequence in the SMC-specific transcription of the beta -TM gene in differentiated SMCs, We further isolated a novel homologue of the Barx homeoprotein family, Barx1b, from chicken gizzard, Barx1b was exclusively localized to SMCs of the upper digestive organs and their attached arteries and to craniofacial structures. Serum response factor and Barx1b bound each other directly, coordinately transactivated the beta -TM gene in differentiated SMCs and heterologous cells, and formed a ternary complex with a CArG probe. Taken together, these results suggest that SRF and Barx1b are coordinately involved in the SMC-specific transcription of the beta -TM gene in the upper digestive organs and their attached arteries.	Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Neurosci D13, Suita, Osaka 5650871, Japan; Ehime Univ, Sch Med, Dept Internal Med 2, Matsuyama, Ehime 7910295, Japan	Osaka University; Ehime University	Sobue, K (corresponding author), Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Neurosci D13, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Nakamura, Mako/0000-0002-6129-7560				Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Barlow AJ, 1999, DEV DYNAM, V214, P291, DOI 10.1002/(SICI)1097-0177(199904)214:4<291::AID-AJA2>3.0.CO;2-E; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; BUCKINGHAM ME, 1985, ESSAYS BIOCHEM, V20, P77; Carson JA, 2000, J BIOL CHEM, V275, P39061, DOI 10.1074/jbc.M006532200; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DEJONG R, 1993, NUCLEIC ACIDS RES, V21, P4711, DOI 10.1093/nar/21.20.4711; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; FORRYSCHAUDIES S, 1990, J MOL BIOL, V211, P321, DOI 10.1016/0022-2836(90)90354-O; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; Gould DB, 2000, GENOMICS, V68, P336, DOI 10.1006/geno.2000.6307; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; Hayashi K, 1999, J CELL BIOL, V145, P727, DOI 10.1083/jcb.145.4.727; Herring BP, 1997, AM J PHYSIOL-CELL PH, V272, pC1394, DOI 10.1152/ajpcell.1997.272.4.C1394; HERRING BP, 2001, J BIOL CHEM     0129; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; Jones FS, 1997, P NATL ACAD SCI USA, V94, P2632, DOI 10.1073/pnas.94.6.2632; Kashiwada K, 1997, J BIOL CHEM, V272, P15396, DOI 10.1074/jbc.272.24.15396; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; LINTS TJ, 1993, DEVELOPMENT, V119, P419; Mack CP, 2000, CIRC RES, V86, P221, DOI 10.1161/01.RES.86.2.221; Mericskay M, 2000, DEV BIOL, V226, P192, DOI 10.1006/dbio.2000.9865; Miano JM, 2000, J BIOL CHEM, V275, P9814, DOI 10.1074/jbc.275.13.9814; Miano JM, 1996, P NATL ACAD SCI USA, V93, P900, DOI 10.1073/pnas.93.2.900; Momiyama T, 1998, BIOCHEM BIOPH RES CO, V242, P429, DOI 10.1006/bbrc.1997.7959; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Obata H, 1997, J BIOL CHEM, V272, P26643, DOI 10.1074/jbc.272.42.26643; ORKIN SH, 1992, BLOOD, V80, P575; PATEL CV, 1992, J BIOL CHEM, V267, P26085; Ranganayakulu G, 1998, DEVELOPMENT, V125, P3037; Saito T, 1998, DEV BIOL, V199, P216, DOI 10.1006/dbio.1998.8889; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Sciavolino PJ, 1997, DEV DYNAM, V209, P127, DOI 10.1002/(SICI)1097-0177(199705)209:1<127::AID-AJA12>3.0.CO;2-Z; SELLERS JR, 1985, CURR TOP CELL REGUL, V27, P51; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; SOBUE K, 1991, J BIOL CHEM, V266, P12115; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TISSIERSETA JP, 1995, MECH DEVELOP, V51, P3, DOI 10.1016/0925-4773(94)00343-L; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; TOUTANT M, 1994, NUCLEIC ACIDS RES, V22, P1838, DOI 10.1093/nar/22.10.1838; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tribioli C, 1997, MECH DEVELOP, V65, P145, DOI 10.1016/S0925-4773(97)00067-1; YANO H, 1995, J BIOL CHEM, V270, P23661, DOI 10.1074/jbc.270.40.23661; Zilberman A, 1998, CIRC RES, V82, P566, DOI 10.1161/01.RES.82.5.566	56	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18313	18320		10.1074/jbc.M101127200	http://dx.doi.org/10.1074/jbc.M101127200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359793	hybrid			2022-12-27	WOS:000168866500094
J	Drewett, V; Devitt, A; Saxton, J; Portman, N; Greaney, P; Cheong, N; Alnemri, TF; Alnemri, E; Shaw, PE				Drewett, V; Devitt, A; Saxton, J; Portman, N; Greaney, P; Cheong, N; Alnemri, TF; Alnemri, E; Shaw, PE			Serum response factor cleavage by caspases 3 and 7 linked to apoptosis in human BJAB cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; DNA-BINDING ACTIVITY; C-FOS PROMOTER; TERNARY COMPLEX-FORMATION; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; PHOSPHORYLATION SITES; MEDIATED ACTIVATION; FACTOR ELK-1; EXPRESSION	Apoptosis involves the cessation of cellular processes, the breakdown of intracellular organelles, and, finally, the nonphlogistic clearance of apoptotic cells from the body. Important for these events is a family of proteases, caspases, which are activated by a proteolytic cleavage cascade and drive apoptosis by targeting key proteins within the cell. Here, we demonstrate that serum response factor (SRF), a transcription factor essential for proliferative gene expression, is cleaved by caspases and that this cleavage occurs in proliferating murine fibroblasts and can be induced in the human B-cell line BJAB. We identify the two major sites at which SRF cleavage occurs as Asp(245) and Asp(254), the caspases responsible for the cleavage and generate a mutant of SRF resistant to cleavage in BJAB cells. Investigation of the physiological and functional significance of SRF cleavage reveals that it correlates with the loss of e-fos expression, whereby neither SRF cleavage fragment retains transcriptional activity. Moreover, the expression of a noncleavable SRF in BJAB cells suppresses apoptosis induced by Fas cross-linking. These results suggest that for apoptosis to proceed, the transcriptional events promoting cell survival and proliferation, in which SRF is involved, must first be inactivated.	Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	University of Nottingham; Jefferson University	Shaw, PE (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England.		Alnemri, Emad S/B-4526-2010	Devitt, Andrew/0000-0002-4651-6761; Portman, Neil/0000-0003-0248-0258; SHAW, Peter/0000-0002-2598-4283				AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cotter T.G., 1996, TECHNIQUES APOPTOSIS; Crouch DH, 1996, ONCOGENE, V12, P2689; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Drewett V, 2001, NUCLEIC ACIDS RES, V29, P479, DOI 10.1093/nar/29.2.479; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; GauthierRouviere C, 1996, MOL BIOL CELL, V7, P719, DOI 10.1091/mbc.7.5.719; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; King P, 1998, J BIOL CHEM, V273, P8699, DOI 10.1074/jbc.273.15.8699; Kortenjann M, 1995, CRIT REV ONCOGENESIS, V6, P99; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; Ravi R, 1998, CANCER RES, V58, P882; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHAW PE, 1994, FOS JUN FAMILIES TRA, P71; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Soulez M, 1996, MOL CELL BIOL, V16, P6065; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; ZHU H, 1994, J BIOL CHEM, V269, P3489	64	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33444	33451		10.1074/jbc.M103877200	http://dx.doi.org/10.1074/jbc.M103877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11387340	hybrid, Green Accepted			2022-12-27	WOS:000170910200022
J	Drake, MT; Traub, LM				Drake, MT; Traub, LM			Interaction of two structurally distinct sequence types with the clathrin terminal domain beta-propeller	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AP-3 ADAPTER COMPLEX; ARRESTIN/CLATHRIN INTERACTION; CRYSTAL-STRUCTURE; BINDING; AMPHIPHYSIN; COAT; IDENTIFICATION; LOCALIZATION; RECOGNITION; APPENDAGE	The amino-terminal domain of the clathrin heavy chain, which folds into a seven-bladed P-propeller, binds directly to several endocytic proteins via short sequences based on the consensus residues LLDLD. In addition to a single LLDLD-based, type I clathrin-binding sequence, both amphiphysin and epsin contain a second, distinct sequence that is also capable of binding to clathrin directly. Here, we analyzed these sequences, which we term type II sequences, and show that the (257)LMDLA sequence in rat epsin 1 appears to be a weak clathrin-binding variant of the sequence (PWDLW)-P-417 originally found in human amphiphysin Il. The structural features of the type II sequence required for association with clathrin are distinct from the LLDLD-based sequence. In the central segment of amphiphysin, the type I and type II sequences cooperate to effect optimal clathrin binding and the formation of sedimentable assemblies. Together, the data provide evidence for two interaction surfaces upon certain endocytic accessory proteins that could cooperate with other coat components to enhance clathrin bud formation at the cell surface.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Washington University (WUSTL)	Traub, LM (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S325 Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15261 USA.	traub+@pitt.edu		Traub, Linton/0000-0002-1303-0298	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053249] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07088] Funding Source: Medline; NIDDK NIH HHS [R01 DK53249] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; BECK KA, 1992, J CELL BIOL, V119, P787, DOI 10.1083/jcb.119.4.787; BECK KA, 1991, J BIOL CHEM, V266, P4437; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DORAY B, 2001, IN PRESS MOL BIOL CE, V12; Drake MT, 2000, MOL BIOL CELL, V11, P3723, DOI 10.1091/mbc.11.11.3723; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Greene B, 2000, TRAFFIC, V1, P69, DOI 10.1034/j.1600-0854.2000.010110.x; Hao WH, 1999, J BIOL CHEM, V274, P22785, DOI 10.1074/jbc.274.32.22785; HEUSER J, 1985, J ULTRA MOL STRUCT R, V92, P1, DOI 10.1016/0889-1605(85)90123-5; Huang KM, 1999, EMBO J, V18, P3897, DOI 10.1093/emboj/18.14.3897; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kay BK, 1999, PROTEIN SCI, V8, P435; KIRCHHAUSEN T, 1986, J ULTRA MOL STRUCT R, V94, P199, DOI 10.1016/0889-1605(86)90067-4; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; LIU SH, 1995, CELL, V83, P257, DOI 10.1016/0092-8674(95)90167-1; Morgan JR, 2000, J NEUROSCI, V20, P8667; Morgan JR, 1999, J NEUROSCI, V19, P10201; MURPHY JE, 1992, J BIOL CHEM, V267, P10850; Musacchio A, 1999, MOL CELL, V3, P761, DOI 10.1016/S1097-2765(01)80008-3; Nonet ML, 1999, MOL BIOL CELL, V10, P2343, DOI 10.1091/mbc.10.7.2343; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; Ramjaun AR, 1999, J BIOL CHEM, V274, P19785, DOI 10.1074/jbc.274.28.19785; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Riley LG, 1996, PROTEIN ENG, V9, P223, DOI 10.1093/protein/9.2.223; Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Slepnev VI, 2000, J BIOL CHEM, V275, P17583, DOI 10.1074/jbc.M910430199; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Ybe JA, 1999, NATURE, V399, P371, DOI 10.1038/20708; Yeung BG, 1999, MOL BIOL CELL, V10, P3643, DOI 10.1091/mbc.10.11.3643; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	54	59	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28700	28709		10.1074/jbc.M104226200	http://dx.doi.org/10.1074/jbc.M104226200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382783	hybrid			2022-12-27	WOS:000170346000010
J	Lee, S; Park, JB; Kim, JH; Kim, Y; Kim, JH; Shin, KJ; Lee, JS; Ha, SH; Suh, PG; Ryu, SH				Lee, S; Park, JB; Kim, JH; Kim, Y; Kim, JH; Shin, KJ; Lee, JS; Ha, SH; Suh, PG; Ryu, SH			Actin directly interacts with phospholipase D, inhibiting its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; STRESS FIBER FORMATION; PLASMA-MEMBRANE; REGULATED EXOCYTOSIS; DEPENDENT ACTIVATION; PHOSPHATIDIC-ACID; ALPHA-ACTININ; BINDING; CLONING	Mammalian phospholipase D (PLD) plays a key role in several signal transduction pathways and is involved in many diverse functions. To elucidate the complex molecular regulation of PLD, we investigated PLD-binding proteins obtained from rat brain extract. Here we report that a 43-kDa protein in the rat brain, beta -actin, acts as a major PLD2 direct-binding protein as revealed by peptide mass fingerprinting in combination with matrix-assisted laser desorption ionization time-of-flight mass spectrometry. We also determined that the region between amino acids 613 and 723 of PLD2 is required for the direct binding of beta -actin, using bacterially expressed glutathione S-transferase fusion proteins of PLD2 fragments. Intriguingly, purified beta -actin potently inhibited both phosphaticlylinositol-4,5-bisphosphate and oleate-dependent PLD2 activities in a concentration-dependent manner (IC50 = 5 nM). In a previous paper, we reported that alpha -actinin inhibited PLD2 activity in an interaction-dependent and an ADP-ribosylation factor 1 (ARF1)-reversible manner (Park, J. B., Kim, J. H., Kim, Y., Ha, S. H., Kim, J. H., Yoo, J.-S., Du, G., Frohman, M. A., Sub, P.-G., and Ryu, S. H. (2000) J. Biol. Chem. 275, 21295-21301). In vitro binding analyses showed that beta -actin could displace alpha -actinin binding to PLD2, demonstrating independent interaction between cytoskeletal proteins and PLD2. Furthermore, ARF1 could steer the PLD2 activity in a positive direction regardless of the inhibitory effect of beta -actin on PLD2. We also observed that beta -actin regulates PLD1 and PLD2 with similar binding and inhibitory potencies. Immunocytochemical. and co-immunoprecipitation studies demonstrated the in vivo interaction between the two PLD isozymes and actin in cells. Taken together, these results suggest that the regulation of PLD by cytoskeletal proteins, beta -actin and a-actinin, and ARF1 may play an important role in cytoskeleton-related PLD functions.	Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH)	Kim, Y (corresponding author), Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea.	sungho@postech.ac.kr	Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048; Kim, Yong/0000-0002-1387-2962; Kim, Jung Hwan/0000-0001-8548-4435				Banno Y, 1999, J BIOL CHEM, V274, P27385, DOI 10.1074/jbc.274.39.27385; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY D, 1976, J MOL BIOL, V105, P527, DOI 10.1016/0022-2836(76)90233-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; DANNIEL LW, 1999, BIOCHIM BIOPHYS ACTA, V1439, P265; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; FROHMAN MA, 1999, BIOCHIM BIOPHYS ACTA, V30, P175; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; HA KS, 1994, BIOCHEM J, V303, P55, DOI 10.1042/bj3030055; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Han JS, 1998, BIOCHEM MOL BIOL INT, V45, P1089; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; Hodgkin MN, 1999, BIOCHEM J, V339, P87, DOI 10.1042/0264-6021:3390087; Hodgkin MN, 2000, CURR BIOL, V10, P43, DOI 10.1016/S0960-9822(99)00264-X; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Iyer SS, 1999, J BIOL CHEM, V274, P2350, DOI 10.1074/jbc.274.4.2350; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; JOHN RG, 1992, J BIOL CHEM, V257, P9781; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; Kim JH, 1999, FEBS LETT, V454, P42, DOI 10.1016/S0014-5793(99)00745-0; Kim JH, 1998, FEBS LETT, V430, P231, DOI 10.1016/S0014-5793(98)00661-9; Kim JH, 1999, J IMMUNOL, V163, P5462; Kim Y, 1999, BBA-MOL CELL BIOL L, V1436, P319, DOI 10.1016/S0005-2760(98)00120-9; Kim Y, 2000, J BIOL CHEM, V275, P13621, DOI 10.1074/jbc.275.18.13621; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; LEBART MC, 1990, BIOCHEM BIOPH RES CO, V173, P120, DOI 10.1016/S0006-291X(05)81030-7; Lee C, 2000, J BIOL CHEM, V275, P18751, DOI 10.1074/jbc.M001695200; Lee CH, 1997, J BIOL CHEM, V272, P15986, DOI 10.1074/jbc.272.25.15986; Lee SD, 2000, J NEUROCHEM, V75, P1053, DOI 10.1046/j.1471-4159.2000.0751053.x; Lee TG, 1997, BBA-LIPID LIPID MET, V1347, P199, DOI 10.1016/S0005-2760(97)00083-0; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Lukowski S, 1996, J BIOL CHEM, V271, P24164, DOI 10.1074/jbc.271.39.24164; Lukowski S, 1998, BIOCHEM BIOPH RES CO, V248, P278, DOI 10.1006/bbrc.1998.8942; MARIECHRISTINE L, 1993, J BIOL CHEM, V268, P5642; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Olson SC, 1996, CHEM PHYS LIPIDS, V80, P3, DOI 10.1016/0009-3084(96)02541-8; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; Steed PM, 1996, BIOCHEMISTRY-US, V35, P5229, DOI 10.1021/bi952370j; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659	58	97	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28252	28260		10.1074/jbc.M008521200	http://dx.doi.org/10.1074/jbc.M008521200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373276	Green Published, hybrid			2022-12-27	WOS:000170093400069
J	Segev, DL; Hoshiya, Y; Stephen, AE; Hoshiya, M; Tran, TT; MacLaughlin, DT; Donahoe, PK; Maheswaran, S				Segev, DL; Hoshiya, Y; Stephen, AE; Hoshiya, M; Tran, TT; MacLaughlin, DT; Donahoe, PK; Maheswaran, S			Mullerian inhibiting substance regulates NF kappa B signaling and growth of mammary epithelial cells in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; II RECEPTOR; FEMALE RATS; EXPRESSION; GLAND; APOPTOSIS; HORMONE; SURVIVAL; PUBERTY; ONSET	Mullerian inhibiting substance (MIS) inhibits breast cancer cell growth in vitro through interference with cell cycle progression and induction of apoptosis, a process associated with NF kappaB activation and up-regulation of one of its important target genes, IEX-1S (Segev, D. L., Ha, T., Tran, T. T., Kenneally, M., Harkin, P., Jung, M., MacLaughlin, D. T., Donahoe, P. K., and Maheswaran, S. (2000) J. Biol. Chem. 275, 28371-28379). Here we demonstrate that MIS activates the NF kappaB signaling cascade, induces IEX-1S mRNA, and inhibits the growth of MCF10A, an immortalized human breast epithelial cell line with characteristics of normal cells. In vivo an inverse correlation was found to exist between various stages of mammary growth and MIS type II receptor expression. Receptor mRNA significantly diminished during puberty, when the ductal system branches and invades the adipose stroma and during the expansive growth at lactation, but it was up-regulated during involution, a time of regression and apoptosis. Peripartum variations in MIS type II receptor expression correlated with NF kappaB activation and IEX-1S mRNA expression. Administration of MIS to female mice induced NF kappaB DNA binding and IEX-1S mRNA expression in the breast. Furthermore, exposure to MIS in vivo increased apoptosis in the mouse mammary ductal epithelium. Thus, MIS may function as an endogenous hormonal regulator of NF kappaB signaling and growth in the breast.	Massachusetts Gen Hosp, Pediat Surg Res Labs, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Maheswaran, S (corresponding author), Massachusetts Gen Hosp, Pediat Surg Res Labs, WRN1024,55 Fruit St, Boston, MA 02114 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032112] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA071345, R01CA017393, F32CA077945] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA-71345-04, F32 CA77945-01A1, CA17393] Funding Source: Medline; NICHD NIH HHS [HD32112] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; BAARENDS WM, 1994, DEVELOPMENT, V120, P189; Baichwal V. R., 1997, CURR BIOL, V7, P94; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Brantley DM, 2000, MECH DEVELOP, V97, P149, DOI 10.1016/S0925-4773(00)00405-6; Clarke TR, 2001, MOL ENDOCRINOL, V15, P946, DOI 10.1210/me.15.6.946; Clarkson RWE, 2000, J BIOL CHEM, V275, P12737, DOI 10.1074/jbc.275.17.12737; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; Geymayer S, 2000, FASEB J, V14, P1159, DOI 10.1096/fasebj.14.9.1159; Gouedard L, 2000, J BIOL CHEM, V275, P27973; Han ZS, 1999, J BIOL CHEM, V274, P21355, DOI 10.1074/jbc.274.30.21355; HOWLETT AR, 1995, J CELL SCI, V108, P1945; HUDSON PL, 1990, J CLIN ENDOCR METAB, V70, P16, DOI 10.1210/jcem-70-1-16; Juarez J, 2000, ALCOHOL, V21, P181, DOI 10.1016/S0741-8329(00)00086-0; Kleinberg DL, 1998, BREAST CANCER RES TR, V47, P201, DOI 10.1023/A:1005998832636; Lee MM, 1996, J CLIN ENDOCR METAB, V81, P571, DOI 10.1210/jc.81.2.571; Masso-Welch PA, 2000, J MAMMARY GLAND BIOL, V5, P165, DOI 10.1023/A:1026491221687; MCGIVERN RF, 1992, ALCOHOL, V9, P335, DOI 10.1016/0741-8329(92)90077-N; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; Nguyen AV, 2000, DEVELOPMENT, V127, P3107; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; RAGIN RC, 1992, PROTEIN EXPRES PURIF, V3, P236, DOI 10.1016/1046-5928(92)90020-W; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SINHA YN, 1966, AM J PHYSIOL, V210, P601, DOI 10.1152/ajplegacy.1966.210.3.601; SOULE HD, 1990, CANCER RES, V50, P6075; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Teixeira J, 1996, ENDOCRINOLOGY, V137, P160, DOI 10.1210/en.137.1.160; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Visser JA, 2001, MOL ENDOCRINOL, V15, P936, DOI 10.1210/me.15.6.936; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998	34	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26799	26806		10.1074/jbc.M103092200	http://dx.doi.org/10.1074/jbc.M103092200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356848	hybrid			2022-12-27	WOS:000169966900011
J	Wang, YZ; Guan, J; Wang, HY; Wang, Y; Leeper, D; Iliakis, G				Wang, YZ; Guan, J; Wang, HY; Wang, Y; Leeper, D; Iliakis, G			Regulation of DNA replication after heat shock by replication protein A-nucleolin interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; NUCLEOTIDE EXCISION-REPAIR; SIMIAN VIRUS-40 DNA; BINDING-PROTEIN; MAMMALIAN-CELLS; HELA-CELLS; MACROMOLECULAR-SYNTHESIS; ATAXIA-TELANGIECTASIA; ELEVATED-TEMPERATURES; DAMAGE RESPONSE	Heat shock inhibits replicative DNA synthesis, but the underlying mechanism remains unknown. We investigated mechanistic aspects of this regulation in melanoma cells using a simian virus 40 (SV40)-based in vitro DNA replication assay. Heat shock (44 degreesC) caused a monotonic inhibition of cellular DNA replication following exposures for 5-90 min. SV40 DNA replication activity in extracts of similarly heated cells also decreased after 5-30 min of exposure, but returned to near control levels after 60-90 min of exposure, This transient inhibition of SV40 DNA replication was eliminated by recombinant replication protein A (rRPA), suggesting a regulatory process targeting this key DNA replication factor. SV40 DNA replication inhibition was associated with a transient increase in the interaction between nucleolin and RPA that peaked at 20-30 min. Because binding to nucleolin compromises the ability of RPA to support SV40 DNA replication, we suggest that the observed interaction reflects a mechanism whereby DNA replication is regulated after heat shock. The relevance of this interaction to the regulation of cellular DNA replication is indicated by the transient translocation in heated cells of nucleolin from the nucleolus into the nucleoplasm with kinetics very similar to those of SV40 DNA replication inhibition and of RPA-nucleolin interaction. Because the targeting of RPA by nucleolin in heated cells occurs in an environment that preserves the activity of several essential DNA replication factors, active processes may contribute to DNA replication inhibition to a larger degree than presently thought. RPA-nucleolin interactions may reflect an early step in the regulation of DNA replication, as nucleolin relocalized into the nucleolus 1-2 h after heat exposure but cellular DNA replication remained inhibited for up to 8 h. We propose that the nucleolus functions as a heat sensor that uses nucleolin as a signaling molecule to initiate inhibitory responses equivalent to a checkpoint.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol,Div Expt Radiat Oncol, Philadelphia, PA 19107 USA	Jefferson University	Iliakis, G (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol,Div Expt Radiat Oncol, Philadelphia, PA 19107 USA.				NATIONAL CANCER INSTITUTE [R01CA056706, P30CA056036, P01CA056690] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA56706, P30 CA56036-03, P01 CA 56690] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEGREN N, 1995, J CELL BIOCHEM, V59, P91, DOI 10.1002/jcb.240590111; BELL J, 1988, MOL CELL BIOL, V8, P91, DOI 10.1128/MCB.8.1.91; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Cheng XB, 1996, RADIOTHER ONCOL, V39, P43, DOI 10.1016/0167-8140(96)01712-4; CHU GL, 1993, J CELL PHYSIOL, V154, P217, DOI 10.1002/jcp.1041540202; CORRY PM, 1977, RADIOLOGY, V123, P475, DOI 10.1148/123.2.475; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; Daniely Y, 2000, J CELL BIOL, V149, P799, DOI 10.1083/jcb.149.4.799; David-Pfeuty T, 1999, ONCOGENE, V18, P7409, DOI 10.1038/sj.onc.1203103; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; DEWEY WC, 1978, RADIAT RES, V76, P48, DOI 10.2307/3574926; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Ginisty H, 2000, J BIOL CHEM, V275, P18845, DOI 10.1074/jbc.M002350200; Ginisty H, 1999, J CELL SCI, V112, P761; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; Guan J, 2000, NUCLEIC ACIDS RES, V28, P1183, DOI 10.1093/nar/28.5.1183; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENLE KJ, 1976, RADIOLOGY, V121, P451, DOI 10.1148/121.2.451; HENLE KJ, 1979, CANCER RES, V39, P2665; HIGASHIKUBO R, 1993, RADIAT RES, V134, P193, DOI 10.2307/3578459; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Iliakis G, 1997, SEMIN ONCOL, V24, P602; ILIAKIS GE, 1989, CANCER RES, V49, P1254; JORRITSMA JBM, 1984, RADIAT RES, V98, P198, DOI 10.2307/3576063; Larner JM, 1997, CANCER SURV, V29, P25; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Liu JS, 2000, J BIOL CHEM, V275, P1391, DOI 10.1074/jbc.275.2.1391; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; Murti KG, 1996, EXP CELL RES, V223, P279, DOI 10.1006/excr.1996.0083; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; Park JS, 1999, J BIOL CHEM, V274, P32520, DOI 10.1074/jbc.274.45.32520; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; Roti J.L., 1988, HYPERTHERMIA ONCOLOG, P13; Roti JLR, 1998, CELL STRESS CHAPERON, V3, P245, DOI 10.1379/1466-1268(1998)003<0245:NMAATF>2.3.CO;2; SADIS S, 1988, J CELL PHYSIOL, V135, P377, DOI 10.1002/jcp.1041350304; SMITH J, 1995, MOL CELL BIOL, V15, P1632; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; van der Zee J, 2000, LANCET, V355, P1119, DOI 10.1016/S0140-6736(00)02059-6; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wang M, 2000, BIOCHEMISTRY-US, V39, P6433, DOI 10.1021/bi000472q; Wang Y, 1998, RADIAT RES, V149, P284, DOI 10.2307/3579962; Wang Y, 1999, J BIOL CHEM, V274, P22060, DOI 10.1074/jbc.274.31.22060; Wang Y, 1997, CANCER RES, V57, P1654; Wang Y, 1999, RADIAT RES, V151, P59, DOI 10.2307/3579747; Wang Y, 1996, RADIAT RES, V145, P408, DOI 10.2307/3579062; WAROCQUI.R, 1969, EUR J BIOCHEM, V10, P362, DOI 10.1111/j.1432-1033.1969.tb00699.x; WARTERS RL, 1983, RADIAT RES, V93, P71, DOI 10.2307/3575945; WARTERS RL, 1990, J CELL PHYSIOL, V142, P365, DOI 10.1002/jcp.1041420220; WARTERS RL, 1984, J CELL PHYSIOL, V118, P153, DOI 10.1002/jcp.1041180207; WARTERS RL, 1988, RADIAT RES, V115, P258, DOI 10.2307/3577162; WARTERS RL, 1985, J CELL PHYSIOL, V124, P481, DOI 10.1002/jcp.1041240318; WARTERS RL, 1987, J CELL PHYSIOL, V133, P144, DOI 10.1002/jcp.1041330118; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WONG RSL, 1982, RADIAT RES, V92, P370, DOI 10.2307/3576013; WONG RSL, 1988, RADIAT RES, V114, P125, DOI 10.2307/3577150; WONG RSL, 1989, BIOCHIM BIOPHYS ACTA, V1007, P224, DOI 10.1016/0167-4781(89)90043-2; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	74	50	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20579	20588		10.1074/jbc.M100874200	http://dx.doi.org/10.1074/jbc.M100874200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11389152	hybrid			2022-12-27	WOS:000169135100122
J	Bacolla, A; Pradhan, S; Larson, JE; Roberts, RJ; Wells, RD				Bacolla, A; Pradhan, S; Larson, JE; Roberts, RJ; Wells, RD			Recombinant human DNA (cytosine-5) methyltransferase - III. Allosteric control, reaction order, and influence of plasmid topology and triplet repeat length on methylation of the fragile X CGG center dot CCG sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO; ICF SYNDROME; FMR1 GENE; MAINTENANCE METHYLATION; HISTONE DEACETYLASE; DELAYED REPLICATION; SATELLITE DNA; STEADY-STATE; CELLS; DOMAIN	Steady-state kinetic analyses revealed that the methylation reaction of the human DNA (cytosine-5) methyltransferase 1 (DNMT1) is repressed by the N-terminal domain comprising the first 501 amino acids, and that repression is relieved when methylated DNA binds to this region. DNMT1 lacking the first 501 amino acids retains its preference for hemimethylated DNA, The methylation reaction proceeds by a sequential mechanism, and either substrate (S-adenosyl-L-methionine and unmethylated DNA) may be the first to bind to the active site. However, initial binding of S-adenosyl-L-methionine is preferred. The binding affinities of DNA for both the regulatory and the catalytic sites increase in the presence of methylated CpG; dinucleotides and vary considerably (more than one hundred times) according to DNA sequence. DNA topology strongly influences the reaction rates, which increased with increasing negative superhelical tension. These kinetic data are consistent with the role of DNMT1 in maintaining the methylation patterns throughout development and suggest that the enzyme may be involved in the etiology of fragile X, a syndrome characterized by de novo methylation of a greatly expanded CGG.CCG triplet repeat sequence.	Texas A&M Univ, Hlth Sci Ctr, Texas Med Ctr, Ctr Genome Res,Inst Biosci & Technol, Houston, TX 77030 USA; New England Biolabs Inc, Beverly, MA 01915 USA	Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Wells, RD (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Texas Med Ctr, Ctr Genome Res,Inst Biosci & Technol, 2121 Holcombe Blvd, Houston, TX 77030 USA.		Bacolla, Albino/N-3877-2013; Bacolla, Albino/AAP-1727-2020	Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423; Roberts, Richard/0000-0002-4348-0169	NIGMS NIH HHS [GM46127, GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046127, P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bacolla A, 1999, J BIOL CHEM, V274, P33011, DOI 10.1074/jbc.274.46.33011; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; BACOLLA A, 1995, J BIOL CHEM, V270, P24556, DOI 10.1074/jbc.270.41.24556; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bonfils C, 2000, J BIOL CHEM, V275, P10754, DOI 10.1074/jbc.275.15.10754; BOWATER R, 1991, BIOCHEMISTRY-US, V30, P11495, DOI 10.1021/bi00113a003; Boyer P.D., 1990, ENZYMES, V19, P99; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Carotti D, 1998, BIOCHEMISTRY-US, V37, P1101, DOI 10.1021/bi971031i; Chuang LSH, 1996, J MOL BIOL, V257, P935, DOI 10.1006/jmbi.1996.0213; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cleland W. W, 1970, ENZYMES, V2, P1; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; deVries BBA, 1996, J MED GENET, V33, P1007, DOI 10.1136/jmg.33.12.1007; Eberhart DE, 1996, SOMAT CELL MOLEC GEN, V22, P435, DOI 10.1007/BF02369435; Flynn J, 1998, BIOCHEMISTRY-US, V37, P15162, DOI 10.1021/bi9810609; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; Ghosh AK, 1999, BIOCHEM BIOPH RES CO, V260, P405, DOI 10.1006/bbrc.1999.0921; Glickman JF, 1997, J BIOL CHEM, V272, P17851, DOI 10.1074/jbc.272.28.17851; GRANT RC, 1968, J AM CHEM SOC, V90, P4474, DOI 10.1021/ja01018a060; GRUNWALD S, 1984, INT J BIOCHEM, V16, P883, DOI 10.1016/0020-711X(84)90147-2; Hagerman R, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P15; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; Hansen RS, 1997, P NATL ACAD SCI USA, V94, P4587, DOI 10.1073/pnas.94.9.4587; HITT MM, 1988, J BIOL CHEM, V263, P4392; Imbert G, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P27; Ivanchenko M, 1997, BIOPHYS J, V72, P1388, DOI 10.1016/S0006-3495(97)78785-X; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Ji WZ, 1997, MUTAT RES-FUND MOL M, V379, P33, DOI 10.1016/S0027-5107(97)00088-2; Klein CB, 1997, MUTAT RES-REV MUTAT, V386, P163, DOI 10.1016/S1383-5742(96)00052-X; Kondo T, 2000, HUM MOL GENET, V9, P597, DOI 10.1093/hmg/9.4.597; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Margot JB, 2000, J MOL BIOL, V297, P293, DOI 10.1006/jmbi.2000.3588; Mariappan SVS, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P647; Merenstein SA, 1996, AM J MED GENET, V64, P388, DOI 10.1002/(SICI)1096-8628(19960809)64:2<388::AID-AJMG31>3.3.CO;2-S; Mertineit C, 1998, DEVELOPMENT, V125, P889; Morales V, 2000, MOL CELL BIOL, V20, P7230, DOI 10.1128/MCB.20.19.7230-7237.2000; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P124; PATTERTON HG, 1993, J MOL BIOL, V229, P623, DOI 10.1006/jmbi.1993.1068; Pearson CE, 1998, BIOCHEMISTRY-US, V37, P2701, DOI 10.1021/bi972546c; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Pradhan S, 1997, NUCLEIC ACIDS RES, V25, P4666, DOI 10.1093/nar/25.22.4666; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; RUCHIRAWAT M, 1987, MOL CELL BIOCHEM, V76, P45; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUFFENHAUER S, 1995, HUM GENET, V96, P562, DOI 10.1007/BF00197412; Segel I. H., 1975, ENZYME KINETICS BEHA, P505; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Steyaert J, 1996, AM J MED GENET, V64, P274, DOI 10.1002/(SICI)1096-8628(19960809)64:2<274::AID-AJMG8>3.0.CO;2-U; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; Wells R.D., 1988, UNUSUAL DNA STRUCTUR; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287; Yeshaya J, 1999, HUM GENET, V105, P86, DOI 10.1007/s004390051068; Yeshaya J, 1998, HUM GENET, V102, P6, DOI 10.1007/s004390050647; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279; ZHENG GX, 1991, J MOL BIOL, V221, P107, DOI 10.1016/0022-2836(91)80208-C; Zimmermann C, 1997, BIOL CHEM, V378, P393, DOI 10.1515/bchm.1997.378.5.393	71	53	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18605	18613		10.1074/jbc.M100404200	http://dx.doi.org/10.1074/jbc.M100404200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359795	hybrid			2022-12-27	WOS:000168866500131
J	Wasmeier, C; Hutton, JC				Wasmeier, C; Hutton, JC			Secretagogue-dependent phosphorylation of the insulin granule membrane protein phogrin is mediated by cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; ALPHA-AMIDATING MONOOXYGENASE; TYROSINE-PHOSPHATASE HOMOLOG; GLUCAGON-LIKE PEPTIDE-1; SECRETORY GRANULES; CYTOSOLIC DOMAIN; SYNAPSIN-I; EXOCYTOSIS; ACTIVATION; CALCIUM	Phogrin, a 60/64-kDa integral membrane protein of dense-core granules in neuroendocrine cells, is phosphorylated in a Ca2+-sensitive manner in response to secretagogue stimulation of pancreatic beta -cells. Phosphorylation of the phogrin cytosolic domain by beta -cell homogenates was Ca2+-independent but stimulated by cAMP. Recombinant protein kinase A (PKA) could phosphorylate phogrin directly. High performance liquid chromatography analysis of tryptic phosphopeptides, combined with site-directed mutagenesis of candidate sites, revealed the presence of two phosphorylation sites at Ser-680 and Thr-699, located in the juxtamembrane region between the transmembrane span and the protein-tyrosine phosphatase homology domain of phogrin. Full-length wild-type phogrin, as well as mutant versions where Ser-680 and Thr-699 had been replaced either by alanines or by aspartic acid residues, were targeted to secretory granules in transfected AtT20 neuroendocrine cells. Stimulation of these cells with a range of secretagogues, including K+, BaCl2, and forskolin, demonstrated that the in vivo phosphorylation sites are the same as those identified in vitro. In MIN6 beta -cells, the PKA inhibitor H-89 prevented Ca2+-dependent phogrin phosphorylation in response to glucose, suggesting that Ca2+ exerts its effect on phogrin phosphorylation through regulating the activity of PKA.	Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hutton, JC (corresponding author), Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, 4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052068, R56DK052068, P30DK057516, R01DK055597] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 57516-02, DK 52068-02, DK 55597-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; ASHCROFT SJH, 1994, DIABETOLOGIA, V37, pS21, DOI 10.1007/BF00400822; Bhatt HS, 2000, BIOCHEM PHARMACOL, V60, P1655, DOI 10.1016/S0006-2952(00)00483-4; Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4; Easom RA, 1999, DIABETES, V48, P675, DOI 10.2337/diabetes.48.4.675; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; GROMADA J, 1995, DIABETES, V44, P767, DOI 10.2337/diabetes.44.7.767; Gromada J, 1998, PFLUG ARCH EUR J PHY, V435, P583, DOI 10.1007/s004240050558; Guenifi A, 2000, HISTOCHEM CELL BIOL, V113, P81, DOI 10.1007/s004180050010; Hisatomi M, 1996, ENDOCRINOLOGY, V137, P4644, DOI 10.1210/en.137.11.4644; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; HOLZ GG, 1995, J BIOL CHEM, V270, P17749, DOI 10.1074/jbc.270.30.17749; HOWELL SL, 1994, DIABETOLOGIA, V37, P30; Jones PM, 1998, ENDOCR REV, V19, P429, DOI 10.1210/er.19.4.429; Krueger KA, 1999, DIABETES, V48, P499, DOI 10.2337/diabetes.48.3.499; Krueger KA, 1997, J BIOL CHEM, V272, P27464, DOI 10.1074/jbc.272.43.27464; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; LIDA Y, 1997, AM J PHYSIOL, V273, pE782; MATSUMOTO K, 1995, ENDOCRINOLOGY, V136, P3784, DOI 10.1210/en.136.9.3784; METZ SA, 1988, DIABETES, V37, P3, DOI 10.2337/diabetes.37.1.3; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PEARSON RB, 1992, PROTEIN PHOSPHORYLAT, P265; Pouli AE, 1998, BIOCHEM J, V333, P193, DOI 10.1042/bj3330193; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; RAJAN AS, 1989, DIABETES, V38, P874, DOI 10.2337/diabetes.38.7.874; Renstrom E, 1997, J PHYSIOL-LONDON, V502, P105, DOI 10.1111/j.1469-7793.1997.105bl.x; Steveson TC, 1999, J BIOL CHEM, V274, P21128, DOI 10.1074/jbc.274.30.21128; Takahashi N, 1999, P NATL ACAD SCI USA, V96, P760, DOI 10.1073/pnas.96.2.760; Thorens B, 1996, J BIOL CHEM, V271, P8075, DOI 10.1074/jbc.271.14.8075; Wasmeier C, 1999, BIOCHEM J, V341, P563, DOI 10.1042/0264-6021:3410563; Wasmeier C, 1996, J BIOL CHEM, V271, P18161, DOI 10.1074/jbc.271.30.18161; WENHAM RM, 1994, J BIOL CHEM, V269, P4947; Xia ZG, 1997, CURR OPIN NEUROBIOL, V7, P391, DOI 10.1016/S0959-4388(97)80068-2; Yaekura K, 1996, DIABETES, V45, P295, DOI 10.2337/diabetes.45.3.295; YUN HY, 1995, J BIOL CHEM, V270, P30075	37	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31919	31928		10.1074/jbc.M102580200	http://dx.doi.org/10.1074/jbc.M102580200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11353772	hybrid			2022-12-27	WOS:000170613500063
J	Erlenbach, I; Kostenis, E; Schmidt, C; Serradeil-Le Gal, C; Raufaste, D; Dumont, ME; Pausch, MH; Wess, J				Erlenbach, I; Kostenis, E; Schmidt, C; Serradeil-Le Gal, C; Raufaste, D; Dumont, ME; Pausch, MH; Wess, J			Single amino acid substitutions and deletions that alter the G protein coupling properties of the V2 vasopressin receptor identified in yeast by receptor random mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MOLECULAR-BASIS; C5A RECEPTOR; WILD-TYPE; EXPRESSION; BINDING; SELECTIVITY; CLONING; SPECIFICITY; ACTIVATION	To facilitate structure-function relationship studies of the V2 vasopressin receptor, a prototypical G(s)-coupled receptor, we generated V2 receptor-expressing yeast strains (Saccharomyces cerevisiae) that required arginine vasopressin-dependent receptor/G protein coupling for cell growth. V2 receptors heterologously expressed in yeast were unable to productively interact with the endogenous yeast G protein alpha subunit, Gpa1p, or a mutant Gpa1p subunit containing the C-terminal G alpha (q) sequence (Gq5). In contrast, the V2 receptor efficiently coupled to a Gpa1p/G alpha (s) hybrid subunit containing the C-terminal Gas sequence (Gs5), indicating that the V2 receptor retained proper G protein coupling selectivity in yeast. To gain insight into the molecular basis underlying the selectivity of V2 receptor/G protein interactions, we used receptor saturation random mutagenesis to generate a yeast library expressing mutant V2 receptors containing mutations within the second intracellular loop. A subsequent yeast genetic screen of about 30,000 mutant receptors yielded four mutant receptors that, in contrast to the wild-type receptor, showed substantial coupling to Gq5. Functional analysis of these mutant receptors, followed by more detailed site-directed mutagenesis studies, indicated that single amino acid substitutions at position Met(145) in the central portion of the second intracellular loop of the V2 receptor had pronounced effects on receptor/G protein coupling selectivity. We also observed that deletion of single amino acids N-terminal of Met145 led to misfolded receptor proteins, whereas single amino acid deletions C-terminal of Met(145) had no effect on V2 receptor function. These findings highlight the usefulness of combining receptor random mutagenesis and yeast expression technology to study mechanisms governing receptor/G protein coupling selectivity and receptor folding.	NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; Sanofi Synthelabo Rech, Exploratory Res Dept, F-31036 Toulouse, France; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Wyeth Ayerst Res, Dept Neurosci, Princeton, NJ 08543 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Sanofi-Aventis; Sanofi France; University of Rochester; Pfizer	Wess, J (corresponding author), NIDDK, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05, Bethesda, MD 20892 USA.	jwess@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown AJ, 2000, YEAST, V16, P11, DOI 10.1002/(SICI)1097-0061(20000115)16:1<11::AID-YEA502>3.0.CO;2-K; Burbach JPH, 1995, CELL MOL NEUROBIOL, V15, P573, DOI 10.1007/BF02071318; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Erickson JP, 1998, J BIOL CHEM, V273, P1506, DOI 10.1074/jbc.273.3.1506; Erlenbach I, 1998, J BIOL CHEM, V273, P26549, DOI 10.1074/jbc.273.41.26549; Erlenbach I, 2001, J NEUROCHEM, V77, P1327, DOI 10.1046/j.1471-4159.2001.00344.x; Geva A, 2000, J BIOL CHEM, V275, P35393, DOI 10.1074/jbc.M005602200; GIETZ RD, 1994, MOL GENETICS YEAST P, P124; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Innamorati G, 1996, MOL PHARMACOL, V50, P467; Kajkowski EM, 1997, J RECEPT SIGNAL TR R, V17, P293, DOI 10.3109/10799899709036610; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; Kostenis E, 1997, J BIOL CHEM, V272, P23675, DOI 10.1074/jbc.272.38.23675; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MORO O, 1993, J BIOL CHEM, V268, P22273; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pausch Mark H., 1998, P196; Price LA, 1996, MOL PHARMACOL, V50, P829; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; Serradeil-Le Gal C, 2000, KIDNEY INT, V58, P1613, DOI 10.1046/j.1523-1755.2000.00322.x; SerradeilLeGal C, 1996, J CLIN INVEST, V98, P2729, DOI 10.1172/JCI119098; Smit MJ, 1996, J BIOL CHEM, V271, P7574, DOI 10.1074/jbc.271.13.7574; Sommers CM, 1997, J MOL BIOL, V266, P559, DOI 10.1006/jmbi.1996.0816; SOMMERS CM, 1999, REC BIOCH M, P141; STAPLES RR, 1993, GENETICS, V135, P981; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Swift S, 2000, J BIOL CHEM, V275, P2627, DOI 10.1074/jbc.275.4.2627; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; WATSON S, 1994, G PROTEIN LINKED REC, P1; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Yun J, 2000, J CLIN INVEST, V106, P1361, DOI 10.1172/JCI9154; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	52	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29382	29392		10.1074/jbc.M103203200	http://dx.doi.org/10.1074/jbc.M103203200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11375990	hybrid			2022-12-27	WOS:000170346000100
J	Goldshmidt, O; Zcharia, E; Aingorn, H; Guatta-Rangini, Z; Atzmon, R; Michal, I; Pecker, I; Mitrani, E; Vlodavsky, I				Goldshmidt, O; Zcharia, E; Aingorn, H; Guatta-Rangini, Z; Atzmon, R; Michal, I; Pecker, I; Mitrani, E; Vlodavsky, I			Expression pattern and secretion of human and chicken heparanase are determined by their signal peptide sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN HEPARANASE; INTRACELLULAR DEGRADATION; MATRIX-METALLOPROTEINASE; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; ENDOTHELIAL-CELLS; TUMOR INVASION; GROWTH-FACTOR; PROTEOGLYCANS; CLONING	Cleavage of heparan sulfate (HS) proteoglycans affects the integrity and function of tissues and thereby fundamental phenomena, involving cell migration and response to changes in the extracellular microenvironment. The role of HS-degrading enzymes, commonly referred to as heparanases, in normal development has not been identified. The present study focuses on cloning, expression, and properties of a chicken heparanase and its distribution in the developing chicken embryo. We have identified a chicken EST, homologous to the recently cloned human heparanase, to clone and express a functional chicken heparanase, 60% homologous to the human enzyme. The full-length chicken heparanase cDNA encodes a 60-kDa proenzyme that is processed at the N terminus into a 45-kDa highly active enzyme. The most prominent difference between the chicken and human enzymes resides in the predicted signal peptide sequence, apparently accounting for the chicken heparanase being readily secreted and localized in close proximity to the cell surface. In contrast, the human enzyme is mostly intracellular, localized in perinuclear granules. Cells transfected with a chimeric construct composed of the chicken signal peptide preceding the human heparanase exhibited cell surface localization and secretion of heparanase, similar to cells transfected with the full-length chicken enzyme. We examined the distribution pattern of the heparanase enzyme in the developing chicken embryo. Both the chicken heparanase mRNA and protein were expressed, as early as 12 h post fertilization, in cells migrating from the epiblast and forming the hypoblast layer. Later on (72 h), the enzyme is preferentially expressed in cells of the developing vascular and nervous systems. Cloning and characterization of heparanase, the first and single functional vertebrate HS-degrading enzyme, may lead to identification of other glycosaminoglycan degrading enzymes, toward elucidation of their significance in normal and pathological processes.	Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; InSight Ltd, IL-76121 Rehovot, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Dept Cell & Anim Biol, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Vlodavsky, I (corresponding author), Hadassah Univ Hosp, Dept Oncol, POB 12000, IL-91120 Jerusalem, Israel.	Vlodavsk@cc.huji.ac.il						Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; BARTLETT MR, 1995, J LEUKOCYTE BIOL, V57, P207, DOI 10.1002/jlb.57.2.207; BARTLETT MR, 1995, IMMUNOL CELL BIOL, V73, P113, DOI 10.1038/icb.1995.19; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bovolenta P, 2000, PROG NEUROBIOL, V61, P113, DOI 10.1016/S0301-0082(99)00044-1; Carson DD, 1998, BIOESSAYS, V20, P577, DOI 10.1002/(SICI)1521-1878(199807)20:7<577::AID-BIES9>3.0.CO;2-H; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; Hulett MD, 2000, BIOCHEMISTRY-US, V39, P15659, DOI 10.1021/bi002080p; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jackson SM, 1997, DEVELOPMENT, V124, P4113; KJELLEN L, 1985, J BIOL CHEM, V260, P8416; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Marchetti D, 2000, CANCER RES, V60, P4767; MATZNER Y, 1992, J LEUKOCYTE BIOL, V51, P519, DOI 10.1002/jlb.51.6.519; McKenzie E, 2000, BIOCHEM BIOPH RES CO, V276, P1170, DOI 10.1006/bbrc.2000.3586; Mollinedo F, 1997, BIOCHEM J, V327, P917, DOI 10.1042/bj3270917; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Parish CR, 1999, CANCER RES, V59, P3433; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; Ribatti D, 1999, J ANAT, V195, P39, DOI 10.1046/j.1469-7580.1999.19510039.x; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Selleck SB, 1999, AM J HUM GENET, V64, P372, DOI 10.1086/302266; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Vlodavsky I, 1997, TUMOUR ANGIOGENESIS, P125; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; VLODAVSKY I, 2001, J CLIN INVEST PERSPE, V108; VLODAVSKY I, 1999, CURRENT PROTOCOLS CE, V1; WEISS RE, 1990, J UROLOGY, V144, P798, DOI 10.1016/S0022-5347(17)39595-2; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; YANAGISHITA M, 1985, J BIOL CHEM, V260, P1075; Yang MZ, 1996, J BIOL CHEM, V271, P25548, DOI 10.1074/jbc.271.41.25548	48	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29178	29187		10.1074/jbc.M102462200	http://dx.doi.org/10.1074/jbc.M102462200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387326	hybrid			2022-12-27	WOS:000170346000074
J	Kadyrov, FA; Drake, JW				Kadyrov, FA; Drake, JW			Conditional coupling of leading-strand and lagging-strand DNA synthesis at bacteriophage T4 replication forks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GP41 FORMS; HELICASE; PROTEIN; POLYMERASE; PURIFICATION; HOLOENZYME; SEQUENCE; COMPLEX	Eight proteins encoded by bacteriophage T4 are required for the replicative synthesis of the leading and lagging strands of T4 DNA. We show here that active T4 replication forks, which catalyze the coordinated synthesis of leading and lagging strands, remain stable in the face of dilution provided that the gp44/62 clamp loader, the gp45 sliding clamp, and the gp32 ssDNA-binding protein are present at sufficient levels after dilution. If any of these accessory proteins is omitted from the dilution mixture, uncoordinated DNA synthesis occurs, and/or large Okazaki fragments are formed. Thus, the accessory proteins must be recruited from solution for each round of initiation of lagging-strand synthesis. A modified bacteriophage T7 DNA polymerase (Sequenase) can replace the T4 DNA polymerase for leading-strand synthesis but not for well coordinated lagging-strand synthesis. Although T4 DNA polymerase has been reported to self-associate, gel-exclusion chromatography displays it as a monomer in solution in the absence of DNA. It forms no stable holoenzyme complex in solution with the accessory proteins or with the gp41-gp61 helicase-primase. Instead, template DNA is required for the assembly of the T4 replication complex, which then catalyzes coordinated synthesis of leading and lagging strands in a conditionally coupled manner.	NIEHS, Lab Mol Genet E3 01, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kadyrov, FA (corresponding author), NIEHS, Lab Mol Genet E3 01, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES061055, ZIAES061055] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BARRY J, 1994, J BIOL CHEM, V269, P33049; Chastain PD, 2000, MOL CELL, V6, P803, DOI 10.1016/S1097-2765(05)00093-6; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; Delagoutte E, 2001, BIOCHEMISTRY-US, V40, P4459, DOI 10.1021/bi001306l; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Dong F, 1996, J BIOL CHEM, V271, P19625, DOI 10.1074/jbc.271.32.19625; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HUBER HE, 1987, J BIOL CHEM, V262, P16224; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; MOSIG G, 1994, MOL BIOL BACTERIOP T, V4, P54; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; Schrock RD, 1996, J BIOL CHEM, V271, P16678, DOI 10.1074/jbc.271.28.16678; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064	30	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29559	29566		10.1074/jbc.M101310200	http://dx.doi.org/10.1074/jbc.M101310200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390383	hybrid			2022-12-27	WOS:000170346000121
J	Torgersen, KM; Vang, T; Abrahamsen, H; Yaqub, S; Horejsi, V; Schraven, B; Rolstad, B; Mustelin, T; Tasken, K				Torgersen, KM; Vang, T; Abrahamsen, H; Yaqub, S; Horejsi, V; Schraven, B; Rolstad, B; Mustelin, T; Tasken, K			Release from tonic inhibition of T cell activation through transient displacement of C-terminal Src kinase (Csk) from lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN-RECEPTOR; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; PHOSPHATASE PEP; FAMILY KINASES; SH2 DOMAINS; P50(CSK); LYMPHOCYTES; ZAP-70	In resting peripheral T cells, Csk is constitutively present in lipid rafts through an interaction with the Csk SH2-binding protein, PAG, also known as Cbp. Upon triggering of the T cell antigen receptor (TCR), PAG/Cbp is rapidly dephosphorylated leading to dissociation of Csk from lipid rafts. However, tyrosine phosphorylation of PAG/Cbp resumes after 3-5 min, at which time Csk reassociates with the rafts. Cells overexpressing a mutant Csk that lacks the catalytic domain, but displaces endogenous Csk from lipid rafts, have elevated basal levels of TCR-zeta -chain phosphorylation and spontaneous activation of an NFAT-AP1 reporter from the proximal interleukin-2 promoter as well as stronger and more sustained responses to TCR triggering than controls. We suggest that a transient release from Csk-mediated inhibition by displacement of Csk from lipid rafts is important for normal T cell activation.	Univ Oslo, Inst Basic Med Sci, Dept Med Biochem, N-0317 Oslo, Norway; Univ Oslo, Inst Basic Med Sci, Dept Anat, N-0317 Oslo, Norway; Acad Sci Czech Republ, Inst Mol Genet, CR-14220 Prague, Czech Republic; Univ Heidelberg, Immunomodulat Lab, Inst Immunol, D-69120 Heidelberg, Germany; Otto Von Guericke Univ, Inst Immunol, D-39120 Magdeburg, Germany; Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	University of Oslo; University of Oslo; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Ruprecht Karls University Heidelberg; Otto von Guericke University; Sanford Burnham Prebys Medical Discovery Institute	Tasken, K (corresponding author), Univ Oslo, Inst Basic Med Sci, Dept Med Biochem, POB 1112, N-0317 Oslo, Norway.		Abrahamsen, Hilde/E-5323-2010; Horejsi, Vaclav/G-3113-2014; Yaqub, Sheraz/AAC-3906-2019	Horejsi, Vaclav/0000-0003-4925-0142; Yaqub, Sheraz/0000-0002-5696-2319; Mustelin, Tomas/0000-0001-5912-8840; Tasken, Kjetil/0000-0003-2841-4697	NIAID NIH HHS [AI48032, AI41481, AI40552, AI35603] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040552, R21AI040552, R01AI048032, R01AI041481, R01AI035603] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aandahl EM, 1998, FASEB J, V12, P855, DOI 10.1096/fasebj.12.10.855; Aman MJ, 2000, CURR BIOL, V10, P393, DOI 10.1016/S0960-9822(00)00415-2; Arbet-Engels C, 1999, J BIOL CHEM, V274, P5422, DOI 10.1074/jbc.274.9.5422; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; Gjorloff-Wingren A, 1999, EUR J IMMUNOL, V29, P3845, DOI 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Holdorf AD, 1999, J EXP MED, V190, P375, DOI 10.1084/jem.190.3.375; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; MUSTELIN T, 1994, SRC FAMILY TYROSINE, P1; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; OKADA M, 1991, J BIOL CHEM, V266, P24249; Schmedt C, 1998, NATURE, V394, P901, DOI 10.1038/29802; Sheets ED, 1999, CURR OPIN CHEM BIOL, V3, P95, DOI 10.1016/S1367-5931(99)80017-9; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TORGERSEN KM, 2001, IN PRESS CELL SIGNAL; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; Vang T, 1998, BBA-PROTEIN STRUCT M, V1384, P285, DOI 10.1016/S0167-4838(97)00202-1; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	38	129	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29313	29318		10.1074/jbc.C100014200	http://dx.doi.org/10.1074/jbc.C100014200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390365	hybrid			2022-12-27	WOS:000170346000091
J	Chan, SW; Hong, WJ				Chan, SW; Hong, WJ			Retinoblastoma-binding protein 2 (Rbp2) potentiates nuclear hormone receptor-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE; GENE-PRODUCT; CELL-CYCLE; COACTIVATOR; COMPLEX; ACTIVATION; REPRESSION; SEQUENCE; CBP; IDENTIFICATION	Retinoblastoma-binding protein 2 (Rbp2) was originally identified as a retinoblastoma protein (RB) pocket domain-binding protein. Although Rbp2 has been shown to interact with RB, p107, TATA-binding protein, and T-cell oncogene rhombotin-2, the physiological function of Rbp2 remains unclear. Here we demonstrate that Rbp2 not only binds to nuclear receptors (NRs) but also enhances the transcription mediated by them. Rbp2 interacts with the DNA-binding domains of NRs and potentiates NR-mediated transcription in an AF-2-dependent manner. Both the N-terminal and C-terminal domains of Rbp2 are critical for the transactivation activity of Rbp2 on NRs. The C terminus is the NR-interacting region. In addition, RB functions in maximizing the effect of Rbp2 on the transcription by NRs. These results suggest that Rbp2 is a coregulator of NRs and define a potential role for Rbp2 in NR-mediated transcription.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hong, WJ (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		HONG, Wanjin/E-9927-2010					AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; Dallas PB, 2000, MOL CELL BIOL, V20, P3137, DOI 10.1128/MCB.20.9.3137-3146.2000; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; FATTAEY AR, 1993, ONCOGENE, V8, P3149; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Gregory SL, 1996, MOL CELL BIOL, V16, P792; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HUANG HJ, 1998, SCIENCE, V242, P1563; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KIM YW, 1994, MOL CELL BIOL, V14, P7256, DOI 10.1128/MCB.14.11.7256; Kortschak RD, 2000, TRENDS BIOCHEM SCI, V25, P294, DOI 10.1016/S0968-0004(00)01597-8; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mao SF, 1997, ONCOGENE, V14, P1531, DOI 10.1038/sj.onc.1200988; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; ONATE SA, 1995, SCIENCE, V270, P1354; OTTERSON GA, 1993, ONCOGENE, V8, P949; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Singh P, 2001, J BIOL CHEM, V276, P13762, DOI 10.1074/jbc.M100137200; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takemaru K, 1997, P NATL ACAD SCI USA, V94, P7251, DOI 10.1073/pnas.94.14.7251; TAVOSIAN SG, 1997, GENE DEV, V11, P383; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; VOEGEL JJ, 1996, EMBO J, V15, P8667; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	50	65	69	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28402	28412		10.1074/jbc.M100313200	http://dx.doi.org/10.1074/jbc.M100313200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11358960	hybrid			2022-12-27	WOS:000170093400088
J	Chen, S; Zhou, DJ; Yang, C; Sherman, M				Chen, S; Zhou, DJ; Yang, C; Sherman, M			Molecular basis for the constitutive activity of estrogen-related receptor alpha-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN RECEPTOR; IDENTIFICATION; ANTAGONISM; ASSAY	Some orphan nuclear receptors, including estrogen-related receptor alpha -1 (ERR alpha -1), can activate gene transcription in a constitutive manner. Little is known about the molecular basis of the constitutive activity of these receptors. Our results from site-directed mutagenesis experiments have revealed that Phe-329 (analogous to Ala-350 in estrogen receptor alpha (ER alpha)) is responsible for the constitutive activity of ERR alpha -1. The ERR alpha -1 mutant F329A lost the transactivation activity and acted as a dominant negative mutant. The mammalian cell transfection experiments revealed that the ERR alpha -1 mutant F329A, like wild-type ER alpha, recognized toxaphene (an organochlorine pesticide) as an agonist. This compound was previously shown to be an antagonist of wild-type ERR alpha -1. On the other hand, like wild-type ERR alpha -1, the ER alpha mutant A350F was found to be constitutively active (as demonstrated by mammalian cell transfection and yeast two-hybrid assays). These results indicate that Phe-329 in ERR alpha -1 and Ala-350 in ER alpha play important roles in both ligand binding and transactivation function.	City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Chen, S (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA.				NCI NIH HHS [CA44735] Funding Source: Medline; NIEHS NIH HHS [ES08258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Norris JD, 1997, MOL ENDOCRINOL, V11, P747, DOI 10.1210/me.11.6.747; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P705; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.1289/ehp.95103s7113; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Vanacker JM, 1999, MOL ENDOCRINOL, V13, P764, DOI 10.1210/me.13.5.764; Yang C, 1999, CANCER RES, V59, P4519; Yang C, 1998, CANCER RES, V58, P5695	14	58	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28465	28470		10.1074/jbc.M102638200	http://dx.doi.org/10.1074/jbc.M102638200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11356845	hybrid			2022-12-27	WOS:000170093400096
J	Hofmann, RM; Pickart, CM				Hofmann, RM; Pickart, CM			In vitro assembly and recognition of Lys-63 polyubiquitin chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING-ENZYME; POSTREPLICATION REPAIR PATHWAYS; SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; MULTIUBIQUITIN CHAIN; PROTEIN-DEGRADATION; ERROR-PRONE; YEAST RAD6; PROTEASOME; COMPLEX	Polyubiquitin chains assembled through lysine 48 (Lys-48) of ubiquitin act as a signal for substrate proteolysis by 26 S proteasomes, whereas chains assembled through Lys-63 play a mechanistically undefined role in post-replicative DNA repair. We showed previously that the products of the UBC13 and MMS2 genes function in error-free post-replicative DNA repair in the yeast Saccharomyces cerevisiae and form a complex that assembles Lys-63-linked polyubiquitin chains in vitro. Here we confirm that the Mms2.Ubc13 complex functions as a high affinity heterodimer in the chain assembly reaction in vitro and report the results of a kinetic characterization of the polyubiquitin chain assembly reaction. To test whether a Lys-63-linked polyubiquitin chain can signal degradation, we conjugated Lys-63-linked tetra-ubiquitin to a model substrate of 26 S proteasomes. Although the noncanonical chain effectively signaled substrate degradation, the results of new genetic epistasis studies agree with previous genetic data in suggesting that the proteolytic activity of proteasomes is not required for error-free post-replicative repair.	Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Pickart, CM (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem & Mol Biol, Rm 8041,615 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060372] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60372] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 1997, EMBO J, V16, P4826; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Bailly V, 1997, MOL CELL BIOL, V17, P4536, DOI 10.1128/MCB.17.8.4536; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Brusky J, 2000, CURR GENET, V37, P168, DOI 10.1007/s002940050515; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; COOK WJ, 1992, J BIOL CHEM, V267, P16467; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dor Y, 1996, MOL MICROBIOL, V21, P1197, DOI 10.1046/j.1365-2958.1996.671433.x; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; FRASER J, 1991, CURR GENET, V20, P17, DOI 10.1007/BF00312760; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1985, J BIOL CHEM, V260, P2464; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; LAM YA, 1997, J BIOL CHEM, V272, P28348; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; Moore DD, 1995, GLOB MOB SURV; Phillips CL, 2001, ACTA CRYSTALLOGR D, V57, P341, DOI 10.1107/S090744490001800X; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; PICKART CM, 1992, J BIOL CHEM, V267, P14418; PICKART CM, 1988, J BIOL CHEM, V263, P12028; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; RICHTERRUOFF B, 1994, FEBS LETT, V354, P50, DOI 10.1016/0014-5793(94)01085-4; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; SCHORK SM, 1994, FEBS LETT, V349, P270, DOI 10.1016/0014-5793(94)00668-7; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Xiao W, 2000, GENETICS, V155, P1633; Xiao W, 1999, MUTAT RES-DNA REPAIR, V435, P1, DOI 10.1016/S0921-8777(99)00034-8; Yao TT, 2000, J BIOL CHEM, V275, P36862, DOI 10.1074/jbc.M006050200; Yin LM, 2000, BIOCHEMISTRY-US, V39, P10001, DOI 10.1021/bi0007019; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	64	202	213	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27936	27943		10.1074/jbc.M103378200	http://dx.doi.org/10.1074/jbc.M103378200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369780	hybrid			2022-12-27	WOS:000170093400027
J	El-Fasakhany, FM; Uchimura, K; Kannagi, R; Muramatsu, T				El-Fasakhany, FM; Uchimura, K; Kannagi, R; Muramatsu, T			A novel human Gal-3-O-sulfotransferase - Molecular cloning, characterization, and its implication in biosynthesis of (SO4-3)Gal beta 1-4(Fuc alpha 1-3)GlcNAc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-SELECTIN LIGAND; HIGH ENDOTHELIAL VENULES; CARBOHYDRATE UNITS; SULFOTRANSFERASE; EXPRESSION; SPECIFICITIES; RESIDUES; SULFATE; CDNA; IDENTIFICATION	Based on sequence homology with the previously cloned human cerebroside sulfotransferase (CST) cDNA, a novel sulfotransferase was cloned by screening a human fetal brain cDNA library. The novel sulfotransferase gene was present on human chromosome 11q13; the location was different from human CST and from that of the recently cloned human beta -Gal 3'-sulfotransferase (GP3ST). The isolated cDNA contained an open reading frame that encoded a predicted protein of 431 amino acid residues with type II transmembrane topology. The amino acid sequence showed 33% identity with that of human CST and 38% with that of human GP3ST. The recombinant enzyme expressed in Chinese hamster ovary cells catalyzed transfer of sulfate to position 3 of non-reducing beta -galactosyl residues in Gal beta1-4GlcNAc. Type 2 chains served as good accepters, whereas type 1 chains served as poor accepters, and intermediate activity was found toward Gal beta1-3GalNAc. Therefore, the substrate specificity was different from that of GP3ST. CST activity was not detected in the newly cloned enzyme. Northern blotting analysis showed that the sulfotransferase mRNA was strongly expressed in the thyroid and moderately expressed in the brain, heart, kidney, and spinal cord. Co-transfection of the enzyme cDNA and fucosyltransferase III into COS-7 cells resulted in expression of (SO4-3) Gal beta1- 4(Fuc alpha1-3) GlcNAc and a small amount of (SO4-3) Gal beta1-3(Fuc alpha1-4)GlcNAc. These results indicated that the newly cloned enzyme is a novel Gal-3-O-sulfotransferase and is involved in biosynthesis of the (SO4-3)Gal beta1-4(Fuc alpha1-3)GlcNAc structure.	Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Aichi Canc Ctr, Res Inst, Program Expt Pathol, Nagoya, Aichi 4648681, Japan	Nagoya University; Aichi Cancer Center	Uchimura, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	ihcu@med.nagoya-u.ac.jp	Uchimura, Kenji/AFV-1802-2022; Kannagi, Reiji/Q-6459-2018; Uchimura, Kenji/C-9635-2014	Uchimura, Kenji/0000-0003-3009-248X; Kannagi, Reiji/0000-0003-4202-2921; Uchimura, Kenji/0000-0003-3009-248X				Akama TO, 2000, NAT GENET, V26, P237, DOI 10.1038/79987; Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Chai WG, 1997, GLYCOBIOLOGY, V7, P861, DOI 10.1093/glycob/7.6.861; Chandrasekaran EV, 1997, GLYCOBIOLOGY, V7, P753, DOI 10.1093/glycob/7.6.753; Chandrasekaran EV, 1999, GLYCOCONJUGATE J, V16, P523, DOI 10.1023/A:1007074005371; ENDO A, 1995, CARBOHYD RES, V270, pC9, DOI 10.1016/0008-6215(95)00112-7; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Galustian C, 1999, J BIOL CHEM, V274, P18213, DOI 10.1074/jbc.274.26.18213; GOLDSTEIN I. J., 1965, METHOD CARBOHYD CHEM, V5, P361; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; Honke K, 2001, J BIOL CHEM, V276, P267, DOI 10.1074/jbc.M005666200; Hooper LV, 1996, FASEB J, V10, P1137, DOI 10.1096/fasebj.10.10.8751716; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; KATO Y, 1989, J BIOL CHEM, V264, P3364; KAWANO M, 1989, ANAL BIOCHEM, V182, P9, DOI 10.1016/0003-2697(89)90709-4; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUHNS W, 1995, GLYCOBIOLOGY, V5, P689, DOI 10.1093/glycob/5.7.689; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; LOGUIDICE JM, 1995, J BIOL CHEM, V270, P27544, DOI 10.1074/jbc.270.46.27544; Mitsuoka C, 1997, BIOCHEM BIOPH RES CO, V230, P546, DOI 10.1006/bbrc.1996.6012; Mitsuoka C, 1997, BIOCHEM BIOPH RES CO, V233, P576, DOI 10.1006/bbrc.1997.6463; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Muramatsu T, 2000, J BIOCHEM, V127, P171, DOI 10.1093/oxfordjournals.jbchem.a022590; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUMOMURA S, 1994, CARBOHYD RES, V263, pC1, DOI 10.1016/0008-6215(94)00264-9; OBAMA H, 1995, GLYCOCONJUGATE J, V12, P795, DOI 10.1007/BF00731241; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SPIRO RG, 1988, J BIOL CHEM, V263, P14351; SUZUKI A, 2001, J BIOL CHEM; Uchimura K, 2000, BIOCHEM BIOPH RES CO, V274, P291, DOI 10.1006/bbrc.2000.3141; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Veerman ECI, 1997, GLYCOBIOLOGY, V7, P37, DOI 10.1093/glycob/7.1.37; WESTON BW, 1992, J BIOL CHEM, V267, P4152; YUEN CT, 1994, J BIOL CHEM, V269, P1595	42	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26988	26994		10.1074/jbc.M100348200	http://dx.doi.org/10.1074/jbc.M100348200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356829	hybrid			2022-12-27	WOS:000169966900035
J	Grimme, SJ; Westfall, BA; Wiedman, JM; Taron, CH; Orlean, P				Grimme, SJ; Westfall, BA; Wiedman, JM; Taron, CH; Orlean, P			The essential Smp3 protein is required for addition of the side-branching fourth mannose during assembly of yeast glycosylphosphatidylinositols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHOR BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; MEMBRANE ANCHORS; 3RD MANNOSE; FIRST STEP; TRANSFERRING PHOSPHOETHANOLAMINE; PLASMODIUM-FALCIPARUM; MAMMALIAN-CELLS; CORE STRUCTURE	The major glycosylphosphatidylinositols (GPIs) transferred to protein in mammals and trypanosomes contain three mannoses, In Saccharomyces cerevisiae, however, the GPI transferred to protein bears a fourth, alpha1,2-linked Man on the alpha1,2-Man that receives the phosphoethanolamine (EthN-P) moiety through which GPIs become linked to protein. We report that temperature-sensitive smp3 mutants accumulate a GPI containing three mannoses and that smp3 is epistatic to the gpi11, gpi13, and gaa1 mutations, which normally result in the accumulation of Man(4)-GPIs, including the presumed substrate for the yeast GPI transamidase. The Smp3 protein, which is encoded by an essential gene, is therefore required for addition of the fourth Man to yeast GPI precursors. The finding that smp3 prevents the formation of the Man(4)-GPI that accumulates when addition of EthN-P to Man-3 is blocked in a gpi13 mutant suggests that the presence of the fourth Man is important for transfer of EthN-P to Man-3 of yeast GPIs, The Man(3)-GPI that accumulates in smp3 is a mixture of two dominant isoforms, one bearing a single EthN-P side branch on Man-1, the other with EthN-P on Man-2, and these isoforms can be placed in separate arms of a branched GPI assembly pathway. Smp3-related proteins are encoded in the genomes of Schizosaccharomyces pombe, Candida albicans, Drosophila melanogaster, and Homo sapiens and form a subgroup of a family of proteins, the other groups of which are defined by the Pig-B(Gpi10) protein, which adds the third GPI mannose, and by the Alg9 and Alg12 proteins, which act in the dolichol pathway for N-glycosylation, Because Man(4)-containing GPI precursors are normally formed in yeast and Plasmodium falciparum, whereas addition of a fourth Man during assembly of mammalian GPIs is rare and not required for GPI transfer to protein, Smp3p-dependent addition of a fourth Man represents a target for antifungal and antimalarial drugs.	Univ Illinois, Dept Biochem, Roger Adams Lab 309, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Orlean, P (corresponding author), Univ Illinois, Dept Biochem, Roger Adams Lab 309, 606 S Mathews Ave, Urbana, IL 61801 USA.	p-orlean@uiuc.edu		Taron, Christopher/0000-0001-8149-4556	NIGMS NIH HHS [GM46220] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; BENGHEZAL M, 1995, J CELL BIOL, V130, P1333, DOI 10.1083/jcb.130.6.1333; BREWIS IA, 1995, J BIOL CHEM, V270, P22946, DOI 10.1074/jbc.270.39.22946; Burda P, 1999, GLYCOBIOLOGY, V9, P617, DOI 10.1093/glycob/9.6.617; Canivenc-Gansel E, 1998, GLYCOBIOLOGY, V8, P761, DOI 10.1093/glycob/8.8.761; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Colussi PA, 1997, YEAST, V13, P139, DOI 10.1002/(SICI)1097-0061(199702)13:2<139::AID-YEA69>3.3.CO;2-J; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; Flury I, 2000, J BIOL CHEM, V275, P24458, DOI 10.1074/jbc.M003844200; Fujii T, 1999, BBA-GEN SUBJECTS, V1427, P133, DOI 10.1016/S0304-4165(99)00012-4; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; GEROLD P, 1994, J BIOL CHEM, V269, P2597; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; Hong Y, 2000, J BIOL CHEM, V275, P20911, DOI 10.1074/jbc.M001913200; Hong YJ, 1999, J BIOL CHEM, V274, P35099, DOI 10.1074/jbc.274.49.35099; Ilgoutz SC, 1999, EMBO J, V18, P2746, DOI 10.1093/emboj/18.10.2746; INOUE N, 1993, J BIOL CHEM, V268, P6882; IRIE K, 1991, MOL GEN GENET, V225, P257, DOI 10.1007/BF00269857; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; Kawagoe K, 1996, BLOOD, V87, P3600, DOI 10.1182/blood.V87.9.3600.bloodjournal8793600; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; Leidich SD, 1996, J BIOL CHEM, V271, P27829, DOI 10.1074/jbc.271.44.27829; Lipke PN, 1998, J BACTERIOL, V180, P3735, DOI 10.1128/JB.180.15.3735-3740.1998; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; McConville MJ, 2000, MOL MEMBR BIOL, V17, P1; MOHNEY RP, 1994, J BIOL CHEM, V269, P6536; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Naik RS, 2000, J BIOL CHEM, V275, P24506, DOI 10.1074/jbc.M002151200; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; Ohishi K, 2000, MOL BIOL CELL, V11, P1523, DOI 10.1091/mbc.11.5.1523; Orlean P., 1997, MOL CELLULAR BIOL YE, V21, P229; PUOTI A, 1993, J BIOL CHEM, V268, P7215; PUOTI A, 1992, J BIOL CHEM, V267, P22673; SCHNEIDER P, 1995, METHOD ENZYMOL, V250, P614; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; Smith TK, 1997, EMBO J, V16, P6667, DOI 10.1093/emboj/16.22.6667; STEVENS VL, 1995, BIOCHEM J, V310, P361, DOI 10.1042/bj3100361; Sutterlin C, 1998, BIOCHEM J, V332, P153; Sutterlin C, 1997, EMBO J, V16, P6374, DOI 10.1093/emboj/16.21.6374; Takahashi M, 1996, EMBO J, V15, P4254, DOI 10.1002/j.1460-2075.1996.tb00800.x; TAKEDA J, 1995, TRENDS BIOCHEM SCI, V20, P367, DOI 10.1016/S0968-0004(00)89078-7; Taron CH, 2000, MOL BIOL CELL, V11, P1611, DOI 10.1091/mbc.11.5.1611; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tiede A, 1999, BIOL CHEM, V380, P503, DOI 10.1515/BC.1999.066; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; UEDA E, 1993, J BIOL CHEM, V268, P9998; Watanabe R, 1998, EMBO J, V17, P877, DOI 10.1093/emboj/17.4.877; ZIELER HA, 1995, MOL CELL BIOL, V15, P3227	56	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27731	27739		10.1074/jbc.M101986200	http://dx.doi.org/10.1074/jbc.M101986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356840	hybrid			2022-12-27	WOS:000169966900131
J	Park, K; Evans, RL; Watson, GE; Nehrke, K; Richardson, L; Bell, SM; Schultheis, PJ; Hand, AR; Shull, GE; Melvin, JE				Park, K; Evans, RL; Watson, GE; Nehrke, K; Richardson, L; Bell, SM; Schultheis, PJ; Hand, AR; Shull, GE; Melvin, JE			Defective fluid secretion and NaCl absorption in the parotid glands of Na+/H+ exchanger-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANDIBULAR SALIVARY-GLAND; THICK ASCENDING LIMB; ACINAR-CELLS; INTRACELLULAR PH; TARGETED DISRUPTION; MUSCARINIC AGONIST; APICAL MEMBRANE; RAT; ACTIVATION; AMILORIDE	Multiple Na+/H+ exchangers (NHEs) are expressed in salivary gland cells; however, their functions in the secretion of saliva by acinar cells and the subsequent modification of the ionic composition of this-fluid by the ducts are unclear. Mice with targeted disruptions of the Nhe1, Nhe2, and Nhe3 genes were used to study the,in vivo functions of these exchangers in parotid glands. Immunohistochemistry indicated that NHE1 was localized to the basolateral and NHE2 to apical membranes of both acinar and duct cells, whereas NHE3 was restricted to the apical region of duct cells. Na+/H+ exchange was reduced more than 95% in acinar cells and greater than 80% in duet cells of NKE1-deficient mice (Nhe1(-/-)). Salivation in response to pilocarpine stimulation was reduced significantly in both Nhe1(-/-) and Nhe2(-/-) mice, particularly during prolonged stimulation, whereas the loss of NHE3 had no effect on secretion. Expression of Na+/K+/2Cl(-) cotransporter mRNA increased dramatically in Nhe1(-/-) parotid glands but not in those of Nhe2(-/-) or Nhe3(-/-) mice, suggesting that compensation occurs for the Loss of NHE1. The sodium content, chloride activity and osmolality of saliva in Nhe2(-/-) or Nhe3(-/-) mice were comparable with those of wild-type mice. In contrast, Nhe1(-/-) mice displayed impaired NaCl absorption. These results suggest that in parotid duct cells apical NHE2 and NHE3 do not play a major role in Na+ absorption. These results also demonstrate that basolateral NHE1 and apical NHE2 modulate saliva secretion in viva, especially during sustained stimulation when secretion depends less on Na+/K+/2Cl(-) cotransporter activity.	Univ Rochester, Med Ctr, Ctr Oral Biol, Rochester Inst Biomed Sci, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Eastman Dept Dent, Rochester, NY 14642 USA; Univ Connecticut, Dept Pediat Dent, Farmington, CT 06030 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA	University of Rochester; University of Rochester; University of Connecticut; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Melvin, JE (corresponding author), Univ Rochester, Med Ctr, Ctr Oral Biol, Rochester Inst Biomed Sci, Box 611,601 Elmwood Ave, Rochester, NY 14642 USA.			Nehrke, Keith/0000-0001-9697-726X; Bell, Sheila/0000-0002-1946-0969; Watson, Gene/0000-0002-3397-1116	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009692, R37DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050594, R01DK050594] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE09692, DE08921] Funding Source: Medline; NIDDK NIH HHS [DK50594] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; ARREOLA J, 1995, J MEMBRANE BIOL, V147, P95; Bell SM, 1999, AM J PHYSIOL-CELL PH, V276, pC788, DOI 10.1152/ajpcell.1999.276.4.C788; Bookstein C, 1997, AM J PHYSIOL-CELL PH, V273, pC1496, DOI 10.1152/ajpcell.1997.273.5.C1496; Brooks HL, 2001, J PHYSIOL-LONDON, V530, P359, DOI 10.1111/j.1469-7793.2001.0359k.x; Cook D. I., 1994, P1061; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; Cox GA, 1997, CELL, V91, P139, DOI 10.1016/S0092-8674(01)80016-7; DINUDOM A, 1993, PFLUG ARCH EUR J PHY, V423, P164, DOI 10.1007/BF00374977; DISSING S, 1990, AM J PHYSIOL, V259, pG1044, DOI 10.1152/ajpgi.1990.259.6.G1044; Evans RL, 1999, J BIOL CHEM, V274, P29025, DOI 10.1074/jbc.274.41.29025; Evans RL, 2000, J BIOL CHEM, V275, P26720; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Good DW, 1995, P NATL ACAD SCI USA, V92, P12525, DOI 10.1073/pnas.92.26.12525; He XJ, 1997, PFLUG ARCH EUR J PHY, V433, P260; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; LAU KR, 1989, AM J PHYSIOL, V256, pC288, DOI 10.1152/ajpcell.1989.256.2.C288; LAU KR, 1990, J PHYSIOL-LONDON, V425, P407, DOI 10.1113/jphysiol.1990.sp018111; Lee MG, 1998, J PHYSIOL-LONDON, V513, P341, DOI 10.1111/j.1469-7793.1998.341bb.x; MANGANEL M, 1989, J MEMBRANE BIOL, V111, P191, DOI 10.1007/BF01871782; MARMARY Y, 1987, COMP BIOCHEM PHYS A, V88, P307, DOI 10.1016/0300-9629(87)90488-9; MARTINEZ JR, 1966, PFLUG ARCH GES PHYS, V290, P124, DOI 10.1007/BF00363690; MARTINEZ JR, 1985, ARCH ORAL BIOL, V30, P797, DOI 10.1016/0003-9969(85)90134-7; McSwine RL, 1998, AM J PHYSIOL-CELL PH, V275, pC693, DOI 10.1152/ajpcell.1998.275.3.C693; MELVIN JE, 1988, J BIOL CHEM, V263, P19564; Melvin JE, 1999, CRIT REV ORAL BIOL M, V10, P199, DOI 10.1177/10454411990100020601; Nguyen HV, 2000, J PHYSIOL-LONDON, V523, P139, DOI 10.1111/j.1469-7793.2000.t01-2-00139.x; OKADA M, 1991, PFLUG ARCH EUR J PHY, V419, P338, DOI 10.1007/BF00371116; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PARK K, 1995, AM J PHYSIOL-CELL PH, V268, pC647, DOI 10.1152/ajpcell.1995.268.3.C647; Park K, 1999, AM J PHYSIOL-GASTR L, V276, pG470, DOI 10.1152/ajpgi.1999.276.2.G470; PIRANI D, 1987, PFLUG ARCH EUR J PHY, V408, P178, DOI 10.1007/BF00581349; ROBERTSON MA, 1994, AM J PHYSIOL, V267, pC146, DOI 10.1152/ajpcell.1994.267.1.C146; Robertson MA, 1997, J BIOL CHEM, V272, P287; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; SEO JT, 1995, J PHYSIOL-LONDON, V487, P185, DOI 10.1113/jphysiol.1995.sp020870; SOLTOFF SP, 1989, J GEN PHYSIOL, V93, P285, DOI 10.1085/jgp.93.2.285; THAYSEN JH, 1954, AM J PHYSIOL, V178, P155, DOI 10.1152/ajplegacy.1954.178.1.155; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; YOUNG JA, 1966, PFLUG ARCH GES PHYS, V291, P85, DOI 10.1007/BF00362654; YU FH, 1993, J BIOL CHEM, V268, P25536; YUN CH, 1995, AM J PHYSIOL, V269, pGY1	45	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27042	27050		10.1074/jbc.M102901200	http://dx.doi.org/10.1074/jbc.M102901200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11358967	hybrid			2022-12-27	WOS:000169966900042
J	Ito, K; Inoue, T; Takahashi, T; Huang, HS; Esumi, T; Hatakeyama, S; Tanaka, N; Nakamura, KT; Yoshimoto, T				Ito, K; Inoue, T; Takahashi, T; Huang, HS; Esumi, T; Hatakeyama, S; Tanaka, N; Nakamura, KT; Yoshimoto, T			The mechanism of substrate recognition of pyroglutamyl-peptidase I from Bacillus amyloliquefaciens as determined by x-ray crystallography and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRROLIDONE CARBOXYL PEPTIDASE; PROLYL AMINOPEPTIDASE; CRYSTAL-STRUCTURE; GENE; PCP; INHIBITOR; CLONING	Pyroglutamyl-peptidase is able to specifically remove the amino-terminal pyroglutamyl residue protecting proteins or peptides from aminopeptidases. To clarify the mechanism of substrate recognition for the unique structure of the pyrrolidone ring, x-ray crystallography and site-directed mutagenesis were applied. The crystal structure of pyroglutamyl-peptidase bound to a transition state analog inhibitor (Inh), pyroglutaminal, was determined. Two hydrogen bonds were located between the main chain of the enzyme and the inhibitor (71:O . . .H-N:Inh and Gln71:N-H . . . OE:Inh and the pyrrolidone ring of the inhibitor was inserted into the hydrophobic pocket composed of Phe-10, Phe-13, Thr-45, Ile-92, Phe-142, and Val-143, To study in detail the hydrophobic pocket, Phe-10, Phe-13, and Phe-142 were selected for mutation experiments. The k(cat) value of the F10Y mutant decreased, but the two phenylalanine mutants F13Y and F142Y did not exhibit significant changes in kinetic parameters compared with the wild-type enzyme, The catalytic efficiencies (K-cat/K-m) for the F13A and F142A mutants were less than 1000-fold that of the wild-type enzyme. The x-ray crystallographic study of the F142A mutant showed no significant change except for a minor one in the hydrophobic pocket compared with the wild type. These findings indicate that the molecular recognition of pyroglutamic acid is achieved through two hydrogen bonds and an insertion in the hydrophobic pocket. In the pocket, Phe-10 is more important to the hydrophobic interaction than is Phe-142, and furthermore Phe-13 serves as an "induced fit" mechanism.	Nagasaki Univ, Fac Pharmaceut Sci, Nagasaki 8528521, Japan; Showa Univ, Sch Pharmaceut Sci, Shinagawa Ku, Tokyo 1428555, Japan	Nagasaki University; Showa University	Yoshimoto, T (corresponding author), Nagasaki Univ, Fac Pharmaceut Sci, Bunkyo Machi 1-14, Nagasaki 8528521, Japan.	t-yoshimoto@cc.nagasaki-u.ac.jp	Ito, Kiyoshi/E-9652-2011	Tanaka, Nobutada/0000-0001-5365-4698				AWADE A, 1992, FEBS LETT, V305, P67, DOI 10.1016/0014-5793(92)80656-2; BRUGER AT, 1989, X PLOR VERSION 3 1 S; CLEUZIAT P, 1992, MOL MICROBIOL, V6, P2051, DOI 10.1111/j.1365-2958.1992.tb01378.x; Daveran-Mingot ML, 1998, J BACTERIOL, V180, P4834, DOI 10.1128/JB.180.18.4834-4842.1998; FRIEDMAN TC, 1985, BIOCHEMISTRY-US, V24, P3907, DOI 10.1021/bi00336a015; FRIGERIO M, 1995, J ORG CHEM, V60, P7272, DOI 10.1021/jo00127a036; FUJIWARA K, 1982, BIOCHIM BIOPHYS ACTA, V702, P149; FUJIWARA K, 1981, J BIOCHEM-TOKYO, V90, P433, DOI 10.1093/oxfordjournals.jbchem.a133490; FUJIWARA K, 1981, BIOCHIM BIOPHYS ACTA, V658, P10, DOI 10.1016/0005-2744(81)90244-8; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; GONZALES T, 1994, J BACTERIOL, V176, P2569, DOI 10.1128/JB.176.9.2569-2576.1994; Ito K, 2000, J BIOCHEM, V128, P673, DOI 10.1093/oxfordjournals.jbchem.a022800; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Odagaki Y, 1999, STRUCTURE, V7, P399, DOI 10.1016/S0969-2126(99)80053-7; PATTI JM, 1995, GENE, V166, P95, DOI 10.1016/0378-1119(95)00561-0; Robert-Baudouy J., 1998, HDB PROTEOLYTIC ENZY, P791; ROUSSEL A, 1992, TURBO FRODO; Singleton MR, 1999, STRUCT FOLD DES, V7, P237, DOI 10.1016/S0969-2126(99)80034-3; Tsunasawa S, 1998, J BIOCHEM, V124, P778, DOI 10.1093/oxfordjournals.jbchem.a022179; TSURU D, 1978, J BIOCHEM, V84, P467, DOI 10.1093/oxfordjournals.jbchem.a132148; YOSHIMOTO T, 1993, J BIOCHEM-TOKYO, V113, P67; Yoshimoto T, 1999, J BIOCHEM, V126, P559, DOI 10.1093/oxfordjournals.jbchem.a022486	22	12	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18557	18562		10.1074/jbc.M011724200	http://dx.doi.org/10.1074/jbc.M011724200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359794	hybrid			2022-12-27	WOS:000168866500125
J	Grenard, P; Bates, MK; Aeschlimann, D				Grenard, P; Bates, MK; Aeschlimann, D			Evolution of transglutaminase genes: Identification of a transglutaminase gene cluster on human chromosome 15q15 - Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; PROSTATE-SPECIFIC TRANSGLUTAMINASE; HUMAN ERYTHROCYTE PROTEIN-4.2; MURINE PALLID MUTATION; AMINO-ACID-SEQUENCE; TISSUE TRANSGLUTAMINASE; FACTOR-XIII; KERATINOCYTE TRANSGLUTAMINASE; CROSS-LINKING; TRANSCRIPTION FACTORS	We isolated and characterized the gene encoding human transglutaminase (TG)(X) (TGM5) and mapped it to the 15q15.2 region of chromosome 15 by fluorescence in situ hybridization. The gene consists of 13 exons separated by 12 introns and spans about 35 kilobases. Further sequence analysis and mapping showed that this locus contained three transglutaminase genes arranged in tandem: EPB42 (band 4.2 protein), TGM5, and a novel gene (TGM7). A full-length cDNA for the novel transglutaminase (TG(Z)) was obtained by anchored polymerase chain reaction. The deduced amino acid sequence encoded a protein with 710 amino acids and a molecular mass of 80 kDa. Northern blotting showed that the three genes are differentially expressed in human tissues. Band 4.2 protein expression was associated with hematopoiesis, whereas TG(X) and TG(Z) showed widespread expression in different tissues. Interestingly, the chromosomal segment containing the human TGM5, TGM7, and EPB42 genes and the segment containing the genes encoding TG(C),TG(E), and another novel gene (TGM6) on chromosome 20q11 are in mouse all found on distal chromosome 2 as determined by radiation hybrid mapping. This finding suggests that in evolution these six genes arose from local duplication of a single gene and subsequent redistribution to two distinct chromosomes in the human genome.	Univ Wales Coll Cardiff, Connect Tissue Biol Labs, Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Wisconsin, Div Orthoped Surg, Madison, WI 53792 USA	Cardiff University; University of Wisconsin System; University of Wisconsin Madison	Aeschlimann, D (corresponding author), Univ Wales Coll Cardiff, Connect Tissue Biol Labs, Sch Biosci, Museums Ave, Cardiff CF10 3US, S Glam, Wales.			Aeschlimann, Daniel/0000-0003-0930-7706				Aeschlimann D, 1998, J BIOL CHEM, V273, P3452, DOI 10.1074/jbc.273.6.3452; Aeschlimann D, 2000, CONNECT TISSUE RES, V41, P1, DOI 10.3109/03008200009005638; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Ausubel FM, 1991, CURRENT PROTOCOLS MO, V1; BEBBINGTON CR, 1987, DNA CLONING PRACTICA, V3, P184; BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOARD PG, 1993, BLOOD REV, V7, P229, DOI 10.1016/0268-960X(93)90010-2; BOARD PG, 1988, CYTOGENET CELL GENET, V48, P25, DOI 10.1159/000132580; CHIANNILKULCHAI N, 1995, HUM MOL GENET, V4, P717, DOI 10.1093/hmg/4.4.717; Corbett SA, 1997, J BIOL CHEM, V272, P24999, DOI 10.1074/jbc.272.40.24999; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Dubbink HJ, 1998, GENOMICS, V51, P434, DOI 10.1006/geno.1998.5393; Dubbink HJ, 1996, BIOCHEM J, V315, P901, DOI 10.1042/bj3150901; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Eppig JT, 1996, CURR OPIN GENET DEV, V6, P723, DOI 10.1016/S0959-437X(96)80027-X; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; Fraij BM, 1997, BBA-GENE STRUCT EXPR, V1354, P65, DOI 10.1016/S0167-4781(97)00132-2; Gaudry CA, 1999, J BIOL CHEM, V274, P30707, DOI 10.1074/jbc.274.43.30707; GENTILE V, 1995, GENOMICS, V27, P219, DOI 10.1006/geno.1995.1032; GENTILE V, 1994, GENOMICS, V20, P295, DOI 10.1006/geno.1994.1170; GENTILE V, 1991, J BIOL CHEM, V266, P478; Gibson TJ, 2000, BIOCHEM SOC T, V28, P259, DOI 10.1042/bst0280259; GRANT FJ, 1994, BIOCHEM BIOPH RES CO, V203, P1117, DOI 10.1006/bbrc.1994.2298; GRUNDMANN U, 1986, P NATL ACAD SCI USA, V83, P8024, DOI 10.1073/pnas.83.21.8024; Gwynn B, 1997, GENOMICS, V42, P532, DOI 10.1006/geno.1997.4764; ICHINOSE A, 1988, P NATL ACAD SCI USA, V85, P5829, DOI 10.1073/pnas.85.16.5829; KELLER EB, 1984, P NATL ACAD SCI-BIOL, V81, P7417, DOI 10.1073/pnas.81.23.7417; Kim H. T., 2000, P 6 INT C TRANSGL TR, P16; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1993, J BIOL CHEM, V268, P12682; KIM IG, 1992, J BIOL CHEM, V267, P7710; KIM IG, 1994, J INVEST DERMATOL, V103, P137, DOI 10.1111/1523-1747.ep12392470; KORSGREN C, 1991, P NATL ACAD SCI USA, V88, P4840, DOI 10.1073/pnas.88.11.4840; KORSGREN C, 1990, P NATL ACAD SCI USA, V87, P613, DOI 10.1073/pnas.87.2.613; KORSGREN C, 1994, GENOMICS, V21, P478, DOI 10.1006/geno.1994.1304; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lee JH, 1996, J BIOL CHEM, V271, P4561; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAJFELD V, 1992, AM J HUM GENET, V50, P71; Nanda N, 1999, ARCH BIOCHEM BIOPHYS, V366, P151, DOI 10.1006/abbi.1999.1189; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Noguchi K, 2001, J BIOL CHEM, V276, P12055, DOI 10.1074/jbc.M009862200; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P4476, DOI 10.1073/pnas.89.10.4476; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Spring J, 1997, FEBS LETT, V400, P2, DOI 10.1016/S0014-5793(96)01351-8; SUNG LPA, 1992, BLOOD, V79, P2763; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; WHITE RA, 1992, NAT GENET, V2, P80, DOI 10.1038/ng0992-80; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; Yee Vivien C., 1996, Seminars in Thrombosis and Hemostasis, V22, P377, DOI 10.1055/s-2007-999035	62	163	171	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33066	33078		10.1074/jbc.M102553200	http://dx.doi.org/10.1074/jbc.M102553200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11390390	hybrid			2022-12-27	WOS:000170746000092
J	Siegmund, D; Mauri, D; Peters, N; Juo, P; Thome, M; Reichwein, M; Blenis, J; Scheurich, P; Tschopp, J; Wajant, H				Siegmund, D; Mauri, D; Peters, N; Juo, P; Thome, M; Reichwein, M; Blenis, J; Scheurich, P; Tschopp, J; Wajant, H			Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL PROLIFERATION; NF-KAPPA-B; LYMPHOPROLIFERATIVE SYNDROME; ACTIVATION; MICE; LYMPHOCYTES; FIBROBLASTS; FADD/MORT1; KINASE; CYTOTOXICITY	Fas, a death domain-containing member of the tumor necrosis factor receptor family and its ligand FasL have been predominantly studied with respect to their capability to induce cell death. However, a few studies indicate a proliferation-inducing signaling activity of these molecules too. We describe here a novel signaling pathway of FasL and the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that triggers transcriptional activation of the proto-oncogene c-fos, a typical target gene of mitogenic pathways. FasL- and TRAIL-mediated up-regulation of c-Fos was completely dependent on the presence of Fas-associated death domain protein (FADD) and caspase-8, but caspase activity seemed to be dispensable as a pan inhibitor of caspases had no inhibitory effect. Upon overexpression of the long splice form of cellular FADD-like interleukin-1-converting enzyme (FLICE) inhibitory protein (cFLIP) in Jurkat cells, FasL- and TRAIL-induced up-regulation of c-Fos was almost completely blocked. The short splice form of FLIP, however, showed a rather stimulatory effect on c-Fos induction. Together these data demonstrate the existence of a death receptor-induced, FADD- and caspase-8-dependent pathway leading to c-Fos induction that is inhibited by the long splice form FLIP-L.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Apotech Biochem Ltd, CH-1066 Epalinges, Switzerland; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of Stuttgart; University of California System; University of California Berkeley; University of Lausanne; Harvard University; Harvard Medical School	Wajant, H (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.		Juo, Peter/CJY-3695-2022; Thome, Margot/F-8167-2011; Wajant, Harald/A-3020-2017	Juo, Peter/0000-0002-3039-2266; Thome, Margot/0000-0002-5656-2139; Wajant, Harald/0000-0002-2005-3949				AGGARWAL BB, 1995, FEBS LETT, P3645; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Desbarats J, 1999, P NATL ACAD SCI USA, V96, P8104, DOI 10.1073/pnas.96.14.8104; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Freiberg RA, 1997, J INVEST DERMATOL, V108, P215, DOI 10.1111/1523-1747.ep12334273; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; Jelaska A, 1998, J CELL PHYSIOL, V175, P19, DOI 10.1002/(SICI)1097-4652(199804)175:1<19::AID-JCP3>3.0.CO;2-F; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Kurasawa K, 2000, J ALLERGY CLIN IMMUN, V106, pS19, DOI 10.1067/mai.2000.106773; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Rescigno M, 2000, J EXP MED, V192, P1661, DOI 10.1084/jem.192.11.1661; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wu JG, 1996, J CLIN INVEST, V98, P1107, DOI 10.1172/JCI118892; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	55	58	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32585	32590		10.1074/jbc.M100444200	http://dx.doi.org/10.1074/jbc.M100444200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11384965	hybrid			2022-12-27	WOS:000170746000029
J	Bell, JK; Yennawar, HP; Wright, SK; Thompson, JR; Viola, RE; Banaszak, LJ				Bell, JK; Yennawar, HP; Wright, SK; Thompson, JR; Viola, RE; Banaszak, LJ			Structural analyses of a malate dehydrogenase with a variable active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MOLECULAR-REPLACEMENT; SUBSTRATE-SPECIFICITY; TERNARY COMPLEX; RESOLUTION; CRYSTALLOGRAPHY; REFINEMENT; CITRATE; MODEL	Malate dehydrogenase specifically oxidizes malate to oxaloacetate. The specificity arises from three arginines in the active site pocket that coordinate the carboxyl groups of the substrate and stabilize the newly forming hydroxyl/keto group during catalysis. Here, the role of Arg-153 in distinguishing substrate specificity is examined by the mutant R153C. The x-ray structure of the NAD binary complex at 2.1 Angstrom reveals two sulfate ions bound in the closed form of the active site. The sulfate that occupies the substrate binding site has been translated similar to2 Angstrom toward the opening of the active site cavity. Its new location suggests that the low catalytic turnover observed in the R153C mutant may be due to misalignment of the hydroxyl or ketone group of the substrate with the appropriate catalytic residues. In the NAD-pyruvate ternary complex, the monocarboxylic inhibitor is bound in the open conformation of the active site. The pyruvate is coordinated not by the active site arginines, but through weak hydrogen bonds to the amide backbone. Energy minimized molecular models of unnatural analogues of R153C (Wright, S. K., and Viola, R. E. (2001) J. Biol Chem. 276, 31151-31155) reveal that the regenerated amino and amido side chains can form favorable hydrogen-bonding interactions with the substrate, although a return to native enzymatic activity is not observed. The low activity of the modified R153C enzymes suggests that precise positioning of the guanidino side chain is essential for optimal orientation of the substrate.	Univ Toledo, Dept Chem, Toledo, OH 43606 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Univ Toledo, Dept Chem, Toledo, OH 43606 USA	University System of Ohio; University of Toledo; University of Minnesota System; University of Minnesota Twin Cities; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University System of Ohio; University of Toledo	Viola, RE (corresponding author), Univ Toledo, Dept Chem, 2801 W Bancroft St, Toledo, OH 43606 USA.		Viola, Ronald/C-5904-2011	Yennawar, Hemant P./0000-0003-2869-1109				BIRKTOFT JJ, 1989, BIOCHEMISTRY-US, V28, P6065, DOI 10.1021/bi00440a051; BIRKTOFT JJ, 1983, J BIOL CHEM, V258, P472; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CASTELLANO EE, 1992, J APPL CRYSTALLOGR, V25, P281, DOI 10.1107/S0021889891012773; Chapman ADM, 1999, J MOL BIOL, V285, P703, DOI 10.1006/jmbi.1998.2357; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; HALL MD, 1991, J MOL BIOL, V220, P551, DOI 10.1016/0022-2836(91)90099-R; HALL MD, 1993, J MOL BIOL, V232, P213, DOI 10.1006/jmbi.1993.1377; HALL MD, 1992, J MOL BIOL, V226, P867, DOI 10.1016/0022-2836(92)90637-Y; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS DJ, 1992, BIOCHEM BIOPH RES CO, V189, P1057, DOI 10.1016/0006-291X(92)92311-K; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; Wright SK, 2000, J BIOL CHEM, V275, P31689, DOI 10.1074/jbc.M003652200; Wright SK, 2001, J BIOL CHEM, V276, P31151, DOI 10.1074/jbc.M100892200	21	23	24	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31156	31162		10.1074/jbc.M100902200	http://dx.doi.org/10.1074/jbc.M100902200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11389141	hybrid			2022-12-27	WOS:000170472900075
J	Hsu, LS; Chen, GD; Lee, LS; Chi, CW; Cheng, JF; Chen, JY				Hsu, LS; Chen, GD; Lee, LS; Chi, CW; Cheng, JF; Chen, JY			Human Ca2+/calmodulin-dependent protein kinase kinase beta gene encodes multiple isoforms that display distinct kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT-RAT BRAIN; MOLECULAR-CLONING; 2 ISOFORMS; MESSENGER-RNAS; CALMODULIN; ACTIVATION; CASCADE; EXPRESSION; CALCIUM; LOCALIZATION	Ca+2/calmodulin-dependent protein kinases (CaMKs) are activated upon binding of Ca+2/calmodulin. To gain maximal activity, CaMK I and CaMK TV can be further phosphorylated by an upstream kinase, CaMK kinase (CaMKK). We previously isolated cDNA clones encoding human CaMKK beta isoforms that are heterogeneous in their 3 ' -sequences (Hsu, L.-S., Tsou, A.-P., Chi, C.-W,, Lee, C.-H., and Chen, J.-Y. (1998) J. Biomed. Sci. 5,141-149). In the present study, we examined the genomic organization and transcription of the human CaMKK beta gene. The human CaMKK beta locus spans more than 40 kilobase pairs and maps to chromosome 12q24.2. It is organized into 18 exons and 17 introns that are flanked by typical splice donor and acceptor sequences. Two major species of transcripts, namely the beta1 (5.6 kilobase pairs) and beta2 (2.9 kilobase pairs), are generated through differential usage of polyadenylation sites located in the last and penultimate exons. Additional forms of CaMKK beta transcripts were also identified that resulted from alternative splicing of the internal exons 14 and/or 16. These isoforms display differential expression patterns in human tissues and tumor-derived cell lines. They also exhibit a distinct ability to undergo autophosphorylation and to phosphorylate the downstream kinases CaMK I and CaMK IV. The differential expression of CaMKK beta isoforms with distinct activity further suggests the complexity of the regulation of the CaMKK/CaMK cascade and an important role for CaMKK in the action of Ca+2- mediated cellular responses.	Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Inst Neurol, Taipei, Taiwan; Vet Gen Hosp, Med Res & Educ Dept, Taipei, Taiwan; Natl Yang Ming Univ, Taipei 112, Taiwan; Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA	Academia Sinica - Taiwan; National Defense Medical Center; National Yang Ming Chiao Tung University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Chen, JY (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.			Cheng, Jan-Fang/0000-0001-7315-7613				ACHESON NH, 1984, MOL CELL BIOL, V4, P722, DOI 10.1128/MCB.4.4.722; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMARA SG, 1984, MOL CELL BIOL, V4, P2151, DOI 10.1128/MCB.4.10.2151; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; CHEN JY, 1993, ONCOGENE, V8, P2159; CRENSHAW EB, 1987, CELL, V49, P389, DOI 10.1016/0092-8674(87)90291-1; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Eto K, 1999, J BIOL CHEM, V274, P22556, DOI 10.1074/jbc.274.32.22556; GuptaRoy B, 1996, J BIOL CHEM, V271, P19846, DOI 10.1074/jbc.271.33.19846; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Heist EK, 1998, CELL CALCIUM, V23, P103; Hsu LS, 1998, J BIOMED SCI, V5, P141, DOI 10.1007/BF02258368; Kitani T, 1997, J BIOCHEM-TOKYO, V122, P243; LEE JSC, 1994, J BIOL CHEM, V269, P2158; Loseth OP, 2000, BRAIN RES, V869, P137, DOI 10.1016/S0006-8993(00)02359-3; Means AR, 2000, MOL ENDOCRINOL, V14, P4, DOI 10.1210/me.14.1.4; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Naito Y, 1997, J BIOL CHEM, V272, P32704, DOI 10.1074/jbc.272.51.32704; OHSAKO S, 1993, J BIOL CHEM, V268, P2052; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; Sakagami H, 1998, MOL BRAIN RES, V54, P311, DOI 10.1016/S0169-328X(97)00362-8; Sakagami H, 2000, EUR J NEUROSCI, V12, P89, DOI 10.1046/j.1460-9568.2000.00883.x; Sambrook J., 2002, MOL CLONING LAB MANU; Santella L, 1998, BIOCHEM BIOPH RES CO, V244, P317, DOI 10.1006/bbrc.1998.8086; SCHULMAN H, 1993, NEUROCHEM RES, V18, P65, DOI 10.1007/BF00966924; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; SUGITA R, 1994, BIOCHEM BIOPH RES CO, V203, P694, DOI 10.1006/bbrc.1994.2238; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Tokumitsu H, 1999, J BIOL CHEM, V274, P15803, DOI 10.1074/jbc.274.22.15803; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Tombes RM, 1999, BBA-MOL CELL RES, V1452, P1, DOI 10.1016/S0167-4889(99)00113-5; Tombes RM, 1997, BBA-MOL CELL RES, V1355, P281, DOI 10.1016/S0167-4889(96)00141-3; Uemura A, 1998, BIOCHEM BIOPH RES CO, V249, P355, DOI 10.1006/bbrc.1998.9154; URQUIDI V, 1995, FEBS LETT, V358, P23, DOI 10.1016/0014-5793(94)01381-A; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zeng WR, 2000, GENE, V241, P75, DOI 10.1016/S0378-1119(99)00465-5	47	34	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31113	31123		10.1074/jbc.M011720200	http://dx.doi.org/10.1074/jbc.M011720200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11395482	hybrid			2022-12-27	WOS:000170472900070
J	Hilairet, S; Foord, SM; Marshall, FH; Bouvier, M				Hilairet, S; Foord, SM; Marshall, FH; Bouvier, M			Protein-protein interaction and not glycosylation determines the binding selectivity of heterodimers between the calcitonin receptor-like receptor and the receptor activity-modifying proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; AMYLIN RECEPTOR; LIGAND-BINDING; CELLS; RAMPS; IDENTIFICATION; TERMINUS; PRODUCT; VECTOR; STATE	The receptor activity-modifying proteins (RAMPs) and the calcitonin receptor-like receptor (CRLR) are both required to generate adrenomedullin (AM) and calcitonin gene-related peptide (CGRP) receptors. A mature, fully glycosylated, form of CRLR was associated with I-125-CGRP binding, upon co-expression of RAMP1 and CRLR. In contrast, RAMP2 and -3 promoted the expression of smaller, core-glycosylated, CRLR forms, which were linked to AM receptor pharmacology. Since core glycosylation is classically a trademark of immature proteins, we tested the hypothesis that the core-glycosylated CRLR forms the AM receptor. Although significant amounts of core-glycosylated CRLR were produced upon co-expression with RAMP2 or -3, crosslinking experiments revealed that I-125-AM only bound to the fully glycosylated forms. Similarly, I-125-CGRP selectively recognized the mature CRLR species upon co-expression with RAMP1, indicating that the glycosylation does not determine ligand-binding selectivity. Our results also show that the three RAMPs lie close to the peptide binding pocket within the CRLR-RAMP heterodimers, since I-125-AM and I-125-CGRP were incorporated in RAMP2, -3, and -1, respectively. Cross-linking also stabilized the peptide-CRLR-RAMP ternary complexes, with the expected ligand selectivity, indicating that the fully processed heterodimers represent the functional receptors. Overall, the data indicate that direct protein-protein interactions dictate the pharmacological properties of the CRLR-RAMP complexes.	Univ Montreal, Fac Med, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Glaxo Wellcome Med Res Ctr, Receptor Syst Unit, Stevenage SG1 2NY, Herts, England	Universite de Montreal; GlaxoSmithKline	Bouvier, M (corresponding author), Univ Montreal, Fac Med, Dept Biochim, POB 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.		Marshall, Fiona/AAZ-9626-2020; Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100; Marshall, Fiona/0000-0002-8681-005X				Aldecoa A, 2000, FEBS LETT, V471, P156, DOI 10.1016/S0014-5793(00)01387-9; Buhlmann N, 1999, ENDOCRINOLOGY, V140, P2883, DOI 10.1210/en.140.6.2883; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; Foord SM, 1999, TRENDS PHARMACOL SCI, V20, P184, DOI 10.1016/S0165-6147(99)01347-4; Foord SM, 1999, BIOCHEM SOC T, V27, P535, DOI 10.1042/bst0270535; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; Leuthauser K, 2000, BIOCHEM J, V351, P347, DOI 10.1042/0264-6021:3510347; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; Muff R, 1998, FEBS LETT, V441, P366, DOI 10.1016/S0014-5793(98)01587-7; Muff R, 1999, ENDOCRINOLOGY, V140, P2924, DOI 10.1210/en.140.6.2924; Owji AA, 1996, J NEUROCHEM, V67, P2172; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Sexton PM, 2001, CELL SIGNAL, V13, P73, DOI 10.1016/S0898-6568(00)00143-1; Zumpe ET, 2000, BIOCHEM BIOPH RES CO, V267, P368, DOI 10.1006/bbrc.1999.1943	17	115	120	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29575	29581		10.1074/jbc.M102722200	http://dx.doi.org/10.1074/jbc.M102722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387328	hybrid			2022-12-27	WOS:000170346000123
J	Li, RH; Wong, N; Jabali, MD; Johnson, P				Li, RH; Wong, N; Jabali, MD; Johnson, P			CD44-initiated cell spreading induces Pyk2 phosphorylation, is mediated by Src family kinases, and is negatively regulated by CD45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; LIPID RAFTS; MONOCLONAL-ANTIBODIES; CYTOPLASMIC DOMAIN; MURINE MACROPHAGES; MEMBRANE DOMAINS; ANTIGEN RECEPTOR; T-LYMPHOCYTES; ADHESION; ACTIVATION	CD44 is a cell adhesion molecule implicated in leukocyte adhesion and migration, co-stimulation of T cells, and tumor metastasis. CD45 is a leukocyte-specific protein tyrosine phosphatase that dephosphorylates the Src family kinases, Lek and Fyn, in T cells. Positive regulation of Lek by CD45 is required for its effective participation in T cell receptor signaling events. Here, immobilized CD44 antibody induced a distinctive cell spreading in CD45(-), but not CD45(+), T cells, and this correlated with the induction of tyrosine-phosphorylated proteins. Two focal adhesion family kinases, Pyk2 and, to a lesser extent, FAK were inducibly phosphorylated, as was a potential substrate, Cas. CD44-mediated cell spreading and induced tyrosine phosphorylation were prevented by the Src family kinase inhibitor, PP2. Furthermore, 2-fold more Lek associated with CD44 in the low density sucrose fraction from CD45- T cells compared with CD45(+) T cells, suggesting that CD45 may regulate the association of Lek with CD44 in this fraction. Therefore, in CD45- T cells, CD44 signaling is mediated by Src family kinases, and this leads to Pyk2 phosphorylation, cytoskeletal changes, and cell spreading. This implicates CD45 in the negative regulation of Src family kinase-mediated CD44 signaling leading to T cell spreading.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Johnson, P (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.		Johnson, Pauline/G-9659-2019; Wong, Nelson/S-5526-2016	Johnson, Pauline/0000-0001-7367-4653; Wong, Nelson/0000-0002-7003-6020				Alexander DR, 2000, SEMIN IMMUNOL, V12, P349, DOI 10.1006/smim.2000.0218; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Ashwell JD, 1999, IMMUNOL TODAY, V20, P412, DOI 10.1016/S0167-5699(99)01505-4; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; BELITSOS PC, 1990, J IMMUNOL, V144, P1661; Berg NN, 1997, J IMMUNOL, V159, P1753; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CAMP RL, 1993, J EXP MED, V178, P497, DOI 10.1084/jem.178.2.497; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; Fujisaki T, 1999, CANCER RES, V59, P4427; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HodgeDufour J, 1997, J IMMUNOL, V159, P2492; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; HOREJSI V, 1994, BRAZ J MED BIOL RES, V27, P255; HUET S, 1989, J IMMUNOL, V143, P798; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; HYMAN R, 1981, IMMUNOGENETICS, V12, P511, DOI 10.1007/BF01561692; Ilangumaran S, 2000, IMMUNOL TODAY, V21, P2, DOI 10.1016/S0167-5699(99)01494-2; Ilangumaran S, 1998, BLOOD, V91, P3901; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Johnson P, 2000, BIOCHEM PHARMACOL, V59, P455, DOI 10.1016/S0006-2952(99)00266-X; Kawakami N, 1999, J IMMUNOL, V163, P3211; KELLEHER D, 1995, J LEUKOCYTE BIOL, V58, P539, DOI 10.1002/jlb.58.5.539; Kim JH, 2000, EXP CELL RES, V256, P445, DOI 10.1006/excr.2000.4852; KOOPMAN G, 1990, J IMMUNOL, V145, P3589; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; LESLEY J, 1985, CELL IMMUNOL, V91, P397, DOI 10.1016/0008-8749(85)90237-0; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; Ng DHW, 1997, BIOCHEM J, V327, P867; Ng DHW, 1996, J BIOL CHEM, V271, P1295, DOI 10.1074/jbc.271.3.1295; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PERSCHL A, 1995, J CELL SCI, V108, P1033; Roach T, 1997, CURR BIOL, V7, P408, DOI 10.1016/S0960-9822(06)00188-6; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; SantosArgumedo L, 1997, IMMUNOLOGY, V90, P147, DOI 10.1046/j.1365-2567.1997.00126.x; Shenoi H, 1999, J IMMUNOL, V162, P7120; Siegelman MH, 1999, J LEUKOCYTE BIOL, V66, P315, DOI 10.1002/jlb.66.2.315; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; Taher TEI, 1996, J BIOL CHEM, V271, P2863, DOI 10.1074/jbc.271.5.2863; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T	52	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28767	28773		10.1074/jbc.M100158200	http://dx.doi.org/10.1074/jbc.M100158200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11369760	hybrid			2022-12-27	WOS:000170346000018
J	Sato, C; Yasukawa, Z; Honda, N; Matsuda, T; Kitajima, K				Sato, C; Yasukawa, Z; Honda, N; Matsuda, T; Kitajima, K			Identification and adipocyte differentiation-dependent expression of the unique disialic acid residue in an adipose tissue-specific glycoprotein, adipo Q	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CDNA CLONING; PROTEIN; FAMILY; ADIPONECTIN; REAGENT; MEMBER; ALPHA; OLIGO; SERUM	Recently, we have shown that alpha2,8-linked disialic acid (diSia) residue occurs in glycoproteins more frequently than ever recognized (Sato, C., Fukuoka, H., Ohta, K., Matsuda, T., Koshino, R., Kobayashi K., Troy, F. A., II, and Kitajima, K. (2000) J. BioL Chem. 275,15422-15431). In the course of identification of the diSia-containing glycoproteins in mammals, the 30-kDa glycoprotein was found in bovine serum. The 30-kDa glycoprotein was shown to be the bovine adipo Q, an adipocyte-specific protein, based on the partial amino acid sequences and the immuno-cross-reactivity with the recombinant mouse adipo Q. The bovine adipo, Q was shown to have no N-linked but O-linked glycan(s) containing the diSia epitope, Neu5Ac alpha2-8Neu5Ac alpha2 --> 3Gal. Furthermore, the diSia epitope was also found in the mouse adipo Q in serum as well as in the 3T3-L1 cells that are fully differentiated into adipocytes. Notably, among the known alpha2,8-sialyltransferases, only the alpha2,8-sialyltransferase III mRNA was detected in the 3T3-L1 cells at any stages of differentiation, and the recombinant alpha2,8-sialyltransferase III could sialylate the purified bovine adipo Q. Thus, this study clearly provides the new findings that adipo Q is the diSia-containing glycoprotein and a physiological substrate of alpha2,8-sialyltransferase III, whose substrates have not been identified so far.	Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Biosci Ctr, Div Oncogenesis, Dept Anim Sci, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University	Kitajima, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan.	kitajima@agr.nagoya-u.ac.jp	SATO, Chihiro/B-7396-2014					Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8625, DOI 10.1074/jbc.275.12.8625; BRUES JL, 2000, MOL CELLULAR GLYCOBI, P116; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; ECKHART M, 1995, NATURE, V373, P213; HARA S, 1986, J CHROMATOGR, V377, P111, DOI 10.1016/S0378-4347(00)80766-5; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; INOUE Y, 1992, POLYSIALIC ACIDS, P171; Kitajima K, 1999, SIALOBIOLOGY OTHER N, P69; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Nagai Y., 1995, BIOL SIALIC ACIDS, P197; NAKAMURA M, 1987, CHEM PHARM BULL, V35, P687; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803; Nakata D, 2000, BIOCHEM BIOPH RES CO, V273, P642, DOI 10.1006/bbrc.2000.2983; Ohta K, 2000, GLYCOCONJUGATE J, V17, P205, DOI 10.1023/A:1026589223811; Okamoto Y, 2000, HORM METAB RES, V32, P47, DOI 10.1055/s-2007-978586; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sato C, 1998, ANAL BIOCHEM, V261, P191, DOI 10.1006/abio.1998.2718; Sato C, 1998, J BIOL CHEM, V273, P2575, DOI 10.1074/jbc.273.5.2575; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; Sato C, 1999, ANAL BIOCHEM, V266, P102, DOI 10.1006/abio.1998.2921; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Sharon N., 1997, GLYCOSCIENCES STATUS, P133; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; Takeuchi Y, 1999, EUR J BIOCHEM, V260, P736, DOI 10.1046/j.1432-1327.1999.00203.x; TROY FA, 1996, BIOL SIALIC ACIDS, P95; TSUJI S, 1997, SIALOBIOLOGY OTHER N, P145; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; Yokota T, 2000, BLOOD, V96, P1723, DOI 10.1182/blood.V96.5.1723; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628	34	86	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28849	28856		10.1074/jbc.M104148200	http://dx.doi.org/10.1074/jbc.M104148200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382781	hybrid			2022-12-27	WOS:000170346000030
J	Wells, CD; Gutowski, S; Bollag, G; Sternweis, PC				Wells, CD; Gutowski, S; Bollag, G; Sternweis, PC			Identification of potential mechanisms for regulation of p115 RhoGEF through analysis of endogenous and mutant forms of the exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY GTPASES; LYSOPHOSPHATIDIC ACID; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; CRYSTAL-STRUCTURE; HOMOLOGY DOMAIN; ALPHA-SUBUNIT; PROTEIN; ACTIVATION; G-ALPHA(13)	Rho GTPases play a fundamental role in numerous cellular processes that are initiated by extracellular stimuli including agonists that work through G protein-coupled receptors. A direct pathway for such regulation was elucidated by the identification of p115 RhoGEF, an exchange factor for RhoA that is activated through its RGS domain by G alpha (13). Endogenous p115 RhoGEF was found mainly in the cytosol of serum-starved cells but partially localized to membranes in cells stimulated with lysophosphatidic acid. Overexpressed p115 RhoGEF was equally distributed between membranes and cytosol; either the RGS or pleckstrin homology domain was sufficient for this partial targeting to membranes. Removal of the pleckstrin homology domain dramatically reduced the in vitro rate of p115 RhoGEF exchange activity. Deletion of amino acids 252-288 in the linker region between the RGS domain and the Dbl homology domain or of the last 150 C-terminal amino acids resulted in non-additive reduction of in vitro exchange activity. In contrast, p115 RhoGEF pieces lacking this extended C terminus were over 5-fold more active than the full-length exchange factor in vivo. These results suggest that p115 RhoGEF is inhibited in the cellular milieu through modification or interaction of inhibitory factors with its C terminus. Endogenous p115 RhoGEF that was immunoprecipitated from cells stimulated with lysophosphatidic acid or sphingosine 1-phosphate was more active than when the enzyme was immunoprecipitated from untreated cells. This indicates an additional and potentially novel long lived mechanism for regulation of p115 RhoGEF by G protein-coupled receptors.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sternweis, PC (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954, T32GM007062] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31954, GM07062] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Meredith JE, 1996, ENDOCR REV, V17, P207, DOI 10.1210/er.17.3.207; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sambrook J., 2002, MOL CLONING LAB MANU; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; VAN AL, 1997, GENE DEV, V11, P2295; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	42	64	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28897	28905		10.1074/jbc.M102913200	http://dx.doi.org/10.1074/jbc.M102913200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384980	hybrid			2022-12-27	WOS:000170346000036
J	Callahan, NA; Xiong, LW; Caughey, B				Callahan, NA; Xiong, LW; Caughey, B			Reversibility of scrapie-associated prion protein aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; BETA-AMYLOID PROTOFIBRILS; CELL-FREE FORMATION; ALZHEIMERS-DISEASE; RESISTANT STATE; INFRARED-SPECTROSCOPY; FIBRILS SAF; PRP 27-30; CONVERSION; FORM	During the course of the transmissible spongiform encephalopathy diseases, a protease-resistant ordered aggregate of scrapie prion protein (PrPSc) accumulates in affected animals. From mechanistic and therapeutic points of view, it is relevant to determine the extent to which PrPSc formation and aggregation are reversible. PrPSc solubilized with 5 M guanidine hydrochloride (GdnHCl) was unfolded to a predominantly random coil conformation. Upon dilution of GdnHCl, PrP refolded into a conformation that was high in a-helix as measured by CD spectroscopy, similar to the normal cellular isoform. of PrP (PrPC). This provided evidence that PrPSc can be induced to revert to a PrPC-like conformation with a strong denaturant. To examine the reversibility of PrPSc formation and aggregation under more physiological conditions, PrPSc aggregates were washed and resuspended in buffers lacking GdnHCl and monitored over time for the appearance of soluble PrP. No dissociation of PrP from the PrPSc aggregates was detected in aqueous buffers at pH 6 and 7.5. The effective solubility of PrP was <0.7 nM. Treatment of PrPSc with proteinase K (PK) before the analysis did not enhance the dissociation of PrP from the PrPSc aggregates. Treatment with 2.5 M GdnHCl, which partially and reversibly unfolds PrPSc, caused only limited dissociation of PrP from the aggregates. The PrP that dissociated from the aggregates over time was entirely PK-sensitive, like PrPC, whereas all of the aggregated PrP was partially PK-resistant. PrP also dissociated from aggregates of protease-resistant PrP generated in a cell-free conversion reaction, but only if treated with GdnHCl. Overall, the results suggest that PrP aggregation is not appreciably reversible under physiological conditions' but dissociation and refolding can be enhanced by treatments with GdnHCl.	NIAID, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Caughey, B (corresponding author), NIAID, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.	beaughey@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000580, Z01AI000580] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; BARRY RA, 1985, J IMMUNOL, V135, P603; BODE L, 1985, J GEN VIROL, V66, P2471, DOI 10.1099/0022-1317-66-11-2471; BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BROWN DR, 1994, NEUROREPORT, V5, P2057, DOI 10.1097/00001756-199410270-00017; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Caughey B, 1997, J VIROL, V71, P4107, DOI 10.1128/JVI.71.5.4107-4110.1997; Caughey B, 1999, METHOD ENZYMOL, V309, P122; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Esler WP, 2000, BIOCHEMISTRY-US, V39, P6288, DOI 10.1021/bi992933h; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GADJUSEK DC, 1988, J NEUROIMMUNOL, V20, P95; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; Hope J, 1996, NEURODEGENERATION, V5, P1, DOI 10.1006/neur.1996.0001; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kocisko DA, 1996, BIOCHEMISTRY-US, V35, P13434, DOI 10.1021/bi9610562; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LANSBURY PT, 1995, CHEM BIOL, V2, P1, DOI 10.1016/1074-5521(95)90074-8; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; Masel J, 1999, BIOPHYS CHEM, V77, P139, DOI 10.1016/S0301-4622(99)00016-2; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; MCKINLEY MP, 1991, LAB INVEST, V65, P622; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; NGUYEN JT, 1995, J MOL BIOL, V252, P412, DOI 10.1006/jmbi.1995.0507; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRIOLA SA, 1995, J BIOL CHEM, V270, P3299, DOI 10.1074/jbc.270.7.3299; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; RUBENSTEIN R, 1996, BOVINE SPONGIFORM EN, P232; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Seshadri S, 1999, METHOD ENZYMOL, V309, P559; SKLAVIADIS TK, 1989, J VIROL, V63, P1212, DOI 10.1128/JVI.63.3.1212-1222.1989; SOMERVILLE RA, 1989, J GEN VIROL, V70, P25, DOI 10.1099/0022-1317-70-1-25; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Supattapone S, 2001, J VIROL, V75, P3453, DOI 10.1128/JVI.75.7.3453-3461.2001; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; Torii Hajime, 1996, P1; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377	60	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28022	28028		10.1074/jbc.M103629200	http://dx.doi.org/10.1074/jbc.M103629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375994	hybrid			2022-12-27	WOS:000170093400038
J	Jeanclos, EM; Lin, L; Treuil, MW; Rao, J; DeCoster, MA; Anand, R				Jeanclos, EM; Lin, L; Treuil, MW; Rao, J; DeCoster, MA; Anand, R			The chaperone protein 14-3-3 eta interacts with the nicotinic acetylcholine receptor alpha 4 subunit - Evidence for a dynamic role in subunit stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRONTAL-LOBE EPILEPSY; GATED ION CHANNELS; ENDOPLASMIC-RETICULUM; MUSCLE-CELLS; GENE YWHAH; PHOSPHORYLATION; 14-3-3-PROTEINS; EXPRESSION; KINASE; MUTATION	By using the large cytoplasmic domain of the nicotinic acetylcholine receptor (AChR) alpha4 subunit as a bait in the yeast two-hybrid system, we isolated the first cytosolic protein, 14-3-3-eta, known to interact directly with neuronal AChRs. 14-3-3-eta is a member of a family of proteins that function as regulatory or chaperone/scaffolding/adaptor proteins. 14-3-3-eta interacted with the recombinant alpha4 subunit alone in tsA 201 cells following activation of cAMP-dependent protein kinase by forskolin. The interaction of 14-3-3-eta with recombinant alpha4 subunits was abolished when serine 441 of the alpha4 subunit was mutated to alanine (alpha4(S441A)). The surface levels of recombinant wild-type alpha4 beta2 AChRs were similar to2-fold higher than those of mutant alpha4(S441A)beta2 AChRs. The interaction significantly increased the steady state levels of the alpha4 subunit and alpha4 beta2 AChRs but not that of the mutant alpha4(S441A) subunit or mutant alpha4(S441A)beta2 AChRs. The EC50 values for activation by acetylcholine were not significantly different for alpha4 beta2 AChRs and alpha4(S441A)beta2 AChRs coexpressed with 14-3-3-eta in oocytes following treatment with forskolin. 14-3-3 coimmunopurified with native alpha4 AChRs from brain. These results support a role for 14-3-3 in dynamically regulating the expression levels of alpha4 beta2 AChRs through its interaction with the alpha4 subunit.	Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Anand, R (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, 2020 Gravier St,Ste D, New Orleans, LA 70112 USA.		DeCoster, Mark/AAF-5224-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS033625] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33625] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; Anand R, 1998, J PHARMACOL EXP THER, V287, P469; Autieri MV, 1996, CELL GROWTH DIFFER, V7, P1453; BARNARD EA, 1992, TRENDS BIOCHEM SCI, V17, P368, DOI 10.1016/0968-0004(92)90002-Q; BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; Breese CR, 2000, NEUROPSYCHOPHARMACOL, V23, P351, DOI 10.1016/S0893-133X(00)00121-4; Broadie K, 1997, NEURON, V19, P391, DOI 10.1016/S0896-6273(00)80948-4; BURGOYNE RD, 1993, J ANAT, V183, P309; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; Cooper ST, 1999, J BIOL CHEM, V274, P27145, DOI 10.1074/jbc.274.38.27145; DENERIS ES, 1991, TRENDS PHARMACOL SCI, V12, P34, DOI 10.1016/0165-6147(91)90486-C; Dubois T, 1997, J PROTEIN CHEM, V16, P513, DOI 10.1023/A:1026321813463; Eertmoed AL, 1999, J NEUROSCI, V19, P6298; FRAIL DE, 1987, P NATL ACAD SCI USA, V84, P6302, DOI 10.1073/pnas.84.17.6302; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; Gopalakrishnan M, 1997, MOL PHARMACOL, V52, P524, DOI 10.1124/mol.52.3.524; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; Hirose S, 1999, NEUROLOGY, V53, P1749, DOI 10.1212/WNL.53.8.1749; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; Keller SH, 1999, J GEN PHYSIOL, V113, P171, DOI 10.1085/jgp.113.2.171; Keller SH, 1998, J BIOL CHEM, V273, P17064, DOI 10.1074/jbc.273.27.17064; Kuwana T, 1998, P NATL ACAD SCI USA, V95, P1056, DOI 10.1073/pnas.95.3.1056; Lindstrom J, 1996, Ion Channels, V4, P377; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; Marubio LM, 1999, NATURE, V398, P805, DOI 10.1038/19756; MCCONNELL JE, 1995, DEV BIOL, V169, P218, DOI 10.1006/dbio.1995.1139; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Muratake T, 1996, GENOMICS, V36, P63, DOI 10.1006/geno.1996.0426; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; Olsson A, 1998, PLANT PHYSIOL, V118, P551, DOI 10.1104/pp.118.2.551; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; PAULSON HL, 1991, J CELL BIOL, V113, P1371, DOI 10.1083/jcb.113.6.1371; PHILLIPS HA, 1995, NAT GENET, V10, P117, DOI 10.1038/ng0595-117; PHILLIPS WD, 1991, J CELL BIOL, V115, P1713, DOI 10.1083/jcb.115.6.1713; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; PICCIOTTO MR, 1995, NATURE, V374, P65, DOI 10.1038/374065a0; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ramarao MK, 1998, P NATL ACAD SCI USA, V95, P4007, DOI 10.1073/pnas.95.7.4007; ROSS AF, 1991, J CELL BIOL, V113, P623, DOI 10.1083/jcb.113.3.623; ROSS AF, 1987, J BIOL CHEM, V262, P14640; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SIVILOTTI L, 1995, SCIENCE, V269, P1681, DOI 10.1126/science.7569892; Skoulakis EMC, 1998, MOL NEUROBIOL, V16, P269, DOI 10.1007/BF02741386; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; Steinlein OK, 1997, HUM MOL GENET, V6, P943, DOI 10.1093/hmg/6.6.943; Toyooka K, 1999, AM J MED GENET, V88, P164, DOI 10.1002/(SICI)1096-8628(19990416)88:2<164::AID-AJMG13>3.0.CO;2-3; Wang WF, 1996, J MOL EVOL, V43, P384; WATANABE M, 1993, DEV BRAIN RES, V73, P225, DOI 10.1016/0165-3806(93)90142-W; WHITING PJ, 1988, J NEUROSCI, V8, P3395; WILLIAMS BM, 1999, NATURE, V1, P557; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zoli M, 1999, EMBO J, V18, P1235, DOI 10.1093/emboj/18.5.1235	56	129	137	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28281	28290		10.1074/jbc.M011549200	http://dx.doi.org/10.1074/jbc.M011549200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11352901	hybrid			2022-12-27	WOS:000170093400073
J	Voskoboinik, I; Mar, J; Strausak, D; Camakaris, J				Voskoboinik, I; Mar, J; Strausak, D; Camakaris, J			The regulation of catalytic activity of the menkes copper-translocating P-type ATPase - Role of high affinity copper-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON-DISEASE PROTEIN; HAMSTER OVARY CELLS; CANDIDATE GENE; CALCIUM-PUMP; SACCHAROMYCES-CEREVISIAE; SARCOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; TRANSPORTING ATPASE; PLASMA-MEMBRANE; DOMAINS	The Menkes protein is a transmembrane copper translocating P-type ATPase. Mutations in the Menkes gene that affect the function of the Menkes protein may cause Menkes disease in humans, which is associated with severe systemic copper deficiency. The catalytic mechanism of the Menkes protein, including the formation of transient acylphosphate, is poorly understood. We transfected and overexpressed wild-type and targeted mutant Menkes protein in yeast and investigated its transient acyl phosphorylation. We demonstrated that the Menkes protein is transiently phosphorylated by ATP in a copper-specific and copper-dependent manner and appears to undergo conformational changes in accordance with the classical P-type ATPase model. Our data suggest that the catalytic cycle of the Menkes protein begins with the binding of copper to high affinity binding sites in the transmembrane channel, followed by ATP binding and transient phosphorylation. We propose that. putative copper-binding sites at the N-terminal domain of the Menkes protein are important as sensors of low concentrations of copper but are not essential for the overall catalytic activity.	Univ Melbourne, Dept Genet, Parkville, Vic 3010, Australia; Deakin Univ, Sch Biol & Chem Sci, Ctr Cellular & Mol Biol, Burwood 3125, Australia	University of Melbourne; Deakin University	Camakaris, J (corresponding author), Univ Melbourne, Dept Genet, Parkville, Vic 3010, Australia.	j.camakaris@unimelb.edu.au		Voskoboinik, Ilia/0000-0002-6410-009X				[Anonymous], 1995, METABOLIC BASIS INHE; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camakaris J, 1999, BIOCHEM BIOPH RES CO, V261, P225, DOI 10.1006/bbrc.1999.1073; CAMAKARIS J, 1995, HUM MOL GENET, V4, P2117, DOI 10.1093/hmg/4.11.2117; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; Forbes JR, 1998, AM J HUM GENET, V63, P1663, DOI 10.1086/302163; Goodyer ID, 1999, HUM MOL GENET, V8, P1473, DOI 10.1093/hmg/8.8.1473; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; La Fontaine S, 1998, HUM MOL GENET, V7, P1293, DOI 10.1093/hmg/7.8.1293; LINDER MC, 1991, BIOCH ELEMENTS, P331; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MOLLMAN JE, 1980, J BIOL CHEM, V255, P569; ONEAL SG, 1979, BIOCHEM BIOPH RES CO, V89, P845, DOI 10.1016/0006-291X(79)91855-2; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; PAYNTER JA, 1994, FEBS LETT, V351, P186, DOI 10.1016/0014-5793(94)00868-X; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rensing C, 1999, J BACTERIOL, V181, P5891, DOI 10.1128/JB.181.19.5891-5897.1999; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SOLIOZ M, 1994, FEBS LETT, V346, P44, DOI 10.1016/0014-5793(94)00316-5; Solioz M, 1997, FEBS LETT, V412, P165, DOI 10.1016/S0014-5793(97)00770-9; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Theophilos MB, 1996, HUM MOL GENET, V5, P1619, DOI 10.1093/hmg/5.10.1619; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Voskoboinik I, 2001, BIOCHEM BIOPH RES CO, V281, P966, DOI 10.1006/bbrc.2001.4445; Voskoboinik I, 1998, FEBS LETT, V435, P178, DOI 10.1016/S0014-5793(98)01059-X; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Wunderli-Ye H, 2001, BIOCHEM BIOPH RES CO, V280, P713, DOI 10.1006/bbrc.2000.4176; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	46	103	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28620	28627		10.1074/jbc.M103532200	http://dx.doi.org/10.1074/jbc.M103532200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373292	hybrid			2022-12-27	WOS:000170093400116
J	Yan, B; Calderwood, DA; Yaspan, B; Ginsberg, MH				Yan, B; Calderwood, DA; Yaspan, B; Ginsberg, MH			Calpain cleavage promotes talin binding to the beta(3) integrin cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; VINCULIN-BINDING; FOCAL ADHESIONS; CELL-ADHESION; ACTIN; ACTIVATION; SITES; ALPHA(IIB)BETA(3); IDENTIFICATION; EQUILIBRIUM	Talin links integrin beta cytoplasmic domains to the actin cytoskeleton and is involved in the clustering and activation of these receptors. To understand how talin recognizes integrin beta cytoplasmic domains, we configured surface plasmon resonance methodology to measure the interaction of talin with the beta (3) integrin cytoplasmic domain. Here we report that the N-terminal similar to 47-kDa talin head domain (talin-H) has a 6-fold higher binding affinity than intact talin for the beta (3) tail. The affinity difference is mainly due to a difference in k(on). Calpain cleavage of intact talin released talin-H and resulted in a 16-fold increase in apparent K-alpha and a 100-fold increase in apparent k(on). The increase in talin binding after cleavage was greater than predicted for stoichiometric liberation of free talin-H. This additional increase in binding was due to cooperative binding of talin-H and talin rod domain to the beta (3) tail. Talin resembles ERM (ezrin, radixin, moesin) proteins in possessing an N-terminal FERM (band four-point-one, ezrin, radixin, moesin) domain. These data show that the talin FERM domain, like that in the ERM proteins, is masked in the intact molecule. Furthermore, they suggest that talin cleavage by calpain may contribute to the effects of the protease on the clustering and activation of integrins.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ginsberg@scripps.edu	Calderwood, David A/AAC-6954-2019	Calderwood, David A/0000-0002-0791-4142; Yaspan, Brian/0000-0002-3787-2510	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900, P01HL048728, P01HL031950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027214, R37AR027214] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31950, HL 57900, HL 48728] Funding Source: Medline; NIAMS NIH HHS [AR 27214] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Croce K, 1999, J BIOL CHEM, V274, P36321, DOI 10.1074/jbc.274.51.36321; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; ELEMER GS, 1994, J BIOL CHEM, V269, P3159; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Goldmann WH, 2000, BIOCHEM BIOPH RES CO, V271, P553, DOI 10.1006/bbrc.2000.2653; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Hemmings L, 1996, J CELL SCI, V109, P2715; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Isenberg G, 1998, FEBS LETT, V426, P165, DOI 10.1016/S0014-5793(98)00336-6; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KAUFMANN S, 1991, FEBS LETT, V284, P187, DOI 10.1016/0014-5793(91)80681-R; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; McCann RO, 1998, MOL BIOL CELL, V9, p138A; OHALLORAN T, 1985, NATURE, V317, P449, DOI 10.1038/317449a0; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; OTTO JJ, 1983, J CELL BIOL, V97, P1283, DOI 10.1083/jcb.97.4.1283; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; Yan B, 2000, J BIOL CHEM, V275, P7249, DOI 10.1074/jbc.275.10.7249; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347	41	182	185	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28164	28170		10.1074/jbc.M104161200	http://dx.doi.org/10.1074/jbc.M104161200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382782	hybrid			2022-12-27	WOS:000170093400057
J	Carrick, FE; Forbes, BE; Wallace, JC				Carrick, FE; Forbes, BE; Wallace, JC			BIAcore analysis of bovine insulin-like growth factor (IGF)-binding protein-2 identifies major IGF binding site determinants in both the amino- and carboxyl-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; FACTOR BINDING-PROTEIN-4; STRUCTURAL ANALOGS; ESCHERICHIA-COLI; AFFINITY; REGION; FRAGMENTS; SERUM; LOCALIZATION; SUPERFAMILY	In the absence of a complete tertiary structure to define the molecular basis of the high affinity binding interaction between insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs), we have investigated binding of IGFs by discrete amino-terminal domains (amino acid residues 1-93, 1-104, 1-132, and 1-185) and carboxyl-terminal domains (amino acid residues 96-279, 136-279, and 182-284) of bovine IGFBP-2 (bIGFSP-2). Both halves of bIGFBP-2 bound IGF-I and IGF-II in BIAcore studies, albeit with different affinities ((1-132)IGFBP-2, K(D) = 36.3 and 51.8 nM; (136-279)IGFBP-2HIS, K(D) = 23.8 and 16.3 nM, respectively). The amino-terminal half appears to contain components responsible for fast association. In contrast, IGF binding by the carboxyl-terminal fragment results in a more stable complex as reflected by its K(D). Furthermore, des(1-3)IGF-I and des(1-6)IGF-II exhibited reduced binding affinity to (1-279)IGFBP-2HIS, (1-132)IGFBP-2, and (136-279)IGFBP-2HIS biosensor surfaces compared with wild-type IGF. A charge reversal at positions 3 and 6 of IGF-I and IGF-II, respectively, affects binding interactions with the amino-terminal fragment and full-length bPGFBP-2 but not the carboxyl-terminal fragment.	Univ Adelaide, Cooperat Res Ctr Tissue Growth & Repair, Dept Mol Biosci, Adelaide, SA 5005, Australia	University of Adelaide	Carrick, FE (corresponding author), Univ Adelaide, Cooperat Res Ctr Tissue Growth & Repair, Dept Mol Biosci, N Terrace, Adelaide, SA 5005, Australia.	francine.carrick@adelaide.edu.au	Forbes, Briony/R-1838-2019; , John/AAP-5150-2020	Forbes, Briony/0000-0003-4360-9927				ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; BACH LA, 1993, J BIOL CHEM, V268, P9246; BAGLEY CJ, 1989, BIOCHEM J, V259, P665, DOI 10.1042/bj2590665; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; BAXTER RC, 1994, HORM RES, V42, P140, DOI 10.1159/000184186; BAYNE ML, 1988, J BIOL CHEM, V263, P6233; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; Bramani S, 1999, J MOL ENDOCRINOL, V23, P117, DOI 10.1677/jme.0.0230117; BRINKMAN A, 1991, MOL ENDOCRINOL, V5, P987, DOI 10.1210/mend-5-7-987; BRINKMAN A, 1991, FEBS LETT, V291, P264, DOI 10.1016/0014-5793(91)81298-M; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; CASCIERI MA, 1989, J BIOL CHEM, V264, P2199; CHERNAUSEK SD, 1995, J BIOL CHEM, V270, P11377, DOI 10.1074/jbc.270.19.11377; CONOVER CA, 1995, J BIOL CHEM, V270, P4395, DOI 10.1074/jbc.270.9.4395; Conover CA, 1998, INT CONGR SER, V1151, P107; DURHAM SK, 1995, ENDOCRINOLOGY, V136, P1374, DOI 10.1210/en.136.4.1374; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; Forbes BE, 1998, J BIOL CHEM, V273, P4647, DOI 10.1074/jbc.273.8.4647; FRANCIS GL, 1993, BIOCHEM J, V293, P713, DOI 10.1042/bj2930713; Galanis M, 2001, J ENDOCRINOL, V169, P123, DOI 10.1677/joe.0.1690123; Hashimoto R, 1997, J BIOL CHEM, V272, P27936, DOI 10.1074/jbc.272.44.27936; Ho PJ, 1997, ENDOCRINOLOGY, V138, P3811, DOI 10.1210/en.138.9.3811; Hobba GD, 1996, J BIOL CHEM, V271, P30529, DOI 10.1074/jbc.271.48.30529; Hobba GD, 1998, J BIOL CHEM, V273, P19691, DOI 10.1074/jbc.273.31.19691; Horney MJ, 2001, J BIOL CHEM, V276, P2880, DOI 10.1074/jbc.M007526200; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; Jones JC, 1998, J FIRE SCI, V16, P3, DOI 10.1177/073490419801600101; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; KING R, 1992, J MOL ENDOCRINOL, V8, P29, DOI 10.1677/jme.0.0080029; KUBLER B, 1999, GROWTH HORM IGF RES, V9, P362; Landale EC, 1995, GROWTH FACTORS, V12, P245, DOI 10.3109/08977199509028963; LOFAS S, 1990, J CHEM SOC CHEM COMM, P1526, DOI 10.1039/c39900001526; LUCIC M, 2000, THESIS ADELAIDE U; Lucic MR, 1998, J BIOTECHNOL, V61, P95, DOI 10.1016/S0168-1656(98)00012-1; Magee BA, 1999, BIOCHEMISTRY-US, V38, P15863, DOI 10.1021/bi9910070; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Qin XZ, 1998, J BIOL CHEM, V273, P23509, DOI 10.1074/jbc.273.36.23509; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; SOMMER A, 1991, MODERN CONCEPTS INSU, P715; Spencer E. Martin, 1995, Progress in Growth Factor Research, V6, P209; Standker L, 1998, FEBS LETT, V441, P281, DOI 10.1016/S0014-5793(98)01497-5; Standker L, 2000, BIOCHEMISTRY-US, V39, P5082, DOI 10.1021/bi992513s; SUN Y, 1993, BIOTECHNIQUES, V15, P372; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7; ZAPF J, 1988, BIOCHEM BIOPH RES CO, V156, P1187, DOI 10.1016/S0006-291X(88)80758-7	49	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27120	27128		10.1074/jbc.M101317200	http://dx.doi.org/10.1074/jbc.M101317200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356837	hybrid			2022-12-27	WOS:000169966900053
J	Fantz, DA; Jacobs, D; Glossip, D; Kornfeld, K				Fantz, DA; Jacobs, D; Glossip, D; Kornfeld, K			Docking sites on substrate proteins direct extracellular signal-regulated kinase to phosphorylate specific residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY INTERACTION; COMPLEX FACTOR ELK-1; ERK MAP KINASE; INTERACTION MOTIF; IN-VIVO; PTP-SL; ACTIVATION; DOMAIN; BINDING; TRANSCRIPTION	Mitogen-activated protein (MAP) kinases such as extracellular signal-regulated kinase (ERK) are important signaling proteins that phosphorylate (S/T)P sites in many different protein substrates, ERK binding to substrate proteins is mediated by docking sites including the FXFP motif and the D-domain, We characterized the sequence of amino acids that can constitute the FXFP motif using peptide and protein substrates, Substitutions of the phenylalanines at positions 1 and 3 had significant effects, indicating that these phenylalanines provide substantial binding affinity, whereas substitutions of the residues at positions 2 and 4 had less effect. The FXFP and D-domain docking sites were analyzed in a variety of positions and arrangements in the proteins ELK-1 and KSR-1, Our results indicate that the FXFP and D-domain docking sites form a flexible, modular system that has two functions. First, the affinity of a substrate for ERK can be regulated by the number, type, position, and arrangement of docking sites. Second, in substrates with multiple potential phosphorylation sites, docking sites can direct phosphorylation of specific (SPT)P residues. In particular, the FQFP motif of ELK-1 is necessary and sufficient to direct phosphorylation of serine 383, whereas the D-domain directs phosphorylation of other (SPT)P sites in ELK-1.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Kornfeld, K (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.							ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dillon N, 2000, BIOESSAYS, V22, P657, DOI 10.1002/1521-1878(200007)22:7<657::AID-BIES8>3.3.CO;2-U; Drewett V, 2000, J BIOL CHEM, V275, P1757, DOI 10.1074/jbc.275.3.1757; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Jacobs D, 1998, GENETICS, V149, P1809; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Johnson TR, 2000, J BIOL CHEM, V275, P31755, DOI 10.1074/jbc.M004182200; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; Sambrook J., 2002, MOL CLONING LAB MANU; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V19, P459; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TRIESMAN R, 1994, CURR OPIN GENET DEV, V4, P96; Volle DJ, 1999, BIOCHEMISTRY-US, V38, P5130, DOI 10.1021/bi983050d; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	49	151	157	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27256	27265		10.1074/jbc.M102512200	http://dx.doi.org/10.1074/jbc.M102512200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11371562	hybrid			2022-12-27	WOS:000169966900071
J	Skipper, L; Campbell, WH; Mertens, JA; Lowe, DJ				Skipper, L; Campbell, WH; Mertens, JA; Lowe, DJ			Pre-steady-state kinetic analysis of recombinant arabidopsis NADP : Nitrate reductase - Rate-limiting processes in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; FLAVOPROTEIN REDUCTASES; CHLORELLA-VULGARIS; MOLYBDENUM CENTER; PROSTHETIC GROUPS; SULFITE OXIDASE; PICHIA-PASTORIS; PH-DEPENDENCE; WILD-TYPE; FRAGMENT	Recombinant Arabidopsis NADH:nitrate reductase was expressed in Pichia pastoris using fermentation. Large enzyme quantities were purified for pre-steady-state kinetic analysis, which had not been done before with any eukaryotic nitrate reductase, Basic biochemical properties of recombinant nitrate reductase were similar to natural enzyme forms. Molybdenum content was lower than expected, which was compensated for by activity calculation on molybdenum basis. Stopped-flow rapid-scan spectrophotometry showed that the enzyme FAD and heme were rapidly reduced by NADH with and without nitrate present. NADPH reduced FAD at less than one-tenth of NADH rate. Reaction of NADH-reduced enzyme with nitrate yielded rapid initial oxidation of heme with slower oxidation of flavin, Rapid-reaction freeze-quench EPR spectra revealed molybdenum was maintained in a partially reduced state during turnover. Rapid-reaction chemical quench for quantifying nitrite production showed that the rate of nitrate reduction was initially greater than the steady-state rate, but rapidly decreased to near steady-state turnover rate. However, rates of internal electron transfer and nitrate reduction were similar in magnitude with no one step in the catalytic process appearing to be much slower than the others. This leads to the conclusion that the catalytic rate is determined by a combination of rates with no overall rate-limiting individual process.	Michigan Technol Univ, Dept Biol Sci, Houghton, MI 49931 USA; John Innes Inst, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	Michigan Technological University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Campbell, WH (corresponding author), Michigan Technol Univ, Dept Biol Sci, Houghton, MI 49931 USA.			Campbell, Wilbur/0000-0001-6432-7537				Abraham ZHL, 1997, BIOCHEM J, V324, P511, DOI 10.1042/bj3240511; BARBER MJ, 1989, PLANT PHYSIOL, V90, P70, DOI 10.1104/pp.90.1.70; Barber MJ, 1997, ARCH BIOCHEM BIOPHYS, V345, P88, DOI 10.1006/abbi.1997.0223; Boll M, 2000, J BIOL CHEM, V275, P31857, DOI 10.1074/jbc.M001508200; BRAY RC, 1961, BIOCHEM J, V81, P189, DOI 10.1042/bj0810189; Campbell WH, 1999, ANNU REV PLANT PHYS, V50, P277, DOI 10.1146/annurev.arplant.50.1.277; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; George GN, 1999, J AM CHEM SOC, V121, P9730, DOI 10.1021/ja990310l; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; GUTTERIDGE S, 1983, BIOCHEM J, V213, P137, DOI 10.1042/bj2130137; KAY CJ, 1990, BIOCHEMISTRY-US, V29, P10823, DOI 10.1021/bi00500a015; KAY CJ, 1989, BIOCHEMISTRY-US, V28, P5750, DOI 10.1021/bi00440a008; KAY CJ, 1991, BIOCHEMISTRY-US, V30, P11445, DOI 10.1021/bi00112a011; KAY CJ, 1988, BIOCHEMISTRY-US, V27, P6142, DOI 10.1021/bi00416a047; KAY CJ, 1986, J BIOL CHEM, V261, P14125; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; LU GG, 1995, J MOL BIOL, V248, P931, DOI 10.1006/jmbi.1995.0273; LU GG, 1994, STRUCTURE, V2, P809, DOI 10.1016/S0969-2126(94)00082-4; Mertens J.A., 1999, FLAVINS FLAVOPROTEIN, P131; Mertens JA, 2000, PLANT PHYSIOL, V123, P743, DOI 10.1104/pp.123.2.743; Pacheco A, 1999, J BIOL INORG CHEM, V4, P390, DOI 10.1007/s007750050325; RATNAM K, 1995, J BIOL CHEM, V270, P24067, DOI 10.1074/jbc.270.41.24067; Ratnam K, 1997, J BIOL CHEM, V272, P2122; REDINBAUGH MG, 1985, J BIOL CHEM, V260, P3380; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; SOLOMONSON LP, 1990, ANNU REV PLANT PHYS, V41, P225, DOI 10.1146/annurev.pp.41.060190.001301; SOLOMONSON LP, 1984, J BIOL CHEM, V259, P849; SOLOMONSON LP, 1975, J BIOL CHEM, V250, P4120; Su WP, 1997, PLANT PHYSIOL, V115, P1135, DOI 10.1104/pp.115.3.1135	29	38	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26995	27002		10.1074/jbc.M100356200	http://dx.doi.org/10.1074/jbc.M100356200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356830	hybrid			2022-12-27	WOS:000169966900036
J	Urbatsch, IL; Gimi, K; Wilke-Mounts, S; Lerner-Marmarosh, N; Rousseau, ME; Gros, P; Senior, AE				Urbatsch, IL; Gimi, K; Wilke-Mounts, S; Lerner-Marmarosh, N; Rousseau, ME; Gros, P; Senior, AE			Cysteines 431 and 1074 are responsible for inhibitory disulfide cross-linking between the two nucleotide-binding sites in human P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATPASE ACTIVITY; CATALYTIC CYCLE; PURIFICATION; IDENTIFICATION; EXPRESSION; MUTATIONS; TRANSPORT; AZIDOPINE; RESIDUES; PASTORIS	Human wild-type and Cys-less P-glycoproteins were expressed in Pichia pastoris and purified in high yield in detergent-soluble form. Both ran on SDS gels as a single 140-kDa band in the presence of reducing agent and showed strong verapamil-stimulated ATPase activity in the presence of added lipid. The wild type showed spontaneous formation of higher molecular mass species in the absence of reducing agent, and its ATPase was activated by dithiothreitol. Oxidation with Cu2+ generated the same higher molecular mass species, primarily at 200 and similar to 300 kDa, in high yield. Cross-linking was reversed by dithiothreitol and prevented by pretreatment with N-ethylmaleimide. Using proteins containing different combinations of naturally occurring Cys residues, it was demonstrated that an inhibitory intramolecular disulfide bond forms between Cys-431 and Cys-1074 (located in the Walker A sequences of nucleotide-binding sites 1 and 2, respectively), giving rise to the 800-kDa species, in addition, dimeric P-glycoprotein species (similar to 300 kDa) form by intermolecular disulfide bonding between Cys-431 and Cys-1074. The ready formation of the intramolecular disulfide between Cys-431 and Cys-1074 establishes that the two nucleotide-binding sites of P-glycoprotein are structurally very close and capable of intimate functional interaction, consistent with available information on the catalytic mechanism. Formation of such a disulfide in vivo could,in principle,underlie a regulatory mechanism and might provide a means of intervention to inhibit P-glycoprotein.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	University of Rochester; McGill University	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.	alan_senior@urmc.rochester.edu		Rousseau, Marc-Etienne/0000-0001-6281-1691	NIGMS NIH HHS [GM50156] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050156] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Beaudet L, 1998, METHOD ENZYMOL, V292, P397; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Demeule M, 1998, BIOCHEMISTRY-US, V37, P18110, DOI 10.1021/bi981992c; Demmer A, 1999, EUR J BIOCHEM, V264, P800, DOI 10.1046/j.1432-1327.1999.00702.x; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; Figler RA, 2000, ARCH BIOCHEM BIOPHYS, V376, P34, DOI 10.1006/abbi.2000.1712; Forgac M, 1999, J BIOL CHEM, V274, P1301, DOI 10.1074/jbc.274.3.1301; Goodfellow HR, 1996, J BIOL CHEM, V271, P13668, DOI 10.1074/jbc.271.23.13668; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HINNEBUSCH AG, 1991, MOL CELLULAR BIOL YE, V1, P625; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Innis A. M., 1990, PCR PROTOCOLS GUIDE, P3; *INV CORP, 1999, PICH EXPR KIT VERS J, P2; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Oluwatosin YE, 1997, J BIOL CHEM, V272, P28149, DOI 10.1074/jbc.272.44.28149; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; Stein WD, 1997, PHYSIOL REV, V77, P545, DOI 10.1152/physrev.1997.77.2.545; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441; Zhou TQ, 2000, EMBO J, V19, P4838, DOI 10.1093/emboj/19.17.4838	42	68	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26980	26987		10.1074/jbc.M010829200	http://dx.doi.org/10.1074/jbc.M010829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356825	hybrid			2022-12-27	WOS:000169966900034
J	Wang, HY; Altman, Y; Fang, D; Elly, C; Dai, Y; Shao, Y; Liu, YC				Wang, HY; Altman, Y; Fang, D; Elly, C; Dai, Y; Shao, Y; Liu, YC			Cbl promotes ubiquitination of the T cell receptor zeta through an adaptor function of Zap-70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SYK TYROSINE KINASE; NEGATIVE REGULATOR; C-CBL; ANTIGEN RECEPTOR; PHOSPHORYLATION SITE; SIGNAL-TRANSDUCTION; RING FINGER; ACTIVATION; PROTEIN	Triggering of the T cell antigen receptor (TCR). CD3 complex induces its ubiquitination, However, the molecular events that lead to ubiquitin conjugation to these cell surface molecules have not been defined, Here we report that Cbl, a RING-type E3 ubiquitin-protein ligase, promotes ubiquitination of TCR zeta chain, which requires its functional variant Src homology 2 domain and an intact RING finger. The tyrosine kinase Zap-70, which binds to both TCR zeta and Cbl, plays an adaptor role in these events, Mutations in TCR zeta, Zap-70, or Cbl that disrupt the interaction between TCR zeta and Zap-70 or between Zap-70 and Cbl reduce ubiquitination of TCR zeta Our results suggest a novel mechanism by which Cbl negatively regulates T cell development and activation by inducing ubiquitination of the TCR CD3 components.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Liu, YC (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	yuncail@liai.org	Fang, Deyu/I-7245-2013	Fang, Deyu/0000-0002-4211-2751; LIU, YUN-CAI/0000-0002-0996-7109	NIDDK NIH HHS [R01DK-56588] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Cenciarelli C, 1996, J BIOL CHEM, V271, P8709, DOI 10.1074/jbc.271.15.8709; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; FANG D, 2001, J BIOL CHEM, V276, P15547; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOU D, 1994, J BIOL CHEM, V269, P14244; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Jose ES, 2000, IMMUNITY, V12, P161, DOI 10.1016/S1074-7613(00)80169-7; Krummel MF, 2000, SCIENCE, V289, P1349, DOI 10.1126/science.289.5483.1349; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Love PE, 2000, IMMUNITY, V12, P591, DOI 10.1016/S1074-7613(00)80210-1; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PANTALEO G, 1987, J EXP MED, V166, P619, DOI 10.1084/jem.166.2.619; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Rao N, 2000, J IMMUNOL, V164, P4616, DOI 10.4049/jimmunol.164.9.4616; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; Sosinowski T, 2000, J EXP MED, V191, P463, DOI 10.1084/jem.191.3.463; Tang J, 1999, P NATL ACAD SCI USA, V96, P9775, DOI 10.1073/pnas.96.17.9775; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	36	133	136	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26004	26011		10.1074/jbc.M010738200	http://dx.doi.org/10.1074/jbc.M010738200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11353765	hybrid			2022-12-27	WOS:000169823300050
J	Way, JM; Gorgun, CZ; Tong, Q; Uysal, KT; Brown, KK; Harrington, WW; Oliver, WR; Willson, TM; Kliewer, SA; Hotamisligil, GS				Way, JM; Gorgun, CZ; Tong, Q; Uysal, KT; Brown, KK; Harrington, WW; Oliver, WR; Willson, TM; Kliewer, SA; Hotamisligil, GS			Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIDIABETIC THIAZOLIDINEDIONE; INSULIN-RESISTANCE	Elevated levels of the hormone resistin, which is secreted by fat cells, are proposed to cause insulin resistance and to serve as a link between obesity and type 2 diabetes, In this report we show that resistin expression is significantly decreased in the white adipose tissue of several different models of obesity including the ob/ob, db/db, tub/tub, and KKA(Y) mice compared with their lean counterparts. Furthermore, in response to several different classes of antidiabetic peroxisome proliferator-activated receptor gamma agonists, adipose tissue resistin expression is increased in both ob/ob mice and Zucker diabetic fatty rats. These data demonstrate that experimental obesity in rodents is associated with severely defective resistin expression, and decreases in resistin expression are not required for the antidiabetic actions of peroxisome proliferator-activated receptor gamma agonists.	Harvard Univ, Sch Publ Hlth, Div Biol Sci, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; GlaxoSmithKline Res & Dev, Res Triangle Pk, NC 27709 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; GlaxoSmithKline	Hotamisligil, GS (corresponding author), Harvard Univ, Sch Publ Hlth, Div Biol Sci, 665 Huntington Ave, Boston, MA 02115 USA.		feinstein, doug/M-9414-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052539] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52539] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Brown KK, 1999, DIABETES, V48, P1415, DOI 10.2337/diabetes.48.7.1415; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Reginato MJ, 1998, J BIOL CHEM, V273, P32679, DOI 10.1074/jbc.273.49.32679; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269	12	362	390	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25651	25653		10.1074/jbc.C100189200	http://dx.doi.org/10.1074/jbc.C100189200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11373275	hybrid			2022-12-27	WOS:000169823300004
J	Xu, BE; Stippec, S; Robinson, FL; Cobb, MH				Xu, BE; Stippec, S; Robinson, FL; Cobb, MH			Hydrophobic as well as charged residues in both MEK1 and ERK2 are important for their proper docking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; RIBOSOMAL S6 KINASE; MAP KINASE; SIGNAL-TRANSDUCTION; IN-VIVO; PHOSPHORYLATION; SITE; IDENTIFICATION; RESOLUTION; SEQUENCE	Docking between MEK1 and ERK2 is required for their stable interaction and efficient signal transmission. The MEK1 N terminus contains the ERK docking or D domain that consists of conserved hydrophobic and basic residues. We mutated the hydrophobic and basic residues individually and found that loss of either type reduced MEK1 phosphorylation of ERK2 in vitro and its ability to bind to ERK2 in vivo, Moreover, ERK2 was localized in both the cytoplasm and the nucleus when co-expressed with MEK1 that had mutations in either the hydrophobic or the basic residues. We then identified two conserved hydrophobic residues on ERK2 that play roles in docking with MEK1, Mutating these residues to alanine reduced the interaction of ERK2 with MEK1 in cells. These mutations also reduced the phosphorylation of MEK1 by ERK2 but had little effect on phosphorylation of MBP by ERK2, Finally, we generated docking site mutants in ERK2-MEK1 fusion proteins. Although the mutation of the MEK1 D domain significantly reduced ERK2-MEK1 activity, mutations of the putatively complementary acidic residues and hydrophobic residues on ERK2 did not change its activity. However, both types of mutations decreased the phosphorylation of Elk-l caused by ERK2-MEK1 fusion proteins. These findings suggest complex interactions of MEK1 D domains with ERK2 that influence its activation and its effects on substrates.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRUNET A, 1996, SCIENCE, V272, P1653; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Eblen ST, 2001, MOL CELL BIOL, V21, P249, DOI 10.1128/MCB.21.1.249-259.2001; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Resing KA, 1998, BIOCHEMISTRY-US, V37, P463, DOI 10.1021/bi971750x; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SEGER R, 1992, J BIOL CHEM, V267, P14373; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Smith JK, 2000, J BIOL CHEM, V275, P31588, DOI 10.1074/jbc.M005892200; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	26	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26509	26515		10.1074/jbc.M102769200	http://dx.doi.org/10.1074/jbc.M102769200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352917	hybrid			2022-12-27	WOS:000169823300114
J	McAllister-Lucas, LM; Inohara, N; Lucas, PC; Ruland, J; Benito, A; Li, QT; Chen, S; Chen, FF; Yamaoka, S; Verma, IM; Mak, TW; Nunez, G				McAllister-Lucas, LM; Inohara, N; Lucas, PC; Ruland, J; Benito, A; Li, QT; Chen, S; Chen, FF; Yamaoka, S; Verma, IM; Mak, TW; Nunez, G			Bimp1, a MAGUK family member linking protein kinase C activation to Bcl10-mediated NF-kappa B induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE RECRUITMENT DOMAIN; LYMPHOID-TISSUE; CELL LYMPHOMA; SIGNALING PATHWAYS; MALT LYMPHOMA; GENE; THETA; T(11-18)(Q21-Q21); COSTIMULATION; APOPTOSIS	Bcl10 and MALT1, products of distinct chromosomal translocations in mucosa-associated lymphoid tissue lymphoma, cooperate in activating NF-kappaB Mice lacking Bcl10 demonstrate severe immunodeficiency associated with failure of lymphocytes to activate nuclear factor kappaB (NF-kappaB) in response to antigen receptor stimulation and protein kinase C activation. We characterize Bimp1, a new signaling protein that binds Bcl10 and activates NF-kappaB. Bimp1-mediated NF-kappaB activation requires Bcl10 and I kappaB kinases, indicating that Bimp1 acts upstream of these mediators. Bimp1, Bcl10, and MALT1 form a ternary complex, with Bcl10 bridging the Bimp1/ MALT1 interaction. A dominant negative Bimp1 mutant inhibits NF-kappaB activation by anti-CD3 ligation, phorbol ester, and protein kinase C expression. These results suggest that Bimp1 links surface receptor stimulation and protein kinase C activation to Bcl10/MALT1, thus leading to NF-kappaB induction.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat & Commun Dis, Ann Arbor, MI 48109 USA; Univ Toronto, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Tokyo Med & Dent Univ, Sch Med, Dept Microbiol, Bunkyo Ku, Tokyo 1138519, Japan	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Salk Institute; Tokyo Medical & Dental University (TMDU)	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		Ruland, Jürgen/Q-6680-2018; Nuñez, Gabriel/A-7160-2014	Ruland, Jürgen/0000-0002-8381-3597; Lucas, Peter/0000-0003-4880-7172	NATIONAL CANCER INSTITUTE [F32CA088470, R01CA084064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007622] Funding Source: NIH RePORTER; NCI NIH HHS [CA84064, F23-CA88470-01] Funding Source: Medline; NHLBI NIH HHS [T32-HL07622] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Bertin J, 2000, J BIOL CHEM, V275, P41082, DOI 10.1074/jbc.C000726200; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Costanzo A, 1999, J BIOL CHEM, V274, P20127, DOI 10.1074/jbc.274.29.20127; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Li QT, 2000, GENE DEV, V14, P1729; Li RCX, 2000, AM J PHYSIOL-HEART C, V279, pH1679, DOI 10.1152/ajpheart.2000.279.4.H1679; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Morgan JA, 1999, CANCER RES, V59, P6205; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Srinivasula SM, 1999, J BIOL CHEM, V274, P17946, DOI 10.1074/jbc.274.25.17946; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Thome M, 1999, J BIOL CHEM, V274, P9962, DOI 10.1074/jbc.274.15.9962; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Tokoyoda K, 2000, J BIOL CHEM, V275, P11728, DOI 10.1074/jbc.275.16.11728; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Vertegaal ACO, 2000, CELL SIGNAL, V12, P759, DOI 10.1016/S0898-6568(00)00133-9; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zucca E, 2000, BLOOD, V96, P410	42	154	162	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30589	30597		10.1074/jbc.M103824200	http://dx.doi.org/10.1074/jbc.M103824200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11387339	hybrid			2022-12-27	WOS:000170472900003
J	Yan, WH; Nehrke, K; Choi, J; Barber, DL				Yan, WH; Nehrke, K; Choi, J; Barber, DL			The Nck-interacting kinase (NIK) phosphorylates the Na+-H+ exchanger NHE1 and regulates NHE1 activation by platelet-derived growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2/SH3 ADAPTER PROTEIN; STE20-RELATED KINASE; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; MAMMALIAN-CELLS; ISOFORM-1 NHE1; ANTIPORTER; MISSHAPEN; CASCADE; STE20	NIK, a recently identified Nck-interacting kinase, acts upstream of the MEK kinase MEKK1 to activate the c-Jun N-terminal kinase JNK. We now show that NIK binds to and divergently activates the plasma membrane Na+-H+ exchanger NHE1 In a genetic screen, NHE1 interacted with NIK at a site N-terminal (amino acids 407-502) to the Nck-binding domain, and this site is critical for its association with NHE1 in vivo. NIK also phosphorylates NHE1; however, the phosphorylation sites, which are distal to amino acid 638, are distinct from the NIK-binding site on NHE1 (amino acids 538-638). Expression of wild-type, but not a kinase-inactive, NIK in fibroblasts increased NHE1 phosphorylation and activity. The kinase domain of NIK, however, was not sufficient for this response in vivo. Full phosphorylation and activation of NHE1 required both the kinase and the NHE1-binding domains of NIK, suggesting that the NHE1-binding site functions as a targeting signal. The functional significance of an interaction between NIK and NHE1 was confirmed by the ability of a kinase-inactive NIK to selectively inhibit activation of NHE1 by platelet-derived growth factor but not by thrombin. Moreover, although NIK activates JNK through a mechanism dependent on MEKK1, it phosphorylated and activated NHE1 independently of MEKK1. These findings indicate that NIK acts downstream of platelet-derived growth factor receptors to phosphorylate and activate NHE1 divergently of its activation of JNK.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Rochester, Ctr Oral Biold, Rochester, NY 14642 USA; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of Rochester; University of California System; University of California San Francisco	Barber, DL (corresponding author), Univ Calif San Francisco, Dept Stomatol, Box 0512,513 Parnassus ave, San Francisco, CA 94143 USA.	barber@itsa.ucsf.edu		Nehrke, Keith/0000-0001-9697-726X	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040259, R29DK040259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047413] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08921] Funding Source: Medline; NIDDK NIH HHS [DK40259] Funding Source: Medline; NIGMS NIH HHS [GM47413] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Bianchini L, 1997, J BIOL CHEM, V272, P271; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GOSS GG, 1994, J BIOL CHEM, V269, P8741; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; HU QJ, 1995, MOL CELL BIOL, V15, P1169; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Paricio N, 1999, EMBO J, V18, P4669, DOI 10.1093/emboj/18.17.4669; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Ruan WJ, 1999, NEURON, V24, P595, DOI 10.1016/S0896-6273(00)81115-0; SARDET C, 1991, J BIOL CHEM, V266, P19166; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Tominaga T, 1998, MOL BIOL CELL, V9, P2287, DOI 10.1091/mbc.9.8.2287; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WINKEL GK, 1993, J BIOL CHEM, V268, P3396	46	86	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31349	31356		10.1074/jbc.M102679200	http://dx.doi.org/10.1074/jbc.M102679200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11369779	hybrid			2022-12-27	WOS:000170472900099
J	Henion, TR; Zhou, DP; Wolfer, DP; Jungalwala, FB; Hennet, T				Henion, TR; Zhou, DP; Wolfer, DP; Jungalwala, FB; Hennet, T			Cloning of a mouse beta 1,3 N-acetylglucosaminyltransferase GlcNAc(beta 1,3)Gal(beta 1,4)Glc-ceramide synthase gene encoding the key regulator of lacto-series glycolipid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; GLYCOSPHINGOLIPID BIOSYNTHESIS; CARBOHYDRATE ANTIGENS; EXPRESSION CLONING; HUMAN-LEUKOCYTES; UDP-GALACTOSE; CELL-LINES; BETA-1,3-GALACTOSYLTRANSFERASE; DIFFERENTIATION; CEREBELLUM	The distinction between the different classes of glycolipids is conditioned by the action of specific core transferases. The entry point for lacto-series glycolipids is catalyzed by the beta1,3 N-acetylglucosaminyltransferase GlcNAc(beta1,3)Gal(beta1,4)Glc-ceramide (Lc3) synthase enzyme. The Lc3 synthase activity has been shown to be regulated during development, especially during brain morphogenesis. Here, we report the molecular cloning of a mouse gene encoding an Lc3 synthase enzyme. The mouse cDNA included an open reading frame of 1131 base pairs encoding a protein of 376 amino acids. The Lc3 synthase protein shared several structural motifs previously identified in the members of the beta1,3 glycosyltransferase superfamily. The Lc3 synthase enzyme efficiently utilized the lactosyl ceramide glycolipid acceptor. The identity of the reaction products of Lc3 synthase-transfected CHOP2/1 cells was confirmed by thin-layer chromatography immunostaining using antibodies TE-8 and 1B2 that recognize Lc3 and Gal(beta1,4)GlcNAc(beta1,3)Gal(beta1,4)Glc-ceramide (nLc4) structures, respectively. In addition to the initiating activity for lacto-chain synthesis, the Lc3 synthase could extend the terminal N-acetyllactosamine unit of nLc4 and also had a broad specificity for gangliosides GA1, GM1, and GD1b to generate neolacto-ganglio hybrid structures. The mouse Lc3 synthase gene was mainly expressed during embryonic development. In situ hybridization analysis revealed that that the Lc3 synthase was expressed in most tissues at embryonic day 11 with elevated expression in the developing central nervous system. Postnatally, the expression was restricted to splenic B-cells, the placenta, and cerebellar Purkinje cells where it colocalized with HNK-1 reactivity. These data support a key role for the Lc3 synthase in regulating neolacto-series glycolipid synthesis during embryonic development.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Anat, CH-8057 Zurich, Switzerland; Univ Massachusetts, Sch Med, Eunice Kennedy Shriver Ctr Mental Retardat Inc, Waltham, MA 02452 USA	University of Zurich; University of Zurich; University of Massachusetts System	Hennet, T (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		zhou, dapeng/GXG-9715-2022; Wolfer, David P/B-3293-2016; Zhou, Dapeng/A-6446-2019	Wolfer, David P/0000-0002-5957-1401; Zhou, Dapeng/0000-0003-1347-3811	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD005515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024405] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 05515] Funding Source: Medline; NINDS NIH HHS [NS 24405] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGSTROM J, 1994, P NATL ACAD SCI USA, V91, P11859, DOI 10.1073/pnas.91.25.11859; BHAT S, 1991, P NATL ACAD SCI USA, V88, P7131, DOI 10.1073/pnas.88.16.7131; Chou DKH, 1996, GLYCOCONJUGATE J, V13, P295, DOI 10.1007/BF00731504; Chou DKH, 1996, J BIOL CHEM, V271, P28868, DOI 10.1074/jbc.271.46.28868; CHOU DKH, 1993, J BIOL CHEM, V268, P21727; Chou DKH, 1998, J BIOL CHEM, V273, P8508, DOI 10.1074/jbc.273.14.8508; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CUMMINGS L, 1993, BIOCHEM BIOPH RES CO, V195, P814, DOI 10.1006/bbrc.1993.2118; EPAND RM, 1995, BIOCHEMISTRY-US, V34, P1084, DOI 10.1021/bi00003a045; FELDINGHABERMANN B, 1990, BIOCHEMISTRY-US, V29, P6314, DOI 10.1021/bi00478a028; FENDERSON BA, 1990, BIOESSAYS, V12, P173, DOI 10.1002/bies.950120406; HENDRICKS SP, 1990, J BIOL CHEM, V265, P17621; Hennet T, 1998, J BIOL CHEM, V273, P58, DOI 10.1074/jbc.273.1.58; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; HU J, 1994, GLYCOBIOLOGY, V4, P251; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; MACHER BA, 1982, MOL CELL BIOCHEM, V47, P81; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; NAKAMURA M, 1992, J BIOL CHEM, V267, P23507; NOHARA K, 1994, BIOCHEMISTRY-US, V33, P4661, DOI 10.1021/bi00181a601; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; NORDQUIST DT, 1988, J NEUROSCI, V8, P4780; NORIHISA Y, 1994, J IMMUNOL, V152, P485; Ogiso M, 1997, GLYCOBIOLOGY, V7, P605, DOI 10.1093/glycob/7.5.605; Okajima T, 2000, J BIOL CHEM, V275, P40498, DOI 10.1074/jbc.M006902200; Sheikh KA, 1999, P NATL ACAD SCI USA, V96, P7532, DOI 10.1073/pnas.96.13.7532; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; SINGHAL A, 1990, BIOESSAYS, V12, P223, DOI 10.1002/bies.950120506; STULTS CLM, 1993, ARCH BIOCHEM BIOPHYS, V303, P125, DOI 10.1006/abbi.1993.1263; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; TOLE S, 1995, J NEUROSCI, V15, P957; YAMAMOTO M, 1985, P NATL ACAD SCI USA, V82, P3045, DOI 10.1073/pnas.82.9.3045; Zhou DP, 2000, P NATL ACAD SCI USA, V97, P11673; Zhou DP, 1999, EUR J BIOCHEM, V263, P571, DOI 10.1046/j.1432-1327.1999.00541.x; Zhou DP, 2000, J BIOL CHEM, V275, P22631, DOI 10.1074/jbc.C000263200; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	38	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30261	30269		10.1074/jbc.M102979200	http://dx.doi.org/10.1074/jbc.M102979200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11384981	hybrid			2022-12-27	WOS:000170558000087
J	Maturana, A; Arnaudeau, S; Ryser, S; Banfi, B; Hossle, JP; Schlegel, W; Krause, KH; Demaurex, N				Maturana, A; Arnaudeau, S; Ryser, S; Banfi, B; Hossle, JP; Schlegel, W; Krause, KH; Demaurex, N			Heme histidine ligands within gp91(phox) modulate proton conduction by the phagocyte NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; H+ CHANNEL; HUMAN-NEUTROPHILS; FLAVOCYTOCHROME B(558); CYTOCHROME B(558); ELECTRON-TRANSFER; INTRACELLULAR PH; ARACHIDONATE; ACTIVATION	The membrane subunit of the phagocyte NADPH oxidase, gp91(phox), possesses a H+ channel motif formed by membrane-spanning histidines postulated to coordinate the two heme groups forming the redox center of the flavocytochrome. To study the role of heme-binding histidines on proton conduction, we stably expressed the gp91(phox) cytochrome in human embryonic kidney 293 cells and measured proton currents with the patch clamp technique. Similar to its shorter homologue, NADPH oxidase homologue 1, which is predicted not to bind heme, gp91(phox) generated voltage-activated, pH-dependent, H+-selective currents that were reversibly blocked by Zn2+. The gp91(phox) currents, however, activated faster, deactivated more slowly, and were markedly affected by the inhibition of heme synthesis. Upon heme removal, the currents had larger amplitude, activated faster and at lower voltages, and became sensitive to the histidine reagent diethylpyrocarbonate. Mutation of the His-115 residue to leucine abolished both the gp91(phox) characteristic 558-nm absorbance peak and voltage-activated currents, indicating that His-115 is involved in both heme ligation and proton conduction. These results indicate that the gp91(phox) proton channel is activated upon release of heme from its His-115 ligand. During activation of the oxidase complex, changes in heme coordination within the cytochrome might increase the mobility of histidine ligands, thereby coupling electron and proton transport.	Univ Geneva, Med Ctr, Dept Physiol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Fdn Rech Med, CH-1211 Geneva, Switzerland; Geneva Sch Med, Dept Geriatr, Biol Aging Lab, CH-1225 Geneva, Switzerland; Univ Zurich, Childrens Hosp, Div Immunol & Hematol, CH-8032 Zurich, Switzerland	University of Geneva; University of Geneva; University of Geneva; University Children's Hospital Zurich; University of Zurich	Demaurex, N (corresponding author), Univ Geneva, Med Ctr, Dept Physiol, 1 Michel Servet, CH-1211 Geneva 4, Switzerland.		Krause, Karl-Heinz/E-8030-2011	Krause, Karl-Heinz/0000-0002-9033-6768; Demaurex, Nicolas/0000-0002-9933-6772; Banfi, Botond/0000-0001-9273-1318				Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Banfi B, 1999, J EXP MED, V190, P183, DOI 10.1084/jem.190.2.183; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Batot G, 1998, BBA-MOL BASIS DIS, V1406, P188, DOI 10.1016/S0925-4439(98)00004-0; BOKOCH GM, 1994, CURR OPIN IMMUNOL, V6, P98, DOI 10.1016/0952-7915(94)90040-X; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; Cherny VV, 1999, J GEN PHYSIOL, V114, P819, DOI 10.1085/jgp.114.6.819; CLARK RA, 1990, HOSP PRACT, V25, P51; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; DeCoursey TE, 2000, P NATL ACAD SCI USA, V97, P6885, DOI 10.1073/pnas.100047297; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; DeCoursey TE, 1998, FRONT BIOSCI, V3, P477; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; DEMAUREX N, 1993, J PHYSIOL-LONDON, V466, P329; Demaurex N, 1996, J CELL BIOL, V133, P1391, DOI 10.1083/jcb.133.6.1391; Doussiere J, 1996, BIOCHEMISTRY-US, V35, P13400, DOI 10.1021/bi960916b; Doussiere J, 1999, BIOCHEMISTRY-US, V38, P16394, DOI 10.1021/bi991502w; EBERT PS, 1979, BIOCHEM BIOPH RES CO, V88, P1382, DOI 10.1016/0006-291X(79)91133-1; ELLIS JA, 1989, BIOCHEM J, V262, P575, DOI 10.1042/bj2620575; Henderson LM, 1999, J GEN PHYSIOL, V114, P771, DOI 10.1085/jgp.114.6.771; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1992, BIOCHEM J, V283, P171, DOI 10.1042/bj2830171; HENDERSON LM, 1988, BIOCHEM J, V255, P285; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; Henderson LM, 1998, J BIOL CHEM, V273, P33216, DOI 10.1074/jbc.273.50.33216; Henderson LM, 1996, BBA-BIOENERGETICS, V1273, P87, DOI 10.1016/0005-2728(95)00140-9; Henderson LM, 1997, BIOCHEM J, V325, P701, DOI 10.1042/bj3250701; Lowenthal A, 1999, J BIOL CHEM, V274, P21603, DOI 10.1074/jbc.274.31.21603; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; NANDA A, 1994, J CLIN INVEST, V93, P1770, DOI 10.1172/JCI117162; NUSSE O, 1990, J EXP MED, V171, P775, DOI 10.1084/jem.171.3.775; Schneider SD, 1997, GENE THER, V4, P524, DOI 10.1038/sj.gt.3300432; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; Verhoeven AJ, 1997, ANN NY ACAD SCI, V832, P85, DOI 10.1111/j.1749-6632.1997.tb46239.x; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; Yu LX, 1999, J BIOL CHEM, V274, P4364, DOI 10.1074/jbc.274.7.4364; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993	39	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30277	30284		10.1074/jbc.M010438200	http://dx.doi.org/10.1074/jbc.M010438200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11389135	hybrid, Green Published			2022-12-27	WOS:000170558000089
J	Scarselli, M; Novi, F; Schallmach, E; Ling, RW; Baragli, A; Colzi, A; Griffon, N; Corsini, GU; Sokoloff, P; Levenson, R; Vogel, Z; Maggio, R				Scarselli, M; Novi, F; Schallmach, E; Ling, RW; Baragli, A; Colzi, A; Griffon, N; Corsini, GU; Sokoloff, P; Levenson, R; Vogel, Z; Maggio, R			D-2/D-3 dopamine receptor heterodimers exhibit unique functional properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ADENYLYL-CYCLASE; D-3 RECEPTOR; LINKED RECEPTORS; RAT-BRAIN; EXPRESSION; DIMERS; COEXPRESSION; FRAGMENTS; CELLS	Evidence for heterodimerization has recently been provided for dopamine D-1 and adenosine A(1) receptors as well as for dopamine D-2 and somatostatin SSTR5 receptors. In this paper, we have studied the possibility that D2 and Da receptors interact functionally by forming receptor heterodimers. Initially, we split the two receptors at the level of the third cytoplasmic loop into two fragments. The first, containing transmembrane domains (TM) I to V and the N-terminal part of the third cytoplasmic loop, was named D-2trunk or D-3trunk, and the second, containing the C-terminal part of the third cytoplasmic loop, TAM and TMVII, and the C-terminal tail, was named D-2tail or D-3tail. Then we defined the pharmacological profiles of the homologous (D-2trunk/ D-2tail and D-3trunk/D-3tail) as well as of the heterologous (D-2trunk/D-3tail and D-3trunk/D-2tail) cotransfected receptor fragments. The pharmacological profile of the cross-cotransfected fragments was different from that of the native D-2 or D-3 receptors. In most cases, the D-3trunk/D-2tail was the one with the highest affinity for most agonists and antagonists. Moreover, we observed that all of these receptor fragments reduced the expression of the wild type dopamine D-2, and D-3 receptors, suggesting that D-2 and D-3 receptors can form complexes with these fragments and that these complexes bind [H-3]nemonapride less efficiently or are not correctly targeted to the membrane. In a second set of experiments, we tested the ability of the split and the wild type receptors to inhibit adenylyl cyclase (AC) types V and VI. All of the native and split receptors inhibited AC-V and AC-VI, with the exception of D-3, which was unable to inhibit AC-VI. We therefore studied the ability of D2 and D3 to interact functionally with one another to inhibit AC-VI. We found that with D-2 alone, R-(+)-7-hydroxydypropylaminotetralin hydrobromide inhibited AC-VI with an IC50 of 2.05 +/- 0.15 nM, while in the presence of D2 and D3 it inhibited AC-Vr with an IC50 of 0.083 +/- 0.011 nM. Similar results were obtained with a chimeric cyclase made from AC-V and AC-VI. Coimmunoprecipitation experiments indicate that D-2 and D-3 receptors are capable of physical interaction.	Univ Pisa, Dept Neurosci, I-56100 Pisa, Italy; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Penn State Univ, Milton S Hershey Med Ctr, Sch Med, Dept Pharmacol, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr, Sch Med, Grad Program Neurosci, Hershey, PA 17033 USA; Eli Lilly Italia & Co, I-50019 Sesto Fiorentino, Italy; Ctr Paul Broca, INSERM, Unite Neurobiol & Pharmacol, F-75014 Paris, France	University of Pisa; Weizmann Institute of Science; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Eli Lilly; Institut National de la Sante et de la Recherche Medicale (Inserm)	Maggio, R (corresponding author), Univ Pisa, Dept Neurosci, Via Roma 55, I-56100 Pisa, Italy.		maggio, Roberto/Q-2032-2015	Maggio, Roberto/0000-0003-4436-2356; Levenson, Robert/0000-0002-0936-8421; Scarselli, Marco/0000-0001-5087-3182				AvidorReiss T, 1997, J BIOL CHEM, V272, P5040, DOI 10.1074/jbc.272.8.5040; AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; Filteau F, 1999, FEBS LETT, V447, P251, DOI 10.1016/S0014-5793(99)00290-2; FISHBURN CS, 1993, J BIOL CHEM, V268, P5872; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Gouldson PR, 1997, J MED CHEM, V40, P3871, DOI 10.1021/jm960647n; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Gurevich EV, 1999, NEUROPSYCHOPHARMACOL, V20, P60, DOI 10.1016/S0893-133X(98)00066-9; Hall DA, 1997, BRIT J PHARMACOL, V121, P731, DOI 10.1038/sj.bjp.0701196; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Karpa KD, 2000, MOL PHARMACOL, V58, P677, DOI 10.1124/mol.58.4.677; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; Lachowicz JE, 1997, BIOCHEM BIOPH RES CO, V237, P394, DOI 10.1006/bbrc.1997.7146; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; LeMoine C, 1996, NEUROSCIENCE, V73, P131, DOI 10.1016/0306-4522(96)00029-2; LEVESQUE D, 1992, P NATL ACAD SCI USA, V89, P8155, DOI 10.1073/pnas.89.17.8155; Maggio R, 1999, J PHARMACOL EXP THER, V291, P251; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; MCELROY JF, 1994, PHARMACOL BIOCHEM BE, V48, P531, DOI 10.1016/0091-3057(94)90565-7; Millan MJ, 2000, J PHARMACOL EXP THER, V293, P1063; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Nielsen SM, 1998, EUR J BIOCHEM, V251, P217, DOI 10.1046/j.1432-1327.1998.2510217.x; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Robinson SW, 1997, MOL PHARMACOL, V52, P508, DOI 10.1124/mol.52.3.508; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Scarselli M, 2000, EUR J PHARMACOL, V397, P291, DOI 10.1016/S0014-2999(00)00272-7; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; SOKOLOFF P, 1995, TRENDS PHARMACOL SCI, V16, P270, DOI 10.1016/S0165-6147(00)89044-6; Varga EV, 1998, EUR J PHARMACOL, V348, pR1, DOI 10.1016/S0014-2999(98)00258-1; Zawarynski P, 1998, FEBS LETT, V441, P383, DOI 10.1016/S0014-5793(98)01588-9; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	39	175	177	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30308	30314		10.1074/jbc.M102297200	http://dx.doi.org/10.1074/jbc.M102297200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11373283	hybrid			2022-12-27	WOS:000170558000093
J	Simon, E; Clotet, J; Calero, F; Ramos, J; Arino, J				Simon, E; Clotet, J; Calero, F; Ramos, J; Arino, J			A screening for high copy suppressors of the sit4 hal3 synthetically lethal phenotype reveals a role for the yeast Nha1 antiporter in cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY K+ TRANSPORTER; SACCHAROMYCES-CEREVISIAE; PROTEIN PHOSPHATASE; SALT-TOLERANCE; NA+/H+-ANTIPORTER; FISSION YEAST; ZYGOSACCHAROMYCES-ROUXII; POTASSIUM TRANSPORTER; FUNCTIONAL EXPRESSION; ESCHERICHIA-COLI	A screening for multicopy suppressors of the G(1)/S blockage of a conditional sit4 hal3 mutant yielded the NHA1 gene, encoding a Na+, K+/H+ antiporter, composed of a transmembrane domain and a large carboxyl-terminal tail, which has been related to cation detoxification processes. Expression of either the powerful Saccharomyces cerevisiae, Ena-1 Na+/H+-ATPase or the Schizosaccharomyces pombe Sod2 Na+/H+ antiporter, although increasing tolerance to sodium, was unable to mimic the Nha1 function in the cell cycle. Mutation of the conserved Asp residues Asp(266)-Asp(267) selectively abolished Na+ efflux without modifying K+ efflux and did not affect the capacity of Nha1 to relieve the G(1) blockage. Mutagenesis analysis revealed that the region near the carboxyl-terminal end of Nha1 comprising residues 800 - 948 is dispensable for sodium detoxification. but necessary for transport of K+ cations. Therefore, this portion of the protein contains structural elements that selectively modulate Nha1 antiporter functions. This region is also required for Nha1 to function in the cell cycle. However,. expression of the closely related Cnh1 antiporter from Candida albicans, which also contains a long carboxyl-terminal extension, although allowing efficient K+ transport does not relieve cell cycle blockage. This indicates that although the determinants for Nha1-mediated regulation of potassium transport and the cell cycle map very closely in the protein, most probably the function of Nha1 on cell cycle is independent of its ability to extrude potassium cations.	Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, Bellaterra 08193, Barcelona, Spain; Univ Int Catalunya, Fac Ciencies Salut, Dept Bioquim, Barcelona 08190, Spain; Escuela Tecn Super Ingn Agron & Montes, Dept Microbiol, Cordoba 14080, Spain	Autonomous University of Barcelona; Universitat Internacional de Catalunya (UIC)	Arino, J (corresponding author), Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, Ed V, Bellaterra 08193, Barcelona, Spain.		Clotet, Josep/ABC-8727-2020; Clotet, Josep/AAF-2618-2019; Arino, Joaquin/D-3756-2011; Ramos, Jose/K-4307-2014; Zhang, Ning/F-1387-2014	Clotet, Josep/0000-0001-5462-8598; Arino, Joaquin/0000-0002-6774-2987; Ramos, Jose/0000-0002-9797-1561; Arino Carmona, Joaquin/0000-0002-0390-4270				Adams A, 1997, METHODS YEAST GENETI; Aloy P, 1997, COMPUT APPL BIOSCI, V13, P231; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; Banuelos MA, 1998, MICROBIOL-UK, V144, P2749, DOI 10.1099/00221287-144-10-2749; BANUELOS MA, 1995, EMBO J, V14, P3021, DOI 10.1002/j.1460-2075.1995.tb07304.x; Bastians H, 1996, J CELL SCI, V109, P2865; Belli G, 1998, YEAST, V14, P1127, DOI 10.1002/(SICI)1097-0061(19980915)14:12<1127::AID-YEA300>3.0.CO;2-#; Benito B, 1997, BBA-BIOMEMBRANES, V1328, P214, DOI 10.1016/S0005-2736(97)00098-9; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Calero F, 2000, J BACTERIOL, V182, P394, DOI 10.1128/JB.182.2.394-399.2000; Cedano J, 1997, J MOL BIOL, V266, P594, DOI 10.1006/jmbi.1996.0804; Clotet J, 1999, MOL CELL BIOL, V19, P2408; CORMAK B, 1997, CURRENT PROTOCOLS MO; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; de Nadal E, 1999, J BACTERIOL, V181, P6456, DOI 10.1128/JB.181.20.6456-6462.1999; de Nadal E, 1998, P NATL ACAD SCI USA, V95, P7357, DOI 10.1073/pnas.95.13.7357; Diatloff E, 1998, FEBS LETT, V432, P31, DOI 10.1016/S0014-5793(98)00833-3; Dibrov P, 1998, FEBS LETT, V424, P1, DOI 10.1016/S0014-5793(98)00119-7; Dibrov P, 1998, BIOCHEMISTRY-US, V37, P8282, DOI 10.1021/bi9801457; DICOMO CJ, 1995, GENETICS, V139, P95; Espinosa-Ruiz A, 1999, PLANT J, V20, P529, DOI 10.1046/j.1365-313X.1999.00626.x; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gillies R. J., 1982, INTRACELLULAR PH ITS, P341; Hahnenberger KM, 1996, P NATL ACAD SCI USA, V93, P5031, DOI 10.1073/pnas.93.10.5031; Iwaki T, 1998, YEAST, V14, P1167, DOI 10.1002/(SICI)1097-0061(19980930)14:13<1167::AID-YEA318>3.0.CO;2-5; JIA ZP, 1992, EMBO J, V11, P1631, DOI 10.1002/j.1460-2075.1992.tb05209.x; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; MANN DJ, 1993, EMBO J, V12, P4833, DOI 10.1002/j.1460-2075.1993.tb06173.x; Mulet JM, 1999, MOL CELL BIOL, V19, P3328; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; Prior C, 1996, FEBS LETT, V387, P89, DOI 10.1016/0014-5793(96)00470-X; Ramirez J, 1998, J BACTERIOL, V180, P5860; Rodriguez-Navarro A, 2000, BBA-REV BIOMEMBRANES, V1469, P1, DOI 10.1016/S0304-4157(99)00013-1; Rubio F, 1999, J BIOL CHEM, V274, P6839, DOI 10.1074/jbc.274.11.6839; SAMBROOK J, 1989, MOL CLONING LAB MANU, P145; SHIMANUKI M, 1993, MOL BIOL CELL, V4, P303, DOI 10.1091/mbc.4.3.303; Soong TW, 2000, MICROBIOL-UK, V146, P1035, DOI 10.1099/00221287-146-5-1035; SUTTON A, 1991, COLD SPRING HARB SYM, V56, P75; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; Sychrova H, 1999, FEMS MICROBIOL LETT, V171, P167, DOI 10.1111/j.1574-6968.1999.tb13428.x; WATANABE Y, 1995, YEAST, V11, P829, DOI 10.1002/yea.320110905	43	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29740	29747		10.1074/jbc.M101992200	http://dx.doi.org/10.1074/jbc.M101992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11382758	hybrid			2022-12-27	WOS:000170558000020
J	Song, L; Dentler, WL				Song, L; Dentler, WL			Flagellar protein dynamics in Chlamydomonas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE CAPPING STRUCTURES; INTRAFLAGELLAR TRANSPORT IFT; LEFT-RIGHT ASYMMETRY; DYNEIN LIGHT-CHAIN; CYTOPLASMIC DYNEIN; KINESIN-II; CHEMOSENSORY NEURONS; TUBULIN SYNTHESIS; CILIARY; GENE	Cilia and flagella appear to be stable, terminal, microtubule-containing organelles, but they also elongate and shorten in response to a variety of signals. To understand mechanisms that regulate flagellar dynamics, Chlamydomonas cells with nongrowing flagella were labeled with S-35, and flagella and basal body components were examined for labeled polypeptides. Maximal incorporation of label into the flagella occurred within 3 h. Twenty percent of the flagellar polypeptides were exchanged. These included tubulins, dyneins, and 80 other axonemal and membrane plus matrix polypeptides. The most stable flagellar structure is the PF-ribbon, which comprises part of the wall of each doublet microtubule and is composed of tubulin and three other polypeptides. Most 35S was incorporated into the high molecular weight ribbon polypeptide, rib240, and little, if any, S-35 is incorporated into PF-ribbon-associated tubulin. Both wild-type (9 + 2) and 9 + 0 flagella, which lack central microtubules, exhibited nearly identical exchange patterns, so labeling is not due to turnover of relatively labile central microtubules. To determine if flagellar length is balanced by protein exchange, 35S incorporation into disassembling flagella was examined, as was exchange in flagella in which microtubule assembly was blocked by colchicine. Incorporation of S-35-Iabeled polypeptides was found to occur into flagellar axonemes during wavelength-dependent shortening in pf78 and in fla-10 cells induced to shorten flagella by incubation at 33 degreesC. Colchicine blocked tubulin addition but did not affect the exchange of the other exchangeable polypeptides; nor did it induce any change in flagellar length. Basal bodies also incorporated newly synthesized proteins. These data reveal that Chlamydomonas flagella are dynamic structures that incorporate new protein both during steady state and as flagella shorten and that protein exchange does not, alone, explain length regulation.	Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA	University of Kansas	Dentler, WL (corresponding author), Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA.	wdent@ukans.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032556] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Afzelius BA, 1999, INT J DEV BIOL, V43, P283; Asleson CM, 1998, GENETICS, V148, P693; BLOODGOOD RA, 1984, EXP CELL RES, V150, P488, DOI 10.1016/0014-4827(84)90594-9; BLOODGOOD RA, 1974, CYTOBIOS, V9, P143; Brown JM, 1999, MOL BIOL CELL, V10, P3081, DOI 10.1091/mbc.10.10.3081; Cleveland DW, 1989, CURR OPIN CELL BIOL, V1, P10, DOI 10.1016/S0955-0674(89)80030-4; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; DENTLER WL, 1987, INT REV CYTOL, P391; DENTLER WL, 1980, J CELL SCI, V42, P207; DENTLER WL, 1992, J CELL BIOL, V117, P1289, DOI 10.1083/jcb.117.6.1289; DENTLER WL, 1982, CELL MOTIL CYTOSKEL, V2, P549, DOI 10.1002/cm.970020605; DRENCKHAHN D, 1993, METHOD CELL BIOL, V37, P7, DOI 10.1016/S0091-679X(08)60242-3; GONZALEZSANTANDER R, 1976, ACTA ANAT, V95, P368, DOI 10.1159/000144626; GOROVSKY MA, 1970, ANAL BIOCHEM, V35, P359, DOI 10.1016/0003-2697(70)90196-X; GOULD RR, 1975, J CELL BIOL, V65, P65, DOI 10.1083/jcb.65.1.65; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; JOHNSON KA, 1992, J CELL BIOL, V119, P1605, DOI 10.1083/jcb.119.6.1605; KING SM, 1995, METHOD CELL BIOL, V47, P9, DOI 10.1016/S0091-679X(08)60783-9; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; KOZMINSKI KG, 1993, P NATL ACAD SCI USA, V90, P5519, DOI 10.1073/pnas.90.12.5519; LEFEBVRE PA, 1986, ANNU REV CELL BIOL, V2, P517, DOI 10.1146/annurev.cb.02.110186.002505; LEFEBVRE PA, 1978, J CELL BIOL, V78, P8, DOI 10.1083/jcb.78.1.8; Margolis RL, 1998, BIOESSAYS, V20, P830, DOI 10.1002/(SICI)1521-1878(199810)20:10<830::AID-BIES8>3.0.CO;2-N; Marshall W, 1998, MOL BIOL CELL, V9, p278A; Marshall WF, 2000, MOL BIOL CELL, V11, p368A; Marszalek JR, 1999, P NATL ACAD SCI USA, V96, P5043, DOI 10.1073/pnas.96.9.5043; Morris RL, 1997, J CELL BIOL, V138, P1009, DOI 10.1083/jcb.138.5.1009; Murcia NS, 2000, DEVELOPMENT, V127, P2347; NAKAMURA S, 1987, CELL STRUCT FUNCT, V12, P369, DOI 10.1247/csf.12.369; NAKAO T, 1984, AM J ANAT, V170, P55, DOI 10.1002/aja.1001700105; NELSEN EM, 1975, EXP CELL RES, V94, P152, DOI 10.1016/0014-4827(75)90542-X; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Norrander JM, 2000, MOL BIOL CELL, V11, P201, DOI 10.1091/mbc.11.1.201; Orozco JT, 1999, NATURE, V398, P674, DOI 10.1038/19448; Ostrowski LE, 1999, AM J RESP CELL MOL, V20, P675, DOI 10.1165/ajrcmb.20.4.3496; Pazour GJ, 1999, J CELL BIOL, V144, P473, DOI 10.1083/jcb.144.3.473; Pazour GJ, 1998, J CELL BIOL, V141, P979, DOI 10.1083/jcb.141.4.979; Piperno G, 1996, J CELL BIOL, V133, P371, DOI 10.1083/jcb.133.2.371; Piperno G, 1998, J CELL BIOL, V143, P1591, DOI 10.1083/jcb.143.6.1591; Porter ME, 1999, MOL BIOL CELL, V10, P693, DOI 10.1091/mbc.10.3.693; PORTMAN RW, 1987, J CELL SCI, V87, P85; REMILLARD SP, 1982, J CELL BIOL, V93, P615, DOI 10.1083/jcb.93.3.615; RIEDERERHENDERSON MA, 1979, DEV BIOL, V70, P500, DOI 10.1016/0012-1606(79)90041-1; ROSENBAU.JL, 1969, J CELL BIOL, V41, P600, DOI 10.1083/jcb.41.2.600; ROSENBAUM JL, 1967, J CELL BIOL, V34, P345, DOI 10.1083/jcb.34.1.345; SHAKIR MA, 1993, NEUROREPORT, V4, P891, DOI 10.1097/00001756-199307000-00013; Signor D, 1999, J CELL BIOL, V147, P519, DOI 10.1083/jcb.147.3.519; Smith EF, 1997, CELL MOTIL CYTOSKEL, V38, P1; SNELL WJ, 1986, METHOD ENZYMOL, V134, P252; STEPHENS RE, 1994, J EXP ZOOL, V269, P106, DOI 10.1002/jez.1402690204; STEPHENS RE, 1994, J CELL SCI, V107, P683; Stephens RE, 2000, CELL MOTIL CYTOSKEL, V47, P130, DOI 10.1002/1097-0169(200010)47:2<130::AID-CM4>3.0.CO;2-0; Stephens RE, 1997, MOL BIOL CELL, V8, P2187, DOI 10.1091/mbc.8.11.2187; STEPHENS RE, 1995, METHOD CELL BIOL, V47, P361, DOI 10.1016/S0091-679X(08)60830-4; SULIK K, 1994, DEV DYNAM, V201, P260, DOI 10.1002/aja.1002010309; TABISH M, 1995, J MOL BIOL, V247, P377, DOI 10.1006/jmbi.1994.0146; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; Tuxhorn J, 1998, CELL MOTIL CYTOSKEL, V40, P133, DOI 10.1016/j.semcdb.2008.07.005; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; WALTHER Z, 1994, J CELL BIOL, V126, P175, DOI 10.1083/jcb.126.1.175; Wilson NF, 2000, MOL BIOL CELL, V11, p368A; WITMAN GB, 1972, J CELL BIOL, V54, P507, DOI 10.1083/jcb.54.3.507; WITMAN GB, 1975, ANN NY ACAD SCI, V253, P178, DOI 10.1111/j.1749-6632.1975.tb19199.x	64	64	65	0	19	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29754	29763		10.1074/jbc.M103184200	http://dx.doi.org/10.1074/jbc.M103184200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11384985	hybrid			2022-12-27	WOS:000170558000022
J	Zhang, TT; Prives, C				Zhang, TT; Prives, C			Cyclin A-CDK phosphorylation regulates MDM2 protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; RING FINGER DOMAIN; DEPENDENT KINASES; S-PHASE; ONCOPROTEIN MDM2; UBIQUITIN LIGASE; CELL-CYCLE; IN-VITRO; RETINOBLASTOMA PROTEIN; EMBRYONIC LETHALITY	The product of the MDM2 gene interacts with and regulates a number of proteins, in particular the tumor suppressor p53. The MDM2 protein is likely to be extensively modified in vivo, and such modification may regulate its functions in cells. We identified a potential cyclin-dependent kinase (CDK) site in murine MDM2,, and found the protein to be efficiently phosphorylated in vitro by cyclin A-containing complexes (cyclin A-CDK2 and cyclin A-CDK1), but MDM2 was either weakly or not phosphorylated by other cyclin-containing complexes. Moreover, a peptide containing a putative, MDM2 cyclin recognition motif specifically inhibited phosphorylation by cyclin A-CDK2. The site of cyclin A-CDK2 phosphorylation was identified as Thr-216 by two-dimensional phosphopeptide mapping and mutational analysis. Phosphorylation of MDM2 at Thr-216 both weakens its interaction with p53 and modestly augments its binding to p19(ARF) Interestingly, an MDM2-specific monoclonal antibody, SMP14, cannot recognize MDM2 phosphorylated at Thr-216. Changes in SMP14 reactivity of MDM2 in staged cell extracts indicate that phosphorylation of MDM2 at Thr-216 in vivo is most prevalent at the onset of S phase when cyclin A first becomes detectable.	Columbia Univ, Dept Sci Biol, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Sci Biol, New York, NY 10027 USA.	clp3@columbia.edu			NATIONAL CANCER INSTITUTE [R37CA058316, P01CA087497, R01CA058316] Funding Source: NIH RePORTER; NCI NIH HHS [CA87497, CA58316] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1999, MOL CELL BIOL, V19, P1068; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Adkins JN, 2000, BIOCHEMISTRY-US, V39, P13925, DOI 10.1021/bi001524e; Argentini M, 2000, ONCOGENE, V19, P3849, DOI 10.1038/sj.onc.1203737; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bond GL, 2000, MOL CELL BIOL, V20, P5310, DOI 10.1128/MCB.20.14.5310-5320.2000; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; Endicott JA, 1999, CURR OPIN STRUC BIOL, V9, P738, DOI 10.1016/S0959-440X(99)00038-X; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gibbs E, 1996, J BIOL CHEM, V271, P22847, DOI 10.1074/jbc.271.37.22847; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Gotz C, 1999, EUR J BIOCHEM, V266, P493, DOI 10.1046/j.1432-1327.1999.00882.x; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hay TJ, 2000, FEBS LETT, V478, P183, DOI 10.1016/S0014-5793(00)01850-0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LENG P, 1995, ONCOGENE, V10, P1275; LENG P, 1995, INT J ONCOL, V6, P251; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mayo LD, 1997, CANCER RES, V57, P5013; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PRICE BD, 1995, ONCOGENE, V11, P73; Prives C, 1999, J PATHOL, V187, P112; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SORENSEN SB, 1991, FEBS LETT, V294, P195, DOI 10.1016/0014-5793(91)80667-R; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	85	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29702	29710		10.1074/jbc.M011326200	http://dx.doi.org/10.1074/jbc.M011326200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11359766	hybrid			2022-12-27	WOS:000170558000016
J	Charest, A; Lane, K; McMahon, K; Housman, DE				Charest, A; Lane, K; McMahon, K; Housman, DE			Association of a novel PDZ domain-containing peripheral golgi protein with the Q-SNARE (Q-soluble N-ethylmaleimide-sensitive fusion protein (NSF) attachment protein receptor) protein syntaxin 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; DYSTROPHIN-ASSOCIATED PROTEIN; TYROSINE-PHOSPHATASE-PEST; ENDOPLASMIC-RETICULUM; LEUCINE-ZIPPER; CIS-GOLGI; MEMBRANE-FUSION; COPI VESICLES; INTERMEDIATE COMPARTMENT; INTRACELLULAR-TRANSPORT	PDZ domains are involved in the scaffolding and assembly of multi-protein complexes at various subcellular sites. We describe here the isolation and characterization of a novel PDZ domain-containing protein that localizes to the Golgi apparatus. Using an in silico cloning approach, we have identified and isolated a cDNA encoding a ubiquitously expressed 59-kDa protein that we call FIG. It is composed of two coiled coil regions, a leucine zipper, and a single PDZ domain. Cytological studies using indirect immunofluorescence microscopy revealed that FIG is a peripheral protein that uses one of its coiled coil domains to localize to the Golgi apparatus. To ascertain the modalities of this Golgi localization, the same coiled coil region was tested for its ability to interact with a panel of coiled coil domain-containing integral membrane Golgi proteins. Using a series of GST fusion protein binding assays, co-immunofluorescence and co-immunoprecipitation experiments, we show that FIG specifically binds to the coiled coil domain-containing Q-SNARE (Q-soluble NSF attachment protein receptor) protein syntaxin 6 both in vitro and in vivo. The structural features of FIG and its interaction with a SNARE protein suggest that FIG may play a role in membrane vesicle trafficking. This is the first example of a PDZ domain-containing peripheral protein that localizes to the Golgi through a coiled coil-mediated interaction with a resident membrane protein. Our results broaden the scope of PDZ domain-mediated functions.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Charest, A (corresponding author), MIT, Ctr Canc Res, E17-536,77 Massachusetts Ave, Cambridge, MA 02139 USA.				NHGRI NIH HHS [HG00299] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000299] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ADAMS ME, 1995, J BIOL CHEM, V270, P25859, DOI 10.1074/jbc.270.43.25859; ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; ALCALDE J, 1994, J CELL BIOL, V124, P649, DOI 10.1083/jcb.124.5.649; AUSUBEL FM, 2001, CURRENT PROTOCOLS MO; Betz A, 1997, J BIOL CHEM, V272, P2520; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Bock JB, 1999, P NATL ACAD SCI USA, V96, P12227, DOI 10.1073/pnas.96.22.12227; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; DASCHER C, 1994, J BIOL CHEM, V269, P1437; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; Froehner SC, 1997, SOC GEN PHY, V52, P197; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; Fuh G, 2000, J BIOL CHEM, V275, P21486, DOI 10.1074/jbc.275.28.21486; Gleeson PA, 1996, J CELL SCI, V109, P2811; Glick BS, 2000, CURR OPIN CELL BIOL, V12, P450, DOI 10.1016/S0955-0674(00)00116-2; Harlow E., 1988, ANTIBODIES LAB MANUA; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kjer-Nielsen L, 1999, J CELL SCI, V112, P1645; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; KOOY J, 1992, J BIOL CHEM, V267, P20255; Koushika SP, 2000, CURR OPIN CELL BIOL, V12, P517, DOI 10.1016/S0955-0674(00)00125-3; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Malsam J, 1999, FEBS LETT, V462, P267, DOI 10.1016/S0014-5793(99)01543-4; Misumi Y, 1997, J BIOL CHEM, V272, P23851, DOI 10.1074/jbc.272.38.23851; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Pepperkok R, 2000, J CELL SCI, V113, P135; PODOS SD, 1994, J CELL BIOL, V127, P679, DOI 10.1083/jcb.127.3.679; RIOS RM, 1994, J CELL BIOL, V125, P997, DOI 10.1083/jcb.125.5.997; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Sambrook J., 2002, MOL CLONING LAB MANU; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; Saras J, 1997, J BIOL CHEM, V272, P24333, DOI 10.1074/jbc.272.39.24333; SARASTE J, 1991, J CELL SCI, V100, P415; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Scales SJ, 2000, NATURE, V407, P144, DOI 10.1038/35025176; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; SHARMA S, 1989, ONCOGENE RES, V5, P91; Simon JP, 1998, P NATL ACAD SCI USA, V95, P11181, DOI 10.1073/pnas.95.19.11181; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Steegmaier M, 1999, MOL BIOL CELL, V10, P1957, DOI 10.1091/mbc.10.6.1957; Storrie B, 2000, TRENDS CELL BIOL, V10, P385, DOI 10.1016/S0962-8924(00)01818-3; SUBRAMANIAM VN, 1995, J CELL SCI, V108, P2405; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Toki C, 1997, CELL STRUCT FUNCT, V22, P565, DOI 10.1247/csf.22.565; Waters MG, 1999, CURR OPIN CELL BIOL, V11, P453, DOI 10.1016/S0955-0674(99)80065-9; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; Wong SH, 1999, MOL BIOL CELL, V10, P119, DOI 10.1091/mbc.10.1.119; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	75	84	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29456	29465		10.1074/jbc.M104137200	http://dx.doi.org/10.1074/jbc.M104137200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384996	hybrid			2022-12-27	WOS:000170346000108
J	Wang, GF; Nikovits, W; Bao, ZZ; Stockdale, FE				Wang, GF; Nikovits, W; Bao, ZZ; Stockdale, FE			Irx4 forms an inhibitory complex with the vitamin D and retinoic X receptors to regulate cardiac chamber-specific slow MyHC3 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; NATRIURETIC-FACTOR GENE; HEART TUBE; SKELETAL-MUSCLE; ANTEROPOSTERIOR POLARITY; TRANSGENIC MICE; PROTEIN; NKX2-5; ACID; DNA	The slow myosin heavy chain 3 gene (slow MyHC3) is restricted in its expression to the atrial chambers of the heart. Understanding its regulation provides a basis for determination of the mechanisms controlling chamber-specific gene expression in heart development. The observed chamber distribution results from repression of slow MyHC3 gene expression in the ventricles. A binding site, the vitamin D response element (VDRE), for a heterodimer of vitamin D receptor (VDR) and retinoic X receptor alpha (RXR alpha) within the slow MyHC3 promoter mediates chamber-specific expression of the gene. Irx4, an Iroquois family homeobox gene whose expression is restricted to the ventricular chambers at all stages of development, inhibits AMHC1, the chick homolog of quail slow MyHC3, gene expression within developing ventricles. Repression of the slow MyHC3 gene in ventricular cardiomyocytes by Irx4 requires the VDRE. Unlike VDR and RXR alpha, Irx4 does not bind directly to the VDRE. Instead two-hybrid and co-immunoprecipitation assays show that Irx4 interacts with the RXR alpha component of the VDR/RXR alpha heterodimer and that the amino terminus of the Irx4 protein is required for its inhibitory action. These observations indicate that the mechanism of atrial chamber-specific expression requires the formation of an inhibitory protein complex composed of VDR, RXR alpha, and Irx4 that binds at the VDRE inhibiting slow MyHC3 expression in the ventricles.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	Stanford University; University of Massachusetts System; University of Massachusetts Worcester	Stockdale, FE (corresponding author), Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA.	mlfes@stanford.edu						Bao ZZ, 1999, SCIENCE, V283, P1161, DOI 10.1126/science.283.5405.1161; BISAHA JG, 1991, DEV BIOL, V148, P355, DOI 10.1016/0012-1606(91)90343-2; Bruneau BG, 1999, DEV BIOL, V211, P100, DOI 10.1006/dbio.1999.9298; Bruneau BG, 2000, DEV BIOL, V217, P266, DOI 10.1006/dbio.1999.9548; Bruneau BG, 2001, MOL CELL BIOL, V21, P1730, DOI 10.1128/MCB.21.5.1730-1736.2001; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Durocher D, 1996, MOL CELL BIOL, V16, P4648, DOI 10.1128/mcb.16.9.4648; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; ELION EA, 1999, CURRENT PROTOCOLS MO, V4; EVANS D, 1988, DEV BIOL, V127, P376, DOI 10.1016/0012-1606(88)90324-7; Fishman MC, 1997, DEVELOPMENT, V124, P2099; GomezSkarmeta JL, 1996, CELL, V85, P95, DOI 10.1016/S0092-8674(00)81085-5; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383; KUBALAK SW, 1994, J BIOL CHEM, V269, P16961; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lee Y, 2000, CIRC RES, V86, P932, DOI 10.1161/01.RES.86.9.932; Li XL, 1999, EMBO J, V18, P198, DOI 10.1093/emboj/18.1.198; Liberatore CM, 2000, DEV BIOL, V223, P169, DOI 10.1006/dbio.2000.9748; Lin NUT, 1996, J CLIN ENDOCR METAB, V81, P2564, DOI 10.1210/jc.81.7.2564; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Nikovits W, 1996, J BIOL CHEM, V271, P17047, DOI 10.1074/jbc.271.29.17047; Oana S, 1998, BIOL CELL, V90, P605; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; STAINIER DYR, 1992, DEV BIOL, V153, P91, DOI 10.1016/0012-1606(92)90094-W; SUBRAMANIAM A, 1993, J BIOL CHEM, V268, P4331; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Thomas T, 1998, DEV BIOL, V196, P228, DOI 10.1006/dbio.1998.8849; Wang GF, 1998, MOL CELL BIOL, V18, P6023, DOI 10.1128/MCB.18.10.6023; Wang GF, 1996, J BIOL CHEM, V271, P19836, DOI 10.1074/jbc.271.33.19836; WANG GF, 1999, HEART DEV, P357; Xavier-Neto J, 1999, DEVELOPMENT, V126, P2677; Yelon D, 1999, DEV BIOL, V214, P23, DOI 10.1006/dbio.1999.9406; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0; YUTZEY KE, 1995, CIRC RES, V77, P216, DOI 10.1161/01.RES.77.2.216; YUTZEY KE, 1994, DEVELOPMENT, V120, P871; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693; Zou YM, 1997, DEVELOPMENT, V124, P793; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	47	54	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28835	28841		10.1074/jbc.M103716200	http://dx.doi.org/10.1074/jbc.M103716200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382777	hybrid			2022-12-27	WOS:000170346000028
J	Kusanagi, K; Kawabata, M; Mishima, HK; Miyazono, K				Kusanagi, K; Kawabata, M; Mishima, HK; Miyazono, K			alpha-Helix 2 in the amino-terminal mad homology 1 domain is responsible for specific DNA binding of Smad3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TUMOR SUPPRESSORS SMAD2; MH1 DOMAIN; PROMOTER; PROTEINS; TRANSCRIPTION; MUTATIONS; ELEMENT; ACTIVATION; RECEPTORS	Smads, signal transducers of the transforming growth factor-beta (TGF-beta) superfamily proteins, directly bind to DNA and regulate transcription of target genes. Smad3 binds to CAGA box, whereas Smad1 and Smad5 preferentially bind to GC-rich sequences. The beta -hairpin loop in the amino-terminal Mad homology 1 (MH1) domain is the direct DNA-binding site of Smad3; however, the amino acid sequences of the beta -hairpin loop of Smad3 and Smad1/5 are identical, suggesting that other regions may be responsible for the differential DNA binding of Smad3 and Smad1/5. To identify regions other than the beta -hairpin loop responsible for specific DNA binding of Smad3, we generated chimeras containing various regions of Smad3 and Smad1. Luciferase assays using a TGF-beta -responsive reporter (CAGA)(9)-MLP-Luc and gel-mobility shift assays using 3xCAGA as a probe revealed that alpha -helix 2 (H2) in the amino-terminal part of the MH1 domain plays an important role in specific DNA binding and transcriptional activation of Smad3. Luciferase assays using natural TGF-beta -responsive reporters also revealed the functional importance of H2 in the Smad3 AMI domain in direct DNA binding. Smad3 thus binds to DNA directly through the beta -hairpin loop, and H2 supports specific DNA binding of Smad3.	Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Hiroshima Univ, Sch Med, Dept Ophthalmol, Minami Ku, Hiroshima 7348551, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan	Japanese Foundation for Cancer Research; Hiroshima University; University of Tokyo	Miyazono, K (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.	miyazono-ind@umin.ac.jp						ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810; Das P, 1999, GENES CELLS, V4, P123, DOI 10.1046/j.1365-2443.1999.00244.x; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Gouedard L, 2000, J BIOL CHEM, V275, P27973; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Jones JB, 2000, NUCLEIC ACIDS RES, V28, P2363, DOI 10.1093/nar/28.12.2363; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kaestner KH, 2000, GENE DEV, V14, P142; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kirkpatrick H, 2001, J BIOL CHEM, V276, P18216, DOI 10.1074/jbc.M101365200; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Marquez RM, 2001, GENETICS, V157, P1639; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Moren A, 2000, ONCOGENE, V19, P4396, DOI 10.1038/sj.onc.1203798; Nagarajan RP, 2000, BIOCHEM J, V350, P253, DOI 10.1042/0264-6021:3500253; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398-247; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Tang SJ, 1998, DEVELOPMENT, V125, P1877; Wu JW, 2001, J BIOL CHEM, V276, P20688, DOI 10.1074/jbc.M100174200; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yakmovych I, 2001, FASEB J, V15, P553; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	45	19	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28155	28163		10.1074/jbc.M103371200	http://dx.doi.org/10.1074/jbc.M103371200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382774	hybrid			2022-12-27	WOS:000170093400056
J	Morisco, C; Seta, K; Hardt, SE; Lee, Y; Vatner, SF; Sadoshima, J				Morisco, C; Seta, K; Hardt, SE; Lee, Y; Vatner, SF; Sadoshima, J			Glycogen synthase kinase 3 beta regulates GATA4 in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-4; HEAVY-CHAIN GENE; NUCLEAR EXPORT; PROTEIN-KINASE; ALPHA(1)-ADRENERGIC AGONIST; MOLECULAR CHARACTERIZATION; RESPONSIVE TRANSCRIPTION; COVALENT MODIFICATION; IN-VITRO; HYPERTROPHY	Inactivation of glycogen synthase kinase 3 beta (GSK3 beta) is critical for transcription of atrial natriuretic factor (ANF) by beta -adrenergic receptors in cardiac myocytes. We examined the mechanism by which GSK3 beta regulates ANF transcription. Stimulation of beta -adrenergic receptors induced nuclear accumulation of GATA4, whereas beta -adrenergic ANF transcription was suppressed by dominant negative GATA4, suggesting that GATA4 plays an important role in beta -adrenergic ANF transcription. Interestingly, GATA4-mediated transcription was markedly attenuated by GSK3 beta. GSK3 beta physically associates with GATA4 and phosphorylates GATA4 in vitro. Overexpression of GSK3 beta suppressed both basal and beta -adrenergic increases in nuclear expression of GATA4, whereas inhibition of GSK3 beta by LiCl caused nuclear accumulation of GATA4, suggesting that GSK3 beta negatively regulates nuclear expression of GATA4. The nuclear exportin Crm1 reduced nuclear expression of GATA4, and the reduction was enhanced by GSK3 beta but not by kinase-inactive GSK3 beta. Leptomycin B, an inhibitor for Crm1, increased basal nuclear GATA4 and suppressed GSK3 beta -induced decreases in nuclear GATA4. These results suggest that GSK3 beta negatively regulates nuclear expression of GATA4 by stimulating Crm1-dependent nuclear export. Inhibition of GSK3 beta by beta -adrenergic stimulation abrogates GSK3 beta -induced nuclear export of GATA4, causing nuclear accumulation of GATA4, which may represent an important signaling mechanism mediating cardiac hypertrophy.	Univ Med & Dent New Jersey, New Jersey Med Sch, Inst Cardiovasc Res, Newark, NJ 07103 USA; Hackensack Univ, Med Ctr, Hackensack, NJ 07601 USA; Univ Wisconsin, Sch Med, Dept Anat, Madison, WI 53706 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Hackensack University Medical Center; University of Wisconsin System; University of Wisconsin Madison	Sadoshima, J (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Inst Cardiovasc Res, 185 S Orange Ave,MSB,Rm I-574, Newark, NJ 07103 USA.	sadoshju@umdnj.edu		Sadoshima, Junichi/0000-0003-3724-4132; MORISCO, Carmine/0000-0002-2158-6317				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Aoki H, 2000, BIOCHEM J, V347, P275, DOI 10.1042/0264-6021:3470275; Aoki H, 1998, CIRC RES, V82, P666, DOI 10.1161/01.RES.82.6.666; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Charron F, 1999, MOL CELL BIOL, V19, P4355; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Ginger RS, 2000, EMBO J, V19, P5483, DOI 10.1093/emboj/19.20.5483; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hasegawa K, 1997, CIRCULATION, V96, P3943; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KELLEY C, 1993, DEVELOPMENT, V118, P817; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lien CL, 1999, DEVELOPMENT, V126, P75; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Malhotra R, 1999, CIRC RES, V85, P137, DOI 10.1161/01.RES.85.2.137; Mann DL, 1999, CIRCULATION, V100, P999, DOI 10.1161/01.CIR.100.9.999; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Molkentin JD, 1997, CIRCULATION, V96, P3833; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Morimoto T, 1999, J BIOL CHEM, V274, P12811, DOI 10.1074/jbc.274.18.12811; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Morisco C, 2001, J MOL CELL CARDIOL, V33, P561, DOI 10.1006/jmcc.2000.1332; Morrisey EE, 1997, J BIOL CHEM, V272, P8515, DOI 10.1074/jbc.272.13.8515; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Olson EN, 1999, CIRC RES, V84, P623, DOI 10.1161/01.RES.84.6.623; Reecy JM, 1999, DEVELOPMENT, V126, P839; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Takeda K, 2000, HUM MOL GENET, V9, P125, DOI 10.1093/hmg/9.1.125; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855	66	174	183	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28586	28597		10.1074/jbc.M103166200	http://dx.doi.org/10.1074/jbc.M103166200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382772	hybrid			2022-12-27	WOS:000170093400112
J	Norris, RA; Kern, MJ				Norris, RA; Kern, MJ			The identification of Prx1 transcription regulatory domains provides a mechanism for unequal compensation by the Prx1 and Prx2 loci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; SERUM RESPONSE FACTOR; DNA-BINDING ACTIVITY; HOMEOBOX GENE; HOMEODOMAIN PROTEIN; DROSOPHILA; EXPRESSION; ACTIVATION; HOX; SKELETOGENESIS	Transcription regulatory domains of the Prx1a and Prx1b homeoproteins were analyzed in transient transfection assays using artificial promoters as well as an established downstream target promoter (tenascin-c), Activation and repression domains were detected in their common amino end. In the carboxyl end of Prx1a an activation domain and an inhibition/masking region (OAR domain) were detected. The Prx1b isoform, generated by alternative splicing, does not contain these carboxyl activation or inhibition domains. Instead, the data demonstrate that the carboxyl tail of Prx1b contains a potent repressor region. This difference in the carboxyl tail accounts for a 45-fold difference observed in transcription regulatory activity between Prx1a and Prx1b, The data also support the likelihood that this difference between Prx1a and Prx1b is higher in the presence of still undetermined cofactors, DNA binding affinities of Prx1a, Prx1b, and a series of truncation mutants were also examined. The carboxyl tail of Prx1a, which inhibited transcription activation in the transfection assays, also inhibited DNA binding, These differences in biochemical function between Prx1a and Prx1b, as well as the recently described activities of Prx2, provide a mechanism for the unequal compensation between the Prx1 and Prx2 loci.	Med Univ S Carolina, Dept Anat & Cell Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Kern, MJ (corresponding author), Med Univ S Carolina, Dept Anat & Cell Biol, 171 Ashley Ave, Charleston, SC 29425 USA.				NHLBI NIH HHS [HL-56596] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056596] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amendt BA, 1999, MOL CELL BIOL, V19, P7001; ANANTHAN J, 1993, MOL CELL BIOL, V13, P1599, DOI 10.1128/MCB.13.3.1599; Bergwerff M, 2000, VIRCHOWS ARCH, V436, P12, DOI 10.1007/PL00008193; Catron KM, 1996, MECH DEVELOP, V55, P185, DOI 10.1016/0925-4773(96)00503-5; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DEJONG R, 1993, NUCLEIC ACIDS RES, V21, P4711, DOI 10.1093/nar/21.20.4711; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; Galliot B, 1999, DEV GENES EVOL, V209, P186, DOI 10.1007/s004270050243; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; JAYARAMAN PS, 1994, EMBO J, V13, P2192, DOI 10.1002/j.1460-2075.1994.tb06496.x; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.3.CO;2-7; Kataoka K, 2001, J BIOL CHEM, V276, P819, DOI 10.1074/jbc.M007643200; KERN MJ, 1992, NUCLEIC ACIDS RES, V20, P5189, DOI 10.1093/nar/20.19.5189; KERN MJ, 1994, GENOMICS, V19, P334, DOI 10.1006/geno.1994.1066; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; KURATANI S, 1994, DEV BIOL, V161, P357, DOI 10.1006/dbio.1994.1037; LEUSSINK B, 1995, MECH DEVELOP, V52, P51, DOI 10.1016/0925-4773(95)00389-I; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; Lu MF, 1999, DEV BIOL, V205, P145, DOI 10.1006/dbio.1998.9116; Lu MF, 1999, DEVELOPMENT, V126, P495; Lu Q, 1996, MOL CELL BIOL, V16, P1632; MADDEN SL, 1993, ONCOGENE, V8, P1713; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; NOHNO T, 1993, DEV BIOL, V158, P254, DOI 10.1006/dbio.1993.1184; Norris RA, 2000, MAMM GENOME, V11, P1000, DOI 10.1007/s003350010193; Okubo Y, 1999, BIOCHEM BIOPH RES CO, V262, P739, DOI 10.1006/bbrc.1999.1281; OPSTELTEN DJE, 1991, MECH DEVELOP, V34, P29, DOI 10.1016/0925-4773(91)90089-O; Pai SR, 1997, ANTICANCER RES, V17, P3265; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Qu SM, 1999, DEVELOPMENT, V126, P359; SIMEONE A, 1994, NEURON, V13, P83, DOI 10.1016/0896-6273(94)90461-8; ten Berge D, 1998, DEVELOPMENT, V125, P3831; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	45	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26829	26837		10.1074/jbc.M100239200	http://dx.doi.org/10.1074/jbc.M100239200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11373278	hybrid			2022-12-27	WOS:000169966900015
J	Thorsteinsson, MV; Kerby, RL; Youn, H; Conrad, M; Serate, J; Staples, CR; Roberts, GP				Thorsteinsson, MV; Kerby, RL; Youn, H; Conrad, M; Serate, J; Staples, CR; Roberts, GP			Redox-mediated transcriptional activation in a CooA variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; CAMP RECEPTOR PROTEIN; CARBON-MONOXIDE; RHODOSPIRILLUM-RUBRUM; NITRIC-OXIDE; ESCHERICHIA-COLI; CYCLIC-NUCLEOTIDE; GUANYLATE-CYCLASE; GENE-EXPRESSION; OXYGEN SENSOR	CoOA, the carbon monoxide-sensing transcription factor from Rhodospirillum rubrum, binds CO at a reduced (Fe-II) heme moiety with resulting conformational changes that promote DNA binding, In this study, we report a variant of CooA, M124R, that is active in transcriptional activation in a redox-dependent manner. Where wild-type CooA is active only in the Fe-II + CO form, M124R CooA is active in both Fe-II + CO and Fe-III forms. Analysis of the pH dependence of the activity of Fe-III M124R CooA demonstrated that the activity was also coordination state-dependent with a five-coordinate, high-spin species identified as the active form and Cys(75) as the retained ligand, In contrast, the active Fe-II + CO forms of both wild-type and M124R CooA are six coordinate and low-spin with a protein ligand other than Cys(75), so that WT and Fe-III M124R CooA are apparently achieving an active conformation despite two different heme coordination and ligation states. A hypothesis to explain these results is proposed. This study demonstrates the utility of CooA as a model system for the isolation of functionally interesting heme proteins.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Roberts, GP (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.				NIGMS NIH HHS [GM53228] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Ausubel F. M., 1995, SHORT PROTOCOLS MOL, P21; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BURSTYN JN, 1996, BIOCHEMISTRY-US, V35, P5896; Cheng XD, 1998, J BIOL CHEM, V273, P705, DOI 10.1074/jbc.273.2.705; CHENG XD, 1995, BIOCHEMISTRY-US, V34, P10816, DOI 10.1021/bi00034a014; Chiang L W, 1993, PCR Methods Appl, V2, P210; DEDUVE C, 1948, ACTA CHEM SCAND, V2, P264, DOI 10.3891/acta.chem.scand.02-0264; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Friebe A, 1999, BIOCHEMISTRY-US, V38, P15253, DOI 10.1021/bi9908944; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; KILEY PJ, 1991, J BACTERIOL, V173, P16, DOI 10.1128/jb.173.1.16-22.1991; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; LEE FJ, 1994, NUCLEIC ACIDS RES, V22, P2894; Lukat-Rodgers GS, 1998, BIOCHEMISTRY-US, V37, P13543, DOI 10.1021/bi981439v; LukatRodgers GS, 1997, BIOCHEMISTRY-US, V36, P4178, DOI 10.1021/bi9628230; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; Makino R, 1999, J BIOL CHEM, V274, P7714, DOI 10.1074/jbc.274.12.7714; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Matsui T, 1996, BIOCHEMISTRY-US, V35, P13118, DOI 10.1021/bi960459z; McLaughlin BE, 2000, CAN J PHYSIOL PHARM, V78, P343, DOI 10.1139/cjpp-78-4-343; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; PIERIK AJ, 1991, EUR J BIOCHEM, V195, P505, DOI 10.1111/j.1432-1033.1991.tb15731.x; Schmidt K, 2001, MOL PHARMACOL, V59, P220, DOI 10.1124/mol.59.2.220; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; SONO M, 1982, J BIOL CHEM, V257, P5496; SPIRO S, 1994, ANTON LEEUW INT J G, V66, P23, DOI 10.1007/BF00871630; Stone JR, 1998, CHEM BIOL, V5, P255, DOI 10.1016/S1074-5521(98)90618-4; Thorsteinsson MV, 2000, BIOCHEMISTRY-US, V39, P8284, DOI 10.1021/bi000327c; Thorsteinsson MV, 2000, J BIOL CHEM, V275, P39332, DOI 10.1074/jbc.M007691200; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200	39	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26807	26813		10.1074/jbc.M102758200	http://dx.doi.org/10.1074/jbc.M102758200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11359778	hybrid			2022-12-27	WOS:000169966900012
J	Zwaagstra, JC; El-Alfy, M; O'Connor-McCourt, MD				Zwaagstra, JC; El-Alfy, M; O'Connor-McCourt, MD			Transforming growth factor (TGF)-beta 1 internalization - Modulation by ligand interaction with TGF-beta receptors types I and II and a mechanism that is distinct from clathrin-mediated endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; DOWN-REGULATION; CELLS; CAVEOLAE; DYNAMIN; EGF; TRANSGLUTAMINASE; CHLOROQUINE	Transforming growth factor-p (TGF-P) internalization was studied by monitoring the uptake of I-125-TGF-beta1 in Mv1Lu cells, which endogenously express TGF-P receptors types I (RI), II (RII), and III (RIII), and 293 cells transfected with RI and RII. At 37 degreesC internalization occurred rapidly, within 10 min of ligand addition. Internalization was optimal in 293 cells expressing both RI and RII, Internalization was prevented by phenylarsine oxide, a nonspecific inhibitor of receptor internalization, but was not affected by reagents that interfere with clathrin-mediated endocytosis such as monodansylcadaverine, K44A dynamin, and inhibitors of endosomal acidification. Electron microscopic examination of Mv1Lu cells treated with I-125-TGF-beta1 at 37 degreesC indicated that internalization occurred via a noncoated vesicular mechanism. Internalization was prevented by prebinding cells with TGF-beta1 at 4 degreesC for 2 h prior to switching the cells to 37 degreesC. This was attributed to a loss of receptor binding, as indicated by a rapid decrease in the amount of TGF-beta1 bound to the cell surface at 37 degreesC and by a reduction in the labeling intensities of RI and RII in I-125-TGF-beta1-cross-linking experiments. Mv1Lu or 293 (RI+RII) cells, prebound with TGF-beta1 at 4 degreesC and subsequently stripped of ligand by an acid wash, nevertheless initiated a signaling response upon transfer to 37 degreesC, suggesting that prebinding promotes formation of stable RI RII complexes that can signal independently of ligand.	Natl Res Council Canada, Biotechnol Res Inst, Cell Surface Recognit Grp, Montreal, PQ H4P 2R2, Canada; Ctr Rech, Mol Endocrinol Lab, Ste Foy, PQ G1V 4G2, Canada	National Research Council Canada	Zwaagstra, JC (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Cell Surface Recognit Grp, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	john.zwaagstra@nrc.ca						ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Anders RA, 1997, MOL BIOL CELL, V8, P2133, DOI 10.1091/mbc.8.11.2133; Anders RA, 1998, J BIOL CHEM, V273, P23118, DOI 10.1074/jbc.273.36.23118; Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; Bergeron JJM, 1995, BIOSCIENCE REP, V15, P411, DOI 10.1007/BF01204345; Bevan AP, 1997, J BIOL CHEM, V272, P26833, DOI 10.1074/jbc.272.43.26833; Bohm SK, 1997, BIOCHEM J, V322, P1; CAPALA J, 1991, INT J RADIAT BIOL, V60, P497, DOI 10.1080/09553009114552341; CARPENTIER JL, 1994, ANN NY ACAD SCI, V733, P266, DOI 10.1111/j.1749-6632.1994.tb17276.x; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; CHARBY J, 1993, J BIOL CHEM, V268, P17138; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; COOPER JL, 1988, J CELL PHYSIOL, V134, P387, DOI 10.1002/jcp.1041340309; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; FRENCH AR, 1995, J BIOL CHEM, V270, P4334, DOI 10.1074/jbc.270.9.4334; Gekle M, 1999, J PHYSIOL-LONDON, V520, P709, DOI 10.1111/j.1469-7793.1999.00709.x; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; HERTEL C, 1985, J BIOL CHEM, V260, P2547; HOSOI K, 1993, J CELL PHYSIOL, V157, P1, DOI 10.1002/jcp.1041570102; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Kang Y, 2000, BIOCHEMISTRY-US, V39, P13551, DOI 10.1021/bi001196i; KATOH S, 1994, BIOL PHARM BULL, V17, P1003; KOPRIWA BM, 1967, J HISTOCHEM CYTOCHEM, V15, P501, DOI 10.1177/15.9.501; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1986, J CELL PHYSIOL, V128, P216, DOI 10.1002/jcp.1041280212; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; NADLER NJ, 1979, J HISTOCHEM CYTOCHEM, V27, P1531, DOI 10.1177/27.11.512340; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Ray E, 1996, FEBS LETT, V378, P235, DOI 10.1016/0014-5793(95)01462-4; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; Simpson JC, 1998, EXP CELL RES, V239, P293, DOI 10.1006/excr.1997.3921; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WATERS CM, 1990, BIOCHEMISTRY-US, V29, P3563, DOI 10.1021/bi00466a020; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zwaagstra JC, 1999, EXP CELL RES, V252, P352, DOI 10.1006/excr.1999.4640	54	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27237	27245		10.1074/jbc.M100033200	http://dx.doi.org/10.1074/jbc.M100033200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356827	hybrid			2022-12-27	WOS:000169966900069
J	Asante-Appiah, E; Ball, K; Bateman, K; Skorey, K; Friesen, R; Desponts, C; Payette, P; Bayly, C; Zamboni, R; Scapin, G; Ramachandran, C; Kennedy, BP				Asante-Appiah, E; Ball, K; Bateman, K; Skorey, K; Friesen, R; Desponts, C; Payette, P; Bayly, C; Zamboni, R; Scapin, G; Ramachandran, C; Kennedy, BP			The YRD motif is a major determinant of substrate and inhibitor specificity in T-cell protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN SENSITIVITY; STRUCTURAL BASIS; MICE; 1B; PHOSPHORYLATION; IDENTIFICATION; MUTATIONS; SELECTION; BINDING; WEIGHT	We have studied T-cell protein-tyrosine phosphatase (TCPTP) as a model phosphatase in an attempt to unravel amino acid residues that may influence the design of specific inhibitors. Residues 48-50, termed the YRD motif, a region that is found in protein-tyrosine phosphatases, but absent in dual-specificity phosphatases was targeted. YRD derivatives of TCPTP were characterized by steady-state kinetics and by inhibition studies with BzN-EJJ-amide, a potent inhibitor of TCPTP, Substitution of Asp(50) to alanine or Arg(49) to lysine, methionine, or alanine significantly affected substrate hydrolysis and led to a substantial decrease in affinity for BzN-EJJ-amide, The influence of residue 49 on substrate/inhibitor selectivity was further investigated by comparing subsite amino acid preferences of TCPTP and its R49K derivative by affinity selection coupled with mass spectrometry, The greatest effect on selectivity was observed on the residue that precedes the phosphorylated tyrosine, Unlike wild-type TCPTP, the R49K derivative preferred tyrosine to aspartic or glutamic acid. BzN-EJJ-amide which retains the preferred specificity requirements of TCPTP and PTP1B was equipotent on both enzymes but greater than 30-fold selective over other phosphatases, These results suggest that Ar-49 and Asp(50) may be targeted for the design of potent and selective inhibitors of TCPTP and PTP1B.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck Frosst Ctr Therapeut Res, Dept Med Chem, Pointe Claire, PQ H9R 4P8, Canada; Merck Res Lab, Dept Endocrinol & Cell Biol, Rahway, NJ 07065 USA	Merck & Company; Merck & Company; Merck & Company	Asante-Appiah, E (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada.	Ernest_Asanteappiah@merck.com		Bateman, Kevin/0000-0002-4026-6685				Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Desmarais S, 1999, BIOCHEM J, V337, P219, DOI 10.1042/0264-6021:3370219; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; Huang Z, 1999, J BIOMOL SCREEN, V4, P327, DOI 10.1177/108705719900400608; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; Huyer G, 1998, ANAL BIOCHEM, V258, P19, DOI 10.1006/abio.1997.2541; Iversen LF, 2000, J BIOL CHEM, V275, P10300, DOI 10.1074/jbc.275.14.10300; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; RUZZENE M, 1993, EUR J BIOCHEM, V211, P289, DOI 10.1111/j.1432-1033.1993.tb19897.x; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; Sarmiento M, 1998, J BIOL CHEM, V273, P26368, DOI 10.1074/jbc.273.41.26368; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; van Huijsduijnen RH, 1998, GENE, V225, P1; YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683; Zhang YL, 2000, J BIOL CHEM, V275, P34205, DOI 10.1074/jbc.M004490200; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161	31	54	58	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26036	26043		10.1074/jbc.M011697200	http://dx.doi.org/10.1074/jbc.M011697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352902	hybrid			2022-12-27	WOS:000169823300054
J	Ciciarello, M; Mangiacasale, R; Casenghi, M; Limongi, MZ; D'Angelo, M; Soddu, S; Lavia, P; Cundari, E				Ciciarello, M; Mangiacasale, R; Casenghi, M; Limongi, MZ; D'Angelo, M; Soddu, S; Lavia, P; Cundari, E			p53 displacement from centrosomes and p53-mediated G(1) arrest following transient inhibition of the mitotic spindle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; MICROTUBULE NUCLEATION; VERTEBRATE CELLS; MAMMALIAN-CELLS; ANIMAL-CELLS; DNA-DAMAGE; APOPTOSIS; INSTABILITY; DUPLICATION; NOCODAZOLE	Growing evidence indicates a central role for p53 in mediating cell cycle arrest in response to mitotic spindle defects so as to prevent rereplication in cells in which the mitotic division has failed. Here we report that a transient inhibition of spindle assembly induced by nocodazole, a tubulin-depolymerizing drug, triggers a stable activation of p53, which can transduce a cell cycle inhibitory signal even when the spindle-damaging agent is removed and the spindle is allowed to reassemble. Cells transiently exposed to nocodazole continue to express high levels of p53 and p21 in the cell cycle that follows the transient exposure to nocodazole and become arrested in G,, regardless of whether they carry a diploid or polyploid genome after mitotic exit. We also show that p53 normally associates with centrosomes in mitotic cells, whereas nocodazole disrupts this association. Together these results suggest that the induction of spindle damage, albeit transient, interferes with the subcellular localization of p53 at specific mitotic locations, which in turn dictates cell cycle arrest in the offspring of such defective mitoses.	Univ Rome La Sapienza, Dept Genet & Mol Biol, CNR, Ctr Evolutionary Genet, I-00185 Rome, Italy; Regina Elena Canc Inst, Mol Oncogenesis Lab, I-00158 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Cundari, E (corresponding author), Univ Rome La Sapienza, Dept Genet & Mol Biol, CNR, Ctr Evolutionary Genet, Via Apuli 4, I-00185 Rome, Italy.		Soddu, Silvia/K-2467-2018; Lavia, Patrizia/AAL-3982-2021; Ciciarello, Marilena/AAA-7950-2022; Soddu, Silvia/ABH-6774-2020; Lavia, Patrizia/J-5793-2019; Ciciarello, Marilena/A-4401-2015	Soddu, Silvia/0000-0001-8526-0044; Ciciarello, Marilena/0000-0002-4744-507X; Soddu, Silvia/0000-0001-8526-0044; Lavia, Patrizia/0000-0003-3310-6701; 				Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Battistoni A, 1997, J CELL SCI, V110, P2345; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Di Fiore B, 1999, J BIOL CHEM, V274, P10339, DOI 10.1074/jbc.274.15.10339; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEAD J, 1985, J BIOL CHEM, V260, P1060; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOEBEKE J, 1976, BIOCHEM BIOPH RES CO, V69, P319, DOI 10.1016/0006-291X(76)90524-6; JORDAN MA, 1992, J CELL SCI, V102, P401; Kirsch-Volders M, 1998, MUTAGENESIS, V13, P321, DOI 10.1093/mutage/13.4.321; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Meek DW, 2000, PATHOL BIOL, V48, P246; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Merdes A, 1997, J CELL BIOL, V138, P953, DOI 10.1083/jcb.138.5.953; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Paoletti A, 1996, J CELL SCI, V109, P3089; Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317; Pietenpol JA, 1996, P NATL ACAD SCI USA, V93, P8390, DOI 10.1073/pnas.93.16.8390; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Sablina AA, 1998, J CELL SCI, V111, P977; Schiebel E, 2000, CURR OPIN CELL BIOL, V12, P113, DOI 10.1016/S0955-0674(99)00064-2; Sorger PK, 1997, CURR OPIN CELL BIOL, V9, P807, DOI 10.1016/S0955-0674(97)80081-6; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Stewart ZA, 2001, ONCOGENE, V20, P113, DOI 10.1038/sj.onc.1204060; Tarapore P, 2000, CANCER INVEST, V18, P148, DOI 10.3109/07357900009038246; Tassin AM, 1999, BIOL CELL, V91, P343, DOI 10.1016/S0248-4900(99)80095-1; Verdoodt B, 1999, MUTAGENESIS, V14, P513, DOI 10.1093/mutage/14.5.513; Vessey CJ, 2000, PROG NUCLEIC ACID RE, V63, P189, DOI 10.1016/S0079-6603(08)60723-0; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Zimmerman W, 1999, CURR OPIN CELL BIOL, V11, P122, DOI 10.1016/S0955-0674(99)80015-5	50	106	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19205	19213		10.1074/jbc.M009528200	http://dx.doi.org/10.1074/jbc.M009528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376010	hybrid			2022-12-27	WOS:000169091000077
J	Patallo, EP; Blanco, G; Fischer, C; Brana, AF; Rohr, J; Mendez, C; Salas, JA				Patallo, EP; Blanco, G; Fischer, C; Brana, AF; Rohr, J; Mendez, C; Salas, JA			Deoxysugar methylation during biosynthesis of the antitumor polyketide elloramycin by Streptomyces olivaceus - Characterization of three methyltransferase genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECT FERMENTATIVE PRODUCTION; SUBSTRATE-SPECIFICITY; O-METHYLTRANSFERASE; METABOLIC PRODUCTS; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; DRUG MITHRAMYCIN; IDENTIFICATION; FRADIAE; TYLOSIN	The anthracycline-like polyketide drug elloramycin is produced by Streptomyces olivaceus Tu2353. Elloramycin has antibacterial activity against Gram-positive bacteria and also exhibits antitumor activity. From a cosmid clone (cos16F4) containing part of the elloramycin biosynthesis gene cluster, three genes (elmMI, elmMII, and elmMIII) have been cloned. Sequence analysis and data base comparison showed that their deduced products resembled S-adenosylmethionine-dependent O-methyltransferases. The genes were individually expressed in Streptomyces albus and also coexpressed with genes involved in the biosynthesis of L-rhamnose, tbe 6-deoxysugar attached to the elloramycin aglycon, The resulting recombinant strains were used to biotransform three different elloramycin-type compounds: L-rhamnosyl-tetracenomycin C, L-olivosyl-tetracenomycin C, and L-oleandrosyl-tetracenomycin, which differ in their 2'-, 3'-, and 4'-substituents of the sugar moieties, When only the three methyltransferase-encoding genes elmMI elmMII, and elmMIII were individually expressed in S. albus, the methylating activity of the three methyltransferases was also assayed in vitro using various externally added glycosylated substrates, From the combined results of all of these experiments, it is proposed that methyltransferases ElmMI, ElmMII, and ElmMIII are involved in the biosynthesis of the permethylated L-rhamnose moiety of elloramycin, ElmMI, ElmMII, and ElmMIII are responsible for the consecutive methylation of the hydroxy groups at the 2'-, 3'-, and 4'-position, respectively, after the sugar moiety has been attached to the aglycon.	Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA; Univ Oviedo, Dept Biol Func, E-33006 Oviedo, Spain; Univ Oviedo, Inst Univ Oncol Principado Asturias, E-33006 Oviedo, Spain	Medical University of South Carolina; University of Oviedo; University of Oviedo; Instituto Universitario de Oncologia de Asturias	Rohr, J (corresponding author), Med Univ S Carolina, Dept Pharmaceut Sci, 171 Ashley Ave, Charleston, SC 29425 USA.		Patallo, Eugenio P./AAT-7342-2021; Brana, Alfredo/M-1836-2014; Rohr, Jurgen/G-5375-2014; Mendez-Fernandez, Carmen/ABE-5745-2020; Fernandez-Brana, Alfredo/O-1488-2019; Blanco, Gloria/K-5850-2014	Brana, Alfredo/0000-0002-3277-9085; Rohr, Jurgen/0000-0001-6447-5951; Mendez-Fernandez, Carmen/0000-0003-2729-841X; Fernandez-Brana, Alfredo/0000-0002-3277-9085; Blanco-Blanco, Maria Gloria/0000-0002-6388-4929; Perez Patallo, Eugenio/0000-0003-1857-8022				Aguirrezabalaga I, 2000, ANTIMICROB AGENTS CH, V44, P1266, DOI 10.1128/AAC.44.5.1266-1275.2000; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARISAWA A, 1994, APPL ENVIRON MICROB, V60, P2657, DOI 10.1128/AEM.60.7.2657-2660.1994; Arisawa A, 1996, J ANTIBIOT, V49, P349, DOI 10.7164/antibiotics.49.349; Bate N, 1999, J IND MICROBIOL BIOT, V23, P118, DOI 10.1038/sj.jim.2900707; Blanco G, 2001, CHEM BIOL, V8, P253, DOI 10.1016/S1074-5521(01)00010-2; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHATER KF, 1980, J GEN MICROBIOL, V116, P323; DECKER H, 1995, GENE, V166, P121, DOI 10.1016/0378-1119(95)00573-7; Decker H, 1996, FEMS MICROBIOL LETT, V141, P195, DOI 10.1016/0378-1097(96)00221-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAUTZ H, 1985, J ANTIBIOT, V38, P1291, DOI 10.7164/antibiotics.38.1291; EPP JK, 1989, GENE, V85, P293, DOI 10.1016/0378-1119(89)90421-6; Fernandez E, 1998, J BACTERIOL, V180, P4929; FIEDLER HP, 1986, J ANTIBIOT, V39, P856, DOI 10.7164/antibiotics.39.856; Fouces R, 1999, MICROBIOL-UK, V145, P855, DOI 10.1099/13500872-145-4-855; Hopwood D.A., 1985, GENETIC MANIPULATION; INOUYE M, 1994, GENE, V141, P121; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KIRST HA, 1991, TETRAHEDRON LETT, V32, P4839, DOI 10.1016/S0040-4039(00)93474-9; KREUZMAN AJ, 1988, J BIOL CHEM, V263, P15626; LIU HW, 1994, ANNU REV MICROBIOL, V48, P223, DOI 10.1146/annurev.micro.48.1.223; Lozano MJF, 2000, J BIOL CHEM, V275, P3065, DOI 10.1074/jbc.275.5.3065; Olano C, 1998, MOL GEN GENET, V259, P299, DOI 10.1007/s004380050816; PAULUS TJ, 1990, J BACTERIOL, V172, P2541, DOI 10.1128/jb.172.5.2541-2546.1990; PIEPERSBERG W, 1994, CRIT REV BIOTECHNOL, V14, P251, DOI 10.3109/07388554409079835; Rodriguez L, 2000, J MOL MICROB BIOTECH, V2, P271; ROHR J, 1990, J ANTIBIOT, V43, P1169, DOI 10.7164/antibiotics.43.1169; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULMAN MD, 1990, J BIOL CHEM, V265, P16965; SENO ET, 1981, ANTIMICROB AGENTS CH, V20, P370, DOI 10.1128/AAC.20.3.370; Steffensky M, 2000, ANTIMICROB AGENTS CH, V44, P1214, DOI 10.1128/AAC.44.5.1214-1222.2000; Trefzer A, 1999, NAT PROD REP, V16, P283, DOI 10.1039/a804431g; Wohlert SE, 1998, J AM CHEM SOC, V120, P10596, DOI 10.1021/ja981687e; Ylihonko K, 1996, MOL GEN GENET, V251, P113	36	48	53	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18765	18774		10.1074/jbc.M101225200	http://dx.doi.org/10.1074/jbc.M101225200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376004	hybrid			2022-12-27	WOS:000169091000018
J	Beerens, N; Groot, F; Berkhout, B				Beerens, N; Groot, F; Berkhout, B			Initiation of HIV-1 reverse transcription is regulated by a primer activation signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; RNA SECONDARY STRUCTURE; BINDING-SITE; EFFICIENT INITIATION; SEQUENCE ELEMENTS; TYPE-1 PARTICLES; DNA-SYNTHESIS; LEADER RNA; RICH LOOP	Reverse transcription of the human immunodeficiency virus type 1 (HIV-1) RNA genome appears to be strictly regulated at the level of initiation. The primer binding site (PBS), at which the tRNA(3)(LYS) molecule anneals and reverse transcription is initiated, is present in a highly structured region of the untranslated leader RNA. Detailed mutational analysis of the U5 leader stem identified a sequence motif in the U5 region that is critical for activation of the PBS-bound tRNA(3)(Lys) primer. This U5 motif, termed the primer activation signal Lys (PAS), may interact with the T psiC arm of the tRNA(3)(Lys) primer, similar to the additional interaction proposed for the genome of Rous sarcoma virus and its tRNA(Trp) primer. This suggests that reverse transcription is regulated by a common mechanism in all retroviruses. In HIV-1, the PAS is masked through base pairing in the U5 leader stem. This provides a mechanism for positive and negative regulation of reverse transcription. Based on structure probing of the mutant and wild-type RNAs, an RNA secondary structure model is proposed that juxtaposes the critical PAS and PBS motifs.	Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Berkhout, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, POB 22700, NL-1100 DE Amsterdam, Netherlands.							AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; ARTS EJ, 1994, J GEN VIROL, V75, P1605, DOI 10.1099/0022-1317-75-7-1605; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; Beerens N, 2000, NUCLEIC ACIDS RES, V28, P4130, DOI 10.1093/nar/28.21.4130; Beerens N, 2000, J VIROL, V74, P2227, DOI 10.1128/JVI.74.5.2227-2238.2000; Berkhout B, 1997, NUCLEIC ACIDS RES, V25, P4013, DOI 10.1093/nar/25.20.4013; BERKHOUT B, 1993, NUCLEIC ACIDS RES, V21, P1171, DOI 10.1093/nar/21.5.1171; Berkhout B, 1996, PROG NUCLEIC ACID RE, V54, P1, DOI 10.1016/S0079-6603(08)60359-1; Berkhout B, 2000, RNA, V6, P282, DOI 10.1017/S1355838200991684; COBRINIK D, 1988, J VIROL, V62, P3622, DOI 10.1128/JVI.62.10.3622-3630.1988; COBRINIK D, 1991, J VIROL, V65, P3864, DOI 10.1128/JVI.65.7.3864-3872.1991; CORDELL B, 1979, J BIOL CHEM, V254, P1866; Damgaard CK, 1998, NUCLEIC ACIDS RES, V26, P3667, DOI 10.1093/nar/26.16.3667; Das AT, 1997, J VIROL, V71, P2346, DOI 10.1128/JVI.71.3.2346-2356.1997; Dhellin O, 1997, EMBO J, V16, P6590, DOI 10.1093/emboj/16.21.6590; El Kharroubi A, 1998, MOL CELL BIOL, V18, P2535, DOI 10.1128/MCB.18.5.2535; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Essink BBO, 1996, J MOL BIOL, V264, P243, DOI 10.1006/jmbi.1996.0638; Huang Y, 1998, J VIROL, V72, P3907, DOI 10.1128/JVI.72.5.3907-3915.1998; Huang Y, 1997, J VIROL, V71, P726, DOI 10.1128/JVI.71.1.726-728.1997; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; KLAVER B, 1994, J VIROL, V68, P3830, DOI 10.1128/JVI.68.6.3830-3840.1994; Lenz C, 1997, J VIROL, V71, P2757, DOI 10.1128/JVI.71.4.2757-2764.1997; Liang C, 1997, J MOL BIOL, V272, P167, DOI 10.1006/jmbi.1997.1239; Liang C, 1998, J BIOL CHEM, V273, P21309, DOI 10.1074/jbc.273.33.21309; Liang C, 2000, J VIROL, V74, P6251, DOI 10.1128/JVI.74.14.6251-6261.2000; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; Masuda T, 1998, J VIROL, V72, P8396, DOI 10.1128/JVI.72.10.8396-8402.1998; Miller JT, 1997, J VIROL, V71, P7648, DOI 10.1128/JVI.71.10.7648-7656.1997; Morris S, 1999, J VIROL, V73, P6307, DOI 10.1128/JVI.73.8.6307-6318.1999; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; RIZVI TA, 1993, J VIROL, V67, P2681, DOI 10.1128/JVI.67.5.2681-2688.1993; Telesnitsky A., 1997, P121; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; VanLint C, 1997, J VIROL, V71, P6113, DOI 10.1128/JVI.71.8.6113-6127.1997; VICENZI E, 1994, J VIROL, V68, P7879, DOI 10.1128/JVI.68.12.7879-7890.1994; Wakefield JK, 1996, VIROLOGY, V220, P290, DOI 10.1006/viro.1996.0317; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996	46	106	106	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31247	31256		10.1074/jbc.M102441200	http://dx.doi.org/10.1074/jbc.M102441200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11384976	hybrid			2022-12-27	WOS:000170472900087
J	Bartl, FJ; Ritter, E; Hofmann, KP				Bartl, FJ; Ritter, E; Hofmann, KP			Signaling states of rhodopsin - Absorption of light in active metarhodopsin II generates an all-trans-retinal bound inactive state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FTIR SPECTROSCOPY; VISUAL EXCITATION; BOVINE RHODOPSIN; PROTEIN; BACTERIORHODOPSIN; ACTIVATION; PIGMENTS; PEPTIDES; BINDING; MECHANISM	Absorption of light in rhodopsin leads through 11-cis- and all-trans-retinal isomerization, proton transfers, and structural changes to the active G-protein binding meta-II state. When meta-II is photolysed by blue light absorption, the activating pathway is apparently reverted, and rhodopsin is photoregenerated. However, the product formed, a P subspecies with A(max) = 500 nm (P-500), is different from the ground state based on the following observations: (i) the ground state fingerprint of 11-cis-retinal does not appear in the infrared spectra, although the proton transfers and structural changes are reverted; (ii) extraction of the retinal from P-500 does not yield the expected stoichiometric amount of 11-cis-retinal but predominantly yields all-trans-retinal; (iii) the infrared spectrum of P-500 is similar to the classical meta-III intermediate, which arises from meta-II by thermal decay; and (iv) both P-500 and meta-III can be photoconverted to meta-II with the same changes in the infrared spectrum and without a significant change in the isomerization state of the extracted chromophore. The data indicate the presence of a "second switch" between active and inactive conformations that operates by photolysis but without isomerization around the C-11-C-12 double bond. This emphasizes the exclusivity of the ground state, which is only accessible by the metabolic regeneration with 11-cis-retinal.	Humboldt Univ, Med Fak Charite, Inst Med Phys & Biophys, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Bartl, FJ (corresponding author), Humboldt Univ, Med Fak Charite, Inst Med Phys & Biophys, Schumann Str 20-21, D-10098 Berlin, Germany.							Aharoni A, 2000, J BIOL CHEM, V275, P21010, DOI 10.1074/jbc.M001208200; ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; Bartl F, 2000, FEBS LETT, V473, P259, DOI 10.1016/S0014-5793(00)01544-1; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; COOPER A, 1976, BIOCHEMISTRY-US, V15, P2970, DOI 10.1021/bi00659a006; COOPER A, 1979, NATURE, V282, P531, DOI 10.1038/282531a0; DEGRIP WJ, 2000, MOL MECH VISUAL TRAN, P1, DOI DOI 10.1016/S1383-8121(00)80004-4; DeLange F, 1998, BIOCHEMISTRY-US, V37, P1411, DOI 10.1021/bi972397y; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Grimm C, 2000, INVEST OPHTH VIS SCI, V41, P3984; GROENENDIJK GWT, 1979, ANAL BIOCHEM, V99, P304, DOI 10.1016/S0003-2697(79)80011-1; Haupts U, 1999, ANNU REV BIOPH BIOM, V28, P367, DOI 10.1146/annurev.biophys.28.1.367; Heberle J, 2000, BIOPHYS CHEM, V85, P229, DOI 10.1016/S0301-4622(99)00154-4; HOFMANN KP, 2000, MOL MECH VISUAL TRAN, P99; JAGER F, 1994, BIOCHEMISTRY-US, V33, P7389; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; Jang GF, 2001, J BIOL CHEM, V276, P26148, DOI 10.1074/jbc.M102212200; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; KLINGER AL, 1992, BIOPHYS J, V63, P1244, DOI 10.1016/S0006-3495(92)81700-9; LANDERS GM, 1988, J CHROMATOGR, V438, P383, DOI 10.1016/S0021-9673(00)90269-3; LIU RSH, 1988, J AM CHEM SOC, V110, P8617, DOI 10.1021/ja00234a007; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; Meyer CK, 2000, J BIOL CHEM, V275, P19713, DOI 10.1074/jbc.M000603200; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; PAULSEN R, 1983, NATURE, V302, P417, DOI 10.1038/302417a0; Pulvermuller A, 2000, J BIOL CHEM, V275, P37679, DOI 10.1074/jbc.M006776200; ROTHSCHILD KJ, 1987, BIOPHYS J, V51, P345, DOI 10.1016/S0006-3495(87)83341-6; Rousso I, 1997, P NATL ACAD SCI USA, V94, P7937, DOI 10.1073/pnas.94.15.7937; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SCHERRER P, 1989, BIOCHEMISTRY-US, V28, P829, DOI 10.1021/bi00428a063; Siebert F, 1995, ISRAEL J CHEM, V35, P309; WILLIAMS TP, 1968, VISION RES, V8, P1457, DOI 10.1016/0042-6989(68)90120-X; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0	37	41	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30161	30166		10.1074/jbc.M101506200	http://dx.doi.org/10.1074/jbc.M101506200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11384968	hybrid			2022-12-27	WOS:000170558000075
J	Allen, NPC; Huang, L; Burlingame, A; Rexach, M				Allen, NPC; Huang, L; Burlingame, A; Rexach, M			Proteomic analysis of nucleoporin interacting proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; GTPASE-ACTIVATING PROTEIN; MESSENGER-RNA EXPORT; IN-VIVO; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; BINDING-PROTEINS; RAN GTPASE; TRANSPORT; YEAST	The Saccharomyces cerevisiae nuclear pore complex is a supramolecular assembly of 30 nucleoporins that cooperatively facilitate nucleocytoplasmic transport. Thirteen nucleoporins that contain FG peptide repeats (FG Nups) are proposed to function as stepping stones in karyopherin-mediated transport pathways. Here, protein interactions that occur at individual FG Nups were sampled using immobilized nucleoporins and yeast extracts. We find that many proteins bind to FG Nups in highly reproducible patterns. Among 135 proteins identified by mass spectrometry, most were karyopherins and nucleoporins. The PSFG nucleoporin Nup42p and the GLFG nucleoporins Nup49p, Nup57p, Nup100p, and Nup116p exhibited generic interactions with karyopherins; each bound 6-10 different karyopherin betas, including importins as well as exportins. Unexpectedly, the same Nups also captured the hexameric Nup84p complex and Nup2p. In contrast, the FXFG nucleoporins Nup1p, Nup2p, and Nup60p were more selective and captured mostly the Kap95p . Kap60p heterodimer. When the concentration of Gsp1p-GTP was elevated in the extracts to mimic the nucleoplasmic environment, the patterns of interacting proteins changed; exportins exhibited enhanced binding to FG Nups, and importins exhibited reduced binding. The results demonstrate a global role for Gsp1p-GTP on karyopherin-nucleoporin interactions and provide a rudimentary map of the routes that karyopherins take as they cross the nuclear pore complex.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, Mass Spectrometry Facil, San Francisco, CA 94143 USA	Stanford University; University of California System; University of California San Francisco	Rexach, M (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.		Huang, Lan/C-3618-2011					Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; BARLOWE C, 1995, FEBS LETT, V369, P93, DOI 10.1016/0014-5793(95)00618-J; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Delphin C, 1997, MOL BIOL CELL, V8, P2379, DOI 10.1091/mbc.8.12.2379; Fahrenkrog B, 1998, J CELL BIOL, V143, P577, DOI 10.1083/jcb.143.3.577; Feng WQ, 1999, J CELL SCI, V112, P339; Floer M, 1999, J BIOL CHEM, V274, P16279, DOI 10.1074/jbc.274.23.16279; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Gagny B, 2000, J CELL SCI, V113, P3309; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gray NK, 2000, EMBO J, V19, P4723, DOI 10.1093/emboj/19.17.4723; Hood JK, 2000, J CELL SCI, V113, P1471; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nanduri J, 1999, J BIOL CHEM, V274, P33785, DOI 10.1074/jbc.274.47.33785; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; Peng RW, 2000, J BIOL CHEM, V275, P11521, DOI 10.1074/jbc.275.15.11521; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Schlaich NL, 1997, MOL BIOL CELL, V8, P33, DOI 10.1091/mbc.8.1.33; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Siniossoglou S, 2000, J CELL BIOL, V149, P41, DOI 10.1083/jcb.149.1.41; Solsbacher J, 2000, MOL CELL BIOL, V20, P8468, DOI 10.1128/MCB.20.22.8468-8479.2000; Stage-Zimmermann T, 2000, MOL BIOL CELL, V11, P3777, DOI 10.1091/mbc.11.11.3777; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; Yoshida K, 2001, J CELL BIOL, V152, P729, DOI 10.1083/jcb.152.4.729; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	39	146	157	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29268	29274		10.1074/jbc.M102629200	http://dx.doi.org/10.1074/jbc.M102629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387327	hybrid			2022-12-27	WOS:000170346000085
J	Jourd'heuil, D; Jourd'heuil, FL; Kutchukian, PS; Musah, RA; Wink, DA; Grisham, MB				Jourd'heuil, D; Jourd'heuil, FL; Kutchukian, PS; Musah, RA; Wink, DA; Grisham, MB			Reaction of superoxide and nitric oxide with peroxynitrite - Implications for peroxynitrite-mediated oxidation reactions in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL FORMATION; TYROSINE NITRATION; SIMULTANEOUS GENERATION; CHEMISTRY; (NO)-N-CENTER-DOT	Peroxynitrite (ONOO-/ONOOH), the product of the diffusion-limited reaction of nitric oxide ((NO)-N-.) with superoxide (O-2(radical anion)), has been implicated as an important mediator of tissue injury during conditions associated with enhanced (NO)-N-. and O-2(radical anion) production. Although several groups of investigators have demonstrated substantial oxidizing and cytotoxic activities of chemically synthesized peroxynitrite, others have proposed that the relative rates of (NO)-N-. and production may be critical in determining the reactivity of peroxynitrite formed in situ (Miles, A. M., Bohle, D. S., Glassbrenner, P. A., Hansert, B., Wink, D. A., and Grisham, At B. (1996) J. Biol. Chem. 271, 40-47). In the present study, we examined the mechanisms by which excess O-2(radical anion) or (NO)-N-. production 2 inhibits peroxynitrite-mediated oxidation reactions. Peroxynitrite was generated in situ by the co-addition of a chemical source of (NO)-N-., spermineNONOate, and an enzymatic source of O-2(radical anion), xanthine oxidase, with either hypoxanthine or lumazine as a substrate. We found that the oxidation of the model compound dihydrorhodamine by peroxynitrite occurred via the free radical intermediates OH and NO2, formed during the spontaneous decomposition of peroxynitrite and not via direct reaction with peroxynitrite. The inhibitory effect of excess O-2(radical anion) on the oxidation of dihydrorhodamine could not be ascribed to the accumulation of the peroxynitrite scavenger urate produced from the oxidation of hypoxanthine by xanthine oxidase. A biphasic oxidation profile was also observed upon oxidation of NADH by the simultaneous generation of (NO)-N-. and O-2(radical anion). Conversely, the oxidation of glutathione, which 2 occurs via direct reaction with peroxynitrite, was not affected by excess production of (NO)-N-.. We conclude that the oxidative processes initiated by the free radical intermediates formed from the decomposition of peroxynitrite, are inhibited by excess production of (NO)-N-. or O-2(radical anion), whereas oxidative pathways involving a direct reaction with peroxynitrite are not altered. The physiological implications of these findings are discussed.	Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; SUNY Albany, Dept Chem, Albany, NY 12222 USA; NCI, Tumor Biol Sect, Radiat Biol Branch, Bethesda, MD 20892 USA; Louisiana State Univ, Med Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA	Albany Medical College; State University of New York (SUNY) System; State University of New York (SUNY) Albany; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Jourd'heuil, D (corresponding author), Albany Med Coll, Ctr Cardiovasc Sci, 47 New Scotland Ave,MC8, Albany, NY 12208 USA.	jourdhd@mail.amc.edu	Kutchukian, Peter/A-9826-2016	Kutchukian, Peter/0000-0002-5684-1971; Jourd'heuil, David/0000-0002-6555-5061; Azad, Mahan/0000-0002-8633-3513; Wink, David/0000-0002-5652-7480				BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Coddington JW, 1999, J AM CHEM SOC, V121, P2438, DOI 10.1021/ja982887t; Fukuto JM, 1997, ACCOUNTS CHEM RES, V30, P149, DOI 10.1021/ar960010y; Goldstein S, 2000, CHEM RES TOXICOL, V13, P736, DOI 10.1021/tx000099n; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; Grisham MB, 1999, AM J PHYSIOL-GASTR L, V276, pG315, DOI 10.1152/ajpgi.1999.276.2.G315; Hodges GR, 2000, CHEM RES TOXICOL, V13, P1287, DOI 10.1021/tx0001272; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V365, P92, DOI 10.1006/abbi.1999.1143; Kirsch M, 2000, J BIOL CHEM, V275, P16702, DOI 10.1074/jbc.M909228199; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1998, INORG CHEM, V37, P294, DOI 10.1021/ic970946i; Merenyi G, 1998, CHEM RES TOXICOL, V11, P243, DOI 10.1021/tx980026s; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; NAGANO T, 1985, Journal of Free Radicals in Biology and Medicine, V1, P39, DOI 10.1016/0748-5514(85)90027-3; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; RADI R, 1991, J BIOL CHEM, V266, P4244; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; Richeson CE, 1998, J AM CHEM SOC, V120, P7211, DOI 10.1021/ja980871x; ROSS AB, 1998, NDRL NIST SOLUTION K; Rota C, 1999, FREE RADICAL BIO MED, V27, P873, DOI 10.1016/S0891-5849(99)00137-9; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Sawa T, 2000, J BIOL CHEM, V275, P32467, DOI 10.1074/jbc.M910169199; Wink DA, 1997, J BIOL CHEM, V272, P11147	27	192	196	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28799	28805		10.1074/jbc.M102341200	http://dx.doi.org/10.1074/jbc.M102341200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11373284	hybrid			2022-12-27	WOS:000170346000022
J	Saha, D; Datta, PK; Beauchamp, RD				Saha, D; Datta, PK; Beauchamp, RD			Oncogenic Ras represses transforming growth factor-beta/Smad signaling by degrading tumor suppressor Smad4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; FACTOR-BETA; COLORECTAL-CANCER; EXPRESSION; PATHWAY; DPC4; GENE; DEGRADATION; INHIBITION; TGF-BETA-1	The loss of growth-inhibitory responses to transforming growth factor-beta (TGF-beta) is a frequent consequence of malignant transformation. Smad2, Smad3, and Smad4 proteins are important mediators of the antiproliferative responses to TGF-beta and may become inactivated in some human cancers. Epithelial cells harboring oncogenic Ras mutations often exhibit a loss of TGF-beta antiproliferative responses. To further investigate the effect of oncogenic Ras in TGF-beta signaling, we used an isopropyl-1-thio-beta -D-galactopyranoside-inducible expression system to express Ha-Ras (Val-12) in intestinal epithelial cells. Induction of Ha-Ras(Val-12) caused a decrease in the level of Smad4 expression, inhibited TGF-beta -induced complex formation between Smad2/Smad3 and Smad4, blocked Smad4 nuclear translocation, inhibited the TGF-beta -mediated decrease in [H-3]thymidine incorporation, and repressed TGF-beta -activated transcriptional responses. The withdrawal of isopropyl-1-thio-beta -D-galactopyranoside or the addition of an inhibitor of the ubiquitin-proteasome pathway restored the Smad4 level and TGF-beta -induced Smad complex formation. Forced expression of Smad4 resulted in partial recovery of the TGF-beta -mediated growth inhibition and transcriptional responses in the presence of oncogenic Ras. Further, PD98059, a specific inhibitor of the MEK/ERF/mitogenactivated protein kinase pathway prevented the Ras-induced decrease in Smad4 expression and complex formation. Our results suggest a novel mechanism by which oncogenic Ras represses TGF-beta signaling by mitogen-activated protein kinase-dependent down-regulation of Smad4, thereby subverting the tumor suppressor function of TGF-beta.	Vanderbilt Univ, Ctr Med, Dept Surg, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Med, Dept Cell Biol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Beauchamp, RD (corresponding author), Vanderbilt Univ, Ctr Med, Dept Surg, Vanderbilt Ingram Canc Ctr, D5230 MCN,21st Ave S, Nashville, TN 37232 USA.			Beauchamp, Robert Daniel/0000-0002-8446-4114	NATIONAL CANCER INSTITUTE [P01CA077839, R01CA069457, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK010138, R01DK052334] Funding Source: NIH RePORTER; NCI NIH HHS [CA77839, CA69457, CA68485] Funding Source: Medline; NIDDK NIH HHS [F32 DK10138, DK52334] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FILMUS J, 1992, ONCOGENE, V7, P521; Grady WM, 1999, CANCER RES, V59, P320; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Iglesias M, 2000, ONCOGENE, V19, P4134, DOI 10.1038/sj.onc.1203764; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; RIGGINS GJ, 1997, CANCER RES, V57, P4221; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Takaku K, 1999, CANCER RES, V59, P6113; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	30	96	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29531	29537		10.1074/jbc.M100069200	http://dx.doi.org/10.1074/jbc.M100069200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11371552	hybrid			2022-12-27	WOS:000170346000118
J	Kremer, L; Nampoothiri, KM; Lesjean, S; Dover, LG; Graham, S; Betts, J; Brennan, PJ; Minnikin, DE; Locht, C; Besra, GS				Kremer, L; Nampoothiri, KM; Lesjean, S; Dover, LG; Graham, S; Betts, J; Brennan, PJ; Minnikin, DE; Locht, C; Besra, GS			Biochemical characterization of acyl carrier protein (AcpM) and malonyl-CoA : AcpM transacylase (mtFabD), two major components of Mycobacterium tuberculosis fatty acid synthase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; POLYKETIDE SYNTHASE; CELL-WALL; STREPTOMYCES-GLAUCESCENS; LIPID BIOSYNTHESIS; CRYSTAL-STRUCTURE; FABD GENE; PURIFICATION; RHIZOBIUM	Malonyl coenzyme A (CoA)-acyl carrier protein (ACP) transacylase (MCAT) is an essential enzyme in the biosynthesis of fatty acids in all bacteria, including Mycobacterium tuberculosis. MCAT catalyzes the transacylation of malonate from malonyl-CoA to activated holo-ACP, to generate malonyl-ACP, which is an elongation substrate in fatty acid biosynthesis. To clarify the roles of the mycobacterial acyl carrier protein (AcpM) and MCAT in fatty acid and mycolic acid biosynthesis, we have cloned, expressed, and purified acpM and mtfabD (malonyl-COA: AcpM transacylase) from M. tuberculosis. According to the culture conditions used, AcpM was produced in Escherichia coli in two or three different forms: apo-AcpM, holo-AcpM, and palmitoylated-AcpM, as revealed by electrospray mass spectrometry. The mtfabD gene encoding a putative MCAT was used to complement a thermosensitive E. coli fabD mutant. Expression and purification of mtFabD resulted in an active enzyme displaying strong MCAT activity in vitro. Enzymatic studies using different ACP substrates established that holo-AcpM constitutes the preferred substrate for mtFabD. In order to provide further insight into the structure-function relationship of mtFabD, different mutant proteins were generated. All mutations (Q9A, R116A, H194A, Q243A, S91T, and S91A) completely abrogated MCAT activity in vitro, thus underlining the importance of these residues in transacylation. The generation and characterization of the AcpM forms and mtFabD opens the way for further studies relating to fatty acid and mycolic acid biosynthesis to be explored in M. tuberculosis. Since a specific type of FabD is found in mycobacterial species, it represents an attractive new drug target waiting to be exploited.	Univ Newcastle Upon Tyne, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Inst Pasteur, INSERM, U447, F-59019 Lille, France; GlaxoSmithKine Res & Dev, Stevenage SG1 2NY, Herts, England; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Univ Newcastle Upon Tyne, Dept Chem, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; GlaxoSmithKline; Colorado State University; Newcastle University - UK	Besra, GS (corresponding author), Univ Newcastle Upon Tyne, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Dover, Lynn George/Q-6778-2019; Dover, Lynn G/F-3021-2010; Kremer, Laurent/M-4935-2017; Locht, Camille/L-3516-2018; Nampoothiri, K.Madhavan/J-4727-2017	Dover, Lynn George/0000-0002-4776-2665; Dover, Lynn G/0000-0002-4776-2665; Kremer, Laurent/0000-0002-6604-4458; Nampoothiri, K.Madhavan/0000-0003-4151-0974; Besra, Gurdyal/0000-0002-5605-0395	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038087] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-38087] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; Choi KH, 2000, J BIOL CHEM, V275, P28201; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; DEBELLE F, 1986, NUCLEIC ACIDS RES, V14, P7453, DOI 10.1093/nar/14.18.7453; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; Dreier J, 1999, J BIOL CHEM, V274, P25108, DOI 10.1074/jbc.274.35.25108; Epple G, 1998, J BACTERIOL, V180, P4950, DOI 10.1128/JB.180.18.4950-4954.1998; GEIGER O, 1991, J BACTERIOL, V173, P2872, DOI 10.1128/JB.173.9.2872-2878.1991; George KM, 1999, SCIENCE, V283, P854, DOI 10.1126/science.283.5403.854; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; Kremer L, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P173; Kutchma AJ, 1999, J BACTERIOL, V181, P5498, DOI 10.1128/JB.181.17.5498-5504.1999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1995, P NATL ACAD SCI USA, V92, P11254, DOI 10.1073/pnas.92.24.11254; MAGNUSON K, 1992, FEBS LETT, V299, P262, DOI 10.1016/0014-5793(92)80128-4; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; McAllister KA, 2000, J BIOL CHEM, V275, P30864, DOI 10.1074/jbc.M004475200; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; MINNIKIN DE, 1982, BIOL MYCOBACTERIA, V1, P95; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Morbidoni HR, 1996, J BACTERIOL, V178, P4794, DOI 10.1128/jb.178.16.4794-4800.1996; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; PRESCOTT DJ, 1972, ADV ENZYMOL RAMB, V36, P269; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; REVILL WP, 1995, J BACTERIOL, V177, P3946, DOI 10.1128/jb.177.14.3946-3952.1995; Sambrook J., 2002, MOL CLONING LAB MANU; SERRE L, 1995, J BIOL CHEM, V270, P12961, DOI 10.1074/jbc.270.22.12961; SHEN B, 1992, J BACTERIOL, V174, P3818, DOI 10.1128/JB.174.11.3818-3821.1992; Slayden RA, 2000, MOL MICROBIOL, V38, P514, DOI 10.1046/j.1365-2958.2000.02145.x; SUMMERS RG, 1995, BIOCHEMISTRY-US, V34, P9389, DOI 10.1021/bi00029a015; VERWOERT IIGS, 1994, FEBS LETT, V348, P311, DOI 10.1016/0014-5793(94)00630-X; VERWOERT IIGS, 1992, J BACTERIOL, V174, P2851, DOI 10.1128/JB.174.9.2851-2857.1992; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833; Yuan Y, 1998, J BIOL CHEM, V273, P21282, DOI 10.1074/jbc.273.33.21282; Zhou P, 1999, CHEM BIOL, V6, P577, DOI 10.1016/S1074-5521(99)80090-8	43	102	108	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27967	27974		10.1074/jbc.M103687200	http://dx.doi.org/10.1074/jbc.M103687200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373295	hybrid			2022-12-27	WOS:000170093400031
J	Miller, WE; McDonald, PH; Cai, SF; Field, ME; Davis, RJ; Lefkowitz, RJ				Miller, WE; McDonald, PH; Cai, SF; Field, ME; Davis, RJ; Lefkowitz, RJ			Identification of a motif in the carboxyl terminus of beta-arrestin2 responsible for activation of JNK3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MAP KINASE CASCADE; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; SACCHAROMYCES-CEREVISIAE; SCAFFOLD PROTEINS; CLATHRIN ADAPTER; ENDOCYTOSIS; COMPLEX	Accumulating evidence indicates that the beta -arrestins act as scaffold molecules that couple G-protein-coupled receptors to mitogen-activated protein (MAP) kinase signaling pathways. Recently, we identified the c-Jun N-terminal kinase 3 (JNK3) as a beta -arrestin2-interacting protein in yeast-two hybrid and co-immunoprecipitation studies. beta -Arrestin2 acts as a scaffold to enhance signaling to JNK3 stimulated by overexpression of the MAP3 kinase ASK1 or by agonist activation of the angiotensin 1A receptor. Whereas beta -arrestin1 is a very strong activator of JNK3 signaling, beta -arrestin1 is very weak in this regard. The data also indicate that the specific step enhanced by beta -arresting involves phosphozylation of JNK3 by the MAP2 kinase MKK4. We reasoned that defining the region (or domain) in beta -arrestin2 responsible for high level JNK3 activation would provide insight into the mechanism by which beta -arrestin2 enhances the activity of this signaling pathway. Using chimeric beta -arrestin2, we have determined that sequences in the carboxyl-terminal region of beta -arrestin2 are important for the enhancement of JNK3 phosphorylation. More detailed analysis of the carboxyl-terminal domains of the beta -arrestins indicated that beta -arrestin2, but not beta -arrestin2, contains a sequence (RRSLHL) highly homologous to the conserved docking motif present in many MAP kinase-binding proteins. Replacement of the beta -arrestin2 RRS residues with the corresponding KP residues present in beta -arrestin1 dramatically reduced both JNK3 interaction and enhancement of JNK3 phosphorylation. Conversely, replacement of the HP residues in beta -arrestin1 with RRS significantly increased both JNK3 binding and enhancement of JNK3 phosphorylation. These results delineate a mechanism by which beta -arrestin2 functions as a scaffold protein in the JNK3 signaling pathway and implicate the conserved docking site in beta -arrestin2 as an important factor in binding JNK3 and stimulating the phosphorylation of JNK3 by MKK4.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	Duke University; Howard Hughes Medical Institute; Duke University; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021	Cai, Sheng/0000-0002-2708-887X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alloway PG, 2000, NEURON, V28, P129, DOI 10.1016/S0896-6273(00)00091-X; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CHOI KY, 1994, CELL, V78, P499; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DAVIS RJ, 1999, IN PRESS BIOCH SOC S, V64, P1; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Ito M, 1999, MOL CELL BIOL, V19, P7539; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kiselev A, 2000, NEURON, V28, P139, DOI 10.1016/S0896-6273(00)00092-1; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	45	94	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27770	27777		10.1074/jbc.M102264200	http://dx.doi.org/10.1074/jbc.M102264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11356842	hybrid			2022-12-27	WOS:000170093400006
J	Whitehead, JP; Molero, JC; Clark, S; Martin, S; Meneilly, G; James, DE				Whitehead, JP; Molero, JC; Clark, S; Martin, S; Meneilly, G; James, DE			The role of Ca2+ in insulin-stimulated glucose transport in 3T3-L1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CALCIUM; ISOLATED SKELETAL-MUSCLE; GLUT4 TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; 3T3L1 ADIPOCYTES; HEXOSE-TRANSPORT; RAT ADIPOCYTES; KINASE-B; FUSION	We have examined the requirement for Ca2+ in the signaling and trafficking pathways involved in insulin-stimulated glucose uptake in 3T3-LI adipocytes. Chelation of intracellular Ca2+, using 1,2-bis (o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetra (acetoxymethyl) ester (BAPTA-AM), resulted in >95% inhibition of insulin-stimulated glucose uptake. The calmodulin antagonist, W13, inhibited insulin-stimulated glucose uptake by 60%. Both BAPTA-AM and W13 inhibited Akt phosphorylation by 70-75%. However, analysis of insulin-dose response curves indicated that this inhibition was not sufficient to explain the effects of BAPTA-AM and W13 on glucose uptake. BAPTA-AM inhibited insulin-stimulated translocation of GLUT4 by 50%, as determined by plasma membrane lawn assay and subcellular fractionation. In contrast, the insulin-stimulated appearance of HA-tagged GLUT4 at the cell surface, as measured by surface binding, was blocked by BAPTA/AM.. While the ionophores A23187 or ionomycin prevented the inhibition of Akt phosphorylation and GLUT4 translocation by BAPTA-AM, they did not overcome the inhibition of glucose transport. Moreover, glucose uptake of cells pretreated with insulin followed by rapid cooling to 4 degreesC, to promote cell surface expression of GLUT4 and prevent subsequent endocytosis, was inhibited specifically by BAPTA-AM. This indicates that inhibition of glucose uptake by BAPTA-AM is independent of both trafficking and signal transduction. These data indicate that Ca2+ is involved in at least two different steps of the insulin-dependent recruitment of GLUT4 to the plasma membrane. One involves the translocation step. The second involves the fusion of GLUT4 vesicles with the plasma membrane. These data are consistent with the hypothesis that Ca2+/cahnodulin plays a fundamental role in eukaryotic vesicle docking and fusion. Finally, BAPTA-AM may inhibit the activity of the facilitative transporters by binding directly to the transporter itself.	Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia	University of Queensland; University of Queensland	Whitehead, JP (corresponding author), Univ Queensland, Inst Mol Biosci, Ritchie Res Bldg,Res Rd, St Lucia, Qld 4072, Australia.		Clark, Sharon/B-8057-2009; Martin, Sally/A-7150-2010; Whitehead, Jonathan/F-5022-2014	Martin, Sally/0000-0001-9294-5404; Whitehead, Jonathan/0000-0003-3978-3148; James, David/0000-0001-5946-5257				Benzeroual K, 2000, BBA-MOL CELL RES, V1495, P14, DOI 10.1016/S0167-4889(99)00147-0; Brozinick JT, 1999, BIOCHEM J, V339, P533, DOI 10.1042/0264-6021:3390533; Bruton JD, 1999, P NATL ACAD SCI USA, V96, P3281, DOI 10.1073/pnas.96.6.3281; CARTEE GD, 1992, AM J PHYSIOL, V263, pR70, DOI 10.1152/ajpregu.1992.263.1.R70; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CHEUNG JY, 1987, AM J PHYSIOL, V252, pC163, DOI 10.1152/ajpcell.1987.252.2.C163; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; Garza LA, 2000, J BIOL CHEM, V275, P2560, DOI 10.1074/jbc.275.4.2560; GRIFFIN JF, 1982, P NATL ACAD SCI-BIOL, V79, P3759, DOI 10.1073/pnas.79.12.3759; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Holroyd C, 1999, MOL BIOL CELL, V10, P3035, DOI 10.1091/mbc.10.9.3035; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; KELLY KL, 1989, J BIOL CHEM, V264, P12754; Khayat ZA, 1998, AM J PHYSIOL-CELL PH, V275, pC1487, DOI 10.1152/ajpcell.1998.275.6.C1487; Khayat ZA, 2000, J CELL SCI, V113, P279; Khil LY, 1997, BIOCHEM PHARMACOL, V54, P97, DOI 10.1016/S0006-2952(97)00145-7; KLIP A, 1984, AM J PHYSIOL, V247, pE297, DOI 10.1152/ajpendo.1984.247.3.E297; KLIP A, 1987, J BIOL CHEM, V262, P9141; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LEE AD, 1995, AM J PHYSIOL-REG I, V268, pR997, DOI 10.1152/ajpregu.1995.268.4.R997; Mayer A, 1999, CURR OPIN CELL BIOL, V11, P447, DOI 10.1016/S0955-0674(99)80064-7; Munshi HG, 1996, BIOCHEMISTRY-US, V35, P15883, DOI 10.1021/bi962107y; Oatey PB, 1999, BIOCHEM J, V344, P511, DOI 10.1042/0264-6021:3440511; PERSHADSINGH HA, 1987, P NATL ACAD SCI USA, V84, P1025, DOI 10.1073/pnas.84.4.1025; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; PIPER RC, 1991, AM J PHYSIOL, V260, P570; Porat A, 2000, J BIOL CHEM, V275, P29233, DOI 10.1074/jbc.M005316200; Pryor PR, 2000, J CELL BIOL, V149, P1053, DOI 10.1083/jcb.149.5.1053; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SHASHKIN P, 1995, J BIOL CHEM, V270, P25613, DOI 10.1074/jbc.270.43.25613; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2; Wang QH, 1999, MOL CELL BIOL, V19, P4008; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yang CM, 2000, MOL ENDOCRINOL, V14, P317, DOI 10.1210/me.14.2.317	44	121	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27816	27824		10.1074/jbc.M011590200	http://dx.doi.org/10.1074/jbc.M011590200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375387	Green Submitted			2022-12-27	WOS:000170093400012
J	Hegde, V; Kelley, MR; Xu, Y; Mian, IS; Deutsch, WA				Hegde, V; Kelley, MR; Xu, Y; Mian, IS; Deutsch, WA			Conversion of the bifunctional 8-oxoguanine/beta-delta apurinic/apyrimidinic DNA repair activities of Drosophila ribosomal protein S3 into the human S3 monofunctional P-elimination catalyst through a single amino acid change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME ENDONUCLEASE-III; ESCHERICHIA-COLI; DAMAGED DNA; DEOXYRIBOSE PHOSPHATE; GLYCOSYLASE ACTIVITY; DELTA-ELIMINATION; BETA-ELIMINATION; STRUCTURAL BASIS; ABASIC SITES; FPG PROTEIN	The Drosophila 53 ribosomal protein has important roles in both protein translation and DNA repair. In regards to the latter activity, it has been shown that 53 contains vigorous N-glycosylase activity for the removal of 8-oxoguanine residues in DNA that leaves baseless sites in their places. Drosophila 53 also possesses an apurinic/apyrimidinic (AP) lyase activity in which the enzyme catalyzes a beta -elimination reaction that cleaves phosphodiester bonds 3' and adjacent to an AP lesion in DNA. In certain situations, this is followed by a delta -elimination reaction that ultimately leads to the formation of a single nucleotide gap in DNA bordered by 5' and 3'-phosphate groups. The human 53 protein, although 80% identical to its Drosophila homolog and shorter by only two amino acids, has only marginal N-glycosylase activity. Its lyase activity only cleaves AP DNA by a beta -elimination reaction, thus further distinguishing itself from the Drosophila 53 protein in lacking a delta -elimination activity. Using a hidden Markov model analysis based on the crystal structures of several DNA repair proteins, the enzymatic differences between Drosophila and human 53 were suggested by the absence of a conserved glutamine residue in human 53 that usually resides at the cleft of the deduced active site pocket of DNA glycosylases. Here we show that the replacement of the Drosophila glutamine by an alanine residue leads to the complete loss of glycosylase activity. Unexpectedly, the delta -elimination reaction at AP sites was also abrogated by a change in the Drosophila glutamine residue. Thus, a single amino acid change converted the Drosophila activity into one that is similar to that possessed by the human 53 protein. In support of this were experiments executed in vivo that showed that human 53 and the Drosophila site-directed glutamine-changed 53 performed poorly when compared with Drosophila wildtype 53 and its ability to protect a bacterial mutant from the harmful effects of DNA-damaging agents.	Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; Indiana Univ, Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Cell & Mol Biol, Div Life Sci, Berkeley, CA 94720 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Deutsch, WA (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, 6400 Perkins, Baton Rouge, LA 70808 USA.			Kelley, Mark/0000-0002-6120-9532				BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; BORISH ET, 1985, BIOCHEM BIOPH RES CO, V133, P780, DOI 10.1016/0006-291X(85)90972-6; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; Dellinger B, 2000, P COMBUST INST, V28, P2675, DOI 10.1016/S0082-0784(00)80687-6; Deutsch WA, 1997, J BIOL CHEM, V272, P32857, DOI 10.1074/jbc.272.52.32857; Dherin C, 2000, NUCLEIC ACIDS RES, V28, P4583, DOI 10.1093/nar/28.23.4583; Dizdaroglu M, 1996, MUTAT RES-DNA REPAIR, V362, P1, DOI 10.1016/0921-8777(95)00025-9; DODSON ML, 1994, J BIOL CHEM, V269, P32709; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; KANE CM, 1981, J BIOL CHEM, V256, P3405; Kelley MR, 2001, MUTAT RES-DNA REPAIR, V485, P107, DOI 10.1016/S0921-8777(00)00067-7; KIM J, 1995, J BIOL CHEM, V270, P13620, DOI 10.1074/jbc.270.23.13620; KOW YW, 1989, BIOCHEMISTRY-US, V28, P3280, DOI 10.1021/bi00434a024; KUHNLEIN U, 1976, P NATL ACAD SCI USA, V73, P1169, DOI 10.1073/pnas.73.4.1169; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LATHAM KA, 1995, BIOCHEMISTRY-US, V34, P8796, DOI 10.1021/bi00027a031; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lindahl T, 1980, Methods Enzymol, V65, P284; MANOHARAN M, 1988, J AM CHEM SOC, V110, P2690, DOI 10.1021/ja00216a074; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; Mian IS, 1998, J COMPUT BIOL, V5, P57, DOI 10.1089/cmb.1998.5.57; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; POGUEGEILE K, 1991, MOL CELL BIOL, V11, P3842, DOI 10.1128/MCB.11.8.3842; Sandigursky M, 1997, J BIOL CHEM, V272, P17480, DOI 10.1074/jbc.272.28.17480; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Yacoub A, 1996, EMBO J, V15, P2306, DOI 10.1002/j.1460-2075.1996.tb00584.x; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6	38	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27591	27596		10.1074/jbc.M101213200	http://dx.doi.org/10.1074/jbc.M101213200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11353770	hybrid			2022-12-27	WOS:000169966900113
J	Kim, JW; Joe, CO; Choi, EJ				Kim, JW; Joe, CO; Choi, EJ			Role of receptor-interacting protein in tumor necrosis factor-alpha-dependent MEKK1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DOMAIN KINASE RIP; SIGNALING COMPLEX DISC; INDUCED CELL-DEATH; TNF RECEPTOR; INDUCED APOPTOSIS; TERMINAL KINASE; IKK ACTIVATION; JNK; PHOSPHORYLATION	Receptor-interacting protein (RIP), a death domain serine/threonine kinase, has been Shown to play a critical role in tumor necrosis factor-alpha (TNF-alpha)-induced activation of the nuclear factor-kappaB signaling pathway. We demonstrate here that ectopically expressed RIP induces I-kappaB kinase-beta (IKK beta) activation in intact cells and that RIP-induced IKK beta activation can be blocked by a kinase-inactive form of MEKK1, MEKK1(K1253M). Interestingly, RIP physically associated with MEKK1 both in vitro and in vivo. RIP phosphorylated MEKK1 at Ser-957 and Ser-994. Our data also indicate that RIP induced the stimulation of MEKK1 but not MEKK1 (S957A/S994A) in transfected cells. Furthermore, overexpressed MEKK1 (S957A/S994A) inhibited the RIP-induced activation of both IKK beta and nuclear factor-kappaB. We also demonstrated that the TNF-alpha -induced MEKK1 activation was defective in RIP-deficient Jurkat cells. Taken together, our results suggest that RIP phosphorylates and activates MEKK1 and that RIP is involved in TNF-alpha -induced MEKK1 activation.	Korea Univ, Natl Creat Res Instiat Ctr Cell Death, Grad Sch Biotechnol, Seoul 156701, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea University; Korea Advanced Institute of Science & Technology (KAIST)	Choi, EJ (corresponding author), Korea Univ, Natl Creat Res Instiat Ctr Cell Death, Grad Sch Biotechnol, Seoul 156701, South Korea.	cojoe@mail.kaist.ac.kr; ejchoi@mail.korea.ac.kr	KIM, JIN WOO/C-1655-2011; Joe, Cheol O/C-1917-2011	KIM, JIN WOO/0000-0003-0767-1918; 				Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CHAPLIN DD, 1980, J IMMUNOL, V124, P2390; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Karin M, 1998, CANCER J SCI AM, V4, pS92; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kim JW, 2000, ONCOGENE, V19, P4491, DOI 10.1038/sj.onc.1203796; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Navas TA, 1999, J BIOL CHEM, V274, P33684, DOI 10.1074/jbc.274.47.33684; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Ozes ON, 1999, NATURE, V401, P82; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	50	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27064	27070		10.1074/jbc.M009364200	http://dx.doi.org/10.1074/jbc.M009364200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369754	hybrid			2022-12-27	WOS:000169966900045
J	Simpson, LL; Maksymowych, AB; Hao, S				Simpson, LL; Maksymowych, AB; Hao, S			The role of zinc binding in the biological activity of botulinum toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETANUS TOXIN; NEUROTRANSMITTER RELEASE; NEUROTOXIN; PROTEINS; CLEAVAGE; SYNAPTOBREVIN; PURIFICATION; CELLS	Botulinum toxin is a zinc-dependent endoprotease that acts on vulnerable cells to cleave polypeptides that are essential for exocytosis. To exert this poisoning effect, the toxin must proceed through a complex sequence of events that involves binding, productive internalization, and intracellular expression of catalytic activity. Results presented in this study show that soluble chelators rapidly strip Zn2+ from its binding site in botulinum toxin, and this stripping of cation results in the loss of catalytic activity in cell-free or broken cell preparations. Stripped toxin is still active against intact neuromuscular junctions, presumably because internalized toxin binds cytosolic Zn2+. In contrast to soluble chelators, immobilized chelators have no effect on bound Zn2+, nor do they alter toxin activity. The latter finding is because of the fact that the spontaneous loss of Zn2+ from its coordination site in botulinum toxin is relatively slow .When exogenous Zn2+ is added to toxin that has been stripped by soluble chelators, the molecule rebinds cation and regains catalytic and neuromuscular blocking activity. Exogenous Zn2+ can restore toxin activity either when the toxin is free in solution on the cell exterior or when it has been internalized and is in the cytosol. The fact that stripped toxin can reach the cytosol means that the loss of bound Zn2+ does not produce conformational changes that block internalization. Similarly, the fact that stripped toxin in the cytosol can be reactivated by ambient Zn2+ or exogenous Zn2+ means that productive internalization does not produce conformational changes that block rebinding of cation.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Mol Pharmacol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Biochem, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Simpson, LL (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA.	lance.simpson@mail.tju.edu			NIGMS NIH HHS [GM53742] Funding Source: Medline; NINDS NIH HHS [NS22153] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022153] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmed SA, 2000, J PROTEIN CHEM, V19, P475, DOI 10.1023/A:1026549431380; Coffield JA, 1997, J PHARMACOL EXP THER, V280, P1489; DASGUPTA BR, 1984, TOXICON, V22, P415, DOI 10.1016/0041-0101(84)90085-0; Fu FN, 1998, BIOCHEMISTRY-US, V37, P5267, DOI 10.1021/bi9723966; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOHNEZELL B, 1993, FEBS LETT, V336, P175, DOI 10.1016/0014-5793(93)81635-D; Humeau Y, 2000, BIOCHIMIE, V82, P427, DOI 10.1016/S0300-9084(00)00216-9; Kiyatkin N, 1997, INFECT IMMUN, V65, P4586, DOI 10.1128/IAI.65.11.4586-4591.1997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; Montecucco C, 1995, Q REV BIOPHYS, V28, P423, DOI 10.1017/S0033583500003292; MONTECUCCO C, 1986, TRENDS BIOCHEM SCI, V11, P314, DOI 10.1016/0968-0004(86)90282-3; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; SAKAGUCHI G, 1982, PHARMACOL THERAPEUT, V19, P165, DOI 10.1016/0163-7258(82)90061-4; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, J BIOL CHEM, V267, P23479; SIMPSON LL, 1988, METHOD ENZYMOL, V165, P76; SIMPSON LL, 1993, J PHARMACOL EXP THER, V267, P720; SIMPSON LL, 1981, PHARMACOL REV, V33, P155; SIMPSON LL, 1980, J PHARMACOL EXP THER, V212, P16; Tonello F, 1997, BIOCHEM J, V322, P507, DOI 10.1042/bj3220507; Wong SH, 1998, MOL BIOL CELL, V9, P1549, DOI 10.1091/mbc.9.6.1549	24	33	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27034	27041		10.1074/jbc.M102172200	http://dx.doi.org/10.1074/jbc.M102172200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11358966				2022-12-27	WOS:000169966900041
J	Speigelman, VS; Stavropoulos, P; Latres, E; Pagano, M; Ronai, Z; Slaga, TJ; Fuchs, SY				Speigelman, VS; Stavropoulos, P; Latres, E; Pagano, M; Ronai, Z; Slaga, TJ; Fuchs, SY			Induction of beta-transducin repeat-containing protein by JNK signaling and its role in the activation of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-BOX PROTEINS; INTERLEUKIN-2 MESSENGER-RNA; JUN NH2-TERMINAL KINASE; UBIQUITIN LIGASE; C-JUN; DEPENDENT DEGRADATION; ALPHA UBIQUITINATION; CELL-DEATH; TNF-ALPHA; IN-VITRO	Activation of Jun N-kinase (JNK) and NF-kappaB transcription factor are the hallmarks of cellular response to stress. Phosphorylation of NF-kappaB inhibitor (I kappaB) by respective stress-inducible kinases (IKK) is:a key event in NF-kappaB activation. beta -TrCP F-box protein mediates ubiquitination of phosphorylated I kappaB via recruitment of SCFbeta -TrCP-Roc1 E3 ubiquitin Ligase complex. Subsequent proteasome-dependent degradation of I kappaB results in activation of the NF-kappaB pathway, We found that a variety of cellular stress stimuli induce an increase in the steady state levels of beta -TrCP mRNA and protein levels in human cells. Activation of stress-activated protein kinases JNK (and, to a lesser extent, p38) by forced expression of constitutively active mutants of JNKK2 and MKK6 (but not MEK1 or IKK beta) also leads to accumulation of beta -TrCP. Transcription of the beta -TrCP gene is not required for JNK-mediated induction of beta -TrCP. A synergistic effect of stimulation of IKK and JNK on the transcriptional activity of NF-kappaB was observed. The mechanisms of beta -TrCP induction via stress and its role in NF-kappaB activation are discussed.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; AMC Canc Res Ctr, Lakewood, CO 80214 USA; CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; NYU, Dept Pathol, New York, NY 10016 USA	University of Pennsylvania; AMC Cancer Research Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; New York University	Fuchs, SY (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St,Rm 161E VET, Philadelphia, PA 19104 USA.	sfuks@vet.upenn.edu		pagano, michele/0000-0003-3210-2442; Spiegelman, Vladimir S/0000-0003-4847-155X; RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA 92900, CA 76262] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Alpert D, 2000, J BIOL CHEM, V275, P10925, DOI 10.1074/jbc.275.15.10925; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen CY, 2000, GENE DEV, V14, P1236; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Das KC, 2001, J BIOL CHEM, V276, P4662, DOI 10.1074/jbc.M006206200; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hattori K, 1999, J BIOL CHEM, V274, P29641, DOI 10.1074/jbc.274.42.29641; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, MOL CELL BIOL, V19, P2021; KEKULE AS, 1992, ARCH VIROL, P63; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mazars A, 2000, ONCOGENE, V19, P1277, DOI 10.1038/sj.onc.1203420; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Ronai Z, 1999, ONCOGENE, V18, P6084, DOI 10.1038/sj.onc.1203175; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Shi CS, 1999, J IMMUNOL, V163, P3279; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Weil R, 1999, MOL CELL BIOL, V19, P6345; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zwacka RM, 2000, J GENE MED, V2, P334, DOI 10.1002/1521-2254(200009/10)2:5<334::AID-JGM129>3.0.CO;2-Q	60	60	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27152	27158		10.1074/jbc.M100031200	http://dx.doi.org/10.1074/jbc.M100031200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375388	hybrid			2022-12-27	WOS:000169966900057
J	Wyckoff, MH; Chambliss, KL; Mineo, C; Yuhanna, IS; Mendelsohn, ME; Mumby, SM; Shaul, PW				Wyckoff, MH; Chambliss, KL; Mineo, C; Yuhanna, IS; Mendelsohn, ME; Mumby, SM; Shaul, PW			Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through G alpha(i)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ALPHA-SUBUNITS; PHOSPHOLIPASE-C; ACTIVATION; CELLS; MOBILIZATION; SUBFAMILY; ESTRADIOL; HORMONES; CALCIUM; BETA	Estrogen causes rapid endothelial nitric oxide (NO) production because of the activation of plasma membrane-associated estrogen receptors (ER) coupled to endothelial NO synthase (eNOS). In the present study, we determined the role of G proteins in eNOS activation by estrogen. Estradiol-17 beta (E-2, 10(-8) M) and acetylcholine (10(-5) hr) caused comparable increases in NOS activity (15 min) in intact endothelial cells that were fully blocked by pertussis toxin (Ptox). In addition, exogenous guanosine 5'-O-(2- thiodiphosphate) inhibited E-2-mediated eNOS stimulation in isolated endothelial plasma membranes, and Ptox prevented enzyme activation by E-2 in COS-7 cells expressing ER alpha and eNOS. Coimmunoprecipitation studies of plasma membranes from COS-7 cells transfected with ER alpha and specific G alpha proteins demonstrated E-2-stimulated interaction between ER alpha and G alpha (i) but not between ER alpha and either G alpha (q) or G alpha (s); the observed ER alpha -G alpha (i) interaction was blocked by the ER antagonist ICI 182,780 and by Ptox, E-2-stimulated ER alpha -G alpha (i) interaction was also demonstrable in endothelial cell plasma membranes. Cotransfection of G alpha (i) into COS-7 cells expressing ER alpha and eNOS yielded a 3-fold increase in E-2-mediated eNOS stimulation, whereas cotransfection with a protein regulator of G protein signaling, RGS4, inhibited the E-2 response. These findings indicate that eNOS stimulation by E-2 requires plasma membrane ER alpha coupling to G alpha (i) and that activated G alpha (i) mediates the requisite downstream signaling events. Thus, novel G protein coupling enables a subpopulation of ER alpha to initiate signal transduction at the cell surface. Similar mechanisms may underly the nongenomic actions of other steroid hormones.	Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tufts Medical Center; Tufts University	Shaul, PW (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030276] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059953, R01HL053546, R01HL058888, R01HL056069] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59953, HL58888, HL53546, HL56069] Funding Source: Medline; NICHD NIH HHS [HD30276] Funding Source: Medline; NIGMS NIH HHS [GM50515] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benten WPM, 1999, MOL BIOL CELL, V10, P3113, DOI 10.1091/mbc.10.10.3113; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; CALDWELL JD, 1995, BRAIN RES, V693, P225, DOI 10.1016/0006-8993(95)00727-8; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CARTY DJ, 1994, METHOD ENZYMOL, V237, P63; CaulinGlaser T, 1997, CIRC RES, V81, P885; Chen Y Z, 1999, Mol Cell Biol Res Commun, V2, P145, DOI 10.1006/mcbr.1999.0163; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; Kelly MJ, 1999, STEROIDS, V64, P64, DOI 10.1016/S0039-128X(98)00095-6; LantinHermoso RL, 1997, AM J PHYSIOL-LUNG C, V273, pL119, DOI 10.1152/ajplung.1997.273.1.L119; LeMellay V, 1997, J BIOL CHEM, V272, P11902, DOI 10.1074/jbc.272.18.11902; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Machelon V, 1996, J CELL BIOCHEM, V61, P619, DOI 10.1002/(SICI)1097-4644(19960616)61:4<619::AID-JCB16>3.0.CO;2-A; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Morelli S, 1996, MOL CELL ENDOCRINOL, V122, P207, DOI 10.1016/0303-7207(96)03886-5; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PAPPAS TC, 1995, ENDOCRINE, V3, P743, DOI 10.1007/BF03000207; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8	26	244	256	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27071	27076		10.1074/jbc.M100312200	http://dx.doi.org/10.1074/jbc.M100312200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369763	hybrid			2022-12-27	WOS:000169966900046
J	Chen, YA; Scales, SJ; Duvvuri, V; Murthy, M; Patel, SM; Schulman, H; Scheller, RH				Chen, YA; Scales, SJ; Duvvuri, V; Murthy, M; Patel, SM; Schulman, H; Scheller, RH			Calcium regulation of exocytosis in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; MEMBRANE-FUSION; SNARE COMPLEX; CA2+-DEPENDENT EXOCYTOSIS; NEUROTRANSMITTER RELEASE; SECRETORY VESICLES; PROTEIN-KINASE; CALMODULIN; BINDING; CA2+	The calcium (Ca2+) regulation of neurotransmitter release is poorly understood. Here we investigated several aspects of this process in PC12 cells. We first showed that osmotic shock by 1 M sucrose stimulated rapid release of neurotransmitters from intact PC12 cells, indicating that most of the vesicles were docked at the plasma membrane. Second, we further investigated the mechanism of rescue of botulinum neurotoxin E inhibition of release by recombinant SNAP-25 COOH-terminal coil, which is known to be required in the triggering stage. We confirmed here that Ca2+ was required simultaneously with the SNAP-25 peptide, with no significant increase in release if either the peptide or Ca2+ was present during the priming stage as well as the triggering, suggesting that SNARE (soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptor) complex assembly was involved in the final Ca2+-triggered event. Using this rescue system, we also identified a series of acidic surface SNAP-25 residues that rescued better than wild-type when mutated, due to broadened Ca2+ sensitivity, suggesting that this charged patch may interact electrostatically with a negative regulator of membrane fusion, Finally, we showed that the previously demonstrated stimulation of exocytosis in this system by calmodulin required calcium binding, since calmodulin mutants defective in Ca2+-binding were not able to enhance release.	Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	Scheller, RH (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	scheller@gene.com	Duvvuri, Vikas/M-1904-2013; Scales, Suzie J./H-4507-2019	Scales, Suzie J./0000-0003-2544-0283	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH020016] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 08327, GM40600] Funding Source: Medline; NIMH NIH HHS [5T32 MH20016-04] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0; Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BIRCH KA, 1992, J CELL BIOL, V118, P1501, DOI 10.1083/jcb.118.6.1501; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Brunger AT, 2000, CURR OPIN NEUROBIOL, V10, P293, DOI 10.1016/S0959-4388(00)00098-2; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Coppola T, 1999, EMBO J, V18, P5885, DOI 10.1093/emboj/18.21.5885; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; FRIEDBERG F, 1990, Protein Sequences and Data Analysis, V3, P335; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; Itakura M, 1999, BIOCHEM BIOPH RES CO, V265, P691, DOI 10.1006/bbrc.1999.1756; Kasai H, 1999, TRENDS NEUROSCI, V22, P88, DOI 10.1016/S0166-2236(98)01293-4; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; Lonart G, 1998, NEURON, V21, P1141, DOI 10.1016/S0896-6273(00)80631-5; MARSHAK DR, 1996, STRATEGIES PROTEIN P, P74; Martin TFJ, 1997, J BIOL CHEM, V272, P14447, DOI 10.1074/jbc.272.22.14447; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Quetglas S, 2000, P NATL ACAD SCI USA, V97, P9695, DOI 10.1073/pnas.97.17.9695; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEINHARDT RA, 1982, NATURE, V295, P154, DOI 10.1038/295154a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tokumaru H, 2001, CELL, V104, P421, DOI 10.1016/S0092-8674(01)00229-X; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	48	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26680	26687		10.1074/jbc.M103522200	http://dx.doi.org/10.1074/jbc.M103522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11359785	hybrid			2022-12-27	WOS:000169823300134
J	Hill, MM; Andjelkovic, M; Brazil, DP; Ferrari, S; Fabbro, D; Hemmings, BA				Hill, MM; Andjelkovic, M; Brazil, DP; Ferrari, S; Fabbro, D; Hemmings, BA			Insulin-stimulated protein kinase B phosphorylation on Ser-473 is independent of its activity and occurs through a staurosporine-insensitive kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-LINKED KINASE; 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN-KINASE-1; ACTIVATION; CELLS; MECHANISM; GROWTH; PDK1; SITE; APOPTOSIS; INHIBITOR	Full activation of protein kinase B (PKB, also called Akt) requires phosphorylation on two regulatory sites, Thr-308 in the activation loop and Ser-473 in the hydrophobic C-terminal regulatory domain (numbering for PKB alpha /Akt-1), Although 3 ' -phosphoinositide-dependent protein kinase 1 (PDK1) has now been identified as the Thr-308 kinase, the mechanism of the Ser-473 phosphorylation remains controversial. As a step to further characterize the Ser-473 kinase, we examined the effects of a range of protein kinase inhibitors on the activation and phosphorylation of PKB. We found that staurosporine, a broad-specificity kinase inhibitor and inducer of cell apoptosis, attenuated PKB activation exclusively through the inhibition of Thr-308 phosphorylation, with Ser-473 phosphorylation unaffected. The increase in Thr-308 phosphorylation because of overexpression of PDK1 was also inhibited by staurosporine, We further show that staurosporine (CGP 39360) potently inhibited PDK1 activity in vitro with an IC50 of similar to0.22 muM. These data indicate that agonist-induced phosphorylation of Ser-473 of PKB is independent of PDK1 or PKB activity and occurs through a distinct Ser-473 kinase that is not inhibited by staurosporine, Moreover, our results suggest that inhibition of PKB signaling is involved in the proapoptotic action of staurosporine.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Novartis Pharma AG, Dept Oncol, CH-4057 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis	Hemmings, BA (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.		Hill, Michelle Mei Chih/G-4417-2010; Ferrari, Stefano/I-7357-2016	Hill, Michelle Mei Chih/0000-0003-1134-0951; Ferrari, Stefano/0000-0002-6607-215X; Brazil, Derek/0000-0003-1375-1076				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Begemann M, 1998, ANTICANCER RES, V18, P3139; Begemann M, 1998, ANTICANCER RES, V18, P2275; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Fabbro D, 2000, ANTI-CANCER DRUG DES, V15, P17; Fabbro D, 1999, PROTEIN EXPRES PURIF, V17, P83, DOI 10.1006/prep.1999.1102; Flynn P, 2000, CURR BIOL, V10, P1439, DOI 10.1016/S0960-9822(00)00801-0; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Geiges D, 1997, BIOCHEM PHARMACOL, V53, P865, DOI 10.1016/S0006-2952(96)00885-4; HILL MM, 2001, IN PRESS METHODS ENZ, V345; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toledo LM, 1999, CURR MED CHEM, V6, P775; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3	25	113	123	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25643	25646		10.1074/jbc.C100174200	http://dx.doi.org/10.1074/jbc.C100174200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11373274	hybrid, Green Accepted			2022-12-27	WOS:000169823300002
J	Yang, HL; Reinherz, EL				Yang, HL; Reinherz, EL			Dynamic recruitment of human CD2 into lipid rafts - Linkage to T cell signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-T; CYTOPLASMIC DOMAIN; MEMBRANE DOMAINS; TYROSINE KINASE; ERYTHROPOIETIN RECEPTOR; BIOLOGICAL-MEMBRANES; ANTIGEN RECOGNITION; PLASMA-MEMBRANE; N-GLYCANS; ACTIVATION	CD2 mediates T cell adhesion via its ectodomain and signal transduction utilizing its 117-amino acid cytoplasmic tail. Here we show that a significant fraction of human CD2 molecules is inducibly recruited into lipid rafts upon CD2 cross-linking by a specific pair of mitogenic anti-CD2 monoclonal antibodies (anti-T11(2), + anti-T11(3)) or during cellular conjugate formation by CD58, the physiologic ligand expressed on antigen-presenting cells. Translocation to lipid microdomains is independent of the T cell receptor (TCR) and, unlike inducible TCR-raft association, requires no tyrosine phosphorylation. Structural integrity of rafts is necessary for CDS stimulated elevation of intracellular free calcium and tyrosine phosphorylation of cellular substrates, Whereas murine CD2 contains two membrane-proximal intracellular cysteines, partitioning CD2 into cholesterol-rich lipid rafts constitutively, human CD2 has no cytoplasmic cysteines. Mapping studies using CD2 point mutation, deletion, and chimeric molecules suggest that conformational change in the CD2 ectodomain participates in inducible raft association and excludes the membrane-proximal N-linked glycans, the transmembrane segment, and the CD2 cytoplasmic region (residues 8-117) as necessary for translocation. Translocation of CD2 into lipid rafts may reorganize the membrane into an activation-ready state prior to TCR engagement by a peptide associated with a major histocompatibility complex molecule, accounting for synergistic T cell stimulation by CD2 and the TCR.	Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Reinherz, EL (corresponding author), Dana Farber Canc Inst, Immunobiol Lab, 44 Binney St, Boston, MA 02115 USA.	ellis_reinherz@dfci.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021226] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21226] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aman MJ, 2000, CURR BIOL, V10, P393, DOI 10.1016/S0960-9822(00)00415-2; ARULANANDAM AR, 1993, LEUCOCYTE TYPING 5, V1, P349; ARULANANDAM ARN, 1994, J EXP MED, V180, P1861, DOI 10.1084/jem.180.5.1861; ARULANANDAM ARN, 1993, J EXP MED, V177, P1439, DOI 10.1084/jem.177.5.1439; Bachmann MF, 1999, J EXP MED, V190, P1383, DOI 10.1084/jem.190.10.1383; Bell GM, 1996, J EXP MED, V183, P169, DOI 10.1084/jem.183.1.169; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BOUSSIOTIS VA, 1994, J EXP MED, V180, P1665, DOI 10.1084/jem.180.5.1665; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; Cebecauer M, 1998, BIOCHEM BIOPH RES CO, V243, P706, DOI 10.1006/bbrc.1998.8149; CHANG HC, 1989, J EXP MED, V169, P2073, DOI 10.1084/jem.169.6.2073; CHANG HC, 1990, J EXP MED, V172, P351, DOI 10.1084/jem.172.1.351; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; CLAYTON LK, 1987, EUR J IMMUNOL, V17, P1367, DOI 10.1002/eji.1830170922; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Deans JP, 1998, J BIOL CHEM, V273, P344, DOI 10.1074/jbc.273.1.344; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; Fukai I, 2000, EUR J IMMUNOL, V30, P3507, DOI 10.1002/1521-4141(2000012)30:12<3507::AID-IMMU3507>3.0.CO;2-O; Gollob JA, 1996, J IMMUNOL, V157, P1886; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Green JM, 2000, J IMMUNOL, V164, P3591, DOI 10.4049/jimmunol.164.7.3591; HAHN WC, 1993, J EXP MED, V178, P1831, DOI 10.1084/jem.178.5.1831; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; King PD, 1996, INT IMMUNOL, V8, P1707, DOI 10.1093/intimm/8.11.1707; Kivens WJ, 1998, MOL CELL BIOL, V18, P5291, DOI 10.1128/MCB.18.9.5291; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; KOYASU S, 1990, P NATL ACAD SCI USA, V87, P2603, DOI 10.1073/pnas.87.7.2603; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Lanzavecchia A, 1999, CELL, V96, P1, DOI 10.1016/S0092-8674(00)80952-6; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Li J, 1998, EMBO J, V17, P7320, DOI 10.1093/emboj/17.24.7320; Li J, 1996, J MOL BIOL, V263, P209, DOI 10.1006/jmbi.1996.0570; Lin HM, 1998, J BIOL CHEM, V273, P19914, DOI 10.1074/jbc.273.31.19914; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MOINGEON P, 1989, NATURE, V339, P312, DOI 10.1038/339312a0; MOINGEON P, 1989, IMMUNOL REV, V111, P111, DOI 10.1111/j.1600-065X.1989.tb00544.x; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; Nishizawa K, 1998, P NATL ACAD SCI USA, V95, P14897, DOI 10.1073/pnas.95.25.14897; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; RECNY MA, 1992, J BIOL CHEM, V267, P22428; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SILICIANO RF, 1985, NATURE, V317, P428, DOI 10.1038/317428a0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stauffer TP, 1997, J CELL BIOL, V139, P1447, DOI 10.1083/jcb.139.6.1447; TAVERNOR AS, 1994, EUR J BIOCHEM, V219, P969, DOI 10.1111/j.1432-1033.1994.tb18579.x; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; van der Merwe PA, 2000, SEMIN IMMUNOL, V12, P5, DOI 10.1006/smim.2000.0203; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Xavier R, 1999, CURR OPIN IMMUNOL, V11, P265, DOI 10.1016/S0952-7915(99)80043-0; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; YANG SY, 1986, J IMMUNOL, V137, P1097; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	80	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18775	18785		10.1074/jbc.M009852200	http://dx.doi.org/10.1074/jbc.M009852200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376005	hybrid			2022-12-27	WOS:000169091000019
J	Thomas, CJ; Surolia, N; Surolia, A				Thomas, CJ; Surolia, N; Surolia, A			Kinetic and thermodynamic analysis of the interactions of 23-residue peptides with endotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; GRAM-NEGATIVE BACTERIA; HOST-DEFENSE PEPTIDES; POLYMYXIN-B; ANTIMICROBIAL PEPTIDES; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; OUTER-MEMBRANE; LIPID-A; SALMONELLA-TYPHIMURIUM	Many naturally occurring peptides exhibit lipopolysaccharide binding properties. In this work we describe the endotoxin binding properties of a series of 23-residue peptides based on the sequence corresponding to the antisense strand of the magainin gene. Biochemical and biophysical characterization of these peptides reveals that they have the tendency to perturb both the inner and outer membranes of test pathogens. Structurally these peptides are amphiphilic and adopt helical conformations in membranes. Three of the seven peptides tested have high affinities for endotoxin that approach the values shown by polymyxin B, a cyclic cationic acylated decapeptide, which is used clinically in treating extreme cases of sepsis. The kinetic parameters obtained using stopped-flow methods and BIA-core (TM) analysis, when considered in conjunction with the isothermal titration calorimetry-derived thermodynamic parameters, allow us to highlight the key structural features essential for lipopolysaccharide (LPS) recognition by these peptides. The studies stress the role of ionic forces in the initial recognition of LPS. The fortification of the strength of these ionic charges increases affinity for LPS, whereas the hydrophobic residues involved in interactions are more amenable to disruptions in contiguity. Peptides that improve these features further are expected to perform better as endotoxin-neutralizing agents.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci & Res Jakkur, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.		SUROLIA, AVADESHA/C-5442-2009					Bechinger B, 1999, BBA-BIOMEMBRANES, V1462, P157, DOI 10.1016/S0005-2736(99)00205-9; Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; BERKOWITZ BA, 1990, BIOCHEM PHARMACOL, V39, P625, DOI 10.1016/0006-2952(90)90138-B; Boman HG, 2000, IMMUNOL REV, V173, P5, DOI 10.1034/j.1600-065X.2000.917301.x; BOMAN HG, 1993, INFECT IMMUN, V61, P2978, DOI 10.1128/IAI.61.7.2978-2984.1993; Brandenburg K, 1997, BBA-BIOMEMBRANES, V1329, P183, DOI 10.1016/S0005-2736(97)00109-0; Chaby R, 1999, DRUG DISCOV TODAY, V4, P209, DOI 10.1016/S1359-6446(99)01336-7; Chen HM, 1997, BBA-GEN SUBJECTS, V1336, P171, DOI 10.1016/S0304-4165(97)00024-X; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; Datta AK, 1999, INDIAN J BIOCHEM BIO, V36, P55; Evans ME, 1999, ANN PHARMACOTHER, V33, P960, DOI 10.1345/aph.18426; FINK PF, 1990, SEPSIS SYNDROME HDB, P619; Frecer V, 2000, EUR J BIOCHEM, V267, P837, DOI 10.1046/j.1432-1327.2000.01069.x; GALANOS C, 1977, INT REV BIOCH BIOCH, V14, P239; HANCOCK REW, 1981, ANTIMICROB AGENTS CH, V19, P777, DOI 10.1128/AAC.19.5.777; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; JUAN TSC, 1995, J BIOL CHEM, V270, P17237, DOI 10.1074/jbc.270.29.17237; Kato N, 2000, MOL MICROBIOL, V36, P796, DOI 10.1046/j.1365-2958.2000.01893.x; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; LIEVE L, 1974, ANN NY ACAD SCI, V235, P109; Lockey TD, 1996, EUR J BIOCHEM, V236, P263, DOI 10.1111/j.1432-1033.1996.00263.x; LOH B, 1984, ANTIMICROB AGENTS CH, V26, P546, DOI 10.1128/AAC.26.4.546; MALOY WL, 1995, BIOPOLYMERS, V37, P105, DOI 10.1002/bip.360370206; MOORE RA, 1986, ANTIMICROB AGENTS CH, V29, P496, DOI 10.1128/AAC.29.3.496; Morrison D C, 1981, Contemp Top Mol Immunol, V8, P187; Oren Z, 1998, BIOPOLYMERS, V47, P451; PATHAK N, 1995, PROTEINS, V22, P182, DOI 10.1002/prot.340220210; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RIETSCHEL ET, 1992, SCI AM, V267, P26; SANDERSON KE, 1974, CAN J MICROBIOL, V20, P1135, DOI 10.1139/m74-176; SCHINDLER PRG, 1975, ANTIMICROB AGENTS CH, V8, P95, DOI 10.1128/AAC.8.1.95; Srimal S, 1996, BIOCHEM J, V315, P679, DOI 10.1042/bj3150679; Thomas CJ, 1999, J BIOL CHEM, V274, P29624, DOI 10.1074/jbc.274.42.29624; Thomas CJ, 1998, J AM CHEM SOC, V120, P12428, DOI 10.1021/ja981777j; Thomas CJ, 1999, FEBS LETT, V445, P420, DOI 10.1016/S0014-5793(99)00150-7; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; Wong PMC, 2000, SCAND J IMMUNOL, V51, P123; YIN ET, 1972, BIOCHIM BIOPHYS ACTA, V261, P284; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910; ZEIGLER EJ, 1991, NEW ENGL J MED, V324, P429	41	24	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35701	35706		10.1074/jbc.M011319200	http://dx.doi.org/10.1074/jbc.M011319200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11384964	hybrid			2022-12-27	WOS:000171109300066
J	Williamson, RA; Hutton, M; Vogt, G; Rapti, M; Knauper, V; Carr, MD; Murphy, G				Williamson, RA; Hutton, M; Vogt, G; Rapti, M; Knauper, V; Carr, MD; Murphy, G			Tyrosine 36 plays a critical role in the interaction of the AB loop of tissue inhibitor of metalloproteinases-2 with matrix metalloproteinase-14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; KINETIC-ANALYSIS; ACTIVE DOMAIN; GELATINASE-A; BINDING; SITE; STROMELYSIN-1; MECHANISM; PROGRAM; TIMP-2	The tissue inhibitor of metalloproteinases-2 (TIMP-2) is potentially an important inhibitor of all known matrix metalloproteinases (MMPs). However, it has been shown to undergo specific interactions with both MMP-2 (gelatinase A) and MMP-14 (MT1-MMP), and it has been proposed that these three proteins function as a cell surface-based activation cascade for matrix metalloproteinases and as a focus of proteolytic activity. In this study, we have carried out mutagenesis and kinetic analyses to examine the unique interactions between the AB loop of TIMP-2 and MMP-14. The results demonstrate that the major binding contribution of the AB loop is due solely to residue Tyr-36 at the tip of the hairpin. From this work, we propose that TIMP-2 may be engineered to abrogate MMP-14 binding, whereas its binding properties for other MMPs, including MMP-2, are maintained. Mutants of MMP-2 with more directed specificity may be of use in gene therapeutic approaches to human disease.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	University of East Anglia; University of Kent	Murphy, G (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	g.murphy@uea.ac.uk		Carr, Mark/0000-0002-3939-0996; Knauper, Vera/0000-0002-3965-9924				BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Butler GS, 1999, J BIOL CHEM, V274, P20391, DOI 10.1074/jbc.274.29.20391; De Alba E, 1999, PROTEIN SCI, V8, P2234; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Gunasekaran K, 1997, PROTEIN ENG, V10, P1131, DOI 10.1093/protein/10.10.1131; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang W, 1997, J BIOL CHEM, V272, P22086, DOI 10.1074/jbc.272.35.22086; Hutton M, 1998, BIOCHEMISTRY-US, V37, P10094, DOI 10.1021/bi980616p; Knauper V, 1998, BIOL EXTRAC, P199; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Tuuttila A, 1998, J MOL BIOL, V284, P1133, DOI 10.1006/jmbi.1998.2223; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; WILLIAMSON RA, 1994, PROTEIN ENG, V7, P1035, DOI 10.1093/protein/7.8.1035; Williamson RA, 1996, EUR J BIOCHEM, V241, P476, DOI 10.1111/j.1432-1033.1996.00476.x; Williamson RA, 1997, BIOCHEMISTRY-US, V36, P13882, DOI 10.1021/bi9712091; Williamson RA, 1999, J BIOL CHEM, V274, P37226, DOI 10.1074/jbc.274.52.37226; Wu B, 2000, J MOL BIOL, V295, P257, DOI 10.1006/jmbi.1999.3362	32	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32966	32970		10.1074/jbc.M101843200	http://dx.doi.org/10.1074/jbc.M101843200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11390386	hybrid			2022-12-27	WOS:000170746000079
J	Cunto-Amesty, G; Dam, TK; Luo, P; Monzavi-Karbassi, B; Brewer, CF; Van Cott, TC; Kieber-Emmons, T				Cunto-Amesty, G; Dam, TK; Luo, P; Monzavi-Karbassi, B; Brewer, CF; Van Cott, TC; Kieber-Emmons, T			Directing the immune response to carbohydrate antigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DIOCLEA-GRANDIFLORA LECTIN; CONCANAVALIN-A; HTLV-III; CAPSULAR POLYSACCHARIDE; MONOCLONAL-ANTIBODY; CONJUGATE VACCINES; FUNCTIONAL MIMICRY; PEPTIDE MIMOTOPES; STRUCTURAL BASIS	Peptide mimetics may substitute for carbohydrate antigens in vaccine design applications. At present, the structural and immunological aspects of antigenic, mimicry, which translate into immunologic mimicry, as well as the functional correlates of each, are unknown. In contrast to screening peptide display libraries, we demonstrate the feasibility of a structure-assisted vaccine design approach to identify functional mimeotopes. By using concanavalin A (ConA), as a recognition template, peptide mimetics reactive with ConA were identified. Designed peptides were observed to compete with synthetic carbohydrate probes for ConA binding, as demonstrated by enzyme-linked immunosorbent assay and isothermal titration calorimetry (ITC) analysis' ITC measurements indicate that a multivalent form of one particular mimetic binds to ConA with.. ar affinity as does trimannoside. Splenocytes from mimeotope-immunized mice display a peptide-specific cellular response,, confirming a T-cell-dependent nature for the mimetic. As ConA binds to the Envelope protein of the human immunodeficiency virus, type I (HIV-1), we observed that mimeotope-induced serum also binds to HIV-1-infected cells, as assessed by flow cytometry, and could neutralize T-cell line adapted HIV-1 isolates in vitro, albeit at low titers. These studies emphasize that mimicry is based more upon functional rather than structural determinants that regulate mimeotope-induced T-dependent antibody responses to polysaccharide and emphasize that rational approaches can be employed to develop further vaccine candidates.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Albert Einstein Coll Med, Dept Mol Pharmacol & Microbiol & Immunol, Bronx, NY 10461 USA; Henry M Jackson Fdn, Rockville, MD 20850 USA	University of Pennsylvania; Yeshiva University; Albert Einstein College of Medicine; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc	Kieber-Emmons, T (corresponding author), Univ Penn, Dept Pathol & Lab Med, Rm 205,John Morgan Bldg,36th & Hamilton Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI044412] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44412] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARENDRUP M, 1993, J GEN VIROL, V74, P855, DOI 10.1099/0022-1317-74-5-855; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410; BHATTACHARYYA L, 1990, BIOCHEMISTRY-US, V29, P7523, DOI 10.1021/bi00484a022; BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P593, DOI 10.1007/BF00126217; CHESEBRO B, 1988, J VIROL, V62, P3779, DOI 10.1128/JVI.62.10.3779-3788.1988; CUNTOARNESTY G, 2001, VACCINE, V19, P2861; Dam TK, 1998, J BIOL CHEM, V273, P32826, DOI 10.1074/jbc.273.49.32826; Dam TK, 2000, J BIOL CHEM, V275, P14223, DOI 10.1074/jbc.275.19.14223; Fleuridor R, 2001, J IMMUNOL, V166, P1087, DOI 10.4049/jimmunol.166.2.1087; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GATTEGNO L, 1992, AIDS RES HUM RETROV, V8, P27, DOI 10.1089/aid.1992.8.27; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Goldblatt D, 1998, J MED MICROBIOL, V47, P563, DOI 10.1099/00222615-47-7-563; Gupta D, 1997, J BIOL CHEM, V272, P6388, DOI 10.1074/jbc.272.10.6388; HAERTLE T, 1988, J BIOL CHEM, V263, P5870; Hansen JES, 1996, ARCH VIROL, V141, P291, DOI 10.1007/BF01718400; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; Harris SL, 1997, P NATL ACAD SCI USA, V94, P2454, DOI 10.1073/pnas.94.6.2454; Hruby VJ, 2000, CURR MED CHEM, V7, P945, DOI 10.2174/0929867003374499; Jain D, 2000, BIOCHEM BIOPH RES CO, V272, P843, DOI 10.1006/bbrc.2000.2871; JOHNSON VA, 1990, TECHNIQUES HIV RES, P71; Kaur KJ, 1997, J BIOL CHEM, V272, P5539, DOI 10.1074/jbc.272.9.5539; Kieber-Emmons T, 2000, J IMMUNOL, V165, P623, DOI 10.4049/jimmunol.165.2.623; Kieber-Emmons T, 1999, J BIOL CHEM, V274, P9648, DOI 10.1074/jbc.274.14.9648; Kieber-Emmons T, 1999, NAT BIOTECHNOL, V17, P660, DOI 10.1038/10870; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Kudryashov V, 2001, P NATL ACAD SCI USA, V98, P3264, DOI 10.1073/pnas.051623598; Lin CL, 2000, J EXP MED, V192, P587, DOI 10.1084/jem.192.4.587; LIN CM, 1994, J BIOL CHEM, V269, P2805; Lo-Man R, 2001, J IMMUNOL, V166, P2849, DOI 10.4049/jimmunol.166.4.2849; LOPALCO L, 1993, EUR J IMMUNOL, V23, P2016, DOI 10.1002/eji.1830230844; Luo P, 1998, MOL IMMUNOL, V35, P865, DOI 10.1016/S0161-5890(98)00067-4; Luo P, 2000, J BIOL CHEM, V275, P16146, DOI 10.1074/jbc.M909121199; Mbemba E, 1996, AIDS RES HUM RETROV, V12, P47, DOI 10.1089/aid.1996.12.47; McCool TL, 1999, INFECT IMMUN, V67, P4862, DOI 10.1128/IAI.67.9.4862-4869.1999; Moe GR, 1999, FEMS IMMUNOL MED MIC, V26, P209; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; Moothoo DN, 1998, GLYCOBIOLOGY, V8, P173, DOI 10.1093/glycob/8.2.173; MULLER WEG, 1991, J ACQ IMMUN DEF SYND, V4, P694; MULLER WEG, 1990, AIDS, V4, P159, DOI 10.1097/00002030-199002000-00010; Murali R, 1997, J MOL RECOGNIT, V10, P269, DOI 10.1002/(SICI)1099-1352(199711/12)10:6<269::AID-JMR370>3.0.CO;2-9; Murthy MRN, 1997, BIOPHYS CHEM, V68, P33, DOI 10.1016/S0301-4622(97)00005-7; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; O I, 2000, BIOCHEM BIOPH RES CO, V268, P106, DOI 10.1006/bbrc.1999.2061; Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651; PINCUS SH, 1989, J IMMUNOL, V142, P3070; Pinilla C, 1998, J MOL BIOL, V283, P1013, DOI 10.1006/jmbi.1998.2137; POPOVIC M, 1984, LANCET, V2, P1472; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROBBINS JB, 1990, J INFECT DIS, V161, P821, DOI 10.1093/infdis/161.5.821; ROBINSON WE, 1987, AIDS RES HUM RETROV, V3, P265, DOI 10.1089/aid.1987.3.265; Saifuddin M, 2000, J GEN VIROL, V81, P949, DOI 10.1099/0022-1317-81-4-949; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SCHNEERSON R, 1980, J EXP MED, V152, P361, DOI 10.1084/jem.152.2.361; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SMITH SD, 1984, CANCER RES, V44, P5657; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; STEIN KE, 1992, J INFECT DIS, V165, P549; Vos Q, 2000, IMMUNOL REV, V176, P154; WESTERINK MAJ, 1995, P NATL ACAD SCI USA, V92, P4021, DOI 10.1073/pnas.92.9.4021; Zhu XG, 2000, BIOCHEMISTRY-US, V39, P11194, DOI 10.1021/bi000432m; Zou W, 1999, J IMMUNOL, V163, P820	65	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30490	30498		10.1074/jbc.M103257200	http://dx.doi.org/10.1074/jbc.M103257200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11384987	hybrid			2022-12-27	WOS:000170558000116
J	Malbec, O; Schmitt, C; Bruhns, P; Krystal, G; Fridman, WH; Daeron, M				Malbec, O; Schmitt, C; Bruhns, P; Krystal, G; Fridman, WH; Daeron, M			Src homology 2 domain-containing inositol 5-phosphatase 1 mediates cell cycle arrest by Fc gamma RIIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NEGATIVE REGULATION; B-CELLS; C-KIT; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; INHIBITION MOTIF; PHOSPHATASE SHIP; PROGENITOR CELLS; LYMPHOCYTES-B	We previously found that low affinity receptors for the Fc portion of IgG, Fc-/RUB, which are widely expressed by hematopoietic cells, can negatively regulate receptor tyrosine kinase-dependent cell proliferation. We investigated here the mechanisms of this inhibition. We used as experimental models wild-type mast cells, which constitutively express the stem cell factor receptor Kit and Fc gamma RIIB, Fc gamma RIIB-deficient mast cells reconstituted with wild-type or mutated Fc gamma RIIB, and Src homology 2 domain-containing inositol polyphosphate 5-phosphatase 1 (SHIP1)deficient mast cells. We found that, upon coaggregation with Kit, Fc gamma RIIB are tyrosyl-phosphorylated, recruit SHIP1, but not SHIP2, SH2 domain-containing protein tyrosine phosphatase-1 or -2, abrogate Akt phosphorylation, shorten the duration of the activation of mitogen-activated protein kinases of the Ras and Rac pathways, abrogate cyclin induction, prevent cells from entering the cell cycle, and block thymidine incorporation. Fc gamma RIIB-mediated inhibition of Mt-dependent cell proliferation was reduced in SHIP1-deficient mast cells, whereas inhibition of IgE-induced responses was abrogated. Cell proliferation was, however, inhibited by coaggregating Mt with Fc gamma RIIB whose intracytoplasmic domain was replaced with the catalytic domain of SHIP1. These results demonstrate that Fc gamma RIIB use SHIP1 to inhibit pathways shared by receptor tyrosine kinases and immunoreceptors to trigger cell proliferation and cell activation, respectively, but that, in the absence of SHIP1, Fc-/RUB can use other effectors that specifically inhibit cell proliferation.	Inst Curie, INSERM U 255, Lab Immunol Cellulaire & Clin, F-75005 Paris, France; Hop La Pitie Salpetriere, CNRS UMR 7627, Lab Immunol Cellulaire, F-75013 Paris, France; Terry Fox Lab, Vancouver, BC B5Z 1L3, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Daeron, M (corresponding author), Inst Biomed Cordeliers, INSERM U 255, Lab Immunol Cellulaire & Clin, 15 Rue Ecole Med, F-75006 Paris, France.	Marc.Daeron@U255.bhdc.jussieu.fr	Bruhns, Pierre/F-5567-2013	Bruhns, Pierre/0000-0002-4709-8936; Krystal, Gerald/0000-0002-1961-6281; fridman, wolf herman/0000-0002-1332-0973				AMIGORENA S, 1989, EUR J IMMUNOL, V19, P1379, DOI 10.1002/eji.1830190805; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BENHAMOU M, 1990, J IMMUNOL, V144, P3071; BERLIOZ C, 1995, J VIROL, V69, P2214, DOI 10.1128/JVI.69.4.2214-2222.1995; Bruhns P, 2000, J BIOL CHEM, V275, P37357, DOI 10.1074/jbc.M003518200; Bruhns P, 1999, J IMMUNOL, V162, P3168; Carver DJ, 2000, BLOOD, V96, P1449, DOI 10.1182/blood.V96.4.1449.h8001449_1449_1456; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; DAERON M, 1992, J IMMUNOL, V149, P1365; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DUBREUIL P, 1990, ANN NY ACAD SCI, V599, P58; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KIMURA S, 1981, IMMUNOGENETICS, V14, P3, DOI 10.1007/BF00344295; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Latour S, 1996, J IMMUNOL, V157, P189; LATOUR S, 1992, J IMMUNOL, V149, P2155; Lesourne R, 2001, J BIOL CHEM, V276, P6327, DOI 10.1074/jbc.M006537200; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU FT, 1980, J IMMUNOL, V124, P2728; Malbec O, 1999, CURR TOP MICROBIOL, V244, P13; Malbec O, 1998, J IMMUNOL, V160, P1647; Malbec O, 1999, J IMMUNOL, V162, P4424; Muraille E, 2000, IMMUNOL LETT, V72, P7, DOI 10.1016/S0165-2478(00)00162-0; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Pearse RN, 1999, IMMUNITY, V10, P753, DOI 10.1016/S1074-7613(00)80074-6; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SAUTES C, 1991, EUR J IMMUNOL, V21, P231, DOI 10.1002/eji.1830210135; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SINCLAIR NRS, 1971, ADV EXP MED BIOL, V12, P609; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Tridandapani S, 1997, J IMMUNOL, V158, P1125; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720	48	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30381	30391		10.1074/jbc.M011094200	http://dx.doi.org/10.1074/jbc.M011094200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11359765	hybrid			2022-12-27	WOS:000170558000102
J	Matassa, AA; Carpenters, L; Biden, TJ; Humphries, MJ; Reyland, ME				Matassa, AA; Carpenters, L; Biden, TJ; Humphries, MJ; Reyland, ME			PKC delta is required for mitochondrial-dependent apoptosis in salivary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-DELTA; MEMBRANE POTENTIAL LOSS; PROTEIN-KINASE; PROTEOLYTIC ACTIVATION; CLEAVAGE; RELEASE; DEATH; TRANSLOCATION; PATHWAYS; PHOSPHORYLATION	We report here that the novel protein kinase C isoform, PKC delta, is required at or prior to the level of the mitochondria for apoptosis induced by a diverse group of cell toxins. We have used adenoviral expression of a kinase-dead (KD) mutant of PKC delta to explore the requirement for PKC delta in the mitochondrial-dependent apoptotic pathway. Expression of PKC delta KD, but not PKC delta KD, in salivary epithelial cells resulted in a dose-dependent inhibition of apoptosis induced by etoposide, UV-irradiation, brefeldin A, and paclitaxel. DNA fragmentation was blocked up to 71% in parotid C5 cells infected with the PKC delta KD adenovirus, whereas caspase-3 activity was inhibited up to 65%. The activation of caspase-9-like proteases by all agents was also inhibited in parotid C5 cells expressing PKC delta KD. The ability of PKC delta KD to block the loss of mitochondrial membrane potential was similarly determined. Expression of PKC delta KD blocked the decrease in mitochondrial membrane potential observed in cells treated with etoposide, UV, brefeldin A, or paclitaxel in a dose-dependent manner. In contrast to the protective function of PKC delta KD, expression of PKC delta WT resulted in a potent induction of apoptosis, which could be inhibited by coinfection with PKC delta KD. These results suggest that PKC delta is a common intermediate in mitochondrial-dependent apoptosis in salivary epithelial cells.	Univ Colorado, Hlth Sci Ctr, Dept Basic Sci & Oral Res, Sch Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Cell & Struct Biol, Sch Med, Denver, CO 80262 USA; Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Garvan Institute of Medical Research	Reyland, ME (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Basic Sci & Oral Res, Sch Med, 4200 E 9th Ave,Box C286, Denver, CO 80262 USA.	mary.reyland@UCHSC.edu	Biden, Trevor/AAW-2829-2021	Biden, Trevor/0000-0001-5211-0234	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012798] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12798] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anderson SM, 1999, CELL DEATH DIFFER, V6, P454, DOI 10.1038/sj.cdd.4400507; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Carpenter L, 2001, J BIOL CHEM, V276, P5368, DOI 10.1074/jbc.M010036200; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Keenan C, 1997, FEBS LETT, V415, P101, DOI 10.1016/S0014-5793(97)01104-6; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1999, BLOOD, V94, P291, DOI 10.1182/blood.V94.1.291.413k10_291_301; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Li LW, 1999, MOL CELL BIOL, V19, P8547; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; McGregor WG, 1999, J INVEST DERM SYMP P, V4, P1, DOI 10.1038/sj.jidsp.5640172; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Quissell DO, 1998, IN VITRO CELL DEV-AN, V34, P58; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Reyland ME, 2000, CELL DEATH DIFFER, V7, P1200, DOI 10.1038/sj.cdd.4400744; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; SCHAACK J, 1995, J VIROL, V69, P3920, DOI 10.1128/JVI.69.6.3920-3923.1995; Scheel-Toellner D, 1999, EUR J IMMUNOL, V29, P2603, DOI 10.1002/(SICI)1521-4141(199908)29:08<2603::AID-IMMU2603>3.0.CO;2-L; Schwarz T, 1998, J PHOTOCH PHOTOBIO B, V44, P91, DOI 10.1016/S1011-1344(98)00126-2; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Smith L, 2000, J BIOL CHEM, V275, P40620, DOI 10.1074/jbc.M908517199; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; TORII S, 1995, J BIOL CHEM, V270, P11574, DOI 10.1074/jbc.270.19.11574; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; YANG L, 1985, CANCER RES, V45, P5872; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	51	113	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29719	29728		10.1074/jbc.M100273200	http://dx.doi.org/10.1074/jbc.M100273200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11369761	hybrid			2022-12-27	WOS:000170558000018
J	Rodriguez, C; Huang, LJS; Son, JK; McKee, A; Xiao, Z; Lodish, HF				Rodriguez, C; Huang, LJS; Son, JK; McKee, A; Xiao, Z; Lodish, HF			Functional cloning of the proto-oncogene brain factor-1 (BF-1) as a smad-binding antagonist of transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR-1 GENE; TGF-BETA; TRANSCRIPTION FACTORS; RECEPTOR COMPLEX; QIN PROTEIN; EXPRESSION; RESPONSES; SPECIFICITY; ONCOPROTEIN; REPRESSOR	Using the plasminogen activator inhibitor (PAI) promoter to drive the expression of a reporter gene (mouse CD2), we devised a system to clone negative regulators of the transforming growth factor-beta (TGF-beta) signaling pathway. We infected a TGF-beta -responsive cell line (MvLu1) with a retroviral cDNA library, selecting by fluorescence-activated cell sorter single cells displaying low PAI promoter activity in response to TGF-beta. Using this strategy we cloned the proto-oncogene brain factor-1 (BF-1). BF-1 represses the PAI promoter in part by associating with both unphosphorylated Smad3 (in the cytoplasm) and phosphorylated Smad3 (in the nucleus), thus preventing its binding to DNA BF-1 also associates with Smad1, -2, and -4, the Smad MH2 domain binds to BF-1, and the C-terminal segment of BF-1 is uniquely and solely required for binding to Smads. Further, BF-1 represses another TGF-beta -induced promoter (p15), it upregulates a TGF-beta -repressed promoter (Cyclin A), and it reverses the growth arrest caused by TGF-beta. Our results suggest that BF-1 is a general inhibitor of TGF-beta signaling and as such may play a key role during brain development.	Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA.			rodriguez, carlos/0000-0001-9593-8680	NCI NIH HHS [CA63260] Funding Source: Medline; NHLBI NIH HHS [5F32HL10048-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063260] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010048] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Amoroso SR, 1998, P NATL ACAD SCI USA, V95, P189, DOI 10.1073/pnas.95.1.189; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bergelson S, 1998, J BIOL CHEM, V273, P2396, DOI 10.1074/jbc.273.4.2396; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chang HW, 1996, ONCOGENE, V13, P441; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; DeCoteau JF, 1997, P NATL ACAD SCI USA, V94, P5877, DOI 10.1073/pnas.94.11.5877; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Dou CL, 2000, MOL CELL BIOL, V20, P6201, DOI 10.1128/MCB.20.17.6201-6211.2000; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Li J, 1997, P NATL ACAD SCI USA, V94, P10885, DOI 10.1073/pnas.94.20.10885; LI J, 1995, CANCER RES, V55, P5540; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Mahony D, 1998, MECH DEVELOP, V75, P95, DOI 10.1016/S0925-4773(98)00092-6; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Onishi M, 1996, EXP HEMATOL, V24, P324; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Rodriguez C, 1998, BIOTECHNIQUES, V24, P750, DOI 10.2144/98245bm11; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; TEN DP, 2000, TRENDS BIOCHEM SCI, V25, P64; Watanabe M, 1999, CELL MOL BIOL, V45, P537; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yang YL, 1999, NAT GENET, V21, P216, DOI 10.1038/6005	45	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30224	30230		10.1074/jbc.M102759200	http://dx.doi.org/10.1074/jbc.M102759200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11387330	hybrid			2022-12-27	WOS:000170558000083
J	Rundlof, AK; Carlsten, M; Arner, ESJ				Rundlof, AK; Carlsten, M; Arner, ESJ			The core promoter of human thioredoxin reductase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE INSERTION-SEQUENCE; MESSENGER-RNA STABILITY; MAMMALIAN THIOREDOXIN; TRANSCRIPTION FACTORS; MOLECULAR-CLONING; REDOX REGULATION; GENE-EXPRESSION; GROWTH-FACTOR; SELENOPROTEIN; CELLS	The selenoprotein thioredoxin reductase 1 (TrxR1) carries many vital antioxidant and redox regulatory functions, Its mRNA levels are known to be post-transcriptionally modulated via AUUUA motifs (AU-rich elements (AREs)), but the promoter yet remains unknown. Here we. have cloned and determined the sequence of a 0.8-kilobase pair human genomic. fragment containing the proximal promoter for TrxR1, which has transcriptional. activity in several different cell types. The core promoter (-115 to +167) had an increased GC content and lacked TATA or CCAAT boxes. It contained a POU motif binding the Oct-1 transcription factor and two sites binding Sp1 and Sp3, which were identified with electrophoretic mobility shift assays using crude nuclear extracts of A549 cells. The TrxR1 promoter fulfills the typical criteria of a housekeeping gene. To our knowledge this is the first housekeeping-type promoter characterized for a gene with post-transcriptional regulation via ARE motifs generally possessed by transiently expressed proto-oncogenes, nuclear transcription factors, or cytokines and influencing mRNA stability in response to diverse exogenous factors. Expression of TrxR1 as an ARE-regulated housekeeping gene agrees with a role for the enzyme to maintain a balance between intracellular signaling via reactive oxygen species and protection of cells from excessive oxidative damage.	Karolinska Inst, Dept Med Biochem & Biophys, Nobel Inst Biochem, SE-17177 Stockholm, Sweden	Karolinska Institutet	Arner, ESJ (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Nobel Inst Biochem, SE-17177 Stockholm, Sweden.		Arnér, Elias/K-6737-2019; Arnér, Elias S.J./J-5832-2012; Carlsten, Mattias/AAH-7001-2019	Arnér, Elias/0000-0002-4807-6114; Arnér, Elias S.J./0000-0002-4807-6114; Carlsten, Mattias/0000-0001-9815-0012				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Anema SM, 1999, BIOCHEM J, V342, P111, DOI 10.1042/0264-6021:3420111; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1996, BIOCHEM BIOPH RES CO, V225, P268, DOI 10.1006/bbrc.1996.1165; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Berggren M, 1996, ANTICANCER RES, V16, P3459; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fujiwara N, 1999, BIOCHEM J, V340, P439, DOI 10.1042/0264-6021:3400439; Gasdaska JR, 1996, GENOMICS, V37, P257, DOI 10.1006/geno.1996.0554; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Ghosh R, 1999, NUCLEIC ACIDS RES, V27, P3213, DOI 10.1093/nar/27.15.3213; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gunther M, 2000, MOL CELL BIOCHEM, V210, P131, DOI 10.1023/A:1007177623283; HOLMGREN A, 1980, P NATL ACAD SCI-BIOL, V77, P5149, DOI 10.1073/pnas.77.9.5149; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; Howie AF, 1998, J CLIN ENDOCR METAB, V83, P2052, DOI 10.1210/jc.83.6.2052; Jensen DE, 1997, J CELL BIOCHEM, V67, P24, DOI 10.1002/(SICI)1097-4644(19971001)67:1<24::AID-JCB3>3.0.CO;2-Y; Kawai H, 2000, GENE, V242, P321, DOI 10.1016/S0378-1119(99)00498-9; Koishi R, 1997, J BIOL CHEM, V272, P2570; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; Lickteig K, 1996, MOL REPROD DEV, V44, P146, DOI 10.1002/(SICI)1098-2795(199606)44:2<146::AID-MRD2>3.0.CO;2-N; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Pesce M, 1999, CELLS TISSUES ORGANS, V165, P144, DOI 10.1159/000016694; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; Rundlof AK, 2000, BIOCHEM J, V347, P661, DOI 10.1042/0264-6021:3470661; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Scherf M, 2000, J MOL BIOL, V297, P599, DOI 10.1006/jmbi.2000.3589; Schutze N, 1998, BIOFACTORS, V7, P299, DOI 10.1002/biof.5520070402; Schutze N, 1999, BIOFACTORS, V10, P329, DOI 10.1002/biof.5520100403; Soderberg A, 2000, CANCER RES, V60, P2281; Strom AC, 1996, NUCLEIC ACIDS RES, V24, P1981, DOI 10.1093/nar/24.11.1981; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	60	74	76	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30542	30551		10.1074/jbc.M101452200	http://dx.doi.org/10.1074/jbc.M101452200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11375392	hybrid			2022-12-27	WOS:000170558000123
J	Ananthanarayanan, M; Balasubramanian, N; Makishima, M; Mangelsdorf, DJ; Suchy, FJ				Ananthanarayanan, M; Balasubramanian, N; Makishima, M; Mangelsdorf, DJ; Suchy, FJ			Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; NUCLEAR RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; P-GLYCOPROTEIN; APICAL DOMAIN; PROTEIN GENE; SISTER GENE; TRANSPORT; EXPRESSION; IDENTIFICATION	The bile salt excretory pump (BSEP, ABCb11) is critical for ATP-dependent transport of bile acids across the hepatocyte canalicular membrane and for generation of bile acid-dependent bile secretion. Recent studies have demonstrated that the expression of this transporter is sensitive to the flux of bile acids through the hepatocyte, possibly at the level of transcription of the BSEP gene. To determine the mechanisms underlying the regulation of BSEP by bile acids, the promoter of the BSEP gene was cloned. The sequence of the promoter contained an inverted repeat (IR)-1 element (5 ' -GGGACA T TGATCCT-3 ') at base pairs -63/-50 consisting of two nuclear receptor half-sites organized as an inverted repeat and separated by a single nucleotide. This IR-1 element has been shown in several recent studies to serve as a binding site for the farnesoid X receptor (FXR), a nuclear receptor for bile acids. FXR activity requires heterodimerization with RXR alpha, and when bound by bile acids, the complex effectively regulates the transcription of several genes involved in bile acid homeostasis. Gel mobility shift assays demonstrated specific binding of FXR/RXR alpha heterodimers to the IR-1 element in the BSEP promoter. In HepG2 cells, co-transfection of FXR and RXRa is required to attain full transactivation of the BSEP promoter by bile acids. Two FXR transactivation-deficient mutants (an AF-2 deletion and a W469A point mutant) failed to transactivate, indicating that the effect of bile acids is FXR-dependent. Further, mutational analysis confirms that the FXR/RXRa heterodimer activates transcription through the IR-1 site in the human BSEP promoter. These results demonstrate a mechanism by which bile acids transcriptionally regulate the activity of the bile salt excretory pump, a critical component involved in the enterohepatic circulation of bile acids.	Mt Sinai Med Ctr, Dept Pediat, Lab Dev & Mol Hepatol, New York, NY 10029 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	Icahn School of Medicine at Mount Sinai; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ananthanarayanan, M (corresponding author), Mt Sinai Med Ctr, Dept Pediat, Lab Dev & Mol Hepatol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	meena_ananth@mssm.edu		Mangelsdorf, David/0000-0002-4355-0796	NICHD NIH HHS [HD20632] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020632, R37HD020632] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARRESE M, 2000, GASTROENTEROLOGY, V118, pA33; Ausubel FM, 1988, MOL REPROD DEV; BALASUBRAMANIAN N, 2001, FASEB J, V15, P762; BOYER JL, 1995, GASTROENTEROLOGY, V109, P1600, DOI 10.1016/0016-5085(95)90649-5; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chawla A, 2000, CELL, V103, P1, DOI 10.1016/S0092-8674(00)00097-0; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; Childs S, 1998, CANCER RES, V58, P4160; CHILDS S, 1995, CANCER RES, V55, P2029; Denson LJ, 2000, HEPATOLOGY, V32, p297A; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FICKERT P, 2000, GASTROENTEROLOGY, V118, pA33; Gartung C, 1996, GASTROENTEROLOGY, V110, P199, DOI 10.1053/gast.1996.v110.pm8536857; Gatmaitan ZC, 1997, AM J PHYSIOL-GASTR L, V272, pG1041, DOI 10.1152/ajpgi.1997.272.5.G1041; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Green RM, 1996, GASTROENTEROLOGY, V111, P193, DOI 10.1053/gast.1996.v111.pm8698199; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; JAVITT NB, 1989, J BIOL CHEM, V264, P10384; KADONAGA JT, 1980, TRENDS BIOCHEM SCI, V11, P20; Kipp H, 2000, J BIOL CHEM, V275, P15917, DOI 10.1074/jbc.M909875199; Kullak-Ublick GA, 2000, SEMIN LIVER DIS, V20, P273, DOI 10.1055/s-2000-9426; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Lee JM, 2000, GASTROENTEROLOGY, V118, P163, DOI 10.1016/S0016-5085(00)70425-2; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Misra S, 1999, P NATL ACAD SCI USA, V96, P5814, DOI 10.1073/pnas.96.10.5814; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Moseley RH, 1996, AM J PHYSIOL-GASTR L, V271, pG137, DOI 10.1152/ajpgi.1996.271.1.G137; Muller M, 2000, SEMIN LIVER DIS, V20, P323, DOI 10.1055/s-2000-9387; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Thompson R, 2000, SEMIN LIVER DIS, V20, P365, DOI 10.1055/s-2000-9384; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; ZHANG L, 2000, J BIOL CHEM, V276, P2663	45	598	635	5	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28857	28865		10.1074/jbc.M011610200	http://dx.doi.org/10.1074/jbc.M011610200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387316	hybrid			2022-12-27	WOS:000170346000031
J	Jun, CD; Carman, CV; Redick, SD; Shimaoka, M; Erickson, HP; Springer, TA				Jun, CD; Carman, CV; Redick, SD; Shimaoka, M; Erickson, HP; Springer, TA			Ultrastructure and function of dimeric, soluble intercellular adhesion molecule-1 (ICAM-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; SURFACE-PLASMON RESONANCE; ELECTRON-MICROSCOPY; MASS-TRANSPORT; LIGAND-BINDING; COILED-COILS; RHINOVIRUS; RECEPTOR; DOMAINS; LFA-1	Previous studies have demonstrated dimerization of intercellular adhesion molecule-1 (ICAM-1) on the cell surface and suggested a role for immunoglobulin superfamily domain 5 and/or the transmembrane domain in mediating such dimerization. Crystallization studies suggest that domain I may also mediate dimerization. ICAM-1 binds through domain 1 to the I domain of the integrin alpha (L)beta (2) (lymphocyte function-associated antigen 1). Soluble C-terminally dimerized ICAM-1 was made by replacing the transmembrane and cytoplasmic domains with an a-helical coiled coil. Electron microscopy revealed C-terminal dimers that were straight, slightly bent, and sometimes U-shaped. A small number of apparently closed ring-like dimers and W-shaped tetramers were found. To capture ICAM-1 dimerized at the crystallographically defined dimer interface in domain 1, cysteines were introduced into this interface. Several of these mutations resulted in the formation of soluble disulfide-bonded ICAM-1 dimers (domain 1 dimers). Combining a domain I cysteine mutation with the C-terminal dimers (domain 1/C-terminal dimers) resulted in significant amounts of both closed ring-like dimers and W-shaped tetramers. Surface plasmon resonance studies showed that all of the dimeric forms of ICAM-1 (domain 1, C-terminal, and domain 1/C-terminal dimers) bound similarly to the integrin alpha (L)beta (2) I domain, with affinities similar to1.5-3-fold greater than that of monomeric ICAM-1. These studies demonstrate that ICAM-1 can form at least three different topologies and that dimerization at domain 1 does not interfere with binding in domain I to alpha (L)beta (2).	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Duke University	Springer, TA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.		Carman, Christopher V./AAX-8995-2020; Carman, Christopher/L-8108-2016	Carman, Christopher V./0000-0001-7358-2548; Carman, Christopher/0000-0001-7358-2548				Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; CARRELL NA, 1989, J BIOL CHEM, V264, P551; CASASNOVAS JM, 1994, J VIROL, V68, P5882, DOI 10.1128/JVI.68.9.5882-5889.1994; CASASNOVAS JM, 1995, J BIOL CHEM, V270, P13216, DOI 10.1074/jbc.270.22.13216; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; de Mol NJ, 2000, ANAL BIOCHEM, V279, P61, DOI 10.1006/abio.1999.4464; DEFOUGEROLLES AR, 1994, J EXP MED, V179, P619, DOI 10.1084/jem.179.2.619; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1999, GUIDEBOOK EXTRACELLU, P228; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HAZES B, 1988, PROTEIN ENG, V2, P119, DOI 10.1093/protein/2.2.119; Janin J, 1997, NAT STRUCT BIOL, V4, P973, DOI 10.1038/nsb1297-973; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIRCHHAUSEN T, 1993, J LEUKOCYTE BIOL, V53, P342, DOI 10.1002/jlb.53.3.342; Labadia ME, 1998, J IMMUNOL, V161, P836; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; MAIO M, 1989, J IMMUNOL, V143, P181; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; Parkos CA, 1996, MOL MED, V2, P489, DOI 10.1007/BF03401908; REILLY PL, 1995, J IMMUNOL, V155, P529; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; Schuck P, 1996, BIOPHYS J, V70, P1230, DOI 10.1016/S0006-3495(96)79681-9; Schurmann G, 2001, MOL BIOL CELL, V12, P1765, DOI 10.1091/mbc.12.6.1765; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Wagschal K, 1999, J MOL BIOL, V285, P785, DOI 10.1006/jmbi.1998.2284; Wang JH, 1998, IMMUNOL REV, V163, P197, DOI 10.1111/j.1600-065X.1998.tb01198.x	38	56	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29019	29027		10.1074/jbc.M103394200	http://dx.doi.org/10.1074/jbc.M103394200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390397	hybrid			2022-12-27	WOS:000170346000053
J	Spradling, KD; McDaniel, AE; Lohi, J; Pilcher, BK				Spradling, KD; McDaniel, AE; Lohi, J; Pilcher, BK			Epsin 3 is a novel extracellular matrix-induced transcript specific to wounded epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; EH-DOMAIN; COLLAGENASE EXPRESSION; MEDIATED ENDOCYTOSIS; EDGE KERATINOCYTES; ACUTE INJURY; PROTEIN; CLATHRIN; BINDING; MIGRATION	Using an in vitro model of keratinocyte activation by the extracellular matrix following injury, we have identified epsin 3, a novel protein closely related to, but distinct from previously described epsins. Epsin 3 contains a domain structure common to this gene family, yet demonstrates novel differences in its regulation and pattern of expression. Epsin 3 mRNA and protein were undetectable in keratinocytes isolated from unwounded skin, but induced in cells following contact with fibrillar type I collagen. The native triple helical structure of collagen was required to mediate this response as cells failed to express epsin 3 when plated on gelatin. Consistent with the reported function of other epsins, epsin 3 was evident in keratinocytes as punctate vesicles throughout the cytoplasm that partially co-localized with clathrin. In addition, epsin 3 exhibited nuclear accumulation when mr. clear export was inhibited. In contrast to other known epsins, epsin 3 was restricted to keratinocytes migrating across collagen and down-regulated following cell differentiation, suggesting that expression was spatially and temporally regulated. Indeed, epsin 3 was localized specifically to migrating keratinocytes in cutaneous wounds, but not found in intact skin. Intriguingly, Northern hybridization and reverse transcriptase-polymerase chain reaction experiments indicated that epsin 3 expression was restricted to epithelial wounds or pathologies exhibiting altered cell-extracellular matrix interactions. Thus, we have identified a novel type I collagen-induced epsin that demonstrates structural and behavioral similarity to this gene family, yet exhibits restricted and regulated expression, suggesting that epsin 3 may serve an important function in activated epithelial cells during tissue morphogenesis.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75390 USA; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00290 Helsinki, Finland	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Helsinki	Pilcher, BK (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.							BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark R. A. F, 1996, MOL CELLULAR BIOL WO; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; Coulombe PA, 1997, BIOCHEM BIOPH RES CO, V236, P231, DOI 10.1006/bbrc.1997.6945; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; GRINNELL F, 1990, J TRAUMA, V30, pS144; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; INOUE M, 1995, J INVEST DERMATOL, V104, P479, DOI 10.1111/1523-1747.ep12605917; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; Marchese C, 1998, J CELL SCI, V111, P3517; McPherson PS, 1998, BIOCHEM BIOPH RES CO, V244, P701, DOI 10.1006/bbrc.1998.8331; NISHI K, 1994, J BIOL CHEM, V269, P6320; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Paladini RD, 1996, J CELL BIOL, V132, P381, DOI 10.1083/jcb.132.3.381; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; Pilcher BK, 1998, ARCH DERMATOL RES, V290, pS37, DOI 10.1007/PL00007452; Pilcher BK, 1999, J BIOL CHEM, V274, P10372, DOI 10.1074/jbc.274.15.10372; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; Sudbeck BD, 1997, J BIOL CHEM, V272, P22103, DOI 10.1074/jbc.272.35.22103; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; WOODLEY DT, 1986, J INVEST DERMATOL, V86, P418, DOI 10.1111/1523-1747.ep12285689	33	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29257	29267		10.1074/jbc.M101663200	http://dx.doi.org/10.1074/jbc.M101663200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11359770	hybrid			2022-12-27	WOS:000170346000084
J	Xu, FP; Zhao, RX; Peng, YD; Guerrah, A; Zhao, ZZJ				Xu, FP; Zhao, RX; Peng, YD; Guerrah, A; Zhao, ZZJ			Association of tyrosine phosphatase SHP-2 with F-actin at low cell densities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; INTEGRIN-MEDIATED ADHESION; SRC-FAMILY KINASES; DOMINANT-NEGATIVE MUTANT; TUMOR-SUPPRESSOR PTEN; SUBSTRATUM ADHESION; INTERACTING PROTEIN; IN-VIVO; PTP-MU; GROWTH	SHP-2 is an intracellular SH2 domain-containing protein-tyrosine phosphatase with an essential role in cell signaling. Here we demonstrate that localization of SHP-2 is regulated by cell density in a cell adhesion-dependent manner. When cells were plated at low densities, SHP-2 was distributed in Triton X-100-insoluble fractions, whereas it was totally soluble when cells were plated at high densities or when low density cells approached confluency. In all cases, the total protein level of SHP-2 was not changed. Fluorescent cell staining revealed that SHP-2 was co-localized with actin stress fibers to the cell peripheral at low cell densities but was diffused in the entire cytoplasm at high cell densities. Transient transfection of cells with truncated forms of SHP-2 demonstrated that the catalytic domain of the enzyme was responsible for the density-regulated distribution of SHP-2, but the catalytic activity was not required. An in vitro co-sedimentation study demonstrated direct binding of full-length and SH2 domain-truncated forms of SHP-2 to F-actin. The data indicate that SHP-2 is regulated by cell density and that it may have a role in assembling and disassembling of the actin network.	Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Med Hematol Oncol, Nashville, TN 37232 USA	Vanderbilt University	Zhao, ZZJ (corresponding author), 547,PRB,2220 Pierce Ave, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [R01CA075218, P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015555, T32DK007186] Funding Source: NIH RePORTER; NCI NIH HHS [CA-68485, CA75218] Funding Source: Medline; NHLBI NIH HHS [HL-57393] Funding Source: Medline; NIDDK NIH HHS [DK-15555, T32-DK07186] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; BARNEA G, 1994, J BIOL CHEM, V269, P14349; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT PA, 1993, J CELL SCI, V106, P891; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Flinn HM, 1996, J CELL SCI, V109, P1133; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; HOWARD PK, 1993, SCIENCE, V259, P241, DOI 10.1126/science.7678470; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; Huang C, 1997, J BIOL CHEM, V272, P19248, DOI 10.1074/jbc.272.31.19248; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Manes S, 1999, MOL CELL BIOL, V19, P3125; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Ogata M, 1999, J BIOL CHEM, V274, P12905, DOI 10.1074/jbc.274.18.12905; Oh ES, 1999, MOL CELL BIOL, V19, P3205; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Qu CK, 2000, CELL RES, V10, P279, DOI 10.1038/sj.cr.7290055; Retta SF, 1996, EXP CELL RES, V229, P307, DOI 10.1006/excr.1996.0376; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Roach T, 1997, CURR BIOL, V7, P408, DOI 10.1016/S0960-9822(06)00188-6; Roach TIA, 1998, CURR BIOL, V8, P1035, DOI 10.1016/S0960-9822(07)00426-5; Sabe H, 1997, ONCOGENE, V14, P1779, DOI 10.1038/sj.onc.1201022; Sagawa K, 1997, J BIOL CHEM, V272, P31086, DOI 10.1074/jbc.272.49.31086; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Stein-Gerlach M, 1998, INT J BIOCHEM CELL B, V30, P559, DOI 10.1016/S1357-2725(98)00002-8; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, CANCER RES, V59, P442; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VAN AL, 1997, GENE DEV, V11, P2295; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; Weng LP, 1999, GENES CELLS, V4, P185, DOI 10.1046/j.1365-2443.1999.00251.x; Xu FP, 2001, EXP CELL RES, V262, P49, DOI 10.1006/excr.2000.5075; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhao RX, 2000, J BIOL CHEM, V275, P5453, DOI 10.1074/jbc.275.8.5453; Zhao RX, 1999, BIOCHEM J, V338, P35, DOI 10.1042/0264-6021:3380035; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	66	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29479	29484		10.1074/jbc.M104428200	http://dx.doi.org/10.1074/jbc.M104428200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382784	hybrid			2022-12-27	WOS:000170346000110
J	Furumura, M; Potter, SB; Toyofuku, K; Matsunaga, J; Muller, J; Hearing, VJ				Furumura, M; Potter, SB; Toyofuku, K; Matsunaga, J; Muller, J; Hearing, VJ			Involvement of ITF2 in the transcriptional regulation of melanogenic genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGOUTI-RELATED PROTEIN; MELANOCYTE-SPECIFIC TRANSCRIPTION; WAARDENBURG SYNDROME; IN-VITRO; SIGNAL PROTEIN; MELANOCORTIN RECEPTORS; TYROSINASE GENE; SPLICE VARIANT; CYCLIC-AMP; E-BOX	In response to agouti signal protein, melanocytes switch from producing eumelanin to pheomelanin concomitant with the down-regulation of melanogenic gene transcription. We previously reported that a ubiquitous basic helix-loop-helix transcription factor, known as ITF2, is up-regulated during this switch, and we now report that treatment of melanocytes with melanocyte-stimulating hormone down-regulates expression of ITF2. To more fully characterize the involvement of ITF2 in regulating melanogenic gene transcription, ITF2 sense or antisense constructs were introduced into melan-a melanocytes. Gene and protein expression analyses and luciferase reporter assays using promoters from melanogenic genes showed that up-regulation of ITF2 suppressed melanogenic gene expression as well as the expression of Mitf, a melanocyte-specific transcription factor. In addition, stable ITF2 sense transfectants had significant reductions in pigmentation and a less dendritic phenotype compared with mock transfectants. In contrast, ITF2 antisense-transfected melanocytes were more pigmented and more dendritic. These results demonstrate that up-regulation of ITF2 during the pheomelanin switch is functionally significant and reveal that differential expression of a ubiquitous basic helix-loop-helix transcription factor can modulate expression of melanogenic genes and the differentiation of melanocytes.	NCI, Pigment Cell Biol Sect, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Div Virol, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)	Hearing, VJ (corresponding author), NCI, Pigment Cell Biol Sect, Cell Biol Lab, NIH, Bldg 37,Rm 1B25, Bethesda, MD 20892 USA.							ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; ABDELMALEK Z, 1992, J CELL PHYSIOL, V150, P416, DOI 10.1002/jcp.1041500226; Aberdam E, 1998, J BIOL CHEM, V273, P19560, DOI 10.1074/jbc.273.31.19560; AROCA P, 1993, J BIOL CHEM, V268, P25650; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; Barsh GS, 1996, TRENDS GENET, V12, P299, DOI 10.1016/0168-9525(96)10031-7; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7997; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Chen BB, 1997, J BIOL CHEM, V272, P2459, DOI 10.1074/jbc.272.4.2459; Cone RD, 1996, RECENT PROG HORM RES, V51, P287; Dinulescu DM, 2000, J BIOL CHEM, V275, P6695, DOI 10.1074/jbc.275.10.6695; Furumura M, 1998, P NATL ACAD SCI USA, V95, P7374, DOI 10.1073/pnas.95.13.7374; He L, 2001, NAT GENET, V27, P40, DOI 10.1038/83741; Hearing VJ, 2000, PIGM CELL RES, V13, P23, DOI 10.1034/j.1600-0749.13.s8.7.x; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUNT G, 1995, PIGM CELL RES, V8, P202, DOI 10.1111/j.1600-0749.1995.tb00664.x; JACKSON IJ, 1993, NATURE, V362, P587, DOI 10.1038/362587a0; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; KOBAYASHI T, 1995, J CELL SCI, V108, P2301; Lamoreux ML, 1995, PIGM CELL RES, V8, P263, DOI 10.1111/j.1600-0749.1995.tb00673.x; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; Liu Y, 1998, J BIOL CHEM, V273, P19269, DOI 10.1074/jbc.273.30.19269; Matsunaga N, 2000, BIOCHEM BIOPH RES CO, V270, P176, DOI 10.1006/bbrc.2000.2409; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; Nobukuni Y, 1996, AM J HUM GENET, V59, P76; Ollmann MM, 1999, J BIOL CHEM, V274, P15837, DOI 10.1074/jbc.274.22.15837; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Ollmann MM, 1998, GENE DEV, V12, P316, DOI 10.1101/gad.12.3.316; Opdecamp K, 1997, DEVELOPMENT, V124, P2377; OZEKI H, 1995, J INVEST DERMATOL, V105, P361, DOI 10.1111/1523-1747.ep12320792; Price ER, 1998, J BIOL CHEM, V273, P33042, DOI 10.1074/jbc.273.49.33042; Price ER, 1998, J BIOL CHEM, V273, P17983, DOI 10.1074/jbc.273.29.17983; Prota G., 1992, MELANINS MELANOGENES; Sakai C, 1997, EMBO J, V16, P3544, DOI 10.1093/emboj/16.12.3544; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIRACUSA LD, 1994, TRENDS GENET, V10, P423, DOI 10.1016/0168-9525(94)90112-0; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; Suzuki I, 1997, J INVEST DERMATOL, V108, P838, DOI 10.1111/1523-1747.ep12292572; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Yang YK, 1999, J BIOL CHEM, V274, P14100, DOI 10.1074/jbc.274.20.14100; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YAVUZER U, 1995, ONCOGENE, V10, P123; YOON SO, 1994, J BIOL CHEM, V269, P18453	53	35	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28147	28154		10.1074/jbc.M101626200	http://dx.doi.org/10.1074/jbc.M101626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382753	hybrid			2022-12-27	WOS:000170093400055
J	Nagai, T; Osaki, T; Kawabata, S				Nagai, T; Osaki, T; Kawabata, S			Functional conversion of hemocyanin to phenoloxidase by horseshoe crab antimicrobial peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-PHENOL-OXIDASE; TACHYPLEUS-TRIDENTATUS; BOMBYX-MORI; ARTHROPOD HEMOCYANIN; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; CATECHOL OXIDASE; CDNA CLONING; INSECT; PROTEIN	Arthropod hemocyanins and phenoloxidases serve different physiological functions as oxygen transporters and enzymes involved in defense reactions, respectively. However, they are equipped with a structurally similar oxygen-binding center, We have shown that the clotting enzyme of the horseshoe crab, Tachypleus tridentatus, functionally converts hemocyanin to phenoloxidase by forming a complex without proteolytic cleavage (Nagai, T., and Kawabata, S, (2000) J. Biol, Chem. 275, 35297-35301), Here we show that chitin-binding antimicrobial peptides of the horseshoe crab induce the intrinsic phenoloxidase activity of hemocyanin, Tachyplesin, a major Tachypleus antimicrobial peptide with an amphiphilic structure, converted the hemocyanin to phenoloxidase, Surface plasmon resonance analysis revealed the specific interaction of tachyplesin with hemocyanin at Kd = 3.4 x 10(-6) M. The chemical modification of Trp or Tyr in tachyplesin, but not Lys or Arg, dramatically reduced the affinity to hemocyanin, suggesting that the binding site is located in the hydrophobic face of tachyplesin. Hemocyanin has no affinity with chitin, but it significantly binds to tachyplesin-coated chitin, leading to the expression of phenoloxidase activity. The chitin coated with antimicrobial peptides may serve as a scaffold for the binding of hemocyanin, and the resulting phenoloxidase activity appears to function as a trigger of exoskeleton wound healing.	Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan; Kyushu Univ, Dept Mol Biol, Grad Sch Med Sci, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Kawabata, S (corresponding author), Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan.	skawascb@mbox.nc.kyushu-u.ac.jp		Osaki, Tsukasa/0000-0002-9487-3253				Asano T, 2001, J BIOL CHEM, V276, P11100, DOI 10.1074/jbc.M008426200; Asano T, 2001, J BIOL CHEM, V276, P11113, DOI 10.1074/jbc.M008425200; Ashida M., 1990, P239; ASHIDA M, 1995, P NATL ACAD SCI USA, V92, P10698, DOI 10.1073/pnas.92.23.10698; Ashida Masaaki, 1998, P135; ASPAN A, 1995, P NATL ACAD SCI USA, V92, P939, DOI 10.1073/pnas.92.4.939; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burmester T, 1996, J MOL EVOL, V42, P713, DOI 10.1007/BF02338804; CUATRECASAS P, 1968, J BIOL CHEM, V243, P4787; Daquinag AC, 1999, BIOCHEMISTRY-US, V38, P2179, DOI 10.1021/bi9819834; DAQUINAG AC, 1995, P NATL ACAD SCI USA, V92, P2964, DOI 10.1073/pnas.92.7.2964; Decker H, 1998, J BIOL CHEM, V273, P25889, DOI 10.1074/jbc.273.40.25889; Decker H, 2000, J EXP BIOL, V203, P1777; Eicken C, 1999, CURR OPIN STRUC BIOL, V9, P677, DOI 10.1016/S0959-440X(99)00029-9; FUJIMOTO K, 1995, P NATL ACAD SCI USA, V92, P7769, DOI 10.1073/pnas.92.17.7769; HAZES B, 1993, PROTEIN SCI, V2, P597; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HOPKINS TL, 1992, ANNU REV ENTOMOL, V37, P273, DOI 10.1146/annurev.en.37.010192.001421; Iwanaga S, 1998, J BIOCHEM, V123, P1; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Kawabata S, 1999, DEV COMP IMMUNOL, V23, P391, DOI 10.1016/S0145-305X(99)00019-1; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; Kawabata Shun-ichiro, 1996, P255; KAWABATA T, 1995, P NATL ACAD SCI USA, V92, P7774, DOI 10.1073/pnas.92.17.7774; KAWANO K, 1990, J BIOL CHEM, V265, P15365; KIM JI, 1995, J MOL BIOL, V250, P659, DOI 10.1006/jmbi.1995.0406; Klabunde T, 1998, NAT STRUCT BIOL, V5, P1084, DOI 10.1038/4193; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; LINZEN B, 1985, SCIENCE, V229, P519, DOI 10.1126/science.4023698; MAGNUS KA, 1994, PROTEINS, V19, P302, DOI 10.1002/prot.340190405; Nagai T, 2000, J BIOL CHEM, V275, P29264, DOI 10.1074/jbc.M002556200; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; Nellaiappan K, 1996, COMP BIOCHEM PHYS B, V113, P163, DOI 10.1016/0305-0491(95)02047-0; Okino N, 1995, J BIOL CHEM, V270, P31008, DOI 10.1074/jbc.270.52.31008; Omecinsky DO, 1996, BIOCHEMISTRY-US, V35, P2836, DOI 10.1021/bi952605r; Osaki T, 1999, J BIOL CHEM, V274, P26172, DOI 10.1074/jbc.274.37.26172; PATTHY L, 1975, J BIOL CHEM, V250, P565; RZEPECKI LM, 1989, ANAL BIOCHEM, V179, P375, DOI 10.1016/0003-2697(89)90148-6; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; Salvato B, 1998, BIOCHEMISTRY-US, V37, P14065, DOI 10.1021/bi980879j; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; SHECHTER Y, 1972, BIOCHEMISTRY-US, V11, P653, DOI 10.1021/bi00754a030; SHIGENAGA T, 1993, J BIOCHEM-TOKYO, V114, P307, DOI 10.1093/oxfordjournals.jbchem.a124173; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; Suetake T, 2000, J BIOL CHEM, V275, P17929, DOI 10.1074/jbc.C000184200; SUGITA H, 1979, DEV BIOL, V73, P183, DOI 10.1016/0012-1606(79)90062-9; Sugumaran M, 1998, ADV INSECT PHYSIOL, V27, P229, DOI 10.1016/S0065-2806(08)60014-4; Sugumaran Manickam, 1993, P317; TAKAGI T, 1980, J BIOCHEM, V87, P1785, DOI 10.1093/oxfordjournals.jbchem.a132923; TELFER WH, 1991, ANNU REV ENTOMOL, V36, P205, DOI 10.1146/annurev.en.36.010191.001225; Terwilliger NB, 1999, P NATL ACAD SCI USA, V96, P2013, DOI 10.1073/pnas.96.5.2013; Terwilliger NB, 1999, AM ZOOL, V39, P589; TSUKAMOTO T, 1992, BIOCHEM BIOPH RES CO, V184, P86, DOI 10.1016/0006-291X(92)91161-I; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; WINDER AJ, 1991, EUR J BIOCHEM, V198, P317, DOI 10.1111/j.1432-1033.1991.tb16018.x; Zlateva T, 1996, FEBS LETT, V384, P251, DOI 10.1016/0014-5793(96)00326-2	60	158	173	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27166	27170		10.1074/jbc.M102596200	http://dx.doi.org/10.1074/jbc.M102596200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375396	hybrid			2022-12-27	WOS:000169966900059
J	Wilstermann, AM; Osheroff, N				Wilstermann, AM; Osheroff, N			Positioning the 3 '-DNA terminus for topoisomerase II-mediated religation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN DNA LIGASES; TARGETED DRUGS; CLEAVAGE; MECHANISM; ENZYME; YEAST; SITE; BREAKPOINTS; ETOPOSIDE; LESIONS	Despite the importance of the topoisomerase II DNA cleavage/rejoining cycle to genomic integrity, the mechanistic details of religation are poorly understood. Topoisomerase II utilizes covalent protein-DNA interactions to align the 5'-termini of cleaved DNA for religation, However, because the enzyme does not form covalent bonds with the 3'-DNA termini, the basis for the alignment of the 3'-ends is less clear. Three major possibilities exist. The 3'-termini may be positioned for religation (i) by base pairing to their complementary DNA strands, (ii) by base stacking to the adjacent residues, or (iii) by noncovalent interactions with topoisomerase II. To distinguish between these possibilities, the ability of human topoisomerase II alpha to religate a series of oligonucleotides with altered base pairing or base stacking at their 3'-termini was determined. Substrates containing modifications that disrupted terminal base pairing or base stacking with-out affecting the 3'-terminal base were resealed at wild-type rates. In contrast, substrates that lacked the terminal base (or contained an altered base) displayed very low rates of religation. On the basis of these results, we propose that topoisomerase II positions the 3'-DNA termini for religation through noncovalent protein-DNA contacts.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Hematol Oncol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Robinsin Res Bldg, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09385] Funding Source: Medline; NIGMS NIH HHS [GM3394, GM53960] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson VE, 1999, J BIOL CHEM, V274, P35927, DOI 10.1074/jbc.274.50.35927; Baguley BC, 1998, BBA-GENE STRUCT EXPR, V1400, P213, DOI 10.1016/S0167-4781(98)00137-7; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Berger JM, 1998, BBA-GENE STRUCT EXPR, V1400, P3, DOI 10.1016/S0167-4781(98)00124-9; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; CORBETT AH, 1992, J BIOL CHEM, V267, P683; FELIX CA, 1995, CANCER RES, V55, P4287; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; FREUDENREICH CH, 1993, EMBO J, V12, P2085, DOI 10.1002/j.1460-2075.1993.tb05857.x; FREUDENREICH CH, 1994, P NATL ACAD SCI USA, V91, P11007, DOI 10.1073/pnas.91.23.11007; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; Kingma PS, 1998, J BIOL CHEM, V273, P17999, DOI 10.1074/jbc.273.29.17999; LEHMAN IR, 1974, SCIENCE, V186, P790; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; Liu QY, 1998, J BIOL CHEM, V273, P20252, DOI 10.1074/jbc.273.32.20252; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF NE, 1998, BIOCH BIOPHYS ACTA, V1400; POMMIER Y, 1997, CANC THERAPEUTICS EX, V1, P153; Pommier Y., 1996, CANC CHEMOTHERAPY BI, P435; PRICHARD CE, 1997, NUCLEIC ACIDS RES, V25, P3403; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; SAENGER W, 1984, PRINCIPLES NUCL ACID, P137; SANDER M, 1983, J BIOL CHEM, V258, P8421; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; Xia TB, 1998, BIOCHEMISTRY-US, V37, P14719, DOI 10.1021/bi9809425; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	37	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17727	17731		10.1074/jbc.M100197200	http://dx.doi.org/10.1074/jbc.M100197200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359787	hybrid			2022-12-27	WOS:000168866500016
J	Ruponen, M; Ronkko, S; Honkakoski, P; Pelkonen, J; Tammi, M; Urtti, A				Ruponen, M; Ronkko, S; Honkakoski, P; Pelkonen, J; Tammi, M; Urtti, A			Extracellular glycosaminoglycans modify cellular trafficking of lipoplexes and polyplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE-TRANSFER; SMOOTH-MUSCLE CELLS; DELIVERY SYSTEMS; MAMMALIAN-CELLS; DNA COMPLEXES; IN-VIVO; PROTEOGLYCANS; HYALURONAN; EXPRESSION; HEPARIN	It has been shown that extracellular glycosaminoglycans (GAGs) limit the gene transfer by cationic lipids and polymers. The purpose of this study was to clarify how interactions with anionic GAGS (hyaluronic acid and heparan sulfate) modify the cellular uptake and distribution of lipoplexes and polyplexes. Experiments on cellular DNA uptake and GFP reporter gene expression showed that decreased gene expression can rarely be explained by lower cellular uptake. In most cases, the cellular uptake is not changed by GAG binding to the lipoplexes or polyplexes. Reporter gene expression is decreased or blocked by heparan sulfate, but it is increased by hyaluronic acid; this suggests that intracellular factors are involved. Confocal microscopy experiments demonstrated that extracellular heparan sulfate and hyaluronic acid are taken into cells both with free and DNA-associated carriers. We conclude that extracellular GAGs may alter both the cellular uptake and the intracellular behavior of the DNA complexes.	Univ Kuopio, Dept Pharmaceut, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Clin Microbiol, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Anat, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Dept Pediat, FIN-70211 Kuopio, Finland	University of Eastern Finland; University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital	Ruponen, M (corresponding author), Univ Kuopio, Dept Pharmaceut, POB 1627, FIN-70211 Kuopio, Finland.		Honkakoski, Paavo/AAJ-1278-2020	Honkakoski, Paavo/0000-0002-4332-3577				ARSCOTT PG, 1990, BIOPOLYMERS, V30, P619, DOI 10.1002/bip.360300514; Barzu T, 1996, J CELL PHYSIOL, V167, P8, DOI 10.1002/(SICI)1097-4652(199604)167:1<8::AID-JCP2>3.0.CO;2-T; BEHR JP, 1986, TETRAHEDRON LETT, V27, P5861, DOI 10.1016/S0040-4039(00)85347-2; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; Belting M, 1999, J BIOL CHEM, V274, P19375, DOI 10.1074/jbc.274.27.19375; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P13, DOI 10.1002/jcp.1041240104; DEBALDER AN, 1975, CARBOHYD RES, V44, P251; Evanko SP, 1999, J HISTOCHEM CYTOCHEM, V47, P1331, DOI 10.1177/002215549904701013; Felgner PL, 1997, HUM GENE THER, V8, P511, DOI 10.1089/hum.1997.8.5-511; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; GUSTAFSSON J, 1995, BBA-BIOMEMBRANES, V1235, P305, DOI 10.1016/0005-2736(95)80018-B; HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012; HICKMAN MA, 1994, HUM GENE THER, V5, P1477, DOI 10.1089/hum.1994.5.12-1477; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; Ledley FD, 1996, PHARM RES-DORDR, V13, P1595, DOI 10.1023/A:1016420102549; Lesley J, 2000, J BIOL CHEM, V275, P26967; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; LINDAHL U, 1973, J BIOL CHEM, V248, P7234; Lukacs GL, 2000, J BIOL CHEM, V275, P1625, DOI 10.1074/jbc.275.3.1625; MCGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365; MEYER KB, 1995, GENE THER, V2, P450; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Mosser DD, 1997, BIOTECHNIQUES, V22, P150, DOI 10.2144/97221rr02; Mounkes LC, 1998, J BIOL CHEM, V273, P26164, DOI 10.1074/jbc.273.40.26164; NAGASAWA K, 1978, BIOCHIM BIOPHYS ACTA, V544, P430, DOI 10.1016/0304-4165(78)90110-1; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; Ruponen M, 1999, BBA-BIOMEMBRANES, V1415, P331, DOI 10.1016/S0005-2736(98)00199-0; STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2; Tang MX, 1997, GENE THER, V4, P823, DOI 10.1038/sj.gt.3300454; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Xu YH, 1999, BIOPHYS J, V77, P341, DOI 10.1016/S0006-3495(99)76894-3; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997	36	178	182	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33875	33880		10.1074/jbc.M011553200	http://dx.doi.org/10.1074/jbc.M011553200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11390375	hybrid			2022-12-27	WOS:000170910200080
J	Franzetti, B; Schoehn, G; Ebel, C; Gagnon, J; Ruigrok, RWH; Zaccai, G				Franzetti, B; Schoehn, G; Ebel, C; Gagnon, J; Ruigrok, RWH; Zaccai, G			Characterization of a novel complex from halophilic archaebacteria, which displays chaperone-like activities in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALATE-DEHYDROGENASE; ESCHERICHIA-COLI; SEDIMENTATION ANALYSIS; THERMAL-DENATURATION; MOLECULAR CHAPERONES; HALOFERAX-VOLCANII; ATP HYDROLYSIS; CENTRAL CAVITY; PROTEIN; GROEL	We isolated a protein, P45, from the extreme halophilic archaeon Haloarcula marismortui, which displays molecular chaperone activities in vitro. P45 is a weak ATPase that assembles into a large ring-shaped oligomeric complex comprising about 10 subunits. The protein shows no significant homology to any known protein. P45 forms complexes with halophilic malate dehydrogenase during its salt-dependent denaturation/renaturation and decreases the rate of deactivation of the enzyme in an ATP-dependent manner. Compared with other halophilic proteins, the P45 complex appears to be much less dependent on salt for its various activities or stability. In vivo experiments showed that P45 accumulates when cells are exposed to a low salt environment. We suggest, therefore, that P45 could protect halophilic proteins against denaturation under conditions of cellular hyposaline stress.	Univ Grenoble 1, CEA, CNRS, Inst Biol Struct,Lab Biophys Mol, F-38027 Grenoble 1, France; Univ Grenoble 1, CEA, CNRS, Inst Biol Struct,Lab Enzymol Mol, F-38027 Grenoble, France; EMBL, EMBL Grenoble Outstn, F-38042 Grenoble 9, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); European Molecular Biology Laboratory (EMBL)	Franzetti, B (corresponding author), Univ Grenoble 1, CEA, CNRS, Inst Biol Struct,Lab Biophys Mol, 41 Rue J Horowitz, F-38027 Grenoble 1, France.		Gagnon, Jean/C-3136-2008	Gagnon, Jean/0000-0002-0177-824X; Ebel, Christine/0000-0002-6912-500X; Schoehn, Guy/0000-0002-1459-3201				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; Behlke J, 1997, BIOCHEMISTRY-US, V36, P5149, DOI 10.1021/bi962755h; BONNETE F, 1994, J MOL BIOL, V244, P436, DOI 10.1006/jmbi.1994.1741; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cannac-Caffrey V, 1998, BIOCHIMIE, V80, P1003, DOI 10.1016/S0300-9084(99)80005-4; CENDRIN F, 1993, BIOCHEMISTRY-US, V32, P4308, DOI 10.1021/bi00067a020; Ebel C, 1999, BIOCHEMISTRY-US, V38, P9039, DOI 10.1021/bi9900774; EBEL C, 1992, J MOL BIOL, V223, P361, DOI 10.1016/0022-2836(92)90737-5; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; Ellis RJ, 2000, TRENDS BIOCHEM SCI, V25, P210, DOI 10.1016/S0968-0004(00)01576-0; Franzetti B, 1997, J BACTERIOL, V179, P1180, DOI 10.1128/jb.179.4.1180-1185.1997; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GINZBURG M, 1970, Journal of General Physiology, V55, P187, DOI 10.1085/jgp.55.2.187; GUAGLIARDI A, 1994, PROTEIN SCI, V3, P1436, DOI 10.1002/pro.5560030910; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HARTMAN DJ, 1993, P NATL ACAD SCI USA, V90, P2276, DOI 10.1073/pnas.90.6.2276; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Klumpp M, 1998, FEBS LETT, V430, P73, DOI 10.1016/S0014-5793(98)00541-9; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; Kuo YP, 1997, J BACTERIOL, V179, P6318, DOI 10.1128/jb.179.20.6318-6324.1997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 2000, CURR BIOL, V10, pR260, DOI 10.1016/S0960-9822(00)00432-2; Macario AJL, 1999, MICROBIOL MOL BIOL R, V63, P923, DOI 10.1128/MMBR.63.4.923-967.1999; Madern D, 2000, EXTREMOPHILES, V4, P91, DOI 10.1007/s007920050142; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MEVARECH M, 1977, BIOCHEMISTRY-US, V16, P3781, DOI 10.1021/bi00636a009; Mevarech M, 2000, BIOPHYS CHEM, V86, P155, DOI 10.1016/S0301-4622(00)00126-5; Mojica FJM, 1997, J BACTERIOL, V179, P5471, DOI 10.1128/jb.179.17.5471-5481.1997; NH WV, 2000, P NATL ACAD SCI USA, V97, P12176; Oesterhelt D, 1974, Methods Enzymol, V31, P667; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Ranson NA, 1998, BIOCHEM J, V333, P233, DOI 10.1042/bj3330233; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schuck P, 1999, BIOPHYS J, V76, P2288, DOI 10.1016/S0006-3495(99)77384-4; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; Tokunaga M, 1997, FEMS MICROBIOL LETT, V152, P321, DOI 10.1016/S0378-1097(97)00218-8; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; van den Berg B, 1999, EMBO J, V18, P6927, DOI 10.1093/emboj/18.24.6927; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; Wilson HL, 2000, J BACTERIOL, V182, P1680, DOI 10.1128/JB.182.6.1680-1692.2000; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; ZACCAI G, 1989, J MOL BIOL, V208, P491, DOI 10.1016/0022-2836(89)90512-3; ZACCAI G, 1986, J MOL BIOL, V192, P155, DOI 10.1016/0022-2836(86)90471-7; Zwickl P, 1999, J BIOL CHEM, V274, P26008, DOI 10.1074/jbc.274.37.26008	57	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29906	29914		10.1074/jbc.M102098200	http://dx.doi.org/10.1074/jbc.M102098200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395490	hybrid			2022-12-27	WOS:000170558000041
J	Li, BQ; Lee, MYW				Li, BQ; Lee, MYW			Transcriptional regulation of the human DNA polymerase delta catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; CELL-NUCLEAR-ANTIGEN; SACCHAROMYCES-CEREVISIAE; DOWN-REGULATION; G1 CHECKPOINT; IN-VITRO; EXPRESSION; BINDING; REPLICATION; PROTEIN	The DNA polymerase delta catalytic subunit gene (POLD1) was studied as a transcriptional target of p53. Northern blotting showed that a significantly decreased steady-state level of POLD1 mRNA was associated with increased wild-type p53 expression in cells treated with methyl methanesulfonate. When ectopic wild-type p53 expression was induced to a physiologically relevant level in "tet-off" cultured cells in which p53 expression was tightly regulated by tetracycline, it was found that POLD1 steady-state mRNA was repressed by about 65%. Transient cotransfection experiments using a POLD1 promoter luciferase reporter construct showed that: (i) POLD1 promoter activity was inhibited by transfected wild-type p53 plasmid to a maximum of about 86%; (ii) p53 mediated a large part of the transcriptional repression through a sequence-specific interaction with a site identified as the P4 site of the POLD1 promoter; (iii) tumor-derived p53 mutations in the p53 DNA-binding domain completely abolished the p53 transrepression activity. Moreover, transfection assays demonstrated that p53 was able to repress Sp1-stimulated POLD1 promoter activity and that this repression was largely due to the loss of the sequence-specific interaction between Sp1 protein and the P4 Spl-binding site, which overlaps the P4 p53-binding site. Finally, gel shift assays suggested that p53 competes with Sp1 protein for binding to the P4 sequence of the POLD1 promoter.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Lee, MYW (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31973] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; BARTEK J, 1990, ONCOGENE, V5, P893; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; Carr AM, 2000, SCIENCE, V287, P1765, DOI 10.1126/science.287.5459.1765; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; Halas A, 1997, CURR GENET, V31, P292, DOI 10.1007/s002940050208; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HAO HL, 1992, CHROMOSOMA, V102, pS121, DOI 10.1007/BF02451795; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; Longley MJ, 1997, J BIOL CHEM, V272, P10917; MACLEOD MC, 1993, NUCLEIC ACIDS RES, V21, P1439, DOI 10.1093/nar/21.6.1439; MOORE AL, 1994, CELL GROWTH DIFFER, V5, P485; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; PERREM K, 1995, ONCOGENE, V11, P1299; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wang QJ, 1998, CANCER RES, V58, P5762; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; YAMAGUCHI M, 1994, EUR J BIOCHEM, V221, P227, DOI 10.1111/j.1432-1033.1994.tb18733.x; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZENG XR, 1994, J BIOL CHEM, V269, P24027; ZENG XR, 1994, J BIOL CHEM, V269, P13748; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhang LL, 2000, CANCER RES, V60, P3655; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869; Zhao RB, 2000, GENE DEV, V14, P981; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	57	57	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29729	29739		10.1074/jbc.M101167200	http://dx.doi.org/10.1074/jbc.M101167200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11375983	hybrid			2022-12-27	WOS:000170558000019
J	Zentner, MD; Lin, HH; Deng, HT; Kim, KJ; Shih, HM; Ann, DK				Zentner, MD; Lin, HH; Deng, HT; Kim, KJ; Shih, HM; Ann, DK			Requirement for high mobility group protein HMGI-C interaction with STAT3 inhibitor PIAS3 in repression of a-subunit of epithelial Na+ channel (alpha-ENaC) transcription by Ras activation in salivary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP CHROMOSOMAL-PROTEINS; IFN-BETA GENE; NEOPLASTIC TRANSFORMATION; GLUCOCORTICOID HORMONE; THYROID CELLS; GROWTH-FACTOR; EXPRESSION; KINASE; LUNG; INDUCTION	Previously, we have demonstrated that oxidative stress or Ras/ERK activation leads to the transcriptional repression of alpha -subunit of epithelial Na+ channel (ENaC in lung and salivary epithelial cells. Here, we further investigated the coordinated molecular mechanisms by which alpha -ENaC expression is regulated. Using both stable and transient transfection assays, we demonstrate that the overexpression of high mobility group protein I-C (HMGI-C), a Ras/ERK-inducible HMG-I family member, represses glucocorticoid receptor (GR)/dexamethasone (Dex)-stimulated alpha -ENaC/reporter activity in salivary epithelial cells. Northern analyses further confirm that the expression of endogenous a-ENaC gene in salivary Pa-4 cells is suppressed by an ectopic HMGI-C overexpression. Through yeast two-hybrid screening and co-immunoprecipitation assays from eukaryotic cells, we also discovered the interaction between HMGI-C and PIAS3 (protein inhibitor of activated STAT3 (signal transducer and activator of transcription 3)). A low level of ectopically expressed PIAS3 cooperatively inhibits GR/Dex-dependent alpha -ENaC transcription in the presence of HMGI-C. Reciprocally, HMGI-C expression also coordinately enhances PIAS3-mediated repression of STAT3-dependent transactivation. Moreover, overexpression of antisense HMGI-C construct is capable of reversing the repression mediated by Ras V12 on GR- and STAT3-dependent transcriptional activation. Together, our results demonstrate that Ras/ERK-mediated induction of HMGI-C is required to effectively repress GR/Dex-stimulated transcription of alpha -ENaC gene and STAT3-mediated transactivation. These findings delineate a network of inhibitory signaling pathways that converge on HMGI-C.PIAS3 complex, causally associating Ras/ERK activation with the repression of both GR and STAT3 signaling pathways in salivary epithelial cells.	Univ So Calif, Will Rogers Inst, Pulm Res Ctr, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Will Rogers Inst, Pulm Res Ctr, Dept Med, Los Angeles, CA 90033 USA; Univ So Calif, Will Rogers Inst, Pulm Res Ctr, Dept Physiol & Biophys, Los Angeles, CA 90033 USA; Univ So Calif, Will Rogers Inst, Pulm Res Ctr, Dept Biomed Engn, Los Angeles, CA 90033 USA; Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 11529, Taiwan	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; National Health Research Institutes - Taiwan	Ann, DK (corresponding author), Univ So Calif, Sch Pharm, PSC 210B,1985 Zonal Ave, Los Angeles, CA 90033 USA.	ann@hsc.usc.edu	Shih, Hsiu-Ming/S-7023-2018		NHLBI NIH HHS [HL64365, HL38658] Funding Source: Medline; NIDCR NIH HHS [DE07211, DE10742] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064365, R01HL038658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007211] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; BARTEL P, 1997, YEAST 2 HYDRID SYSTE; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; CHAMPIGNY G, 1994, EMBO J, V13, P2177, DOI 10.1002/j.1460-2075.1994.tb06494.x; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; Himes SR, 2000, J IMMUNOL, V164, P3157, DOI 10.4049/jimmunol.164.6.3157; Jui HY, 2000, J BIOL CHEM, V275, P41124, DOI 10.1074/jbc.M007772200; Ke SA, 1999, PROG BIOPHYS MOL BIO, V71, P405, DOI 10.1016/S0079-6107(98)00051-0; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LI D, 1997, THESIS U SO CALIFORN; Li DX, 1997, J BIOL CHEM, V272, P25062, DOI 10.1074/jbc.272.40.25062; Lin HH, 1999, J BIOL CHEM, V274, P21544, DOI 10.1074/jbc.274.31.21544; Lin HH, 1996, J BIOL CHEM, V271, P27637, DOI 10.1074/jbc.271.44.27637; Quissell DO, 1998, IN VITRO CELL DEV-AN, V34, P58; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; REEVES R, 1990, J BIOL CHEM, V265, P8573; Sayegh R, 1999, J BIOL CHEM, V274, P12431, DOI 10.1074/jbc.274.18.12431; Stewart PM, 1999, LANCET, V353, P1341, DOI 10.1016/S0140-6736(98)06102-9; Stokes JB, 1998, AM J PHYSIOL-CELL PH, V274, pC1699, DOI 10.1152/ajpcell.1998.274.6.C1699; Tallini G, 1999, ADV ANAT PATHOL, V6, P237, DOI 10.1097/00125480-199909000-00001; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Volk KA, 1995, J CLIN INVEST, V96, P2748, DOI 10.1172/JCI118344; Wang HC, 2000, J BIOL CHEM, V275, P8600, DOI 10.1074/jbc.275.12.8600; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Zentner MD, 1998, J BIOL CHEM, V273, P30770, DOI 10.1074/jbc.273.46.30770; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	39	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29805	29814		10.1074/jbc.M103153200	http://dx.doi.org/10.1074/jbc.M103153200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390395	hybrid			2022-12-27	WOS:000170558000028
J	Blouin, C; Wallace, CJA				Blouin, C; Wallace, CJA			Protein matrix and dielectric effect in cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ISO-1-CYTOCHROME-C; CONFORMATION CHANGE; FERRICYTOCHROME-C; WATER MOLECULE; RESOLUTION; HEME; TYROSINE-67; REFINEMENT; STABILITY	The effect of the protein matrix on the standard potential of a buried redox center has been investigated by using a selection of mutants and chemical derivatives in Saccharomyces cerevisiae cytochrome c isoform 1. Assuming only local structural perturbation and no alteration of the iron-ligation chemistry, DeltaE(m)(0,) can be regarded as a measure of the difference in polypeptide solvation of the heme charge, which reflects the dielectric properties of the protein. The evaluation of an apparent dielectric constant (U-exp/U-theo) yields variable, and sometimes even negative, values if U-exp = DeltaG(0)redox. However, some consistent result are observed if U-exp = DeltaH(0)redox with a measured epsilon (Delta Delta Hredox) = 19 +/- 6. The variability is thus attributed to an entropic factor (epsilon (Delta Delta Sredox)) that is investigated using a series of substitutions of Asn(52) and/or Tyr(67). In double mutants Y67F/N521 Y67F/ N52V, where most of the hydrogen bond network in the heme crevice is eliminated, DeltaS(redox). compares to the wild type. This indicates that a fully consistent hydrogen bond network has a similar polarizability as an apolar matrix. We therefore argue that the variability in net dielectric susceptibility arises from conformational polarizability, a factor that is not a function of atomic properties and coordinates and is therefore hard to predict using conventional physical relationships.	Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University	Blouin, C (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada.			Blouin, Christian/0000-0002-4434-4142				Banci L, 1999, J BIOL INORG CHEM, V4, P21, DOI 10.1007/s007750050285; BERGHUIS AM, 1994, J MOL BIOL, V235, P1326, DOI 10.1006/jmbi.1994.1086; BERGHUIS AM, 1992, J MOL BIOL, V223, P959, DOI 10.1016/0022-2836(92)90255-I; BERGHUIS AM, 1994, J MOL BIOL, V236, P786, DOI 10.1006/jmbi.1994.1189; CHURG AK, 1986, BIOCHEMISTRY-US, V25, P1675, DOI 10.1021/bi00355a035; Edholm O, 2000, BIOCHEM BIOPH RES CO, V268, P683, DOI 10.1006/bbrc.2000.2201; Hill T.L., 1986, INTRO STAT THERMODYN; KOSHY TI, 1994, BIOCHEM J, V299, P347, DOI 10.1042/bj2990347; Lett CM, 1996, J BIOL CHEM, V271, P29088, DOI 10.1074/jbc.271.46.29088; LINSKEOCONNELL LI, 1995, BIOCHEMISTRY-US, V34, P7094, DOI 10.1021/bi00021a022; LOUIE GV, 1990, J MOL BIOL, V214, P527, DOI 10.1016/0022-2836(90)90197-T; MOORE GR, 1983, FEBS LETT, V161, P171, DOI 10.1016/0014-5793(83)81001-1; MOORE GR, 1980, BIOCHIM BIOPHYS ACTA, V590, P261, DOI 10.1016/0005-2728(80)90030-4; Qi PXR, 1996, BIOCHEMISTRY-US, V35, P12275, DOI 10.1021/bi961042w; REES DC, 1980, J MOL BIOL, V141, P323, DOI 10.1016/0022-2836(80)90184-9; SCHEJTER A, 1994, BIOCHEM J, V302, P95, DOI 10.1042/bj3020095; Schroeder HR, 1997, BIOCHEM CELL BIOL, V75, P191, DOI 10.1139/bcb-75-3-191; Sharp K, 2001, PROTEIN SCI, V10, P661, DOI 10.1110/ps.37801; SIMONSON T, 1995, P NATL ACAD SCI USA, V92, P1082, DOI 10.1073/pnas.92.4.1082; SIMONSON T, 1991, BIOPHYS J, V59, P670, DOI 10.1016/S0006-3495(91)82282-2; SOBER HA, 1970, HDB BIOCH, pJ41; Springs SL, 2000, BIOCHEMISTRY-US, V39, P6075, DOI 10.1021/bi0001675; TAKANO T, 1981, J MOL BIOL, V153, P95, DOI 10.1016/0022-2836(81)90529-5; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; WALLACE CJA, 1986, BIOPOLYMERS, V25, P2121, DOI 10.1002/bip.360251107; Woods AC, 1996, J BIOL CHEM, V271, P32008, DOI 10.1074/jbc.271.50.32008	26	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28814	28818		10.1074/jbc.M103348200	http://dx.doi.org/10.1074/jbc.M103348200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11375991	hybrid			2022-12-27	WOS:000170346000024
J	Gomez, I; Oltean, DI; Gill, SS; Bravo, A; Soberon, M				Gomez, I; Oltean, DI; Gill, SS; Bravo, A; Soberon, M			Mapping the epitope in cadherin-like receptors involved in Bacillus thuringiensis Cry1A toxin interaction using phage display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; CRYIA(C) DELTA-ENDOTOXIN; BY-PASSING IMMUNIZATION; AMINOPEPTIDASE-N; MANDUCA-SEXTA; INSECTICIDAL TOXIN; CRYSTAL-STRUCTURE; HUMAN-ANTIBODIES; BINDING-PROTEIN; BOMBYX-MORI	In susceptible lepidopteran insects, aminopeptidase N and cadherin-like proteins are the putative receptors for Bacillus thuringiensis (Bt) toxins. Using phage display, we identified a key epitope that is involved in toxin-receptor interaction. Three different scFv molecules that bind Cry1Ab toxin were obtained, and these scFv proteins have different amino acid sequences in the complementary determinant region 3 (CDR3). Binding analysis of these scFv molecules to different members of the Cry1A toxin family and to Escherichia coli clones expressing different Cry1A toxin domains showed that the three selected scFv molecules recognized only domain 11. Heterologous binding competition of Cry1Ab toxin to midgut membrane vesicles from susceptible Manduca sexta larvae using the selected scFv molecules showed that scFv73 competed with Cry1Ab binding to the receptor. The calculated binding affinities (Kd) of scFv73 to Cry1Aa, Cry1Ab, and Cry1Ac toxins are in the range of 20-51 nm. Sequence analysis showed this scFv73 molecule has a CDR3 significantly homologous to a region present in the cadherin-like protein from M. sexta (Bt-R-1), Bombyx mori (Bt-R-175), and Lymantria dispar. We demonstrated that peptides of 8 amino acids corresponding to the CDR3 from scFv73 or to the corresponding regions of Bt-R-1 or Bt-R-175 are also able to compete with the binding of Cry1Ab and Cry1Aa toxins to the Bt-R-1 or Bt-R-175 receptors. Finally, we showed that synthetic peptides homologous to Bt-R-1 and scFv73 CDR3 and the scFv73 antibody decreased the in vivo toxicity of Cry1Ab to M. sexta larvae. These results show that we have identified the amino acid region of Bt-Ri and Bt-R-175 involved in Cry1A toxin interaction.	Univ Nacl Autonoma Mexico, Dept Mol Microbiol, Inst Biotecnol, Cuernavaca 62250, Morelos, Mexico; Univ Calif Riverside, Dept Neurosci & Cell Biol, Riverside, CA 92521 USA	Universidad Nacional Autonoma de Mexico; University of California System; University of California Riverside	Soberon, M (corresponding author), Univ Nacl Autonoma Mexico, Dept Mol Microbiol, Inst Biotecnol, Apdo Postal 510-3, Cuernavaca 62250, Morelos, Mexico.	mario@ibt.unam.mx	de la Parra, Maria Alejandra Bravo/R-6740-2017	Bravo, Alejandra/0000-0002-7573-7475				Aranda E, 1996, J INVERTEBR PATHOL, V68, P203, DOI 10.1006/jipa.1996.0087; ARANTES O, 1991, GENE, V108, P115, DOI 10.1016/0378-1119(91)90495-W; BELFIORE CJ, 1994, BIOCHEM BIOPH RES CO, V200, P359, DOI 10.1006/bbrc.1994.1456; BRAVO A, 1992, J INVERTEBR PATHOL, V60, P237, DOI 10.1016/0022-2011(92)90004-N; Burton SL, 1999, J MOL BIOL, V287, P1011, DOI 10.1006/jmbi.1999.2649; CORTESE R, 1994, TRENDS BIOTECHNOL, V12, P262, DOI 10.1016/0167-7799(94)90137-6; Dean DH, 1996, GENE, V179, P111, DOI 10.1016/S0378-1119(96)00442-8; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; Demangel C, 2000, EUR J BIOCHEM, V267, P2345, DOI 10.1046/j.1432-1327.2000.01244.x; Denolf P, 1997, EUR J BIOCHEM, V248, P748, DOI 10.1111/j.1432-1033.1997.t01-1-00748.x; Flores H, 1997, FEBS LETT, V414, P313, DOI 10.1016/S0014-5793(97)01015-6; GARCZYNSKI SF, 1995, INSECT BIOCHEM MOLEC, V25, P409, DOI 10.1016/0965-1748(94)00072-7; GARCZYNSKI SF, 1991, APPL ENVIRON MICROB, V57, P2816, DOI 10.1128/AEM.57.10.2816-2820.1991; GILL SS, 1995, J BIOL CHEM, V270, P27277, DOI 10.1074/jbc.270.45.27277; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; IHARA H, 1993, BIOSCI BIOTECH BIOCH, V57, P200, DOI 10.1271/bbb.57.200; Jenkins JL, 2000, J BIOL CHEM, V275, P14423, DOI 10.1074/jbc.275.19.14423; Keeton TP, 1997, APPL ENVIRON MICROB, V63, P3419, DOI 10.1128/AEM.63.9.3419-3425.1997; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; KNOWLES BH, 1991, P ROY SOC B-BIOL SCI, V245, P31, DOI 10.1098/rspb.1991.0084; Lee MK, 1996, APPL ENVIRON MICROB, V62, P2845, DOI 10.1128/AEM.62.8.2845-2849.1996; LERECLUS D, 1989, FEMS MICROBIOL LETT, V60, P211, DOI 10.1016/0378-1097(89)90511-9; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; LORENCE A, 1995, FEBS LETT, V360, P217, DOI 10.1016/0014-5793(95)00092-N; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; Luo K, 1997, APPL ENVIRON MICROB, V63, P1024, DOI 10.1128/AEM.63.3.1024-1027.1997; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MASSON L, 1995, J BIOL CHEM, V270, P20309, DOI 10.1074/jbc.270.35.20309; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nagamatsu Y, 1998, BIOSCI BIOTECH BIOCH, V62, P718, DOI 10.1271/bbb.62.718; Nagamatsu Y, 1999, FEBS LETT, V460, P385, DOI 10.1016/S0014-5793(99)01327-7; Nakanishi K, 1999, BBA-PROTEIN STRUCT M, V1432, P57, DOI 10.1016/S0167-4838(99)00086-2; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; Oltean DI, 1999, APPL ENVIRON MICROB, V65, P4760; Pietrantonio P. V., 1996, P345; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; SCHWARTZ JL, 1993, J MEMBRANE BIOL, V132, P53, DOI 10.1007/BF00233051; Soberon M, 2000, FEMS MICROBIOL LETT, V191, P221, DOI 10.1016/S0378-1097(00)00394-3; Szardenings M, 1997, J BIOL CHEM, V272, P27943, DOI 10.1074/jbc.272.44.27943; THOMAS WE, 1983, J CELL SCI, V60, P181; VADLAMUDI RK, 1995, J BIOL CHEM, V270, P5490, DOI 10.1074/jbc.270.10.5490; Valaitis AP, 1995, INSECT BIOCHEM MOLEC, V25, P1143, DOI 10.1016/0965-1748(95)00050-X; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; Yaoi K, 1997, EUR J BIOCHEM, V246, P652, DOI 10.1111/j.1432-1033.1997.t01-1-00652.x	47	88	110	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28906	28912		10.1074/jbc.M103007200	http://dx.doi.org/10.1074/jbc.M103007200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384982	hybrid			2022-12-27	WOS:000170346000037
J	Singla, SI; Hudmon, A; Goldberg, JM; Smith, JL; Schulman, H				Singla, SI; Hudmon, A; Goldberg, JM; Smith, JL; Schulman, H			Molecular characterization of calmodulin trapping by calcium/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAM-KINASE; TRANSITION-STATE; CA2+; AUTOPHOSPHORYLATION; ALPHA; DISSOCIATION; RECOGNITION; ACTIVATION; PHOSPHORYLATION; CA2+-CALMODULIN	Autophosphorylation of alpha -Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) at Thr(286) results in cal. modulin (CaM) trapping, a > 10,000-fold decrease in the dissociation rate of CaM from the enzyme. Here we present the first site-directed mutagenesis study on the dissociation of the high affinity complex between CaM and full-length CaM kinase IEL We measured dissociation kinetics of CaM and CaM kinase II proteins by using a fluorescently modified CaM that is sensitive to binding to target proteins. In low [Ca2+], the phosphorylated mutant kinase F293A and the CaM mutant E120A/M124A exhibited deficient trapping compared with wild-type. In high [Ca2+], the CaM mutations E120A, M124A, and E120A/M124A and the CaM kinase II mutations F293A, F293E, N294A, N294P, and R297E increased dissociation rate constants by factors ranging from 2.3 to 116. We have also identified residues in CaM and CaM kinase II that interact in the trapped state by mutant cycle-based analysis, which suggests that interactions between Phe(293) in the kinase and Glu(120) and Met(124) in CaM specifically stabilize the trapped CaM-CaM kinase II complex. Our studies farther show that Phe(293) and Asn(294) in CaM kinase II play dual roles, because they likely destabilize the low affinity state of CaM complexed to unphosphorylated kinase but stabilize the trapped state of CaM bound to phosphorylated kinase.	Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA; Boston Biomed Res Inst, Watertown, MA 02472 USA	Stanford University; Boston Biomedical Research Institute	Schulman, H (corresponding author), Stanford Univ, Sch Med, Dept Neurobiol, 299 Campus Dr, Stanford, CA 94305 USA.	schulman@cmgm.stanford.edu			NIGMS NIH HHS [GM40600] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040600] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; Chin D, 1997, J BIOL CHEM, V272, P31235, DOI 10.1074/jbc.272.50.31235; Chin D, 2000, CRC METH SIG TRANS, P297; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; FINN BE, 1995, STRUCTURE, V3, P7, DOI 10.1016/S0969-2126(01)00130-7; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; Goldberg JM, 1999, P NATL ACAD SCI USA, V96, P2019, DOI 10.1073/pnas.96.5.2019; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; KENNEDY MB, 1990, COLD SH Q B, V55, P101; Kolodziej SJ, 2000, J BIOL CHEM, V275, P14354, DOI 10.1074/jbc.275.19.14354; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLA ME, 1995, BIOCHEMISTRY-US, V34, P13914, DOI 10.1021/bi00042a024; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; OHYA Y, 1987, EUR J BIOCHEM, V168, P13, DOI 10.1111/j.1432-1033.1987.tb13380.x; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Peersen OB, 1997, PROTEIN SCI, V6, P794; Persechini A, 1996, J BIOL CHEM, V271, P62, DOI 10.1074/jbc.271.1.62; Persechini A, 1999, J BIOL CHEM, V274, P6827, DOI 10.1074/jbc.274.11.6827; Putkey JA, 1996, J BIOL CHEM, V271, P29619, DOI 10.1074/jbc.271.47.29619; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Rich RC, 1998, J BIOL CHEM, V273, P28424, DOI 10.1074/jbc.273.43.28424; Schulman H, 1999, CALCIUM AS A CELLULAR REGULATOR, P311; Shen K, 2000, NAT NEUROSCI, V3, P881, DOI 10.1038/78783; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; Sosnick TR, 1996, PROTEINS, V24, P427; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Teruel MN, 2000, CURR BIOL, V10, P86, DOI 10.1016/S0960-9822(00)00295-5; VALLANO ML, 1989, J NEUROSCI METH, V30, P1, DOI 10.1016/0165-0270(89)90067-8; Waxham MN, 1998, J BIOL CHEM, V273, P17579, DOI 10.1074/jbc.273.28.17579; Xavier KA, 1999, PROTEIN ENG, V12, P79, DOI 10.1093/protein/12.1.79; Yang EY, 1999, J BIOL CHEM, V274, P26199, DOI 10.1074/jbc.274.37.26199	45	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29353	29360		10.1074/jbc.M101744200	http://dx.doi.org/10.1074/jbc.M101744200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384969	hybrid			2022-12-27	WOS:000170346000096
J	Sjogren, T; Hajdu, J				Sjogren, T; Hajdu, J			The structure of an alternative form of Paracoccus pantotrophus cytochrome cd(1) nitrite reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOSPHAERA-PANTOTROPHA; PSEUDOMONAS-AERUGINOSA; HEME; BINDING; CRYSTALLOGRAPHY; REFINEMENT; CATALYSIS; ENZYME; OXIDE	Cytochrome ed(1) nitrite reductase is a bifunctional enzyme, which can catalyze the I-electron reduction of nitrite to nitric oxide and the 4-electron reduction of dioxygen to water. Here we describe the structure of reduced nitrite reductase, crystallized under anaerobic conditions. The structure reveals substantial domain rearrangements with the c domain rotated by 60 degrees and shifted by approximately 20 Angstrom compared with previously known structures from crystals grown under oxidizing conditions. This alternative conformation gives rise to different electron transfer routes between the c and d(1) domains and points to the involvement of elements of very large structural changes in the function in this enzyme. In the present structure, the c heme has a His-69/Met-106 ligation, and this ligation does not change upon oxidation in the crystal. The d(1) heme is penta-coordinated, and the d(1) iron is displaced from the heme plane by 0.5 Angstrom toward the proximal ligand, His-200. After oxidation, the iron moves into the d(1) heme plane. A surprising finding is that although reduced nitrite reductase can be readily oxidized by dioxygen in the new crystal, it cannot turnover with its other substrate, nitrite. The results suggest that the rearrangement of the domains affects catalysis and substrate selectivity.	Univ Uppsala, Dept Biochem, S-75123 Uppsala, Sweden	Uppsala University	Hajdu, J (corresponding author), Univ Uppsala, Dept Biochem, Box 576, S-75123 Uppsala, Sweden.							Allen JWA, 2000, NAT STRUCT BIOL, V7, P885; Baker SC, 1997, J MOL BIOL, V269, P440, DOI 10.1006/jmbi.1997.1070; Brown K, 2000, NAT STRUCT BIOL, V7, P191; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cutruzzola F, 2001, P NATL ACAD SCI USA, V98, P2232, DOI 10.1073/pnas.041365298; Einsle O, 1999, NATURE, V400, P476, DOI 10.1038/22802; FULOP V, 1993, J MOL BIOL, V232, P1211, DOI 10.1006/jmbi.1993.1473; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; George SJ, 2000, J BIOL CHEM, V275, P33231, DOI 10.1074/jbc.M005033200; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Jafferji A, 2000, J BIOL CHEM, V275, P25089, DOI 10.1074/jbc.M001377200; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kobayashi K, 1997, BIOCHEMISTRY-US, V36, P13611, DOI 10.1021/bi971045o; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4243, DOI 10.1021/bi000192a; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nurizzo D, 1997, STRUCTURE, V5, P1157, DOI 10.1016/S0969-2126(97)00267-0; Nurizzo D, 1998, BIOCHEMISTRY-US, V37, P13987, DOI 10.1021/bi981348y; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perutz MF, 1998, ANNU REV BIOPH BIOM, V27, P1, DOI 10.1146/annurev.biophys.27.1.1; Ranghino G, 2000, BIOCHEMISTRY-US, V39, P10958, DOI 10.1021/bi000178y; Sjogren T, 2000, BIOCHEMISTRY-US, V39, P10967, DOI 10.1021/bi000179q; Sjogren T, 2001, J BIOL CHEM, V276, P13072, DOI 10.1074/jbc.M011312200; Steensma E, 2001, J BIOL CHEM, V276, P5846, DOI 10.1074/jbc.M007345200; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; WILLIAMS PA, 1996, THESIS OXFORD U; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	30	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29450	29455		10.1074/jbc.M103657200	http://dx.doi.org/10.1074/jbc.M103657200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11373294	hybrid			2022-12-27	WOS:000170346000107
J	Ashida, H; Anderson, K; Nakayama, J; Maskos, K; Chou, CW; Cole, RB; Li, SC; Li, YT				Ashida, H; Anderson, K; Nakayama, J; Maskos, K; Chou, CW; Cole, RB; Li, SC; Li, YT			A novel endo-beta-galactosidase from Clostridium perfringens that liberates the disaccharide GlcNAc alpha 1 -> 4Gal from glycans specifically expressed in the gastric gland mucous cell-type mucin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; FLAVOBACTERIUM-KERATOLYTICUS; ESCHERICHIA-FREUNDII; MONOCLONAL-ANTIBODY; H-1-NMR SPECTRA; SPECTROSCOPY; PURIFICATION; CLONING; DIFFERENTIATION; RESOLUTION	We found that commercially available sialidases prepared from Clostridium perfringens ATCC10543 were contaminated with an endoglycosidase capable of releasing the disaccharide GlcNAc alpha1->4Gal from glycans expressed in the gastric gland mucous cell-type mucin. We have isolated this enzyme in electrophoretically homogeneous form from the culture supernatant of this organism by ammonium sulfate precipitation followed by affinity chromatography using a Sephacryl S-200 HR column. The enzyme was specifically retained by and eluted from the column with methyl-alpha -Glc. By spectroscopy, the structure of the disaccharide released from porcine gastric mucin by this enzyme was established to be GlcNAc alpha1-->4Gal. The specificity of this enzyme as an endo-beta -galactosidase was established by analyzing the liberation of GlcNAc alpha1-->4Gal from GlcNAc alpha1--->4Gal beta1-->4GlcNAc beta1-->6(GlcNAc alpha1-->4Gal beta1-3)GalNAc-ol by mass spectrometry. Because this novel endo-beta -galactosidase specifically releases the GlcNAc alpha1-->4Gal moiety from porcine gastric mucin, we propose to call this enzyme a GlcNAc alpha1-->4Gal-releasing endo-beta -galactosidase (Endo-beta -Gal(GnGa)). Endo-beta -Gal(GnGa) was found to remove the GlcNAc alpha1-->4Gal epitope expressed in gastric adenocarcinoma AGS cells transfected with alpha1,4-N-acetylglucosaminyltransferase cDNA. Endo-beta -Gal(GnGa) should become useful for studying the structure and function of glycoconjugates containing the terminal GlcNAc alpha1-->4Gal epitope.	Tulane Univ, Hlth Sci Ctr, Sch Med, Dept Biochem, New Orleans, LA 70112 USA; Shinshu Univ, Grad Sch Med, Inst Organ Transplants Reconstruct Med & Tissue E, Matsumoto, Nagano 3908621, Japan; Tulane Univ, Coordinated Instrumentat Facil, New Orleans, LA 70118 USA; Univ New Orleans, Dept Chem, New Orleans, LA 70148 USA	Tulane University; Shinshu University; Tulane University; University of Louisiana System; University of New Orleans	Li, YT (corresponding author), Tulane Univ, Hlth Sci Ctr, Sch Med, Dept Biochem, SL43,1430 Tulane Ave, New Orleans, LA 70112 USA.		Ashida, Hisashi/HCI-0293-2022	Ashida, Hisashi/0000-0001-5844-4075	NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson K, 2000, ANAL BIOCHEM, V287, P337, DOI 10.1006/abio.2000.4829; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BORRIELLO SP, 1995, CLIN INFECT DIS, V20, pS242, DOI 10.1093/clinids/20.Supplement_2.S242; BOX A, 1986, J AM CHEM SOC, V108, P2093; CASSIDY JT, 1965, J BIOL CHEM, V240, P3501; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; FUKUDA MN, 1976, J BIOL CHEM, V251, P6218; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; Honda T, 1998, AM J CLIN PATHOL, V109, P423; Ishihara K, 1996, BIOCHEM J, V318, P409, DOI 10.1042/bj3180409; Ishii K, 1998, VIRCHOWS ARCH, V432, P315, DOI 10.1007/s004280050172; Jung E, 1998, EUR J BIOCHEM, V253, P517, DOI 10.1046/j.1432-1327.1998.2530517.x; KATSUYAMA T, 1978, J HISTOCHEM CYTOCHEM, V26, P233, DOI 10.1177/26.4.351046; KITAMIKADO M, 1981, J BIOL CHEM, V256, P3906; KOCHETKOV NK, 1976, EUR J BIOCHEM, V67, P129, DOI 10.1111/j.1432-1033.1976.tb10641.x; Leng L, 1998, GENE, V222, P187, DOI 10.1016/S0378-1119(98)00496-X; LI SC, 1970, J BIOL CHEM, V245, P5153; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LLOYD KO, 1969, J IMMUNOL, V102, P1354; MOORE GL, 1969, ANAL BIOCHEM, V32, P122, DOI 10.1016/0003-2697(69)90111-0; NAKAGAWA H, 1971, B JPN SOC SCI FISH, V37, P919; NAKAGAWA H, 1980, J BIOL CHEM, V255, P5955; Nakamura N, 1998, J HISTOCHEM CYTOCHEM, V46, P793, DOI 10.1177/002215549804600702; Nakayama J, 1999, P NATL ACAD SCI USA, V96, P8991, DOI 10.1073/pnas.96.16.8991; NIILO L, 1980, CAN VET J, V21, P141; NORWOOD TJ, 1990, J MAGN RESON, V87, P488, DOI 10.1016/0022-2364(90)90306-T; Ogawa H, 2000, J BIOL CHEM, V275, P19368, DOI 10.1074/jbc.M001888200; Ota H, 1998, HISTOCHEM CELL BIOL, V110, P113, DOI 10.1007/s004180050272; Previato JO, 1998, J BIOL CHEM, V273, P14982, DOI 10.1074/jbc.273.24.14982; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; ROOD JI, 1991, MICROBIOL REV, V55, P621, DOI 10.1128/MMBR.55.4.621-648.1991; SCUDDER P, 1983, BIOCHEM J, V213, P485, DOI 10.1042/bj2130485; SHAKA AJ, 1983, J MAGN RESON, V51, P169, DOI 10.1016/0022-2364(83)90117-8; SMITH LDS, 1979, REV INFECT DIS, V1, P254; Sterne M, 1981, Br Vet J, V137, P443; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; TAKASAKI S, 1976, J BIOL CHEM, V251, P3603; VANHALBEEK H, 1983, BIOCHIM BIOPHYS ACTA, V747, P107, DOI 10.1016/0167-4838(83)90128-0	39	17	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28226	28232		10.1074/jbc.M103589200	http://dx.doi.org/10.1074/jbc.M103589200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382776	hybrid			2022-12-27	WOS:000170093400066
J	Li, N; Zhang, WP; Wan, T; Zhang, J; Chen, TY; Yu, YZ; Wang, JL; Cao, XT				Li, N; Zhang, WP; Wan, T; Zhang, J; Chen, TY; Yu, YZ; Wang, JL; Cao, XT			Cloning and characterization of Siglec-10, a novel sialic acid binding member of the Ig superfamily, from human dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; PROTEIN-TYROSINE PHOSPHATASES; MOLECULAR-CLONING; INHIBITORY RECEPTOR; SIALOADHESIN FAMILY; NEGATIVE REGULATOR; B-CELLS; CD22; IDENTIFICATION; CD33	The Siglecs (sialic acid-binding Ig-like lectins) are a subfamily of I-type lectins, which specifically recognize sialic acids. Nine members of the family have been identified thus far. We have obtained a novel cDNA clone from a human dendritic cell cDNA library encoding a protein with sequence and structural features of the Siglec family, hence designated as Siglec-10. The full-length Siglec-10 cDNA encodes a type I transmembrane protein containing four extracellular immunoglobulinlike domains, a transmembrane region, and a cytoplasmic tail with two classical immunoreceptor tyrosine-based inhibitory motifs. The N-terminal V-set Ig domain has most of the amino acid residues typical of the Siglecs. Siglec-10 shows the closest homology to Siglec-5 and Siglec-3/CD33. Various cells and cell lines including monocytes and dendritic cells express Siglec-10. High levels of mRNA expression were seen in peripheral blood leukocytes, spleen, and liver. When expressed on COS-7 cells, Siglec-10 was able to bind human red blood cells and soluble sialoglycoconjugates in a sialic acid-dependent manner. The identification of Siglec-1-0 as a new Siglec family member and its expression profile, together with its sialic acid-dependent binding capacity, suggest that it may be involved in cell-cell recognition by interacting with sialylated ligands expressed on specific cell populations.	Second Mil Med Univ, Inst Immunol, Shanghai 200433, Peoples R China; Zhejiang Univ, Inst Immunol, Hangzhou 310031, Zhejiang, Peoples R China	Naval Medical University; Zhejiang University	Cao, XT (corresponding author), Second Mil Med Univ, Inst Immunol, 800 Xiangyin Rd, Shanghai 200433, Peoples R China.	caoxt@public3.sta.net.cn	yu, yizhi/ADP-7854-2022					Angata T, 2000, J BIOL CHEM, V275, P22127, DOI 10.1074/jbc.M002775200; Angata T, 2000, GLYCOBIOLOGY, V10, P431, DOI 10.1093/glycob/10.4.431; Bolland S, 1999, ADV IMMUNOL, V72, P149, DOI 10.1016/S0065-2776(08)60019-X; Borges L, 1997, J IMMUNOL, V159, P5192; Cao XT, 2000, J IMMUNOL, V165, P2588, DOI 10.4049/jimmunol.165.5.2588; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker P R, 1998, Glycobiology, V8, pv; Crocker PR, 1996, BIOCHEM SOC T, V24, P150, DOI 10.1042/bst0240150; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Dupont B, 1997, TISSUE ANTIGENS, V49, P557, DOI 10.1111/j.1399-0039.1997.tb02802.x; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; Foussias G, 2000, GENOMICS, V67, P171, DOI 10.1006/geno.2000.6208; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; JARAMILLO ML, 1994, J BIOL CHEM, V269, P27240; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; Kikly KK, 2000, J ALLERGY CLIN IMMUN, V105, P1093, DOI 10.1067/mai.2000.107127; LAW CL, 1995, J IMMUNOL, V155, P3368; May VR, 1998, NEUROREHABILITATION, V11, P1; Munday J, 2001, BIOCHEM J, V355, P489, DOI 10.1042/0264-6021:3550489; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; Newman PJ, 1999, J CLIN INVEST, V103, P5, DOI 10.1172/JCI5928; Nicoll G, 1999, J BIOL CHEM, V274, P34089, DOI 10.1074/jbc.274.48.34089; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; PEDRAZA L, 1990, J CELL BIOL, V111, P2651, DOI 10.1083/jcb.111.6.2651; PEIPER SC, 1988, BLOOD, V72, P314; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; SGROI D, 1993, J BIOL CHEM, V268, P7011; Takei Y, 1997, CYTOGENET CELL GENET, V78, P295, DOI 10.1159/000134676; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tropak MB, 1997, J NEUROCHEM, V68, P1753; Ulyanova T, 1999, EUR J IMMUNOL, V29, P3440, DOI 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.3.CO;2-3; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; Vely F, 1997, J IMMUNOL, V159, P2075; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; Wende H, 1999, MAMM GENOME, V10, P154, DOI 10.1007/s003359900961; Zhang JQ, 2000, J BIOL CHEM, V275, P22121, DOI 10.1074/jbc.M002788200	49	73	78	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28106	28112		10.1074/jbc.M100467200	http://dx.doi.org/10.1074/jbc.M100467200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11358961	hybrid			2022-12-27	WOS:000170093400049
J	Potapova, O; Basu, S; Mercola, D; Holbrook, NJ				Potapova, O; Basu, S; Mercola, D; Holbrook, NJ			Protective role for c-Jun in the cellular response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ACTIVATION DOMAIN; CYCLE PROGRESSION; INDUCED APOPTOSIS; PROTEIN-KINASE; MEK KINASE-1; PHOSPHORYLATION; INDUCTION; AP-1; JNK	c-Jun, a member of the activation protein 1 (AP-1) family of transcription factors, has been implicated in the regulation of many important biological processes including cell cycle progression, transformation, differentiation, and apoptosis. Accordingly, its expression and function are upregulated in response to diverse stimuli including mitogens and a wide range of stresses. Transcriptional activation of the e-Jun protein is dependent on its phosphorylation at Ser-63 and Ser-73, process mediated by c-Jun N-terminal kinase. Active c-Jun is required for AP-1 transactivation and c-Jun-mediated transformation, but its role during stress remains unclear as both pro-apoptotic and pro-survival effects of e-Jun have been observed. Here we investigated the importance of c-Jun N-terminal phosphorylation in influencing the sensitivity of human T98G glioblastoma cells to a variety of cytotoxic agents. Stable expression of a nonphosphorylatable dominant negative protein c-Jun(S63A,S73A) markedly inhibited the activation of AP-1-driven transcription and greatly increased the cytotoxic effects of DNA-damaging agents associated with enhanced apoptosis. However, the same cells expressing the mutant Jun protein did not differ from parental cells in their sensitivity to several non-DNA-damaging cytotoxic agents. Our results suggest that activated e-Jun has a selective role in protecting human tumor cells from apoptosis induced by DNA damage.	NIA, Cell Stress & Aging Sect, Cellular & Mol Biol Lab, Baltimore, MD 21224 USA; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Holbrook, NJ (corresponding author), NIA, Cell Stress & Aging Sect, Cellular & Mol Biol Lab, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		mercola, dan/L-4182-2013; Roszak, Joanna/F-4003-2010	mercola, dan/0000-0002-0281-9840; 				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bost F, 2000, METHOD ENZYMOL, V314, P342; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fritz G, 1999, ONCOGENE, V18, P1033, DOI 10.1038/sj.onc.1202394; GALANG CK, 1994, ONCOGENE, V9, P2913; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang Y, 2000, J BIOL CHEM, V275, P18234, DOI 10.1074/jbc.M909431199; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; OLIVE PL, 1990, JNCI-J NATL CANCER I, V82, P779, DOI 10.1093/jnci/82.9.779; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Pourquier P, 1998, BIOCHEM PHARMACOL, V55, P1963, DOI 10.1016/S0006-2952(98)00006-9; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056	32	95	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28546	28553		10.1074/jbc.M102075200	http://dx.doi.org/10.1074/jbc.M102075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11352915	hybrid			2022-12-27	WOS:000170093400107
J	Tatsuki, M; Mori, H				Tatsuki, M; Mori, H			Phosphorylation of tomato 1-aminocyclopropane-1-carboxylic acid synthase, LE-ACS2, at the C-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYLENE BIOSYNTHESIS; MESSENGER-RNA; KEY ENZYME; INDUCTION; ELICITOR; PROTEIN; CLONING; PLANTS; CELLS; METHIONINE	1-Aminocyclopropane-1-carboxylic acid synthase is a key enzyme in the ethylene biosynthesis pathway. Recent studies raise the possibility that 1-aminocyclopropane-1-carboxylic acid synthase (ACS) is regulated not only transcriptionally but also post-translationally. To elucidate post-translational ACS regulation, we analyzed the modification of LE-ACS2 protein, a wound-inducible isozyme in the ACS family, in tomato fruit (Lycopersicon esculentum L.) using an anti-LE-ACS2 antibody. We detected phosphorylated LE-ACS2 at 55-kDa using immunoprecipitation from an extract of wounded fruit fed with [P-32]inorganic phosphate. Analysis of LE-ACS2 phosphoamino acids indicated that serine residue(s) were phosphorylated. In vitro phosphorylation analyses using site-directed mutagenesis of recombinant LE-ACS2 as a substrate demonstrate that serine 460 located at the C-terminal region of ACS is phosphorylated. During tomato ripening stages, expression of both LE-ACS2 and LE-ACS4 mRNA increased. LE-ACS4, however, was not phosphorylated in vitro. These results suggest that ACS isozymes have different post-translational regulatory mechanisms, such as phosphorylation.	Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Aichi 4648601, Japan	Nagoya University	Mori, H (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Furo Cho, Aichi 4648601, Japan.	morihito@agr.nagoya-u.ac.jp						Abeles F, 1992, ETHYLENE PLANT BIOL; ADAMS DO, 1979, P NATL ACAD SCI USA, V76, P170, DOI 10.1073/pnas.76.1.170; Capitani G, 1999, J MOL BIOL, V294, P745, DOI 10.1006/jmbi.1999.3255; CHAPPELL J, 1984, PLANTA, V161, P475, DOI 10.1007/BF00394581; EDELMAN L, 1990, PLANTA, V182, P635, DOI 10.1007/BF02341042; FELIX G, 1991, PLANT PHYSIOL, V97, P19, DOI 10.1104/pp.97.1.19; Hardie D. G., 1996, V39, P3; ICHIHARA Y, 1993, GENE, V130, P153, DOI 10.1016/0378-1119(93)90361-6; Im KH, 2000, PLANT PHYSIOL, V123, P463, DOI 10.1104/pp.123.2.463; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; KING MM, 1983, J BIOL CHEM, V258, P9925; Li N, 1996, FEBS LETT, V378, P286, DOI 10.1016/0014-5793(95)01464-0; LI N, 1994, J BIOL CHEM, V269, P6908; LIZADA MCC, 1979, ANAL BIOCHEM, V100, P140, DOI 10.1016/0003-2697(79)90123-4; NAKAJIMA N, 1988, PLANT CELL PHYSIOL, V29, P989; Oetiker JH, 1997, PLANT MOL BIOL, V34, P275, DOI 10.1023/A:1005800511372; OLSON DC, 1995, J BIOL CHEM, V270, P14056, DOI 10.1074/jbc.270.23.14056; Sambrook J., 2001, MOL CLONING LAB MANU; SATO T, 1991, J BIOL CHEM, V266, P3752; SATO T, 1989, P NATL ACAD SCI USA, V86, P6621, DOI 10.1073/pnas.86.17.6621; SATOH S, 1989, PLANT PHYSIOL, V91, P1036, DOI 10.1104/pp.91.3.1036; SPANU P, 1994, PLANT PHYSIOL, V106, P529, DOI 10.1104/pp.106.2.529; Tatsuki M, 1999, PLANT CELL PHYSIOL, V40, P709, DOI 10.1093/oxfordjournals.pcp.a029597; Tuomainen J, 1997, PLANT J, V12, P1151, DOI 10.1046/j.1365-313X.1997.12051151.x; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VAN DER STRAETEN D, 1990, P NATL ACAD SCI USA, V87, P4859, DOI 10.1073/pnas.87.12.4859; Vogel JP, 1998, P NATL ACAD SCI USA, V95, P4766, DOI 10.1073/pnas.95.8.4766; Woeste KE, 1999, PLANT PHYSIOL, V119, P521, DOI 10.1104/pp.119.2.521; YOSHII H, 1981, PLANT CELL PHYSIOL, V22, P369; ZAREMBINSKI TI, 1994, PLANT MOL BIOL, V26, P1579, DOI 10.1007/BF00016491	31	118	127	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28051	28057		10.1074/jbc.M101543200	http://dx.doi.org/10.1074/jbc.M101543200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375393	hybrid			2022-12-27	WOS:000170093400042
J	Wiederschain, D; Gu, JJ; Yuan, ZM				Wiederschain, D; Gu, JJ; Yuan, ZM			Evidence for a distinct inhibitory factor in the regulation of p53 functional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; APOPTOTIC RESPONSE; MUTANT P53; IDENTIFICATION; ACTIVATION; PROTEIN; PEPTIDE; DOMAINS; GROWTH; REGION	Under normal conditions, tumor suppressor protein p53 exists in the cell in its latent form and is unable to function as a transcription factor. The allosteric model of p53 regulation postulates that the extreme portion of p53 carboxyl terminus (aa 364-393) binds to the core domain of the protein, thereby abrogating specific DNA binding in that region. In this study we propose an alternative mechanism of p53 functional regulation, which involves a separate molecule acting in trans to inhibit p53 transcriptional activity. Through the use of chimeric proteins of p53, p63 gamma and p73 beta, we show that the extreme COOH-terminal domain of p53 exerts a powerful and specific inhibitory effect on the p73- and p63-driven expression of a reporter gene. Moreover, fusion of p53 extreme COOH terminus to a completely unrelated transcriptional activator Gal4-VP16 also results in significant inhibition of transactivation. activity. Since p73, p63, or Gal4-VP16 cannot associate with any part of the p53 molecule, we conclude that p53(aa 364-393) represses transcriptional activity of chimeric proteins and p53 itself through the binding of external negative modulator(s) in that region and not by the allosteric mechanism of regulation. In accordance with the "distinct inhibitor" hypothesis, the activity of wild type p53 is substantially increased by overexpression of chimeric proteins bearing p53(aa 364-393), which might be due to the competitive removal of trancriptional inhibitor(s). Our findings provide the basis for the identification of such negative modulators of p53 transcriptional activity.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Harvard Univ, Grad Sch Arts & Sci, Program Biol Sci Publ Hlth, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Bldg 1,Rm 209,665 Huntington Ave, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu						Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zotchev SB, 2000, NUCLEIC ACIDS RES, V28, P4005, DOI 10.1093/nar/28.20.4005	22	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27999	28005		10.1074/jbc.M102400200	http://dx.doi.org/10.1074/jbc.M102400200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382762	hybrid			2022-12-27	WOS:000170093400035
J	Zhang, CX; Reiter, C; Eiserich, JP; Boersma, B; Parks, DA; Beckman, JS; Barnes, S; Kirk, M; Baldus, S; Darley-Usmar, VM; White, CR				Zhang, CX; Reiter, C; Eiserich, JP; Boersma, B; Parks, DA; Beckman, JS; Barnes, S; Kirk, M; Baldus, S; Darley-Usmar, VM; White, CR			L-arginine chlorination products inhibit endothelial nitric oxide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS EMPLOY; ALPHA-AMINO-ACIDS; ISCHEMIA-REPERFUSION; DEPENDENT RELAXATION; REACTIVE ALDEHYDES; MYELOPEROXIDASE; MECHANISMS; INJURY; INFLAMMATION; DYSFUNCTION	The myeloperoxidase-derived oxidant hypochlorous acid (HOCl) is thought to contribute to endothelial dysfunction, but the mechanisms underlying this inhibitory effect are unknown. The present study tested the hypothesis that HOCl and L-arginine (L-Arg) react to form novel compounds that adversely affect endothelial function by inhibiting nitric oxide (NO) formation. Using spectrophotometric techniques, we found that HOCl and L-Arg react rapidly (k = 7.1 x 10(5) M-1 s(-1)) to form two major products that were identified by mass spectrometry as monochlorinated and dichlorinated adducts of L-Arg. Pretreatment of bovine aortic endothelial cells with the chlorinated L-Arg metabolites (Cl-L-Arg) inhibited the A23187-induced formation of the NO metabolites nitrate (NO3-) and nitrite (NO2-) in a concentration-dependent manner. Preincubation of rat aortic ring segments with Cl-L-Arg resulted in concentration-dependent inhibition of acetylcholine-induced relaxation, In contrast, blood vessels relaxed normally to the endothelium-independent vasodilator sodium nitroprusside, In vivo administration of Cl-L-Arg to anesthetized rats increased carotid artery vascular resistance. A greater than 10-fold excess of L-Arg was required to reverse the inhibitory effects of Cl-L-Arg in vivo and in vitro. Reaction of HOCl with D-arginine (D-Arg) did not result in the formation of inhibitory products. These results suggest that HOCl reacts with L-Arg to form chlorinated products that act as nitric-oxide synthase inhibitors.	Univ Alabama, Ctr Free Rad Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Vasc Biol & Hypertens Program, Birmingham, AL 35294 USA; Univ Alabama, Dept Anesthesiol, Birmingham, AL 35294 USA; Univ Alabama, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Comprehens Canc, Mass Spectrometry Shared Facil, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	White, CR (corresponding author), Univ Alabama, Ctr Free Rad Biol, Zeigler Res Bldg,Rm 1046, Birmingham, AL 35294 USA.		Boersma, Brenda/A-9270-2009; zhang, xiang chun/HCH-7063-2022	Boersma, Brenda/0000-0002-8992-2735; zhang, xiang chun/0000-0001-8303-6495; Darley-Usmar, Victor/0000-0001-8921-7086	NCI NIH HHS [P30 CA13148] Funding Source: Medline; NCRR NIH HHS [S10RR06487] Funding Source: Medline; NHLBI NIH HHS [HL-03812, HL-54815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006487] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boger RH, 1998, CIRCULATION, V98, P1842, DOI 10.1161/01.CIR.98.18.1842; Cameron EM, 1998, SHOCK, V9, P184, DOI 10.1097/00024382-199803000-00005; Campbell B, 2000, BRIT J PHARMACOL, V129, P71, DOI 10.1038/sj.bjp.0703010; Conner EM, 1996, NUTRITION, V12, P274, DOI 10.1016/S0899-9007(96)00000-8; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; FLISS H, 1988, MOL CELL BIOCHEM, V84, P177, DOI 10.1007/BF00421053; FOLKES LK, 1995, ARCH BIOCHEM BIOPHYS, V323, P120, DOI 10.1006/abbi.1995.0017; Friese RS, 1996, J SURG RES, V63, P23, DOI 10.1006/jsre.1996.0216; Fullerton DA, 1996, AM J PHYSIOL-LUNG C, V271, pL326, DOI 10.1152/ajplung.1996.271.2.L326; Granger DN, 1999, MICROCIRCULATION, V6, P167; Grisham MB, 1998, FREE RADICAL BIO MED, V25, P404, DOI 10.1016/S0891-5849(98)00094-X; Hayward R, 1998, AM J PHYSIOL-HEART C, V275, pH23, DOI 10.1152/ajpheart.1998.275.1.H23; Hazen SL, 1998, BIOCHEMISTRY-US, V37, P6864, DOI 10.1021/bi972449j; Hazen SL, 1997, FREE RADICAL BIO MED, V23, P909, DOI 10.1016/S0891-5849(97)00084-1; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; Heinecke JW, 1999, J LAB CLIN MED, V133, P321, DOI 10.1016/S0022-2143(99)90061-6; HOBBS AJ, 1999, HAEMODYNAMIC EFFECTS, P52; Huang YI, 1998, J LEUKOCYTE BIOL, V64, P322, DOI 10.1002/jlb.64.3.322; Ito A, 1999, CIRCULATION, V99, P3092, DOI 10.1161/01.CIR.99.24.3092; Jorge PAR, 1997, EXP TOXICOL PATHOL, V49, P147; LEIPERT B, 1992, AM J PHYSIOL, V262, pH1676, DOI 10.1152/ajpheart.1992.262.6.H1676; Marcinkiewicz J, 1997, IMMUNOPHARMACOLOGY, V37, P35, DOI 10.1016/S0162-3109(96)00168-3; McKenna R, 1996, SHOCK, V6, P106, DOI 10.1097/00024382-199608000-00005; Miyazaki H, 1999, CIRCULATION, V99, P1141, DOI 10.1161/01.CIR.99.9.1141; Nauseef WM, 1998, J MOL MED-JMM, V76, P661, DOI 10.1007/s001090050265; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; SCHRAUFSTATTER IU, 1990, J CLIN INVEST, V85, P554, DOI 10.1172/JCI114472; Shabani F, 1998, FREE RADICAL RES, V28, P115, DOI 10.3109/10715769809065797; Thomas E L, 1986, Methods Enzymol, V132, P569; Vinten-Johansen J, 1999, ANN NY ACAD SCI, V874, P354, DOI 10.1111/j.1749-6632.1999.tb09251.x; Wang P, 1999, CRIT CARE MED, V27, P959, DOI 10.1097/00003246-199905000-00035; Whiteman M, 1999, BRIT J PHARMACOL, V126, P1646, DOI 10.1038/sj.bjp.0702465; Whitman SC, 1999, ARTERIOSCL THROM VAS, V19, P1238, DOI 10.1161/01.ATV.19.5.1238; WONG JM, 1995, NITRIC OXIDE BIOCH M, P155	34	70	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27159	27165		10.1074/jbc.M100191200	http://dx.doi.org/10.1074/jbc.M100191200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375389	hybrid			2022-12-27	WOS:000169966900058
J	Izem, L; Morton, RE				Izem, L; Morton, RE			Cholesteryl ester transfer protein biosynthesis and cellular cholesterol homeostasis are tightly interconnected	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-TRANSFER PROTEIN; MESSENGER-RNA LEVELS; HORMONE-SENSITIVE LIPASE; HUMAN ADIPOSE-TISSUE; STEROL UP-REGULATION; TRANSGENIC MICE; HUMAN-PLASMA; GENE-EXPRESSION; MONOCLONAL-ANTIBODY; RABBIT PLASMA	Cholesteryl ester transfer protein (CETP) mediates triglyceride and cholesteryl ester (CE) transfer between lipoproteins, and its activity is strongly modulated by dietary cholesterol. To better understand the regulation of CETP synthesis and the relationship between CETP levels and cellular lipid metabolism, we selected the SW872 adipocytic cell line as a model. These cells secrete CETP in a time-dependent manner at levels exceeding those observed for Caco-2 or HepG2 cells. The addition of LDL, 25OH-cholesterol, oleic acid, or acetylated LDL to SW872 cells increased CETP secretion (activity and mass) up to 6-fold. In contrast, CETP production was decreased by almost 60% after treatment with lipoprotein-deficient serum or P-cyclodextrin, These effects, which were paralleled by changes in CETP mRNA, show that CETP biosynthesis in SW872 cells directly correlates with cellular lipid status. To investigate a possible, reciprocal relationship between CETP expression and cellular lipid homeostasis, CETP biosynthesis in SW872 cells was suppressed with CETP antisense oligonucleotides. Antisense oligonucleotides reduced CETP secretion (activity and mass) by 60% compared with sense-treated cells. When CETP synthesis was suppressed for 24 h, triglyceride synthesis was unchanged, but cholesterol biosynthesis was reduced by 20%, and acetate incorporation into CE increased 31%, After 3 days of suppressed CETP synthesis, acetate incorporation into the CE pool increased 3-fold over control. This mirrored a similar increase in CE mass. The efflux of free cholesterol to HDL was the same in sense and antisense-treated cells; however, HDL-induced CE hydrolysis in antisense-treated cells was diminished a-fold even though neutral CE hydrolase activity was unchanged. Thus, CETP-compromised SW872 cells display a phenotype characterized by inefficient mobilization of CE stores leading to CE accumulation. These results strongly suggest that CETP expression levels contribute to normal cholesterol homeostasis in adipocytic cells. Overall, these studies demonstrate that lipid homeostasis and CETP expression are tightly coupled.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Morton, RE (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave,NC10, Cleveland, OH 44195 USA.				NHLBI NIH HHS [HL60934] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060934] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1992, J BIOL CHEM, V267, P22336; Atger VM, 1997, J CLIN INVEST, V99, P773, DOI 10.1172/JCI119223; Benoist F, 1997, J BIOL CHEM, V272, P23572, DOI 10.1074/jbc.272.38.23572; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Bruce C, 1998, ANNU REV NUTR, V18, P297, DOI 10.1146/annurev.nutr.18.1.297; Chouinard RA, 1998, J BIOL CHEM, V273, P22409, DOI 10.1074/jbc.273.35.22409; CLEVIDENCE BA, 1984, ARTERIOSCLEROSIS, V4, P196, DOI 10.1161/01.ATV.4.3.196; Dessi M, 1997, MOL CELL BIOCHEM, V177, P107, DOI 10.1023/A:1006823601032; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; FAUST RA, 1987, ARTERIOSCLEROSIS, V7, P267, DOI 10.1161/01.ATV.7.3.267; FAUST RA, 1988, J BIOL CHEM, V263, P8786; FRAENKELCONRAT H, 1957, METHOD ENZYMOL, V4, P247, DOI 10.1016/0076-6879(57)04059-8; Gauthier B, 1999, ATHEROSCLEROSIS, V142, P301, DOI 10.1016/S0021-9150(98)00245-7; HASHIMOTO S, 1984, BIOCHEM BIOPH RES CO, V120, P586, DOI 10.1016/0006-291X(84)91295-6; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HESLER CB, 1987, J BIOL CHEM, V262, P2275; INAZU A, 1992, BIOCHEMISTRY-US, V31, P2352, DOI 10.1021/bi00123a021; JIANG XC, 1992, J CLIN INVEST, V90, P1290, DOI 10.1172/JCI115993; JIANG XC, 1991, J BIOL CHEM, V266, P4631; JIANG XC, 1993, J BIOL CHEM, V268, P27406; KRAEMER FB, 1993, J LIPID RES, V34, P663; KURUSHIMA H, 1995, BBA-LIPID LIPID MET, V1258, P251, DOI 10.1016/0005-2760(95)00122-S; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; MARTIN LJ, 1993, J LIPID RES, V34, P437; MCPHERSON R, 1991, ARTERIOSCLER THROMB, V11, P797, DOI 10.1161/01.ATV.11.4.797; MENDEZ AJ, 1986, ANAL BIOCHEM, V156, P386, DOI 10.1016/0003-2697(86)90269-1; MORTON RE, 1981, J BIOL CHEM, V256, P1992; MORTON RE, 1983, J BIOL CHEM, V258, P1751; MORTON RE, 1988, J LIPID RES, V29, P1367; PAPE ME, 1991, ARTERIOSCLER THROMB, V11, P1759, DOI 10.1161/01.ATV.11.6.1759; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; QUIG DW, 1990, ANNU REV NUTR, V10, P169, DOI 10.1146/annurev.nu.10.070190.001125; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; Radeau T, 1995, J LIPID RES, V36, P2552; RAVNIK SE, 1992, BIOL REPROD, V47, P1126, DOI 10.1095/biolreprod47.6.1126; Richardson MA, 1996, J LIPID RES, V37, P1162; Sattler W, 1996, LIPIDS, V31, P1303, DOI 10.1007/BF02587917; Serdyuk AP, 1997, METABOLISM, V46, P833, DOI 10.1016/S0026-0495(97)90131-1; SHEN GX, 1995, AM J PHYSIOL, V269, P99; SON YSC, 1986, ARTERIOSCLEROSIS, V6, P345, DOI 10.1161/01.ATV.6.3.345; SPEIJER H, 1991, ATHEROSCLEROSIS, V90, P159, DOI 10.1016/0021-9150(91)90110-O; SPERKER B, 1993, EUR J BIOCHEM, V218, P945, DOI 10.1111/j.1432-1033.1993.tb18451.x; SWENSON TL, 1987, J BIOL CHEM, V262, P16271; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TOLLEFSON JH, 1985, J BIOL CHEM, V260, P5887; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; WHITLOCK ME, 1989, J CLIN INVEST, V84, P129, DOI 10.1172/JCI114132; Yang TP, 1996, J BIOL CHEM, V271, P12603, DOI 10.1074/jbc.271.21.12603; YEN FT, 1989, J CLIN INVEST, V83, P2018, DOI 10.1172/JCI114112; ZILVERSMIT DB, 1975, BIOCHIM BIOPHYS ACTA, V409, P393, DOI 10.1016/0005-2760(75)90036-3	55	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26534	26541		10.1074/jbc.M103624200	http://dx.doi.org/10.1074/jbc.M103624200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352921	hybrid			2022-12-27	WOS:000169823300117
J	Fukushima, K; Hara-Kuge, S; Ideo, H; Yamashita, K				Fukushima, K; Hara-Kuge, S; Ideo, H; Yamashita, K			Carbohydrate recognition site of interleukin-2 in relation to cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BETA-CHAIN; SIGNAL-TRANSDUCTION; POSSIBLE INVOLVEMENT; 3RD COMPONENT; ALPHA-CHAIN; BINDING; COMPLEX; AFFINITY; IL-2; SPECIFICITY	Interleukin-2 (IL-2) is a cytokine with important roles in the immune system. IL-2 initially binds a high mannose-type glycan and a specific peptide sequence of the IL-2 receptor a-subunit and sequentially forms a high affinity complex of IL-2 . IL-2 receptor alpha-, beta-, and gamma -subunits. This formation induces cellular signaling and cell proliferation (Fukushima, K., and Yamashita, IL (2001) J. Biol Chem. 276, 7351-7356). To determine the carbohydrate-binding site of IL-2, we prepared wild-type and point-mutated S-35-IL-2 by an in vitro transcription and translation method. We found that wild-type 35S-IL-2 tends to form a dimer spontaneously, and the dimeric form has both carbohydrate recognition activity and cell proliferation activity. Moreover, substitution of Asn-26 in IL-2 with Gln or Asp conserved the dimeric form and affected the carbohydrate recognition activities in correspondence with the cell proliferation activities, suggesting that Asn-26 in IL-2 is involved in the carbohydrate recognition site. These results suggest that the carbohydrate recognition of IL-2 dimer triggers formation of high affinity complex (IL-2-IL-2R alpha, -beta, -gamma)(2), and the hetero-octamer stimulates IL-2-dependent T-cell proliferation by intensifying cellular signaling.	Sasaki Inst, Dept Biochem, Chiyoda Ku, Tokyo 1010062, Japan; Japan Sci & Technol Corp, CREST, Chiyoda Ku, Tokyo 1010062, Japan	Japan Science & Technology Agency (JST)	Yamashita, K (corresponding author), Sasaki Inst, Dept Biochem, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.							ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; Aritomi M, 1999, NATURE, V401, P713, DOI 10.1038/44394; ASAO H, 1994, FEBS LETT, V351, P201, DOI 10.1016/0014-5793(94)00831-0; BAMBOROUGH P, 1994, STRUCTURE LONDON, V2, P677; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BRANDHUBER BJ, 1987, J BIOL CHEM, V262, P12306; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; EZEKOWITZ RAB, 1988, J EXP MED, V167, P1034, DOI 10.1084/jem.167.3.1034; Fukushima K, 2001, J BIOL CHEM, V276, P7351, DOI 10.1074/jbc.M008781200; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; IMLER JL, 1992, EMBO J, V11, P2047, DOI 10.1002/j.1460-2075.1992.tb05262.x; ITO S, 1977, J BIOCHEM, V81, P1621, DOI 10.1093/oxfordjournals.jbchem.a131621; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; LAMBERT G, 1989, J BIOL CHEM, V264, P12730; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIANG CJ, 1980, J BIOCHEM-TOKYO, V88, P51; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; Moreau JL, 1995, MOL IMMUNOL, V32, P1047, DOI 10.1016/0161-5890(95)00084-4; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; SAUVE K, 1991, P NATL ACAD SCI USA, V88, P4636, DOI 10.1073/pnas.88.11.4636; SHERBLOM AP, 1989, J IMMUNOL, V143, P939; SHIMUZU A, 1985, NUCLEIC ACIDS RES, V13, P1505, DOI 10.1093/nar/13.5.1505; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TAI T, 1975, J BIOL CHEM, V250, P8569; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; TSUJI T, 1987, BIOCHEMISTRY-US, V26, P3129, DOI 10.1021/bi00385a028; VOSS SD, 1993, P NATL ACAD SCI USA, V90, P2428, DOI 10.1073/pnas.90.6.2428; Ward LD, 1996, J BIOL CHEM, V271, P20138, DOI 10.1074/jbc.271.33.20138; YAMASHITA K, 1983, J BIOL CHEM, V258, P1098; YAYON A, 1991, CELL, V64, P844; ZURAWSKI SM, 1990, EMBO J, V9, P3899, DOI 10.1002/j.1460-2075.1990.tb07610.x	36	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31202	31208		10.1074/jbc.M102789200	http://dx.doi.org/10.1074/jbc.M102789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11390392	hybrid			2022-12-27	WOS:000170472900081
J	Honda, A; Endo, A; Mizumoto, K; Ishihama, A				Honda, A; Endo, A; Mizumoto, K; Ishihama, A			Differential roles of viral RNA and cRNA in functional modulation of the influenza virus RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BINDING-SITE; SUBUNIT CONSTITUTE; MOLECULAR ANATOMY; INFECTED-CELLS; GENOME RNA; 3 SUBUNITS; IN-VITRO; POLYADENYLATION; TRANSCRIPTION	The RNA-dependent RNA polymerase of influenza virus is composed of three viral P proteins (PB1, PB2, and PA) and involved in both transcription and replication of the RNA genome. For the molecular anatomy of this multifunctional enzyme, we have established a simultaneous expression of three P proteins in cultured insect cells using recombinant baculoviruses. For purification of P protein complexes, the PA protein was expressed as a fusion with a histidine tag added at its N terminus. By using affinity chromatography, a complex consisting of the three P proteins was isolated from nuclear extracts of virus-infected cells. The affinity-purified 3P complex showed the activities of capped RNA binding, capped RNA cleavage, viral model RNA binding, model RNA-directed RNA synthesis, and polyadenylation of newly synthesized RNA. We conclude that a functional form of the viral RNA polymerase with the catalytic specificity of transcriptase is formed in recombinant baculovirus-infected insect cells. Using the viral RNA-free 3P complex, we found that the capped RNA cleavage takes place in the presence of vRNA but not of cRNA, indicating that the vRNA functions as a regulatory factor for the specificity control of viral RNA polymerase as well as a template for transcription. The structural elements of RNA directing the expression of RNA polymerase functions were analyzed using variant forms of the model RNA templates.	Natl Inst Genet, Dept Mol Genet, Shizuoka 4118540, Japan; Japan Sci & Technol Corp, Kawaguchi, Saitama 3320012, Japan; Daiichi Pharmaceut Co Ltd, Exploratory Res Labs, Tokyo 1340081, Japan; Kitasato Univ, Fac Pharmaceut Sci, Minato Ku, Tokyo 1088641, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Japan Science & Technology Agency (JST); Daiichi Sankyo Company Limited; Kitasato University	Honda, A (corresponding author), Natl Inst Genet, Dept Mol Genet, Shizuoka 4118540, Japan.							BEATON AR, 1981, NUCLEIC ACIDS RES, V9, P4423, DOI 10.1093/nar/9.17.4423; BOULOY M, 1978, P NATL ACAD SCI USA, V75, P4886, DOI 10.1073/pnas.75.10.4886; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; CIANCI C, 1995, J VIROL, V69, P3995, DOI 10.1128/JVI.69.7.3995-3999.1995; FODOR E, 1993, J GEN VIROL, V74, P1327, DOI 10.1099/0022-1317-74-7-1327; Galarza JM, 1996, J VIROL, V70, P2360, DOI 10.1128/JVI.70.4.2360-2368.1996; Gonzalez S, 1999, EMBO J, V18, P3767, DOI 10.1093/emboj/18.13.3767; HAGEN M, 1994, J VIROL, V68, P1509, DOI 10.1128/JVI.68.3.1509-1515.1994; HAY AJ, 1982, VIROLOGY, V116, P517, DOI 10.1016/0042-6822(82)90144-1; HERZ C, 1981, CELL, V26, P391, DOI 10.1016/0092-8674(81)90208-7; Honda A, 1999, GENES CELLS, V4, P475, DOI 10.1046/j.1365-2443.1999.00275.x; Honda A, 1998, VIRUS RES, V55, P199, DOI 10.1016/S0168-1702(98)00048-3; Honda A, 1997, BIOL CHEM, V378, P483; HONDA A, 1990, J BIOCHEM-TOKYO, V107, P624, DOI 10.1093/oxfordjournals.jbchem.a123097; HONDA A, 1987, J BIOCHEM-TOKYO, V102, P1241, DOI 10.1093/oxfordjournals.jbchem.a122163; HORISBERGER MA, 1980, VIROLOGY, V107, P302, DOI 10.1016/0042-6822(80)90296-2; HSU MT, 1987, P NATL ACAD SCI USA, V84, P8140, DOI 10.1073/pnas.84.22.8140; Hwang JS, 2000, J VIROL, V74, P4074, DOI 10.1128/JVI.74.9.4074-4084.2000; Ishihama A, 1996, BIOCHIMIE, V78, P1097, DOI 10.1016/S0300-9084(97)86735-1; ISHIHAMA A, 1986, J BIOL CHEM, V261, P417; ITO N, 1987, J BIOL CHEM, V262, P1989; JACKSON DA, 1982, NATURE, V296, P366, DOI 10.1038/296366a0; KATO A, 1985, VIRUS RES, V3, P115; KAWAKAMI K, 1985, J BIOCHEM-TOKYO, V97, P655, DOI 10.1093/oxfordjournals.jbchem.a135101; KAWAKAMI K, 1983, NUCLEIC ACIDS RES, V11, P3637, DOI 10.1093/nar/11.11.3637; KAWAKAMI K, 1981, J BIOCH, V89, P18751; Kimura M, 2000, NUCLEIC ACIDS RES, V28, P952, DOI 10.1093/nar/28.4.952; KOBAYASHI M, 1992, VIRUS RES, V22, P235, DOI 10.1016/0168-1702(92)90055-E; KRUG RM, 1989, INFLUENZA VIRUSES, P89; Li ML, 1998, EMBO J, V17, P5844, DOI 10.1093/emboj/17.19.5844; LUO GX, 1991, J VIROL, V65, P2861, DOI 10.1128/JVI.65.6.2861-2867.1991; MAHY BWJ, 1981, REPLICATION NEGATIVE, P379; NAITO S, 1976, J BIOL CHEM, V251, P4307; PALESE P, 1983, GENETICS INFLUENZA V; PARVIN JD, 1989, J VIROL, V63, P5142, DOI 10.1128/JVI.63.12.5142-5152.1989; PLOTCH SJ, 1981, CELL, V23, P847, DOI 10.1016/0092-8674(81)90449-9; Pritlove DC, 1998, J VIROL, V72, P1280, DOI 10.1128/JVI.72.2.1280-1286.1998; ROBERTSON JS, 1981, J VIROL, V38, P157, DOI 10.1128/JVI.38.1.157-163.1981; Roy P, 1997, GENE, V190, P119, DOI 10.1016/S0378-1119(96)00619-1; SCHOLTISSEK C, 1978, ARCH VIROL, V58, P323, DOI 10.1007/BF01317824; SEONG BL, 1992, J GEN VIROL, V73, P3115, DOI 10.1099/0022-1317-73-12-3115; SEONG BL, 1992, J BIOCHEM-TOKYO, V111, P496, DOI 10.1093/oxfordjournals.jbchem.a123786; SHAW MW, 1984, VIRUS RES, V1, P455, DOI 10.1016/0168-1702(84)90003-0; SZEWCZYK B, 1988, P NATL ACAD SCI USA, V85, P7907, DOI 10.1073/pnas.85.21.7907; Toyoda T, 1996, J GEN VIROL, V77, P2149, DOI 10.1099/0022-1317-77-9-2149; Zuker M., 1999, V70, P11	46	27	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31179	31185		10.1074/jbc.M102856200	http://dx.doi.org/10.1074/jbc.M102856200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11373286	hybrid			2022-12-27	WOS:000170472900078
J	Brown, CL; Coffey, RJ; Dempsey, PJ				Brown, CL; Coffey, RJ; Dempsey, PJ			The proamphiregulin cytoplasmic domain is required for basolateral sorting, but is not essential for constitutive or stimulus-induced processing in polarized Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR EGF RECEPTOR; TGF-ALPHA PRECURSOR; HEPARIN-BINDING; EPITHELIAL-CELLS; PHORBOL-ESTER; PROTGF-ALPHA; METALLOPROTEINASE CLEAVAGE; AUTOCRINE REGULATION; ECTODOMAIN CLEAVAGE	In this study, the role of the amphiregulin precursor (pro-AR) cytoplasmic domain in the basolateral. sorting and cell-surface processing of pro-AR in polarized epithelial cells has been investigated using Madin-Darby canine kidney cells stably expressing various human pro-AR forms. Our results demonstrate that newly synthesized wild-type pro-AR (50 kDa) is delivered directly to the basolateral membrane domain with > 95% efficiency, where it is sequentially cleaved within the ectodomain to release several soluble amphiregulin (AR) forms. Analyses of a pro-AR cytoplasmic domain truncation mutant (ARTL27) and two pro-AR secretory mutants (ARsec184 and ARsec190) indicated that the pro-AR cytoplasmic domain is not required for efficient delivery to the plasma membrane, but does contain essential basolateral sorting information. We show that the pro-AR cytoplasmic domain truncation mutant (ARTL27) is not sorted in polarized Madin-Darby canine kidney cells, with similar to 65% of the newly synthesized protein delivered to the apical cell surface. Under base-line conditions, ARTL27 was preferentially cleaved from the basolateral surface with 4-fold greater efficiency compared with cleavage from the apical membrane domain. However, ARTL27 ectodomain cleavage could be stimulated equivalently from either membrane domain by a variety of different stimuli. The metalloprotease inhibitor BB-94 could inhibit both base-line and stimulus-induced ectodomain cleavage of wild-type pro-AR and ARTL27. These results indicate that the pro-AR cytoplasmic domain is required for basolateral sorting, but is not essential for ectodomain processing. Preferential constitutive cleavage of ARTL27 from the basolateral cell surface also suggests that the metalloprotease activity involved in base-line and stimulus-induced ARTL27 ectodomain cleavage may be regulated differently in the apical and basolateral membrane domains of polarized epithelial cells.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Coffey, RJ (corresponding author), Vanderbilt Univ, Ctr Med, Dept Med, CC-2201 Med Ctr N, Nashville, TN 37232 USA.	coffeyrj@ctrvax.vanderbilt.edu			NCI NIH HHS [CA46413] Funding Source: Medline; NHLBI NIH HHS [5 T32 HL-07751] Funding Source: Medline; NIAMS NIH HHS [5P30 AR41943-05] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; PHS HHS [CS68485] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046413] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aroeti B, 1998, BBA-REV BIOMEMBRANES, V1376, P57, DOI 10.1016/S0304-4157(98)00005-7; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; Cook PW, 1999, J INVEST DERMATOL, V113, P860, DOI 10.1046/j.1523-1747.1999.00753.x; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; Damstrup L, 1999, BRIT J CANCER, V80, P1012, DOI 10.1038/sj.bjc.6690456; DAVIES B, 1993, CANCER RES, V53, P2087; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; Dong JY, 2000, J BIOL CHEM, V275, P557, DOI 10.1074/jbc.275.1.557; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Eldering JA, 1997, EUR J BIOCHEM, V247, P920, DOI 10.1111/j.1432-1033.1997.00920.x; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Han B, 1999, J BIOL CHEM, V274, P26407, DOI 10.1074/jbc.274.37.26407; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; Inui S, 1997, J CELL PHYSIOL, V171, P291, DOI 10.1002/(SICI)1097-4652(199706)171:3<291::AID-JCP7>3.0.CO;2-J; Iwamoto R, 1999, J BIOL CHEM, V274, P25906, DOI 10.1074/jbc.274.36.25906; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Kuo A, 2000, EMBO J, V19, P6427, DOI 10.1093/emboj/19.23.6427; LANZREIN M, 1995, BIOCHEM J, V310, P285, DOI 10.1042/bj3100285; LEE DC, 1995, PHARMACOL REV, V47, P51; Liu XF, 1998, J BIOL CHEM, V273, P34335, DOI 10.1074/jbc.273.51.34335; Lottaz D, 1999, EUR J BIOCHEM, V259, P496, DOI 10.1046/j.1432-1327.1999.00071.x; MartinezLacaci I, 1996, J CELL PHYSIOL, V169, P497, DOI 10.1002/(SICI)1097-4652(199612)169:3<497::AID-JCP10>3.0.CO;2-3; Merlos-Suarez A, 1999, BIOCHEM SOC T, V27, P243, DOI 10.1042/bst0270243; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; PIEPKORN M, 1995, J INVEST DERMATOL, V105, P802, DOI 10.1111/1523-1747.ep12326567; Piepkorn M, 1998, J INVEST DERMATOL, V111, P715, DOI 10.1046/j.1523-1747.1998.00390.x; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; THORNE BA, 1994, MOL CELL BIOL, V14, P1635, DOI 10.1128/MCB.14.3.1635; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Urena JM, 1999, J CELL SCI, V112, P773; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Wiley HS, 1998, J CELL BIOL, V143, P1317, DOI 10.1083/jcb.143.5.1317; Wong L, 1999, J BIOL CHEM, V274, P8900, DOI 10.1074/jbc.274.13.8900; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	65	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29538	29549		10.1074/jbc.M102114200	http://dx.doi.org/10.1074/jbc.M102114200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382759	hybrid			2022-12-27	WOS:000170346000119
J	Chen, PL; Hutter, D; Yang, XL; Gorospe, M; Davis, RJ; Liu, YS				Chen, PL; Hutter, D; Yang, XL; Gorospe, M; Davis, RJ; Liu, YS			Discordance between the binding affinity of mitogen-activated protein kinase subfamily members for MAP kinase phosphatase-2 and their ability to activate the phosphatase catalytically	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; DUAL-SPECIFICITY PHOSPHATASES; TYROSINE-PHOSPHATASE; CRYSTAL-STRUCTURE; IN-VIVO; HEAT-SHOCK; C-JUN; STRESS; DOMAIN; EXPRESSION	MKP-2 is a member of the mitogen-activated protein (MAP) kinase phosphatase family which has been suggested to play an important role in the feedback control of MAP kinase-mediated gene expression. Although MKP-2 preferentially inactivates extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) MAP kinase subfamilies, the mechanisms underlying its own regulation remain unclear. In this report, we have examined the MKP-2 interaction with and catalytic activation by distinct MAP kinase subfamilies. We found that the catalytic activity of MKP-2 was enhanced dramatically by ERK and JNK but was affected only minimally by p38. By contrast, p38 and ERK bound MKP-2 with comparably strong affinities, whereas JNK and MKP-2 interacted very weakly. Through site-directed mutagenesis, we defined the ERK/p38-binding site as a cluster of arginine residues in the NH2-terminal domain of MKP-2. Mutation of the basic motif abrogated its interaction with both ERK and p38 and severely compromised the catalytic activation of MKP-2 by these kinases. Unexpectedly, such mutations had little effect on JNK-triggered catalytic activation. Both in vitro and in vivo, wild type MKP-2 effectively inactivated ERK2 whereas MKP-2 mutants incapable of binding to ERK/p38 did not. Finally, in addition to its role as a docking site for ERK and p38, the MKP-2 basic motif plays a role in regulating its nuclear localization. Our studies provided a mechanistic explanation for the substrate preference of MKP-2 and suggest that catalytic activation of MKP-2 upon binding to its substrates is crucial for its function.	NIA, Mol & Cellular Biol Lab, NIH, Baltimore, MD 21224 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med,Dept BIochem & Mol Biol, Worcester, MA 01605 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Liu, YS (corresponding author), NIA, Mol & Cellular Biol Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Liu, Yusen/E-3527-2011	Liu, Yusen/0000-0002-0994-0109	NATIONAL INSTITUTE ON AGING [Z01AG000511, Z01AG000510, ZIAAG000511] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Butch ER, 1996, J BIOL CHEM, V271, P4230; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dowd S, 1998, J CELL SCI, V111, P3389; Eckstein JW, 1996, PROTEIN SCI, V5, P5; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Fjeld CC, 2000, J BIOL CHEM, V275, P6749, DOI 10.1074/jbc.275.10.6749; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Johnson TR, 2000, J BIOL CHEM, V275, P31755, DOI 10.1074/jbc.M004182200; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Puri PL, 2000, GENE DEV, V14, P574; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; RON D, 1992, BIOTECHNIQUES, V13, P866; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WALKER J, 1993, MOL BIOCHEM PARASIT, V61, P255, DOI 10.1016/0166-6851(93)90071-5; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	53	91	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29440	29449		10.1074/jbc.M103463200	http://dx.doi.org/10.1074/jbc.M103463200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387337	hybrid			2022-12-27	WOS:000170346000106
J	Conkright, MD; Wani, MA; Lingrel, JB				Conkright, MD; Wani, MA; Lingrel, JB			Lung Kruppel-like factor contains an autoinhibitory domain that regulates its transcriptional activation by binding WWP1, an E3 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; NF-KAPPA-B; PROTEASOME PATHWAY; IN-VIVO; C-FOS; IDENTIFICATION; DEGRADATION; SYSTEM; CELLS; CLONING	Lung Kruppel-like factor (LKLF/Kruppel-like factor 2), a member of the Kruppel-like factor family of transcription factors, is expressed predominately in the lungs, with low levels of expression in other organs such as heart, spleen, skeletal muscle, and testis. LKLF is essential during pulmonary development and single-positive T-cell development and is indispensable during mouse embryogenesis. In this study, we performed a series of experiments to define the activation domain of LKLF as a means to further advance the understanding of the molecular mechanisms underlying transcriptional regulation by this transcription factor. Using deletion analysis, it is shown that LKLF contains a transcriptional activation domain as well as a strong autoinhibitory subdomain. The inhibitory subdomain is able to independently suppress transcriptional activation of other strong activators such as viral protein 16, VP16. This occurs either when the inhibitory domain is fused directly to VP16 or when the inhibitory domain is independently bound to DNA by GAL4 DNA-binding domain independent of the VP16 activator. Overexpression of the LKLF autoinhibitory domain alone potentiates transactivation by wild type LKLF, suggesting that the inhibitory domain binds a cofactor that prevents LKLF from transactivating. A yeast-two hybrid screen identified WWP1, an E3 ubiquitin ligase that binds specifically to the LKLF inhibitory domain but not to other transcription factors. In mammalian cells, WWP1 functions as a cofactor by binding LKLF and suppressing transactivation. These data demonstrate that LKLF contains multiple domains that either potentiate or inhibit the ability of this factor to function as an activator of transcription; moreover, regulation of LKLF transactivation is attenuated by an E3 ubiquitin ligase, WWP1.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Lingrel, JB (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007752, R01HL057281] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 57281, 5-T32 HL07752] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Chen XY, 1996, EMBO J, V15, P5888, DOI 10.1002/j.1460-2075.1996.tb00975.x; CIECHANOVER A, 1991, PROG CLIN BIOL RES, V366, P37; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DEGEIMAN TTH, 2000, NUCLEIC ACIDS RES, V28, P1106; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Huang K, 2000, GENE, V252, P137, DOI 10.1016/S0378-1119(00)00216-X; James P, 1996, GENETICS, V144, P1425; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V278, P788; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; Matsumoto N, 1998, J BIOL CHEM, V273, P28229, DOI 10.1074/jbc.273.43.28229; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; NIRMALA PB, 1995, BIOCHEM BIOPH RES CO, V213, P24, DOI 10.1006/bbrc.1995.2093; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Wani MA, 1998, TRANSGENIC RES, V7, P229, DOI 10.1023/A:1008809809843; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; Wani MA, 1999, GENOMICS, V60, P78, DOI 10.1006/geno.1999.5888; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974	43	55	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29299	29306		10.1074/jbc.M103670200	http://dx.doi.org/10.1074/jbc.M103670200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11375995	hybrid			2022-12-27	WOS:000170346000089
J	Izaguirre, G; Aguirre, L; Hu, YP; Lee, HY; Schlaepfer, DD; Aneskievich, BJ; Haimovich, B				Izaguirre, G; Aguirre, L; Hu, YP; Lee, HY; Schlaepfer, DD; Aneskievich, BJ; Haimovich, B			The cytoskeletal/non-muscle isoform of alpha-actinin is phosphorylated on its actin-binding domain by the focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; MECHANICAL-PROPERTIES; STRESS FIBERS; CROSS-LINKING; ACTIVATED PLATELETS; CELL-MIGRATION; C-SRC; ALPHA-ACTININ-1; IDENTIFICATION; PURIFICATION	alpha -Actinin is tyrosine-phosphorylated in activated human platelets (Izaguirre, G., Aguirre, L., Ji, P., Aneskievich, B., and Haimovich, B. (1999) J. Biol. Chem. 274, 37012-37020). Analysis of platelet RNA by reverse transcription-polymerase chain reaction revealed that a-actinin expressed in platelets is identical to the cytoskeletal/non-muscle isoform. A construct of this isoform containing a His(6) tag at the amino terminus was generated. Robust tyrosine phosphorylation of the recombinant protein was detected in cells treated with the tyrosine phosphatase inhibitor vanadate. The tyrosine phosphorylation site was localized to the amino-terminal domain by proteolytic digestion. A recombinant a-actinin protein containing a Tyr --> Phe mutation at position 12 (Y12F) was no longer phosphorylated when expressed in vanadate-treated cells, indicating that tyrosine 12 is the site of phosphorylation. The wild type recombinant protein was not phosphorylated in cells lacking the focal adhesion kinase (FAR). Re-expression of FAK in these cells restored alpha -actinin phosphorylation. Purified wild type alpha -actinin, but not the Y12F mutant, was phosphorylated in vitro by wild type as well as a Phe-397 mutant of FAK. In contrast, no phosphorylation was detected in the presence of a kinase-dead FAK. Tyrosine phosphorylation reduced the amount of a-actinin that cosedimented with actin filaments. These results establish that alpha -actinin is a direct substrate for FAK and suggest that alpha -actinin mediates FAK-dependent signals that could impact the physical properties of the cytoskeleton.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, New Brunswick, NJ 08903 USA; Univ Connecticut, Dept Pharmaceut Sci, Storrs, CT 06269 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Connecticut; Scripps Research Institute	Haimovich, B (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, CINJ Rm 2050,195 Little Albany St, New Brunswick, NJ 08903 USA.			Aguirre, Lina/0000-0003-0711-314X	NCI NIH HHS [R29 CA75240] Funding Source: Medline; NHLBI NIH HHS [HL-541044] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA075240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5; Bauer K, 2000, BLOOD, V96, P4236; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; DAVISON MD, 1989, INT J BIOL MACROMOL, V11, P81, DOI 10.1016/0141-8130(89)90047-0; DEARRUDA MV, 1990, J CELL BIOL, V111, P1069, DOI 10.1083/jcb.111.3.1069; Egerton M, 1996, BIOCHEM BIOPH RES CO, V224, P666, DOI 10.1006/bbrc.1996.1082; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Goldsmith SC, 1997, NAT STRUCT BIOL, V4, P708, DOI 10.1038/nsb0997-708; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; Hammell RL, 1996, J BIOL CHEM, V271, P4236; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; Heiska L, 1996, J BIOL CHEM, V271, P26214, DOI 10.1074/jbc.271.42.26214; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Ilic D, 1997, J CELL SCI, V110, P401; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; IMAMURA M, 1992, J BIOL CHEM, V267, P25927; Izaguirre G, 1999, J BIOL CHEM, V274, P37012, DOI 10.1074/jbc.274.52.37012; Johnson RP, 2000, J BIOL CHEM, V275, P95, DOI 10.1074/jbc.275.1.95; Keep NH, 1999, J MOL BIOL, V285, P1257, DOI 10.1006/jmbi.1998.2406; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LANDON F, 1985, EUR J BIOCHEM, V153, P231, DOI 10.1111/j.1432-1033.1985.tb09291.x; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Mukai H, 1997, J BIOL CHEM, V272, P4740, DOI 10.1074/jbc.272.8.4740; Nieset JE, 1997, J CELL SCI, V110, P1013; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Parast MM, 2000, J CELL BIOL, V150, P643, DOI 10.1083/jcb.150.3.643; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Puius YA, 1998, CURR OPIN CELL BIOL, V10, P23, DOI 10.1016/S0955-0674(98)80083-5; Ren XD, 2000, J CELL SCI, V113, P3673; ROSENBERG S, 1981, J BIOL CHEM, V256, P2986; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; Vallenius T, 2000, J BIOL CHEM, V275, P11100, DOI 10.1074/jbc.275.15.11100; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; WACHSSTOCK DH, 1994, BIOPHYS J, V66, P801, DOI 10.1016/S0006-3495(94)80856-2; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; WAITES GT, 1992, J BIOL CHEM, V267, P6263; Weyrich AS, 1998, P NATL ACAD SCI USA, V95, P5556, DOI 10.1073/pnas.95.10.5556; WITKE W, 1993, J CELL BIOL, V121, P599, DOI 10.1083/jcb.121.3.599; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62	65	116	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28676	28685		10.1074/jbc.M101678200	http://dx.doi.org/10.1074/jbc.M101678200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11369769	hybrid			2022-12-27	WOS:000170346000007
J	Miller, GJ; Ball, EH				Miller, GJ; Ball, EH			Conformational change in the vinculin C-terminal depends on a critical histidine residue (His-906)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ASSOCIATION; ACIDIC PHOSPHOLIPIDS; BINDING-SITE; TAIL DOMAIN; ADHERENS JUNCTIONS; FOCAL ADHESIONS; TALIN-BINDING; ACTIN-BINDING; HEAD; PURIFICATION	A phospholipid-controlled interaction between the N-terminal and C-terminal domains of vinculin is thought to be a major mechanism that regulates binding activities of the protein. To probe the mechanisms underlying these interactions we used chemical modification and site-directed mutagenesis directed at histidine residues. Diethylpyrocarbonate (DEPC) modification of the C-terminal, but not the N-terminal, domain greatly decreased affinity of the N-terminal-C-terminal binding, implicating histidine residues in the C-terminal. Mutation of either or both C-terminal histidines (at positions 906 and 1026), however, did not affect N-C binding at neutral pH. The H906A mutation did prevent DEPC effects and also prevented the normal decrease in binding affinity for the N-terminal at lower pH. We found that the wild type C-terminal domain, but not the H906A mutant, underwent a conformational change at pH 6.5, reflected in an altered circular dichroism spectrum and apparent oligomerization. Phospholipid also induced conformational changes in the wild type C-terminal domain but not in the H906A mutant, even though the mutant protein did bind to the phospholipid. Finally, the sensitivity of the N-C interaction to phospholipid was much reduced by the H906A mutation. These results show that H906 plays a key role in the conformational dynamics of the C-terminal domain and thus the regulation of vinculin.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Ball, EH (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	ehball@uwo.ca		Ball, Eric/0000-0003-2542-9156				ALMOG R, 1990, ANAL BIOCHEM, V188, P237, DOI 10.1016/0003-2697(90)90559-R; Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; BALL EH, 1986, J CELL BIOL, V103, P641, DOI 10.1083/jcb.103.2.641; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Clement-Collin V, 1999, EUR J BIOCHEM, V264, P358, DOI 10.1046/j.1432-1327.1999.00608.x; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; GEIGER B, 1985, J CELL BIOL, V101, P1523, DOI 10.1083/jcb.101.4.1523; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Goldmann WH, 1996, J MUSCLE RES CELL M, V17, P1, DOI 10.1007/BF00140319; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Jockusch BM, 1996, TRENDS CELL BIOL, V6, P311, DOI 10.1016/0962-8924(96)10022-2; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; Johnson RP, 2000, J BIOL CHEM, V275, P95, DOI 10.1074/jbc.275.1.95; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; JUDD RC, 1990, METHOD ENZYMOL, V182, P613; KROEMKER M, 1994, FEBS LETT, V355, P259, DOI 10.1016/0014-5793(94)01216-4; Miles E W, 1977, Methods Enzymol, V47, P431; Miller GJ, 2001, J BIOL CHEM, V276, P11729, DOI 10.1074/jbc.M008646200; OTTO JJ, 1990, CELL MOTIL CYTOSKEL, V16, P1, DOI 10.1002/cm.970160102; Rai SS, 1998, J BIOL CHEM, V273, P31131, DOI 10.1074/jbc.273.47.31131; Rudiger M, 1998, BIOESSAYS, V20, P733; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHLESSINGER J, 1983, CELL MOTIL CYTOSKEL, V3, P399, DOI 10.1002/cm.970030508; Steinmetz MO, 1998, EMBO J, V17, P1883, DOI 10.1093/emboj/17.7.1883; TEMPEL M, 1995, BIOPHYS J, V69, P228, DOI 10.1016/S0006-3495(95)79894-0; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Xu WM, 1998, DEVELOPMENT, V125, P327	35	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28829	28834		10.1074/jbc.M102561200	http://dx.doi.org/10.1074/jbc.M102561200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382765	hybrid			2022-12-27	WOS:000170346000027
J	Mitchell, DA; Fadden, AJ; Drickamer, K				Mitchell, DA; Fadden, AJ; Drickamer, K			A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR - Subunit organization and binding to multivalent ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; OLIGOSACCHARIDE; EXPRESSION; RECEPTOR; DOMAINS	DC-SIGN and DC-SIGNR are cell-surface receptors that mediate cell-cell interactions within the immune system by binding to intercellular adhesion molecule-3. The receptor polypeptides share 77% amino acid sequence identity and are type 11 transmembrane proteins. The extracellular domain of each comprises seven 23-residue tandem repeats and a C-terminal C-type carbohydrate-recognition domain (CRD). Cross-linking, equilibrium ultracentrifugation, and circular dichroism studies of soluble recombinant fragments of DC-SIGN and DC-SIGNR have been used to show that the extracellular domain of each receptor is a tetramer stabilized by an a-helical stalk. Both DC-SIGN and DC-SIGNR bind ligands bearing mannose and related sugars through the CRDs. The CRDs of DC-SIGN and DC-SIGNR bind Man(9)GIcNAc(2) oligosaccharide 130- and 17-fold more tightly than mannose, and affinity for a glycopeptide bearing two such oligosaccharides is increased by a further factor of 5- to 25-fold. These results indicate that the CRDs contain extended or secondary oligosaccharide binding sites that accommodate mammalian-type glycan structures. When the CRDs are clustered in the tetrameric extracellular domain, their arrangement provides a means of amplifying specificity for multiple glycans on host molecules targeted by DC-SIGN and DC-SIGNR, Binding to clustered oligosaccharides may also explain the interaction of these receptors with the gp120 envelope protein of human immunodeficiency virus-1, which contributes to virus infection.	Univ Oxford, Dept Biochem, Inst Glycobiol, Oxford OX1 3QU, England	University of Oxford	Drickamer, K (corresponding author), Univ Oxford, Dept Biochem, Inst Glycobiol, S Parks Rd, Oxford OX1 3QU, England.	kd@glycob.ox.ac.uk	Mitchell, Daniel A/A-6580-2009	Mitchell, Daniel A/0000-0003-0936-6212				ASHFORD D, 1987, EUR J BIOCHEM, V166, P311, DOI 10.1111/j.1432-1033.1987.tb13516.x; Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DUNCAN RJS, 1983, ANAL BIOCHEM, V132, P68, DOI 10.1016/0003-2697(83)90426-8; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; Funatsu O, 2001, EUR J BIOCHEM, V268, P1020, DOI 10.1046/j.1432-1327.2001.01960.x; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; GORDON JA, 1972, FEBS LETT, V24, P193, DOI 10.1016/0014-5793(72)80765-8; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Hirs C. H. W., 1967, METHOD ENZYMOL, V11, P325; HUDGIN RL, 1974, J BIOL CHEM, V249, P5536; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langone J J, 1980, Methods Enzymol, V70, P221; LEE RT, 1991, J BIOL CHEM, V266, P4810; LEE RT, 1992, ARCH BIOCHEM BIOPHYS, V299, P129, DOI 10.1016/0003-9861(92)90254-T; LEE YC, 1983, J BIOL CHEM, V258, P199; Maniatis T., 1982, MOL CLONING; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MIZUOCHI T, 1989, J BIOL CHEM, V264, P13834; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; Stetefeld J, 2000, NAT STRUCT BIOL, V7, P772, DOI 10.1038/79006; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x	34	417	449	3	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28939	28945		10.1074/jbc.M104565200	http://dx.doi.org/10.1074/jbc.M104565200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384997	hybrid			2022-12-27	WOS:000170346000042
J	Raghavan, SC; Kirsch, IR; Lieber, MR				Raghavan, SC; Kirsch, IR; Lieber, MR			Analysis of the V(D)J recombination efficiency at lymphoid chromosomal translocation breakpoints	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; T-CELL RECEPTOR; DEVELOPMENTAL-STAGE; LOCUS; GENE; DELTA; METHYLATION; T(10-14); CLUSTER; REGION	Chromosomal translocations and deletions are among the major events that initiate neoplasia. For lymphoid chromosomal translocations, misrecognition by the RAG (recombination activating gene) complex of V(D)J recombination is one contributing factor that has long been proposed. The chromosomal translocations involving LMO2 (t(11;14)(p13;q11)), Ttg-1 (t(11;14)(p15;q11)), and Hox11 (t(10;14)(q24;q11)) are among the clearest examples in which it appears that a D or J segment has synapsed with an adventitious heptamer/nonamer at a gene outside of one of the antigen receptor loci. The interstitial deletion at 1p32 involving SIL (SCL-interrupting locus)/SCL (stem cell leukemia) is a case involving two non-V(D)J sites that have been suggested to be V(D)J recombination mistakes. Here we have used our human extrachromosomal substrate assay to formally test the hypothesis that these regions are V(D)J recombination misrecognition sites and, more importantly, to quantify their efficiency as V(D)J recombination targets within the cell. We find that the LMO2 fragile site functions as a 12-signal at an efficiency that is only 27-fold lower than that of a consensus 12-signal. The Ttg-1 site functions as a 23-signal at an efficiency 530-fold lower than that of a consensus 23-signal. Hox11 failed to undergo recombination as a 12. or 23-signal and was at least 20,000-fold less efficient than consensus signals. SIL has been predicted to function as a 12-signal and SCL as a 23-signal. However, we find that SH, actually functions as a 23-signal. These results provide a formal demonstration that certain chromosomal fragile sites can serve as RAG complex targets, and they determine whether these sites function as 12- versus 23-signals. These results quantify one of the three major factors that determine the frequency of these translocations in T-cell acute lymphocytic leukemia.	Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Biol Sci, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; NCI, Med Branch, NIH, Bethesda, MD 20889 USA; NCI, Dept Genet, NIH, Bethesda, MD 20889 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lieber, MR (corresponding author), Univ So Calif, Keck Sch Med, Dept Pathol, Rm 5428,1441 Eastlake Ave, Los Angeles, CA 90089 USA.	lieber@usc.edu		Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345				AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; APLAN PD, 1992, BLOOD, V79, P1327; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; BASH RO, 1993, BLOOD, V81, P2110; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHENG JT, 1990, J EXP MED, V171, P489, DOI 10.1084/jem.171.2.489; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; FORONI L, 1990, GENE CHROMOSOME CANC, V1, P301, DOI 10.1002/gcc.2870010407; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; GARCIA IS, 1991, ONCOGENE, V6, P577; GAUSS GH, 1993, MOL CELL BIOL, V13, P3900, DOI 10.1128/MCB.13.7.3900; Gauss GH, 1996, MOL CELL BIOL, V16, P258; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; Gauss GH, 1998, EUR J IMMUNOL, V28, P351, DOI 10.1002/(SICI)1521-4141(199801)28:01<351::AID-IMMU351>3.0.CO;2-#; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HECHT F, 1984, SCIENCE, V226, P1445, DOI 10.1126/science.6438800; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; Hsieh CL, 2000, CURR OPIN GENET DEV, V10, P224, DOI 10.1016/S0959-437X(00)00064-2; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; HURWITZ R, 1979, INT J CANCER, V23, P174, DOI 10.1002/ijc.2910230206; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAGAN J, 1987, P NATL ACAD SCI USA, V84, P4543, DOI 10.1073/pnas.84.13.4543; LARSON RC, 1994, ONCOGENE, V9, P3675; Lewis SM, 1997, MOL CELL BIOL, V17, P3125, DOI 10.1128/MCB.17.6.3125; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; Lieber MR, 1998, AM J PATHOL, V153, P1323, DOI 10.1016/S0002-9440(10)65716-1; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Lieber MR., 1993, CAUSES CONSEQUENCES, P239; LU M, 1990, GENE CHROMOSOME CANC, V2, P217, DOI 10.1002/gcc.2870020309; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; RABBITTS TH, 1993, CAUSES CONSEQUENCES, P393; RAMSDEN DA, 1991, P NATL ACAD SCI USA, V88, P10721, DOI 10.1073/pnas.88.23.10721; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; YOFFE G, 1989, BLOOD, V74, P374; Yu KF, 2000, MOL CELL BIOL, V20, P7914, DOI 10.1128/MCB.20.21.7914-7921.2000; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	49	100	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29126	29133		10.1074/jbc.M103797200	http://dx.doi.org/10.1074/jbc.M103797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390401	hybrid			2022-12-27	WOS:000170346000067
J	Alderton, F; Rakhit, S; Kong, KC; Palmer, T; Sambi, B; Pyne, S; Pyne, NJ				Alderton, F; Rakhit, S; Kong, KC; Palmer, T; Sambi, B; Pyne, S; Pyne, NJ			Tethering of the platelet-derived growth factor ss receptor to G-protein-coupled receptors - A novel platform for integrative signaling by these receptor classes in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY SMOOTH-MUSCLE; MEDIATED TYROSINE PHOSPHORYLATION; SPHINGOSINE 1-PHOSPHATE RECEPTOR; KINASE ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; G(BETA-GAMMA) SUBUNITS; STIMULATION; PATHWAY; ASSOCIATION; REQUIRES	Here we provide evidence to show that the platelet-derived growth factor beta receptor is tethered to endogenous G-protein-coupled receptor(s) in human embryonic kidney 293 cells. The tethered receptor complex provides a platform on which receptor tyrosine kinase and G-protein-coupled receptor signals can be integrated to produce more efficient stimulation of the p42/p44 mitogen-activated protein kinase pathway. This was based on several lines of evidence. Fix st, we have shown that pertussis toxin (which uncouples G-protein-coupled receptors from inhibitory G-proteins) reduced the platelet-derived growth factor stimulation of p42/p44 mitogen-activated protein kinase. Second, transfection of cells with inhibitory G-protein a subunit increased the activation of p42/p44 mitogen-activated protein kinase by platelet-derived growth factor. Third, platelet-derived growth factor stimulated the tyrosine phosphorylation of the inhibitory G-protein a subunit, which was blocked by the platelet-derived growth factor kinase inhibitor, tyrphostin AG 1296. We have also shown that the platelet-derived growth factor beta receptor forms a tethered complex with Myc-tagged endothelial differentiation gene 1 (a G-protein-coupled receptor whose agonist is sphingosine I-phosphate) in cells co-transfected with these receptors. This facilitates platelet-derived growth factor-stimulated tyrosine phosphorylation of the inhibitory G-protein a subunit and increases p42/p44 mitogen-activated protein kinase activation. In addition, we found that G-protein-coupled receptor kinase 2 and beta -arrestin I can associate with the platelet-derived growth factor beta receptor. These proteins play an important role in regulating endocytosis of G-protein-coupled receptor signal complexes, which is required for activation of p42/p44 mitogen-activated protein kinase. Thus, platelet-derived growth factor beta receptor signaling may be initiated by G-protein-coupled receptor kinase 2/beta -arrestin I that has been recruited to the platelet-derived growth factor beta receptor by its tethering to a G-protein-coupled receptor(s). These results provide a model that may account for the co-mitogenic effect of certain G-protein-coupled receptor agonists with platelet-derived growth factor on DNA synthesis.	Univ Strathclyde, Dept Physiol & Pharmacol, Strathclyde Inst Biomed Sci, Glasgow G4 0NR, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	University of Strathclyde; University of Glasgow	Pyne, NJ (corresponding author), Univ Strathclyde, Dept Physiol & Pharmacol, Strathclyde Inst Biomed Sci, 27 Taylor St, Glasgow G4 0NR, Lanark, Scotland.		Pyne, Susan/AAF-5001-2019	Pyne, Susan/0000-0002-6608-9584; Pyne, Nigel/0000-0002-5657-4578				Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; HLA T, 1990, J BIOL CHEM, V265, P9308; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Karoor V, 1998, J BIOL CHEM, V273, P33035, DOI 10.1074/jbc.273.49.33035; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; KRUPINSKI J, 1988, J BIOL CHEM, V263, P12333; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; OBRIEN RM, 1987, FEBS LETT, V212, P281, DOI 10.1016/0014-5793(87)81361-3; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; Rakhit S, 2001, MOL PHARMACOL, V60, P63, DOI 10.1124/mol.60.1.63; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wang HY, 2000, J BIOL CHEM, V275, P36086, DOI 10.1074/jbc.M004404200; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351	28	139	141	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28578	28585		10.1074/jbc.M102771200	http://dx.doi.org/10.1074/jbc.M102771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11359779	hybrid			2022-12-27	WOS:000170093400111
J	Pellicena, P; Miller, WT				Pellicena, P; Miller, WT			Processive phosphorylation of p130Cas by Src depends on SH3-polyproline interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED TYROSINE PHOSPHORYLATION; PROTEIN-PROTEIN INTERACTIONS; V-SRC; DUAL PHOSPHORYLATION; HOMOLOGY DOMAINS; SH3 DOMAINS; KINASE HCK; C-SRC; P130(CAS); SPECIFICITY	Many in vivo substrates of Src family tyrosine kinases possess sequences conforming to Src homology 2 and 3 (SH2 and SH3) domain-binding motifs. One such substrate is p130Cas, a protein that is hyperphosphorylated in v-Src transformed cells. Cas contains a substrate domain consisting of 15 potential tyrosine phosphorylation sites, C- and N-terminal polyproline regions fitting the consensus sequence for SH3 domain ligands, and a YDYV motif that binds the Src SH2 domain when phosphorylated. In an effort to understand the mechanisms of processive phosphorylation, we have explored the regions of Cas necessary for interaction with Src using the yeast two-hybrid system. Mutations in the SH2 domain-binding region of Cas or the Src SH2 domain have little effect in Cas-Src complex formation or phosphorylation. However, disruption of the C-terminal polyproline region of Cas completely abolishes interaction between the two proteins and results in impaired phosphorylation of Cas. Kinetic analyses using purified proteins indicated that multisite phosphorylation of Cas by Src follows a processive rather than a distributive mechanism. Furthermore, the kinetic studies show that there are two properties of the polyproline region of Cas that are important in enhancing substrate phosphorylation. First, the C-terminal polyproline serves to activate Src kinases through the process of SH3 domain displacement. Second, this region aids in anchoring the kinase to Cas to facilitate processive phosphorylation of the substrate domain. The two processes combine to ensure phosphorylation of Cas with high efficiency.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Basic Sci Tower,T-6, Stony Brook, NY 11794 USA.	miller@physiology.pnb.sunysb.edu			NATIONAL CANCER INSTITUTE [R01CA058530, R29CA058530] Funding Source: NIH RePORTER; NCI NIH HHS [CA58530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Astier A, 1997, J BIOL CHEM, V272, P228; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Burack WR, 1997, BIOCHEMISTRY-US, V36, P5929, DOI 10.1021/bi970535d; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Burnham MR, 1996, ONCOGENE, V12, P2467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GARCIA P, 1993, J BIOL CHEM, V268, P25146; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; Keegan K, 1996, ONCOGENE, V12, P1537; Lewis LA, 1997, J IMMUNOL, V159, P2292; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Tian MX, 1997, MOL BIOL CELL, V8, P1183, DOI 10.1091/mbc.8.7.1183; TILL JH, 1994, J BIOL CHEM, V269, P7423; WU JZ, 1994, BIOCHEMISTRY-US, V33, P14825, DOI 10.1021/bi00253a022; Xu B, 1996, MOL CELL BIOCHEM, V158, P57; Yokoyama N, 1999, FEBS LETT, V456, P403, DOI 10.1016/S0014-5793(99)00992-8; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	102	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28190	28196		10.1074/jbc.M100055200	http://dx.doi.org/10.1074/jbc.M100055200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11389136	hybrid			2022-12-27	WOS:000170093400061
J	Wei, RR; Richardson, JP				Wei, RR; Richardson, JP			Identification of an RNA-binding site in the ATP binding domain of Escherichia coli Rho by H2O2/Fe-EDTA cleavage protection studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION TERMINATION FACTOR; PROTEIN-RHO; MICROCOCCUS-LUTEUS; CRYSTAL-STRUCTURE; MESSENGER-RNA; SEQUENCES; RECOGNITION; POLYMERASE; COMPLEXES; AFFINITY	Transcription factor Rho is a ring-shaped, homohexameric protein that causes transcript termination through actions on nascent RNAs that are coupled to ATP hydrolysis. The Rho polypeptide has a distinct RNA binding domain of known structure as well as an ATP binding domain for which a structure has been proposed based on homology modeling. Treatment of Rho with H2O2 in the presence of Fe-EDTA caused single-cut cleavage at a number of points that coincide with solvent-exposed loops in both the known and predicted structures, thereby providing support for the validity of the tertiary and quaternary structural models of Rho. The binding of ATP caused one distinct change in the cleavage pattern, a strong protection at a cleavage point in the P-loop of the ATP binding domain. Binding of RNA and single-stranded DNA (poly(dC)) caused strong protection at several accessible parts of the oligosaccharide/oligonucleotide binding (OB) fold in the RNA binding domain. RNA molecules but not DNA molecules also caused a strong, ATP-dependent protection at a cleavage site in the predicted Q-loop of the ATP binding domain. These results suggest that Rho has two distinct binding sites for RNA. Besides the site composed of multiples of the RNA binding domain, to which single-stranded DNA as well as RNA can bind, it has a separate, RNA-specific site on the Q-loop in the ATP binding main. In the proposed quaternary structure of Rho, the Q-loops from the six subunits form the upper entrance to the hole in the ring-shaped hexamer through which the nascent transcript is translocated by actions coupled to ATP hydrolyses.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Richardson, JP (corresponding author), Indiana Univ, Dept Chem, 800 E Kirkwood Ave, Bloomington, IN 47405 USA.	richardj@indiana.edu			NIGMS NIH HHS [GM 56095] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BERNOWITZ M, 1986, METHOD ENZYMOL, V30, P133; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; Briercheck DM, 1996, J BIOMOL NMR, V8, P429; Briercheck DM, 1998, NAT STRUCT BIOL, V5, P393, DOI 10.1038/nsb0598-393; Burgess BR, 2001, J BIOL CHEM, V276, P4182, DOI 10.1074/jbc.M007066200; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18810; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; Gan E, 1999, BIOCHEMISTRY-US, V38, P16882, DOI 10.1021/bi991559i; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GEISELMANN J, 1992, PROTEIN SCI, V1, P850, DOI 10.1002/pro.5560010703; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; Loizos N, 1999, J BIOL CHEM, V274, P23378, DOI 10.1074/jbc.274.33.23378; Martinez A, 1996, J MOL BIOL, V257, P909, DOI 10.1006/jmbi.1996.0211; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nowatzke W, 1996, METHOD ENZYMOL, V274, P353; Nowatzke WL, 1996, J BIOL CHEM, V271, P742, DOI 10.1074/jbc.271.2.742; O IS, 1994, J BIOL CHEM, V269, P5009; ODA T, 1972, J MOL BIOL, V71, P799; OPPERMAN T, 1994, J BACTERIOL, V176, P5033, DOI 10.1128/jb.176.16.5033-5043.1994; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; PLATIS IE, 1993, BIOCHEMISTRY-US, V32, P12761, DOI 10.1021/bi00210a027; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; RANA TM, 1991, P NATL ACAD SCI USA, V88, P10578, DOI 10.1073/pnas.88.23.10578; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Stitt BL, 1998, J BIOL CHEM, V273, P26477, DOI 10.1074/jbc.273.41.26477; STITT BL, 1988, J BIOL CHEM, V263, P11130; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; WOOD TC, 1999, THESIS U VIRGINIA; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009; Yu X, 2000, J MOL BIOL, V299, P1279, DOI 10.1006/jmbi.2000.3810	47	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28380	28387		10.1074/jbc.M102444200	http://dx.doi.org/10.1074/jbc.M102444200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369775	hybrid			2022-12-27	WOS:000170093400085
J	Xiao, R; Solovyov, A; Gilbert, HF; Holmgren, A; Lundstrom-Ljung, J				Xiao, R; Solovyov, A; Gilbert, HF; Holmgren, A; Lundstrom-Ljung, J			Combinations of protein-disulfide isomerase domains show that there is little correlation between isomerase activity and wild-type growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOREDOXIN-LIKE DOMAINS; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; BOND FORMATION; SACCHAROMYCES-CEREVISIAE; RIBONUCLEASE-A; SITE CYSTEINE; REDUCTASE; CHAPERONE; CATALYSIS	Protein-disulfide isomerase (PDI) has five domains: a, b, b', a' and c, all of which except c have a thioredoxin fold. A single catalytic domain (a or a') is effective in catalyzing oxidation of a reduced protein but not isomerization of disulfides (Darby, N. J., and Creighton, T. E. (1995) Biochemistry 34, 11725-11735). To examine the structural basis for this oxidase and isomerase activity of PDI, shuffled domain mutants were generated using a method that should be generally applicable to multidomain proteins. Domains a and a' along with constructs ab, aa', aba', ab'a' display low disulfide isomerase activity, but all show significant reactivity with mammalian thioredoxin reductase, suggesting that the structure is not seriously compromised. The only domain order that retains significant isomerase activity has the b' domain coupled to the N terminus of the a' domain. This b'a'c has 38% of the isomerase activity of wild-type PDI, equivalent to the activity of full-length PDI with one of the active sites inactivated by mutation (Walker, K. W., Lyles, M. M., and Gilbert, H. F. (1996) Biochemistry 35, 1972-1980). Individual a and a' domains, despite their very low isomerase activities in vitro, support wild-type growth of a pdi1 Delta Saccharomyces cerevisiae strain yeast. Thus, most of the PDI structure is dispensable for its essential function in yeast, and high-level isomerase activity appears not required for viability or rapid growth.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden; Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA	Karolinska Institutet; Baylor College of Medicine	Lundstrom-Ljung, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden.				NIGMS NIH HHS [GM-40379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; CREIGHTON TE, 1995, TRENDS BIOTECHNOL, V13, P18, DOI 10.1016/S0167-7799(00)88896-4; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; Darby NJ, 1996, BIOCHEMISTRY-US, V35, P10517, DOI 10.1021/bi960763s; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FARQUHAR R, 1991, GENE, V108, P81, DOI 10.1016/0378-1119(91)90490-3; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Holst B, 1997, J CELL BIOL, V138, P1229, DOI 10.1083/jcb.138.6.1229; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Koivunen P, 1999, EMBO J, V18, P65, DOI 10.1093/emboj/18.1.65; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; Laboissiere MCA, 1997, BIOL CHEM, V378, P431; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; Puig A, 1997, J BIOL CHEM, V272, P32988, DOI 10.1074/jbc.272.52.32988; SIKORSKI RS, 1989, GENETICS, V122, P19; Sun XX, 2000, BBA-PROTEIN STRUCT M, V1481, P45, DOI 10.1016/S0167-4838(00)00122-9; VUORI K, 1992, J BIOL CHEM, V267, P7211; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	34	22	25	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27975	27980		10.1074/jbc.M104203200	http://dx.doi.org/10.1074/jbc.M104203200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375405	hybrid			2022-12-27	WOS:000170093400032
J	Zhang, HF; Lu, SL; Morrison, SL; Tomlinson, S				Zhang, HF; Lu, SL; Morrison, SL; Tomlinson, S			Targeting the functional antibody-decay-accelerating factor fusion proteins to a cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-SYSTEM; FACTOR-I; CD59; INHIBITION; C9; TRANSPLANTATION; INFLAMMATION; ACTIVATION; CLONING; DISEASE	Recombinant soluble complement inhibitors hold promise for the treatment, of inflammatory disease and disease states associated with transplantation. Targeting complement inhibitors to the site of complement activation and disease may enhance their efficacy and safety. Data presented show that targeting of decay-accelerating factor (DAF, an inhibitor of complement activation) to a cell surface by means of antibody fragments is feasible and that cell-targeted DAF provides significantly enhanced protection from complement deposition and lysis compared with soluble untargeted DAF. An extracellular region of DAF was joined to an antibody combining site with specificity for the hapten dansyl, at the end of either C(H)1 or C(H)3 Tg regions. The recombinant IgG-DAF chimeric proteins retained antigen specificity and bound to dansylated Chinese hamster ovary cells. Both soluble C(H)1-DAF and C(H)3-DAF were effective at inhibiting complement-mediated lysis of untargeted Chinese hamster ovary cells at molar concentrations within the range reported by others for soluble DAF. However, when targeted to a dansyl-labeled cell membrane, C(H)1-DAF was significantly more potent at inhibiting complement deposition and complement-mediated lysis. Cell-bound C(H)1-DAF also provided cells with protection from complement lysis after removal of unbound C(H)1-DAF. Of further importance, the insertion of a nonfunctional protein domain of DAF (the N-terminal short consensus repeat) between C(H)1 and the functional DAF domain increased activity of the fusion protein. In contrast to C(H)1-DAF, C(H)3-DAF was not significantly better at protecting targeted versus untargeted cells from complement, indicating that a small targeting vehicle is preferable to a large one. We have previously shown that for effective functioning of soluble complement inhibitor CD59, binding of CD59 to the cell surface close to the site of complement activation is required. Significantly, such a constraint did:not apply for effective DAF function.	Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	Medical University of South Carolina; University of California System; University of California Los Angeles	Tomlinson, S (corresponding author), Med Univ S Carolina, Dept Microbiol & Immunol, BSB 201,173 Ashley Ave, Charleston, SC 29425 USA.	tomlinss@musc.edu			NIAID NIH HHS [AI 34451] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034451, R29AI034451] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asghar SS, 2000, FRONT BIOSCI-LANDMRK, V5, pE63, DOI 10.2741/asghar; Brodbeck WG, 1996, J IMMUNOL, V156, P2528; Byrne G, 1997, TRANSPLANTATION, V63, P149, DOI 10.1097/00007890-199701150-00027; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; Christiansen D, 1996, EUR J IMMUNOL, V26, P578, DOI 10.1002/eji.1830260312; COYNE KE, 1992, J IMMUNOL, V149, P2906; FODOR WL, 1995, J IMMUNOL, V155, P4135; Harlow E., 1988, ANTIBODIES LAB MANUA; Higgins PJ, 1997, J IMMUNOL, V158, P2872; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; Kirschfink M, 1997, IMMUNOPHARMACOLOGY, V38, P51, DOI 10.1016/S0162-3109(97)00057-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW SKA, 1995, IN FOCUS, P46; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; MERI S, 1990, IMMUNOLOGY, V71, P1; MORAN P, 1992, J IMMUNOL, V149, P1736; Morgan BP, 1996, BIOCHEM SOC T, V24, P224, DOI 10.1042/bst0240224; Morgan BP, 1998, BIOCHEM SOC T, V26, P49, DOI 10.1042/bst0260049; NINOMIYA H, 1992, J BIOL CHEM, V267, P13675; POON PH, 1995, J BIOL CHEM, V270, P8571, DOI 10.1074/jbc.270.15.8571; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; RYAN US, 1995, NAT MED, V1, P967, DOI 10.1038/nm0995-967; SHIN SU, 1994, J BIOL CHEM, V269, P4979; SHIN SU, 1990, P NATL ACAD SCI USA, V87, P5322, DOI 10.1073/pnas.87.14.5322; Squinto SP, 1996, CURR OPIN BIOTECH, V7, P641, DOI 10.1016/S0958-1669(96)80076-0; Wang H, 1999, TRANSPLANTATION, V68, P1643, DOI 10.1097/00007890-199912150-00007; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955; Wang Y, 1996, P NATL ACAD SCI USA, V93, P8563, DOI 10.1073/pnas.93.16.8563; Yu JH, 1997, J EXP MED, V185, P745, DOI 10.1084/jem.185.4.745; Zhang HF, 1999, J CLIN INVEST, V103, P55, DOI 10.1172/JCI4607	31	23	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27290	27295		10.1074/jbc.M100436200	http://dx.doi.org/10.1074/jbc.M100436200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11352906	hybrid			2022-12-27	WOS:000169966900075
J	Percherancier, Y; Planchenault, T; Valenzuela-Fernandez, A; Virelizier, JL; Arenzana-Seisdedos, F; Bachelerie, F				Percherancier, Y; Planchenault, T; Valenzuela-Fernandez, A; Virelizier, JL; Arenzana-Seisdedos, F; Bachelerie, F			Palmitoylation-dependent control of degradation, life span, and membrane expression of the CCR5 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN-COUPLED RECEPTORS; MANNOSE 6-PHOSPHATE RECEPTOR; HIV-1 CORECEPTOR ACTIVITY; CHEMOKINE RECEPTORS; CYTOPLASMIC TAIL; CYSTEINE RESIDUES; POSTTRANSLATIONAL MODIFICATION; SIGNAL-TRANSDUCTION; ADENOSINE RECEPTOR	We have shown that the chemokine and HIV receptor CCR5 is palmitoylated on a cluster of cysteine residues located at the boundary between the seventh transmembrane region and the cytoplasmic tail. Single or combined substitutions of the three cysteines (Cys-321, Cys-323, and Cys-324) or incubation of wild-type CCR5-transfected cells with the palmitic acid analog 2-bromopalmitate prevented palmitoylation of the receptor. Moreover, failure of CCR5 to be palmitoylated resulted in both accumulation in intracellular stores and a profound decrease of membrane expression of the receptor. Upon metabolic labeling, kinetic experiments showed that the half-life of palmitoylation-deficient CCR5 is profoundly decreased. Bafilomycin A1, but not a specific proteasome inhibitor, prevented early degradation of palmitoylation-deficient CCR5 and promoted its accumulation in lysosomal compartments. Although membrane expression of the CCR5 mutant was diminished, the molecules reaching the membrane were still able to interact efficiently with the chemokine ligand MIP1 beta and remained able to function as BW co-receptors. Thus we conclude that palmitoylation controls CCR5 expression through regulation of the life span of this receptor.	Inst Pasteur, Unite Immunol Virale, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Bachelerie, F (corresponding author), Inst Pasteur, Unite Immunol Virale, 25-28 Rue Dr Roux, F-75724 Paris 15, France.	fbachele@pasteur.fr	Arenzana-Seisdedos, Fernando/E-5835-2016; BACHELERIE, FRANCOISE/F-8823-2013; Valenzuela-Fernández, Agustín/B-6219-2014; Valenzuela-Fernández, Agustín/P-1638-2019	BACHELERIE, FRANCOISE/0000-0002-0399-3277; Valenzuela-Fernández, Agustín/0000-0002-2585-8703; Valenzuela-Fernández, Agustín/0000-0002-2585-8703; percherancier, yann/0000-0002-2410-5806				Alfano M, 2000, J VIROL, V74, P8767, DOI 10.1128/JVI.74.18.8767-8770.2000; Alfano M, 1999, J EXP MED, V190, P597, DOI 10.1084/jem.190.5.597; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; AnsariLari MA, 1997, NAT GENET, V16, P221, DOI 10.1038/ng0797-221; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Blanpain C, 1999, BLOOD, V94, P1899; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; BOUVIER M, 1995, BIOCHEM SOC T, V23, P577, DOI 10.1042/bst0230577; Breuer P, 1998, J BIOL CHEM, V273, P33254, DOI 10.1074/jbc.273.50.33254; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CRISE B, 1992, J BIOL CHEM, V267, P13593; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DRAGIC T, 1993, J VIROL, V67, P2355, DOI 10.1128/JVI.67.4.2355-2359.1993; Drose S, 1997, J EXP BIOL, V200, P1; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Gao ZH, 1999, BIOCHEM J, V342, P387, DOI 10.1042/0264-6021:3420387; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Guntermann C, 1999, BIOCHEM BIOPH RES CO, V256, P429, DOI 10.1006/bbrc.1999.0333; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hayashi MK, 1997, ARCH BIOCHEM BIOPHYS, V340, P376, DOI 10.1006/abbi.1997.9906; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; JENSEN AA, 1995, J NEUROCHEM, V65, P1325, DOI 10.1046/j.1471-4159.1995.65031325.x; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JING SQ, 1990, J BIOL CHEM, V265, P11555; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KAWATE N, 1994, J BIOL CHEM, V269, P30651; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; Margolis LB, 1998, J CLIN INVEST, V101, P1876, DOI 10.1172/JCI2015; MERRITT EA, 1994, PROTEIN SCI, V3, P166; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; MOENCH SJ, 1994, BIOCHEMISTRY-US, V33, P5791, DOI 10.1021/bi00185a017; Moffett S, 2001, J NEUROCHEM, V76, P269, DOI 10.1046/j.1471-4159.2001.00005.x; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Morello JP, 1996, BIOCHEM CELL BIOL, V74, P449, DOI 10.1139/o96-049; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; OBRIEN PJ, 1984, J BIOL CHEM, V259, P5054; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; Palmer TM, 2000, MOL PHARMACOL, V57, P539, DOI 10.1124/mol.57.3.539; Paoletti F, 1997, J CELL PHYSIOL, V172, P63, DOI 10.1002/(SICI)1097-4652(199707)172:1<63::AID-JCP7>3.3.CO;2-F; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; PLANELLES V, 1995, J VIROL, V69, P5883, DOI 10.1128/JVI.69.9.5883-5889.1995; Quillent C, 1998, LANCET, V351, P14, DOI 10.1016/S0140-6736(97)09185-X; Renard P, 2000, J BIOL CHEM, V275, P15193, DOI 10.1074/jbc.275.20.15193; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Sadeghi HM, 1997, MOL PHARMACOL, V52, P21, DOI 10.1124/mol.52.1.21; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Segerer S, 1999, KIDNEY INT, V56, P52, DOI 10.1046/j.1523-1755.1999.00544.x; Shioda T, 2001, J VIROL, V75, P3462, DOI 10.1128/JVI.75.7.3462-3468.2001; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; van de Loo JWHP, 2000, BIOCHEM J, V352, P827, DOI 10.1042/0264-6021:3520827; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141	79	120	123	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31936	31944		10.1074/jbc.M104013200	http://dx.doi.org/10.1074/jbc.M104013200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11390405	hybrid			2022-12-27	WOS:000170613500065
J	Lee-Kwon, W; Johns, DC; Cha, BY; Cavet, M; Park, J; Tsichlis, P; Donowitz, M				Lee-Kwon, W; Johns, DC; Cha, BY; Cavet, M; Park, J; Tsichlis, P; Donowitz, M			Constitutively active phosphatidylinositol 3-kinase and AKT are sufficient to stimulate the epithelial Na+/H+ exchanger 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE B; C-TERMINAL DOMAINS; GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; GLUT4 TRANSLOCATION; GLUCOSE-TRANSPORT; LIPID PRODUCTS; INSULIN STIMULATION; ADENOVIRUS VECTORS; 3T3-L1 ADIPOCYTES	Phosphatidylinositol 3-kinase (PI 3-kinase) is a cytoplasmic signaling molecule that is recruited to activated growth factor receptors and has been shown to be involved in regulation of stimulated exocytosis and endocytosis. One of the downstream signaling molecules activated by PI 3-kinase is the protein kinase Akt. Previous studies have indicated that PI 3-kinase is necessary for basal Na+/H+ exchanger 3 (NHE3) transport and for fibroblast growth factor-stimulated NHE3 activity in PS120 fibroblasts. However, it is not known whether activation of PI 3-kinase is sufficient to stimulate NHE3 activity or whether Akt is involved in this PI 3-kinase effect. We used an adenoviral infection system to test the possibility that activation of PI 3-kinase or Akt alone is sufficient to stimulate NHE3 activity. This hypothesis was investigated in PS120 fibroblasts stably expressing NHE3 after somatic gene transfer using a replication-deficient recombinant adenovirus containing constitutively active catalytic subunit of PI 3-kinase or constitutively active Akt. The adenovirus construct used was engineered with an upstream ecdysone promoter to allow time-regulated expression. Adenoviral infection was nearly 100% at 48 h after infection. Forty-eight hours after infection (24 It after activation of the ecdysone promoter), PI 3-kinase and Akt amount and activity were increased. Increases in both PI 3-kinase activity and Akt activity stimulated NHE3 transport. In addition, a membrane-permeant synthetic 10-mer peptide that binds polyphosphoinositides and increases PI 3-kinase activity similarly enhanced NHE3 transport activity and also increased the percentage of NHE3 on the plasma membrane. The magnitudes of stimulation of NHE3 by constitutively active PI 3-kinase, PI 3-kinase peptide, and constitutively active Akt were similar to each other. These results demonstrate that activation of PI 3-kinase or Akt is sufficient to stimulate NHE3 transport activity in PS120/NHE3 cells.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Thomas Jefferson Univ, Dept Microbiol, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Jefferson University; Jefferson University; Johns Hopkins University	Donowitz, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 725 Rutland Ave, Baltimore, MD 21205 USA.	mdonowit@jhmi.edu			NIDDK NIH HHS [R01 DK26523] Funding Source: Medline; PHS HHS [P01 44484] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026523] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhter S, 2000, BIOCHEMISTRY-US, V39, P1990, DOI 10.1021/bi991739s; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; DONOWITZ M, 1994, AM J PHYSIOL, V266, pG647, DOI 10.1152/ajpgi.1994.266.4.G647; Donowitz M, 2001, CURR TOP MEMBR, V50, P437; Foster LJ, 2000, AM J PHYSIOL-CELL PH, V279, pC877, DOI 10.1152/ajpcell.2000.279.4.C877; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frevert EU, 1998, J BIOL CHEM, V273, P25480, DOI 10.1074/jbc.273.39.25480; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; Hoogerwerf WA, 1996, AM J PHYSIOL-GASTR L, V270, pG29, DOI 10.1152/ajpgi.1996.270.1.G29; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Hubner S, 1998, EUR J BIOCHEM, V258, P846, DOI 10.1046/j.1432-1327.1998.2580846.x; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Janecki AJ, 2000, J HISTOCHEM CYTOCHEM, V48, P1479, DOI 10.1177/002215540004801105; Janecki AJ, 2000, J BIOL CHEM, V275, P8133, DOI 10.1074/jbc.275.11.8133; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; Janmey PA, 1999, CHEM PHYS LIPIDS, V101, P93, DOI 10.1016/S0009-3084(99)00058-4; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; Johns DC, 1999, J NEUROSCI, V19, P1691; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lee-Kwon W, 1998, BIOCHEMISTRY-US, V37, P15747, DOI 10.1021/bi9805947; Lee-Kwon W, 1998, EXP CELL RES, V241, P458, DOI 10.1006/excr.1998.4087; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; Misra S, 1999, P NATL ACAD SCI USA, V96, P5814, DOI 10.1073/pnas.96.10.5814; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Noel J, 1996, J CELL SCI, V109, P929; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TSE CM, 1993, P NATL ACAD SCI USA, V90, P9110, DOI 10.1073/pnas.90.19.9110; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Valverde AM, 1999, BIOCHEM J, V337, P397, DOI 10.1042/0264-6021:3370397; Wang LH, 1999, J BIOL CHEM, V274, P19246, DOI 10.1074/jbc.274.27.19246; Wang QH, 1999, MOL CELL BIOL, V19, P4008	54	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31296	31304		10.1074/jbc.M103900200	http://dx.doi.org/10.1074/jbc.M103900200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11375999	hybrid			2022-12-27	WOS:000170472900093
J	Charpilienne, A; Nejmeddine, M; Berois, M; Parez, N; Neumann, E; Hewat, E; Trugnan, G; Cohen, J				Charpilienne, A; Nejmeddine, M; Berois, M; Parez, N; Neumann, E; Hewat, E; Trugnan, G; Cohen, J			Individual rotavirus-like particles containing 120 molecules of fluorescent protein are visible in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-LIKE PARTICLES; 3-DIMENSIONAL RECONSTRUCTION; CAPSID PROTEINS; VP2; EXPRESSION; MICROSCOPY; IMMUNITY; EPITOPE; MODEL; LAYER	Rotaviruses are large, complex icosahedral particles consisting of three concentric capsid layers. When the innermost capsid protein VP2 is expressed in the baculovirus-insect cell system it assembles as core-like particles. The amino terminus region of VP2 is dispensable for assembly of virus-like particles (VLP). Coexpression of VP2 and VP6 produces double layered VLP. We hypothesized that the amino end of VP2 could be extended without altering the auto assembly properties of VP2. Using the green fluorescent protein (GFP) or the DsRed protein as model inserts we have shown that the chimeric protein GFP (or DsRed)-VP2 auto assembles perfectly well and forms fluorescent VLP (GFP-VLP2/6 or DsRed-VLP2/6) when coexpressed with VP6. The presence of GFP inside the core does not prevent the assembly of the outer capsid layer proteins VP7 and VP4 to give VLP2/6/7/4. Cryo-electron microscopy of purified GFP-VLP2/6 showed that GFP molecules are located at the 5-fold vertices of the core. It is possible to visualize a single fluorescent VLP in living cells by confocal fluorescent microscopy. In vitro VLP2/6 did not enter into permissive cells or in dendritic cells. In contrast, fluorescent VLP2/6/7/4 entered the cells and then the fluorescence signal disappear rapidly. Presented data indicate that fluorescent VLP are interesting tools to follow in real time the entry process of rotavirus and that chimeric VLP could be envisaged as "nanoboxes" carrying macromolecules to living cells.	INRA, F-78352 Jouy En Josas, France; Univ Paris 06, INSERM, U538, F-75571 Paris 12, France; Hop Armand Trousseau, Virol Lab, EA 2391, UFR St Antoine, Paris, France; Inst Biol Struct, Lab Microscopie Elect Struct, F-38027 Grenoble 1, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Cohen, J (corresponding author), INRA, F-78352 Jouy En Josas, France.			Nejmeddine, Mohamed/0000-0003-0160-2727				Baird GS, 2000, P NATL ACAD SCI USA, V97, P11984, DOI 10.1073/pnas.97.22.11984; Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; Ball JM, 1996, ARCH VIROL, P243; BELYAEV AS, 1992, VIROLOGY, V190, P840, DOI 10.1016/0042-6822(92)90922-C; Canque B, 2000, BLOOD, V96, P3748, DOI 10.1182/blood.V96.12.3748.h8003748_3748_3756; CRAWFORD SE, 1994, J VIROL, V68, P5945, DOI 10.1128/JVI.68.9.5945-5952.1994; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; FRANCO MA, 1993, J GEN VIROL, V74, P2579, DOI 10.1099/0022-1317-74-12-2579; Fuller SD, 1996, J STRUCT BIOL, V116, P48, DOI 10.1006/jsbi.1996.0009; GEORGI A, 1990, P NATL ACAD SCI USA, V87, P6579, DOI 10.1073/pnas.87.17.6579; Gilbert JM, 1997, J VIROL, V71, P4555, DOI 10.1128/JVI.71.6.4555-4563.1997; Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280; Greenstone HL, 1998, P NATL ACAD SCI USA, V95, P1800, DOI 10.1073/pnas.95.4.1800; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; Hewat EA, 1996, EMBO J, V15, P1515, DOI 10.1002/j.1460-2075.1996.tb00495.x; Hill CL, 1999, NAT STRUCT BIOL, V6, P565, DOI 10.1038/9347; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; Kratz PA, 1999, P NATL ACAD SCI USA, V96, P1915, DOI 10.1073/pnas.96.5.1915; LABBE M, 1994, J GEN VIROL, V75, P3423, DOI 10.1099/0022-1317-75-12-3423; LABBE M, 1991, J VIROL, V65, P2946; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT S, 1994, J VIROL, V68, P6794, DOI 10.1128/JVI.68.10.6794-6798.1994; Lawton JA, 1997, J VIROL, V71, P7353, DOI 10.1128/JVI.71.10.7353-7360.1997; Liprandi F, 1997, VIROLOGY, V237, P430, DOI 10.1006/viro.1997.8803; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; MIYAMURA K, 1994, P NATL ACAD SCI USA, V91, P8507, DOI 10.1073/pnas.91.18.8507; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; ONeal CM, 1997, J VIROL, V71, P8707, DOI 10.1128/JVI.71.11.8707-8717.1997; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; PEARSON LD, 1993, IMMUNOL CELL BIOL, V5, P381; Prasad BVV, 1996, NATURE, V382, P471, DOI 10.1038/382471a0; PRASAD BVV, 1988, J MOL BIOL, V199, P269, DOI 10.1016/0022-2836(88)90313-0; Rollo EE, 1999, J IMMUNOL, V163, P4442; Ruiz MC, 1996, J VIROL, V70, P4877, DOI 10.1128/JVI.70.8.4877-4883.1996; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; Sedlik C, 1997, P NATL ACAD SCI USA, V94, P7503, DOI 10.1073/pnas.94.14.7503; YOSHIMURA A, 1984, J VIROL, V51, P497, DOI 10.1128/JVI.51.2.497-504.1984; ZENG CQY, 1994, VIROLOGY, V201, P55, DOI 10.1006/viro.1994.1265; Zeng CQY, 1998, J VIROL, V72, P201, DOI 10.1128/JVI.72.1.201-208.1998	39	128	130	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29361	29367		10.1074/jbc.M101935200	http://dx.doi.org/10.1074/jbc.M101935200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11356839	hybrid, Green Published			2022-12-27	WOS:000170346000097
J	Egloff, AM; Desiderio, S				Egloff, AM; Desiderio, S			Identification of phosphorylation sites for Bruton's tyrosine kinase within the transcriptional regulator BAP/TFII-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; B-CELL MATURATION; C-FOS PROMOTER; TFII-I; IMMUNODEFICIENT MICE; BINDING PROTEIN; FAMILY KINASES; TEC KINASE; SRC FAMILY; ACTIVATION	Bruton's tyrosine kinase (Btk), a member of the Tee family of cytosolic kinases, is essential for B cell development and function. BAP/TFII-I, a protein implicated in transcriptional regulation, is associated with Btk in B cells and is transiently phosphorylated on tyrosine following B cell receptor engagement. BAP/TFII-I is a substrate for Btk in vitro and is hyperphosphorylated on tyrosine upon coexpression with Btk in mammalian cells. In an effort to understand the physiologic consequences of BAP/TFII-I tyrosine phospholylation following B cell receptor stimulation, site-directed mutagenesis and phosphopeptide mapping were used to locate the predominant sites of BAP/TFII-I phosphorylation by Btk in vitro. These residues, Tyr(248), Tyr(357), and Tyr(462), were also found to be the major sites for Btk-dependent phosphorylation of BAP/TFII-I in vivo. Residues Tyr(357) and Tyr(462) are contained within the loop regions of adjacent helix-loop-helix-like repeats within BAP/TFII-L Mutation of either Tyr(248), Tyr(357), or Tyr(462) to phenylalanine reduced transcription from a c-fos promoter relative to wild-type BAP/TFII-I in transfected COS-7 cells, consistent with the interpretation that phosphorylation at these sites contributes to transcriptional activation. Phosphorylation of BAP/TFII-I by Btk may link engagement of receptors such as surface immunoglobulin to modulation of gene expression.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Desiderio, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.				NCI NIH HHS [CA16519] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Cheriyath V, 2000, J BIOL CHEM, V275, P26300, DOI 10.1074/jbc.M002980200; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HARDY RR, 1983, NATURE, V306, P270, DOI 10.1038/306270a0; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P450, DOI 10.1002/eji.1830160423; HU Q, 1995, J BIOL CHEM, V270, P1928, DOI 10.1074/jbc.270.4.1928; HUNTER T, 1991, METHOD ENZYMOL, V210, P110; JONES DH, 1992, BIOTECHNIQUES, V12, P528; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Khan WN, 1997, INT IMMUNOL, V9, P395, DOI 10.1093/intimm/9.3.395; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Kim DW, 2000, MOL CELL BIOL, V20, P1140, DOI 10.1128/MCB.20.4.1140-1148.2000; KOIKE M, 1995, INT IMMUNOL, V7, P21, DOI 10.1093/intimm/7.1.21; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; MANO H, 1993, ONCOGENE, V8, P417; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Novina CD, 1998, J BIOL CHEM, V273, P33443, DOI 10.1074/jbc.273.50.33443; Novina CD, 1999, MOL CELL BIOL, V19, P5014; PABORSKY LR, 1990, PROTEIN ENG, V3, P547, DOI 10.1093/protein/3.6.547; PEARL ER, 1978, J IMMUNOL, V120, P1169; PERLMUTTER RM, 1979, J EXP MED, V149, P993, DOI 10.1084/jem.149.4.993; Rawlings DJ, 1999, CLIN IMMUNOL, V91, P243, DOI 10.1006/clim.1999.4732; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SANTOSARGUMEDO L, 1995, INT IMMUNOL, V7, P163, DOI 10.1093/intimm/7.2.163; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	44	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27806	27815		10.1074/jbc.M103692200	http://dx.doi.org/10.1074/jbc.M103692200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373296	hybrid			2022-12-27	WOS:000170093400011
J	Kawaguchi, T; Veech, RL; Uyeda, K				Kawaguchi, T; Veech, RL; Uyeda, K			Regulation of energy metabolism in macrophages during hypoxia - Roles of fructose 2,6-bisphosphate and ribose 1,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT-LIVER; KINETIC-PROPERTIES; PHOSPHOLIPASE-C; PATHWAY; ACTIVATION; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE; PHOSPHOFRUCTOKINASES; HEPATOCYTES; GLYCOLYSIS	Macrophages can adapt to the absence of oxygen by switching to anaerobic glycolysis. In this study, we investigated (a) the roles of fructose 2,6-bisphosphate (Fru-2,6-P-2) and ribose 1,5-bisphosphate (Rib-1,5-P-2), Potent activators of phosphofructokinase, (b) the enzymes responsible for the synthesis of Rib-1,5-P-2, and (c) the mechanisms of regulation of these enzymes in H36.12j macrophages during the initial phase of hypoxia. Within I min after initiating hypoxia, glycolysis was activated through activation of phosphofructokinase. Over the same period, Fru-2,6-P-2 decreased 50% and recovered completely upon reoxygenation. Similar changes in cAMP levels were observed. In contrast, the Rib-1,5-P-2 concentration rapidly increased to a maximum level of 8.0 +/- 0.9 nmol/g cell 30 s after hypoxia. Thus, Rib-1,5-P-2 was the major factor increasing the rate of glycolysis during the initial phase of hypoxia. Moreover, we found that Rib-1,5-P-2 was synthesized by two steps: the ribose-phosphate pyrophosphokinase (5-phosphoribosyl-1-pyrophosphate synthetase; PRPP synthetase) reaction (EC 2.7.6.1) catalyzing the reaction, Rib-5-P + ATP --> PRPP + AMP and a new enzyme, "PRPP pyrophosphatase" catalyzing the reaction, PRPP --> Rib-1,5-P-2 + P-i. Both PRPP synthetase and PRPP pyrophosphatase were significantly activated 30 s after hypoxia. Pretreatment with 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine and calphostin C prevented the activation of ribose PRPP synthetase and PRPP pyrophosphatase as well as increase in Rib-1,5-P-2 and activation of phosphofructokinase 30 s after hypoxia. These data suggest that the activation of the above enzymes was mediated by protein kinase C acting via activation of phosphatidylinositol specific phospholipase C in the macrophages during hypoxia.	Dallas Vet Affairs Med Ctr, Dept Biochem, Dallas, TX 75216 USA; Univ Texas, SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75223 USA; NIAAA, Rockville, MD 20852 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Uyeda, K (corresponding author), Dallas Vet Affairs Med Ctr, Dept Biochem, 4500 S Lancaster Rd, Dallas, TX 75216 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016194] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK16194] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beitner-Johnson D, 1998, BIOCHEM BIOPH RES CO, V242, P61, DOI 10.1006/bbrc.1997.7907; BLACKMORE PF, 1982, FEBS LETT, V142, P255, DOI 10.1016/0014-5793(82)80147-6; Derevianko A, 1996, J SURG RES, V62, P32, DOI 10.1006/jsre.1996.0169; FEDOROV S, 1992, J BIOL CHEM, V267, P20826; GUHA SK, 1986, ARCH BIOCHEM BIOPHYS, V250, P513, DOI 10.1016/0003-9861(86)90756-3; HUE L, 1982, BIOCHEM J, V206, P359, DOI 10.1042/bj2060359; ISHIKAWA E, 1990, J BIOL CHEM, V265, P18875; Kato H, 2000, BRAIN PATHOL, V10, P137; KIM YA, 1992, AM J PHYSIOL, V262, pE344, DOI 10.1152/ajpendo.1992.262.3.E344; KING MT, 1990, ANAL BIOCHEM, V187, P179, DOI 10.1016/0003-2697(90)90438-F; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KORNBERG A, 1955, J BIOL CHEM, V215, P389; Lewis JS, 1999, J LEUKOCYTE BIOL, V66, P889, DOI 10.1002/jlb.66.6.889; NISHIMURA M, 1994, J BIOL CHEM, V269, P26100; OGUSHI S, 1990, J BIOL CHEM, V265, P10943; Okamura N, 1998, BIOSCI BIOTECH BIOCH, V62, P2039, DOI 10.1271/bbb.62.2039; POWIS G, 1992, CANCER RES, V52, P2835; RACKER E, 1974, METHOD ENZYMAT AN, V2, P1342; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; ROSE IA, 1974, BIOCHEM BIOPH RES CO, V59, P1333, DOI 10.1016/0006-291X(74)90460-4; Sakai A, 1996, J BIOCHEM-TOKYO, V119, P506; Sakakibara R, 1997, J BIOCHEM-TOKYO, V122, P122; SAKAKIBARA R, 1984, J BIOL CHEM, V259, P41; Sakakibara R, 1999, BIOCHEM BIOPH RES CO, V257, P177, DOI 10.1006/bbrc.1999.0429; Simakajornboon N, 2000, NEUROSCI LETT, V278, P17, DOI 10.1016/S0304-3940(99)00887-3; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; UYEDA K, 1981, J BIOL CHEM, V256, P8394; UYEDA K, 1991, STUDY ENZYMES, V2, P445; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VINCENT MF, 1982, BIOCHEM J, V202, P117, DOI 10.1042/bj2020117; Weissmann N, 1999, AM J PHYSIOL-LUNG C, V276, pL90, DOI 10.1152/ajplung.1999.276.1.L90	31	55	60	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28554	28561		10.1074/jbc.M101396200	http://dx.doi.org/10.1074/jbc.M101396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373280	hybrid			2022-12-27	WOS:000170093400108
J	Mayer, IA; Verma, A; Grumbach, IM; Uddin, S; Lekmine, F; Ravandi, F; Majchrzak, B; Fujita, S; Fish, EN; Platanias, LC				Mayer, IA; Verma, A; Grumbach, IM; Uddin, S; Lekmine, F; Ravandi, F; Majchrzak, B; Fujita, S; Fish, EN; Platanias, LC			The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACTIVATED PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATION; SERINE PHOSPHORYLATION; STRUCTURAL BASIS; ADAPTER PROTEIN; STAT PROTEINS; I INTERFERONS; GENE; CRKL	The mechanisms by which interferon-alpha (IFN-alpha) mediates its anti-leukemic effects in chronic myelogenous leukemia (CML) cells are not known. We determined whether p38 MAPK is activated by IFN-alpha in BCR-ABLexpressing cells and whether its function is required for the generation of growth inhibitory responses. IFN-alpha treatment induced phosphorylation/activation of p38 in the IFN-alpha -sensitive KT-1 cell line, but not in IFN-alpha -resistant K562 cells. Consistent with this, IFN-alpha treatment of KT-1 (but not K562) cells induced activation of the small GTPase Racl, which functions as an upstream regulator of p38. In addition, IFN-alpha -dependent phosphorylationfactivation of p38 was induced by treatment of primary granulocytes isolated from the peripheral blood of patients with CAIL. To define the functional role of the Rac1/p38 ALkPK pathway in IFN-alpha signaling, the effects of pharmacological inhibition of p38 on the induction of IFN-alpha responses were determined. Treatment of KT-1 cells with the p38-specific inhibitors SB203580 and SB202190 reversed the growth inhibitory effects of IFN-alpha. On the other hand, the MEK kinase inhibitor PD09SO59 had no effects, further demonstrating the specificity of these findings. To directly determine the significance of IFN-alpha -dependent activation of p38 in the induction of the anti-leukemic effects of IFN-alpha, we evaluated the effects of p38 inhibition on leukemic colony formation in bone marrow samples of patients with CML. IFN-alpha inhibited leukemic granulocyte/ macrophage colony formation in a dose-dependent manner, whereas concomitant treatment with p38 inhibitors reversed such an inhibition. Thus, the Rac1-/p38 MAPK pathway is activated by IFN-alpha in BCR-ABL-expressing cells and appears to play a key role in the generation of the growth inhibitory effects of IFN-alpha in CAIL cells.	Univ Illinois, Hematol Oncol Sect, MBRB, Dept Med, Chicago, IL 60607 USA; W Side Vet Affairs Med Ctr, Chicago, IL 60607 USA; Univ Toronto, Dept Immunol, Toronto, ON M5S 3E2, Canada; Univ Toronto, UNiv Network, Toronto Res Inst, Div Cell & Mol Biol, Toronto, ON M5S 3E2, Canada; Ehime Univ, Dept Internal Med 1, Matsuyama, Ehime 7910295, Japan	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Toronto; University of Toronto; Ehime University	Platanias, LC (corresponding author), Univ Illinois, Hematol Oncol Sect, MBRB, Dept Med, MC-734,Rm 3150,900 S Ashland Ave, Chicago, IL 60607 USA.			Grumbach, Isabella/0000-0002-2285-3157; Uddin, Shahab/0000-0003-1886-6710	NATIONAL CANCER INSTITUTE [R29CA073381, R01CA077816] Funding Source: NIH RePORTER; NCI NIH HHS [CA77816, CA73381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; FISH EN, 1992, J INTERFERON RES, V12, P257, DOI 10.1089/jir.1992.12.257; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; GOEBERT M, 1997, EMBO J, V16, P3563; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Grumbach IM, 2001, BRIT J HAEMATOL, V112, P327, DOI 10.1046/j.1365-2141.2001.02556.x; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Pane F, 1999, BLOOD, V94, P2200, DOI 10.1182/blood.V94.7.2200.419a33_2200_2207; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Pfeffer LM, 1998, CANCER RES, V58, P2489; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 1999, EXP HEMATOL, V27, P1315, DOI 10.1016/S0301-472X(99)00060-0; Salojin KV, 1999, J IMMUNOL, V163, P844; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Stadler M, 1995, ONCOGENE, V11, P2565; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; WETZLER M, 1995, AM J MED, V99, P402, DOI 10.1016/S0002-9343(99)80189-2; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Yanagisawa K, 1998, BLOOD, V91, P641, DOI 10.1182/blood.V91.2.641.641_641_648; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	42	124	129	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28570	28577		10.1074/jbc.M011685200	http://dx.doi.org/10.1074/jbc.M011685200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11353767	hybrid			2022-12-27	WOS:000170093400110
J	Marin, EP; Krishna, AG; Sakmar, TP				Marin, EP; Krishna, AG; Sakmar, TP			Rapid activation of transducin by mutations distant from the nucleotide-binding site - Evidence for a mechanistic model of receptor-catalyzed nucleotide exchange by G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; STRUCTURAL DETERMINANTS; TRANSITION-STATE; RHODOPSIN; RAS; PHOSPHODIESTERASE; G(I-ALPHA-1); G(S-ALPHA); PEPTIDES	G proteins act as molecular switches in which information flow depends on whether the bound nucleotide is GDP ("off") or GTP ("on"). We studied the basal and receptor-catalyzed nucleotide exchange rates of site-directed mutants of the alpha subunit of transducin, We identified three amino acid residues (Thr-325, Val-328, and Phe-332) in which mutation resulted in dramatic increases (up to 165-fold) in basal nucleotide exchange rates in addition to enhanced receptor-catalyzed nucleotide exchange rates. These three residues are located on the inward facing surface of the alpha5 helix, which lies between the carboxyl-terminal tail and a loop contacting the nucleotide-binding pocket, Mutation of amino acid residues on the outward facing surface of the same alpha5 helix caused a decrease in receptor-catalyzed nucleotide exchange. We propose that the alpha5 helix comprises a functional microdomain in G proteins that affects basal nucleotide release rates and mediates receptor-catalyzed nucleotide exchange at a distance from the nucleotide-binding pocket.	Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Sakmar, TP (corresponding author), Rockefeller Univ, Biochem & Mol Biol Lab, 1230 York Ave, New York, NY 10021 USA.	sakmar@rockvax.rockefeller.edu	Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953; Aradhyam, Gopala Krishna/0000-0001-8232-3935	NIGMS NIH HHS [GM07982, GM07739] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Bohm A, 1997, CURR OPIN BIOTECH, V8, P480, DOI 10.1016/S0958-1669(97)80072-9; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DENKER BM, 1995, BIOCHEMISTRY-US, V34, P5544, DOI 10.1021/bi00016a028; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; Marin EP, 2001, J BIOL CHEM, V276, P23873, DOI 10.1074/jbc.M101197200; Marsh SR, 1998, MOL PHARMACOL, V53, P981; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MENON ST, 2001, IN PRESS PHYSL REV; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Min KC, 2000, PROTEIN EXPRES PURIF, V20, P514, DOI 10.1006/prep.2000.1326; MIXONMB, 1995, SCIENCE, V20, P954; Muradov KG, 2000, BIOCHEMISTRY-US, V39, P3937, DOI 10.1021/bi992156l; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Posner BA, 1998, J BIOL CHEM, V273, P21752, DOI 10.1074/jbc.273.34.21752; QUILLIAM LA, 1995, P NATL ACAD SCI USA, V92, P1272, DOI 10.1073/pnas.92.5.1272; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; SAKMAR TP, 1988, NUCLEIC ACIDS RES, V16, P6361, DOI 10.1093/nar/16.14.6361; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014	45	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27400	27405		10.1074/jbc.C100198200	http://dx.doi.org/10.1074/jbc.C100198200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356823	hybrid			2022-12-27	WOS:000169966900089
J	Reuther, GW; Lambert, QT; Booden, MA; Wennerberg, K; Becknell, B; Marcucci, G; Sondek, J; Caligiuri, MA; Der, CJ				Reuther, GW; Lambert, QT; Booden, MA; Wennerberg, K; Becknell, B; Marcucci, G; Sondek, J; Caligiuri, MA; Der, CJ			Leukemia-associated Rho guanine nucleotide exchange factor, a Dbl family protein found mutated in leukemia, causes transformation by activation of RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; HETEROTRIMERIC G-PROTEINS; STRESS FIBER FORMATION; GTP-BINDING PROTEINS; RAS TRANSFORMATION; SIGNAL-TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; STRUCTURAL SIMILARITIES; DEPENDENT ACTIVATION; EXPRESSION CLONING	Leukemia-associated Rho guanine nucleotide exchange factor (LARG) was originally identified as a fusion partner with mixed-lineage leukemia in a patient with acute myeloid leukemia. LARG possesses a tandem Dbl homology and pleckstrin homology domain structure and, consequently, may function as an activator of Rho GTPases. In this study, we demonstrate that LARG is a functional Dbl protein. Expression of LARG in cells caused activation of the serum response factor, a known downstream target of Rho-mediated signaling pathways. Transient overexpression of LARG did not activate the extracellular signal-regulated kinase or c-Jun NH2-terminal kinase mitogen-activated protein kinase cascade, suggesting LARG is not an activator of Ras, Rac, or Cdc42, We performed in vitro exchange assays where the isolated Dbl homology (DH) or DH/pleckstrin homology domains of LARG functioned as a strong activator of RhoA, but exhibited no activity toward Rad or Cdc42. We found that LARG could complex with RhoA, but not Rac or Cdc42, in vitro, and that expression of LARG caused an increase in the levels of the activated GTP-bound form of RhoA, but not Rad or Cdc42, in vivo. Thus, we conclude that LARG is a RhoA-specific guanine nucleotide exchange factor. Finally, like activated RhoA, we determined that LARG cooperated with activated Raf-1 to transform NIH3T3 cells. These data demonstrate that LARG is the first functional Dbl protein mutated in cancer and indicate LARG-mediated activation of RhoA may play a role in the development of human leukemias.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Ohio State Univ, Coll Med & Publ Hlth, Div Hematol & Oncol, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Div Human Canc Genet, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Virol Immunol & Med Genet, Ctr Comprehens Canc, Columbus, OH 43210 USA	University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Reuther, GW (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.	greuther@med.unc.edu	Reuther, Gary/AFR-2892-2022; Wennerberg, Krister/AFM-0539-2022; Wennerberg, Krister/AAH-2919-2022	Wennerberg, Krister/0000-0002-1352-4220; Wennerberg, Krister/0000-0002-1352-4220; Sondek, John/0000-0002-1127-8310; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978, K08CA090469, R01CA063071, R01CA055008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057391] Funding Source: NIH RePORTER; NCI NIH HHS [CA63071, CA42978, KO8-CA90469, CA55008] Funding Source: Medline; NIGMS NIH HHS [R01-GM57391] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN SY, 1994, ONCOGENE, V9, P2691; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; GRAZIANI G, 1989, ONCOGENE, V4, P823; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART M, 1995, METHOD ENZYMOL, V255, P129; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Manser E, 1999, Prog Mol Subcell Biol, V22, P115; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reid T, 1999, J BIOL CHEM, V274, P33587, DOI 10.1074/jbc.274.47.33587; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 2000, METHOD ENZYMOL, V325, P264; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Rumenapp U, 1999, FEBS LETT, V459, P313, DOI 10.1016/S0014-5793(99)01270-3; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Solski PA, 2000, METHOD ENZYMOL, V325, P425; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	73	101	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27145	27151		10.1074/jbc.M103565200	http://dx.doi.org/10.1074/jbc.M103565200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11373293	hybrid			2022-12-27	WOS:000169966900056
J	Reffey, SB; Wurthner, JU; Parks, WT; Roberts, AB; Duckett, CS				Reffey, SB; Wurthner, JU; Parks, WT; Roberts, AB; Duckett, CS			X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; PROGRAMMED CELL-DEATH; TGF-BETA; CYTOCHROME-C; TRANSCRIPTIONAL REGULATION; BACULOVIRUS IAP; SMAD4 COOPERATE; GENE-EXPRESSION; KINASE RECEPTOR	X-linked inhibitor of apoptosis protein (XIAP) is a potent suppressor of apoptotic cell death, which functions by directly inhibiting caspases, the principal effecters of apoptosis. Here we report that XIAP can also function as a cofactor in the regulation of gene expression by transforming growth factor-beta (TGF-beta), XIAP, but not the related proteins c-IAP1 or c-IAP2, associated with several members of the type I class of the TGF-beta receptor superfamily and potentiated TGF-beta -induced signaling, Although XIAP-mediated activation of c-Jun N-terminal kinase and nuclear factor kappaB was found to require the TGF-beta signaling intermediate Smad4, the ability of XIAP to suppress apoptosis was found to be Smad4-independent, These data implicate a role for XIAP in TGF-beta -mediated signaling that is distinct from its anti-apoptotic functions.	NCI, Metab Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NCI, Lab Cell Regulat & Carcinogenesis, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Duckett, CS (corresponding author), NCI, Metab Branch, Canc Res Ctr, NIH, 10 Ctr Dr,Room 6B-05, Bethesda, MD 20892 USA.			Parks, W. Tony/0000-0001-7341-3277; Duckett, Colin/0000-0001-9413-2263				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Freathy C, 2000, HEPATOLOGY, V32, P750, DOI 10.1053/jhep.2000.18329; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Huang HK, 2000, J BIOL CHEM, V275, P26661; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Massague J, 2000, GENE DEV, V14, P627; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Nagata S, 1996, CURR BIOL, V6, P1241, DOI 10.1016/S0960-9822(02)70706-9; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Oeda E, 1998, J BIOL CHEM, V273, P9353, DOI 10.1074/jbc.273.16.9353; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PERKINS ND, 1994, J VIROL, V68, P6820, DOI 10.1128/JVI.68.10.6820-6823.1994; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sanna MG, 1998, P NATL ACAD SCI USA, V95, P6015, DOI 10.1073/pnas.95.11.6015; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	70	122	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26542	26549		10.1074/jbc.M100331200	http://dx.doi.org/10.1074/jbc.M100331200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11356828	hybrid			2022-12-27	WOS:000169823300118
J	Valenzuela-Fernandez, A; Palanche, T; Amara, A; Magerus, A; Altmeyer, R; Delaunay, T; Virelizier, JL; Baleux, F; Galzi, JL; Arenzana-Seisdedos, F				Valenzuela-Fernandez, A; Palanche, T; Amara, A; Magerus, A; Altmeyer, R; Delaunay, T; Virelizier, JL; Baleux, F; Galzi, JL; Arenzana-Seisdedos, F			Optimal inhibition of X4 HIV isolates by the CXC chemokine stromal cell-derived factor 1 alpha requires interaction with cell surface heparan sulfate proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CXCR4; ENVELOPE GLYCOPROTEIN; DENDRITIC CELLS; LYMPHOCYTE CHEMOATTRACTANT; GASTROINTESTINAL-TRACT; EPITHELIAL-CELLS; RHESUS MACAQUES; FACTOR-I; T-CELLS; SDF-1	The chemokine stromal cell-derived factor 1 (SDF-1) is the natural ligand for CXC chemokine receptor 4 (CXCR4), SDF-1 inhibits infection of CD4+ cells by X4 (CXCR4-dependent) human immunodeficiency virus (HIV) strains. We previously showed that SDF-1 alpha interacts specifically with heparin or heparan sulfates (HSs), Herein, we delimited the boundaries of the MS-binding domain located in the first beta -strand of SDF-1 alpha as the critical residues. We also provide evidence that binding to cell surface heparan sulfate proteoglycans (MSPGs) determines the capacity of SDF-1 alpha to prevent the fusogenic activity of HIV-1 X4 isolates in leukocytes. Indeed, SDF-1 alpha mutants lacking the capacity to interact with HSPGs showed a substantially reduced capacity to prevent cell-to-cell fusion mediated by X4 HIV envelope glycoproteins. Moreover, the enzymatic removal of cell surface MS diminishes the HIV-inhibitory capacity of the chemokine to the levels shown by the HS-binding-disabled mutant counterparts, The mechanisms underlying the optimal HIV-inhibitory activity of SDF-1 alpha when attached to MSPGs were investigated, Combining fluorescence resonance energy transfer and laser confocal microscopy, we demonstrate the concomitant binding of SDF-1 alpha to CXCR4 and MSPGs at the cell membrane. Using FRET between a Texas Red-labeled SDF-1 alpha and an enhanced green fluorescent protein-tagged CXCR4, we show that binding of SDF-1 alpha to cell surface HSPGs modifies neither the kinetics of occupancy nor activation in real time of CXCR4 by the chemokine. Moreover, attachment to HSPGs does not modify the potency of the chemokine to promote internalization of CXCR4, Attachment to cellular MSPGs may co-operate in the optimal anti-HIV activity of SDF-1 alpha by increasing the local concentration of the chemokine in the surrounding environment of CXCR4, thus facilitating sustained occupancy and down-regulation of the HIV coreceptor.	Inst Pasteur, Unite Immunol Virale, F-75724 Paris 15, France; Inst Pasteur, Unite Chim Organ, F-75724 Paris 15, France; Ecole Super Biotecnol Strasbourg, Dept Recepteurs & Prot Membranaires, CNRS UPR 9050, F-67400 Illkirch Graffenstaden, France; INRA, Stn Pathol Vegetale, F-33833 Villenave Dornon, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); INRAE	Arenzana-Seisdedos, F (corresponding author), Inst Pasteur, Unite Immunol Virale, 28 Rue Dr Roux, F-75724 Paris 15, France.	farenzan@pasteur.fr	Valenzuela-Fernández, Agustín/P-1638-2019; Valenzuela-Fernández, Agustín/B-6219-2014; Amara, Ali/E-8803-2017; Arenzana-Seisdedos, Fernando/E-5835-2016; Magerus-Chatinet, Aude/I-6245-2017; AMARA, Ali/ABX-9903-2022	Valenzuela-Fernández, Agustín/0000-0002-2585-8703; Valenzuela-Fernández, Agustín/0000-0002-2585-8703; Magerus-Chatinet, Aude/0000-0001-7365-699X; AMARA, Ali/0000-0002-0283-1815				Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8; Agace WW, 2000, EUR J IMMUNOL, V30, P819, DOI 10.1002/1521-4141(200003)30:3<819::AID-IMMU819>3.0.CO;2-Y; Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Amzazi S, 1998, VIROLOGY, V252, P96, DOI 10.1006/viro.1998.9452; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1998, J EXP MED, V187, P753, DOI 10.1084/jem.187.5.753; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Bohm SK, 1997, BIOCHEM J, V322, P1; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Burns JM, 1999, P NATL ACAD SCI USA, V96, P14499, DOI 10.1073/pnas.96.25.14499; Chabot DJ, 1999, J VIROL, V73, P6598, DOI 10.1128/JVI.73.8.6598-6609.1999; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; Coulomb-L'Hermine A, 1999, P NATL ACAD SCI USA, V96, P8585, DOI 10.1073/pnas.96.15.8585; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gleichmann M, 2000, EUR J NEUROSCI, V12, P1857, DOI 10.1046/j.1460-9568.2000.00048.x; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Harouse JM, 1999, SCIENCE, V284, P816, DOI 10.1126/science.284.5415.816; HEIDMANN T, 1979, EUR J BIOCHEM, V94, P255, DOI 10.1111/j.1432-1033.1979.tb12893.x; Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1; Hu JJ, 2000, J VIROL, V74, P6087, DOI 10.1128/JVI.74.13.6087-6095.2000; Ianelli CJ, 1998, J BIOL CHEM, V273, P23367, DOI 10.1074/jbc.273.36.23367; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Michael NL, 1999, NAT MED, V5, P740, DOI 10.1038/10462; Miller CJ, 1999, J INFECT DIS, V179, pS413, DOI 10.1086/314795; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; NEUBIG RR, 1993, MOL PHARMACOL, V43, P734; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Ohshiro Y, 1996, MICROBIOL IMMUNOL, V40, P827, DOI 10.1111/j.1348-0421.1996.tb01148.x; Oravecz T, 1997, J IMMUNOL, V159, P4587; Pablos JL, 1999, AM J PATHOL, V155, P1577, DOI 10.1016/S0002-9440(10)65474-0; Puri A, 1998, P NATL ACAD SCI USA, V95, P14435, DOI 10.1073/pnas.95.24.14435; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; SCHWARTZ O, 1994, VIROLOGY, V198, P360, DOI 10.1006/viro.1994.1042; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tanabe S, 1997, J IMMUNOL, V159, P905; TERSMETTE M, 1989, LANCET, V1, P983; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; Vollmer JY, 1999, J BIOL CHEM, V274, P37915, DOI 10.1074/jbc.274.53.37915; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	53	68	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26550	26558		10.1074/jbc.M100411200	http://dx.doi.org/10.1074/jbc.M100411200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352904	hybrid, Green Published			2022-12-27	WOS:000169823300119
J	West, KL; Ito, Y; Birger, Y; Postnikov, Y; Shirakawa, H; Bustin, M				West, KL; Ito, Y; Birger, Y; Postnikov, Y; Shirakawa, H; Bustin, M			HMGN3a and HMGN3b, two protein isoforms with a tissue-specific expression pattern, expand the cellular repertoire of nucleosome-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILITY-GROUP PROTEINS; GROUP CHROMOSOMAL-PROTEINS; HUMAN CDNA SEQUENCE; MULTIGENE FAMILY; FUNCTIONAL GENE; HISTONE H1; NF-Y; CHROMATIN; HMG-14; TRANSCRIPTION	HMGN1 (HMG-14) and HMGN2 (HMG-17) are nuclear proteins that bind specifically to nucleosomes reduce the compactness of the chromatin fiber, and enhance transcription from chromatin templates. Here we report that many vertebrates contain an additional type of HMGN protein named HMGN3 (Trip 7), The human HMGN3 gene is located on chromosome 6 and spans 32 kilobase pairs, which is nearly 10-fold longer than the closely related HMGN2 gene. However, the intron/exon boundaries of the HMGN3 gene are identical to those of HMGN1 and HMGN2. Unique within the HMGN family, the HMGN3 transcript undergoes alternative splicing and generates two different variants, HMGN3a and HMGN3b. The shorter variant, HMGN3b, arises from an additional splice site that truncates exon V and causes a frameshift. The resulting HMGN3b protein lacks the majority of the C-terminal chromatin-unfolding domain. Both splice variants are found in many vertebrates from frogs to man and are expressed in many tissues. The pattern of tissue-specific expression differs considerably from those of HMGN1 and HMGN2 at both the mRNA and the protein level. Our results expand the multiplicity of the HMGN protein family and raise the possibility that these nucleosome-binding proteins function as co-activators in tissue-specific gene expression.	NCI, Div Basic Sci, Prot Sect,Lab Metab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	West, KL (corresponding author), NCI, Div Basic Sci, Prot Sect,Lab Metab, NIH, Bldg 37,Rm 3C12, Bethesda, MD 20892 USA.	klmarsh@pop.nci.nih.gov	Shirakawa, Hitoshi/D-1406-2009; Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242; West, Katherine/0000-0002-5994-8969; SHIRAKAWA, HITOSHI/0000-0002-4828-5274				ALFONSO PJ, 1994, J MOL BIOL, V236, P189, DOI 10.1006/jmbi.1994.1128; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Bergel M, 2000, J BIOL CHEM, V275, P11514, DOI 10.1074/jbc.275.15.11514; BUSTIN M, 1989, METHOD ENZYMOL, V170, P214; BUSTIN M, 1995, SEMIN CELL BIOL, V6, P247, DOI 10.1006/scel.1995.0033; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Cook T, 1999, ANN NY ACAD SCI, V880, P94, DOI 10.1111/j.1749-6632.1999.tb09513.x; COOPER E, 1983, ENDOCRINOLOGY, V112, P1816, DOI 10.1210/endo-112-5-1816; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; Ding HF, 1997, MOL CELL BIOL, V17, P5843, DOI 10.1128/MCB.17.10.5843; FLETCHER TM, 1995, J BIOL CHEM, V270, P25359, DOI 10.1074/jbc.270.43.25359; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Herrera JE, 1999, MOL CELL BIOL, V19, P3466; Hock R, 1998, EMBO J, V17, P6992, DOI 10.1093/emboj/17.23.6992; Hock R, 1998, J CELL BIOL, V143, P1427, DOI 10.1083/jcb.143.6.1427; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; LANDSMAN D, 1986, J BIOL CHEM, V261, P6082; LANDSMAN D, 1986, J BIOL CHEM, V261, P7479; LANDSMAN D, 1989, NUCLEIC ACIDS RES, V17, P2301, DOI 10.1093/nar/17.6.2301; LANDSMAN D, 1989, J BIOL CHEM, V264, P3421; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEVYWILSON B, 1981, P NATL ACAD SCI-BIOL, V78, P2189, DOI 10.1073/pnas.78.4.2189; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MARDIAN JKW, 1980, SCIENCE, V209, P1534, DOI 10.1126/science.7433974; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; PARANJAPE SM, 1995, GENE DEV, V9, P1978, DOI 10.1101/gad.9.16.1978; PASH J, 1990, P NATL ACAD SCI USA, V87, P3836, DOI 10.1073/pnas.87.10.3836; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; POSTNIKOV YV, 1995, J MOL BIOL, V252, P423, DOI 10.1006/jmbi.1995.0508; POSTNIKOV YV, 1994, NUCLEIC ACIDS RES, V22, P4520, DOI 10.1093/nar/22.21.4520; Postnikov YV, 1997, J MOL BIOL, V274, P454, DOI 10.1006/jmbi.1997.1391; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; SANDEEN G, 1980, NUCLEIC ACIDS RES, V8, P3757, DOI 10.1093/nar/8.17.3757; Shirakawa H, 2000, J BIOL CHEM, V275, P37937, DOI 10.1074/jbc.M000989200; Shirakawa H, 2000, J BIOL CHEM, V275, P6368, DOI 10.1074/jbc.275.9.6368; SPAULDING SW, 1991, MOL ENDOCRINOL, V5, P42, DOI 10.1210/mend-5-1-42; STERNER R, 1981, J BIOL CHEM, V256, P8892; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; Trieschmann L, 1998, P NATL ACAD SCI USA, V95, P5468, DOI 10.1073/pnas.95.10.5468; TRIESCHMANN L, 1995, MOL CELL BIOL, V15, P6663; TRIESCHMANN L, 1995, EMBO J, V14, P1478, DOI 10.1002/j.1460-2075.1995.tb07134.x; Vestner B, 1998, J BIOL CHEM, V273, P9409, DOI 10.1074/jbc.273.16.9409; Weigmann N, 1997, DNA CELL BIOL, V16, P1207, DOI 10.1089/dna.1997.16.1207; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Wolffe AP, 1998, PROG NUCLEIC ACID RE, V61, P379, DOI 10.1016/S0079-6603(08)60832-6	55	38	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25959	25969		10.1074/jbc.M101692200	http://dx.doi.org/10.1074/jbc.M101692200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11356838	hybrid			2022-12-27	WOS:000169823300044
J	Ikebe, M; Komatsu, S; Woodhead, JL; Mabuchi, K; Ikebe, R; Saito, J; Craig, R; Higashihara, M				Ikebe, M; Komatsu, S; Woodhead, JL; Mabuchi, K; Ikebe, R; Saito, J; Craig, R; Higashihara, M			The tip of the coiled-coil rod determines the filament formation of smooth muscle and nonmuscle myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; AMINO-ACID-SEQUENCES; LIGHT-CHAIN; UNCONVENTIONAL MYOSINS; DICTYOSTELIUM MYOSIN; ESCHERICHIA-COLI; IONIC-STRENGTH; DNA-SEQUENCE; REGION; EXPRESSION	Myosin II self-assembles to form thick filaments that are attributed to its long coiled-coil tail domain. The present study has determined a region critical for filament formation of vertebrate smooth muscle and nonmuscle myosin IL A monoclonal antibody recognizing the 28 residues from the C-terminal end of the coiled-coil domain of smooth muscle myosin II completely inhibited filament formation, whereas other antibodies recognizing other parts of the coiled-coil did not. To determine the importance of this region in the filament assembly in vivo, green fluorescent protein (GFP)-tagged smooth muscle myosin was expressed in COS-7 cells, and the filamentous localization of the GFP signal was monitored by fluorescence microscopy. Wild type GFP-tagged smooth muscle myosin colocalized with F-actin during interphase and was also recruited into the contractile ring during cytokinesis. Myosin with the nonhelical tail piece deleted showed similar behavior, whereas deletion of the 28 residues at the C-terminal end of the coiled-coil domain abolished this localization. Deletion of the corresponding region of GFP-tagged nonmuscle myosin IIA also abolished this localization. We conclude that the C-terminal end of the coiled-coil domain, but not the nonhelical tail piece, of myosin II is critical for myosin filament formation both in vitro and in vivo.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Boston Biomed Res Inst, Watertown, MA 02472 USA; Kitasato Univ, Sch Med, Dept Internal Med, Sagamihara, Kanagawa 2288555, Japan	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Boston Biomedical Research Institute; Kitasato University	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056218, R01HL062468] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653, P01AR041637] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56218, HL62468] Funding Source: Medline; NIAMS NIH HHS [AR41637, AR41653, R01 AR041653] Funding Source: Medline; PHS HHS [MG55834] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ATKINSON SJ, 1991, J CELL SCI, V99, P823; Baker JP, 1997, J MOL BIOL, V272, P523, DOI 10.1006/jmbi.1997.1232; Cohen C, 1998, J STRUCT BIOL, V122, P180, DOI 10.1006/jsbi.1998.3983; CRAIG R, 1977, J CELL BIOL, V75, P990, DOI 10.1083/jcb.75.3.990; CROSS RA, 1986, FEBS LETT, V200, P355, DOI 10.1016/0014-5793(86)81168-1; CROSS RA, 1984, EUR J BIOCHEM, V145, P305, DOI 10.1111/j.1432-1033.1984.tb08553.x; CROSS RA, 1984, FEBS LETT, V176, P197, DOI 10.1016/0014-5793(84)80940-0; CROSS RA, 1991, EMBO J, V10, P747, DOI 10.1002/j.1460-2075.1991.tb08006.x; DELOZANNE A, 1987, J CELL BIOL, V105, P2999, DOI 10.1083/jcb.105.6.2999; Ford HL, 1997, BIOCHEMISTRY-US, V36, P16321, DOI 10.1021/bi971182l; Higashihara M, 1989, J BIOL CHEM, V264, P5218; Hodge T, 2000, J CELL SCI, V113, P3353; HODGE TP, 1992, J CELL BIOL, V118, P1085, DOI 10.1083/jcb.118.5.1085; HOPE PE, 1996, J CELL BIOL, V135, P371; IKEBE M, 1991, J BIOL CHEM, V266, P7030; IKEBE M, 1994, J BIOL CHEM, V269, P28173; IKEBE M, 1985, J BIOL CHEM, V260, P3146; KELLERMAN KA, 1992, J CELL BIOL, V119, P823, DOI 10.1083/jcb.119.4.823; KING L, 1995, BIOCHEM J, V312, P511, DOI 10.1042/bj3120511; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RJ, 1994, J CELL SCI, V107, P2875; MABUCHI K, 1990, J STRUCT BIOL, V103, P249, DOI 10.1016/1047-8477(90)90043-C; MABUCHI K, 1991, J STRUCT BIOL, V107, P22, DOI 10.1016/1047-8477(91)90027-T; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NYITRAY L, 1983, J BIOL CHEM, V258, P3213; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; PAGH K, 1984, EMBO J, V3, P3271, DOI 10.1002/j.1460-2075.1984.tb02289.x; PARRY DAD, 1981, J MOL BIOL, V153, P459, DOI 10.1016/0022-2836(81)90290-4; PARRY DAD, 1979, FIBROUS PROTEINS SCI, V1, P393; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; SCHOLEY JM, 1980, NATURE, V287, P233, DOI 10.1038/287233a0; Sellers J. R., 1999, MYOSINS; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SINARD JH, 1990, J CELL BIOL, V111, P2417, DOI 10.1083/jcb.111.6.2417; Sohn RL, 1997, J MOL BIOL, V266, P317, DOI 10.1006/jmbi.1996.0790; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STREHLER EE, 1986, J MOL BIOL, V190, P291, DOI 10.1016/0022-2836(86)90003-3; SUZUKI H, 1978, J BIOCHEM, V84, P1529, DOI 10.1093/oxfordjournals.jbchem.a132278; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Titus MA, 1997, TRENDS CELL BIOL, V7, P119, DOI 10.1016/S0962-8924(97)01019-2; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; VISTROM KL, 1993, CELL MOTIL CYTOSKEL, V26, P192; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433; Xu JQ, 1996, J CELL BIOL, V134, P53, DOI 10.1083/jcb.134.1.53; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016	47	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30293	30300		10.1074/jbc.M101969200	http://dx.doi.org/10.1074/jbc.M101969200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395487	hybrid			2022-12-27	WOS:000170558000091
J	Poon, KKH; Chu, JCL; Wong, SL				Poon, KKH; Chu, JCL; Wong, SL			Roles of glucitol in the GutR-mediated transcription activation process in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; BIOTIN HOLOENZYME SYNTHETASE; COLI MALTOSE SYSTEM; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ATP-BINDING; PSEUDOMONAS-PUTIDA; TERMINAL DOMAIN; GTP-HYDROLYSIS; DNA-BINDING	GutR is a 95-kDa glucitol-dependent transcription activator that mediates the expression of the Bacillus subtilis glucitol operon. Glucitol allows GutR to bind tightly to its binding site located upstream of the gut promoter. In this study, a second functional role of glucitol is identified. Glucitol induces GutR to change its conformation and triggers GutR to bind ATP efficiently. After sequential binding of glucitol and ATP to GutR, GutR adopts a new conformation by forming a compact structure that is resistant to trypsin digestion. Under this condition, the ATP.glucitiol.GutR complex can dissociate slowly from the gutR-binding site (t(1/2) = 274 min). Interestingly, if ATP in the ATP.glucitiol.GutR complex is replaced by ADP, GutR adopts another conformation and can dissociate from the gutR-binding site even faster (t(1/2) = 82 min). In all these GutR-DNA binding studies in the presence of different ligands (glucitol, ATP, or ADP), only the off-rate is affected. The vital role of ATP in the GutR-mediated transcription activation process is reflected by the poor transcription from the gut promoter with GutR(D285A) which has a mutation in the motif B of the putative ATP-binding site. A working model for this transcription activation process is presented.	Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, Calgary, AB T2N 1N4, Canada	University of Calgary	Wong, SL (corresponding author), Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, Calgary, AB T2N 1N4, Canada.							BARKER DF, 1981, J MOL BIOL, V146, P451, DOI 10.1016/0022-2836(81)90042-5; Boos W, 2000, TRENDS GENET, V16, P404, DOI 10.1016/S0168-9525(00)02086-2; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; Bowman WC, 1998, GENE DEV, V12, P1884, DOI 10.1101/gad.12.12.1884; BUONCRISTIANI MR, 1986, GENE, V44, P255, DOI 10.1016/0378-1119(86)90189-7; CHALUMEAU H, 1978, J BACTERIOL, V134, P921; Chapman A G, 1977, Adv Microb Physiol, V15, P253, DOI 10.1016/S0065-2911(08)60318-5; DELOBBE A, 1975, EUR J BIOCHEM, V51, P503; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GAY P, 1983, J BACTERIOL, V153, P1133, DOI 10.1128/JB.153.3.1133-1137.1983; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; MARQUES S, 1993, MOL MICROBIOL, V9, P923, DOI 10.1111/j.1365-2958.1993.tb01222.x; Mizushima T, 1998, J BIOL CHEM, V273, P20847, DOI 10.1074/jbc.273.33.20847; Neri D, 1996, TRENDS BIOTECHNOL, V14, P465, DOI 10.1016/S0167-7799(96)10067-6; NG K, 1992, J BIOL CHEM, V267, P24989; OSHANNESSY DJ, 1994, METHOD ENZYMOL, V240, P323; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Peng HL, 1997, J BACTERIOL, V179, P1497, DOI 10.1128/jb.179.5.1497-1504.1997; PEREZMARTIN J, 1995, P NATL ACAD SCI USA, V92, P9392, DOI 10.1073/pnas.92.20.9392; PerezMartin J, 1996, J MOL BIOL, V258, P575, DOI 10.1006/jmbi.1996.0270; Poon KKH, 2001, J BIOL CHEM, V276, P9620, DOI 10.1074/jbc.M009864200; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; Rombel I, 1999, J BACTERIOL, V181, P4628, DOI 10.1128/JB.181.15.4628-4638.1999; Sato K, 1996, J BIOL CHEM, V271, P17439, DOI 10.1074/jbc.271.29.17439; Schweins T, 1997, J MOL BIOL, V266, P847, DOI 10.1006/jmbi.1996.0814; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; WU XC, 1990, J BIOL CHEM, V265, P6845; YE RQ, 1994, J BACTERIOL, V176, P3314, DOI 10.1128/jb.176.11.3314-3320.1994; YE RQ, 1994, J BACTERIOL, V176, P3321, DOI 10.1128/jb.176.11.3321-3327.1994; Zhong XT, 1998, J BACTERIOL, V180, P1347, DOI 10.1128/JB.180.6.1347-1353.1998	33	11	11	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29819	29825		10.1074/jbc.M100905200	http://dx.doi.org/10.1074/jbc.M100905200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390381	hybrid			2022-12-27	WOS:000170558000030
J	Jia, HW; Kaur, P				Jia, HW; Kaur, P			Role of the linker region of the anion-stimulated ATPase ArsA - Effect of deletion and point mutations in the linker region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING; PROTEIN; DOMAIN	The anion-stimulated ATPase ArsA in Escherichia coli consists of two homologous halves, Al and A2, which are connected by a 40-amino acid long stretch of residues designated as the linker region. The linker region of ArsA lies in close proximity of the nucleotide-binding domain(s) of ArsA and is involved in significant conformational changes on binding of the substrates. Hence, it has been suggested earlier that the linker may play an important role in the function of ArsA. The aim of the present study was to determine the role of the linker by deletion and by site-directed mutagenesis of specific residues. Effect of deletion of the linker was determined by using the in vivo complementation approach where two halves of ArsA were co-expressed either with or without the linker region. Two co-expressed halves of ArsA conferred arsenite resistance only if the linker region was present on one of the halves. Of the six different point mutations created in the linker region, three (G284S, R290S, and D303G) were seen to drastically affect the catalytic function of ArsA. In addition, these three mutant alleles conferred arsenite sensitivity in cells carrying the wild type arsB gene. Trypsin proteolysis studies carried out with the purified proteins showed that the Al nucleotide-binding domain in D303G protein has a conformation different from the wild type ArsA, suggesting that the linker region interacts with the nucleotide-binding domain(s) of ArsA. Based on the studies presented here, we propose that, in addition to providing flexibility, the nature of the residues themselves in the linker region is important for the conformation of the nucleotide-binding domains and for the catalytic function of ArsA.	Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University System of Georgia; Georgia State University	Kaur, P (corresponding author), Georgia State Univ, Dept Biol, POB 4010, Atlanta, GA 30303 USA.				NIGMS NIH HHS [R29 GM51981] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051981] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES SK, 1999, P NATL ACAD SCI; Bhattacharjee H, 1996, J BIOL CHEM, V271, P24465, DOI 10.1074/jbc.271.40.24465; DEY S, 1995, J BACTERIOL, V177, P385, DOI 10.1128/jb.177.2.385-389.1995; Hrycyna CA, 1998, BIOCHEMISTRY-US, V37, P13660, DOI 10.1021/bi9808823; KAUR P, 1993, J BACTERIOL, V175, P351, DOI 10.1128/JB.175.2.351-357.1993; KAUR P, 1994, BIOCHEMISTRY-US, V33, P6456, DOI 10.1021/bi00187a010; Kaur P, 1999, J BIOL CHEM, V274, P25849, DOI 10.1074/jbc.274.36.25849; Kaur P, 1997, J BACTERIOL, V179, P569, DOI 10.1128/jb.179.3.569-575.1997; Kolling R, 1997, EMBO J, V16, P2251, DOI 10.1093/emboj/16.9.2251; Li JX, 2000, MOL MICROBIOL, V35, P361, DOI 10.1046/j.1365-2958.2000.01696.x; Ramaswamy S, 1998, J BIOL CHEM, V273, P9243, DOI 10.1074/jbc.273.15.9243; Vankeerberghen A, 1999, BIOCHEMISTRY-US, V38, P14988, DOI 10.1021/bi991520d	12	1	1	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29582	29587		10.1074/jbc.M103042200	http://dx.doi.org/10.1074/jbc.M103042200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11389146	hybrid			2022-12-27	WOS:000170346000124
J	Kim, BY; Kramer, H; Yamamoto, A; Kominami, E; Kohsaka, S; Akazawa, C				Kim, BY; Kramer, H; Yamamoto, A; Kominami, E; Kohsaka, S; Akazawa, C			Molecular characterization of mammalian homologues of class CVPS proteins that interact with syntaxin-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATE ENDOSOME-LYSOSOME; VACUOLAR BIOGENESIS; SACCHAROMYCES-CEREVISIAE; VESICLE TRAFFICKING; DEEP-ORANGE; YEAST; MUTANTS; COMPLEX; FUSION; GENE	Vesicle-mediated protein sorting plays an important role in segregation of intracellular molecules into distinct organelles. Extensive genetic studies using yeast have identified more than 40 vacuolar protein sorting (VPS) genes involved in vesicle transport to vacuoles. However, their mammalian counterparts are not fully elucidated. In this study, we identified two human homologues of yeast Class C VPS genes, human VPS11 (hVPS11) and human VPS18 (hVPS18). We also characterized the subcellular localization and interactions of the protein products not only from these genes but also from the other mammalian Class C VPS homologue genes, hVPS16 and rVPS33a. The protein products of hVPS11 (hVps11) and hVPS18 (hVps18) were ubiquitously expressed in peripheral tissues, suggesting that they have a fundamental role in cellular function. Indirect immunofluoreseence microscopy revealed that the mammalian Class C Vps proteins are predominantly associated with late endosomes/lysosomes. Immunoprecipitation and gel filtration studies showed that the mammalian Class C Vps proteins constitute a large hetero-oligomeric complex that interacts with syntaxin-7. These results indicate that like their yeast counterparts, mammalian Class C Vps proteins mediate vesicle trafficking steps in the endosome/lysosome pathway.	NCNP, Natl Inst Neurosci, Dept Neurochem, Tokyo 1878502, Japan; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75235 USA; Kansai Med Univ, Dept Physiol, Osaka 5708506, Japan; Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, Tokyo 1138421, Japan	National Center for Neurology & Psychiatry - Japan; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Kansai Medical University; Juntendo University	Akazawa, C (corresponding author), NCNP, Natl Inst Neurosci, Dept Neurochem, Tokyo 1878502, Japan.	akazawa@ncnp.go.jp	Kominami, Eiki/D-3802-2009	Kramer, Helmut/0000-0002-1167-2676	NATIONAL EYE INSTITUTE [R01EY010199] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY010199, EY 10199] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DULIC V, 1989, EMBO J, V8, P1349, DOI 10.1002/j.1460-2075.1989.tb03515.x; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Mullock BM, 2000, MOL BIOL CELL, V11, P3137, DOI 10.1091/mbc.11.9.3137; Nakamura N, 2000, J BIOL CHEM, V275, P6523, DOI 10.1074/jbc.275.9.6523; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Rieder SE, 1997, MOL BIOL CELL, V8, P2307, DOI 10.1091/mbc.8.11.2307; ROBINSON JS, 1991, MOL CELL BIOL, V11, P5813, DOI 10.1128/MCB.11.12.5813; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sato TK, 2000, MOL CELL, V6, P661, DOI 10.1016/S1097-2765(00)00064-2; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Sevrioukov EA, 1999, MOL CELL, V4, P479, DOI 10.1016/S1097-2765(00)80199-9; Shestopal SA, 1997, MOL GEN GENET, V253, P642; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Smith CJ, 1999, TRENDS CELL BIOL, V9, P335, DOI 10.1016/S0962-8924(99)01631-1; Stenmark H, 1999, J CELL SCI, V112, P4175; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; WADA Y, 1992, J BIOL CHEM, V267, P18665; Wang H, 1997, GENE, V199, P39, DOI 10.1016/S0378-1119(97)00343-0; Ward DM, 2000, MOL BIOL CELL, V11, P2327, DOI 10.1091/mbc.11.7.2327; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Wong SH, 1998, J BIOL CHEM, V273, P375, DOI 10.1074/jbc.273.1.375; WOOLFORD CA, 1990, GENETICS, V125, P739; Wurmser AE, 2000, J CELL BIOL, V151, P551, DOI 10.1083/jcb.151.3.551; Ybe JA, 1999, NATURE, V399, P371, DOI 10.1038/20708	42	67	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29393	29402		10.1074/jbc.M101778200	http://dx.doi.org/10.1074/jbc.M101778200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382755	hybrid			2022-12-27	WOS:000170346000101
J	Lin, J; Weiss, A				Lin, J; Weiss, A			Identification of the minimal tyrosine residues required for linker for activation of T cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN SLP-76; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; SH3 DOMAIN; LAT; PLC-GAMMA-1; KINASES; TCR; RAS	The linker for activation of T cells (LAT) is essential for signaling through the T cell receptor (TOR). Following TCR stimulation, LAT becomes tyrosine-phosphorylated, creating docking sites for other signaling proteins such as phospholipase C-gamma (1) (PLC-gamma (1)), Grb2, and Gads. In this study, we have attempted to identify the critical tyrosine residues in LAT that mediate TCR activation-induced mobilization of intracellular Ca2+ and activation of the MAP kinase Erk2. By using the LAT-deficient Jurkat derivative, J.CaM2, stable cell lines were established expressing various tyrosine mutants of LAT. We show that three spe. cific tyrosine residues (Tyr(132), Tyr(171), and Tyr(191)) are necessary and sufficient to achieve a Ca2+ flux following TOR stimulation. These tyrosine residues function by reconstituting PLC-gamma (1) phosphorylation and recruitment to LAT. However, these same tyrosines can only partially reconstitute Erk activation. Full reconstitution of Erk requires two additional tyrosine residues (Tyr(110) and Tyr(226)), both of which have the Grb2-binding motif YXN. This reconstitution of Erk activation requires that the critical tyrosine residues be on the same molecule of LAT, suggesting that a single LAT molecule nucleates multiple protein-protein interactions required for optimal signal transduction.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, Biomed Sci Grad Program, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Weiss, A (corresponding author), Univ Calif San Francisco, Dept Med, 3rd & Parnassus Ave, San Francisco, CA 94143 USA.							Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Ching KA, 2000, J IMMUNOL, V165, P256, DOI 10.4049/jimmunol.165.1.256; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; DeBell KE, 1999, MOL CELL BIOL, V19, P7388; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Ebinu JO, 2000, BLOOD, V95, P3199; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Genot E, 2000, CURR OPIN IMMUNOL, V12, P289, DOI 10.1016/S0952-7915(00)00089-3; GOLDSMITH MA, 1988, P NATL ACAD SCI USA, V85, P8613, DOI 10.1073/pnas.85.22.8613; Ishiai M, 2000, J EXP MED, V192, P847, DOI 10.1084/jem.192.6.847; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kim MJ, 2000, BIOCHEMISTRY-US, V39, P8674, DOI 10.1021/bi992558t; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Scholler JK, 2000, EUR J IMMUNOL, V30, P2378, DOI 10.1002/1521-4141(2000)30:8<2378::AID-IMMU2378>3.0.CO;2-E; Sekiya F, 1999, CHEM PHYS LIPIDS, V98, P3, DOI 10.1016/S0009-3084(99)00013-4; Shan XC, 1999, J BIOL CHEM, V274, P29323, DOI 10.1074/jbc.274.41.29323; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; Tomlinson MG, 2000, IMMUNOL TODAY, V21, P584, DOI 10.1016/S0167-5699(00)01716-3; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; van Oers NSC, 1999, SEMIN IMMUNOL, V11, P227, DOI 10.1006/smim.1999.0179; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	43	141	146	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29588	29595		10.1074/jbc.M102221200	http://dx.doi.org/10.1074/jbc.M102221200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11395491	hybrid			2022-12-27	WOS:000170346000125
J	Siebers, B; Brinkmann, H; Dorr, C; Tjaden, B; Lilie, H; van der Oost, J; Verhees, CH				Siebers, B; Brinkmann, H; Dorr, C; Tjaden, B; Lilie, H; van der Oost, J; Verhees, CH			Archaeal fructose-1,6-bisphosphate aldolases constitute a new family of archaeal type class I aldolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; ENTNER-DOUDOROFF-PATHWAY; PYROCOCCUS-FURIOSUS; THERMOPROTEUS-TENAX; ESCHERICHIA-COLI; DEPENDENT PHOSPHOFRUCTOKINASE; THERMOPLASMA-ACIDOPHILUM; SULFOLOBUS-SOLFATARICUS; SUGAR FERMENTATION; EUGLENA-GRACILIS	Fructose-1,6-bisphosphate (FBP) aldolase activity has been detected previously in several Archaea. However, no obvious orthologs of the bacterial and eucaryal Class I and II FBP aldolases have yet been identified in sequenced archaeal genomes. Based on a recently described novel type of bacterial aldolase, we report on the identification and molecular characterization of the first archaeal FBP aldolases. We have analyzed the FBP aldolases of two hyperthermophilic Archaea, the facultatively heterotrophic Crenarchaeon Thermoproteus tenax and the obligately heterotrophic Euryarchaeon Pyrococcus furiosus. For enzymatic studies the fba genes of T. tenax and P. furiosus were expressed in Escherichia coli. The recombinant FBP aldolases show preferred substrate specificity for FBP in the catabolic direction and exhibit metal-independent Class I FBP aldolase activity via a Schiff-base mechanism. Transcript analyses reveal that the expression of both archaeal genes is induced during sugar fermentation. Remarkably, the fbp gene of T. tenax is co-transcribed with the pfp gene that codes for the reversible PPi-dependent phosphofructokinase. As revealed by phylogenetic analyses, orthologs of the T. tenax and P. furiosus enzyme appear to be present in almost all sequenced archaeal genomes, as well as in some bacterial genomes, strongly suggesting that this new enzyme family represents the typical archaeal FBP aldolase. Because this new family shows no significant sequence similarity to classical Class I and II enzymes, a new name is propose, archaeal type Class I FBP aldolases (FBP aldolase lass IA).	Univ Essen Gesamthsch, FB 9, Dept Microbiol, D-45117 Essen, Germany; Univ Konstanz, Dept Biol, Inst Evolut Biol, D-78547 Constance, Germany; Univ Halle Wittenberg, Dept Biochem & Biotechnol, Inst Biotechnol, D-06120 Halle Saale, Saale, Germany; Univ Wageningen & Res Ctr, Microbiol Lab, NL-6703 CT Wageningen, Netherlands	University of Duisburg Essen; University of Konstanz; Martin Luther University Halle Wittenberg; Wageningen University & Research	Siebers, B (corresponding author), Univ Essen Gesamthsch, FB 9, Dept Microbiol, Univ Str 5, D-45117 Essen, Germany.		van+der+Oost, John/Y-2548-2019	Siebers, Bettina/0000-0002-9905-541X				ADACHI J, 1996, MOLPHY VERSION 2 3; ALEFOUNDER PR, 1989, BIOCHEM J, V257, P529, DOI 10.1042/bj2570529; Bell SD, 2001, CURR OPIN MICROBIOL, V4, P208, DOI 10.1016/S1369-5274(00)00190-9; Blom NS, 1996, NAT STRUCT BIOL, V3, P856, DOI 10.1038/nsb1096-856; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunner NA, 1998, J BIOL CHEM, V273, P6149, DOI 10.1074/jbc.273.11.6149; Brunner NA, 2001, EXTREMOPHILES, V5, P101, DOI 10.1007/s007920100181; BUDGEN N, 1986, FEBS LETT, V196, P207, DOI 10.1016/0014-5793(86)80247-2; Choi KH, 1999, BIOCHEMISTRY-US, V38, P12655, DOI 10.1021/bi9828371; Condo I, 1999, MOL MICROBIOL, V34, P377, DOI 10.1046/j.1365-2958.1999.01615.x; Copley RR, 2000, J MOL BIOL, V303, P627, DOI 10.1006/jmbi.2000.4152; DHAR NM, 1986, FEMS MICROBIOL LETT, V35, P177, DOI 10.1016/0378-1097(86)90087-X; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; FISCHER F, 1983, NATURE, V301, P511, DOI 10.1038/301511a0; FOTHERGILLGILMORE LA, 1993, PROG BIOPHYS MOL BIO, V59, P105, DOI 10.1016/0079-6107(93)90001-Z; FUCHS G, 1983, ARCH MICROBIOL, V136, P160, DOI 10.1007/BF00404793; Galperin MY, 2000, FEMS MICROBIOL LETT, V183, P259, DOI 10.1016/S0378-1097(99)00612-6; GIBSON JL, 1991, J BIOL CHEM, V266, P14646; GROSS W, 1994, PLANT PHYSIOL, V105, P1393, DOI 10.1104/pp.105.4.1393; Henze K, 1998, GENE, V222, P163, DOI 10.1016/S0378-1119(98)00499-5; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; KENGEN SWM, 1993, EUR J BIOCHEM, V213, P305, DOI 10.1111/j.1432-1033.1993.tb17763.x; Kengen SWM, 1995, J BIOL CHEM, V270, P30453, DOI 10.1074/jbc.270.51.30453; KRISHNAN G, 1991, EUR J BIOCHEM, V195, P343, DOI 10.1111/j.1432-1033.1991.tb15712.x; Lang D, 2000, SCIENCE, V289, P1546, DOI 10.1126/science.289.5484.1546; LEBHERZ HG, 1969, BIOCHEMISTRY-US, V8, P109, DOI 10.1021/bi00829a016; MARSH JJ, 1992, TRENDS BIOCHEM SCI, V17, P110, DOI 10.1016/0968-0004(92)90247-7; MUKUND S, 1995, J BIOL CHEM, V270, P8389, DOI 10.1074/jbc.270.15.8389; PELZERREITH B, 1994, PLANT PHYSIOL, V106, P1137, DOI 10.1104/pp.106.3.1137; PHILIPPE H, 1993, NUCLEIC ACIDS RES, V21, P5264, DOI 10.1093/nar/21.22.5264; Plaumann M, 1997, CURR GENET, V31, P430, DOI 10.1007/s002940050226; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Ruepp A, 2000, NATURE, V407, P508, DOI 10.1038/35035069; RUTTER WJ, 1964, FED PROC, V23, P1248; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFER T, 1992, ARCH MICROBIOL, V158, P188, DOI 10.1007/BF00290815; Schramm A, 2000, J BACTERIOL, V182, P2001, DOI 10.1128/JB.182.7.2001-2009.2000; Siebers B, 1997, ARCH MICROBIOL, V168, P120, DOI 10.1007/s002030050477; SIEBERS B, 1993, FEMS MICROBIOL LETT, V111, P1; Siebers B, 1998, J BACTERIOL, V180, P2137, DOI 10.1128/JB.180.8.2137-2143.1998; Soppa J, 1999, MOL MICROBIOL, V31, P1589, DOI 10.1046/j.1365-2958.1999.01274.x; Soppa J, 1999, MOL MICROBIOL, V31, P1295, DOI 10.1046/j.1365-2958.1999.01273.x; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; SWOFFORD DL, 1999, PAUP VERSION 4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thomson GJ, 1998, BIOCHEM J, V331, P437, DOI 10.1042/bj3310437; Tolstrup N, 2000, EXTREMOPHILES, V4, P175, DOI 10.1007/s007920070032; Tuininga JE, 1999, J BIOL CHEM, V274, P21023, DOI 10.1074/jbc.274.30.21023; van der Oost J, 1998, J BIOL CHEM, V273, P28149, DOI 10.1074/jbc.273.43.28149; van der Oost J, 1998, Adv Biochem Eng Biotechnol, V61, P87; vandenBergh ERE, 1996, J BACTERIOL, V178, P888, DOI 10.1128/jb.178.3.888-893.1996; Ward DE, 2000, J BACTERIOL, V182, P2559, DOI 10.1128/JB.182.9.2559-2566.2000; WITKE C, 1993, J BACTERIOL, V175, P7495, DOI 10.1128/JB.175.22.7495-7499.1993; YU JP, 1994, J BACTERIOL, V176, P325, DOI 10.1128/JB.176.2.325-332.1994; ZILLIG W, 1981, ZBL BAKT MIK HYG I C, V2, P205, DOI 10.1016/S0721-9571(81)80001-4	59	86	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28710	28718		10.1074/jbc.M103447200	http://dx.doi.org/10.1074/jbc.M103447200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387336	hybrid			2022-12-27	WOS:000170346000011
J	Tous, C; Vega-Palas, MA; Vioque, A				Tous, C; Vega-Palas, MA; Vioque, A			Conditional expression of RNase P in the cyanobacterium Synechocystis sp PCC6803 allows detection of precursor RNAs - Insight in the in vivo maturation pathway of transfer and other stable RNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RIBONUCLEASE-P; GENE; SEQUENCE; PCC-6803; PROTEIN; SUBUNIT; SUBSTRATE; MOLECULE; CLONING	We have constructed a strain (CTI) that expresses RNase P conditionally with the aim to analyze the in vivo tRNA processing pathway and the biological role that RNase P plays in Synechocystis 6803. In this strain, the rnpB gene, coding for the RNA subunit of RNase P, has been placed under the control of the petJ gene promoter (P-petJ), which is repressed by copper, cell growth, and accumulation of RNase P RNA is inhibited in CT1 after the addition of copper, indicating that the regulation by copper is maintained in the chimerical P-petJ rnpB gene and that RNase P is essential for growth in Synechocystis. We have analyzed several RNAs by Northern blot and primer extension in CT1. Upon addition of copper to the culture medium, precursors of the mature tRNAs are detected. Furthermore, our results indicate that there is a preferred order in the action of RNase P when it processes a dimeric tRNA precursor. The precursors detected are 3 ' -processed, indicating that 3 ' processing can occur before 5 ' processing by RNase P. The size of the precursors suggests that the terminal CCA sequence is already present before RNase P processing. We have also analyzed other potential RNase P substrates, such as the precursors of tmRNA and 4.5 S RNA. In both cases, accumulation of larger than mature size RNAs is observed after transferring the cells to a copper-containing medium.	Univ Seville, CSIC, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF)	Vioque, A (corresponding author), Univ Seville, CSIC, Inst Bioquim Vegetal & Fotosintesis, C Amer Vespucio S-N, Seville 41092, Spain.	vioque@cica.es	tous, cristina/X-5472-2019; Vioque, Agustín/K-1809-2014; Palas, Miguel Angel Vega/K-6424-2014	tous, cristina/0000-0002-3590-1904; Vioque, Agustín/0000-0002-3975-7348; Palas, Miguel Angel Vega/0000-0003-1841-540X				ALTMAN S, 1971, NATURE-NEW BIOL, V233, P35, DOI 10.1038/newbio233035a0; Altman S., 1999, RNA WORLD, P351; BANTA AB, 1992, NUCLEIC ACIDS RES, V20, P911, DOI 10.1093/nar/20.4.911; BOTHWELL ALM, 1976, J BIOL CHEM, V251, P7709; Buikema WJ, 2001, P NATL ACAD SCI USA, V98, P2729, DOI 10.1073/pnas.051624898; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; Deutscher MP, 2001, PROG NUCLEIC ACID RE, V66, P67; Deutscher Murray P., 1995, P51; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; Garcia-Dominguez M, 1997, PLANT MOL BIOL, V35, P723, DOI 10.1023/A:1005846626187; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HARTMANN RK, 1995, P NATL ACAD SCI USA, V92, P5822, DOI 10.1073/pnas.92.13.5822; Kaneko T, 1997, PLANT CELL PHYSIOL, V38, P1171, DOI 10.1093/oxfordjournals.pcp.a029103; Kaneko T, 1996, DNA Res, V3, P109; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; MacKinney G, 1941, J BIOL CHEM, V140, P315; Pascual A, 1999, P NATL ACAD SCI USA, V96, P6672, DOI 10.1073/pnas.96.12.6672; Pascual A, 1996, EUR J BIOCHEM, V241, P17, DOI 10.1111/j.1432-1033.1996.0017t.x; REYES JC, 1994, J BACTERIOL, V176, P1260, DOI 10.1128/jb.176.5.1260-1267.1994; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHEDL P, 1973, P NATL ACAD SCI USA, V70, P2091, DOI 10.1073/pnas.70.7.2091; SCHMIDT FJ, 1978, J BIOL CHEM, V253, P4730; VIOQUE A, 1992, NUCLEIC ACIDS RES, V20, P6331, DOI 10.1093/nar/20.23.6331; WAUGH DS, 1990, J BACTERIOL, V172, P6316, DOI 10.1128/jb.172.11.6316-6322.1990; ZHANG L, 1992, J BIOL CHEM, V267, P19054	28	28	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29059	29066		10.1074/jbc.M103418200	http://dx.doi.org/10.1074/jbc.M103418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384989	hybrid, Green Published			2022-12-27	WOS:000170346000058
J	van Rossum, GSAT; Klooster, R; van den Bosch, H; Verkleij, AJ; Boonstra, J				van Rossum, GSAT; Klooster, R; van den Bosch, H; Verkleij, AJ; Boonstra, J			Phosphorylation of p42/44(MAPK) by various signal transduction pathways activates cytosolic phospholipase A(2) to variable degrees	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; ARACHIDONIC-ACID METABOLISM; SMOOTH-MUSCLE; INDEPENDENT PATHWAYS; DEPENDENT ACTIVATION; MAP KINASE; RELEASE; ALPHA; STIMULATION	Arachidonic acid has been implicated to play a role in physiological and pathophysiological processes and is selectively released by the 85-kDa cytosolic phospholipase A(2) (cPLA(2)). The activity of cPLA(2) is regulated by calcium, translocating the enzyme to its substrate, and by phosphorylation by a mitogen-activated protein kinase (MAPK) family member and a MAPK-activated protein kinase. In this study, the signal transduction pathways in growth factor-induced phosphorylation of p42/44(MAPK) and cPLA(2) activation were investigated in Her14 fibroblasts. p42/44MAPK in response to epidermal growth factor was not only phosphorylated via the Raf-MEK pathway but mainly through protein kinase C (PKC) or a related or unrelated kinase in which the phosphorylated p42/ 44(MAPK) corresponded with cPLA(2) activity. Serum-induced phosphorylation of p42/44(MAPK) also corresponded with cPLA(2) activity but is predominantly mediated via Raf-MEK and partly through PKC or a related or un elated kinase. In contrast, activation of PKC by phorbol. ester did not result in increased cPLA2 activity, while p42/44(MAPK) is phosphorylated, mainly via Raf-MEK and through MEM Moreover, p42/44(MAPK) phosphorylation is present in quiescent and proliferating cells, and p42/ 44(MAPK) is entirely phosphorylated via Raf-MEK, but it only corresponds to cPLA(2) activity in the former cells. Collectively, these data show that p42/44(MAPK) in proliferating, quiescent, and stimulated cells is phosphorylated by various signal transduction pathways, suggesting the activation of different populations of p42/44(MAPK) and cPLA(2).	Univ Utrecht, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands	Utrecht University; Utrecht University	van Rossum, GSAT (corresponding author), Univ Utrecht, Dept Mol Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	G.S.A.T.vanRossum@bio.uu.nl						Adomeit A, 1999, MOL CELL BIOL, V19, P5289; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Bokemeyer D, 1996, KIDNEY INT, V49, P1187, DOI 10.1038/ki.1996.172; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bunt G, 1997, J CELL SCI, V110, P2449; Bunt G, 2000, BIOCHEMISTRY-US, V39, P7847, DOI 10.1021/bi992725p; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burke JR, 1999, ARCH BIOCHEM BIOPHYS, V365, P239, DOI 10.1006/abbi.1999.1151; Cifone MG, 1997, J IMMUNOL, V159, P309; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; COULDWELL WT, 1994, FEBS LETT, V345, P43, DOI 10.1016/0014-5793(94)00415-3; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DOORNBOS RP, 2000, THESIS UTRECHT U, P67; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Heller A, 1998, DRUGS, V55, P487, DOI 10.2165/00003495-199855040-00001; Hernandez M, 1999, J NEUROCHEM, V73, P1641, DOI 10.1046/j.1471-4159.1999.0731641.x; Hirabayashi T, 2000, BBA-MOL CELL BIOL L, V1488, P124, DOI 10.1016/S1388-1981(00)00115-3; Husain S, 1998, BBA-LIPID LIPID MET, V1392, P127, DOI 10.1016/S0005-2760(98)00011-3; HUWILER A, 1992, FEBS LETT, V300, P259, DOI 10.1016/0014-5793(92)80858-E; HUWILER A, 1993, EXP NEPHROL, V1, P19; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Korystov YN, 1998, FEBS LETT, V431, P224, DOI 10.1016/S0014-5793(98)00757-1; Kramer HK, 1999, J NEUROCHEM, V72, P594, DOI 10.1046/j.1471-4159.1999.0720594.x; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NEWBY AC, 1995, BRIT J PHARMACOL, V114, P1652, DOI 10.1111/j.1476-5381.1995.tb14953.x; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; Pol A, 1998, FEBS LETT, V441, P34, DOI 10.1016/S0014-5793(98)01517-8; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; Romanelli A, 1997, METABOLISM, V46, P548, DOI 10.1016/S0026-0495(97)90193-1; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; Schalkwijk CG, 1996, BIOCHEM J, V313, P91, DOI 10.1042/bj3130091; SCHALKWIJK CG, 1995, EUR J BIOCHEM, V231, P593, DOI 10.1111/j.1432-1033.1995.tb20737.x; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SOZERI O, 1992, ONCOGENE, V7, P2259; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; van Rossum GSAT, 1999, LIPIDS, V34, pS65, DOI 10.1007/BF02562230; VANDENBOSCH H, 1974, BIOCHIM BIOPHYS ACTA, V348, P197, DOI 10.1016/0005-2760(74)90231-8; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; WITMER MR, 1995, ARCH BIOCHEM BIOPHYS, V318, P430, DOI 10.1006/abbi.1995.1251	69	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28976	28983		10.1074/jbc.M101361200	http://dx.doi.org/10.1074/jbc.M101361200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390384	hybrid			2022-12-27	WOS:000170346000047
J	Zhang, LJ; Lawrence, R; Schwartz, JJ; Bai, XM; Wei, G; Esko, JD; Rosenberg, RD				Zhang, LJ; Lawrence, R; Schwartz, JJ; Bai, XM; Wei, G; Esko, JD; Rosenberg, RD			The effect of precursor structures on the action of glucosaminyl 3-O-sulfotransferase-1 and the biosynthesis of anticoagulant heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-DEACETYLASE/N-SULFOTRANSFERASE; EMBRYONAL CARCINOMA-CELLS; HAMSTER OVARY CELLS; MOLECULAR-CLONING; ANTITHROMBIN-III; CDNA CLONING; PROTEOGLYCANS; EXPRESSION; BINDING; ACID	To understand how 2-O-sulfation of uronic acid residues influences the biosynthesis of anticoagulant heparan sulfate, the cDNA encoding glucosaminyl 3-O-sulfotransferase-1 (3-OST-1) was introduced into wild-type Chinese hamster ovary cells and mutant pgsF-17 cells, which are defective in 2-O-sulfation. 3-OST-1-transduced cells gained the ability to bind to antithrombin. Structural analysis of the heparan sulfate chains showed that 3-OST-1 generates sequences containing GlcUA-GlcN(SO3)3(SO3) and GlcUA-GlcN(SO3)3(SO3)6(SO.) in both wild-type and mutant cells. In addition, IdoUA-GIcN(SO3)3(SO3) and IdoUA-GIcN(SO3)3(SO3)6(SO3) accumulate in the mutant chain. These disaccharides were also observed by tagging [6-H-3]GIcN-labeled pgsF-17 heparan sulfate in vitro with [S-35]PAPs and purified 3-OST-1. Heparan sulfate derived from the transduced mutant also had similar to2-fold higher affinity for antithrombin than heparan sulfate derived from the transduced wildtype cells, and it inactivated factor Xa more efficiently. This study demonstrates for the first time that (i) 3-O-sulfation by 3-OST-1 can occur independently of the 2-O-sulfation of uronic acids, (ii) 2-0-sulfation usually occurs before 3-O-sulfation, (iii) 2-0-sulfation blocks the action of 3-OST-1 at glucosamine residues located to the reducing side of IdoUA units, and (iv) that alternative antithrombin-binding structures can be made in the absence of 2-0-sulfation.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, BIDMC, Dept Med, Boston, MA 02215 USA; Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of California System; University of California San Diego	Rosenberg, RD (corresponding author), MIT, Dept Biol, Bldg 68-480,77 Massachusetts Ave, Cambridge, MA 02139 USA.				NHLBI NIH HHS [5R01-HL58479, 5P01-HL41484] Funding Source: Medline; NIGMS NIH HHS [R37-GM33063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; Bai XM, 1997, J BIOL CHEM, V272, P23172, DOI 10.1074/jbc.272.37.23172; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1991, J BIOL CHEM, V266, P10287; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; EDGE ASB, 1990, J BIOL CHEM, V265, P15874; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Fersht AR, 1985, ENZYME STRUCTURES ME; FIELDSBERRY SC, 1992, P NATL ACAD SCI USA, V89, P693, DOI 10.1073/pnas.89.2.693; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HAWLEY RG, 1994, GENE THER, V1, P136; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Lindqvist C, 1999, SKANDINAVISTIK, V29, P1; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; LOGANATHAN D, 1990, BIOCHEMISTRY-US, V29, P4362, DOI 10.1021/bi00470a015; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; PERUCHO M, 1980, CELL, V22, P309, DOI 10.1016/0092-8674(80)90178-6; Petitou M, 1992, Fortschr Chem Org Naturst, V60, P143; Rosenberg RD, 1997, J CLIN INVEST, V100, pS67; Rostand KS, 1997, INFECT IMMUN, V65, P1; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; Zhang LJ, 1999, J BIOL CHEM, V274, P5681, DOI 10.1074/jbc.274.9.5681; Zhang LJ, 1998, J BIOL CHEM, V273, P27998, DOI 10.1074/jbc.273.43.27998	41	53	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28806	28813		10.1074/jbc.M100204200	http://dx.doi.org/10.1074/jbc.M100204200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11375390	hybrid			2022-12-27	WOS:000170346000023
J	Zhang, Y; Dimtchev, A; Dritschilo, A; Jung, M				Zhang, Y; Dimtchev, A; Dritschilo, A; Jung, M			Ionizing radiation-induced apoptosis in ataxia-telangiectasia fibroblasts - Roles of caspase-9 and cellular inhibitor of apoptosis protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY PROTEINS; CYTOCHROME-C; POLY(ADP-RIBOSE) POLYMERASE; CYSTEINE PROTEASES; DEATH PROTEASES; MITOCHONDRIA; ATM; ACTIVATION; REQUIREMENT; INDUCTION	Ionizing radiation (IR) has been shown to induce apoptosis to a greater extent in a fibroblast cell line AT5BIVA derived from an individual with ataxia-telangiectasia (AT) than in control fibroblasts. However, the signaling pathway that underlies IR-induced apoptosis in AT cells has remained unknown. The mechanism of apoptosis in response to gamma -irradiation has now been examined in three AT fibroblast lines (AT3BIVA, AT4BIVA, and AT5BIVA) derived from different individuals with AT. The apoptotic indexes of these cell lines at 72 h after irradiation were 12, 31, and 35%, respectively, compared with a value of 2.3% for control fibroblasts. Immunoblot analysis and fluorometric assays revealed that the extents of IR-induced activation of caspase-3 and caspase-9 were markedly greater in AT4BrVA and AT5BIVA cells than in AT3BIVA and control cells. Furthermore, the basal abundance of the apoptotic inhibitor, a cellular inhibitor of apoptosis proteins (c-IAP-1), was markedly reduced in AT4BIVA and AT5BIVA cells compared with that in AT3BIVA and control cells. The overexpression of either caspase-9 mutant forms or recombinant c-IAP-1 in AT5BIVA cells inhibited the IR-induced activation of caspases-3 and 9 and reduced the apoptotic index of the irradiated cells. These results indicate that the extent of IR-induced apoptosis in different AT cell lines is inversely related to the abundance of c-IAP-1 and directly related to the extent of activation of caspases-3 and 9.	Georgetown Univ, Sch Med, Vincent T Lombardi Canc Res Ctr, Dept Radiat Med,Div Radiat Res,Med Ctr, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Vincent T Lombardi Canc Res Ctr, Dept Microbiol,Div Radiat Res, Washington, DC 20007 USA	Georgetown University; Georgetown University	Jung, M (corresponding author), Georgetown Univ, Sch Med, Vincent T Lombardi Canc Res Ctr, Dept Radiat Med,Div Radiat Res,Med Ctr, Res Bldg,Rm E211A,3970 Reservoir Rd NW, Washington, DC 20007 USA.				NCI NIH HHS [CA74175, CA68023, CA45408] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045408, P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han ZY, 1998, CELL DEATH DIFFER, V5, P469, DOI 10.1038/sj.cdd.4400367; HERMANN S, 1995, SCIENCE, V267, P1445; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MEYN MS, 1995, CANCER RES, V55, P5991; MEYN MS, 1994, INT J RADIAT BIOL, V66, P141; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1999, CANCER RES, V59, P999; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Takao N, 2000, FEBS LETT, V472, P133, DOI 10.1016/S0014-5793(00)01422-8; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	48	19	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28842	28848		10.1074/jbc.M010525200	http://dx.doi.org/10.1074/jbc.M010525200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382748	hybrid			2022-12-27	WOS:000170346000029
J	Col, E; Caron, C; Seigneurin-Berny, D; Gracia, J; Favier, A; Khochbin, S				Col, E; Caron, C; Seigneurin-Berny, D; Gracia, J; Favier, A; Khochbin, S			The histone acetyltransferase, hGCN5, interacts with and acetylates the HIV transactivator, Tat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVITY; COACTIVATORS P300; FAMILY MEMBERS; DNA-DAMAGE; IN-VIVO; BROMODOMAIN; GCN5; ACTIVATION; P/CAF	Factor acetyltransferase activity associated with several histone acetyltransferases plays a key role in the control of transcription. Here we report that hGCN5, a well known histone acetyltransferase, specifically interacts with and acetylates the human immunodeficiency virus type 1 (HIV-1) transactivator protein, Tat. The interaction between Tat and hGCN5 is direct and involves the acetyltransferase and the bromodomain regions of hGCN5, as well as a limited region of Tat encompassing the cysteine-rich domain of the protein. Tat lysines 50 and 51, target of acetylation by p300/CBP, were also found to be acetylated by hGCN5. The acetylation of these two lysines by p300/CBP has been recently shown to stimulate Tat transcriptional activity and accordingly, we have found that hGCN5 can considerably enhance Tat-dependent transcription of the HIV-1 long terminal repeat. These data highlight the importance of the acetylation of lysines 50 and 51 in the function of Tat, since different histone acetyltransferases involved in distinct signaling pathways, GCN5 and p300/CBP, converge to acetylate Tat on the same site.	Fac Med, Inst Albert Bonniot, INSERM, U309,Lab Biol Mol & Cellulaire Differenciat, F-38706 La Tronche, France; Fac Pharm, Lab Biol Stress Oxydant, F-38700 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Khochbin, S (corresponding author), Fac Med, Inst Albert Bonniot, INSERM, U309,Lab Biol Mol & Cellulaire Differenciat, Domaine Merci, F-38706 La Tronche, France.		Khochbin, Saadi/M-8090-2013; SEIGNEURIN-BERNY, Daphne/C-8412-2017	Khochbin, Saadi/0000-0002-0455-0857; SEIGNEURIN-BERNY, Daphne/0000-0002-7436-9885				Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Candau R, 1996, MOL CELL BIOL, V16, P593; Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Herrera JE, 1999, MOL CELL BIOL, V19, P3466; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kuo CH, 1996, IEEE SIGNAL PROC LET, V3, P269, DOI 10.1109/97.536598; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Smith ER, 1998, NUCLEIC ACIDS RES, V26, P2948, DOI 10.1093/nar/26.12.2948; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; VESCHAMBRE P, 1995, J MOL BIOL, V250, P169, DOI 10.1006/jmbi.1995.0368; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681	44	120	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28179	28184		10.1074/jbc.M101385200	http://dx.doi.org/10.1074/jbc.M101385200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11384967	hybrid			2022-12-27	WOS:000170093400059
J	Fatyol, K; Szalay, AA				Fatyol, K; Szalay, AA			The p14(ARF) tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1 alpha (HIF-1 alpha) and inhibits HIF-1-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 1-ALPHA HIF-1-ALPHA; ENDOTHELIAL GROWTH-FACTOR; P53; MDM2; EXPRESSION; P19(ARF); PATHWAY; HIF-1; CELL; LOCALIZATION	Oncogenic alterations can influence tumor cell survival partly by affecting the activity of the hypoxia-inducible factor-1 (HIF-1) transcription factor. The a subunit of HIF-1 was found to be frequently overexpressed in advanced tumors, which was proposed to help the adaptation of tumor cells to hypoxia. Here we show that an important tumor suppressor protein, p14(ARF) (alternative reading frame product of the INK4A locus) can directly inhibit the transcriptional activity of HIF-1 by sequestering its alpha subunit into the nucleolus. The interaction requires neither p53 nor HDM2. This is one of the first reports that describe the interaction of p14(ARF) with a protein besides HDM2, which may define a p53-independent tumor suppressor activity for p14(ARF).	Loma Linda Univ, Dept Biochem, Loma Linda, CA 92350 USA	Loma Linda University	Fatyol, K (corresponding author), Loma Linda Univ, Dept Biochem, Loma Linda, CA 92350 USA.							Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jiang BH, 1997, CANCER RES, V57, P5328; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazure NM, 1996, CANCER RES, V56, P3436; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sambrook J., 2002, MOL CLONING LAB MANU; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P372, DOI 10.1016/S0955-0674(00)00102-2; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 1999, CANCER RES, V59, P5830; Zundel W, 2000, GENE DEV, V14, P391	35	94	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28421	28429		10.1074/jbc.M102847200	http://dx.doi.org/10.1074/jbc.M102847200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382768	hybrid			2022-12-27	WOS:000170093400090
J	Keren, T; Roth, IG; Henis, YI				Keren, T; Roth, IG; Henis, YI			Internalization-competent influenza hemagglutinin mutants form complexes with clathrin-deficient multivalent AP-2 oligomers in live cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; FACTOR-BETA RECEPTORS; COATED PIT FORMATION; VIRUS HEMAGGLUTININ; SORTING SIGNALS; PLASMA-MEMBRANE; CYTOPLASMIC DOMAIN; VESICLE FORMATION; APPENDAGE DOMAIN; TYROSINE	Most membrane proteins are endocytosed through clathrin-coated pits via AP-2 adaptor complexes. However, little is known about the interaction of internalization signals with AP-2 in live cells in the absence of clathrin lattices. To investigate this issue, we employed cells cotransfected with pairs of antigenically distinct influenza hemagglutinin (HA) mutants containing different internalization signals of the YXXZ family. To enable studies on the possible association of the naturally trimeric HAs into higher order complexes via binding to AP-2, we exploited the inability of HAs from different influenza strains to form mutual trimers. Thus, we coexpressed HA pairs from different strains (Japan and X:31) bearing similar cytoplasmic tails mutated to include internalization signals. Using antibody-mediated immunofluorescence co-patching on live cells, we demonstrate that internalization-competent HA mutants form higher order complexes and that this clustering depends on the strength of the internalization signal. The clustering persisted in cells treated with hypertonic medium to disperse the clathrin lattices, as validated by co-immunoprecipitation experiments. The clustering of HAs bearing strong internalization signals appears to be mediated via binding to AP-2, as indicated by (i) the coprecipitation of alpha -adaptin with these HAs, even in hypertonically treated cells; (ii) the co-localization (after hypertonic treatment) of AP-2 with antibody-mediated patches of these mutants; and (iii) the dispersal of the higher order HA complexes following chlorpromazine treatment, which removes AP-2 from the plasma membrane. These results suggest that even in the absence of clathrin lattices, AP-2 exists in multivalent complexes capable of simultaneously binding several internalization signals from the same family.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Tel Aviv University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Henis, YI (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	henis@post.tau.ac.il		Henis, Yoav/0000-0002-1408-3877; Roth, Michael/0000-0002-9056-332X	NIGMS NIH HHS [GM37547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; BOULAY F, 1988, J CELL BIOL, V106, P629, DOI 10.1083/jcb.106.3.629; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Brown CM, 1999, BIOCHEMISTRY-US, V38, P15166, DOI 10.1021/bi991170v; CHIN DJ, 1989, P NATL ACAD SCI USA, V86, P9289, DOI 10.1073/pnas.86.23.9289; DANIELS RS, 1983, J GEN VIROL, V64, P1657, DOI 10.1099/0022-1317-64-8-1657; Fire E, 1997, J BIOL CHEM, V272, P29538, DOI 10.1074/jbc.272.47.29538; FIRE E, 1995, J BIOL CHEM, V270, P21075, DOI 10.1074/jbc.270.36.21075; FIRE E, 1991, J CELL BIOL, V115, P1585, DOI 10.1083/jcb.115.6.1585; GETHING MJ, 1980, NATURE, V287, P301, DOI 10.1038/287301a0; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; Lewis CM, 2000, TRAFFIC, V1, P282, DOI 10.1034/j.1600-0854.2000.010310.x; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Musacchio A, 1999, MOL CELL, V3, P761, DOI 10.1016/S1097-2765(01)80008-3; NAIM HY, 1994, METHOD CELL BIOL, V43, P113; NAIM HY, 1993, J VIROL, V67, P4831, DOI 10.1128/JVI.67.8.4831-4841.1993; NAIM HY, 1994, J BIOL CHEM, V269, P3928; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Owen DJ, 2001, TRAFFIC, V2, P105, DOI 10.1034/j.1600-0854.2001.020205.x; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; SUBTIL A, 1994, J CELL SCI, V107, P3461; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; Tugizov S, 1999, J VIROL, V73, P8677, DOI 10.1128/JVI.73.10.8677-8688.1999; von Poser C, 2000, J BIOL CHEM, V275, P30916, DOI 10.1074/jbc.M005559200; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Wells RG, 1999, J BIOL CHEM, V274, P5716, DOI 10.1074/jbc.274.9.5716; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zwart DE, 1996, J BIOL CHEM, V271, P907, DOI 10.1074/jbc.271.2.907	58	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28356	28363		10.1074/jbc.M102235200	http://dx.doi.org/10.1074/jbc.M102235200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369772	hybrid			2022-12-27	WOS:000170093400082
J	Mariner, DJ; Anastasiadis, P; Keilhack, H; Bohmer, FD; Wang, J; Reynolds, AB				Mariner, DJ; Anastasiadis, P; Keilhack, H; Bohmer, FD; Wang, J; Reynolds, AB			Identification of Src phosphorylation sites in the catenin p120(ctn)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; CELL-CELL ADHESION; E-CADHERIN; ALPHA-CATENIN; P120 CATENIN; BETA-CATENIN; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; CARCINOMA-CELLS	p120-catenin (p120(ctn)) interacts with the cytoplasmic tail of cadherins and is thought to regulate cadherin clustering during formation of adherens junctions. Several observations suggest that p120 can both positively and negatively regulate cadherin adhesiveness depending on signals that so far remain unidentified. Although p120 tyrosine phosphorylation is a leading candidate, the role of this modification in normal and Src-transformed cells remains unknown. Here, as a first step toward pinpointing this role, we have employed two-dimensional tryptic mapping to directly identify the major sites of Src-induced p120 phosphorylation. Eight sites were identified by direct mutation of candidate tyrosines to phenylalanine and elimination of the accompanying spots on the two-dimensional maps. Identical sites were observed in vitro and in vivo, strongly suggesting that the physiologically important sites have been correctly identified. Changing all of these sites to phenylalanine resulted in a p120 mutant, p120-8F, that could not be efficiently phosphorylated by Src and failed to interact with SHP-1, a tyrosine phosphatase shown previously to interact selectively with tyrosine-phosphorylated p120 in cells stimulated with epidermal growth factor. Using selected tyrosine to phenylalanine p120 mutants as dominant negative reagents, it may now be possible to selectively block events postulated to be dependent on p120 tyrosine phosphorylation.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Univ Jena, Fac Med, Res Unit Mol Cell Biol, D-07747 Jena, Germany	Vanderbilt University; Friedrich Schiller University of Jena	Reynolds, AB (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 1161 21st Ave S,MCN C-2310, Nashville, TN 37232 USA.	al.reynolds@mcmail.vanderbilt.edu			NATIONAL CANCER INSTITUTE [R29CA055724, R01CA055724] Funding Source: NIH RePORTER; NCI NIH HHS [CA69485, CA55724] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Cozzolino M, 2000, J CELL SCI, V113, P1601; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; DOWNING JR, 1991, ONCOGENE, V6, P607; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Grosheva I, 2001, J CELL SCI, V114, P695; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Keilhack H, 2000, J BIOL CHEM, V275, P26376, DOI 10.1074/jbc.M001315200; KIM L, 1995, MOL CELL BIOL, V15, P4553; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lampugnani MG, 1997, J CELL SCI, V110, P2065; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nieset JE, 1997, J CELL SCI, V110, P1013; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Ozawa M, 2001, J CELL SCI, V114, P503; Papkoff J, 1997, J BIOL CHEM, V272, P4536; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RIMM DL, 1994, BIOCHEM BIOPH RES CO, V203, P1691, DOI 10.1006/bbrc.1994.2381; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Skoudy A, 1996, BIOCHEM J, V317, P279, DOI 10.1042/bj3170279; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; Tamir I, 2000, CURR OPIN IMMUNOL, V12, P307, DOI 10.1016/S0952-7915(00)00092-3; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	47	116	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28006	28013		10.1074/jbc.M102443200	http://dx.doi.org/10.1074/jbc.M102443200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382764	hybrid			2022-12-27	WOS:000170093400036
J	Yamazaki, S; Muta, T; Takeshige, K				Yamazaki, S; Muta, T; Takeshige, K			A novel I kappa B protein, I kappa B-zeta, induced by proinflammatory stimuli, negatively regulates nuclear factor-kappa B in the nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; INNATE IMMUNE-RESPONSE; ZINC-FINGER PROTEIN; DROSOPHILA TOLL; ALPHA; ACTIVATION; TNF; EXPRESSION; APOPTOSIS; INHIBITOR	The transcription factor nuclear factor-kappaB (NF-kappaB) plays crucial roles in a wide variety of cellular functions and its activity is strictly regulated by cytosolic inhibitors known as I kappa Bs. We here report a new member of the I kappaB protein family, I kappaB-zeta, harboring six ankyrin repeats at its carboxyl terminus. I kappaB-zeta mRNA is strongly induced after stimulation by lipopolysaccharide. The induction of I kappaB-zeta is also observed by stimulation with interleukin-1 beta but not by tumor necrosis factor-alpha. In contrast to cytosolic I kappaB-alpha, -beta, and -epsilon, the induced I kappaB-zeta localizes in the nucleus via its amino-terminal region, which shows no homology with other proteins. Transiently expressed I kappaB-zeta inhibits the NF-kappaB activity without affecting the nuclear translocation of NF-kappaB upon stimulation. The expressed I kappaB-zeta preferentially associates with the NF-kappaB subunit p50 rather than p65 and recombinant I kappaB-zeta proteins inhibit the DNA binding of the p65/p50 heterodimer and the p50/p50 homodimer, Thus, I kappaB-zeta negatively regulates NF-kappaB activity in the nucleus, possibly in order to prevent excessive inflammation. Moreover, transfection of I kappaB-zeta renders cells more susceptible to apoptosis induced by tumor necrosis factor-alpha. The proapoptotic activity of I kappaB-zeta further suggests that it might be one of key regulators for inflammation and other biologically relevant processes.	Kyushu Univ, Grad Sch Med Sci, Dept Mol & Cellular Biochem, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Muta, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol & Cellular Biochem, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.			Yamazaki, Soh/0000-0001-5038-1567				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2000, BIOCHEM SOC T, V28, P551, DOI 10.1042/bst0280551; Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Haruta H, 2001, J BIOL CHEM, V276, P12485, DOI 10.1074/jbc.C100075200; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Jaattela M, 1996, J IMMUNOL, V156, P1166; Kitamura H, 2000, FEBS LETT, V485, P53, DOI 10.1016/S0014-5793(00)02185-2; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Na SY, 1999, J BIOL CHEM, V274, P28491, DOI 10.1074/jbc.274.40.28491; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SCOTT ML, 1993, GENE DEV, V7, P1226; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Ulevitch RJ, 2000, IMMUNOL RES, V21, P49, DOI 10.1385/IR:21:2-3:49; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; Yamamoto H, 1997, BIOCHEM J, V325, P223, DOI 10.1042/bj3250223	31	221	242	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27657	27662		10.1074/jbc.M103426200	http://dx.doi.org/10.1074/jbc.M103426200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356851	hybrid			2022-12-27	WOS:000169966900121
J	Davis, TL; Rabinovitz, I; Futscher, BW; Schnolzer, M; Burger, F; Liu, YG; Kulesz-Martin, M; Cress, AE				Davis, TL; Rabinovitz, I; Futscher, BW; Schnolzer, M; Burger, F; Liu, YG; Kulesz-Martin, M; Cress, AE			Identification of a novel structural variant of the alpha(6) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; SUBUNIT CYTOPLASMIC DOMAIN; CELL-ADHESION MOLECULES; EXTRACELLULAR-MATRIX; LIGAND-BINDING; LAMININ RECEPTOR; ALPHA-6-BETA-4 INTEGRIN; FIBRONECTIN RECEPTOR; MONOCLONAL-ANTIBODY; TISSUE DISTRIBUTION	The alpha P-6 integrin is a 140-kDa (nonreduced) laminin receptor. We have identified a novel 70-kDa (nonreduced) form of the alpha (6) integrin called alpha P-6 for the latin word parvus, meaning small. The variant was immunoprecipitated from human cells using four different alpha (6)-specific monoclonal antibodies but not with alpha (3) or alpha (5) antibodies. The alpha P-6 integrin contained identical amino acid sequences within exons 13-25, corresponding to the extracellular "stalk region" and the cytoplasmic tail of the alpha (6) integrin. The light chains of alpha P-6 and alpha P-6 were identical as judged by alpha (6)A-specific antibodies and electrophoretic properties. The alpha P-6 variant paired with either beta (1) or beta (4) subunits and was retained on the cell surface three times longer than alpha (6). Reverse transcription/polymerase chain reaction analysis revealed a single polymerase chain reaction product. The alpha P-6 variant was found in human prostate (DU145H, LnCaP, PC3) and colon (SW480) cancer cell lines but not in normal prostate (PrEC), breast cancer (MCF-7), or lung cancer (H69) cell lines or a variant of a prostate carcinoma cell line (PC3-N), Protein levels of alpha P-6 increased 3-fold during calcium-induced terminal differentiation in a normal mouse keratinocyte model system. A novel form of the alpha (6) integrin exists on cell surfaces that contains a dramatically altered extracellular domain.	Univ Arizona, Arizona Canc Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Helmholtz Association; German Cancer Research Center (DKFZ); Oregon Health & Science University	Cress, AE (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Radiat Oncol, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	cress@azcc.arizona.edu	Cress, Anne/V-6527-2019	Cress, Anne/0000-0001-6194-0061	NATIONAL CANCER INSTITUTE [P30CA023074, P01CA056666, R01CA075152, R01CA031101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NCI NIH HHS [CA75152, CA23074, P30 CA023074, R01 CA075152, CA31101, P01 CA056666-120002, P01 CA056666, R01 CA075152-08, P30 CA023074-22] Funding Source: Medline; NIEHS NIH HHS [ES06694, P30 ES006694] Funding Source: Medline; PHS HHS [P01-56666] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREW SM, 1992, BRIT J DERMATOL, V127, P359, DOI 10.1111/j.1365-2133.1992.tb00454.x; BEDNARCZYK JL, 1992, J BIOL CHEM, V267, P25274; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Berthet V, 2000, J BIOL CHEM, V275, P33308, DOI 10.1074/jbc.M004834200; Breitkreutz D, 1998, EUR J CELL BIOL, V75, P273, DOI 10.1016/S0171-9335(98)80123-4; Brown TA, 1996, J INVEST DERMATOL, V107, P384, DOI 10.1111/1523-1747.ep12363370; Bullock TNJ, 1996, J EXP MED, V184, P1319, DOI 10.1084/jem.184.4.1319; Callebaut I, 1998, CELL MOL LIFE SCI, V54, P880, DOI 10.1007/s000180050216; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843; Cress AE, 2000, BIOTECHNIQUES, V29, P776, DOI 10.2144/00294st03; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; DAMSKY CH, 1994, DEVELOPMENT, V120, P3657; Delwel GO, 1997, BIOCHEM J, V324, P263, DOI 10.1042/bj3240263; DROZ D, 1994, LAB INVEST, V71, P710; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; ENGELBERGKULKA H, 1993, TRENDS BIOCHEM SCI, V18, P294, DOI 10.1016/0968-0004(93)90039-P; FALCIONI R, 1988, CANCER RES, V48, P816; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; FRIEDRICHS K, 1995, CANCER RES, V55, P901; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; GAIETTA G, 1994, J CELL SCI, V107, P3339; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GIL SG, 1994, J INVEST DERMATOL, V103, pS31, DOI 10.1111/1523-1747.ep12398953; HEMLER ME, 1988, J BIOL CHEM, V263, P7660; Hennings H, 1980, Curr Probl Dermatol, V10, P3; HESSLE H, 1984, DIFFERENTIATION, V26, P49, DOI 10.1111/j.1432-0436.1984.tb01372.x; HOGERVORST F, 1993, J CELL BIOL, V121, P179, DOI 10.1083/jcb.121.1.179; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HONDA T, 1995, J CLIN ENDOCR METAB, V80, P2899, DOI 10.1210/jc.80.10.2899; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; Jaspars LH, 1996, CELL ADHES COMMUN, V4, P269, DOI 10.3109/15419069609010771; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; KNOX JD, 1994, AM J PATHOL, V145, P167; KOUKOULIS GK, 1993, VIRCHOWS ARCH B, V63, P373, DOI 10.1007/BF02899286; KULESZMARTIN MF, 1988, CARCINOGENESIS, V9, P171, DOI 10.1093/carcin/9.1.171; KULESZMARTIN MF, 1980, CARCINOGENESIS, V1, P995, DOI 10.1093/carcin/1.12.995; LESSEY BA, 1995, AM J PATHOL, V146, P717; LIEBERT M, 1993, HYBRIDOMA, V12, P67, DOI 10.1089/hyb.1993.12.67; Lu CF, 1997, J IMMUNOL, V159, P268; MECHTERSHEIMER G, 1993, VIRCHOWS ARCH A, V422, P203, DOI 10.1007/BF01621803; MIETTINEN M, 1993, AM J PATHOL, V142, P1009; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; NAGLE RB, 1995, AM J PATHOL, V146, P1498; Niessen CM, 1996, J CELL SCI, V109, P1695; Oxvig C, 1998, P NATL ACAD SCI USA, V95, P4870, DOI 10.1073/pnas.95.9.4870; Paoli M, 1999, NAT STRUCT BIOL, V6, P926; PARKER CM, 1993, J BIOL CHEM, V268, P7028; PATEY N, 1994, CELL ADHES COMMUN, V2, P159, DOI 10.3109/15419069409004434; Pattaramalai S, 1996, EXP CELL RES, V222, P281, DOI 10.1006/excr.1996.0036; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; Price AA, 1997, J EXP MED, V186, P1725, DOI 10.1084/jem.186.10.1725; Pulkkinen L, 1997, LAB INVEST, V76, P823; Putz E, 1999, CANCER RES, V59, P241; RABINOVITZ I, 1995, CLIN EXP METASTAS, V13, P481, DOI 10.1007/BF00118187; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; SHAW LM, 1993, J CELL BIOL, V123, P1017, DOI 10.1083/jcb.123.4.1017; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimizu H, 1996, ARCH DERMATOL, V132, P919, DOI 10.1001/archderm.132.8.919; SIMON EE, 1990, AM J PHYSIOL, V259, pF783, DOI 10.1152/ajprenal.1990.259.5.F783; SONNENBERG A, 1990, J CELL SCI, V96, P207; Sonnenberg A, 1993, Curr Top Microbiol Immunol, V184, P7; SONNENBERG A, 1987, J BIOL CHEM, V262, P10376; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; Sterk LMT, 2000, J CELL BIOL, V149, P969, DOI 10.1083/jcb.149.4.969; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; TERPE HJ, 1994, HISTOCHEMISTRY, V101, P41, DOI 10.1007/BF00315830; Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2; VANWAES C, 1991, CANCER RES, V51, P2395; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; vonBredow DC, 1997, EXP CELL RES, V236, P341, DOI 10.1006/excr.1997.3711; Wagner S, 1997, STROKE, V28, P858, DOI 10.1161/01.STR.28.4.858; WATT FM, 1993, DEVELOPMENT, P185; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WEINEL RJ, 1995, GASTROENTEROLOGY, V108, P523, DOI 10.1016/0016-5085(95)90082-9; WEINEL RJ, 1992, INT J CANCER, V52, P827, DOI 10.1002/ijc.2910520526; Witkowski CM, 2000, CARCINOGENESIS, V21, P325, DOI 10.1093/carcin/21.2.325; WITKOWSKI CM, 1993, J CANCER RES CLIN, V119, P637, DOI 10.1007/BF01215981	89	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26099	26106		10.1074/jbc.M102811200	http://dx.doi.org/10.1074/jbc.M102811200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11359780	Green Accepted, hybrid			2022-12-27	WOS:000169823300063
J	Mao, CG; Xu, RJ; Szulc, ZM; Bielawska, A; Galadari, SH; Obeid, LM				Mao, CG; Xu, RJ; Szulc, ZM; Bielawska, A; Galadari, SH; Obeid, LM			Cloning and characterization of a novel human alkaline ceramidase - A mammalian enzyme that hydrolyzes phytoceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC STRESS-RESPONSE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; PSEUDOMONAS-AERUGINOSA; NEUTRAL CERAMIDASE; ANCHORED PROTEINS; FUMONISIN B-1; CELL-GROWTH; SPHINGOLIPIDS; INHIBITION	Ceramidases are enzymes involved in regulating cellular levels of ceramides, sphingoid bases, and their phosphates, Based on sequence homology to the yeast alkaline ceramidases YPC1p (Mao, C,, Xu, R,, Bielawska, A., and Obeid, L, M, (2000) J. Biol, Chem. 275, 6876-6884) and YDC1p (Mao, C,, Xu, R,, Bielawska, A., Szulc, Z, M,, and Obeid, L, RI. (2000) J. Biol Chem, 275, 31369-31378), we report the identification and cloning of a cDNA encoding for a novel human alkaline ceramidase (aPHC) that hydrolyzes phytoceramide selectively, Northern blot analysis showed that aPHC was ubiquitously expressed, with the highest expression in placenta. Green fluorescent protein tagging showed that it was localized in both the Golgi apparatus and endoplasmic reticulum. Overexpression of aPHC in mammalian cells elevated in vitro ceramidase activity toward N-4-nitrobenz-2-oxa-1,3-diazole-C-12-phytoceramide. Its expression in a yeast mutant strain devoid of any ceramidase activity restored the ceramidase activity and caused an increase in the hydrolysis of phytoceramide in yeast cells, thus leading to the decreased biosynthesis of sphingolipids. These data collectively suggest that, similar to the yeast phytoceramidase YPC1p, aPHC has phytoceramidase activity both in vitro and in cells; hence, it is a functional homolog of the yeast phytoceramidase YPC1p, However, in contrast to YPC1p, aPHC exhibited no reverse activity of ceramidase either in vitro or in cells. Biochemical characterization showed that aPHC had a pH optimum of 9.5, was activated by Ca2+, but was inhibited by Zn2+ and sphingosine, Substrate specificity showed that aPHC hydrolyzed phytoceramide preferentially, Together, these data demonstrate that aPHC is a novel human alkaline phytoceramidase, the first mammalian alkaline ceramidase to be identified as being specific for the hydrolysis of phytoceramide.	Med Univ S Carolina, Ralph H Johnson Vet Affairs Hosp, Div Gen Internal Med, Charleston, SC 29425 USA; United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Biochem, Abu Dhabi, U Arab Emirates	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; United Arab Emirates University	Mao, CG (corresponding author), Dept Med, 114 Doughty St,Rm 605 STB,POB 250779, Charleston, SC 29425 USA.		Galadari, Sehamuddin/AAK-6039-2020; xu, rui/GRX-5734-2022	obeid, lina/0000-0002-0734-0847				Ardail D, 2001, FEBS LETT, V488, P160, DOI 10.1016/S0014-5793(00)02332-2; Birt DF, 1998, NUTR CANCER, V31, P119, DOI 10.1080/01635589809514690; Bleck O, 1999, J INVEST DERMATOL, V113, P894, DOI 10.1046/j.1523-1747.1999.00809.x; Brini M, 2000, CELL MOL LIFE SCI, V57, P354, DOI 10.1007/PL00000698; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; El Bawab S, 2001, J BIOL CHEM, V276, P16758, DOI 10.1074/jbc.M009331200; English D, 2001, CARDIOVASC RES, V49, P588, DOI 10.1016/S0008-6363(00)00230-3; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hannun YA, 1997, ADV EXP MED BIOL, V407, P145; Hannun YA, 1997, BIOCHEM SOC T, V25, P1171, DOI 10.1042/bst0251171; HASSLER DF, 1993, ADV LIPID RES, V26, P49; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Kim S, 2000, GENETICS, V156, P1519; Kita K, 2000, BBA-MOL CELL BIOL L, V1485, P111, DOI 10.1016/S1388-1981(00)00029-9; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Mao CG, 2000, J BIOL CHEM, V275, P31369, DOI 10.1074/jbc.M003683200; MARCHESINI S, 1990, CHEM PHYS LIPIDS, V53, P165, DOI 10.1016/0009-3084(90)90042-P; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MIKAMI M, 1992, BIOCHIM BIOPHYS ACTA, V1125, P104, DOI 10.1016/0005-2760(92)90162-O; Nikolova-Karakashian M, 2000, METHOD ENZYMOL, V311, P194; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; RODER B, 1990, CHEM PHYS LIPIDS, V53, P85, DOI 10.1016/0009-3084(90)90136-F; Schmelz EM, 1998, NUTRITION, V14, P717, DOI 10.1016/S0899-9007(98)00052-5; Schmelz EM, 1998, TOXICOL APPL PHARM, V148, P252, DOI 10.1006/taap.1997.8356; Selzner M, 2001, CANCER RES, V61, P1233; Skrzypek M, 1997, J BACTERIOL, V179, P1513, DOI 10.1128/jb.179.5.1513-1520.1997; Smith ER, 2000, METHOD ENZYMOL, V312, P361; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Sutterlin C, 1997, J CELL SCI, V110, P2703; Takamatsu Kiyoshi, 1992, Keio Journal of Medicine, V41, P161; TamiyaKoizumi K, 1997, BIOCHEM MOL BIOL INT, V41, P1179; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171	44	115	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26577	26588		10.1074/jbc.M102818200	http://dx.doi.org/10.1074/jbc.M102818200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11356846	hybrid			2022-12-27	WOS:000169823300122
J	Sorensen, CE; Novak, I				Sorensen, CE; Novak, I			Visualization of ATP release in pancreatic acini in response to cholinergic stimulus - Use of fluorescent probes and confocal microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY GRANULES; FIREFLY LUCIFERASE; EXTRACELLULAR ATP; EPITHELIAL-CELLS; CONDUCTANCE; MECHANISM; CHANNELS; MEMBRANE; DUCTS	The energy providing substrate ATP can be released from various cells and act extracellularly to regulate the same cells or neighboring cells. However, the pathway for ATP release and the eliciting physiological stimulus are unclear. Recently, we showed that ATP activates P2X and P2Y purinergic receptors on pancreatic ducts. Thus, it was relevant to ask whether the upstream acini could be the source of releasable ATP and what the stimulus might be. We used freshly prepared rat pancreatic acini and applied conventional luminescence measurements of luciferin/luciferase reaction. As a new application of this reaction in confocal microscopy, we monitored luciferin fluorescence as a sign of ATP release by single acini. In addition we used quinacrine to mark ATP stores, which were similar to those marked with fluorescent ATP, 2 '-(or-3 ')-O-(N-methylanthraniloyl) adenosine 5 ' -triphosphate, but only partially overlapping with those marked by aeridine orange and LysoTracker Red. In functional studies we show that native pancreatic acini release ATP in response to various stimuli but most importantly to cholinergic stimulation, a very likely physiological stimulus in this epithelium. In a close vicinity of acini we detect about 9 mum ATP after cholinergic stimulation. Thus, ATP is poised as the paracrine mediator between pancreatic acini and ducts.	Univ Copenhagen, August Krogh Inst, DK-2100 Copenhagen O, Denmark	University of Copenhagen	Novak, I (corresponding author), Univ Copenhagen, August Krogh Inst, Univ Pk 13, DK-2100 Copenhagen O, Denmark.		Novak, Ivana/M-2791-2014	Novak, Ivana/0000-0002-8917-8010; Soerensen, Christiane/0000-0001-6814-1166				ARVAN P, 1984, J BIOL CHEM, V259, P3567; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Belan PV, 1996, J BIOL CHEM, V271, P7615, DOI 10.1074/jbc.271.13.7615; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; CHEY WY, 1979, J PHYSIOL-LONDON, V293, P435, DOI 10.1113/jphysiol.1979.sp012898; DELISLE RC, 1987, AM J PHYSIOL, V253, pG711, DOI 10.1152/ajpgi.1987.253.6.G711; Fields RD, 2000, TRENDS NEUROSCI, V23, P625, DOI 10.1016/S0166-2236(00)01674-X; Ford SR, 1996, J BIOLUM CHEMILUM, V11, P149, DOI 10.1002/(SICI)1099-1271(199605)11:3<149::AID-BIO411>3.0.CO;2-Q; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; Gualix J, 1999, J NEUROCHEM, V73, P1098, DOI 10.1046/j.1471-4159.1999.0731098.x; HAMLYN JM, 1983, BIOCHEM J, V214, P59, DOI 10.1042/bj2140059; Hazama A, 1998, PFLUG ARCH EUR J PHY, V437, P31, DOI 10.1007/s004240050742; Hede SE, 1999, J BIOL CHEM, V274, P31784, DOI 10.1074/jbc.274.45.31784; Ishiguro H, 1999, J PHYSIOL-LONDON, V519, P551, DOI 10.1111/j.1469-7793.1999.0551m.x; Konig J, 1999, HEPATOLOGY, V29, P1156, DOI 10.1002/hep.510290404; LEITNER JW, 1975, ENDOCRINOLOGY, V96, P662; NIEDERAU C, 1986, GASTROENTEROLOGY, V91, P1433, DOI 10.1016/0016-5085(86)90197-6; NOVAK I, 1995, CELL PHYSIOL BIOCHEM, V5, P344, DOI 10.1159/000154770; NOVAK I, 2000, DRUG DEVELOP RES, V50, P112; OLSON L, 1976, CELL TISSUE RES, V171, P407; ORCI L, 1987, NATURE, V326, P77, DOI 10.1038/326077a0; Park HS, 1998, AM J PHYSIOL-GASTR L, V274, pG413, DOI 10.1152/ajpgi.1998.274.2.G413; Roman RM, 1999, AM J PHYSIOL-GASTR L, V276, pG1391, DOI 10.1152/ajpgi.1999.276.6.G1391; Saito H, 1996, J BIOL CHEM, V271, P20719, DOI 10.1074/jbc.271.34.20719; Schneider SW, 1999, P NATL ACAD SCI USA, V96, P12180, DOI 10.1073/pnas.96.21.12180; Schreiber R, 1999, J BIOL CHEM, V274, P11811, DOI 10.1074/jbc.274.17.11811; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Sevigny J, 1998, AM J PHYSIOL-GASTR L, V275, pG473, DOI 10.1152/ajpgi.1998.275.3.G473; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; WHITE PN, 1995, HEARING RES, V90, P97, DOI 10.1016/0378-5955(95)00151-1; WHITE TD, 1987, J NEUROCHEM, V49, P1266, DOI 10.1111/j.1471-4159.1987.tb10019.x	33	148	151	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32925	32932		10.1074/jbc.M103313200	http://dx.doi.org/10.1074/jbc.M103313200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11387334	hybrid			2022-12-27	WOS:000170746000074
J	Inoue, S; Inoue, Y				Inoue, S; Inoue, Y			Developmental profile of neural cell adhesion molecule glycoforms with a varying degree of polymerization of polysialic acid chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-EXCHANGE CHROMATOGRAPHY; PERFORMANCE LIQUID-CHROMATOGRAPHY; ESCHERICHIA-COLI K1; RAT SPINAL-CORD; N-CAM; ADULT-RAT; SIALIC-ACID; EMBRYONIC FORM; GROUP-B; NCAM EXPRESSION	More precise information on the degree of polymerization (DP) of polysialie acid (polySia) chains expressed on neural cell adhesion molecule (NCAM) and its developmental stage-dependent variation are considered important in understanding the mechanism of regulated polysialylation and fine-tuning of NCAM-mediated cell adhesion by polySia. In this paper, first we performed a kinetic study of acid-catalyzed hydrolysis of polySia and report our findings that (a) in (--> 8Neu5Ac alpha2 -->)(n)--> 8Neu5Ac alpha2 --> 3Gal beta1 -->R, the proximal Neu5Ac residue alpha2 -->3 linked to Gal is cleaved about 2.5-4 times faster than the alpha2 -->8 linkages and (b) in contrary to general belief that alpha2 -->8 linkages in polySia are extremely labile, the kinetic consideration showed that they are not so unstable, and every ketosidic bond is hydrolyzed at the same rate. These findings are the basis of our strategy for DP analysis of polySia on NCAM. Second, using the recently developed method that provides base-line resolution of oligo/polySia from DP 2 to > 80 with detection thresholds of 1.4 fmol per resolved peak, we have determined the DP of polySia chains expressed in embryonic chicken brains at different developmental stages. Our results support the presence of numerous NCAM glycoforms differing in DPs of oligo/polySia chains and a delicate change in their distribution during development.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Academia Sinica - Taiwan	Inoue, Y (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.							Abrous DN, 1997, BRAIN RES, V744, P285, DOI 10.1016/S0006-8993(96)01115-8; Allan DW, 1998, J COMP NEUROL, V391, P275, DOI 10.1002/(SICI)1096-9861(19980216)391:3<275::AID-CNE1>3.0.CO;2-Z; Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; ASHWELL G, 1994, ANAL BIOCHEM, V222, P495, DOI 10.1006/abio.1994.1523; BARTSCH U, 1990, J NEUROCYTOL, V19, P550, DOI 10.1007/BF01257243; BERARDI M, 1995, CELL TISSUE RES, V280, P463, DOI 10.1007/s004410050375; BONFANTI L, 1992, NEUROSCIENCE, V49, P419, DOI 10.1016/0306-4522(92)90107-D; Bruses JL, 1998, J CELL BIOL, V140, P1177, DOI 10.1083/jcb.140.5.1177; Butler AK, 1997, J COMP NEUROL, V389, P289, DOI 10.1002/(SICI)1096-9861(19971215)389:2<289::AID-CNE8>3.0.CO;2-Y; Bystricky S, 1997, BIOPHYS CHEM, V63, P147, DOI 10.1016/S0301-4622(96)02242-9; Cheng MC, 1998, ANAL BIOCHEM, V260, P154, DOI 10.1006/abio.1998.2701; Chuck ET, 1997, DEV DYNAM, V209, P182, DOI 10.1002/(SICI)1097-0177(199706)209:2<182::AID-AJA4>3.3.CO;2-T; CUNNINGHAM BA, 1983, P NATL ACAD SCI-BIOL, V80, P3116, DOI 10.1073/pnas.80.10.3116; Dey PM, 1997, NEUROTOXICOLOGY, V18, P633; DUBOIS C, 1995, J IMMUNOL METHODS, V181, P125, DOI 10.1016/0022-1759(94)00336-U; FigarellaBranger D, 1996, J CLIN ONCOL, V14, P2066, DOI 10.1200/JCO.1996.14.7.2066; FRIEDLANDER DR, 1985, J CELL BIOL, V101, P412, DOI 10.1083/jcb.101.2.412; FROST G, 1991, NEUROPATH APPL NEURO, V17, P207, DOI 10.1111/j.1365-2990.1991.tb00716.x; Gerety M, 1997, ANAT REC, V247, P71; GLASS JD, 1994, NEUROENDOCRINOLOGY, V60, P87; GRIFFITH CM, 1991, ANAT EMBRYOL, V183, P205; HALLENBECK PC, 1987, ANAL BIOCHEM, V161, P181, DOI 10.1016/0003-2697(87)90670-1; HARA S, 1987, ANAL BIOCHEM, V164, P138, DOI 10.1016/0003-2697(87)90377-0; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HOFFMAN S, 1984, P NATL ACAD SCI-BIOL, V81, P6881, DOI 10.1073/pnas.81.21.6881; HUSMANN M, 1989, EUR J IMMUNOL, V19, P1761, DOI 10.1002/eji.1830190935; Inoue S, 2000, J BIOL CHEM, V275, P29968, DOI 10.1074/jbc.M004150200; INOUE S, 2001, IN PRESS BIOCH, P83; JOOSTEN EAJ, 1994, DEV BRAIN RES, V78, P226, DOI 10.1016/0165-3806(94)90030-2; KABAT EA, 1988, J EXP MED, V168, P699, DOI 10.1084/jem.168.2.699; Kakehi K, 1999, ANAL CHEM, V71, P1592, DOI 10.1021/ac981248y; KITAJIMA K, 1992, ANAL BIOCHEM, V205, P244, DOI 10.1016/0003-2697(92)90430-F; KITAZUME S, 1994, J BIOL CHEM, V269, P22712; KITAZUME S, 1992, ANAL BIOCHEM, V202, P25, DOI 10.1016/0003-2697(92)90200-Q; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; Kudo M, 1998, GLYCOBIOLOGY, V8, P771, DOI 10.1093/glycob/8.8.771; Kudo M, 1996, J BIOL CHEM, V271, P32667, DOI 10.1074/jbc.271.51.32667; LASALLE GL, 1991, CR ACAD SCI III-VIE, V312, P43; LIFELY MR, 1986, CARBOHYD RES, V156, P123, DOI 10.1016/S0008-6215(00)90104-6; Lin SL, 1999, GLYCOBIOLOGY, V9, P807, DOI 10.1093/glycob/9.8.807; Lin SL, 2000, CARBOHYD RES, V329, P447, DOI 10.1016/S0008-6215(00)00177-4; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MANZI AE, 1994, J BIOL CHEM, V269, P23617; MIRAGALL F, 1990, J NEUROCYTOL, V19, P899, DOI 10.1007/BF01186818; MIRAGALL F, 1988, DEV BIOL, V129, P516, DOI 10.1016/0012-1606(88)90397-1; Muhlenhoff M, 1996, CURR BIOL, V6, P1188, DOI 10.1016/S0960-9822(02)70687-8; MULLER D, 1994, NEUROSCIENCE, V61, P441, DOI 10.1016/0306-4522(94)90424-3; NADANO D, 1986, J BIOL CHEM, V261, P1550; Nishiyama I, 1996, ANAT EMBRYOL, V194, P419; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; Nothias F, 1997, EUR J NEUROSCI, V9, P1553, DOI 10.1111/j.1460-9568.1997.tb01513.x; OUMESMAR BN, 1995, EUR J NEUROSCI, V7, P480, DOI 10.1111/j.1460-9568.1995.tb00344.x; PERERA AD, 1993, ENDOCRINOLOGY, V133, P2729, DOI 10.1210/en.133.6.2729; ROHR TE, 1980, J BIOL CHEM, V255, P2332; ROTH J, 1989, VERH DEUT G, V73, P372; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; SATO C, 1993, J BIOL CHEM, V268, P23675; Sato C, 1999, ANAL BIOCHEM, V266, P102, DOI 10.1006/abio.1998.2921; SCHLOSSHAUER B, 1984, NATURE, V310, P141, DOI 10.1038/310141a0; SEKI T, 1991, NEUROSCI RES, V12, P503, DOI 10.1016/S0168-0102(09)80003-5; SEKI T, 1991, ANAT EMBRYOL, V184, P395, DOI 10.1007/BF00957900; SEKI T, 1993, DEV BRAIN RES, V73, P141, DOI 10.1016/0165-3806(93)90056-G; Seki T, 1998, J NEUROSCI, V18, P3757; SUNSHINE J, 1987, P NATL ACAD SCI USA, V84, P5986, DOI 10.1073/pnas.84.16.5986; THEODOSIS DT, 1991, P NATL ACAD SCI USA, V88, P5494, DOI 10.1073/pnas.88.13.5494; Wood GK, 1997, MOL BRAIN RES, V51, P69, DOI 10.1016/S0169-328X(97)00209-X; Zhang Y, 1999, J BIOL CHEM, V274, P6183, DOI 10.1074/jbc.274.10.6183; Zhang Y, 1997, ANAL BIOCHEM, V250, P245, DOI 10.1006/abio.1997.2225; ZHANG Y, 1995, J COMP NEUROL, V361, P193, DOI 10.1002/cne.903610202	70	43	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31863	31870		10.1074/jbc.M103336200	http://dx.doi.org/10.1074/jbc.M103336200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11371567	hybrid			2022-12-27	WOS:000170613500055
J	Zhao, DZ; Letterman, J; Schreiber, BM				Zhao, DZ; Letterman, J; Schreiber, BM			beta-migrating very low density lipoprotein (beta VLDL) activates smooth muscle cell mitogen-activated protein (MAP) kinase via G protein-coupled receptor-mediated transactivation of the epidermal growth factor (EGF) receptor - Effect of map kinase activation on beta VLDL plus EGF-induced cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID; TYROSINE KINASE; ANGIOTENSIN-II; CYCLIN D1; C-FOS; NEURONAL DIFFERENTIATION; NEOINTIMA FORMATION; PORCINE CORONARY; DOWN-REGULATION; GENE-TRANSFER	This study examined the premise that the atherogenic lipoprotein, beta -migrating very low density lipoprotein (beta VLDL), might activate the mitogen-activated protein (MAP) kinases ERK1/ERK2, thereby contributing to the induction of smooth muscle cell proliferation in atherosclerosis. The data show that beta VLDL activates rabbit smooth muscle cell ERK1/ERK2. Interestingly, ERK1/ ERK2 activation is mediated by G protein-coupled receptors that transactivate the epidermal growth factor (EGF) receptor.,beta VLDL-induced MAP kinase activation depends on Ras and Src activity as well as protein kinase C. The inhibition of lysosomal degradation of beta VLDL has no effect on ERK1/ERK2 activation. The contribution of beta VLDL-induced activation of ERK1/ERK2 to smooth muscle cell proliferation was also explored. beta VLDL induces expression of egr-1 and c-fos mRNA. Despite its ability to stimulate early gene expression, beta VLDL alone is unable to inspire quiescent cells into S phase. When added in conjunction with EGF, however, stimulation of [H-3]thymidine incorporation into DNA and an increase in histone gene expression are observed. Moreover, beta VLDL plus EGF synergistically induce cyclin D1 expression and down-regulate p27(KIP1) expression. The addition of either,beta VLDL or EGF stimulates a robust activation of ERK1/ ERK2, but the addition of both agents simultaneously sustains the activation for a longer time period. Inhibition of MAP kinase kinase, pertussis toxin-sensitive G proteins, the EGF receptor, or protein kinase C blocks beta VLDL plus EGF-induced proliferation, demonstrating that activation of the beta VLDL-induced signaling pathway results in smooth muscle cell proliferation.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Schreiber, BM (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	schreibe@biochem.bumc.bu.edu		Schreiber, Barbara/0000-0001-8560-4249	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-13262] Funding Source: Medline; NIA NIH HHS [AG-9006] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; Balagopalakrishna C, 1997, MOL CELL BIOCHEM, V170, P85, DOI 10.1023/A:1006840927835; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Chatterjee S, 1997, GLYCOBIOLOGY, V7, P703, DOI 10.1093/glycob/7.5.703; CHATTERJEE S, 1992, MOL CELL BIOCHEM, V111, P143; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; CHEN JK, 1986, J CELL PHYSIOL, V129, P207, DOI 10.1002/jcp.1041290212; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Deigner HP, 1996, FEBS LETT, V385, P149, DOI 10.1016/0014-5793(96)00371-7; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FLESS GM, 1982, ATHEROSCLEROSIS, V41, P171, DOI 10.1016/0021-9150(82)90183-6; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; Gallo R, 1999, CIRCULATION, V99, P2164, DOI 10.1161/01.CIR.99.16.2164; GOLDSTEIN JL, 1980, J BIOL CHEM, V255, P1839; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HERBER B, 1994, ONCOGENE, V9, P1295; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Horiuchi A, 1999, MOL HUM REPROD, V5, P139, DOI 10.1093/molehr/5.2.139; Iaccarino G, 1999, P NATL ACAD SCI USA, V96, P3945, DOI 10.1073/pnas.96.7.3945; Inagami T, 1999, J AM SOC NEPHROL, V10, pS57; Indolfi C, 1997, BASIC RES CARDIOL, V92, P378, DOI 10.1007/BF00796211; IZUMI H, 1994, EXP CELL RES, V214, P654, DOI 10.1006/excr.1994.1303; KAMANNA VS, 1999, KIDNEY INT S, V71, P70; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Koyama H, 1998, CIRC RES, V82, P713, DOI 10.1161/01.RES.82.6.713; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; Kusuhara M, 1997, ARTERIOSCL THROM VAS, V17, P141, DOI 10.1161/01.ATV.17.1.141; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laufs U, 1999, J BIOL CHEM, V274, P21926, DOI 10.1074/jbc.274.31.21926; Lavoie J N, 1996, Prog Cell Cycle Res, V2, P49; LIBBY P, 1985, J CELL PHYSIOL, V124, P1, DOI 10.1002/jcp.1041240102; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsumura T, 1997, ARTERIOSCL THROM VAS, V17, P3013, DOI 10.1161/01.ATV.17.11.3013; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NATARAJAN V, 1995, J LIPID RES, V36, P2005; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Pyles JM, 1997, CIRC RES, V81, P904; RESINK TJ, 1995, J VASC RES, V32, P328, DOI 10.1159/000159107; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sachinidis A, 1997, MOL PHARMACOL, V52, P389, DOI 10.1124/mol.52.3.389; SACHINIDIS A, 1993, BIOCHEM BIOPH RES CO, V192, P794, DOI 10.1006/bbrc.1993.1484; SACHINIDIS A, 1990, HYPERTENSION, V15, P704, DOI 10.1161/01.HYP.15.6.704; Sakai T, 1999, J BIOL CHEM, V274, P15480, DOI 10.1074/jbc.274.22.15480; SCHREIBER BM, 1988, ATHEROSCLEROSIS, V69, P69, DOI 10.1016/0021-9150(88)90290-0; SCHREIBER BM, 1992, ATHEROSCLEROSIS, V95, P201, DOI 10.1016/0021-9150(92)90023-A; SCHREIBER BM, 1994, J LIPID RES, V35, P1177; SCOTTBURDEN T, 1989, J BIOL CHEM, V264, P12582; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Takahashi E, 1998, ACTA PHYSIOL SCAND, V164, P611, DOI 10.1111/j.1365-201X.1998.tb10705.x; Takahashi T, 1997, J BIOL CHEM, V272, P16018, DOI 10.1074/jbc.272.25.16018; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; WEISGRABER KH, 1990, ANN NY ACAD SCI, V598, P37, DOI 10.1111/j.1749-6632.1990.tb42274.x; YOSHIDA Y, 1984, EXP MOL PATHOL, V41, P258, DOI 10.1016/0014-4800(84)90042-X; Zou YZ, 1998, CIRC RES, V82, P337, DOI 10.1161/01.RES.82.3.337	73	28	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30579	30588		10.1074/jbc.M103761200	http://dx.doi.org/10.1074/jbc.M103761200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11375998	hybrid			2022-12-27	WOS:000170472900002
J	Breitinger, HG; Villmann, C; Becker, K; Becker, CM				Breitinger, HG; Villmann, C; Becker, K; Becker, CM			Opposing effects of molecular volume and charge at the hyperekplexia site alpha 1 (P250) govern glycine receptor activation and desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID	Allelic variants of the glycine receptor al subunit gene GLRA1 underlie the human neurological disorder hyperekplexia. Among these, the subunit variant alpha1(P250T) is characterized by an amino acid substitution within the cytoplasmic TM1-2 loop. To identify structural elements at position alpha1(250) that govern receptor function, homomeric mutant receptor channels were subjected to electrophysiological analysis after recombinant expression in HEK293 cells. Wild-type alpha1(P250) channels were nondesensitizing with an ECO for glycine of 8 muM, whereas bulky hydrophobic side chains of the channel variants alpha1(P250V/I/L/F) showed rapid desensitization (tau (desens), 50-250 ms) and EC50 values of 400-1800 mum. Small side chains (P250G/A/S) gave rise to wild-type-like channels. Effects of volume were counteracted by charge: alpha1(P250E/R) were nondesensitizing; EC50 was similar to 70 muM. The mutants alpha1(P250C/Y) displayed intermediate channel properties (EC50, 42/70 muM,4 tau (desens), 3300/2800 ms, respectively). The isotropic forces volume and hydropathy were sufficient to account for the observed effects of residue alpha1(250) on receptor function. Indeed, channel behavior was best predicted by a combined hydropathy/volume index describing the hydrophobic surface of individual amino acids. These observations characterize the short intracellular TM1-2 loop as a regulatory domain for channel activation and a crucial mediator of glycine receptor desensitization.	Univ Erlangen Nurnberg, Emil Fischer Zentrum, Inst Biochem, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Becker, CM (corresponding author), Univ Erlangen Nurnberg, Emil Fischer Zentrum, Inst Biochem, Fahrstr 17, D-91054 Erlangen, Germany.	cmb@biochem.uni-erlangen.de	Breitinger, Hans-Georg/ABD-3247-2021	Breitinger, Hans-Georg/0000-0003-0111-3528				Becker C. M., 1995, NEUROSCIENTIST, V1, P130; BECKER CM, 1998, FRONT NEUROBIOL, V3, P93; Becker K, 2000, CHANNELOPATHIES - COMMON MECHANISMS IN AURA, ARRHYTHMIA AND ALKALOSIS, P199, DOI 10.1016/B978-044450489-0/50010-0; Breitinger HG, 1998, CURR PHARM DESIGN, V4, P315; Breitinger HG, 2001, NEUROSCIENTIST, V7, P95, DOI 10.1177/107385840100700204; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; HESS GP, 1993, BIOCHEMISTRY-US, V32, P989, DOI 10.1021/bi00055a001; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Kling C, 1997, NEUROSCIENCE, V78, P411, DOI 10.1016/S0306-4522(96)00567-2; KRISHTAL OA, 1980, NEUROSCIENCE, V5, P2325, DOI 10.1016/0306-4522(80)90149-9; Lewis TM, 1999, ANN NY ACAD SCI, V868, P681, DOI 10.1111/j.1749-6632.1999.tb11345.x; LEWIS TM, 1998, J PHYSIOL-LONDON, V15, P25; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; Nikolic Z, 1998, J BIOL CHEM, V273, P19708, DOI 10.1074/jbc.273.31.19708; Saul B, 1999, J NEUROSCI, V19, P869; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; UDGAONKAR JB, 1987, P NATL ACAD SCI USA, V84, P8758, DOI 10.1073/pnas.84.24.8758; Wick MJ, 1998, P NATL ACAD SCI USA, V95, P6504, DOI 10.1073/pnas.95.11.6504; Yamakura T, 1999, J BIOL CHEM, V274, P23006, DOI 10.1074/jbc.274.33.23006; Ye Q, 1998, J BIOL CHEM, V273, P3314, DOI 10.1074/jbc.273.6.3314; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	21	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29657	29663		10.1074/jbc.M100446200	http://dx.doi.org/10.1074/jbc.M100446200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395484	hybrid			2022-12-27	WOS:000170558000010
J	Lee, CH; Chung, JH				Lee, CH; Chung, JH			The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; DEPENDENT PROTEIN-KINASE; FHA DOMAIN; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; HUMAN CDC25C; ATM PROTEIN; CHK2; LINKAGE; CDS1	hCds1 (Chk2) (1-4) is an evolutionarily conserved kinase that functions in DNA damage response and cell cycle checkpoint. The Cds1 family of kinases are activated by a family of large phosphatidylinositol 3-kinase-like kinases. In humans, ataxia telangiectasia-mutated (ATM) (5) and ataxia-telangiectasia and Rad3-related (6) kinases activate hCds1 by phosphorylating Thr(68) (7-9). hCds1 and Cds1-related kinases contain the FHA (fork. head-associated) domain (10), which appears to be important for integrating the DNA damage signal. It is not known how ATM phosphorylation activates hCds1 function and whether the phosphorylation is linked to the FHA. Here, we demonstrate that the hCds1-FHA domain is essential for Thr(68) phosphorylation. Thr(68) phosphorylation, in turn, is required for ionizing radiation-induced autophosphorylation of two amino acid residues in hCds1, Thr(383) and Thr(387). These two amino acid residues, located in the activation loop of hCds1, are conserved in hCds1-related kinases and are essential for hCds1 activity. Thus, the hCds1-FRA domain mediates a chain of phosphorylation events on hCds1, which includes phosphorylation by ATM and hCds1 autophosphorylation, in response to DNA damage.	NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA; Yonsei Univ, Coll Med, Dept Pathol, Brain Korea Projects Med Sci 21, Seoul 120752, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Yonsei University; Yonsei University Health System	Chung, JH (corresponding author), NHLBI, Lab Biochem Genet, NIH, Bldg 10-7D13,10 Ctr Dr, Bethesda, MD 20892 USA.							Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Shieh SY, 2000, GENE DEV, V14, P289; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	33	125	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30537	30541		10.1074/jbc.M104414200	http://dx.doi.org/10.1074/jbc.M104414200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390408	hybrid			2022-12-27	WOS:000170558000122
J	Qian, R; Chen, C; Colley, KJ				Qian, R; Chen, C; Colley, KJ			Location and mechanism of alpha 2,6-sialyltransferase dimer formation - Role of cysteine residues in enzyme dimerization, localization, activity and processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; ENDOPLASMIC-RETICULUM; GOLGI RETENTION; SIGNAL ANCHOR; MEDIAL GOLGI; DOMAIN; CELLS; SIALYLTRANSFERASES; OLIGOSACCHARIDES; GLYCOSYLATION	A significant proportion of the alpha2,6-sialyltransferase of protein Asn-linked glycosylation (ST6Gal 1) forms di. sulfide-bonded dimers that exhibit decreased activity, but retain the ability to bind asialoglycoprotein substrates. Here, we have investigated the subcellular location and mechanism of ST6Gal I dimer formation, as well as the role of Cys residues in the enzyme's trafficking, localization, and catalytic activity. Pulse-chase analysis demonstrated that the ST6Gal I disulfide-bonded dimer forms in the endoplasmic reticulum. Mutagenesis experiments showed that Cys-24 in the transmembrane region is required for dimerization, while catalytic domain Cys residues are required for trafficking and catalytic activity. Replacement of Cys-181 and Cys-332 generated proteins that are largely retained in the endoplasmic reticulum and minimally active or inactive, respectively. Replacement of Cys-350 or Cys-361 inactivated the enzyme without compromising its localization or processing, suggesting that these amino acids are part of the enzyme's active site. Replacement of Cys-139 or Cys-403 generated proteins that are catalytically active and appear to be more stably localized in the Golgi, since they exhibited decreased cleavage and secretion. The Cys-139 mutant also exhibited increased dimer formation suggesting that ST6Gal I dimers may be critical in the oligomerization process involved in stable ST6Gal I Golgi localization.	Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colley, KJ (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Biol, 1819 W Polk St,M-C 536, Chicago, IL 60612 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048134, R29GM048134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; Borsig L, 1998, GLYCOBIOLOGY, V8, P259, DOI 10.1093/glycob/8.3.259; BOSSHART H, 1992, EUR J BIOCHEM, V208, P341, DOI 10.1111/j.1432-1033.1992.tb17192.x; Chen C, 2000, GLYCOBIOLOGY, V10, P531, DOI 10.1093/glycob/10.5.531; Chen C, 2000, J BIOL CHEM, V275, P13819, DOI 10.1074/jbc.275.18.13819; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DATTA A, 2001, J BIOL CHEM, V276, P15696; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; Geremia RA, 1997, GLYCOBIOLOGY, V7, pR5; JACKIEWICZ E, 1996, J BIOL CHEM, V271, P26395; KUROSAWA N, 1994, J BIOL CHEM, V269, P19048; Li JH, 2000, J BIOL CHEM, V275, P41476, DOI 10.1074/jbc.M007480200; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; Ma JY, 1997, J BIOL CHEM, V272, P672; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; Ma JY, 1999, J BIOL CHEM, V274, P8046, DOI 10.1074/jbc.274.12.8046; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; NAVARATNAM N, 1988, EUR J BIOCHEM, V171, P623, DOI 10.1111/j.1432-1033.1988.tb13833.x; Opat AS, 2000, J BIOL CHEM, V275, P11836, DOI 10.1074/jbc.275.16.11836; Ouzzine M, 2000, J BIOL CHEM, V275, P28254; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170; Zhu GF, 1997, GLYCOBIOLOGY, V7, P987, DOI 10.1093/glycob/7.7.987	31	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28641	28649		10.1074/jbc.M103664200	http://dx.doi.org/10.1074/jbc.M103664200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11356854	hybrid			2022-12-27	WOS:000170346000003
J	Ramjaun, AR; Angers, A; Legendre-Guillemin, V; Tong, XK; McPherson, PS				Ramjaun, AR; Angers, A; Legendre-Guillemin, V; Tong, XK; McPherson, PS			Endophilin regulates JNK activation through its interaction with the germinal center kinase-like kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; DOMAIN-CONTAINING PROTEINS; SH3 DOMAIN; BINDING PARTNERS; NERVOUS-SYSTEM; RAT-BRAIN; FAMILY; AMPHIPHYSIN; IDENTIFICATION; SYNAPTOJANIN	The endophilin family of proteins function in clathrin-mediated endocytosis. Here, we have identified and cloned the rat germinal center kinase-like kinase (rGLK), a member of the GCK (germinal center kinase) family of e-Jun N-terminal kinase (JNK) activating enzymes, as a novel endophilin I-binding partner. The interaction occurs both in vitro and in cells and is mediated by the Src homology 3 domain of endophilin I and a region of rGLK containing the endophilin consensus-binding sequence PPRPPPPR. Overlay analysis of rat brain extracts demonstrates that endophilin I is a major Src homology 3 domain-binding partner for rGLK. Overexpression of full-length endophilin I activates rGLK-mediated JNK activation, whereas N- and C-terminal fragments of endophilin I block JNK activation. Thus, endophilin I appears to have a novel function in JNK activation.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University	McPherson, PS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada.		Angers, Annie/P-1217-2018	Angers, Annie/0000-0003-0131-256X				Adams A, 2000, J BIOL CHEM, V275, P27414; Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Fish KN, 2000, J CELL BIOL, V150, P145, DOI 10.1083/jcb.150.1.145; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Rasmussen RK, 1998, BIOCHEM J, V335, P119, DOI 10.1042/bj3350119; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Tong XK, 2000, J BIOL CHEM, V275, P29894, DOI 10.1074/jbc.M004096200; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	35	41	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28913	28919		10.1074/jbc.M103198200	http://dx.doi.org/10.1074/jbc.M103198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384986	hybrid, Green Accepted			2022-12-27	WOS:000170346000038
J	Westbroek, I; van der Plas, A; de Rooij, KE; Klein-Nulend, J; Nijweide, PJ				Westbroek, I; van der Plas, A; de Rooij, KE; Klein-Nulend, J; Nijweide, PJ			Expression of serotonin receptors in bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; HUMAN 5-HYDROXYTRYPTAMINE(2B) RECEPTOR; MESSENGER-RNA EXPRESSION; OSTEOBLAST-LIKE CELLS; 5-HT2B RECEPTOR; NITRIC-OXIDE; POSTMENOPAUSAL WOMEN; SIGNAL-TRANSDUCTION; SMOOTH-MUSCLE; BW 723C86	The 5-hydroxytryptamine (5-HT) receptors 5-HT(2A), 5-HT(2B), and 5-HT(2C) belong to a subfamily of serotonin receptors. Amino acid and mRNA sequences of these receptors have been published for several species including man. The 5-HT(2) receptors have been reported to act on nervous, muscle, and endothelial tissues. Here we report the presence of 5-HT(2B) receptor in fetal chicken bone cells. 5-HT(2B) receptor mRNA expression was demonstrated in osteocytes, osteoblasts, and periosteal fibroblasts, a population containing osteoblast precursor cells. Pharmacological studies using several agonists and antagonists showed that occupancy of the 5-HT2. receptor stimulates the proliferation of periosteal fibroblasts. Activity of the 5-HT(2A) receptor could however not be excluded. mRNA for both receptors was shown to be equally present in adult mouse osteoblasts. Osteocytes, which showed the highest expression of 5-HT(2B) receptor mRNA in chicken, and to a lesser extent osteoblasts, are considered to be mechanosensor cells involved in the adaptation of bone to its mechanical usage. Nitric oxide is one of the signaling molecules that is released upon mechanical stimulation of osteocytes and osteoblasts. The serotonin analog alpha -methyl-5-HT, which preferentially binds to 5-HT2 receptors, decreased nitric oxide release by mechanically stimulated mouse osteoblasts. These results demonstrate that serotonin is involved in bone metabolism and its mechanoregulation.	Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands; Free Univ Amsterdam, Acad Ctr Dent Amsterdam, Dept Oral Cell Biol, NL-1081 BT Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam	Nijweide, PJ (corresponding author), Leiden Univ, Med Ctr, Dept Mol Cell Biol, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.	P.J.Nijweide@LUMC.NL						Ajubi NE, 1996, BIOCHEM BIOPH RES CO, V225, P62, DOI 10.1006/bbrc.1996.1131; Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb-76-6-899; BAXTER G, 1995, TRENDS PHARMACOL SCI, V16, P105, DOI 10.1016/S0165-6147(00)88991-9; BECKSTEAD JH, 1994, J HISTOCHEM CYTOCHEM, V42, P1127, DOI 10.1177/42.8.8027531; Berendsen HHG, 2000, MATURITAS, V36, P155, DOI 10.1016/S0378-5122(00)00151-1; BESSEY OA, 1946, J BIOL CHEM, V164, P321; Blum I, 1996, ISRAEL J MED SCI, V32, P1158; BONHAUS DW, 1995, BRIT J PHARMACOL, V115, P622, DOI 10.1111/j.1476-5381.1995.tb14977.x; Borman RA, 1997, ANN NY ACAD SCI, V812, P222, DOI 10.1111/j.1749-6632.1997.tb48182.x; Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101; Choi DS, 1995, BEHAV BRAIN RES, V73, P253; Choi DS, 1996, FEBS LETT, V391, P45, DOI 10.1016/0014-5793(96)00695-3; CHOPRA RK, 1992, MOL CELL BIOCHEM, V117, P127; Chow JWM, 1998, J BONE MINER RES, V13, P1039, DOI 10.1359/jbmr.1998.13.6.1039; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Duxon MS, 1997, NEUROPHARMACOLOGY, V36, P601, DOI 10.1016/S0028-3908(97)00042-7; Duxon MS, 1997, NEUROSCIENCE, V76, P323, DOI 10.1016/S0306-4522(96)00480-0; ELLIS ES, 1995, BRIT J PHARMACOL, V114, P400, DOI 10.1111/j.1476-5381.1995.tb13240.x; Fanburg BL, 1997, AM J PHYSIOL-LUNG C, V272, pL795, DOI 10.1152/ajplung.1997.272.5.L795; FANBURG BL, 1997, AM J PHYSIOL, V272, pF795; FORBES IT, 1995, J MED CHEM, V38, P2524, DOI 10.1021/jm00014a004; Forwood MR, 1996, J BONE MINER RES, V11, P1688; FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; FUTO J, 1992, LIFE SCI, V50, P1165, DOI 10.1016/0024-3205(92)90459-3; Glusa E, 1996, BRIT J PHARMACOL, V119, P330, DOI 10.1111/j.1476-5381.1996.tb15990.x; GODA SK, 1995, NUCLEIC ACIDS RES, V23, P3357, DOI 10.1093/nar/23.16.3357; GONZALES GF, 1993, MATURITAS, V17, P23, DOI 10.1016/0378-5122(93)90120-7; GOODSHIP AE, 1979, J BONE JOINT SURG AM, V61, P539, DOI 10.2106/00004623-197961040-00008; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GUICHENEY P, 1988, EUR J CLIN INVEST, V18, P297, DOI 10.1111/j.1365-2362.1988.tb01262.x; HAGENAARS CE, 1989, BONE MINER, V6, P179, DOI 10.1016/0169-6009(89)90049-4; HARMS G, 1986, HISTOCHEMISTRY, V85, P139, DOI 10.1007/BF00491761; HARRIS SA, 1996, PRINCIPLES BONE BIOL, P6507; HOHMANN EL, 1983, ENDOCRINOLOGY, V112, P1233, DOI 10.1210/endo-112-4-1233; HOYER D, 1994, PHARMACOL REV, V46, P157; ISMAIEL AM, 1990, J MED CHEM, V33, P755, DOI 10.1021/jm00164a046; Kennett GA, 1998, NEUROPHARMACOLOGY, V37, P1603, DOI 10.1016/S0028-3908(98)00115-4; Kennett GA, 1997, NEUROPHARMACOLOGY, V36, P233, DOI 10.1016/S0028-3908(96)00171-2; Klein-Nulend J, 1998, BIOCHEM BIOPH RES CO, V250, P108, DOI 10.1006/bbrc.1998.9270; KleinNulend J, 1995, BIOCHEM BIOPH RES CO, V217, P640, DOI 10.1006/bbrc.1995.2822; KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017; KleinNulend J, 1997, J BONE MINER RES, V12, P45, DOI 10.1359/jbmr.1997.12.1.45; Konttinen YT, 1996, ACTA ORTHOP SCAND, V67, P632, DOI 10.3109/17453679608997772; KURSAR JD, 1994, MOL PHARMACOL, V46, P227; Lauder JM, 2000, INT J DEV NEUROSCI, V18, P653, DOI 10.1016/S0736-5748(00)00032-0; Launay JM, 1996, J BIOL CHEM, V271, P3141, DOI 10.1074/jbc.271.6.3141; LEAN JM, 1995, AM J PHYSIOL-ENDOC M, V268, pE318, DOI 10.1152/ajpendo.1995.268.2.E318; Lerner Ulf H., 1996, P581; LOSCALZO J, 1995, NEW ENGL J MED, V333, P251, DOI 10.1056/NEJM199507273330410; Mason DJ, 1997, BONE, V20, P199, DOI 10.1016/S8756-3282(96)00386-9; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P2591, DOI 10.1073/pnas.050282397; Nijweide P. J., 1996, P115; NIJWEIDE PJ, 1975, P K NED AKAD C BIOL, V78, P410; NIJWEIDE PJ, 1986, HISTOCHEMISTRY, V84, P342, DOI 10.1007/BF00482961; Pakala R, 1997, CIRCULATION, V96, P2280; PAKALA R, 1994, CIRCULATION, V90, P1919, DOI 10.1161/01.CIR.90.4.1919; Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756-3282(98)00061-1; Porter RHP, 1999, BRIT J PHARMACOL, V128, P13, DOI 10.1038/sj.bjp.0702751; Saucier C, 1998, BIOCHEM PHARMACOL, V56, P1347, DOI 10.1016/S0006-2952(98)00244-5; SCHEVEN BAA, 1986, NATURE, V321, P79, DOI 10.1038/321079a0; Schirrmacher K, 1998, BONE, V23, P521, DOI 10.1016/S8756-3282(98)00142-2; SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P1255, DOI 10.1093/nar/18.5.1255; SKERRY TM, 1989, J BONE MINER RES, V4, P783, DOI 10.1002/jbmr.5650040519; Sterck JGH, 1996, J BONE MINER RES, V11, P367; STROEBEL M, 1994, J BIOL CHEM, V269, P22952; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; ULLMER C, 1995, FEBS LETT, V370, P215, DOI 10.1016/0014-5793(95)00828-W; VANDERPLAS A, 1985, BIOCHEM BIOPH RES CO, V129, P918, DOI 10.1016/0006-291X(85)91979-5; VANDERPLAS A, 1992, J BONE MINER RES, V7, P389; VANDERPLAS A, 1994, J BONE MINER RES, V9, P1697; Wainscott DB, 1996, J PHARMACOL EXP THER, V276, P720; Winding B, 1997, EXP PHYSIOL, V82, P871, DOI 10.1113/expphysiol.1997.sp004070	73	156	167	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28961	28968		10.1074/jbc.M101824200	http://dx.doi.org/10.1074/jbc.M101824200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387323	hybrid			2022-12-27	WOS:000170346000045
J	Bhagwat, M; Nossal, NG				Bhagwat, M; Nossal, NG			Bacteriophage T4 RNase H removes both RNA primers and adjacent DNA from the 5 ' end of lagging strand fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OKAZAKI FRAGMENT; REPLICATION FORK; SACCHAROMYCES-CEREVISIAE; POLYMERASE HOLOENZYME; SLIDING CLAMPS; PROTEINS; 5'-EXONUCLEASE; ENDONUCLEASE; HELICASE	Bacteriophage T4 RNase H belongs to a family of prokaryotic and eukaryotic nucleases that remove RNA primers from lagging strand fragments during DNA replication. Each enzyme has a flap endonuclease activity, cutting at or near the junction between single- and double-stranded DNA, and a 5'- to 3-exonuclease, degrading both RNA-DNA and DNA-DNA duplexes. On model substrates for lagging strand synthesis, T4 RNase H functions as an exonuclease removing short oligonucleotides, rather than as an endonuclease removing longer flaps created by the advancing polymerase. The combined length of the DNA oligonucleotides released from each fragment ranges from 3 to 30 nucleotides, which corresponds to one round of processive degradation by T4 RNase H with 32 single-stranded DNA-binding protein present. Approximately 30 nucleotides are removed from each fragment during coupled leading and lagging strand synthesis with the complete T4 replication system. We conclude that the presence of 32 protein on the single-stranded DNA between lagging strand fragments guarantees that the nuclease will degrade processively, removing adjacent DNA as well as the RNA primers, and that the difference in the relative rates of synthesis and hydrolysis ensures that there is usually only a single round of degradation during each lagging strand cycle.	NIDDKD, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Nossal, NG (corresponding author), NIDDKD, Mol & Cellular Biol Lab, NIH, Bldg 8,Rm 2A19, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057801] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bhagwat M, 1997, J BIOL CHEM, V272, P28523, DOI 10.1074/jbc.272.45.28523; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Chastain PD, 2000, MOL CELL, V6, P803, DOI 10.1016/S1097-2765(05)00093-6; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HINTON DM, 1987, J BIOL CHEM, V262, P10873; Hobbs LJ, 1996, J BACTERIOL, V178, P6772, DOI 10.1128/jb.178.23.6772-6777.1996; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KITANI T, 1985, J MOL BIOL, V184, P45, DOI 10.1016/0022-2836(85)90042-7; Kornberg A., 1992, DNA REPLICATION; Kreuzer KN, 2000, TRENDS BIOCHEM SCI, V25, P165, DOI 10.1016/S0968-0004(00)01559-0; Lee KH, 2000, NUCLEIC ACIDS RES, V28, P2873, DOI 10.1093/nar/28.15.2873; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Mosig G, 1998, ANNU REV GENET, V32, P379, DOI 10.1146/annurev.genet.32.1.379; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; OGAWA T, 1984, MOL GEN GENET, V193, P231, DOI 10.1007/BF00330673; Park K, 1998, J BIOL CHEM, V273, P5260, DOI 10.1074/jbc.273.9.5260; Qiu JZ, 1999, MOL CELL BIOL, V19, P8361, DOI 10.1128/mcb.19.12.8361; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Soumillion P, 1998, BIOCHEMISTRY-US, V37, P1819, DOI 10.1021/bi972526a; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WAGA S, 1994, J BIOL CHEM, V269, P10923; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Xu Y, 2000, J BIOL CHEM, V275, P20949, DOI 10.1074/jbc.M909135199; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x	42	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28516	28524		10.1074/jbc.M103914200	http://dx.doi.org/10.1074/jbc.M103914200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11376000	hybrid			2022-12-27	WOS:000170093400103
J	Perez-Canadillas, JM; Zaballos, A; Gutierrez, J; Varona, R; Roncal, F; Albar, JP; Marquez, G; Bruix, M				Perez-Canadillas, JM; Zaballos, A; Gutierrez, J; Varona, R; Roncal, F; Albar, JP; Marquez, G; Bruix, M			NMR solution structure of murine CCL20/MIP-3 alpha, a chemokine that specifically chemoattracts immature dendritic cells and lymphocytes through its highly specific interaction with the beta-chemokine receptor CCR6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CC-CHEMOKINE; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; SPECTROSCOPY; ACTIVATION; DYNAMICS; DISTINCT; INTERLEUKIN-8; LOCALIZATION; ASSIGNMENTS	CCL20/MIP-3 alpha is a beta -chemokine expressed in the thymus, skin, and intestinal epithelial cells that exclusively binds and activates the CCR6 receptor in both mice and humans. The strict receptor binding specificity of CCL20 is exceptional; other chemokines and their receptors bind promiscuously with multiple partners. Toward determining the structural basis for the selective receptor specificity of CCL20, we have determined its three-dimensional structure by H-1 NMR spectroscopy. CCL20 exhibits the same monomeric structure previously described for other chemokines: a three-stranded beta -sheet and an overlying alpha -helix. The CCL20 receptor selectivity could arise from the rigid conformation of the N-terminal DCCL motif as well as the groove between the N-loop and the beta (2)-beta (3) hairpin, which is significantly narrower in CCL20 than in other chemokines. Similar structural features are seen in human beta -defensin 2, a small nonchemokine polypeptide reported to selectively bind and activate CCR6, which stresses their importance for the specific binding of both CCL20 and beta -defensin 2 to CCR6. CCL20's structure will be useful to design tools aimed to modulate its important biological functions.	CSIC, Inst Estructura Mat, E-28006 Madrid, Spain; Ctr Nacl Biotecnol, Dept Inmunol & Oncol, Madrid 28040, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Estructura de la Materia (IEM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Bruix, M (corresponding author), CSIC, Inst Estructura Mat, Serrano 119, E-28006 Madrid, Spain.	marta@malika.iem.csic.es	Perez-Canadillas, Jose M/J-5748-2013; Bruix, Marta/H-4161-2011; Zaballos, Ángel/O-2853-2015; Pérez-Cañadillas, Jose Manuel/AAN-1864-2020	Perez-Canadillas, Jose M/0000-0002-8266-5502; Bruix, Marta/0000-0002-0096-3558; Zaballos, Angel/0000-0002-7555-5815				ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Carramolino L, 1999, J LEUKOCYTE BIOL, V66, P837, DOI 10.1002/jlb.66.5.837; CHUNG C, 1995, BIOCHEMISTRY-US, V34, P5329; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; Cook DN, 2000, IMMUNITY, V12, P495, DOI 10.1016/S1074-7613(00)80201-0; COVELL DG, 1994, PROTEIN SCI, V3, P2064, DOI 10.1002/pro.5560031119; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; FAIRBROTHER WJ, 1994, J MOL BIOL, V242, P252, DOI 10.1006/jmbi.1994.1577; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; HANZAWA H, 1994, FEBS LETT, V354, P207, DOI 10.1016/0014-5793(94)01081-1; Hoover DM, 2000, J BIOL CHEM, V275, P32911, DOI 10.1074/jbc.M006098200; Iwasaki A, 2000, J EXP MED, V191, P1381, DOI 10.1084/jem.191.8.1381; Keizer DW, 2000, BIOCHEMISTRY-US, V39, P6053, DOI 10.1021/bi000089l; KIM KS, 1994, J BIOL CHEM, V269, P32909; Kim KS, 1996, FEBS LETT, V395, P277, DOI 10.1016/0014-5793(96)01024-1; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Liao F, 1999, J IMMUNOL, V162, P186; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MALKOWSKI MG, 1995, J BIOL CHEM, V270, P7077, DOI 10.1074/jbc.270.13.7077; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Mayer KL, 2000, BIOCHEMISTRY-US, V39, P8382, DOI 10.1021/bi000523j; Meunier S, 1997, BIOCHEMISTRY-US, V36, P4412, DOI 10.1021/bi9627929; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy PM, 2000, PHARMACOL REV, V52, P145; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RAJARATHNAM K, 1995, BIOCHEMISTRY-US, V34, P12983, DOI 10.1021/bi00040a008; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; Schutyser E, 2000, J IMMUNOL, V165, P4470, DOI 10.4049/jimmunol.165.8.4470; Shao WP, 1998, BIOCHEMISTRY-US, V37, P8303, DOI 10.1021/bi980112r; Skelton NJ, 1999, STRUCTURE, V7, P157, DOI 10.1016/S0969-2126(99)80022-7; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; Stone MJ, 2000, CHEMOKINES IN ALLERGIC DISEASE, P67; Tanaka Y, 1999, EUR J IMMUNOL, V29, P633, DOI 10.1002/(SICI)1521-4141(199902)29:02<633::AID-IMMU633>3.0.CO;2-I; van Gunsteren W. F., 1987, GRONINGEN MOL SIMULA; Varona R, 1998, FEBS LETT, V440, P188, DOI 10.1016/S0014-5793(98)01450-1; Varona R, 2001, J CLIN INVEST, V107, pR37, DOI 10.1172/JCI11297; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	63	68	74	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28372	28379		10.1074/jbc.M103121200	http://dx.doi.org/10.1074/jbc.M103121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373289	Green Published, hybrid			2022-12-27	WOS:000170093400084
J	Thiriot, DS; Ruoho, AE				Thiriot, DS; Ruoho, AE			Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; VESICULAR AMINE TRANSPORTER; SCANNING MUTAGENESIS; TRANSMEMBRANE DOMAIN; RESIDUES CONTRIBUTE; LIGAND RECOGNITION; KNOCKOUT MICE; ACETYLCHOLINE; SENSITIVITY; AMPHETAMINE	The vesicle monoamine transporter (VMAT2) concentrates monoamine neurotransmitter into synaptic vesicles. Photoaffinity labeling, chimera analysis, and mutagenesis have identified functionally important amino acids and provided some information regarding structure and ligand binding sites. To extend these studies, we engineered functional human VMAT2 constructs with reduced numbers of cysteines. Subsets of cysteines were discovered, which restore function to an inactive cysteine-less human VMAT2. Replacement of three transmembrane (TM) cysteines together (net removal/replacement of three atoms) significantly enhanced monoamine transport. Cysteine modification studies involving single and combination cysteine mutants with methanethiosulfonate ethylamine revealed that [H-3]dihydrotetrabenazine binding is >90% inhibited by modification of two sets of cysteines, The primary target (responsible for similar to 80% of inhibition) is Cys(439) in TM 11. The secondary target (responsible for similar to 20% of inhibition) is one or more of the four non-TM cysteines, [H-3]Dihydrotetrabenazine protects against modification of Cys(439) by a 10,000-fold molar excess of methanethiosulfonate ethylamine, demonstrating that Cys(439) is either at the tetrabenazine binding site, or conformationally linked to tetrabenazine binding. Supporting a direct effect, the position of tetrabenazine-protectable Cys439 is consistent with previous mutagenesis, chimera, and photoaffinity labeling data, demonstrating involvement of TM 10-12 in a tetrabenazine binding domain.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ruoho, AE (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	aeruoho@facstaff.wisc.edu			NINDS NIH HHS [R01NS33650] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033650] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Duerr JS, 1999, J NEUROSCI, V19, P72, DOI 10.1523/JNEUROSCI.19-01-00072.1999; Eiden LE, 2000, FASEB J, V14, P2396, DOI 10.1096/fj.00-0817rev; Erickson J D, 1998, Adv Pharmacol, V42, P227; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Erickson JD, 2000, FASEB J, V14, P2450, DOI 10.1096/fj.00-0206rev; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Finn JP, 1998, J BIOL CHEM, V273, P3943, DOI 10.1074/jbc.273.7.3943; Finn JP, 1997, J BIOL CHEM, V272, P16301, DOI 10.1074/jbc.272.26.16301; Fon EA, 1997, NEURON, V19, P1271, DOI 10.1016/S0896-6273(00)80418-3; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Itokawa K, 1999, MOL BRAIN RES, V71, P354, DOI 10.1016/S0169-328X(99)00194-1; Javitch JA, 1998, METHOD ENZYMOL, V296, P331; Keller JE, 2000, J NEUROCHEM, V74, P1739, DOI 10.1046/j.1471-4159.2000.0741739.x; Kimura-Someya T, 2000, J BIOL CHEM, V275, P18692, DOI 10.1074/jbc.M000354200; Kubo Y, 2000, J BIOL CHEM, V275, P5270, DOI 10.1074/jbc.275.8.5270; LIMBIRD LE, 1996, CELL SURFACE RECEPTO, P70; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; MERICKEL A, 1995, J BIOL CHEM, V270, P25798, DOI 10.1074/jbc.270.43.25798; Merickel A, 1997, J BIOL CHEM, V272, P5403, DOI 10.1074/jbc.272.9.5403; Parsons SM, 2000, FASEB J, V14, P2423, DOI 10.1096/fj.00-0203rev; Peter D, 1996, J BIOL CHEM, V271, P2979, DOI 10.1074/jbc.271.6.2979; SCHERMAN D, 1988, MOL PHARMACOL, V33, P72; Sievert MK, 1998, BIOCHEM J, V330, P959; Sievert MK, 1997, J BIOL CHEM, V272, P26049, DOI 10.1074/jbc.272.41.26049; SteinerMordoch S, 1996, J BIOL CHEM, V271, P13048, DOI 10.1074/jbc.271.22.13048; STERNBACH Y, 1990, J BIOL CHEM, V265, P3961; SURRATT CK, 1993, FEBS LETT, V318, P325, DOI 10.1016/0014-5793(93)80539-7; Takahashi N, 1997, MOL BRAIN RES, V49, P7, DOI 10.1016/S0169-328X(97)00116-2; Takahashi N, 1997, P NATL ACAD SCI USA, V94, P9938, DOI 10.1073/pnas.94.18.9938; Tan PK, 1998, J BIOL CHEM, V273, P17351, DOI 10.1074/jbc.273.28.17351; Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5; Yelin R, 1998, J NEUROCHEM, V71, P2518	36	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27304	27315		10.1074/jbc.M103947200	http://dx.doi.org/10.1074/jbc.M103947200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375404	hybrid			2022-12-27	WOS:000169966900077
J	Tulin, EE; Onoda, N; Maeda, M; Hasegawa, M; Nosaka, T; Nomura, H; Asano, S; Kitamura, T				Tulin, EE; Onoda, N; Maeda, M; Hasegawa, M; Nosaka, T; Nomura, H; Asano, S; Kitamura, T			A novel secreted form of immune suppressor factor with high homology to vacuolar ATPases identified by a forward genetic approach of functional screening based on cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MARROW STROMAL CELLS; BONE-MARROW; EXPRESSION; MURINE; CDNA; APOPTOSIS; RECEPTOR; MOLECULE; SUBUNIT	In the search for stromal-derived growth factors, we have identified a novel secreted short form of immune suppressor factor (ISF) using a combination of a genetic approach and retrovirus-mediated functional screening. This protein, which we termed ShIF, was isolated based on its ability to support proliferation of a mutant clone S21, which was established from Ba/F3 cells that are usually interleukin 3-dependent but became dependent on a stroma cell line ST2 after chemical mutagenesis. ISF, a membrane protein harboring six transmembrane domains, was reported to have immunosuppressive functions. The coding region of ShIF started from the third transmembrane domain of ISF. Biochemical analysis demonstrated that ShIF was expressed in both the secreted and membrane-bound forms of 27-kDa protein, which was supposed to have an internal ATG present in the third transmembrane domain of ISF as a start codon, In addition to the full-length form of ISF, a major protein with a molecular size of 27 kDa was also expressed through the proteolytic process of ISF, ShIF resembles this naturally occurring short form of ISF (sISF). Deletion analysis of the major domains of ISF cDNA revealed that ShIF is an active functional domain of ISF with a capability to support proliferation of S21 cells. Enforced expression of ShIF in MS10 cells, bone marrow stroma cells that do not express endogenous ShIF or ISF, conferred on the cells an ability to support the growth of S21 cells as well as bone marrow cells. Interestingly, ShIF shows a high sequence homology to the C-terminal part of a 95-kDa yeast vacuolar H (+)-ATPase subunit, Vph1p (39%), and a 116-kDa proton pump (VPP1) (54%) of the rat and bovine synaptic vesicle. Therefore, it is possible that ShIF also acts as a proton pump and somehow prevents the cells from undergoing apoptosis.	Univ Tokyo, Div Hematopoiet Factors, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Div Mol Therapy,Adv Clin Res Ctr, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; Chugai Res Inst Mol Med, Ibaraki, Osaka 3004101, Japan	University of Tokyo; University of Tokyo	Kitamura, T (corresponding author), Univ Tokyo, Div Hematopoiet Factors, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan.		Kitamura, Toshio/AAA-2071-2021					DORSHKIND K, 1990, ANNU REV IMMUNOL, V8, P111, DOI 10.1146/annurev.iy.08.040190.000551; Gottlieb RA, 1996, J CLIN INVEST, V97, P2391, DOI 10.1172/JCI118683; HARTWELL LH, 1991, GENETICS, V129, P975; KAISHO T, 1992, J IMMUNOL, V149, P4088; KINCADE PW, 1989, ANNU REV IMMUNOL, V7, P111, DOI 10.1146/annurev.iy.07.040189.000551; Kitamura T, 1998, INT J HEMATOL, V67, P351; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; LEE CK, 1990, MOL IMMUNOL, V27, P1137; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; MIYAJIMA A, 1986, EMBO J, V5, P1193, DOI 10.1002/j.1460-2075.1986.tb04346.x; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Onishi M, 1996, EXP HEMATOL, V24, P324; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERIN MS, 1991, J BIOL CHEM, V266, P3877; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980	19	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27519	27526		10.1074/jbc.M101781200	http://dx.doi.org/10.1074/jbc.M101781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375395	hybrid			2022-12-27	WOS:000169966900103
J	Thiede, B; Dimmler, C; Siejak, F; Rudel, T				Thiede, B; Dimmler, C; Siejak, F; Rudel, T			Predominant identification of RNA-binding proteins in Fas-induced apoptosis by proteome analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; LYMPHOMA CELL-LINE; HNRNP A/B PROTEINS; IN-VIVO; MEDIATED APOPTOSIS; MASS-SPECTROMETRY; IMMUNE PRIVILEGE; SPLICING FACTORS; DEATH; CASPASES	Proteome analysis of Jurkat T cells was performed in order to identify proteins that are modified during apoptosis, Subtractive analysis of two-dimensional gel patterns of apoptotic and nonapoptotic cells revealed differences in 45 protein spots. 37 protein spots of 21 different proteins were identified by peptide mass fingerprinting using matrix-assisted laser desorption/ionization mass spectrometry, The hnRNPs A0, A2/B1, A3, K and R; the splicing factors p54(nrb), SRp30c, ASF-2, and KH-type splicing regulatory protein (FUSE-binding protein 2); and alpha NAG, NS1-associated protein 1, and poly(A)-binding protein 4 were hitherto unknown to be involved in apoptosis, The putative cleavage sites of the majority of the proteins could be calculated by the molecular masses and isoelectric points in the two-dimensional electrophoresis gel, the peptide mass fingerprints, and after translation by treatment with recombinant caspase-3, Remarkably, 15 of the 21 identified proteins contained the RNP or KH motif, the best characterized RNA-binding motifs.	Max Planck Inst Infektionsbiol, Abt Mol Biol, D-10117 Berlin, Germany	Max Planck Society	Rudel, T (corresponding author), Max Planck Inst Infektionsbiol, Abt Mol Biol, Schumannstr 21-22, D-10117 Berlin, Germany.							AEBERSOLD R, 1990, ELECTROPHORESIS, V11, P517, DOI 10.1002/elps.1150110702; Anderson NL, 1998, ELECTROPHORESIS, V19, P1853, DOI 10.1002/elps.1150191103; Appel RD, 1996, ELECTROPHORESIS, V17, P540, DOI 10.1002/elps.1150170324; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bai YD, 1999, NUCLEIC ACIDS RES, V27, P1126, DOI 10.1093/nar/27.4.1126; Blackstock WP, 1999, TRENDS BIOTECHNOL, V17, P121, DOI 10.1016/S0167-7799(98)01245-1; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; Brockstedt E, 1999, J PROTEIN CHEM, V18, P225, DOI 10.1023/A:1020636308270; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Celis JE, 1998, FEBS LETT, V430, P64, DOI 10.1016/S0014-5793(98)00527-4; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GATTOKONCZAK F, 1999, MOL CELL BIOL, V19, P251; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; Gerner C, 2000, J BIOL CHEM, V275, P39018, DOI 10.1074/jbc.M006495200; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Griffith TS, 1997, IMMUNOL TODAY, V18, P240, DOI 10.1016/S0167-5699(97)81663-5; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Jungblut PR, 1999, ELECTROPHORESIS, V20, P2100; JUNGBLUT PR, 1990, J BIOCHEM BIOPH METH, V21, P47, DOI 10.1016/0165-022X(90)90044-D; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KLOSE J, 1975, HUMANGENETIK, V26, P231; KLOSE J, 1995, ELECTROPHORESIS, V16, P1034, DOI 10.1002/elps.11501601175; Lemkin PF, 1997, ELECTROPHORESIS, V18, P461, DOI 10.1002/elps.1150180321; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; O'Connell J, 1999, IMMUNOL TODAY, V20, P46, DOI 10.1016/S0167-5699(98)01382-6; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Reed JC, 1999, NAT BIOTECHNOL, V17, P1064, DOI 10.1038/15048; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; Rickers A, 1998, EUR J IMMUNOL, V28, P296, DOI 10.1002/(SICI)1521-4141(199801)28:01<296::AID-IMMU296>3.0.CO;2-4; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Stegh AH, 2000, MOL CELL BIOL, V20, P5665, DOI 10.1128/MCB.20.15.5665-5679.2000; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Thiede B, 2000, ELECTROPHORESIS, V21, P2713, DOI 10.1002/1522-2683(20000701)21:13<2713::AID-ELPS2713>3.0.CO;2-U; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wilkins MR, 1996, BIO-TECHNOL, V14, P61, DOI 10.1038/nbt0196-61; Williams KL, 1999, ELECTROPHORESIS, V20, P678, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<678::AID-ELPS678>3.0.CO;2-R; Yates JR, 1998, J MASS SPECTROM, V33, P1	58	110	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26044	26050		10.1074/jbc.M101062200	http://dx.doi.org/10.1074/jbc.M101062200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352910	hybrid, Green Published			2022-12-27	WOS:000169823300055
J	Wasiak, S; Quinn, CC; Ritter, B; de Heuvel, E; Baranes, D; Plomann, M; McPherson, PS				Wasiak, S; Quinn, CC; Ritter, B; de Heuvel, E; Baranes, D; Plomann, M; McPherson, PS			The Ras/Rac guanine nucleotide exchange factor mammalian son-of-sevenless interacts with PACSIN 1/syndapin I, a regulator of endocytosis and the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; N-WASP; KINASE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; EGF RECEPTOR; SH3 DOMAINS; HUMAN SOS1; RAS; GRB2	Mammalian Son-of-sevenless (mSos) functions as a guanine nucleotide exchange factor for Res and Rac, thus regulating signaling to mitogen-activated protein kinases and actin dynamics. In the current study, we have identified a new mSos-binding protein of 50 kDa (p50) that interacts with the mSos1 proline-rich domain. Mass spectrometry analysis and immunodepletion studies reveal p50 as PACSIN 1/syndapin I, a Src homology 3 domain-containing protein functioning in endocytosis and regulation of actin dynamics. In addition to PACSIN 1, which is neuron-specific, mSos also interacts with PACSIN 2, which is expressed in neuronal and nonneuronal tissues. PACSIN 2 shows enhanced binding to the mSos proline-rich domain in pull-down assays from brain extracts as compared with lung extracts, suggesting a tissue-specific regulation of the interaction. Proline to leucine mutations within the Src homology 3 domains of PACSIN 1 and 2 abolish their binding to mSos, demonstrating the specificity of the interactions. In situ, PACSIN 1 and mSos1 are co-expressed in growth cones and actin-rich filopodia in hippocampal and dorsal root ganglion neurons, and the two proteins coimmunoprecipitate from brain extracts. Moreover, epidermal growth factor treatment of COS-7 cells causes co-localization of PACSIN 1 and mSos1 in actin-rich membrane ruffles, and their interaction is regulated through epidermal growth factor-stimulated mSos1 phosphorylation, These data suggest that PACSINs may function with mSos1 in regulation of actin dynamics.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Univ Cologne, Inst Biochem, D-50931 Cologne, Germany; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	McGill University; Yale University; University of Cologne; McGill University	McPherson, PS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Rue Univ, Montreal, PQ H3A 2B4, Canada.			Ritter, Brigitte/0000-0002-0094-0460	NINDS NIH HHS [NS22807] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022807] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Bretscher MS, 1998, CURR BIOL, V8, P721, DOI 10.1016/S0960-9822(98)70281-7; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Glogauer M, 2000, J CELL BIOL, V150, P785, DOI 10.1083/jcb.150.4.785; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Modregger J, 2000, J CELL SCI, V113, P4511; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Plomann M, 1998, EUR J BIOCHEM, V256, P201, DOI 10.1046/j.1432-1327.1998.2560201.x; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ritter B, 1999, FEBS LETT, V454, P356, DOI 10.1016/S0014-5793(99)00830-3; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Tong XK, 2000, J BIOL CHEM, V275, P29894, DOI 10.1074/jbc.M004096200; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; VAN AL, 1997, GENE DEV, V11, P2295; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Zhao H, 1998, J BIOL CHEM, V273, P12061, DOI 10.1074/jbc.273.20.12061; Zheng JQ, 1996, J NEUROSCI, V16, P1140	51	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26622	26628		10.1074/jbc.M100591200	http://dx.doi.org/10.1074/jbc.M100591200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352907	hybrid			2022-12-27	WOS:000169823300127
J	Zhang, H; Zhu, ZN; Vidanes, G; Mbangkollo, D; Liu, YL; Siede, W				Zhang, H; Zhu, ZN; Vidanes, G; Mbangkollo, D; Liu, YL; Siede, W			Characterization of DNA damage-stimulated self-interaction of Saccharomyces cerevisiae checkpoint protein Rad17p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE RAD1(+); CELL-CYCLE ARREST; BUDDING YEAST; RAD9 CHECKPOINT; FISSION YEAST; STRAND BREAKS; MEC1-DEPENDENT PHOSPHORYLATION; SLIDING CLAMP; GENE-PRODUCT; G(1) ARREST	Saccharomyces cerevisiae Rad17p is necessary for cell cycle checkpoint arrests in response to DNA damage. Its known interactions with the checkpoint proteins Mec3p and Ddc1p in a PCNA-like complex indicate a sensor role in damage recognition. In a novel application of the yeast two-hybrid system and by immunoprecipitation, we show here that Rad17p is capable of increased self-interaction following DNA damage introduced by 4-nitroquinoline-N-oxide, camptothecin or partial inactivation of DNA ligase I. Despite overlap of regions required for Rad17p interactions with Rad17p or Mec3p, single amino acid substitutions revealed that Rad17p(.)Rad17p complex formation is independent of Mec3p. E128K (rad17-1) was found to inhibit Rad17p interaction with Mec3p but not with Rad17p. On the other hand, Phe-121 is essential for Rad17p self-interaction, and its function in checkpoint arrest but not for Mec3p interaction. These differential effects indicate that Rad17p-Rad17p interaction plays a role that is independent of the Rad17p(.)Mec3p(.)Ddc1p complex, although our results are also compatible with Rad17p-mediated supercomplex formation of the Rad17p(.)Mec3(.)pDdc1p heterotrimer in response to DNA damage.	Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA	Emory University; Emory University	Siede, W (corresponding author), Emory Univ, Sch Med, Winship Canc Inst, B5111,1365 B Clifton Rd, Atlanta, GA 30322 USA.				NATIONAL CANCER INSTITUTE [R01CA087381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055381] Funding Source: NIH RePORTER; NCI NIH HHS [CA87381] Funding Source: Medline; NIGMS NIH HHS [GM55381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aboussekhra A, 1996, EMBO J, V15, P3912, DOI 10.1002/j.1460-2075.1996.tb00765.x; Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; Bashkirov VI, 2000, MOL CELL BIOL, V20, P4393, DOI 10.1128/MCB.20.12.4393-4404.2000; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; Bluyssen HAR, 1998, GENOMICS, V54, P331, DOI 10.1006/geno.1998.5582; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Caspari T, 1999, BIOCHIMIE, V81, P173, DOI 10.1016/S0300-9084(99)80050-9; Chang MS, 1999, J BIOL CHEM, V274, P36544, DOI 10.1074/jbc.274.51.36544; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; de la Torre-Ruiz MA, 1998, EMBO J, V17, P2687, DOI 10.1093/emboj/17.9.2687; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Freire R, 1998, GENE DEV, V12, P2560, DOI 10.1101/gad.12.16.2560; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; Guo ZJ, 2000, MOL BIOL CELL, V11, P1535, DOI 10.1091/mbc.11.5.1535; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; HARPER JW, 1993, CELL, V75, P805; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Kaiser C., 1994, METHODS YEAST GENETI; Kiser GL, 1996, MOL BIOL CELL, V7, P703, DOI 10.1091/mbc.7.5.703; Kondo T, 1999, MOL CELL BIOL, V19, P1136; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu Y, 2000, MOL GEN GENET, V262, P1132, DOI 10.1007/PL00008656; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; Marathi UK, 1998, GENOMICS, V54, P344, DOI 10.1006/geno.1998.5589; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; MEYN MS, 1995, CANCER RES, V55, P5991; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Naiki T, 2000, MOL CELL BIOL, V20, P5888, DOI 10.1128/MCB.20.16.5888-5896.2000; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Neecke H, 1999, EMBO J, V18, P4485, DOI 10.1093/emboj/18.16.4485; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Osmani SA, 1997, TRENDS CELL BIOL, V7, P283, DOI 10.1016/S0962-8924(97)01086-6; Paciotti V, 2000, GENE DEV, V14, P2046; Paciotti V, 1998, EMBO J, V17, P4199, DOI 10.1093/emboj/17.14.4199; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; PRINTEN JA, 1994, GENETICS, V138, P609; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; ROSE MD, 1987, METHOD ENZYMOL, V152, P481; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; SCHIESTL RH, 1989, MOL CELL BIOL, V9, P1882, DOI 10.1128/MCB.9.5.1882; Shimomura T, 1998, MOL CELL BIOL, V18, P5485, DOI 10.1128/MCB.18.9.5485; Siede W, 1996, J BACTERIOL, V178, P5841, DOI 10.1128/jb.178.19.5841-5843.1996; SIEDE W, 1994, GENETICS, V138, P271; Siede W, 1996, NUCLEIC ACIDS RES, V24, P1669, DOI 10.1093/nar/24.9.1669; Soulier J, 1999, CURR BIOL, V9, P551, DOI 10.1016/S0960-9822(99)80242-5; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; THELEN MP, 1994, J BIOL CHEM, V269, P747; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P372, DOI 10.1016/S0955-0674(00)00102-2; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wan SH, 1999, YEAST, V15, P821, DOI 10.1002/(SICI)1097-0061(199907)15:10A<821::AID-YEA422>3.3.CO;2-R; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Xin H, 2000, NUCLEIC ACIDS RES, V28, P2847, DOI 10.1093/nar/28.14.2847; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	79	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26715	26723		10.1074/jbc.M103682200	http://dx.doi.org/10.1074/jbc.M103682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11356855	hybrid			2022-12-27	WOS:000169823300139
J	Chai, ZL; Sarcevic, B; Mawson, A; Toh, BH				Chai, ZL; Sarcevic, B; Mawson, A; Toh, BH			SET-related cell division autoantigen-1 (CDA1) arrests cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-2; PROTEIN PHOSPHATASE 2A; SRC HOMOLOGY-3 DOMAINS; AUG INITIATOR CODON; SH3 DOMAINS; MOLECULAR CHARACTERIZATION; MYELOID LEUKEMOGENESIS; EUKARYOTIC RIBOSOMES; HUMAN AUTOANTIBODIES; LUPUS-ERYTHEMATOSUS	We used an autoimmune serum from a patient with discoid lupus erythematosus to clone a cDNA of 2808 base pairs. Its open reading frame of 2079 base pairs encodes a predicted polypeptide of 693 amino acids named CDA1 (cell division autoantigen-1). CDA1 has a predicted molecular mass of 79,430 Daltons and a pl of 4.26. The size of the cDNA is consistent with its estimated mRNA size. CDA1 comprises an N-terminal proline-rich domain, a central basic domain, and a C-terminal bipartite acidic domain. It has four putative nuclear localization signals and potential sites for phosphorylation by cAMP and cGMP-dependent kinases, protein kinase C, thymidine kinase, casein kinase II, and cyclin-dependent kinases (CDKs). CDA1 is phosphorylated in HeLa cells and by cyclin D1/CDK4, cyclin A/CDK2, and cyclin B/CDK1 in vitro. Its basic and acidic domains contain regions homologous to almost the entire human leukemia-associated SET protein. The same basic region is also homologous to nucleosome assembly proteins, testis TSPY protein, and an uncharacterized brain protein. CDA1 is present in the nuclear fraction of HeLa cells and localizes to the nucleus and nucleolus in HeLa cells transfected with CDA1 or its N terminus containing all four nuclear localization signals. Its acidic C terminus localizes mainly to the cytoplasm. CDA1 levels are low in serum-starved cells, increasing dramatically with serum stimulation. Expression of the CDA1 transgene, but not its N terminus, arrests HeLa cell growth, colony numbers, cell density, and bromodeoxyuridine uptake in a dose-dependent manner. The ability of CDA1 to arrest cell growth is abolished by mutation of the two CDK consensus phosphorylation sites. We propose that CDA1 is a negative regulator of cell growth and that its activity is regulated by its expression level and phosphorylation.	Monash Univ, Sch Med, Dept Pathol & Immunol, Prahran, Vic 3181, Australia; St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	Monash University; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Toh, BH (corresponding author), Monash Univ, Sch Med, Dept Pathol & Immunol, Prahran, Vic 3181, Australia.	Ban-Hock.Toh@med.monash.edu.au	CHAI, ZHONGLIN/X-1342-2019; Chai, Zhonglin/E-7482-2010	CHAI, ZHONGLIN/0000-0001-8182-8579; Sarcevic, Boris/0000-0002-8063-1050				ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; ALDERUCCIO F, 1991, J EXP MED, V173, P941, DOI 10.1084/jem.173.4.941; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; CALLEN JP, 1982, ARCH DERMATOL, V118, P412, DOI 10.1001/archderm.118.6.412; Campbell DH, 1999, CANCER RES, V59, P5376; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; Erlich R, 1996, J BIOL CHEM, V271, P8328, DOI 10.1074/jbc.271.14.8328; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Gitlits VM, 1997, IMMUNOLOGY, V92, P362, DOI 10.1046/j.1365-2567.1997.00355.x; Gitlits VM, 2000, J INVEST MED, V48, P172; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KELLOGG DR, 1995, J CELL BIOL, V130, P675, DOI 10.1083/jcb.130.3.675; KOOY J, 1992, J BIOL CHEM, V267, P20255; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORTON CJ, 1994, CURR BIOL, V4, P615, DOI 10.1016/S0960-9822(00)00134-2; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROBSON B, 1976, J MOL BIOL, V107, P327, DOI 10.1016/S0022-2836(76)80008-3; Rodriguez P, 2000, J MOL BIOL, V298, P225, DOI 10.1006/jmbi.2000.3674; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Spector D. L., 1998, CELLS LAB MANUAL; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Toh BH, 1997, NEW ENGL J MED, V337, P1441, DOI 10.1056/NEJM199711133372007; TOH BH, 1990, P NATL ACAD SCI USA, V87, P6418, DOI 10.1073/pnas.87.16.6418; Ueki N, 1998, NAT BIOTECHNOL, V16, P1338, DOI 10.1038/4315; VONLINDERN M, 1992, BAILLIERE CLIN HAEM, V5, P857, DOI 10.1016/S0950-3536(11)80049-1; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; XIE WQ, 1991, BIOTECHNIQUES, V11, P324; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158	56	65	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33665	33674		10.1074/jbc.M007681200	http://dx.doi.org/10.1074/jbc.M007681200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11395479	hybrid			2022-12-27	WOS:000170910200052
J	Hwang, J; Inouye, M				Hwang, J; Inouye, M			An essential GTPase, Der, containing double GTP-binding domains from Escherichia coli and Thermotoga maritima	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; PROTEIN; DNA; RECOMBINATION; ELONGATION; FRAGMENTS; SEQUENCE; HOMOLOG; MOTIF	A gene encoding a putative GTPase containing two tandemly repeated GTP-binding domains from a hyperthermophilic bacterium, Thermotoga maritima, was cloned and expressed in Escherichia coli. The gene (TM1446) termed der is highly conserved in Eubacteria including E. coli. The purified der product (Tm-Der) has GTPase activity but no ATPase activity. GTP, GDP, and dGTP but not GMP, ATP, CTP, and UTP compete for GTP binding to Tm-Der. An optimal condition for the GTPase assay was determined to be pH 7.5 in 400 mm KCI and 5 mM MgCl2 at 70 degreesC, where K-m, V-max, and k(cat) values were determined to be 110 mum, 3.46 mum/min, and 0.87 min(-1), respectively. A der deletion strain of E. coli was constructed by replacing the der gene (originally annotated yfgK) with a kanamycin resistance gene. The deletion strain was found to form colonies only if the cells harbored a plasmid containing der, indicating that der is essential for E. coli growth.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.							AHNN J, 1986, P NATL ACAD SCI USA, V83, P8849, DOI 10.1073/pnas.83.23.8849; ARMSTRONG KA, 1984, J MOL BIOL, V175, P331, DOI 10.1016/0022-2836(84)90352-8; BELFIELD GP, 1995, J MOL EVOL, V41, P376, DOI 10.1007/BF01215185; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Cabedo H, 1999, EMBO J, V18, P7063, DOI 10.1093/emboj/18.24.7063; Chen X, 1999, P NATL ACAD SCI USA, V96, P8396, DOI 10.1073/pnas.96.15.8396; Farmery M, 1998, BBA-PROTEIN STRUCT M, V1385, P61, DOI 10.1016/S0167-4838(98)00045-4; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; JASIN M, 1984, J BACTERIOL, V159, P783, DOI 10.1128/JB.159.2.783-786.1984; Kawabata S, 2000, ORAL MICROBIOL IMMUN, V15, P58, DOI 10.1034/j.1399-302x.2000.150110.x; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; Lu Q, 1996, P NATL ACAD SCI USA, V93, P5720, DOI 10.1073/pnas.93.12.5720; MARCH PE, 1988, ONCOGENE, V2, P539; Mehr IJ, 2000, GENETICS, V154, P523; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P21; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; STAHL FW, 1986, GENETICS, V113, P215; Yamanaka K, 2000, J BACTERIOL, V182, P7078, DOI 10.1128/JB.182.24.7078-7082.2000	21	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31415	31421		10.1074/jbc.M104455200	http://dx.doi.org/10.1074/jbc.M104455200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11387344	hybrid			2022-12-27	WOS:000170472900107
J	Boskovic, DS; Bajzar, LS; Nesheim, ME				Boskovic, DS; Bajzar, LS; Nesheim, ME			Channeling during prothrombin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-VA; FACTOR-XA; CATALYZED ACTIVATION; MEIZOTHROMBIN; INTERMEDIATE; SUBSTRATE; BINDING; COMPLEX; THROMBOMODULIN; SPECIFICITY	The plasma zymogen prothrombin (II) is converted to the clotting enzyme thrombin (IIa) by two prothrombinase-catalyzed proteolytic cleavages. Thus, two intermediates, meizothrombin (mIIa) and prethrombin-2 (P2), are possible on the reaction pathway. Measurements of the time courses of II, mIIa, P2, and IIa suggested a channeling phenomenon, whereby a portion of the Il is converted directly to IIa without free mlIa and P2 as obligatory intermediates. Evidence for this was that the maximum rate of IIa formation preceded the maximum in the level of either intermediate. In addition, analysis of the data according to a model that included two parallel pathways through mIIa and P2 indicated that about 40% of the II consumed did not yield free mlIa or P2. Further studies were carried out in which II was continuously infused in a reactor at a constant rate. Under these conditions II, mIIa, and P2 reached constant steady-state levels, and IIa was produced at a constant rate, equal to that of II infusion. During the steady state, traces of II, mIIa, and P2 were introduced as radiolabels. Time courses of isotope consumption were first order, thus allowing the rates of consumption of II, mIIa, and P2 to be calculated. Under these conditions the rate of II consumption equaled the rate of IIa formation. Rates of consumption of the free intermediates, however, were only 22 (mlIa) and 15% (P2), respectively, of the rate of thrombin formation. Thus, both the time course experiments and the steady-state experiments indicate that an appreciable fraction of II is channeled directly to IIa without proceeding through the free intermediates mIIa and P2.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada	Queens University - Canada; Queens University - Canada; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; McMaster University	Nesheim, ME (corresponding author), Queens Univ, Dept Biochem, Botterell Hall,Rm A212, Kingston, ON K7L 3N6, Canada.		Boskovic, Danilo/D-4670-2012	Boskovic, Danilo/0000-0001-6919-3726				Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; BAJAJ SP, 1973, J BIOL CHEM, V248, P7729; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BOSKOVIC DS, 1989, THESIS QUEENS U KING; Cote HCF, 1997, J BIOL CHEM, V272, P6194, DOI 10.1074/jbc.272.10.6194; DAVIE EW, 1964, SCIENCE, V145, P1310, DOI 10.1126/science.145.3638.1310; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; KANE WH, 1980, J BIOL CHEM, V255, P1170; Kassell B., 1970, METHOD ENZYMOL, V19, P853; Kornberg A, 1992, DNA REPLICATION, P471; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; MACFARLANE RG, 1964, NATURE, V202, P498, DOI 10.1038/202498a0; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1990, BLOOD, V76, P1; MANN KG, 1987, TRENDS BIOCHEM SCI, V12, P229, DOI 10.1016/0968-0004(87)90115-0; MANN KG, 1992, ARCH PATHOL LAB MED, V116, P1330; MANN KG, 1974, THROMB DIATH HAEMO, V57, P179; MANN KG, 1986, BLOOD COAGULATION, P15; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1984, SURV SYN PATHOL RES, V3, P219; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; ROSING J, 1986, J BIOL CHEM, V261, P4224; ROSING J, 1980, J BIOL CHEM, V255, P274; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Wolberg AS, 1997, BIOCHEMISTRY-US, V36, P4074, DOI 10.1021/bi962274y	33	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28686	28693		10.1074/jbc.M101813200	http://dx.doi.org/10.1074/jbc.M101813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384970	hybrid			2022-12-27	WOS:000170346000008
J	Brodbeck, D; Hill, MM; Hemmings, BA				Brodbeck, D; Hill, MM; Hemmings, BA			Two splice variants of protein kinase B gamma have different regulatory capacity depending on the presence or absence of the regulatory phosphorylation site serine 472 in the carboxyl-terminal hydrophobic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; FORKHEAD TRANSCRIPTION FACTOR; GLYCOGEN-SYNTHASE KINASE-3; P70 S6 KINASE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN-KINASE-1; PHOSPHOINOSITIDE-3-OH KINASE; INSULIN-LIKE; IN-VITRO	We have reported previously the cloning and characterization of human and mouse protein kinase By (PKB gamma), the third member of the PKB family of second messenger-regulated serine/threonine kinases (Brodbeck, D., Cron, P., and Hemmings, B. A (1999) J. Biol Chem. 274, 9133-9136). Here we report the isolation of human and mouse PKB gamma1, a splice variant lacking the second regulatory phosphorylation site Ser-472 in the hydrophobic C-terminal domain. Expression of PKB gamma1 is low compared with PKB gamma, and it is regulated in different human tissues. We show that PKB gamma and PKB gamma1 differ in their response to stimulation by insulin, pervanadate, peroxide, or okadaic acid. Activation of PKB gamma1 requires phosphorylation at a single regulatory site Thr-305. Interestingly, this site is phosphorylated to a higher extent in PKB gamma compared with PKB gamma1 upon maximal stimulation by pervanadate, and this is reflected in the respective specific kinase activities. Furthermore, upon insulin stimulation of transfected cells, PKB gamma1 translocates to the plasma membrane to a lesser extent than PKB gamma. Taken together, these results suggest that phosphorylation of the hydrophobic motif at the extreme C terminus of PKB gamma may facilitate translocation of the kinase to the membrane and/or its phosphorylation on the activation loop site by phosphoinositide-dependent protein kinase-1.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.		Hill, Michelle Mei Chih/G-4417-2010	Hill, Michelle Mei Chih/0000-0003-1134-0951				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BELLACOSA A, 1993, ONCOGENE, V8, P745; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chalfant CE, 1998, J BIOL CHEM, V273, P910, DOI 10.1074/jbc.273.2.910; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Groenen PJTA, 2000, HUM MOL GENET, V9, P605, DOI 10.1093/hmg/9.4.605; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	67	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29550	29558		10.1074/jbc.M104633200	http://dx.doi.org/10.1074/jbc.M104633200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387345	hybrid			2022-12-27	WOS:000170346000120
J	Rebrin, I; Geha, RM; Chen, K; Shih, JC				Rebrin, I; Geha, RM; Chen, K; Shih, JC			Effects of carboxyl-terminal truncations on the activity and solubility of human monoamine oxidase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OUTER-MEMBRANE; BOUND FAD; LIVER; PROTEINS; BEHAVIOR; CLONING; GENES; YEAST; CELLS	Monoamine oxidase is an outer mitochondrial membrane protein that catalyzes the deamination of a number of neurotransmitters and dietary amines. To determine the roles of the carboxyl-terminal amino acids on the activity and solubility of human monoamine oxidase (MAO B), 10 sequential mutants were made with stop codons at amino acid positions 511, 504, 498, 492, 486, 481, 476, 467, 417, and 397, respectively. All truncated mutants were expressed in Sf21 insect cells using baculovirus, and the enzyme kinetic parameters were determined. Truncations at amino acid positions 511, 504, and 498 slightly decreased MAO B catalytic activity and had no significant changes on deprenyl inhibition. Further deletions up to amino acid 417 decreased the specific activity 10-100-fold without significant changes of the K-m for phenylethylamine or dopamine or the IC50 for deprenyl and clorgyline. The truncation mutant C397, which lacks covalently attached FAD, was inactive. Progressive carboxylterminal truncations up to position 481 were correlated with increased solubility of MAO B mutants. 47% of the activity of the truncated C481 was found in the 105,000 x g supernatant in the absence of detergent. However, further truncated mutants, C476, C467, and C417, remained associated with the membrane fraction. In contrast to crude homogenate, the water-soluble C481 mutant was rapidly inactivated at 4 degreesC and 37 degreesC, which indicates that the membrane environment is required for the stability of MAO B. Expression of the green fluorescent protein-MAO B C481 fusion protein revealed that this mutant was located in the cytoplasm, whereas its counterpart in MAO A, truncated mutant C490, was located on the mitochondria. These results suggest that the carboxyl-terminal amino acid residues 417-520 of MAO B are not directly involved in the active site but are required for maintaining the appropriate conformation and interaction with the outer mitochondrial membrane. The different solubilities of the various carboxyl-terminal truncation mutants indicate that the interaction of MAO B with mitochondrial membrane is not simply anchoring through the carboxyl. terminal hydrophobic tail. Further, our results suggest that the carboxyl-terminal of MAO A and B plays different roles in mitochondrial attachment.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Shih, JC (corresponding author), Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, 1985 Zonal Ave, Los Angeles, CA 90089 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037020, R37MH039085, K05MH000796] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH37020, R37 MH039085, K05 MH00796, R37 MH39085] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; Binda C, 1999, STRUCTURE, V7, P265, DOI 10.1016/S0969-2126(99)80037-9; Chen K, 1996, J NEUROCHEM, V66, P797; CHEN K, 1994, MOL PHARMACOL, V46, P1226; GOTTOWIK J, 1993, FEBS LETT, V317, P152, DOI 10.1016/0014-5793(93)81512-X; GREENAWALT JW, 1970, J CELL BIOL, V46, P173, DOI 10.1083/jcb.46.1.173; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; Hirashiki I, 1995, BIOCHEM MOL BIOL INT, V37, P39; Hiro I, 1996, J BIOCHEM-TOKYO, V120, P759; JOHNSTON JP, 1968, BIOCHEM PHARMACOL, V17, P1285, DOI 10.1016/0006-2952(68)90066-X; Knoll J, 1972, Adv Biochem Psychopharmacol, V5, P393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN NC, 1989, J NEUROCHEM, V52, P1652, DOI 10.1111/j.1471-4159.1989.tb09223.x; Lu G, 1996, PROTEIN EXPRES PURIF, V7, P315, DOI 10.1006/prep.1996.0045; MITOMA J, 1992, J BIOCHEM-TOKYO, V111, P20, DOI 10.1093/oxfordjournals.jbchem.a123712; NGUYEN M, 1993, J BIOL CHEM, V268, P2565; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shih JC, 1999, AM J HUM GENET, V65, P593, DOI 10.1086/302562; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Shiloff BA, 1996, EUR J BIOCHEM, V242, P41, DOI 10.1111/j.1432-1033.1996.0041r.x; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; URBAN P, 1991, FEBS LETT, V286, P142, DOI 10.1016/0014-5793(91)80960-B; WALKER WH, 1971, EUR J BIOCHEM, V24, P328, DOI 10.1111/j.1432-1033.1971.tb19690.x; WEYLER W, 1994, J NEURAL TRANSM-SUPP, P3; WEYLER W, 1990, BIOCHEM BIOPH RES CO, V173, P1205, DOI 10.1016/S0006-291X(05)80914-3; Wouters J, 1998, PROTEINS, V32, P97; WU HF, 1993, MOL PHARMACOL, V43, P888	27	46	50	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29499	29506		10.1074/jbc.M100431200	http://dx.doi.org/10.1074/jbc.M100431200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11371556	hybrid			2022-12-27	WOS:000170346000113
J	Blazyk, J; Wiegand, R; Klein, J; Hammer, J; Epand, RM; Epand, RF; Maloy, WL; Kari, UP				Blazyk, J; Wiegand, R; Klein, J; Hammer, J; Epand, RM; Epand, RF; Maloy, WL; Kari, UP			A novel linear amphipathic beta-sheet cationic antimicrobial peptide with enhanced selectivity for bacterial lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; PHOSPHOLIPID-BILAYERS; MEMBRANE INTERFACES; CYTOLYTIC ACTIVITY; PORE FORMATION; MAGAININ-2; ANALOGS; PROTEINS; DESIGN; PGLA	All known naturally occurring linear cationic peptides adopt an amphipathic alpha -helical conformation upon binding to lipids as an initial step in the induction of cell leakage. We designed an 18-residue peptide, (KIGAKI)(3)-NH2, that has no amphipathic character as an alpha -helix but can form a highly amphipathic beta -sheet. When bound to lipids, (KIGAKI)(3)-NH2 did indeed form a beta -sheet structure as evidenced by Fourier transform infrared and circular dichroism spectroscopy. The antimicrobial activity of this peptide was compared with that of (KIAGKIA)(3)-NH2, and it was better than that of GMASKA-GAIAGKIAKVALKAL-NH2 (PGLa) and (KLAGLAK)(3)NH2, all of which form amphipathic alpha -helices when bound to membranes. (KIGAKI)(3)-NH2 was much less effective at inducing leakage in lipid vesicles composed of mixtures of the acidic lipid, phosphatidylglycerol, and the neutral lipid, phosphatidylcholine, as compared with the other peptides. However, when phosphatidylethanolamine replaced phosphatidylcholine, the lytic potency of PGLa and the alpha -helical model peptides was reduced, whereas that of (KIGAKI)(3)-NH2 was improved. Fluorescence experiments using analogs containing a single tryptophan residue showed significant differences between (KIGAKI)(3)-NH2 and the alpha -helical peptides in their interactions with lipid vesicles. Because the data suggest enhanced selectivity between bacterial and mammalian lipids, linear amphipathic beta -sheet peptides such as (KIGAKI)3-NH2 warrant further investigation as potential antimicrobial agents.	Ohio Univ, Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA; Ohio Univ, Coll Arts & Sci, Dept Chem & Biochem, Athens, OH 45701 USA; McMaster Univ, Hlth Sci Ctr, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Genaera Corp, Plymouth Meeting, PA USA	University System of Ohio; Ohio University; University System of Ohio; Ohio University; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Blazyk, J (corresponding author), Ohio Univ, Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA.		, Richard/R-2316-2019	, Richard/0000-0002-9602-9558	NIAID NIH HHS [AI47165] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI047165] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bechinger B, 1998, BIOPHYS J, V74, P981, DOI 10.1016/S0006-3495(98)74021-4; BECHINGER B, 1993, PROTEIN SCI, V2, P2077, DOI 10.1002/pro.5560021208; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; Castano S, 2000, BBA-BIOMEMBRANES, V1463, P65, DOI 10.1016/S0005-2736(99)00175-3; CHEN HC, 1988, FEBS LETT, V236, P462, DOI 10.1016/0014-5793(88)80077-2; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CUERVO JH, 1990, PEPTIDES CHEM STRUCT, P124; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; Epand RM, 1998, BBA-REV BIOMEMBRANES, V1376, P353, DOI 10.1016/S0304-4157(98)00015-X; Hirsh DJ, 1996, BIOCHEMISTRY-US, V35, P12733, DOI 10.1021/bi961468a; HOFFMANN W, 1983, EMBO J, V2, P711, DOI 10.1002/j.1460-2075.1983.tb01489.x; Hong J, 1999, BIOCHEMISTRY-US, V38, P16963, DOI 10.1021/bi991850y; JACKSON M, 1992, BIOCHEMISTRY-US, V31, P7289, DOI 10.1021/bi00147a012; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LUDTKE SJ, 1994, BBA-BIOMEMBRANES, V1190, P181, DOI 10.1016/0005-2736(94)90050-7; Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621; MALOY WL, 1995, BIOPOLYMERS, V37, P105, DOI 10.1002/bip.360370206; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; MATSUZAKI K, 1994, BIOCHEMISTRY-US, V33, P3342, DOI 10.1021/bi00177a027; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; Oh JE, 1999, J PEPT RES, V53, P41, DOI 10.1111/j.1399-3011.1999.tb01615.x; ONO S, 1990, BIOCHIM BIOPHYS ACTA, V1022, P237, DOI 10.1016/0005-2736(90)90119-9; Oren Z, 1997, J BIOL CHEM, V272, P14643, DOI 10.1074/jbc.272.23.14643; Oren Z, 1999, EUR J BIOCHEM, V259, P360, DOI 10.1046/j.1432-1327.1999.00047.x; OSTERMAN DG, 1985, J CELL BIOCHEM, V29, P57, DOI 10.1002/jcb.240290202; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P9482, DOI 10.1021/bi00154a022; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; Sitaram N, 1999, BBA-BIOMEMBRANES, V1462, P29, DOI 10.1016/S0005-2736(99)00199-6; SORAVIA E, 1988, FEBS LETT, V228, P337, DOI 10.1016/0014-5793(88)80027-9; TYTLER EM, 1993, J BIOL CHEM, V268, P22112; White SH, 1998, METHOD ENZYMOL, V295, P62; Wieprecht T, 2000, BIOCHEMISTRY-US, V39, P442, DOI 10.1021/bi992146k; Wieprecht T, 1996, BIOCHEMISTRY-US, V35, P10844, DOI 10.1021/bi960362c; WILLIAMS RW, 1990, BIOCHEMISTRY-US, V29, P4490, DOI 10.1021/bi00470a031; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	39	129	134	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27899	27906		10.1074/jbc.M102865200	http://dx.doi.org/10.1074/jbc.M102865200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11352918	hybrid			2022-12-27	WOS:000170093400022
J	Hilber, K; Sandtner, W; Kudlacek, O; Glaaser, IW; Weisz, E; Kyle, JW; French, RJ; Fozzard, HA; Dudley, SC; Todt, H				Hilber, K; Sandtner, W; Kudlacek, O; Glaaser, IW; Weisz, E; Kyle, JW; French, RJ; Fozzard, HA; Dudley, SC; Todt, H			The selectivity filter of the voltage-gated sodium channel is involved in channel activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-CONOTOXIN-GIIIA; TRANSMEMBRANE SEGMENT IVS6; POST-REPOLARIZATION BLOCK; ULTRA-SLOW INACTIVATION; EPICARDIAL BORDER ZONE; NA+-CHANNEL; CYSTEINE MUTAGENESIS; PERIODIC PARALYSIS; LIDOCAINE BLOCK; K+-CHANNEL	Amino acids located in the outer vestibule of the voltage-gated Na+ channel determine the permeation properties of the channel. Recently, residues lining the outer pore have also been implicated in channel gating. The domain (D) IV P-loop residue alanine 1529 forms a part of the putative selectivity filter of the adult rat skeletal muscle (mu1) Na+ channel. Here we report that replacement of alanine 1529 by aspartic acid enhances entry to an ultraslow inactivated state. Ultra-slow inactivation is characterized by recovery time constants on the order of similar to 100 s from prolonged depolarizations and by the fact that entry to this state can be reduced by binding to the pore of a mutant p-conotoxin GIIIA, suggesting that ultra-slow inactivation may reflect a structural rearrangement of the outer vestibule. The voltage dependence of ultra-slow inactivation in DIV-A1529D is U-shaped, with a local maximum near -60 mV, whereas activation is maximal only above -20 mV. Furthermore, a train of brief depolarizations produces more ultra-slow inactivation than a single maintained depolarization of the same duration. These data suggest that ultra-slow inactivation emanates from "partially activated" closed states and that the P-loop in DIV may undergo a conformational change during channel activation, which is accentuated by DIV-A1529D.	Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Emory Univ, Div Cardiol, Atlanta, GA 30033 USA; Atlanta Vet Adm Hosp, Decatur, GA 30033 USA; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Chicago, Cardiac Electrophysiol Lab, Chicago, IL 60637 USA	University of Vienna; Emory University; University of Calgary; University of Chicago	Todt, H (corresponding author), Univ Vienna, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	hannes.todt@univie.ac.at	Dudley, Samuel C/A-7085-2009; Dudley, Samuel/AAR-7950-2021	Dudley, Samuel/0000-0001-5843-5961; Kudlacek, Oliver/0000-0002-3086-8551; Hilber, Karlheinz/0000-0002-3033-0874	NHLBI NIH HHS [HL-P01-20592, HL64828] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020592, R01HL064828] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDRICH RW, 1979, J PHYSIOL-LONDON, V291, P507, DOI 10.1113/jphysiol.1979.sp012828; ALDRICH RW, 1981, BIOPHYS J, V36, P519, DOI 10.1016/S0006-3495(81)84750-9; BECKER S, 1992, BIOCHEMISTRY-US, V31, P8229, DOI 10.1021/bi00150a016; Benitah JP, 1997, BIOPHYS J, V73, P603, DOI 10.1016/S0006-3495(97)78096-2; Bertoli A, 1996, EXP BRAIN RES, V110, P401; BULATKO AK, 1995, J PHYSIOL-LONDON, V484, P307, DOI 10.1113/jphysiol.1995.sp020666; CANNON SC, 1993, PFLUG ARCH EUR J PHY, V423, P155, DOI 10.1007/BF00374974; CANNON SC, 1993, NEURON, V10, P317, DOI 10.1016/0896-6273(93)90321-H; Cannon SC, 1996, TRENDS NEUROSCI, V19, P3, DOI 10.1016/0166-2236(96)81859-5; Cha A, 1999, NEURON, V22, P73, DOI 10.1016/S0896-6273(00)80680-7; Chahine M, 1998, BIOPHYS J, V75, P236, DOI 10.1016/S0006-3495(98)77510-1; CHANDLER WK, 1970, J PHYSIOL-LONDON, V211, P653, DOI 10.1113/jphysiol.1970.sp009298; Chang SY, 1996, BIOPHYS J, V70, P2581, DOI 10.1016/S0006-3495(96)79829-6; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; Chiamvimonvat N, 1996, J PHYSIOL-LONDON, V491, P51, DOI 10.1113/jphysiol.1996.sp021195; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P7; Cummins TR, 1996, BIOPHYS J, V71, P227, DOI 10.1016/S0006-3495(96)79219-6; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; DECOURSEY TE, 1990, J GEN PHYSIOL, V95, P617, DOI 10.1085/jgp.95.4.617; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Dudley SC, 2000, J GEN PHYSIOL, V116, P679, DOI 10.1085/jgp.116.5.679; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; Favre I, 1996, BIOPHYS J, V71, P3110, DOI 10.1016/S0006-3495(96)79505-X; Featherstone DE, 1996, BIOPHYS J, V71, P3098, DOI 10.1016/S0006-3495(96)79504-8; Fleidervish IA, 1996, J PHYSIOL-LONDON, V493, P83, DOI 10.1113/jphysiol.1996.sp021366; FOX JM, 1976, BIOCHIM BIOPHYS ACTA, V426, P232, DOI 10.1016/0005-2736(76)90334-5; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; French R J, 1999, Methods Enzymol, V294, P575; French RJ, 1996, NEURON, V16, P407, DOI 10.1016/S0896-6273(00)80058-6; French RJ, 1997, SER CENT ES, P67; Hanck DA, 2000, PFLUG ARCH EUR J PHY, V439, P814, DOI 10.1007/s004240051009; Hayward LJ, 1997, BIOPHYS J, V72, P1204, DOI 10.1016/S0006-3495(97)78768-X; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B., 1992, IONIC CHANNELS EXCIT; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; Horn R, 2000, J GEN PHYSIOL, V116, P461, DOI 10.1085/jgp.116.3.461; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; Jones LP, 1999, BIOPHYS J, V76, P2530, DOI 10.1016/S0006-3495(99)77407-2; Kambouris NG, 1998, J PHYSIOL-LONDON, V512, P693, DOI 10.1111/j.1469-7793.1998.693bd.x; KHODOROV BI, 1985, PROG BIOPHYS MOL BIO, V45, P57, DOI 10.1016/0079-6107(85)90005-7; Klemic KG, 1998, BIOPHYS J, V74, P1779, DOI 10.1016/S0006-3495(98)77888-9; Linford NJ, 1998, P NATL ACAD SCI USA, V95, P13947, DOI 10.1073/pnas.95.23.13947; Lipkind GM, 2000, BIOCHEMISTRY-US, V39, P8161, DOI 10.1021/bi000486w; LIPKIND GM, 1994, BIOPHYS J, V66, P1, DOI 10.1016/S0006-3495(94)80746-5; MAKIELSKI JC, 1993, BIOPHYS J, V65, P790, DOI 10.1016/S0006-3495(93)81102-0; MAROM S, 1993, RECEPTOR CHANNEL, V1, P81; Mathes C, 1997, J GEN PHYSIOL, V109, P435, DOI 10.1085/jgp.109.4.435; MATTESON DR, 1984, NATURE, V307, P468, DOI 10.1038/307468a0; MCPHEE JC, 1994, P NATL ACAD SCI USA, V91, P12346, DOI 10.1073/pnas.91.25.12346; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; Mitrovic N, 2000, J GEN PHYSIOL, V115, P707, DOI 10.1085/jgp.115.6.707; NEHER E, 1971, PFLUG ARCH EUR J PHY, V322, P35, DOI 10.1007/BF00586662; Nuss HB, 1996, J PHYSIOL-LONDON, V494, P411, DOI 10.1113/jphysiol.1996.sp021502; Nuss HB, 1995, J GEN PHYSIOL, V106, P1171, DOI 10.1085/jgp.106.6.1171; Nuss HB, 2000, BIOPHYS J, V78, P200, DOI 10.1016/S0006-3495(00)76585-4; Nuss HB, 1995, J GEN PHYSIOL, V106, P1193, DOI 10.1085/jgp.106.6.1193; Ong BH, 2000, J GEN PHYSIOL, V116, P653, DOI 10.1085/jgp.116.5.653; Patil PG, 1998, NEURON, V20, P1027, DOI 10.1016/S0896-6273(00)80483-3; PATTON DE, 1992, P NATL ACAD SCI USA, V89, P10905, DOI 10.1073/pnas.89.22.10905; PATTON DE, 1994, J BIOL CHEM, V269, P17649; PerezGarcia MT, 1997, BIOPHYS J, V72, P989, DOI 10.1016/S0006-3495(97)78751-4; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Pu JL, 1998, CIRC RES, V83, P431, DOI 10.1161/01.RES.83.4.431; Pu JL, 1997, CIRC RES, V81, P110, DOI 10.1161/01.RES.81.1.110; QUATTROCKI EA, 1994, NEURON, V12, P73, DOI 10.1016/0896-6273(94)90153-8; RUFF RL, 1987, J PHYSIOL-LONDON, V383, P339; SATIN J, 1994, BIOPHYS J, V66, P1353, DOI 10.1016/S0006-3495(94)80926-9; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; Sunami A, 2000, P NATL ACAD SCI USA, V97, P2326, DOI 10.1073/pnas.030438797; Sunami A, 1997, P NATL ACAD SCI USA, V94, P14126, DOI 10.1073/pnas.94.25.14126; Todt H, 2000, BIOPHYS J, V78, p83A; Todt H, 1999, BIOPHYS J, V76, P1335, DOI 10.1016/S0006-3495(99)77296-6; Tsushima RG, 1997, J GEN PHYSIOL, V109, P463, DOI 10.1085/jgp.109.4.463; Tsushima RG, 1997, J GEN PHYSIOL, V110, P59, DOI 10.1085/jgp.110.1.59; UKOMADU C, 1992, NEURON, V8, P663, DOI 10.1016/0896-6273(92)90088-U; Vedantham V, 1999, J GEN PHYSIOL, V113, P7, DOI 10.1085/jgp.113.1.7; Vedantham V, 2000, BIOPHYS J, V78, P2943, DOI 10.1016/S0006-3495(00)76834-2; WANG GK, 1992, J GEN PHYSIOL, V99, P1, DOI 10.1085/jgp.99.1.1; Wang SY, 1996, PFLUG ARCH EUR J PHY, V432, P692, DOI 10.1007/s004240050187; Wang SY, 1999, BIOPHYS J, V76, P3141, DOI 10.1016/S0006-3495(99)77465-5; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; Wright SN, 1998, MOL PHARMACOL, V54, P733; ZHOU JY, 1991, NEURON, V7, P775, DOI 10.1016/0896-6273(91)90280-D	84	45	46	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27831	27839		10.1074/jbc.M101933200	http://dx.doi.org/10.1074/jbc.M101933200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382756	hybrid			2022-12-27	WOS:000170093400014
J	Hong, SH; Park, SJ; Kong, HJ; Shuman, JD; Cheong, JH				Hong, SH; Park, SJ; Kong, HJ; Shuman, JD; Cheong, JH			Functional interaction of bZIP proteins and the large subunit of replication factor C in liver and adipose cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; C/EBP-ALPHA GENE; TERMINAL ADIPOCYTE DIFFERENTIATION; EUKARYOTIC DNA-REPLICATION; ACTIVATED RECEPTOR-GAMMA; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; NUCLEAR ANTIGEN; LEUCINE-ZIPPER; EXPRESSION	The transcription factor CCAAT/enhancer-binding protein-vt (C/EBP alpha) has a vital role in cell growth and differentiation. To delineate further a mechanism for C/EBP alpha -mediated differentiation, we screened C/EBP alpha -interacting proteins through far-Western screening. One of the strongest interactions was with RFC140, the large subunit of the replication factor C complex. C/EBPa specifically interacted with RFC140 from rat liver nuclear extract as determined by a combination of affinity chromatography and co-immunoprecipitation. Subsequent far-Western blotting showed that the bZIP domain of C/EBPa interacted with the DNA-binding region of RFC140. Overexpression of RFC140 in mammalian cells increased the transactivation activity of C/EBPa on both minimal and native promoters. Consistent with the enhanced transactivation, a complex of C/EBP alpha and RFC140 proteins with the cognate DNA element was detected in vitro. The specific interaction between C/EBP alpha and RFC140 was detected in the terminal differentiation of 3T3-LI preadipocytes to adipocytes. The synergistic transcription effect of these two proteins increased the promoter activity and protein expression of peroxisome proliferator-activated receptor-gamma, which is a main regulator of adipocyte differentiation. Our results demonstrate that the specific transcription factor C/EBPa and the general DNA replication factor RFC140 interact functionally and physically. This observation highlights a unique mechanism by which the levels of the general replication factor can strongly modulate the functional activity of the specific transcription factor as a coactivator.	Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; NCI, Regulat Cell Growth Lab, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21701 USA	Chonnam National University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Cheong, JH (corresponding author), Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea.							Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; Cayrol C, 1996, EMBO J, V15, P2748, DOI 10.1002/j.1460-2075.1996.tb00635.x; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DIEHL AM, 1994, GASTROENTEROLOGY, V106, P1625, DOI 10.1016/0016-5085(94)90420-0; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; GUO K, 1995, MOL CELL BIOL, V15, P3823; Hansen JB, 1999, J BIOL CHEM, V274, P2386, DOI 10.1074/jbc.274.4.2386; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HOWELL EA, 1994, MOL CELL BIOL, V14, P255, DOI 10.1128/MCB.14.1.255; Jiang MS, 2000, P NATL ACAD SCI USA, V97, P12519, DOI 10.1073/pnas.220426097; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEVAVASSEUR F, 1995, FEBS LETT, V363, P132, DOI 10.1016/0014-5793(95)00305-S; Lyle RE, 1996, BIOCHEM BIOPH RES CO, V228, P709, DOI 10.1006/bbrc.1996.1721; MCGEHEE RE, 1995, MOL ENDOCRINOL, V9, P487, DOI 10.1210/me.9.4.487; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Podust VN, 1998, J BIOL CHEM, V273, P31992, DOI 10.1074/jbc.273.48.31992; Puigserver P, 1998, EUR J CELL BIOL, V77, P117, DOI 10.1016/S0171-9335(98)80079-4; RAMOS RA, 1992, SCIENCE, V251, P288; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	42	21	21	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28098	28105		10.1074/jbc.M010912200	http://dx.doi.org/10.1074/jbc.M010912200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11356826	hybrid			2022-12-27	WOS:000170093400048
J	Leslie, EM; Ito, K; Upadhyaya, P; Hecht, SS; Deeley, RG; Cole, SPC				Leslie, EM; Ito, K; Upadhyaya, P; Hecht, SS; Deeley, RG; Cole, SPC			Transport of the beta-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1) - Requirement for glutathione or a non-sulfur-containing analog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG CARCINOGEN; EXPORT PUMP; MONOCLONAL-ANTIBODIES; SUBSTRATE-SPECIFICITY; VINCRISTINE TRANSPORT; REDUCED GLUTATHIONE; LEUKOTRIENE C-4; CDNA CLONING; CELL-LINES; GENE	Nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its metabolite 4-(methylnitrosamino)-1(3-pyridyl)-1-butanol (NNAL) play a crucial role in the induction of lung cancer, and NNAL-O-glucuronide formation and elimination are important steps in detoxification of these compounds. In the present study, we investigated the ATP-binding cassette (ABC) protein, MRP1 (ABCC1), as a candidate transporter responsible for NNAL-O-glucuronide export. MRP1 mediates the active transport of numerous GSH-, sulfate-, and glucuronide-conjugated organic anions and can transport certain xenobiotics by a mechanism that may involve co-transport with GSH. Using membrane vesicles prepared from transfected cells, we found that MRP1 transports [H-3]NNAL-O-glucuronide but is dependent on the presence of GSH (K-m 39 muM, V-max 48 pmol mg(-1) min(-1)). We also found that the sulfur atom in GSH was dispensable because transport was supported by the GSH analog, gamma -glutamyl-alpha -aminobutyryl-glycine. Despite stimulation of NNAL-O-glueuronide transport by GSH, there was no detectable reciprocal stimulation of [H-3]GSH transport. Moreover, whereas the MRP1 substrates leukotriene C-4 (LTC4) and 17 beta -estradiol 17 beta-(D-glucuronide) (E(2)17 betaG) inhibited GSH-dependent uptake of [H-3]NNAL-O-glucuronide, only [H-3]LTC4 transport was inhibited by NNAL-O-glucuronide (+GSH) and the kinetics of inhibition were complex. A mutant form of MRP1, which transports LTC4 but not E(2)17 betaG, also did not transport NNAL-O-glucuronide suggesting a commonality in the binding elements for these two glucuronidated substrates, despite their lack of reciprocal transport inhibition. Finally, the related MRP2 transported NNAL-O-glucuronide with higher efficiency than MRP1 and unexpectedly, GSH inhibited rather than stimulated uptake. These studies provide further insight into the complex interactions of the MRP-related proteins with GSH and their conjugated organic anion substrates, and extend the range of xenotoxins transported by MRP1 and MRP2 to include metabolites of known carcinogens involved in the etiology of lung and other cancers.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA	Queens University - Canada; Queens University - Canada; University of Minnesota System; University of Minnesota Twin Cities	Cole, SPC (corresponding author), Queens Univ, Canc Res Labs, Rm 328,Botterell Hall, Kingston, ON K7L 3N6, Canada.		Cole, Susan P.C./I-6389-2017; Deeley, Roger/J-4828-2012	Cole, Susan P.C./0000-0001-6571-6884; Hecht, Stephen/0000-0001-7228-1356; Leslie, Elaine/0000-0003-1825-348X				Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Buchler M, 1996, J BIOL CHEM, V271, P15091; Carmella SG, 1999, CANCER RES, V59, P3602; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Evers R, 1997, FEBS LETT, V419, P112, DOI 10.1016/S0014-5793(97)01442-7; Flens MJ, 1996, AM J PATHOL, V148, P1237; GRANT CE, 1994, CANCER RES, V54, P357; Hecht SS, 2000, P NATL ACAD SCI USA, V97, P12493, DOI 10.1073/pnas.220207697; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; HECHT SS, 1980, CANCER RES, V40, P4144; Hecht SS, 2000, CARCINOGENESIS, V21, P850, DOI 10.1093/carcin/21.4.850; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Heijn M, 1997, BBA-BIOMEMBRANES, V1326, P12, DOI 10.1016/S0005-2736(97)00003-5; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hirohashi T, 1998, MOL PHARMACOL, V53, P1068; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Jedlitschky G, 1996, CANCER RES, V56, P988; Kiuchi Y, 1998, FEBS LETT, V433, P149, DOI 10.1016/S0014-5793(98)00899-0; Konig J, 1999, HEPATOLOGY, V29, P1156, DOI 10.1002/hep.510290404; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kool M, 1997, CANCER RES, V57, P3537; LESLIE EM, 2001, IN PRESS TOXICOLOGY; Li LQ, 2000, MOL PHARMACOL, V58, P335, DOI 10.1124/mol.58.2.335; Liu GS, 2001, J BIOL CHEM, V276, P8648, DOI 10.1074/jbc.M009690200; Loe DW, 2000, BIOCHEM BIOPH RES CO, V275, P795, DOI 10.1006/bbrc.2000.3384; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Mao QC, 2000, J BIOL CHEM, V275, P34166, DOI 10.1074/jbc.M004584200; Maser E, 1996, EUR J BIOCHEM, V238, P484, DOI 10.1111/j.1432-1033.1996.0484z.x; Meger M, 1999, DRUG METAB DISPOS, V27, P471; Meiser H, 2000, Eur J Med Res, V5, P241; MURPHY SE, 1995, CHEM RES TOXICOL, V8, P772, DOI 10.1021/tx00047a018; Murphy SE, 1997, CHEM-BIOL INTERACT, V103, P153, DOI 10.1016/S0009-2797(96)03756-8; Ogawa K, 2000, AM J PHYSIOL-GASTR L, V278, pG438, DOI 10.1152/ajpgi.2000.278.3.G438; Ortiz DF, 1999, AM J PHYSIOL-GASTR L, V276, pG1493, DOI 10.1152/ajpgi.1999.276.6.G1493; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Rappa G, 1997, CANCER RES, V57, P5232; Ren Q, 2000, DRUG METAB DISPOS, V28, P1352; Renes J, 2000, BIOCHEM J, V350, P555, DOI 10.1042/0264-6021:3500555; Sakamoto H, 1999, CANCER LETT, V135, P113; Schaub TP, 1999, J AM SOC NEPHROL, V10, P1159; Staretz ME, 1997, CARCINOGENESIS, V18, P1715, DOI 10.1093/carcin/18.9.1715; Stockel B, 2000, EUR J BIOCHEM, V267, P1347, DOI 10.1046/j.1432-1327.2000.01106.x; Stride BD, 1999, J BIOL CHEM, V274, P22877, DOI 10.1074/jbc.274.32.22877; Su T, 2000, CANCER RES, V60, P5074; Suzuki H, 1998, SEMIN LIVER DIS, V18, P359, DOI 10.1055/s-2007-1007170; Upadhyaya P, 1999, CARCINOGENESIS, V20, P1577, DOI 10.1093/carcin/20.8.1577; Vazquez-Laslop N, 2000, BIOCHEM SOC T, V28, P517, DOI 10.1042/0300-5127:0280517; VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281; WALEY SG, 1956, BIOCHEM J, V64, P715, DOI 10.1042/bj0640715; WIENCH K, 1992, CARCINOGENESIS, V13, P867, DOI 10.1093/carcin/13.5.867; Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; Wijnholds J, 1998, J EXP MED, V188, P797, DOI 10.1084/jem.188.5.797; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; Zeng H, 2000, CANCER RES, V60, P4779; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200; Zheleznova EE, 2000, TRENDS BIOCHEM SCI, V25, P39, DOI 10.1016/S0968-0004(99)01514-5	68	142	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27846	27854		10.1074/jbc.M102453200	http://dx.doi.org/10.1074/jbc.M102453200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375986	hybrid			2022-12-27	WOS:000170093400016
J	Pei, Y; Hausmann, S; Ho, CK; Schwer, B; Shuman, S				Pei, Y; Hausmann, S; Ho, CK; Schwer, B; Shuman, S			The length, phosphorylation state, and primary structure of the RNA polymerase II carboxyl-terminal domain dictate interactions with mRNA capping enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; LARGEST SUBUNIT; GUANYLYLTRANSFERASE; TRIPHOSPHATASE; CTD; ASSOCIATION; COMPLEX; COMPONENT; SEQUENCE; BINDING	The carboxyl-terminal domain (CTD) of elongating RNA polymerase Il serves as a landing pad for macromolecular assemblies that regulate mRNA synthesis and processing. The capping apparatus is the first of the assemblies to act on the nascent pre-mRNA and the one for which binding of the catalytic components is most clearly dependent on CTD phosphorylation. The present study highlights a distinctive strategy of cap targeting in fission yeast whereby the triphosphatase (Pct1) and guanylyltransferase (Peel) enzymes of the capping apparatus do not interact physically with each other (as they do in budding yeast and metazoans), but instead bind independently to the phosphorylated CTD. In vivo interactions of Pct1 and Pce1 with the CTD in a two-hybrid assay require 12 and 14 tandem repeats of the CTD heptapeptide, respectively. Pct1 and Pce1 bind in vitro to synthetic CTD peptides containing phosphoserine uniquely at position 5 or doubly at positions 2 and 5 of each of four tandem YSPTSPS repeats, but they bind weakly (Pce1) or not at all (Pct1) to a peptide containing phosphoserine at position 2. These results illustrate how remodeling of the CTD phosphorylation array might influence the recruitment and dissociation of the capping enzymes during elongation. But how does the CTD structure itself dictate interactions with the RNA processing enzymes independent of the phosphorylation state? Using CTD-Ser5 phosphopeptides containing alanine substitutions at other positions of the heptad, we define essential roles for Tyr-1 and Pro-3 (but not Thr-4 or Pro-6) in the binding of Schizosaccharomyces pombe guanylyltransferase. Tyr-l is also essential for binding and allosteric activation of mammalian guanylyltransferase by CTD Ser5-PO4, whereas alanine mutations of Pro-3 and Pro-6 reduce the affinity for the allosteric CTD-binding site. These are the first structure-activity relationships deduced for an effector function of the phosphorylated CTD.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s.shuman@ski.mskcc.org	Pei, Yi/D-8998-2011; Ho, KIong/GPP-6051-2022	Pei, Yi/0000-0002-3466-760X; 	NIGMS NIH HHS [GM52470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZUMA Y, 1991, NUCLEIC ACIDS RES, V19, P461, DOI 10.1093/nar/19.3.461; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Gebara MM, 1997, J CELL BIOCHEM, V64, P390; Hirose Y, 2000, GENE DEV, V14, P1415; Ho CK, 1999, NUCLEIC ACIDS RES, V27, P4671, DOI 10.1093/nar/27.24.4671; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; Ho CK, 2000, J VIROL, V74, P5486, DOI 10.1128/JVI.74.12.5486-5494.2000; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Rickert P, 1999, ONCOGENE, V18, P1093, DOI 10.1038/sj.onc.1202399; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Schwer B, 2001, J BIOL CHEM, V276, P1857, DOI 10.1074/jbc.M006072200; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; Stiller JW, 2000, YEAST, V16, P57, DOI 10.1002/(SICI)1097-0061(20000115)16:1<57::AID-YEA509>3.0.CO;2-E; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; WEST ML, 1995, GENETICS, V140, P1223; Yamada-Okabe T, 1998, FEBS LETT, V435, P49, DOI 10.1016/S0014-5793(98)01037-0; YamadaOkabe T, 1996, MICROBIOL-UK, V142, P2515, DOI 10.1099/00221287-142-9-2515; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898; Yuryev A, 1996, GENETICS, V143, P661; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000	34	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28075	28082		10.1074/jbc.M102170200	http://dx.doi.org/10.1074/jbc.M102170200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11387325	hybrid			2022-12-27	WOS:000170093400045
J	Blom, AM; Kask, L; Dahlback, B				Blom, AM; Kask, L; Dahlback, B			Structural requirements for the complement regulatory activities of C4BP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C4B-BINDING PROTEIN; HUMAN FACTOR-H; HUMAN C4-BINDING PROTEIN; CHARGED AMINO-ACIDS; I COFACTOR FUNCTION; ALPHA-CHAIN; LIGAND-BINDING; C3B/C4B RECEPTOR; C3B INACTIVATOR; SITES	C4b-binding protein (C4BP) is a regulator of the classical complement pathway C3 convertase (C4bC2a complex). It is a disulfide-linked polymer of seven cr-chains and a unique beta -chain; the alpha- and beta -chains are composed of eight and three complement control protein (CCP) domains, respectively. To elucidate the importance of the polymeric nature of C4BP and the structural requirements for the interaction between C4b and the alpha -chain, 19 recombinant C4BP variants were created. Six truncated monomeric variants, nine polymeric variants in which individual CCPs were deleted, and finally, four variants in which double alanine residues were introduced between CCPs were functionally characterized. The smallest truncated C4BP variant still active in regulating fluid phase C4b comprised CCPI-3, The monomeric variants were less efficient than polymeric C4BP in degrading C4b on cell surfaces. All three N-terminal CCP domains contributed to the binding of C4b and mere important for full functional activity; CCP2 and CCPS were the most important. The spatial arrangements of the first CCPs were found to be important, as introduction of alanine residues between CCPs 1 and 2, CCPs 2 and 3, and CCPs 3 and 4 resulted in functional impairment. The results presented here elucidate the structural requirements of individual CCPs of C4BP, as well as their spatial arrangements within and between subunits for expression of full functional activity.	Univ Lund, Malmo Univ Hosp, Wallenberg Lab, Dept Clin Chem, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Blom, AM (corresponding author), Univ Lund, Malmo Univ Hosp, Wallenberg Lab, Dept Clin Chem, S-20502 Malmo, Sweden.		Blom, Anna/AFS-7369-2022; Blom, Anna/B-9607-2009	Blom, Anna/0000-0002-1348-1734; Kask, Lena/0000-0002-4380-4354; Dahlback, Bjorn/0000-0003-1546-0328				Accardo P, 1996, J IMMUNOL, V157, P4935; ADAMS EM, 1991, J IMMUNOL, V147, P3005; ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389; ANDERSSON M, 1991, EUR J CLIN PHARMACOL, V40, P261, DOI 10.1007/BF00315206; Berggard K, 1997, INFECT IMMUN, V65, P3638; Blom AM, 2000, MOL IMMUNOL, V37, P445, DOI 10.1016/S0161-5890(00)00059-6; Blom AM, 2000, J IMMUNOL, V164, P5328, DOI 10.4049/jimmunol.164.10.5328; Blom AM, 1999, J BIOL CHEM, V274, P19237, DOI 10.1074/jbc.274.27.19237; Brodbeck WG, 1996, J IMMUNOL, V156, P2528; CHUNG LP, 1985, BIOSCIENCE REP, V5, P855, DOI 10.1007/BF01119897; CROSSLEY LG, 1980, BIOCHEM J, V191, P173, DOI 10.1042/bj1910173; DAHLBACK B, 1983, BIOCHEM J, V209, P857, DOI 10.1042/bj2090857; DAHLBACK B, 1984, J BIOL CHEM, V259, P1631; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; FUJITA T, 1985, J IMMUNOL, V134, P3320; FUJITA T, 1983, J EXP MED, V157, P1239, DOI 10.1084/jem.157.4.1239; GIGLI I, 1976, BIOCHEM J, V157, P541, DOI 10.1042/bj1570541; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; Goodfellow RM, 2000, CLIN EXP IMMUNOL, V119, P210, DOI 10.1046/j.1365-2249.2000.01129.x; GORDON DL, 1995, J IMMUNOL, V155, P348; Hardig Y, 1997, BIOCHEM J, V323, P469; HESSING M, 1993, FEBS LETT, V317, P228, DOI 10.1016/0014-5793(93)81281-4; HILLARP A, 1988, J BIOL CHEM, V263, P12759; Hourcade D, 2000, IMMUNOPHARMACOLOGY, V49, P103, DOI 10.1016/S0162-3109(00)80296-9; IWATA K, 1995, J BIOL CHEM, V270, P15148, DOI 10.1074/jbc.270.25.15148; Jokiranta TS, 2000, J BIOL CHEM, V275, P27657; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; KRISTENSEN T, 1987, BIOCHEMISTRY-US, V26, P4668, DOI 10.1021/bi00389a012; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; KRYCH M, 1994, J BIOL CHEM, V269, P13273; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; KUHN S, 1995, J IMMUNOL, V155, P5663; Linton SM, 1999, MOL IMMUNOL, V36, P905, DOI 10.1016/S0161-5890(99)00113-3; Mikata S, 1998, MOL IMMUNOL, V35, P537, DOI 10.1016/S0161-5890(98)00046-7; NAGASAWA S, 1982, J BIOCHEM-TOKYO, V92, P1329, DOI 10.1093/oxfordjournals.jbchem.a134052; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; OGATA RT, 1993, J IMMUNOL, V150, P2273; Ram S, 2001, J EXP MED, V193, P281, DOI 10.1084/jem.193.3.281; SAHU A, 1993, MOL IMMUNOL, V30, P679, DOI 10.1016/0161-5890(93)90079-Q; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; Villoutreix BO, 1998, PROTEINS, V31, P391, DOI 10.1002/(SICI)1097-0134(19980601)31:4<391::AID-PROT6>3.0.CO;2-L; ZICCARDI RJ, 1984, J BIOL CHEM, V259, P3674	44	107	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27136	27144		10.1074/jbc.M102445200	http://dx.doi.org/10.1074/jbc.M102445200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369776	hybrid			2022-12-27	WOS:000169966900055
J	He, H; Levitzki, A; Zhu, HJ; Walker, F; Burgess, A; Maruta, H				He, H; Levitzki, A; Zhu, HJ; Walker, F; Burgess, A; Maruta, H			Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MOTILITY; RAS; SRC; EXPRESSION; TRANSMODULATION; PROTEINS; AFFINITY; ALPHA; GENE; PP1	The platelet-derived growth factor (PDGF) receptor (PDGFR) transactivates the epidermal growth factor (EGF) receptor (ErbB1) to stimulate the cell migration of fibroblasts through an unknown mechanism (Li, J., Rim, Y.N. & Bertics, P. (2000) J. Biol. Chem. 275, 2951-2958). In this paper we provide evidence that the transactivation of the EGF receptor (EGFR) by PDGFR is essential for PDGF to activate pal-activated kinase (PAK) family kinases. Fetal calf serum (10%) transiently stimulates the PAK activity in NIH 3T3 fibroblasts. The activation of PAK was completely inhibited by either PDGFR-specific inhibitor (AG1295) or EGFR-specific inhibitor (AG1478), suggesting that serum requires either the PDGF- or EGF-dependent pathway or the combination of both to activate PAK, PDGF-induced activation of PAR is completely inhibited by either AG1295 or AG1478, indicating that PDGF requires both PDGFR and EGFR for PAK activation. In support of this notion, a mouse embryo fibroblast cell line derived from the EGFR -/- mouse (from Dr. Erwin Wagner) doesn't activate PAT( in response to PDGF. Expression of human EGFR in this cell line restores the ability of the PDGF to induce PAK activation. Our results indicate that PDGF activates PAK through transactivation of ErbB1.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Hebrew University of Jerusalem	He, H (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Melbourne, Vic 3050, Australia.	Hong.He@ludwig.edu.au		Zhu, Hong-Jian/0000-0002-1478-995X				Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; COLLINS MKL, 1983, J BIOL CHEM, V258, P1689; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Dharmawardhane S, 2000, MOL BIOL CELL, V11, P3341, DOI 10.1091/mbc.11.10.3341; DOWNWARD J, 1998, MOL B INT U, V3, P171; GLICK AB, 1991, MOL CARCINOGEN, V4, P210, DOI 10.1002/mc.2940040308; He H, 2000, CANCER J, V6, P243; He H, 2001, CANCER J, V7, P191; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li J, 2000, J BIOL CHEM, V275, P2951, DOI 10.1074/jbc.275.4.2951; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Maruta H, 1999, MICROSC RES TECHNIQ, V47, P61; MARUTA H, 1991, J BIOL CHEM, V266, P11661; Mincione G, 1996, J CELL BIOCHEM, V60, P437, DOI 10.1002/(SICI)1097-4644(19960315)60:4<437::AID-JCB1>3.0.CO;2-T; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SUSA M, 1992, J BIOL CHEM, V267, P22951; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VALGEIRSDOTTIR S, 1995, J BIOL CHEM, V270, P10161, DOI 10.1074/jbc.270.17.10161; WALKER F, 1988, BIOCHEM J, V256, P109, DOI 10.1042/bj2560109; WALKER F, 1991, J BIOL CHEM, V266, P2746; Zhu HJ, 1999, J BIOL CHEM, V274, P32258, DOI 10.1074/jbc.274.45.32258	31	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26741	26744		10.1074/jbc.C100229200	http://dx.doi.org/10.1074/jbc.C100229200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356824	hybrid			2022-12-27	WOS:000169966900003
J	Boxrud, PD; Verhamme, IMA; Fay, WP; Bock, PE				Boxrud, PD; Verhamme, IMA; Fay, WP; Bock, PE			Streptokinase triggers conformational activation of plasminogen through specific interactions of the amino-terminal sequence and stabilizes the active zymogen conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; BOVINE TRYPSINOGEN; ACID-SEQUENCE; SITE; MECHANISM; PEPTIDES; BINDING; COMPLEX; TRANSITION	Cleavage of Arg(561)-Val(562) in plasminogen (Pg) generates plasmin (Pm) through a classical activation mechanism triggered by an insertion of the new amino terminus into a binding pocket in the Pg catalytic domain. Streptokinase (SK) circumvents this process and activates Pg through a unique nonproteolytic mechanism postulated to be initiated by the intrusion of IIe(1) of SK in place of Val(562). This hypothesis was evaluated in equilibrium binding and kinetic studies of Pg activation with an SK mutant lacking IIe(1) (SK2-414). SK2-414 retained the affinity of native SK for fluorescein-labeled [Lys]Pg and [Lys]Pm but induced no detectable conformational activation of Pg. The activity of SK2-414 was partially restored by the peptides SK1-2, Sg(1-5), SK1-10, and SK1-15, whereas Pg(562-569) peptides were much less effective. Active site-specific fluorescence labeling demonstrated directly that the active catalytic site was formed on the Pg zymogen by the combination of SK1-10 and Sk(2-414), whereas sequence-scrambled SK1-10 was inactive. The characterization of SK1-10 containing single Ala substitutions demonstrated the sequence specificity of the interaction. SK1-10 did not restore activity to the further truncated mutant SK55-414, which was correlated with the loss of binding affinity of SK55-414 for labeled [Lys]Pm but not for [Lys]Pg. The studies support a mechanism for conformational activation in which the insertion of II1 of SK into the Pg amino-terminal binding cleft occurs through sequence-specific interactions of the first 10 SK residues. This event and the preferentially higher affinity of SK2-414 for the activated proteinase domain of Pm are thought to function cooperatively to trigger the conformational change and stabilize the active zymogen conformation.	Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr N C3321A, Nashville, TN 37232 USA; Vet Affairs Hosp, Med Serv, Ann Arbor, MI 48109 USA	Vanderbilt University	Bock, PE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr N C3321A, Nashville, TN 37232 USA.				NHLBI NIH HHS [HL-56181, HL-10082] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056181, F32HL010082] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKJAERSIG N, 1959, J BIOL CHEM, V234, P832; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; Bock PE, 1996, J BIOL CHEM, V271, P1072, DOI 10.1074/jbc.271.2.1072; BODE W, 1976, FEBS LETT, V68, P231, DOI 10.1016/0014-5793(76)80443-7; BODE W, 1979, J MOL BIOL, V127, P357, DOI 10.1016/0022-2836(79)90227-4; Boxrud PD, 2000, J BIOL CHEM, V275, P14579, DOI 10.1074/jbc.275.19.14579; Boxrud PD, 2000, BIOCHEMISTRY-US, V39, P13974, DOI 10.1021/bi000594i; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; Fay WP, 1998, THROMB HAEMOSTASIS, V79, P985; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JACKSON KW, 1982, BIOCHEMISTRY-US, V21, P6620, DOI 10.1021/bi00269a001; KERR MA, 1976, BIOCHEMISTRY-US, V15, P5566, DOI 10.1021/bi00670a022; Khan AR, 1998, PROTEIN SCI, V7, P815; KOSOW DP, 1975, BIOCHEMISTRY-US, V20, P4459; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; NIEUWENHUIZEN W, 1989, THROMB HAEMOSTASIS, V61, P208; Peisach E, 1999, BIOCHEMISTRY-US, V38, P11180, DOI 10.1021/bi991130r; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REED GL, 1995, BIOCHEMISTRY-US, V34, P10266, DOI 10.1021/bi00032a021; TAYLOR FB, 1968, BIOCHEMISTRY-US, V7, P232, DOI 10.1021/bi00841a028; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang SG, 2000, EUR J BIOCHEM, V267, P3994, DOI 10.1046/j.1432-1327.2000.01434.x; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; Wang XQ, 2000, J MOL BIOL, V295, P903, DOI 10.1006/jmbi.1999.3397; WOHL RC, 1980, J BIOL CHEM, V255, P2005; YOUNG KC, 1995, J BIOL CHEM, V270, P29601, DOI 10.1074/jbc.270.49.29601	30	38	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26084	26089		10.1074/jbc.M101966200	http://dx.doi.org/10.1074/jbc.M101966200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11369771	hybrid			2022-12-27	WOS:000169823300061
J	Branum, ME; Reardon, JT; Sancar, A				Branum, ME; Reardon, JT; Sancar, A			DNA repair excision nuclease attacks undamaged DNA - A potential source of spontaneous mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MISMATCH REPAIR; REPLICATION FIDELITY; MAMMALIAN-CELLS; BASE DAMAGE; TRANSCRIPTION; EXCINUCLEASE; RECOGNITION; MECHANISM; LESIONS	Nucleotide excision repair is a general repair system that eliminates many dissimilar lesions from DNA. In an effort to understand substrate determinants of this repair system, we tested DNAs with minor backbone modifications using the ultrasensitive excision assay. We found that a phosphorothioate and a methylphosphonate were excised with low efficiency. Surprisingly, we also found that fragments of 23-28 nucleotides and of 12-13 nucleotides characteristic of human and Escherichia coli excision repair, respectively, were removed from undamaged DNA at a significant rate. Considering the relative abundance of undamaged DNA in comparison to damaged DNA in the course of the life of an organism, we conclude that, in general, excision from and resynthesis of undamaged DNA may exceed the excision and resynthesis caused by DNA damage. As resynthesis is invariably associated with mutations, we propose that gratuitous repair may be an important source of spontaneous mutations.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sancar, A (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Mary Ellen Jones Bldg,CB 7260, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bacolla A, 2001, J BIOL CHEM, V276, P18597, DOI 10.1074/jbc.M100845200; Beletskii A, 1996, P NATL ACAD SCI USA, V93, P13919, DOI 10.1073/pnas.93.24.13919; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; Buschta-Hedayat N, 1999, P NATL ACAD SCI USA, V96, P6090, DOI 10.1073/pnas.96.11.6090; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P7855, DOI 10.1093/nar/16.16.7855; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; DATTA A, 1995, SCIENCE, V268, P1616, DOI 10.1126/science.7777859; DAVIS BD, 1989, P NATL ACAD SCI USA, V86, P5005, DOI 10.1073/pnas.86.13.5005; DIZDAROGLU M, 1993, FEBS LETT, V315, P1, DOI 10.1016/0014-5793(93)81120-O; Douki T, 1997, CARCINOGENESIS, V18, P2385, DOI 10.1093/carcin/18.12.2385; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FIX DF, 1987, MOL GEN GENET, V209, P78, DOI 10.1007/BF00329839; Gordienko I, 1998, EMBO J, V17, P626, DOI 10.1093/emboj/17.2.626; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Hanawalt PC, 2001, MUTAT RES-DNA REPAIR, V485, P3, DOI 10.1016/S0921-8777(00)00071-9; Hess MT, 1997, P NATL ACAD SCI USA, V94, P6664, DOI 10.1073/pnas.94.13.6664; Holmquist GP, 1998, MUTAT RES-FUND MOL M, V400, P59, DOI 10.1016/S0027-5107(98)00051-7; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moolenaar GF, 1998, J BIOL CHEM, V273, P34896, DOI 10.1074/jbc.273.52.34896; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Reardon JT, 1997, NUCLEIC ACIDS RES, V25, P1015, DOI 10.1093/nar/25.5.1015; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Senturker S, 1999, FREE RADICAL BIO MED, V27, P370, DOI 10.1016/S0891-5849(99)00069-6; SMITH CA, 1993, J BIOL CHEM, V268, P11143; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; VANHOUTEN B, 1987, J BACTERIOL, V169, P540, DOI 10.1128/jb.169.2.540-545.1987; Wakasugi M, 1998, P NATL ACAD SCI USA, V95, P6669, DOI 10.1073/pnas.95.12.6669; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wyatt MD, 1999, BIOESSAYS, V21, P668, DOI 10.1002/(SICI)1521-1878(199908)21:8<668::AID-BIES6>3.3.CO;2-4; Ye N, 1999, MUTAT RES-DNA REPAIR, V435, P43, DOI 10.1016/S0921-8777(99)00022-1	37	85	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25421	25426		10.1074/jbc.M101032200	http://dx.doi.org/10.1074/jbc.M101032200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11353769	hybrid			2022-12-27	WOS:000169800700132
J	Kawakami, K; Takeshita, F; Puri, RK				Kawakami, K; Takeshita, F; Puri, RK			Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor alpha 2 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; CARCINOMA CELL-LINES; DI-LEUCINE MOTIF; CYTOPLASMIC DOMAIN; TRANSFERRIN RECEPTOR; PSEUDOMONAS EXOTOXIN; IL-13R-ALPHA-1 CHAIN; JANUS KINASE; GAMMA-CHAIN; IN-VITRO	Interleukin (IL)-13 receptor alpha2 (IL-13R alpha2) chain is an essential binding component for IL-13-mediated ligand binding. Recently, we have demonstrated that this receptor chain also plays an important role in the internalization of IL-13. To study the mechanism of IL-13 internalization, we generated mutated IL-13R alpha2 chains that targeted trileucine residues (Leu(335), Leu(336), and Leu(337)) in the transmembrane domain and a tyrosine motif (Tyr(343)) in the intracellular domain and transfected these cDNAs in COS-7 cells. Cells that expressed a C-terminally truncated IL-13R alpha2 chain (Delta 335) did not bind IL-13, suggesting that the trileucine region modulates IL-13 binding. Truncation of IL-13R alpha2 chain with a mutation in the trileucine region resulted in significantly decreased internalization compared with wild type IL-13R alpha2 chain transfected cells. COS-7 cells transfected with tyrosine motif mutants exhibited a similar internalization level compared with wild type IL-13R alpha2 chain transfected cells; however, dissociation of cell surface IL-13 was faster compared with wild type IL-13R alpha2 transfectants. These results were further confirmed by determining the cytotoxicity of a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin (IL13-PE38QQR) to cells that expressed IL-13R alpha2 chain mutants. We further demonstrate that the IL-13R alpha2 chain is not ubiquitinated and that internalization of IL-13R alpha2 did not depend on ubiquitination, Together, our findings suggest that the dileucine motif in the trileucine region and tyrosine motif participate in IL-13R alpha2 internalization in distinct manners.	US FDA, NIH, Lab Mol Tumor Biol,Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Retroviral Immunol Sect, Div Viral Prod, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Puri, RK (corresponding author), US FDA, NIH, Lab Mol Tumor Biol,Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Bldg 29B,Rm 2NN10,29 Lincoln Dr,MSC 4555, Bethesda, MD 20892 USA.	puri@cber.fda.gov						Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; Feng NP, 1998, LAB INVEST, V78, P591; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Govers P, 1998, J BIOL CHEM, V273, P16426, DOI 10.1074/jbc.273.26.16426; Hamer I, 1997, J BIOL CHEM, V272, P21685, DOI 10.1074/jbc.272.35.21685; Hart PH, 1999, EUR J IMMUNOL, V29, P2087, DOI 10.1002/(SICI)1521-4141(199907)29:07<2087::AID-IMMU2087>3.0.CO;2-J; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Hunter MG, 1999, BLOOD, V93, P440, DOI 10.1182/blood.V93.2.440.402k23_440_446; Kawakami K, 2000, HUM GENE THER, V11, P1829, DOI 10.1089/10430340050129459; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681; Kil SJ, 1999, J BIOL CHEM, V274, P3141, DOI 10.1074/jbc.274.5.3141; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kuznetsov VA, 1999, BIOPHYS J, V77, P154, DOI 10.1016/S0006-3495(99)76879-7; Levin I, 1998, FEBS LETT, V427, P164, DOI 10.1016/S0014-5793(98)00414-1; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Murata T, 1998, INT J MOL MED, V1, P551; Murata T, 1997, INT J CANCER, V70, P230, DOI 10.1002/(SICI)1097-0215(19970117)70:2<230::AID-IJC15>3.0.CO;2-M; Murata T, 1997, CELL IMMUNOL, V175, P33, DOI 10.1006/cimm.1996.1051; Murata T, 1996, J IMMUNOL, V156, P2972; Murata T, 1997, BIOCHEM BIOPH RES CO, V238, P90, DOI 10.1006/bbrc.1997.7248; Nakamura K, 1999, MOL PHARMACOL, V56, P728; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; Obiri NI, 1997, J BIOL CHEM, V272, P20251, DOI 10.1074/jbc.272.32.20251; Obiri NI, 1997, J IMMUNOL, V158, P756; Ohmori Y, 1996, J IMMUNOL, V157, P2058; Oshima Y, 2000, J BIOL CHEM, V275, P14375, DOI 10.1074/jbc.275.19.14375; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Puri RK, 1996, BLOOD, V87, P4333, DOI 10.1182/blood.V87.10.4333.bloodjournal87104333; PYTOWSKI B, 1995, J BIOL CHEM, V270, P9067, DOI 10.1074/jbc.270.16.9067; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; Thiel S, 1998, BIOCHEM J, V330, P47, DOI 10.1042/bj3300047; Thiel S, 1999, BIOCHEM J, V339, P15, DOI 10.1042/0264-6021:3390015; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017	51	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25114	25120		10.1074/jbc.M100936200	http://dx.doi.org/10.1074/jbc.M100936200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11352909	hybrid			2022-12-27	WOS:000169800700092
J	Liu, Y; Ranish, JA; Aebersold, R; Hahn, S				Liu, Y; Ranish, JA; Aebersold, R; Hahn, S			Yeast nuclear extract contains two major forms of RNA polymerase II mediator complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; HOLOENZYME; PROTEINS; REQUIREMENT; REGULATORS; IDENTIFICATION; COACTIVATORS; COMPONENTS; DATABASE	The yeast Mediator complex is required for transcription by RNA polymerase II (pol II) in vivo and in vitro. This complex of over 20 polypeptides associates with pol II and is recruited to transcription complexes at promoters. Previous isolations of yeast Mediator-containing complexes in different laboratories have identified several distinct complexes. To identify the major forms of Mediator in yeast, Mediator was isolated from nuclear extracts using a two-step chromatographic procedure, avoiding ion exchange chromatography and high salt conditions to prevent dissociation of subunits during purification. Components of the Mediator complexes were identified by mass spectrometry and Western analysis. The major form of Mediator, termed pol II Med, contained pol II and Mediator, including the Srb8-11 module. A second lower molecular size complex was also identified, termed Mediator core (Medc), which lacked pol II, Srb8-11, Rox3, Nut1, and the Rgr1 module. Both of these complexes were active in transcription in vitro, although the Medc complex had significantly lower activity and could compete with the activity of the pol II Med complex in vitro.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Howard Hughes Med Inst, Seattle, WA 98109 USA; Inst Syst Biol, Seattle, WA 98105 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Institute for Systems Biology (ISB)	Hahn, S (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,Mailstop A1-162,POB 19024, Seattle, WA 98109 USA.			Hahn, Steven/0000-0001-7240-2533				Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Chang MP, 1999, MOL CELL BIOL, V19, P1056; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; GELBART M, 2001, IN PRESS MOL CELL BI; Gustafsson CM, 1998, J BIOL CHEM, V273, P30851, DOI 10.1074/jbc.273.47.30851; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Han SJ, 1999, MOL CELL BIOL, V19, P979; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; Koleske AJ, 1996, METHOD ENZYMOL, V273, P176; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; Lee DK, 1999, GENE DEV, V13, P2934, DOI 10.1101/gad.13.22.2934; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Lee YC, 1999, MOL CELL BIOL, V19, P2967; Lee YC, 1998, MOL CELL BIOL, V18, P5364, DOI 10.1128/MCB.18.9.5364; Li Y, 1996, METHOD ENZYMOL, V273, P172; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; McNeil JB, 1998, GENE DEV, V12, P2510, DOI 10.1101/gad.12.16.2510; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; RANISH JA, 1991, J BIOL CHEM, V266, P19320; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; THOMPSON CM, 1993, CELL, V73, P1367; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603	43	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7169	7175		10.1074/jbc.M009586200	http://dx.doi.org/10.1074/jbc.M009586200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11383511	hybrid			2022-12-27	WOS:000167442900045
J	Hille, R; Anderson, RF				Hille, R; Anderson, RF			Coupled Electron/Proton transfer in complex flavoproteins - Solvent kinetic isotope effect studies of electron transfer in xanthine oxidase and trimethylamine dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTERS; SITE-DIRECTED MUTAGENESIS; MOLYBDENUM ENZYMES; CRYSTAL-STRUCTURE; REDUCTION POTENTIALS; RATE CONSTANTS; MECHANISM; FLAVIN; OXIDATION; OXIDOREDUCTASE	A solvent kinetic isotope effect study of electron transfer in two complex flavoproteins, xanthine oxidase and trimethylamine dehydrogenase, has been undertaken. With xanthine oxidase, electron transfer from the molybdenum center to the proximal iron-sulfur center of the enzyme occurs with a modest solvent kinetic isotope effect of 2.2, indicating that electron transfer out of the molybdenum center is at least partially coupled to deprotonation of the Mo(V) donor. A Marcus-type analysis yields a decay factor, beta, of 1.4 Angstrom (-1), indicating that, although the pyranopterin cofactor of the molybdenum center forms a nearly contiguous covalent bridge from the molybdenum atom to the proximal iron-sulfur center of the enzyme, it affords no exceptionally effective mode of electron transfer between the two centers. For trimethylamine dehydrogenase, rates of electron equilibration between the flavin and iron-sulfur center of the one-electron reduced enzyme have been determined, complementing previous studies of electron transfer in the two-electron reduced form. The results indicate a substantial solvent kinetic isotope effect of 10 +/- 4, consistent with a model for electron transfer that involves discrete protonation/deprotonation and electron transfer steps. This contrasts to the behavior seen with xanthine oxidase, and the basis for this difference is discussed in the context of the structures for the two proteins and the ionization properties of their flavin sites. With xanthine oxidase, a rationale is presented as to why it is desirable in certain cases that the physical layout of redox-active sites not be uniformly increasing in reduction potential in the direction of physiological electron transfer.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Univ Auckland, Dept Chem, Auckland, New Zealand	University System of Ohio; Ohio State University; University of Auckland	Hille, R (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059953, R01GM058481] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58481, GM59953] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RF, 2000, J BIOL CHEM, V275, P30781, DOI 10.1074/jbc.M001256200; ANDERSON RF, 1986, J BIOL CHEM, V261, P5870; ANDERSON RF, 1984, J CHEM SOC FARAD T 1, V80, P2693, DOI 10.1039/f19848002693; ANDERSON RF, 1987, FLAVINS FLAVOPROTEIN, P279; BORDAS J, 1980, BIOCHEM J, V191, P499, DOI 10.1042/bj1910499; BRAY RC, 1969, BIOCHEM J, V114, P725, DOI 10.1042/bj1140725; Caldeira J, 2000, BIOCHEMISTRY-US, V39, P2700, DOI 10.1021/bi9921485; CAMMACK R, 1976, BIOCHEM J, V157, P469, DOI 10.1042/bj1570469; CRAMER SP, 1985, J AM CHEM SOC, V107, P8164, DOI 10.1021/ja00312a059; CRAMMER SP, 1981, J AM CHEM SOC, V102, P7721; Cukier RI, 1996, J PHYS CHEM-US, V100, P15428, DOI 10.1021/jp961025g; Cukier RI, 1998, ANNU REV PHYS CHEM, V49, P337, DOI 10.1146/annurev.physchem.49.1.337; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Gremer L, 2000, J BIOL CHEM, V275, P1864, DOI 10.1074/jbc.275.3.1864; GUTFREUND H, 1977, ENZYMES PHYSICAL PRI, P173; HILLE R, 1991, J BIOL CHEM, V266, P5608; HILLE R, 1985, J BIOL CHEM, V260, P569; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HILLE R, 1991, BIOCHEMISTRY-US, V30, P8522, DOI 10.1021/bi00099a004; HILLE R, 1986, J BIOL CHEM, V261, P1241; HILLE R, 1981, J BIOL CHEM, V257, P8933; Huber R, 1996, P NATL ACAD SCI USA, V93, P8846, DOI 10.1073/pnas.93.17.8846; Ilich P, 1999, J PHYS CHEM B, V103, P5406, DOI 10.1021/jp9904825; Iwasaki T, 2000, J BIOCHEM, V127, P771, DOI 10.1093/oxfordjournals.jbchem.a022669; Jones RM, 1999, INORG CHEM, V38, P4963, DOI 10.1021/ic990154j; KASPRZAK AA, 1983, BIOCHEM J, V211, P15870; KIM JH, 1993, J BIOL CHEM, V268, P44; LIM LW, 1986, J BIOL CHEM, V261, P5140; LOWE DJ, 1978, BIOCHEM J, V169, P471, DOI 10.1042/bj1690471; LOWE DJ, 1972, BIOCHEM J, V130, P239, DOI 10.1042/bj1300239; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARCUS RA, 1965, J CHEM PHYS, V43, P679, DOI 10.1063/1.1696792; MASSEY V, 1969, J BIOL CHEM, V244, P1682; Moser C C, 2000, Subcell Biochem, V35, P1; MOSER CC, 1995, J BIOENERG BIOMEMBR, V27, P263, DOI 10.1007/BF02110096; MULAZZANI QG, 1986, J PHYS CHEM-US, V90, P5347, DOI 10.1021/j100412a090; OLSON JS, 1974, J BIOL CHEM, V249, P4363; PACE CP, 1991, ARCH BIOCHEM BIOPHYS, V287, P97, DOI 10.1016/0003-9861(91)90393-W; PALMER G, 1969, J BIOL CHEM, V244, P2614; Pershad HR, 1999, BIOCHEMISTRY-US, V38, P8992, DOI 10.1021/bi990108v; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; ROHLFS RJ, 1995, J BIOL CHEM, V270, P22196, DOI 10.1074/jbc.270.38.22196; ROHLFS RJ, 1991, J BIOL CHEM, V266, P15244; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; Rousset M, 1998, P NATL ACAD SCI USA, V95, P11625, DOI 10.1073/pnas.95.20.11625; SCHULER RH, 1980, J PHYS CHEM-US, V84, P2088, DOI 10.1021/j100453a020; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; Stiefel E. I., 1977, PROG INORG CHEM, V21, P1; STIEFEL EI, 1973, P NATL ACAD SCI USA, V70, P988, DOI 10.1073/pnas.70.4.988; Thauer RK, 1996, CHEM REV, V96, P3031, DOI 10.1021/cr9500601; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Wilson EK, 1997, BIOCHEMISTRY-US, V36, P41, DOI 10.1021/bi961224q	53	28	29	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31193	31201		10.1074/jbc.M100673200	http://dx.doi.org/10.1074/jbc.M100673200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11395485	hybrid			2022-12-27	WOS:000170472900080
J	Wright, SK; Viola, RE				Wright, SK; Viola, RE			Alteration of the specificity of malate dehydrogenase by chemical modulation of an active site arginine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; LACTATE-DEHYDROGENASE; AMINO-ACIDS; QUANTITATION; RESOLUTION; PROTEINS; COMPLEX; MODEL	Malate dehydrogenase from Escherichia coli is highly specific for the oxidation of malate to oxaloacetate. The technique of site-specific modulation has been used to alter the substrate binding site of this enzyme. Introduction of a cysteine in place of the active site binding residue arginine 153 results in a mutant enzyme with diminished catalytic activity, but with K-m values for malate and oxaloacetate that are surprisingly unaffected. Reaction of this introduced cysteine with a series of amino acid analog reagents leads to the incorporation of a range of functional groups at the active site of malate dehydrogenase. The introduction of a positively charged group such as an amine or an amidine at this position results in improved affinity for several inhibitors over that observed with the native enzyme. However, the recovery of catalytic activity is less dramatic, with less than one third of the native activity achieved with the optimal reagents. These modified enzymes do have altered substrate specificity, with a-ketoglutarate and hydroxypyruvate no longer functioning as alternative substrates.	Univ Toledo, Dept Chem, Toledo, OH 43606 USA	University System of Ohio; University of Toledo	Viola, RE (corresponding author), Univ Toledo, Dept Chem, 2801 W Bancroft St, Toledo, OH 43606 USA.		Viola, Ronald/C-5904-2011					Bell JK, 2001, J BIOL CHEM, V276, P31156, DOI 10.1074/jbc.M100902200; BOERNKE WE, 1995, ARCH BIOCHEM BIOPHYS, V322, P43, DOI 10.1006/abbi.1995.1434; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GOWARD CR, 1994, PROTEIN SCI, V3, P1883, DOI 10.1002/pro.5560031027; GRAU UM, 1981, J MOL BIOL, V151, P289, DOI 10.1016/0022-2836(81)90516-7; HALL MD, 1991, J MOL BIOL, V220, P551, DOI 10.1016/0022-2836(91)90099-R; HALL MD, 1992, J MOL BIOL, V226, P867, DOI 10.1016/0022-2836(92)90637-Y; JONES DH, 1993, PCR PROTOCOLS CURREN, P269; NICHOLLS DJ, 1992, BIOCHEM BIOPH RES CO, V189, P1057, DOI 10.1016/0006-291X(92)92311-K; Schindler JF, 1996, J PROTEIN CHEM, V15, P737, DOI 10.1007/BF01887147; TARRAGONAFIOL A, 1993, PROTEIN ENG, V6, P901, DOI 10.1093/protein/6.8.901; WAKO H, 1994, J MOL BIOL, V238, P682, DOI 10.1006/jmbi.1994.1329; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; Wright SK, 1998, ANAL BIOCHEM, V265, P8, DOI 10.1006/abio.1998.2858; WRIGHT SK, 1995, ARCH BIOCHEM BIOPHYS, V321, P289, DOI 10.1006/abbi.1995.1397; Wright SK, 2000, J BIOL CHEM, V275, P31689, DOI 10.1074/jbc.M003652200	18	16	19	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31151	31155		10.1074/jbc.M100892200	http://dx.doi.org/10.1074/jbc.M100892200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11389140	hybrid			2022-12-27	WOS:000170472900074
J	Craggs, G; Finan, PM; Lawson, D; Wingfield, J; Perera, T; Gadher, S; Totty, NF; Kellie, S				Craggs, G; Finan, PM; Lawson, D; Wingfield, J; Perera, T; Gadher, S; Totty, NF; Kellie, S			A nuclear SH3 domain-binding protein that colocalizes with mRNA splicing factors and intermediate filament-containing perinuclear networks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; PHAGOCYTE NADPH OXIDASE; PROLINE-RICH PEPTIDES; TYROSINE KINASES; SIGNALING MOLECULES; CRYSTAL-STRUCTURES; SRC; COMPONENTS; IDENTIFICATION; TRANSCRIPTION	A protein (SNP70) has been isolated that binds to the Src homology domain 3 of p47(phox), p85 alpha, and c-src. Cloning and sequencing of the polypeptide revealed it to be a 70-kDa protein that has a number of potential domains, including Src homology 3 binding motifs and several nuclear localization signals. Immunofluorescence using anti-peptide antibodies revealed SNP70 to be primarily concentrated in the nucleus but excluded from nucleoli, in interphase cells. However, it was distributed throughout the cytoplasm in dividing cells. Extraction and subfractionation experiments indicated that SNP70 did not bind directly to DNA but did bind to poly(G)-rich oligonucleotides and was resistant to extraction with nonionic detergents but was solubilized by treatment with RNase,. high salt, or ammonium sulfate. Double-immunofluorescence experiments showed that SNP70 co-localized with two pre-mRNA splicing factors SC35 and U2B " within the nucleus. A population of SNP70 was found outside the nucleus, and double-immunofluorescence and immunoelectron microscopy demonstrated that it associated with vimentin-containing intermediate filaments, particularly those surrounding the nucleus. The data suggest that SNP70 associates with nuclear or perinuclear filaments and may play a role in the regulation of pre-mRNA processing.	Yamanouchi Res Inst, Oxford OX4 4XS, England; UCL, Sch Med, Dept Mol Pathol, London W1, England; UCL, Ludwig Inst Canc Res, London W1P 8BT, England	University of London; University College London; UCL Medical School; Ludwig Institute for Cancer Research; University of London; University College London	Kellie, S (corresponding author), Yamanouchi Res Inst, Littlemore Pk, Oxford OX4 4XS, England.	skellie@yam-res.co.uk	Kellie, Stuart/A-6036-2010; Wingfield, Jonathan/AAA-2246-2020	Kellie, Stuart/0000-0002-8163-1474				BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FINAN P, 1994, J BIOL CHEM, V269, P13752; Finan P, 1996, J MOL BIOL, V261, P173, DOI 10.1006/jmbi.1996.0450; Finan PM, 1996, FEBS LETT, V389, P141, DOI 10.1016/0014-5793(96)00552-2; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HABETS WJ, 1989, J IMMUNOL, V143, P2560; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HOBERT O, 1994, J BIOL CHEM, V269, P20225; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; Komuro A, 1999, J BIOL CHEM, V274, P36513, DOI 10.1074/jbc.274.51.36513; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lawe DC, 1997, ONCOGENE, V14, P223, DOI 10.1038/sj.onc.1200821; LAWSON D, 1983, J CELL BIOL, V97, P1891, DOI 10.1083/jcb.97.6.1891; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; Misteli T, 2000, J CELL SCI, V113, P1841; Misteli T, 1998, CURR OPIN CELL BIOL, V10, P323, DOI 10.1016/S0955-0674(98)80007-0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENMAN S, 1995, P NATL ACAD SCI USA, V92, P5251, DOI 10.1073/pnas.92.12.5251; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Stein GS, 2000, J CELL SCI, V113, P2527; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Wilson L, 1997, INFLAMM RES, V46, P265, DOI 10.1007/s000110050185; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30552	30560		10.1074/jbc.M103142200	http://dx.doi.org/10.1074/jbc.M103142200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11375989	hybrid			2022-12-27	WOS:000170558000124
J	Mitrasinovic, OM; Perez, GV; Zhao, FF; Lee, YL; Poon, C; Murphy, GM				Mitrasinovic, OM; Perez, GV; Zhao, FF; Lee, YL; Poon, C; Murphy, GM			Overexpression of macrophage colony-stimulating factor receptor on microglial cells induces an inflammatory response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ORGANOTYPIC SLICE CULTURES; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; ALZHEIMERS-DISEASE; FACTOR-I; HUMAN MONOCYTES; MOUSE MODEL; CYTOKINE PRODUCTION; INTERFERON-GAMMA	Microglia are important in the inflammatory response in Alzheimer's disease (AD). We showed previously that macrophage colony-stimulating factor receptor (M-CSFR), encoded by the c-fins protooncogene, is overexpressed on microglia surrounding amyloid beta (A beta) deposits in the APP(V717F) mouse model for AD. The M-CSFR is also increased on microglia after experimental brain injury and in AD. To determine the relevance of these findings, we transiently expressed M-CSFR on murine BV-2 and human SV-A3 microglial cell lines using an SV40-promoted c-fms construct. M-CSFR overexpression resulted in microglial proliferation and increased expression of inducible nitric-oxide synthase, the proinflammatory cytokines interleukin-1 alpha, macrophage inflammatory protein 1-alpha, and interleukin-6 and of macrophage colony-stimulating factor (M-CSF) itself. Antibody neutralization of M-CSF showed that the M-CSFR-induced proinflammatory response was dependent on M-CSF in the culture media. By using a co-culture of c-fins-transfected murine microglia and rat organotypic hippocampal slices and. a species-specific real time reverse transcriptase-polymerase chain reaction assay and enzyme-linked immunosorbent assay, we showed that M-CSFR overexpression on exogenous microglia induced expression of interleukin-1 alpha by the organotypic culture. These results show that increased M-CSFR expression induces microglial proliferation, cytokine expression, and a paracrine inflammatory response, suggesting that in APP(V717F) mice increased M-CSFR on microglia could be an important factor in Ap-induced inflammatory response.	Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Neurosci Res Labs, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Murphy, GM (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Neurosci Res Labs, MSLS P-104, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057833] Funding Source: NIH RePORTER; NIMH NIH HHS [MH57833] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; AKIYAMA H, 1994, BRAIN RES, V639, P171, DOI 10.1016/0006-8993(94)91779-5; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Anthony JC, 2000, NEUROLOGY, V54, P2066, DOI 10.1212/WNL.54.11.2066; ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; Bales KR, 2000, NEUROBIOL AGING, V21, P427, DOI 10.1016/S0197-4580(00)00143-3; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bitting L, 1996, J BIOL CHEM, V271, P16084, DOI 10.1074/jbc.271.27.16084; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Bornemann KD, 2001, AM J PATHOL, V158, P63, DOI 10.1016/S0002-9440(10)63945-4; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; CARLBERG K, 1994, MOL BIOL CELL, V5, P81, DOI 10.1091/mbc.5.1.81; CARPENTER AF, 1993, J NEUROPATH EXP NEUR, V52, P601, DOI 10.1097/00005072-199311000-00007; CHUNG Y, 1994, J NEUROIMMUNOL, V52, P9; Coltman BW, 1996, INT J DEV NEUROSCI, V14, P707, DOI 10.1016/S0736-5748(96)00071-8; Czapiga M, 1999, J NEUROSCI RES, V56, P644, DOI 10.1002/(SICI)1097-4547(19990615)56:6<644::AID-JNR10>3.0.CO;2-9; Ding M, 1997, MOL PSYCHIATR, V2, P117, DOI 10.1038/sj.mp.4000222; Ding MZ, 1997, J BIOL CHEM, V272, P11327; Du Y, 2000, NEUROLOGY, V55, P480, DOI 10.1212/WNL.55.4.480; Eikelenboom P, 1999, EXP GERONTOL, V34, P453, DOI 10.1016/S0531-5565(99)00022-4; Frautschy SA, 1998, AM J PATHOL, V152, P307; Gahtan E, 1999, NEUROSCI BIOBEHAV R, V23, P615, DOI 10.1016/S0149-7634(98)00058-X; GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205; GIULIAN D, 1988, J NEUROSCI, V8, P4707; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Good PF, 1996, AM J PATHOL, V149, P21; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Grimaldi LME, 2000, ANN NEUROL, V47, P361, DOI 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.3.CO;2-E; HAGA S, 1989, ACTA NEUROPATHOL, V77, P569, DOI 10.1007/BF00687883; Hamilton JA, 1997, IMMUNOL TODAY, V18, P313, DOI 10.1016/S0167-5699(97)01084-0; HAO C, 1990, J NEUROSCI RES, V27, P314, DOI 10.1002/jnr.490270310; Keshava N, 1999, J SOC GYNECOL INVEST, V6, P41, DOI 10.1016/S1071-5576(98)00041-0; Kloss CUA, 1997, J NEUROSCI RES, V49, P248; Lee SC, 1999, J NEUROPATH EXP NEUR, V58, P1163, DOI 10.1097/00005072-199911000-00006; LEE SC, 1993, J IMMUNOL, V150, P2659; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; Licastro F, 2000, J NEUROIMMUNOL, V103, P97, DOI 10.1016/S0165-5728(99)00226-X; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Liu J, 1996, J IMMUNOL, V157, P3569; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Lorton D, 1996, J NEUROIMMUNOL, V67, P21, DOI 10.1016/S0165-5728(96)00030-6; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCGEER PL, 1989, CAN J NEUROL SCI, V16, P516, DOI 10.1017/S0317167100029863; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Meda L, 1999, J NEUROIMMUNOL, V93, P45, DOI 10.1016/S0165-5728(98)00188-X; MERRILL JE, 1991, DEV NEUROSCI-BASEL, V13, P130, DOI 10.1159/000112150; MURPHY GM, 1995, J NEUROSCI RES, V40, P755, DOI 10.1002/jnr.490400607; Murphy GM, 1998, J BIOL CHEM, V273, P20967, DOI 10.1074/jbc.273.33.20967; Murphy GM, 2000, AM J PATHOL, V157, P895, DOI 10.1016/S0002-9440(10)64603-2; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.0.CO;2-G; NOHAVA K, 1992, EUR J IMMUNOL, V22, P2539, DOI 10.1002/eji.1830221012; O'Barr S, 2000, J NEUROIMMUNOL, V109, P87, DOI 10.1016/S0165-5728(00)00291-5; Peterson PK, 1997, J INFECT DIS, V175, P478, DOI 10.1093/infdis/175.2.478; Pratico D, 2000, NEUROBIOL AGING, V21, P441, DOI 10.1016/S0197-4580(00)00141-X; Raivich G, 1998, J COMP NEUROL, V395, P342, DOI 10.1002/(SICI)1096-9861(19980808)395:3<342::AID-CNE6>3.0.CO;2-2; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; SAWADA M, 1990, BRAIN RES, V509, P119, DOI 10.1016/0006-8993(90)90317-5; SHAFITZAGARDO B, 1993, INT J DEV NEUROSCI, V11, P189, DOI 10.1016/0736-5748(93)90078-R; SHENG JG, 1995, NEUROPATH APPL NEURO, V21, P290, DOI 10.1111/j.1365-2990.1995.tb01063.x; Smith MA, 1997, J NEUROSCI, V17, P2653; Stacey KJ, 1996, J IMMUNOL, V157, P2116; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Szabo C, 1995, Adv Pharmacol, V34, P113; THERY C, 1992, J NEUROCHEM, V59, P1183, DOI 10.1111/j.1471-4159.1992.tb08366.x; ULVESTAD E, 1994, J NEUROPATH EXP NEUR, V53, P492, DOI 10.1097/00005072-199409000-00008; vanMuiswinkel FL, 1996, J NEUROCHEM, V66, P2468; Wallace MN, 1997, EXP NEUROL, V144, P266, DOI 10.1006/exnr.1996.6373; Wang YQ, 1999, J NEUROSCI RES, V57, P616, DOI 10.1002/(SICI)1097-4547(19990901)57:5<616::AID-JNR4>3.0.CO;2-E; Weltzien RB, 2000, J NEUROSCI RES, V59, P522, DOI 10.1002/(SICI)1097-4547(20000215)59:4<522::AID-JNR7>3.3.CO;2-C; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WILLIAMS K, 1992, J NEUROPATH EXP NEUR, V51, P538, DOI 10.1097/00005072-199209000-00009; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296	73	48	58	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30142	30149		10.1074/jbc.M104265200	http://dx.doi.org/10.1074/jbc.M104265200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11387343	hybrid			2022-12-27	WOS:000170558000073
J	Wu, X; Davis, GE; Meininger, GA; Wilson, E; Davis, MJ				Wu, X; Davis, GE; Meininger, GA; Wilson, E; Davis, MJ			Regulation of the L-type calcium channel by alpha(5)beta(1) integrin requires signaling between focal adhesion proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TYROSINE KINASE INHIBITOR; EXTRACELLULAR-MATRIX MOLECULES; ION CHANNELS; C-SRC; POTASSIUM CHANNEL; SODIUM-CHANNELS; CA2+ CHANNELS; K+ CHANNEL; PHOSPHORYLATION	The L-type calcium channel is the major calcium influx pathway in vascular smooth muscle and is regulated by integrin ligands, suggesting an important link between extracellular matrix and vascular tone regulation in tissue injury and remodeling. We examined the role of integrin-linked tyrosine kinases and focal adhesion proteins in regulation of L-type calcium current in single vascular myocytes. Soluble tyrosine kinase inhibitors blocked the increase in current produced by alpha (5) integrin antibody or fibronectin, whereas tyrosine phosphatase inhibition enhanced the effect. Cell dialysis with an antibody to focal adhesion kinase or with FRNK, the C-terminal noncatalytic domain of focal adhesion kinase, produced moderate (24 or 18%, respectively) inhibition of basal current but much greater inhibition (63 or 68%, respectively) of integrin-enhanced current. A c-Src antibody and peptide inhibitors of the Src homology-2 domain or a putative Src tyrosine phosphorylation site on the channel produced similar inhibition. Antibodies to the cytoskeletal proteins paxillin and vinculin, but not a-actinin, inhibited integrin-dependent current by 65-80%. Therefore, alpha (5)beta (1). integrin appears to regulate a tyrosine phosphorylation cascade involving Src and various focal adhesion proteins that control the function of the L-type calcium channel. This interaction may represent a novel mechanism for control of calcium influx in vascular smooth muscle and other cell types.	Texas A&M Univ, Hlth Sci Ctr, Dept Med Physiol, College Stn, TX 77843 USA; Texas A&M Univ, Hlth Sci Ctr, Cardiovasc Res Inst, College Stn, TX 77843 USA; Texas A&M Univ, Hlth Sci Ctr, Dept Pathol & Lab Med, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Davis, MJ (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Med Physiol, 336 Reynolds Med Bldg, College Stn, TX 77843 USA.			wu, xin/0000-0002-5005-6358	NHLBI NIH HHS [HL-55050, HL-59971, HL-60180, HL-46502] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060180, R01HL046502, R01HL059971] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Arnoult C, 1997, EMBO J, V16, P1593, DOI 10.1093/emboj/16.7.1593; Bence-Hanulec KK, 2000, NEURON, V27, P121, DOI 10.1016/S0896-6273(00)00014-3; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; Bowlby MR, 1997, J GEN PHYSIOL, V110, P601, DOI 10.1085/jgp.110.5.601; Chicurel ME, 1998, NATURE, V392, P730, DOI 10.1038/33719; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; DAngelo G, 1997, AM J PHYSIOL-HEART C, V273, pH175, DOI 10.1152/ajpheart.1997.273.1.H175; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; Doughty JM, 1998, J PHYSIOL-LONDON, V507, P433, DOI 10.1111/j.1469-7793.1998.433bt.x; Ekinci FJ, 1999, J BIOL CHEM, V274, P30322, DOI 10.1074/jbc.274.42.30322; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Evans GJO, 1999, EUR J NEUROSCI, V11, P279, DOI 10.1046/j.1460-9568.1999.00427.x; FLEMING I, 1995, CIRC RES, V76, P522, DOI 10.1161/01.RES.76.4.522; Fraser IDC, 1999, NEURON, V23, P423, DOI 10.1016/S0896-6273(00)80795-3; Gerhardstein BL, 2000, J BIOL CHEM, V275, P8556, DOI 10.1074/jbc.275.12.8556; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hill MA, 1996, J PHARMACOL EXP THER, V276, P867; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Hu XQ, 1998, J BIOL CHEM, V273, P5337, DOI 10.1074/jbc.273.9.5337; Huang RQ, 2000, NEUROPHARMACOLOGY, V39, P2195, DOI 10.1016/S0028-3908(00)00046-0; Hughes AD, 1995, J VASC RES, V32, P353, DOI 10.1159/000159111; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; Levitan IB, 1999, ADV SEC MESS PHOSPH, V33, P3; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Ling SZ, 2000, J BIOL CHEM, V275, P30683, DOI 10.1074/jbc.M004292200; Maguire G, 1998, NEUROREPORT, V9, P665, DOI 10.1097/00001756-199803090-00019; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MIRONNEAU J, 1995, CELL SIGNAL, V7, P471, DOI 10.1016/0898-6568(95)00014-G; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Mogford JE, 1997, J CLIN INVEST, V100, P1647, DOI 10.1172/JCI119689; Mogford JE, 1996, CIRC RES, V79, P821, DOI 10.1161/01.RES.79.4.821; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Paillart C, 1997, J PHARMACOL EXP THER, V280, P521; RAE JL, 1991, NEWS PHYSIOL SCI, V6, P273; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Rogalski SL, 2000, J BIOL CHEM, V275, P25082, DOI 10.1074/jbc.M000183200; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; Sachs F, 1997, SOC GEN PHY, V52, P209; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SELINFREUND RH, 1994, MOL PHARMACOL, V45, P1215; SMIRNOV SV, 1995, CIRC RES, V76, P310, DOI 10.1161/01.RES.76.2.310; Srinivasan J, 1998, P NATL ACAD SCI USA, V95, P15753, DOI 10.1073/pnas.95.26.15753; Strauss O, 2000, BIOCHEM BIOPH RES CO, V270, P806, DOI 10.1006/bbrc.2000.2513; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Vuori K, 1998, J MEMBRANE BIOL, V165, P191, DOI 10.1007/s002329900433; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wijetunge S, 1996, FEBS LETT, V399, P63, DOI 10.1016/S0014-5793(96)01177-5; Wijetunge S, 1995, BIOCHEM BIOPH RES CO, V217, P1039, DOI 10.1006/bbrc.1995.2874; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; XIONG ZL, 1995, J MOL CELL CARDIOL, V27, P75, DOI 10.1016/S0022-2828(08)80009-0; Xu WX, 1996, PFLUG ARCH EUR J PHY, V432, P159, DOI 10.1007/s004240050119; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	60	137	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30285	30292		10.1074/jbc.M102436200	http://dx.doi.org/10.1074/jbc.M102436200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11382763	hybrid			2022-12-27	WOS:000170558000090
J	Ballesteros, JA; Jensen, AD; Liapakis, G; Rasmussen, SGF; Shi, L; Gether, U; Javitch, JA				Ballesteros, JA; Jensen, AD; Liapakis, G; Rasmussen, SGF; Shi, L; Gether, U; Javitch, JA			Activation of the beta(2)-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2) ADRENERGIC-RECEPTOR; CONSTITUTIVE ACTIVATION; STRUCTURAL INSTABILITY; HORMONE RECEPTOR; ALPHA-HELICES; ALPHA(1B)-ADRENERGIC RECEPTOR; BINDING-SITES; DRY MOTIF; RHODOPSIN	The movements of transmembrane segments (TMs) 3 and 6 at the cytoplasmic side of the membrane play an important role in the activation of G-protein-coupled receptors. Here we provide evidence for the, existence of an ionic lock that constrains the relative mobility of the cytoplasmic ends of TM3 and TM6 in the inactive state of the beta (2)-adrenergic receptor. We propose that the highly conserved Arg-131(3.50) at the cytoplasmic end of TM3 interacts both with the adjacent Asp-130(3.49) and with Glu268(6.30) at the cytoplasmic end of TM6. Such a network of ionic interactions has now been directly supported by the high-resolution structure of the inactive state of rhodopsin. We hypothesized that the network of interactions would serve to constrain the receptor in the inactive state, and the release of this ionic lock could be a key step in receptor activation. To test this hypothesis, we made charge-neutralizing mutations of Glu-268(6.30) and of Asp-130(3.49) in the beta (2)-adrenergic receptor. Alone and in combination, we observed a significant increase in basal and pindolol-stimulated cAMP accumulation in COS-7 cells transiently transfected with the mutant receptors. Moreover, based on the increased accessibility of Cys-285(6.47) in TM6, we provide evidence for a conformational rearrangement of TM6 that is highly correlated with the extent of constitutive activity of the different mutants. The present experimental data together with the recent high-resolution structure of rhodopsin suggest that ionic interactions between Asp/Glu(3.49), Arg(3.50), and Glu(6.30) may constitute a common switch governing the activation of many rhodopsin-like G-protein-coupled receptors.	Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Novasite Pharmaceut Inc, San Diego, CA 92121 USA; Univ Copenhagen, Panum Inst, Dept Med Physiol, Div Cellular & Mol Physiol, DK-2200 Copenhagen, Denmark; Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Univ Crete, Sch Med, Dept Pharmacol, GR-71110 Iraklion, Greece	Columbia University; University of Copenhagen; Columbia University; Columbia University; University of Crete	Javitch, JA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Psychiat, 630 W 168th St,P&S 11-401, New York, NY 10032 USA.		Shi, Lei/AAV-1321-2020	Shi, Lei/0000-0002-4137-096X; Gether, Ulrik/0000-0002-0020-3807; Javitch, Jonathan/0000-0001-7395-2967; Rasmussen, Soren/0000-0002-1853-1841	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054137] Funding Source: NIH RePORTER; NIMH NIH HHS [MH57324, MH54137] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; ARNIS S, 1994, J BIOL CHEM, V269, P23879; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; GETHER U, 1992, FEBS LETT, V296, P241, DOI 10.1016/0014-5793(92)80295-R; Ghanouni P, 2000, J BIOL CHEM, V275, P3121, DOI 10.1074/jbc.275.5.3121; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Hjorth SA, 1998, MOL ENDOCRINOL, V12, P78, DOI 10.1210/mend.12.1.0045; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; Kosugi S, 1998, MOL PHARMACOL, V53, P894; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; MIN KC, 1993, J BIOL CHEM, V268, P9400; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Rees S, 1996, BIOTECHNIQUES, V20, P102; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; ROSENTHAL W, 1993, J BIOL CHEM, V268, P13030; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SANKARARAMAKRISHNAN R, 1992, INT J PEPT PROT RES, V39, P356; SANKARARAMAKRISHNAN R, 1990, BIOPOLYMERS, V30, P287, DOI 10.1002/bip.360300307; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Seibold A, 1998, RECEPTOR CHANNEL, V5, P375; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316	44	508	523	2	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29171	29177		10.1074/jbc.M103747200	http://dx.doi.org/10.1074/jbc.M103747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11375997	hybrid			2022-12-27	WOS:000170346000073
J	Thomas, DDH; Taft, WB; Kaspar, KM; Groblewski, GE				Thomas, DDH; Taft, WB; Kaspar, KM; Groblewski, GE			CRHSP-28 regulates Ca2+-stimulated secretion in permeabilized acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE STRING PROTEIN; RAT PANCREATIC ACINI; ACTIN CYTOSKELETON; MEMBRANE RETRIEVAL; ZYMOGEN GRANULES; GENE FAMILY; EXOCYTOSIS; IDENTIFICATION; CHOLECYSTOKININ; CLONING	CRHSP-28 is a Ca2+-regulated heat-stable phosphoprotein, abundant in the apical cytoplasm of epithelial cells that are specialized in exocrine protein secretion. To define a functional role for the protein in pancreatic secretion, recombinant CRHSP-28 (rCRHSP-28) was introduced into streptolysin-O-permeabilized acinar cells, and amylase secretion in response to elevated Ca2+ was determined. Secretion was enhanced markedly by rCRHSP-28 over a time course that closely corresponded with the loss of the native protein from the intracellular compartment. No effects of rCRHSP-28 were detected until similar to 50% of the native protein was lost from the cytosol. Secretion was enhanced by rCRHSP-28 over a physiological range of Ca2+ concentrations with 2-3-fold increases in amylase release occurring in response to low micromolar levels of free Ca2+. Further, rCRHSP-28 augmented secretion in a concentration-dependent manner with minimal and maximal effects occurring at 1 and 25 mug/ml, respectively. Covalent cross-linking experiments demonstrated that native CRHSP-28 was present in a 60-kDa complex in cytosolic fractions and in a high molecular mass complex in particulate fractions, consistent with the slow leak rate of the protein from streptolysin-O-permeabilized cells. Probing acinar lysates with rCRHSP-28 in a gel-overlay assay identified two CRHSP-28-binding proteins of 35 (pp35) and 70 kDa (pp70). Interestingly, preparation of lysates in the presence of 1 mm Ca2+ resulted in a marked redistribution of both proteins from a cytosolic to a Triton X-100-insoluble fraction, suggesting a Ca2+- sensitive interaction of these proteins with the acinar cell cytoskeleton. In agreement with our previous study immunohistochemically localizing CRHSP-28 around secretory granules in acinar cells, gel-overlay analysis revealed pp70 copurified with acinar cell secretory granule membranes. These findings demonstrate an important cell physiological function for CRHSP-28 in the Ca2+-regulated secretory pathway of acinar cells.	Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Groblewski, GE (corresponding author), Univ Wisconsin, Dept Nutr Sci, 1415 Linden Dr, Madison, WI 53706 USA.							BRAUN JEA, 1995, NEUROPHARMACOLOGY, V34, P1361, DOI 10.1016/0028-3908(95)00114-L; Brown H, 1998, EMBO J, V17, P5048, DOI 10.1093/emboj/17.17.5048; BURNHAM DB, 1988, AM J PHYSIOL, V254, pG130, DOI 10.1152/ajpgi.1988.254.1.G130; BURNHAM DB, 1982, J BIOL CHEM, V257, P523; BYRNE JA, 1995, CANCER RES, V55, P2896; Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393; Byrne JA, 1998, ONCOGENE, V16, P873, DOI 10.1038/sj.onc.1201604; Chen SL, 1997, ONCOGENE, V15, P2577, DOI 10.1038/sj.onc.1201437; Chen SL, 1996, ONCOGENE, V12, P741; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; Gaisano HY, 2000, PANCREAS, V20, P217, DOI 10.1097/00006676-200004000-00001; GROBLEWSKI GE, 1995, J BIOL CHEM, V270, P1437, DOI 10.1074/jbc.270.3.1437; Groblewski GE, 1999, AM J PHYSIOL-GASTR L, V276, pG219, DOI 10.1152/ajpgi.1999.276.1.G219; Groblewski GE, 1996, J BIOL CHEM, V271, P31502, DOI 10.1074/jbc.271.49.31502; Hansen NJ, 1999, J BIOL CHEM, V274, P22871, DOI 10.1074/jbc.274.32.22871; KITAGAWA M, 1990, AM J PHYSIOL, V259, pG157, DOI 10.1152/ajpgi.1990.259.2.G157; Kraemer J, 1999, EUR J CELL BIOL, V78, P265, DOI 10.1016/S0171-9335(99)80060-0; Ku NO, 1999, AM J PHYSIOL-GASTR L, V277, pG1108, DOI 10.1152/ajpgi.1999.277.6.G1108; Lantz VA, 1998, J CELL BIOL, V140, P897, DOI 10.1083/jcb.140.4.897; Marlowe KJ, 1998, EUR J CELL BIOL, V75, P140, DOI 10.1016/S0171-9335(98)80056-3; Matovcik LM, 1996, J HISTOCHEM CYTOCHEM, V44, P1243, DOI 10.1177/44.11.8918899; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; Muallem S, 1997, CELL CALCIUM, V22, P1, DOI 10.1016/S0143-4160(97)90083-X; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Nourse CR, 1998, BBA-GENE STRUCT EXPR, V1443, P155, DOI 10.1016/S0167-4781(98)00211-5; Ohnishi H, 1996, AM J PHYSIOL-GASTR L, V271, pG531, DOI 10.1152/ajpgi.1996.271.3.G531; Padfield PJ, 2000, FEBS LETT, V484, P129, DOI 10.1016/S0014-5793(00)02126-8; PADFIELD PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG647, DOI 10.1152/ajpgi.1995.269.5.G647; Parente JA, 1996, J BIOL CHEM, V271, P20096, DOI 10.1074/jbc.271.33.20096; POUNCELLHATTON S, 1997, GASTROENTEROLOGY, V113, P649; Proux V, 1996, J BIOL CHEM, V271, P30790, DOI 10.1074/jbc.271.48.30790; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Torgerson RR, 2000, J CELL PHYSIOL, V182, P438, DOI 10.1002/(SICI)1097-4652(200003)182:3<438::AID-JCP15>3.0.CO;2-N; Ueda N, 2000, GASTROENTEROLOGY, V119, P1123, DOI 10.1053/gast.2000.18145; Valentijn JA, 2000, P NATL ACAD SCI USA, V97, P1091, DOI 10.1073/pnas.97.3.1091; Valentijn K, 1999, BIOCHEM BIOPH RES CO, V266, P652, DOI 10.1006/bbrc.1999.1883; Valentijn KM, 1999, J CELL SCI, V112, P81; Wang L, 2000, J BIOL CHEM, V275, P22862, DOI 10.1074/jbc.M001447200; Williams JA, 1997, DIGESTION, V58, P42, DOI 10.1159/000201524; Williams John A., 1993, P167; WISHART MJ, 1994, AM J PHYSIOL-GASTR L, V267, pG676, DOI 10.1152/ajpgi.1994.267.4.G676; Yule DI, 1997, J BIOL CHEM, V272, P9093	42	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28866	28872		10.1074/jbc.M102214200	http://dx.doi.org/10.1074/jbc.M102214200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384973	hybrid			2022-12-27	WOS:000170346000032
J	Utani, A; Nomizu, M; Matsuura, H; Kato, K; Kobayashi, T; Takeda, U; Aota, S; Nielsen, PK; Shinkai, H				Utani, A; Nomizu, M; Matsuura, H; Kato, K; Kobayashi, T; Takeda, U; Aota, S; Nielsen, PK; Shinkai, H			A unique sequence of the laminin alpha 3 G domain binds to heparin and promotes cell adhesion through syndecan-2 and -4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT G-DOMAIN; BASEMENT-MEMBRANES; EPITHELIAL-CELLS; INTEGRIN ALPHA-3-BETA-1; EPIDERMOLYSIS-BULLOSA; DYSTROGLYCAN BINDING; PERIPHERAL-NERVE; GAMMA-2 CHAIN; VII COLLAGEN; GENE LAMC2	Laminin-5, consisting of the alpha3, beta3, and gamma2 chains, is localized in the skin basement membrane and supports the structural stability of the epidermo-dermal linkage and regulates various cellular functions. The alpha chains of laminins have been shown to have various biological activities. In this study, we identified a sequence of the alpha3 chain C-terminal globular domain (LG1-LG5 modules) required for both heparin binding and cell adhesion using recombinant proteins and synthetic peptides. We found that the LG3 and LG4 modules have activity for heparin binding and that LG4 has activity for cell adhesion. Studies with synthetic peptides delineated the A3G75aR sequence (NSFMALYLSKGR, residues 1412-1423) within LG4 as a major site for both heparin and cell binding. Substitution mutations in LG4 and A3G75aR identified the Lys and Arg of the A3G75aR sequence as critical for these activities. Cell adhesion to LG4 and A3G75aR was inhibited by heparitinase I treatment of cells, suggesting that cell binding to the A3G75aR site was mediated by cell surface heparan sulfate proteoglycans. We showed by affinity chromatography that syndecan-2 from fibroblasts bound to LG4. Solid-phase assays confirmed that syndecan-2 interacted with the A3G75aR peptide sequence. Stably transfected 293T cells with expression vectors for syndecan-2 and -4, but not glypican-1, specifically adhered to LG4 and A3G75aR. These results indicate that the A3G75aR sequence within the laminin alpha3 LG4 module is responsible for cell adhesion and suggest that syndecan-2 and -4 mediate this activity.	Chiba Univ, Sch Med, Dept Dermatol, Chuou Ku, Chiba 260, Japan; Hokkaido Univ, Grad Sch Environm Earth Sci, Sapporo, Hokkaido 060, Japan; Biomol Engn Res Inst, Suita, Osaka 565, Japan; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	Chiba University; Hokkaido University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Utani, A (corresponding author), Chiba Univ, Sch Med, Dept Dermatol, Chuou Ku, 1-8-1 Inohana, Chiba 260, Japan.							ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Chen M, 1997, J BIOL CHEM, V272, P14516, DOI 10.1074/jbc.272.23.14516; Chiba A, 1997, J BIOL CHEM, V272, P2156; Couchman JR, 1999, J CELL SCI, V112, P3415; Durbeej M, 1998, CURR OPIN CELL BIOL, V10, P594, DOI 10.1016/S0955-0674(98)80034-3; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Hirosaki T, 2000, J BIOL CHEM, V275, P22495, DOI 10.1074/jbc.M001326200; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Iivanainen A, 1999, J BIOL CHEM, V274, P14107, DOI 10.1074/jbc.274.20.14107; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; LACALLE RA, 1989, GENE, V79, P375, DOI 10.1016/0378-1119(89)90220-5; Lampe PD, 1998, J CELL BIOL, V143, P1735, DOI 10.1083/jcb.143.6.1735; Lebakken CS, 1996, J CELL BIOL, V132, P1209, DOI 10.1083/jcb.132.6.1209; Longley RL, 1999, J CELL SCI, V112, P3421; MARCHISIO PC, 1993, EXP CELL RES, V205, P205, DOI 10.1006/excr.1993.1078; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; Nielsen PK, 2000, J BIOL CHEM, V275, P14517, DOI 10.1074/jbc.275.19.14517; NUMA F, 1995, CANCER RES, V55, P4676; Pall EA, 1996, J BIOL CHEM, V271, P3817; PULKKINEN L, 1994, NAT GENET, V6, P293, DOI 10.1038/ng0394-293; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; Rees S, 1996, BIOTECHNIQUES, V20, P102; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; SONNENBERG A, 1993, J CELL SCI, V106, P1083; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Utani A, 1997, J BIOL CHEM, V272, P2814, DOI 10.1074/jbc.272.5.2814; UTANI A, 1995, J BIOL CHEM, V270, P3292, DOI 10.1074/jbc.270.7.3292; UTANI A, 1994, J BIOL CHEM, V269, P19167; Yamada H, 1996, J NEUROCHEM, V66, P1518; Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418; Yamaguchi H, 2000, J BIOL CHEM, V275, P29458, DOI 10.1074/jbc.M003103200; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347	52	117	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28779	28788		10.1074/jbc.M101420200	http://dx.doi.org/10.1074/jbc.M101420200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11373281	hybrid			2022-12-27	WOS:000170346000020
J	Liang, JS; Ginsberg, HN				Liang, JS; Ginsberg, HN			Microsomal triglyceride transfer protein binding and lipid transfer activities are independent of each other, but both are required for secretion of apolipoprotein B lipoproteins from liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; ABETALIPOPROTEINEMIA GENE; ENDOPLASMIC-RETICULUM; DISULFIDE-ISOMERASE; AMINO-TERMINUS; HEPG2 CELLS; DEGRADATION; B100; INHIBITION; RESPONSIVENESS	Recent studies indicate that microsomal triglyceride transfer protein (MTP) and apolipoprotein B (apoB) interact physically via two specific binding sites located within the amino-terminal globular region of apoB100. The first site is thought to be within the first 5.8% of the amino-terminal sequence, and the second site is between 9 and 16% of the amino-terminal sequence. It is not clear from prior studies whether these sites have unique or overlapping functions. Furthermore, there are no data differentiating between lipid transfer and potential chaperone functions of MTP. In the present study we have attempted to further characterize the physiologic interaction between apoB and MTP and to determine the relationship between the binding and lipid transfer aspects of the interaction. HepG2 cells were transiently transfected with apoB cDNAs, and MTP binding to apoB polypeptides was determined by two-step immunoprecipitation. MTP bound equally well to apoB polypeptides with (apoB13, 1.6, beta, apoB34, and apoB42) or without (apoB16, apoB13, and 16 or apoB13, 13, and 16) beta sheet domains. When proteasomal degradation of newly synthesized apoB polypeptides was blocked, MTP binding to all of the apoB polypeptides was only modestly affected by lipid availability and was independent of MTP-associated lipid transfer. Furthermore, MTP did not bind directly to a portion of the first 13 sheet domain. We created two apoB constructs (apoB16(del) and apoB34(del)) by deleting the first 210 amino acids of apoB16 and apoB34. These apoB polypeptides, therefore, lacked the putative first MTP binding site. MTP binding to apoB16(del) and apoB34(del) was decreased significantly. However, the secretion of apoB16(del) was not different from apoB16, whereas the secretion of apoB34(del) was impaired significantly. Our results indicate that the interact-ion between MTP and apoB involves independent binding and lipid transfer activities but that both activities are required for the secretion of apolipoprotein B from liver cells.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University	Ginsberg, HN (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055638, T32HL007343] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55638, T32HL07343] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bakillah A, 1998, BIOCHEMISTRY-US, V37, P3727, DOI 10.1021/bi972629t; Bakillah A, 2000, BIOCHEMISTRY-US, V39, P4892, DOI 10.1021/bi9924009; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BOREN J, 1994, J BIOL CHEM, V269, P25879; Bradbury P, 1999, J BIOL CHEM, V274, P3159, DOI 10.1074/jbc.274.5.3159; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DIXON JL, 1993, J LIPID RES, V34, P167; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; Haghpassand M, 1996, J LIPID RES, V37, P1468; HEINEMANN T, 1994, J LIPID RES, V35, P2200; Huang XF, 1997, J BIOL CHEM, V272, P31872, DOI 10.1074/jbc.272.50.31872; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Liang JS, 1998, J BIOL CHEM, V273, P35216, DOI 10.1074/jbc.273.52.35216; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SWIFT LL, 1995, J LIPID RES, V36, P395; Taghibiglou C, 2000, J BIOL CHEM, V275, P8416, DOI 10.1074/jbc.275.12.8416; Tietge UJF, 1999, J LIPID RES, V40, P2134; Tran K, 1998, J BIOL CHEM, V273, P7244, DOI 10.1074/jbc.273.13.7244; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; WETTERAU JR, 1986, BIOCHIM BIOPHYS ACTA, V875, P610, DOI 10.1016/0005-2760(86)90084-6; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	37	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28606	28612		10.1074/jbc.M100294200	http://dx.doi.org/10.1074/jbc.M100294200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11358959	hybrid			2022-12-27	WOS:000170093400114
J	Shida, T; Hattori, H; Ise, F; Sekiguchi, J				Shida, T; Hattori, H; Ise, F; Sekiguchi, J			Mutational analysis of catalytic sites of the cell wall lytic N-acetylmuramoyl-L-alanine amidases Cw1C and Cw1V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI K-12; BACILLUS-SUBTILIS; HYDROLASE GENE; AFFECTS GERMINATION; MOLECULAR-CLONING; AUTOLYSINS; LYSOZYME; ENZYME; IDENTIFICATION	The Bacillus subtilis CwlC and the Bacillus polymyxa var. colistinus CwIV are the cell wall lytic N-acetylmuramoyl-L-alanine amidases in the CwlB (LytC) family. Deletion in the CwlC amidase from the C terminus to residue 177 did not change the amidase activity. However, when the deletion was extended slightly toward the N terminus, the amidase activity was entirely lost. Further, the N-terminal deletion mutant without the first 19 amino acids did not have the amidase activity. These results indicate that the N-terminal half (residues 1-176) of the CwlC amidase, the region homologous to the truncated CwIV (CwlVt), is a catalytic domain. Site-directed mutagenesis was performed on 20 highly conserved amino acid residues within the catalytic domain of CwlC. The amidase activity was lost completely on single amino acid substitutions at two residues (Glu-24 and Glu-141). Similarly, the substitution of the two glutamic acid residues (E26Q and E142Q) of the truncated CwIV (CwIV1), which corresponded to Glu-24 and Glu-141 of CwIC, was critical to the amidase activity. The EDTA-treated CwIV1. did not have amidase activity. The amidase activity of the EDTA-treated CwIV1 was restored by the addition of Zn2+, Mn2+, and Co2+ but not by the addition of Me2+ and Ca2+. These results suggest that the amidases in the CwlB family are zinc amidases containing two glutamic acids as catalytic residues.	Shinshu Univ, Fac Text Sci & Technol, Dept Appl Biol, Nagano 3868567, Japan	Shinshu University	Sekiguchi, J (corresponding author), Shinshu Univ, Fac Text Sci & Technol, Dept Appl Biol, 3-15-1 Tokida, Nagano 3868567, Japan.	jsekigu@giptc.shinshu-u.ac.jp	Sekiguchi, Junichi/F-9963-2010					AKAMATSU T, 1987, AGR BIOL CHEM TOKYO, V51, P2901; ARCHIBALD AR, 1989, BIOTECHNOLOGY HDB, V2, P217; Auld DS, 1997, STRUCT BOND, V89, P29; BAGINSKI ES, 1967, CLIN CHEM, V13, P326; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DEHART HP, 1995, APPL ENVIRON MICROB, V61, P1475, DOI 10.1128/AEM.61.4.1475-1479.1995; DOYLE RJ, 1987, CRC CR REV MICROBIOL, V15, P169, DOI 10.3109/10408418709104457; FEIN JE, 1976, J BACTERIOL, V127, P1427, DOI 10.1128/JB.127.3.1427-1442.1976; HARZ H, 1990, ANAL BIOCHEM, V190, P120, DOI 10.1016/0003-2697(90)90144-X; HOLTJE JV, 1991, J GEN MICROBIOL, V137, P441, DOI 10.1099/00221287-137-3-441; Imoto T., 1972, ENZYMES, V7, P665; Ishikawa S, 1998, J BACTERIOL, V180, P1375, DOI 10.1128/JB.180.6.1375-1380.1998; Ishikawa S, 1999, MOL GEN GENET, V262, P738, DOI 10.1007/s004380051136; Kaneko T, 1996, DNA Res, V3, P109; KELLY JA, 1979, NATURE, V282, P875, DOI 10.1038/282875a0; KURODA A, 1992, MOL GEN GENET, V234, P129, DOI 10.1007/BF00272354; KURODA A, 1993, J BACTERIOL, V175, P6260, DOI 10.1128/JB.175.19.6260-6268.1993; KURODA A, 1990, J GEN MICROBIOL, V136, P2209, DOI 10.1099/00221287-136-11-2209; KURODA A, 1991, J BACTERIOL, V173, P7304, DOI 10.1128/jb.173.22.7304-7312.1991; Kuroki R, 1997, J BIOL CHEM, V272, P19976, DOI 10.1074/jbc.272.32.19976; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mackenzie LF, 1997, J BIOL CHEM, V272, P3161, DOI 10.1074/jbc.272.6.3161; MIKI T, 1987, PROTEIN ENG, V1, P327, DOI 10.1093/protein/1.4.327; Moriyama R, 1996, J BACTERIOL, V178, P6059, DOI 10.1128/jb.178.20.6059-6063.1996; Nugroho FA, 1999, J BACTERIOL, V181, P6230, DOI 10.1128/JB.181.20.6230-6237.1999; PHILLIPS DC, 1966, SCI AM, V215, P78, DOI 10.1038/scientificamerican1166-78; RASHID MH, 1995, FEMS MICROBIOL LETT, V132, P131, DOI 10.1016/0378-1097(95)00299-K; SEKIGUCHI J, 1995, J BACTERIOL, V177, P5582, DOI 10.1128/jb.177.19.5582-5589.1995; Shida T, 2000, BIOSCI BIOTECH BIOCH, V64, P1522, DOI 10.1271/bbb.64.1522; SMITH HO, 1995, SCIENCE, V269, P538, DOI 10.1126/science.7542802; SMITH TJ, 1995, J BACTERIOL, V177, P3855, DOI 10.1128/jb.177.13.3855-3862.1995; Smith TJ, 2000, MICROBIOL-UK, V146, P249, DOI 10.1099/00221287-146-2-249; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TROUP B, 1994, J BACTERIOL, V176, P673, DOI 10.1128/jb.176.3.673-680.1994; TSUI HCT, 1994, MOL MICROBIOL, V11, P189, DOI 10.1111/j.1365-2958.1994.tb00300.x; Vazeux G, 1996, J BIOL CHEM, V271, P9069, DOI 10.1074/jbc.271.15.9069; WU HC, 1986, CURR TOP MICROBIOL, V125, P127; XU KP, 1993, J BACTERIOL, V175, P4990, DOI 10.1128/JB.175.16.4990-4999.1993	43	44	45	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28140	28146		10.1074/jbc.M103903200	http://dx.doi.org/10.1074/jbc.M103903200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375403	hybrid			2022-12-27	WOS:000170093400054
J	Cao, WH; Medvedev, AV; Daniel, KW; Collins, S				Cao, WH; Medvedev, AV; Daniel, KW; Collins, S			beta-adrenergic activation of p38 MAP kinase in adipocytes - cAMP induction of the uncoupling protein 1 (UCP1) gene requires p38 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; BETA(3)-ADRENERGIC RECEPTOR; STIMULATING-HORMONE; CYCLIC-AMP; EXPRESSION; GAMMA; PATHWAY; PHOSPHORYLATION; DIFFERENTIATION; MECHANISM	Because of increasing evidence that G protein-coupled receptors activate multiple signaling pathways, it becomes important to determine the coordination of these pathways and their physiological significance. Here we show that the beta (3)-adrenergic receptor (beta (3)AR) stimulates p38 mitogen-activated protein kinase (p38 MAPK) via PKA in adipocytes and that cAMP-dependent transcription of the mitochondrial uncoupling protein 1 (UCP1) promoter by beta (3)AR requires p38 MAPK. The selective beta (3)AR agonist CL316,243 (CL) stimulates phosphorylation of MAP kinase kinase 3/6 and p38 MAPK in a time- and dose-dependent manner in both white and brown adipocytes, Isoproterenol and forskolin mimicked the effect of CL on p38 MAPK. In all cases activation was blocked by the specific p38 MAPK inhibitor SB202190 (SB; 1-10 muM). The involvement of PKA in beta (3)AR-dependent p38 MAPK activation was confirmed by the ability of the PKA inhibitors H89 (20 muM) and (R-p)-cAMP-S (1 mM) to block phosphorylation of p38 MAPK. Treatment of primary brown adipocytes with CL or forskolin induced the expression of UCP1 mRNA levels (6.8- +/- 0.8-fold), and this response was eliminated by PKA inhibitors and SB202190. A similar stimulation of a 3.7-kilobase UCP1 promoter by CL and forskolin was also completely inhibited by PKA inhibitors and SB202190, indicating that these effects on UCP1 expression are transcriptional. Moreover, the PKA-dependent transactivation of the UCP1 promoter, as well as its sensitivity to SB202190, was fully reproduced by a 220-nucleotide enhancer element from the UCP1 gene. We similarly observed that increased phosphorylation of ATF-2 by CL was sensitive to both H89 and SB202190, while phosphorylation of cAMP-response element-binding protein was inhibited only by H89. Together, these studies illustrate that p38 MAPK is an important downstream target of the beta -adrenergic/cAMP/PKA signaling pathway in adipocytes, and one of the functional consequences of this cascade is stimulation of UCP1 gene expression in brown adipocytes.	Duke Univ, Dept Pharmacol & Canc Biol, Med Ctr, Box 3557, Durham, NC 27710 USA; Duke Univ, Dept Psychiat & Behav Sci, Med Ctr, Durham, NC 27710 USA	Duke University; Duke University	Collins, S (corresponding author), Duke Univ, Dept Pharmacol & Canc Biol, Med Ctr, Box 3557, Durham, NC 27710 USA.	colli008@mc.duke.edu		Medvedev, Alexander/0000-0001-6983-1687	NIDDK NIH HHS [R01-DK53092, R01-DK57698] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057698, R01DK053092] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Cassard-Doulcier AM, 1998, BIOCHEM J, V333, P243, DOI 10.1042/bj3330243; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; Collins S., 2001, Nutrient-gene interactions in health and disease, P261; Collins S, 2001, RECENT PROG HORM RES, V56, P309, DOI 10.1210/rp.56.1.309; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Feoktistov I, 2000, MOL PHARMACOL, V58, P903, DOI 10.1124/mol.58.5.903; Gerhardt CC, 1999, MOL PHARMACOL, V55, P255, DOI 10.1124/mol.55.2.255; GRANNEMAN JG, 1995, ENDOCRINOLOGY, V136, P2007, DOI 10.1210/en.136.5.2007; Gutkind J.S, 2000, SCI STKE; Irie Y, 1999, BIOCHEM BIOPH RES CO, V255, P221, DOI 10.1006/bbrc.1998.9999; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOZAK LP, 1988, J BIOL CHEM, V263, P12274; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; Lazennec G, 2000, MOL ENDOCRINOL, V14, P1962, DOI 10.1210/me.14.12.1962; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maizels ET, 1998, ENDOCRINOLOGY, V139, P3353, DOI 10.1210/en.139.7.3353; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; MIYAMOTO NG, 1987, NUCLEIC ACIDS RES, V15, P9095, DOI 10.1093/nar/15.21.9095; Pomerance M, 2000, J BIOL CHEM, V275, P40539, DOI 10.1074/jbc.M002097200; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; REHNMARK S, 1989, EXP CELL RES, V182, P75, DOI 10.1016/0014-4827(89)90280-2; RICQUIER D, 1983, BIOCHEM J, V210, P859, DOI 10.1042/bj2100859; ROBISON GA, 1970, CIRC RES, V27, pI147; ROHLFS EM, 1995, J BIOL CHEM, V270, P10723, DOI 10.1074/jbc.270.18.10723; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Silva JE, 1997, EUR J ENDOCRINOL, V136, P251, DOI 10.1530/eje.0.1360251; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Yan SZ, 1998, MOL PHARMACOL, V53, P182, DOI 10.1124/mol.53.2.182; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhen XC, 1998, MOL PHARMACOL, V54, P453, DOI 10.1124/mol.54.3.453; Zheng M, 2000, J BIOL CHEM, V275, P40635, DOI 10.1074/jbc.M006325200	44	222	228	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27077	27082		10.1074/jbc.M101049200	http://dx.doi.org/10.1074/jbc.M101049200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369767	hybrid			2022-12-27	WOS:000169966900047
J	Kabayama, K; Ito, N; Honke, K; Igarashi, Y; Inokuchi, J				Kabayama, K; Ito, N; Honke, K; Igarashi, Y; Inokuchi, J			Suppression of integrin expression and tumorigenicity by sulfation of lactosylceramide in 3LL Lewis lung carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBRONECTIN RECEPTOR; RENAL-CANCER CELLS; CEREBROSIDE SULFOTRANSFERASE; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; RAT-BRAIN; SYNTHASE; SURFACE; PROTEIN; GLYCOSPHINGOLIPIDS	To investigate the cellular functions of sulfated glycosphingolipids, we introduced the cerebroside sulfotransferase (CST) gene into J5 cells, a subclone of 3LL, Lewis lung carcinoma cells. The J5 cells lack acidic glycosphingolipids but accumulate their common biosynthetic precursor, lactosylceramide. We established the stable CST transfectants, J5/CST-1 and J5/CST-2 clones, highly expressing sulfated lactosylceramide (SM3). Both clones exhibited more spherical morphology in comparison to mock transfectant, and their adhesiveness to fibronectin and laminin was significantly lower. The loss of cell-substratum interactions in these SM3-expressing cells could be attributed to decreased expression of integrins (alpha (5), alpha (6), and beta (1)) on the cell surface and their whole cellular levels. However, the levels of H-2K(b) and H-2D(b) antigens remained unchanged. Reverse transcriptase-polymerase chain reaction and Northern blot analyses for these integrins exhibited significant decrease of beta (1) gene expression in J5/CST-1 and 2, but there was no change in the levels of alpha (5) and alpha (6) transcripts. Deglycosylation by endoglycosidase H treatment clearly demonstrated that the precursor form of beta (1) integrin, possessing high mannose oligosaccharide chains, was preferentially decreased in the CST transfectants. These results demonstrate that endogenous SM3 negatively regulates beta (1) integrin expression at the transcriptional level, and the decrease of alpha integrin proteins in the CST transfectants was due to the posttranscriptional modification. We suggest the putative importance of the intracellular pre-beta (1) integrin pool for normal integrin maturation and subsequent function. Although the rates of cell proliferation in vitro for mock and CST transfectants were similar, tumorigenicity of J5/ CST-1 and -2 cells inoculated into syngeneic C57/BL6 mice was greatly decreased or even absent. This was probably due to global loss of the efficient cell-matrix interactions, which are essential for the development of malignant tumors in vivo. Thus, we showed the evidence that cellular SM3 negatively regulates the cell substratum interaction, resulting in the loss of tumorigenicity.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan	Hokkaido University; Osaka University	Inokuchi, J (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Kita 12 jo,Nishi 6 chome, Sapporo, Hokkaido 0600812, Japan.		Kabayama, Kazuya/ABD-5748-2020; Inokuchi, Jin-ichi/AAW-9964-2020	Kabayama, Kazuya/0000-0002-7583-5454; Inokuchi, Jin-ichi/0000-0002-0703-5746				AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; BENJAMINS JA, 1982, J NEUROCHEM, V38, P233, DOI 10.1111/j.1471-4159.1982.tb10875.x; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chester MA, 1997, PURE APPL CHEM, V69, P2475, DOI 10.1351/pac199769122475; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Cornish-Bowden A, 1998, CARBOHYD RES, V312, P167; Frank M, 1998, J NEUROSCI, V18, P4901; FUJITA S, 1992, JPN J CANCER RES, V83, P1317, DOI 10.1111/j.1349-7006.1992.tb02764.x; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gong JG, 1997, CELL GROWTH DIFFER, V8, P83; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HEINO J, 1989, J BIOL CHEM, V264, P380; Hirahara Y, 2000, EUR J BIOCHEM, V267, P1909, DOI 10.1046/j.1432-1327.2000.01139.x; HIRAIWA N, 1990, CANCER RES, V50, P2917; Honke K, 1996, J BIOCHEM-TOKYO, V119, P421; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; Honke K, 2001, J BIOL CHEM, V276, P267, DOI 10.1074/jbc.M005666200; INOKUCHI J, 1993, CLIN EXP METASTAS, V11, P27, DOI 10.1007/BF00880063; INOKUCHI J, 2000, GLYCOCONJ J, V17, P1; Ishii A, 1998, J BIOL CHEM, V273, P31652, DOI 10.1074/jbc.273.48.31652; Ishizuka I, 1997, PROG LIPID RES, V36, P245, DOI 10.1016/S0163-7827(97)00011-8; JASPERS M, 1988, FEBS LETT, V231, P402, DOI 10.1016/0014-5793(88)80859-7; Keusch JJ, 2000, J BIOL CHEM, V275, P25308, DOI 10.1074/jbc.M002629200; Keusch JJ, 2000, J BIOL CHEM, V275, P25315, DOI 10.1074/jbc.M002630200; Kim LT, 1997, P SOC EXP BIOL MED, V214, P123; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; KOBAYASHI T, 1993, BRIT J CANCER, V67, P76, DOI 10.1038/bjc.1993.12; KOBAYASHI T, 1994, INT J CANCER, V56, P281, DOI 10.1002/ijc.2910560223; KOIVISTO L, 1994, BIOCHEM J, V300, P771, DOI 10.1042/bj3000771; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; LENTER M, 1994, J BIOL CHEM, V269, P12263; Mannion BA, 1996, J IMMUNOL, V157, P2039; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Ono M, 2000, BIOCHEM BIOPH RES CO, V279, P744, DOI 10.1006/bbrc.2000.4030; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; Radford KJ, 1996, BIOCHEM BIOPH RES CO, V222, P13, DOI 10.1006/bbrc.1996.0690; ROBERTS DD, 1988, ARCH BIOCHEM BIOPHYS, V267, P405, DOI 10.1016/0003-9861(88)90046-X; SACCHI A, 1989, CANCER RES, V49, P2615; SheikhHamad D, 1997, AM J PHYSIOL-CELL PH, V273, pC902, DOI 10.1152/ajpcell.1997.273.3.C902; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SLUPSKY JR, 1989, J BIOL CHEM, V264, P12289; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; Stroeken PJM, 1998, CANCER RES, V58, P1569; Svennerholm L, 1980, Adv Exp Med Biol, V125, P11; Svineng G, 1999, J CELL SCI, V112, P4751; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; TADANO K, 1979, BIOCHIM BIOPHYS ACTA, V575, P421; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; TENNEKOON G, 1983, J CELL BIOL, V97, P1107, DOI 10.1083/jcb.97.4.1107; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97	56	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26777	26783		10.1074/jbc.M100428200	http://dx.doi.org/10.1074/jbc.M100428200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11352905	hybrid			2022-12-27	WOS:000169966900008
J	Kupke, T				Kupke, T			Molecular characterization of the 4 '-phosphopantothenoylcysteine decarboxylase domain of bacterial Dfp flavoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OXIDATIVE DECARBOXYLATION; PURIFICATION; BIOSYNTHESIS; SUBSTRATE; PROTEINS; ATHAL3; GENE	The NH2-terminal domain of the bacterial flavoprotein Dfp catalyzes the decarboxylation of (R)-4'-phospho-N-pantothenoylcysteine to 4'-phosphopantetheine, a key step in coenzyme A biosynthesis, Dfp proteins, LanD proteins (for example EpiD, which is involved in epidermin biosynthesis), and the salt tolerance protein AtHAL3a from Arabidopsis thaliana are homooligomeric flavin-containing Cys decarboxylases (HFCD protein family), The crystal structure of the peptidyl-cysteine decarboxylase EpiD complexed with a pentapeptide substrate has recently been determined. The peptide is bound by an NH2-terminal substrate binding helix, residue Asn(117), which contacts the cysteine residue of the substrate, and a COOH-terminal substrate recognition clamp, The conserved motif G-G/S-I-A-X-Y-K of the Dfp proteins aligns partly with the substrate binding helix of EpiD. Point mutations within this motif resulted in loss of coenzyme binding (G14S) or in significant decrease of Dfp activity (G15A, I16L, A17D, K20N, K20Q), Exchange of Asn(125) of Dfp, which corresponds to Asn(117) of EpiD, and exchange of Cys(158), which is within the proposed substrate recognition clamp of Dfp, led to inactivity of the enzyme, Molecular analysis of the conditional lethality of the Escherichia coli dfp-707 mutant revealed that the single point mutation G11D of Dfp is related to decreased amounts of soluble Dfp protein at 37 degreesC.	Univ Tubingen, Lehrstuhl Mikrobielle Genet, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Kupke, T (corresponding author), Univ Tubingen, Lehrstuhl Mikrobielle Genet, Morgenstelle 15, D-72076 Tubingen, Germany.		Zhang, Ning/F-1387-2014	Kupke, Thomas/0000-0003-2341-1710				Albert A, 2000, STRUCTURE, V8, P961, DOI 10.1016/S0969-2126(00)00187-8; Begley TP, 2001, VITAM HORM, V61, P157; Blaesse M, 2000, EMBO J, V19, P6299, DOI 10.1093/emboj/19.23.6299; Espinosa-Ruiz A, 1999, PLANT J, V20, P529, DOI 10.1046/j.1365-313X.1999.00626.x; Geerlof A, 1999, J BIOL CHEM, V274, P27105, DOI 10.1074/jbc.274.38.27105; JACKOWSKI S, 1996, ESCHERICHIA COLI SAL, V1, P687; Kupke T, 2000, J BIOL CHEM, V275, P31838, DOI 10.1074/jbc.M004273200; KUPKE T, 1992, J BACTERIOL, V174, P5354, DOI 10.1128/JB.174.16.5354-5361.1992; KUPKE T, 1994, J BIOL CHEM, V269, P5653; Kupke T, 2001, J BIOL CHEM, V276, P19190, DOI 10.1074/jbc.M100776200; KUPKE T, 1995, J BIOL CHEM, V270, P11282, DOI 10.1074/jbc.270.19.11282; Mishra PK, 2001, J BACTERIOL, V183, P2774, DOI 10.1128/JB.183.9.2774-2778.2001; SCANDURRA R, 1987, FEBS LETT, V212, P79, DOI 10.1016/0014-5793(87)81560-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEVASTOPOULOS CG, 1977, P NATL ACAD SCI USA, V74, P3485, DOI 10.1073/pnas.74.8.3485; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; SPITZER ED, 1988, J BACTERIOL, V170, P872, DOI 10.1128/jb.170.2.872-876.1988; SPITZER ED, 1985, J BACTERIOL, V164, P994, DOI 10.1128/JB.164.3.994-1003.1985; Strauss E, 2001, J BIOL CHEM, V276, P13513, DOI 10.1074/jbc.C100033200; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333	20	30	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27597	27604		10.1074/jbc.M103342200	http://dx.doi.org/10.1074/jbc.M103342200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11358972	hybrid			2022-12-27	WOS:000169966900114
J	Menendez-Arias, L; Abraha, A; Quinones-Mateu, ME; Mas, A; Camarasa, MJ; Arts, EJ				Menendez-Arias, L; Abraha, A; Quinones-Mateu, ME; Mas, A; Camarasa, MJ; Arts, EJ			Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O strains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; (-)-STRAND DNA-SYNTHESIS; P51 SUBUNIT; TEMPLATE-PRIMER; NONNUCLEOSIDE INHIBITORS; ANGSTROM RESOLUTION; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; DRUG-RESISTANCE; TSAO	Human immunodeficiency virus (HPV)-1 strains have been divided into three groups: main (M), outlier (O), and non-M non-O (N). Biochemical analyses of HIV-1 reverse transcriptase (RT) have been performed predominantly with enzymes derived from HIV-1 group M:subtype B laboratory strains. This study was designed to optimize the expression and to characterize the enzymatic properties of HIV-1 group O RTs as well as chimeric RTs composed of group M and O p66 and p51 subunits. The DNA-dependent DNA polymerase activity on a short heteropolymeric template-primer was similar with all enzymes, i.e. the HIV-1 group O and M and chimeric RTs. Our data revealed that the 51-kDa subunit in the chimeric heterodimer p66(M:B)/p51(O) confers increased heterodimer stability and partial resistance to non-nucleoside RT inhibitors. Chimeric:RTs (p66(M:B)/p51(O) and p66(O)/p51(M:B)) were unable to initiate reverse transcription from tRNA(3)(Lys) using HIV-1 group O or group M:subtype B RNA templates. In contrast, HIV-1 group O and M RTs supported (-)-strand DNA synthesis from tRNA(3)(Lys) hybridized to any of their corresponding HIV-1 RNA templates. HIV-2 RT could not initiate-reverse transcription on tRNA(3)(Lys)-primed HIV-1 genomic RNA. These findings suggest that the initiation event is conserved between HIV-1 groups, but not HIV types.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain; Case Western Reserve Univ, Dept Med, Div Infect Dis, Cleveland, OH 44106 USA; CSIC, Inst Quim Med, E-28006 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Case Western Reserve University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Medica (IQM); CSIC - Instituto de Quimica Organica General (IQOG)	Menendez-Arias, L (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain.		Quinones-Mateu, Miguel/H-3846-2019; Mas, Antonio/F-2505-2011; Camarasa, María-José/B-6340-2015; Camarasa, María-José/N-8845-2019; Menendez Arias, Luis/G-2436-2016; Arias, Luis Menendez/N-7447-2016	Mas, Antonio/0000-0003-2563-570X; Camarasa, María-José/0000-0002-4978-6468; Camarasa, María-José/0000-0002-4978-6468; Arias, Luis Menendez/0000-0002-1251-6640; Arts, Eric/0000-0002-4880-7968; Quinones-Mateu, Miguel/0000-0001-9170-5601	NHLBI NIH HHS [KO1-HL67610-01] Funding Source: Medline; NIAID NIH HHS [R01-AI31147, AI36219] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL067610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036219, R01AI031147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amacker M, 1998, J MOL BIOL, V278, P757, DOI 10.1006/jmbi.1998.1739; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; Arts EJ, 1998, J BIOL CHEM, V273, P14523, DOI 10.1074/jbc.273.23.14523; ARTS EJ, 1994, J BIOL CHEM, V269, P16571; BALZARINI J, 1993, P NATL ACAD SCI USA, V90, P6952, DOI 10.1073/pnas.90.15.6952; CAMARASA MJ, 1992, J MED CHEM, V35, P2721, DOI 10.1021/jm00093a002; Chiba J, 1996, J GEN VIROL, V77, P2921, DOI 10.1099/0022-1317-77-12-2921; Descamps D, 1997, J VIROL, V71, P8893, DOI 10.1128/JVI.71.11.8893-8898.1997; DIVITA G, 1993, FEBS LETT, V324, P153, DOI 10.1016/0014-5793(93)81383-B; DIVITA G, 1994, J BIOL CHEM, V269, P13080; Divita G, 1995, BIOCHEMISTRY-US, V34, P16337, DOI 10.1021/bi00050a014; Dufour E, 1998, EUR J BIOCHEM, V251, P487, DOI 10.1046/j.1432-1327.1998.2510487.x; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; GOEL R, 1993, BIOCHEMISTRY-US, V32, P13012, DOI 10.1021/bi00211a009; Harris D, 1998, BIOCHEMISTRY-US, V37, P5903, DOI 10.1021/bi9728452; HOTTIGER M, 1994, J BIOL CHEM, V269, P986; HOWARD KJ, 1991, J BIOL CHEM, V266, P23003; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUANG SC, 1992, BIOCHEM BIOPH RES CO, V184, P986, DOI 10.1016/0006-291X(92)90688-H; ISEL C, 1993, J BIOL CHEM, V268, P25269; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P1388; JONCKHEERE H, 1994, J BIOL CHEM, V269, P25255; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LOYA S, 1994, AIDS RES HUM RETROV, V10, P939, DOI 10.1089/aid.1994.10.939; MartinHernandez AM, 1996, EMBO J, V15, P4434, DOI 10.1002/j.1460-2075.1996.tb00816.x; MartinHernandez AM, 1997, NUCLEIC ACIDS RES, V25, P1383, DOI 10.1093/nar/25.7.1383; Mas A, 2000, EMBO J, V19, P5752, DOI 10.1093/emboj/19.21.5752; Menendez-Arias L, 1998, BIOCHEMISTRY-US, V37, P16636, DOI 10.1021/bi981830g; MISHIMA Y, 1995, EMBO J, V14, P2679, DOI 10.1002/j.1460-2075.1995.tb07266.x; MULLER B, 1991, J BIOL CHEM, V266, P14709; Palmer S, 1998, AIDS RES HUM RETROV, V14, P157, DOI 10.1089/aid.1998.14.157; PEREZPEREZ MJ, 1992, J MED CHEM, V35, P2988, DOI 10.1021/jm00094a009; PEREZPEREZ MJ, 1992, TETRAHEDRON LETT, V33, P3029, DOI 10.1016/S0040-4039(00)79591-8; Quinones-Mateu ME, 1998, J VIROL, V72, P9002; QuinonesMateu ME, 1997, VIROLOGY, V236, P364, DOI 10.1006/viro.1997.8748; QUINONESMATEU ME, 2000, AIDS REV, V2, P190; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; Sluis-Cremer N, 2000, BIOCHEMISTRY-US, V39, P1427, DOI 10.1021/bi991682+; Tachedjian G, 2000, P NATL ACAD SCI USA, V97, P6334, DOI 10.1073/pnas.97.12.6334; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242; Wohrl BM, 1997, J BIOL CHEM, V272, P17581, DOI 10.1074/jbc.272.28.17581; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	48	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27470	27479		10.1074/jbc.M104342200	http://dx.doi.org/10.1074/jbc.M104342200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11353775	hybrid			2022-12-27	WOS:000169966900098
J	Grundmann, O; Mosch, HU; Braus, GH				Grundmann, O; Mosch, HU; Braus, GH			Repression of GCN4 mRNA translation by nitrogen starvation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BIOSYNTHETIC GENES; EXCHANGE FACTOR EIF2B; PROTEIN-KINASE; TRANSFER-RNA; TRANSCRIPTIONAL ACTIVATOR; CATABOLITE REPRESSION; PSEUDOHYPHAL DIFFERENTIATION; INVASIVE GROWTH; AMINO-ACIDS; YEAST	Saccharomyces cerevisiae activates a regulatory network called "general control" that provides the cell with sufficient amounts of protein precursors during amino acid starvation, We investigated how starvation for nitrogen affects the general control regulatory system, because amino acid biosynthesis is part of nitrogen metabolism. Amino acid limitation results in the synthesis of the central transcription factor Gcn4p, which binds to specific DNA-binding motif sequences called Gcn4-protein-responsive elements (GCREs) that are present in the promoter regions of its target genes. Nitrogen starvation increases GCN4 transcription but efficiently represses expression of both a synthetic GCRE6::lacZ reporter gene and the natural amino acid biosynthetic gene ARO4. Repression of Gcn4p-regulated transcription by nitrogen starvation is independent of the ammonium sensing systems that include Mep2p and Gpa2p or Ure2p and Gln3p but depends on the four upstream open reading frames in the GCN4 mRNA leader sequence. Efficient translation of GCN4 mRNA is completely blocked by nitrogen starvation, even when cells are simultaneously starved for amino acids and eukaryotic initiation factor-2 alpha is fully phosphorylated by Gcn2p. Our data suggest that nitrogen starvation regulates translation of GCN4 by a novel mechanism that involves the four upstream open reading frames but that still acts independently of eukaryotic initiation factor-2 alpha phosphorylation by Gcn2p.	Univ Gottingen, Inst Microbiol & Genet, D-37077 Gottingen, Germany	University of Gottingen	Braus, GH (corresponding author), Univ Gottingen, Inst Microbiol & Genet, Grisebachstr 8, D-37077 Gottingen, Germany.	gbraus@gwdg.de	Braus, Gerhard/ABC-6293-2021; Braus, Gerhard H/G-3999-2012	Braus, Gerhard/0000-0002-3117-5626; Braus, Gerhard H/0000-0002-3117-5626				Albrecht G, 1998, J BIOL CHEM, V273, P12696, DOI 10.1074/jbc.273.21.12696; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUS G, 1989, EMBO J, V8, P939, DOI 10.1002/j.1460-2075.1989.tb03455.x; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Erdman S, 1998, J CELL BIOL, V140, P461, DOI 10.1083/jcb.140.3.461; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HANNIG EM, 1988, MOL CELL BIOL, V8, P4808, DOI 10.1128/MCB.8.11.4808; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1990, PROG NUCLEIC ACID RE, V38, P195; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1992, MOL CELLULAR BIOL YE, V3, P319; Hoffmann B, 1999, MOL MICROBIOL, V31, P807, DOI 10.1046/j.1365-2958.1999.01219.x; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Kubler E, 1997, J BIOL CHEM, V272, P20321, DOI 10.1074/jbc.272.33.20321; KUNZLER M, 1992, GENE, V113, P67, DOI 10.1016/0378-1119(92)90670-K; Lorenz MC, 1998, GENETICS, V150, P1443; Lorenz MC, 1997, EMBO J, V16, P7008, DOI 10.1093/emboj/16.23.7008; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; MEUSSDOERFFER F, 1983, J BIOL CHEM, V258, P6293; MIRANDE M, 1988, J BIOL CHEM, V263, P18443; Mosch HU, 1999, MOL BIOL CELL, V10, P1325, DOI 10.1091/mbc.10.5.1325; MOSCH HU, 1990, EMBO J, V9, P2951, DOI 10.1002/j.1460-2075.1990.tb07487.x; MOSCH HU, 1991, J BIOL CHEM, V266, P20453; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; ROSE M, 1983, METHOD ENZYMOL, V101, P167; ROUSSOU I, 1988, MOL CELL BIOL, V8, P2132, DOI 10.1128/MCB.8.5.2132; Schnappauf G, 1997, P NATL ACAD SCI USA, V94, P8491, DOI 10.1073/pnas.94.16.8491; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Stanhill A, 1999, MOL CELL BIOL, V19, P7529; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; THIREOS G, 1984, P NATL ACAD SCI-BIOL, V81, P5096, DOI 10.1073/pnas.81.16.5096; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK SA, 1995, MOL CELL BIOL, V15, P4497; WENZEL TJ, 1995, NUCLEIC ACIDS RES, V23, P883, DOI 10.1093/nar/23.5.883; WIAME JM, 1985, ADV MICROB PHYSIOL, V26, P1, DOI 10.1016/S0065-2911(08)60394-X; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; Yang WM, 1996, MOL CELL BIOL, V16, P6603	51	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25661	25671		10.1074/jbc.M101068200	http://dx.doi.org/10.1074/jbc.M101068200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11356835	hybrid			2022-12-27	WOS:000169823300006
J	Nguyen, TV; Fyjioka, H; Kang, AS; Rogers, WO; Fidock, DA; James, AA				Nguyen, TV; Fyjioka, H; Kang, AS; Rogers, WO; Fidock, DA; James, AA			Stage-dependent localization of a novel gene product of the malaria parasite, Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCUMSPOROZOITE PROTEIN; POLYBASIC DOMAIN; SURFACE-ANTIGEN; NEW-GENERATION; SPOROZOITE; IDENTIFICATION; EXPRESSION; RICH; DNA; PALMITOYLATION	A novel Plasmodium falciparum gene, MB2, was identified by screening a sporozoite cDNA library with the serum of a human volunteer protected experimentally by the bites of P, falciparum-infected and irradiated mosquitoes. The single-exon, single-copy MB2 gene is predicted to encode a protein with an M-r of 187,000. The MB2 protein has an amino-terminal basic domain, a central acidic domain, and a carboxyl-terminal domain with similarity to the GTP-binding domain of the prokaryotic translation initiation factor 2. MB2 is expressed in sporozoites, the liver, and blood-stage parasites and gametocytes. The MB2 protein is distributed as a similar to 120-kDa moiety on the surface of sporozoites and is imported into the nucleus of blood-stage parasites as a similar to 66-kDa species. Proteolytic processing is favored as the mechanism regulating the distinct subcellular localization of the MB2 protein, This differential localization provides multiple opportunities to exploit the MB2 gene product as a vaccine or therapeutic target.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Diversa Corp, San Diego, CA 92121 USA; USN, Med Res Ctr, Silver Spring, MD 20910 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	University of California System; University of California Irvine; Case Western Reserve University; United States Department of Defense; United States Navy; Yeshiva University; Albert Einstein College of Medicine	James, AA (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3205 Bio Sci 2, Irvine, CA 92697 USA.	aajames@uci.edu		James, Anthony/0000-0001-5577-3308; Kang, Angray/0000-0002-4672-4114; Fidock, David/0000-0001-6753-8938	NIAID NIH HHS [AI35827] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035827] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKAWA M, 1990, ADV PARASIT, V29, P151, DOI 10.1016/S0065-308X(08)60106-2; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; ATKINSON CT, 1989, AM J TROP MED HYG, V41, P9, DOI 10.4269/ajtmh.1989.41.1.TM0410010009; BALLOU WR, 1987, LANCET, V1, P1277; Barale JC, 1997, MOL BIOCHEM PARASIT, V87, P169, DOI 10.1016/S0166-6851(97)00065-0; Barale JC, 1997, INFECT IMMUN, V65, P3003, DOI 10.1128/IAI.65.8.3003-3010.1997; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; Fidock DA, 2000, EXP PARASITOL, V95, P220, DOI 10.1006/expr.2000.4528; FIDOCK DA, 1994, MOL BIOCHEM PARASIT, V64, P219, DOI 10.1016/0166-6851(94)00012-3; Fidock DA, 1998, EXP PARASITOL, V89, P125, DOI 10.1006/expr.1998.4262; GALEY B, 1990, INFECT IMMUN, V58, P2995, DOI 10.1128/IAI.58.9.2995-3001.1990; GYSIN J, 1993, J IMMUNOL METHODS, V159, P209, DOI 10.1016/0022-1759(93)90159-5; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HERRINGTON D, 1991, AM J TROP MED HYG, V45, P539, DOI 10.4269/ajtmh.1991.45.539; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HOFFMAN SL, 1993, MOL IMMUNOLOGICAL CO, P149; Hyde J E, 1993, Methods Mol Biol, V21, P133; HYDE JE, 1987, GENE, V61, P177, DOI 10.1016/0378-1119(87)90112-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOKESHWAR VB, 1990, J BIOL CHEM, V265, P1665; MCCUTCHAN TF, 1984, SCIENCE, V225, P625, DOI 10.1126/science.6330899; Miller LH, 1998, NAT MED, V4, P520, DOI 10.1038/nm0598supp-520; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROGERS WO, 1992, P NATL ACAD SCI USA, V89, P9176, DOI 10.1073/pnas.89.19.9176; Sambrook J., 1989, IMMUNOLOGY, V2nd; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMYTHE JA, 1988, P NATL ACAD SCI USA, V85, P5195, DOI 10.1073/pnas.85.14.5195; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657; Stratmann T, 1997, PROTEIN EXPRES PURIF, V11, P72, DOI 10.1006/prep.1997.0768; SUHRBIER A, 1988, EUR J CELL BIOL, V46, P25; USUI H, 1994, J NEUROSCI, V14, P4915; WEBER JL, 1987, GENE, V52, P103, DOI 10.1016/0378-1119(87)90399-4; WEISS WR, 1992, J IMMUNOL, V149, P2103; *WHO, 1998, FACT SHEET N, V94; YOSHIDA N, 1980, SCIENCE, V207, P71, DOI 10.1126/science.6985745; ZAVALA F, 1983, J EXP MED, V157, P1947, DOI 10.1084/jem.157.6.1947	44	21	21	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26724	26731		10.1074/jbc.M103375200	http://dx.doi.org/10.1074/jbc.M103375200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11371568	Green Accepted, hybrid			2022-12-27	WOS:000169823300140
J	Ruiz, FA; Rodrigues, CO; Docampo, R				Ruiz, FA; Rodrigues, CO; Docampo, R			Rapid changes in polyphosphate content within acidocalcisomes in response to cell growth, differentiation, and environmental stress in Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOTOLERANT ALGA DUNALIELLA; NUCLEAR-MAGNETIC-RESONANCE; INORGANIC POLYPHOSPHATE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; LEISHMANIA-MAJOR; ACIDIC VACUOLES; ALKALINE STRESS; CALCIUM-PUMP; H+-ATPASE	Inorganic polyphosphate (polyP) has been identified and measured in different stages of Trypanosoma cruzi, Millimolar levels (in terms of Pi residues) in chains of less than 50 residues long, and micromolar levels in chains of about 700-800 residues long, were found in different stages of T, cruzi, Analysis of purified T, cruzi acidocalcisomes indicated that polyPs were preferentially located in these organelles. This was confirmed by visualization of polyPs in the acidocalcisomes using 4 ' ,6-diamidino-2-phenylindole. A rapid increase (within 2-4 h) in the levels of short and long chain polyPs was detected during trypomastigote to amastigote differentiation and during the lag phase of growth of epimastigotes (within 12-24 h), Levels rapidly decreased after the epimastigotes resumed growth. Short and long chain polyP levels rapidly decreased upon exposure of epimastigotes to hypo-osmotic or alkaline stresses, whereas levels increased after hyperosmotic stress. Ca2+ release from acidocalcisomes by a combination of ionophores (ionomycin and nigericin) was associated with the hydrolysis of short and long chain polyPs, In agreement with these results, acidocalcisomes were shown to contain polyphosphate kinase and exopolyphosphatase activities. Together, these results suggest a critical role for these organelles in the adaptation of the parasite to environmental changes.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.		Ruiz, Felix A./B-1032-2008	Ruiz, Felix A./0000-0003-0748-5015	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023259, R21AI023259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN RA, 1980, CAN J MICROBIOL, V26, P912, DOI 10.1139/m80-158; Ault-Riche D, 1998, J BACTERIOL, V180, P1841; BONE GJ, 1956, NATURE, V178, P308, DOI 10.1038/178308a0; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; CASTRO CD, 1995, APPL ENVIRON MICROB, V61, P4448, DOI 10.1128/AEM.61.12.4448-4453.1995; Castrol CD, 1999, BIOTECHNOL PROGR, V15, P65, DOI 10.1021/bp9800743; Chapman A G, 1977, Adv Microb Physiol, V15, P253, DOI 10.1016/S0065-2911(08)60318-5; CROOKE E, 1994, J BIOL CHEM, V269, P6290; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Furuya T, 2000, J BIOL CHEM, V275, P6428, DOI 10.1074/jbc.275.9.6428; HAROLD FM, 1966, BACTERIOL REV, V30, P772, DOI 10.1128/MMBR.30.4.772-794.1966; Ho AM, 2000, SCIENCE, V289, P265, DOI 10.1126/science.289.5477.265; JACOBSON L, 1982, BIOCHEM J, V201, P473, DOI 10.1042/bj2010473; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; KORNBERG A, 1956, J BIOL CHEM, V218, P23; Kulaev I, 1999, J BIOSCI BIOENG, V88, P111, DOI 10.1016/S1389-1723(99)80189-3; Kulaev I S, 1999, Prog Mol Subcell Biol, V23, P27; KUMBLE KD, 1995, J BIOL CHEM, V270, P5818, DOI 10.1074/jbc.270.11.5818; Kumble KD, 1996, J BIOL CHEM, V271, P27146, DOI 10.1074/jbc.271.43.27146; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LeFurgey A, 2001, COMP BIOCHEM PHYS A, V128, P385, DOI 10.1016/S1095-6433(00)00319-6; LIU CM, 1978, J BIOL CHEM, V253, P5892; Lorenz B, 1997, ANAL BIOCHEM, V246, P176, DOI 10.1006/abio.1996.9998; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; Lu HG, 1997, J BIOL CHEM, V272, P9464, DOI 10.1074/jbc.272.14.9464; Meyer A., 1904, BOT Z, V62, P113; Miranda K, 2000, PARASITOL RES, V86, P373, DOI 10.1007/s004360050682; Moreno B, 2000, J BIOL CHEM, V275, P28356, DOI 10.1074/jbc.M003893200; Myler PJ, 1999, P NATL ACAD SCI USA, V96, P2902, DOI 10.1073/pnas.96.6.2902; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; PICK U, 1991, PLANT PHYSIOL, V97, P1234, DOI 10.1104/pp.97.3.1234; PICK U, 1991, PLANT PHYSIOL, V97, P1226, DOI 10.1104/pp.97.3.1226; RANGELALDAO R, 1987, MOL BIOCHEM PARASIT, V22, P39, DOI 10.1016/0166-6851(87)90067-3; Rao NN, 1998, J BACTERIOL, V180, P2186, DOI 10.1128/JB.180.8.2186-2193.1998; Rao NN, 1996, J BACTERIOL, V178, P1394, DOI 10.1128/jb.178.5.1394-1400.1996; Rodrigues CO, 1999, BIOCHEM J, V340, P759, DOI 10.1042/0264-6021:3400759; Rodrigues CO, 1999, MOL CELL BIOL, V19, P7712; ROSENBERG H, 1969, BIOCHIM BIOPHYS ACTA, V184, P191, DOI 10.1016/0304-4165(69)90114-7; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 1997, J BIOL CHEM, V272, P28020, DOI 10.1074/jbc.272.44.28020; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; TIJSSEN JPF, 1982, BIOCHIM BIOPHYS ACTA, V721, P394, DOI 10.1016/0167-4889(82)90094-5; Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609; Vanderheyden N, 1996, BIOCHEM J, V318, P103, DOI 10.1042/bj3180103; Vercesi AE, 1996, BIOCHEM J, V315, P265, DOI 10.1042/bj3150265; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; Vieira LL, 1997, MOL BIOCHEM PARASIT, V90, P449, DOI 10.1016/S0166-6851(97)00180-1; WEISS M, 1991, PLANT PHYSIOL, V97, P1241, DOI 10.1104/pp.97.3.1241; *WHO, 1997, 13 WHO UNDPWBTDR, P112; WILKINSON JF, 1960, INT REV CYTOL, V9, P1, DOI 10.1016/S0074-7696(08)62744-8; WURST H, 1994, J BIOL CHEM, V269, P10996; WURST H, 1995, J BACTERIOL, V177, P898, DOI 10.1128/jb.177.4.898-906.1995; YANG YC, 1993, BIOCHIM BIOPHYS ACTA, V1179, P141, DOI 10.1016/0167-4889(93)90135-C	54	126	128	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26114	26121		10.1074/jbc.M102402200	http://dx.doi.org/10.1074/jbc.M102402200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11371561	hybrid			2022-12-27	WOS:000169823300065
J	Jansen, SM; Groener, JEM; Bax, W; Suter, A; Saftig, P; Somerharju, P; Poorthuis, BJHM				Jansen, SM; Groener, JEM; Bax, W; Suter, A; Saftig, P; Somerharju, P; Poorthuis, BJHM			Biosynthesis of phosphatidylcholine from a phosphocholine precursor pool derived from the late endosomal/lysosomal degradation of sphingomyelin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL ACID-PHOSPHATASE; TARTRATE-RESISTANT; ALKALINE-PHOSPHATASE; PHOSPHOLIPID ANALOG; SKIN FIBROBLASTS; KIDNEY CELLS; HEXADECYLPHOSPHOCHOLINE; LOCALIZATION; METABOLITES; SEPARATION	Previous studies suggest that the steps of the CDP-choline pathway of phosphatidylcholine synthesis are tightly linked in a so-called metabolon, Evidence has been presented that only choline that enters cells through the choline transporter, and not phosphocholine administered to cells by membrane permeabilization, is incorporated into phosphatidylcholine, Here, we show that [C-14]phosphocholine derived from the lysosomal degradation of [C-14]choline-labeled sphingomyelin is incorporated as such into phosphatidylcholine in human and mouse fibroblasts, Low density lipoprotein receptor-mediated endocytosis was used to specifically direct [C-14]sphingomyelin to the lysosomal degradation pathway, Free labeled choline was not found either intracellularly or in the medium, not even when the cells were energy-depleted. Deficiency of lysosomal acid phosphatases in mouse or alkaline phosphatase in human fibroblasts did not affect the incorporation of lysosomal [C-14]sphingomyelin-derived [C-14]phosphocholine into phosphatidylcholine, supporting our finding that phosphocholine is not degraded to choline prior to its incorporation into phosphatidylcholine. Inhibition studies and analysis of molecular species showed that exogenous [H-3]choline and sphingomyelin-derived [C-14]phosphocholine are incorporated into phosphatidylcholine via a common pathway of synthesis. Our findings provide evidence that, in fibroblasts, phosphocholine derived from sphingomyelin is transported out of the lysosome and subsequently incorporated into phosphatidylcholine without prior hydrolysis of phosphocholine to choline, The findings do not support the existence of a phosphatidylcholine synthesis metabolon in fibroblasts.	Leiden Univ, Med Ctr, Dept Pediat, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Genet, NL-2300 RC Leiden, Netherlands; Univ Helsinki, Inst Biomed, Dept Med Chem, Helsinki 00016, Finland; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Helsinki; University of Gottingen	Poorthuis, BJHM (corresponding author), Leiden Univ, Med Ctr, Dept Pediat, Bldg 1,P3-P,POB 9600, NL-2300 RC Leiden, Netherlands.		Saftig, Paul/A-7966-2010					ARSENIS C, 1968, J BIOL CHEM, V243, P5702; Bladergroen BA, 1998, BIOCHEM J, V334, P511, DOI 10.1042/bj3340511; Boggs K, 1998, BBA-LIPID LIPID MET, V1389, P1, DOI 10.1016/S0005-2760(97)00145-8; CLARK SA, 1989, J BONE MINER RES, V4, P399; DECHAVES EP, 1995, BIOCHEM J, V312, P411, DOI 10.1042/bj3120411; DETMAR M, 1994, J INVEST DERMATOL, V102, P490, DOI 10.1111/1523-1747.ep12373109; DREXLER HG, 1994, LEUKEMIA, V8, P359; FEDDE KN, 1990, AM J HUM GENET, V47, P776; FEDDE KN, 1990, AM J HUM GENET, V47, P767; FOLCH J, 1957, J BIOL CHEM, V226, P497; GEILEN CC, 1992, J BIOL CHEM, V267, P6719; GEILEN CC, 1994, J LIPID RES, V35, P625; GEORGE TP, 1989, BIOCHIM BIOPHYS ACTA, V1004, P283, DOI 10.1016/0005-2760(89)90075-1; Hayman AR, 1996, DEVELOPMENT, V122, P3151; Jansen SM, 1999, BBA-MOL CELL BIOL L, V1436, P363, DOI 10.1016/S0005-2760(98)00129-5; KATES M, 1991, TECHNIQUES LIPIDOLOG, P251; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; Koivusalo M, 2001, J LIPID RES, V42, P663; KUNZE H, 1993, BIOCHIM BIOPHYS ACTA, V1169, P273, DOI 10.1016/0005-2760(93)90251-4; KUNZE H, 1993, J CHROMATOGR, V636, P221, DOI 10.1016/0021-9673(93)80235-Z; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OBRIEN JS, 1970, NEW ENGL J MED, V283, P15, DOI 10.1056/NEJM197007022830104; PATTON GM, 1982, J LIPID RES, V23, P190; Saftig P, 1997, J BIOL CHEM, V272, P18628, DOI 10.1074/jbc.272.30.18628; VAN HELVOORT A, 1994, J BIOL CHEM, V269, P1763; WAHEED A, 1985, BIOCHEM GENET, V23, P309, DOI 10.1007/BF00504327; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WANDERS RJA, 1993, BIOCHIM BIOPHYS ACTA, V1181, P219, DOI 10.1016/0925-4439(93)90024-U; Wieder T, 1996, CANCER LETT, V100, P71, DOI 10.1016/0304-3835(95)04072-2; Zlatkine P, 1996, BIOCHEM J, V315, P983, DOI 10.1042/bj3150983	30	12	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18722	18727		10.1074/jbc.M101817200	http://dx.doi.org/10.1074/jbc.M101817200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376003	hybrid			2022-12-27	WOS:000169091000012
J	Shang, ML; Koshikawa, N; Schenk, S; Quaranta, V				Shang, ML; Koshikawa, N; Schenk, S; Quaranta, V			The LG3 module of laminin-5 harbors a binding site for integrin alpha(3)beta(1) that promotes cell adhesion, spreading, and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-3 CHAIN; LIGAND-BINDING; STRUCTURAL REQUIREMENT; DIRECTED MUTAGENESIS; SIGNAL-TRANSDUCTION; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; CRYSTAL-STRUCTURE; EPITHELIAL-CELLS; GLOBULAR DOMAIN	Laminins are a family of extracellular matrix glycoproteins involved in cell adhesion and migration. A major obstacle to understanding their structure-function relationships is the lack of small laminin domains capable of replicating integrin-binding, cell-adhesive, and migratory functions of the intact molecule. Here, we show that the recombinant LG3 (rLG3) module (26 kDa) of laminin-5 (Ln-5) alpha (3) chain replicated key Ln-5 activities. rLG3 but not rLG1 or rLG2 supported cell adhesion and migration of at least two distinct cell lines, in an integrin alpha (3)beta (1)-dependent manner. Cell adhesion to rLG3 was regulated by divalent cations and accompanied by cell spreading and tyrosine phosphorylation of FAK focal adhesion kinase. The integrin binding activity of rLG3 was confirmed by rLG3 affinity chromatography of detergent cell lysates, which resulted in specific purification of integrin alpha (3)beta (1). To our knowledge, this is the first report directly demonstrating that a recombinant laminin LG module is an active domain capable of supporting integrin-dependent cell adhesion and migration.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Quaranta, V (corresponding author), Scripps Res Inst, Dept Cell Biol, SBR-12,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Quaranta, Vito/G-6512-2016	Quaranta, Vito/0000-0001-7491-8672	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046902] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46902] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOTA S, 1991, J BIOL CHEM, V266, P15938; Ay J, 1998, P NATL ACAD SCI USA, V95, P6613, DOI 10.1073/pnas.95.12.6613; Baker SE, 1996, J CELL SCI, V109, P2509; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Bazzoni G, 1998, J BIOL CHEM, V273, P6670, DOI 10.1074/jbc.273.12.6670; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CRENNELL S, 1994, STRUCTURE, V2, P535, DOI 10.1016/S0969-2126(00)00053-8; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; DOMLOGEHULTSCH N, 1992, J CLIN INVEST, V90, P1628, DOI 10.1172/JCI116033; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; GALLIANO MF, 1995, J BIOL CHEM, V270, P21820, DOI 10.1074/jbc.270.37.21820; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; GIL SG, 1994, J INVEST DERMATOL, V103, pS31, DOI 10.1111/1523-1747.ep12398953; Gonzales M, 1999, MOL BIOL CELL, V10, P259, DOI 10.1091/mbc.10.2.259; Hintermann E, 2001, J CELL BIOL, V153, P465, DOI 10.1083/jcb.153.3.465; Hirosaki T, 2000, J BIOL CHEM, V275, P22495, DOI 10.1074/jbc.M001326200; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; Kim MG, 2000, J IMMUNOL, V165, P192, DOI 10.4049/jimmunol.165.1.192; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lampe PD, 1998, J CELL BIOL, V143, P1735, DOI 10.1083/jcb.143.6.1735; LEONG L, 1995, J CELL SCI, V108, P3817; Malinda KM, 1996, INT J BIOCHEM CELL B, V28, P957, DOI 10.1016/1357-2725(96)00042-8; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; Mathus TL, 2000, METH MOL B, V139, P27; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; Nagai T, 1991, Seikagaku, V63, P507; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Plopper GE, 1998, BREAST CANCER RES TR, V51, P57, DOI 10.1023/A:1006086218174; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; ROUSSELLE P, 1995, J BIOL CHEM, V270, P13766, DOI 10.1074/jbc.270.23.13766; Rudenko G, 1999, CELL, V99, P93, DOI 10.1016/S0092-8674(00)80065-3; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Skyldberg B, 1999, J NATL CANCER I, V91, P1882, DOI 10.1093/jnci/91.21.1882; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; Sordat I, 1998, J PATHOL, V185, P44, DOI 10.1002/(SICI)1096-9896(199805)185:1<44::AID-PATH46>3.0.CO;2-A; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Takeda A, 1999, J INVEST DERMATOL, V113, P38, DOI 10.1046/j.1523-1747.1999.00645.x; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; Tozer EC, 1996, BIOCHEM CELL BIOL, V74, P785, DOI 10.1139/o96-085; Tsubota Y, 2000, BIOCHEM BIOPH RES CO, V278, P614, DOI 10.1006/bbrc.2000.3851; Tsunenaga M, 1998, MATRIX BIOL, V17, P603, DOI 10.1016/S0945-053X(98)90111-1; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280; [No title captured]	65	81	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33045	33053		10.1074/jbc.M100798200	http://dx.doi.org/10.1074/jbc.M100798200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11395486	hybrid			2022-12-27	WOS:000170746000089
J	Brasier, AR; Lu, MP; Hai, T; Lu, Y; Boldogh, I				Brasier, AR; Lu, MP; Hai, T; Lu, Y; Boldogh, I			NF-kappa B-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-kappa B1 residence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDATE PROTOONCOGENE BCL-3; RENIN-ANGIOTENSIN SYSTEM; TRANSCRIPTION FACTOR; ONCOPROTEIN BCL-3; SIGNAL-TRANSDUCTION; ALPHA PROTEOLYSIS; EPITHELIAL-CELLS; FEEDBACK LOOP; TNF RECEPTOR; REL-A	NF-kappaB is a transcription factor whose nuclear residence is controlled by I kappaB family members. In the NF kappaB-I kappaB autoregulatory loop, activated (nuclear) ReI A.NF-kappa B1 induces the resynthesis of I kappaB alpha recapturing nuclear Rel A back into the cytoplasm within 1 h of stimulation. In contrast, NF-kappa B1 subunits redistribute more slowly into the cytoplasm (from 6 to 12 h). Here we examine the role of inducible cytoplasmic BCL-3 expression in terminating nuclear NF-kappaB 1. Although BCL-3 is a nuclear protein in B lymphocytes, surprisingly, BCL-3 is primarily a cytoplasmic protein in HepG2 cells. Cytoplasmic BCL-3 abundance is induced 6-12 h after tumor necrosis factor-a stimulation where it complexes with NF-kappa B1 homodimers. Moreover, BCL-3 mRNA and protein expression are induced by NF-kappaB-activating agents. Two observations are interpreted to indicate that bcl-3 is transactivated by NF-kappaB/Rel A: 1) expression of a dominant negative NF-kappaB inhibitor blocks tumor necrosis factor-a-induced BCL-3 expression and 2) expression of constitutively active Rel A is sufficient to induce BCL-3 expression. In gene transfer studies, we identify two high affinity NF-kappaB-binding sites, kappa B1 (located at -872 to -861 nucleotides) and kappa B2 (-106 to -96 nucleotides), and although both bind with high affinity to Rel A only kappa B2 is required for NF-v-B-dependent induction of the native BCL-3 promoter. Down-regulation of BCL-3 induction results in prolonged, enhanced NF-kappa B1 binding and increased NF-kappaB-dependent transcription. Together, these data suggest the presence of an N-F-kappaB-BCL-3 autoregulatory loop important in terminating NF-kappa B1 action and that individual NF-kappaB isoforms are actively terminated through coordinate induction of inhibitory I kappaB molecules to restore cellular homeostasis.	Univ Texas, Med Branch, Div Endocrinol, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Brasier, AR (corresponding author), Univ Texas, Med Branch, Div Endocrinol, Dept Microbiol & Immunol, MRB 8-138,301 Univ Blvd, Galveston, TX 77555 USA.		Hai, Tsonwin/E-3185-2011	Hai, Tsonwin/0000-0003-4510-0315; Brasier, Allan/0000-0002-5012-4090	NATIONAL CANCER INSTITUTE [R01CA084461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084461] Funding Source: Medline; NIEHS NIH HHS [ES06676, P30 ES006676] Funding Source: Medline; PHS HHS [55630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; BRASIER AR, 1990, CURRENT PROTOCOLS MO; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; CHENG Q, 1994, J BIOL CHEM, V269, P13551; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Garofalo R, 1996, J VIROL, V70, P8773, DOI 10.1128/JVI.70.12.8773-8781.1996; HAN Y, 1997, J BIOL CHEM, V272, P9823; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Han YQ, 1999, J BIOL CHEM, V274, P939, DOI 10.1074/jbc.274.2.939; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JAFFREY SR, 1993, NUCLEIC ACIDS RES, V21, P4627, DOI 10.1093/nar/21.19.4627; Jamaluddin M, 2000, MOL ENDOCRINOL, V14, P99, DOI 10.1210/me.14.1.99; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Li JY, 1996, MOL ENDOCRINOL, V10, P252, DOI 10.1210/me.10.3.252; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PADMANABHAN R, 1993, METHOD ENZYMOL, V218, P637; Pastore L, 1999, CIRCULATION, V100, P1646, DOI 10.1161/01.CIR.100.15.1646; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Richard M, 1999, BLOOD, V93, P4318, DOI 10.1182/blood.V93.12.4318.412k09_4318_4327; RON D, 1990, MOL CELL BIOL, V10, P4389, DOI 10.1128/MCB.10.8.4389; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tummala PE, 1999, CIRCULATION, V100, P1223, DOI 10.1161/01.CIR.100.11.1223; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; Zhang MY, 1998, BLOOD, V92, P1225, DOI 10.1182/blood.V92.4.1225.416k20_1225_1234; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	62	84	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32080	32093		10.1074/jbc.M102949200	http://dx.doi.org/10.1074/jbc.M102949200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11387332	hybrid			2022-12-27	WOS:000170613500084
J	Lambeir, AM; Proost, P; Durinx, C; Bal, G; Senten, K; Augustyns, K; Scharpe, S; Van Damme, J; De Meester, I				Lambeir, AM; Proost, P; Durinx, C; Bal, G; Senten, K; Augustyns, K; Scharpe, S; Van Damme, J; De Meester, I			Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE-DERIVED CHEMOKINE; HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL GROWTH; ANTI-HIV-1 ACTIVITY; CHEMOTACTIC ACTIVITY; FACTOR 1-ALPHA; HUMAN EOTAXIN; CD26; RECEPTOR; RANTES	Chemokines coordinate many aspects of leukocyte migration. As chemoattractants they play an important role in the innate and acquired immune response. There is good experimental evidence that N-terminal truncation by secreted or cell surface proteases is a way of modulating chemokine action. The localization of CD26/dipeptidyl peptidase IV on cell surfaces and in biological fluids, its primary specificity, and the type of naturally occurring truncated chemokines are consistent with such a function. We determined the steady-state catalytic parameters for a relevant selection of chemokines (CCL3b, CCL5, CCL11, CCL22, CXCL9, CXCL10, CXCL11, and CXCL12) previously reported to alter their chemotactic behavior due to CD26/dipeptidyl peptidase IV-catalyzed truncation. The results reveal a striking selectivity for stromal cell-derived factor-la (CXCL12) and macrophage-derived chemokine (CCL22). The kinetic parameters support the hypothesis that CD26/dipeptidyl peptidase IV contributes to the degradation of certain chemokines in vivo. The data not only provide insight into the selectivity of the enzyme for specific chemokines, but they also contribute to the general understanding of CD26/dipeptidyl peptidase IV secondary substrate specificity.	Univ Antwerp, Med Biochem Lab, Dept Pharmaceut Sci, B-2610 Antwerp, Belgium; Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium; Univ Antwerp, Dept Pharmaceut Sci, Med Chem Lab, B-2610 Antwerp, Belgium	University of Antwerp; KU Leuven; University of Antwerp	Lambeir, AM (corresponding author), Univ Antwerp, Med Biochem Lab, Dept Pharmaceut Sci, Univ Pl 1 S6, B-2610 Antwerp, Belgium.		Augustyns, Koen/ABG-2306-2020; De Meester, Ingrid/A-6881-2017; Proost, Paul/V-3052-2017; Lambeir, Anne-Marie/B-2477-2017; Augustyns, Koen/C-1102-2008	Augustyns, Koen/0000-0002-5203-4339; De Meester, Ingrid/0000-0002-3421-0124; Proost, Paul/0000-0002-0133-5545; Lambeir, Anne-Marie/0000-0001-9386-3777; Augustyns, Koen/0000-0002-5203-4339; Durinx, Christine/0000-0003-4237-8899				Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Belyaev A, 1999, J MED CHEM, V42, P1041, DOI 10.1021/jm981033g; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BONGERS J, 1992, BIOCHIM BIOPHYS ACTA, V1122, P147, DOI 10.1016/0167-4838(92)90317-7; BREZINSCHEK RI, 1995, J IMMUNOL, V154, P3062; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; Delgado MB, 2001, EUR J IMMUNOL, V31, P699, DOI 10.1002/1521-4141(200103)31:3<699::AID-IMMU699>3.0.CO;2-6; DeMeester I, 1996, J IMMUNOL METHODS, V189, P99, DOI 10.1016/0022-1759(95)00239-1; DEMEESTER IA, 1995, J LEUKOCYTE BIOL, V58, P325, DOI 10.1002/jlb.58.3.325; Durinx C, 2000, EUR J BIOCHEM, V267, P5608, DOI 10.1046/j.1432-1327.2000.01634.x; Fulop V, 2001, J BIOL CHEM, V276, P1262, DOI 10.1074/jbc.M007003200; Garzino-Demo A, 2000, IMMUNOL REV, V177, P79, DOI 10.1034/j.1600-065X.2000.17711.x; Huhn J, 2000, IMMUNOL LETT, V72, P127, DOI 10.1016/S0165-2478(00)00170-X; Iwata S, 1999, INT IMMUNOL, V11, P417, DOI 10.1093/intimm/11.3.417; Kahne T, 1999, INT J MOL MED, V4, P3; Kinter A, 2000, IMMUNOL REV, V177, P88, DOI 10.1034/j.1600-065X.2000.17708.x; Lambeir AM, 1997, BBA-PROTEIN STRUCT M, V1340, P215, DOI 10.1016/S0167-4838(97)00045-9; Lee B, 1999, P NATL ACAD SCI USA, V96, P5215, DOI 10.1073/pnas.96.9.5215; Menten P, 1999, J CLIN INVEST, V104, pR1, DOI 10.1172/JCI7318; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nibbs RJB, 1999, J BIOL CHEM, V274, P17478, DOI 10.1074/jbc.274.25.17478; Noso N, 1998, EUR J BIOCHEM, V253, P114, DOI 10.1046/j.1432-1327.1998.2530114.x; NOSO N, 1996, J IMMUNOL, V156, P1046; Ohtsuki T, 1998, FEBS LETT, V431, P236, DOI 10.1016/S0014-5793(98)00763-7; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Pal R, 1997, SCIENCE, V278, P695, DOI 10.1126/science.278.5338.695; PAL R, 1998, SCIENCE, V281, P487; Pauly RP, 1996, J BIOL CHEM, V271, P23222, DOI 10.1074/jbc.271.38.23222; Pospisilik JA, 2001, REGUL PEPTIDES, V96, P133, DOI 10.1016/S0167-0115(00)00170-1; Proost P, 2000, BLOOD, V96, P1674, DOI 10.1182/blood.V96.5.1674.h8001674a_1674_1680; Proost P, 1998, FEBS LETT, V432, P73, DOI 10.1016/S0014-5793(98)00830-8; Proost P, 1999, J BIOL CHEM, V274, P3988, DOI 10.1074/jbc.274.7.3988; Proost P, 1998, EUR CYTOKINE NETW, V9, P73; Proost P, 1998, J BIOL CHEM, V273, P7222, DOI 10.1074/jbc.273.13.7222; Ruiz P, 1997, TRANSPL IMMUNOL, V5, P152, DOI 10.1016/S0966-3274(97)80056-1; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; SCHLECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157; Schols D, 1998, ANTIVIR RES, V39, P175, DOI 10.1016/S0166-3542(98)00039-4; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; Simmons G, 2000, IMMUNOL REV, V177, P112, DOI 10.1034/j.1600-065X.2000.17719.x; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; Struyf S, 1999, J IMMUNOL, V162, P4903; Struyf S, 1998, J IMMUNOL, V161, P2672; Struyf S, 1998, EUR J IMMUNOL, V28, P1262, DOI 10.1002/(SICI)1521-4141(199804)28:04<1262::AID-IMMU1262>3.0.CO;2-G; Tensen CP, 1999, J INVEST DERMATOL, V112, P716, DOI 10.1046/j.1523-1747.1999.00581.x; Van Coillie E, 1998, BIOCHEMISTRY-US, V37, P12672, DOI 10.1021/bi980497d; VANHAM G, 1993, J ACQ IMMUN DEF SYND, V6, P749; Vulcano M, 2001, EUR J IMMUNOL, V31, P812, DOI 10.1002/1521-4141(200103)31:3<812::AID-IMMU812>3.0.CO;2-L; Willheim M, 1997, J ALLERGY CLIN IMMUN, V100, P348, DOI 10.1016/S0091-6749(97)70248-3; Wrenger S, 2000, J BIOL CHEM, V275, P22180, DOI 10.1074/jbc.M002338200; Wrenger S, 1997, J BIOL CHEM, V272, P30283, DOI 10.1074/jbc.272.48.30283; Wuyts A, 1999, EUR J BIOCHEM, V260, P421, DOI 10.1046/j.1432-1327.1999.00166.x; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1	59	225	244	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29839	29845		10.1074/jbc.M103106200	http://dx.doi.org/10.1074/jbc.M103106200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390394	hybrid			2022-12-27	WOS:000170558000033
J	Cochran, JR; Cameron, TO; Stone, JD; Lubetsky, JB; Stern, LJ				Cochran, JR; Cameron, TO; Stone, JD; Lubetsky, JB; Stern, LJ			Receptor proximity, not intermolecular orientation, is critical for triggering T-cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC-PEPTIDE COMPLEXES; CLASS-II MOLECULES; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; INFLUENZA HEMAGGLUTININ; MULTIVALENT STRUCTURE; ZETA-CHAIN; HLA-DR; DIMERIZATION; HLA-DR1	Engagement of antigen receptors on the surface of T-cells with peptides bound to major histocompatibility complex (MHC) proteins triggers T-cell activation in a mechanism involving receptor oligomerization. Receptor dimerization by soluble MHC oligomers is sufficient to induce several characteristic activation processes in T-cells including internalization of engaged receptors and up-regulation of cell surface proteins. In this work, the influence of intermolecular orientation within the activating receptor dimer was studied. Dimers of class II MHC proteins coupled in a variety of orientations and topologies each were able to activate CD4(+) T-cells, indicating that triggering was not dependent on a particular receptor orientation. In contrast to the minimal influence of receptor orientation, T-cell triggering was affected by the inter-molecular distance between MHC molecules, and MHC dimers coupled through shot-ter cross-linkers were consistently more potent than those coupled through longer cross-linkers. These results are consistent with a mechanism in which intermolecular receptor proximity, but not intermolecular orientation, is the key determinant for antigen-induced CD4(+) T-cell activation.	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Stern, LJ (corresponding author), MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	stern@mit.edu			NIAID NIH HHS [N01AI95361] Funding Source: Medline; NIGMS NIH HHS [T32 GM08334] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008334] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1995, J EXP MED, V182, P439, DOI 10.1084/jem.182.2.439; Aivazian D, 2000, NAT STRUCT BIOL, V7, P1023; Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; Appel H, 2000, J BIOL CHEM, V275, P312, DOI 10.1074/jbc.275.1.312; Bachmann MF, 1999, IMMUNOL TODAY, V20, P568, DOI 10.1016/S0167-5699(99)01543-1; BEKOFF M, 1986, J IMMUNOL, V137, P1411; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUBIS J, 1990, J BIOL CHEM, V265, P12995; Cameron TO, 2001, J IMMUNOL, V166, P741, DOI 10.4049/jimmunol.166.2.741; Casares S, 1999, J EXP MED, V190, P543, DOI 10.1084/jem.190.4.543; Chambers CA, 1999, CURR OPIN CELL BIOL, V11, P203, DOI 10.1016/S0955-0674(99)80027-1; Chambers CA, 2001, TRENDS IMMUNOL, V22, P217, DOI 10.1016/S1471-4906(01)01868-3; Cherry RJ, 1998, J CELL BIOL, V140, P71, DOI 10.1083/jcb.140.1.71; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; Cochran JR, 2000, IMMUNITY, V12, P241, DOI 10.1016/S1074-7613(00)80177-6; Cochran JR, 2000, CHEM BIOL, V7, P683, DOI 10.1016/S1074-5521(00)00019-3; Cochran JR, 2001, TRENDS BIOCHEM SCI, V26, P304, DOI 10.1016/S0968-0004(01)01815-1; Delon J, 1998, IMMUNITY, V9, P467, DOI 10.1016/S1074-7613(00)80630-5; EXLEY M, 1995, MOL IMMUNOL, V32, P829, DOI 10.1016/0161-5890(95)00046-H; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Fernandez-Miguel G, 1999, P NATL ACAD SCI USA, V96, P1547, DOI 10.1073/pnas.96.4.1547; Fields BA, 1996, IMMUNOL TODAY, V17, P330, DOI 10.1016/0167-5699(96)10020-7; FOX BS, 1987, J IMMUNOL, V138, P3367; Frayser M, 1999, PROTEIN EXPRES PURIF, V15, P105, DOI 10.1006/prep.1998.0987; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Glimcher LH, 1999, CELL, V96, P13, DOI 10.1016/S0092-8674(00)80955-1; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hamad ARA, 1998, J EXP MED, V188, P1633, DOI 10.1084/jem.188.9.1633; Hennecke J, 2001, CELL, V104, P1, DOI 10.1016/S0092-8674(01)00185-4; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; Itoh Y, 1999, J IMMUNOL, V162, P2073; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Jose ES, 1998, EUR J IMMUNOL, V28, P12; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; LAMB JR, 1982, NATURE, V300, P66, DOI 10.1038/300066a0; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Ponka P, 1999, INT J BIOCHEM CELL B, V31, P1111, DOI 10.1016/S1357-2725(99)00070-9; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Reay PA, 2000, J IMMUNOL, V164, P5626, DOI 10.4049/jimmunol.164.11.5626; ROCHE PA, 1990, J IMMUNOL, V144, P1849; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; Roucard C, 1996, J BIOL CHEM, V271, P13993, DOI 10.1074/jbc.271.24.13993; Schafer P H, 1995, Semin Immunol, V7, P389, DOI 10.1006/smim.1995.0043; Schafer PH, 1998, J IMMUNOL, V161, P2307; Sousa J, 2000, EUR J IMMUNOL, V30, P3219, DOI 10.1002/1521-4141(200011)30:11<3219::AID-IMMU3219>3.0.CO;2-7; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; Triantafilou K, 2000, HUM IMMUNOL, V61, P585, DOI 10.1016/S0198-8859(00)00112-9; Triantafilou K, 2000, CRIT REV IMMUNOL, V20, P359; Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; van der Merwe PA, 2000, SEMIN IMMUNOL, V12, P5, DOI 10.1006/smim.2000.0203; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WATTS TH, 1988, J IMMUNOL, V141, P3708; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; YOON ST, 1994, IMMUNITY, V1, P563; Zarutskie JA, 1999, BIOCHEMISTRY-US, V38, P5878, DOI 10.1021/bi983048m	67	53	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28068	28074		10.1074/jbc.M103280200	http://dx.doi.org/10.1074/jbc.M103280200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11384988	hybrid			2022-12-27	WOS:000170093400044
J	Huecas, S; Villalba, M; Rodriguez, R				Huecas, S; Villalba, M; Rodriguez, R			Ole e 9, a major olive pollen allergen is a 1,3-beta-glucanase - Isolation, characterization, amino acid sequence, and tissue specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGENESIS-RELATED PROTEINS; DUST-MITE ALLERGEN; TREE POLLEN; EUROPEA POLLEN; E-I; BETA-1,3-GLUCANASE; TOBACCO; EXPRESSION; IDENTIFICATION; PURIFICATION	Olive pollen allergy is a clinical disorder affecting the human population of Mediterranean areas. A novel major allergen, Ole e 9, has been isolated from olive pollen by gel permeation, hydrophobic affinity, and reverse-phase high performance liquid chromatographies. It is involved in the allergic responses of 65% of patients suffering olive pollinosis. Ole e 9 (molecular mass of 46.4 kDa) displays 1,3-beta -endoglucanase activity (38.9 +/- 5.6 mg of glucose released/min x mu mol of protein at pH 4.5-6.0 using laminarin as substrate). It is the first 1,3-beta -glucanase, a member of the "pathogenesis-related" protein family, detected in pollen tissue. Seven tryptic peptides of the allergen were sequenced by Edman degradation and used for designing primers to clone the cDNA codifying the protein. Specific cDNA for Ole e 9 was synthesized from total RNA and amplified using the polymerase chain reaction. The allergen sequence showed an open reading frame of 460 amino acids comprising a putative signal peptide of 26 residues. It shows 39, 33, and 32% sequence identity including the catalytic residues when compared with 1,3-beta -glucanases from wheat, willow, and Arabidopsis thaliana, respectively. Northern blot analysis showed that Ole e 9 transcript is specifically expressed in the pollen tissue, and highly conserved counterparts were only detected in taxonomically related pollens.	Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol 1, E-28040 Madrid, Spain	Complutense University of Madrid	Rodriguez, R (corresponding author), Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol 1, Avda Complutense S-N, E-28040 Madrid, Spain.		Huecas, Sonia/P-2542-2019; Villalba, María Teresa/AAW-1067-2020; Villalba, Mayte/K-5365-2014; RODRIGUEZ, ROSALIA/K-4993-2014; Huecas, Sonia/K-1754-2014	Huecas, Sonia/0000-0002-6419-441X; Villalba, María Teresa/0000-0002-0042-9953; RODRIGUEZ, ROSALIA/0000-0002-4280-3691; Huecas, Sonia/0000-0002-6419-441X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; BALDO BA, 1992, MOL IMMUNOL, V29, P1209, DOI 10.1016/0161-5890(92)90057-5; BATANERO E, 1994, MOL IMMUNOL, V31, P31, DOI 10.1016/0161-5890(94)90135-X; Batanero E, 1997, FEBS LETT, V410, P293, DOI 10.1016/S0014-5793(97)00582-6; Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; BLANCA M, 1983, CLIN ALLERGY, V13, P473, DOI 10.1111/j.1365-2222.1983.tb02624.x; Boluda L, 1998, J ALLERGY CLIN IMMUN, V101, P210, DOI 10.1016/S0091-6749(98)70385-9; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BUCCIAGLIA PA, 1994, PLANT MOL BIOL, V24, P903, DOI 10.1007/BF00014444; CHEN L, 1993, J BIOL CHEM, V268, P13318; CHEN L, 1995, J BIOL CHEM, V270, P8093, DOI 10.1074/jbc.270.14.8093; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; CHYE ML, 1995, PLANT MOL BIOL, V29, P397, DOI 10.1007/BF00043663; CruzOrtega R, 1997, PLANT PHYSIOL, V114, P1453, DOI 10.1104/pp.114.4.1453; DELCAMPILLO E, 1992, PLANT PHYSIOL, V99, P1015, DOI 10.1104/pp.99.3.1015; Delp G, 1999, PLANT MOL BIOL, V39, P565, DOI 10.1023/A:1006194822666; DUDLER T, 1995, J IMMUNOL, V155, P2605; Futamura N, 2000, PLANT CELL PHYSIOL, V41, P16, DOI 10.1093/pcp/41.1.16; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; HIRD DL, 1993, PLANT J, V4, P1023, DOI 10.1046/j.1365-313X.1993.04061023.x; Hoffmann-Sommergruber K, 2000, INT ARCH ALLERGY IMM, V122, P155, DOI 10.1159/000024392; HOJ PB, 1995, PLANT J, V7, P367, DOI 10.1046/j.1365-313X.1995.7030367.x; Huecas S, 1999, EUR J BIOCHEM, V261, P539, DOI 10.1046/j.1432-1327.1999.00307.x; Juers DH, 1999, PROTEIN SCI, V8, P122; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUZURICA P, 1988, MOL IMMUNOL, V25, P329, DOI 10.1016/0161-5890(88)90027-2; Ledesma A, 1998, ALLERGY, V53, P520, DOI 10.1111/j.1398-9995.1998.tb04090.x; Ledesma A, 2000, FEBS LETT, V466, P192, DOI 10.1016/S0014-5793(99)01790-1; Leubner-Metzger G, 1999, PATHOGENESIS-RELATED PROTEINS IN PLANTS, P49; LOTAN T, 1989, PLANT CELL, V1, P881, DOI 10.1105/tpc.1.9.881; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACCHIA L, 1991, ALLERGENIC POLLEN PO, P87; Meins F. Jr., 1992, Genes involved in plant defense., P245; MEMELINK J, 1990, PLANT MOL BIOL, V14, P119, DOI 10.1007/BF00018553; Nelson N, 1944, J BIOL CHEM, V153, P375; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; ORI N, 1990, EMBO J, V9, P3429, DOI 10.1002/j.1460-2075.1990.tb07550.x; Peumans WJ, 2000, EUR J BIOCHEM, V267, P1188, DOI 10.1046/j.1432-1327.2000.01117.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sessa G, 1995, PLANT MOL BIOL, V29, P969, DOI 10.1007/BF00014970; SHINSHI H, 1988, P NATL ACAD SCI USA, V85, P5541, DOI 10.1073/pnas.85.15.5541; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; Stone BA, 1992, CHEM BIOL 1 3 BETA G; Subroto T, 1996, PHYTOCHEMISTRY, V43, P29, DOI 10.1016/0031-9422(96)00196-3; SUNDERASAN E, 1995, J RUBBER RES, V10, P82; TANIGUCHI Y, 1995, ALLERGY, V50, P90, DOI 10.1111/j.1398-9995.1995.tb02489.x; Tejera ML, 1999, J ALLERGY CLIN IMMUN, V104, P797, DOI 10.1016/S0091-6749(99)70290-3; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1998, INT ARCH ALLERGY IMM, V117, P160, DOI 10.1159/000024005; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; VANLOON LC, 1970, VIROLOGY, V40, P199, DOI 10.1016/0042-6822(70)90395-8; vanRee R, 1997, ALLERGY, V52, P795; VELA C, 1982, INT ARCH ALLER A IMM, V68, P289, DOI 10.1159/000233116; VILLALBA M, 1994, J BIOL CHEM, V269, P15217; VILLALBA M, 1993, EUR J BIOCHEM, V216, P863, DOI 10.1111/j.1432-1033.1993.tb18208.x; VOGELILANGE R, 1994, PLANT J, V5, P273, DOI 10.1046/j.1365-313X.1994.05020273.x; WARD ER, 1991, PLANT PHYSIOL, V96, P390, DOI 10.1104/pp.96.2.390; WHEELER AW, 1992, CLIN EXP ALLERGY, V22, P1052, DOI 10.1111/j.1365-2222.1992.tb00129.x; WHEELER AW, 1990, MOL IMMUNOL, V27, P631, DOI 10.1016/0161-5890(90)90005-K; Yagami T, 1998, J ALLERGY CLIN IMMUN, V101, P379, DOI 10.1016/S0091-6749(98)70251-9	68	90	92	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27959	27966		10.1074/jbc.M103041200	http://dx.doi.org/10.1074/jbc.M103041200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373288	hybrid			2022-12-27	WOS:000170093400030
J	Machin, A; Alonso, JMM; Parra, F				Machin, A; Alonso, JMM; Parra, F			Identification of the amino acid residue involved in rabbit hemorrhagic disease virus VPg uridylylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; DIVALENT-CATION MODULATION; POLIOVIRUS RNA; LINKED PROTEIN; CALICIVIRUS; GENOME; POLYPROTEIN; EXPRESSION; TEMPLATE; CLEAVAGE	The virus genome-linked protein (VPg) coding region from rabbit hemorrhagic disease virus (RHDV) (isolate AST/89) was expressed in Escherichia coli by using a glutathione S-transferase-based vector. The recombinant polypeptide could be purified in good yields and was uridylylated in vitro from [alpha-P-32]UTP in a reaction catalyzed by the recombinant RNA-dependent RNA polymerase from RHDV in the absence of added template RNA. The use of deletion and point mutants allowed the identification of Tyr-21 as the residue involved in uridylylation and consequently in the linkage between VPg and the viral genome. These data constitute the first report on the identity of the amino acid residue involved in VPg uridylylation in a member of the Caliciviridae family.	Univ Oviedo, Dept Bioquim & Biol Mol, Inst Univ Biotecnol Asturias, Consejo Super Invest Cient, E-33006 Oviedo, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Oviedo	Parra, F (corresponding author), Univ Oviedo, Dept Bioquim & Biol Mol, Inst Univ Biotecnol Asturias, Consejo Super Invest Cient, E-33006 Oviedo, Spain.	fparra@correo.uniovi.es	Parra, Francisco/D-5401-2009; Martin Alonso, Jose Manuel/C-7763-2013	Parra, Francisco/0000-0002-1885-9521; Martin Alonso, Jose Manuel/0000-0003-1725-6216				Alonso JMM, 1996, J VIROL, V70, P1261; AMBROS V, 1978, J BIOL CHEM, V253, P5263; Arnold JJ, 1999, J BIOL CHEM, V274, P37060, DOI 10.1074/jbc.274.52.37060; Boga J. A., 1999, Recent Research Developments in Virology, V1, P107; BURROUGHS JN, 1978, J GEN VIROL, V41, P443, DOI 10.1099/0022-1317-41-2-443; CIRINO NM, 1995, BIOCHEMISTRY-US, V34, P9936, DOI 10.1021/bi00031a016; Dunham DM, 1998, ARCH VIROL, V143, P2421, DOI 10.1007/s007050050471; Huang Y, 1997, BIOCHEMISTRY-US, V36, P13718, DOI 10.1021/bi971609o; Konig M, 1998, J VIROL, V72, P4492; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Meyers G, 2000, VIROLOGY, V276, P349, DOI 10.1006/viro.2000.0545; MEYERS G, 1991, VIROLOGY, V184, P677, DOI 10.1016/0042-6822(91)90437-G; OHLINGER VF, 1990, J VIROL, V64, P3331, DOI 10.1128/JVI.64.7.3331-3336.1990; PALMENBERG A, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1371, DOI 10.1073/pnas.71.4.1371; PARRA F, 1990, J VIROL, V64, P4013, DOI 10.1128/JVI.64.8.4013-4015.1990; Paul AV, 2000, J VIROL, V74, P10359, DOI 10.1128/JVI.74.22.10359-10370.2000; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Pringle C R, 1998, Arch Virol, V143, P1449, DOI 10.1007/s007050050389; ROTHBERG PG, 1978, P NATL ACAD SCI USA, V75, P4868, DOI 10.1073/pnas.75.10.4868; SOSNOVTSEV S, 1995, VIROLOGY, V210, P383, DOI 10.1006/viro.1995.1354; Sosnovtsev SV, 2000, VIROLOGY, V277, P193, DOI 10.1006/viro.2000.0579; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; Vazquez AL, 2000, J VIROL, V74, P3888, DOI 10.1128/JVI.74.8.3888-3891.2000; Vazquez AL, 2001, ARCH VIROL, V146, P59, DOI 10.1007/s007050170191; Vazquez AL, 1998, J VIROL, V72, P2999; Wirblich C, 1996, J VIROL, V70, P7974, DOI 10.1128/JVI.70.11.7974-7983.1996; WIRBLICH C, 1995, J VIROL, V69, P7159, DOI 10.1128/JVI.69.11.7159-7168.1995	27	44	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27787	27792		10.1074/jbc.M100707200	http://dx.doi.org/10.1074/jbc.M100707200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369764	hybrid			2022-12-27	WOS:000170093400008
J	Zhao, HH; Herrera, RE; Coronado-Heinsohn, E; Yang, MC; Ludes-Meyers, JH; Seybold-Tilson, KJ; Nawaz, Z; Yee, D; Barr, FG; Diab, SG; Brown, PH; Fuqua, SAW; Osborne, CK				Zhao, HH; Herrera, RE; Coronado-Heinsohn, E; Yang, MC; Ludes-Meyers, JH; Seybold-Tilson, KJ; Nawaz, Z; Yee, D; Barr, FG; Diab, SG; Brown, PH; Fuqua, SAW; Osborne, CK			Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR FKHR; PAX3-FKHR FUSION PROTEIN; ALVEOLAR RHABDOMYOSARCOMA; BREAST-CANCER; HORMONE-RECEPTOR; CHROMOSOMAL TRANSLOCATIONS; STEROID-RECEPTORS; THYROID-HORMONE; CO-REPRESSOR; N-COR	In a search for novel transcriptional intermediary factors for the estrogen receptor (ER), we used the ligand-binding domain and hinge region of ER as bait in a yeast two-hybrid screen of a cDNA library derived from tamoxifen-resistant MCF-7 human breast tumors from an in vivo athymic nude mouse model. Here we report the isolation and characterization of the forkhead homologue in rhabdomyosarcoma (FKHR), a recently described member of the hepatocyte nuclear factor 3/forkhead homeotic gene family, as a nuclear hormone receptor (NR) intermediary protein. FKHR interacts with both steroid and nonsteroid NRs, although the effect of ligand on this interaction varies by receptor type. The interaction of FKHR with ER is enhanced by estrogen, whereas its interaction with thyroid hormone receptor and retinoic acid receptor is ligand-independent. In addition, FKHR differentially regulates the transactivation mediated by different NRs. Transient transfection of FKHR into mammalian cells dramatically represses transcription mediated by the ER, glucocorticoid receptor, and progesterone receptor. In contrast, FKHR stimulates rather than represses retinoic acid receptor- and thyroid hormone receptor-mediated transactivation. Most intriguingly, overexpression of FKHR dramatically inhibits the proliferation of ER-dependent MCF-7 breast cancer cells. Therefore, FKHR represents a bifunctional NR intermediary protein that can act as either a coactivator or corepressor, depending on the receptor type.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Oncol, San Antonio, TX 78284 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine; Baylor College of Medicine; University of Pennsylvania	Herrera, RE (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Roszak, Joanna/F-4003-2010	Yee, Douglas/0000-0002-3387-4009	NCI NIH HHS [P50CA58183, P30CA54174, CA64202] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058183, R01CA064202, P30CA054174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BARR FG, 1995, JAMA-J AM MED ASSOC, V273, P553, DOI 10.1001/jama.273.7.553; Barr FG, 1997, INT J BIOCHEM CELL B, V29, P1449, DOI 10.1016/S1357-2725(97)00095-2; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; BIEGEL JA, 1995, GENE CHROMOSOME CANC, V12, P186, DOI 10.1002/gcc.2870120305; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Douarin BL, 1996, EMBO J, V15, P6701; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; FUQUA SAW, 1995, ENDOCR-RELAT CANCER, V2, P19, DOI 10.1677/erc.0.0020019; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; HANSEN RK, 1998, BREAST CANC MOL GENE, P1; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; Kelly KM, 1996, CANCER, V78, P1320, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1320::AID-CNCR22>3.3.CO;2-F; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; OSBORNE CK, 1985, CANCER RES, V45, P584; Osborne CK, 1996, BREAST, V5, P181, DOI 10.1016/S0960-9776(96)90090-9; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; OSBORNE CK, 1996, SCI AM SCI MED S, V3, P31; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SHAPIRO DN, 1993, CANCER RES, V53, P108; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; SUBLETT JE, 1995, ONCOGENE, V11, P545; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; TONETTI DA, 1995, ANTI-CANCER DRUG, V6, P498, DOI 10.1097/00001813-199508000-00002; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Vogt PK, 1997, VIROLOGY, V238, P1, DOI 10.1006/viro.1997.8846; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513	57	147	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27907	27912		10.1074/jbc.M104278200	http://dx.doi.org/10.1074/jbc.M104278200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11353774	hybrid			2022-12-27	WOS:000170093400023
J	Buczynski, G; Slepenkov, SV; Sehorn, MG; Witt, SN				Buczynski, G; Slepenkov, SV; Sehorn, MG; Witt, SN			Characterization of a lidless form of the molecular chaperone DnaK - Deletion of the lid increases peptide on- and off-rate constants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; GLUTATHIONE-S-TRANSFERASE; SUBSTRATE-BINDING; ESCHERICHIA-COLI; ATP HYDROLYSIS; BACTERIOPHAGE-LAMBDA; HSP70; PROTEIN; OLIGOMERIZATION; DISSOCIATION	The C-terminal, polypeptide binding domain of the 70-kDa molecular chaperone DnaK is composed of a unique lidlike subdomain that appears to hinder steric access to the peptide binding site. We have expressed, purified, and characterized a lidless form of DnaK to test the influence of the lid on the ATPase activity, on interdomain communication, and on the kinetics of peptide binding. The principal findings are that loss of the lid creates an activated form of DnaK which is not equivalent to ATP-bound DnaK. For example, at 25 degreesC the NR peptide (NRLLLTG) dissociates from the ADP and ATP states of DnaK with observed off-rate constants of 0.001 and 4.8 s(-1), respectively. In contrast, for DnaK that lacks most of the helical lid, residues 518-638, the NR peptide dissociates with observed off-rate constants of 0.1 and 188 s(-1). These results show that the loss of the lid does not interfere with interdomain communication, that the beta -sandwich peptide binding domain can exist in two discrete conformations, and that the lid functions to increase the lifetime of a DnaK peptide complex. We discuss several mechanisms to explain how the lid affects the lifetime of a DnaK peptide complex.	Louisiana State Univ, Dept Biochem & Mol Biol, Hlth Sci Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Witt, SN (corresponding author), Louisiana State Univ, Dept Biochem & Mol Biol, Hlth Sci Ctr, 1501 Kings Highway, Shreveport, LA 71130 USA.		Witt, Stephan N/M-7922-2013; Slepenkov, Sergey/D-4039-2016	Witt, Stephan N/0000-0002-6462-2840; 				Bevington P. R, 1969, DATA REDUCTION ERROR; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; FARR CD, 1995, BIOCHEMISTRY-US, V34, P15574, DOI 10.1021/bi00047a024; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; Fouchaq B, 1999, EUR J BIOCHEM, V259, P379, DOI 10.1046/j.1432-1327.1999.00053.x; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Haugland R.P., 1992, HDB FLUORESCENT PROB; Hiromi K., 1979, KINETICS FAST ENZYME; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; Russell R, 1998, BIOCHEMISTRY-US, V37, P596, DOI 10.1021/bi972025p; SAITO H, 1977, J MOL BIOL, V113, P1, DOI 10.1016/0022-2836(77)90038-9; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Slepenkov SV, 1998, BIOCHEMISTRY-US, V37, P16749, DOI 10.1021/bi981738k; Slepenkov SV, 1998, BIOCHEMISTRY-US, V37, P1015, DOI 10.1021/bi9720484; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; TACK BF, 1980, J BIOL CHEM, V255, P8842; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Tudyka T, 1997, PROTEIN SCI, V6, P2180; WELCH WJ, 1998, MOL CHAPERONES LIFE, P71; YOCHEM J, 1978, MOL GEN GENET, V164, P9, DOI 10.1007/BF00267593; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	29	67	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27231	27236		10.1074/jbc.M100237200	http://dx.doi.org/10.1074/jbc.M100237200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11352903	hybrid			2022-12-27	WOS:000169966900068
J	Hii, CST; Moghadammi, N; Dunbar, A; Ferrante, A				Hii, CST; Moghadammi, N; Dunbar, A; Ferrante, A			Activation of the phosphatidylinositol 3-kinase-Akt/protein kinase B signaling pathway in arachidonic acid-stimulated human myeloid and endothelial cells - Involvement of the ErbB receptor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); POLYUNSATURATED FATTY-ACIDS; P38 MAP KINASE; PROTEIN-KINASE; GROWTH-FACTOR; HUMAN NEUTROPHILS; PHOSPHOINOSITIDE 3-KINASE; DIFFERENTIAL ACTIVATION; SUPEROXIDE-PRODUCTION; REGULATED KINASES	Although arachidonic acid has been demonstrated to stimulate a wide variety of cellular functions, the responsible mechanisms remain poorly defined. We now report that arachidonic acid stimulated the activity of class Ia phosphatidylinositol S-kinase (PI3K) in human umbilical vein endothelial cells, HL60 cells, and human neutrophils. Pretreatment of endothelial cells with AG-1478, an inhibitor of the ErbB receptor family, resulted in the suppression of PI3K activation by arachidonic acid. The fatty acid enhanced the tyrosine phosphorylation of ErbB4 but not of ErbB2 or ErbB3. The ability of arachidonic acid to stimulate PI3K activity in neutrophils was suppressed by indomethacin and nordihydroguaiaretic acid, inhibitors of the cyclooxygenases and lipoxygenases, respectively, but not by 17-octadecynoic acid, an inhibitor of omega -hydroxylation of arachidonic acid by cytochrome P450 monooxygenases. Consistent with this, the activity of PI3K in neutrophils was stimulated by 5-hydroxyeicosatetraenoic acid. Arachidonic acid also transiently stimulated the phosphorylation of Akt on Thr-308 and Ser-473. Although PI3K was not required for the activation of the mitogen-activated protein kinases, ERK1, ERM2, and p38, in arachidonic acid-stimulated neutrophils, the:fatty acid acted via PI3K to stimulate the respiratory burst. These results not only define a novel mechanism through which some of the actions of arachidonic acid are mediated but also demonstrate that, in addition to ErbB1 (epidermal growth factor receptor), ErbB4 can also be transactivated by a non-epidermal growth factor-like ligand.	Womens & Childrens Hosp, Dept Immunopathol, Adelaide, SA 5006, Australia; CSIRO, Mol & Cellular Biol Lab, Cooperat Res Ctr Tissue Growth & Repair, Div Hlth Sci & Nutr, Thebarton, SA 5031, Australia; Univ Adelaide, Dept Paediat, Adelaide, SA 5005, Australia; Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Adelaide, SA 5001, Australia	Womens & Childrens Hospital Australia; Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Adelaide; University of South Australia	Hii, CST (corresponding author), Womens & Childrens Hosp, Dept Immunopathol, 72 King William Rd, Adelaide, SA 5006, Australia.	chii01@mail.staff.adelaide.edu.au						Anderson KM, 1997, J BIOL CHEM, V272, P30504, DOI 10.1074/jbc.272.48.30504; AYLSWORTH CF, 1986, CANCER RES, V46, P4527; BADWEY JA, 1981, J BIOL CHEM, V256, P2640; Balsinde J, 2000, J BIOL CHEM, V275, P4783, DOI 10.1074/jbc.275.7.4783; BAND AM, 1992, J MOL ENDOCRINOL, V8, P95, DOI 10.1677/jme.0.0080095; Bertagnolo V, 1999, CANCER RES, V59, P542; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Burgermeister E, 2000, EUR J PHARMACOL, V388, P195, DOI 10.1016/S0014-2999(99)00816-X; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chang LC, 1999, FEBS LETT, V454, P165, DOI 10.1016/S0014-5793(99)00717-6; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Dulin NO, 1998, HYPERTENSION, V32, P1089, DOI 10.1161/01.HYP.32.6.1089; Egeblad M, 2001, BIOCHEM BIOPH RES CO, V281, P25, DOI 10.1006/bbrc.2001.4302; FERRANTE A, 1982, J IMMUNOL METHODS, V48, P81, DOI 10.1016/0022-1759(82)90212-5; FINSTAD HS, 1994, BLOOD, V84, P3799, DOI 10.1182/blood.V84.11.3799.bloodjournal84113799; Gabrilovich D. I., 1999, NEUTROPHILS NEW OUTL, P79; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Haeggstrom JZ, 1999, CURR INFLAMMAT RES, P51; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; Hii CST, 1999, INFECT IMMUN, V67, P1297, DOI 10.1128/IAI.67.3.1297-1302.1999; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Hii CST, 2001, IMMUNOLOGY, V102, P59, DOI 10.1046/j.1365-2567.2001.01156.x; HII CST, 1995, CARCINOGENESIS, V16, P1505, DOI 10.1093/carcin/16.7.1505; Hii CST, 1999, ADV EXP MED BIOL, V469, P365; Huang ZH, 1997, CIRC RES, V80, P149, DOI 10.1161/01.RES.80.2.149; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Kunapuli P, 1998, J BIOL CHEM, V273, P22442, DOI 10.1074/jbc.273.35.22442; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; LAVIOLETTE M, 1986, J CLIN INVEST, V77, P54, DOI 10.1172/JCI112301; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Marcil J, 1999, BIOCHEM J, V337, P185, DOI 10.1042/0264-6021:3370185; McMahon B, 2000, J BIOL CHEM, V275, P27566; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; Metzler B, 1998, J BIOL CHEM, V273, P33320, DOI 10.1074/jbc.273.50.33320; MURAKAMI K, 1985, FEBS LETT, V192, P189, DOI 10.1016/0014-5793(85)80105-8; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; Panaretou C, 1997, J BIOL CHEM, V272, P2477; Rao GN, 1999, J BIOL CHEM, V274, P12925, DOI 10.1074/jbc.274.18.12925; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; Rizzo MT, 1996, BLOOD, V88, P3792, DOI 10.1182/blood.V88.10.3792.bloodjournal88103792; Robinson BS, 1997, IMMUNOLOGY, V91, P274, DOI 10.1046/j.1365-2567.1997.d01-2227.x; Robinson BS, 1998, BIOCHEM J, V336, P611, DOI 10.1042/bj3360611; Russell KS, 1999, AM J PHYSIOL-HEART C, V277, pH2205, DOI 10.1152/ajpheart.1999.277.6.H2205; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Schwartz Z, 1999, ENDOCRINOLOGY, V140, P2991, DOI 10.1210/en.140.7.2991; SHIKANO M, 1994, BBA-LIPID LIPID MET, V1212, P211, DOI 10.1016/0005-2760(94)90255-0; Smirnov SV, 1996, CIRC RES, V79, P20, DOI 10.1161/01.RES.79.1.20; Stuhlmeier KM, 1997, J BIOL CHEM, V272, P24679, DOI 10.1074/jbc.272.39.24679; Sun WY, 2000, J BIOL CHEM, V275, P24421, DOI 10.1074/jbc.M003148200; Suzuki K, 2000, BIOCHEM BIOPH RES CO, V272, P111, DOI 10.1006/bbrc.2000.2737; Syrbu SI, 1999, J IMMUNOL, V162, P2334; Tang DG, 1997, INT J CANCER, V72, P1078, DOI 10.1002/(SICI)1097-0215(19970917)72:6<1078::AID-IJC24>3.0.CO;2-#; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vinante F, 1999, BLOOD, V94, P3169, DOI 10.1182/blood.V94.9.3169.421k30_3169_3177; Wieland SJ, 1996, J BIOL CHEM, V271, P19037, DOI 10.1074/jbc.271.32.19037; WOLF BA, 1986, J BIOL CHEM, V261, P3501; Wymann MP, 2000, IMMUNOL TODAY, V21, P260, DOI 10.1016/S0167-5699(00)01649-2	65	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27246	27255		10.1074/jbc.M103250200	http://dx.doi.org/10.1074/jbc.M103250200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11359783	hybrid			2022-12-27	WOS:000169966900070
J	Masuda, A; Matsuguchi, T; Yamaki, K; Hayakawa, T; Yoshikai, Y				Masuda, A; Matsuguchi, T; Yamaki, K; Hayakawa, T; Yoshikai, Y			Interleukin-15 prevents mouse mast cell apoptosis through STAT6-mediated Bcl-x(L) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-KIT LIGAND; ACTIVATED KILLER-CELLS; BCL-X; IL-2 RECEPTOR; GROWTH-FACTOR; BETA-CHAIN; GENE-EXPRESSION; T-CELLS; SURVIVAL; DEATH	Interleukin (IL)-15 is a member of the cytokine family with T and natural killer (NK) cell growth-promoting activity. In mast cells, however, IL-15 uses a distinct receptor system different from that used in T and NK cells. We recently reported that IL-15 induces STAT6 activation and IL-4 production in a mouse mast cell line (MC/9) and bone marrow-derived mast cells. In the present study, we have demonstrated that IL-15 prevents MC/9 and bone marrow-derived mast cell apoptosis induced by factor withdrawal or anti-Fas antibody treatment, IL-15 increased mRNA and protein levels of an anti-apoptotic protein (Bcl-x(L)) in these cells, whereas bcl-2 mRNA remained unchanged. In addition, the transcriptional activity of the bcl-x(L), promoter was increased by IL-15 in MC/9 eels. In an electrophoretic mobility shift assay, IL-15 induced STAT6 binding to the STAT recognition site in the bcl-x(L) gene promoter. Furthermore, the expression of a dominant-negative form of STAT6 abrogated the effects of IL-15 on both bcl-x(L) mRNA up-regulation and prevention of apoptosis in mast cells. Altogether, our results suggest that IL-15 plays an important role in maintaining the number of mast cells through Bcl-xL expression mediated by STAT6.	Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Lab Host Def & Germfree Life,Showa Ku, Nagoya, Aichi 4688550, Japan; Nagoya Univ, Sch Med, Dept Internal Med 2, Nagoya, Aichi 4688550, Japan	Nagoya University; Nagoya University	Matsuguchi, T (corresponding author), Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Lab Host Def & Germfree Life,Showa Ku, Nagoya, Aichi 4688550, Japan.	tmatsugu@med.nagoya-u.ac.jp	Masuda, Akio/H-6323-2012					Arena A, 2000, MICROBIOLOGICA, V23, P105; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BROOME HE, 1995, J IMMUNOL, V155, P2311; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; Bullock ED, 1996, J BIOL CHEM, V271, P27500, DOI 10.1074/jbc.271.44.27500; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; BUSSE WW, 1994, AM J RESP CRIT CARE, V150, pS77, DOI 10.1164/ajrccm/150.5_Pt_2.S77; BUSSE WW, 1989, CLIN EXP ALLERGY, V19, P1, DOI 10.1111/j.1365-2222.1989.tb02336.x; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Chehimi J, 1997, J IMMUNOL, V158, P5978; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHLEQDESCHAMPS CM, 1993, BLOOD, V81, P293; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; DEL PL, 1997, SCIENCE, V278, P687; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HAIG DM, 1988, IMMUNOLOGY, V65, P205; Hartmann K, 1997, J IMMUNOL, V159, P4006; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IEMURA A, 1994, AM J PATHOL, V144, P321; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Lin RH, 1997, J IMMUNOL, V158, P598; Lomo J, 1997, BLOOD, V89, P4415; Masuda A, 2000, J BIOL CHEM, V275, P29331, DOI 10.1074/jbc.M910290199; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; MEKORI YA, 1993, J IMMUNOL, V151, P3775; Miho Y, 1999, CELL DEATH DIFFER, V6, P463, DOI 10.1038/sj.cdd.4400506; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; Naora H, 1999, IMMUNOL LETT, V68, P359, DOI 10.1016/S0165-2478(99)00077-2; Pastorino JG, 1999, J BIOL CHEM, V274, P19411, DOI 10.1074/jbc.274.27.19411; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RENNICK D, 1995, BLOOD, V85, P57, DOI 10.1182/blood.V85.1.57.bloodjournal85157; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Tagaya Y, 1996, EMBO J, V15, P4928, DOI 10.1002/j.1460-2075.1996.tb00873.x; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; TSAI M, 1991, J EXP MED, V174, P125, DOI 10.1084/jem.174.1.125; Vella A, 1997, J EXP MED, V186, P325, DOI 10.1084/jem.186.2.325; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Yeatman CF, 2000, J EXP MED, V192, P1093, DOI 10.1084/jem.192.8.1093; YEE NS, 1994, J EXP MED, V179, P1777, DOI 10.1084/jem.179.6.1777; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	58	65	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26107	26113		10.1074/jbc.M011475200	http://dx.doi.org/10.1074/jbc.M011475200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11369758	hybrid			2022-12-27	WOS:000169823300064
J	Takeuchi, K; Shibamoto, S; Nagamine, K; Shigemori, I; Omura, S; Kitamura, N; Ito, F				Takeuchi, K; Shibamoto, S; Nagamine, K; Shigemori, I; Omura, S; Kitamura, N; Ito, F			Signaling pathways leading to transcription and translation cooperatively regulate the transient increase in expression of c-Fos protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE-GROWTH-FACTOR; TUMOR NECROSIS FACTOR; TERNARY COMPLEX-FORMATION; RECEPTOR TYROSINE KINASE; SCATTER FACTOR-RECEPTOR; MESSENGER-RNA; EGF-RECEPTOR; PHAS-I; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE	The mechanisms by which growth factors trigger signal transduction pathways leading to the regulation of c-Fos expression are of great interest. in this study we investigated the effect of hepatocyte growth factor (HGF/SF) and epidermal growth factor (EGF) on the expression of c-fos and its product, c-Fos, in human epithelial cell line MKN74, The expression level of c-Fos protein in HGF/SF-stimulated cells was 5-10-fold higher than that in EGF-stimulated cells, whereas the level of c-fos mRNA induced by HGF/SF was similar to that by EGF, The hyperphosphorylation of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), indicative of an increased number of translation initiation complexes, was detected only in HGF/SF-induced MKN74 cells. Activation of phosphatidylinositol-3 ' -OH kinase and FKBP12-rapamycin associated mammalian target of rapamycin (FRAP/mTOR) was observed after the treatment with HGF/SF, Pretreatment with an inhibitor of either one, i.e. LY294002 for phosphatidylinositol-3 ' -OH kinase or rapamycin for FRAP/mTOR, completely inhibited 4E-BP1 phosphorylation and decreased the c-Fos synthesis induced by HGF/SF down to the level found in EGF-induced cells. These results suggest that the phosphorylation of 4E-BP1 is stimulated by HGF/SF in a manner requiring both phosphatidy-linositol-3 ' -OH kinase-dependent and FRAP/mTOR-dependent pathways, thereby stimulating c-fos mRNA translation. Regulation of the translation process of c-fos mRNA in addition to the immediate activation of c-fos transcription is necessary for the transient increase in the level of c-Fos protein to stimulate cell proliferation.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Kitasato Inst, Res Ctr Biol Funct, Minato Ku, Tokyo 1088642, Japan; Setsunan Univ, Fac Pharmaceut Sci, Dept Biochem, Hirakata, Osaka 5730101, Japan	Tokyo Institute of Technology; Setsunan University	Shibamoto, S (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way,MS 40, S San Francisco, CA 94080 USA.			Ito, Fumiaki/0000-0002-4129-4899				Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CHATANI Y, 1992, BIOCHEM BIOPH RES CO, V185, P860, DOI 10.1016/0006-291X(92)91706-V; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; KIM HH, 1994, J BIOL CHEM, V269, P24747; Kleijn M, 1998, EUR J BIOCHEM, V253, P531, DOI 10.1046/j.1432-1327.1998.2530531.x; Kleijn M, 1996, FEBS LETT, V396, P165, DOI 10.1016/0014-5793(96)01097-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN JX, 1987, J BIOL CHEM, V262, P11908; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; Nagamine K, 1996, EUR J BIOCHEM, V236, P476, DOI 10.1111/j.1432-1033.1996.t01-1-00476.x; NALDINI L, 1991, ONCOGENE, V6, P501; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHIBAMOTO S, 1992, CELL STRUCT FUNCT, V17, P185, DOI 10.1247/csf.17.185; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990	56	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26077	26083		10.1074/jbc.M102704200	http://dx.doi.org/10.1074/jbc.M102704200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352916	hybrid			2022-12-27	WOS:000169823300060
J	Lopes, CMB; Zilberberg, N; Goldstein, SAN				Lopes, CMB; Zilberberg, N; Goldstein, SAN			Block of Kcnk3 by protons - Evidence that 2-p-domain potassium channel subunits function as homodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN K+ CHANNEL; 2 PORE DOMAINS; EXTRACELLULAR K+; LEAK CHANNEL; TASK-1; SELECTIVITY; EXPRESSION; FAMILY; TANDEM; REGION	KCNK subunits have two pore-forming P domains and four predicted transmembrane segments. To assess the number of subunits in each pore, we studied external proton block of Kcnk3, a subunit prominent in rodent heart and brain. Consistent with a pore-blocking mechanism, inhibition was dependent on voltage, potassium concentration, and a histidine in the first P domain (P1H). Thus, at pH 6.8 with 20 mM potassium half the current passed by P1H channels was blocked (apparently via two sites similar to 10% into the electrical field) whereas channels with an asparagine substitution (P1N) were fully active. Furthermore, pore blockade by barium was sensitive to pH in P1H but not P1N channels. Although linking two Kcnk3 subunits in tandem to produce P1H-P1H and P1N-P1N channels bearing four P domains did not alter these attributes, the mixed tandems P1H-P1N and P1N-P1H were half-blocked at pH similar to6.4, apparently via a single site. This implicates a dimeric structure for Kcnk3 channels with two (and only two) P1 domains in each pore and argues that P2 domains also contribute to pore formation.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06536 USA	Yale University; Yale University	Goldstein, SAN (corresponding author), 295 Congress Ave, New Haven, CT 06536 USA.		Zilberberg, Noam/F-2005-2012; Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061; Zilberberg, Noam/0000-0002-7848-2391				Bockenhauer D, 2001, NAT NEUROSCI, V4, P486, DOI 10.1038/87434; Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; Czirjak G, 2000, MOL ENDOCRINOL, V14, P863, DOI 10.1210/me.14.6.863; Decher N, 2001, FEBS LETT, V492, P84, DOI 10.1016/S0014-5793(01)02222-0; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; HODGKIN AL, 1952, J PHYSIOL-LONDON, V116, P424, DOI 10.1113/jphysiol.1952.sp004716; Ilan N, 2001, BIOPHYS J, V80, P241, DOI 10.1016/S0006-3495(01)76010-9; Jiang YX, 2000, J GEN PHYSIOL, V115, P269, DOI 10.1085/jgp.115.3.269; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Kim Y, 1999, AM J PHYSIOL-HEART C, V277, pH1669, DOI 10.1152/ajpheart.1999.277.5.H1669; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lopes CMB, 2000, J BIOL CHEM, V275, P16969, DOI 10.1074/jbc.M001948200; Loukin SH, 1997, EMBO J, V16, P4817, DOI 10.1093/emboj/16.16.4817; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; Morrill JA, 1999, J GEN PHYSIOL, V114, P71, DOI 10.1085/jgp.114.1.71; NEYTON J, 1988, J GEN PHYSIOL, V92, P569, DOI 10.1085/jgp.92.5.569; Sabirov RZ, 1997, J GEN PHYSIOL, V110, P665, DOI 10.1085/jgp.110.6.665; Talley EM, 2000, NEURON, V25, P399, DOI 10.1016/S0896-6273(00)80903-4; Vergani P, 1997, FEBS LETT, V405, P337, DOI 10.1016/S0014-5793(97)00211-1; Vergani P, 1998, EMBO J, V17, P7190, DOI 10.1093/emboj/17.24.7190; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Zilberberg N, 2000, J GEN PHYSIOL, V116, P721, DOI 10.1085/jgp.116.5.721	28	103	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24449	24452		10.1074/jbc.C100184200	http://dx.doi.org/10.1074/jbc.C100184200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11358956	hybrid			2022-12-27	WOS:000169800700005
J	Virts, EL; Raschke, WC				Virts, EL; Raschke, WC			The role of intron sequences in high level expression from CD45 cDNA constructs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; TISSUE-SPECIFIC EXPRESSION; LEUKOCYTE-COMMON ANTIGEN; CELL-RECEPTOR COMPLEX; ALTERNATE EXON USE; TRANSGENIC MICE; B-CELLS; GENE-EXPRESSION; T-CELLS; DEVELOPMENTAL EXPRESSION	Consistent expression from CD45 cDNA constructs has proven difficult to achieve. Through the use of new CD45 cDNA constructs and reporter genes, the role 5', 3', and intron sequences play in CD45 expression was determined. The CD45 polyadenylation signal sequence was fully functional in a beta -galactosidase reporter construct. Furthermore, the CD45 3'-untranslated region and downstream sequences were shown to contain no negative regulatory elements. Several new CD45 cDNA constructs were designed that contain either the cytomegalovirus promoter, the leukocyte function-associated antigen (LFA-1; CD11a) promoter, or various CD45 5' regions. Neither the cytomegalovirus nor the LFA-1 promoter was capable of generating detectable levels of expression in constructs with CD45 cDNA However, when CD45 intron sequences between exrons 3 and 9 were inserted in the cDNA construct to generate a CD45 minigene, the LFA-1 promoter was able to drive reproducible, significant expression of CD45. CD45 minigenes using the CD45 5' sequences up to 19 kilobases upstream of the transcriptional start produced very little protein. The LFA-1 CD45 minigene construct produced correct cell type-specific isoforms when expressed in T and B lymphocyte lines. Therefore, we conclude that the regulation of CD45 expression and cell type-specific splicing requires elements within the intron sequences.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA		Raschke, WC (corresponding author), Sidney Kimmel Canc Ctr, 10835 Altman Row, San Diego, CA 92121 USA.	braschke@skcc.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040259, R01AI040259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashwell JD, 1999, IMMUNOL TODAY, V20, P412, DOI 10.1016/S0167-5699(99)01505-4; Baler R, 1999, BIOL CELL, V91, P699, DOI 10.1016/S0248-4900(00)88533-0; BERGER SA, 1994, J EXP MED, V180, P471, DOI 10.1084/jem.180.2.471; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CALLIS J, 1987, GENE DEV, V1, P1183, DOI 10.1101/gad.1.10.1183; Chan RYY, 1999, P NATL ACAD SCI USA, V96, P4627, DOI 10.1073/pnas.96.8.4627; CHANG HL, 1991, J IMMUNOL, V147, P1687; CHANG HL, 1989, J IMMUNOL, V143, P315; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CHUI D, 1994, EMBO J, V13, P798, DOI 10.1002/j.1460-2075.1994.tb06322.x; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; CORNWELL RD, 1993, P NATL ACAD SCI USA, V90, P4221, DOI 10.1073/pnas.90.9.4221; D'Oro U, 1999, J IMMUNOL, V162, P1879; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; DIMARTINO JF, 1994, INT IMMUNOL, V6, P1279, DOI 10.1093/intimm/6.8.1279; Galvagni F, 2000, J BIOL CHEM, V275, P3168, DOI 10.1074/jbc.275.5.3168; Gaunitz F, 1997, BIOL CHEM, V378, P11, DOI 10.1515/bchm.1997.378.1.11; GOROCHOV G, 1992, INT J CANCER, P53; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Haghighi K, 1997, GENE, V203, P199, DOI 10.1016/S0378-1119(97)00514-3; Hall SR, 1999, EUR J IMMUNOL, V29, P2098, DOI 10.1002/(SICI)1521-4141(199907)29:07<2098::AID-IMMU2098>3.3.CO;2-2; HATHCOCK KS, 1992, J IMMUNOL, V149, P2286; Hoflich C, 1998, INT IMMUNOL, V10, P1837, DOI 10.1093/intimm/10.12.1837; JOHNSON P, 1989, J EXP MED, V169, P1179, DOI 10.1084/jem.169.3.1179; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; Katagiri T, 1999, J IMMUNOL, V163, P1321; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LANE PJL, 1991, J IMMUNOL, V146, P715; Leitenberg D, 1996, J EXP MED, V183, P249, DOI 10.1084/jem.183.1.249; Leitenberg D, 1999, IMMUNITY, V10, P701, DOI 10.1016/S1074-7613(00)80069-2; LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103; Makar KW, 1998, J IMMUNOL, V160, P1268; MARTH JD, 1994, ADV EXP MED BIOL, V365, P149; McHeyzer-Williams LJ, 2000, J EXP MED, V191, P1149, DOI 10.1084/jem.191.7.1149; Mee PJ, 1999, EUR J IMMUNOL, V29, P2923, DOI 10.1002/(SICI)1521-4141(199909)29:09<2923::AID-IMMU2923>3.3.CO;2-P; Murakami K, 2000, INT IMMUNOL, V12, P169, DOI 10.1093/intimm/12.2.169; NOVAK TJ, 1994, IMMUNITY, V1, P109, DOI 10.1016/1074-7613(94)90104-X; NUEDA A, 1993, J BIOL CHEM, V268, P19305; OGIMOTO M, 1993, CELL IMMUNOL, V151, P97, DOI 10.1006/cimm.1993.1224; Oka S, 2000, IMMUNOLOGY, V100, P417, DOI 10.1046/j.1365-2567.2000.00063.x; ONG CJ, 1994, J IMMUNOL, V152, P3793; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RASCHKE WC, 1995, IMMUNOGENETICS, V41, P144, DOI 10.1007/BF00182327; RASCHKE WC, 1987, P NATL ACAD SCI USA, V84, P161, DOI 10.1073/pnas.84.1.161; Renno T, 1998, EUR J IMMUNOL, V28, P540, DOI 10.1002/(SICI)1521-4141(199802)28:02<540::AID-IMMU540>3.3.CO;2-P; RITCHIE KA, 1995, BLOOD, V86, P147, DOI 10.1182/blood.V86.1.147.bloodjournal861147; ROTHSTEIN DM, 1992, J BIOL CHEM, V267, P7139; Sabourin JC, 1996, J BIOL CHEM, V271, P3469, DOI 10.1074/jbc.271.7.3469; SAGA Y, 1987, P NATL ACAD SCI USA, V84, P5364, DOI 10.1073/pnas.84.15.5364; SAGA Y, 1990, IMMUNOGENETICS, V31, P296, DOI 10.1007/BF02115003; SAGA Y, 1990, P NATL ACAD SCI USA, V87, P3728, DOI 10.1073/pnas.87.10.3728; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; SELDIN MF, 1987, IMMUNOGENETICS, V26, P74, DOI 10.1007/BF00345457; Shamsher MK, 2000, HUM GENET, V107, P458; SHEN FW, 1985, P NATL ACAD SCI USA, V82, P7360, DOI 10.1073/pnas.82.21.7360; SIU G, 1994, EMBO J, V13, P3570, DOI 10.1002/j.1460-2075.1994.tb06664.x; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; THUDE H, 1995, EUR J IMMUNOL, V25, P2101, DOI 10.1002/eji.1830250745; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Veillette A, 1999, J BIOL CHEM, V274, P14392, DOI 10.1074/jbc.274.20.14392; Virts E, 1998, MOL IMMUNOL, V35, P167, DOI 10.1016/S0161-5890(98)00025-X; Virts E, 1997, MOL IMMUNOL, V34, P1191, DOI 10.1016/S0161-5890(97)00142-9; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; WILDIN RS, 1995, J IMMUNOL, V155, P1286; Zabel MD, 2000, J IMMUNOL, V165, P4437, DOI 10.4049/jimmunol.165.8.4437; Zebedee S L, 1991, Dev Immunol, V1, P243, DOI 10.1155/1991/52686	74	19	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19913	19920		10.1074/jbc.M100448200	http://dx.doi.org/10.1074/jbc.M100448200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11389149	hybrid			2022-12-27	WOS:000169135100032
J	Douglas, P; Moorhead, GBG; Ye, RQ; Lees-Miller, SP				Douglas, P; Moorhead, GBG; Ye, RQ; Lees-Miller, SP			Protein phosphatases regulate DNA-dependent protein kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CATALYTIC SUBUNIT; PHOSPHORYLATION; CELLS; AUTOPHOSPHORYLATION; INHIBITOR-2; DEFICIENT; 3-KINASE; GENE; PP2A	DNA-dependent protein kinase (DNA-PK) is a complex of DNA-PK catalytic subunit (DNA-PKcs) and the DNA end-binding Ku70/Ku80 heterodimer. DNA-PK is required for DNA double strand break repair by the process of nonhomologous end joining. Nonhomologous end joining is a major mechanism for the repair of DNA double strand breaks in mammalian cells. As such, DNA-PK plays essential roles in the cellular response to ionizing radiation and in V(D)J recombination. In vitro, DNA-PK undergoes phosphorylation of all three protein subunits (DNA-PK catalytic subunit, Ku70 and Ku80) and phosphorylation correlates with inactivation of the serine/threonine protein kinase activity of DNA-PK. Here we show that phosphorylation-induced loss of the protein kinase activity of DNA-PK is restored by the addition of the purified catalytic subunit of either protein phosphatase 1 or protein phosphatase 2A (PP2A) and that this reactivation is blocked by the potent protein phosphatase inhibitor, microcystin, We also show that treating human lymphoblastoid cells with either okadaic acid or fostriecin, at PP2A-selective concentrations, causes a 50-60% decrease in DNA-PK protein kinase activity, although the protein phosphatase 1 activity in these cells was unaffected. In vivo phosphorylation of DNA-PKcs, Ku70, and Ku80 was observed when cells were labeled with [P-32]inorganic phosphate in the presence of the protein phosphatase inhibitor, okadaic acid. Together, our data suggest that reversible protein phosphorylation is an important mechanism for the regulation of DNA-PK protein kinase activity and that the protein phosphatase responsible for reactivation in vivo is a PP2A-like enzyme.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Calgary	Lees-Miller, SP (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.			Lees-Miller, Susan/0000-0001-5809-2516				ALLALUNISTURNER MJ, 1995, CANCER RES, V55, P5200; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Anderson CW, 1995, METHODS IN PROTEIN STRUCTURE ANALYSIS, P395; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; Chan DW, 1996, BIOCHEM CELL BIOL, V74, P67, DOI 10.1139/o96-007; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P427; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1983, METHOD ENZYMOL, V99, P243; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; Kutuzov MA, 1998, FEBS LETT, V440, P147, DOI 10.1016/S0014-5793(98)01428-8; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MACKINTOSH C, 1999, PROTEIN PHOSPHORYLAT; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	34	131	138	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18992	18998		10.1074/jbc.M011703200	http://dx.doi.org/10.1074/jbc.M011703200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376007	hybrid			2022-12-27	WOS:000169091000047
J	Liu, CJ; Dib-Hajj, SD; Waxman, SG				Liu, CJ; Dib-Hajj, SD; Waxman, SG			Fibroblast growth factor homologous factor 1B binds to the C terminus of the tetrodotoxin-resistant sodium channel rNa(v)1.9a (NaN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; NERVOUS-SYSTEM; SENSORY NEURONS; ALPHA-SUBUNIT; TRANSCRIPTION FACTOR; MESSENGER-RNAS; TENASCIN-R; FACTOR FGF; PROTEIN; EXPRESSION	In this study we demonstrate a direct interaction between a cytosolic fibroblast growth factor family member and a sodium channel. A yeast two hybrid screen for proteins that associate with the cytoplasmic domains of the tetrodotoxin-resistant sodium channel rNa(v)1.9a (NaN) led to the identification of fibroblast growth factor homologous factor 1B (FHF1B), a member of the fibroblast growth factor family, as an interacting partner of rNa(v)1.9a. FHF1B selectively interacts with the C-terminal region but not the other four intracellular segments of rNa(v)1.9a. FHF1B binds directly to the C-terminal polypeptide of rNa(v)1.9a both in vitro and in mammalian cell lines. The N-terminal 5-77 amino acid residues of FHF1B are essential for binding to rNa(v)1.9a. FHF1B did not interact with C termini of two other sodium channels hNa(v)1.7a (hNaNE) and rNa(v)1.8a (SNS), which share 50% similarity to the C-terminal polypeptide of rNa(v)1.9a. FHF1B is the first growth factor found to bind specifically to a sodium channel. Although the functional significance of this interaction is not clear, FHF1B may affect the rNa(v)1.9a channel directly or by recruiting other proteins to the channel complex. Alternatively, it is possible that rNa(v)1.9a may help deliver this factor to the cell membrane, where it exerts its function.	Yale Univ, Sch Med, Neurosci Res Ctr, PVA,EPVA, West Haven, CT 06516 USA; Yale Univ, Sch Med, Neurosci Res Ctr, Dept Neurol, West Haven, CT 06516 USA; Vet Affairs Med Ctr, Rehabil Res Ctr, West Haven, CT 06516 USA	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Dib-Hajj, SD (corresponding author), Yale Univ, Sch Med, Neurosci Res Ctr, PVA,EPVA, 127A,Bldg 34,950 Campbell Ave, West Haven, CT 06516 USA.	sulayman.dib-hajj@yale.edu	Waxman, Stephen/Z-2507-2019	Waxman, Stephen/0000-0001-5718-7177; liu, chuanju/0000-0002-7181-8032				Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARCHI RL, 1995, ANNU REV PHYSIOL, V57, P355; BECKH S, 1989, EMBO J, V8, P3611, DOI 10.1002/j.1460-2075.1989.tb08534.x; Braithwaite SP, 2000, NEUROPHARMACOLOGY, V39, P919, DOI 10.1016/S0028-3908(99)00171-9; Cannon SC, 1997, NEUROMUSCULAR DISORD, V7, P241, DOI 10.1016/S0960-8966(97)00430-6; Cantrell AR, 1999, J NEUROSCI, V19, P5301; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; Cummins TR, 2000, J NEUROSCI, V20, P8754; Cummins TR, 1999, J NEUROSCI, V19, DOI 10.1523/JNEUROSCI.19-24-j0001.1999; Dib-Hajj SD, 1999, FEBS LETT, V462, P117, DOI 10.1016/S0014-5793(99)01519-7; Dib-Hajj SD, 1998, P NATL ACAD SCI USA, V95, P8963, DOI 10.1073/pnas.95.15.8963; DibHajj SD, 1996, FEBS LETT, V384, P78, DOI 10.1016/0014-5793(96)00273-6; Dumaine R, 1996, CIRC RES, V78, P916, DOI 10.1161/01.RES.78.5.916; Felts PA, 1997, MOL BRAIN RES, V45, P71, DOI 10.1016/S0169-328X(96)00241-0; FENG GP, 1995, CELL, V82, P1001, DOI 10.1016/0092-8674(95)90279-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fjell J, 1999, MOL BRAIN RES, V67, P267, DOI 10.1016/S0169-328X(99)00070-4; Fjell J, 2000, NEUROREPORT, V11, P199, DOI 10.1097/00001756-200001170-00039; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; Gee SH, 1998, J NEUROSCI, V18, P128; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Hartung H, 1997, MECH DEVELOP, V64, P31, DOI 10.1016/S0925-4773(97)00042-7; HERZOG RI, 2000, SOC NEUR ABSTR, V26, P1111; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Jeong SY, 2000, BIOCHEM BIOPH RES CO, V267, P262, DOI 10.1006/bbrc.1999.1916; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; McCormick KA, 1999, J BIOL CHEM, V274, P32638, DOI 10.1074/jbc.274.46.32638; Mori M, 2000, BIOCHEMISTRY-US, V39, P1316, DOI 10.1021/bi9912600; Munoz-Sanjuan I, 1999, DEVELOPMENT, V126, P409; Munoz-Sanjuan I, 2000, J BIOL CHEM, V275, P2589, DOI 10.1074/jbc.275.4.2589; Nehring RB, 2000, J NEUROSCI, V20, P156, DOI 10.1523/JNEUROSCI.20-01-00156.2000; PATTON DE, 1994, J BIOL CHEM, V269, P17649; Ptacek LJ, 1997, NEUROMUSCULAR DISORD, V7, P250, DOI 10.1016/S0960-8966(97)00046-1; Qu YS, 1999, J BIOL CHEM, V274, P32647, DOI 10.1074/jbc.274.46.32647; Ratcliffe CF, 2000, NAT NEUROSCI, V3, P437, DOI 10.1038/74805; Rizzo MA, 1996, EUR NEUROL, V36, P3, DOI 10.1159/000117192; Roche KW, 1999, J NEUROSCI, V19, P3926; Sampo B, 2000, P NATL ACAD SCI USA, V97, P3666, DOI 10.1073/pnas.97.7.3666; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Srinivasan J, 1998, P NATL ACAD SCI USA, V95, P15753, DOI 10.1073/pnas.95.26.15753; Tate S, 1998, NAT NEUROSCI, V1, P653, DOI 10.1038/3652; Tibbs VC, 1998, J BIOL CHEM, V273, P25783, DOI 10.1074/jbc.273.40.25783; Trudel C, 2000, J CELL PHYSIOL, V185, P260, DOI 10.1002/1097-4652(200011)185:2<260::AID-JCP11>3.0.CO;2-X; Verdier AS, 1997, GENOMICS, V40, P151, DOI 10.1006/geno.1996.4492; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang H, 2000, J BIOL CHEM, V275, P27377; Waxman SG, 1999, P NATL ACAD SCI USA, V96, P7635, DOI 10.1073/pnas.96.14.7635; Waxman SG, 2000, BRAIN RES, V886, P5, DOI 10.1016/S0006-8993(00)02774-8; Xiao ZC, 1999, J BIOL CHEM, V274, P26511, DOI 10.1074/jbc.274.37.26511	56	104	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18925	18933		10.1074/jbc.M101606200	http://dx.doi.org/10.1074/jbc.M101606200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376006	hybrid			2022-12-27	WOS:000169091000038
J	Majumder, A; Fang, M; Tsai, KJ; Ueguchi, C; Mizuno, T; Wu, HY				Majumder, A; Fang, M; Tsai, KJ; Ueguchi, C; Mizuno, T; Wu, HY			LeuO expression in response to starvation for branched-chain amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; LEU-500 PROMOTER; GENE; MUTATION; PPGPP; DNA; ACTIVATION; MUTANTS; RELAY	The recently identified role of LeuO in the regulation of transcription has prompted us to search for the specific function(s) of LeuO in bacterial physiology, The cryptic nature of expression of leuO has previously limited such analysis. A conditional leuO expression was found when bacteria enter stationary phase and was shown to be guanosine 3 ' ,5 ' -bispyrophosphate-dependent, Multiple physiological events, including the stringent response, are induced upon the increase of the bacterial stress signal, guanosine 3 ' ,5 ' -bispyrophosphate, In this study, we tested whether LeuO was directly involved in the bacterial stringent response. LeuO was shown to be indispensable for growth resumption following a 2-h growth arrest caused by starvation for branched-chain amino acids in an E, coli K-12 relA1 strain. This result supports a functional role for LeuO in the bacterial stringent response.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Chung Shan Med & Dent Coll, Sch Med Technol, Taichung 402, Taiwan; Nagoya Univ, Sch Agr, Biosci Ctr, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Sch Agr, Mol Microbiol Lab, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Wayne State University; Chung Shan Medical University; Nagoya University; Nagoya University	Wu, HY (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave, Detroit, MI 48201 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053617, R29GM053617] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53617] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFOLDI L, 1964, BIOCHIM BIOPHYS ACTA, V91, P155, DOI 10.1016/0926-6550(64)90179-3; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CASHEL M, 1996, ESCHERICHIA COLI SAL, V1, P1458; Chen CC, 2001, J BIOL CHEM, V276, P9478, DOI 10.1074/jbc.M010501200; Fang M, 1998, J BIOL CHEM, V273, P29929, DOI 10.1074/jbc.273.45.29929; Fang M, 2000, BIOCHEM BIOPH RES CO, V276, P64, DOI 10.1006/bbrc.2000.3440; Fang M, 1998, J BACTERIOL, V180, P626, DOI 10.1128/JB.180.3.626-633.1998; FILL N., 1968, J BACTERIOL, V95, P729; GEMMILL RM, 1983, J MOL BIOL, V170, P39, DOI 10.1016/S0022-2836(83)80226-5; HAUGHN GW, 1985, J BACTERIOL, V163, P186, DOI 10.1128/JB.163.1.186-198.1985; Klauck E, 1997, MOL MICROBIOL, V25, P559, DOI 10.1046/j.1365-2958.1997.4911852.x; Landgraf JR, 1996, J BACTERIOL, V178, P6930, DOI 10.1128/jb.178.23.6930-6936.1996; LANGE R, 1995, J BACTERIOL, V177, P4676, DOI 10.1128/jb.177.16.4676-4680.1995; METZGER S, 1989, J BIOL CHEM, V264, P21146; PAO CC, 1978, MOL GEN GENET, V158, P271, DOI 10.1007/BF00267198; RICHARDSON SMH, 1988, EMBO J, V7, P1863, DOI 10.1002/j.1460-2075.1988.tb03019.x; RICHARDSON SMH, 1984, EMBO J, V3, P1745, DOI 10.1002/j.1460-2075.1984.tb02041.x; SHI XL, 1995, J BACTERIOL, V177, P810, DOI 10.1128/jb.177.3.810-814.1995; TAN JY, 1994, J BACTERIOL, V176, P1077, DOI 10.1128/JB.176.4.1077-1086.1994; Ueguchi C, 1998, J BACTERIOL, V180, P190, DOI 10.1128/JB.180.1.190-193.1998; UMBARGER HE, 1996, ESCHERICHIA COLI SAL, V1, P442; UZAN M, 1978, MOL GEN GENET, V165, P21, DOI 10.1007/BF00270372; UZAN M, 1976, BIOCHEM BIOPH RES CO, V69, P751, DOI 10.1016/0006-291X(76)90939-6; WANG Q, 1993, EMBO J, V12, P2495, DOI 10.1002/j.1460-2075.1993.tb05904.x; WU HY, 1995, CELL, V82, P445, DOI 10.1016/0092-8674(95)90433-6; XIAO H, 1991, J BIOL CHEM, V266, P5980	26	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19046	19051		10.1074/jbc.M100945200	http://dx.doi.org/10.1074/jbc.M100945200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376008	hybrid			2022-12-27	WOS:000169091000055
J	Moll, M; Klenk, HD; Herrler, G; Maisner, A				Moll, M; Klenk, HD; Herrler, G; Maisner, A			A single amino acid change in the cytoplasmic domains of measles virus glycoproteins H and F alters targeting, endocytosis, and cell fusion in polarized Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE COFACTOR PROTEIN; COATED PITS; INTERNALIZATION SIGNAL; EPITHELIAL-CELLS; SORTING SIGNALS; MDCK CELLS; HEMAGGLUTININ; RECEPTOR; ENVELOPE; RECOGNITION	As we have shown previously, release of measles virus (MV) from polarized epithelial cells is not determined by the viral envelope proteins H and F, Although virus budding is restricted to the apical surfaces, both proteins were abundantly expressed on the basolateral surface of Madin-Darby canine kidney cells. In this report, we provide evidence that the basolateral expression of the viral proteins is of biological importance for the MV infection of polarized epithelial cells. We demonstrate that both MV glycoproteins possess a basolateral targeting signal that is dependent upon the unique tyrosine in the cytoplasmic tails. These tyrosines are shown to be also part of an endocytosis signal. In MV-infected cells, internalization of the glycoproteins was not observed, indicating that recognition of the endocytosis signals is disturbed by viral factors. In contrast, basolateral transport was not substantially hindered, resulting in efficient cell-to-cell fusion of polarized Madin-Darby canine kidney cells. Thus, recognition of the signals for endocytosis and polarized transport is differently regulated in infected cells. Mutation of the basolateral sorting signal in one of the MV glycoproteins prevented fusion of polarized cells. These results suggest that basolateral expression of the MV glycoproteins favors virus spread in epithelia.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany; Tierarztlichen Hsch Hannover, Inst Virol, D-30559 Hannover, Germany	Philipps University Marburg; University of Veterinary Medicine Hannover, Foundation	Maisner, A (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.			Moll, Markus/0000-0003-4592-3063				Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Cathomen T, 1995, VIROLOGY, V214, P628, DOI 10.1006/viro.1995.0075; Cathomen T, 1998, J VIROL, V72, P1224, DOI 10.1128/JVI.72.2.1224-1234.1998; Cathomen T, 1998, EMBO J, V17, P3899, DOI 10.1093/emboj/17.14.3899; DAVIS CG, 1986, CELL, V45, P14; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Egan MA, 1996, J VIROL, V70, P6547, DOI 10.1128/JVI.70.10.6547-6556.1996; FULLER S, 1984, CELL, V38, P65, DOI 10.1016/0092-8674(84)90527-0; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; GONZALEZ A, 1987, P NATL ACAD SCI USA, V84, P3738, DOI 10.1073/pnas.84.11.3738; GRAEVE L, 1989, J CELL BIOL, V109, P2809, DOI 10.1083/jcb.109.6.2809; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; Lazarovits J, 1996, J CELL BIOL, V134, P339, DOI 10.1083/jcb.134.2.339; Leser GP, 1996, MOL BIOL CELL, V7, P155, DOI 10.1091/mbc.7.1.155; Lin S, 1997, J BIOL CHEM, V272, P26300, DOI 10.1074/jbc.272.42.26300; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; Maisner A, 1997, J BIOL CHEM, V272, P20793, DOI 10.1074/jbc.272.33.20793; Maisner A, 2000, J GEN VIROL, V81, P441, DOI 10.1099/0022-1317-81-2-441; Maisner A, 1998, J VIROL, V72, P5276, DOI 10.1128/JVI.72.6.5276-5278.1998; MCQUEEN N, 1986, P NATL ACAD SCI USA, V83, P9318, DOI 10.1073/pnas.83.24.9318; Naim HY, 2000, EMBO J, V19, P3576, DOI 10.1093/emboj/19.14.3576; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; OWENS RJ, 1991, P NATL ACAD SCI USA, V88, P3987, DOI 10.1073/pnas.88.9.3987; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROTH MG, 1980, J VIROL, V35, P547, DOI 10.1128/JVI.35.2.547-550.1980; ROTH MG, 1983, CELL, V33, P435, DOI 10.1016/0092-8674(83)90425-7; ROTH MG, 1987, J CELL BIOL, V104, P769, DOI 10.1083/jcb.104.3.769; ROTH MG, 1986, J CELL BIOL, V103, P2607; ROUX L, 1985, J GEN VIROL, V66, P987, DOI 10.1099/0022-1317-66-5-987; Sauter MM, 1996, J CELL BIOL, V132, P795, DOI 10.1083/jcb.132.5.795; SIMONS K, 1980, J GEN VIROL, V50, P1, DOI 10.1099/0022-1317-50-1-1; Spielhofer P, 1998, J VIROL, V72, P2150, DOI 10.1128/JVI.72.3.2150-2159.1998; Tatsuo H, 2000, NATURE, V406, P893, DOI 10.1038/35022579; Teuchert M, 1999, J BIOL CHEM, V274, P19979, DOI 10.1074/jbc.274.28.19979; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; TUCKER SP, 1993, ADV VIRUS RES, V42, P187, DOI 10.1016/S0065-3527(08)60086-X; VEY M, 1992, VIROLOGY, V188, P408, DOI 10.1016/0042-6822(92)90775-K; WILD TF, 1991, J GEN VIROL, V72, P429; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39; [No title captured]	45	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17887	17894		10.1074/jbc.M010183200	http://dx.doi.org/10.1074/jbc.M010183200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359789	hybrid			2022-12-27	WOS:000168866500038
J	Butt, E; Immler, D; Meyer, HE; Kotlyarov, A; Laass, K; Gaestel, M				Butt, E; Immler, D; Meyer, HE; Kotlyarov, A; Laass, K; Gaestel, M			Heat shock protein 27 is a substrate of cGMP-dependent protein kinase in intact human platelets - Phosphorylation-induced actin polymerization caused by Hsp27 mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; NITRIC-OXIDE; MAPKAP KINASE-2; IN-VITRO; CALCIUM; INHIBITION; IDENTIFICATION; ACTIVATION; ADHESION	Phosphorylation of heat shock protein 27 (Hsp27) in human platelets by mitogen activated protein kinase-activated protein kinase (MAPKAP) 2 is associated with signaling events involved in platelet aggregation and regulation of microfilament organization. We now show that Hsp27 is also phosphorylated by cGMP-dependent protein kinase (cGK), a signaling system important for the inhibition of platelet aggregation. Stimulation of washed platelets with 8-para-chlorophenylthio-cGMP, a cGK specific activator, resulted in a time-dependent phosphorylation of Hsp27. This is supported by the ability of cGK to phosphorylate Hsp27 in vitro to an extent comparable with the cGK-mediated phosphorylation of its established substrate vasodilator-stimulated phosphoprotein. Studies with Hsp27 mutants identified threonine 143 as a yet uncharacterized phosphorylation site in Hsp27 specifically targeted by cGK. To test the hypothesis that cGK could inhibit platelet aggregation by phosphorylating Hsp27 and interfering with the MAP-KAP kinase phosphorylation of Hsp27, the known MAP-KAP kinase 2-phosphorylation sites (Ser(15), Ser(78), and Ser(82)) as well as Thr(143) were replaced by negatively charged amino acids, which are considered to mimic phosphate groups, and tested in actin polymerization experiments. Mimicry at the MAPKAP kinase 2 phosphorylation sites led to mutants with a stimulating effect on actin polymerization, Mutation of the cGK-specific site Thr(143) alone had no effect on actin polymerization, but in the MAPKAP kinase 2 phosphorylation-mimicking mutant, this mutation reduced the stimulation of actin polymerization significantly. These data suggest that phosphorylation of Hsp27 and Hsp27-dependent regulation of actin microfilaments contribute to the inhibitory effects of cGK on platelet function.	Univ Wurzburg, Med Clin, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Bayer AG, ZAS, ZF, D-5090 Leverkusen, Germany; Ruhr Univ Bochum, Inst Physiol Chem, Prot Struct Lab, D-44780 Bochum, Germany; Univ Halle, Inst Pharmaceut Biol, D-06120 Halle, Germany	University of Wurzburg; Bayer AG; Ruhr University Bochum; Martin Luther University Halle Wittenberg	Butt, E (corresponding author), Univ Wurzburg, Med Clin, Inst Clin Biochem & Pathobiochem, Josef Schneider Str 2, D-97080 Wurzburg, Germany.		Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652				Beall A, 1999, J BIOL CHEM, V274, P11344, DOI 10.1074/jbc.274.16.11344; Beall AC, 1997, J BIOL CHEM, V272, P11283; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Brophy CM, 1999, J BIOL CHEM, V274, P6324, DOI 10.1074/jbc.274.10.6324; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; BUTT E, 1994, J BIOL CHEM, V269, P14509; BUTT E, 1997, ADV MOL CEL, V18, P311; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; ElDaher SS, 1996, THROMB HAEMOSTASIS, V76, P1063; Fotis H, 1999, EUR J BIOCHEM, V260, P904, DOI 10.1046/j.1432-1327.1999.00237.x; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GAESTEL M, 1992, J BIOL CHEM, V267, P21607; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; Gevaert K, 1996, ELECTROPHORESIS, V17, P918, DOI 10.1002/elps.1150170513; Hall KU, 1999, J BIOL CHEM, V274, P3485, DOI 10.1074/jbc.274.6.3485; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; Haslam RJ, 1999, THROMB HAEMOSTASIS, V82, P412; Haug LS, 1999, J BIOL CHEM, V274, P7467, DOI 10.1074/jbc.274.11.7467; Hofmann F, 2000, J CELL SCI, V113, P1671; HORSTRUP K, 1994, EUR J BIOCHEM, V225, P21, DOI 10.1111/j.1432-1033.1994.00021.x; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Khan IU, 1998, P NATL ACAD SCI USA, V95, P10425, DOI 10.1073/pnas.95.18.10425; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; LANDRY J, 1992, J BIOL CHEM, V267, P794; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; Massberg S, 1999, J EXP MED, V189, P1255, DOI 10.1084/jem.189.8.1255; MENDELSOHN ME, 1991, P NATL ACAD SCI USA, V88, P11212, DOI 10.1073/pnas.88.24.11212; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8429; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; Reep BR, 1996, BIOCHEM BIOPH RES CO, V219, P1, DOI 10.1006/bbrc.1996.0171; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAKLATVALA J, 1996, J BIOL CHEM, V271, P6486; Scheler C, 1999, ELECTROPHORESIS, V20, P3623, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3623::AID-ELPS3623>3.0.CO;2-R; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; TORTI M, 1992, P NATL ACAD SCI USA, V89, P7796, DOI 10.1073/pnas.89.16.7796; VONBRUCHHAUSEN F, 1997, HDB EXP PHARM, V126, P181; WALTER U, 1980, J BIOL CHEM, V255, P3757; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; ZHU Y, 1994, J BIOL CHEM, V269, P22379; ZHU Y, 1994, BLOOD, V84, P3715, DOI 10.1182/blood.V84.11.3715.bloodjournal84113715	47	102	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7108	7113		10.1074/jbc.M009234200	http://dx.doi.org/10.1074/jbc.M009234200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11383510	hybrid			2022-12-27	WOS:000167442900036
J	Greenberg, RB; Alberti, M; Hearst, JE; Chua, MA; Saffran, WA				Greenberg, RB; Alberti, M; Hearst, JE; Chua, MA; Saffran, WA			Recombinational and mutagenic repair of psoralen interstrand cross-links in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; MAMMALIAN-CELL EXTRACTS; GENE CONVERSION TRACTS; DOUBLE-STRAND BREAKS; ESCHERICHIA-COLI; DNA-POLYMERASE; RECIPROCAL RECOMBINATION; 8-METHOXYPSORALEN PLUS; PLASMID RECOMBINATION; THYMINE DIMER	Psoralen photoreacts with DNA to form interstrand cross-links, which can be repaired by both nonmutagenic nucleotide excision repair and recombinational repair pathways and by mutagenic pathways. In the yeast Saccharomyces cerevisiae, psoralen cross-links are processed by nucleotide excision repair to form double-strand breaks (DSBs). In yeast, DSBs are repaired primarily by homologous recombination, predicting that cross-link and DSB repair should induce similar recombination end points. We compared psoralen cross-link, psoralen monoadduct, and DSB repair using plasmid substrates with site-specific lesions and measured the patterns of gene conversion, crossing over, and targeted mutation. Psoralen cross-link induced both recombination and mutations, whereas DSBs induced only recombination, and monoadducts were neither recombinogenic nor mutagenic. Although the cross-link- and DSB-induced patterns of plasmid integration and gene conversion were similar in most respects, they showed opposite asymmetries in their unidirectional conversion tracts: primarily upstream from the damage site for cross-links but downstream for DSBs. Cross-links induced targeted mutations in 5% of the repaired plasmids; all were base substitutions, primarily T --> C transitions. The major pathway of psoralen cross-link repair in yeast is error-free and involves the formation of DSB intermediates followed by homologous recombination. A fraction of the cross-links enter an error-prone pathway, resulting in mutations at the damage site.	CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA; Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Dept Chem, Berkeley, CA 94720 USA	City University of New York (CUNY) System; Queens College NY (CUNY); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Saffran, WA (corresponding author), CUNY Queens Coll, Dept Chem & Biochem, 65-30 Kissena Blvd, Flushing, NY 11367 USA.	Wilma_Saffran@qc.edu			NCI NIH HHS [CA42377] Funding Source: Medline; NIGMS NIH HHS [GM47945] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042377] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047945] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILERA A, 1989, GENETICS, V123, P683; AHN BY, 1986, MOL CELL BIOL, V6, P3685, DOI 10.1128/MCB.6.11.3685; ALANI E, 1994, GENETICS, V137, P19; AVERBECK D, 1989, PHOTOCHEM PHOTOBIOL, V50, P859, DOI 10.1111/j.1751-1097.1989.tb02917.x; Averbeck D, 1998, PHOTOCHEM PHOTOBIOL, V68, P289, DOI 10.1111/j.1751-1097.1998.tb09683.x; Barre FX, 1999, J MOL BIOL, V286, P1379, DOI 10.1006/jmbi.1999.2550; Barre FX, 1999, NUCLEIC ACIDS RES, V27, P743, DOI 10.1093/nar/27.3.743; Baynton K, 1998, MOL CELL BIOL, V18, P960, DOI 10.1128/MCB.18.2.960; Bessho T, 1997, MOL CELL BIOL, V17, P6822, DOI 10.1128/MCB.17.12.6822; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; CHENG S, 1988, J BIOL CHEM, V263, P15110; CHENG S, 1991, NUCLEIC ACIDS RES, V19, P657, DOI 10.1093/nar/19.3.657; CHIOU CC, 1995, CARCINOGENESIS, V16, P1357, DOI 10.1093/carcin/16.6.1357; Cho JW, 1998, CURR GENET, V34, P269; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; COLE RS, 1976, J MOL BIOL, V103, P39, DOI 10.1016/0022-2836(76)90051-6; COLE RS, 1973, P NATL ACAD SCI USA, V70, P1064, DOI 10.1073/pnas.70.4.1064; DARDALHON M, 1995, MUTAT RES-DNA REPAIR, V336, P49, DOI 10.1016/0921-8777(94)00037-7; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; Ferguson DO, 1996, P NATL ACAD SCI USA, V93, P5419, DOI 10.1073/pnas.93.11.5419; HAN EK, 1992, MOL GEN GENET, V236, P8, DOI 10.1007/BF00279637; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; JONES BK, 1990, J BIOL CHEM, V265, P3489; Kohn KW, 1996, CANCER RES, V56, P5533; Kumaresan KR, 1995, J BIOL CHEM, V270, P30709, DOI 10.1074/jbc.270.51.30709; Kumaresan KR, 2000, CARCINOGENESIS, V21, P741, DOI 10.1093/carcin/21.4.741; LAQUERBE A, 1995, J MOL BIOL, V254, P38, DOI 10.1006/jmbi.1995.0597; Li L, 1999, MOL CELL BIOL, V19, P5619; MAGANASCHWENCKE N, 1982, P NATL ACAD SCI-BIOL, V79, P1722, DOI 10.1073/pnas.79.6.1722; McHugh PJ, 2000, MOL CELL BIOL, V20, P3425, DOI 10.1128/MCB.20.10.3425-3433.2000; MEIRA LB, 1995, NUCLEIC ACIDS RES, V23, P1614, DOI 10.1093/nar/23.9.1614; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MILLER RD, 1982, MOL CELL BIOL, V2, P939, DOI 10.1128/MCB.2.8.939; Mu D, 2000, MOL CELL BIOL, V20, P2446, DOI 10.1128/MCB.20.7.2446-2454.2000; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Nickoloff JA, 1999, GENETICS, V153, P665; PAPADOPOULO D, 1993, MUTAT RES, V294, P167, DOI 10.1016/0921-8777(93)90025-C; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; ROCCANOVA LP, 1999, THESIS CITY U NEW YO; ROTHSTEIN RJ, 1981, METHOD ENZYMOL, V194, P281; SAFFRAN WA, 1994, NUCLEIC ACIDS RES, V22, P2823, DOI 10.1093/nar/22.14.2823; SAFFRAN WA, 1992, MUTAT RES, V274, P1, DOI 10.1016/0921-8777(92)90038-5; SAFFRAN WA, 1991, NUCLEIC ACIDS RES, V19, P5681, DOI 10.1093/nar/19.20.5681; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASTRY SS, 1992, J PHOTOCH PHOTOBIO B, V14, P65, DOI 10.1016/1011-1344(92)85083-7; Sherman F., 1986, METHODS YEAST GENETI; SLADEK FM, 1989, J BIOL CHEM, V264, P6755; SPIELMANN HP, 1992, P NATL ACAD SCI USA, V89, P4514, DOI 10.1073/pnas.89.10.4514; Stern RS, 1998, ARCH DERMATOL, V134, P1582, DOI 10.1001/archderm.134.12.1582; STINCHCOMB DT, 1980, P NATL ACAD SCI-BIOL, V77, P4559, DOI 10.1073/pnas.77.8.4559; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; SWEETSER DB, 1994, MOL CELL BIOL, V14, P3863, DOI 10.1128/MCB.14.6.3863; TESSMAN JW, 1985, BIOCHEMISTRY-US, V24, P1669, DOI 10.1021/bi00328a015; VANHOUTEN B, 1986, P NATL ACAD SCI USA, V83, P8077; Wang X, 2001, MOL CELL BIOL, V21, P713, DOI 10.1128/MCB.21.3.713-720.2001	57	29	30	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31551	31560		10.1074/jbc.M103588200	http://dx.doi.org/10.1074/jbc.M103588200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11390398	hybrid			2022-12-27	WOS:000170613500013
J	Fernandez-Velasco, JG; Jamshidi, A; Gong, XS; Zhou, JH; Ueng, RY				Fernandez-Velasco, JG; Jamshidi, A; Gong, XS; Zhou, JH; Ueng, RY			Photosynthetic electron transfer through the cytochrome b(6)f complex can bypass cytochrome f	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BC(1) COMPLEX; PLASTOCYANIN; DOMAIN; PLASTOQUINONE; CHLOROPLASTS; PURIFICATION; CONVERSION; REDUCTION; TRANSPORT	The cytochrome b(6)f complex is an obligatory electron transfer and proton-translocating enzyme in all oxygenic photosynthesis. Its operation has been described by the "Q-cycle." This model proposes that electrons are transferred from plastoquinol to plastocyanin (the reductant of P700 in Photosystem I) through, obligatorily in series, the iron-sulfur and the cytochrome f redox centers in the cytochrome b6f complex. However, here we demonstrate that (a) the iron-sulfur center-dependent reductions of plastocyanin and P700 are much faster than cytochrome f reduction, both in Chlamydomonas reinhardtii cytochrome f mutants and in the wild type, and (b) the steady-state photosynthetic electron transport does not correlate with strongly inhibited cytochrome f reduction kinetics in the mutants. Thus, cytochrome f is not an obligatory intermediate for electrons flowing through the cytochrome b6f complex. The oxidation equivalents from Photosystem I are delivered to the high potential chain of the cytochrome b,f complex both at the cytochrome f level and, independently, at another site connected to the quinol-oxidizing site, possibly the iron-sulfur center.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Fernandez-Velasco, JG (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, 421 Koshland Hall, Berkeley, CA 94720 USA.	jfernand@nature.berkeley.edu			NIGMS NIH HHS [GM-20571] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020571] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; Chi YI, 2000, BIOCHEMISTRY-US, V39, P7689, DOI 10.1021/bi000090k; Comolli LR, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1589; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; DELOSME R, 1987, BIOCHIM BIOPHYS ACTA, V893, P1, DOI 10.1016/0005-2728(87)90141-1; Drepper F, 1996, BIOCHEMISTRY-US, V35, P1282, DOI 10.1021/bi951471e; ERECINSKA M, 1972, P NATL ACAD SCI USA, V69, P50, DOI 10.1073/pnas.69.1.50; Fernandez-Velasco JG, 1999, BIOPHYS J, V76, pA20; Gong XS, 2001, J BIOL CHEM, V276, P24365, DOI 10.1074/jbc.M010721200; GRAY JC, 1992, PHOTOSYNTH RES, V34, P359, DOI 10.1007/BF00029811; HAEHNEL W, 1977, BIOCHIM BIOPHYS ACTA, V459, P418, DOI 10.1016/0005-2728(77)90043-3; HAEHNEL W, 1973, BIOCHIM BIOPHYS ACTA, V305, P618, DOI 10.1016/0005-2728(73)90081-9; Harris E.H., 1989, CHLAMYDOMONAS SOURCE, P26; Hauska G, 1996, ADV PHOTOSYNTH, V4, P377; He W. Z., 1998, P29; Hippler M, 1998, BBA-BIOENERGETICS, V1367, P1, DOI 10.1016/S0005-2728(98)00136-4; HIYAMA T, 1972, BIOCHIM BIOPHYS ACTA, V267, P160, DOI 10.1016/0005-2728(72)90147-8; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; JOLIOT P, 1994, P NATL ACAD SCI USA, V91, P1034, DOI 10.1073/pnas.91.3.1034; JUNGE W, 1977, PHOTOSYNTHESIS, V1, P59; KATOH S, 1962, J BIOCHEM-TOKYO, V51, P32, DOI 10.1093/oxfordjournals.jbchem.a127497; KSENZHEK OS, 1998, PLANT ENERGETICS, P1; KURAS R, 1995, BIOCHEMISTRY-US, V34, P7468, DOI 10.1021/bi00022a021; MALKIN R, 1975, BIOCHEM BIOPH RES CO, V63, P1157, DOI 10.1016/0006-291X(75)90690-7; Martinez SE, 1996, PROTEIN SCI, V5, P1081; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; MCCARTY RE, 1996, OXYGENIC PHOTOSYNTHE, P439; Melandri B.A., 1997, BIOENERGETICS, P95; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Mulkidjanian A, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P547; NITSCHKE W, 1989, BIOCHIM BIOPHYS ACTA, V974, P223, DOI 10.1016/S0005-2728(89)80376-7; ORT DR, 1986, PHOTOSYNTHESIS, V3, P143; PETERS FALJ, 1984, BIOCHIM BIOPHYS ACTA, V766, P179, DOI 10.1016/0005-2728(84)90230-5; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; Ponamarev MV, 1998, BIOCHEMISTRY-US, V37, P17199, DOI 10.1021/bi981814j; Ponamarev MV, 2000, BIOCHEMISTRY-US, V39, P5971, DOI 10.1021/bi9928997; SANDERSON DG, 1986, BIOCHIM BIOPHYS ACTA, V852, P269, DOI 10.1016/0005-2728(86)90232-X; SELAK MA, 1982, FEBS LETT, V150, P286, DOI 10.1016/0014-5793(82)80753-9; Soriano GM, 1999, J BIOENERG BIOMEMBR, V31, P201, DOI 10.1023/A:1005463527752; TREBST A, 1985, COENZYME Q, P257; Whitmarsh J., 1998, P87; WIKSTROM MK, 1972, BIOCHIM BIOPHYS ACTA, V283, P403, DOI 10.1016/0005-2728(72)90258-7; WITT HT, 1979, BIOCHIM BIOPHYS ACTA, V505, P355, DOI 10.1016/0304-4173(79)90008-9; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zhou JH, 1996, J BIOL CHEM, V271, P6225, DOI 10.1074/jbc.271.11.6225	49	20	20	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30598	30607		10.1074/jbc.M102241200	http://dx.doi.org/10.1074/jbc.M102241200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11395492	hybrid			2022-12-27	WOS:000170472900004
J	Boudin, H; Craig, AM				Boudin, H; Craig, AM			Molecular determinants for PICK1 synaptic aggregation and mGluR7a receptor coclustering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEINS; KINASE-C-ALPHA; AMPA RECEPTOR; GLUTAMATE RECEPTORS; BINDING-PROTEIN; PDZ DOMAINS; CHANNEL; PSD-95; YEAST; GLUR2	PSD-95/Disc-large/ZO-1 (PDZ) domain-containing proteins play a central role in synaptic organization by their involvement in neurotransmitter receptor clustering and signaling complex assembly. The protein interacting. with protein kinase C (PICK1), a synaptic PDZ domain protein that also contains a coiled-coil and acidic domain, binds to several synaptic components including the metabotropic glutamate receptor mGluR7a. Coexpression of PICK1 and mGluR7a in heterologous cells induces coclustering of these two proteins. To examine the role of the different structural motifs of PICK1 in synaptic aggregation of PICK1. and mGluR7a coclustering, several PICK1 mutants were generated to analyze their distribution in transfected hippocampal cultured neurons and to test their ability to induce coclusters with mGluR7a when coexpressed in fibroblast cells. The PDZ and coiled-coil domains are both required, whereas the acidic region plays an inhibitory role in these processes. Our data suggest that synaptic aggregation and receptor coclustering depend on PICK1 binding to a target membrane receptor, e.g. mGluR7a, by a PDZ-mediated interaction and on PICK1 oligomerization through the coiled-coil domain. This study defined three structural signals within PICK1 regulating its synaptic localization and receptor coclustering activity, which could represent molecular substrates involved in synaptic development and plasticity.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Craig, AM (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid Ave,Box 8108,958 McDonnell Sci Bldg, St Louis, MO 63110 USA.		Boudin, Helene/K-2400-2015; Craig, Ann Marie/M-2054-2014	Boudin, Helene/0000-0002-9714-2384	NINDS NIH HHS [NS39286] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039286] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; BAKSH S, 1991, J BIOL CHEM, V266, P21458; Boudin H, 2000, NEURON, V28, P485, DOI 10.1016/S0896-6273(00)00127-6; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Chung HJ, 2000, J NEUROSCI, V20, P7258; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; Dev KK, 1999, NEUROPHARMACOLOGY, V38, P635, DOI 10.1016/S0028-3908(98)00230-5; Dev KK, 2000, J NEUROSCI, V20, P7252; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Firestein BL, 1999, NEURON, V24, P659, DOI 10.1016/S0896-6273(00)81120-4; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Goslin K., 1998, RAT HIPPOCAMPAL NEUR, P339; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; James P, 1996, GENETICS, V144, P1425; Li HS, 2000, J CELL BIOL, V150, P1411, DOI 10.1083/jcb.150.6.1411; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Matsuda S, 2000, EMBO J, V19, P2765, DOI 10.1093/emboj/19.12.2765; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; OHNISHI M, 1987, BIOCHEMISTRY-US, V26, P7458, DOI 10.1021/bi00397a039; Osten P, 2000, NEURON, V27, P313, DOI 10.1016/S0896-6273(00)00039-8; Ramarao MK, 2001, J BIOL CHEM, V276, P7475, DOI 10.1074/jbc.M009888200; Rao A, 2000, J NEUROSCI, V20, P8344, DOI 10.1523/JNEUROSCI.20-22-08344.2000; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Takumi Y, 1999, ANN NY ACAD SCI, V868, P474, DOI 10.1111/j.1749-6632.1999.tb11316.x; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Tsunoda S, 2001, J NEUROSCI, V21, P150, DOI 10.1523/JNEUROSCI.21-01-00150.2001; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; Xiang Y, 2000, MOL BIOL CELL, V11, P1257, DOI 10.1091/mbc.11.4.1257	42	35	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30270	30276		10.1074/jbc.M102991200	http://dx.doi.org/10.1074/jbc.M102991200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11375398	hybrid			2022-12-27	WOS:000170558000088
J	Evans, JH; Spencer, DM; Zweifach, A; Leslie, CC				Evans, JH; Spencer, DM; Zweifach, A; Leslie, CC			Intracellular calcium signals regulating cytosolic phospholipase A(2) translocation to internal membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; ACTIVATED PROTEIN-KINASE; CANINE KIDNEY-CELLS; C2 DOMAIN; NUCLEAR-ENVELOPE; HYDROLYZING PHOSPHOLIPASE-A2; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; BINDING DOMAIN; GOLGI-COMPLEX	Increased intracellular Ca2+ concentrations ([Ca2+](i)) promote cytosolic phospholipase A(2) (cPLA(2)) translocation to intracellular membranes. The specific membranes to which cPLA(2) translocates and the [Ca2+](i) signals required were investigated. Plasmids of EGFP fused to full-length cPLA(2) (EGFP-FL) or to the cPLA(2) C2 domain (EGFP-C2) were used in C2+/EGFP imaging experiments of cells treated with [Ca2+](i)-mobilizing agonists. EGFP-FL, and -C2 translocated to Golgi in response, to sustained [Ca2+](i) greater than similar to 100-125 nM and to Golgi,. ER, and perinuclear membranes (PNM) at [Ca2+](i) greater than similar to 210-280 nm. In response to short duration [Ca2+](i) transients, EGFP-C2 translocated to Golgi, ER, and PNM, but EGFP-FL translocation was restricted to Golgi. However, EGFP-FL translocated to Golgi, ER, and PNM in response to long, duration transients. In response to declining, [Ca2+](i), EGFP-C2 readily dissociated from Golgi, but EGFP FL dissociation was delayed. Agonist-induced arachidonic acid release was proportional to the [Ca2+](i) and to the extent of cPLA(2) translocation. In summary, we, find that the differential translocation of cPLA(2) to Golgi or to ER and PNM is a function of [Ca2+](i) amplitude and duration., These results suggest that the cPLA(2), C2 domain regulates differential, Ca2+-dependent membrane targeting and that the catalytic domain regulates both the rate of translocation and enzyme residence.	Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Physiol, Denver, CO 80262 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leslie, CC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303, R01HL061378, F32HL010507] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL10507, HL34303, HL61378, P01 HL034303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; Bunt G, 1997, J CELL SCI, V110, P2449; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; Choukroun GJ, 2000, J CLIN INVEST, V106, P983, DOI 10.1172/JCI8914; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; de Figueiredo P, 1998, P NATL ACAD SCI USA, V95, P8642, DOI 10.1073/pnas.95.15.8642; de Figueiredo P, 1999, MOL BIOL CELL, V10, P1763, DOI 10.1091/mbc.10.6.1763; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; Drecktrah D, 1999, MOL BIOL CELL, V10, P4021, DOI 10.1091/mbc.10.12.4021; Evans JH, 1999, AM J PHYSIOL-LUNG C, V277, pL30, DOI 10.1152/ajplung.1999.277.1.L30; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GRIFFITHS G, 1984, J CELL BIOL, V98, P2133, DOI 10.1083/jcb.98.6.2133; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; HONDA Z, 1994, J BIOL CHEM, V269, P2307; Kim SW, 2001, FEBS LETT, V489, P243, DOI 10.1016/S0014-5793(00)02326-7; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; Liou JY, 2000, J BIOL CHEM, V275, P15314, DOI 10.1074/jbc.275.20.15314; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Marsh BJ, 2001, P NATL ACAD SCI USA, V98, P2399, DOI 10.1073/pnas.051631998; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; PetersGolden M, 1996, BIOCHEM J, V318, P797, DOI 10.1042/bj3180797; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Rottingen JA, 1997, CELL CALCIUM, V21, P195, DOI 10.1016/S0143-4160(97)90044-0; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Seemann J, 2000, NATURE, V407, P1022, DOI 10.1038/35039538; Slomiany A, 1998, ALCOHOL CLIN EXP RES, V22, P167, DOI 10.1097/00000374-199802000-00023; SLOMIANY A, 1992, INT J BIOCHEM, V24, P1397, DOI 10.1016/0020-711X(92)90065-9; TAGAYA M, 1993, FEBS LETT, V324, P201, DOI 10.1016/0014-5793(93)81393-E; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; Xing MB, 1996, J CLIN INVEST, V97, P1302, DOI 10.1172/JCI118546; Xing MZ, 1997, J CLIN INVEST, V99, P805, DOI 10.1172/JCI119227; Xing MZ, 1999, J BIOL CHEM, V274, P10035, DOI 10.1074/jbc.274.15.10035; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874	50	208	209	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30150	30160		10.1074/jbc.M100943200	http://dx.doi.org/10.1074/jbc.M100943200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11375391	hybrid			2022-12-27	WOS:000170558000074
J	Janiyani, K; Bordelon, T; Waldrop, GL; Cronan, JE				Janiyani, K; Bordelon, T; Waldrop, GL; Cronan, JE			Function of Escherichia coli biotin carboxylase requires catalytic activity of both subunits of the homodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; COENZYME-A CARBOXYLASE; SITE	Biotin carboxylase catalyzes the ATP-dependent carboxylation of biotin and is one component of the multienzyme. complex acetyl-CoA carboxylase that catalyzes the first committed step in fatty acid synthesis. The Escherichia coli biotin carboxylase is readily isolated from the other components of the acetyl-CoA carboxylase complex such that enzymatic activity is retained. The three-dimensional structure of biotin carboxylase, determined by x-ray crystallography, demonstrated that the enzyme is a homodimer consisting of two active sites in which each subunit contains a complete active site. To understand how each subunit contributes to the overall function of biotin carboxylase, we made hybrid molecules in which one subunit had a wild-type active site, and the other subunit contained an active site mutation known to significantly affect the activity of the enzyme. One of the two genes encoded a poly-histidine tag at its N terminus, whereas the other gene had an N-terminal FLAG epitope tag. The two genes were assembled into a mini-operon that was induced to give high level expression of both enzymes. "Hybrid" dimers composed of one subunit with a wild-type active site and a second subunit having a mutant, active site were obtained by sequential chromatographic steps on columns of immobilized nickel chelate and anti-FLAG affinity matrices. In vitro kinetic studies of biotin carboxylase dimers in which both subunits were wild type revealed that the presence of the N-terminal tags did not alter the activity of the enzyme. However, kinetic assays of hy brid dimer biotin carboxylase molecules in which one subunit had an active site mutation (R292A, N290A, K238Q or E288K) and the other subunit had a wild-type active site resulted in 39-, 28-, 94-, and 285-fold decreases in the activity of these enzymes, respectively. The dominant negative effects of these mutant subunits were also detected in vivo by monitoring the rate of fatty acid biosynthesis by [C-14]acetate labeling of cellular lipids. Expression of the mutant biotin carboxylase genes from an inducible arabinose promoter resulted in a significantly reduced rate of fatty acid synthesis relative to the same strain that expressed the wild type gene. Thus, both the in vitro and in vivo data indicate that both subunits of biotin carboxylase are required for activity and that the two subunits must be in communication during enzyme function.	Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Louisiana State Univ, Div Biochem & Mol Biol, Baton Rouge, LA 70803 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Louisiana State University System; Louisiana State University	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA.		Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051261] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15650] Funding Source: Medline; NIGMS NIH HHS [GM51261] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blanchard CZ, 1999, BIOCHEMISTRY-US, V38, P3393, DOI 10.1021/bi982660a; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; Davis MS, 2000, J BIOL CHEM, V275, P28593, DOI 10.1074/jbc.M004756200; Dennis JJ, 1998, APPL ENVIRON MICROB, V64, P2710; EISENSTEIN E, 1992, J BIOL CHEM, V267, P22148; GIBBONS I, 1976, BIOCHEMISTRY-US, V15, P52, DOI 10.1021/bi00646a009; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; KAPLAN NO, 1968, ANN NY ACAD SCI, V151, P382, DOI 10.1111/j.1749-6632.1968.tb11902.x; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; Levert KL, 2000, BIOCHEMISTRY-US, V39, P4122, DOI 10.1021/bi992662a; LI SJ, 1992, J BIOL CHEM, V267, P855; PENHOET EE, 1971, J BIOL CHEM, V246, P318; TANABE T, 1975, EUR J BIOCHEM, V57, P15, DOI 10.1111/j.1432-1033.1975.tb02272.x; Thoden JB, 2000, J BIOL CHEM, V275, P16183, DOI 10.1074/jbc.275.21.16183; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P301	17	53	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29864	29870		10.1074/jbc.M104102200	http://dx.doi.org/10.1074/jbc.M104102200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390406	hybrid			2022-12-27	WOS:000170558000036
J	Lee, SP; Hwang, YS; Kim, YJ; Kwon, KS; Kim, HJ; Kim, K; Chae, HZ				Lee, SP; Hwang, YS; Kim, YJ; Kwon, KS; Kim, HJ; Kim, K; Chae, HZ			Cyclophilin a binds to peroxiredoxins and activates its peroxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; MITOCHONDRIAL PERMEABILITY TRANSITION; NF-KAPPA-B; CYCLOSPORINE-A; MAMMALIAN PEROXIREDOXIN; THIOREDOXIN PEROXIDASE; ESCHERICHIA-COLI; GLUTATHIONE-PEROXIDASE; OXIDATIVE STRESS; REDUCE PEROXIDES	Six distinct peroxiredoxin (Prx) proteins (Prx I-VI) from distinct genes have been identified in mammalian tissues. Prxs are members of a group of peroxidases that have conserved reactive cysteine residue(s) in the active site(s). An immediate physiological electron donor for the peroxidase catalysis for five Prx proteins (Prx I-V) has been identified as thioredoxin (Trx), but that for Prx VI (I-Cys Prx) is still unclear. To identify an immediate electron donor and a binding protein for Prx VI, we performed a Prx VI protein overlay assay. A 20-kDa binding protein was identified by the Prx VI protein overlay assay with flow-through fractions from a High-Q column with rat lung crude extracts. Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) and MS-Fit, we identified the 20-kDa Prx Vl-binding protein as a cyclophilin A (CyP-A). The binding of recombinant human CyP-A (hCyP-A) to Prx VI was confirmed by using the hCyP-A protein overlay assay and Western immunoblot analysis with hCyP-A-specific antibodies. hCyP-A enhanced the antioxidant activity of Prx VI, as well as the other known mammalian Prx isotypes. hCyP-A supported antioxidant activity of Prx II and Prx VI both against thiol (dithiothreitol)-containing metal-catalyzed oxidation (MCO) systems and ascorbate-containing MCO systems. Prx II was reduced by hCyP-A without help from any other reductant, and the reduction was cyclosporin A-independent. These results strongly suggest that CyP-A not only binds to Prx proteins but also supports its peroxidase activity as an immediate electron donor. In addition, Cys(115) and Cys(161) of hCyP-A were found to be involved in the activation and the reduction of Prx.	Chonnam Natl Univ, Coll Nat Sci, Dept Sci Biol, Buk Ku, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Food & Nutr, Kwangju 500757, South Korea; Chonnam Natl Univ, Mol Endocrinol Program, Kwangju 500757, South Korea; Yonsei Univ, Coll Med, Dept Internal Med, Seoul 135270, South Korea; Korea Res Inst Biosci & Biotechnol, Taejon 30560, South Korea	Chonnam National University; Chonnam National University; Chonnam National University; Yonsei University; Yonsei University Health System; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Chae, HZ (corresponding author), Chonnam Natl Univ, Coll Nat Sci, Dept Sci Biol, Buk Ku, Kwangju 500757, South Korea.							AALEN RB, 1994, PLANT J, V5, P385, DOI 10.1111/j.1365-313X.1994.00385.x; BROEKEMEIER KM, 1992, FEBS LETT, V304, P192, DOI 10.1016/0014-5793(92)80616-O; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200; Cheong NE, 1999, PLANT MOL BIOL, V40, P825, DOI 10.1023/A:1006271823973; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Doyle V, 1999, BIOCHEM J, V341, P127, DOI 10.1042/0264-6021:3410127; FEJZO J, 1994, BIOCHEMISTRY-US, V33, P5711, DOI 10.1021/bi00185a007; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; GALAT A, 1998, PROTEIN PROFILE PEPT; GOGVADZE V, 1993, FEBS LETT, V333, P334, DOI 10.1016/0014-5793(93)80682-K; GRIFFITHS EJ, 1993, J MOL CELL CARDIOL, V25, P1461, DOI 10.1006/jmcc.1993.1162; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; Haridas V, 1998, J IMMUNOL, V161, P1; Jaschke A, 1998, J MOL BIOL, V277, P763, DOI 10.1006/jmbi.1998.1644; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kim TS, 1997, J BIOL CHEM, V272, P2542; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; Lee KO, 2000, FEBS LETT, V486, P103, DOI 10.1016/S0014-5793(00)02230-4; Leventhal L, 2000, J COMP NEUROL, V425, P471, DOI 10.1002/1096-9861(20001002)425:4<471::AID-CNE1>3.0.CO;2-U; LIM YS, 1994, BIOCHEM BIOPH RES CO, V199, P199, DOI 10.1006/bbrc.1994.1214; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; Munz B, 1997, BIOCHEM J, V326, P579, DOI 10.1042/bj3260579; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; RHEE SG, 1985, METHOD ENZYMOL, V113, P213; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Singh AK, 1998, J BIOL CHEM, V273, P26171, DOI 10.1074/jbc.273.40.26171; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wong A, 1997, BIOCHEM BIOPH RES CO, V239, P139, DOI 10.1006/bbrc.1997.7443; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615; Zhou Y, 2000, BIOCHEM BIOPH RES CO, V268, P921, DOI 10.1006/bbrc.2000.2231	46	316	337	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29826	29832		10.1074/jbc.M101822200	http://dx.doi.org/10.1074/jbc.M101822200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390385	hybrid			2022-12-27	WOS:000170558000031
J	Van Huffel, S; Delaei, F; Heyninck, K; De Valck, D; Beyaert, R				Van Huffel, S; Delaei, F; Heyninck, K; De Valck, D; Beyaert, R			Identification of a novel A20-binding inhibitor of nuclear factor-kappa B activation termed ABIN-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; DEPENDENT GENE-EXPRESSION; CELL-DEATH; INDUCED APOPTOSIS; TNF RECEPTOR; KINASE-ALPHA; IKK-GAMMA; I TAX; A20; RIP	The nuclear factor kappaB (NF-kappaB) plays a central role in the regulation of genes implicated immune responses, inflammatory processes, and apoptotic cell death. The zinc finger protein A20 is a cellular inhibitor of NF-kappaB activation by various stimuli and plays a critical role in terminating NF-kappaB responses. The underlying mechanism for NF-kappaB inhibition by A20 is still unknown. A20 has been shown to interact with several proteins including tumor necrosis factor (TNF) receptor-associated factors 2 and 6, as well as the inhibitory protein of kappaB kinase (IKK) gamma protein. Here we report the cloning and characterization of ABIN-2, a previously unknown protein that binds to the COOH-terminal zinc finger domain of A20. NF-kappaB activation induced by TNF and interleukin-1 is inhibited by overexpression. of ABIN-2. The latter also inhibits NF-kappaB activation induced by overexpression of receptor-interacting protein or TNF receptor-associated factor 2. In contrast, NF-kappaB activation by overexpression of IKK beta or direct activators of the IKK complex, such as Tax, cannot be inhibited by ABIN-2. These results indicate that ABIN-2 interferes with NF-kappaB activation upstream of the IKK complex and that it might contribute to the NF-kappaB-inhibitory function of A20.	Flanders Interuniv Inst Biotechnol, Dept Mol Biol, Unit Mol Signal Transduct Inflammat, B-9000 Ghent, Belgium; Univ Ghent, B-9000 Ghent, Belgium	Ghent University	Beyaert, R (corresponding author), Flanders Interuniv Inst Biotechnol, Dept Mol Biol, Unit Mol Signal Transduct Inflammat, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	rudi.beyaert@dmb.rug.ac.be	Beyaert, Rudi/B-2589-2009	Beyaert, Rudi/0000-0002-5704-582X				BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Chen F, 1999, CLIN CHEM, V45, P7; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Desmedt M, 1998, J IMMUNOL, V160, P5300; DeValck D, 1996, FEBS LETT, V384, P61, DOI 10.1016/0014-5793(96)00283-9; DeValck D, 1997, BIOCHEM BIOPH RES CO, V238, P590, DOI 10.1006/bbrc.1997.7343; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Heyninck K, 1999, FEBS LETT, V442, P147, DOI 10.1016/S0014-5793(98)01645-7; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Inohara N, 2000, J BIOL CHEM, V275, P27823; Jaattela M, 1996, J IMMUNOL, V156, P1166; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kajino S, 2000, ONCOGENE, V19, P2233, DOI 10.1038/sj.onc.1203560; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Klinkenberg M, 2001, FEBS LETT, V498, P93, DOI 10.1016/S0014-5793(01)02504-2; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lademann U, 2001, CELL DEATH DIFFER, V8, P265, DOI 10.1038/sj.cdd.4400805; LAHERTY CD, 1993, J BIOL CHEM, V268, P5032; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Mori T, 2000, FEBS LETT, V465, P124, DOI 10.1016/S0014-5793(99)01726-3; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; Olsen Ole, 1992, Methods in Molecular and Cellular Biology, V3, P159; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; TEWARI M, 1995, J IMMUNOL, V154, P1699; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANHAESEBROECK B, 1991, CANCER RES, V51, P2469; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	56	82	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30216	30223		10.1074/jbc.M100048200	http://dx.doi.org/10.1074/jbc.M100048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390377	hybrid			2022-12-27	WOS:000170558000082
J	Cordeaux, Y; Nickolls, SA; Flood, LA; Graber, SG; Strange, PG				Cordeaux, Y; Nickolls, SA; Flood, LA; Graber, SG; Strange, PG			Agonist regulation of D-2 dopamine receptor/G protein interaction - Evidence for agonist selection of G protein subtype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX MODEL; BETA-ADRENERGIC-RECEPTOR; LIGAND-BINDING; CELL-MEMBRANES; MOLECULAR DETERMINANTS; FUNCTIONAL ASSAYS; COUPLED RECEPTORS; ADENYLYL-CYCLASE; ALPHA-SUBUNITS; INSECT CELLS	The D-2 dopamine receptor has been expressed in Sf21. insect cells together with the G proteins G(o) and G(i2), using the baculovirus system. Expression levels of receptor and G protein (alpha, beta, and gamma subunits) in the two preparations were similar as shown by binding of [H-3]spiperone and quantitative Western blot, respectively. For several agonists, binding data were fitted best by a two-binding site model in either preparation, showing interaction of expressed receptor and G protein. For some agonists, binding to the higher affinity site was of higher affinity in D-2/G(o) than in the D-2/G(i2), preparation. Some agonists exhibited binding data that were best fitted by a two-binding site model in D-2/G(o) and a one-binding site model in D-2/G(i2.) Therefore, receptor/G protein interaction seemed to be stronger in the D-2/G(o) preparation. Agonist stimulation of [S-35]GTP gammaS (guanosine 5'-3-O-(thio)triphosphate) binding in the two preparations also gave evidence for higher affinity D-2/G(o), interaction. In the D-2/G(o) preparation, agonist stimulation of [S-35]GTP gammaS binding occurred at higher potency for several agonists, and a higher stimulation (relative to dopamine) was achieved in D-2/G(o) compared with D2/Gi2, Some agonists were able to stimulate [S-35]GTP gammaS binding in the D-2/G(o) preparation but not in D2/Gi2. The extent of D2 receptor selectivity for Go over Gi2 is therefore dependent on the agonist used, and thus agonists may stabilize different conformations of the receptor with different abilities to couple to and activate G proteins.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; W Virginia Univ, Dept Pharmacol & Toxicol, Morgantown, WV 26506 USA	University of Reading; West Virginia University	Strange, PG (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.							Airriess CN, 1997, BRIT J PHARMACOL, V122, P191, DOI 10.1038/sj.bjp.0701348; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Barr AJ, 1997, J BIOL CHEM, V272, P32979, DOI 10.1074/jbc.272.52.32979; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; Boundy VA, 1996, J PHARMACOL EXP THER, V276, P784; CASTRO SW, 1993, FEBS LETT, V315, P223, DOI 10.1016/0014-5793(93)81168-Y; CASTRO SW, 1993, J NEUROCHEM, V60, P372, DOI 10.1111/j.1471-4159.1993.tb05863.x; Chidiac P, 1998, BIOCHEM PHARMACOL, V55, P549, DOI 10.1016/S0006-2952(97)00361-4; Clarke WP, 1998, TRENDS PHARMACOL SCI, V19, P270, DOI 10.1016/S0165-6147(97)01138-3; Clawges HM, 1997, BIOCHEMISTRY-US, V36, P12930, DOI 10.1021/bi970112b; DELEAN A, 1980, J BIOL CHEM, V255, P7108; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; Figler RA, 1996, MOL PHARMACOL, V50, P1587; Gardner B, 1998, BRIT J PHARMACOL, V124, P978, DOI 10.1038/sj.bjp.0701926; Gardner B, 1996, BRIT J PHARMACOL, V118, P1544, DOI 10.1111/j.1476-5381.1996.tb15572.x; Gardner BR, 1997, J NEUROCHEM, V69, P2589; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GETTYS TW, 1994, BIOCHEMISTRY-US, V33, P4283, DOI 10.1021/bi00180a024; Ghahremani MH, 1999, J BIOL CHEM, V274, P9238, DOI 10.1074/jbc.274.14.9238; GRABER SG, 1992, J BIOL CHEM, V267, P1271; Grunewald S, 1996, BIOCHEMISTRY-US, V35, P15162, DOI 10.1021/bi960757w; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; Jakubik J, 1998, MOL PHARMACOL, V54, P899, DOI 10.1124/mol.54.5.899; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kenakin TP., 1993, PHARM ANAL DRUG RECE, V2; LEE TWT, 1986, BIOCHEMISTRY-US, V25, P7009, DOI 10.1021/bi00370a038; LIU YF, 1994, J BIOL CHEM, V269, P13880; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCALLUM JF, 1995, BIOCHEM J, V310, P1021, DOI 10.1042/bj3101021; MELLER E, 1992, J PHARMACOL EXP THER, V263, P462; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Neve KA, 1997, DOPAMINE RECEPTORS; RANSNAS LA, 1988, J BIOL CHEM, V263, P9482; RANSNAS LA, 1992, BIOCHEM J, V283, P519, DOI 10.1042/bj2830519; Raymond JR, 1999, BRIT J PHARMACOL, V127, P1751, DOI 10.1038/sj.bjp.0702723; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SANDERSON EM, 1995, BRIT J PHARMACOL, V115, P102; Selley DE, 1997, MOL PHARMACOL, V51, P87, DOI 10.1124/mol.51.1.87; SIBLEY DR, 1983, MOL PHARMACOL, V23, P585; Strange PG, 1997, NEUROPSYCHOPHARMACOL, V16, P116; Strange PG, 1998, TRENDS PHARMACOL SCI, V19, P85, DOI 10.1016/S0165-6147(98)01175-4; Strange PG, 1999, BIOCHEM PHARMACOL, V58, P1081; SUMMERS MD, 1987, TEX AGR EXP STA B, V1555, P5; Svoboda P, 1996, MOL PHARMACOL, V49, P646; Weiss JM, 1996, J THEOR BIOL, V178, P151, DOI 10.1006/jtbi.1996.0014; Wenzel-Seifert K, 2000, MOL PHARMACOL, V58, P954, DOI 10.1124/mol.58.5.954; Wenzel-Seifert K, 1998, J BIOL CHEM, V273, P24181, DOI 10.1074/jbc.273.37.24181; WREGGETT KA, 1984, MOL PHARMACOL, V26, P214; Yang Q, 1999, MOL PHARMACOL, V56, P651, DOI 10.1124/mol.56.3.651	50	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28667	28675		10.1074/jbc.M008644200	http://dx.doi.org/10.1074/jbc.M008644200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11369753	hybrid, Green Submitted			2022-12-27	WOS:000170346000006
J	Puri, N; Majumdar, A; Cuenoud, B; Natt, F; Martin, P; Boyd, A; Miller, PS; Seidman, MM				Puri, N; Majumdar, A; Cuenoud, B; Natt, F; Martin, P; Boyd, A; Miller, PS; Seidman, MM			Targeted gene knockout by 2 '-O-aminoethyl modified triplex forming oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC RECOGNITION; PHOTO-CROSS-LINKING; DOUBLE-STRANDED DNA; DOUBLE-HELICAL DNA; MAMMALIAN-CELLS; 3RD STRAND; EXONUCLEASE RESISTANCE; BACKBONE COMPOSITION; BIOLOGICAL-ACTIVITY; PURINE-MOTIF	Triplex forming oligonucleotides (TFOs) are of interest because of their potential for facile gene targeting. However, the failure of TFOs to bind target sequences at physiological pH and Mg2+ concentration has limited their biological applications. Recently, pyrimidine TFOs with 2 ' -O-aminoethyl (AE) substitutions were shown to have enhanced kinetics and stability of triplex formation (Cuenoud, B., Casset, F., Husken, D., Natt, F., Wolf, R. M., Altmann, K. H., Martin, P., and Moser H. E. (1998) Angew. Chem. Int, Ed. 37,1288-1291). We have prepared psoralen-linked TFOs with varying amounts of the AE-modified residues, and have characterized them in biochemical assays in vitro, and in stability and HPRT gene knockout assays in vivo. The AE TFOs showed higher affinity for the target in vitro than a TFO with uniform 2 ' -OMe substitution, with relatively little loss of affinity when the assay was performed in reduced Mg2+. Once formed they were also more stable in "physiological" buffer, with the greatest affinity and stability displayed by the TFO with all but one residue in the AE format. However, TFOs with lesser amounts of the AE modification formed the most stable triplexes in vivo, and showed the highest HPRT gene knockout activity. We conclude that the AE modification can enhance the biological activity of pyrimidine TFOs, but that extensive substitution is deleterious.	NIA, LMG, NIH, Baltimore, MD 21224 USA; Novartis Horshan Res Ctr, Horsham RH12 4AB, W Sussex, England; Novartis Pharma Ltd, CH-4002 Basel, Switzerland; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Novartis; Novartis; Johns Hopkins University	Seidman, MM (corresponding author), NIA, LMG, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.				NATIONAL INSTITUTE ON AGING [Z01AG000738, ZIAAG000738] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Asensio JL, 1999, J AM CHEM SOC, V121, P11063, DOI 10.1021/ja991949s; Barre FX, 2000, P NATL ACAD SCI USA, V97, P3084, DOI 10.1073/pnas.050368997; BEAL PA, 1992, NUCLEIC ACIDS RES, V20, P2773, DOI 10.1093/nar/20.11.2773; Bijapur J, 1999, NUCLEIC ACIDS RES, V27, P1802, DOI 10.1093/nar/27.8.1802; Blommers MJJ, 1998, BIOCHEMISTRY-US, V37, P17714, DOI 10.1021/bi9816352; Blume SW, 1999, NUCLEIC ACIDS RES, V27, P695, DOI 10.1093/nar/27.2.695; Boal JH, 1996, NUCLEIC ACIDS RES, V24, P3115, DOI 10.1093/nar/24.15.3115; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; Cassidy RA, 2000, BIOCHEMISTRY-US, V39, P8683, DOI 10.1021/bi000657x; Chan PP, 1997, J MOL MED, V75, P267, DOI 10.1007/s001090050112; Cheng AJ, 1998, ANTISENSE NUCLEIC A, V8, P215, DOI 10.1089/oli.1.1998.8.215; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Cuenoud B, 1998, ANGEW CHEM INT EDIT, V37, P1288, DOI 10.1002/(SICI)1521-3773(19980518)37:9<1288::AID-ANIE1288>3.0.CO;2-U; Dagneaux C, 1995, BIOCHEMISTRY-US, V34, P16618, DOI 10.1021/bi00051a009; ESCUDE C, 1992, CR ACAD SCI III-VIE, V315, P521; ESCUDE C, 1993, NUCLEIC ACIDS RES, V21, P5547, DOI 10.1093/nar/21.24.5547; Faria M, 2001, J MOL BIOL, V306, P15, DOI 10.1006/jmbi.2000.4386; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FOSSELLA JA, 1993, NUCLEIC ACIDS RES, V21, P4511, DOI 10.1093/nar/21.19.4511; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; GREENBERG WA, 1995, J AM CHEM SOC, V117, P5016, DOI 10.1021/ja00123a002; Griffey RH, 1996, J MED CHEM, V39, P5100, DOI 10.1021/jm950937o; HAN HY, 1993, P NATL ACAD SCI USA, V90, P3806, DOI 10.1073/pnas.90.9.3806; Hildbrand S, 1997, J AM CHEM SOC, V119, P5499, DOI 10.1021/ja9704904; Kobertz WR, 1997, J AM CHEM SOC, V119, P5960, DOI 10.1021/ja9703178; Lacroix L, 2000, BIOCHEM BIOPH RES CO, V270, P363, DOI 10.1006/bbrc.2000.2438; Lacroix L, 1999, BIOCHEMISTRY-US, V38, P1893, DOI 10.1021/bi982290q; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; Levy DD, 1996, J MOL BIOL, V255, P435, DOI 10.1006/jmbi.1996.0036; Lin FLM, 2000, J BIOL CHEM, V275, P39117, DOI 10.1074/jbc.M005404200; Maher L J 3rd, 1991, Antisense Res Dev, V1, P277; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; Maher LJ, 1996, CANCER INVEST, V14, P66, DOI 10.3109/07357909609018437; Majumdar A, 1998, NAT GENET, V20, P212, DOI 10.1038/2530; Maksimenko AV, 2000, EUR J BIOCHEM, V267, P3592, DOI 10.1046/j.1432-1327.2000.01388.x; MANOR H, 1988, J MOL EVOL, V27, P96, DOI 10.1007/BF02138367; Marquez VE, 1996, J MED CHEM, V39, P3739, DOI 10.1021/jm960306+; Mullah B, 1997, TETRAHEDRON LETT, V38, P5751, DOI 10.1016/S0040-4039(97)01286-0; Neidle S, 1997, ANTI-CANCER DRUG DES, V12, P433; NOONBERG SB, 1995, NUCLEIC ACIDS RES, V23, P1956, DOI 10.1093/nar/23.11.1956; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; PIELES U, 1989, NUCLEIC ACIDS RES, V17, P285, DOI 10.1093/nar/17.1.285; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; Pradeepkumar PI, 2000, TETRAHEDRON LETT, V41, P8601, DOI 10.1016/S0040-4039(00)01510-0; RADHAKRISHNAN I, 1994, BIOCHEMISTRY-US, V33, P11405, DOI 10.1021/bi00204a001; ROBERTS RW, 1992, SCIENCE, V258, P1463, DOI 10.1126/science.1279808; SEIDMAN MM, 1985, GENE, V38, P233, DOI 10.1016/0378-1119(85)90222-7; SHIMIZU M, 1992, FEBS LETT, V302, P155, DOI 10.1016/0014-5793(92)80428-J; SVINARCHUK F, 1995, J BIOL CHEM, V270, P14068, DOI 10.1074/jbc.270.23.14068; SVINARCHUK F, 1995, NUCLEIC ACIDS RES, V23, P3831, DOI 10.1093/nar/23.19.3831; Teplova M, 1999, P NATL ACAD SCI USA, V96, P14240, DOI 10.1073/pnas.96.25.14240; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; Torigoe H, 2001, J BIOL CHEM, V276, P2354, DOI 10.1074/jbc.M007783200; Vasquez KM, 1998, TRENDS BIOCHEM SCI, V23, P4, DOI 10.1016/S0968-0004(97)01158-4; Vasquez KM, 1996, BIOCHEMISTRY-US, V35, P10712, DOI 10.1021/bi960881f; WANG G, 1995, MOL CELL BIOL, V15, P1759; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802	57	51	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28991	28998		10.1074/jbc.M103409200	http://dx.doi.org/10.1074/jbc.M103409200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11389147	hybrid			2022-12-27	WOS:000170346000049
J	Fabini, G; Freilinger, A; Altmann, F; Wilson, IBH				Fabini, G; Freilinger, A; Altmann, F; Wilson, IBH			Identification of core alpha 1,3-fucosylated glycans and cloning of the requisite fucosyltransferase cDNA from Drosophila melanogaster - Potential basis of the neural anti-horseradish peroxidase epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; GDP-L-FUCOSE; ALPHA-1,3-LINKED FUCOSE; CARBOHYDRATE MOIETY; CELL-SURFACE; INSECT CELLS; GLYCOPROTEINS; ANTIBODIES; EXPRESSION; PROTEINS	For many years, polyclonal antibodies raised against the plant glycoprotein horseradish peroxidase have been used to specifically stain the neural and male reproductive tissue of Drosophila melanogaster. This epitope is considered to be of carbohydrate origin, but no glycan structure from Drosophila has yet been isolated that could account for this cross-reactivity. Here we report that N-glycan core alpha1,3-linked fucose is, as judged by pre-absorption experiments, indispensable for recognition of Drosophila embryonic nervous system by anti-horseradish peroxidase antibody. Further, we describe the identification by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry and high performance liquid chromatography of two Drosophila N-glycans that, as already detected in other insects, carry both alpha1,3- and alpha1,6-linked fucose residues on the proximal core GlcNAc. Moreover, we have isolated three cDNAs encoding alpha1,3-fucosyltransferase homologues from Drosophila. One of the cDNAs, when transformed into Pichia pastoris, was found to direct expression of core alpha1,3-fucosyltransferase activity. This recombinant enzyme preferred as substrate a biantennary core alpha1,6-fucosylated N-glycan carrying two non-reducing N-acetylglucosamine residues (GnGnF(6), K-m 11 muM) over the same structure lacking a core fucose residue (GnGn; K-m 46 muM). The Drosophila core alpha1,3-fucosyltransferase enzyme was also shown to be able to fucosylate N-glycan structures of human transferrin in. vitro, this modification correlating with the acquisition of binding to anti-horseradish peroxidase antibody.	Univ Bodenkultur Wien, Inst Chem, Glycobiol Div, A-1190 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna	Wilson, IBH (corresponding author), Univ Bodenkultur Wien, Inst Chem, Glycobiol Div, Muthgasse 18, A-1190 Vienna, Austria.	iwilson@edv2.boku.ac.at	Wilson, Iain/B-3326-2009	Wilson, Iain/0000-0001-8996-1518; Altmann, Friedrich/0000-0002-0112-7877				ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; ALTMANN F, 1992, ANAL BIOCHEM, V204, P215, DOI 10.1016/0003-2697(92)90164-3; ALTMANN F, 1993, GLYCOBIOLOGY, V3, P619, DOI 10.1093/glycob/3.6.619; Breton C, 1998, GLYCOBIOLOGY, V8, P87, DOI 10.1093/glycob/8.1.87; DESAI CJ, 1994, J NEUROSCI, V14, P7272; FAYE L, 1993, ANAL BIOCHEM, V209, P104, DOI 10.1006/abio.1993.1088; FAYE L, 1988, GLYCOCONJUGATE J, V5, P245, DOI 10.1007/BF01049085; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; Haslam SM, 1996, J BIOL CHEM, V271, P30561, DOI 10.1074/jbc.271.48.30561; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; KATZ F, 1988, EMBO J, V7, P3471, DOI 10.1002/j.1460-2075.1988.tb03222.x; Khoo KH, 1997, GLYCOBIOLOGY, V7, P663, DOI 10.1093/glycob/7.5.663; Kolarich D, 2000, ANAL BIOCHEM, V285, P64, DOI 10.1006/abio.2000.4737; KUBELKA V, 1995, GLYCOCONJUGATE J, V12, P77, DOI 10.1007/BF00731872; KUBELKA V, 1994, ARCH BIOCHEM BIOPHYS, V308, P148, DOI 10.1006/abbi.1994.1021; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; Leiter H, 1999, J BIOL CHEM, V274, P21830, DOI 10.1074/jbc.274.31.21830; LONGMORE GD, 1982, CARBOHYD RES, V100, P365, DOI 10.1016/S0008-6215(00)81049-6; MCMANUS MT, 1988, PLANTA, V175, P506, DOI 10.1007/BF00393072; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; PRENNER C, 1992, BIOCHEM J, V284, P377, DOI 10.1042/bj2840377; Roitinger A, 1998, GLYCOCONJUGATE J, V15, P89, DOI 10.1023/A:1006951802623; Sarkar M, 2001, BIOL CHEM, V382, P209, DOI 10.1515/BC.2001.028; Seppo A, 1999, GLYCOBIOLOGY, V9, P1138; Seppo A, 2000, GLYCOBIOLOGY, V10, P751, DOI 10.1093/glycob/10.8.751; SIDDIQUI SS, 1991, J NEUROGENET, V7, P193, DOI 10.3109/01677069109167433; SNOW PM, 1987, J NEUROSCI, V7, P4137; Staudacher E, 1998, GLYCOCONJUGATE J, V15, P355, DOI 10.1023/A:1006969701231; Struppe E, 2000, BBA-GEN SUBJECTS, V1475, P360, DOI 10.1016/S0304-4165(00)00092-1; SUN BH, 1995, J NEUROCHEM, V65, P434, DOI 10.1046/j.1471-4159.1995.65010434.x; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; van Die I, 1999, FEBS LETT, V463, P189, DOI 10.1016/S0014-5793(99)01508-2; WANG X, 1994, INSECT BIOCHEM MOLEC, V24, P233, DOI 10.1016/0965-1748(94)90002-7; WHITLOCK KE, 1993, DEVELOPMENT, V117, P1251; WILLIAMS PJ, 1991, BIOCHIM BIOPHYS ACTA, V1075, P146, DOI 10.1016/0304-4165(91)90245-C; Wilson IBH, 2001, GLYCOBIOLOGY, V11, P261, DOI 10.1093/glycob/11.4.261; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651; Wilson IBH, 1998, GLYCOCONJUGATE J, V15, P1055, DOI 10.1023/A:1006960401562; Wilson IBH, 2001, BBA-GEN SUBJECTS, V1527, P88, DOI 10.1016/S0304-4165(01)00151-9; Yang BY, 1996, CARBOHYD RES, V287, P203, DOI 10.1016/0008-6215(96)00073-0; Zeleny R, 1997, ANAL BIOCHEM, V246, P96, DOI 10.1006/abio.1996.9973	42	133	140	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28058	28067		10.1074/jbc.M100573200	http://dx.doi.org/10.1074/jbc.M100573200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382750	hybrid			2022-12-27	WOS:000170093400043
J	Fujii, Y; Kimoto, H; Ishikawa, K; Watanabe, K; Yokota, Y; Nakai, N; Taketo, A				Fujii, Y; Kimoto, H; Ishikawa, K; Watanabe, K; Yokota, Y; Nakai, N; Taketo, A			Taxon-specific zeta-crystallin in Japanese tree frog (Hyla japonica) lens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG LENS; STRUCTURAL PROTEINS; BOVINE LUNG; EYE LENS; PURIFICATION; RECRUITMENT; NADPH	The present study demonstrated that the 38-kDa protein, instead of rho -crystallin (36 kDa), is expressed taxon specifically in the lens of Japanese tree frog (Hyla japonica). The 38-kDa protein was distinguished from rho -crystallin expressed in the lenses of bullfrog (Rana catesbeiana) and European common frog (Rana temporaria) immunochemically. Although the N terminus of the 38-kDa protein was blocked, the analyses of partial amino acid sequences showed that the protein was zeta -crystallin. Analysis of cDNA sequence encoding zeta -crystallin of the tree frog lens demonstrated that the deduced protein consisted of 329 amino acids including initial methionine and having 62.2 and 62.9% identity with zeta -crystallin of camel and guinea pig lenses, respectively. The molecular mass of the deduced structure was calculated to be 35,564 Da. zeta -Crystallin of the tree frog lens exhibited the intrinsic enzymatic activity of quinone reductase (EC 1.6.99.2, NADPH:quinone oxidoreductase). The crystallin specifically catalyzed the reduction of 9,10-phenanthrenequinone (K-m, 42 mum) using NADPH (K-m, 60 mum) as a cofactor. The enzymatic activity was inhibited by dicumarol, anti-coagulant drug, with IC50 of 4 mum. On gel filtration chromatography, the crystallin was recovered as 150-kDa molecular mass complex, indicating that the crystallin was homotetramer consisting of 38-kDa subunits. The crystallin gene was expressed specifically in the lens. These results show that taxon-specific crystallins such as zeta- and rho -crystallins maybe available for the biochemical discrimination of Hyla- and Rana groups among frogs.	Fukui Med Univ, Fac Med, Dept Chem, Fukui 9101193, Japan; Fukui Med Univ, Fac Med, Dept Biochem, Fukui 9101193, Japan; Univ E Asia, Grad Sch Integrated Sci & Arts, Div Appl Life Sci, Yamaguchi 7518503, Japan; Fukui Univ Technol, Dept Appl Phys & Chem, Fukui 9108505, Japan	University of Fukui; University of Fukui	Fujii, Y (corresponding author), Fukui Med Univ, Fac Med, Dept Chem, 23-3 Shimoaizuki, Fukui 9101193, Japan.			Fujii, Yutaka/0000-0001-6357-3795				BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Duhaiman AS, 1996, BIOCHEM MOL BIOL INT, V38, P251; FUJII Y, 1990, J BIOL CHEM, V265, P9914; GONZALEZ P, 1995, MOL BIOL EVOL, V12, P773; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HUNG QL, 1990, EXP EYE RES, V50, P317; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEDA N, 1990, FROGS TOADS JAPAN, P8; RAO PV, 1992, EXP EYE RES, V54, P627, DOI 10.1016/0014-4835(92)90142-F; RAO PV, 1992, J BIOL CHEM, V267, P96; RAO PV, 1990, BIOCHEM BIOPH RES CO, V167, P1221, DOI 10.1016/0006-291X(90)90654-6; RODOKANAKI A, 1989, GENE, V78, P215, DOI 10.1016/0378-1119(89)90224-2; TOMAREV SI, 1984, FEBS LETT, V171, P297, DOI 10.1016/0014-5793(84)80508-6; WATANABE K, 1985, J BIOL CHEM, V260, P7035; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; Wermuth B, 1985, Prog Clin Biol Res, V174, P209; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZIGLER JS, 1991, FASEB J, V5, P223, DOI 10.1096/fasebj.5.2.2004667	22	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28134	28139		10.1074/jbc.M102880200	http://dx.doi.org/10.1074/jbc.M102880200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11371565	hybrid			2022-12-27	WOS:000170093400053
J	Miller, MJ; Rauer, H; Tomita, H; Rauer, H; Gargus, JJ; Gutman, GA; Cahalan, MD; Chandy, KG				Miller, MJ; Rauer, H; Tomita, H; Rauer, H; Gargus, JJ; Gutman, GA; Cahalan, MD; Chandy, KG			Nuclear localization and dominant-negative suppression by a mutant SKCa3N-terminal channel fragment identified in a patient with schizophrenia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; CA2+-ACTIVATED K+ CHANNEL; NIGRAL DOPAMINE NEURONS; POLYMORPHIC CAG REPEAT; SMALL-CONDUCTANCE; CHROMOSOME 1Q21; GENE HSKCA3; BIPOLAR DISORDER; NO EVIDENCE; HKCA3 GENE	The small conductance calcium-activated K+ channel gene SKCa3/KCNN3 maps to 1q2l, a region strongly linked to schizophrenia. Recently, a 4-base pair deletion in SKCa3 was reported in a patient with schizophrenia, which truncates the protein at the end of the N-terminal cytoplasmic region (SKCa3 Delta). We generated a green fluorescent protein-SKCa3 N-terminal construct (SKCa3-1/285) that is identical to SKCa3 Delta except for the last two residues. Using confocal microscopy we demonstrate that SKCa3-1/285 localizes rapidly and exclusively to the nucleus of mammalian cells like several other pathogenic polyglutamine-containing proteins. This nuclear targeting is mediated in part by two polybasic sequences present at the C-terminal end of SKCa3-1/285. In contrast, full-length SKCa3, SKCa2, and IKCal polypeptides are all excluded from the nucleus and express as functional channels. When overexpressed in human Jurkat T cells, SKCa3-1/285 can suppress endogenous SKCa2 currents but not voltage-gated K+ currents. This dominant-negative suppression is most likely mediated through the co-assembly of SKCa3-1/285 with native subunits and the formation of non-functional tetramers. The nuclear localization of SKCa3-1/285 may alter neuronal architecture, and its ability to dominantly suppress endogenous small conductance K-Ca currents may affect patterns of neuronal firing. Together, these two effects may play a part in the pathogenesis of schizophrenia and other neuropsychiatric disorders.	Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Pediat, Div Human Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Chandy, KG (corresponding author), Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA.	gchandy@uci.edu		Tomita, Hiroaki/0000-0003-2628-880X; Miller, Mark/0000-0001-5676-389X	NIMH NIH HHS [MH59222] Funding Source: Medline; NINDS NIH HHS [NS14609] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS014609, R01NS014609] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antonarakis SE, 1999, AM J MED GENET, V88, P348, DOI 10.1002/(SICI)1096-8628(19990820)88:4<348::AID-AJMG11>3.3.CO;2-E; Bonnet-Brilhault F, 1999, EUR J HUM GENET, V7, P247, DOI 10.1038/sj.ejhg.5200278; Bowen T, 1998, MOL PSYCHIATR, V3, P266, DOI 10.1038/sj.mp.4000400; Bowen T, 2001, MOL PSYCHIATR, V6, P259, DOI 10.1038/sj.mp.4000128; Brzustowicz LM, 2000, SCIENCE, V288, P678, DOI 10.1126/science.288.5466.678; Cardno AG, 1999, BIOL PSYCHIAT, V45, P1592, DOI 10.1016/S0006-3223(99)00033-5; Chandy KG, 1998, MOL PSYCHIATR, V3, P32, DOI 10.1038/sj.mp.4000353; Chowdari KV, 2000, MOL PSYCHIATR, V5, P237, DOI 10.1038/sj.mp.4000694; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; Dawson LA, 1995, BRIT J PHARMACOL, V116, P3260, DOI 10.1111/j.1476-5381.1995.tb15133.x; Desai R, 2000, J BIOL CHEM, V275, P39954, DOI 10.1074/jbc.M001562200; Dror V, 1999, MOL PSYCHIATR, V4, P254, DOI 10.1038/sj.mp.4000508; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Fanger CM, 2001, J BIOL CHEM, V276, P12249, DOI 10.1074/jbc.M011342200; Farde L, 1997, SCHIZOPHR RES, V28, P157, DOI 10.1016/S0920-9964(97)00121-7; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Hackam AS, 1999, HUM MOL GENET, V8, P25, DOI 10.1093/hmg/8.1.25; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Halliday GM, 2001, CLIN EXP PHARMACOL P, V28, P64, DOI 10.1046/j.1440-1681.2001.03398.x; Hawi Z, 1999, MOL PSYCHIATR, V4, P488, DOI 10.1038/sj.mp.4000560; HILLE B, 1992, IONIC CHANNELS EXCIT, P121; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Jager H, 2000, FEBS LETT, V469, P196, DOI 10.1016/S0014-5793(00)01236-9; Joober R, 1999, AM J MED GENET, V88, P154, DOI 10.1002/(SICI)1096-8628(19990416)88:2<154::AID-AJMG11>3.3.CO;2-1; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; MANLEY LD, 1992, J NEUROCHEM, V58, P1491, DOI 10.1111/j.1471-4159.1992.tb11369.x; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; McGlashan TH, 2000, ARCH GEN PSYCHIAT, V57, P637, DOI 10.1001/archpsyc.57.7.637; Morikawa H, 2000, J NEUROSCI, V20, part. no.; O'Donovan MC, 1999, AM J HUM GENET, V65, P587, DOI 10.1086/302560; Pedarzani P, 2001, J BIOL CHEM, V276, P9762, DOI 10.1074/jbc.M010001200; Ping HX, 1999, J NEUROPHYSIOL, V81, P977, DOI 10.1152/jn.1999.81.3.977; Ping HX, 1996, NEUROREPORT, V7, P809, DOI 10.1097/00001756-199602290-00031; Rimini R, 2000, MOL BRAIN RES, V85, P218, DOI 10.1016/S0169-328X(00)00255-2; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; SHEPARD PD, 1988, BRAIN RES, V463, P380, DOI 10.1016/0006-8993(88)90414-3; STEKETEE JD, 1990, J PHARMACOL EXP THER, V254, P711; Stober G, 1998, NEUROREPORT, V9, P3595; Stober G, 2000, EUR ARCH PSY CLIN N, V250, P163, DOI 10.1007/s004060070020; Stocker M, 2000, MOL CELL NEUROSCI, V15, P476, DOI 10.1006/mcne.2000.0842; Tacconi S, 2001, NEUROSCIENCE, V102, P209, DOI 10.1016/S0306-4522(00)00486-3; TU LW, 1995, BIOPHYS J, V68, P147, DOI 10.1016/S0006-3495(95)80169-4; Wittekindt O, 1998, NEUROGENETICS, V1, P259, DOI 10.1007/s100480050038; Wolfart J, 2001, J NEUROSCI, V21, P3443, DOI 10.1523/JNEUROSCI.21-10-03443.2001; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758	49	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27753	27756		10.1074/jbc.C100221200	http://dx.doi.org/10.1074/jbc.C100221200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11395478	hybrid			2022-12-27	WOS:000170093400003
J	de Gregorio, R; Iniguez, MA; Fresno, M; Alemany, S				de Gregorio, R; Iniguez, MA; Fresno, M; Alemany, S			Cot kinase induces cyclooxygenase-2 expression in T cells through activation of the nuclear factor of activated T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GENE-EXPRESSION; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; INVOLVEMENT; INDUCTION; ONCOPROTEIN; INHIBITION; ONCOGENE	Cyclooxygenase-2 (COX-2) is induced in human T lymphocytes upon T cell receptor triggering. Here we report that Cot kinase, a mitogen-activated protein kinase kinase kinase involved in T cell activation, up-regulates COX-2 gene expression in Jurkat T cells. Induction of COX-2 promoter activity by Cot kinase occurred mainly through activation of the nuclear factor of activated T cells (NFAT). Mutation of the distal (-105/-97) and proximal (-76/-61) NEAT response elements in the COX-2 promoter abolished the activation induced by Cot kinase. Even more, coexpression of a dominant negative version of NFAT inhibited Cot kinase-mediated COX-2 promoter activation, whereas cotransfection of a constitutively active version of the calcium-dependent phosphatase calcineurin synergizes with Cot kinase in the up-regulation of COX-2 promoter-driven transcription. Strikingly, Cot kinase increased transactivation mediated by a GAL4-NFAT fusion protein containing the N-terminal transactivation domain of NFATp. In contrast to phorbol ester plus calcium ionophore A23187, Cot kinase increases both COX-2 promoter activity and NFAT-mediated transactivation in a cyclosporin A-independent manner. These data indicate that Cot kinase up-regulates COX-2 promoter-driven transcription through the NFAT response elements, being the Cot kinase-induced NFAT-dependent transactivation presumably implicated in this up-regulation.	Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, Ctr Biol Mol, CSIC, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Alemany, S (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Alemany, Susana/J-6307-2014; Peña, Miguel Angel Iñiguez/J-8518-2012	Alemany, Susana/0000-0002-4089-7620; Peña, Miguel Angel Iñiguez/0000-0001-8262-6119; Fresno Escudero, Manuel/0000-0002-9223-5477				Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; AOKI M, 1991, ONCOGENE, V6, P1515; AOKI M, 1993, J BIOL CHEM, V268, P22723; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; Ballester A, 1998, J BIOL CHEM, V273, P14099, DOI 10.1074/jbc.273.23.14099; Ballester A, 1997, J IMMUNOL, V159, P1613; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Brueggemeier RW, 1999, CANCER LETT, V140, P27, DOI 10.1016/S0304-3835(99)00050-6; CHAN AML, 1993, ONCOGENE, V8, P1329; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Garcia-Rodriguez C, 2000, EUR J IMMUNOL, V30, P2432, DOI 10.1002/1521-4141(2000)30:8<2432::AID-IMMU2432>3.0.CO;2-F; Hagemann D, 1999, ONCOGENE, V18, P1391, DOI 10.1038/sj.onc.1202431; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Hida T, 1998, CANCER RES, V58, P3761; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Iniguez MA, 1999, J IMMUNOL, V163, P111; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Jones MK, 1999, NAT MED, V5, P1418; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Luo C, 1996, MOL CELL BIOL, V16, P3955; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; Nakao S, 2000, MOL CELL BIOCHEM, V209, P113, DOI 10.1023/A:1007155525020; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANO H, 1995, CANCER RES, V55, P3785; Sawaoka H., 1998, AM J PHYSIOL, V274, P1061; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; SIVER PA, 1984, P NATL ACAD SCI USA, V81, P5951; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; von Knethen A, 1999, MOL BIOL CELL, V10, P361, DOI 10.1091/mbc.10.2.361; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yan ZP, 2000, J BIOL CHEM, V275, P4949, DOI 10.1074/jbc.275.7.4949; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	57	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27003	27009		10.1074/jbc.M100885200	http://dx.doi.org/10.1074/jbc.M100885200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356833	hybrid			2022-12-27	WOS:000169966900037
J	Li, LY; Shih, HM; Liu, MY; Chen, JY				Li, LY; Shih, HM; Liu, MY; Chen, JY			The cellular protein PRA1 modulates the anti-apoptotic activity of Epstein-Barr virus BHRF1, a homologue of Bcl-2, through direct interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NASOPHARYNGEAL CARCINOMA; VIRAL HOMOLOG; CYTOCHROME-C; B-CELLS; EPITHELIAL-CELLS; MAMMALIAN-CELLS; PRENYLATED RAB; GENE-PRODUCT; FAMILY; DEATH	The Epstein-Barr virus-encoded early protein, BHRF1, is a structural and functional homologue of the anti-apoptotic protein, Bcl-2. There is accumulating evidence that BHRF1 protects a variety of cell types from apoptosis induced by various external stimuli. To identify specific proteins from normal epithelial cells that interact with BHRF1 and that might promote or inhibit its anti-apoptotic activity, we screened a yeast two-hybrid cDNA library derived from human normal foreskin keratinocytes and identified a cellular gene encoding human prenylated rab acceptor 1 (hPRA1). The interaction of hPRA1. with BHRF1 was confirmed using glutathione S-transferase pull-down assays, confocal laser scanning microscopy, and co-immunoprecipitation. Two regions of PRA1, amino acids 30-53 and the carboxyl-terminal 21 residues, are important for BHRF1 interactions and two regions of BHRF1, amino acids 1-18 and 89-142, including the Bcl-2 homology domains BH4 and BH1, respectively, are crucial for PRA1 interactions. PRA1 expression interferes with the anti-apoptotic activity of BHRF1, although not of Bcl-2. These results indicate that the PRA1 interacts selectively with BHRF1 to reduce its anti-apoptotic activity and might play a role in the impeding completion of virus maturation.	Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 100, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan; Natl Taipei Coll Nursing, Dept Gen Educ, Taipei 112, Taiwan	National Taiwan University; National Health Research Institutes - Taiwan	Chen, JY (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Rm 743,Number 1,Sevt 1,Jen Ai Rd, Taipei 100, Taiwan.		Shih, Hsiu-Ming/S-7023-2018; Chen, Jen-Yang/D-2085-2010	Li, Long-Yuan/0000-0001-7472-8318				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Bellows DS, 2000, J VIROL, V74, P5024, DOI 10.1128/JVI.74.11.5024-5031.2000; BORNER C, 1994, BIOCHEM CELL BIOL, V72, P463, DOI 10.1139/o94-062; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Bucci C, 1999, BIOCHEM BIOPH RES CO, V258, P657, DOI 10.1006/bbrc.1999.0651; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen MR, 2000, J VIROL METHODS, V85, P35, DOI 10.1016/S0166-0934(99)00148-2; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DAWSON CW, 1995, ONCOGENE, V10, P69; Everett H, 1999, TRENDS MICROBIOL, V7, P160, DOI 10.1016/S0966-842X(99)01487-0; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Foghsgaard L, 1997, J VIROL, V71, P7509, DOI 10.1128/JVI.71.10.7509-7517.1997; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HELLER M, 1981, J VIROL, V38, P632, DOI 10.1128/JVI.38.2.632-648.1981; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HICKISH T, 1994, CANCER RES, V54, P2808; Huang H, 1999, ANN OTO RHINOL LARYN, V108, P481; Huang H, 1997, J LARYNGOL OTOL, V111, P1147, DOI 10.1017/S0022215100139568; Hutt DM, 2000, J BIOL CHEM, V275, P18511, DOI 10.1074/jbc.M909309199; Kawanishi M, 1997, J VIROL, V71, P3319, DOI 10.1128/JVI.71.4.3319-3322.1997; Khanim F, 1997, J GEN VIROL, V78, P2987, DOI 10.1099/0022-1317-78-11-2987; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Lee JH, 1999, ONCOGENE, V18, P6183, DOI 10.1038/sj.onc.1203043; LEE MA, 1992, J VIROL, V66, P1899, DOI 10.1128/JVI.66.4.1899-1906.1992; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liu MY, 2000, J MED VIROL, V61, P241, DOI 10.1002/(SICI)1096-9071(200006)61:2&lt;241::AID-JMV11&gt;3.0.CO;2-2; Liu MY, 1998, J MED VIROL, V56, P179, DOI 10.1002/(SICI)1096-9071(199811)56:3<179::AID-JMV1>3.0.CO;2-4; MARCHINI A, 1991, J VIROL, V65, P5991, DOI 10.1128/JVI.65.11.5991-6000.1991; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; ODA K, 1993, AM J PATHOL, V143, P1063; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; Poommipanit PB, 1999, J BIOL CHEM, V274, P1033, DOI 10.1074/jbc.274.2.1033; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RHIM JS, 1989, ANTICANCER RES, V9, P1345; Rickinson AB, 1996, VIROLOGY, P2397; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SU IJ, 1992, LEUKEMIA LYMPHOMA, V7, P47, DOI 10.3109/10428199209053601; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; TARODI B, 1994, VIROLOGY, V201, P404, DOI 10.1006/viro.1994.1309; Theodorakis P, 1996, ONCOGENE, V12, P1707; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tsai CH, 1997, J BIOMED SCI, V4, P69, DOI 10.1007/BF02255596; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; WANG HG, 1994, ONCOGENE, V9, P2751; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	68	34	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27354	27362		10.1074/jbc.M103821200	http://dx.doi.org/10.1074/jbc.M103821200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11373297	hybrid			2022-12-27	WOS:000169966900083
J	Yin, BWT; Lloyd, KO				Yin, BWT; Lloyd, KO			Molecular cloning of the CA125 ovarian cancer antigen - Identification as a new mucin, MUC16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; CA-125 ANTIGEN; TYROSINE PHOSPHORYLATION; GENE; PROTEINS; CELLS; SPECIFICITY; EXPRESSION; SITES	CA125 is an ovarian cancer antigen that is the basis for a widely used serum assay for the monitoring of patients with ovarian cancer; however, detailed information on its biochemical and molecular nature is lacking. We now report the isolation of a long, but partial, cDNA that corresponds to the CA125 antigen. A rabbit polyclonal antibody produced to purified CA125 antigen was used to screen a lambda ZAP cDNA library from OVCAR-3 cells in Escherichia coli. The longest insert from the 54 positive isolated clones had a 5797-base pair sequence containing a stop codon and a poly(A) sequence but no clear 5' initiation sequence. The deduced amino acid sequence has many of the attributes of a mucin molecule and was designated CA125/MUC16 (gene MUC16). These features include a high serine, threonine, and proline content in an N-terminal region of nine partially conserved tandem repeats (156 amino acids each) and a C-terminal region non-tandem repeat sequence containing a possible transmembrane region and a potential tyrosine phosphorylation site. Northern blotting showed that the level of MUC16 mRNA correlated with the expression of CA125 in a panel of cell lines. The molecular cloning of the CA125 antigen will lead to a better understanding of its role in ovarian cancer.	Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Lloyd, KO (corresponding author), Mem Sloan Kettering Canc Ctr, Program Immunol, 1275 York Ave, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [P30CA008748, P01CA052477] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52477, CA 08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Bast RC, 1998, INT J BIOL MARKER, V13, P179, DOI 10.1177/172460089801300402; BORK P, 1995, PROTEIN SCI, V49, P1421; BOSHELL M, 1992, BIOCHEM BIOPH RES CO, V185, P1, DOI 10.1016/S0006-291X(05)80946-5; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; Chambers JA, 1996, GENOMICS, V38, P305, DOI 10.1006/geno.1996.0633; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DAVIS HM, 1986, CANCER RES, V46, P6143; DELOSFRAILES MT, 1993, TUMOR BIOL, V14, P18, DOI 10.1159/000217821; Fendrick JL, 1997, TUMOR BIOL, V18, P278, DOI 10.1159/000218041; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; KIM YS, 1991, AM REV RESPIR DIS, V144, pS10, DOI 10.1164/ajrccm/144.3_pt_2.S10; KOBAYASHI H, 1993, AM J OBSTET GYNECOL, V169, P725, DOI 10.1016/0002-9378(93)90652-Y; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; Lloyd KO, 1997, INT J CANCER, V71, P842, DOI 10.1002/(SICI)1097-0215(19970529)71:5<842::AID-IJC24>3.0.CO;2-8; Lloyd KO, 2001, TUMOR BIOL, V22, P77, DOI 10.1159/000050600; Lloyd KO, 2000, BBA-GEN SUBJECTS, V1474, P410, DOI 10.1016/S0304-4165(00)00037-4; MATSUOKA Y, 1987, CANCER RES, V47, P6335; Meden H, 1998, INT J BIOL MARKER, V13, P231, DOI 10.1177/172460089801300411; Menon U, 2000, CURR OPIN OBSTET GYN, V12, P39, DOI 10.1097/00001703-200002000-00007; Meyer T, 2000, BRIT J CANCER, V82, P1535; NAGATA A, 1991, TUMOR BIOL, V12, P279, DOI 10.1159/000217716; Nustad K, 1996, TUMOR BIOL, V17, P196, DOI 10.1159/000217982; PANDEY P, 1995, CANCER RES, V55, P4000; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Seregni E, 1997, TUMORI J, V83, P625, DOI 10.1177/030089169708300301; TAYLOR-PAPADIMITRIOU J-T, 1988, Cancer Reviews, V11-12, P11; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; Verheijen RHM, 1999, SEMIN CANCER BIOL, V9, P117, DOI 10.1006/scbi.1998.0114; Williams SJ, 1999, CANCER RES, V59, P4083; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; WREISCHNER DH, 2000, P 6 INT WORKSH CARC, P25; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2; ZURAWSKI V R JR, 1988, Cancer Reviews, V11-12, P102	37	465	537	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27371	27375		10.1074/jbc.M103554200	http://dx.doi.org/10.1074/jbc.M103554200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369781	hybrid			2022-12-27	WOS:000169966900085
J	Nitiss, JL; Nitiss, KC; Rose, A; Waltman, JL				Nitiss, JL; Nitiss, KC; Rose, A; Waltman, JL			Overexpression of type I topoisomerases sensitizes yeast cells to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE TYROSINE; CLEAVABLE COMPLEXES; REPLICATION FORKS; ABASIC SITES; MECHANISM; GENE; POLY(ADP-RIBOSYLATION); INVOLVEMENT; RESISTANCE; EXPRESSION	DNA topoisomerases play essential roles in many DNA metabolic processes. It has been suggested that topoisomerases play an essential role in DNA repair. Topoisomerases can introduce DNA damage upon exposure to drugs that stabilize the covalent protein-DNA intermediate of the topoisomerase reaction. Lesions in DNA are also able to trap topoisomerase-DNA intermediates, suggesting that topoisomerases have the potential to either assist in DNA repair by locating sites of damage or exacerbating DNA damage by generation of additional damage at the site of a lesion. We have shown that overexpression of yeast topoisomerase I (TOP1) conferred hypersensitivity to methyl methanesulfonate and other DNA-damaging agents, whereas expression of a catalytically inactive enzyme did not. Overexpression of topoisomerase II did not change the sensitivity of cells to these DNA-damaging agents, Yeast cells lacking TOP1 were not more resistant to DNA damage than cells expressing wild type levels of the enzyme, Yeast topoisomerase I covalent complexes can be trapped efficiently on UV-damaged DNA. We suggest that TOP1 does not participate in the repair of DNA damage in yeast cells. However, the enzyme has the potential of exacerbating DNA damage by forming covalent DNA-protein complexes at sites of DNA damage.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Nitiss, JL (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale St, Memphis, TN 38105 USA.	john.nitiss@stjude.org	Nitiss, John/E-9974-2010	Nitiss, John/0000-0002-1013-4972	NCI NIH HHS [CA21765, CA52814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA052814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BHATIA K, 1990, CARCINOGENESIS, V11, P123, DOI 10.1093/carcin/11.1.123; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; BOOTHMAN DA, 1994, CANCER RES, V54, P4618; BOREHAM DR, 1990, RADIAT RES, V123, P203, DOI 10.2307/3577546; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CORBETT AH, 1991, J BIOL CHEM, V266, P19666; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; DANKS MK, 1988, BIOCHEMISTRY-US, V27, P8861, DOI 10.1021/bi00424a026; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; ENG WK, 1989, J BIOL CHEM, V264, P13373; FERRO AM, 1984, J BIOL CHEM, V259, P547; FERRO AM, 1984, COLD SPRING HARB SYM, V49, P683, DOI 10.1101/SQB.1984.049.01.077; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HSIANG YH, 1989, CANCER RES, V49, P5077; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; KINGMA PS, 1995, J BIOL CHEM, V270, P21441, DOI 10.1074/jbc.270.37.21441; Kingma PS, 1998, BBA-GENE STRUCT EXPR, V1400, P223, DOI 10.1016/S0167-4781(98)00138-9; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; Kretz-Remy C, 1999, BIOCHEM CELL BIOL, V77, P299, DOI 10.1139/bcb-77-4-299; KROGH S, 1991, NUCLEIC ACIDS RES, V19, P1235, DOI 10.1093/nar/19.6.1235; Lanza A, 1996, J BIOL CHEM, V271, P6978, DOI 10.1074/jbc.271.12.6978; LIU LF, 1983, J BIOL CHEM, V258, P5365; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Nitiss JL, 1998, CONT CANC RES, P517; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Nitiss JL, 1998, BIOCHEMISTRY-US, V37, P3078, DOI 10.1021/bi9723257; NITISS JL, 1992, CANCER RES, V52, P4467; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P2040, DOI 10.1073/pnas.040397497; Postow L, 1999, BIOESSAYS, V21, P805, DOI 10.1002/(SICI)1521-1878(199910)21:10<805::AID-BIES1>3.0.CO;2-7; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Pourquier P, 1998, J BIOL CHEM, V273, P27245, DOI 10.1074/jbc.273.42.27245; Rubin E H, 1996, Cancer Treat Res, V87, P243; RUBY SW, 1985, MOL CELL BIOL, V5, P75, DOI 10.1128/MCB.5.1.75; Subramanian D, 1998, CANCER RES, V58, P976; TRASK DK, 1984, EMBO J, V3, P671, DOI 10.1002/j.1460-2075.1984.tb01865.x; TSAO YP, 1993, CANCER RES, V53, P5908; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534; YEH YC, 1994, J BIOL CHEM, V269, P15498; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G; Zhu J, 1996, MOL CELL BIOL, V16, P1805	53	32	33	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26708	26714		10.1074/jbc.M102674200	http://dx.doi.org/10.1074/jbc.M102674200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11353773	hybrid			2022-12-27	WOS:000169823300138
J	Hjalm, G; MacLeod, RJ; Kifor, O; Chattopadhyay, N; Brown, EM				Hjalm, G; MacLeod, RJ; Kifor, O; Chattopadhyay, N; Brown, EM			Filamin-A binds to the carboxyl-terminal tail of the calcium-sensing receptor, an interaction that participates in CaR-mediated activation of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR CA2+-SENSING RECEPTOR; CYTOPLASMIC DOMAIN; MEMBRANE DOMAINS; PLASMA-MEMBRANE; ACTIN; IDENTIFICATION; TRANSDUCTION; MIGRATION; CLONING; ABP-280	The G protein-coupled, extracellular calcium-sensing receptor (CaR) regulates parathyroid hormone secretion and parathyroid cellular proliferation as well as the functions of diverse other cell types. The CaR resides in caveolae-plasma membrane microdomains containing receptors and associated signaling molecules that are thought to serve as cellular "message centers." An additional mechanism for coordinating cellular signaling is the presence of scaffold proteins that bind and organize components of signal transduction cascades. With the use of the yeast two-hybrid system, we identified filamin-A (an actin-cross-linking, putative scaffold protein that binds mitogen-activated protein kinase (MAPK) components activated by the CaR) as an intracellular binding partner of the CaR's carboxyl (COOH)-terminal tail. A direct interaction of the two proteins was confirmed by an in vitro binding assay. Moreover, confocal microscopy combined with two color immunofluorescence showed co-localization of the CaR and filamin-A within parathyroid cells as well as HEK-293 cells stably transfected with the CaR. Deletion mapping localized the sites of interaction between the two proteins to a stretch of 60 amino acid residues within the distal portion of the CaR's COOH-terminal tail and domains 14 and 15 in filamin-A, respectively. Finally, introducing the portion of filamin-A interacting with the CaR into CaR-transfected HEK-293 cells using protein transduction with a His-tagged, Tat-filamin-A fusion protein nearly abolished CaR-mediated activation of ERK1/2 MAPK but had no effect on ERK1/2 activity stimulated by ADP. Therefore, the binding of the CaR's COOH-terminal tail to filamin-A may contribute to its localization in caveolae, link it to the actin-based cytoskeleton, and participate in CaR-mediated activation of MAPK.	Brigham & Womens Hosp, Dept Med, Div Endocrine Hypertens, Calcium Sect, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Membrane Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Brown, EM (corresponding author), Brigham & Womens Hosp, Dept Med, Div Endocrine Hypertens, Calcium Sect, 221 Longwood Ave, Boston, MA 02115 USA.	embrown@rics.bwh.harvard.edu	Chattopadhyay, Naibedya/AAQ-3213-2021; Chattopadhyay, Naibedya/AAF-2058-2019	Chattopadhyay, Naibedya/0000-0003-2473-0246; 	NIDDK NIH HHS [DK41415, DK48330, DK52005] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041415, R01DK048330, R01DK052005] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; Arthur JM, 2000, BIOCHEM BIOPH RES CO, V275, P538, DOI 10.1006/bbrc.2000.3226; BROWN EM, 1976, ENDOCRINOLOGY, V99, P1582, DOI 10.1210/endo-99-6-1582; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1999, VITAM HORM, V55, P1; Chattopadhyay N, 1998, TRENDS ENDOCRIN MET, V9, P354, DOI 10.1016/S1043-2760(98)00090-3; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Handlogten ME, 2001, J BIOL CHEM, V276, P13941, DOI 10.1074/jbc.M007306200; Kifor O, 1997, J BONE MINER RES, V12, P715, DOI 10.1359/jbmr.1997.12.5.715; Kifor O, 2001, AM J PHYSIOL-RENAL, V280, pF291, DOI 10.1152/ajprenal.2001.280.2.F291; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Schlegel A, 1998, CELL SIGNAL, V10, P457, DOI 10.1016/S0898-6568(98)00007-2; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Yamaguchi T, 2000, BIOCHEM BIOPH RES CO, V279, P363, DOI 10.1006/bbrc.2000.3955	29	159	162	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34880	34887		10.1074/jbc.M100784200	http://dx.doi.org/10.1074/jbc.M100784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11390380	hybrid			2022-12-27	WOS:000171024600072
J	Hansen, GH; Immerdal, L; Thorsen, E; Niels-Christiansen, LL; Nystrom, BT; Demant, EJF; Danielsen, EM				Hansen, GH; Immerdal, L; Thorsen, E; Niels-Christiansen, LL; Nystrom, BT; Demant, EJF; Danielsen, EM			Lipid rafts exist as stable cholesterol-independent microdomains in the brush border membrane of enterocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; APICAL SURFACE; AMINOPEPTIDASE-N; CAVEOLAE; DOMAINS; FAMILY; MODEL; BIOSYNTHESIS; RESOLUTION; COMPLEXES	Glycosphingolipid/cholesterol-rich membranes ("rafts")can be isolated from many types of cells, but their existence as stable microdomains in the cell membrane has been elusive. Addressing this problem, we studied the distribution of galectin-4, a raft marker, and lactase, a protein excluded from rafts, on microvillar vesicles from the enterocyte brush border membrane. Magnetic beads coated with either anti-galectin-4 or anti-lactase antibodies were used for immunoisolation of vesicles followed by double immunogold labeling of the two proteins. A morphometric analysis revealed subpopulations of raft-rich and raft-poor vesicles by the following criteria: 1) the lactase/galectin-4 labeling ratio/vesicle captured by the anti-lactase beads was significantly higher (p less than or equal to 0.01) than that of vesicles captured by anti-galectin-4 beads, 2) subpopulations of vesicles labeled by only one of the two antibodies were preferentially captured by beads coated with the respective antibody (p less than or equal to 0.01), 3) the average diameter of "galectin-4 positive only" vesicles was smaller than that of vesicles labeled for lactase. Surprisingly, pretreatment with methyl-beta -cyclodextrin, which removed > 70% of microvillar cholesterol, did not affect the microdomain localization of galectin-4. We conclude that stable, cholesterol-independent raft microdomains exist in the enterocyte brush border.	Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, DK-2200 Copenhagen N, Denmark	University of Copenhagen	Danielsen, EM (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	midan@imbg.ku.dk						Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Booth A G, 1974, Biochem J, V142, P575; BOOTH AG, 1976, J CELL SCI, V21, P449; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHRISTIANSEN K, 1981, BIOCHIM BIOPHYS ACTA, V647, P188, DOI 10.1016/0005-2736(81)90245-5; Danielsen EM, 1997, MOL BIOL CELL, V8, P2241, DOI 10.1091/mbc.8.11.2241; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DANIELSEN EM, 1995, J CELL BIOL, V131, P939, DOI 10.1083/jcb.131.4.939; DANIELSEN EM, 1995, GASTROENTEROLOGY, V109, P1039, DOI 10.1016/0016-5085(95)90561-8; DANIELSEN EM, 1982, BIOCHEM J, V202, P647, DOI 10.1042/bj2020647; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Fujimoto T, 1996, J HISTOCHEM CYTOCHEM, V44, P929, DOI 10.1177/44.8.8756764; GAMBLE W, 1978, J LIPID RES, V19, P1068; Gheber LA, 1999, BIOPHYS J, V77, P3163, DOI 10.1016/S0006-3495(99)77147-X; HANNAN LA, 1993, J CELL BIOL, V120, P353, DOI 10.1083/jcb.120.2.353; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Hansen GH, 1999, GASTROENTEROLOGY, V116, P610, DOI 10.1016/S0016-5085(99)70183-6; HANSEN GH, 1992, HISTOCHEM J, V24, P132, DOI 10.1007/BF01047462; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HARRISON FL, 1991, J CELL SCI, V100, P9; Hooper NM, 1998, CURR BIOL, V8, pR114, DOI 10.1016/S0960-9822(98)70984-4; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Riemann D, 2001, BIOCHEM J, V354, P47, DOI 10.1042/0264-6021:3540047; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SKOVBJERG H, 1982, BIOCHIM BIOPHYS ACTA, V707, P89, DOI 10.1016/0167-4838(82)90400-9; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SUZUKI K, 1965, J NEUROCHEM, V12, P629, DOI 10.1111/j.1471-4159.1965.tb04256.x; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Verkade P, 2000, J CELL BIOL, V148, P727, DOI 10.1083/jcb.148.4.727	48	103	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32338	32344		10.1074/jbc.M102667200	http://dx.doi.org/10.1074/jbc.M102667200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11389144	hybrid			2022-12-27	WOS:000170613500116
J	Svanem, BIG; Strand, WI; Ertesvag, H; Skjak-Braek, G; Hartmann, M; Barbeyron, T; Valla, S				Svanem, BIG; Strand, WI; Ertesvag, H; Skjak-Braek, G; Hartmann, M; Barbeyron, T; Valla, S			The catalytic activities of the bifunctional Azotobacter vinelandii mannuronan C-5-epimerase and alginate lyase AlgE7 probably originate from the same active site in the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA ALGG; O-ACETYL GROUPS; NITROGEN-FIXATION; CLONING; BIOSYNTHESIS; SEQUENCE; GENE; EXPRESSION; PROTEIN; ACID	The Azotobacter vinelandii genome encodes a family of seven secreted Ca2+-dependent epimerases (AlgE1-7) catalyzing the polymer level epimerization of beta -D-mannuronic. acid. (Al) to alpha -L-guluronic acid (G) in the commercially important polysaccharide alginate. AlgE1-7 are composed of two types of protein modules, A and R, and the A-modules have previously been found to be sufficient for epimerization. AlgE7 is both an epimerase and an alginase, and here we show that the lyase activity is Ca2+-dependent and also responds similarly to the epimerases in the presence of other divalent cations. The AlgE7 lyase degraded M-rich alginates and a relatively G-rich alginate from the brown algae Macrocystis pyrifera most effectively, producing oligomers of 4 (mannuronan) to 7 units. The sequences cleaved were mainly G down arrow MM and/or G down arrow GM. Since G-moieties dominated at the reducing ends even when mannuronan was used as substrate, the AlgE7 epimerase probably stimulates the lyase pathway, indicating a complex interplay between the two activities. A truncated form of AlgE1 (AlgE1-1) was converted to a combined epimerase and lyase by replacing the 5 ' -798 base pairs in the algE1-1 gene with the corresponding A-module-encoding DNA sequence from algE7. Furthermore, substitution of an aspartic acid residue at position 152 with glycine in AlgE7A eliminated almost all of both the lyase and epimerase activities. Epimerization and lyase activity are believed to be mechanistically related, and the results reported here strongly support this hypothesis by suggesting that the same enzymatic site can catalyze both reactions.	Norwegian Univ Sci & Technol, Dept Biotechnol, N-7491 Trondheim, Norway; CNRS, Ctr Etudes Oceanol & Biol Marine, F-29680 Roscoff, France	Norwegian University of Science & Technology (NTNU); Centre National de la Recherche Scientifique (CNRS)	Valla, S (corresponding author), Norwegian Univ Sci & Technol, Dept Biotechnol, N-7491 Trondheim, Norway.	svein.valla@chembio.ntnu.no		Ertesvag, helga/0000-0001-9437-9469				BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; Bertsova YV, 1997, FEBS LETT, V414, P369, DOI 10.1016/S0014-5793(97)01047-8; Bertsova YV, 1998, BBA-BIOENERGETICS, V1363, P125, DOI 10.1016/S0005-2728(97)00094-7; Binet R, 1997, GENE, V192, P7, DOI 10.1016/S0378-1119(96)00829-3; BULEN WA, 1964, BIOCHEM BIOPH RES CO, V17, P265, DOI 10.1016/0006-291X(64)90395-X; Campos ME, 1996, J BACTERIOL, V178, P1793, DOI 10.1128/jb.178.7.1793-1799.1996; CHITNIS CE, 1990, J BACTERIOL, V172, P2894, DOI 10.1128/jb.172.6.2894-2900.1990; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Clementi F, 1997, CRIT REV BIOTECHNOL, V17, P327, DOI 10.3109/07388559709146618; DARZINS A, 1984, J BACTERIOL, V159, P9, DOI 10.1128/JB.159.1.9-18.1984; DAVIDSON IW, 1977, J GEN MICROBIOL, V98, P603, DOI 10.1099/00221287-98-2-603; DAVIDSON IW, 1977, J GEN MICROBIOL, V98, P223, DOI 10.1099/00221287-98-1-223; Ertesvag H, 1998, J BIOL CHEM, V273, P30927, DOI 10.1074/jbc.273.47.30927; ERTESVAG H, 1995, MOL MICROBIOL, V16, P719, DOI 10.1111/j.1365-2958.1995.tb02433.x; ERTESVAG H, 1994, J BACTERIOL, V176, P2846; Ertesvag H, 1999, J BACTERIOL, V181, P3033; Ertesvag H, 1998, J BACTERIOL, V180, P3779; Ertesvag H, 1999, METAB ENG, V1, P262, DOI 10.1006/mben.1999.0130; FEINGOLD DS, 1987, FEBS LETT, V223, P207, DOI 10.1016/0014-5793(87)80290-9; FISCHER FG, 1955, H-S Z PHYSIOL CHEM, V302, P186, DOI 10.1515/bchm2.1955.302.1-2.186; FRANKLIN MJ, 1994, J BACTERIOL, V176, P1821, DOI 10.1128/JB.176.7.1821-1830.1994; GACESA P, 1992, INT J BIOCHEM, V24, P545, DOI 10.1016/0020-711X(92)90325-U; GACESA P, 1987, FEBS LETT, V212, P199, DOI 10.1016/0014-5793(87)81344-3; GRASDALEN H, 1979, CARBOHYD RES, V68, P23, DOI 10.1016/S0008-6215(00)84051-3; GRASDALEN H, 1983, CARBOHYD RES, V118, P255, DOI 10.1016/0008-6215(83)88053-7; GREENER A, 1990, STRATEGIES MOL BIOL, V3, P5; HAUG A, 1974, CARBOHYD RES, V32, P217, DOI 10.1016/S0008-6215(00)82100-X; HAUG A, 1967, ACTA CHEM SCAND, V21, P691, DOI 10.3891/acta.chem.scand.21-0691; Heyraud A, 1996, CARBOHYD RES, V289, P11, DOI 10.1016/0008-6215(96)00060-2; Hoidal HK, 1999, J BIOL CHEM, V274, P12316, DOI 10.1074/jbc.274.18.12316; Hoidal HK, 2000, ENVIRON MICROBIOL, V2, P27, DOI 10.1046/j.1462-2920.2000.00074.x; KENNEDY L, 1992, J GEN MICROBIOL, V138, P2465, DOI 10.1099/00221287-138-11-2465; LARSEN B, 1971, CARBOHYD RES, V17, P287, DOI 10.1016/S0008-6215(00)82536-7; LINKERHAGNER K, 1995, J BACTERIOL, V177, P5289, DOI 10.1128/jb.177.18.5289-5293.1995; MAGDWICK J, 1973, ACTA CHEM SCAND, V27, P3592; Mejia-Ruiz H, 1997, FEMS MICROBIOL LETT, V156, P101, DOI 10.1016/S0378-1097(97)00409-6; Moreno S, 1998, J BACTERIOL, V180, P2766, DOI 10.1128/JB.180.10.2766-2769.1998; PAGE WJ, 1975, J BACTERIOL, V122, P145, DOI 10.1128/JB.122.1.145-151.1975; Pecina A, 1999, J BACTERIOL, V181, P1409; PREISS J, 1962, J BIOL CHEM, V237, P309; PUPPO A, 1986, FEBS LETT, V201, P187, DOI 10.1016/0014-5793(86)80605-6; Ramstad MV, 2001, ENZYME MICROB TECH, V28, P57, DOI 10.1016/S0141-0229(00)00273-8; Ramstad MV, 1999, ENZYME MICROB TECH, V24, P636, DOI 10.1016/S0141-0229(98)00148-3; Rehm BH, 1996, J BACTERIOL, V178, P5884, DOI 10.1128/jb.178.20.5884-5889.1996; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHERINGS G, 1977, EUR J BIOCHEM, V77, P621, DOI 10.1111/j.1432-1033.1977.tb11706.x; SKJAKBRAEK G, 1986, CARBOHYD RES, V154, P239; SKJAKBRAEK G, 1986, INT J BIOL MACROMOL, V8, P330, DOI 10.1016/0141-8130(86)90051-6; SKJAKBRAEK G, 1989, CARBOHYD RES, V185, P119, DOI 10.1016/0008-6215(89)84027-3; SKJAKBRAEK G, 1985, CARBOHYD RES, V145, P169; SKJAKBRAEK G, 1982, CARBOHYD RES, V103, P133, DOI 10.1016/S0008-6215(82)80013-X; SOCOLOFSKY MD, 1962, J BACTERIOL, V84, P119, DOI 10.1128/JB.84.1.119-124.1962; Sutherland IW, 1999, CARBOHYD POLYM, V38, P319, DOI 10.1016/S0144-8617(98)00114-3; SUTHERLAND IW, 1995, FEMS MICROBIOL REV, V16, P323, DOI 10.1016/0168-6445(95)00020-D; Svanem BIG, 1999, J BACTERIOL, V181, P68, DOI 10.1128/JB.181.1.68-77.1999; THORNELEY RNF, 1989, BIOCHEM J, V261, P181, DOI 10.1042/bj2610181; Wong TY, 2000, ANNU REV MICROBIOL, V54, P289, DOI 10.1146/annurev.micro.54.1.289; WYSS O, 1961, J BIOPHYS BIOCHEM CY, V10, P555, DOI 10.1083/jcb.10.4.555; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	59	48	53	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31542	31550		10.1074/jbc.M102562200	http://dx.doi.org/10.1074/jbc.M102562200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11390391	hybrid			2022-12-27	WOS:000170613500012
J	Shintani, T; Suzuki, K; Kamada, Y; Noda, T; Ohsumi, Y				Shintani, T; Suzuki, K; Kamada, Y; Noda, T; Ohsumi, Y			Apg2p functions in autophagosome formation on the perivacuolar structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; VACUOLE TARGETING PATHWAY; AMINOPEPTIDASE-I; CYTOPLASM; COMPLEX; SYSTEM; MACROAUTOPHAGY; APG7P/CVT2P; BIOGENESIS; COMPONENT	Autophagy is a degradative process in which cytoplasmic components are non-selectively sequestered by double-membrane structures, termed autophagosomes, and transported to the vacuole. We have identified and characterized a novel protein Apg2p essential for autophagy in yeast. Biochemical and fluorescence microscopic analyses indicate that Apg2p functions at the step of autophagosome formation. Apg2p localizes to some membranous structure distinct from any known organelle. Using fluorescent protein-tagged Apg2p, we showed that Apg2p localizes to a dot structure close to the vacuole, where Apg8p also exists, but not on autophagosomes unlike Apg8p. This punctate localization of Apg2p depends on the function of Apg1p kinase, phosphatidylinositol 3-kinase complex and Apg9p. Apg2p(G83E), encoded by an apg2-2 allele, shows a severely reduced activity of autophagy and a dispersed localization in the cytoplasm. Overexpression of the mutant Apg2p lessens the defect in autophagy. These results suggest that the dot structure is physiologically important. Apg2p and Apg8p are independently recruited to the structure but coordinately function there to form the autophagosome.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan	Ohsumi, Y (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan.		SHINTANI, Takahiro/ABE-1267-2020; Ohsumi, Yoshinori/C-6449-2009; Noda, Takeshi/B-7240-2008	Ohsumi, Yoshinori/0000-0003-2384-2166; Noda, Takeshi/0000-0003-3581-7961; Kamada, Yoshiaki/0000-0001-7395-660X; Shintani, Takahiro/0000-0001-6630-5892				Abeliovich H, 1999, EMBO J, V18, P6005, DOI 10.1093/emboj/18.21.6005; Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Baba M, 1995, CELL STRUCT FUNCT, V20, P465, DOI 10.1247/csf.20.465; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; George MD, 2000, MOL BIOL CELL, V11, P969, DOI 10.1091/mbc.11.3.969; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; Jones EW., 1997, MOL CELLULAR BIOL YE, VIII, P363; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Saiz JE, 1999, YEAST, V15, P155, DOI 10.1002/(SICI)1097-0061(19990130)15:2<155::AID-YEA342>3.0.CO;2-U; Sambrook J., 2002, MOL CLONING LAB MANU; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wurmser AE, 2000, J CELL BIOL, V151, P551, DOI 10.1083/jcb.151.3.551	40	95	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30452	30460		10.1074/jbc.M102346200	http://dx.doi.org/10.1074/jbc.M102346200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11382761	hybrid			2022-12-27	WOS:000170558000111
J	Atkinson, SF; Bettinger, T; Seymour, LW; Behr, JP; Ward, CM				Atkinson, SF; Bettinger, T; Seymour, LW; Behr, JP; Ward, CM			Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A CHAIN; PROTEIN-SYNTHESIS; IN-VIVO; INTACT-CELLS; TUMOR; DEGLYCOSYLATION; HORMONOTOXINS; IMMUNOTOXINS; ENDOCYTOSIS; INHIBITION	Conjugation of folate to proteins permits receptor-mediated endocytosis via the folate receptor (FR) and delivery of the conjugate into the cytoplasm of cells. Since many cancers up-regulate the FR it has enabled the targeting of toxins to tumor cells resulting in specific cell death. However, current conjugation methods rely on chemistries that can affect certain catalytic subunits, such as the A-chain of the plant toxin gelonin. As a result many folate-targeted tons are a compromise between receptor/ligand interaction and toxin activity. We describe the first example of folate conjugated to a protein via carbohydrate residues, using a novel SH-folate intermediate. The folate-gelonin conjugate retains over 99% of toxin activity in a cell-free translational assay compared with unmodified gelonin and is able to bind the FR at the same affinity as free folic acid (10(-10) M). Additionally, the conjugate exhibits prolonged inhibition of protein synthesis in FR positive cell lines in vitro. Folate linked to gelonin via amino conjugation exhibits the same affinity for FR as free folic acid but the toxin is 225-fold less active in a cell-free translational assay. The effect of different conjugation methods on toxin activity and the implications for folate targeting of other glycoproteins are discussed.	Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Immunol, Manchester M20 4BX, Lancs, England; Univ Birmingham, CRC Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Fac Pharm, UMR 7514, F-67401 Illkirch Graffenstaden, France	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Birmingham; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Ward, CM (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Immunol, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	wardcm@hotmail.com		Ward, Christopher/0000-0001-7389-4488				BLAKEY DC, 1987, CANCER RES, V47, P947; EIKLID K, 1980, EXP CELL RES, V126, P321, DOI 10.1016/0014-4827(80)90270-0; Fu QL, 2001, BIOCONJUGATE CHEM, V12, P271, DOI 10.1021/bc000100u; FULTON RJ, 1988, CANCER RES, V48, P2618; FULTON RJ, 1988, CANCER RES, V48, P2626; Gabizon A, 1999, BIOCONJUGATE CHEM, V10, P289, DOI 10.1021/bc9801124; Koivunen E, 1999, METH MOL B, V129, P3; Kreitman RJ, 1998, ADV DRUG DELIVER REV, V31, P53, DOI 10.1016/S0169-409X(97)00094-X; Leamon CP, 2001, DRUG DISCOV TODAY, V6, P44, DOI 10.1016/S1359-6446(00)01594-4; LEAMON CP, 1992, J BIOL CHEM, V267, P24966; Leamon CP, 1999, J DRUG TARGET, V7, P157, DOI 10.3109/10611869909085499; LEE RJ, 1994, J BIOL CHEM, V269, P3198; MAGNUSSON S, 1993, BIOCHEM J, V291, P749, DOI 10.1042/bj2910749; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROSENBLUM MG, 1992, MOL BIOTHER, V4, P122; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; Sforzini S, 1995, J Hematother, V4, P429, DOI 10.1089/scd.1.1995.4.429; Sharma S, 1999, MOL CELL BIOCHEM, V200, P133, DOI 10.1023/A:1007043218769; Shinoda T, 1998, J PHARM SCI, V87, P1521, DOI 10.1021/js980215v; SINGH V, 1989, BIOCHEM J, V263, P417, DOI 10.1042/bj2630417; SINGH V, 1991, BIOCHEM INT, V24, P677; SINGH V, 1991, BIOCHEM INT, V25, P531; SINGH V, 1994, MOL CELL BIOCHEM, V130, P91, DOI 10.1007/BF01084272; STIRPE F, 1980, J BIOL CHEM, V255, P6947; Toffoli G, 1997, INT J CANCER, V74, P193, DOI 10.1002/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F; TUREK JJ, 1993, J CELL SCI, V106, P423; Wang S, 1997, BIOCONJUGATE CHEM, V8, P673, DOI 10.1021/bc9701297; Wang S, 1998, J CONTROL RELEASE, V53, P39, DOI 10.1016/S0168-3659(97)00236-8; Ward CM, 2000, J DRUG TARGET, V8, P119, DOI 10.3109/10611860008996857; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; YAZDI PT, 1995, CANCER RES, V55, P3763	31	74	104	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27930	27935		10.1074/jbc.M102825200	http://dx.doi.org/10.1074/jbc.M102825200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11359781	Green Published, hybrid			2022-12-27	WOS:000170093400026
J	Martinez, J; Ren, YG; Nilsson, P; Ehrenberg, M; Virtanen, A				Martinez, J; Ren, YG; Nilsson, P; Ehrenberg, M; Virtanen, A			The mRNA cap structure stimulates rate of poly(A) removal and amplifies processivity of degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; IN-VITRO; POLY(A)-BINDING PROTEIN; TRANSLATION INITIATION; BINDING-PROTEIN; POLY(A)-SPECIFIC RIBONUCLEASE; CRYSTAL-STRUCTURE; DNA-REPLICATION; XENOPUS OOCYTES	Poly(A) -specific ribonuclease (PARN) is an oligomeric, processive, and cap-interacting 3' exonuclease. We have studied how the m(7)G(5')ppp(5')G cap structure affects the activity of PARN. It is shown that the cap has four distinct effects: (i) It stimulates the rate of deadenylation if provided in cis; (ii) it inhibits deadenylation if provided at high concentration in trans; (iii) it stimulates deadenylation if provided at low concentration in trans; and (iv) it increases the processivity of PARN when provided in cis. It is shown that the catalytic and cap binding sites on PARN are separate. The important roles of the 7-methyl group and the inverted guanosine residue of the cap are demonstrated. An active deadenylation complex, consisting of the poly(A)-tailed RNA substrate and PARN, has been identified. Complex formation does not require a cap structure on the RNA substrate. The multiple effects of cap are all accounted for by a simple, kinetic model that takes the processivity of PARN into account.	Uppsala Univ, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden	Uppsala University	Virtanen, A (corresponding author), Uppsala Univ, Dept Cell & Mol Biol, Box 596, SE-75124 Uppsala, Sweden.			Martinez, Javier/0000-0001-9152-7323				ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; ASTROM J, 1992, J BIOL CHEM, V267, P18154; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; Boeck R, 1998, MOL CELL BIOL, V18, P5062, DOI 10.1128/MCB.18.9.5062; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; BRAWERMAN G, 1981, CRC CR REV BIOCH MOL, V10, P1, DOI 10.3109/10409238109114634; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; Brown CE, 1996, MOL CELL BIOL, V16, P5744; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Ford LP, 1997, MOL CELL BIOL, V17, P398, DOI 10.1128/MCB.17.1.398; Gallie DR, 1998, BIOCHEM BIOPH RES CO, V245, P295, DOI 10.1006/bbrc.1998.8427; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Hsu PC, 2000, BIOCHEMISTRY-US, V39, P13730, DOI 10.1021/bi000623p; Keck JL, 2000, CHEM BIOL, V7, pR63, DOI 10.1016/S1074-5521(00)00094-6; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Korner CG, 1997, J BIOL CHEM, V272, P10448; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; LaGrandeur TE, 1998, EMBO J, V17, P1487, DOI 10.1093/emboj/17.5.1487; LARIMER FW, 1992, GENE, V120, P51, DOI 10.1016/0378-1119(92)90008-D; Martinez J, 2000, J BIOL CHEM, V275, P24222, DOI 10.1074/jbc.M001705200; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; Morino S, 1996, EUR J BIOCHEM, V239, P597, DOI 10.1111/j.1432-1033.1996.0597u.x; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; Preiss T, 1999, CURR OPIN GENET DEV, V9, P515, DOI 10.1016/S0959-437X(99)00005-2; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sachs AB, 2000, NAT STRUCT BIOL, V7, P356, DOI 10.1038/75120; SHATKIN AJ, 1987, BIOESSAYS, V7, P275, DOI 10.1002/bies.950070611; STEVENS A, 1980, J BIOL CHEM, V255, P3080; TABOR S, 1987, J BIOL CHEM, V262, P16212; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Virtanen A, 1997, Prog Mol Subcell Biol, V18, P199; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X; Wormington M, 1996, EMBO J, V15, P900, DOI 10.1002/j.1460-2075.1996.tb00424.x; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	59	79	101	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27923	27929		10.1074/jbc.M102270200	http://dx.doi.org/10.1074/jbc.M102270200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11359775	hybrid			2022-12-27	WOS:000170093400025
J	Poyet, JL; Srinivasula, SM; Tnani, M; Razmara, M; Fernandes-Alnemri, T; Alnemri, ES				Poyet, JL; Srinivasula, SM; Tnani, M; Razmara, M; Fernandes-Alnemri, T; Alnemri, ES			Identification of Ipaf, a human caspase-1-activating protein related to Apaf-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C; CYSTEINE PROTEASE; MICE DEFICIENT; FAMILY-MEMBER; ACTIVATION; ENZYME; OLIGOMERIZATION; PROCASPASE-9; EXPRESSION	Procaspase-9 contains an NH2-terminal caspase-associated recruitment domain (CARD), which is essential for direct association with Apaf-1 and activation. Procaspase-1 also contains an NH2-terminal CARD domain, suggesting that its mechanism of activation, like that of procaspase-9, involves association with an Apaf-1-related molecule. Here we describe the identification of a human Apaf-1-related protein, named Ipaf that contains an NH2-terminal CARD domain, a central nucleotide-binding domain, and a COOH-terminal regulatory leucine-rich repeat domain (LRR). Ipaf associates directly and specifically with the CARD domain of procaspase-1 through CARD-CARD interaction. A constitutively active Ipaf lacking its COOH-terminal LRR domain can induce autocatalytic processing and activation of procaspase-1 and caspase-1-dependent apoptosis in transfected cells. Our results suggest that Ipaf is a specific and direct activator of procaspase-1 and could be involved in activation of caspase-1 in response to pro-inflammatory and apoptotic stimuli.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg,Rm 904,233 S 10th St, Philadelphia, PA 19107 USA.	E_Alnemri@lac.jci.tju.edu	Alnemri, Emad S/B-4526-2010; Poyet, Jean-Luc/G-7114-2017	Poyet, Jean-Luc/0000-0002-3747-255X	NATIONAL INSTITUTE ON AGING [R01AG014357] Funding Source: NIH RePORTER; NIA NIH HHS [AG14357] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmad M, 1997, CANCER RES, V57, P615; ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Benedict MA, 2000, J BIOL CHEM, V275, P8461, DOI 10.1074/jbc.275.12.8461; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; DRUILHE A, 2001, IN PRESS CELL DEATH; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Horvitz HR, 1999, CANCER RES, V59, p1701S; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	31	329	343	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28309	28313		10.1074/jbc.C100250200	http://dx.doi.org/10.1074/jbc.C100250200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11390368	hybrid			2022-12-27	WOS:000170093400076
J	Reddy, KB; Bialkowska, K; Fox, JEB				Reddy, KB; Bialkowska, K; Fox, JEB			Dynamic modulation of cytoskeletal proteins linking integrins to signaling complexes in spreading cells - Role of skelemin in initial integrin-induced spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; FOCAL ADHESION KINASE; CYTOPLASMIC DOMAIN MUTANTS; BETA(3) SUBUNIT; ALPHA-ACTININ; GPIIB-IIIA; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; MEDIATED ACTIVATION; CALPAIN CLEAVAGE	Recently we showed that signaling across beta (3)-integrin leads to activation of calpain and formation of integrin clusters that are involved in Rac activation. The subsequent activation of Rac and Rho leads to the formation of focal complexes and focal adhesions, respectively. The goal of the present study was to determine whether different, proteins link the integrin to the cytoskeleton in the different complexes. We show that talin is present in focal adhesions but not in the calpain-induced clusters. alpha -Actinin colocalized with integrin at various sites, including the calpain-induced clusters. Skelemin, a protein shown recently to interact with beta (1)- and beta (3)-integrin in vitro, colocalized with integrin in calpain-induced clusters but was absent from focal adhesions. Cells transiently expressing skelemin C2 motifs, which contain the integrin binding site, failed to form integrin clusters or to spread on a substrate for beta (1)- and beta (3)-integrins. These results 1) suggest a dynamic reorganization of integrin complexes during cell spreading, 2) show that different cytoskeletal proteins link integrins in different complexes, and 3) demonstrate that skelemin is responsible for linking integrin to the calpain-induced clusters, and 4) show that the integrin-skelemin interaction is essential for transmission of signals leading to the initial steps of cell spreading.	Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol NB5, Dept Mol Cardiol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Fox, JEB (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol NB5, Dept Mol Cardiol, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056264, R23HL030657, R37HL030657, R01HL030657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30657, HL56264] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Auerbach D, 1999, MOL BIOL CELL, V10, P1297, DOI 10.1091/mbc.10.5.1297; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; CHEN WT, 1982, J CELL BIOL, V95, P205, DOI 10.1083/jcb.95.1.205; CHRZANOWSKAWODNICKA M, 1992, BIOESSAYS, V14, P777, DOI 10.1002/bies.950141110; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; EARNEST JP, 1995, J BIOL CHEM, V270, P27259, DOI 10.1074/jbc.270.45.27259; FERAMISCO JR, 1979, P NATL ACAD SCI USA, V76, P3967, DOI 10.1073/pnas.76.8.3967; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; Fox J. E. B, 1999, CALPAIN PHARM TOXICO, P103; FOX JEB, 1983, J BIOL CHEM, V258, P9973; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1995, J CELL BIOCH B S, V19, pA136; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GINSBERG MH, 1990, CELL DIFFER DEV, V32, P203, DOI 10.1016/0922-3371(90)90033-S; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; Harlow E., 1988, ANTIBODIES LAB MANUA; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kaapa A, 1999, EXP CELL RES, V250, P524, DOI 10.1006/excr.1999.4533; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LaFlamme SE, 1996, SEMIN CANCER BIOL, V7, P111, DOI 10.1006/scbi.1996.0016; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Lyman S, 1997, J BIOL CHEM, V272, P22538, DOI 10.1074/jbc.272.36.22538; Meredith J, 1998, J BIOL CHEM, V273, P19525, DOI 10.1074/jbc.273.31.19525; Meredith JE, 1996, ENDOCR REV, V17, P207, DOI 10.1210/er.17.3.207; MURACHI T, 1981, ADV ENZYME REGUL, V19, P407; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Norris FA, 1997, J BIOL CHEM, V272, P10987; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Pfaff M, 1999, FEBS LETT, V460, P17, DOI 10.1016/S0014-5793(99)01250-8; PHILLIPS DR, 1988, BLOOD, V71, P831; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; PRICE MG, 1987, J CELL BIOL, V104, P1325, DOI 10.1083/jcb.104.5.1325; PRICE MG, 1993, J BIOL CHEM, V268, P21800; Reddy KB, 1998, J BIOL CHEM, V273, P35039, DOI 10.1074/jbc.273.52.35039; SAMUELSSON SJ, 1993, J CELL BIOL, V122, P485, DOI 10.1083/jcb.122.2.485; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; TAPLEY P, 1989, ONCOGENE, V4, P325; Whitlock BB, 2000, J CELL BIOL, V151, P1305, DOI 10.1083/jcb.151.6.1305; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1991, Journal of Cell Biology, V115, p132A	63	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28300	28308		10.1074/jbc.M102794200	http://dx.doi.org/10.1074/jbc.M102794200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382766	hybrid			2022-12-27	WOS:000170093400075
J	Ku, NO; Omary, MB				Ku, NO; Omary, MB			Effect of mutation and phosphorylation of type I keratins on their caspase-mediated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMOLYSIS-BULLOSA SIMPLEX; INTERMEDIATE FILAMENTS; CULTURED-CELLS; ANTIGEN TPS; APOPTOSIS; DISEASE; PROTEINS; CYTOKERATINS; EPITHELIA; CLEAVAGE	Type I keratins K18 and K19 undergo caspase-mediated degradation during apoptosis, Two known K18 caspase cleavage sites are aspartates in the consensus sequences VEVDA and DALDS, located within the rod domain and tail domain, respectively. Several K14 (another type I keratin) mutations within the caspase cleavage motif have been described inpatients with epidermolysis bullosa simplex. Here we use extensive mutational analysis to show that K19 and K14 are caspase substrates and that the ability to undergo caspase-mediated digestion of K18, K19, or K14 is highly dependent on the location and nature of the mutation within the caspase cleavage motif, Caspase cleavage of K14 occurs at the aspartate of VEMDA, a consensus sequence found in type I keratins K12-17 with similar but not identical sequences in K18 and K19. For K18, apoptosis-induced cleavage occurs sequentially, first at (393)DALD and then at (VEVD)-V-234. Hyperphosphorylation of K18 protects from caspase-3 in vitro digestion at (VEVD)-V-234 but not at (393)DALD. Hence, keratins K12-17 are likely caspase substrates during apoptosis. Keratin hyperphosphorylation, which occurs early in apoptosis, protects from caspase-mediated K18 digestion in a cleavage site-specific manner. Mutations in epidermolysis bullosa simplex patients could interfere with K14 degradation during apoptosis, depending on their location.	Vet Affairs Med Ctr, Dept Med, Palo Alto, CA 94304 USA; Stanford Univ, Palo Alto, CA 94304 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University	Omary, MB (corresponding author), Vet Affairs Med Ctr, Dept Med, Mail Code 154J,3801 Miranda Ave, Palo Alto, CA 94304 USA.			Omary, Bishr/0000-0002-8624-2347	NIDDK NIH HHS [DK47918] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047918] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Badock V, 2001, CELL DEATH DIFFER, V8, P308, DOI 10.1038/sj.cdd.4400812; Bjorklund B, 1978, Antibiot Chemother (1971), V22, P16; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; CHEN H, 1995, J INVEST DERMATOL, V105, P629, DOI 10.1111/1523-1747.ep12323846; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Gniadecki R, 1998, ARCH DERMATOL RES, V290, P528, DOI 10.1007/s004030050347; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; HUMPHRIES MM, 1993, HUM MUTAT, V2, P37, DOI 10.1002/humu.1380020107; Irvine AD, 1999, BRIT J DERMATOL, V140, P815, DOI 10.1046/j.1365-2133.1999.02810.x; Ku NO, 1999, AM J PHYSIOL-GASTR L, V277, pG1108, DOI 10.1152/ajpgi.1999.277.6.G1108; Ku NO, 1997, J BIOL CHEM, V272, P33197, DOI 10.1074/jbc.272.52.33197; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; Liao J, 1997, J BIOL CHEM, V272, P17565, DOI 10.1074/jbc.272.28.17565; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Muller FB, 1998, J INVEST DERMATOL, V111, P900, DOI 10.1046/j.1523-1747.1998.00374.x; Omary M B, 1998, Subcell Biochem, V31, P105; Prasad S, 1999, INT J ONCOL, V14, P563; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rosenthal DS, 1998, J INVEST DERMATOL, V111, P64, DOI 10.1046/j.1523-1747.1998.00250.x; RUGG EL, 1993, NAT GENET, V5, P294, DOI 10.1038/ng1193-294; Rydlander L, 1996, EUR J BIOCHEM, V241, P309, DOI 10.1111/j.1432-1033.1996.00309.x; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; Slesak B, 2000, CANCER, V89, P83, DOI 10.1002/1097-0142(20000701)89:1<83::AID-CNCR12>3.0.CO;2-J; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Stigbrand T, 2001, TUMOR BIOL, V22, P1, DOI 10.1159/000030148; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TINNEMANS MMFJ, 1995, EUR J CELL BIOL, V68, P35; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valik D, 2000, BRIT J CANCER, V82, P1756; van Dalen A, 1999, INT J BIOL MARKER, V14, P45, DOI 10.1177/172460089901400109; vanDalen A, 1996, ANTICANCER RES, V16, P2345; vanEngeland M, 1997, EXP CELL RES, V235, P421, DOI 10.1006/excr.1997.3738; WEBER K, 1984, EMBO J, V3, P2707, DOI 10.1002/j.1460-2075.1984.tb02198.x	40	75	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26792	26798		10.1074/jbc.M103315200	http://dx.doi.org/10.1074/jbc.M103315200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356849	hybrid			2022-12-27	WOS:000169966900010
J	Miller, JT; Ehresmann, B; Hubscher, U; Le Grice, SFJ				Miller, JT; Ehresmann, B; Hubscher, U; Le Grice, SFJ			A novel interaction of tRNA(Lys,3) with the feline immunodeficiency virus RNA genome governs initiation of minus strand DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE TRANSCRIPTION; PRIMER-BINDING-SITE; EFFICIENT INITIATION; SECONDARY STRUCTURE; POSTTRANSCRIPTIONAL MODIFICATIONS; TY1 RETROTRANSPOSON; GENETIC-ANALYSIS; TYPE-1; COMPLEMENTARY; TRNA(3)(LYS)	Complementarity between nucleotides at the 5' terminus of tRNA(Lys,3) and the U5-IR loop of the feline immunodeficiency virus RNA genome suggests a novel intermolecular interaction controls initiation of minus strand synthesis in a manner analogous to other retroviral systems. Base pairing of this tRNA-viral RNA duplex was confirmed by nuclease mapping of the RNA genome containing full-length or 5'-deleted variants of tRNA(Lys,3) hybridized to the primer-binding site. A major pause in RNA-dependent DNA synthesis occurred 14 nucleotides ahead of the primer-binding site with natural and synthetic tRNA(Lys,3) primers, indicating it was not a consequence of tRNA base modifications. The majority of the paused complexes resulted in dissociation of the reverse transcriptase from the template/primer, as demonstrated by an assay limited to a single binding event. Hybridization of a tRNA mutant whose 5' nucleotides are deleted relieved pausing at this position and subsequently allowed high level DNA synthesis. Additional experiments with tRNA-DNA chimeric primers were used to localize the stage of minus strand synthesis at which the tRNA-viral RNA interaction was disrupted. Finally, replacing nucleotides of the feline immunodeficiency virus US-IR loop with the (A), sequence of its human immunodeficiency virus (HIV)-1 counterpart also relieved pausing, but did not induce pausing immediately downstream of the primer-binding site previously noted during initiation of HIV-1 DNA synthesis. These combined observations provide further evidence of cis-acting sequences immediately adjacent to the primer-binding site controlling initiation of minus strand DNA synthesis in retroviruses and retrotransposons.	NCI, HIV Drug Resistance Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; CNRS, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France; Univ Zurich Irchel, Inst Vet Biochem, CH-8057 Zurich, Switzerland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Zurich	Le Grice, SFJ (corresponding author), NCI, HIV Drug Resistance Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA.	slegrice@mail.ncifcrf.gov						AIYAR A, 1994, J VIROL, V68, P611, DOI 10.1128/JVI.68.2.611-618.1994; AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; Amacker M, 1998, J MOL BIOL, V278, P757, DOI 10.1006/jmbi.1998.1739; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; Auxilien S, 1999, J BIOL CHEM, V274, P4412, DOI 10.1074/jbc.274.7.4412; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; Beard WA, 1996, J BIOL CHEM, V271, P12213, DOI 10.1074/jbc.271.21.12213; Boulme F, 1998, FEBS LETT, V430, P165, DOI 10.1016/S0014-5793(98)00649-8; Brule F, 2000, NUCLEIC ACIDS RES, V28, P634, DOI 10.1093/nar/28.2.634; COBRINIK D, 1988, J VIROL, V62, P3622, DOI 10.1128/JVI.62.10.3622-3630.1988; Coffin J, 1997, RETROVIRUSES; CORDELL B, 1979, J BIOL CHEM, V254, P1866; Cullen BR, 1998, VIROLOGY, V249, P203, DOI 10.1006/viro.1998.9331; Fosse P, 1996, BIOCHEMISTRY-US, V35, P16601, DOI 10.1021/bi9613786; Friant S, 1998, MOL CELL BIOL, V18, P799, DOI 10.1128/MCB.18.2.799; Friant S, 1996, NUCLEIC ACIDS RES, V24, P441, DOI 10.1093/nar/24.3.441; Gabus C, 1998, EMBO J, V17, P4873, DOI 10.1093/emboj/17.16.4873; Gotte M, 1999, J BIOL CHEM, V274, P11159, DOI 10.1074/jbc.274.16.11159; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; ISEL C, 1993, J BIOL CHEM, V268, P25269; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; Kang SM, 1999, J VIROL, V73, P1818, DOI 10.1128/JVI.73.3.1818-1827.1999; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; KATI WM, 1992, J BIOL CHEM, V267, P25988; KEENEY JB, 1995, MOL CELL BIOL, V15, P217, DOI 10.1128/MCB.15.1.217; Lanchy JM, 1998, J BIOL CHEM, V273, P24425, DOI 10.1074/jbc.273.38.24425; Lanchy JM, 2000, J BIOL CHEM, V275, P12306, DOI 10.1074/jbc.275.16.12306; Lanchy JM, 1996, BIOCHIMIE, V78, P1087, DOI 10.1016/S0300-9084(97)86734-X; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Li Y, 1997, VIROLOGY, V238, P273, DOI 10.1006/viro.1997.8837; Li Y, 1997, J VIROL, V71, P6315, DOI 10.1128/JVI.71.9.6315-6322.1997; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; LINIAL ML, 1990, CURR TOP MICROBIOL, V157, P125; Morris S, 1999, J VIROL, V73, P6307, DOI 10.1128/JVI.73.8.6307-6318.1999; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REIN A, 1994, ARCH VIROL, P513; Roebuck KA, 1999, GENE EXPRESSION, V8, P67; Souquet M, 1998, BIOCHEMISTRY-US, V37, P12144, DOI 10.1021/bi9731596; Stello T, 1999, NUCLEIC ACIDS RES, V27, P4823, DOI 10.1093/nar/27.24.4823; TALBOTT RL, 1989, P NATL ACAD SCI USA, V86, P5743, DOI 10.1073/pnas.86.15.5743; Tisne C, 2000, RNA, V6, P1403, DOI 10.1017/S1355838200000947; Wakefield JK, 1996, VIROLOGY, V220, P290, DOI 10.1006/viro.1996.0317; WAKEFIELD JK, 1995, J VIROL, V69, P6021, DOI 10.1128/JVI.69.10.6021-6029.1995; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343; WOHRL BM, 1995, SCIENCE, V267, P96, DOI 10.1126/science.7528942; Zhang ZJ, 1998, AIDS RES HUM RETROV, V14, P979, DOI 10.1089/aid.1998.14.979; Zhang ZJ, 1998, RNA, V4, P394; Zhang ZJ, 1996, VIROLOGY, V226, P306, DOI 10.1006/viro.1996.0658; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	56	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27721	27730		10.1074/jbc.M100513200	http://dx.doi.org/10.1074/jbc.M100513200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11353768	Green Accepted, hybrid			2022-12-27	WOS:000169966900130
J	Fukuda, M; Saegusa, C; Kanno, E; Mikoshiba, K				Fukuda, M; Saegusa, C; Kanno, E; Mikoshiba, K			The C2A domain of double C2 protein gamma contains a functional nuclear localization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT OLIGOMERIZATION; PHOSPHOLIPID-BINDING; SYNAPTIC VESICLE; SYNAPTOTAGMIN-I; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; DOC2; FAMILY; EXOCYTOSIS; ISOFORMS	The C2 domain was originally defined as a homologous domain to the C2 regulatory region of Ca2+-dependent protein kinase C and has been identified in more than 50 different signaling molecules. The original C2 domain of protein kinase C alpha functions as a Ca2+ binding module, and the Ca2+ binding to the C2 domain allows translocation of proteins to phospholipid membranes. By contrast, however, some C2 domains do not exhibit Ca2+ binding activity because of amino acid substitutions at Ca2+-binding sites, and their physiological meanings remain largely unknown. In this study, we discovered an unexpected function of the Ca2+-independent C2A domain of double C2 protein gamma (Doc2 gamma) in nuclear localization. Deletion and mutation analyses revealed that the putative Ca2+ binding loop 3 of Doc2 gamma contains six Arg residues ((RLRRRRR183)-R-177) and that this basic cluster is both necessary and sufficient for nuclear localization of Doc2 gamma. Because of the presence of the basic cluster, the C2A domain of Doc2 gamma did not show Ca2+ dependent phospholipid binding activity. Our findings indicate that by changing the nature of the putative Ca2+ binding loops the C2 domain has more diversified function in cellular signaling than a simple Ca2+ binding moth.	RIKEN, Inst Phys & Chem Res, Dev Neurobiol Lab, Brain Sci Inst, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan	RIKEN; University of Tokyo	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Dev Neurobiol Lab, Brain Sci Inst, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Mikoshiba, Katsuhiko/N-7943-2015; Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Damer CK, 1996, J NEUROCHEM, V67, P1661; DAVIETOV BA, 1993, J BIOL CHEM, V268, P26386; Duncan RR, 2000, BIOCHIMIE, V82, P421, DOI 10.1016/S0300-9084(00)00214-5; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fukuda M, 2000, BIOCHEM BIOPH RES CO, V276, P626, DOI 10.1006/bbrc.2000.3520; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 1997, BIOCHEM J, V323, P421, DOI 10.1042/bj3230421; Fukuda M, 2001, BIOCHEM J, V354, P249, DOI 10.1042/0264-6021:3540249; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; Fukuda M, 2000, J BIOCHEM, V128, P637, DOI 10.1093/oxfordjournals.jbchem.a022796; Ibata K, 1998, J BIOL CHEM, V273, P12267, DOI 10.1074/jbc.273.20.12267; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kojima T, 1996, J BIOCHEM-TOKYO, V120, P671; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mizutani A, 2000, J BIOL CHEM, V275, P9823, DOI 10.1074/jbc.275.13.9823; Mochida S, 1998, P NATL ACAD SCI USA, V95, P11418, DOI 10.1073/pnas.95.19.11418; Naito A, 1997, MOL BRAIN RES, V44, P198, DOI 10.1016/S0169-328X(96)00198-2; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Orita S, 1997, J BIOL CHEM, V272, P16081, DOI 10.1074/jbc.272.26.16081; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; Ponting CP, 1996, PROTEIN SCI, V5, P162; Sakaguchi G, 1995, BIOCHEM BIOPH RES CO, V217, P1053, DOI 10.1006/bbrc.1995.2876; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Schivell AE, 1996, J BIOL CHEM, V271, P27770, DOI 10.1074/jbc.271.44.27770; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	53	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24441	24444		10.1074/jbc.C100119200	http://dx.doi.org/10.1074/jbc.C100119200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11371549	hybrid			2022-12-27	WOS:000169800700003
J	Ji, C; Kozak, KR; Marnett, LJ				Ji, C; Kozak, KR; Marnett, LJ			I kappa B kinase, a molecular target for inhibition by 4-hydroxy-2-nonenal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; LIPID-PEROXIDATION; DEOXYGUANOSINE ADDUCTS; DNA LESIONS; C-MYC; ACTIVATION; PHOSPHORYLATION; ALPHA; PROTEIN; IKK	In unstimulated cells, transcription factor NF-kappaB is retained in the cytoplasm by interaction with the inhibitory protein, I kappaB alpha. Appropriate cellular stimuli inactivate I kappaB alpha by phosphorylation, ubiquination, and proteolytic degradation, which allows NF-kappaB to translocate to the nucleus and modulate gene expression. 4-Hydroxy-2-nonenal (HNE), a major lipid peroxidation product, inhibits activation of NF-kappaB in the human colorectal carcinoma cell line (RKO) and human lung carcinoma cell line (H1299), Pretreatment of cells with HNE dose-dependently suppresses tetradecanoylphorbol acetate (TPA)/ionomycin (IM)-induced NF-kappaB DNA binding activity and transactivation of luciferase-based reporter constructs. HNE pretreatment has no affect on TPA/IM-induced AP-1 DNA binding activity. HNE inhibits TPA/ IM-induced degradation of I kappaB alpha in both H1299 and Jurkat T cells. The accumulation of I kappaB alpha parallels the inhibition of its phosphorylation. At doses that inhibit I kappaB alpha degradation, HNE inhibits I kappaB kinase (IKK) activity by direct reaction with IKK, Covalent adducts of HNE to IKK are detected on Western blots using antibodies against IKK or HNE-protein conjugates, Addition of dithiothreitol prevents HNE modification of IKK. Thus, HNE is an endogenous inhibitor of NF-kappaB activation that acts by preventing IKK activation and subsequent I kappaB alpha degradation.	Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37232 USA.	marnett@toxicology.mc.vanderbilt.edu			NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NCI NIH HHS [CA47479] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; BARRERA G, 1987, TOXICOL PATHOL, V15, P238, DOI 10.1177/019262338701500219; Barrera G, 1996, BIOCHEM BIOPH RES CO, V227, P589, DOI 10.1006/bbrc.1996.1550; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; Chung FL, 2000, CANCER RES, V60, P1507; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ESTERBAUER H, 1993, AM J CLIN NUTR, V57, P779, DOI 10.1093/ajcn/57.5.779S; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FAZIO VM, 1992, CANCER RES, V52, P4866; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Ji C, 1998, CARCINOGENESIS, V19, P1275, DOI 10.1093/carcin/19.7.1275; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kirichenko A, 1996, TOXICOL APPL PHARM, V141, P416, DOI 10.1006/taap.1996.0307; Kruman I, 1997, J NEUROSCI, V17, P5089; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li L, 1999, AM J PHYSIOL-LUNG C, V277, pL550, DOI 10.1152/ajplung.1999.277.3.L550; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Liu W, 2000, J CELL SCI, V113, P635; Marnett LJ, 1999, MUTAT RES-FUND MOL M, V424, P83, DOI 10.1016/S0027-5107(99)00010-X; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; Page S, 1999, J BIOL CHEM, V274, P11611, DOI 10.1074/jbc.274.17.11611; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Schauenstein E., 1977, ALDEHYDES BIOL SYSTE; Soh YJ, 2000, MOL PHARMACOL, V58, P535, DOI 10.1124/mol.58.3.535; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6	48	159	166	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18223	18228		10.1074/jbc.M101266200	http://dx.doi.org/10.1074/jbc.M101266200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359792	hybrid			2022-12-27	WOS:000168866500082
J	Buschmann, T; Lerner, D; Lee, CG; Ronai, Z				Buschmann, T; Lerner, D; Lee, CG; Ronai, Z			The Mdm-2 amino terminus is required for Mdm2 binding and SUMO-1 conjugation by the E2 SUMO-1 conjugating enzyme Ubc9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-RELATED PROTEIN; TUMOR-SUPPRESSOR P53; COVALENT MODIFICATION; LIGASE ACTIVITY; C-JUN; YEAST; DEGRADATION; PATHWAY; SYSTEM; LOCALIZATION	Covalent attachment of SUMO-1 to Mdm2 requires the activation of a heterodimeric Aos1-Uba2 enzyme (ubiquitin-activating enzyme (El)) followed by the conjugation of Sumo-1 to Mdm2 by Ubc9, a protein with a strong sequence similarity to ubiquitin carrier proteins (E2s). Upon Sumo-1 conjugation, Mdm2 is protected from self-ubiquitination and elicits greater ubiquitin-protein isopeptide ligase (E3) activity toward p53, thereby increasing its oncogenic potential. Because of the biological implication of Mdm2 sumoylation, we mapped Ubc9 binding on Mdm2. Here we demonstrate that Ubc9 can associate with Mdm2 only if amino acids 40-59 within the N terminus of Mdm2 are present. Mdm2 from which amino acids 40-59 have been deleted can no longer be sumoylated. Furthermore, addition of a peptide that corresponds to amino acids 40-59 on Mdm2 to a sumoylation reaction efficiently inhibits Mdm2 sumoylation in vitro and in vivo. In UV-treated cells Mdm2 exhibits reduced association with Ubc9, which coincides with decreased Mdm2 sumoylation. Our findings regarding the association of Ubc9 with Mdm2, and the effect of UV-irradiation on Ubc9 binding, point to an additional level in the regulation of Mdm2 sumoylation under normal growth conditions as well as in response to stress conditions.	Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Univ Med & Dent New Jersey, Dept Biochem & Mol Biol, Newark, NJ 07013 USA	Icahn School of Medicine at Mount Sinai; Rutgers State University New Brunswick; Rutgers State University Medical Center	Ronai, Z (corresponding author), Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA.	zeev.ronai@mssm.edu		RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA059908] Funding Source: NIH RePORTER; NCI NIH HHS [CA59908] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Becker K, 1997, FEBS LETT, V412, P102, DOI 10.1016/S0014-5793(97)00758-8; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Ciechanover A, 2000, J CELL BIOCHEM, P40; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Duprez E, 1999, J CELL SCI, V112, P381; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hofmann H, 2000, J VIROL, V74, P2510, DOI 10.1128/JVI.74.6.2510-2524.2000; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lehembre F, 2000, MOL CELL BIOL, V20, P1072, DOI 10.1128/MCB.20.3.1072-1082.2000; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu Q, 1999, BIOCHEMISTRY-US, V38, P1415, DOI 10.1021/bi981840h; Liu Q, 1999, J BIOL CHEM, V274, P16979, DOI 10.1074/jbc.274.24.16979; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Masson M, 1997, GENE, V190, P287, DOI 10.1016/S0378-1119(97)00015-2; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rangasamy D, 2000, J BIOL CHEM, V275, P30487, DOI 10.1074/jbc.M003898200; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Varshavsky A, 2000, BIOL CHEM, V381, P779, DOI 10.1515/BC.2000.101; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	55	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40389	40395		10.1074/jbc.M103786200	http://dx.doi.org/10.1074/jbc.M103786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11384992	hybrid			2022-12-27	WOS:000171925600006
J	De Falco, S; Ruvoletto, MG; Verdoliva, A; Ruvo, M; Raucci, A; Marino, M; Senatore, S; Cassani, G; Alberti, A; Pontisso, P; Fassina, G				De Falco, S; Ruvoletto, MG; Verdoliva, A; Ruvo, M; Raucci, A; Marino, M; Senatore, S; Cassani, G; Alberti, A; Pontisso, P; Fassina, G			Cloning and expression of a novel hepatitis B virus-binding protein from HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PLASMA-MEMBRANES; ADULT HUMAN HEPATOCYTES; CARCINOMA ANTIGEN; PRES1 DOMAIN; HUMAN-SERUM; ANNEXIN-V; RECEPTOR; HBV; SERPIN; INHIBITOR	A direct involvement of the hepatitis B virus (HBV) preS1-(21-47) sequence in virus attachment to cell membrane receptor(s) and the presence on the plasma membranes of HepG2 cells of protein(s) with receptor activity for HBV have been suggested by many previous experiments. In this study, by using a tetravalent derivative of the preS1-(21-47) sequence, we have isolated by affinity chromatography from detergent-solubilized HepG2 plasma membranes a 44-kDa protein (HBV-binding protein; HBV-BP), which was found to closely correspond to the human squamous cell carcinoma antigen I (SCCA1), a member of the ovalbumin family of serine protease inhibitors. Comparison of SCCA1 sequence with the sequence of the corresponding HBV-BP cDNA, cloned by polymerase chain reaction starting from RNA poly(A)(+) fractions extracted from HepG2 cells, indicated the presence of only four nucleotide substitutions in the coding region, leading to three amino acid changes. Intact recombinant HBV-BP lacked inhibitory activity for serine proteases such as alpha -chymotrypsin and trypsin but inhibited with high potency cysteine proteases such as papain and cathepsin L. Direct binding experiments confirmed the interaction of recombinant HBV-BP with the HBV preS1 domain. HepG2 cells overexpressing HBV-BP after transfection of corresponding cDNA showed a virus binding capacity increased by 2 orders of magnitude compared with untransfected cells, while Chinese hamster ovary cells, which normally do not bind to HBV, acquired susceptibility to HBV binding after transfection. Native HBV particle entry was enhanced in transfected cells. Both recombinant HBV-BP and antibodies to recombinant HBV-BP blocked virus binding and internalization in transfected cells as well as in primary human helpatocytes in a dose-dependent manner. Our findings suggest that this protein plays a major role in HBV infection.	TECNOGEN SCpA, I-81015 Caserta, CE, Italy; Univ Padua, Dipartimento Med Clin & Sperimentale, Clin Med 5, I-35128 Padua, Italy	University of Padua	Fassina, G (corresponding author), TECNOGEN SCpA, Parco Sci, I-81015 Caserta, CE, Italy.	fassina@tecnogen.it	De Falco, Sandro/P-6724-2015; Fassina, Giorgio/I-7127-2012; Raucci, Angela/K-3722-2018; PONTISSO, PATRIZIA/K-3574-2018	Fassina, Giorgio/0000-0003-1845-2657; De Falco, Sandro/0000-0002-6501-1697; PONTISSO, PATRIZIA/0000-0003-2077-9202; Raucci, Angela/0000-0003-1333-9671; ALBERTI, ALFREDO/0000-0001-9926-2382				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BIBB JA, 1994, J VIROL, V68, P6111, DOI 10.1128/JVI.68.9.6111-6115.1994; BOLANDER FF, 1994, J CELL PHYSIOL, V161, P124, DOI 10.1002/jcp.1041610115; Breiner KM, 1998, J VIROL, V72, P8098, DOI 10.1128/JVI.72.10.8098-8104.1998; BUDKOWSKA A, 1993, J VIROL, V67, P4316, DOI 10.1128/JVI.67.7.4316-4322.1993; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; De Falco S, 2001, J PEPT RES, V57, P390, DOI 10.1034/j.1399-3011.2001.00848.x; De Moliner L, 1998, GUT, V42, P856, DOI 10.1136/gut.42.6.856; FASSINA G, 1992, ARCH BIOCHEM BIOPHYS, V296, P137, DOI 10.1016/0003-9861(92)90555-B; FRANCO A, 1992, J EXP MED, V175, P1195, DOI 10.1084/jem.175.5.1195; FREISTADT MS, 1995, ANN NY ACAD SCI, V25, P37; GALLE PR, 1994, GASTROENTEROLOGY, V106, P664, DOI 10.1016/0016-5085(94)90700-5; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; Gong ZJ, 1999, HEPATOLOGY, V29, P576, DOI 10.1002/hep.510290238; GRIPON P, 1993, VIROLOGY, V192, P534, DOI 10.1006/viro.1993.1069; GUIDOTTI LG, 1995, J VIROL, V58, P945; HERTOGS K, 1993, VIROLOGY, V197, P549, DOI 10.1006/viro.1993.1628; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; HWANG SR, 1994, P NATL ACAD SCI USA, V74, P5463; KATO H, 1977, CANCER, V40, P1621, DOI 10.1002/1097-0142(197710)40:4<1621::AID-CNCR2820400435>3.0.CO;2-I; Kato H., 1992, SEROLOGICAL CANC MAR, P437; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Mabit H, 1996, J HEPATOL, V24, P403, DOI 10.1016/S0168-8278(96)80160-7; MANTERO G, 1991, CLIN CHEM, V37, P422; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MEHDI H, 1994, J VIROL, V68, P2415, DOI 10.1128/JVI.68.4.2415-2424.1994; MILLER RH, 1984, VIROLOGY, V137, P390, DOI 10.1016/0042-6822(84)90231-9; Nagai Yoshiyuki, 1993, Trends in Microbiology, V1, P81, DOI 10.1016/0966-842X(93)90112-5; Nawata S, 1997, ELECTROPHORESIS, V18, P784, DOI 10.1002/elps.1150180521; NAWATA S, 1995, ELECTROPHORESIS, V16, P1027, DOI 10.1002/elps.11501601173; NEURATH AR, 1986, CELL, V46, P429, DOI 10.1016/0092-8674(86)90663-X; NEURATH AR, 1994, VIROLOGY, V204, P475, DOI 10.1006/viro.1994.1558; NEURATH AR, 1990, VIROLOGY, V178, P631, DOI 10.1016/0042-6822(90)90368-2; NEURATH AR, 1992, J EXP MED, V176, P1561, DOI 10.1084/jem.176.6.1561; NEURATH AR, 1985, NATURE, V315, P154, DOI 10.1038/315154a0; NEURATH AR, 1992, J EXP MED, V175, P461, DOI 10.1084/jem.175.2.461; PONTISSO P, 1993, GASTROENTEROLOGY, V105, P1529, DOI 10.1016/0016-5085(93)90161-5; PONTISSO P, 1992, J GEN VIROL, V73, P2041, DOI 10.1099/0022-1317-73-8-2041; PONTISSO P, 1985, J MED VIROL, V17, P145, DOI 10.1002/jmv.1890170207; PONTISSO P, 1989, J VIROL, V63, P1981, DOI 10.1128/JVI.63.5.1981-1988.1989; PONTISSO P, 1989, VIROLOGY, V173, P522, DOI 10.1016/0042-6822(89)90564-3; QIAO M, 1994, VIROLOGY, V201, P356, DOI 10.1006/viro.1994.1301; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; RIJNTJES PJM, 1986, J HEPATOL, V3, P7, DOI 10.1016/S0168-8278(86)80140-4; ROJKIND M, 1980, J CELL BIOL, V87, P255, DOI 10.1083/jcb.87.1.255; RUVO M, 1999, PEPTIDES, V97, P537; Ryu CJ, 2000, J VIROL, V74, P110, DOI 10.1128/JVI.74.1.110-116.2000; Schick C, 1997, J BIOL CHEM, V272, P1849, DOI 10.1074/jbc.272.3.1849; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; SHIH CH, 1989, P NATL ACAD SCI USA, V86, P6323, DOI 10.1073/pnas.86.16.6323; SINCLAIR AJ, 1995, J VIROL, V69, P5461, DOI 10.1128/JVI.69.9.5461-5468.1995; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; SUREAU C, 1986, CELL, V47, P37, DOI 10.1016/0092-8674(86)90364-8; TAKEDA A, 1995, FEBS LETT, V359, P78, DOI 10.1016/0014-5793(94)01456-B; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; Tong SP, 1999, J VIROL, V73, P8696, DOI 10.1128/JVI.73.10.8696-8702.1999; TREICHEL U, 1994, J GEN VIROL, V75, P3021, DOI 10.1099/0022-1317-75-11-3021; Uemura Y, 2000, INT J CANCER, V89, P368, DOI 10.1002/1097-0215(20000720)89:4<368::AID-IJC9>3.0.CO;2-6	60	62	64	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36613	36623		10.1074/jbc.M102377200	http://dx.doi.org/10.1074/jbc.M102377200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11389143	hybrid			2022-12-27	WOS:000171194500075
J	Das, D; Scovell, WM				Das, D; Scovell, WM			The binding interaction of HMG-1 with the TATA-binding protein/TATA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILITY-GROUP PROTEIN-1; RNA-POLYMERASE-II; GROUP CHROMOSOMAL-PROTEINS; N-TERMINAL DOMAIN; TRANSCRIPTION FACTOR; DNA-BINDING; FUNCTIONAL DOMAINS; CORE DOMAIN; BOX DOMAINS; IN-VITRO	High mobility protein-1 (HMG-1) has been shown to regulate transcription by RNA polymerase II. In the context that it acts as a transcriptional repressor, it binds to the TATA-binding protein (TBP) to form the HMG-1/ TBP/TATA complex, which is proposed to inhibit the assembly of the preinitiation complex. By using electrophoretic mobility shift assays, we show that the acidic C-terminal domain of HMG-1 and the N terminus of human TBP are the domains that are essential for the formation of a stable HMG-1/TBP/TATA complex. HMG-1 binding increases the affinity of TBP for the TATA element by 20-fold, which is reflected in a significant stimulation of the rate of TBP binding, with little effect on the dissociation rate constant. In support of the binding target of HMG-1 being the N terminus of hTBP, the N-terminal polypeptide of human TBP competes with and inhibits HMG-1/TBP/TATA complex formation. Deletion of segments of the N terminus of human TBP was used to map the region(s) where HMG-1 binds. These findings indicate that interaction of HMG-1 with the Q-tract (amino acids 55-95) in hTBP is primarily responsible for stable complex formation. In addition, HMG-1 and the monoclonal antibody, 1C2, specific to the Q-tract, compete for the same site. Furthermore, calf thymus HMG-1 forms a stable complex with the TBP/TATA complex that contains TBP from either human or Drosophila but not yeast. This is again consistent with the importance of the Q-tract for this stable interaction and shows that the interaction extends over many species but does not include yeast TBP.	Bowling Green State Univ, Dept Chem, Bowling Green, OH 43403 USA; Bowling Green State Univ, Dept Biol Sci, Bowling Green, OH 43403 USA	University System of Ohio; Bowling Green State University; University System of Ohio; Bowling Green State University	Scovell, WM (corresponding author), Bowling Green State Univ, Dept Chem, Bowling Green, OH 43403 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM054357] Funding Source: NIH RePORTER; NIGMS NIH HHS [R15GM54357] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Carrozza MJ, 1998, J VIROL, V72, P6752, DOI 10.1128/JVI.72.8.6752-6757.1998; Ellwood KB, 2000, MOL CELL BIOL, V20, P4359, DOI 10.1128/MCB.20.12.4359-4370.2000; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; GE H, 1994, J BIOL CHEM, V269, P17136; Grasser KD, 1998, EUR J BIOCHEM, V253, P787, DOI 10.1046/j.1432-1327.1998.2530787.x; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HASHIMOTO S, 1992, NUCLEIC ACIDS RES, V20, P3788, DOI 10.1093/nar/20.14.3788; Henry RW, 1998, COLD SPRING HARB SYM, V63, P111, DOI 10.1101/sqb.1998.63.111; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Lu W, 2000, J BIOL CHEM, V275, P35006, DOI 10.1074/jbc.M004735200; MAJUMDAR A, 1991, NUCLEIC ACIDS RES, V19, P6643, DOI 10.1093/nar/19.23.6643; MAREKOV LN, 1984, BIOCHIM BIOPHYS ACTA, V789, P63, DOI 10.1016/0167-4838(84)90061-X; Mittal V, 1997, SCIENCE, V275, P1136, DOI 10.1126/science.275.5303.1136; NAKASHIMA K, 1995, GENE, V152, P209, DOI 10.1016/0378-1119(94)00681-H; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PUGH F, 1995, METHOD MOL BIOL, V37, P359; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SHEFLIN LG, 1993, BIOCHEMISTRY-US, V32, P3238, DOI 10.1021/bi00064a005; STELZER G, 1994, MOL CELL BIOL, V14, P4712, DOI 10.1128/MCB.14.7.4712; STROS M, 1994, FEBS LETT, V344, P201, DOI 10.1016/0014-5793(94)00364-5; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; Sutrias-Grau M, 1999, J BIOL CHEM, V274, P1628, DOI 10.1074/jbc.274.3.1628; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; Verrier CS, 1997, MOL ENDOCRINOL, V11, P1009, DOI 10.1210/me.11.8.1009; Weideman CA, 1997, J MOL BIOL, V271, P61, DOI 10.1006/jmbi.1997.1152; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; Wolner BS, 2001, J BIOL CHEM, V276, P6260, DOI 10.1074/jbc.M008273200; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x	57	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32597	32605		10.1074/jbc.M011792200	http://dx.doi.org/10.1074/jbc.M011792200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11390376	hybrid			2022-12-27	WOS:000170746000031
J	Billiard, J; Grewal, SS; Lukaesko, L; Stork, PJS; Rotwein, P				Billiard, J; Grewal, SS; Lukaesko, L; Stork, PJS; Rotwein, P			Hormonal control of insulin-like growth factor I gene transcription in human osteoblasts - Dual actions of cAMP-dependent protein kinase on CCAAT/enhancer-binding protein delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; FETAL-RAT BONE; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE CAMP; PARATHYROID-HORMONE; CATALYTIC SUBUNIT; RESPONSE ELEMENT; IGF-I; ENRICHED CULTURES; NUCLEAR-LOCALIZATION; C/EBP-BETA	Insulin-like growth factor-I (IGF-I) is essential for somatic growth and promotes bone cell replication and differentiation. IGF-I production by rat osteoblasts is stimulated by activation of cAMP-dependent protein kinase (PKA). In this report, we define two interacting PKA-regulated pathways that control IGF-I gene transcription in cultured human osteoblasts. Stimulation of cAMP led to a 12-fold increase in IGF-I mRNA and enhanced IGF-I promoter activity through a DNA response element termed HS3D and the transcription factor CCAAT/enhancer-binding protein delta (C/EBP delta). Under basal conditions, C/EBP delta was found in osteoblast nuclei but was transcriptionally silent. Treatment with the PKA inhibitor H-89 caused redistribution of C/EBP delta to the cytoplasm. After hormone treatment, the catalytic subunit of PKA accumulated in osteoblast nuclei. Inhibition of active PKA with targeted nuclear expression of PKA inhibitor had no effect on the subcellular location of C/EBP delta but prevented hormone-induced IGF-I gene activation, while cytoplasmic PKA inhibitor additionally caused the removal of C/EBP delta from the nucleus. These results show that IGF-I gene expression is controlled in human osteoblasts by two PKA-dependent pathways. Cytoplasmic PKA mediates nuclear localization of C/EBP delta under basal conditions, and nuclear PKA stimulates its transcriptional activity upon hormone treatment. Both mechanisms are indirect, since PKA failed to phosphorylate human C/EBP delta in vitro.	Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, Portland, OR 97201 USA; Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University	Rotwein, P (corresponding author), Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, 3181 SW Sam Jackson Pk Rd,Mail Code NRC3, Portland, OR 97201 USA.	rotweinp@ohsu.edu	Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NIDDK NIH HHS [5F32-DK09802, T32 DK007674, 5-RO1-DK37449] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007674, R01DK037449, F32DK009802] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BICHELL DP, 1993, ENDOCRINOLOGY, V133, P1020, DOI 10.1210/en.133.3.1020; Billiard J, 2001, J BIOL CHEM, V276, P15354, DOI 10.1074/jbc.M009973200; BURR DB, 1989, BONE, V10, P223, DOI 10.1016/8756-3282(89)90057-4; CANALIS E, 1988, ENDOCRINOLOGY, V122, P22, DOI 10.1210/endo-122-1-22; CANALIS E, 1988, CALCIFIED TISSUE INT, V43, P346, DOI 10.1007/BF02553277; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CHENU C, 1990, BONE, V11, P81, DOI 10.1016/8756-3282(90)90054-3; Dohrman DP, 1996, P NATL ACAD SCI USA, V93, P10217, DOI 10.1073/pnas.93.19.10217; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; Feliciello A, 2000, CELL GROWTH DIFFER, V11, P649; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo-122-1-254; HOWARD GA, 1981, P NATL ACAD SCI-BIOL, V78, P3204, DOI 10.1073/pnas.78.5.3204; Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KANZAKI S, 1995, J BONE MINER RES, V10, P854; KASSEM M, 1993, CALCIFIED TISSUE INT, V52, P222, DOI 10.1007/BF00298723; KIM SW, 1991, MOL ENDOCRINOL, V5, P1964, DOI 10.1210/mend-5-12-1964; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo-128-6-2895; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MIDDLETON J, 1995, BONE, V16, P287, DOI 10.1016/8756-3282(94)00040-9; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Mittanck DW, 1997, MOL CELL ENDOCRINOL, V126, P153, DOI 10.1016/S0303-7207(96)03979-2; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MUNDY GR, 1993, J BONE MINER RES, V8, pS505, DOI 10.1002/jbmr.5650081315; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1279, DOI 10.1210/endo-120-4-1279; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; Ohlsson C, 1998, EUR J CLIN INVEST, V28, P184; OKAZAKI R, 1995, BIOCHEM BIOPH RES CO, V207, P963, DOI 10.1006/bbrc.1995.1279; OKAZAKI R, 1995, J BONE MINER RES, V10, P788; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; RAAP AK, 1991, EXP CELL RES, V197, P319, DOI 10.1016/0014-4827(91)90439-2; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; Rittmaster RS, 2000, J CLIN ENDOCR METAB, V85, P2129, DOI 10.1210/jc.85.6.2129; ROTWEIN P, 1987, J BIOL CHEM, V262, P11807; SCHLECHTER NL, 1986, P NATL ACAD SCI USA, V83, P7932, DOI 10.1073/pnas.83.20.7932; SCHMID C, 1989, ENDOCRINOLOGY, V125, P1575, DOI 10.1210/endo-125-3-1575; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHINAR DM, 1993, ENDOCRINOLOGY, V132, P1158, DOI 10.1210/en.132.3.1158; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; STROM P, 1994, BIOCHEM BIOPH RES CO, V199, P78, DOI 10.1006/bbrc.1994.1196; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; Swolin D, 1996, J ENDOCRINOL, V149, P397, DOI 10.1677/joe.0.1490397; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; Umayahara Y, 1999, J BIOL CHEM, V274, P10609, DOI 10.1074/jbc.274.15.10609; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; Wiley JC, 1999, J BIOL CHEM, V274, P6381, DOI 10.1074/jbc.274.10.6381; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yin M, 1996, J BIOL CHEM, V271, P17974, DOI 10.1074/jbc.271.30.17974	62	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31238	31246		10.1074/jbc.M103634200	http://dx.doi.org/10.1074/jbc.M103634200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11390399	hybrid			2022-12-27	WOS:000170472900086
J	Kumari, M				Kumari, M			Differential effects of chronic ethanol treatment on N-methyl-D-aspartate R1 splice variants in fetal cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR SUBUNIT; MESSENGER-RNA EXPRESSION; MOLECULAR-BIOLOGY; GENE-EXPRESSION; TERMINAL DOMAIN; UP-REGULATION; NR1; BRAIN; POTENTIATION; ISOFORMS	Functional N-methyl-D-aspartate receptors consisting of NR1 and NR2 subunits are an important site of action of ethanol. Chronic ethanol treatment increases the NR1 polypeptide levels in vivo and in vitro. Chronic ethanol treatment in vitro does not significantly alter the NR1 mRNA levels, even though under similar culture conditions ethanol (50 mM, 5 days) enhances the half-life of NR1 mRNA in fetal cortical neurons. To address this phenomenon, we determined by reverse transcription-polymerase chain reaction and Western blotting whether ethanol (50 mM, 5 days) has a splice variant-specific effect on the expression of the NR1 subunit in mouse fetal cortical neurons. This report analyzes for the first time the distribution of all NR1 splice variants in these neurons. Our data indicate the presence of NR1-3a,b and NR1-4a,b splice variants in cortical neurons. Chronic, ethanol treatment significantly decreased the mRNA levels of exon 5-containing NR1 splice variants (NR1-3b and NR1-4b) (-E5/+E5 = 4.6 in untreated neurons and 6.1 in ethanol-treated neurons) and had no effect on the mRNA levels of NR1-3 (+E21/-E22) and NR1-4 (-E21/-E22) splice variants. At the polypeptide level,. chronic ethanol treatment significantly reduced exon 5-containing splice variants (NR1-3b and NR1-4b). However, ethanol (50 mm, 5 days) induced a significant increase in polypeptide levels of NR1-4 (-E21/-E22), without any effect on NR1-3 (+E21/-E22) polypeptide levels. These results demonstrate that chronic ethanol treatment, has a selective effect on the expression of NR1 splice variants at both the mRNA and polypeptide levels in mouse fetal cortical neurons.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Kumari, M (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA.	kumari@uthscsa.edu			NIAAA NIH HHS [AA12070] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012070] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Danysz W, 1998, PHARMACOL REV, V50, P597; Darstein MB, 2000, N-S ARCH PHARMACOL, V361, P206, DOI 10.1007/s002109900180; Dunn RJ, 1999, J EXP BIOL, V202, P1319; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; Ehlers MD, 1998, J NEUROSCI, V18, P720; FOLLESA P, 1995, MOL BRAIN RES, V29, P99, DOI 10.1016/0169-328X(94)00235-7; Follesa P, 1996, J BIOL CHEM, V271, P13297, DOI 10.1074/jbc.271.23.13297; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; Hardy PA, 1999, BRAIN RES, V819, P33, DOI 10.1016/S0006-8993(98)01340-7; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hollmann M., 1999, V141, P3; HOLLMANN M, 1994, RENAL PHYSIOL BIOCH, V17, P182; Hu XJ, 1996, MOL BRAIN RES, V36, P211, DOI 10.1016/0169-328X(95)00223-F; Katsura M, 1995, MOL BRAIN RES, V34, P355, DOI 10.1016/0169-328X(95)00192-U; Kumari M, 1998, J NEUROCHEM, V70, P1467; Kumari M, 2000, PROG DRUG RES, V54, P152; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; LAURIE DJ, 1995, MOL BRAIN RES, V32, P94, DOI 10.1016/0169-328X(95)00067-3; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; Logan SM, 1999, J NEUROSCI, V19, P974; Lovinger DM, 1996, ALCOHOL CLIN EXP RES, V20, pA187, DOI 10.1111/j.1530-0277.1996.tb01773.x; MHATRE MC, 1992, MOL PHARMACOL, V42, P415; MONTPIED P, 1991, MOL PHARMACOL, V39, P157; MORI H, 1995, NEUROPHARMACOLOGY, V34, P1219, DOI 10.1016/0028-3908(95)00109-J; Okabe S, 1999, J NEUROSCI, V19, P7781; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIGNS SA, 1994, MOL CELL BIOCHEM, V139, P21, DOI 10.1007/BF00944199; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TREVISAN L, 1994, J NEUROCHEM, V62, P1635; VEDOVA FD, 1994, NEUROREPORT, V5, P581; Vezzani A, 1995, EUR J NEUROSCI, V7, P2513, DOI 10.1111/j.1460-9568.1995.tb01050.x; Weiss SW, 1998, J NEUROSCI, V18, P1725; Winkler A, 1999, MOL BRAIN RES, V72, P166, DOI 10.1016/S0169-328X(99)00218-1; Ying Z, 1998, J NEUROPATH EXP NEUR, V57, P47; ZHANG L, 1994, P NATL ACAD SCI USA, V91, P10883, DOI 10.1073/pnas.91.23.10883; ZHENG X, 1994, NEURON, V12, P811; ZHONG J, 1995, J NEUROCHEM, V64, P531; ZUKIN RS, 1995, TRENDS NEUROSCI, V18, P306, DOI 10.1016/0166-2236(95)93920-S	41	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29764	29771		10.1074/jbc.M100317200	http://dx.doi.org/10.1074/jbc.M100317200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11387318	hybrid			2022-12-27	WOS:000170558000023
J	Lee, SJ; Gralla, JD				Lee, SJ; Gralla, JD			Sigma38 (rpoS) RNA polymerase promoter engagement via-10 region on nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORK JUNCTION DNA; ESCHERICHIA-COLI; TRANSCRIPTION; RECOGNITION; GENE; SIGMA(38); SEQUENCE; SELECTIVITY; HOLOENZYME; GROWTH	Band shift assays using DNA probes that mimic closed and open complexes were used to explore the determinants of promoter recognition by sigma38 (rpoS) RNA polymerase. Duplex recognition was found to be much weaker than that observed in sigma70 promoter usage. However, binding to fork junction probes, which attempt to mimic melted DNA, was very strong. This binding occurs via the non-template strand with the identity of the two conserved junction nucleotides (-12T and -11A) being of paramount importance. A modified promoter consensus sequence identified these two nucleotides as among only four (underlined) that are highly conserved, and all four were in the -10 region (CTAcacT from -13 to -7). The remaining two nucleotides were shown to have different roles, -13C in pre-venting recognition by the heterologous sigma70 polymerase and -7T in directing enzyme isomerization. These -10 region nucleotides appear to have their primary function prior to fall melting because probes that had a melted start site were relatively insensitive to substitution at these positions. These results suggest the sigma38 mechanism differs from the sigma70 mechanism, and this difference likely contributes to selective use of sigma38 under conditions that exist during stationery phase.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gralla, JD (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, POB 951569, Los Angeles, CA 90095 USA.	gralla@chem.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35754] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1993, GENE, V132, P1, DOI 10.1016/0378-1119(93)90507-Y; ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; Becker G, 2001, MOL MICROBIOL, V39, P1153, DOI 10.1046/j.1365-2958.2001.02313.x; Bordes P, 2000, MOL MICROBIOL, V35, P845, DOI 10.1046/j.1365-2958.2000.01758.x; Chen YF, 1997, J MOL BIOL, V267, P47, DOI 10.1006/jmbi.1996.0853; Colland F, 1999, EMBO J, V18, P4049, DOI 10.1093/emboj/18.14.4049; Colland F, 2000, EMBO J, V19, P3028, DOI 10.1093/emboj/19.12.3028; Conter A, 1997, J MOL BIOL, V273, P75, DOI 10.1006/jmbi.1997.1308; DING QQ, 1995, MOL MICROBIOL, V16, P649, DOI 10.1111/j.1365-2958.1995.tb02427.x; Dombroski AJ, 1997, J BIOL CHEM, V272, P3487; EspinosaUrgel M, 1996, MOL MICROBIOL, V21, P657; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; FENTON MS, 2001, IN PRESS P NATL ACAD; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; Hengge-Aronis R, 1999, CURR OPIN MICROBIOL, V2, P148, DOI 10.1016/S1369-5274(99)80026-5; Hiratsu K, 1995, MOL MICROBIOL, V18, P841, DOI 10.1111/j.1365-2958.1995.18050841.x; Kusano S, 1996, J BIOL CHEM, V271, P1998, DOI 10.1074/jbc.271.4.1998; Kusano S, 1997, J BACTERIOL, V179, P3649, DOI 10.1128/jb.179.11.3649-3654.1997; LISSER S, 1993, NUCLEIC ACIDS RES, V21, P1507, DOI 10.1093/nar/21.7.1507; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Marschall C, 1998, J MOL BIOL, V276, P339, DOI 10.1006/jmbi.1997.1533; Matlock DL, 2000, BIOCHEMISTRY-US, V39, P12274, DOI 10.1021/bi001433h; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Nguyen LH, 1997, BIOCHEMISTRY-US, V36, P1748, DOI 10.1021/bi961175h; OHLSEN KL, 1992, MOL MICROBIOL, V6, P2243, DOI 10.1111/j.1365-2958.1992.tb01400.x; Qi HY, 1997, J MOL BIOL, V267, P481, DOI 10.1006/jmbi.1997.0901; Schellhorn HE, 1998, J BACTERIOL, V180, P6283; TANAKA K, 1995, NUCLEIC ACIDS RES, V23, P827, DOI 10.1093/nar/23.5.827; TANAKA K, 1993, P NATL ACAD SCI USA, V90, P3511, DOI 10.1073/pnas.90.8.3511; Villarroya M, 1998, EMBO J, V17, P1829, DOI 10.1093/emboj/17.6.1829; Wilson C, 1997, J MOL BIOL, V267, P60, DOI 10.1006/jmbi.1997.0875; Wise A, 1996, J BACTERIOL, V178, P2785, DOI 10.1128/jb.178.10.2785-2793.1996; Xu JM, 1997, J MOL BIOL, V270, P346, DOI 10.1006/jmbi.1997.1133	34	77	80	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30064	30071		10.1074/jbc.M102886200	http://dx.doi.org/10.1074/jbc.M102886200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11375988	hybrid			2022-12-27	WOS:000170558000062
J	Niiro, N; Ikebe, M				Niiro, N; Ikebe, M			Zipper-interacting protein kinase induces Ca2+-free smooth muscle contraction via myosin light chain phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULUS-SPECIFIC PATTERNS; OKADAIC ACID; SERINE/THREONINE KINASE; PHOSPHATASE INHIBITOR; CALYCULIN-A; RHO-KINASE; CALCIUM; CA-2+; ARTERY; ACTIVATION	The inhibition of myosin phosphatase evokes smooth muscle contraction in the absence of Ca2+, yet the underlying mechanisms are not understood. To this end, we have cloned smooth muscle zipper-interacting pro. tein (ZIP) kinase cDNA. ZIP kinase is present in various smooth muscle tissues including arteries. Triton X-100 skinning did not diminish ZIP kinase content, suggesting that ZIP kinase associates with the filamentous component in smooth muscle. Smooth muscle ZIP kinase phosphorylated smooth muscle myosin as well as the isolated 20-kDa myosin light chain in a Ca2+/calmodulin-independent manner. ZIP kinase phosphorylated myosin light chain at both Ser(19) and Thr(18) residues with the same rate constant. The actin-activated ATPase activity of myosin increased significantly following ZIP kinase-induced phosphorylation. Introduction of ZIP kinase into Triton X-100-permeabilized rabbit mesenteric artery provoked a Ca2+-free contraction. A protein phosphatase inhibitor, microcystin LR, also induced contraction in the absence of Ca2+, which was accompanied by an increase in both mono- and diphosphorylation of myosin light chain. The observed sensitivity of the microcystin-induced contraction to various protein kinase inhibitors was identical to the sensitivity of isolated ZIP kinase to these inhibitors. These results suggest that ZIP kinase is responsible for Ca2+ independent myosin phosphorylation and contraction in smooth muscle.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061426, R01HL060831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61426, HL60831] Funding Source: Medline; NIAMS NIH HHS [AR41653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; COLBURN JC, 1988, J BIOL CHEM, V263, P19166; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; EDELMAN AM, 1990, MOL CELL BIOCHEM, V97, P87; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; GERTHOFFER WT, 1989, AM J PHYSIOL, V257, pC1062, DOI 10.1152/ajpcell.1989.257.6.C1062; GONG MC, 1992, J BIOL CHEM, V267, P21492; GONG MC, 1992, J BIOL CHEM, V267, P14662; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; HIGHASHIHARA M, 1989, J BIOL CHEM, V264, P5218; HIRANO K, 1989, BRIT J PHARMACOL, V98, P1261, DOI 10.1111/j.1476-5381.1989.tb12672.x; HORI M, 1991, FEBS LETT, V285, P145, DOI 10.1016/0014-5793(91)80745-O; IKEBE M, 1987, J BIOL CHEM, V262, P9569; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; IKEBE M, 1987, J BIOL CHEM, V262, P13828; IKEBE M, 1985, J BIOL CHEM, V260, P27; Ikebe M, 1996, BIOCHEM BIOPH RES CO, V225, P370, DOI 10.1006/bbrc.1996.1182; ISHIHARA H, 1989, J PHARMACOL EXP THER, V250, P388; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KARAKI H, 1988, EUR J PHARMACOL, V151, P325, DOI 10.1016/0014-2999(88)90817-5; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; Komatsu S, 2000, J BIOL CHEM, V275, P34512, DOI 10.1074/jbc.M003019200; Komatsu S, 1996, BIOCHEM BIOPH RES CO, V223, P741, DOI 10.1006/bbrc.1996.0966; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; MASUO M, 1994, J GEN PHYSIOL, V104, P265, DOI 10.1085/jgp.104.2.265; MORGAN JP, 1984, J PHYSIOL-LONDON, V351, P155, DOI 10.1113/jphysiol.1984.sp015239; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; NISHIMURA J, 1988, BIOCHEM BIOPH RES CO, V157, P677, DOI 10.1016/S0006-291X(88)80303-6; OBARA K, 1989, PFLUG ARCH EUR J PHY, V414, P134, DOI 10.1007/BF00580954; OZAKI H, 1987, J PHARMACOL EXP THER, V243, P1167; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PERSECHINI A, 1986, J BIOL CHEM, V261, P6293; REMBOLD CM, 1988, CIRC RES, V63, P593, DOI 10.1161/01.RES.63.3.593; SETO M, 1990, PFLUG ARCH EUR J PHY, V415, P484, DOI 10.1007/BF00373627; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; SINGER HA, 1990, AM J PHYSIOL, V259, pC631, DOI 10.1152/ajpcell.1990.259.4.C631; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUZUKI A, 1993, BRIT J PHARMACOL, V109, P703, DOI 10.1111/j.1476-5381.1993.tb13631.x; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TOKUI T, 1995, BIOCHEMISTRY-US, V34, P5173, DOI 10.1021/bi00015a031; Van Eyk JE, 1998, J BIOL CHEM, V273, P23433, DOI 10.1074/jbc.273.36.23433; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; Weber LP, 1999, J PHYSIOL-LONDON, V516, P805, DOI 10.1111/j.1469-7793.1999.0805u.x; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016	53	141	153	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29567	29574		10.1074/jbc.M102753200	http://dx.doi.org/10.1074/jbc.M102753200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384979	hybrid			2022-12-27	WOS:000170346000122
J	Hamilton, SR; Yao, SYM; Ingram, JC; Hadden, DA; Ritzel, MWL; Gallagher, MP; Henderson, PJF; Cass, CE; Young, JD; Baldwin, SA				Hamilton, SR; Yao, SYM; Ingram, JC; Hadden, DA; Ritzel, MWL; Gallagher, MP; Henderson, PJF; Cass, CE; Young, JD; Baldwin, SA			Subcellular distribution and membrane topology of the mammalian concentrative Na+-nucleoside cotransporter rCNT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; GLUCOSE-TRANSPORTER; PYRIMIDINE NUCLEOSIDES; TRANSMEMBRANE SEGMENTS; ADENOSINE RECEPTORS; PURINE NUCLEOSIDES; MOLECULAR-CLONING; XENOPUS-LAEVIS; PROTEINS; SYSTEM	The rat transporter rCNT1 is the archetype of a family of concentrative nucleoside transporters (CNTs) found both in eukaryotes and in prokaryotes. In the present study we have used antibodies to investigate the subcellular distribution and membrane topology of this protein. rCNT1 was found to be expressed predominantly in the brush-border membranes of the polarized epithelial cells of rat jejunum and renal cortical tubules and in the bile canalicular membranes of liver parenchymal cells, consistent with roles in the absorption of dietary nucleosides, of nucleosides in the glomerular filtrate, or of nucleosides arising from the action of extracellular nucleotidases, respectively. The effect of endoglycosidase F treatment on wild-type and mutant rCNT1 expressed in Xenopus oocytes revealed that the recombinant transporter could be glycosylated at either or both of Asn(605) and Asn(643), indicating that its C terminus is extracellular. In contrast, potential N-glycosylation sites introduced near the N terminus, or between putative transmembrane (TM) helices 4 and 5, were not glycosylated. The deduced orientation of the N terminus in the cytoplasm was confirmed by immunocytochemistry on intact and saponin-permeabilized Chinese hamster ovary cells expressing recombinant rCNT1. These results, in conjunction with extensive analyses of CNT family protein sequences using predictive algorithms, lead us to propose a revised topological model, in which rCNT1 possesses 13 TM helices with the hydrophilic N-terminal and C-terminal domains on the cytoplasmic and extracellular sides of the membrane, respectively. Furthermore, we show that the first three TM helices, which are absent from prokaryote CNTs, are not essential for transporter function; truncated proteins lacking these helices, derived either from rCNT1 or from its human homolog hCNT1, were found to retain significant sodium-dependent uridine transport activity when expressed in oocytes.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Alberta, Dept Physiol, Membrane Transport Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 2H7, Canada	University of Leeds; University of Edinburgh; University of Alberta; University of Alberta	Baldwin, SA (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.	s.a.balswin@leeds.ac.uk	Gallagher, Maurice P/A-3781-2014; Henderson, Peter JF/Q-1907-2018; Cass, Carol E/F-5861-2010	Henderson, Peter/0000-0002-9187-0938				Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; CASS CE, 1999, MEMBRANE TRANSPORTER, P313; CHE MX, 1992, J BIOL CHEM, V267, P9684; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; DAVIES A, 1990, BIOCHEM J, V266, P799; Felipe A, 1998, BIOCHEM J, V330, P997, DOI 10.1042/bj3300997; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; Hamilton SR, 1997, J PHYSIOL-LONDON, V499P, pP50; HASPEL HC, 1985, J BIOL CHEM, V260, P7219; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; Iseki K, 1996, BBA-BIOMEMBRANES, V1278, P105, DOI 10.1016/0005-2736(95)00198-0; Kaiser SM, 1999, DRUG DISCOV TODAY, V4, P542, DOI 10.1016/S1359-6446(99)01421-X; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; LEHIR M, 1990, RENAL PHYSIOL BIOCH, V13, P154; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Loewen SK, 1999, J BIOL CHEM, V274, P24475, DOI 10.1074/jbc.274.35.24475; Mackey JR, 1998, DRUG RESIST UPDATE, V1, P310, DOI 10.1016/S1368-7646(98)80047-2; MOSELEY RH, 1991, AM J PHYSIOL, V261, pG716, DOI 10.1152/ajpgi.1991.261.5.G716; MURRAY AW, 1971, ANNU REV BIOCHEM, V40, P811, DOI 10.1146/annurev.bi.40.070171.004115; Patil SD, 1997, AM J PHYSIOL-GASTR L, V272, pG1314, DOI 10.1152/ajpgi.1997.272.6.G1314; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Ritzel MWL, 1998, MOL MEMBR BIOL, V15, P203; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; RODEN M, 1991, GASTROENTEROLOGY, V100, P1553, DOI 10.1016/0016-5085(91)90652-2; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; RUIZMONTASELL B, 1992, J MEMBRANE BIOL, V128, P227; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; THORENS B, 1990, AM J PHYSIOL, V259, pC286; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wang J, 1999, J BIOL CHEM, V274, P2298, DOI 10.1074/jbc.274.4.2298; Wang J, 1997, PHARM RES-DORDR, V14, P1524, DOI 10.1023/A:1012113931332; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; YOUNG JD, 2000, GASTROINTESTINAL TRA, P329	41	78	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27981	27988		10.1074/jbc.M100518200	http://dx.doi.org/10.1074/jbc.M100518200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375981	hybrid			2022-12-27	WOS:000170093400033
J	Takatsu, H; Katoh, Y; Shiba, Y; Nakayama, K				Takatsu, H; Katoh, Y; Shiba, Y; Nakayama, K			Golgi-localizing, gamma-adaptin ear homology domain, ADP-ribosylation factor-binding (GGA) proteins interact with acidic dileucine sequences within the cytoplasmic domains of sorting receptors through their Vps27p/Hrs/STAM (VHS) domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI; ARF PROTEINS; FAMILY; IDENTIFICATION; TRAFFICKING; LOCALIZATION; NETWORK; PATHWAY; FURIN; SITE	GGA (Golgi-localizing, <(<gamma>)under bar>-adaptin ear homology domain, ARF-binding) proteins are potential effectors of ADP-ribosylation factors, are associated with the trans-Golgi network (TGN), and are involved in protein transport from this compartment. By yeast two-hybrid screening and subsequent two-hybrid and pull-down analyses, we have shown that GGA proteins, through their VHS (Vps27p/Hrs/STAM) domains, interact with acidic dileucine sequences found in the cytoplasmic domains of TGN-localized sorting receptors such as sortilin and mannose 6-phosphate receptor. A mutational analysis has revealed that a leucine pair and a cluster of acidic residues adjacent to the pair are mainly responsible for the interaction. A chimeric receptor with the sortilin cytoplasmic domain localizes to the TGN, whereas the chimeric receptor with a mutation at the leucine pair or the acidic cluster is mislocalized to punctate structures reminiscent of early endosomes. These results indicate that GGA proteins regulate the localization to or exit from the TGN of the sorting receptors.	Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan; Univ Tsukuba, Gene Expt Ctr, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba; University of Tsukuba	Nakayama, K (corresponding author), Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan.	kazunaka@sakura.cc.tsukuba.ac.jp	Shiba, Yoko/AAX-3885-2020; Katoh, Yohei/AAA-3378-2020; Nakayama, Kazuhisa/ABF-2924-2020	Shiba, Yoko/0000-0001-8229-541X; Katoh, Yohei/0000-0003-1649-4917; Nakayama, Kazuhisa/0000-0001-7701-7183				Black MW, 2000, J CELL BIOL, V151, P587, DOI 10.1083/jcb.151.3.587; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; Chen HJ, 1997, J BIOL CHEM, V272, P7003, DOI 10.1074/jbc.272.11.7003; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Futatsumori M, 2000, J BIOCHEM-TOKYO, V128, P793, DOI 10.1093/oxfordjournals.jbchem.a022817; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; HORAZDOVSKY BF, 1995, CURR OPIN CELL BIOL, V7, P544, DOI 10.1016/0955-0674(95)80012-3; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Ishii H, 1998, GENOMICS, V51, P132, DOI 10.1006/geno.1998.5339; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; Lohi O, 1998, FEBS LETT, V440, P255, DOI 10.1016/S0014-5793(98)01401-X; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; Misra S, 2000, BIOCHEMISTRY-US, V39, P11282, DOI 10.1021/bi0013546; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Poussu A, 2000, J BIOL CHEM, V275, P7176, DOI 10.1074/jbc.275.10.7176; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Takatsu H, 1998, J BIOL CHEM, V273, P24693, DOI 10.1074/jbc.273.38.24693; TORII S, 1995, J BIOL CHEM, V270, P11574, DOI 10.1074/jbc.270.19.11574; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Zhdankina O, 2001, YEAST, V18, P1, DOI 10.1002/1097-0061(200101)18:1<1::AID-YEA644>3.0.CO;2-5	32	160	170	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28541	28545		10.1074/jbc.C100218200	http://dx.doi.org/10.1074/jbc.C100218200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11390366	hybrid			2022-12-27	WOS:000170093400106
J	Ufret-Vincenty, CA; Baro, DJ; Lederer, WJ; Rockman, HA; Quinones, LE; Santana, LF				Ufret-Vincenty, CA; Baro, DJ; Lederer, WJ; Rockman, HA; Quinones, LE; Santana, LF			Role of sodium channel deglycosylation in the genesis of cardiac arrhythmias in heart failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT; MOLECULAR-GENETICS; IONIC CURRENTS; DYNAMIC-MODEL; SUDDEN-DEATH; CALCIUM; EXPRESSION; MECHANISM; MUTATION; DOMAIN	We investigated the cellular and molecular mechanisms underlying arrhythmias in heart failure. A genetically engineered mouse lacking the expression of the muscle LIM protein (MLP-/-) was used in this study as a model of heart failure. We used electrocardiography and patch clamp techniques to examine the electrophysiological properties of MLP-/- hearts. We found that MLP-/- myocytes had smaller Na+ currents with altered voltage dependencies of activation and inactivation and slower rates of inactivation than control myocytes. These changes in Na+ currents contributed to longer action potentials and to a higher probability of early afterdepolarizations in MLP-/- than in control myocytes. Western blot analysis suggested that the smaller Na+ current in MLP-/- myocytes resulted from a reduction in Na+ channel protein. Interestingly, the blots also revealed that the a-subunit of the Na+ channel from the MLP-/- heart had a lower average molecular weight than in the control heart. Treating control myocytes with the sialidase neuraminidase mimicked the changes in voltage dependence and rate of inactivation of Na+ currents observed in MLP-/- myocytes. Neuraminidase had no effect on MLP-/- cells thus suggesting that Na+ channels in these cells were sialic acid-deficient. We conclude that deficient glycosylation of Na+ channel contributes to Na+ current-dependent arrhythmogenesis in heart failure.	Univ Puerto Rico, Inst Neurobiol, San Juan, PR 00901 USA; Univ Puerto Rico, Dept Biochem, San Juan, PR 00936 USA; Univ Maryland, Sch Med, Ctr Med Biotechnol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Duke Univ, Med Ctr, Dept Med & Cell Biol, Durham, NC 27710 USA	University of Puerto Rico; University of Puerto Rico; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Duke University	Santana, LF (corresponding author), Univ Washington, Dept Physiol & Biophys, Box 357290, Seattle, WA 98195 USA.	lsantana@neurobio.upr.clu.edu	Santana, Luis/AAF-9298-2019; Lederer, William/B-1285-2010	Santana, Luis/0000-0002-4297-8029; 	NCRR NIH HHS [G12RR-03051] Funding Source: Medline; NHLBI NIH HHS [R01 HL67927] Funding Source: Medline; NINDS NIH HHS [R01 NS38770, 1 U54 NS39405-02] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U54NS039405, R01NS038770] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Baro DJ, 2000, J NEUROSCI, V20, P6619, DOI 10.1523/JNEUROSCI.20-17-06619.2000; Bennett E, 1997, J GEN PHYSIOL, V109, P327, DOI 10.1085/jgp.109.3.327; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; BEUCKELMANN DJ, 1993, CIRC RES, V73, P379, DOI 10.1161/01.RES.73.2.379; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Esposito G, 2000, AM J PHYSIOL-HEART C, V279, pH3101, DOI 10.1152/ajpheart.2000.279.6.H3101; FRANKENHAEUSER B, 1957, J PHYSIOL-LONDON, V137, P218, DOI 10.1113/jphysiol.1957.sp005808; George AL, 1996, NEPHROL DIAL TRANSPL, V11, P1730; HILLE B, 1975, J PHYSIOL-LONDON, V250, pP34; Kaab S, 1998, CIRCULATION, V98, P1383, DOI 10.1161/01.CIR.98.14.1383; Kambouris NG, 2000, J CLIN INVEST, V105, P1133, DOI 10.1172/JCI9212; KANNEL WB, 1988, AM HEART J, V115, P869, DOI 10.1016/0002-8703(88)90891-5; Kass RS, 1996, CARDIOVASC RES, V32, P443, DOI 10.1016/S0008-6363(96)00122-8; KASS RS, 1978, J PHYSIOL-LONDON, V281, P187, DOI 10.1113/jphysiol.1978.sp012416; Knollmann BC, 2000, J PHYSIOL-LONDON, V525, P483, DOI 10.1111/j.1469-7793.2000.t01-1-00483.x; London B, 1998, P NATL ACAD SCI USA, V95, P2926, DOI 10.1073/pnas.95.6.2926; LUO CH, 1994, CIRC RES, V74, P1097, DOI 10.1161/01.RES.74.6.1097; LUO CH, 1994, CIRC RES, V74, P1071, DOI 10.1161/01.RES.74.6.1071; MA TS, 1979, CARDIOVASC RES, V13, P568, DOI 10.1093/cvr/13.10.568; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; O'Rourke B, 1999, CIRC RES, V84, P562, DOI 10.1161/01.RES.84.5.562; Pak PH, 1997, J AM COLL CARDIOL, V30, P576, DOI 10.1016/S0735-1097(97)00193-9; Pogwizd SM, 1999, CIRC RES, V85, P1009; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Russell MW, 1996, CURR OPIN CARDIOL, V11, P45, DOI 10.1097/00001573-199601000-00008; Sanguinetti MC, 1997, NEUROPHARMACOLOGY, V36, P755, DOI 10.1016/S0028-3908(97)00029-4; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Santana LF, 1997, J PHYSIOL-LONDON, V503, P21, DOI 10.1111/j.1469-7793.1997.021bi.x; Satler CA, 1996, AM J MED GENET, V65, P27, DOI 10.1002/(SICI)1096-8628(19961002)65:1<27::AID-AJMG4>3.3.CO;2-J; Wang DW, 1996, P NATL ACAD SCI USA, V93, P13200, DOI 10.1073/pnas.93.23.13200; Wattanasirichaigoon Duangrurdee, 1998, Current Opinion in Pediatrics, V10, P628; Wehrens XHT, 2000, CIRCULATION, V102, P584; Wilde AAM, 1997, PACE, V20, P2048, DOI 10.1111/j.1540-8159.1997.tb03625.x; Zhang Y, 1999, J MEMBRANE BIOL, V171, P195, DOI 10.1007/s002329900571; Zolk O, 2000, CIRCULATION, V101, P2674, DOI 10.1161/01.CIR.101.23.2674	36	101	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28197	28203		10.1074/jbc.M102548200	http://dx.doi.org/10.1074/jbc.M102548200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369778	hybrid			2022-12-27	WOS:000170093400062
J	Furuta, M; Zhou, A; Webb, G; Carroll, R; Ravazzola, M; Orci, L; Steiner, DF				Furuta, M; Zhou, A; Webb, G; Carroll, R; Ravazzola, M; Orci, L; Steiner, DF			Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PANCREATIC-ISLETS; PROPROTEIN CONVERTASES; PC2; GLUCAGON; PEPTIDES; LOCALIZATION; PROINSULIN; EXPRESSION; MECHANISM; SEQUENCE	Mice homozygous for a deletion in the gene encoding prohormone convertase 2 (PC2) are generally healthy but have mild hypoglycemia and flat glucose-tolerance curves. Their islets show marked alpha (A)-cell hyperplasia, suggesting a possible defect in glucagon processing (Furuta, M., Yano, H., Zhou, A., Rouille, Y,, Holst, J., Carroll, R., Ravazzola, M., Orci, L., Furuta, H., and Steiner, D. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 6646-6651). In this report we have examined the biosynthesis and processing of proglucagon in isolated islets from these mice via pulse-chase labeling and find that proglucagon undergoes essentially no processing in chase periods up to 8 h in duration. Only a small percent of cleavage at the sensitive interdomain site (residues 71 and 72) appears to occur. These observations thus conclusively demonstrate the essentiality of PC2 for the production of glucagon in the islet A-cells, Ultrastructural and immunocytochemical studies indicate the presence of large amounts of proglucagon in atypical appearing secretory granules in the hyperplastic and hypertrophic A-cells, along with morphological evidence of high rates of proglucagon secretion in PC2 null islets. These findings provide strong evidence that active glucagon is required to maintain normal blood glucose levels, counterbalancing the action of insulin at all times.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Geneva, Sch Med, Dept Morphol, CH-1211 Geneva, Switzerland	University of Chicago; Howard Hughes Medical Institute; University of Chicago; University of Geneva	Steiner, DF (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 5841 S Maryland Ave, Chicago, IL 60637 USA.			Zhou, An/0000-0002-9358-8012	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013914, R01DK013914, P60DK020595] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK13914, DK 20595] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRETT A, 1998, HDB PROTEOLYTIC ENZY, P342; BELL GI, 1983, NATURE, V302, P716, DOI 10.1038/302716a0; Berman Y, 2000, J NEUROCHEM, V75, P1763, DOI 10.1046/j.1471-4159.2000.0751763.x; Brand CL, 1996, DIABETES, V45, P1076, DOI 10.2337/diabetes.45.8.1076; Day R, 1998, J BIOL CHEM, V273, P829, DOI 10.1074/jbc.273.2.829; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Dhanvantari S, 1996, MOL ENDOCRINOL, V10, P342, DOI 10.1210/me.10.4.342; Furuta M, 1998, J BIOL CHEM, V273, P3431, DOI 10.1074/jbc.273.6.3431; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; HEINRICH G, 1984, J BIOL CHEM, V259, P4082; HOLST JJ, 1994, J BIOL CHEM, V269, P18827; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; LERNMARK A, 1976, J CELL BIOL, V71, P606, DOI 10.1083/jcb.71.2.606; MARCINKIEWICZ M, 1994, ENDOCRINOLOGY, V135, P1651, DOI 10.1210/en.135.4.1651; MAXWELL MH, 1978, J MICROSC-OXFORD, V112, P253, DOI 10.1111/j.1365-2818.1978.tb01174.x; Muller L, 2000, PROG NUCLEIC ACID RE, V63, P69, DOI 10.1016/S0079-6603(08)60720-5; PAZELT C, 1979, NATURE, V282, P260; Rothenberg ME, 1996, MOL ENDOCRINOL, V10, P331, DOI 10.1210/me.10.4.331; Rouille Y, 1997, FEBS LETT, V413, P119, DOI 10.1016/S0014-5793(97)00892-2; Rouille Y, 1997, J BIOL CHEM, V272, P32810, DOI 10.1074/jbc.272.52.32810; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; ROUILLE Y, 1995, J BIOL CHEM, V270, P26488, DOI 10.1074/jbc.270.44.26488; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; Tanaka S, 1996, ARCH HISTOL CYTOL, V59, P261, DOI 10.1679/aohc.59.261; Viale A, 1999, J BIOL CHEM, V274, P6536, DOI 10.1074/jbc.274.10.6536; Villeneuve P, 2000, J COMP NEUROL, V424, P461, DOI 10.1002/1096-9861(20000828)424:3<461::AID-CNE5>3.0.CO;2-J; Wang J, 2001, DIABETES, V50, P534, DOI 10.2337/diabetes.50.3.534; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	32	126	128	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27197	27202		10.1074/jbc.M103362200	http://dx.doi.org/10.1074/jbc.M103362200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356850	hybrid			2022-12-27	WOS:000169966900063
J	Liu, LH; Boivin, GP; Prasad, V; Periasamy, M; Shull, GE				Liu, LH; Boivin, GP; Prasad, V; Periasamy, M; Shull, GE			Squamous cell tumors in mice heterozygous for a null allele of Atp2a2, encoding the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 Ca2+ pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE CALCIUM; DARIERS-DISEASE; MOUSE KERATINOCYTES; GENE-EXPRESSION; ACINAR-CELLS; SERCA2 GENE; THAPSIGARGIN; CARCINOMA; DIFFERENTIATION; PROMOTER	Mutations in the human ATP2A2 gene, encoding sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 (SERCA2), cause Darier disease, an autosomal dominant skin disease characterized by multiple keratotic papules in the seborrheic regions of the body. Mice with a single functional Atp2a2 allele (the mouse homolog of ATP2A2) were shown previously to have reduced levels of SERCA2 in heart and mildly impaired cardiac contractility and relaxation, Here we show that aged heterozygous mutant (Atp2a2(+/-)) mice develop squamous cell tumors of the forestomach, esophagus, oral mucosa, tongue, and skin, Squamous cell tumors occurred in 13/14 Atp2a2(+/-) mice but were not observed in age- and sex-matched wild-type controls. Hyperkeratinized squamous cell papillomas and carcinomas of the upper digestive tract were the most frequent finding among Atp2a2(+/-) mice, and many animals had multiple tumors. Western blot analyses showed that SERCA2 protein levels were reduced in skin and other affected tissues of heterozygous mice. The development of squamous cell tumors in aged Atp2a2(+/-) mice indicates that SERCA2 haploinsufficiency predisposes murine keratinocytes to neoplasia, These findings provide the first direct demonstration that a perturbation of Ca2+ homeostasis or signaling can serve as a primary initiating event in cancer.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Physiol & Cell Biol, Columbus, OH 43210 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; Ohio State University	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.			Periasamy, Muthu/0000-0001-8834-5975	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382, R01HL064140, R01HL061974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050594, R37DK050594] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64140, HL61974, TG-HL07382] Funding Source: Medline; NIDDK NIH HHS [DK50594] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BURGE SM, 1992, J AM ACAD DERMATOL, V27, P40, DOI 10.1016/0190-9622(92)70154-8; Cheng GM, 1996, ARCH BIOCHEM BIOPHYS, V329, P65, DOI 10.1006/abbi.1996.0192; COLE K, 1994, CANCER METAST REV, V13, P31, DOI 10.1007/BF00690417; Downs AMR, 1997, CLIN EXP DERMATOL, V22, P277; Gafter U, 1997, J LAB CLIN MED, V130, P33, DOI 10.1016/S0022-2143(97)90056-1; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HAKII H, 1986, J CANCER RES CLIN, V111, P177, DOI 10.1007/BF00389230; HASEMAN JK, 1999, PATHOLOGY MOUSE, P679; Ji Y, 2000, J BIOL CHEM, V275, P38073, DOI 10.1074/jbc.M004804200; JONES KT, 1994, EXP CELL RES, V210, P71, DOI 10.1006/excr.1994.1011; KOHN EC, 1995, CANCER RES, V55, P1856; KRUSZEWSKI FH, 1991, AM J PHYSIOL, V261, pC767, DOI 10.1152/ajpcell.1991.261.5.C767; LI LW, 1995, CELL GROWTH DIFFER, V6, P1171; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LINU JM, 1998, J CELL BIOL, V142, P963; Lowry DT, 1996, CARCINOGENESIS, V17, P699, DOI 10.1093/carcin/17.4.699; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MITTING H, 1900, J CUTAN PATHOL, V17, P388; ORIHUELA E, 1995, J UROLOGY, V153, P1940, DOI 10.1016/S0022-5347(01)67363-4; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; PETERSEN CCH, 1993, J BIOL CHEM, V268, P22262; Rodland KD, 1997, MOL ENDOCRINOL, V11, P281, DOI 10.1210/me.11.3.281; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; SCHWEIZER J, 1988, CELL TISSUE RES, V253, P221; Shimizu H, 2000, EUR J DERMATOL, V10, P470; Shull GE, 2000, EUR J BIOCHEM, V267, P5284, DOI 10.1046/j.1432-1327.2000.01568.x; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; Wu YG, 1997, CLIN CANCER RES, V3, P1915	31	84	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26737	26740		10.1074/jbc.C100275200	http://dx.doi.org/10.1074/jbc.C100275200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11389134	hybrid			2022-12-27	WOS:000169966900002
J	Wang, XS; Babu, JR; Harden, JM; Jablonski, SA; Gazi, MH; Lingle, WL; de Groen, PC; Yen, TJ; van Deursen, JMA				Wang, XS; Babu, JR; Harden, JM; Jablonski, SA; Gazi, MH; Lingle, WL; de Groen, PC; Yen, TJ; van Deursen, JMA			The mitotic checkpoint protein hBUB3 and the mRNA export factor hRAE1 interact with GLE2p-binding sequence (GLEBS)-containing proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; SPINDLE ASSEMBLY CHECKPOINT; POLE BODY DUPLICATION; NUCLEOCYTOPLASMIC TRANSPORT; BUDDING YEAST; RNA EXPORT; FISSION YEAST; GENE; KINETOCHORES; RAN	The mRNA export factor RAE1 (also called GLE2) and the mitotic checkpoint protein BUB3 share extensive sequence homology in yeast as well as higher eukaryotes, although the biological relevance of their similarity is unclear. Previous work in HeLa cells has shown that human (h)RAE1 binds the nuclear pore complex protein hNUP98 via a short NUP98 motif called GLEBS (for GLE2p-binding Sequence). Here we report that the two known binding partners of hBUB3, the mitotic checkpoint proteins hBUB1 and hBUBR1, both carry a region with remarkable similarity to the GLEBS motif of hNUP98. We show that the GLEBS-like motifs of mouse (m)BUB1 and mBUBR1 are sufficient for mBUB3 binding. mBUB3 lacks affinity for the hNUP98 GLEBS, demonstrating its binding specificity for GLEBS motifs of mitotic checkpoint proteins. Interestingly, mRAE1 does not exclusively bind to the GLEBS motif of hNUP98 and can cross-interact with the mBUB1 GLEBS. We show that full-length RAE1 and BUB1 proteins interact in mammalian cells and accumulate both at the kinetochores of prometaphase chromosomes. Our findings demonstrate that GLEBS motifs reside in mammalian nucleoporins and mitotic checkpoint proteins and apparently serve as specific binding sites for either BUB3, RAE1, or both.	Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; Mayo Clin, Dept Expt Pathol, Rochester, MN 55905 USA; Mayo Clin, Dept Gastroenterol & Hepatol, Rochester, MN 55905 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Fox Chase Cancer Center	van Deursen, JMA (corresponding author), Mayo Clin, Dept Pediat & Adolescent Med, 200 1st St SW, Rochester, MN 55905 USA.			Ramesh Babu, Jeganathan/0000-0002-3719-932X; Yen, Tim/0000-0003-2159-0997	NATIONAL CANCER INSTITUTE [P30CA021765, R01CA077262] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765, R01 CA77262-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bailer SM, 1998, EMBO J, V17, P1107, DOI 10.1093/emboj/17.4.1107; Bernard P, 1998, J CELL BIOL, V143, P1775, DOI 10.1083/jcb.143.7.1775; BROWN JA, 1995, J BIOL CHEM, V270, P7411, DOI 10.1074/jbc.270.13.7411; Burke DJ, 2000, CURR OPIN GENET DEV, V10, P26, DOI 10.1016/S0959-437X(99)00040-4; Campbell MS, 2001, J CELL SCI, V114, P953; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Chan GKT, 2000, NAT CELL BIOL, V2, P944, DOI 10.1038/35046598; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CHOI YD, 1984, P NATL ACAD SCI-BIOL, V81, P7471, DOI 10.1073/pnas.81.23.7471; Davenport JW, 1999, GENOMICS, V55, P113, DOI 10.1006/geno.1998.5629; Farr KA, 1998, MOL CELL BIOL, V18, P2738, DOI 10.1128/MCB.18.5.2738; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kraemer D, 1997, P NATL ACAD SCI USA, V94, P9119, DOI 10.1073/pnas.94.17.9119; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Martinez-Exposito MJ, 1999, P NATL ACAD SCI USA, V96, P8493, DOI 10.1073/pnas.96.15.8493; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; NEER EJ, 1994, METHOD ENZYMOL, V237, P226; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Pritchard CEJ, 1999, J CELL BIOL, V145, P237, DOI 10.1083/jcb.145.2.237; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; vanDeursen J, 1996, EMBO J, V15, P5574, DOI 10.1002/j.1460-2075.1996.tb00942.x; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Whalen WA, 1997, YEAST, V13, P1167, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1167::AID-YEA154>3.3.CO;2-F; Wiese C, 2001, SCIENCE, V291, P653, DOI 10.1126/science.1057661; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; WINEY M, 1991, COLD SH Q B, V56, P705; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Zhang CM, 1999, J CELL SCI, V112, P2453	50	98	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26559	26567		10.1074/jbc.M101083200	http://dx.doi.org/10.1074/jbc.M101083200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352911	hybrid			2022-12-27	WOS:000169823300120
J	Motteran, L; Pilone, MS; Molla, G; Ghisla, S; Pollegioni, L				Motteran, L; Pilone, MS; Molla, G; Ghisla, S; Pollegioni, L			Cholesterol oxidase from Brevibacterium sterolicum - The relationship between covalent flavinylation and redox properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-HYGROSCOPICUS; CRYSTAL-STRUCTURE; FAD-BINDING; FAMILY	Brevibacterium sterolicum possesses two forms of cholesterol oxidase, one containing noncovalently bound FAD, the second containing a FAD covalently linked to His(69) of the protein backbone. The functional role of the histidyl-FAD bond in the latter cholesterol oxidase was addressed by studying the properties of the H69A mutant in which the FAD is bound tightly, but not covalently, and by comparison with native enzyme. The mutant retains catalytic activity, but with a turnover rate decreased 35-fold; the isomerization step of the intermediate 3-ketosteroid to the final product is also preserved. Stabilization of the flavin semiquinone and binding of sulfite are markedly decreased, this correlates with a lower midpoint redox potential (-204 mV compared with -101 mV for wild-type). Reconstitution with 8-chloro-FAD led to a holoenzyme form of H69A cholesterol oxidase with a midpoint redox potential of -160 mV, In this enzyme form, flavin semiquinone is newly stabilized, and a 3.5-fold activity increase is observed, this mimicking the thermodynamic effects induced by the covalent flavin linkage. It is concluded that the flavin 8 alpha -linkage to a (Nl)histidine is a pivotal factor in the modulation of the redox properties of this cholesterol oxidase to increase its oxidative power.	Univ Insubria, Dept Struct & Funct Biol, I-21100 Varese, Italy; Univ Constance, Fac Biol, D-78434 Constance, Germany	University of Insubria; University of Konstanz	Pollegioni, L (corresponding author), Univ Insubria, Dept Struct & Funct Biol, Via JH Dunant 3, I-21100 Varese, Italy.	loredano.pollegioni@uninsubria.it		Molla, Gianluca/0000-0003-3688-3397; POLLEGIONI, LOREDANO/0000-0003-1733-7243				[Anonymous], [No title captured]; CAVENER DR, 1992, J MOL BIOL, V223, P811, DOI 10.1016/0022-2836(92)90992-S; Clark W.M., 1960, OXIDATION REDUCTION, P184; Croteau N, 1996, J STRUCT BIOL, V116, P317, DOI 10.1006/jsbi.1996.0047; EDMONDSON DE, 1973, J BIOL CHEM, V248, P8144; Fraaije MW, 1999, J BIOL CHEM, V274, P35514, DOI 10.1074/jbc.274.50.35514; Fraaije MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9; Gadda G, 1997, EUR J BIOCHEM, V250, P369, DOI 10.1111/j.1432-1033.1997.0369a.x; GHISLA S, 1986, BIOCHEM J, V239, P1; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; KASS IJ, 1995, BIOCHEM BIOPH RES CO, V206, P688, DOI 10.1006/bbrc.1995.1097; MacLachlan J, 2000, J STEROID BIOCHEM, V72, P169, DOI 10.1016/S0960-0760(00)00044-3; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; MASSEY V, 1964, FED PROC, V3, P18; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; MULLER F, 1991, CHEM BIOCH FLAVOENZY, V1, P261; Mullis K B, 1991, PCR Methods Appl, V1, P1; Pollegioni L, 1999, BIOTECHNOL APPL BIOC, V30, P27; Pollegioni L, 1999, EUR J BIOCHEM, V264, P140, DOI 10.1046/j.1432-1327.1999.00586.x; Sampson NS, 1998, BIOCHEMISTRY-US, V37, P5770, DOI 10.1021/bi973067g; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; VRIELINK A, 1991, J MOL BIOL, V219, P533, DOI 10.1016/0022-2836(91)90192-9; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WILLIAMSON G, 1985, BIOCHEMISTRY-US, V24, P7790, DOI 10.1021/bi00347a043; Yue QK, 1999, BIOCHEMISTRY-US, V38, P4277, DOI 10.1021/bi982497j	27	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18024	18030		10.1074/jbc.M010953200	http://dx.doi.org/10.1074/jbc.M010953200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359791	Green Published, hybrid			2022-12-27	WOS:000168866500055
J	Santiago-Garcia, J; Mas-Oliva, J; Innerarity, TL; Pitas, RE				Santiago-Garcia, J; Mas-Oliva, J; Innerarity, TL; Pitas, RE			Secreted forms of the amyloid-beta precursor protein are ligands for the class A scavenger receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SULFATE PROTEOGLYCAN FORM; BOVINE SERUM-ALBUMIN; ALZHEIMERS-DISEASE; NEXIN-II; INHIBITORY PROPERTIES; IN-VIVO; MACROPHAGE; BINDING; CELLS	Upon activation, platelets secrete a 120-kDa protein that competes for the binding and internalization of acetyl low density lipoproteins (AcLDL) by macrophages. From the amino-terminal amino acid sequence, amino acid composition, and immunoblot analysis, we identified the active factor in platelet secretion products as sAPP, an alpha -secretase cleavage product of the beta -amyloid precursor protein (APP), that contains a Kunitz-type protease inhibitor (KPI) domain. We showed that both sAPP751 (also called Nexin II) and sAPP695, which does not contain a KPI domain, are ligands for the class A scavenger receptor (SR-A). Chinese hamster ovary cells stably transfected to express the SR-A bound and internalized 4-fold more human platelet-derived sAPP than control cells. The binding and internalization of sAPP were inhibited by the SR-A antagonist fucoidin. In addition, sAPP competed as effectively as fucoidin for SR-A-mediated cell association and degradation of I-125-AcLDL. To determine if the KPI domain is required for the binding of sAPP to the SR-A, APP751 and APP695 were expressed in Chinese hamster ovary cells, and sAPP751 and sAPP695 purified from the medium were tested for their binding to the SR-A. sAPP751 and sAPP695 were equally effective in competing for the cell association of I-125-AeLDL by SR-A-expressing cells, demonstrating that the KPI domain is not essential for binding. We also found that sAPP751 is present in extracts of atherosclerotic lesions and that sAPP competes for the SR-A-mediated cell association of oxidized low density lipoprotein. Deletion mutagenesis indicated that a negatively charged region of APP (residues 191-264) contributes to binding to the SR-A. These results suggest that the SR-A contributes to the clearance of sAPP and that sAPP competes for the cell association of other SR-A ligands.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Natl Autonomous Univ Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidad Nacional Autonoma de Mexico	Pitas, RE (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, POB 418100, San Francisco, CA 94141 USA.			Santiago-Garcia, Juan/0000-0003-1737-0270	NIA NIH HHS [AG13619] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013619] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARNOLD KS, 1992, LIPOPROTEIN ANAL PRA, P145; Babaev VR, 2000, ARTERIOSCL THROM VAS, V20, P2593, DOI 10.1161/01.ATV.20.12.2593; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BELL MD, 1994, J NEUROCYTOL, V23, P605, DOI 10.1007/BF01191555; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUSH AI, 1990, J BIOL CHEM, V265, P15977; Christie RH, 1996, AM J PATHOL, V148, P399; DEJAGER S, 1993, ARTERIOSCLER THROMB, V13, P371, DOI 10.1161/01.ATV.13.3.371; DRESEL HA, 1987, EMBO J, V6, P319, DOI 10.1002/j.1460-2075.1987.tb04757.x; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAASS C, 1991, J NEUROSCI, V11, P3783; Henry A, 1997, PROTEIN EXPRES PURIF, V10, P283, DOI 10.1006/prep.1997.0748; Huang F, 1999, AM J PATHOL, V155, P1741, DOI 10.1016/S0002-9440(10)65489-2; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MASOLIVA J, 1994, J BIOL CHEM, V269, P10177; MCGEER PL, 1992, J NEUROSCI RES, V31, P428, DOI 10.1002/jnr.490310305; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; OTTNAD E, 1990, BIOCHEM J, V265, P689, DOI 10.1042/bj2650689; OTTNAD E, 1992, BIOCHEM J, V281, P745, DOI 10.1042/bj2810745; Pangalos MN, 1996, NEURODEGENERATION, V5, P445, DOI 10.1006/neur.1996.0061; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PHILLIPS DR, 1985, NATURE, V316, P746, DOI 10.1038/316746a0; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; REFOLO LM, 1989, BIOCHEM BIOPH RES CO, V164, P664, DOI 10.1016/0006-291X(89)91511-8; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; Sakaguchi H, 1998, LAB INVEST, V78, P423; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIOI J, 1995, J BIOL CHEM, V270, P11839, DOI 10.1074/jbc.270.20.11839; SHIOI J, 1992, J BIOL CHEM, V267, P13819; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SINHA S, 1990, J BIOL CHEM, V265, P8983; SMITH RP, 1992, BLOOD, V80, P2252; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1991, BIOCHEM BIOPH RES CO, V175, P15, DOI 10.1016/S0006-291X(05)81193-3; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1991, P NATL ACAD SCI USA, V88, P10302, DOI 10.1073/pnas.88.22.10302; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; VanVelzen AG, 1997, BIOCHEM J, V322, P411; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Yan SD, 1999, AM J PATHOL, V155, P1403, DOI 10.1016/S0002-9440(10)65452-1	58	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30655	30661		10.1074/jbc.M102879200	http://dx.doi.org/10.1074/jbc.M102879200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11389145	hybrid			2022-12-27	WOS:000170472900011
J	Anthonsen, MW; Solhaug, A; Johansen, B				Anthonsen, MW; Solhaug, A; Johansen, B			Functional coupling between secretory and cytosolic phospholipase A(2) modulates tumor necrosis factor-alpha- and interleukin-1 beta-induced NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONIC-ACID RELEASE; SIGNAL-TRANSDUCTION; HUMAN NEUTROPHILS; CELL-LINE; GROUP-IIA; P388D(1) MACROPHAGES; TRANSCRIPTION FACTOR; PROSTAGLANDIN D-2; MAST-CELLS	Tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 beta are potent activators of the transcription factor NF-kappaB, induced during inflammatory conditions. We have previously shown that both secretory and cytosolic phospholipase A(2) (PLA(2)) are involved in TNF-alpha- and IL-1 beta -induced NF-kappaB activation. In this study, we have addressed the mechanism of PLA, involvement with respect to downstream arachidonic acid (AA) metabolites and the functional coupling between PLA(2)s mediating NF-kappaB activation. We show that in addition to inhibitors of secretory and cytosolic PLA2s, 5-lipoxygenase inhibitors attenuate TNF-alpha- and IL-1 beta -stimulated NF-KB activation. Exogenous addition of leukotriene B-4 (LTB4) restored NF-kappaB activation reduced by 5-lipoxygenase inhibitors or an LTB4 receptor antagonist, thus identifying LTB4 as a mediator in signaling to NF-kappaB. TNF-alpha- and IL-1 beta -induced AA release from cellular membranes was accompanied by phosphorylation of cytosolic PLA(2). Inhibitors of secretory PLA(2) and of 5-lipoxygenase/LTB4 functionality markedly reduced AA release and nearly completely abolished cytosolic PLA2 phosphorylation. This demonstrates that secretory PLA(2) through 5-lipoxygenase metabolites, is an essential upstream regulator of cytosolic PLA2 and AA release. Our results therefore suggest the existence of a functional link between secretory and cytosolic PLA2 in cytokine-activated keratinocytes, providing a molecular explanation for the participation of both secretory and cytosolic PLA(2) in arachidonic acid signaling and NF-KB activation in response to proinflammatory cytokines.	Norwegian Univ Sci & Technol, Fac Chem & Biol, Ctr Mol Biol, UNIGEN, N-7489 Trondheim, Norway	Norwegian University of Science & Technology (NTNU)	Anthonsen, MW (corresponding author), Norwegian Univ Sci & Technol, Fac Chem & Biol, Ctr Mol Biol, UNIGEN, N-7489 Trondheim, Norway.		Solhaug, Anita/AAJ-1063-2020	Solhaug, Anita/0000-0002-1908-406X				Al-Aoukaty A, 1999, J IMMUNOL, V162, P3249; Andersen S, 1996, SARCOIDOSIS VASC DIF, V13, P70; ANDERSEN S, 1994, INFLAMMATION, V18, P1, DOI 10.1007/BF01534593; Anthonsen MW, 2000, ARTERIOSCL THROM VAS, V20, P1276, DOI 10.1161/01.ATV.20.5.1276; Ashraf MDM, 1996, BIOCHEM BIOPH RES CO, V229, P726, DOI 10.1006/bbrc.1996.1872; Baek SH, 2000, J IMMUNOL, V164, P6359, DOI 10.4049/jimmunol.164.12.6359; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Bidgood MJ, 2000, J IMMUNOL, V165, P2790, DOI 10.4049/jimmunol.165.5.2790; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; Burgermeister E, 1999, EUR J PHARMACOL, V369, P373, DOI 10.1016/S0014-2999(99)00011-4; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen F, 1999, CLIN CHEM, V45, P7; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cho W, 2000, BBA-MOL CELL BIOL L, V1488, P48, DOI 10.1016/S1388-1981(00)00109-8; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DEJONG EMGJ, 1992, CLIN EXP DERMATOL, V17, P413; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; Flati V, 1996, EMBO J, V15, P1566, DOI 10.1002/j.1460-2075.1996.tb00501.x; FURSTENBERGER G, 1981, CANCER LETT, V11, P191, DOI 10.1016/0304-3835(81)90107-5; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hernandez M, 1999, J NEUROCHEM, V73, P1641, DOI 10.1046/j.1471-4159.1999.0731641.x; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; HERRON DK, 1992, J MED CHEM, V35, P1818, DOI 10.1021/jm00088a018; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang Z., 1994, MEDIAT INFLAMM, V3, P307; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; JAKOBSSON PJ, 1992, P NATL ACAD SCI USA, V89, P3521, DOI 10.1073/pnas.89.8.3521; JANSSENTIMMEN U, 1995, P NATL ACAD SCI USA, V92, P6966, DOI 10.1073/pnas.92.15.6966; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, J BIOL CHEM, V267, P23451; Lin WW, 1999, BRIT J PHARMACOL, V126, P1419, DOI 10.1038/sj.bjp.0702436; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; Marshall LA, 1997, J BIOL CHEM, V272, P759, DOI 10.1074/jbc.272.2.759; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; METTERS KM, 1995, J LIPID MEDIAT CELL, V12, P413, DOI 10.1016/0929-7855(95)00027-N; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; OFlaherty JT, 1996, J BIOL CHEM, V271, P17821, DOI 10.1074/jbc.271.30.17821; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Schadow A, 2001, J INVEST DERMATOL, V116, P31, DOI 10.1046/j.1523-1747.2001.00179.x; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; Sjursen W, 2000, CYTOKINE, V12, P1189, DOI 10.1006/cyto.1999.0727; Spanbroek R, 1998, P NATL ACAD SCI USA, V95, P663, DOI 10.1073/pnas.95.2.663; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Syrbu SI, 1999, J IMMUNOL, V162, P2334; Takasaki J, 1998, J IMMUNOL, V160, P5066; Terry CM, 1999, AM J PHYSIOL-HEART C, V276, pH1493, DOI 10.1152/ajpheart.1999.276.5.H1493; Thommesen L, 1998, J IMMUNOL, V161, P3421; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; WEIDTMANN A, 1995, ARTERIOSCL THROM VAS, V15, P1131, DOI 10.1161/01.ATV.15.8.1131; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	93	74	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30527	30536		10.1074/jbc.M008481200	http://dx.doi.org/10.1074/jbc.M008481200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390371	hybrid			2022-12-27	WOS:000170558000121
J	Lauber, K; Appel, HAE; Schlosser, SF; Gregor, M; Schulze-Osthoff, K; Wesselborg, S				Lauber, K; Appel, HAE; Schlosser, SF; Gregor, M; Schulze-Osthoff, K; Wesselborg, S			The adapter protein apoptotic protease-activating factor-1 (Apaf-1) is proteolytically processed during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INDUCED APOPTOSIS; WD-40 REPEAT REGION; CYTOCHROME-C; CASPASE ACTIVATION; CELL-DEATH; PROCASPASE-9 ACTIVATION; BCL-2 FAMILY; COMPLEX; CASPASE-8/FLICE; OLIGOMERIZATION	Apoptotle protease-activating factor-1 (Apaf-1), a key regulator of the mitochondrial apoptosis pathway, consists of three functional regions. (i) an N-terminal caspase recruitment domain (CARD) that can bind to procaspase-9, (ii) a CED-4-like region enabling self-oligomerization, and (iii) a regulatory C terminus with WD-40 repeats masking the CARD and CED-4 region. During apoptosis, cytochrome c and dATP can relieve the inhibitory action of the WD-40 repeats and thus enable the oligomerization of Apaf-1 and the subsequent recruitment and activation of procaspase-9. Here, we report that different apoptotic stimuli induced the caspase-mediated cleavage of Apaf-1 into an 84-kDa fragment. The same Apaf-1 fragment was obtained in vitro by incubation of cell lysates with either cytochrome c/dATP or caspase-3 but not with caspase-6 or caspase-8. Apaf-1 was cleaved at the N terminus, leading to the removal of its CARD HI helix. An additional cleavage site was located within the WD-40 repeats and enabled the oligomerization of p84 into a similar to 440-kDa Apaf-1 multimer even in the absence of cytochrome c. Due to the partial loss of its CARD, the p84 multimer was devoid of caspase-9 or other caspase activity. Thus, our data indicate that Apaf-1 cleavage causes the release of caspases from the apoptosome in the course of apoptosis.	Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany; Univ Munster, Dept Immunol & Cell Biol, D-48149 Munster, Germany	Eberhard Karls University of Tubingen; University of Munster	Wesselborg, S (corresponding author), Univ Tubingen, Dept Internal Med 1, Otfried Muller Str 10, D-72076 Tubingen, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Wesselborg, Sebastian/0000-0002-5236-942X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; Bantel H, 1999, CANCER RES, V59, P2083; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Bratton SB, 2001, CELL DEATH DIFFER, V8, P425, DOI 10.1038/sj.cdd.4400834; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Day CL, 1999, CELL DEATH DIFFER, V6, P1125, DOI 10.1038/sj.cdd.4400584; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	50	68	71	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29772	29781		10.1074/jbc.M101524200	http://dx.doi.org/10.1074/jbc.M101524200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11387322	hybrid			2022-12-27	WOS:000170558000024
J	Pacello, F; Langford, PR; Kroll, JS; Indiani, C; Smulevich, G; Desideri, A; Rotilio, G; Battistoni, A				Pacello, F; Langford, PR; Kroll, JS; Indiani, C; Smulevich, G; Desideri, A; Rotilio, G; Battistoni, A			A novel heme protein, the Cu,Zn-superoxide dismutase from Haemophilus ducreyi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; COPPER-BINDING; CLONING; VIRULENCE; BACTERIAL; MUTANTS; PEROXIDASE; ENZYME	Haemophilus ducreyi, the causative agent of the genital ulcerative disease known as chancroid, is unable to synthesize heme, which it acquires from humans, its only known host. Here we provide evidence that the periplasmic Cu,Zn-superoxide dismutase from this organism is a heme-binding protein, unlike all the other known Cu,Zn-superoxide dismutases from bacterial and eukaryotic species. When the H. ducreyi enzyme was expressed in Escherichia coli cells, grown in standard LB medium, it contained only limited amounts of heme covalently bound to the polypeptide but was able efficiently to bind exogenously added hemin. Resonance Raman and electronic spectra at neutral pH indicate that H. ducreyi Cu,Zn-superoxide dismutase contains a 6-coordinated low spin heme, with two histidines as the most likely axial ligands. By site-directed mutagenesis and analysis of a structural model of the enzyme, we identified as a putative axial ligand a histidine residue (His-64) that is present only in the H. ducreyi enzyme and that was located at the bottom of the dimer interface. The introduction of a histidine residue in the corresponding position of the Cu,Zn-superoxide dismutase from Haemophilus parainfluenzae was not sufficient to confer the ability to bind heme, indicating that other residues neighboring His-64 are involved in the formation of the heme-binding pocket. Our results suggest that periplasmic Cu,Zn-superoxide dismutase plays a role in heme metabolism of H. ducreyi and provide further evidence for the structural flexibility of bacterial enzymes of this class.	Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Univ Roma Tor Vergata, INFM, I-00133 Rome, Italy; Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Sch Med, Dept Paediat,Mol Infect Dis Grp, London W2 1PG, England; Univ Florence, Dipartimento Chim, I-50121 Florence, Italy	University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Rome Tor Vergata; Imperial College London; University of Florence	Battistoni, A (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Via Ric Sci, I-00133 Rome, Italy.	andrea.battistoni@uniroma2.it	Battistoni, Andrea/A-4778-2016; smulevich, giulietta/A-6510-2008; Langford, Paul/AAU-4189-2020; Langford, Paul R/B-9092-2008	Battistoni, Andrea/0000-0003-4085-7917; Langford, Paul/0000-0002-6368-4724; Langford, Paul R/0000-0002-6368-4724; desideri, alessandro/0000-0003-1541-4217				Al-Tawfiq JA, 2000, J INFECT DIS, V181, P1049, DOI 10.1086/315309; Banci L, 2000, BIOCHEMISTRY-US, V39, P9108, DOI 10.1021/bi000067z; Battistoni A, 1998, BIOCHEM BIOPH RES CO, V243, P804, DOI 10.1006/bbrc.1998.8182; Battistoni A, 1996, BIOCHEM J, V320, P713, DOI 10.1042/bj3200713; Battistoni A, 1998, J BIOL CHEM, V273, P5655, DOI 10.1074/jbc.273.10.5655; BATTISTONI A, 1995, FEBS LETT, V374, P199, DOI 10.1016/0014-5793(95)01106-O; Battistoni A, 1999, FEBS LETT, V443, P313, DOI 10.1016/S0014-5793(98)01725-6; Battistoni A, 2001, J BIOL CHEM, V276, P30315, DOI 10.1074/jbc.M010527200; Bordo D, 1999, J MOL BIOL, V285, P283, DOI 10.1006/jmbi.1998.2267; BORDO D, 1994, J MOL BIOL, V238, P366, DOI 10.1006/jmbi.1994.1298; Bourne Y, 1996, P NATL ACAD SCI USA, V93, P12774, DOI 10.1073/pnas.93.23.12774; Brentjens RJ, 1996, J BACTERIOL, V178, P808, DOI 10.1128/jb.178.3.808-816.1996; CAMPAGNARI AA, 1991, INFECT IMMUN, V59, P2601, DOI 10.1128/IAI.59.8.2601-2608.1991; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CARRI MT, 1994, FEBS LETT, V356, P314, DOI 10.1016/0014-5793(94)01295-4; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; Cope LD, 1997, P NATL ACAD SCI USA, V94, P4056, DOI 10.1073/pnas.94.8.4056; D'Orazio M, 2000, BIOCHEM BIOPH RES CO, V272, P81, DOI 10.1006/bbrc.2000.2730; DeGroote MA, 1997, P NATL ACAD SCI USA, V94, P13997, DOI 10.1073/pnas.94.25.13997; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DePillis GD, 1997, J BIOL CHEM, V272, P8857; Di Iorio E E, 1981, Methods Enzymol, V76, P57; ELKINS C, 1995, INFECT IMMUN, V63, P1241, DOI 10.1128/IAI.63.4.1241-1245.1995; Fang FC, 1999, P NATL ACAD SCI USA, V96, P7502, DOI 10.1073/pnas.96.13.7502; Farrant JL, 1997, MOL MICROBIOL, V25, P785, DOI 10.1046/j.1365-2958.1997.5151877.x; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; Fiedler TJ, 2000, J BIOL CHEM, V275, P11964, DOI 10.1074/jbc.275.16.11964; Figueroa-Bossi N, 1999, MOL MICROBIOL, V33, P167, DOI 10.1046/j.1365-2958.1999.01461.x; Folcarelli S, 1998, BIOCHEM BIOPH RES CO, V244, P908, DOI 10.1006/bbrc.1998.8364; Forest KT, 2000, J MOL BIOL, V296, P145, DOI 10.1006/jmbi.1999.3448; Foti D, 1997, BIOCHEMISTRY-US, V36, P7109, DOI 10.1021/bi963020f; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.micro.48.1.743; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; KROLL JS, 1991, J BACTERIOL, V173, P7449, DOI 10.1128/jb.173.23.7449-7457.1991; KROLL JS, 1995, MICROBIOL-UK, V141, P2271, DOI 10.1099/13500872-141-9-2271; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langford PR, 1997, FEMS IMMUNOL MED MIC, V17, P235, DOI 10.1016/S0928-8244(97)00011-4; LEE BC, 1991, J MED MICROBIOL, V34, P317, DOI 10.1099/00222615-34-6-317; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; NAKAYASHIKI T, 1995, MOL GEN GENET, V249, P139, DOI 10.1007/BF00290359; Oxvig C, 1999, J BIOL CHEM, V274, P16953, DOI 10.1074/jbc.274.24.16953; Palmer KL, 1995, MOL MICROBIOL, V18, P821, DOI 10.1111/j.1365-2958.1995.18050821.x; Pesce A, 1997, J MOL BIOL, V274, P408, DOI 10.1006/jmbi.1997.1400; Pesce A, 2000, J MOL BIOL, V302, P465, DOI 10.1006/jmbi.2000.4074; PETTIGREW GW, 1990, CYTOCHROME C EVOLUTI; Sambrook J., 1989, MOL CLONING LABORATO, V3, pA3; San Mateo LR, 1998, MOL MICROBIOL, V27, P391, DOI 10.1046/j.1365-2958.1998.00687.x; San Mateo LR, 1999, INFECT IMMUN, V67, P5345, DOI 10.1128/IAI.67.10.5345-5351.1999; Smith L, 1978, Methods Enzymol, V53, P202; SMULEVICH G, 1991, BIOCHEMISTRY-US, V30, P9546, DOI 10.1021/bi00103a023; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; STEINMAN HM, 1990, J BACTERIOL, V172, P2901, DOI 10.1128/jb.172.6.2901-2910.1990; STRITTMATTER P, 1956, J BIOL CHEM, V221, P253; Stroppolo ME, 2000, FEBS LETT, V483, P17, DOI 10.1016/S0014-5793(00)01967-0; TATUM FM, 1992, INFECT IMMUN, V60, P2863, DOI 10.1128/IAI.60.7.2863-2869.1992; TELZAK EE, 1993, ANN INTERN MED, V119, P1181, DOI 10.7326/0003-4819-119-12-199312150-00005; Thomas CE, 1998, INFECT IMMUN, V66, P4254; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; TOTTEN PA, 1994, J CLIN MICROBIOL, V32, P2019, DOI 10.1128/JCM.32.8.2019-2023.1994; Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; Wilks KE, 1998, INFECT IMMUN, V66, P213, DOI 10.1128/IAI.66.1.213-217.1998	69	27	27	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30326	30334		10.1074/jbc.M010488200	http://dx.doi.org/10.1074/jbc.M010488200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11369755	hybrid			2022-12-27	WOS:000170558000095
J	Gardezi, SA; Nguyen, C; Malloy, PJ; Posner, GH; Feldman, D; Peleg, S				Gardezi, SA; Nguyen, C; Malloy, PJ; Posner, GH; Feldman, D; Peleg, S			A rationale for treatment of hereditary vitamin D-resistant rickets with analogs of 1 alpha,25-dihydroxyvitamin D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING DOMAIN; RETINOID-X-RECEPTOR; NUCLEAR RECEPTOR; LIGAND-BINDING; INDUCED HETERODIMERIZATION; 20-EPI ANALOGS; CELL-GROWTH; 1,25-DIHYDROXYVITAMIN-D; TRANSCRIPTION; ACTIVATION	Hereditary vitamin D-resistant rickets (HVDRR) is caused by heterogeneous inactivating mutations in the vitamin D receptor (VDR). Treatment of HVDRR patients with high doses of oral calcium and supraphysiologic doses of 1 alpha ,25-dihydroxyvitamin D-3 (1,25D(3)) has had limited success. In this study we explored the use of vitamin D analogs as a potential therapy for this disorder. The rationale for the use of vitamin D analogs is that they bind the VDR at different amino acid residues than 1,25D(3), and their ability to modulate VDR functions differs from that of the natural hormone. In this report, we examined the VDR from three HVDRR patients with mutations in the ligand-binding domain of the VDR (histidine 305 to glut mine, arginine 274 to leucine, and phenylalanine 251 to cysteine) for their responses to two vitamin D analogs, 20-epi-1,25D(3) and 1 beta -hydroxymethyl-3-epi-16-ene-26a,27a-bishomo-25D(3) (JK-1626-2). Our results reveal that vitamin D analogs partially or completely restore the responsiveness of the mutated VDR. Analog treatment seemed to be more successful when the mutation affects the amino acids directly involved in ligand binding rather than amino acids that contribute to a functional VDR interface with dimerization partners or coactivators of transcription.	Univ Texas, MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Johns Hopkins Univ, Dept Chem, Baltimore, MD 21218 USA	University of Texas System; UTMD Anderson Cancer Center; Stanford University; Johns Hopkins University	Peleg, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, 1515 Holcombe Blvd,Box 435, Houston, TX 77030 USA.				NCI NIH HHS [CA 44530] Funding Source: Medline; NIDDK NIH HHS [DK 50583, DK 42482] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042482, R56DK042482, R01DK050583] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arbour NC, 1998, ANAL BIOCHEM, V255, P148, DOI 10.1006/abio.1997.2439; BALSAN S, 1983, J CLIN ENDOCR METAB, V57, P803, DOI 10.1210/jcem-57-4-803; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; BINDERUP L, 1991, BIOCHEM PHARMACOL, V42, P1569, DOI 10.1016/0006-2952(91)90426-6; BLIZIOTES M, 1988, J CLIN ENDOCR METAB, V66, P294, DOI 10.1210/jcem-66-2-294; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; BROOKS MH, 1978, NEW ENGL J MED, V298, P996, DOI 10.1056/NEJM197805042981804; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; GARDEZI A, 2000, VITAMIN D ENDOCRINE, P931; Haussler M. R., 1997, Vitamin D., P149; HOCHBERG Z, 1992, J PEDIATR-US, V121, P803, DOI 10.1016/S0022-3476(05)81919-5; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; Jurutka PW, 2000, MOL ENDOCRINOL, V14, P401, DOI 10.1210/me.14.3.401; KRISTJANSSON K, 1993, J CLIN INVEST, V92, P12, DOI 10.1172/JCI116539; LIBERMAN UA, 1980, LANCET, V1, P504; Liu YY, 2000, MOL ENDOCRINOL, V14, P1776, DOI 10.1210/me.14.11.1776; Liu YY, 1997, J BIOL CHEM, V272, P3336, DOI 10.1074/jbc.272.6.3336; Malloy PJ, 1997, J CLIN INVEST, V99, P297, DOI 10.1172/JCI119158; Malloy PJ, 1999, ENDOCR REV, V20, P156, DOI 10.1210/er.20.2.156; MALLOY PJ, 1993, ENDOCRINOLOGY, V132, P1952; MALLOY PJ, 2001, IN PRESS MOL GENET M; MCDONNELL DP, 1989, MOL ENDOCRINOL, V3, P635, DOI 10.1210/mend-3-4-635; NAKAJIMA S, 1994, MOL ENDOCRINOL, V8, P159, DOI 10.1210/me.8.2.159; Norman AW, 1999, J CELL BIOCHEM, V74, P323, DOI 10.1002/(SICI)1097-4644(19990901)74:3<323::AID-JCB2>3.0.CO;2-V; Okamura W. H., 1997, Vitamin D., P939; Omdahl J., 1997, Vitamin D., P69; PELEG S, 1995, J BIOL CHEM, V270, P10551, DOI 10.1074/jbc.270.18.10551; Peleg S, 1998, MOL ENDOCRINOL, V12, P525, DOI 10.1210/me.12.4.525; PELEG S, 1994, VITAMIN D, P1011; RITCHIE HH, 1989, P NATL ACAD SCI USA, V86, P9783, DOI 10.1073/pnas.86.24.9783; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; ROSEN JF, 1979, J PEDIATR-US, V94, P729, DOI 10.1016/S0022-3476(79)80139-0; Vaisanen S, 1997, EUR J BIOCHEM, V248, P156, DOI 10.1111/j.1432-1033.1997.t01-1-00156.x; VAN ML, 1996, AM J MED GENET, V64, P506; Wecksler W R, 1980, Methods Enzymol, V67, P488; WHITFIELD GK, 1995, MOL ENDOCRINOL, V9, P1166, DOI 10.1210/me.9.9.1166; Yamamoto K, 2000, P NATL ACAD SCI USA, V97, P1467, DOI 10.1073/pnas.020522697; Yang W, 1999, J BIOL CHEM, V274, P16838, DOI 10.1074/jbc.274.24.16838; Zhao XY, 1997, MOL ENDOCRINOL, V11, P366, DOI 10.1210/me.11.3.366; ZHOU JY, 1989, BLOOD, V74, P82	41	35	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29148	29156		10.1074/jbc.M100898200	http://dx.doi.org/10.1074/jbc.M100898200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11369766	hybrid			2022-12-27	WOS:000170346000070
J	Griesbeck, O; Baird, GS; Campbell, RE; Zacharias, DA; Tsien, RY				Griesbeck, O; Baird, GS; Campbell, RE; Zacharias, DA; Tsien, RY			Reducing the environmental sensitivity of yellow fluorescent protein - Mechanism and applications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; LIVING CELLS; ENDOPLASMIC-RETICULUM; LIVE CELLS; IN-VIVO; CA2+; VARIANTS; PH; INDICATOR; BINDING	Yellow mutants of the green fluorescent protein (YFP) are crucial constituents of genetically encoded indicators of signal transduction and fusions to monitor protein-protein interactions. However, previous YFPs show excessive pH sensitivity, chloride interference, poor photostability, or poor expression at 37 degreesC. Protein evolution in Escherichia coli has produced a new YFP named Citrine, in which the mutation Q69M confers a much lower pK(a) (5.7) than for previous YFPs, indifference to chloride, twice the photostability of previous YFPs, and much better expression at 37 degreesC and in organelles. The halide resistance is explained by a 2.2-Angstrom x-ray crystal structure of Citrine, showing that the methionine side chain fills what was once a large halide-binding cavity adjacent to the chromophore. Insertion of calmodulin within Citrine or fusion of cyan fluorescent protein, calmodulin, a calmodulin-binding peptide and Citrine has generated improved calcium indicators. These chimeras can be targeted to multiple cellular locations and have permitted the first single-cell imaging of free [Ca2+] in the Golgi. Citrine is superior to all previous YFPs except when pH or halide sensitivity is desired and is particularly advantageous within genetically encoded fluorescent indicators of physiological signals.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Med Scientist Training Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Tsien, RY (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	rtsien@ucsd.edu		Griesbeck, Oliver/0000-0001-5883-5594; Campbell, Robert E./0000-0003-0604-092X	NATIONAL CANCER INSTITUTE [P30CA023100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027177, R01NS027177] Funding Source: NIH RePORTER; NCI NIH HHS [5P0CA23100-16] Funding Source: Medline; NINDS NIH HHS [NS-27177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baird GS, 2000, P NATL ACAD SCI USA, V97, P11984, DOI 10.1073/pnas.97.22.11984; Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; Damelin M, 2000, MOL CELL, V5, P133, DOI 10.1016/S1097-2765(00)80409-8; Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048; Ellenberg J, 1999, TRENDS CELL BIOL, V9, P52, DOI 10.1016/S0962-8924(98)01420-2; Elsliger MA, 1999, BIOCHEMISTRY-US, V38, P5296, DOI 10.1021/bi9902182; Green G, 2000, METHOD ENZYMOL, V327, P89, DOI 10.1016/S0076-6879(00)27269-8; Heikal AA, 2000, P NATL ACAD SCI USA, V97, P11996, DOI 10.1073/pnas.97.22.11996; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Honda A, 2001, P NATL ACAD SCI USA, V98, P2437, DOI 10.1073/pnas.051631298; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Jayaraman S, 2000, J BIOL CHEM, V275, P6047, DOI 10.1074/jbc.275.9.6047; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V189, P1008, DOI 10.1016/0006-291X(92)92304-G; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuner T, 2000, NEURON, V27, P447, DOI 10.1016/S0896-6273(00)00056-8; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; Llopis J, 2000, P NATL ACAD SCI USA, V97, P4363, DOI 10.1073/pnas.97.8.4363; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Mahajan NP, 1999, CHEM BIOL, V6, P401, DOI 10.1016/S1074-5521(99)80051-9; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Nagai Y, 2000, NAT BIOTECHNOL, V18, P313, DOI 10.1038/73767; Nakai J, 2001, NAT BIOTECHNOL, V19, P137, DOI 10.1038/84397; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Pearce LL, 2000, P NATL ACAD SCI USA, V97, P477, DOI 10.1073/pnas.97.1.477; Persechini A, 1997, CELL CALCIUM, V22, P209, DOI 10.1016/S0143-4160(97)90014-2; Persechini A, 1999, J BIOL CHEM, V274, P6827, DOI 10.1074/jbc.274.11.6827; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Ruehr ML, 1999, J BIOL CHEM, V274, P33092, DOI 10.1074/jbc.274.46.33092; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Sato M, 2000, ANAL CHEM, V72, P5918, DOI 10.1021/ac0006167; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Tsien RY, 1998, SCIENCE, V280, P1954, DOI 10.1126/science.280.5371.1954; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Vanderklish PW, 2000, P NATL ACAD SCI USA, V97, P2253, DOI 10.1073/pnas.040565597; Wachter RM, 2000, J MOL BIOL, V301, P157, DOI 10.1006/jmbi.2000.3905; Wachter RM, 1999, CURR BIOL, V9, pR628, DOI 10.1016/S0960-9822(99)80408-4; Wachter RM, 1998, STRUCTURE, V6, P1267, DOI 10.1016/S0969-2126(98)00127-0; Zacharias DA, 2000, CURR OPIN NEUROBIOL, V10, P416, DOI 10.1016/S0959-4388(00)00101-X	51	792	841	4	117	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29188	29194		10.1074/jbc.M102815200	http://dx.doi.org/10.1074/jbc.M102815200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387331	hybrid			2022-12-27	WOS:000170346000075
J	Hamilton, M; Liao, JH; Cathcart, MK; Wolfman, A				Hamilton, M; Liao, JH; Cathcart, MK; Wolfman, A			Constitutive association of c-N-Ras with c-Raf-1 and protein kinase C epsilon in latent signaling modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; GROWTH-FACTORS; RAF-1 KINASE; HA-RAS; ACTIVATION; INHIBITION; PATHWAY; SERINE; PHOSPHORYLATION; CELLS	Phorbol ester stimulation of the MAPK cascade is believed to be mediated through the protein kinase C (PKC)dependent activation of Raf-1. Although several studies suggest that phorbol ester stimulation of MAPK is insensitive to dominant-negative Ras, a requirement for Ras in Raf-1 activation by PKC has been suggested recently. We now demonstrate that in normal, quiescent mouse fibroblasts, endogenous c-N-Ras is constitutively associated with both c-Raf-1 and PKC epsilon in a biochemically silent, but latent, signaling module. Chemical inhibition of novel PKCs blocks phorbol 12-myristate 13-acetate (PMA)-mediated activation of MAPKs. Down-regulation of PKC epsilon protein levels by antisense oligodeoxyribonucleotides blocks MAPK activation in response to PMA stimulation, demonstrating that PKC epsilon activity is required for MAPK activation by PMA. c-Raf-1 activity in immunoprecipitated c-N-Ras.c-Raf-1.PKC epsilon complexes is stimulated by PMA and is inhibited by GF109203X, thereby linking c-Raf-1 activation in this complex to PKC activation. These observations suggest that in quiescent cells Ras is organized into ordered, inactive signaling modules. Furthermore, the regulation of the MAPK cascade by both Ras and PKC is intimately linked, converging at the plasma membrane through their association with c-Raf-1.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Wolfman, A (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave,NC10, Cleveland, OH 44195 USA.	hamilton-mark@lilly.com; wolfmaa@ccf.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062644] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62644] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; BISSONNETTE M, 1994, AM J PHYSIOL, V267, pG465, DOI 10.1152/ajpgi.1994.267.3.G465; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Fucini RV, 1999, J BIOL CHEM, V274, P18651, DOI 10.1074/jbc.274.26.18651; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; Hamilton M, 1998, J BIOL CHEM, V273, P28155, DOI 10.1074/jbc.273.43.28155; Hausken ZE, 1996, BIOCHEM SOC T, V24, P986, DOI 10.1042/bst0240986; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAPPALAINEN K, 1994, BBA-BIOMEMBRANES, V1196, P201, DOI 10.1016/0005-2736(94)00224-X; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mineo C, 1997, J BIOL CHEM, V272, P10345; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; RAPP UR, 1991, ONCOGENE, V6, P495; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Tamada M, 1997, ONCOGENE, V15, P2959, DOI 10.1038/sj.onc.1201582; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Ueffing M, 1997, ONCOGENE, V15, P2921, DOI 10.1038/sj.onc.1201477; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wielbo D, 1997, BIOCHEM BIOPH RES CO, V232, P794, DOI 10.1006/bbrc.1997.6329; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	54	69	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29079	29090		10.1074/jbc.M102001200	http://dx.doi.org/10.1074/jbc.M102001200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11358964	hybrid			2022-12-27	WOS:000170346000061
J	Park, SY; Seo, SB; Lee, SJ; Na, JG; Kim, YJ				Park, SY; Seo, SB; Lee, SJ; Na, JG; Kim, YJ			Mutation in PMR1, a Ca2+-ATPase in Golgi, confers salt tolerance in Saccharomyces cerevisiae by inducing expression of PMR2, an Na+-ATPase in plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE CALCINEURIN; TRANSCRIPTION FACTOR; SECRETORY PATHWAY; H+/CA2+ EXCHANGE; GENE-EXPRESSION; NACL TOLERANCE; CA2+ ATPASES; YEAST-CELLS; STRESS; TRANSPORT	Sodium tolerance in yeast is enhanced by continuous activation of calcineurin, a Ca2+/calmodulin-dependent protein phosphatase that is required for modulation of the Na+ efflux mechanism. We isolated several salt-tolerant mutations with the treatment of ethylmethane sulfonate under high salt stress. One of the mutations was mapped in the PMR1 gene. Pmr1p, the P-type Ca2+- ATPase in the Golgi apparatus, regulates a cytosolic Ca2+ level in various responses. Cytosolic Ca2+ concentration in the pmr1 mutant is highly maintained, and thus calcineurin is activated continuously. The treatment of FK506, a specific inhibitor of calcineurin, abolishes the salt-tolerant phenotype of the pmr1 mutant. Activated calcineurin induces the expression of PMR2, encoding the P-type Na+-ATPase, through the specific transcription factor, Tcn1p/Crz1p. Also, expression of the PMR2::lacZ reporter gene in the pmr1 mutant was higher than that in wild type. We propose that the pmr1 mutation confers salt tolerance through continuous activation of calcineurin and that Pmr1p might act as a major Ca2+-ATPase under high salt stress.	Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea; Kunsan Natl Univ, Sch Sci & Technol, Kunsan 573701, South Korea	Pusan National University; Kunsan National University	Kim, YJ (corresponding author), Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea.							ALBERTYN J, 1994, MOL CELL BIOL, V14, P4125; ANTIBI A, 1992, MOL BIOL CELL, V3, P633; CARDENAS ME, 1995, CURR OPIN NEPHROL HY, V4, P427; CUNNINGHAM KW, 1994, J EXP BIOL, V196, P157; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; DANIEL G, 1992, NUCLEIC ACIDS RES, V20, P1425; Danielsson A, 1996, CURR GENET, V30, P476, DOI 10.1007/s002940050159; DUNN T, 1994, J BIOL CHEM, V269, P7273; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HARO R, 1993, PHYSIOL PLANTARUM, V89, P868, DOI 10.1111/j.1399-3054.1993.tb05298.x; HIRATA D, 1995, MOL GEN GENET, V249, P257, DOI 10.1007/BF00290525; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Marchi V, 1999, FEBS LETT, V454, P181, DOI 10.1016/S0014-5793(99)00803-0; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Mendoza I, 1996, J BIOL CHEM, V271, P23061, DOI 10.1074/jbc.271.38.23061; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; Pope B, 1996, NUCLEIC ACIDS RES, V24, P536, DOI 10.1093/nar/24.3.536; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Serrano R, 1996, INT REV CYTOL, V165, P1, DOI 10.1016/S0074-7696(08)62219-6; Sorin A, 1997, J BIOL CHEM, V272, P9895; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Strayle J, 1999, EMBO J, V18, P4733, DOI 10.1093/emboj/18.17.4733; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x	33	31	31	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28694	28699		10.1074/jbc.M101185200	http://dx.doi.org/10.1074/jbc.M101185200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387321	hybrid			2022-12-27	WOS:000170346000009
J	Ueno, M; Yamada, S; Zako, M; Bernfield, M; Sugahara, K				Ueno, M; Yamada, S; Zako, M; Bernfield, M; Sugahara, K			Structural characterization of heparan sulfate and chondroitin sulfate of syndecan-1 purified from normal murine mammary gland epithelial cells - Common phosphorylation of xylose and differential sulfation of galactose in the protein linkage region tetrasaccharide sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE INTESTINAL HEPARIN; SWARM RAT CHONDROSARCOMA; SHARK CARTILAGE; N-ACETYLGALACTOSAMINE; SURFACE PROTEOGLYCAN; NEURITE OUTGROWTH; TRYPSIN-INHIBITOR; NERVOUS-SYSTEM; ZETA/RPTP-BETA; FACTOR MIDKINE	Syndecan-1, present on the surfaces of normal murine mammary gland epithelial cells, is a transmembrane hybrid proteoglycan, which bears glycosaminoglycan (GAG) side chains of heparan sulfate (HS) and chondroitin sulfate WS). Purified syndecan-1 ectodomains were analyzed for disaccharide composition and the GAG-protein linkage region after digestion with bacterial lyases. The HS chains contained predominantly a nonsulfated unit with smaller proportions of two monosulfated, two disulfated, and a trisulfated unit, whereas CS chains were demonstrated for the first time to bear GlcUA-GalNAc(4-O-sulfate) as a major component as well as GlcUA-GalNAc, GlcUA-GalNAc(6-O-sulfate), and an E disaccharide unit GlcUA-GalNAc(4,6-O-disulfate) as minor yet appreciable components. Two kinds of linkage region tetrasaccharides, GlcUA-Gal-Gal-Xyl and GlcUA-Gal-Gal-Xyl(2-O-phosphate), were found for the HS chains in a molar ratio of 55:45. In marked contrast, an additional sulfated tetrasaccharide, GlcUA-Gal(4-O-sulfate)-Gal-Xyl, was demonstrated only for the CS chains, and the unmodified phosphorylated and sulfated components were present at a molar ratio of 55:26:19. The present study thus provided conclusive evidence for the hypothesis that 4-O-sulfation of Gal is peculiar to CS chains in contrast to the phosphorylation of Xyl, which is common to both HS and CS chains. These modifications may be required for biosynthetic maturation of the linkage region tetrasaccharide sequence, which is a prerequisite for creating the repeating disaccharide region of GAG chains and/or biosynthetic selective chain assembly of CS and HS chains.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Kobe Pharmaceutical University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan.				NCI NIH HHS [CA28734] Funding Source: Medline; NICHD NIH HHS [HD06763] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD006763, R37HD006763] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [U10CA028734] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Chen RL, 2001, J BIOL CHEM, V276, P7507, DOI 10.1074/jbc.M008283200; Cheng F, 1996, J BIOL CHEM, V271, P28572, DOI 10.1074/jbc.271.45.28572; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; DAVID G, 1981, J NATL CANCER I, V67, P719; DeBeer T, 1996, EUR J BIOCHEM, V240, P789; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; Dolan M, 1997, J BIOL CHEM, V272, P4316, DOI 10.1074/jbc.272.7.4316; EDWARDS IJ, 1995, ARTERIOSCL THROM VAS, V15, P400, DOI 10.1161/01.ATV.15.3.400; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; HEINEGAR.D, 1972, BIOCHIM BIOPHYS ACTA, V285, P193, DOI 10.1016/0005-2795(72)90191-2; JALKANEN M, 1988, J CELL BIOL, V106, P953, DOI 10.1083/jcb.106.3.953; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KATO M, 1994, J BIOL CHEM, V269, P18881; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; KODA JE, 1985, J BIOL CHEM, V260, P8157; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; Lauder RM, 2000, BIOCHEM J, V347, P339, DOI 10.1042/0264-6021:3470339; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Moses J, 1997, EUR J BIOCHEM, V248, P767, DOI 10.1111/j.1432-1033.1997.t01-1-00767.x; Moses J, 1999, EUR J BIOCHEM, V260, P879, DOI 10.1046/j.1432-1327.1999.00228.x; Moses J, 1997, EUR J BIOCHEM, V248, P521, DOI 10.1111/j.1432-1033.1997.00521.x; Munakata H, 1999, GLYCOBIOLOGY, V9, P1023, DOI 10.1093/glycob/9.10.1023; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; Nadanaka S, 1999, BIOCHEM J, V340, P353, DOI 10.1042/0264-6021:3400353; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Nakanishi T, 1997, J BIOCHEM-TOKYO, V121, P197; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; ROSENFELD L, 1988, J BIOL CHEM, V263, P262; Sakaguchi H, 2001, J BIOCHEM-TOKYO, V129, P107, DOI 10.1093/oxfordjournals.jbchem.a002820; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; SUGAHARA K, 1992, EUR J BIOCHEM, V204, P401, DOI 10.1111/j.1432-1033.1992.tb16649.x; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; SUGAHARA K, 1995, J BIOL CHEM, V270, P22914, DOI 10.1074/jbc.270.39.22914; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; TSUKADA T, 1987, COMP BIOCHEM PHYS B, V86, P565, DOI 10.1016/0305-0491(87)90449-4; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919; YAMADA S, 1995, GLYCOBIOLOGY, V5, P335, DOI 10.1093/glycob/5.3.335; YAMADA S, 1995, EUR J BIOCHEM, V233, P687, DOI 10.1111/j.1432-1033.1995.687_2.x; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; Yamada SH, 1998, TRENDS GLYCOSCI GLYC, V10, P95, DOI 10.4052/tigg.10.95; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	72	62	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29134	29140		10.1074/jbc.M102089200	http://dx.doi.org/10.1074/jbc.M102089200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384972	hybrid			2022-12-27	WOS:000170346000068
J	Baird, CL; Gordon, MS; Andrenyak, DM; Marecek, JF; Lindsley, JE				Baird, CL; Gordon, MS; Andrenyak, DM; Marecek, JF; Lindsley, JE			The ATPase reaction cycle of yeast DNA topoisomerase II - Slow rates of ATP resynthesis and P-i release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE ANALYSIS; N-TERMINAL FRAGMENT; GYRASE-B PROTEIN; INORGANIC-PHOSPHATE; DOUBLE HELIX; TRANSPORT; HYDROLYSIS; MECHANISM; CATALYSIS; ETOPOSIDE	DNA topoisomerase II catalyzes the transport of one DNA duplex through a transient break in a second duplex using a complex ATP hydrolysis mechanism. Two key rates in the ATPase mechanism, ATP resynthesis and phosphate release, were investigated using O-18 exchange and stopped-flow phosphate release experiments, respectively. The O-18 exchange results showed that the rate of ATP resynthesis on the topoisomerase II active site was slow compared with the rate of phosphate release. When topoisomerase II was bound to DNA, phosphate was released slowly, with a lag. Since each of the preceding steps is known to occur rapidly, phosphate release is apparently a rate-determining step. The length of the lag phase was unaffected by etoposide, indicating that inhibiting DNA religation inhibits the ATPase reaction cycle at some step following phosphate release. By combining the O-18 exchange and phosphate release results, the rate constant for ATP resynthesis can be calculated as similar to0.5 s(-1). These data support the mechanism of sequential hydrolysis of two ATP by DNA topoisomerase II.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Ctr Human Toxicol, Salt Lake City, UT 84132 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lindsley, JE (corresponding author), Univ Utah, Sch Med, Dept Biochem, 50 N Med Dr, Salt Lake City, UT 84132 USA.		Baird, Cheryl L/F-6569-2011; Baird, Cheryl/AGM-0065-2022		NIGMS NIH HHS [GM51194, 5T32GM08753] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051194, T32GM008753] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; Baird CL, 1999, P NATL ACAD SCI USA, V96, P13685, DOI 10.1073/pnas.96.24.13685; Berger JM, 1998, CURR OPIN STRUC BIOL, V8, P26, DOI 10.1016/S0959-440X(98)80006-7; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Fass D, 1999, NAT STRUCT BIOL, V6, P322; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; Gutfreund H, 1995, KINETICS LIFE SCI; Hackney D D, 1980, Methods Enzymol, V64, P60; HACKNEY DD, 1980, J BIOL CHEM, V255, P5320; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; HUTTON RL, 1979, J BIOL CHEM, V254, P9990; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEVY HM, 1959, J BIOL CHEM, V234, P1102; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; Maxwell A, 1999, BIOCHEM SOC T, V27, P48, DOI 10.1042/bst0270048; Morris SK, 1999, J BIOL CHEM, V274, P30690, DOI 10.1074/jbc.274.43.30690; Olland S, 1999, J BIOL CHEM, V274, P21688, DOI 10.1074/jbc.274.31.21688; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SHUKLA KK, 1980, J BIOL CHEM, V255, P1344; SLEEP JA, 1978, J BIOL CHEM, V253, P5235; STEMPEL KE, 1986, METHOD ENZYMOL, V126, P618; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884	32	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27893	27898		10.1074/jbc.M102544200	http://dx.doi.org/10.1074/jbc.M102544200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11353771	hybrid			2022-12-27	WOS:000170093400021
J	Borza, DB; Bondar, O; Ninomiya, Y; Sado, Y; Naito, I; Todd, P; Hudson, BG				Borza, DB; Bondar, O; Ninomiya, Y; Sado, Y; Naito, I; Todd, P; Hudson, BG			The NCI domain of collagen IV encodes a novel network composed of the alpha 1, alpha 2, alpha 5, and alpha 6 chains in smooth muscle basement membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED ALPORT SYNDROME; NONCOLLAGENOUS DOMAIN; GOODPASTURE ANTIGEN; DIFFERENTIAL EXPRESSION; DIFFUSE LEIOMYOMATOSIS; MONOCLONAL-ANTIBODIES; GLOBULAR DOMAIN; IDENTIFICATION; ORGANIZATION; COL4A5	Type IV collagen, the major component of basement membranes (BMs), is a family of six homologous chains (alpha1-alpha6) that have a tissue-specific distribution. The chains assemble into supramolecular networks that differ in the chain composition. In this study, a novel network was identified and characterized in the smooth muscle BMs of aorta and bladder. The noncollagenous (NC1) hexamers solubilized by collagenase digestion were fractionated by affinity chromatography using monoclonal antibodies against the alpha5 and alpha6 NC1 domains and then characterized by two-dimensional gel electrophoresis and Western blotting. Both BMs were found to contain a novel alpha1.alpha2.alpha5.alpha6 network besides the classical alpha1.alpha2 network. The alpha1.alpha2.alpha5.alpha6 network represents a new arrangement in which a protomer (triple-helical isoform) containing the alpha5 and alpha6 chains is linked through NC1-NC1 interactions to an adjoining protomer composed of the alpha1 and alpha2 chains. Re-association studies revealed that the NCI domains contain recognition sequences sufficient to encode the assembly of both networks. These findings, together with previous ones, indicate that the six chains of type IV collagen are distributed in three major networks (alpha1.alpha2 alpha3.alpha4.alpha5, and alpha1.alpha2.alpha5.alpha6) whose chain composition is encoded by the NCI domains. The existence of the alpha1.alpha2.alpha5.alpha6 network provides a molecular explanation for the concomitant loss of alpha5 and alpha6 chains from the BMs of patients with X-linked Alport's syndrome.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Okayama Univ, Sch Med, Dept Mol Biol & Biochem, Okayama 700, Japan; Shigei Med Res Inst, Div Immunol & Ultrastruct Biol, Okayama 701, Japan	University of Kansas; University of Kansas Medical Center; Okayama University	Hudson, BG (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.		Borza, Dorin-Bogdan/AAF-2156-2020	Borza, Dorin-Bogdan/0000-0003-4568-279X; Hudson, Billy/0000-0002-5420-4100	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018381, P01DK053763, R37DK018381] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18381, DK53763] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTIGNAC C, 1992, KIDNEY INT, V42, P1178, DOI 10.1038/ki.1992.402; BEJARANO PA, 1989, INFECT IMMUN, V57, P3783, DOI 10.1128/IAI.57.12.3783-3787.1989; BLUMBERG B, 1986, J CELL BIOL, V103, P1711, DOI 10.1083/jcb.103.5.1711; Borza DB, 2000, J BIOL CHEM, V275, P6030, DOI 10.1074/jbc.275.8.6030; Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200; DERRY CJ, 1994, EXP NEPHROL, V2, P249; FESSLER LI, 1982, J BIOL CHEM, V257, P9804; GRUNDMANN M, 1995, J NONLINEAR OPT PHYS, V4, P99, DOI 10.1142/S0218863595000069; GUNWAR S, 1991, J BIOL CHEM, V266, P14088; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; GUNWAR S, 1991, AM J RESP CELL MOL, V5, P107, DOI 10.1165/ajrcmb/5.2.107; Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767; Harvey SJ, 1998, KIDNEY INT, V54, P1857, DOI 10.1046/j.1523-1755.1998.00188.x; Hino S, 1996, PEDIATR NEPHROL, V10, P742, DOI 10.1007/s004670050206; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; JOHANSSON C, 1991, CONNECT TISSUE RES, V25, P229, DOI 10.3109/03008209109029159; JOHANSSON C, 1992, J BIOL CHEM, V267, P24533; Kahsai TZ, 1997, J BIOL CHEM, V272, P17023, DOI 10.1074/jbc.272.27.17023; Kalluri R, 1997, J CLIN INVEST, V99, P2470, DOI 10.1172/JCI119431; KUHN K, 1985, ANN NY ACAD SCI, V460, P14, DOI 10.1111/j.1749-6632.1985.tb51153.x; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; Naito I, 1996, KIDNEY INT, V50, P304, DOI 10.1038/ki.1996.316; NINOMIYA Y, 1995, J CELL BIOL, V130, P1219, DOI 10.1083/jcb.130.5.1219; PEISSEL B, 1995, J CLIN INVEST, V96, P1948, DOI 10.1172/JCI118241; REDDY GK, 1993, BIOCHIM BIOPHYS ACTA, V1157, P241, DOI 10.1016/0304-4165(93)90106-I; Sado Y, 1998, KIDNEY INT, V53, P664, DOI 10.1046/j.1523-1755.1998.00795.x; Saito K, 2000, J BIOCHEM, V128, P427, DOI 10.1093/oxfordjournals.jbchem.a022770; SAUS J, 1988, J BIOL CHEM, V263, P13374; Seki T, 1998, HISTOCHEM CELL BIOL, V110, P359, DOI 10.1007/s004180050296; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TRUEB B, 1982, J BIOL CHEM, V257, P5239; WEBER S, 1984, EUR J BIOCHEM, V139, P401, DOI 10.1111/j.1432-1033.1984.tb08019.x; Zheng KQ, 1999, AM J PATHOL, V154, P1883, DOI 10.1016/S0002-9440(10)65446-6; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449	36	104	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28532	28540		10.1074/jbc.M103690200	http://dx.doi.org/10.1074/jbc.M103690200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375996	hybrid			2022-12-27	WOS:000170093400105
J	Groves, MR; Mant, A; Kuhn, A; Koch, J; Dubel, S; Robinson, C; Sinning, I				Groves, MR; Mant, A; Kuhn, A; Koch, J; Dubel, S; Robinson, C; Sinning, I			Functional characterization of recombinant chloroplast signal recognition particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANE-PROTEIN; METHIONINE-RICH DOMAIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; CONSERVED GTPASE; 54-KDA SUBUNIT; SPOT-SYNTHESIS; BINDING-SITE; SEQUENCE; RECEPTOR	The signal recognition particle (SRP) is a ubiquitous system for the targeting of membrane and secreted proteins. The chloroplast SRP (cpSRP) is unique among SRPs in that it possesses no RNA and is functional in post-translational as well as co-translational targeting. We have expressed and purified the two components of the Arabidopsis thaliana chloroplast signal recognition particle (cpSRP) involved in post-translational transport: cpSRP54 and the chloroplast-specific protein, cpSRP43. Recombinant cpSRP supports the efficient arc vitro insertion of pea preLhcb1 into isolated thylakoid membranes. Recombinant cpSRP is a stable heterodimer with a molecular mass of similar to 100 kDa as determined by analytical ultracentrifugation, gel filtration analysis, and dynamic light scattering. The interactions of the components of the recombinant heterodimer and pea preLhcb1 were probed using an immobilized peptide library (pepscan) approach. These data confirm two previously reported interactions with the L18 region and the third transmembrane helix of Lhcb1 and suggest that the interface of the cpSRP43 and epSRP54 proteins is involved in substrate binding. Additionally, cpSRP components are shown to recognize peptides from the cleavable, N-terminal chloroplast transit peptide of preLhcb1. The interaction of cpSRP43 with epSRP54 was probed in a similar experiment with a peptide library representing cpSPR54. The C terminus of cpSRP54 is essential for the formation of the stable cpSRP complex and cpSPR43 interacts with distinct regions of the M domain of cpSRP54.	European Mol Biol Lab, Struct Biol Programme, D-69117 Heidelberg, Germany; Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Univ Heidelberg, Inst Mol Genet, D-69120 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg; University of Warwick; Ruprecht Karls University Heidelberg	Sinning, I (corresponding author), European Mol Biol Lab, Struct Biol Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Sinning, Irmgard/A-2982-2010	Dubel, Stefan/0000-0001-8811-7390; Groves, Matthew/0000-0001-9859-5177; Mant, Alexandra/0000-0001-7169-209X				Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473; Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brix J, 2000, J MOL BIOL, V303, P479, DOI 10.1006/jmbi.2000.4120; BROCK IW, 1993, PLANT MOL BIOL, V23, P717, DOI 10.1007/BF00021527; CLARK SE, 1990, PLANT CELL, V2, P173, DOI 10.1105/tpc.2.2.173; Clemons WM, 1999, J MOL BIOL, V292, P697, DOI 10.1006/jmbi.1999.3090; Cowieson NP, 2000, CURR BIOL, V10, P517, DOI 10.1016/S0960-9822(00)00467-X; CREETH J. M., 1967, PROGR BIOPHYS MOL BIOL, V17, P217, DOI 10.1016/0079-6107(67)90008-9; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; DeLille J, 2000, P NATL ACAD SCI USA, V97, P1926, DOI 10.1073/pnas.030395197; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; FerreDAmare AR, 1997, METHOD ENZYMOL, V276, P157, DOI 10.1016/S0076-6879(97)76056-7; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; GROVES MR, 2001, IN PRESS IMMOBILIZED; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Heins L, 1998, TRENDS PLANT SCI, V3, P56, DOI 10.1016/S1360-1385(97)01161-8; High S, 1997, J BIOL CHEM, V272, P11622; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; Jagath JR, 1998, BIOCHEMISTRY-US, V37, P15408, DOI 10.1021/bi981523a; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; Keenan RJ, 1998, CELL, V94, P181, DOI 10.1016/S0092-8674(00)81418-X; Klimyuk VI, 1999, PLANT CELL, V11, P87, DOI 10.1105/tpc.11.1.87; Knoblauch NTM, 1999, J BIOL CHEM, V274, P34219, DOI 10.1074/jbc.274.48.34219; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; Montoya G, 2000, STRUCTURE, V8, P515, DOI 10.1016/S0969-2126(00)00131-3; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; Moser C, 1997, P NATL ACAD SCI USA, V94, P11339, DOI 10.1073/pnas.94.21.11339; Nilsson R, 1999, EMBO J, V18, P733, DOI 10.1093/emboj/18.3.733; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Reineke U, 1999, CURR TOP MICROBIOL, V243, P23; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Schuenemann D, 1999, BIOCHEM BIOPH RES CO, V254, P253, DOI 10.1006/bbrc.1998.9923; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Thompson SJ, 1999, J BIOL CHEM, V274, P4059, DOI 10.1074/jbc.274.7.4059; Tu CJ, 2000, J BIOL CHEM, V275, P13187, DOI 10.1074/jbc.C000108200; Tu CJ, 1999, J BIOL CHEM, V274, P27219, DOI 10.1074/jbc.274.38.27219; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	48	61	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27778	27786		10.1074/jbc.M103470200	http://dx.doi.org/10.1074/jbc.M103470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11356852	hybrid, Green Published			2022-12-27	WOS:000170093400007
J	Roche, ED; Sauer, RT				Roche, ED; Sauer, RT			Identification of endogenous SsrA-tagged proteins reveals tagging at positions corresponding to stop codons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL STABLE RNA; ESCHERICHIA-COLI; 10SA RNA; TRANSLATION TERMINATION; BACILLUS-SUBTILIS; LAMBDA-REPRESSOR; MESSENGER-RNA; TMRNA; DEGRADATION; BINDING	The SsrA.SmpB quality control system adds a C-terminal degradation peptide (AANDENYALAA) to nascent chains on stalled ribosomes, thereby freeing the ribosome and ensuring proteolysis of the tagged protein. An SsrA mutant with the tag sequence AANDEHHHHHH was used to slow degradation and facilitate, Ni2+-nitrilotriacetic acid affinity purification. Display of affinity-purified Escherichia coli proteins on two-dimensional gels revealed small quantities of a diverse set of SsrA-H-6-tagged proteins, and mass spectroscopy identified LaeI repressor, lambda cI repressor, YbeL, GalE, RbsK, and a SlyD-kan(R) fusion protein as members of this set. For A repressor and YbeL, the SsrA-H-6 tag was added after the natural C terminus of the protein, suggesting that tagging occurred while the ribosome idled at the termination codon of these genes. Potential causes of tagging for the other proteins include interference from translation of downstream reading frames, rare codons, and gene disruption. These and previous results support a broad role for the SsrA.SmpB system in freeing stalled ribosomes and in directing degradation of the products of these frustrated protein synthesis reactions.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Sauer, RT (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sauer, Robert/0000-0002-1719-5399	NIAID NIH HHS [AI-16892] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016892] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abo T, 2000, EMBO J, V19, P3762, DOI 10.1093/emboj/19.14.3762; ARKOV AL, 1993, NUCLEIC ACIDS RES, V21, P2891, DOI 10.1093/nar/21.12.2891; Bjornsson A, 1996, EMBO J, V15, P1696, DOI 10.1002/j.1460-2075.1996.tb00515.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BREYER RM, 1989, J BIOL CHEM, V264, P13355; DESMIT MH, 1994, J MOL BIOL, V235, P173, DOI 10.1016/S0022-2836(05)80024-5; Felden B, 1997, RNA, V3, P89; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; Huang CH, 2000, EMBO J, V19, P1098, DOI 10.1093/emboj/19.5.1098; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Keiler KC, 2000, P NATL ACAD SCI USA, V97, P7778, DOI 10.1073/pnas.97.14.7778; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KIRBY JE, 1994, J BACTERIOL, V176, P2068, DOI 10.1128/jb.176.7.2068-2081.1994; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; MILLA ME, 1993, PROTEIN SCI, V2, P2198, DOI 10.1002/pro.5560021219; Mottagui-Tabar S, 1998, GENE, V212, P189, DOI 10.1016/S0378-1119(98)00176-0; Muto A, 2000, GENES CELLS, V5, P627, DOI 10.1046/j.1365-2443.2000.00356.x; Nakamura Y, 1996, CELL, V87, P147, DOI 10.1016/S0092-8674(00)81331-8; NELSON HCM, 1985, CELL, V42, P549, DOI 10.1016/0092-8674(85)90112-6; OH BK, 1991, MOL GEN GENET, V229, P52, DOI 10.1007/BF00264212; PARSELL DA, 1990, GENE DEV, V4, P277, DOI 10.1101/gad.4.2.277; Ptashne M., 1986, A GENETIC SWITCH; RETALLACK DM, 1994, J BACTERIOL, V176, P2082, DOI 10.1128/jb.176.7.2082-2089.1994; RETALLACK DM, 1995, CELL, V83, P227, DOI 10.1016/0092-8674(95)90164-7; Roche ED, 1999, EMBO J, V18, P4579, DOI 10.1093/emboj/18.16.4579; SAUER RT, 1981, BIOCHEMISTRY-US, V20, P3591, DOI 10.1021/bi00515a044; SAUER RT, 1978, NATURE, V276, P301, DOI 10.1038/276301a0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392; Williams KP, 1996, RNA, V2, P1306; Withey J, 1999, J BACTERIOL, V181, P2148, DOI 10.1128/JB.181.7.2148-2157.1999; Zhang SP, 1998, J MOL BIOL, V284, P1243, DOI 10.1006/jmbi.1998.2319	36	100	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28509	28515		10.1074/jbc.M103864200	http://dx.doi.org/10.1074/jbc.M103864200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373298	hybrid			2022-12-27	WOS:000170093400102
J	Snyder, PM; Olson, DR; McDonald, FJ; Bucher, DB				Snyder, PM; Olson, DR; McDonald, FJ; Bucher, DB			Multiple WW domains, but not the C2 domain, are required for inhibition of the epithelial Na+ channel by human Nedd4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIDDLES-SYNDROME; SODIUM-CHANNELS; PY MOTIF; EXPRESSION; SUBUNITS; CLONING	The epithelial Na+ channel (ENaC) absorbs Na+ across the apical membrane of epithelia. The activity of ENaC is controlled by its interaction with Nedd4; mutations that disrupt this interaction increase Na+ absorption, causing an inherited form of hypertension (Liddle's syndrome). Nedd4 contains an N-terminal C2 domain, a C-terminal ubiquitin ligase domain, and multiple WW domains. The C2 domain is thought to be involved in the Ca2+-dependent localization of Nedd4 at the cell surface. However, we found that the C2 domain was not required for human Nedd4 (hNedd4) to inhibit ENaC in both Xenopus oocytes and Fischer rat thyroid epithelia. Rather, hNedd4 lacking the C2 domain inhibited ENaC more potently than wild-type hNedd4. Earlier work indicated that the WW domains bind to PY motifs in the C terminus of ENaC. However, it is not known which WW domains mediate this interaction. Glutathione S-transferase-fusion proteins of WW domains 2-4 each bound to alpha, beta, and gamma ENaC in vitro. The interactions were abolished by mutation of two residues. WW domain 3 (but not the other WW domains) was both necessary and sufficient for the binding of hNedd4 to alpha ENaC. WW domain 3 was also required for the inhibition of ENaC by hNedd4; inhibition was nearly abolished when WW domain 3 was mutated. However, the interaction between ENaC and WW domain 3 alone was not sufficient for inhibition. Moreover, inhibition was decreased by mutation of WW domain 2 or WW domain 4. Thus, WW domains 2-4 each participate in the functional interaction between hNedd4 and ENaC in intact cells.	Univ Iowa, Coll Med, Dept Internal Med, EMRB 371, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Otago, Dept Physiol, Dunedin, New Zealand	University of Iowa; University of Iowa; University of Otago	Snyder, PM (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, EMRB 371, Iowa City, IA 52242 USA.	psnyder@blue.weeg.uiowa.edu			NHLBI NIH HHS [HL-58812, HL-03575] Funding Source: Medline; NIDDK NIH HHS [DK-52617] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058812, R29HL058812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK052617] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; Espanel X, 1999, J BIOL CHEM, V274, P17284, DOI 10.1074/jbc.274.24.17284; Farr TJ, 2000, BIOCHEM J, V345, P503, DOI 10.1042/0264-6021:3450503; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHEPPARD DN, 1994, AM J PHYSIOL, V266, pL405, DOI 10.1152/ajplung.1994.266.4.L405; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325	21	74	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28321	28326		10.1074/jbc.M011487200	http://dx.doi.org/10.1074/jbc.M011487200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11359767	hybrid			2022-12-27	WOS:000170093400078
J	Gong, PF; Hu, B; Stewart, D; Ellerbe, M; Figueroa, YG; Blank, V; Beckman, BS; Alam, J				Gong, PF; Hu, B; Stewart, D; Ellerbe, M; Figueroa, YG; Blank, V; Beckman, BS; Alam, J			Cobalt induces heme oxygenase-1 expression by a hypoxia-inducible factor-independent mechanism in Chinese hamster ovary cells - Regulation by Nrf2 and MafG transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; GENE-EXPRESSION; OXIDATIVE STRESS; CARBON-MONOXIDE; MESSENGER-RNA; DEPENDENT TRANSCRIPTION; NF-E2-RELATED FACTOR-2; ERYTHROPOIETIN GENE; HEAVY-METALS; SUBUNIT GENE	We have shown previously that activation of the heme oxygenase-1 (ho-1) gene by hypoxia in aortic smooth muscle cells is mediated by hypoxia-inducible factor-1 (HIF-1). In mutant (Ka13) Chinese hamster ovary cells lacking RIF activity, accumulation of ho-1 mRNA in response to hypoxia and the hypoxia-mimetic CoCl2 was similar to that observed in wild type (K1) cells. These results support the existence of HIF-dependent and HIF-independent mechanisms for ho-1 gene activation by hypoxia and CoCl2. In Ka13 cells, CoCl2 stimulated expression of a luciferase reporter gene under the control of a 15-kilobase pair mouse ho-1 promoter (pHO15luc). Mutation analyses identified the cobalt-responsive sequences as the stress-response elements (StREs). In electrophoretic mobility shift, assays, two specific StRE-protein complexes were observed using extracts from Ka13 cells. In response to cobalt, the level of the slower migrating complex X increased, whereas that of complex Y decreased, in a time-dependent manner. Members of the AP-1 superfamily of basic-leucine zipper factors bind to the StRE. Antibody supershift electrophoretic mobility shift assays did not detect Jun, Fos, or ATF/CREB proteins but identified Nrf2 and the small Maf protein, MafG, as components of complex X. Furthermore, dominant-negative mutants of Nrf2 and small Maf, but not of other bZIP factors, attenuated cobalt-mediated gene activation. Additional experiments demonstrated that induction by cobalt does not result from increased expression of MafG or regulated nuclear translocation of Nrf2 but is dependent on cellular oxidative stress. Unlike cobalt, hypoxia did not stimulate pHO15luc expression and did not increase StRE binding activity, indicating distinct mechanisms for ho-1 gene activation by cobalt and hypoxia in Chinese hamster ovary cells.	Alton Ochsner Med Fdn, Dept Mol Genet, New Orleans, LA 70121 USA; Tulane Univ, Sch Med, Dept Pharmacol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; McGill Univ, Dept Med, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	Ochsner Health System; Tulane University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Lady Davis Institute; McGill University	Alam, J (corresponding author), Alton Ochsner Med Fdn, Dept Mol Genet, 1516 Jefferson Hwy, New Orleans, LA 70121 USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X	NIDDK NIH HHS [DK-43135] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM NG, 1991, J CELL BIOCHEM, V47, P43, DOI 10.1002/jcb.240470106; Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Alam J, 2000, J BIOL CHEM, V275, P27694; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; ALAM J, 1989, J BIOL CHEM, V264, P6371; ALAM J, 2000, CURRENT PROTOCOLS TO, V1; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crawford DR, 1996, FREE RADICAL BIO MED, V21, P521, DOI 10.1016/0891-5849(96)00160-8; CzyzykKrzeska MF, 1997, KIDNEY INT, V51, P585, DOI 10.1038/ki.1997.84; DHAKSHINAMOORTH, 2000, CURR TOP CELL REGUL, V36, P201; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Durante W, 1998, INT J MOL MED, V2, P255; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; GOLDBERG MA, 1991, SEMIN HEMATOL, V28, P35; Gong PF, 2000, IND HEALTH, V38, P224, DOI 10.2486/indhealth.38.224; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Huang LE, 1997, KIDNEY INT, V51, P548, DOI 10.1038/ki.1997.76; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1998, GENE DEV, V13, P67; KATAYOSE D, 1993, BIOCHEM BIOPH RES CO, V191, P587, DOI 10.1006/bbrc.1993.1258; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; Lee JM, 2001, BIOCHEM BIOPH RES CO, V280, P286, DOI 10.1006/bbrc.2000.4106; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LIN JHC, 1990, EUR J BIOCHEM, V192, P577, DOI 10.1111/j.1432-1033.1990.tb19263.x; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Murata M, 1999, J CELL PHYSIOL, V180, P105, DOI 10.1002/(SICI)1097-4652(199907)180:1<105::AID-JCP12>3.0.CO;2-5; MURPHY BJ, 1991, BRIT J CANCER, V64, P69, DOI 10.1038/bjc.1991.241; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Panchenko MV, 2000, AM J PHYSIOL-CELL PH, V278, pC92, DOI 10.1152/ajpcell.2000.278.1.C92; Pioli C, 1999, EUR J IMMUNOL, V29, P856, DOI 10.1002/(SICI)1521-4141(199903)29:03<856::AID-IMMU856>3.0.CO;2-P; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; Semenza GL, 1997, KIDNEY INT, V51, P553, DOI 10.1038/ki.1997.77; Suzuki T, 2001, BIOCHEM BIOPH RES CO, V280, P4, DOI 10.1006/bbrc.2000.4064; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360	59	131	136	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27018	27025		10.1074/jbc.M103658200	http://dx.doi.org/10.1074/jbc.M103658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356853	hybrid			2022-12-27	WOS:000169966900039
J	Qi, XY; Grabowski, GA				Qi, XY; Grabowski, GA			Differential membrane interactions of saposins A and C - Implications for the functional specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BETA-GLUCOSIDASE; SPHINGOLIPID ACTIVATOR PROTEIN-2; ARYLSULFATASE-A ACTIVITY; GAUCHER DISEASE; NK-LYSIN; METACHROMATIC LEUKODYSTROPHY; DEFICIENCY; PATIENT; SAP-2; DEGRADATION	Saposins are small, heat-stable glycoprotein activators of lysosomal glycosphingolipid hydrolases that derive from a single precursor, prosaposin, by proteolytic cleavage. Three of these saposins (B, C, and D) share common structural features including a lack of tryptophan,a single glycosylation sequence, the presence of three conserved disulfide bonds, and a common multi-amphipathic helical bundle motif, SaposinA contains an additional glycosylation site and a single tryptophan, The oligosaccharides on saposins are not required for in vitro activation functions. Saposins A and C were produced in Escherichia coli to contain single tryptophans at various locations to serve as intrinsic fluorescence reporters, i.e. as topological probes, for interaction with phospholipid membranes. Maximum emission shifts, aqueous and solid quenching, and resonance energy transfer were quantified by fluorescence spectroscopy. Amphipathic helices at the amino- and carboxyl termini of saposins A and C were shown to insert into the lipid bilayer to about five carbon bond lengths. In comparison, the middle region of saposins A or C were either embedded in the bilayer or solvent-exposed, respectively. Conformational changes of saposin C induced by phosphatidylserine interaction suggested the reorientation of functional helical domains. Differential interaction models are proposed for the membrane-bound saposins A and C. By site-directed mutagenesis of saposin A and C, their membrane topological structures were correlated with their activation effects on acid beta -glucosidase. These findings show that proper orientation of the middle segment of saposin C tee the outside of the membrane surface is critical for its specific and multivalent interaction with acid beta -glucosidase. Such membrane interactions and orientations of the saposins determine the proximity of their activation and/or binding sites to lysosomal hydrolases or lipoid substrates.	Childrens Hosp Res Fdn, Div Human Genet, Cincinnati, OH 45229 USA; Dept Pediat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Qi, XY (corresponding author), Div & Program Human Genet, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036729, R01DK057690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034071] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36729, DK 57690] Funding Source: Medline; NINDS NIH HHS [NS 34071] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSSON M, 1995, EMBO J, V14, P1615; BERENT SL, 1981, BIOCHIM BIOPHYS ACTA, V664, P572, DOI 10.1016/0005-2760(81)90134-X; CHRISTOMANOU H, 1989, KLIN WOCHENSCHR, V67, P999, DOI 10.1007/BF01716064; CHRISTOMANOU H, 1986, BIOL CHEM H-S, V367, P879, DOI 10.1515/bchm3.1986.367.2.879; FUJIBAYASHI S, 1985, AM J HUM GENET, V37, P741; FUJIBAYASHI S, 1986, BIOCHIM BIOPHYS ACTA, V875, P554; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; GREENBERG P, 1990, BIOCHIM BIOPHYS ACTA, V1039, P12, DOI 10.1016/0167-4838(90)90220-A; Harzer K, 1997, FEBS LETT, V417, P270, DOI 10.1016/S0014-5793(97)01302-1; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V303, P326, DOI 10.1006/abbi.1993.1291; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Kervinen J, 1999, EMBO J, V18, P3947, DOI 10.1093/emboj/18.14.3947; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P388; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P793, DOI 10.1038/nsb1097-793; MORIMOTO S, 1988, BIOCHEM BIOPH RES CO, V156, P403, DOI 10.1016/S0006-291X(88)80855-6; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; MORIMOTO S, 1990, P NATL ACAD SCI USA, V87, P3493, DOI 10.1073/pnas.87.9.3493; MUNFORD RS, 1995, J LIPID RES, V36, P1653; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; Qi XY, 1999, BIOCHEMISTRY-US, V38, P6284, DOI 10.1021/bi990079o; Qi XY, 1998, BIOCHEMISTRY-US, V37, P11544, DOI 10.1021/bi980785+; QI XY, 1994, J BIOL CHEM, V269, P16746; Qi XY, 1996, J BIOL CHEM, V271, P6874, DOI 10.1074/jbc.271.12.6874; RAFI MA, 1993, SOMAT CELL MOLEC GEN, V19, P1, DOI 10.1007/BF01233949; Regis S, 1999, EUR J HUM GENET, V7, P125, DOI 10.1038/sj.ejhg.5200266; REINER O, 1989, J MOL NEUROSCI, V1, P225; RORMAN EG, 1989, GENOMICS, V5, P486, DOI 10.1016/0888-7543(89)90014-1; Ruysschaert JM, 1998, FEBS LETT, V425, P341, DOI 10.1016/S0014-5793(98)00261-0; SANO A, 1988, BIOCHEM BIOPH RES CO, V154, P1197, DOI 10.1016/0006-291X(88)90267-7; SCHLOTE W, 1991, EUR J PEDIATR, V150, P584, DOI 10.1007/BF02072213; SCHNABEL D, 1992, J BIOL CHEM, V267, P3312; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; SHECHTER E, 1971, BIOCHIM BIOPHYS ACTA, V241, P431, DOI 10.1016/0005-2736(71)90043-5; Vaccaro AM, 1995, J BIOL CHEM, V270, P30576, DOI 10.1074/jbc.270.51.30576; Vaccaro AM, 1997, J BIOL CHEM, V272, P16862, DOI 10.1074/jbc.272.27.16862; VACCARO AM, 1995, J BIOL CHEM, V270, P9953, DOI 10.1074/jbc.270.17.9953; VANDENBUSSCHE G, 1992, BIOCHEMISTRY-US, V31, P9169, DOI 10.1021/bi00153a008; WENGER DA, 1989, AM J MED GENET, V33, P255, DOI 10.1002/ajmg.1320330223; WHITSETT JA, 1995, PHYSIOL REV, V75, P749, DOI 10.1152/physrev.1995.75.4.749	44	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27010	27017		10.1074/jbc.M101075200	http://dx.doi.org/10.1074/jbc.M101075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356836	hybrid			2022-12-27	WOS:000169966900038
J	Faber, C; Scharpf, M; Becker, T; Sticht, H; Rosch, P				Faber, C; Scharpf, M; Becker, T; Sticht, H; Rosch, P			The structure of the coliphage HK022 nun protein-lambda-phage boxB RNA complex - Implications for the mechanism of transcription termination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTATO CARBOXYPEPTIDASE INHIBITOR; ARGININE-RICH MOTIF; BACTERIOPHAGE-LAMBDA; NMR-SPECTROSCOPY; ANTITERMINATION; BINDING; RECOGNITION; WATER	Nun protein from coliphage HK022 binds to phage boxB RNA and functions, in contrast to phage lambda N protein, as a transcriptional termination The basic Nun-(10-44) peptide contains the boxB RNA binding arginine rich motif, ARM. The peptide binds boxB RNA and competes with the phage lambda ARM peptide N-(1-36) as indicated by nuclear magnetic resonance (NMR) spectroscopy titrations. In two-dimensional nuclear Overhauser enhancement spectroscopy experiments boxB RNA in complex with Nun-(20-44) exhibits the same pattern of resonances as it does in complex with N peptides containing the ARM, and we could show that Nun-(20-44) forms a bent a-helix upon binding to the boxB RNA. The structure of the boxB RNA-bound Nun-(20-44) was determined on the basis of 191 intra- and 30 intermolecular distance restraints. Ser-24 is anchored to the lower RNA stem, and stacking of Tyr-39 and A7 is clearly experimentally indicated. Arg-28 shows numerous contacts to the RNA stem. Leu-22, IIe30, Trp-33, IIe-37, and Leu-41 form a hydrophobic surface, which could be a recognition site for additional host factors such as NusG. Such a hydrophobic surface area is not present in N-(1-36) bound to boxB RNA.	Univ Bayreuth, Lehrstuhl Biopolymere, D-95447 Bayreuth, Germany	University of Bayreuth	Rosch, P (corresponding author), Univ Bayreuth, Lehrstuhl Biopolymere, Univ Str 30, D-95447 Bayreuth, Germany.		Faber, Cornelius/Q-2689-2016; Rösch, Paul/I-5445-2014	Faber, Cornelius/0000-0001-7683-7710; Rösch, Paul/0000-0003-3330-2446; Sticht, Heinrich/0000-0001-5644-045X				BRUNGER AT, 1996, X PLOR VERSION 3 851; Cai ZP, 1998, NAT STRUCT BIOL, V5, P203, DOI 10.1038/nsb0398-203; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHATTOPADHYAY S, 1995, P NATL ACAD SCI USA, V92, P4061, DOI 10.1073/pnas.92.9.4061; Chattopadhyay S, 1995, P NATL ACAD SCI USA, V92, P12131, DOI 10.1073/pnas.92.26.12131; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; FRANKLIN NC, 1985, J MOL BIOL, V181, P75, DOI 10.1016/0022-2836(85)90325-0; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HOLAK TA, 1989, FEBS LETT, V242, P218, DOI 10.1016/0014-5793(89)80473-9; Kuszewski J, 1996, PROTEIN SCI, V5, P1067; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; Legault P, 1998, CELL, V93, P289, DOI 10.1016/S0092-8674(00)81579-2; LIVE DH, 1984, J AM CHEM SOC, V106, P1939, DOI 10.1021/ja00319a006; Luscombe NM, 1997, NUCLEIC ACIDS RES, V25, P4940, DOI 10.1093/nar/25.24.4940; MOGRIDGE J, 1995, GENE DEV, V9, P2831, DOI 10.1101/gad.9.22.2831; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; ROBERT J, 1987, CELL, V51, P483, DOI 10.1016/0092-8674(87)90644-1; SAYLE R, 1995, RASMOL V 2 6 MOL VIS; Scharpf M, 2000, EUR J BIOCHEM, V267, P2397, DOI 10.1046/j.1432-1327.2000.01251.x; Su LL, 1997, BIOCHEMISTRY-US, V36, P12722, DOI 10.1021/bi971408k; *TRIP INC, SYBYL VERS 6 5; Varani G, 1996, PROG NUCL MAG RES SP, V29, P51, DOI 10.1016/0079-6565(96)01028-X; VARANI G, 1991, Q REV BIOPHYS, V24, P479, DOI 10.1017/S0033583500003875; Watnick RS, 1999, SCIENCE, V286, P2337, DOI 10.1126/science.286.5448.2337; Watnick RS, 1998, P NATL ACAD SCI USA, V95, P1546, DOI 10.1073/pnas.95.4.1546; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC	30	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32064	32070		10.1074/jbc.M102975200	http://dx.doi.org/10.1074/jbc.M102975200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11356847	hybrid, Green Submitted			2022-12-27	WOS:000170613500082
J	Powell, RM; Parkhurst, KM; Brenowitz, M; Parkhurst, LJ				Powell, RM; Parkhurst, KM; Brenowitz, M; Parkhurst, LJ			Marked stepwise differences within a common kinetic mechanism characterize TATA-binding protein interactions with two consensus promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; RNA-POLYMERASE-II; CRYSTAL-STRUCTURE; B-DNA; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; MINOR-GROOVE; A-T; EUKARYOTIC TRANSCRIPTION; DIMER DISSOCIATION	Binding of the TATA-binding protein (TBP) to promoter DNA bearing the TATA sequence is an obligatory initial step in RNA polymerase II transcription initiation. The interactions. of Saccharomyces cerevisiae TBP with the E4 (TATATATA) and adenovirus major late (TATAAAAG) promoters have been modeled via global analysis of kinetic and thermodynamic data obtained using fluorescence resonance energy transfer. A linear two-intermediate kinetic mechanism describes the reaction of both of these consensus strong promoters with TBP. Qualitative features common to both interactions include tightly bound TBP-DNA complexes with similar solution geometries, simultaneous DNA binding and bending, and the presence of intermediate TBP-DNA conformers at high mole fraction throughout most of the reaction and at equilibrium. Despite very similar energetic changes overall, the stepwise entropic and enthalpic compensations along the two pathways differ markedly following the initial binding/bending event. Furthermore, TBP-E4 dissociation ensues from both replacement and displacement processes, in contrast to replacement alone for TBP-adenovirus major late promoter. A model is proposed that explicitly correlates these similarities and differences with the sequence-specific structural properties inherent to each promoter. This detailed mechanistic comparison of two strong promoters interacting with TBP provides a foundation for subsequent comparison between consensus and variant promoter sequences reacting with TBP.	Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	University of Nebraska System; University of Nebraska Lincoln; Yeshiva University; Albert Einstein College of Medicine	Powell, RM (corresponding author), Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA.				NCI NIH HHS [CA76049] Funding Source: Medline; NCRR NIH HHS [RR15635] Funding Source: Medline; NIGMS NIH HHS [GM39929, GM59346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076049] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059346, R01GM039929, R29GM039929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bareket-Samish A, 2000, J MOL BIOL, V299, P965, DOI 10.1006/jmbi.2000.3797; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CALLADINE CR, 1982, J MOL BIOL, V161, P343, DOI 10.1016/0022-2836(82)90157-7; Campbell KM, 2000, BIOCHEMISTRY-US, V39, P2633, DOI 10.1021/bi9922998; CHEUNG HC, 1991, TOPICS FLUORESCENCE, P157; Coleman RA, 1997, P NATL ACAD SCI USA, V94, P7221, DOI 10.1073/pnas.94.14.7221; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; Daugherty MA, 2000, BIOCHEMISTRY-US, V39, P4869, DOI 10.1021/bi992423n; Daugherty MA, 1999, J MOL BIOL, V285, P1389, DOI 10.1006/jmbi.1998.2427; de Souza ON, 1998, BIOPOLYMERS, V46, P403; DICKERSON RE, 1983, J MOL BIOL, V166, P419, DOI 10.1016/S0022-2836(83)80093-X; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; GOODSELL DS, 1994, NUCLEIC ACIDS RES, V22, P5497, DOI 10.1093/nar/22.24.5497; GOODSELL DS, 1994, J MOL BIOL, V239, P79, DOI 10.1006/jmbi.1994.1352; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; Hoopes BC, 1998, J MOL BIOL, V277, P1015, DOI 10.1006/jmbi.1998.1651; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; Jackson-Fisher AJ, 1999, BIOCHEMISTRY-US, V38, P11340, DOI 10.1021/bi990911p; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLUG A, 1979, J MOL BIOL, V131, P669, DOI 10.1016/0022-2836(79)90196-7; KLUG A, 1993, NATURE, V365, P486, DOI 10.1038/365486a0; Lakowicz J R, 1999, PRINCIPLES FLUORESCE, P367, DOI 10.1007/978-1-4757-3061-6; LEVENE SD, 1983, J BIOMOL STRUCT DYN, V1, P429, DOI 10.1080/07391102.1983.10507452; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; McKnight SL, 1996, GENE DEV, V10, P367, DOI 10.1101/gad.10.4.367; Munteanu MG, 1998, TRENDS BIOCHEM SCI, V23, P341, DOI 10.1016/S0968-0004(98)01265-1; Nikolov DB, 1996, P NATL ACAD SCI USA, V93, P4862, DOI 10.1073/pnas.93.10.4862; Packer MJ, 2000, J MOL BIOL, V295, P85, DOI 10.1006/jmbi.1999.3237; Parkhurst KM, 1999, J MOL BIOL, V289, P1327, DOI 10.1006/jmbi.1999.2835; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; PARKHURST KM, 1995, BIOCHEMISTRY-US, V34, P285, DOI 10.1021/bi00001a035; PARKHURST KM, 1995, BIOCHEMISTRY-US, V34, P293, DOI 10.1021/bi00001a036; PARKHURST LJ, 1994, P SOC PHOTO-OPT INS, V2137, P475, DOI 10.1117/12.182758; Pastor N, 2000, J MOL BIOL, V304, P55, DOI 10.1006/jmbi.2000.4173; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; PETRI V, 1995, BIOCHEMISTRY-US, V34, P9977, DOI 10.1021/bi00031a020; Petri V, 1998, BIOCHEMISTRY-US, V37, P15842, DOI 10.1021/bi981072u; QUINTANA JR, 1991, BIOCHEMISTRY-US, V30, P10294, DOI 10.1021/bi00106a030; SUZUKI M, 1995, NUCLEIC ACIDS RES, V23, P2083, DOI 10.1093/nar/23.12.2083; VISWAMITRA MA, 1978, NATURE, V273, P687, DOI 10.1038/273687a0; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WONG JM, 1994, NUCLEIC ACIDS RES, V22, P1890, DOI 10.1093/nar/22.10.1890; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; Wu J, 2001, J BIOL CHEM, V276, P14614, DOI 10.1074/jbc.M004402200; Wu JO, 2001, J BIOL CHEM, V276, P14623, DOI 10.1074/jbc.M004401200; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; WU PG, 1992, BIOCHEMISTRY-US, V31, P7939, DOI 10.1021/bi00149a027	51	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29782	29791		10.1074/jbc.M104099200	http://dx.doi.org/10.1074/jbc.M104099200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11387341	hybrid			2022-12-27	WOS:000170558000025
J	Amici, C; Belardo, G; Rossi, A; Santoro, MG				Amici, C; Belardo, G; Rossi, A; Santoro, MG			Activation of I kappa B kinase by herpes simplex virus type 1 - A novel target for anti-herpetic therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSCRIPTION FACTOR; CYCLOPENTENONE PROSTAGLANDINS; REPLICATION; INHIBITION; INFECTION; INDUCTION; CYTOKINES; HEPATITIS; PROMOTER	Herpes simplex viruses (HSV) are ubiquitous pathogens causing a variety of diseases ranging from mild illness to severe life-threatening infections. HSV utilize cellular signaling pathways and transcription factors to promote their replication. Here we report that HSV type 1 (HSV-1) induces persistent activation of transcription factor NF-kappaB, a critical regulator of genes involved in inflammation, by activating the I kappaB kinase (IKK) in the early phase of infection. Activated NF-kappaB enhances HSV-1 gene expression. HSV-1-induced NF-kappaB activation is dependent on viral early protein synthesis and is not blocked by the anti-herpetic drug acyclovir. IKK inhibition by the anti-inflammatory cyclopentenone prostaglandin A(1) blocks HSV-1 gene expression and reduces virus yield by more than 3000-fold. The results identify IKK as a potential target for anti-herpetic drugs and suggest that cyclopentenone prostaglandins or their derivatives could be used in the treatment of HSV infection.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; CNR, Inst Neurobiol & Mol Med, I-00133 Rome, Italy	University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR)	Santoro, MG (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.		Li, Chia Cheng/D-9906-2015	Santoro, Maria Gabriella/0000-0003-1432-4949; ROSSI, ANTONIO/0000-0003-0383-3828				Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DISNEY GH, 1990, J GEN VIROL, V71, P2999, DOI 10.1099/0022-1317-71-12-2999; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; MARGOLIS DM, 1992, VIROLOGY, V186, P788, DOI 10.1016/0042-6822(92)90048-T; MAVROMARANAZOS P, 1986, VIROLOGY, V149, P152, DOI 10.1016/0042-6822(86)90117-0; McLean TI, 1999, J VIROL, V73, P8415, DOI 10.1128/JVI.73.10.8415-8426.1999; Mikloska Z, 1998, J INFECT DIS, V177, P827, DOI 10.1086/515236; Mole L, 1997, J INFECT DIS, V176, P766, DOI 10.1086/517297; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL GJ, 1988, SCIENCE, V239, P1288; Patel A, 1998, VIROLOGY, V247, P212, DOI 10.1006/viro.1998.9243; RONG BL, 1992, VIROLOGY, V189, P750, DOI 10.1016/0042-6822(92)90599-K; ROSENBERG ZF, 1991, FASEB J, V5, P2382, DOI 10.1096/fasebj.5.10.1676689; Rossi A, 1998, J BIOL CHEM, V273, P16446, DOI 10.1074/jbc.273.26.16446; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rozera C, 1996, J CLIN INVEST, V97, P1795, DOI 10.1172/JCI118609; SANTORO MG, 1980, SCIENCE, V209, P1032, DOI 10.1126/science.6157190; Santoro MG, 1997, TRENDS MICROBIOL, V5, P276, DOI 10.1016/S0966-842X(97)01066-4; SASSONECORSI P, 1985, NATURE, V313, P458, DOI 10.1038/313458a0; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SHIELD MJ, 1995, PHARMACOL THERAPEUT, V65, P125, DOI 10.1016/0163-7258(94)00060-G; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SINCLAIR SB, 1989, J CLIN INVEST, V84, P1063, DOI 10.1172/JCI114268; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; VANE JR, 1993, THERAPEUTIC APPL PRO; YAMAMOTO N, 1987, BIOCHEM BIOPH RES CO, V146, P1425, DOI 10.1016/0006-291X(87)90809-6; Zachos G, 1999, J BIOL CHEM, V274, P5097, DOI 10.1074/jbc.274.8.5097; Zachos G, 2001, J VIROL, V75, P2710, DOI 10.1128/JVI.75.6.2710-2728.2001	35	108	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28759	28766		10.1074/jbc.M103408200	http://dx.doi.org/10.1074/jbc.M103408200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387335	hybrid			2022-12-27	WOS:000170346000017
J	Ronca, F; Andersen, JS; Paech, V; Margolis, RU				Ronca, F; Andersen, JS; Paech, V; Margolis, RU			Characterization of Slit protein interactions with glypican-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; CHONDROITIN SULFATE; AXON GUIDANCE; NEURONAL MIGRATION; NERVOUS-TISSUE; BRAIN; DROSOPHILA; REPELLENT; MIDLINE; GROWTH	We have demonstrated previously that the Slit proteins, which are involved in axonal guidance and related developmental processes in nervous tissue, are ligands of the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan glypican-1 in brain (Liang, Y., Annan, R. S., Carr, S. A., Popp, S., Mevissen, M., Margolis, R. K., and Margolis, R. U. (1999) J. Biol. Chem. 274,17885-17892). To characterize these interactions in more detail, recombinant human Slit-2 protein and the N- and C-terminal portions generated by in vivo proteolytic processing were used in an enzyme-linked immunosorbent assay to measure the binding of a glypican-Fc fusion protein. Saturable and reversible high affinity binding to the full-length protein and to the C-terminal portion that is released from the cell membrane was seen, with dissociation constants in the 80-110 mi range, whereas only a relatively low level of binding to the larger N-terminal segment was detected. Co-transfection of 293 cells with Slit and glypican-1 cDNAs followed by immunoprecipitation demonstrated that these interactions also occur in vivo, and immunocytochemical studies showed colocalization in the embryonic and adult central nervous system. The binding affinity of the glypican core protein to Slit is an order of magnitude lower than that of the glycanated proteoglycan. Glypican binding to Slit was also decreased 80-90% by heparin (2 mug/ml), enzymatic removal of the heparan sulfate chains, and by chlorate inhibition of glypican sulfation. The differential effects of N- or O-desulfated heparin on glypican binding also indicate that O-sulfate groups on the heparan sulfate chains play a critical role in heparin interactions with Slit. Our data suggest that glypican binding to the releasable C-terminal portion of Slit may serve as a mechanism for regulating the biological activity of Slit and/or the proteoglycan.	NYU, Ctr Med, Dept Pharmacol, New York, NY 10016 USA	New York University	Margolis, RU (corresponding author), NYU, Ctr Med, Dept Pharmacol, 550 1St Ave, New York, NY 10016 USA.	margor01@med.nya.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013876] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-09348, NS-13876] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ba-Charvet KTN, 1999, NEURON, V22, P463, DOI 10.1016/S0896-6273(00)80702-3; Battye R, 1999, DEVELOPMENT, V126, P2475; Bhamidipati A, 2000, J CELL BIOL, V149, P1087, DOI 10.1083/jcb.149.5.1087; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Brose K, 2000, CURR OPIN NEUROBIOL, V10, P95, DOI 10.1016/S0959-4388(99)00066-5; Erskine L, 2000, J NEUROSCI, V20, P4975; GOWDA DC, 1989, J BIOL CHEM, V264, P11436; GREVE H, 1988, J BIOL CHEM, V263, P12886; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Hu HY, 1999, NEURON, V23, P703, DOI 10.1016/S0896-6273(01)80029-5; KARTHIKEYAN L, 1992, BIOCHEM BIOPH RES CO, V188, P395, DOI 10.1016/0006-291X(92)92398-H; KARTHIKEYAN L, 1994, J CELL SCI, V107, P3213; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; KLINGER MM, 1985, J BIOL CHEM, V260, P4082; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Liang Y, 1999, J BIOL CHEM, V274, P17885, DOI 10.1074/jbc.274.25.17885; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; Margolis RU, 1997, CELL TISSUE RES, V290, P343, DOI 10.1007/s004410050939; MeyerPuttlitz B, 1996, J COMP NEUROL, V366, P44, DOI 10.1002/(SICI)1096-9861(19960226)366:1<44::AID-CNE4>3.0.CO;2-K; NAKATO H, 1995, DEVELOPMENT, V121, P3687; Niclou SP, 2000, J NEUROSCI, V20, P4962; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Ringstedt T, 2000, J NEUROSCI, V20, P4983; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Safaiyan F, 1999, J BIOL CHEM, V274, P36267, DOI 10.1074/jbc.274.51.36267; TEKOTTE H, 1994, J NEUROCHEM, V62, P1126; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477; Zoo YM, 2000, CELL, V102, P363, DOI 10.1016/S0092-8674(00)00041-6	33	99	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29141	29147		10.1074/jbc.M100240200	http://dx.doi.org/10.1074/jbc.M100240200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11375980	hybrid			2022-12-27	WOS:000170346000069
J	Sun, J; Zhao, J; Schwartz, MA; Wang, JYJ; Wiedmer, T; Sims, PJ				Sun, J; Zhao, J; Schwartz, MA; Wang, JYJ; Wiedmer, T; Sims, PJ			c-Abl tyrosine kinase binds and phosphorylates phospholipid scramblase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PHOSPHOLIPIDS; TRANSBILAYER MOVEMENT; APOPTOTIC CELLS; MESSENGER-RNA; GENE FAMILY; BCR-ABL; PROTEIN; PHOSPHATIDYLSERINE; ACTIVATION; GROWTH	Phospholipid scramblase 1 (PLSCR1) is a plasma membrane protein that has been proposed to play a role in the transbilayer movement of plasma membrane phospholipids. PLSCR1 contains multiple proline-rich motifs resembling Src homology 3 (SH3) domain-binding sites. An initial screen against 13 different SH3 domains revealed a marked specificity of PLSCR1 for binding to the Abl SH3 domain. Binding between intracellular PLSCR1 and c-Abl was demonstrated by co-immunoprecipitation of both proteins from several cell lines. Deletion of the proline-rich segment in PLSCR1 (residues 1-118) abolished its binding to the Abl SH3 domain. PLSCR1 was Tyr-phosphorylated by c-Abl in vitro. Phosphorylation was abolished by mutation of Tyr residues Tyr(69)/Tyr(74) within the tandem repeat sequence (VYN)-V-68-QPVYNQP(77) of PLSCR1, implying that these residues are the likely sites of phosphorylation. Cellular PLSCR1 was found to be constitutively Tyr-phosphorylated in several cell lines. The Tyr phosphorylation of PLSCR1 was increased upon overexpression of c-Abl and significantly reduced either upon cell treatment with the Abl kinase inhibitor ST1571, or in Abl-/- mouse fibroblasts, suggesting that cellular PLSCR1 is a normal substrate of c-Abl. Cell treatment with the DNA-damaging agent cisplatin activated c-Abl kinase and increased Tyr phosphorylation of PLSCR1. The cisplatin-induced phosphorylation of PLSCR1 was inhibited by ST1571 and was not observed in Abl-/- fibroblasts. These findings indicate that c-Abl binds and phosphorylates PLSCR1, and raise the possibility that an interaction between c-Abl and plasma membrane PLSCR1 might contribute to the cellular response to genotoxic stress.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Sims, PJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-275, La Jolla, CA 92037 USA.			schwartz, martin/0000-0002-2071-1243	NCI NIH HHS [R37 CA043054, R01 CA043054] Funding Source: Medline; NHLBI NIH HHS [HL63819, HL61200, HL36946] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043054, R37CA043054] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063819, R01HL061200, R01HL036946] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agami R, 1999, NATURE, V399, P809; Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; Bevers EM, 1998, LUPUS, V7, pS126, DOI 10.1177/096120339800700228; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Gong JG, 1999, NATURE, V399, P806; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kasukabe T, 1997, BLOOD, V89, P2975, DOI 10.1182/blood.V89.8.2975; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Krahling S, 1999, CELL DEATH DIFFER, V6, P183, DOI 10.1038/sj.cdd.4400473; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Stout JG, 1997, J CLIN INVEST, V99, P2232, DOI 10.1172/JCI119397; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Till JH, 1999, J BIOL CHEM, V274, P4995, DOI 10.1074/jbc.274.8.4995; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wiedmer T, 2000, BBA-BIOMEMBRANES, V1467, P244, DOI 10.1016/S0005-2736(00)00236-4; Zhao J, 1998, J BIOL CHEM, V273, P6603, DOI 10.1074/jbc.273.12.6603; Zhao J, 1998, BIOCHEMISTRY-US, V37, P6361, DOI 10.1021/bi980218m; Zhou QS, 2000, BLOOD, V95, P2593, DOI 10.1182/blood.V95.8.2593.008k32_2593_2599; Zhou QS, 1998, BIOCHEMISTRY-US, V37, P2356, DOI 10.1021/bi972625o; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	40	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28984	28990		10.1074/jbc.M102505200	http://dx.doi.org/10.1074/jbc.M102505200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390389	hybrid			2022-12-27	WOS:000170346000048
J	Liao, YH; Satoh, T; Gao, XL; Jin, TG; Hu, CD; Kataoka, T				Liao, YH; Satoh, T; Gao, XL; Jin, TG; Hu, CD; Kataoka, T			RA-GEF-1, a guanine nucleotide exchange factor for Rap1, is activated by translocation induced by association with Rap1-GTP and enhances rap1-dependent B-Raf activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; KINASE ACTIVATION; CELL-ADHESION; MAP KINASE; G-PROTEIN; HA-RAS; FAMILY; DOMAIN; SIGNAL; GTPASE	We previously identified RA-GEF-1, a novel guanine nucleotide exchange factor (GEF) for Rap1 with the ability to associate with Rap1.GTP at its Ras/Rap1-associating (RA) domain. Because it possesses a PSD-95/DlgA/ZO-1 (PDZ) domain, it was also named PDZ-GEF. In this report, we have examined the role of the RA domain of this protein in Rap1-mediated cellular responses. A mutant of RA-GEF-1 (RA-GEF-1 Delta RA) carrying a 21-residue deletion at its RA domain fully retains the in vitro GEF activity toward Rap1 but completely loses the Rap1 binding activity. In contrast, RA-GEF-1 Delta RA, expressed in COS-7 cells, exhibits a 3-fold reduction in its in vivo GEF activity toward Rap I compared with wild-type RA-GEF-1 as examined by the Rap1 pull-down assay. Correspondingly, when coexpressed with wild-type Rap1, RA-GEF-1 Delta RA is unable to further activate B-Raf, whereas RA-GEF-1 stimulates B-Raf as efficiently as activated Rap1. Consistent with these observations, coexpression of activated Rap1 induces translocation of RA-GEF-1, which is otherwise located in the cytoplasm, to the perinuclear compartment, where Rap1 is also predominantly localized. This localization almost coincides with that of the Golgi apparatus, which was detected by anti-trans-Golgi-network 38 antibody. RA-GEF-1 Delta RA fails to show the translocation. These results indicate that RA-GEF-1 defines a novel category of GEF that is translocated to a particular subcellular compartment by association with the GTP-bound form of a small GTPase and catalyzes activation of the GDP-bound form present in the compartment, thereby causing an amplification of cellular responses induced by the small GTPase.	Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Mol Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Kataoka, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Mol Biol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kataoka@kobe-u.ac.jp	Satoh, Takaya/K-2628-2014					BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Ohtsuka T, 1999, BIOCHEM BIOPH RES CO, V265, P38, DOI 10.1006/bbrc.1999.1619; Okada T, 1999, MOL CELL BIOL, V19, P6057; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Schmidt A, 2001, MOL CELL BIOL, V21, P438, DOI 10.1128/MCB.21.2.438-448.2001; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wienecke R, 1996, ONCOGENE, V13, P913; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	38	49	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28478	28483		10.1074/jbc.M101737200	http://dx.doi.org/10.1074/jbc.M101737200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11359771	hybrid			2022-12-27	WOS:000170093400098
J	Gustin, JA; Maehama, T; Dixon, JE; Donner, DB				Gustin, JA; Maehama, T; Dixon, JE; Donner, DB			The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-OH KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; IKK-BETA; TRANSCRIPTION FACTOR; EMBRYONIC LETHALITY; GERMLINE MUTATIONS; CELLULAR-SURVIVAL; INDUCED APOPTOSIS; PROSTATE-CANCER; TNF-ALPHA	Nuclear factor kappaB (NF-kappaB) transcriptionally activates genes that promote immunity and cell survival. Activation of NF-kappaB is induced by an I kappaB kinase (IKK) complex that phosphorylates and promotes dissociation of I kappaB from NF-kappaB, which then translocates into the nucleus. Activation of phosphatidylinositol (PI) 3-kinase/Akt signaling by tumor necrosis factor (TNF) activates IKK and NF-kappaB. The present study shows that PTEN, a tumor suppressor that inhibits PI 3-kinase function, impairs TNF activation of Akt and the IKK complex in 293 cells. Transient expression of PTEN suppressed IKK activation and TNF-induced NF-kappaB DNA binding and transactivation. Studies were conducted with PC-3 prostate cancer cells that do not express PTEN and DU145 prostate cancer cells that express PTEN. TNF activated Akt in PC-3 cells, but not in DU145 cells, and the ability of TNF to activate NF-kappaB was blocked by pharmacological inhibition of PI 3-kinase activity in PC-3 cells, but not in DU145 cells. Expression of PTEN in PC-3 cells to a level comparable with that endogenously present in DU145 cells inhibited TNF activation of NF-kappaB. The cell type-specific ability of PTEN to negatively regulate the PI 3-kinase/AKT/NF-kappaB pathway may be important to its tumor suppressor activity.	Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; University of Michigan System; University of Michigan	Donner, DB (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, 1044 W Walnut St, Indianapolis, IN 46202 USA.	ddonner@IUPUI.edu	Maehama, Tomohiko/AAX-8926-2020; Maehama, Tomohiko/HGB-4896-2022	Maehama, Tomohiko/0000-0002-9685-2317	NCI NIH HHS [CA 67891, CA 73023] Funding Source: Medline; NIDDK NIH HHS [DK 18849] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA067891, R01CA073023, R01CA067891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018849] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Andjelic S, 2000, J IMMUNOL, V165, P3860, DOI 10.4049/jimmunol.165.7.3860; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beutler B, 1998, BLOOD CELL MOL DIS, V24, P216, DOI 10.1006/bcmd.1998.0187; Bonizzi G, 1999, BIOCHEM PHARMACOL, V57, P713, DOI 10.1016/S0006-2952(98)00353-0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kouba DJ, 2001, J BIOL CHEM, V276, P6214, DOI 10.1074/jbc.M004511200; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manna SK, 2000, FEBS LETT, V473, P113, DOI 10.1016/S0014-5793(00)01501-5; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; McMenamin ME, 1999, CANCER RES, V59, P4291; Myers MP, 1997, AM J HUM GENET, V61, P1234, DOI 10.1086/301659; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Ozes ON, 1999, NATURE, V401, P82; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yamamoto Y, 2000, MOL CELL BIOL, V20, P3655, DOI 10.1128/MCB.20.10.3655-3666.2000; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	61	94	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27740	27744		10.1074/jbc.M102559200	http://dx.doi.org/10.1074/jbc.M102559200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356844	hybrid			2022-12-27	WOS:000169966900132
J	Kessler, E; Fichard, A; Chanut-Delalande, H; Brusel, M; Ruggiero, F				Kessler, E; Fichard, A; Chanut-Delalande, H; Brusel, M; Ruggiero, F			Bone morphogenetic protein-1 (BMP-1) mediates C-terminal processing of procollagen V homotrimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TOLLOID-LIKE; COLLAGEN CHAIN; PRO-ALPHA-1(V) COLLAGEN; NH2-TERMINAL DOMAIN; MATRIX-FORMS; FURIN; EXPRESSION; CLEAVAGE; CELLS; METALLOPROTEINASES	The processing of the fibrillar procollagen precursors to mature collagens is an essential requirement for fibril formation. The enzymes involved in these events are known as the procollagen N and C proteinases. The latter, which cleaves the C-propeptides of the fibrillar procollagens I-III, is identical to the previously described bone morphogenetic protein-1 (BMP-1). Surprisingly, unlike the other fibrillar collagens, the processing of the C-propeptide domain of the procollagen V homotrimer was found to be mediated by furin rather than BMP-1. However, the presence of putative BMP-1 cleavage sites in the alpha1(V) C-propeptide sequence prompted us to reconsider the procollagen V C-propeptide cleavage by BMP-1. Using a recombinant system to produce substantial amounts of the pro alpha1(V) homotrimer, we have previously shown that the C-propeptide is spontaneously released in the culture medium. The trimeric C-propeptide fragment, resulting from the furin cleavage, still encompassed the predicted BMP-1 cleavage sites. It was purified and tested as a substrate for BMP-1. In parallel, the release of the C-propeptide in the culture medium was inhibited by the addition of a specific furin inhibitor, allowing the re examination of BMP-1 activity on the intact molecule. We showed that BMP-1 does cleave both substrates at one of the two predicted C-proteinase cleavage sites. Our results favor a role for PCP/BMP-1 in physiological C-terminal processing of procollagen V and imply a general mechanism for fibrillar collagen C-terminal processing.	CNRS, Inst Biol & Chim Prot, Unite Mixte Rech 5086, F-69367 Lyon 07, France; Tel Aviv Univ, Sackler Fac Med, Goldschleger Eye Res Inst, Sheba Med Ctr, IL-52621 Tel Hashomer, Israel	Centre National de la Recherche Scientifique (CNRS); Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Ruggiero, F (corresponding author), CNRS, Inst Biol & Chim Prot, Unite Mixte Rech 5086, 7 Passage Vercors, F-69367 Lyon 07, France.			RUGGIERO, Florence/0000-0003-2915-5359; CHANUT-DELALANDE, Helene/0000-0002-1720-2069				ADAR R, 1986, COLLAGEN REL RES, V6, P267; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BIRK DE, 1990, J CELL SCI, V95, P649; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BROEK DL, 1985, J BIOL CHEM, V260, P555; Chernousov MA, 2000, J BIOL CHEM, V275, P28208; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Fichard A, 1997, J BIOL CHEM, V272, P30083, DOI 10.1074/jbc.272.48.30083; FICHARD A, 1994, MATRIX BIOL, V14, P515; Grassel S, 1996, EUR J BIOCHEM, V242, P576, DOI 10.1111/j.1432-1033.1996.0576r.x; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Imamura Y, 2000, J BIOL CHEM, V275, P8749, DOI 10.1074/jbc.275.12.8749; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Kessler E., 1998, HDB PROTEOLYTIC ENZY, P1236; KIELTY K, 1993, CONNECTIVE TISSUE IT, P103; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; Lonnqvist L, 1998, HUM MOL GENET, V7, P2039, DOI 10.1093/hmg/7.13.2039; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; NIYIBIZI C, 1993, BIOCHIM BIOPHYS ACTA, V1203, P304, DOI 10.1016/0167-4838(93)90099-D; Ovens A, 2000, J PEPT SCI, V6, P489, DOI 10.1002/1099-1387(200009)6:9<489::AID-PSC282>3.3.CO;2-B; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945-053X(98)90013-0; Rousseau JC, 1996, J BIOL CHEM, V271, P23743, DOI 10.1074/jbc.271.39.23743; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; Steinmann Beat, 1993, P351; STOCKER W, 1995, PROTEIN SCI, V4, P823; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; WEIL D, 1987, NUCLEIC ACIDS RES, V15, P181, DOI 10.1093/nar/15.1.181; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	43	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27051	27057		10.1074/jbc.M102921200	http://dx.doi.org/10.1074/jbc.M102921200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11358968	hybrid			2022-12-27	WOS:000169966900043
J	Sang, NL; Severino, A; Russo, P; Baldi, A; Giordano, A; Mileo, AM; Paggi, MG; De Luca, A				Sang, NL; Severino, A; Russo, P; Baldi, A; Giordano, A; Mileo, AM; Paggi, MG; De Luca, A			RACK1 interacts with E1A and rescues E1A-induced yeast growth inhibition and mammalian cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS TYPE-5 E1A; RETINOBLASTOMA GENE FAMILY; PROTEINS INDUCE APOPTOSIS; REGION 1A PROTEINS; MOLECULAR-CLONING; BETA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; BREAST-CANCER; FISSION YEAST; CYCLE CONTROL	The adenoviral E1A proteins are able to promote proliferation and transformation, inhibit differentiation, induce apoptosis, and suppress tumor growth. The extreme N terminus and conserved region one of E1A, which are indispensable for transcriptional regulation and for binding to p300/CBP, TBP, and pCAF, play essential roles in these abilities. These observations strongly suggest an intrinsic link between E1A-mediated transcriptional regulation and other effects. In this report, we show that E1A inhibits the normal growth of Saccharomyces cerevisiae HF7c, and this inhibition also depends on the domains required for transcriptional regulation. We demonstrate that E1A associates with histone acetyltransferase activity and represses the transactivation activity of transcription factor in S. cerevisiae, suggesting that E1A may suppress the expression of genes required for normal growth. Based on yeast growth rescue, we present a genetic screening strategy that identified RACK1 as an E1A antagonizing factor. Expression of human RACK1 efficiently relieves E1A-mediated growth inhibition in HF7c and protects human tumor cells from E1A-induced apoptosis. Finally, we show that RACK1 decreases E1A-associated histone acetyltransferase activity in yeast and mammalian cells, and physically interacts with E1A Our data demonstrate that RACK1 is a repressor of E1A, possibly by antagonizing the effects of E1A on host gene transcription.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Cardeza Fdn, Philadelphia, PA 19107 USA; Regina Elena Inst Canc Res, Lab Cell Metab & Pharmacokinet, Ctr Expt Res, I-00158 Rome, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Anat & Cell Biol, Philadelphia, PA 19107 USA; Regina Elena Inst Canc Res, Biophys Lab, Ctr Expt Res, I-00158 Rome, Italy	Jefferson University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Jefferson University; Jefferson University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	De Luca, A (corresponding author), Regina Elena Inst Canc Res, Lab Cell Metab & Pharmacokinet, Ctr Expt Res, Via Messi Oro 156, I-00158 Rome, Italy.	paggi@ifo.it	De Luca, Antonio/AAD-9562-2020; Severino, Anna/S-3417-2019; Mileo, Anna Maria/J-3667-2016; Paggi, Marco G./K-3494-2018; Giordano, Antonio/F-1927-2010; Baldi, Alfonso/ABG-2397-2021	De Luca, Antonio/0000-0002-3905-6154; Severino, Anna/0000-0002-6276-7747; Mileo, Anna Maria/0000-0002-1970-3297; Giordano, Antonio/0000-0002-5959-016X; Baldi, Alfonso/0000-0002-8693-3842	NATIONAL CANCER INSTITUTE [R01CA056304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 6099-01A1, P01-CA 56304-08] Funding Source: Medline; NINDS NIH HHS [P01 NS 36466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; BONDESSON M, 1994, NUCLEIC ACIDS RES, V22, P3053, DOI 10.1093/nar/22.15.3053; Brader KR, 1997, CLIN CANCER RES, V3, P2017; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang JY, 1996, ONCOGENE, V13, P1405; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; Condorelli G, 1997, J CELL BIOCHEM, V67, P423, DOI 10.1002/(SICI)1097-4644(19971215)67:4<423::AID-JCB1>3.0.CO;2-U; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; Frisch SM, 1996, MUTAT RES-FUND MOL M, V350, P261, DOI 10.1016/0027-5107(95)00103-4; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Hoffmann B, 1999, MOL MICROBIOL, V31, P807, DOI 10.1046/j.1365-2958.1999.01219.x; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; Jones N C, 1990, Semin Cancer Biol, V1, P425; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MAYOL X, 1993, ONCOGENE, V8, P2561; McLeod M, 2000, MOL CELL BIOL, V20, P4016, DOI 10.1128/MCB.20.11.4016-4027.2000; MILLER ME, 1995, ONCOGENE, V11, P1623; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Mymryk JS, 1996, ONCOGENE, V13, P1581; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Okayama H, 1996, ADV CANCER RES, V69, P17, DOI 10.1016/S0065-230X(08)60859-3; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; Sang NL, 1996, ANAL BIOCHEM, V233, P142, DOI 10.1006/abio.1996.0020; Sang NL, 1997, DNA CELL BIOL, V16, P1321, DOI 10.1089/dna.1997.16.1321; Sang NL, 1997, J CELL PHYSIOL, V170, P182, DOI 10.1002/(SICI)1097-4652(199702)170:2<182::AID-JCP10>3.0.CO;2-K; Sang NL, 1997, J CELL BIOCHEM, V66, P277, DOI 10.1002/(SICI)1097-4644(19970901)66:3<277::AID-JCB1>3.0.CO;2-M; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SHENK T, 1991, ADV CANCER RES, V57, P47; TEODORO JG, 1995, ONCOGENE, V11, P467; Ueno NT, 1997, ONCOGENE, V15, P953, DOI 10.1038/sj.onc.1201250; WADA T, 1990, BIOCHEM BIOPH RES CO, V170, P470, DOI 10.1016/0006-291X(90)92115-G; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YU DH, 1993, CANCER RES, V53, P891; ZIELER HA, 1995, MOL CELL BIOL, V15, P3227	66	53	53	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27026	27033		10.1074/jbc.M010346200	http://dx.doi.org/10.1074/jbc.M010346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11358958	hybrid			2022-12-27	WOS:000169966900040
J	Chauhan, D; Hideshima, T; Rosen, S; Reed, JC; Kharbanda, S; Anderson, KC				Chauhan, D; Hideshima, T; Rosen, S; Reed, JC; Kharbanda, S; Anderson, KC			Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; ACTIVATION; PROCASPASE-9; CASPASES; PROTEINS; KINASE; IAP; INTERLEUKIN-6; MITOCHONDRIA; SMAC/DIABLO	Smac, a second mitochondria-derived activator of caspases, promotes caspase activation in the cytochrome c (cyto-c)/Apaf-1/caspase-9 pathway. Here, we show that treatment of multiple myeloma (MM) cells with dexamethasone (Dex) triggers the release of Smac from mitochondria to cytosol and activates caspase-9 without concurrent release of cyto-e and Apaf-1 oligomerization. Smac binds to XIAP tan inhibitor of apoptosis protein) and thereby, at least in part, eliminates its inhibitory effect on caspase-9. Interleukin-6, a growth factor for MM, blocks Dex-induced apoptosis and prevents release of Smac, Taken together, these findings demonstrate that Smac plays a functional role in mediating I)ex-induced caspase-9 activation and apoptosis in MM cells.	Harvard Univ, Sch Med, Dana Farber Canc Inst,Dept Adult Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Burnham Inst, La Jolla, CA 92037 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Sanford Burnham Prebys Medical Discovery Institute	Anderson, KC (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst,Dept Adult Oncol, Jerome Lipper Multiple Myeloma Ctr, Mayer 557,44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA 78373] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bossy-Wetzel E, 1999, MUTAT RES-DNA REPAIR, V434, P243, DOI 10.1016/S0921-8777(99)00032-4; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 2001, APOPTOSIS, V6, P47, DOI 10.1023/A:1009620027205; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mesner PW, 1999, J BIOL CHEM, V274, P22635, DOI 10.1074/jbc.274.32.22635; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; WILLIE AH, 1980, INT REV CYTOL, V68, P251; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	29	174	183	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24453	24456		10.1074/jbc.C100074200	http://dx.doi.org/10.1074/jbc.C100074200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11356822	hybrid			2022-12-27	WOS:000169800700006
J	Levine, RL; Miller, H; Grollman, A; Ohashi, E; Ohmori, H; Masutani, C; Hanaoka, F; Moriya, M				Levine, RL; Miller, H; Grollman, A; Ohashi, E; Ohmori, H; Masutani, C; Hanaoka, F; Moriya, M			Translesion DNA synthesis catalyzed by human pol eta and pol kappa across 1,N-6-ethenodeoxyadenosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRONE LESION BYPASS; POLYMERASE-KAPPA; MOUSE HOMOLOGS; FIDELITY; REPLICATION; CELLS; ENCODES; PROTEIN; ADDUCT; DINB1	1,N-6-Ethenodeoxyadenosine, a DNA adduct generated by exogenous and endogenous sources, severely blocks DNA synthesis and induces miscoding events in human cells. To probe the mechanism for in vivo translesion DNA synthesis across this adduct, in vitro primer extension studies were conducted using newly identified human DNA polymerases (pol) eta and kappa, which have been shown to catalyze translesion DNA synthesis past several DNA lesions. Steady-state kinetic analyses and analysis of translesion products have revealed that the synthesis is > 100-fold more efficient with pol eta than with pol K and that both error-free and error-prone syntheses are observed with these enzymes. The miscoding events include both base substitution and frameshift mutations. These results suggest that both polymerases, particularly pol eta, may contribute to the translesion DNA synthesis events observed for 1,N-6-ethenodeoxyadenosine in human cells.	SUNY Stony Brook, Dept Pharmacol Sci, Chim Biol Lab, Stony Brook, NY 11794 USA; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Kyoto Univ, Inst Virus Res, Dept Genet & Mol Biol, Lab Genet Informat Anal, Kyoto 6068507, Japan	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Osaka University; Kyoto University	Moriya, M (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Chim Biol Lab, Stony Brook, NY 11794 USA.	maki@pharm.sunysb.edu	Masutani, Chikahide/I-6160-2014; Ohashi, Eiji/AAO-5794-2021; Miller, Holly/I-6942-2015; levine, ross/AAE-7658-2019	Ohashi, Eiji/0000-0002-1771-5585; Miller, Holly/0000-0002-9076-5335; Masutani, Chikahide/0000-0002-8600-8227	NCI NIH HHS [CA76163] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076163, R56CA076163] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Creighton S, 1995, METHOD ENZYMOL, V262, P232; Efrati E, 1997, J BIOL CHEM, V272, P2559; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Levine RL, 2000, CANCER RES, V60, P4098; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; Mozzherin DJ, 1999, J BIOL CHEM, V274, P19862, DOI 10.1074/jbc.274.28.19862; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; NG L, 1991, J BIOL CHEM, V266, P11699; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Ohashi E, 2000, GENE DEV, V14, P1589; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Pandya GA, 1996, BIOCHEMISTRY-US, V35, P11487, DOI 10.1021/bi960170h; Sagi J, 1999, IARC SCI PUBL, P191; Shibutani S, 1996, BIOCHEMISTRY-US, V35, P14992, DOI 10.1021/bi961446o; Tissier A, 2000, GENE DEV, V14, P1642; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4717, DOI 10.1093/nar/28.23.4717; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138	29	84	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18717	18721		10.1074/jbc.M102158200	http://dx.doi.org/10.1074/jbc.M102158200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376002	hybrid			2022-12-27	WOS:000169091000011
J	Favre, B; Fontao, L; Koster, J; Shafaatian, R; Jaunin, F; Saurat, JH; Sonnenberg, A; Borradori, L				Favre, B; Fontao, L; Koster, J; Shafaatian, R; Jaunin, F; Saurat, JH; Sonnenberg, A; Borradori, L			The hemidesmosomal protein bullous pemphigoid antigen 1 and the integrin beta 4 subunit bind to ERBIN - Molecular cloning of multiple alternative splice variants of ERBIN and analysis of their tissue expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL PDZ PROTEIN; AMINO-ACID; ALPHA(6)BETA(4) INTEGRIN; TOPOLOGY PREDICTION; TERMINAL DOMAIN; CELL-MIGRATION; ALPHA-6-BETA-4; BP180; PLECTIN; CYTOSKELETON	The bullous pemphigoid antigen I (eBPAG1) is a constituent of hemidesmosomes (HDs), cell-substrate adhesion complexes in stratified epithelia. Although its COOH terminus interacts with intermediate filaments, its NH2 terminus is important for its recruitment into HDs. To identify proteins that interact with the NH2 terminus of human eBPAG1, we performed a yeast two-hybrid screen, which uncovered a protein belonging to the LAP/LERP (for LRR and PDZ domain) protein family with 16 NH2-terminal leucine-rich repeats and a COOH-terminal PDZ domain. The gene for this LAP/LERP protein comprises at least 26 exons located on the long arm of chromosome 5. In most human tissues, several transcripts were detected differing in the coding region situated upstream of or within the PDZ domain. One of the encoded variants was found to correspond to the recently described protein ERBIN. In yeast and in vitro binding experiments, ERBIN was shown to interact not only with eBPAG1 but also with the COOH-terminal region of the cytoplasmic domain of the integrin beta4 subunit, another component of HDs. Antibodies raised against the COOH terminus showed that ERBIN is expressed in keratinocytes. In transfected epithelial cells the protein, however, was not localized in HDs but was either diffusely distributed over the cytoplasm or concentrated at the basolateral plasma membrane. Because ERBIN had been shown previously to interact with the transmembrane tyrosine kinase receptor Erb-B2, which in turn associates with the integrin beta4 subunit, we suggest that ERBIN provides a link between HD assembly and Erb-B2 receptor signaling.	Univ Geneva, Sch Med, Dept Dermatol, CH-1211 Geneva 14, Switzerland; Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	University of Geneva; Netherlands Cancer Institute	Borradori, L (corresponding author), Univ Hosp Geneva, Dept Dermatol, Rue Micheli Du crest 24, CH-1211 Geneva 14, Switzerland.		Lionel, Fontao/AGN-3640-2022; Koster, Jan/C-5934-2008	Koster, Jan/0000-0002-0890-7585; Fontao, Lionel/0000-0002-5950-564X				Aho S, 1998, BIOCHEM BIOPH RES CO, V243, P694, DOI 10.1006/bbrc.1998.8162; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apperson ML, 1996, J NEUROSCI, V16, P6839; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Borradori L, 1997, J CELL BIOL, V136, P1333, DOI 10.1083/jcb.136.6.1333; Borradori L, 1998, EXP CELL RES, V239, P463, DOI 10.1006/excr.1997.3923; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; BROWN A, 1995, GENOMICS, V29, P777, DOI 10.1006/geno.1995.9936; Bryant PJ, 2000, NAT CELL BIOL, V2, pE141, DOI 10.1038/35019616; Burshtyn DN, 1997, J BIOL CHEM, V272, P13066, DOI 10.1074/jbc.272.20.13066; Chao C, 1996, CANCER RES, V56, P4811; Cowburn D, 1997, CURR OPIN STRUC BIOL, V7, P835, DOI 10.1016/S0959-440X(97)80155-8; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Geerts D, 1999, J CELL BIOL, V147, P417, DOI 10.1083/jcb.147.2.417; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; Greaves S, 2000, NAT CELL BIOL, V2, pE140, DOI 10.1038/35019613; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; Harlow E., 1988, ANTIBODIES LAB MANUA; HASHIMOTO T, 1993, J INVEST DERMATOL, V100, P310, DOI 10.1111/1523-1747.ep12469916; Hopkinson SB, 2000, MOL BIOL CELL, V11, P277, DOI 10.1091/mbc.11.1.277; James P, 1996, GENETICS, V144, P1425; Jones JCR, 1998, BIOESSAYS, V20, P488, DOI 10.1002/(SICI)1521-1878(199806)20:6<488::AID-BIES7>3.0.CO;2-I; KENNEL SJ, 1990, HYBRIDOMA, V9, P243, DOI 10.1089/hyb.1990.9.243; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Leung CL, 1999, J CELL BIOL, V144, P435, DOI 10.1083/jcb.144.3.435; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; Nievers MG, 1998, J CELL SCI, V111, P1659; Nikolic B, 1996, J CELL BIOL, V134, P1455, DOI 10.1083/jcb.134.6.1455; Peifer M, 2000, SCIENCE, V289, P67, DOI 10.1126/science.289.5476.67; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Rezniczek GA, 1998, J CELL BIOL, V141, P209, DOI 10.1083/jcb.141.1.209; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Ruhrberg C, 1997, CURR OPIN GENET DEV, V7, P392, DOI 10.1016/S0959-437X(97)80154-2; SAWAMURA D, 1991, J BIOL CHEM, V266, P17784; Schaapveld RQJ, 1998, J CELL BIOL, V142, P271, DOI 10.1083/jcb.142.1.271; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Sinclair NRS, 2000, CRIT REV IMMUNOL, V20, P89; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; STANLEY JR, 1988, J CLIN INVEST, V82, P1864, DOI 10.1172/JCI113803; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; Sterk LMT, 2000, J CELL BIOL, V149, P969, DOI 10.1083/jcb.149.4.969; Strack S, 2000, J BIOL CHEM, V275, P25061, DOI 10.1074/jbc.C000319200; TANAKA T, 1990, J INVEST DERMATOL, V94, P617, DOI 10.1111/1523-1747.ep12876200; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Wiche G, 1998, J CELL SCI, V111, P2477; Yang YM, 1999, CELL, V98, P229, DOI 10.1016/S0092-8674(00)81017-X; Yang YM, 1996, CELL, V86, P655, DOI 10.1016/S0092-8674(00)80138-5; Zimmermann P, 2001, MOL BIOL CELL, V12, P339, DOI 10.1091/mbc.12.2.339	56	64	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32427	32436		10.1074/jbc.M011005200	http://dx.doi.org/10.1074/jbc.M011005200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11375975	hybrid			2022-12-27	WOS:000170746000010
J	Boudreau, F; Zhu, Y; Traber, PG				Boudreau, F; Zhu, Y; Traber, PG			Sucrase-isomaltase gene transcription requires the hepatocyte nuclear factor-1 (HNF-1) regulatory element and is regulated by the ratio of HNF-1 alpha to HNF-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; CRYPT-VILLUS AXIS; HOMEODOMAIN PROTEINS; LINE CACO-2; EXPRESSION; DIFFERENTIATION; ACTIVATION; CDX2; HETERODIMERS; ABUNDANCE	The mouse sucrase-isomaltase (SI) gene is an enterocyte-specific gene expressed in a complex developmental pattern. We previously reported that a short, evolutionarily conserved gene promoter regulates developmental expression of SI in mouse small intestine. Herein, we investigated the role of a hepatocyte nuclear factor-1 (HNF-1) cis-acting element to regulate SI gene expression in vivo. Transgenic SI gene constructs with a mutated HNF-1 element (SIF3) revealed a strong reduction in promoter activity in comparison with a wild-type construct in mice and during Caco-2 cell differentiation. Nuclear proteins isolated from enterocytes showed increased binding of the HNF-1 alpha complex with a concomitant decrease in the HNF-1 beta -containing complex to the SIF3 element both during the suckling-weaning developmental transition and Caco-2 cell differentiation. These changes coincided with a strong induction of SI gene transcription. In transfection experiments, HNF-1 alpha activated the ST promoter via the SIF3 element, and coexpression of HNF-1 beta impaired this transcriptional activation. These findings demonstrate the essential role of the HNF-1 regulatory element to support SI gene transcription in vivo and suggest that the ratio of HNF-1 alpha to HNF-1 beta plays a role in the transcriptional activity of this gene during intestinal development.	Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA	University of Pennsylvania	Traber, PG (corresponding author), 709 Swedeland Rd,POB 1539, King Of Prussia, PA 19406 USA.				NIDDK NIH HHS [P30-DK50306, R01-DK46704] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306, R01DK046704] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BEAULIEU JF, 1991, BIOCHEM J, V280, P599, DOI 10.1042/bj2800599; Boudreau F, 1998, DNA CELL BIOL, V17, P669, DOI 10.1089/dna.1998.17.669; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; Hu CB, 1999, AM J PHYSIOL-GASTR L, V276, pG1181, DOI 10.1152/ajpgi.1999.276.5.G1181; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; LIU SY, 1995, DNA CELL BIOL, V14, P285, DOI 10.1089/dna.1995.14.285; Markowitz AJ, 1995, AM J PHYSIOL-GASTR L, V269, pG925, DOI 10.1152/ajpgi.1995.269.6.G925; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; Menard D., 1994, MEMBRANE PHYSIOPATHO, P319; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; Mitchelmore C, 2000, BIOCHEM J, V346, P529, DOI 10.1042/0264-6021:3460529; PINTO M, 1983, BIOL CELL, V47, P323; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Song YH, 1998, J BIOL CHEM, V273, P28408, DOI 10.1074/jbc.273.43.28408; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; Traber PG, 1998, PHILOS T ROY SOC B, V353, P911, DOI 10.1098/rstb.1998.0255; TRABER PG, 1990, BIOCHEM BIOPH RES CO, V173, P765, DOI 10.1016/S0006-291X(05)80853-8; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; TRABER PG, 1992, AM J PHYSIOL, V262, pG123, DOI 10.1152/ajpgi.1992.262.1.G123; Tung J, 1997, AM J PHYSIOL-GASTR L, V273, pG83, DOI 10.1152/ajpgi.1997.273.1.G83; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; WU GD, 1994, J BIOL CHEM, V269, P17080; WU GD, 1992, J BIOL CHEM, V267, P7863; Zweibaum A, 1989, ADAPTATION DEV GASTR, P103	33	68	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32122	32128		10.1074/jbc.M102002200	http://dx.doi.org/10.1074/jbc.M102002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11395488	hybrid			2022-12-27	WOS:000170613500089
J	Nepomuceno-Silva, JL; Yokoyama, K; de Mello, LDB; Mendonca, SM; Paixao, JC; Baron, R; Faye, JC; Buckner, FS; Van Voorhis, WC; Gelb, MH; Lopes, UG				Nepomuceno-Silva, JL; Yokoyama, K; de Mello, LDB; Mendonca, SM; Paixao, JC; Baron, R; Faye, JC; Buckner, FS; Van Voorhis, WC; Gelb, MH; Lopes, UG			TcRho1, a farnesylated Rho family homologue from Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ACTIN CYTOSKELETON; SIGNALING PATHWAYS; LEISHMANIA-MAJOR; CELL BIOLOGY; S-PHASE; BRUCEI; CLONING; FARNESYLTRANSFERASE; RAS	Rho GTPases are members of the Ras superfamily and are involved in signal transduction pathways, including maintenance of cell morphology and motility, cell cycle progression, and transcription activation. We report the molecular identification in trypanosomatids (Trypanosoma cruzi) of the first member of the Rho family. The cloned Rho protein, TcRho1, shares similar to 40% homology with other members of the Rho family. Southern blot analysis revealed that TcRHO1 is a single copy gene per haploid genome, and Northern blot assays showed a transcript of 1200 nucleotides in length. Mapping the 5 ' -untranslated region of TcRHO1 transcripts revealed at least five different transcripts derived from differential trans-splicing. Three of the five transcripts contain the trans-splicing site within the coding region of the TcRHO1 gene. TeRho1 also contains the C-terminal sequence CQLF (CAAX motif), which is predicted to direct post-translation prenylation of the cysteine residue. A synthetic peptide containing this C-terminal motif, when tested against Q-Sepharose chromatography fractions from T. cruzi cytosol, was shown to be efficiently farnesylated, but not geranylgeranylated, despite the fact that the CAAX motif with X = Phe specifies geranylgeranylation by mammalian protein geranylgeranyltransferase I. Furthermore, immunoblot analyses of epimastigote protein with anti-S-farnesyleysteine methyl ester and anti-TcRhol antisera strongly suggested that TcRhol is farnesylated in vivo. The farnesylation of proteins such as Rho GTPases could be the basis for the selective cytotoxic action of protein farnesyltransferase inhibitors on trypanosomatids versus mammalian cells.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21949 Rio De Janeiro, Brazil; Inst C Regaud, INSERM U397, F-31052 Toulouse, France	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Universidade Federal do Rio de Janeiro; Institut National de la Sante et de la Recherche Medicale (Inserm)	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Seattle, WA 98195 USA.	gelb@chem.washington.edu; lopesu@biof.ufrj.br	Lopes, Ulisses/N-4416-2013; Buckner, Frederick/AAF-3938-2020; Nepomuceno da SIlva, Jose Luciano/L-9657-2013; Lopes, Ulisses Gazos/T-6634-2019	Nepomuceno da SIlva, Jose Luciano/0000-0002-8413-2988; gelb, michael/0000-0001-7000-5219; De Melo, Luiz Dione Barbosa/0000-0003-2445-9943; Buckner, Frederick/0000-0001-7796-6477	NCI NIH HHS [CA52874] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; ALCINA A, 1988, CELL BIOL INT REP, V12, P979, DOI 10.1016/0309-1651(88)90166-X; Ali BRS, 1999, MOL BIOCHEM PARASIT, V104, P67, DOI 10.1016/S0166-6851(99)00131-0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baron R, 2000, P NATL ACAD SCI USA, V97, P11626, DOI 10.1073/pnas.97.21.11626; BENAMAR MF, 1988, MOL CELL BIOL, V8, P2166, DOI 10.1128/MCB.8.5.2166; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bringaud F, 1998, MOL BIOCHEM PARASIT, V94, P249, DOI 10.1016/S0166-6851(98)00080-2; Buckner FS, 2000, J BIOL CHEM, V275, P21870, DOI 10.1074/jbc.M000975200; CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93; CAMPBELLBURK SL, 1995, METHOD ENZYMOL, V255, P3; CAPPAI R, 1993, MOL BIOCHEM PARASIT, V62, P73, DOI 10.1016/0166-6851(93)90179-2; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; Concepcion JL, 1998, ARCH BIOCHEM BIOPHYS, V352, P114, DOI 10.1006/abbi.1998.0577; CONTRERAS VT, 1985, MOL BIOCHEM PARASIT, V16, P315, DOI 10.1016/0166-6851(85)90073-8; COPPENS I, 1995, MOL BIOCHEM PARASIT, V69, P29, DOI 10.1016/0166-6851(94)00192-P; Cuvillier A, 2000, J CELL SCI, V113, P2065; DAGGER F, 1989, MOL BIOL REP, V13, P197, DOI 10.1007/BF00788171; DAGHER MC, 1995, BIOCHIMIE, V77, P651, DOI 10.1016/0300-9084(96)88180-6; de Mendonca SM, 2000, GENE, V243, P179, DOI 10.1016/S0378-1119(99)00480-1; DEARRUDA MV, 1994, GENE, V139, P123, DOI 10.1016/0378-1119(94)90534-7; DESOUZA W, 1984, INT REV CYTOL, V86, P197, DOI 10.1016/S0074-7696(08)60180-1; DESOUZA W, 1983, J PARASITOL, V69, P138, DOI 10.2307/3281288; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Field H, 1996, MOL BIOCHEM PARASIT, V82, P67, DOI 10.1016/0166-6851(96)02723-5; Field H, 1997, J BIOL CHEM, V272, P10498, DOI 10.1074/jbc.272.16.10498; Field H, 2000, MOL BIOCHEM PARASIT, V106, P21, DOI 10.1016/S0166-6851(99)00192-9; Field H, 1998, J BIOL CHEM, V273, P32102, DOI 10.1074/jbc.273.48.32102; Field H, 1999, J CELL SCI, V112, P147; Field MC, 1999, PARASITOL TODAY, V15, P365, DOI 10.1016/S0169-4758(99)01499-4; FIELD MC, 1995, MOL BIOCHEM PARASIT, V69, P131, DOI 10.1016/0166-6851(94)00209-6; Field MC, 1995, EXP PARASITOL, V81, P313, DOI 10.1006/expr.1995.1122; Gelb MH, 1997, SCIENCE, V275, P1750, DOI 10.1126/science.275.5307.1750; *GEN COMP GROUP IN, GCG WISC SEQ AN SOFT; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; Godbold GD, 1998, BRAZ J MED BIOL RES, V31, P1049, DOI 10.1590/S0100-879X1998000800004; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirai A, 1997, J BIOL CHEM, V272, P13; Hummel HS, 2000, J BIOL CHEM, V275, P35522, DOI 10.1074/jbc.M002424200; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Johnston DA, 1999, BIOESSAYS, V21, P131, DOI 10.1002/(SICI)1521-1878(199902)21:2<131::AID-BIES7>3.0.CO;2-I; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LaFlamme AC, 1995, MOL BIOCHEM PARASIT, V75, P25, DOI 10.1016/0166-6851(95)02506-5; Leal ST, 2000, EXP PARASITOL, V96, P23, DOI 10.1006/expr.2000.4549; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; MORTARA RA, 1989, J PROTOZOOL, V36, P8; PERRY RP, 1972, BIOCHIM BIOPHYS ACTA, V262, P220, DOI 10.1016/0005-2787(72)90236-5; POMPLIANO DL, 1993, BIOCHEMISTRY-US, V32, P8341, DOI 10.1021/bi00083a038; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER A, 1988, J CELL SCI, V90, P307; Sowa MPK, 1999, GENE, V230, P155, DOI 10.1016/S0378-1119(99)00072-4; Sturm NR, 1998, BBA-GENE STRUCT EXPR, V1442, P347, DOI 10.1016/S0167-4781(98)00150-X; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; SWINDLE J, 1996, MOL BIOL PARASITIC P, P6; Tanaka K, 1998, CURR OPIN CELL BIOL, V10, P112, DOI 10.1016/S0955-0674(98)80093-8; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VASSELLA E, 1994, NUCLEIC ACIDS RES, V22, P1359, DOI 10.1093/nar/22.8.1359; Vogt A, 1996, ONCOGENE, V13, P1991; Wiese M, 1998, EMBO J, V17, P2619, DOI 10.1093/emboj/17.9.2619; Wilson W, 1997, GENE, V187, P201, DOI 10.1016/S0378-1119(96)00749-4; Winge P, 1997, PLANT MOL BIOL, V35, P483, DOI 10.1023/A:1005804508902; Yokoyama K, 1997, MOL BIOCHEM PARASIT, V87, P61, DOI 10.1016/S0166-6851(97)00043-1; Yokoyama K, 1998, J BIOL CHEM, V273, P26497, DOI 10.1074/jbc.273.41.26497; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; Yokoyama K, 1998, MOL BIOCHEM PARASIT, V94, P87, DOI 10.1016/S0166-6851(98)00053-X	73	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29711	29718		10.1074/jbc.M102920200	http://dx.doi.org/10.1074/jbc.M102920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11359782	hybrid			2022-12-27	WOS:000170558000017
J	Hatanaka, T; Hashimoto, M; Majima, E; Shinohara, Y; Terada, H				Hatanaka, T; Hashimoto, M; Majima, E; Shinohara, Y; Terada, H			Significant effect of the N-terminal region of the mitochondrial ADP/ATP carrier on its efficient expression in yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP ATP CARRIER; SACCHAROMYCES-CEREVISIAE; PROTEIN TRANSLOCATION; TRANSPORT; MEMBRANE; BINDING; IMPORT; HEART; GENES	The low-level expression of the bovine heart mitochondrial ADP/ATP carrier (bovine type I ADP/ATP carrier (bAAC1)) in the yeast mitochondrial membrane is significantly improved by replacement of its N-terminal region with corresponding regions of the yeast type 1 and 2 carriers (yAAC1 and yAAC2) (Hashimoto, M., Shinohara, Y., Majima, E., Hatanaka, T., Yamazaki, N., and Terada, H. (1999) Biochim. Biophys. Acta 1409,113-124). To understand why the bAAC1 chimeras were highly expressed in yeast mitochondria, we examined the effects of the length and sequence of the N-terminal region extending into the cytosol on the expression of bAAC1 and yAAC2 derivatives in yeast mitochondria. For this, their N-terminal regions were replaced with peptide fragments of various lengths and sequences derived from those of bAAC1, yAAC1, and yAAC2. We found that a specific amino acid sequence and a definite length of the N-terminal region of yAAC2 were required for high expression of bAAC1 and yAAC2 in yeast mitochondria. We also examined the steady-state transcript levels and expression of these derivatives in whole yeast cells. Based on our results, we discuss the role of the N-terminal region in efficient expression of bAAC1 and yAAC2 in yeast mitochondria.	Univ Tokushima, Fac Pharmaceut Sci, Tokushima 7708505, Japan; APRO Life Sci Inst, Naruto 7720001, Japan	Tokushima University	Terada, H (corresponding author), Univ Tokushima, Fac Pharmaceut Sci, Shomachi 1, Tokushima 7708505, Japan.	hterada@ph.tokushima-u.ac.jp						ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; Dianoux AC, 2000, BIOCHEMISTRY-US, V39, P11477, DOI 10.1021/bi000618l; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5; Hashimoto M, 1999, BBA-BIOENERGETICS, V1409, P113, DOI 10.1016/S0005-2728(98)00155-8; Hatanaka T, 1999, BIOCHEM BIOPH RES CO, V262, P726, DOI 10.1006/bbrc.1999.1283; Hatanaka T, 2001, BIOL PHARM BULL, V24, P595, DOI 10.1248/bpb.24.595; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; Kaldi K, 1998, BIOFACTORS, V8, P221, DOI 10.1002/biof.5520080308; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KOLAROV J, 1990, J BIOL CHEM, V265, P12711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JE, 1988, J BIOL CHEM, V263, P14812; Nelson DR, 1996, BBA-BIOENERGETICS, V1275, P133, DOI 10.1016/0005-2728(96)00063-1; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PEDERSEN PL, 1993, J BIOENERG BIOMEMBR, V25, P431, DOI 10.1007/BF01108400; PFANNER N, 1987, J BIOL CHEM, V262, P14851; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; ROISE D, 1988, J BIOL CHEM, V263, P4509; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHULTHEISS HP, 1985, ARCH BIOCHEM BIOPHYS, V239, P273, DOI 10.1016/0003-9861(85)90836-7; SMAGULA C, 1988, J BIOL CHEM, V263, P6783; Terada H, 1997, PROG COLL POL SCI S, V106, P192, DOI 10.1007/BF01189519; Trezeguet V, 2000, BBA-BIOENERGETICS, V1457, P81, DOI 10.1016/S0005-2728(99)00115-2; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6	26	8	8	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28881	28888		10.1074/jbc.M102535200	http://dx.doi.org/10.1074/jbc.M102535200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384977	hybrid			2022-12-27	WOS:000170346000034
J	Stricker, TP; Dumin, JA; Dickeson, SK; Chung, L; Nagase, H; Parks, WC; Santoro, SA				Stricker, TP; Dumin, JA; Dickeson, SK; Chung, L; Nagase, H; Parks, WC; Santoro, SA			Structural analysis of the alpha(2) integrin I domain/procollagenase-1 (matrix metalloproteinase-1) interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR; COLLAGENOLYTIC ACTIVITY; BINDING-ACTIVITY; TUMOR INVASION; EXPRESSION; LOCALIZATION; SURFACE; ANGIOGENESIS	Previous studies have established that ligation of keratinocyte alpha (2)beta (1) integrin by type I collagen induces expression of matrix metalloproteinase-1 (MMP-1) and that MMP-1 activity is required for the alpha (2)beta (1) integrin-dependent migration of primary keratinocytes across collagenous matrices. We now present evidence that MMP-1 binds the alpha (2)beta (1) integrin via the I domain of the alpha (2) integrin subunit. Using an enzyme-linked immunosorbent assay with purified human MMP-1 and recombinant alpha (2) integrin I domain, we showed that the alpha (2) integrin I domain specifically bound in a divalent cation-dependent manner to both the pro and active forms of MMP-1, but not to MMP-3 or MMP-13. Although both the I domain and MMP-1 bind divalent cations, MMP-1 bound, in a divalent cation-dependent manner, to alpha (2) integrin I domains containing metal ion-dependent adhesion sites motif mutations that prevent divalent cation binding to the I domain, demonstrating that the metal ion dependence is a function of MMP-1. Using a series of MMP-1-MMP-3 and MMP-1-MMP-13 chimeras, we determined that both the linker domain and the hemopexin-like domain of MMP-1 were required for optimal binding to the I domain. The alpha (2) integrin/MMP-1 interaction described here extends an emerging paradigm in matrix biology involving anchoring of proteinases to the cell surface to regulate their biological activities.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ Kansas, Med Ctr, Sch Med, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ London Imperial Coll Sci Technol & Med, Sch Med, Kennedy Inst Rheumatol, London W6 8LH, England	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Kansas; University of Kansas Medical Center; Imperial College London; University of Oxford	Santoro, SA (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Box 8118, St Louis, MO 63110 USA.		Parks, William C./AAH-6786-2021					AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BUSIEK DF, 1995, J IMMUNOL, V154, P6484; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Dickeson SK, 1998, CELL MOL LIFE SCI, V54, P556, DOI 10.1007/s000180050184; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; Dumin JA, 2001, J BIOL CHEM, V276, P29368, DOI 10.1074/jbc.M104179200; FIELDS GB, 1991, J THEOR BIOL, V153, P585, DOI 10.1016/S0022-5193(05)80157-2; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Hewish MJ, 2000, J VIROL, V74, P228, DOI 10.1128/JVI.74.1.228-236.2000; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; LEE JO, 1995, CELL, V80, P681; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; Li SH, 2000, J BIOL CHEM, V275, P35384, DOI 10.1074/jbc.M005139200; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; Messent AJ, 1998, J CELL SCI, V111, P1127; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; Mueller SC, 1999, J BIOL CHEM, V274, P24947, DOI 10.1074/jbc.274.35.24947; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Ohman T, 2001, VIRUS RES, V76, P1, DOI 10.1016/S0168-1702(01)00226-X; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; PARKS WC, 1998, MATRIX METALLOPROTEI; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073; SAARIALHOKERE UK, 1993, J INVEST DERMATOL, V100, P335, DOI 10.1111/1523-1747.ep12470032; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; STRICKLIN GP, 1993, AM J PATHOL, V143, P1657; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; WOLFE GC, 1993, ARTHRITIS RHEUM-US, V36, P1540, DOI 10.1002/art.1780361108; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183	43	71	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29375	29381		10.1074/jbc.M102217200	http://dx.doi.org/10.1074/jbc.M102217200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11359774	hybrid			2022-12-27	WOS:000170346000099
J	Cioffi, CC; Middleton, DL; Wilson, MR; Miller, NW; Clem, LW; Warr, GW				Cioffi, CC; Middleton, DL; Wilson, MR; Miller, NW; Clem, LW; Warr, GW			An IgH enhancer that drives transcription through basic helix-loop-helix and oct transcription factor binding motifs - Functional analysis of the E mu 3 ' enhancer of the catfish	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ENHANCER; CHANNEL CATFISH; GENE ENHANCER; B-CELLS; EXPRESSION; SITES; TRANSACTIVATION; DETERMINANT; ACTIVATION; PREFERENCE	The transcriptional enhancer (E mu3') of the IgH locus of the channel catfish, Ictalurus punctatus, shows strong B cell-specific activity and differs from the mammalian E mu enhancer in both location and structure. It occurs between the mu and delta genes and contains numerous transcription factor binding sites, predominantly octamer and mu E5 motifs of consensus and variant sequences. It lacks the classical muA-mu E3(CBF)-mu beta core array of binding motifs seen within mammalian IgH E mu enhancers. To determine the functionally important motifs, a series of mutant enhancers was created using sequence-targeted polymerase chain reaction. Whereas the mutation of consensus and variant octamer motifs (individually or in multiples) decreased enhancer function, mutation of a single consensus mu E5 motif destroyed the function of this enhancer in mammalian plasmacytomas. Mutation of this consensus mu E5 site, combined with mutations of certain octamer sites, destroyed function in catfish B cells. Experiments using artificial enhancers containing multimers of motifs or short regions of the native enhancer suggested that the minimal E mu3' enhancer (a) contains a consensus mu E5 site and two octamer sites, (b) is B cell-specific, and (c) is active across species. The dependence of an Ig enhancer on sites that bind basic helix-loop-helix and Oct transcription factors has not previously been observed and confirms large differences in structure and function between fish and mammalian IgH enhancers.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; Univ Mississippi, Med Ctr, Dept Microbiol, Jackson, MS 39216 USA	Medical University of South Carolina; Medical University of South Carolina; University of Mississippi; University of Mississippi Medical Center	Warr, GW (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 AShley Ave,POB 250509, Charleston, SC 29425 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI019530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062317] Funding Source: NIH RePORTER; NIAID NIH HHS [R37-AI-19530] Funding Source: Medline; NIGMS NIH HHS [R01-GM62317] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNWEILER A, 1994, NUCLEIC ACIDS RES, V22, P4250, DOI 10.1093/nar/22.20.4250; ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; Arulampalam V, 1997, IMMUNOL TODAY, V18, P549, DOI 10.1016/S0167-5699(97)01154-7; BACHL J, 1995, P NATL ACAD SCI USA, V5, P2396; Bengten E, 2000, CURR TOP MICROBIOL, V248, P189; CALAME K, 1995, IMMUNOGLOBULIN GENES, P397; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; COGNE M, 1994, CELL, V77, P737, DOI 10.1016/0092-8674(94)90057-4; Dang W, 1998, MOL CELL BIOL, V18, P6870, DOI 10.1128/MCB.18.11.6870; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Erman B, 1998, MOL CELL BIOL, V18, P1322, DOI 10.1128/MCB.18.3.1322; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; Gregoire JM, 1999, J BIOL CHEM, V274, P6567, DOI 10.1074/jbc.274.10.6567; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; Magor BG, 1997, IMMUNOGENETICS, V46, P192, DOI 10.1007/s002510050261; MAGOR BG, 1994, J IMMUNOL, V153, P5556; MICHAELSON JS, 1995, NUCLEIC ACIDS RES, V23, P975, DOI 10.1093/nar/23.6.975; MILLER NW, 1994, J IMMUNOL, V152, P2180; NELSEN B, 1990, MOL CELL BIOL, V10, P3145, DOI 10.1128/MCB.10.6.3145; Nikolajczyk BS, 1996, MOL CELL BIOL, V16, P4544; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; RAST JP, 1995, IMMUNOGLOBULIN GENES, P315; Ross DA, 1999, DEV COMP IMMUNOL, V23, P199, DOI 10.1016/S0145-305X(99)00007-5; Ross DA, 1998, J IMMUNOL, V160, P3874; Sloan SR, 1996, MOL CELL BIOL, V16, P6900; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; Wilson M, 1997, P NATL ACAD SCI USA, V94, P4593, DOI 10.1073/pnas.94.9.4593; WIRTH T, 1995, IMMUNOBIOLOGY, V193, P161, DOI 10.1016/S0171-2985(11)80540-1	29	29	29	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27825	27830		10.1074/jbc.M100110200	http://dx.doi.org/10.1074/jbc.M100110200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375977	hybrid			2022-12-27	WOS:000170093400013
J	Hsu, MH; Savas, V; Griffin, KJ; Johnson, EF				Hsu, MH; Savas, V; Griffin, KJ; Johnson, EF			Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor a in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; ALPHA PPAR-ALPHA; MITOCHONDRIAL 3-HYDROXY-3-METHYLGLUTARYL-COA SYNTHASE; PALMITOYLTRANSFERASE-I GENE; COENZYME-A OXIDASE; BETA-OXIDATION; LIPOPROTEIN METABOLISM; APOLIPOPROTEIN CIII; SPECIES-DIFFERENCES; OMEGA-HYDROXYLASE	In mice and other sensitive species, PPAR alpha mediates the induction of mitochondrial, microsomal, and peroxisomal fatty acid oxidation, peroxisome proliferation, liver enlargement, and tumors by peroxisome proliferators. In order to identify PPAR alpha -responsive human genes, HepG2 cells were engineered to express PPAR alpha at concentrations similar to mouse liver. This resulted in the dramatic induction of mRNAs encoding the mitochondrial HMG-CoA synthase and increases in fatty aryl-CoA synthetase (3-8-fold) and carnitine palmitoyl-CoA transferase IA (2-4-fold) mRNAs that were dependent on PPAR alpha expression and enhanced by exposure to the PPAR alpha agonist Wy14643. A PPAR response element was identified in the proximal promoter of the human HMG-COA synthase gene that is functional in its native context. These data suggest that humans retain a capacity for PPAR alpha regulation of mitochondrial fatty acid oxidation and ketogenesis. Human liver is refractory to peroxisome proliferation, and increased expression of mRNAs for the peroxisomal fatty acyl-CoA oxidase, bifunctional enzyme, or thiolase, which accompanies peroxisome proliferation in responsive species, was not evident following Wy14643 treatment of cells expressing elevated levels of PPAR alpha. Additionally, no significant differences were seen for the expression of apolipoprotein AI, All, or CIII; medium chain acyl-CoA dehydrogenase; or stearoyl-CoA desaturase mRNAs.	Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA	Scripps Research Institute	Johnson, EF (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, MEM-255,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCRR NIH HHS [M01 RR0833] Funding Source: Medline; NICHD NIH HHS [HD 04445] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD004445] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD004445] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALDRIDGE TC, 1995, BIOCHEM J, V306, P473, DOI 10.1042/bj3060473; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Bell AR, 1998, BIOCHEM J, V332, P689, DOI 10.1042/bj3320689; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; BRADY PS, 1989, BIOCHEM J, V260, P93, DOI 10.1042/bj2600093; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; BROCARD C, 1993, BIOL CELL, V77, P37, DOI 10.1016/S0248-4900(05)80172-8; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; Causevic M, 1999, FEBS LETT, V463, P205, DOI 10.1016/S0014-5793(99)01618-X; CHANCE DS, 1995, P SOC EXP BIOL MED, V208, P378; Clavey V, 1999, CELL PHYSIOL BIOCHEM, V9, P139, DOI 10.1159/000016311; CLINKENBEARD KD, 1975, J BIOL CHEM, V250, P3108; Cook WS, 2000, BIOCHEM BIOPH RES CO, V278, P250, DOI 10.1006/bbrc.2000.3739; DeLuca JG, 2000, MOL PHARMACOL, V58, P470, DOI 10.1124/mol.58.3.470; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Duclos S, 1997, EUR J CELL BIOL, V72, P314; Edvardsson U, 1999, J LIPID RES, V40, P1177; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Fredenrich A, 1998, DIABETES METAB, V24, P490; Gervois P, 1999, MOL ENDOCRINOL, V13, P1535, DOI 10.1210/me.13.9.1535; GIBBONS GF, 1994, J LIPID RES, V35, P1801; GIBSON GG, 1993, TOXICOL LETT, V68, P193, DOI 10.1016/0378-4274(93)90130-P; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; Hasmall SC, 2000, ARCH TOXICOL, V74, P85, DOI 10.1007/s002040050657; Hegardt FG, 1999, BIOCHEM J, V338, P569, DOI 10.1042/0264-6021:3380569; Hsu MH, 1998, J BIOL CHEM, V273, P27988, DOI 10.1074/jbc.273.43.27988; HSU MH, 1995, MOL PHARMACOL, V48, P559; IDE T, 1982, METABOLISM, V31, P1065, DOI 10.1016/0026-0495(82)90153-6; Kawashima H, 2000, ARCH BIOCHEM BIOPHYS, V378, P333, DOI 10.1006/abbi.2000.1831; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; LAKE BG, 1995, ANNU REV PHARMACOL, V35, P483, DOI 10.1146/annurev.pa.35.040195.002411; Lazarow P B, 1981, Methods Enzymol, V72, P315; Le May C, 2000, FEBS LETT, V475, P163, DOI 10.1016/S0014-5793(00)01648-3; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; Macdonald N, 1999, CANCER RES, V59, P4776; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; Miller CW, 1996, P NATL ACAD SCI USA, V93, P9443, DOI 10.1073/pnas.93.18.9443; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; MUKHERJEE R, 1994, J STEROID BIOCHEM, V51, P157, DOI 10.1016/0960-0760(94)90089-2; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NILSSON R, 1991, CHEM-BIOL INTERACT, V78, P235, DOI 10.1016/0009-2797(91)90017-2; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; Peters JM, 1997, CARCINOGENESIS, V18, P2029, DOI 10.1093/carcin/18.11.2029; QUANT PA, 1989, BIOCHEM J, V262, P159, DOI 10.1042/bj2620159; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; REISENBICHLER H, 1993, MUTAT RES, V286, P135, DOI 10.1016/0027-5107(93)90177-H; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; STANGL H, 1995, EUR J CLIN CHEM CLIN, V33, P775; Tugwood JD, 1998, ARCH TOXICOL, V72, P169, DOI 10.1007/s002040050483; Varanasi U, 1996, J BIOL CHEM, V271, P2147, DOI 10.1074/jbc.271.4.2147; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Yu GS, 1998, J BIOL CHEM, V273, P32901, DOI 10.1074/jbc.273.49.32901; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505	62	148	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27950	27958		10.1074/jbc.M100258200	http://dx.doi.org/10.1074/jbc.M100258200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11371553	hybrid			2022-12-27	WOS:000170093400029
J	Miyamori, H; Takino, T; Kobayashi, Y; Tokai, H; Itoh, Y; Seiki, M; Sato, H				Miyamori, H; Takino, T; Kobayashi, Y; Tokai, H; Itoh, Y; Seiki, M; Sato, H			Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION STRANDS; CANINE KIDNEY-CELLS; TISSUE INHIBITOR; CATALYTIC DOMAIN; GELATINASE-A; CDNA LIBRARY; MT-MMPS; PROGELATINASE; SURFACE; IDENTIFICATION	Genes associated with regulation of membrane-type matrix metalloproteinase-1 (MT1-MMP)-mediated pro-MMP-2 processing were screened in 293T cells by a newly developed expression cloning method. One of the gene products, which promoted processing of pro-MMP-2 by MT1-MMP was claudin-5, a major component of endothelial tight junctions. Expression of claudin-5 not only replaced TIMP-2 in pro-MMP-2 activation by MT1-MMP but also promoted activation of pro-MMP-2 mediated by all MT-MMPs and MT1-MMP mutants lacking the transmembrane domain (Delta MT1-MMP). A carboxyl-terminal deletion mutant of pro-MMP-2 (pro Delta MMP-2) was processed to an intermediate form by MT1-MMP in 293T cells and was further converted to an activated form by introduction of claudin-5. In contrast to the stimulatory effect of TIMP-2 on pro-MMP-2 activation by MT1-MMP, activation of pro-MMP-2 by Delta MT1-MMP in the presence of claudin-5 and pro Delta MMP-2 processing by MT1-MMP were both inversely repressed by expression of exogenous TIMP-2. These results suggest that TIMP-2 is not involved in cluadin-5-induced pro-MMP-2 activation by MT-MMPs. Stimulation of MT-MMP-mediated pro-MMP-2 activation was also observed with other claudin family members, claudin-1, claudin-2, and claudin-3. Amino acid substitutions or deletions in ectodomain of claudin-1 abolished stimulatory effect. Direct interaction of claudin-1 with MT1-MMP and MMP-2 was demonstrated by immunoprecipitation analysis. MT1-MMP was co-localized with claudin-1 not only at cell-cell borders, but also at other parts of the cells. TIMP-2 enhanced cell surface localization of MMP-2 mediated by MT1-MMP, and claudin-1 also stimulated it. These results suggest that claudin recruits all MT-MMPs and pro-MMP-2 on the cell surface to achieve elevated focal concentrations and, consequently, enhances activation of pro-MMP-2.	Kanazawa Univ, Canc Res Inst, Dept Mol Oncol & Virol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan; Fuji Chem Ind Co Ltd, Toyama 9338511, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, Tokyo 1088639, Japan	Kanazawa University; Kanazawa University; University of Tokyo	Sato, H (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Oncol & Virol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	vhsato@kenroku.kanazawa-u.ac.jp	Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015; TAKINO, Takahisa/D-8460-2015	Itoh, Yoshifumi/0000-0002-2128-2823				Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; FUJIMOTO N, 1993, CLIN CHIM ACTA, V220, P31, DOI 10.1016/0009-8981(93)90004-N; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Gregory M, 2001, ENDOCRINOLOGY, V142, P854, DOI 10.1210/en.142.2.854; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Kadono Y, 1998, CANCER RES, V58, P2240; Kinoshita T, 1996, CANCER RES, V56, P2535; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Kolkenbrock H, 1999, BIOL CHEM, V380, P1103, DOI 10.1515/BC.1999.137; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Llano E, 1999, CANCER RES, V59, P2570; Miyamori H, 2000, BIOCHEM BIOPH RES CO, V267, P796, DOI 10.1006/bbrc.1999.2050; Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Tsukita S, 2000, J CELL BIOL, V149, P13, DOI 10.1083/jcb.149.1.13; Ueno H, 1997, CANCER RES, V57, P2055; Velasco G, 2000, CANCER RES, V60, P877; Wang YH, 1999, J BIOL CHEM, V274, P33043, DOI 10.1074/jbc.274.46.33043; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WOESSNER JF, 1991, J RHEUMATOL, V18, P99; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	45	190	198	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28204	28211		10.1074/jbc.M103083200	http://dx.doi.org/10.1074/jbc.M103083200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382769	Green Submitted, hybrid			2022-12-27	WOS:000170093400063
J	Schofield, MJ; Nayak, S; Scott, TH; Du, CW; Hsieh, P				Schofield, MJ; Nayak, S; Scott, TH; Du, CW; Hsieh, P			Interaction of Escherichia coli MutS and MutL at a DNA mismatch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR PROTEIN MUTS; HETERODUPLEX DNA; ATP-HYDROLYSIS; TRANSLOCATION MECHANISM; CRYSTAL-STRUCTURE; MOLECULAR SWITCH; BINDING; COMPLEX; YEAST; RECOMBINATION	MutS and MutL are both required to activate downstream events in DNA mismatch repair. We examined the rate of dissociation of MutS from a mismatch using linear heteroduplex DNAs or heteroduplexes blocked at one or both ends by four-way DNA junctions in the presence and absence of MutL. In the presence of ATP, dissociation of MutS from linear heteroduplexes or heteroduplexes blocked at only one end occurs within 15 s. When both duplex ends are blocked, MutS remains associated with the DNA in complexes with half-lives of 30 min. DNase I footprinting of MutS complexes is consistent with migration of MutS throughout the DNA duplex region. When MutL is present, it associates with MutS and prevents ATP-dependent migration away from the mismatch in a manner that is dependent on the length of the heteroduplex. The rate and extent of mismatch-provoked cleavage at hemimethylated GATC sites by MutH in the presence of MutS, MutL, and ATP are the same whether the mismatch and GATC sites are in cis or in trans. These results suggest that a MutS-MutL complex in the vicinity of a mismatch is involved in activating MutH.	NIDDKD, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hsieh, P (corresponding author), NIDDKD, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052015] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; BENDE SM, 1991, NUCLEIC ACIDS RES, V19, P1549, DOI 10.1093/nar/19.7.1549; Biswas I, 1997, J BIOL CHEM, V272, P13355, DOI 10.1074/jbc.272.20.13355; Biswas I, 2001, J MOL BIOL, V305, P805, DOI 10.1006/jmbi.2000.4367; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; FANG WH, 1993, J BIOL CHEM, V268, P11838; FENG G, 1995, BIOTECHNIQUES, V19, P956; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; GORBALENYA AE, 1990, J MOL BIOL, V213, P583, DOI 10.1016/S0022-2836(05)80243-8; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Habraken Y, 1997, CURR BIOL, V7, P790, DOI 10.1016/S0960-9822(06)00337-X; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HSIEH P, 1995, NUCL ACIDS MOL BIOL, V9, P42; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Joshi A, 2000, NUCLEIC ACIDS RES, V28, P853, DOI 10.1093/nar/28.4.853; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Murtin C, 1998, J MOL BIOL, V284, P949, DOI 10.1006/jmbi.1998.2256; Nash Howard A., 1996, P149; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Schofield MJ, 1998, BIOCHEMISTRY-US, V37, P7733, DOI 10.1021/bi980399s; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x	40	116	119	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28291	28299		10.1074/jbc.M103148200	http://dx.doi.org/10.1074/jbc.M103148200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11371566	hybrid			2022-12-27	WOS:000170093400074
J	Huss, JM; Levy, FH; Kelly, DP				Huss, JM; Levy, FH; Kelly, DP			Hypoxia inhibits the peroxisome proliferator-activated receptor alpha/retinoid X receptor gene regulatory pathway in cardiac myocytes - A mechanism for O-2-dependent modulation of mitochondrial fatty acid oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARNITINE PALMITOYLTRANSFERASE-I; INDUCIBLE FACTOR-1; TRANSCRIPTIONAL REGULATION; ERYTHROPOIETIN GENE; ENERGY-METABOLISM; RAT-HEART; BINDING; ALPHA; EXPRESSION; PROMOTERS	Hypoxia triggers a cascade of cellular energy metabolic responses including a decrease in mitochondrial oxidative flux. To characterize gene regulatory mechanisms by which mitochondrial fatty acid oxidative capacity is diminished in response to hypoxia, cardiac myocytes in culture were exposed to long-chain fatty acids (LCFA) under normoxic or hypoxic conditions. Hypoxia prevented the known LCFA-induced accumulation of mRNA encoding muscle carnitine palmitoyltransferase I (M-CPT I), an enzyme that catalyzes the rate-limiting step in mitochondrial fatty acid oxidation (FAO). Under hypoxic conditions, myocytes exhibited significant accumulation of intracellular neutral lipid consistent with reduced CPT I activity and diminished FAO capacity. Transient transfection experiments demonstrated that the hypoxia-mediated blunting of M-CPT I gene expression occurs at the transcriptional level, is localized to an LCFA/peroxisome proliferator-activated receptor alpha (PPAR alpha)/retinoid X receptor (RXR) response element within the M-CPT I gene promoter, and is PPAR alpha -dependent. DNA-protein binding studies demonstrated that exposure to hypoxia reduces PPAR alpha /RXR binding activity. Immunoblotting studies demonstrated that whereas hypoxia had no effect on nuclear levels of PPARa protein, nuclear and cellular RXR alpha levels were reduced. Hypoxia also diminished the 9-cis-retinoic acid-mediated activation of a reporter containing an RXR homodimer response element. These results demonstrate that hypoxia deactivates PPAR alpha by reducing the availability of its obligate partner RXR.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Kelly, DP (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.	dkelly@imgate.wustl.edu	Kelly, Daniel/ABG-2056-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003568, R01HL058493, P50HL061006, F32HL010410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045416, P30DK052574, P30DK056341] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL58493, K08 HL03568, F32-HL10410, P50 HL61006] Funding Source: Medline; NIDDK NIH HHS [R01 DK45416, P30 DK52574, P30 DK56341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdel-aleem S, 1998, MOL CELL BIOCHEM, V180, P95, DOI 10.1023/A:1006843107922; Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; BING RJ, 1955, HARVEY LECT, P27; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; CORR PB, 1989, J CLIN INVEST, V83, P927, DOI 10.1172/JCI113978; Cresci S, 1996, AM J PHYSIOL-CELL PH, V270, pC1413, DOI 10.1152/ajpcell.1996.270.5.C1413; Disch DL, 1996, MOL CELL BIOL, V16, P4043; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; FAHEY JT, 1989, PEDIATR RES, V26, P180, DOI 10.1203/00006450-198909000-00003; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GEBEL T, 1992, FEBS LETT, V309, P37, DOI 10.1016/0014-5793(92)80734-X; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; HOLDEN JE, 1995, J APPL PHYSIOL, V79, P222, DOI 10.1152/jappl.1995.79.1.222; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Levy FH, 1997, AM J PHYSIOL-CELL PH, V272, pC457, DOI 10.1152/ajpcell.1997.272.2.C457; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; Nomura Y, 1999, BIOCHEM BIOPH RES CO, V260, P729, DOI 10.1006/bbrc.1999.0969; POIZAT C, 1993, ARCH INT PHYSIOL BIO, V101, P347, DOI 10.3109/13813459309046991; Rumsey WL, 1999, AM J PHYSIOL-HEART C, V276, pH71; Saikumar P, 1998, ONCOGENE, V17, P3341, DOI 10.1038/sj.onc.1202579; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WARSHAW JB, 1972, DEV BIOL, V28, P537, DOI 10.1016/0012-1606(72)90001-2; WEBSTER KA, 1995, J MOL CELL CARDIOL, V27, P453, DOI 10.1016/S0022-2828(08)80041-7; WU JY, 1994, AM J PHYSIOL, V266, pH1034, DOI 10.1152/ajpheart.1994.266.3.H1034; YAMADA KA, 1994, CIRC RES, V74, P83, DOI 10.1161/01.RES.74.1.83; Yamazaki N, 1997, FEBS LETT, V409, P401, DOI 10.1016/S0014-5793(97)00561-9; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3; Yu GS, 1998, J BIOL CHEM, V273, P32901, DOI 10.1074/jbc.273.49.32901	41	144	151	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27605	27612		10.1074/jbc.M100277200	http://dx.doi.org/10.1074/jbc.M100277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11371554	hybrid			2022-12-27	WOS:000169966900115
J	Mathai, JC; Sprott, GD; Zeidel, ML				Mathai, JC; Sprott, GD; Zeidel, ML			Molecular mechanisms of water and solute transport across archaebacterial lipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOTAL POLAR LIPIDS; TETRAETHER LIPIDS; BILAYER-MEMBRANES; SULFOLOBUS-ACIDOCALDARIUS; THERMOPLASMA-ACIDOPHILUM; BIOLOGICAL-MEMBRANES; HYDROTHERMAL VENT; PERMEANT SIZE; ETHER LIPIDS; PERMEABILITY	Archaebacteria thrive in environments characterized by anaeobiosis, saturated salt, and both high and low extremes of temperature and pH, The bulk of their membrane lipids are polar, characterized by the archaeal structural features typified by ether linkage of the glycerol backbone to isoprenoid chains of constant length, often fully saturated, and with sn-2,3 stereochemistry opposite that of glycerolipids of Bacteria and Eukarya, Also unique to these bacteria are macrocyclic archaeol and membrane spanning caldarchaeol lipids that are found in some extreme thermophiles and methanogens, To define the barrier function of archaebacterial membranes and to examine the effects of these unique structural features on permeabilities, we investigated the water, solute (urea and glycerol), proton, and ammonia permeability of liposomes formed by these lipids. Both the macrocyclic archaeol and caldarchaeol lipids reduced the water, ammonia, urea, and glycerol permeability of Liposomes significantly (6-120-fold) compared with diphytanylphosphatidylcholine liposomes, The presence of the ether bond and phytanyl chains did not significantly affect these permeabilities, However, the apparent proton permeability was reduced S-fold by the presence of an ether bond. The presence of macrocyclic archaeol and caldarchaeol structures further reduced apparent proton permeabilities by 10-17-fold, These results indicate that, the limiting mobility of the midplane hydrocarbon region of the membranes formed by macrocyclic archaeol and caldarchaeol lipids play a significant role in reducing the permeability properties of the lipid membrane. In addition, it appears that substituting ether for ester bonds presents an additional barrier to proton flux.	Univ Pittsburgh, Lab Epithelial Cell Biol, Renal Electrolyte Div, Dept Med, Pittsburgh, PA 15261 USA; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Research Council Canada	Mathai, JC (corresponding author), Univ Pittsburgh, Lab Epithelial Cell Biol, Renal Electrolyte Div, Dept Med, A1222 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	mathaij@msx.dept-med.pitt.edu						Bagatolli L, 2000, BIOPHYS J, V79, P416, DOI 10.1016/S0006-3495(00)76303-X; BEVERIDGE TJ, 1993, J BACTERIOL, V175, P1191, DOI 10.1128/JB.175.4.1191-1197.1993; CARRUTHERS A, 1983, BIOCHEMISTRY-US, V22, P5797, DOI 10.1021/bi00294a018; CHANG A, 1994, AM J PHYSIOL-CELL PH, V267, pC1483, DOI 10.1152/ajpcell.1994.267.5.C1483; Choquet CG, 1996, CAN J MICROBIOL, V42, P183, DOI 10.1139/m96-027; COMITA PB, 1983, SCIENCE, V222, P1329, DOI 10.1126/science.222.4630.1329; DARLAND G, 1970, SCIENCE, V170, P1416, DOI 10.1126/science.170.3965.1416; DEAMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P165, DOI 10.1073/pnas.80.1.165; DEAMER DW, 1987, J BIOENERG BIOMEMBR, V19, P457; DEROSA M, 1980, PHYTOCHEMISTRY, V19, P827, DOI 10.1016/0031-9422(80)85120-X; DEROSA M, 1983, J MEMBRANE SCI, V16, P287, DOI 10.1016/S0376-7388(00)81316-2; DEROSA M, 1986, MICROBIOL REV, V50, P70, DOI 10.1128/MMBR.50.1.70-80.1986; ELFERINK MGL, 1994, BBA-BIOMEMBRANES, V1193, P247, DOI 10.1016/0005-2736(94)90160-0; FINKELSTEIN A, 1987, WATER MOVEMENT LIPID, P153; GROSSMAN EB, 1992, AM J PHYSIOL, V262, pC1109, DOI 10.1152/ajpcell.1992.262.5.C1109; HAINES TH, 1994, FEBS LETT, V346, P115, DOI 10.1016/0014-5793(94)00470-6; Hill WG, 2000, J BIOL CHEM, V275, P30176, DOI 10.1074/jbc.M003494200; Hill WG, 1999, J GEN PHYSIOL, V114, P405, DOI 10.1085/jgp.114.3.405; JANSEN M, 1995, BIOPHYS J, V68, P997, DOI 10.1016/S0006-3495(95)80275-4; Jarrell HC, 1998, BBA-BIOMEMBRANES, V1369, P259, DOI 10.1016/S0005-2736(97)00228-9; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; Kate M., 1993, BIOCH ARCHAEA ARCHAE, V26, P261, DOI DOI 10.1016/S0167-7306(08)60258-6; Komatsu H, 1998, BIOCHEMISTRY-US, V37, P107, DOI 10.1021/bi972163e; LANDE MB, 1994, AM J PHYSIOL, V267, pC367, DOI 10.1152/ajpcell.1994.267.2.C367; LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67; Lande MB, 1996, J BIOL CHEM, V271, P5552, DOI 10.1074/jbc.271.10.5552; Langworthy T.A., 1985, BACTERIA, V8, P459; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; Negrete HO, 1996, J BIOL CHEM, V271, P11627, DOI 10.1074/jbc.271.20.11627; NICHOLS JW, 1980, P NATL ACAD SCI-BIOL, V77, P2038, DOI 10.1073/pnas.77.4.2038; NISHIHARA M, 1987, J BIOCHEM-TOKYO, V101, P1007, DOI 10.1093/oxfordjournals.jbchem.a121942; NOZAKI Y, 1981, P NATL ACAD SCI-BIOL, V78, P4324, DOI 10.1073/pnas.78.7.4324; Paula S, 1996, BIOPHYS J, V70, P339, DOI 10.1016/S0006-3495(96)79575-9; Rivers R, 1998, AM J PHYSIOL-RENAL, V274, pF453, DOI 10.1152/ajprenal.1998.274.3.F453; Schafer G, 1999, MICROBIOL MOL BIOL R, V63, P570; SPROTT GD, 1991, J BACTERIOL, V173, P3907, DOI 10.1128/JB.173.12.3907-3910.1991; Sprott GD, 1997, CAN J MICROBIOL, V43, P467, DOI 10.1139/m97-066; Sprott GD, 1999, BBA-MOL CELL BIOL L, V1440, P275, DOI 10.1016/S1388-1981(99)00130-4; SPROTT GD, 1992, J BIOENERG BIOMEMBR, V24, P555, DOI 10.1007/BF00762348; Stein W., 2012, TRANSPORT DIFFUSION; Swain M, 1997, BBA-LIPID LIPID MET, V1345, P56, DOI 10.1016/S0005-2760(96)00163-4; TRINCONE A, 1992, SYST APPL MICROBIOL, V15, P11, DOI 10.1016/S0723-2020(11)80130-X; van de Vossenberg JLCM, 1999, EXTREMOPHILES, V3, P253, DOI 10.1007/s007920050124; WALTER A, 1986, J MEMBRANE BIOL, V90, P207, DOI 10.1007/BF01870127; XIANG TX, 1994, J MEMBRANE BIOL, V140, P111; XIANG TX, 1993, BIOPHYS J, V65, P1108, DOI 10.1016/S0006-3495(93)81156-1; Xiang TX, 1998, BIOPHYS J, V75, P2658, DOI 10.1016/S0006-3495(98)77711-2; Xiang TX, 1997, BIOPHYS J, V72, P223, DOI 10.1016/S0006-3495(97)78661-2; XIANG TX, 1992, BIOPHYS J, V63, P78, DOI 10.1016/S0006-3495(92)81581-3	49	117	120	4	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27266	27271		10.1074/jbc.M103265200	http://dx.doi.org/10.1074/jbc.M103265200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11373291	hybrid			2022-12-27	WOS:000169966900072
J	Pinzon-Ortiz, C; Friedman, J; Esko, J; Sinnis, P				Pinzon-Ortiz, C; Friedman, J; Esko, J; Sinnis, P			The binding of the circumsporozoite protein to cell surface heparan sulfate proteoglycans is required for Plasmodium sporozoite attachment to target cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGION-II-PLUS; MALARIA PARASITE; THROMBOSPONDIN; FALCIPARUM; INVASION; HEPATOCYTES; ANTIBODIES; INFECTIVITY; INHIBITOR; CHLORATE	The major surface protein of malaria sporozoites, the circumsporozoite protein, binds to heparan sulfate proteoglycans on the surface of hepatocytes. It has been proposed that this binding event is responsible for the rapid and specific localization of sporozoites to the liver after their injection into the skin by an infected anopheline mosquito. Previous in vitro studies performed under static conditions have failed to demonstrate a significant role for heparan sulfate proteoglycans during sporozoite invasion of cells. We performed sporozoite attachment and invasion assays under more dynamic conditions and found a dramatic decrease in sporozoite attachment to cells in the presence of heparin, In contrast to its effect on attachment, heparin does not appear to have an effect on sporozoite invasion of cells. When substituted heparins were used as competitive inhibitors of sporozoite attachment, we found that sulfation of the glycosaminoglycan chains at both the Nand O-positions was important for sporozoite adhesion to cells. We conclude that the binding of the circumsporozoite protein to hepatic heparan sulfate proteoglycans is likely to function during sporozoite attachment in the liver and that this adhesion event depends on the sulfated glycosaminoglycan chains of the proteoglycans.	NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	New York University; University of California System; University of California San Diego	Sinnis, P (corresponding author), NYU, Sch Med, Dept Med & Mol Parasitol, 341 E 25th St, New York, NY 10010 USA.			Friedman, Jennifer/0000-0001-5804-9921	NIAID NIH HHS [R01 AI056840, AI44470-02, R01 AI044470] Funding Source: Medline; NIGMS NIH HHS [R01 GM033063, R37 GM033063, GM33063] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056840, R01AI044470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033063, R37GM033063] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CERAMI C, 1994, J EXP MED, V179, P695, DOI 10.1084/jem.179.2.695; CHAROENVIT Y, 1987, INFECT IMMUN, V55, P604, DOI 10.1128/IAI.55.3.604-608.1987; Frevert U, 1996, MOL BIOCHEM PARASIT, V76, P257, DOI 10.1016/0166-6851(95)02563-4; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; Gantt S, 2000, INFECT IMMUN, V68, P3667, DOI 10.1128/IAI.68.6.3667-3673.2000; Gantt SM, 1997, J BIOL CHEM, V272, P19205, DOI 10.1074/jbc.272.31.19205; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V150, P342, DOI 10.1016/0006-291X(88)90526-8; HUMPHRIES DE, 1988, BIOCHEM BIOPH RES CO, V154, P365, DOI 10.1016/0006-291X(88)90694-8; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; INOUE Y, 1976, ANAL BIOCHEM, V71, P46, DOI 10.1016/0003-2697(76)90009-9; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; LINDBLOM A, 1990, GLYCOCONJUGATE J, V7, P545, DOI 10.1007/BF01189076; LYON M, 1994, J BIOL CHEM, V269, P11208; McCormick CJ, 1999, MOL BIOCHEM PARASIT, V100, P111, DOI 10.1016/S0166-6851(99)00052-3; NARDIN EH, 1982, J EXP MED, V156, P20, DOI 10.1084/jem.156.1.20; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; RENIA L, 1988, J IMMUNOL METHODS, V112, P201, DOI 10.1016/0022-1759(88)90358-4; ROBSON KJH, 1995, EMBO J, V14, P3883, DOI 10.1002/j.1460-2075.1995.tb00060.x; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROGERS WO, 1992, MOL BIOCHEM PARASIT, V53, P45, DOI 10.1016/0166-6851(92)90005-5; ROGERS WO, 1992, P NATL ACAD SCI USA, V89, P9176, DOI 10.1073/pnas.89.19.9176; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Sinnis P, 1996, J EXP MED, V184, P945, DOI 10.1084/jem.184.3.945; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; Sinnis P, 1997, TRENDS MICROBIOL, V5, P52, DOI 10.1016/S0966-842X(97)84657-4; Sinnis P, 1998, J IMMUNOL METHODS, V221, P17, DOI 10.1016/S0022-1759(98)00151-3; STEWART MJ, 1986, INFECT IMMUN, V51, P859, DOI 10.1128/IAI.51.3.859-864.1986; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; TAKACS BJ, 1991, J IMMUNOL METHODS, V143, P231, DOI 10.1016/0022-1759(91)90048-K; UNDERHILL CB, 1977, J CELL PHYSIOL, V90, P53, DOI 10.1002/jcp.1040900108; VANDERBERG JP, 1974, J PROTOZOOL, V21, P527, DOI 10.1111/j.1550-7408.1974.tb03693.x; VANDERBERG JP, 1980, MALARIA, V2, P154; Ying P, 1997, EXP PARASITOL, V85, P168, DOI 10.1006/expr.1996.4134; YOSHIDA N, 1980, SCIENCE, V207, P71, DOI 10.1126/science.6985745	37	100	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26784	26791		10.1074/jbc.M104038200	http://dx.doi.org/10.1074/jbc.M104038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11352923	hybrid, Green Accepted			2022-12-27	WOS:000169966900009
J	Adachi, T; Wienands, J; Wakabayashi, C; Yakura, H; Reth, M; Tsubata, T				Adachi, T; Wienands, J; Wakabayashi, C; Yakura, H; Reth, M; Tsubata, T			SHP-1 requires inhibitory co-receptors to down-modulate B cell antigen receptor-mediated phosphorylation of cellular substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; KINASE ACTIVATION; LINKER-PROTEIN; SH2 DOMAIN; IG-ALPHA; MOLECULAR-COMPONENTS; NEGATIVE REGULATION; PIR-B; LYMPHOCYTES; CD22	Signaling through the B cell antigen receptor (BCR) is negatively regulated by the SH2 domain-containing protein-tyrosine phosphatase SHP-1, which requires association with tyrosine-phosphorylated proteins for activation. Upon BCR ligation, SHP-1 has been shown to associate with the BCR, the cytoplasmic protein-tyrosine kinases Lyn and Syk, and the inhibitory co-receptors CD22 and CD72, How SHP-1 is activated by BCR ligation and regulates BCR signaling is, however, not fully understood. Here we demonstrate that, in the BCR-expressing myeloma line JS58L mu m3, CD72 expression reduces the BCR ligation-induced phosphorylation of the BCR component Ig alpha /Ig beta and its cytoplasmic effecters Syk and SLP-GS, Substrate phosphorylation was restored by expression of dominant negative mutants of SHP-1, whereas the SHP-1 mutants failed to enhance phosphorylation of the cellular substrates in the absence of CD72, This indicates that SHP-1 is efficiently activated by CD72 but not by other pathways in J558L mu m3 cells and that inhibition of SHP-1 specifically activated by CD72 reverses CD72-induced dephosphorylation of cellular substrates in these cells. Taken together, BCR-induced SHP-1 activation is likely to require inhibitory co-receptors such as CD72, and SHP-1 appears to mediate the negative regulatory effect of CD72 on BCR signaling by dephosphorylating Ig alpha /Ig beta and its downstream signaling molecules Syk and SLP-65.	Tokyo Med & Dent Univ, Med Res Inst, Dept Immunol, Bunkyo Ku, Tokyo 1138510, Japan; Univ Freiburg, Dept Mol Immunol Biol 3, D-79108 Freiburg, Germany; Max Planck Inst Immunol, D-79108 Freiburg, Germany; Tokyo Metropolitan Inst Neurosci, Fuchu, Tokyo 1838526, Japan	Tokyo Medical & Dental University (TMDU); University of Freiburg; Max Planck Society; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Tsubata, T (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Immunol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.		Tsubata, Takeshi/AAI-7489-2021	Tsubata, Takeshi/0000-0003-0760-1258				Adachi T, 2000, J IMMUNOL, V164, P1223, DOI 10.4049/jimmunol.164.3.1223; Adachi T, 1998, J IMMUNOL, V160, P4662; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Coggeshall KM, 1998, CURR OPIN IMMUNOL, V10, P306, DOI 10.1016/S0952-7915(98)80169-6; Cyster JG, 1997, IMMUNITY, V6, P509, DOI 10.1016/S1074-7613(00)80339-8; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Dustin LB, 1999, J IMMUNOL, V162, P2717; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Fujimoto M, 2000, IMMUNITY, V13, P47, DOI 10.1016/S1074-7613(00)00007-8; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; Kimura T, 1996, MOL CELL BIOL, V16, P1471; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kraus M, 1999, IMMUNITY, V11, P537, DOI 10.1016/S1074-7613(00)80129-6; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; Maeda A, 1999, ONCOGENE, V18, P2291, DOI 10.1038/sj.onc.1202552; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; Mizuno K, 2000, J IMMUNOL, V165, P1344, DOI 10.4049/jimmunol.165.3.1344; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; ORourke L, 1997, CURR OPIN IMMUNOL, V9, P324, DOI 10.1016/S0952-7915(97)80077-5; Pan C, 1999, IMMUNITY, V11, P495, DOI 10.1016/S1074-7613(00)80124-7; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pao LI, 1997, J IMMUNOL, V158, P2663; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; Sen G, 1999, EUR J IMMUNOL, V29, P3319; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Somani AK, 2001, J BIOL CHEM, V276, P1938, DOI 10.1074/jbc.M006820200; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Tooze RM, 1997, IMMUNITY, V7, P59, DOI 10.1016/S1074-7613(00)80510-5; Torres RM, 1999, IMMUNITY, V11, P527, DOI 10.1016/S1074-7613(00)80128-4; Tsubata T, 1999, CURR OPIN IMMUNOL, V11, P249, DOI 10.1016/S0952-7915(99)80041-7; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wu YJ, 1998, CURR BIOL, V8, P1009, DOI 10.1016/S0960-9822(07)00421-6; YAKURA H, 1986, J IMMUNOL, V137, P1475; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; Yoshida K, 1999, J BIOL CHEM, V274, P34663, DOI 10.1074/jbc.274.49.34663	52	55	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26648	26655		10.1074/jbc.M100997200	http://dx.doi.org/10.1074/jbc.M100997200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11356834	hybrid			2022-12-27	WOS:000169823300130
J	Calvo, AM; Gardner, HW; Keller, NP				Calvo, AM; Gardner, HW; Keller, NP			Genetic connection between fatty acid metabolism and sporulation in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS GAEUMANNOMYCES-GRAMINIS; ACYL-LIPID DESATURASES; SACCHAROMYCES-CEREVISIAE; SEXUAL DEVELOPMENT; INDUCED EXPRESSION; NEUROSPORA-CRASSA; IDENTIFICATION; CYANOBACTERIUM; SYNECHOCYSTIS; BIOSYNTHESIS	In the Ascomycete fungus Aspergillus nidulans, the ratio of conidia (asexual spores) to ascospores (sexual spores) is affected by linoleic acid moieties including endogenous sporogenic factors called psi factors. Deletion of odeA (Delta odeA), encoding a Delta -12 desaturase that converts oleic acid to linoleic acid, resulted in a strain depleted of polyunsaturated fatty acids (18:2 and 18:3) but increased in oleic acid (18:1) and total percent fatty acid content. Linoleic acid-derived psi factors were absent in this strain but oleic acid-derived psi factors were increased relative to wild type. The Delta odeA strain was reduced in conidial production and mycelial growth; these effects were most noticeable when cultures were grown at 26 degreesC in the dark. Under these environmental conditions, the Delta odeA strain was delayed in ascospore production but produced more ascospores than wild type over time. This suggests a role for oleic acid-derived psi factors in affecting the asexual to sexual spore ratio in A. nidulans, Fatty acid composition and spore development were also affected by veA, a gene previously shown to control light driven conidial and ascospore development. Taken together our results indicate an interaction between veA and odeA alleles for fatty acid metabolism and spore development in A. nidulans.	Texas A&M Univ, Dept Plant Pathol & Microbiol, College Stn, TX 77843 USA; USDA ARS, Natl Ctr Agr Utilizat Res, Peoria, IL 61604 USA	Texas A&M University System; Texas A&M University College Station; United States Department of Agriculture (USDA)	Keller, NP (corresponding author), Univ Wisconsin, Dept Plant Pathol, 882 Russell Labs,1630 Linden Dr, Madison, WI 53706 USA.		Keller, Nancy P./ABC-5911-2021					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BRODOWSKY ID, 1992, BIOCHIM BIOPHYS ACTA, V1124, P59, DOI 10.1016/0005-2760(92)90126-G; BRODOWSKY ID, 1992, J BIOL CHEM, V267, P14738; BROWSE J, 1993, J BIOL CHEM, V268, P16345; Burow GB, 2000, PLANT MOL BIOL, V42, P689, DOI 10.1023/A:1006361305703; Calvo AM, 1999, APPL ENVIRON MICROB, V65, P3668; CHAMPE SP, 1989, J BACTERIOL, V171, P3982, DOI 10.1128/jb.171.7.3982-3988.1989; CHAMPE SP, 1987, J GEN MICROBIOL, V133, P1383; Fox SR, 2000, LIPIDS, V35, P23, DOI 10.1007/s11745-000-0490-5; Goodrich-Tanrikulu M, 1998, MICROBIOL-UK, V144, P1713, DOI 10.1099/00221287-144-7-1713; Heppard EP, 1996, PLANT PHYSIOL, V110, P311, DOI 10.1104/pp.110.1.311; HYEON B, 1976, CHEM REGUL PLANTS, V11, P69; Kafer E, 1977, Adv Genet, V19, P33, DOI 10.1016/S0065-2660(08)60245-X; KAFER E, 1965, GENETICS, V52, P217; KATAYAMA M, 1978, AGR BIOL CHEM TOKYO, V42, P1431, DOI 10.1080/00021369.1978.10863178; Kis M, 1998, P NATL ACAD SCI USA, V95, P4209, DOI 10.1073/pnas.95.8.4209; Kouba M, 1998, REPROD NUTR DEV, V38, P31, DOI 10.1051/rnd:19980103; Laoteng K, 1999, Mol Cell Biol Res Commun, V1, P36, DOI 10.1006/mcbr.1999.0107; Los DA, 1998, BBA-LIPID LIPID MET, V1394, P3, DOI 10.1016/S0005-2760(98)00091-5; Los DA, 1997, MOL MICROBIOL, V25, P1167, DOI 10.1046/j.1365-2958.1997.5641912.x; MAZUR P, 1990, TETRAHEDRON LETT, V31, P3837, DOI 10.1016/S0040-4039(00)97482-3; MAZUR P, 1991, J CHEM SOC CHEM COMM, P1486, DOI 10.1039/c39910001486; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; MIHARA K, 1990, J BIOCHEM-TOKYO, V108, P1022, DOI 10.1093/oxfordjournals.jbchem.a123301; MILLER BL, 1985, MOL CELL BIOL, V5, P1714, DOI 10.1128/MCB.5.7.1714; MURATA N, 1995, BIOCHEM J, V308, P1; MURATA N, 1989, J BIOENERG BIOMEMBR, V21, P61, DOI 10.1007/BF00762212; Nishiuchi T, 1995, PLANT MOL BIOL, V29, P599, DOI 10.1007/BF00020987; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; NUKINA M, 1981, AGR BIOL CHEM TOKYO, V45, P2371, DOI 10.1080/00021369.1981.10864892; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; ROEDER PE, 1982, BIOCHEMISTRY-US, V21, P4909, DOI 10.1021/bi00263a012; SAKAMOTO T, 1994, PLANT MOL BIOL, V24, P643, DOI 10.1007/BF00023560; Sakamoto T, 1997, MOL MICROBIOL, V23, P1281, DOI 10.1046/j.1365-2958.1997.3071676.x; Sakamoto T, 1997, FEMS MICROBIOL LETT, V152, P313, DOI 10.1016/S0378-1097(97)00217-6; Sakuradani E, 1999, EUR J BIOCHEM, V261, P812, DOI 10.1046/j.1432-1327.1999.00333.x; Sambrook J., 2002, MOL CLONING LAB MANU; SKORY CD, 1992, APPL ENVIRON MICROB, V58, P3527, DOI 10.1128/AEM.58.11.3527-3537.1992; SOMERVILLE C, 1995, P NATL ACAD SCI USA, V92, P6215, DOI 10.1073/pnas.92.14.6215; Tasaka Y, 1996, EMBO J, V15, P6416, DOI 10.1002/j.1460-2075.1996.tb01033.x; Tiku PE, 1996, SCIENCE, V271, P815, DOI 10.1126/science.271.5250.815; WADA H, 1990, PLANT PHYSIOL, V92, P1062, DOI 10.1104/pp.92.4.1062; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; YAGER LN, 1992, ASPERGILLUS BIOL IND, P19; Yu JH, 1996, EMBO J, V15, P5184, DOI 10.1002/j.1460-2075.1996.tb00903.x	46	137	155	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25766	25774		10.1074/jbc.M100732200	http://dx.doi.org/10.1074/jbc.M100732200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352908	hybrid			2022-12-27	WOS:000169823300019
J	Peruzzi, F; Prisco, M; Morrione, A; Valentinis, B; Baserga, R				Peruzzi, F; Prisco, M; Morrione, A; Valentinis, B; Baserga, R			Anti-apoptotic signaling of the insulin-like growth factor-I receptor through mitochondrial translocation of c-Raf and Nedd4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIGASE NEDD4; PHOSPHATIDYLINOSITOL 3-KINASE; INHIBITS APOPTOSIS; SURVIVAL SIGNALS; WW DOMAINS; BAD; PHOSPHORYLATION; ACTIVATION; SUBSTRATE; GRB10	The type 1 insulin-like growth factor receptor (IGF-IR) sends a strong anti-apoptotic signal by at least three different pathways. By using mutants of the IGF-IR, we showed that one of the pathways depends on residues of the IGF-IR (serines 1280-1283) that interact with 14.3.3 proteins. The result is the activation of Raf-1 and the mitochondrial translocation of both Raf-1 and Nedd4, a target of caspases. A mutant IGF-IR in which the serines at positions 1280-1283 have been mutated to alanine does not protect from apoptosis and fails to translocate Nedd4 or Raf-1 to the mitochondria. This failure is accompanied by a loss of cytochrome c from the mitochondria, The 14.3.3/Raf-1/Nedd4 pathway is operative in the presence or absence of the insulin receptor substrate-1.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	r_baserga@lac.jci.tju.edu	Peruzzi, Francesca/M-9804-2014		NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016291] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78890] Funding Source: Medline; NIA NIH HHS [AG 16291] Funding Source: Medline; NIDDK NIH HHS [KO1 DK 0289-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 1999, CONT ENDOCRINOL, V17, P329; Blakesley VA, 1999, CONT ENDOCRINOL, V17, P143; BOURGERON T, 1992, BIOCHEM BIOPH RES CO, V186, P16, DOI 10.1016/S0006-291X(05)80769-7; Craparo A, 1997, J BIOL CHEM, V272, P11663; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Furlanetto RW, 1997, BIOCHEM J, V327, P765; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GOTTLIEB RA, 2000, GENE EXPRESSION, V10, P231; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Harvey KF, 1998, J BIOL CHEM, V273, P13524, DOI 10.1074/jbc.273.22.13524; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kosaki A, 1998, J BIOL CHEM, V273, P940, DOI 10.1074/jbc.273.2.940; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Li SW, 1996, J BIOL CHEM, V271, P12254, DOI 10.1074/jbc.271.21.12254; Morrione A, 1996, CANCER RES, V56, P3165; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Nantel A, 1999, J BIOL CHEM, V274, P35719, DOI 10.1074/jbc.274.50.35719; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Navarro M, 2001, ENDOCRINOLOGY, V142, P1073, DOI 10.1210/en.142.3.1073; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Reuther GW, 1996, VITAM HORM, V52, P149, DOI 10.1016/S0083-6729(08)60410-0; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Rommel C, 1996, ONCOGENE, V12, P609; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Soon L, 1999, MOL CELL BIOL, V19, P3816; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	57	64	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25990	25996		10.1074/jbc.M103188200	http://dx.doi.org/10.1074/jbc.M103188200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352919	hybrid, Green Published			2022-12-27	WOS:000169823300048
J	Paasche, JD; Attramadal, T; Sandberg, C; Johansen, HK; Attramadal, H				Paasche, JD; Attramadal, T; Sandberg, C; Johansen, HK; Attramadal, H			Mechanisms of endothelin receptor subtype-specific targeting to distinct intracellular trafficking pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; CIRCULATING ENDOTHELIN-1; BINDING; DESENSITIZATION; PALMITOYLATION; BETA-ARRESTIN2; ENDOCYTOSIS; CLEARANCE; PEPTIDE	We recently reported that the endothelin (ET) receptor subtypes ETA and ETB are targeted to distinct intracellular destinations upon agonist stimulation (Bremnes, T., Paasche, J. D., Mehlum, A., Sandberg, C., Bremnes, B., and Attramadal, H. (2000) J. Biol. Chem. 275, 17596-17604). The ETA receptor was shown to follow the recycling route of transferrin, whereas ETB is targeted to lysosomes for degradation. In the present study we have investigated the mechanisms of ET receptor subtype-specific targeting to distinct intracellular trafficking pathways. Truncation mutants of the ETA and ETB receptors with deletions of the cytoplasmic carboxyl-terminal tail distal to the palmitoylation site were found to mediate inositol phosphate accumulation and to internalize upon agonist stimulation, although internalization occurred at a slower rate as compared with the wild-type receptors. However, the truncated ETA receptor was no longer able to undergo recycling. Rather, both truncation mutants were recognized by beta -arrestin for recruitment to endocytosis and were sorted to lysosomes by a dynamin-dependent internalization pathway. Furthermore, studies of chimeric ETA and ETB receptors where the cytoplasmic tail of ETA was swapped with the corresponding domain of ETB, and vice versa, revealed that the cytoplasmic tail of ETB is required for efficient lysosomal sorting and that signals for targeting to recycling reside in the cytoplasmic tail of the ETA receptor.	Univ Oslo, Natl Hosp, Inst Surg Res, Merck Sharp & Dohme Cardiovasc Res Ctr, N-0027 Oslo, Norway	University of Oslo; National Hospital Norway	Attramadal, H (corresponding author), Univ Oslo, Natl Hosp, Inst Surg Res, Merck Sharp & Dohme Cardiovasc Res Ctr, A3-1013, N-0027 Oslo, Norway.	havard.attramadal@klinmed.uio.no		Attramadal, Havard/0000-0001-9506-0687				ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Berthiaume N, 2000, HYPERTENSION, V36, P1002, DOI 10.1161/01.HYP.36.6.1002; Bremnes T, 2000, J BIOL CHEM, V275, P17596, DOI 10.1074/jbc.M000142200; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; CHUN MY, 1995, J BIOL CHEM, V270, P10855, DOI 10.1074/jbc.270.18.10855; Cramer H, 1997, BIOCHEMISTRY-US, V36, P13325, DOI 10.1021/bi9708848; CYR CR, 1993, J BIOL CHEM, V268, P26071; Dupuis J, 1996, J APPL PHYSIOL, V81, P1510, DOI 10.1152/jappl.1996.81.4.1510; ELSHOURBAGY NA, 1993, J BIOL CHEM, V268, P3873; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; FUKURODA T, 1994, BIOCHEM BIOPH RES CO, V199, P1461, DOI 10.1006/bbrc.1994.1395; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; KIESELBACH T, 1994, EUR J BIOCHEM, V226, P87, DOI 10.1111/j.1432-1033.1994.tb20029.x; KOSHIMIZU T, 1995, BIOCHEM BIOPH RES CO, V217, P354, DOI 10.1006/bbrc.1995.2784; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MARSAULT R, 1993, AM J PHYSIOL, V264, pC687, DOI 10.1152/ajpcell.1993.264.3.C687; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; Oksche A, 2000, MOL PHARMACOL, V57, P1104; Opgenorth TJ, 2000, J CARDIOVASC PHARM, V36, pS292, DOI 10.1097/00005344-200036051-00086; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; Shibasaki T, 1999, BIOCHEM MOL BIOL INT, V47, P569; SHIBATA T, 1995, BIOMED RES-TOKYO, V16, P97, DOI 10.2220/biomedres.16.97; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; YANAGISAWA M, 1989, BIOCHEM PHARMACOL, V38, P1877; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999	34	52	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34041	34050		10.1074/jbc.M103243200	http://dx.doi.org/10.1074/jbc.M103243200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11382773	hybrid			2022-12-27	WOS:000170910200101
J	Hogg, D; Woo, EJ; Bolam, DN; McKie, VA; Gilbert, HJ; Pickersgill, RW				Hogg, D; Woo, EJ; Bolam, DN; McKie, VA; Gilbert, HJ; Pickersgill, RW			Crystal structure of mannanase 26A from Pseudomonas cellulosa and analysis of residues involved in substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYL HYDROLASE; BETA-MANNANASE; FLUORESCENS; XYLANASE; SPECIFICITY; REFINEMENT; ANGSTROM; COMPLEX; ENZYMES; GENE	The crystal structure of Pseudomonas cellulosa mannanase 26A has been solved by multiple isomorphous replacement and refined at 1.85 Angstrom resolution to an R-factor of 0.182 (R-free = 0.211). The enzyme comprises (beta/alpha)(8)-barrel architecture with two catalytic glutamates at the ends of beta -strands 4 and 7 in precisely the same location as the corresponding glutamates in other 4/7-superfamily glycoside hydrolase enzymes (clan GH-A glycoside hydrolases). The family 26 glycoside hydrolases are therefore members of clan GH-A. Functional analyses of mannanase 26A, informed by the crystal structure of the enzyme, provided important insights into the role of residues close to the catalytic glutamates. These data showed that Trp-360 played a critical role in binding substrate at the -1 subsite, whereas Tyr-285 was important to the function of the nucleophile catalyst. His-211 in mannanase 26A does not have the same function as the equivalent asparagine in the other GH-A enzymes. The data also suggest that Trp-217 and Trp-162 are important for the activity of mannanase 26RA against mannooligosaccharides but are less important for activity against polysaccharides.	Queen Mary Univ London, Sch Biol Sci, London E1 4NS, England; Newcastle Univ, Dept Biol & Nutr Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of London; Queen Mary University London; Newcastle University - UK	Pickersgill, RW (corresponding author), Queen Mary Univ London, Sch Biol Sci, Med Sci Bldg,Mile End Rd, London E1 4NS, England.	r.w.pickersgill@qmw.ac.uk		Bolam, David/0000-0003-0314-3122; Woo, Eui-Jeon/0000-0001-6983-0270				Armand S, 2001, BIOCHEMISTRY-US, V40, P7404, DOI 10.1021/bi002704r; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; Bolam DN, 1996, BIOCHEMISTRY-US, V35, P16195, DOI 10.1021/bi961866d; BRAITHWAITE KL, 1995, BIOCHEM J, V305, P1005, DOI 10.1042/bj3051005; Charnock SJ, 1998, J BIOL CHEM, V273, P32187, DOI 10.1074/jbc.273.48.32187; Charnock SJ, 1997, J BIOL CHEM, V272, P2942, DOI 10.1074/jbc.272.5.2942; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P1926, DOI 10.1021/bi972162m; Garman E, 1999, STRUCT FOLD DES, V7, pR291, DOI 10.1016/S0969-2126(00)88335-5; HARJUNPAA V, 1995, EUR J BIOCHEM, V234, P278, DOI 10.1111/j.1432-1033.1995.278_c.x; Harris GW, 1996, ACTA CRYSTALLOGR D, V52, P393, DOI 10.1107/S0907444995013540; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Hilge M, 1998, STRUCTURE, V6, P1433, DOI 10.1016/S0969-2126(98)00142-7; JENKINS J, 1995, FEBS LETT, V362, P281, DOI 10.1016/0014-5793(95)00252-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; MCCLEARY BV, 1983, CARBOHYD RES, V119, P191, DOI 10.1016/0008-6215(83)84056-7; MillwardSadler SJ, 1996, FEMS MICROBIOL LETT, V141, P183, DOI 10.1016/0378-1097(96)00219-4; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; STALBRAND H, 1995, APPL ENVIRON MICROB, V61, P1090; Stoll D, 1999, APPL ENVIRON MICROB, V65, P2598; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Svensson B, 1999, ROY SOC CH, P272; Timell T. E., 1967, Wood Science and Technology, V1, P45, DOI 10.1007/BF00592255; Toorop PE, 1999, J PLANT PHYSIOL, V154, P679, DOI 10.1016/S0176-1617(99)80244-2	34	78	83	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31186	31192		10.1074/jbc.M010290200	http://dx.doi.org/10.1074/jbc.M010290200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11382747	hybrid			2022-12-27	WOS:000170472900079
J	Maeda, T; Takahashi, Y; Suenaga, H; Suyama, A; Goto, M; Furukawa, K				Maeda, T; Takahashi, Y; Suenaga, H; Suyama, A; Goto, M; Furukawa, K			Functional analyses of Bph-Tod hybrid dioxygenase, which exhibits high degradation activity toward trichloroethylene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PSEUDOALCALIGENES KF707; B-356 BIPHENYL DIOXYGENASE; SITE-DIRECTED MUTAGENESIS; TOLUENE DIOXYGENASE; POLYCHLORINATED-BIPHENYLS; EFFICIENT DEGRADATION; SUBSTRATE-SPECIFICITY; OXIDIZING BACTERIUM; OXYGENASE COMPONENT; ESCHERICHIA-COLI	Biphenyl dioxygenase (BphDox) in Pseudomonas pseudoalcaligenes KF707 is a multicomponent enzyme consisting of an iron-sulfur protein (ISP) that is composed of alpha (BphA1) and beta (BphA2) subunits, a ferredoxin (FDBphA3), and a ferredoxin reductase (FDRBphA4). A recombinant Escherichia coli strain expressing hybrid Dox that had replaced BphA1 with TodC1 (alpha subunit of toluene dioxygenase (TolDox) of Pseudomonas putida) exhibited high activity toward trichloroethylene (TCE) (Furukawa, K., Hirose, J., Hayashida, S., and Nakamura, K. (1994) J. Bacteriol. 176, 2121-2123). In this study, ISP, FD, and FDR were purified and characterized. Reconstitution of the dioxygenase components consisting of purified ISPTodC1BphA2 FDBphA3 and FDRBphA4 exhibited oxygenation activities toward biphenyl, toluene, and TCE. Native polyacrylamide gel electrophoresis followed by the Ferguson plot analyses demonstrated that ISPTodC1BphA2 and ISPBphA1A2 were present as heterohexamers, whereas ISPTodC1C2 was present as a heterotetramer. The molecular activity (k(0)) of the hybrid Dox for TCE was 4.1 min(-1), which is comparable to that of TolDox. The K-m value of the hybrid Dox for TCE was 130 muM, which was lower than 250 muM for TolDox. These results suggest that the alpha subunit of ISP is crucial for the determination of substrate specificity and that the change in the alpha subunit conformation of ISP from alpha (2)beta (2) to alpha (3)beta (3), results in the acquisition of higher affinity to TCE, which may lead to high TCE degradation activity.	Kyushu Univ, Fac Agr, Dept Biosci & Biotechnol, Appl Microbiol Lab, Fukuoka 8128581, Japan	Kyushu University	Furukawa, K (corresponding author), Kyushu Univ, Fac Agr, Dept Biosci & Biotechnol, Appl Microbiol Lab, Fukuoka 8128581, Japan.		KENSUKE, FURUKAWA/R-3105-2019					ARCIERO D, 1989, BIOCHEM BIOPH RES CO, V159, P640, DOI 10.1016/0006-291X(89)90042-9; ASHIUCHI M, 1995, J BIOCHEM, V117, P495, DOI 10.1093/oxfordjournals.jbchem.a124735; Bruhlmann F, 1999, BIOTECHNOL BIOENG, V63, P544, DOI 10.1002/(SICI)1097-0290(19990605)63:5<544::AID-BIT4>3.0.CO;2-6; ERICKSON BD, 1993, APPL ENVIRON MICROB, V59, P3858, DOI 10.1128/AEM.59.11.3858-3862.1993; FURUKAWA K, 1994, J BACTERIOL, V176, P2121, DOI 10.1128/jb.176.7.2121-2123.1994; FURUKAWA K, 1993, J BACTERIOL, V175, P5224, DOI 10.1128/JB.175.16.5224-5232.1993; Furukawa K, 2000, CURR OPIN BIOTECH, V11, P244, DOI 10.1016/S0958-1669(00)00091-4; GALLAGHER SR, 1995, CURRENT PROTOCOLS PR; Gibson DT, 2000, CURR OPIN BIOTECH, V11, P236, DOI 10.1016/S0958-1669(00)00090-2; GIBSON DT, 1993, J BACTERIOL, V175, P4561, DOI 10.1128/JB.175.14.4561-4564.1993; GOSSETT JM, 1987, ENVIRON SCI TECHNOL, V21, P202, DOI 10.1021/es00156a012; HADDOCK JD, 1995, J BACTERIOL, V177, P5834, DOI 10.1128/jb.177.20.5834-5839.1995; HIROSE J, 1994, GENE, V138, P27; Hurtubise Y, 1996, J BIOL CHEM, V271, P8152, DOI 10.1074/jbc.271.14.8152; HURTUBISE Y, 1995, J BACTERIOL, V177, P6610, DOI 10.1128/jb.177.22.6610-6618.1995; INFANTE PF, 1982, ENV SCI RES, V25, P301; Jiang HY, 1996, J BACTERIOL, V178, P3133, DOI 10.1128/jb.178.11.3133-3139.1996; Kimura N, 1997, J BACTERIOL, V179, P3936, DOI 10.1128/jb.179.12.3936-3943.1997; Kumamaru T, 1998, NAT BIOTECHNOL, V16, P663, DOI 10.1038/nbt0798-663; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee K, 1999, J BACTERIOL, V181, P2719, DOI 10.1128/JB.181.9.2719-2725.1999; LI SY, 1992, BIOCHEM BIOPH RES CO, V185, P443, DOI 10.1016/S0006-291X(05)81005-8; LITTLE CD, 1988, APPL ENVIRON MICROB, V54, P951, DOI 10.1128/AEM.54.4.951-956.1988; MAISON JR, 1992, ANNU REV MICROBIOL, V46, P277; Mondello FJ, 1997, APPL ENVIRON MICROB, V63, P3096, DOI 10.1128/AEM.63.8.3096-3103.1997; NELSON MJK, 1987, APPL ENVIRON MICROB, V53, P949, DOI 10.1128/AEM.53.5.949-954.1987; Newman LM, 1997, J BACTERIOL, V179, P90, DOI 10.1128/jb.179.1.90-96.1997; SHIELDS MS, 1991, APPL ENVIRON MICROB, V57, P1935, DOI 10.1128/AEM.57.7.1935-1941.1991; SUBRAMANIAN V, 1979, BIOCHEM BIOPH RES CO, V91, P1131, DOI 10.1016/0006-291X(79)91998-3; Suenaga H, 2001, J BIOL CHEM, V276, P22500, DOI 10.1074/jbc.M101323200; Suyama A, 1996, J BACTERIOL, V178, P4039, DOI 10.1128/jb.178.14.4039-4046.1996; TAIRA K, 1992, J BIOL CHEM, V267, P4844; *US EPA, 1985, NPLU3693 US EPA; WACKETT LP, 1988, APPL ENVIRON MICROB, V54, P1703, DOI 10.1128/AEM.54.7.1703-1708.1988; ZYLSTRA GJ, 1989, J BIOL CHEM, V264, P14940	35	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29833	29838		10.1074/jbc.M102025200	http://dx.doi.org/10.1074/jbc.M102025200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390387	hybrid			2022-12-27	WOS:000170558000032
J	Dumin, JA; Dickeson, SK; Stricker, TP; Bhattacharyya-Pakrasi, M; Roby, JD; Santoro, SA; Parks, WC				Dumin, JA; Dickeson, SK; Stricker, TP; Bhattacharyya-Pakrasi, M; Roby, JD; Santoro, SA; Parks, WC			Pro-collagenase-1 (matrix metalloproteinase-1) binds the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; TISSUE INHIBITOR; CATALYTIC-ACTIVITY; HUMAN NEUTROPHILS; EXPRESSION; ACTIVATION; ADHESION; LOCALIZATION; COMPONENTS; RECEPTORS	In injured skin, collagenase-1 (matrix metalloproteinase-1 (MMP-1)) is induced in migrating keratinocytes. This site-specific expression is regulated by binding of the alpha (2)beta (1) integrin with dermal type I collagen, and the catalytic activity of MMP-1 is required for keratinocyte migration. Because of this functional association among substrate/ligand, receptor, and proteinase, we assessed whether the integrin also directs the compartmentalization of MMP-1 to its matrix target. Indeed, pro-MMP-1 co-localized to sites of alpha (2)beta (1) contacts in migrating keratinocytes. Furthermore, pro-MMP-1 co-immunoprecipitated with alpha (2)beta (1) from keratinocytes, and alpha (2)beta (1) co-immunoprecipitated with pro-MMP-1. No other MMPs bound alpha (2)beta (1) and no other integrins interacted with MMP-1. Pro-MMP-1 also provided a substrate for alpha (2)beta (1)-dependent adhesion of platelets. Complex formation on keratinocytes was most efficient on native type I collagen and reduced or ablated on denatured or cleaved collagen. Competition studies suggested that the alpha (2) I domain interacts with the linker and hemopexin domains of pro-MMP-1, not with the pro-domain. These data indicate that the interaction of pro-MMP-1 with alpha (2)beta (1) confines this proteinase to points of cell contact with collagen and that the ternary complex of integrin, enzyme, and substrate function together to drive and regulate keratinocyte migration.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Parks, WC (corresponding author), Washington Univ, Sch Med, Dept Pediat, Box 8208,660 S Euclid Ave, St Louis, MO 63110 USA.	parks_w@kids.wustl.edu	Parks, William C./AAH-6786-2021		NHLBI NIH HHS [HL63446] Funding Source: Medline; NIAMS NIH HHS [AR45254] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063446] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR045254] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Campbell EJ, 1999, J CLIN INVEST, V104, P337, DOI 10.1172/JCI6092; Campbell EJ, 2000, J IMMUNOL, V165, P3366, DOI 10.4049/jimmunol.165.6.3366; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; COLLER BS, 1989, BLOOD, V74, P182; Dunsmore SE, 1998, J CLIN INVEST, V102, P1321, DOI 10.1172/JCI1516; HAVERSTICK DM, 1985, BLOOD, V66, P946; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; Jeffrey JJ, 1998, BIOL EXTRAC, P15; JUHASZ I, 1993, AM J PATHOL, V143, P1458; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; Mueller SC, 1999, J BIOL CHEM, V274, P24947, DOI 10.1074/jbc.274.35.24947; OWEN CA, 1995, J CELL BIOL, V131, P775, DOI 10.1083/jcb.131.3.775; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; Partridge CA, 1997, AM J PHYSIOL-LUNG C, V272, pL813, DOI 10.1152/ajplung.1997.272.5.L813; PELLEGRINI G, 1992, J CLIN INVEST, V89, P1783, DOI 10.1172/JCI115782; Pilcher BK, 1999, J BIOL CHEM, V274, P10372, DOI 10.1074/jbc.274.15.10372; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SANTORO SA, 1994, METHOD ENZYMOL, V245, P147; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; SIRES UI, 1995, J BIOL CHEM, V270, P1062, DOI 10.1074/jbc.270.3.1062; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STAHLEBACKDAHL M, 1993, AM J PATHOL, V142, P995; Stricker TP, 2001, J BIOL CHEM, V276, P29375, DOI 10.1074/jbc.M102217200; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Sudbeck BD, 1997, MOL BIOL CELL, V8, P811, DOI 10.1091/mbc.8.5.811; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; Sudbeck BD, 1997, J BIOL CHEM, V272, P22103, DOI 10.1074/jbc.272.35.22103; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TAMAI K, 1995, J INVEST DERMATOL, V104, P384, DOI 10.1111/1523-1747.ep12665857; Tarui T, 2001, J BIOL CHEM, V276, P3983, DOI 10.1074/jbc.M008220200; Vaalamo M, 1996, BRIT J DERMATOL, V135, P52; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; YAMADA KM, 1996, MOL CELLULAR BIOL WO, P311; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183	45	168	173	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29368	29374		10.1074/jbc.M104179200	http://dx.doi.org/10.1074/jbc.M104179200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11359786	hybrid			2022-12-27	WOS:000170346000098
J	Harris, TE; Albrecht, JH; Nakanishi, M; Darlington, GJ				Harris, TE; Albrecht, JH; Nakanishi, M; Darlington, GJ			CCAAT/enhancer-binding protein-alpha cooperates with p21 to inhibit cyclin-dependent kinase-2 activity and induces growth arrest independent of DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL REGION; C/EBP-ALPHA; CELL-PROLIFERATION; TRANSCRIPTIONAL ACTIVATOR; NUCLEAR-LOCALIZATION; E7 ONCOPROTEIN; CDK INHIBITORS; NEWBORN MICE; DIFFERENTIATION; PCNA	CCAAT/enhancer-binding protein-alpha (C/EBP alpha) is a basic leucine zipper protein that controls transcription of genes important for liver function, white adipose tissue development, and granulocyte differentiation. In addition to its function in controlling gene expression in differentiated tissues, C/EBP alpha is also associated with an antimitotic activity. We have previously demonstrated that C/EBP alpha interacts with p21, a cyclin-dependent kinase (CDK) inhibitor, and that C/EBP alpha inhibits proliferation when expressed in several different cell types (Timchenko, N. A., Harris, T. E., Wilde, M., Bilyeu, T. A., Burgess-Beusse, B. L., Finegold, M. J., and Darlington, G. J. (1997) Mol. Cell. Biol. 17,7353-7361). Here we define the regions of C/EBP alpha required for interaction with p21 and demonstrate that CDK2 also interacts with C/EBP alpha. We show that C/EBP alpha can cooperate with p21. to inhibit CDK2 activity in vitro. The effect of C/EBP alpha on CDK2 activity requires the p21 and CDK2 interaction sites within C/EBP alpha. C/EBP alpha mutants incapable of inhibiting CDK2 activity in vitro do not inhibit proliferation in cultured cells. However, C/EBP alpha mutants defective in DNA binding inhibit proliferation as effectively as the wild-type protein. These findings show that C/EBP alpha -mediated growth arrest occurs through protein interactions and is independent of its transcriptional activity.	Baylor Coll Med, Roy M & Phyllis Gough Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA; Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA; Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Baylor College of Medicine; Baylor College of Medicine; Hennepin County Medical Center; Nagoya City University	Darlington, GJ (corresponding author), Baylor Coll Med, Roy M & Phyllis Gough Huffington Ctr Aging, Rm N810,1 Baylor Plaza, Houston, TX 77030 USA.				NIA NIH HHS [T32 AG-00183, AG-13663] Funding Source: Medline; NIDDK NIH HHS [DK-54921] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013663, T32AG000183] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albrecht JH, 1999, AM J PHYSIOL-GASTR L, V277, pG1207, DOI 10.1152/ajpgi.1999.277.6.G1207; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Fotedar R, 1996, ONCOGENE, V12, P2155; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Li SL, 1997, BIOTECHNIQUES, V23, P588, DOI 10.2144/97234bm05; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Muller C, 1999, P NATL ACAD SCI USA, V96, P7276, DOI 10.1073/pnas.96.13.7276; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582; Ono T, 2000, J BIOL CHEM, V275, P31145, DOI 10.1074/jbc.M003031200; ORourke J, 1997, J BIOL CHEM, V272, P6291, DOI 10.1074/jbc.272.10.6291; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Taules M, 1999, J BIOL CHEM, V274, P24445, DOI 10.1074/jbc.274.35.24445; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P3621, DOI 10.1093/nar/27.17.3621; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	45	106	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29200	29209		10.1074/jbc.M011587200	http://dx.doi.org/10.1074/jbc.M011587200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11369759	hybrid			2022-12-27	WOS:000170346000077
J	Melman, L; Cao, ZF; Rennke, S; Marzolo, MP; Wardell, MR; Bu, GJ				Melman, L; Cao, ZF; Rennke, S; Marzolo, MP; Wardell, MR; Bu, GJ			High affinity binding of receptor-associated protein to heparin and low density lipoprotein receptor-related protein requires similar basic amino acid sequence motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHRITIS ANTIGENIC COMPLEX; PLASMINOGEN-ACTIVATOR INHIBITOR-1; HUMAN APOLIPOPROTEIN-E; RAT HEPATOMA-CELLS; 39-KDA PROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; LIGAND-BINDING; SPECIALIZED CHAPERONE; MOLECULAR CHAPERONE; TERMINAL DOMAIN	The 39-kDa receptor-associated protein (RAP) is a specialized chaperone for members of the low density lipoprotein receptor gene family, which also binds heparin. Previous studies have identified a triplicate repeat sequence within RAP that appears to exhibit differential functions. Here we generated a series of truncated and site-directed RAP mutants in order to define the sites within RAP that are important for interacting with heparin and low density lipoprotein receptor-related protein (LRP). We found that high affinity binding of RAP to heparin is mediated by the carboxyl-terminal repeat of RAP, whereas both the carboxyl-terminal repeat and a combination of amino and central repeats exhibit high affinity binding to LRP. Several motifs were found to mediate the binding of RAP to heparin, and each contained a cluster of basic amino acids; among them, an intact (RVSRSREK289)-V-282-S-285-E-287 motif is required for high affinity binding of RAP to heparin, whereas two other motifs, (RLRR206)-L-203-R-205 and R(314)ISR(317)AR(319), also contribute to this interaction. We also found that intact motifs of both (RLPR206)-L-203-R-205 and (RVSRSREK289)-V-282-S-285-E-287 are required for high affinity binding of RAP to LRP, with the third motif, R(314)ISR(317)AR(319), contributing little to RAP-LRP interaction. We conclude that electrostatic interactions likely contribute significantly in the binding of RAP to both heparin and LRP and that high affinity interaction with both heparin and LRP appears to require mostly overlapping sequence motifs within RAP.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Univ Chile, Dept Biol, Santiago, Chile	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Universidad de Chile	Bu, GJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, CB 8208,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059150, R01HL060617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056783] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60617, HL59150] Funding Source: Medline; NIDDK NIH HHS [DK56783] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIEMESDERFER D, 1993, AM J PHYSIOL, V264, pF1011, DOI 10.1152/ajprenal.1993.264.6.F1011; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; BU GJ, 1992, J BIOL CHEM, V267, P15595; Bu GJ, 1997, J CELL SCI, V110, P65; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BU GJ, 1994, J BIOL CHEM, V269, P29874; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Ellgaard L, 1997, EUR J BIOCHEM, V244, P544, DOI 10.1111/j.1432-1033.1997.00544.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; Horn IR, 1998, THROMB HAEMOSTASIS, V80, P822; Huang W, 2000, J BIOL CHEM, V275, P1089, DOI 10.1074/jbc.275.2.1089; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Li YH, 1998, J CELL BIOCHEM, V71, P149, DOI 10.1002/(SICI)1097-4644(19981101)71:2<149::AID-JCB1>3.0.CO;2-V; MCKAY EJ, 1981, THROMB RES, V21, P375, DOI 10.1016/0049-3848(81)90138-9; Medved LV, 1999, J BIOL CHEM, V274, P717, DOI 10.1074/jbc.274.2.717; MENZEL HJ, 1983, ARTERIOSCLEROSIS, V3, P310, DOI 10.1161/01.ATV.3.4.310; Nielsen PR, 1997, P NATL ACAD SCI USA, V94, P7521, DOI 10.1073/pnas.94.14.7521; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; OLSON ST, 1991, J BIOL CHEM, V266, P6342; ORLANDO RA, 1994, P NATL ACAD SCI USA, V91, P3161, DOI 10.1073/pnas.91.8.3161; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORLANDO RA, 1993, P NATL ACAD SCI USA, V90, P4082, DOI 10.1073/pnas.90.9.4082; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Rall SC, 1998, J BIOL CHEM, V273, P24152, DOI 10.1074/jbc.273.37.24152; SANT AJ, 1994, CURR OPIN IMMUNOL, V6, P57, DOI 10.1016/0952-7915(94)90034-5; Sato A, 1999, BIOCHEM J, V341, P377, DOI 10.1042/0264-6021:3410377; Savonen R, 1999, J BIOL CHEM, V274, P25877, DOI 10.1074/jbc.274.36.25877; SHELBURNE FA, 1977, J CLIN INVEST, V60, P944, DOI 10.1172/JCI108849; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; Wardell MR, 1997, BIOCHEMISTRY-US, V36, P13133, DOI 10.1021/bi970664u; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1994, J BIOL CHEM, V269, P3325; WARSHAWSKY I, 1995, BIOCHEMISTRY-US, V34, P3404, DOI 10.1021/bi00010a032; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	43	25	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29338	29346		10.1074/jbc.M103717200	http://dx.doi.org/10.1074/jbc.M103717200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382778	hybrid			2022-12-27	WOS:000170346000094
J	Akagi, K; Nagao, T; Urushidani, T				Akagi, K; Nagao, T; Urushidani, T			Reconstitution of acid secretion in digitonin-permeabilized rabbit gastric glands - Identification of cytosolic regulatory factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; PARIETAL-CELL; CA2+-ACTIVATED SECRETION; CHROMAFFIN CELLS; EXOCYTOSIS; ACTIVATION; KINASE; BRAIN; EXO2	When isolated rabbit gastric glands were permeabilized with digitonin, they lost their ability to secrete acid, as monitored by [C-14]aminopyrine accumulation, and they never recovered by supplement with cytosol prepared from gastric mucosa. However, the permeabilized glands elicited acid secretion when brain cytosol was supplemented. Fractionation of gastric cytosol by gel filtration revealed that the fraction at 30 kDa stimulated permeabilized glands by itself, whereas the 200-kDa fraction potently inhibited brain cytosol-stimulated acid secretion. Brain cytosol contained only the former stimulatory factor. With further gel filtration, the 30-kDa activator was separated into two components, 20 kDa (peak 1) and 1.8 kDa (peak 2), both of which are necessary for full activity. We purified peak 1 from bovine brain, and phosphatidylinositol transfer protein (PITP) was identified as the main component of the activity. The stimulating activity in brain and gastric mucosa correlated with the contents of PITP, and recombinant PITP mimicked the effect of peak 1, suggesting that PITP is one of the essential components in gastric acid secretion. When gastric glands were stimulated, the inhibitory activity, but not stimulatory activity, in the cytosol was increased. This suggests a regulatory mechanism such as stimulation translocates the inhibitory component from the secretory site on the membrane to cytosol. These results demonstrate a high degree of usefulness for our present model, the reconstituted digitonin-permeabilized gastric glands.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Tokyo 1130033, Japan	University of Tokyo	Urushidani, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Tokyo 1130033, Japan.	urushi@mol.f.u-tokyo.ac.jp						Akagi K, 1999, AM J PHYSIOL-GASTR L, V277, pG736, DOI 10.1152/ajpgi.1999.277.3.G736; BERGLINDH T, 1990, METHOD ENZYMOL, V192, P93; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Duman JG, 1999, AM J PHYSIOL-CELL PH, V277, pC361, DOI 10.1152/ajpcell.1999.277.3.C361; Edwardson JM, 1997, CELL, V90, P325, DOI 10.1016/S0092-8674(00)80340-2; Fujita-Yoshigaki J, 1999, J BIOL CHEM, V274, P23642, DOI 10.1074/jbc.274.33.23642; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HERSEY SJ, 1985, AM J PHYSIOL, V248, pG561, DOI 10.1152/ajpgi.1985.248.5.G561; MALINOWSKA DH, 1995, AM J PHYSIOL-CELL PH, V268, pC191, DOI 10.1152/ajpcell.1995.268.1.C191; Miller MD, 1996, AM J PHYSIOL-GASTR L, V270, pG962, DOI 10.1152/ajpgi.1996.270.6.G962; MORGAN A, 1993, EMBO J, V12, P3747, DOI 10.1002/j.1460-2075.1993.tb06052.x; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; Muto Y, 2001, AM J PHYSIOL-CELL PH, V280, pC155, DOI 10.1152/ajpcell.2001.280.1.C155; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; OMI N, 2001, IN PRESS AM J PHYSL; PAYNE NA, 1990, METHOD ENZYMOL, V187, P505; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; THIBODEAU A, 1994, BIOCHEM CELL BIOL, V72, P26, DOI 10.1139/o94-005; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; Urushidani T, 1997, AM J PHYSIOL-GASTR L, V272, pG1122, DOI 10.1152/ajpgi.1997.272.5.G1122; Urushidani T, 1997, J MEMBRANE BIOL, V159, P99, DOI 10.1007/s002329900274; URUSHIDANI T, 1989, AM J PHYSIOL, V256, pG1070, DOI 10.1152/ajpgi.1989.256.6.G1070; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; Wiedemann C, 1998, TRENDS ENDOCRIN MET, V9, P324, DOI 10.1016/S1043-2760(98)00080-0	27	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28171	28178		10.1074/jbc.M101190200	http://dx.doi.org/10.1074/jbc.M101190200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11384966	hybrid			2022-12-27	WOS:000170093400058
J	Ichai, C; Guignot, L; El-Mir, MY; Nogueira, V; Guigas, B; Chauvin, C; Fontaine, E; Mithieux, G; Leverve, XM				Ichai, C; Guignot, L; El-Mir, MY; Nogueira, V; Guigas, B; Chauvin, C; Fontaine, E; Mithieux, G; Leverve, XM			Glucose 6-phosphate hydrolysis is activated by glucagon in a low temperature-sensitive manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; LIVER PYRUVATE-KINASE; MICROSOMAL GLUCOSE-6-PHOSPHATASE; HEPATIC GLUCONEOGENESIS; GLYCEROL METABOLISM; GLYCOGEN-SYNTHESIS; HORMONAL-CONTROL; GENE-EXPRESSION; ADIPOSE-TISSUE; FASTED RATS	Glucagon affects liver glucose metabolism mainly by activating glycogen breakdown and by inhibiting pyruvate kinase, whereas a possible effect on glucose-6-phosphatase has also been suggested. Although such a target is of physiological importance for liver glucose production it was never proven. By using a model of liver cells, perifused. with dihydroxyacetone, we show here that the acute stimulation of gluconeogenesis by glucagon (10(-7) M) was not related to the significant inhibition of pyruvate kinase but to a dramatic activation of the hydrolysis of glucose 6-phosphate. We failed to find an acute change in glucose-6-phosphatase activity by glucagon, but the increase in glucose 6-phosphate hydrolysis was abolished at 21 degreesC; conversely the effect on pyruvate kinase was not affected by temperature. The activation of glucose 6-phosphate hydrolysis by glucagon was confirmed in vivo, in postabsorptive rats receiving a constant infusion of glucagon, by the combination of a 2-fold increase in hepatic glucose production and a 60% decrease in liver glucose 6-phosphate concentration. Besides the description of a novel effect of glucagon on glucose 6-phosphate hydrolysis by a temperature-sensitive mechanism, this finding could represent an important breakthrough in the understanding of type II diabetes, because glucose 6-phosphate is proposed to be a key molecule in the transcriptional effect of glucose.	Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, F-38041 Grenoble, France; Fac Med Laennec, INSERM, U449, F-69372 Lyon, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm)	Leverve, XM (corresponding author), Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, BP 53X, F-38041 Grenoble, France.	Xavier.Leverve@ujf-grenoble.fr	Fontaine, Eric/ABA-8853-2020; Guigas, Bruno/M-2515-2015	Fontaine, Eric/0000-0002-5204-9477; Guigas, Bruno/0000-0002-8856-5799; Gilles, Mithieux/0000-0003-3579-8529				Aiston S, 1999, J BIOL CHEM, V274, P24559, DOI 10.1074/jbc.274.35.24559; ARGAUD D, 1991, BIOCHEM J, V280, P663, DOI 10.1042/bj2800663; ARGAUD D, 1993, EUR J BIOCHEM, V213, P1341, DOI 10.1111/j.1432-1033.1993.tb17886.x; ARION WJ, 1980, J BIOL CHEM, V255, P396; BAQUET A, 1990, J BIOL CHEM, V265, P955; BEGLEY PJ, 1981, BIOCHEM BIOPH RES CO, V103, P1029, DOI 10.1016/0006-291X(81)90912-8; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V4, P1196; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BIRNBAUM MJ, 1977, J BIOL CHEM, V252, P528; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; BRIVET M, 1983, PEDIATR RES, V17, P157, DOI 10.1203/00006450-198302000-00015; BURCHELL A, 1990, FASEB J, V4, P2978, DOI 10.1096/fasebj.4.12.2168325; CLARK MG, 1974, J BIOL CHEM, V249, P5695; CLAUS TH, 1981, BIOCHEM BIOPH RES CO, V100, P716, DOI 10.1016/S0006-291X(81)80234-3; CLAUS TH, 1979, J BIOL CHEM, V254, P7855; Daniele N, 1999, J BIOL CHEM, V274, P3597, DOI 10.1074/jbc.274.6.3597; Engstrom L, 1978, Curr Top Cell Regul, V13, P28; FELIU JE, 1976, P NATL ACAD SCI USA, V73, P2762, DOI 10.1073/pnas.73.8.2762; Ferre P, 1999, P NUTR SOC, V58, P621, DOI 10.1017/S0029665199000816; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; Foufelle F, 1996, ADV ENZYME REGUL, V36, P199, DOI 10.1016/0065-2571(95)00010-0; GROEN AK, 1983, J BIOL CHEM, V258, P4346; GROEN AK, 1986, BIOCHEM J, V237, P379, DOI 10.1042/bj2370379; GROEN AK, 1982, EUR J BIOCHEM, V122, P87, DOI 10.1111/j.1432-1033.1982.tb05851.x; Guignot L, 1999, AM J PHYSIOL-ENDOC M, V277, pE984, DOI 10.1152/ajpendo.1999.277.6.E984; Guillam MT, 1998, P NATL ACAD SCI USA, V95, P12317, DOI 10.1073/pnas.95.21.12317; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; HAYNES RC, 1990, ARCH BIOCHEM BIOPHYS, V283, P51, DOI 10.1016/0003-9861(90)90611-2; HERS HG, 1983, ANNU REV BIOCHEM, V52, P617, DOI 10.1146/annurev.bi.52.070183.003153; Keppler D., 1974, METHOD ENZYMAT AN, V3, P1127, DOI DOI 10.1242/JEB.037275; Lang G., 1974, METHODS ENZYMATIC AN, P1238; Leclercq P, 1997, BIOCHEM J, V325, P519, DOI 10.1042/bj3250519; LEVERVE XM, 1986, EUR J BIOCHEM, V155, P551, DOI 10.1111/j.1432-1033.1986.tb09523.x; LEVERVE XM, 1994, EUR J BIOCHEM, V224, P967, DOI 10.1111/j.1432-1033.1994.00967.x; LLORENTE P, 1970, EUR J BIOCHEM, V13, P45, DOI 10.1111/j.1432-1033.1970.tb00897.x; MINASSIAN C, 1995, J NUTR, V125, P2727; Minassian C, 1999, BBA-MOL CELL RES, V1452, P172, DOI 10.1016/S0167-4889(99)00130-5; Mithieux G, 1997, EUR J ENDOCRINOL, V136, P137, DOI 10.1530/eje.0.1360137; Mittelman SD, 1997, J CLIN INVEST, V100, P3121, DOI 10.1172/JCI119867; NILSSON OS, 1978, EUR J BIOCHEM, V82, P627, DOI 10.1111/j.1432-1033.1978.tb12059.x; Odievre M, 1966, Rev Int Hepatol, V16, P1; Paquot N, 1996, DIABETOLOGIA, V39, P580; PILKIS SJ, 1976, J BIOL CHEM, V251, P7841; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Piquet MA, 1996, BIOCHEM J, V317, P667, DOI 10.1042/bj3170667; POLLARDKNIGHT D, 1987, BIOCHEM J, V245, P625, DOI 10.1042/bj2450625; RIOU JP, 1978, J BIOL CHEM, V253, P656; Santer R, 1997, NAT GENET, V17, P324, DOI 10.1038/ng1197-324; SPETH M, 1981, BIOCHEM BIOPH RES CO, V99, P134, DOI 10.1016/0006-291X(81)91723-X; SUTHERLAND EW, 1958, J BIOL CHEM, V232, P1077; THORENS B, 1990, AM J PHYSIOL, V259, P279; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; Unger R H, 1982, Compr Ther, V8, P53; UNGER RH, 1985, DIABETOLOGIA, V28, P574, DOI 10.1007/BF00281991; VANDERMEER R, 1976, FEBS LETT, V67, P36, DOI 10.1016/0014-5793(76)80865-4; VENEZIALE CM, 1972, BIOCHEMISTRY-US, V11, P3286, DOI 10.1021/bi00767a025; ZUURENDONK PF, 1974, BIOCHIM BIOPHYS ACTA, V333, P393, DOI 10.1016/0005-2728(74)90022-X	57	15	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28126	28133		10.1074/jbc.M010186200	http://dx.doi.org/10.1074/jbc.M010186200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11371550	Green Published, hybrid			2022-12-27	WOS:000170093400052
J	Tzarfaty-Majar, V; Lopez-Alemany, R; Feinstein, Y; Gombau, L; Goldshmidt, O; Soriano, E; Munoz-Canoves, P; Klar, A				Tzarfaty-Majar, V; Lopez-Alemany, R; Feinstein, Y; Gombau, L; Goldshmidt, O; Soriano, E; Munoz-Canoves, P; Klar, A			Plasmin-mediated release of the guidance molecule F-spondin from the extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA CIRCUMSPOROZOITE PROTEIN; FIBROBLAST GROWTH-FACTOR; MELANOMA CELL-ADHESION; HEPARIN-BINDING; NERVOUS-SYSTEM; NEURAL DEVELOPMENT; ENDOTHELIAL-CELLS; NEURITE OUTGROWTH; NEURONAL GROWTH; ACTIVATOR GENE	Serine proteases are implicated in a variety of processes during neurogenesis, including cell migration, axon outgrowth, and synapse elimination. Tissue-type plasminogen activator and urokinase-type activator are expressed in the floor plate during embryonic development. F-spondin, a gene also expressed in the floor plate, encodes a secreted, extracellular matrix-attached protein that promotes outgrowth of commissural axons and inhibits outgrowth of motor axons. F-spondin is processed in vivo to yield an amino half protein that contains regions of homology to reelin and mindin, and a carboxyl half protein that contains either six or four thrombospondin type I repeats (TSRs). We have tested F-spondin to see whether it is subjected to processing by plasmin and to determine whether the processing modulates its biological activity. Plasmin cleaves F-spondin at its carboxyl terminus. By using nested deletion proteins and mutating potential plasmin cleavage sites, we have identified two cleavage sites, the first between the fifth and sixth TSRs, and the second at the fifth TSR. Analysis of the extracellular matrix (ECM) attachment properties of the TSRs revealed that the fifth and sixth TSRs bind to the ECM, but repeats 1-4 do not. Structural functional experiments revealed that two basic motives are required to elicit binding of TSR module to the ECM. We demonstrate further that plasmin releases the ECM-bound F-spondin protein.	Ctr Mol Oncol, Inst Recerca Oncol, Barcelona 08907, Spain; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Anat & Cell Biol, IL-91120 Jerusalem, Israel; Hadassah Hebrew Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Univ Barcelona, Fac Biol, Dept Anim & Plant Cell Biol, E-08028 Barcelona, Spain	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Barcelona	Munoz-Canoves, P (corresponding author), Ctr Mol Oncol, Inst Recerca Oncol, Barcelona 08907, Spain.		Munoz-Canoves, Pura/B-3889-2015; Lopez-Alemany, Roser/R-3565-2018; Klar, Avihu/AHC-4770-2022	Lopez-Alemany, Roser/0000-0002-0913-0691; 				Adams JC, 2000, DEV DYNAM, V218, P280; Akassoglou K, 2000, J CELL BIOL, V149, P1157, DOI 10.1083/jcb.149.5.1157; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; BENEZRA M, 1993, BLOOD, V81, P3324; Burstyn-Cohen T, 1998, J NEUROSCI, V18, P8875; Burstyn-Cohen T, 1999, NEURON, V23, P233, DOI 10.1016/S0896-6273(00)80776-X; CAJAL SRY, 1921, TRAB LABOR INVEST BI, V18, P4; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CARROLL PM, 1994, DEVELOPMENT, V120, P3173; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; CHERRY SS, 1995, J BIOL CHEM, V270, P7304; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Debby-Brafman A, 1999, NEURON, V22, P475, DOI 10.1016/S0896-6273(00)80703-5; DEFREITAS MF, 1995, NEURON, V15, P333, DOI 10.1016/0896-6273(95)90038-1; DENT MAR, 1993, EUR J NEUROSCI, V5, P633, DOI 10.1111/j.1460-9568.1993.tb00529.x; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; Feinstein Y, 1999, DEVELOPMENT, V126, P3637; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; Gantt SM, 1997, J BIOL CHEM, V272, P19205, DOI 10.1074/jbc.272.31.19205; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HARPEL PC, 1990, J BIOL CHEM, V265, P11289; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Irigoyen JP, 1999, CELL MOL LIFE SCI, V56, P104, DOI 10.1007/PL00000615; Jaworski DM, 2000, BRAIN RES, V860, P174, DOI 10.1016/S0006-8993(00)02035-7; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KAWAKUBO Y, 1994, APPL MICROBIOL BIOT, V41, P413; Kilpelainen I, 2000, J BIOL CHEM, V275, P13564, DOI 10.1074/jbc.275.18.13564; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; LEFEBVRE O, 1995, DEVELOPMENT, V121, P947; MARS WM, 1993, AM J PATHOL, V143, P949; MCGUIRE PG, 1990, NEURON, V4, P633, DOI 10.1016/0896-6273(90)90121-U; OGRADY RL, 1981, INT J CANCER, V28, P509, DOI 10.1002/ijc.2910280418; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; Panetti TS, 1999, J BIOL CHEM, V274, P430, DOI 10.1074/jbc.274.1.430; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; Seeds NW, 1997, CELL TISSUE RES, V290, P367, DOI 10.1007/s004410050942; Seeds NW, 1996, SEMIN NEUROSCI, V8, P405, DOI 10.1006/smns.1996.0049; Seeds NW, 1999, P NATL ACAD SCI USA, V96, P14118, DOI 10.1073/pnas.96.24.14118; SILVERSTEIN RL, 1986, J BIOL CHEM, V261, P9959; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; SOYOMBO AA, 1994, J BIOL CHEM, V269, P17734; SUMI Y, 1992, DEVELOPMENT, V116, P625; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TUSZYNSKI GP, 1993, J CELL BIOL, V120, P513, DOI 10.1083/jcb.120.2.513; Tzarfati-Majar V, 2001, P NATL ACAD SCI USA, V98, P4722, DOI 10.1073/pnas.081062398; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079	55	27	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28233	28241		10.1074/jbc.M102585200	http://dx.doi.org/10.1074/jbc.M102585200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11359777	hybrid			2022-12-27	WOS:000170093400067
J	Collins, LL; Lin, DL; Mu, XM; Chang, CS				Collins, LL; Lin, DL; Mu, XM; Chang, CS			Feedback regulation between orphan nuclear receptor TR2 and human papilloma virus type 16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; CIS-ACTING ELEMENTS; LONG CONTROL REGION; MAJOR LATE PROMOTER; STEROID-RECEPTOR; RESPONSE ELEMENT; GENE-EXPRESSION; GLUCOCORTICOID HORMONES; SV40-TRANSFORMED CELLS; TUMOR-SUPPRESSOR	The human TR2 orphan receptor (TR2), initially isolated from testis and prostate cDNA libraries, is a member of the steroid receptor superfamily. TR2 can regulate several target genes via binding to a consensus response element (AGGTCA) in direct repeat orientation (AGGTCAX((n))AGGTCA, n = 0-6). Here show that TR2 is able to induce the expression of human papilloma virus type 16 (HPV-16) genes via binding to a DR4 response element in the long control region of HPV-16. Additionally, one of the HPV-16 gene products, the E6 oncogene, regulates TR2 gene expression. A likely mechanism for this regulation involves E6-mediate-degradation of the tumor suppressor p53, a protein known to suppress TR2 expression. Together our data provide evidence for feedback regulation between TR2 and HPV-16, which represents a novel regulatory pathway involving a member of the steroid receptor superfamily and the HPV-16 DNA tumor virus.	Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258, R01DK056884] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56884, DK47258] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Boyer SN, 1996, CANCER RES, V56, P4620; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; Chang CS, 1997, BIOCHEM BIOPH RES CO, V235, P205, DOI 10.1006/bbrc.1997.6760; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; Chang CS, 1998, MOL CELL BIOCHEM, V189, P195, DOI 10.1023/A:1006918402474; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CULLING CFA, 1963, HDB HISTOPATHOLOGICA, P179; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLOSS B, 1989, J VIROL, V63, P1142, DOI 10.1128/JVI.63.3.1142-1152.1989; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Khare S, 1997, EXP CELL RES, V232, P353, DOI 10.1006/excr.1997.3529; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lee HJ, 1999, MOL CELL BIOCHEM, V194, P199, DOI 10.1023/A:1006903202089; LEE HJ, 1993, BIOCHEM BIOPH RES CO, V194, P97, DOI 10.1006/bbrc.1993.1790; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; Lee HJ, 1996, J BIOL CHEM, V271, P10405, DOI 10.1074/jbc.271.17.10405; LEE HJ, 1995, J BIOL CHEM, V270, P30129; Lee YF, 1998, J BIOL CHEM, V273, P13437, DOI 10.1074/jbc.273.22.13437; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Lin DL, 1998, ENDOCRINE, V8, P123, DOI 10.1385/ENDO:8:2:123; Lin DL, 1996, J BIOL CHEM, V271, P14649, DOI 10.1074/jbc.271.25.14649; LIN TM, 1995, J BIOL CHEM, V270, P30121; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MITTAL R, 1993, OBSTET GYNECOL, V81, P5; MIZOKAMI A, 1994, MOL ENDOCRINOL, V8, P77, DOI 10.1210/me.8.1.77; Mu XM, 2000, J BIOL CHEM, V275, P23877, DOI 10.1074/jbc.M910158199; MUNGER K, 1989, J VIROL, V63, P4417; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SIBBET GJ, 1995, J VIROL, V69, P4006, DOI 10.1128/JVI.69.7.4006-4011.1995; Syrjanen SM, 1999, ANN MED, V31, P175, DOI 10.3109/07853899909115976; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Young WJ, 1998, J BIOL CHEM, V273, P20877, DOI 10.1074/jbc.273.33.20877	47	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27316	27321		10.1074/jbc.M104145200	http://dx.doi.org/10.1074/jbc.M104145200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11358973	hybrid			2022-12-27	WOS:000169966900078
J	Suzuki, Y; Nakabayashi, Y; Nakata, K; Reed, JC; Takahashi, R				Suzuki, Y; Nakabayashi, Y; Nakata, K; Reed, JC; Takahashi, R			X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and-7 in distinct modes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR STRUCTURE; BIR DOMAIN; MUTAGENESIS; IAPS	The inhibitor of apoptosis proteins (IAP) regulates cell death by inhibiting caspases. The region of X-linked (X) IAP containing the second baculovirus IAP repeat domain (BIR2) is sufficient for inhibiting caspase-3 and -7. In this study,we found that the modes of inhibition of these two caspases were different: caspase-3 is inhibited in a competitive manner whereas caspase-7 inhibition occurs through a mixed competitive and noncompetitive mechanism. Binding assays revealed that the inhibition of caspase-3 by XIAP was totally dependent on the interaction between the active site of caspase-3 and the linker region between the BIR1 and BIR2 domains of XIAP. In contrast, the active site and the NP2-terminal region of caspase-7 bound to the linker region and the BIR2, respectively. Moreover the BIR2 with a mutated linker region, which inhibited caspase-3 very weakly, still bound to and inhibited caspase-7. Furthermore, a chimeric caspase-7/3 comprising the NH2-terminal portion of caspase-7 and COOH-terminal portion of caspase-3 was inhibited by XIAP by a mixed competitive and noncompetitive mechanism. Our results suggest that the Linker region between BIR1 and BIR2 domains is responsible for active site-directed, competitive inhibition of both caspase-3 and -7, whereas the BIR2 itself is involved in noncompetitive inhibition of caspase-7.	RIKEN, Lab Motor Syst Neurodegenerat, Biol Sci Inst, Wako, Saitama 3510198, Japan; Burnham Inst, La Jolla, CA 92037 USA; Tokyo Metropolitan Inst Neurosci, Tokyo 1838526, Japan	RIKEN; Sanford Burnham Prebys Medical Discovery Institute; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Takahashi, R (corresponding author), RIKEN, Lab Motor Syst Neurodegenerat, Biol Sci Inst, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.							Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Krajewska M, 1997, CANCER RES, V57, P1605; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	16	186	208	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27058	27063		10.1074/jbc.M102415200	http://dx.doi.org/10.1074/jbc.M102415200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11359776	hybrid			2022-12-27	WOS:000169966900044
J	Sakash, JB; Williams, MK; Tsuruta, H; Kantrowitz, ER				Sakash, JB; Williams, MK; Tsuruta, H; Kantrowitz, ER			Domain bridging interactions - A necessary contribution to the function and structure of Escherichia coli aspartate transcarbamoylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCERTED ALLOSTERIC TRANSITION; QUATERNARY-STRUCTURE; HETEROTROPIC INTERACTIONS; HOMOTROPIC COOPERATIVITY; REGULATORY SUBUNIT; CATALYTIC CHAIN; CLOSURE; BINDING; SITE; CARBAMOYLTRANSFERASE	Aspartate transcarbamoylase undergoes a domain closure in the catalytic chains upon binding of the substrates that initiates the allosteric transition. Interdomain bridging interactions between Glu(50) and both Arg(167) and Arg(234) have been shown to be critical for stabilization of the R state. A hybrid version of the enzyme has been generated in vitro containing one wildtype catalytic subunit, one catalytic subunit in which Glu(50) in each catalytic chain has been replaced by Ala (E50A), and wild-type regulatory subunits. Thus, the hybrid enzyme has one catalytic subunit capable of domain closure and one catalytic subunit incapable of domain closure. The hybrid does not behave as a simple mixture of the constituent subunits; it exhibits lower catalytic activity and higher aspartate affinity than would be expected. As opposed to the wild-type enzyme, the hybrid is inhibited allosterically by CTP at saturating substrate concentrations. As opposed to the E50A holoenzyme, the hybrid is not allosterically activated by ATP at saturating substrate concentrations. Small angle x-ray scattering showed that three of the six interdomain bridging interactions in the hybrid is sufficient to cause the global structural change to the R state, establishing the critical nature of these interactions for the allosteric transition of aspartate transcarbamoylase.	Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA; Stanford Linear Accelerator Ctr, Stanford, CA 94309 USA	Boston College; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Kantrowitz, ER (corresponding author), Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER; NCRR NIH HHS [P41RR01209] Funding Source: Medline; NIGMS NIH HHS [GM26237] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker DP, 1996, PROTEIN SCI, V5, P2276, DOI 10.1002/pro.5560051114; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P680; DEMBOWSKI NJ, 1993, PROTEIN ENG, V6, P123, DOI 10.1093/protein/6.1.123; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1962, J BIOL CHEM, V237, P891; HERVE G, 1985, J MOL BIOL, V185, P189, DOI 10.1016/0022-2836(85)90190-1; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KE HM, 1984, P NATL ACAD SCI USA, V81, P4027; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P268, DOI 10.1021/bi00401a041; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BH, 1995, J BIOL CHEM, V270, P15620, DOI 10.1074/jbc.270.26.15620; MANIATIS T, 1982, MOL CLONING LABORATO, P368; MIDDLETON SA, 1988, BIOCHEMISTRY-US, V27, P8653, DOI 10.1021/bi00423a022; NEWTON CJ, 1990, BIOCHEMISTRY-US, V29, P1444, DOI 10.1021/bi00458a015; NEWTON CJ, 1990, P NATL ACAD SCI USA, V87, P2309, DOI 10.1073/pnas.87.6.2309; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; Sakash JB, 2000, J BIOL CHEM, V275, P752, DOI 10.1074/jbc.275.2.752; Sakash JB, 1998, BIOCHEMISTRY-US, V37, P281, DOI 10.1021/bi972102g; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; STEBBINS JW, 1989, BIOCHEMISTRY-US, V28, P2592, DOI 10.1021/bi00432a037; STEBBINS JW, 1990, BIOCHEMISTRY-US, V29, P3821, DOI 10.1021/bi00468a003; TAUC P, 1994, PROTEIN SCI, V3, P1998, DOI 10.1002/pro.5560031112; TAUC P, 1982, J MOL BIOL, V155, P155, DOI 10.1016/0022-2836(82)90442-9; Tsuruta H, 1998, PROTEINS, V31, P383, DOI 10.1002/(SICI)1097-0134(19980601)31:4<383::AID-PROT5>3.3.CO;2-O; WILD JR, 1989, P NATL ACAD SCI USA, V86, P46, DOI 10.1073/pnas.86.1.46	32	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26441	26447		10.1074/jbc.M103226200	http://dx.doi.org/10.1074/jbc.M103226200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352920	hybrid			2022-12-27	WOS:000169823300105
J	Sambasivarao, D; Dawson, HA; Zhang, GJ; Shaw, G; Hu, J; Weiner, JH				Sambasivarao, D; Dawson, HA; Zhang, GJ; Shaw, G; Hu, J; Weiner, JH			Investigation of Escherichia coli dimethyl sulfoxide reductase assembly and processing in strains defective for the sec-independent protein translocation system membrane targeting and translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; EXPORT PATHWAY; BACTERIA; YIDC; EXPRESSION; TRANSPORT; COMPONENT; SEQUENCE; CLUSTER; OPERON	Dimethyl sulfoxide reductase is a heterotrimeric enzyme (DmsABC) localized to the cytoplasmic surface of the inner membrane. Targeting of the DmsA and DmsB catalytic subunits to the membrane requires the membrane targeting and translocation (Mtt) system. The DmsAB dimer is a member of a family of extrinsic, cytoplasmic facing membrane subunits that require Mtt in order to assemble on the membrane. We show that the MttA(2), MttB, and presumably MttA(1) but not the MttC proteins are required for targeting DmsAB to the membrane. Unlike other Mtt substrates such as trimethylamine N-oxide reductase, the soluble cytoplasmic DmsAB dimer that accumulates in the mtt deletions is very labile. Deletion of the mttA(2) or mttB genes also prevents anaerobic growth on fumarate even though fumarate reductase does not require Mtt for assembly. This was due to the lethality of membrane insertion of DmsC in the absence of the DmsAB subunits, In the absence of DmsC, DmsAB accumulates in the cytoplasm, A 45-amino acid leader on DmsA is removed during assembly. Processing does not require DmsC but does require Mtt, Translocation of DmsAB to the periplasm is not required for processing. The leader may be cleaved by a novel leader peptidase, or the long DmsA leader may traverse the membrane through the Mtt system resulting in cleavage by the periplasmic leader peptidase I followed by release of DmsA into the cytoplasm.	Univ Alberta, Dept Biochem, CIHR Grp Mol Bol Membrane Prot, Edmonton, AB T6G 2H7, Canada	University of Alberta	Weiner, JH (corresponding author), Univ Alberta, Dept Biochem, CIHR Grp Mol Bol Membrane Prot, 473 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	joel.weiner@ualberta.ca						Benoit S, 1998, J BACTERIOL, V180, P6625, DOI 10.1128/JB.180.24.6625-6634.1998; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berks BC, 2000, BBA-BIOENERGETICS, V1459, P325, DOI 10.1016/S0005-2728(00)00168-7; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; BILOUS PT, 1988, J BACTERIOL, V170, P1511, DOI 10.1128/jb.170.4.1511-1518.1988; BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Cristobal S, 1999, EMBO J, V18, P2982, DOI 10.1093/emboj/18.11.2982; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; Hynds PJ, 1998, J BIOL CHEM, V273, P34868, DOI 10.1074/jbc.273.52.34868; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NEU HC, 1965, J BIOL CHEM, V240, P3685; NIVIERE V, 1992, J GEN MICROBIOL, V138, P2173, DOI 10.1099/00221287-138-10-2173; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; ROTHERY RA, 1993, BIOCHEMISTRY-US, V32, P5855, DOI 10.1021/bi00073a019; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; RUSSELL CB, 1989, J BACTERIOL, V171, P2609, DOI 10.1128/jb.171.5.2609-2613.1989; SAMBASIVARAO D, 1991, CURR MICROBIOL, V23, P105, DOI 10.1007/BF02092258; SAMBASIVARAO D, 1991, J BACTERIOL, V173, P5935, DOI 10.1128/jb.173.19.5935-5943.1991; SAMBASIVARAO D, 1990, J BACTERIOL, V172, P5938, DOI 10.1128/jb.172.10.5938-5948.1990; Sambasivarao D, 2000, J BIOL CHEM, V275, P22526, DOI 10.1074/jbc.M909289199; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; SANDERS C, 2000, EBEC SHORT REPORTS, V11, P266; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Settles AM, 1998, TRENDS CELL BIOL, V8, P494, DOI 10.1016/S0962-8924(98)01387-7; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Stanley NR, 2001, J BACTERIOL, V183, P139, DOI 10.1128/JB.183.1.139-144.2001; Thorstenson YR, 1997, J BACTERIOL, V179, P5333, DOI 10.1128/jb.179.17.5333-5339.1997; Turner RJ, 1997, PROTEIN ENG, V10, P285, DOI 10.1093/protein/10.3.285; van de Pas BA, 1999, J BIOL CHEM, V274, P20287, DOI 10.1074/jbc.274.29.20287; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; Wu LF, 2000, J MOL MICROB BIOTECH, V2, P179	40	30	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20167	20174		10.1074/jbc.M010369200	http://dx.doi.org/10.1074/jbc.M010369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11389150	hybrid			2022-12-27	WOS:000169135100067
J	Gao, TY; Toker, A; Newton, AC				Gao, TY; Toker, A; Newton, AC			The carboxyl terminus of protein kinase C provides a switch to regulate its interaction with the phosphoinositide-dependent kinase, PDK-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN-KINASE-1; CATALYTIC SUBUNIT; DUAL ROLE; IN-VIVO; PHOSPHORYLATION; ACTIVATION; DOMAIN; SITE; AUTOPHOSPHORYLATION; PHOSPHATIDYLSERINE	The function of protein kinase C family members depends on two tightly coupled phosphorylation mechanisms: phosphorylation of the activation loop by the phosphoinositide-dependent kinase, PDK-1, followed by autophosphorylation at two positions in the COOH terminus, the turn motif, and the hydrophobic motif, Here we address the molecular mechanisms underlying the regulation of protein kinase C PII by PDK-1, Co-immunoprecipitation studies reveal that PDK-1 associates preferentially with its substrate, unphosphorylated protein kinase C, by a direct mechanism. The exposed COOH terminus of protein kinase C provides the primary interaction site for PDK-1, with co-expression of constructs of the carboxyl terminus effectively disrupting the interaction in vivo, Disruption of this interaction promotes the autophosphorylation of protein kinase C, suggesting that the binding of PDK-1 to the carboxyl terminus protects it from autophosphorylation, Studies with constructs of the COOH terminus reveal that the intrinsic affinity of PDK-1 for phosphorylated COOH terminus is over an order of magnitude greater than that for unphosphorylated COOH terminus, contrasting with the finding that PDK-1 does not bind phosphorylated protein kinase C effectively. However, effective binding of the phosphorylated species can be induced by the activated conformation of protein kinase C, This suggests that the carboxyl terminus becomes masked following autophosphorylation, a process that can be reversed by the conformational changes accompanying activation, Our data suggest a model in which PDK-1 provides two points of regulation of protein kinase C: 1) phosphorylation of the activation loop, which is regulated by the intrinsic activity of PDK-1, and 2) phosphorylation of the carboxyl terminus, which is regulated by the release of PDK-1 to allow autophosphorylation.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA	University of California System; University of California San Diego; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Newton, AC (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NATIONAL CANCER INSTITUTE [R01CA075134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER; NCI NIH HHS [CA75134] Funding Source: Medline; NIDDK NIH HHS [P01 DK54441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Johnson LN, 1996, CURR OPIN STRUC BIOL, V6, P762, DOI 10.1016/S0959-440X(96)80005-4; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ORR JW, 1994, J BIOL CHEM, V269, P27715; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sweatt JD, 1998, J NEUROCHEM, V71, P1075; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	36	82	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19588	19596		10.1074/jbc.M101357200	http://dx.doi.org/10.1074/jbc.M101357200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376011	hybrid			2022-12-27	WOS:000169091000123
J	Brenkman, AB; Heideman, MR; Truniger, V; Salas, M; van der Vliet, PC				Brenkman, AB; Heideman, MR; Truniger, V; Salas, M; van der Vliet, PC			The (I/Y)XGG motif of adenovirus DNA polymerase affects template DNA binding and the transition from initiation to elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKER-INSERTION MUTAGENESIS; TERMINAL PROTEIN-PRECURSOR; EXONUCLEASE ACTIVE-SITE; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; REPLICATION INVITRO; FUNCTIONAL DOMAINS; CONSERVED REGION; BACK MECHANISM; ALPHA	Adenovirus DNA polymerase (Ad poI) is a eukaryotic-type DNA polymerase involved in the catalysis of protein-primed initiation as well as DNA polymerization. The functional significance of the (I/Y)XGG motif, highly conserved among eukaryotic-type DNA polymerases, was analyzed in Ad pol by site-directed mutagenesis of four conserved amino acids. All mutant polymerases could bind primer-template DNA efficiently but were impaired in binding duplex DNA. Three mutant polymerases. required higher nucleotide concentrations for effective polymerization and showed higher exonuclease activity on double-stranded DNA. These observations suggest a local destabilization of DNA substrate at the polymerase active site. In agreement with this, the mutant polymerases showed reduced initiation activity and increased K-m(app) for the initiating nucleotide, dCMP. Interestingly, one mutant polymerase, while capable of elongating on the primer-template DNA, failed to elongate after protein priming. Further investigation of this mutant polymerase showed that polymerization activity decreased after each polymerization step and ceased completely after formation of the precursor terminal protein-trinucleotide (pTP-CAT) initiation intermediate. Our results suggest that residues in the conserved motif (I/Y)XGG in Ad pol are involved in binding the template strand in the polymerase active site and play an important role in the transition from initiation to elongation.	Univ Med Ctr, Dept Physiol Chem, Utrecht, Netherlands; Ctr Biomed Genet, Utrecht, Netherlands; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Utrecht University; Utrecht University Medical Center; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	van der Vliet, PC (corresponding author), Universiteitsweg 100,POB 85060, NL-3508 AB Utrecht, Netherlands.	p.c.vandervliet@med.uu.nl	Truniger, Veronica/H-3554-2011; Salas, Margarita/J-9873-2014	Truniger, Veronica/0000-0001-8221-2434; Salas, Margarita/0000-0001-5939-3441	NIGMS NIH HHS [2RO1 GM27242-21] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; Blanco L, 1995, METHOD ENZYMOL, V262, P283; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BLASCO MA, 1995, J BIOL CHEM, V270, P2735, DOI 10.1074/jbc.270.6.2735; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CHEN M, 1989, P NATL ACAD SCI USA, V86, P6116, DOI 10.1073/pnas.86.16.6116; COENJAERTS FEJ, 1994, EMBO J, V13, P5401, DOI 10.1002/j.1460-2075.1994.tb06875.x; Coenjaerts FEJ, 1995, METHOD ENZYMOL, V262, P548; Copeland WC, 1995, METHOD ENZYMOL, V262, P294; de Jong RN, 1999, GENE, V236, P1, DOI 10.1016/S0378-1119(99)00249-8; Dekker J, 1997, EMBO J, V16, P1455, DOI 10.1093/emboj/16.6.1455; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DOBBS L, 1990, VIROLOGY, V178, P43, DOI 10.1016/0042-6822(90)90377-4; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Dufour E, 2000, J MOL BIOL, V304, P289, DOI 10.1006/jmbi.2000.4216; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; HARRIS MPG, 1988, J MOL BIOL, V201, P57, DOI 10.1016/0022-2836(88)90438-X; HAY RT, 1996, ADENOVIRUS DNA REPLI; Hopfner KP, 1999, P NATL ACAD SCI USA, V96, P3600, DOI 10.1073/pnas.96.7.3600; HWANG CBC, 1992, J VIROL, V66, P1774, DOI 10.1128/JVI.66.3.1774-1776.1992; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; JOUNG I, 1992, J VIROL, V66, P5788, DOI 10.1128/JVI.66.10.5788-5796.1992; JOUNG I, 1991, VIROLOGY, V184, P235, DOI 10.1016/0042-6822(91)90840-8; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; King AJ, 1997, NUCLEIC ACIDS RES, V25, P1745, DOI 10.1093/nar/25.9.1745; KING AJ, 1994, EMBO J, V13, P5786, DOI 10.1002/j.1460-2075.1994.tb06917.x; King AJ, 1997, J BIOL CHEM, V272, P24617, DOI 10.1074/jbc.272.39.24617; LARDER BA, 1987, EMBO J, V6, P169, DOI 10.1002/j.1460-2075.1987.tb04735.x; Liu HT, 2000, J VIROL, V74, P11681, DOI 10.1128/JVI.74.24.11681-11689.2000; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; MUL YM, 1993, NUCLEIC ACIDS RES, V21, P641, DOI 10.1093/nar/21.3.641; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P4266, DOI 10.1073/pnas.80.14.4266; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; RehaKrantz LJ, 1995, METHOD ENZYMOL, V262, P323; Rodriguez AC, 2000, J MOL BIOL, V299, P447, DOI 10.1006/jmbi.2000.3728; ROOVERS DJ, 1991, VIROLOGY, V180, P273, DOI 10.1016/0042-6822(91)90032-7; ROOVERS DJ, 1993, J VIROL, V67, P265, DOI 10.1128/JVI.67.1.265-276.1993; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; SUSSENBACH JS, 1983, CURR TOP MICROBIOL, V109, P53; TEMPERLEY SM, 1992, EMBO J, V11, P761, DOI 10.1002/j.1460-2075.1992.tb05109.x; Truniger V, 1999, J MOL BIOL, V286, P57, DOI 10.1006/jmbi.1998.2477; Truniger V, 1996, EMBO J, V15, P3430, DOI 10.1002/j.1460-2075.1996.tb00709.x; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x	48	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29846	29853		10.1074/jbc.M103159200	http://dx.doi.org/10.1074/jbc.M103159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390396	hybrid			2022-12-27	WOS:000170558000034
J	Bulteau, AL; Lundberg, KC; Humphries, KM; Sadek, HA; Szweda, PA; Friguet, B; Szweda, LI				Bulteau, AL; Lundberg, KC; Humphries, KM; Sadek, HA; Szweda, PA; Friguet, B; Szweda, LI			Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKED PROTEIN; KAPPA-B-ALPHA; 26S PROTEASOME; REPERFUSION INJURY; MULTICATALYTIC PROTEASE; OXYGEN RADICALS; DEGRADATION; STRESS; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; PATHWAY	Restoration of blood flow to ischemic myocardial tissue results in an increase in the production of oxygen radicals. Highly reactive, free radical species have the potential to damage cellular components. Clearly, maintenance of cellular viability is dependent, in part, on the removal of altered protein. The proteasome is a major intracellular proteolytic system which degrades oxidized and ubiquitinated forms of protein. Utilizing an in vivo rat model, we demonstrate that coronary occlusion/reperfusion resulted in declines in chymotrypsin-like, peptidylglutamyl-peptide hydrolase, and trypsin-like activities of the proteasome as assayed in cytosolic extracts. Analysis of purified 20 S proteasome revealed that declines in peptidase activities were accompanied by oxidative modification of the protein. We provide conclusive evidence that, upon coronary occlusion/reperfusion, the lipid peroxidation product 4-hydroxy-2-nonenal selectively modifies 20 S proteasome a-like subunits iota, C3, and an isoform of XAPC7. Occlusion/reperfusion-induced declines in trypsin-like activity were largely preserved upon proteasome purification. In contrast, loss in chymotrypsin-like and peptidylglutamyl-peptide hydrolase activities observed in cytosolic extracts were not evident upon purification. Thus, decreases in proteasome activity are likely due to both direct oxidative modification of the enzyme and inhibition of fluorogenic peptide hydrolysis by endogenous cytosolic inhibitory protein(s) and/or substrate(s). Along with inhibition of the proteasome, increases in cytosolic levels of oxidized and ubiquitinated protein(s) were observed. Taken together, our findings provide insight into potential mechanisms of coronary occlusion/reperfusion-induced proteasome inactivation and cellular consequences of these events.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Univ Paris 07, Dept Biochem, F-75251 Paris 05, France; Univ Paris 07, Dept Biol, F-75251 Paris 05, France	Case Western Reserve University; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Szweda, LI (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA.		bulteau, anne-laure/AAN-4004-2020	Friguet, Bertrand/0000-0001-8085-1961; Humphries, Kenneth/0000-0002-6167-3175	NIA NIH HHS [AG-16339] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG016339] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; AMBROSIO G, 1991, J CLIN INVEST, V87, P2056, DOI 10.1172/JCI115236; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BLASIG IE, 1995, AM J PHYSIOL-HEART C, V269, pH14, DOI 10.1152/ajpheart.1995.269.1.H14; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Conconi M, 1998, BIOCHEM J, V333, P407, DOI 10.1042/bj3330407; Conconi M, 1997, MOL BIOL REP, V24, P45, DOI 10.1023/A:1006852506884; Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAS DK, 1989, BIOCHEM BIOPH RES CO, V165, P1004, DOI 10.1016/0006-291X(89)92702-2; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Eble DM, 1999, CELL TISSUE RES, V296, P541, DOI 10.1007/s004410051315; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Ferrari R, 1996, J CARDIOVASC PHARM, V28, pS1; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Haynes RL, 2000, MOL PHARMACOL, V58, P788, DOI 10.1124/mol.58.4.788; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; Keller JN, 2000, J CEREBR BLOOD F MET, V20, P1467, DOI 10.1097/00004647-200010000-00008; KRAMER JH, 1994, ANN NY ACAD SCI, V723, P180, DOI 10.1111/j.1749-6632.1994.tb36725.x; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; Powers SK, 1998, AM J PHYSIOL-REG I, V275, pR1468, DOI 10.1152/ajpregu.1998.275.5.R1468; REIMER KA, 1992, HEART CARDIOVASCULAR, P1875; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V377, P65, DOI 10.1006/abbi.2000.1717; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; Sitte N, 2000, FASEB J, V14, P1490, DOI 10.1096/fj.14.11.1490; Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; SZWEDA LI, 1993, ARCH BIOCHEM BIOPHYS, V301, P391, DOI 10.1006/abbi.1993.1161; Tanaka K, 1997, MOL BIOL REP, V24, P3, DOI 10.1023/A:1006876904158; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353	51	309	317	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30057	30063		10.1074/jbc.M100142200	http://dx.doi.org/10.1074/jbc.M100142200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11375979	hybrid			2022-12-27	WOS:000170558000061
J	Li, Y; Takagi, Y; Jiang, YW; Tokunaga, M; Erdjument-Bromage, H; Tempst, P; Kornberg, RD				Li, Y; Takagi, Y; Jiang, YW; Tokunaga, M; Erdjument-Bromage, H; Tempst, P; Kornberg, RD			A multiprotein complex that interacts with RNA polymerase II elongator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; IN-VIVO; HOLOENZYME; TRANSCRIPTION; PROTEIN; COACTIVATORS; SUBUNIT	A three-subunit Hap complex that interacts with the RNA polymerase If Elongator was isolated fi-om yeast. Deletions of genes for two Hap subunits, HAP1 and HAP3, confer pGKL killer-insensitive and weak Elongator phenotypes. Preferential interaction of the Hap complex with free rather than RNA polymerase II-associated Elongator suggests a role in the regulation of Elongator activity.	Stanford Univ, Dept Biol Struct, Sch Med, Stanford, CA 94305 USA; Texas A&M Univ, Dept Med Biochem & Genet, Hlth Sci Ctr, College Stn, TX 77843 USA; Kagoshima Univ, Fac Agr, Kagoshima 8900065, Japan; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Stanford University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Kagoshima University; Memorial Sloan Kettering Cancer Center	Li, Y (corresponding author), Tularik Inc, 2 Corp Dr, San Francisco, CA 94080 USA.	yli@tularik.com		Erdjument-Bromage, Hediye/0000-0003-0224-3594; Tempst, Paul/0000-0002-6680-3987	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Dou YL, 2000, MOL CELL, V6, P225, DOI 10.1016/S1097-2765(00)00024-1; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Fellows J, 2000, J BIOL CHEM, V275, P12896, DOI 10.1074/jbc.275.17.12896; Kishida M, 1996, BIOSCI BIOTECH BIOCH, V60, P798, DOI 10.1271/bbb.60.798; Li Y, 1996, METHOD ENZYMOL, V273, P172; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; LUE NF, 1991, METHOD ENZYMOL, V194, P545; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Stallcup MR, 2000, BIOCHEM SOC T, V28, P415, DOI 10.1042/0300-5127:0280415; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; Travers A, 1999, P NATL ACAD SCI USA, V96, P13634, DOI 10.1073/pnas.96.24.13634; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Yajima H, 1997, BIOSCI BIOTECH BIOCH, V61, P704, DOI 10.1271/bbb.61.704	21	56	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29628	29631		10.1074/jbc.C100274200	http://dx.doi.org/10.1074/jbc.C100274200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390369	hybrid			2022-12-27	WOS:000170558000006
J	Dai, ZH; Kerzic, P; Schroeder, WG; McNiece, IK				Dai, ZH; Kerzic, P; Schroeder, WG; McNiece, IK			Deletion of the Src homology 3 domain and C-terminal proline-rich sequences in Bcr-Abl prevents Abl interactor 2 degradation and spontaneous cell migration and impairs leukemogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ADAPTER PROTEIN CRKL; TYROSINE KINASE; BINDING-PROTEIN; MYELOPROLIFERATIVE DISEASE; PHILADELPHIA-CHROMOSOME; TRANSFORMING ACTIVITY; MICE; GROWTH; GENE	The hematopoietic cells from patients with Ber-Abl-positive chronic myelogenous leukemia exhibit multiple abnormalities of cytoskeletal function. The molecular events leading to these abnormalities are not fully understood. Previously we showed that Bcr-Abl elicits ubiquitin-dependent degradation of Abl. interactor proteins. Because recent studies have suggested a role of Abl interactor proteins in the pathway that regulates cytoskeletal function, we investigated whether mutations in Ber-Abl that interfere with the signaling to Abl interactor proteins affect its leukemogenic activity. We report here that the Src homology 3 domain and C-terminal proline-rich sequences of Bcr-Abl are required for its binding to Abl interactor 2 as well as for the induction of Abl interactor 2 degradation. Although the deletion of these regions did not affect the ability of the mutant Bcr-Abl to transform hematopoietic cells to growth factor independence, it abrogated its ability to stimulate spontaneous cell migration on fibronectin-coated surfaces. Furthermore, the mutant Bcr-Abl, defective in binding to Abl interactor 2 and inducing its degradation, failed to induce chronic myelogenous leukemia-like disease in mouse. These results are consistent with a role of Abl interactor proteins in the regulation of cytoskeletal function as well as in the pathogenesis of Bcr-Abl-induced leukemogenesis.	Univ Colorado, Hlth Sci Ctr, Bone Marrow Transplant Program, Expt Hematol Lab, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Dai, ZH (corresponding author), Univ Colorado, Hlth Sci Ctr, Bone Marrow Transplant Program, Expt Hematol Lab, Box B116,4200 E 9th Ave, Denver, CO 80262 USA.	zonghan.dai@uchsc.edu						Afar DEH, 1997, IMMUNITY, V6, P773, DOI 10.1016/S1074-7613(00)80452-5; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; BRADLEY TR, 1978, J CELL PHYSIOL, V97, P517, DOI 10.1002/jcp.1040970327; Clarkson BD, 1997, LEUKEMIA, V11, P1404, DOI 10.1038/sj.leu.2400751; Cortez D, 1996, ONCOGENE, V13, P2589; Courtney KD, 2000, MOL CELL NEUROSCI, V16, P244, DOI 10.1006/mcne.2000.0865; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Fan PD, 2000, MOL CELL BIOL, V20, P7591, DOI 10.1128/MCB.20.20.7591-7601.2000; Gotoh A, 1997, Curr Opin Hematol, V4, P3; Gross AW, 1999, MOL CELL BIOL, V19, P6918; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARLOW E, 1999, USING ANTIBODIES LAB, P74; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Salgia R, 1999, BLOOD, V94, P4233; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; VAN AL, 1997, GENE DEV, V11, P2295; Wang BL, 1996, ONCOGENE, V12, P1921; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; YAN XQ, 1995, BLOOD, V86, P4025, DOI 10.1182/blood.V86.11.4025.bloodjournal86114025; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; Ziemnicka-Kotula D, 1998, J BIOL CHEM, V273, P13681, DOI 10.1074/jbc.273.22.13681	42	31	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28954	28960		10.1074/jbc.M101170200	http://dx.doi.org/10.1074/jbc.M101170200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387320	hybrid			2022-12-27	WOS:000170346000044
J	Martemyanov, KA; Liljas, A; Yarunin, AS; Gudkov, AT				Martemyanov, KA; Liljas, A; Yarunin, AS; Gudkov, AT			Mutations in the G-domain of elongation factor G from Thermus thermophilus affect both its interaction with GTP and fusidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; EF-TU; KIRROMYCIN RESISTANCE; TRANSLOCATION; HYDROLYSIS; MUTANTS; CLONING; GDP	Two hypersensitive and two resistant variants of elongation factor-G (EF-G) toward fusidic acid are studied in comparison with the wild type factor. All mutated proteins are active in a cell-free translation system and ribosome-dependent GTP hydrolysis. The EF-G variants with the Thr-84 --> Ala or Asp-109 --> Lys mutations bring about a strong resistance of EF-G to the antibiotic, whereas the EF-Gs with substitutions Gly-16 --> Val or Glu-119 --> Lys are the first examples of fusidic acid-hypersensitive factors. A correlation between fusidic acid resistance of EF-G mutants and their affinity to GTP are revealed in this study, although their interactions with GDP are not changed. Thus, fusidic acid-hypersensitive mutants have the high affinity to an uncleavable analog, but the association of resistant mutants with GTP is decreased. The effects of either fusidic acid-sensitive or resistant mutations can be explained by the conformational changes in the EF-G molecule, which influence its GTP-binding center. The results presented in this paper indicate that fusidic acid-sensitive mutant factors have a conformation favorable for GTP binding and subsequent interaction with the ribosomes.	Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia; Lund Univ, Dept Mol Biophys, S-21100 Lund, Sweden	Russian Academy of Sciences; Lund University	Gudkov, AT (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia.	gudkov@vega.protres.ru						ABDULKARIM F, 1994, FEBS LETT, V352, P118, DOI 10.1016/0014-5793(94)00937-6; Abel K, 1996, STRUCTURE, V4, P1153, DOI 10.1016/S0969-2126(96)00123-2; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Al-Karadaghi S, 1996, STRUCTURE, V4, P555, DOI 10.1016/S0969-2126(96)00061-5; ARAI KI, 1978, EUR J BIOCHEM, V92, P521, DOI 10.1111/j.1432-1033.1978.tb12774.x; BACA OG, 1976, BIOCHEMISTRY-US, V15, P4570, DOI 10.1021/bi00666a004; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BODLEY JW, 1970, J BIOL CHEM, V245, P5662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Czworkowski J, 1996, PROG NUCLEIC ACID RE, V54, P293, DOI 10.1016/S0079-6603(08)60366-9; DAHLFORS AAR, 1990, J MOL BIOL, V215, P549, DOI 10.1016/S0022-2836(05)80167-6; DEVENDITTIS E, 1993, GENE, V136, P41; GIRSHOVICH AS, 1978, FEBS LETT, V85, P283, DOI 10.1016/0014-5793(78)80474-8; Johanson U, 1996, J MOL BIOL, V258, P420, DOI 10.1006/jmbi.1996.0259; JOHANSON U, 1994, GENE, V143, P55, DOI 10.1016/0378-1119(94)90604-1; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laurberg M, 2000, J MOL BIOL, V303, P593, DOI 10.1006/jmbi.2000.4168; Macvanin M, 2000, MOL MICROBIOL, V37, P98, DOI 10.1046/j.1365-2958.2000.01967.x; Martemyanov KA, 2000, PROTEIN EXPRES PURIF, V18, P257, DOI 10.1006/prep.1999.1178; Martemyanov KA, 2000, J BIOL CHEM, V275, P35820, DOI 10.1074/jbc.M002656200; Martemyanov KA, 1998, BIOCHEMISTRY-MOSCOW+, V63, P1216; MESTERS JR, 1994, EMBO J, V13, P4877, DOI 10.1002/j.1460-2075.1994.tb06815.x; OKURA A, 1971, J ANTIBIOT, V24, P655, DOI 10.7164/antibiotics.24.655; PANUSZ HT, 1970, ANAL BIOCHEM, V35, P494, DOI 10.1016/0003-2697(70)90212-5; ROHRBACH MS, 1976, J BIOL CHEM, V251, P930; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Spirin AS, 1999, RIBOSOMES; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; WILLIE GR, 1975, BIOCHEMISTRY-US, V14, P1713, DOI 10.1021/bi00679a025	33	22	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28774	28778		10.1074/jbc.M102023200	http://dx.doi.org/10.1074/jbc.M102023200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11371559	hybrid			2022-12-27	WOS:000170346000019
J	Reith, MEA; Berfield, JL; Wang, LC; Ferrer, JV; Javitch, JA				Reith, MEA; Berfield, JL; Wang, LC; Ferrer, JV; Javitch, JA			The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYLMALEIMIDE-INDUCED REDUCTION; N-ETHYLMALEIMIDE; NEURONAL CARRIER; BINDING DOMAINS; H-3 MAZINDOL; <H-3>WIN-35,428 BINDING; UPTAKE SITES; ACCESSIBILITY; GBR-12783; WIN-35,428	The binding affinity of the cocaine analog [H-3]2 beta -carbomethoxy-3 beta-(4-fluorophenyl) tropane (WIN) for the dopamine transporter (DAT) is increased by the reaction of Cys-90, at the extracellular end of the first transmembrane segment, with methanethiosulfonate (NITS) reagents. Cocaine enhances the reaction of Cys-90 with the sulfhydryl reagents, thereby augmenting the increase in binding. In contrast, cocaine decreases the reaction of Cys-135 and Cys-342, endogenous cysteines in cytoplasmic loops, with NITS reagents. Because this reaction inhibits [H-3]WIN binding, cocaine protects against the loss of binding caused by reaction of these cysteines. In the present work, we compare the abilities of DAT inhibitors and substrates to affect the reaction of Cys-90, Cys-135, and Cys-342 with MTS ethyltrimethyl-ammonium (MTSET). The results indicate that the different abilities of compounds to protect against the MTSET-induced inhibition of binding are attributable to differences in their abilities to attenuate the inhibitory effects of modification of Cys-135 and Cys-342 as well as to enhance the reaction with Cys-90 and the resulting potentiation of binding. The inhibitor benztropine was unique in its inability to protect Cys-135. Moreover, whereas cocaine, WIN, mazindol, and dopamine enhanced the reaction of Cys-90 with MTSET, benztropine had no effect on this reaction. These two features combine to give benztropine its weak potency in protecting ligand binding to wild-type DAT from MTSET. These results indicate that different inhibitors of DAT, such as cocaine and benztropine, produce different conformational changes in the transporter. There are differences in the psychomotor stimulant-like effects of these compounds, and it is possible that the different behavioral effects of these DAT inhibitors stem from their different molecular actions on DAT.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA; Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA	University of Illinois System; University of Illinois Peoria; Columbia University; Columbia University; Columbia University	Reith, MEA (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Box 1649, Peoria, IL 61656 USA.		Reith, Maarten E./AAD-2303-2019; Reith, Maarten E/A-4601-2008	Reith, Maarten E./0000-0002-1900-842X; Javitch, Jonathan/0000-0001-7395-2967	NIDA NIH HHS [DA 08379, DA 11495] Funding Source: Medline; NIGMS NIH HHS [GMH 57324] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008379, R01DA011495] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Acri JB, 1996, J PHARMACOL EXP THER, V277, P198; Berfield JL, 1999, J BIOL CHEM, V274, P4876, DOI 10.1074/jbc.274.8.4876; BONNET JJ, 1990, J PHARMACOL EXP THER, V253, P1206; CALLIGARO DO, 1988, MEMBRANE BIOCHEM, V7, P87, DOI 10.3109/09687688709039986; Cao YW, 1998, J NEUROSCI, V18, P7739; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen NH, 2000, J BIOL CHEM, V275, P1608, DOI 10.1074/jbc.275.3.1608; Do-Rego JC, 1999, J NEUROCHEM, V72, P396, DOI 10.1046/j.1471-4159.1999.0720396.x; Dwoskin L. P., 1996, Society for Neuroscience Abstracts, V22, P1576; Eshleman AJ, 1997, J NEUROCHEM, V69, P1459; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; GIROS B, 1994, J BIOL CHEM, V269, P15985; HERON C, 1994, EUR J PHARMACOL, V264, P391, DOI 10.1016/0014-2999(94)00502-8; Itokawa M, 2000, MOL PHARMACOL, V57, P1093; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; JAVITCH JA, 1984, MOL PHARMACOL, V26, P35; JOHNSON KM, 1992, EUR J PHARM-MOLEC PH, V227, P411, DOI 10.1016/0922-4106(92)90159-S; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; MADRAS BK, 1989, MOL PHARMACOL, V36, P518; MEIERGERD SM, 1994, J NEUROCHEM, V63, P1683; MELTZER PC, 1994, J MED CHEM, V37, P2001, DOI 10.1021/jm00039a014; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; POVLOCK SL, 1997, NEUROTRANSMITTER TRA, P1; REITH MEA, 1986, BIOCHEM PHARMACOL, V35, P1123, DOI 10.1016/0006-2952(86)90148-6; Reith MEA, 1996, N-S ARCH PHARMACOL, V354, P295; Reith MEA, 1996, BIOCHEM PHARMACOL, V52, P1435, DOI 10.1016/S0006-2952(96)00508-4; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; SAADOUNI S, 1994, EUR J PHARM-MOLEC PH, V268, P187, DOI 10.1016/0922-4106(94)90188-0; SCHWERI MM, 1992, J PHARMACOL EXP THER, V261, P936; SCHWERI MM, 1990, NEUROPHARMACOLOGY, V29, P901, DOI 10.1016/0028-3908(90)90140-M; UHL GR, 1993, ADV NEUROL, V60, P321; Vaughan RA, 1999, J NEUROSCI, V19, P630; Woolverton WL, 2000, PSYCHOPHARMACOLOGY, V147, P426, DOI 10.1007/s002130050012; Xu C, 1997, N-S ARCH PHARMACOL, V355, P64; Xu C, 1997, J PHARMACOL EXP THER, V282, P920; ZIMANYI I, 1989, SYNAPSE, V3, P239, DOI 10.1002/syn.890030310; [No title captured]	38	88	89	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29012	29018		10.1074/jbc.M011785200	http://dx.doi.org/10.1074/jbc.M011785200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11395483	hybrid			2022-12-27	WOS:000170346000052
J	Grammatikakis, N; Jaronczyk, K; Siganou, A; Vultur, A; Brownell, HL; Benzaquen, M; Rausch, C; Lapointe, R; Gjoerup, O; Roberts, TM; Raptis, L				Grammatikakis, N; Jaronczyk, K; Siganou, A; Vultur, A; Brownell, HL; Benzaquen, M; Rausch, C; Lapointe, R; Gjoerup, O; Roberts, TM; Raptis, L			Simian virus 40 large tumor antigen modulates the Raf signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; SV40 LARGE T; FULL NEOPLASTIC TRANSFORMATION; GENE ACTIVITY; J DOMAIN; ACTIVATION; PROTEIN; KINASE; PHOSPHORYLATION; CELLS	The large tumor antigen of simian virus 40 (SVLT) is a potent oncogene. Although inactivation of the p53 and pRb tumor suppressors has been causally linked to the transforming properties of SVLT, its exact mechanism of action remains undefined. Previous data indicated that Ras is activated in SVLT-expressing cells. In this report we show that SVLT also increases Raf kinase activity in both insect and mammalian cells, thus identifying the Raf kinase as an additional target of SVLT. Our results further show that SVLT was still able to activate Raf in cells where Ras levels had been drastically reduced through expression of an antisense construct, indicating that SVLT may activate Raf at least partly by a mechanism that is independent of its stimulatory effect on Ras.	Queens Univ, Dept Microbiol & Immunol, Kingston, ON K7L 3N6, Canada; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA	Queens University - Canada; Tufts University; Queens University - Canada; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Raptis, L (corresponding author), Queens Univ, Dept Microbiol & Immunol, Botterell Hall,Rm 715, Kingston, ON K7L 3N6, Canada.	raptisl@post.queensu.ca		Vultur, Adina/0000-0003-0068-9496				Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Broome MA, 2000, ONCOGENE, V19, P2867, DOI 10.1038/sj.onc.1203608; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Lednicky JA, 2001, METH MOL B, V165, P257; Lee KY, 1999, MOL CELL BIOL, V19, P7724; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MORRISON DK, 1995, METHOD ENZYMOL, V255, P301; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Raptis L, 2001, METH MOL B, V165, P151; Raptis L, 1997, CELL GROWTH DIFFER, V8, P891; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RAPTIS L, 1989, J VIROL, V63, P753, DOI 10.1128/JVI.63.2.753-758.1989; Raptis L, 2000, CELL GROWTH DIFFER, V11, P293; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Sullivan CS, 2001, J VIROL, V75, P1601, DOI 10.1128/JVI.75.4.1601-1610.2001; vanderStraten A, 1997, EMBO J, V16, P1961, DOI 10.1093/emboj/16.8.1961; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; Zhai WG, 1999, MOL CELL BIOL, V19, P2791	36	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27840	27845		10.1074/jbc.M101987200	http://dx.doi.org/10.1074/jbc.M101987200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382757	hybrid			2022-12-27	WOS:000170093400015
J	Huggins, GS; Bacani, CJ; Boltax, J; Aikawa, R; Leiden, JM				Huggins, GS; Bacani, CJ; Boltax, J; Aikawa, R; Leiden, JM			Friend of GATA 2 physically interacts with chicken ovalbumin upstream promoter-TF2 (COUP-TF2) and COUP-TF3 and represses COUP-TF2-dependent activation of the atrial natriuretic factor promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; NUCLEAR ORPHAN RECEPTORS; LIGAND-BINDING DOMAIN; HEART TUBE FORMATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; VENTRAL MORPHOGENESIS; TERMINAL DOMAIN; N-COR; FOG-2	Friend of GATA (FOG)-2 is a multi-zinc finger transcriptional corepressor protein that binds specifically to GATA4. Gene targeting studies have demonstrated that FOG-2 is required for normal cardiac morphogenesis, including the development of the coronary vasculature, left ventricular compact zone, and heart valves. To better understand the molecular mechanisms by which FOG-2 regulates these cardiac developmental programs, we screened a mouse day 11 embryo library using a yeast two-hybrid interaction trap with the fifth and sixth zinc fingers of FOG-2 as bait. Using this approach, we isolated clones encoding the orphan nuclear receptors chicken ovalbumin upstream promoter-transcription factor (COUP-TF) 2 and COUP-TF3. COUP-TF2-null embryos die during embryonic development with defective angiogenesis and cardiac defects, a pattern that partly resembles the FOG-2-null phenotype. The interaction between COUP-TF2 and FOG-2 in mammalian cells was confirmed by co-immunoprecipitation of these proteins from transfected COS-7 cells. The sites of binding interaction between COUP-TF2 and FOG-2 were mapped to zinc fingers 5 and 6 and fingers 7 and 8 of FOG-2 and to the carboxyl terminus of the COUP-TF proteins. Binding to COUP-TF2 was specific because FOG-2 did not interact with the ligand-binding domains of retinoid X receptor alpha, glucocorticoid receptor, and peroxisome proliferating antigen receptor gamma, which are related to the COUP-TF proteins. Full-length FOG-2 markedly enhanced transcriptional repression by GAL4-COUP-TF2(117-414), but not by a COUP-TF2 repression domain mutant. Moreover, FOG-2 repressed COUP-TF2dependent synergistic activation of the atrial natriuretic factor promoter by both GATA4 and the FOG-2-independent mutant GATA4-E215K. Taken together, these findings suggest that FOG-2 functions as a corepressor for both GATA and COUP-TF proteins.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Massachusetts Gen Hosp, Cardiac Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Abbott Labs, Abbott Pk, IL 60064 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Abbott Laboratories	Huggins, GS (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 677 Huntington Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [K08 HL03667-01A1, R01 HL54592-06, R01 HL054592] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003667, R01HL054592] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Achatz G, 1997, MOL CELL BIOL, V17, P4914, DOI 10.1128/MCB.17.9.4914; Avram D, 1999, J BIOL CHEM, V274, P14331, DOI 10.1074/jbc.274.20.14331; Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Bailey PJ, 1997, J STEROID BIOCHEM, V63, P165, DOI 10.1016/S0960-0760(97)00079-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Crispino JD, 2001, GENE DEV, V15, P839, DOI 10.1101/gad.875201; Deconinck AE, 2000, DEVELOPMENT, V127, P2031; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Fossett N, 2000, P NATL ACAD SCI USA, V97, P7348, DOI 10.1073/pnas.97.13.7348; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Huang EY, 2000, GENE DEV, V14, P45; Huggins GS, 1999, J BIOL CHEM, V274, P28690, DOI 10.1074/jbc.274.40.28690; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lazennec G, 1997, MOL CELL BIOL, V17, P5053, DOI 10.1128/MCB.17.9.5053; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lien CL, 1999, DEVELOPMENT, V126, P75; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Matthews JM, 2000, EUR J BIOCHEM, V267, P1030, DOI 10.1046/j.1432-1327.2000.01095.x; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Pereira FA, 1999, GENE DEV, V13, P1037, DOI 10.1101/gad.13.8.1037; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; Power SC, 1996, MOL CELL BIOL, V16, P778; Qiu Y, 1996, J STEROID BIOCHEM, V56, P81, DOI 10.1016/0960-0760(95)00225-1; Rosoff ML, 1998, J BIOL CHEM, V273, P9124, DOI 10.1074/jbc.273.15.9124; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; Searcy RD, 1998, DEVELOPMENT, V125, P4461; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Svensson EC, 2000, J BIOL CHEM, V275, P20762, DOI 10.1074/jbc.M001522200; Svensson EC, 2000, NAT GENET, V25, P353, DOI 10.1038/77146; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	46	56	61	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28029	28036		10.1074/jbc.M103577200	http://dx.doi.org/10.1074/jbc.M103577200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382775	hybrid			2022-12-27	WOS:000170093400039
J	Klemm, DJ; Leitner, JW; Watson, P; Nesterova, A; Reusch, JEB; Goalstone, ML; Draznin, B				Klemm, DJ; Leitner, JW; Watson, P; Nesterova, A; Reusch, JEB; Goalstone, ML; Draznin, B			Insulin-induced adipocyte differentiation - Activation of CREB rescues adipogenesis from the arrest caused by inhibition of prenylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE CELLULARITY; BINDING-PROTEIN; GROWTH-FACTOR; 3T3-L1; FARNESYLTRANSFERASE; GENE; PHOSPHORYLATION; POTENTIATION; EXPRESSION; CULTURE	Insulin is a potent adipogenic hormone that triggers an induction of a series of transcription factors governing differentiation of pre-adipocytes into mature adipocytes. However, the exact link between the insulin signaling cascade and the intrinsic cascade of adipogenesis remains incompletely understood. Herein we demonstrate that inhibition of prenylation of p21(ras) and Rho-A arrests insulin-stimulated adipogenesis. Inhibition of farnesylation of p21(ras) also blocked the ability of insulin to activate mitogen-activated protein (MAP) kinase and cyclic AMP response element-binding (CREB) protein. Expression of two structurally different inducible constitutively active CREB constructs rescued insulin-stimulated adipocyte differentiation from the inhibitory influence of prenylation inhibitors. Constitutively active CREB constructs induced expression of PPAR gamma2, fatty acid synthase, GLUT-4, and leptin both in control and prenylation inhibitors-treated cells. It appears that insulin stimulated prenylation of the Ras family GTPases assures normal phosphorylation and activation of CREB that, in turn, triggers the intrinsic cascade of adipogenesis.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80220 USA; Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Draznin, B (corresponding author), Vet Adm Hosp, 1055 Clermont St,151, Denver, CO 80220 USA.	Boris.Draznin@Med.VA.Gov		Reusch, Jane/0000-0001-8620-1003	NIDDK NIH HHS [DK53969] Funding Source: Medline; NIGMS NIH HHS [GM47117] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047117] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACCILI D, 1991, P NATL ACAD SCI USA, V88, P4708, DOI 10.1073/pnas.88.11.4708; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chaika OV, 1997, J BIOL CHEM, V272, P11968, DOI 10.1074/jbc.272.18.11968; Chappell J, 2000, J BIOL CHEM, V275, P31792, DOI 10.1074/jbc.M004798200; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; Draznin B, 2000, ENDOCRINOLOGY, V141, P1310, DOI 10.1210/en.141.4.1310; Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955-0674(98)80138-5; Gagnon A, 1999, DIABETES, V48, P691, DOI 10.2337/diabetes.48.4.691; Gagnon AM, 1998, OBES RES, V6, P157, DOI 10.1002/j.1550-8528.1998.tb00330.x; GINSBERGFELLNER F, 1981, PEDIATR RES, V15, P1381, DOI 10.1203/00006450-198110000-00016; Goalstone M, 1997, ENDOCRINOLOGY, V138, P5119, DOI 10.1210/en.138.12.5119; Goalstone ML, 1999, DIABETOLOGIA, V42, P310, DOI 10.1007/s001250051156; Goalstone ML, 1998, J BIOL CHEM, V273, P23892, DOI 10.1074/jbc.273.37.23892; Goalstone ML, 1996, J BIOL CHEM, V271, P27585, DOI 10.1074/jbc.271.44.27585; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; Golovchenko I, 2000, CIRC RES, V87, P746, DOI 10.1161/01.RES.87.9.746; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAUNER H, 1990, ENDOCRINOLOGY, V127, P865, DOI 10.1210/endo-127-2-865; Hill MM, 2000, J BIOL CHEM, V275, P24313, DOI 10.1074/jbc.M001823200; HIRSCH J, 1976, CLIN ENDOCRINOL META, V5, P299, DOI 10.1016/S0300-595X(76)80023-0; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Klemm DJ, 1998, J BIOL CHEM, V273, P917, DOI 10.1074/jbc.273.2.917; MAGUS R, 1997, ENDOCRINOLOGY, V137, P3590; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Nishio E, 1996, EUR J PHARMACOL, V301, P203, DOI 10.1016/0014-2999(96)00063-5; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Reusch JEB, 1999, ENDOCRINOLOGY, V140, P2935, DOI 10.1210/en.140.7.2935; Sakaue H, 1998, J BIOL CHEM, V273, P28945, DOI 10.1074/jbc.273.44.28945; SOSA H, 1995, BIOCHEM BIOPH RES CO, V212, P263; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tomiyama K, 1999, JPN J PHARMACOL, V80, P375, DOI 10.1254/jjp.80.375; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	39	143	146	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28430	28435		10.1074/jbc.M103382200	http://dx.doi.org/10.1074/jbc.M103382200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375992	hybrid			2022-12-27	WOS:000170093400091
J	Thompson, NA; Haefliger, JA; Senn, A; Tawadros, T; Magara, F; Ledermann, B; Nicod, P; Waeber, G				Thompson, NA; Haefliger, JA; Senn, A; Tawadros, T; Magara, F; Ledermann, B; Nicod, P; Waeber, G			Islet-brain1/JNK-interacting protein-1 is required for early embryogenesis in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETING CELLS; DIODE-LASER BEAM; C-JUN; SIGNAL-TRANSDUCTION; KINASE ACTIVATION; INDUCED APOPTOSIS; JNK; GENE; MOUSE; IB1	Islet-brain1/JNK-interacting protein-1 (IBl/JIP-1) is a scaffold protein that organizes the JNK, MKK7, and MLK1 to allow signaling specificity. Targeted disruption of the gene MAPK8IP1 encoding IB1/JIP-1 in mice led to embryonic death prior to blastocyst implantation. In culture, no IB1/JIP-1(-/-) embryos were identified indicating that accelerated cell death occurred during the first cell cycles. IB1/JIP-1 expression was detected in unfertilized oocytes, in spermatozoa, and in different stages of embryo development. Thus, despite the maternal and paternal transmission of the IB1/JIP-1 protein, early transcription of the MAPK8IP1 gene is required for the survival of the fertilized oocytes.	CHU Vaudois, Univ Hosp, Dept Internal Med, CH-1011 Lausanne, Switzerland; CHU Vaudois, Univ Hosp, Inst Cell Biol & Morphol, CH-1011 Lausanne, Switzerland; CHU Vaudois, Univ Hosp, Dept Obstet & Gynecol, Reprod Med Unit, CH-1011 Lausanne, Switzerland; Univ Zurich, CH-8057 Zurich, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Zurich	Waeber, G (corresponding author), CHU Vaudois, Univ Hosp, Dept Internal Med B, CH-1011 Lausanne, Switzerland.	gwaeber@chuv.hospvd.ch		Haefliger, Jacques-Antoine/0000-0003-2732-1667; Waeber, Gerard/0000-0003-4193-788X				Bagowski CP, 2001, J BIOL CHEM, V276, P1459, DOI 10.1074/jbc.M008050200; Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; GERMOND M, 1995, FERTIL STERIL, V64, P604, DOI 10.1016/S0015-0282(16)57800-5; Germond M, 1996, HUM REPROD, V11, P1043; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Latham KE, 1999, INT REV CYTOL, V193, P71; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Mooser V, 1999, GENOMICS, V55, P202, DOI 10.1006/geno.1998.5641; Pellet JB, 2000, EUR J NEUROSCI, V12, P621, DOI 10.1046/j.1460-9568.2000.00945.x; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	27	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27745	27748		10.1074/jbc.C100222200	http://dx.doi.org/10.1074/jbc.C100222200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11390367	hybrid			2022-12-27	WOS:000170093400001
J	Bergmeier, W; Bouvard, D; Eble, JA; Mokhtari-Nejad, R; Schulte, V; Zirngibl, H; Brakebusch, C; Fassler, R; Nieswandt, B				Bergmeier, W; Bouvard, D; Eble, JA; Mokhtari-Nejad, R; Schulte, V; Zirngibl, H; Brakebusch, C; Fassler, R; Nieswandt, B			Rhodocytin (aggretin) activates platelets lacking alpha(2)beta(1) integrin, glycoprotein VI, and the ligand-binding domain of glycoprotein Ib alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-INDUCED AGGREGATION; VON-WILLEBRAND-FACTOR; SNAKE-VENOM PROTEIN; FCR-GAMMA-CHAIN; IMMUNOGLOBULIN SUPERFAMILY; MONOCLONAL-ANTIBODIES; VONWILLEBRAND-FACTOR; NONHUMAN-PRIMATES; ADHESION; RECEPTOR	Although alpha (2)beta (1) integrin (glycoprotein Ia/IIa) has been established as a platelet collagen receptor, its role in collagen-induced platelet activation has been controversial. Recently, it has been demonstrated that rhodocytin (also termed aggretin), a snake venom toxin purified from the venom of Calloselasma rhodostoma, induces platelet activation that can be blocked by monoclonal antibodies against alpha (2)beta (1) integrin, This finding suggested that clustering of alpha (2)beta (1) integrin by rhodocytin is sufficient to induce platelet activation and led to the hypothesis that collagen may activate platelets by a similar mechanism. In contrast to these findings, we provided evidence that rhodocytin does not bind to alpha (2)beta (1) integrin, Here we show that the Cre/loxP-mediated loss of p, integrin on mouse platelets has no effect on rhodocytin-induced platelet activation, excluding an essential role of ru,p, integrin in this process. Furthermore, proteolytic cleavage of the 45-kDa N-terminal domain of glycoprotein (GP) Ib alpha either on normal or on Pi-null platelets had no significant effect on rhodocytin-induced platelet activation. Moreover, mouse platelets lacking both alpha (2)beta (1) integrin and the activating collagen receptor GPVI responded normally to rhodocytin, Finally, even after additional proteolytic removal of the 45-kDa N-terminal domain of GPIb alpha rhodocytin induced aggregation of these platelets. These results demonstrate that rhodocytin induces platelet activation by mechanisms that are fundamentally different from those induced by collagen.	Univ Witten Herdecke, Dept Mol Oncol Gen Surg, D-42117 Wuppertal, Germany; Univ Lund, Dept Expt Pathol, S-22185 Lund, Sweden; Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany	Witten Herdecke University; Lund University; University of Munster	Nieswandt, B (corresponding author), Ferdinand Sauerbruch Klinikum Elberfeld, Dept Mol Oncol, Arrenbergerstr 20,Haus 10, D-42117 Wuppertal, Germany.		Bouvard, Daniel/B-1260-2017; Bouvard, Daniel/M-2727-2013	Bouvard, Daniel/0000-0002-0845-6681; Brakebusch, Cord/0000-0002-9342-1634				Andrews RK, 1999, THROMB HAEMOSTASIS, V82, P357, DOI 10.1055/s-0037-1615854; Bergmeier W, 2000, BLOOD, V95, P886, DOI 10.1182/blood.V95.3.886.003k45_886_893; CADROY Y, 1994, BLOOD, V83, P3218; Cauwenberghs N, 2000, ARTERIOSCL THROM VAS, V20, P1347, DOI 10.1161/01.ATV.20.5.1347; CAZENAVE JP, 1983, ANN BIOL CLIN-PARIS, V41, P167; Chung CH, 1999, BIOCHEM BIOPH RES CO, V263, P723, DOI 10.1006/bbrc.1999.1457; Dormann D, 2001, BLOOD, V97, P929, DOI 10.1182/blood.V97.4.929; DU XP, 1994, J BIOL CHEM, V269, P18287; Eble JA, 2001, J BIOL CHEM, V276, P12274, DOI 10.1074/jbc.M009338200; Eilers M, 1999, BIOCHEM BIOPH RES CO, V263, P230, DOI 10.1006/bbrc.1999.1352; Gratacap MP, 2000, BLOOD, V96, P3439, DOI 10.1182/blood.V96.10.3439.h8003439_3439_3446; HUANG TF, 1995, BIOCHEM J, V309, P1021, DOI 10.1042/bj3091021; Inoue K, 1999, BIOCHEM BIOPH RES CO, V256, P114, DOI 10.1006/bbrc.1999.0295; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; JandrotPerrus M, 1996, SEMIN THROMB HEMOST, V22, P151, DOI 10.1055/s-2007-999003; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Kawasaki T, 1996, J BIOL CHEM, V271, P10635, DOI 10.1074/jbc.271.18.10635; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Liu LB, 1997, J BIOL CHEM, V272, P1997, DOI 10.1074/jbc.272.3.1997; Lopez J A, 1997, Curr Opin Hematol, V4, P323; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; Navdaev A, 2001, J BIOL CHEM, V276, P20882, DOI 10.1074/jbc.M101585200; Nieswandt B, 2000, BLOOD, V96, P2520; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Nieswandt B, 2001, BLOOD, V97, P3829, DOI 10.1182/blood.V97.12.3829; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Ohlmann P, 2000, BLOOD, V96, P2134, DOI 10.1182/blood.V96.6.2134.h8002134_2134_2139; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; PENG ML, 1993, BLOOD, V81, P2321; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Potocnik AJ, 2000, IMMUNITY, V12, P653, DOI 10.1016/S1074-7613(00)80216-2; Romo GM, 1999, J EXP MED, V190, P803, DOI 10.1084/jem.190.6.803; SAELMAN EUM, 1994, BLOOD, V83, P1244; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Schulte V, 2001, J BIOL CHEM, V276, P364, DOI 10.1074/jbc.M007536200; Shin Y, 1998, BIOCHEM BIOPH RES CO, V245, P741, DOI 10.1006/bbrc.1998.8516; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; Sobocka MB, 2000, BLOOD, V95, P2600; Suzuki-Inoue K, 2001, J BIOL CHEM, V276, P1643, DOI 10.1074/jbc.M006191200; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; WARE J, 1993, J BIOL CHEM, V268, P8376	45	69	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25121	25126		10.1074/jbc.M103892200	http://dx.doi.org/10.1074/jbc.M103892200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11352922	hybrid			2022-12-27	WOS:000169800700093
J	Furuya, T; Okura, M; Ruiz, FA; Scott, DA; Docampo, R				Furuya, T; Okura, M; Ruiz, FA; Scott, DA; Docampo, R			TcSCA complements yeast mutants defective in Ca2+ pumps and encodes a Ca2+-ATPase that localizes to the endoplasmic reticulum of Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SARCOPLASMIC-RETICULUM; CALCIUM-PUMP; SECRETORY PATHWAY; CELL INVASION; PROTEIN; THAPSIGARGIN; ATPASE; ACIDOCALCISOMES; EXPRESSION; MEMBRANE	Intracellular Ca2+ in Trypanosoma cruzi is mainly located in an acidic compartment named the acidocalcisome, which among other pumps and exchangers possesses a plasma membrane-type Ca2+-ATPase. Evidence for an endoplasmic reticulum-located Ca2+ uptake has been more elusive and based on indirect results. Here we report the cloning and sequencing of a gene encoding a sarcoplasmic-endoplasmic reticulum-type Ca2+-ATPase from T. cruzi. The protein (TeSCA) predicted from the nucleotide sequence of the gene has 1006 amino acids and a molecular mass of 109.7 kDa. Several sequence motifs found in sarcoplasmic-endoplasmic reticulum-type Ca2+-ATPases were present in TeSCA. Expression of TcSCA in yeast mutants deficient in the Golgi and vacuolar Ca2+ pumps (pmr1 pmc1 cnb 1) restored growth on EGTA. Membranes were isolated from the pmr1 pmc1 cnb1 mutant transformed with TcSCA, and it was found that the TcSCA polypeptide formed a Ca2+-dependent and hydroxylamine-sensitive P-32-labeled. phosphoprotein of 110 kDa in the presence of [gamma-P-32]ATP. Cyclopiazonic acid, but not thapsigargin, blocked this phosphoprotein formation. Transgenic parasites expressing constructs of TcSCA with green fluorescent protein exhibited co-localization of TcSCA with the endoplasmic reticulum proteins BiP and calreticulin. An endoplasmic reticulum location was also found in amastigotes and trypomastigotes using a polyclonal antibody against a COOH-terminal region of the protein. The ability of TcSCA to restore growth of mutant pmr1 pmc1 cnb 1 on medium containing Mn2+ suggests that TcSCA may also regulate Mn2+ homeostasis by pumping Mn2+ into the endoplasmic reticulum of T. cruzi.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	rodoc@uiuc.edu	Ruiz, Felix A./B-1032-2008; Furuya, Tetsuya/J-5916-2013	Ruiz, Felix A./0000-0003-0748-5015; Furuya, Tetsuya/0000-0003-3979-7072; Scott, David/0000-0002-8668-2449	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023259, R21AI023259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BONE GJ, 1956, NATURE, V178, P308, DOI 10.1038/178308a0; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Carafoli E, 2000, CURR OPIN CHEM BIOL, V4, P152, DOI 10.1016/S1367-5931(99)00069-1; Caspersen C, 2000, J BIOL CHEM, V275, P22363, DOI 10.1074/jbc.M001569200; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Degand I, 1999, MOL MICROBIOL, V31, P545, DOI 10.1046/j.1365-2958.1999.01195.x; DEMEIS L, 1988, METHOD ENZYMOL, V157, P190; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Docampo R, 1996, PARASITOL TODAY, V12, P61, DOI 10.1016/0169-4758(96)80656-9; DOCAMPO R, 1993, MOL BIOCHEM PARASIT, V59, P305, DOI 10.1016/0166-6851(93)90228-P; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; Ferrol N, 1996, PLANT CELL, V8, P1159, DOI 10.2307/3870359; Furuya T, 2000, J BIOL CHEM, V275, P6428, DOI 10.1074/jbc.275.9.6428; Geisler M, 2000, BBA-BIOMEMBRANES, V1465, P52, DOI 10.1016/S0005-2736(00)00131-0; Ghosh SK, 2000, MOL BIOCHEM PARASIT, V108, P125, DOI 10.1016/S0166-6851(00)00196-1; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Hebert DN, 1995, COLD SPRING HARB SYM, V60, P405, DOI 10.1101/SQB.1995.060.01.045; KAUFMAN RJ, 1994, BIOCHEMISTRY-US, V33, P9813, DOI 10.1021/bi00199a001; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Labriola C, 1999, MOL BIOL CELL, V10, P1381, DOI 10.1091/mbc.10.5.1381; Liang F, 1997, P NATL ACAD SCI USA, V94, P8579, DOI 10.1073/pnas.94.16.8579; Liang F, 1998, PLANT PHYSIOL, V118, P817, DOI 10.1104/pp.118.3.817; LODISH HF, 1990, J BIOL CHEM, V265, P10893; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; Lu HG, 1997, J BIOL CHEM, V272, P9464, DOI 10.1074/jbc.272.14.9464; Luo SH, 2001, EMBO J, V20, P55, DOI 10.1093/emboj/20.1.55; Mignaco JA, 1996, J BIOL CHEM, V271, P18423, DOI 10.1074/jbc.271.31.18423; MONIAKIS J, 1995, J BIOL CHEM, V270, P28276; MORENO SNJ, 1994, J EXP MED, V180, P1535, DOI 10.1084/jem.180.4.1535; MORENO SNJ, 1992, MOL BIOCHEM PARASIT, V52, P251, DOI 10.1016/0166-6851(92)90057-Q; NOLAN DP, 1994, J BIOL CHEM, V269, P26045; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Periz G, 1999, EMBO J, V18, P5983, DOI 10.1093/emboj/18.21.5983; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; REVELARD P, 1991, MOL BIOCHEM PARASIT, V46, P241, DOI 10.1016/0166-6851(91)90048-B; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Schatzmann H J, 1978, Ann N Y Acad Sci, V307, P125, DOI 10.1111/j.1749-6632.1978.tb41939.x; SCHATZMANN HJ, 1989, ANNU REV PHYSIOL, V51, P473, DOI 10.1146/annurev.ph.51.030189.002353; SCHMATZ DM, 1982, PARASITOLOGY, V85, P115, DOI 10.1017/S0031182000054202; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 1997, J BIOL CHEM, V272, P28020, DOI 10.1074/jbc.272.44.28020; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; SKEIKY YAW, 1992, J EXP MED, V176, P201, DOI 10.1084/jem.176.1.201; Talla E, 1998, J BIOL CHEM, V273, P27831, DOI 10.1074/jbc.273.43.27831; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOYOFUKU T, 1994, J BIOL CHEM, V269, P22929; VERCESI AE, 1991, CELL CALCIUM, V12, P361, DOI 10.1016/0143-4160(91)90052-G; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994	61	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32437	32445		10.1074/jbc.M104000200	http://dx.doi.org/10.1074/jbc.M104000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11382780	hybrid			2022-12-27	WOS:000170746000011
J	Koch, T; Schulz, S; Pfeiffer, M; Klutzny, M; Schroder, H; Kahl, E; Hollt, V				Koch, T; Schulz, S; Pfeiffer, M; Klutzny, M; Schroder, H; Kahl, E; Hollt, V			C-terminal splice variants of the mouse mu-opioid receptor differ in morphine-induced internalization and receptor resensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; ACTIVATED PROTEIN-KINASE; BETA-ARRESTIN; CARBOXY-TERMINUS; IN-VIVO; ENDOCYTOSIS; CELLS; PHOSPHORYLATION; THREONINE-394; SPECIFICITY	The main analgesic effects of the opioid alkaloid morphine are mediated by the IL-opioid receptor. In contrast to endogenous opioid peptides, morphine activates the mu -opioid receptor without causing its rapid endocytosis. Recently, three novel C-terminal splice variants (MOR1C, MOR1D, and MOR1E) of the mouse mu -opioid receptor (MOR1) have been identified. In the present study, we show that these receptors differ substantially in their agonist-selective membrane trafficking. MOR1 and MOR1C stably expressed in human embryonic kidney 293 cells exhibited phosphorylation, internalization, and down-regulation in the presence of the opioid peptide [D-Ala(2),Me-Phe(4),Gly(5)-ol]enkephalin (DAMGO) but not in response to morphine. In contrast, MOR1D and MOR1E exhibited robust phosphorylation, internalization, and down-regulation in response to both DAMGO and morphine. DAMGO elicited a similar desensitization (during an 8-h exposure) and resensitization (during a 50-min drug-free interval) of all four mu -receptor splice variants. After morphine treatment, however, MOR1 and MOR1C showed a faster desensitization and no resensitization as compared with MOR1D and MOR1E. These results strongly reinforce the hypothesis that receptor phosphorylation and internalization are required for opioid receptor reactivation thus counteracting agonist-induced desensitization. Our findings also suggest a mechanism by which cell- and tissue-specific C-terminal splicing of the mu -opioid receptor may significantly modulate the development of tolerance to the various effects of morphine.	Otto Von Guericke Univ, Dept Pharmacol & Toxicol, D-39120 Magdeburg, Germany	Otto von Guericke University	Koch, T (corresponding author), Otto Von Guericke Univ, Dept Pharmacol & Toxicol, Leipziger Str 44, D-39120 Magdeburg, Germany.		Schulz, Stefan/A-6928-2017	Schulz, Stefan/0000-0002-5997-8885				Abbadie C, 2000, NEUROSCIENCE, V100, P141, DOI 10.1016/S0306-4522(00)00248-7; Abbadie C, 2000, J COMP NEUROL, V419, P244, DOI 10.1002/(SICI)1096-9861(20000403)419:2<244::AID-CNE8>3.0.CO;2-R; Abbadie C, 2000, NEUROREPORT, V11, P1953, DOI 10.1097/00001756-200006260-00029; Burt RP, 1996, BRIT J PHARMACOL, V117, P224, DOI 10.1111/j.1476-5381.1996.tb15178.x; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Deng HB, 2000, BIOCHEMISTRY-US, V39, P5492, DOI 10.1021/bi991938b; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUIRAMAND J, 1995, J BIOL CHEM, V270, P7354, DOI 10.1074/jbc.270.13.7354; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Li LY, 1996, MOL PHARMACOL, V50, P599; LUCAS JJ, 1995, TRENDS PHARMACOL SCI, V16, P246, DOI 10.1016/S0165-6147(00)89034-3; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; Pan YX, 1999, MOL PHARMACOL, V56, P396, DOI 10.1124/mol.56.2.396; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; Schulz S, 1998, EUR J NEUROSCI, V10, P1196, DOI 10.1046/j.1460-9568.1998.00103.x; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; VANETTI M, 1992, FEBS LETT, V311, P290, DOI 10.1016/0014-5793(92)81122-3; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Wolf R, 1999, MOL PHARMACOL, V55, P263, DOI 10.1124/mol.55.2.263; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; ZIMPRICH A, 1995, FEBS LETT, V359, P142, DOI 10.1016/0014-5793(95)00028-8	29	139	150	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31408	31414		10.1074/jbc.M100305200	http://dx.doi.org/10.1074/jbc.M100305200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11359768	hybrid			2022-12-27	WOS:000170472900106
J	Battistoni, A; Pacello, F; Mazzetti, AP; Capo, C; Kroll, JS; Langford, PR; Sansone, A; Donnarumma, G; Valenti, P; Rotilio, G				Battistoni, A; Pacello, F; Mazzetti, AP; Capo, C; Kroll, JS; Langford, PR; Sansone, A; Donnarumma, G; Valenti, P; Rotilio, G			A histidine-rich metal binding domain at the N terminus of Cu,Zn-superoxide dismutases from pathogenic bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; ESCHERICHIA-COLI; COPPER CHAPERONE; SALMONELLA-TYPHIMURIUM; PROTEIN; ZINC; VIRULENCE; IDENTIFICATION; PURIFICATION; MUTANTS	A group of Cu,Zn-superoxide dismutases from pathogenic bacteria is characterized by histidine-rich N-terminal extensions that are in a highly exposed and mobile conformation. This feature allows these proteins to be readily purified in a single step by immobilized metal affinity chromatography. The Cu,Zn-superoxide dismutases from both Haemophilus ducreyi and Haemophilus parainfluenzae display anomalous absorption spectra in the visible region due to copper binding at the N-terminal region. Reconstitution experiments of copper-free enzymes demonstrate that, under conditions of limited copper availability, this metal ion is initially bound at the N-terminal region and subsequently transferred to an active site. Evidence is provided for intermolecular pathways of copper transfer from the N-terminal domain of an enzyme subunit to an active site located on a distinct dimeric molecule. Incubation with EDTA rapidly removes copper bound at the N terminus but is much less effective on the copper ion bound at the active site. This indicates that metal binding by the N-terminal histidines is kinetically favored, but the catalytic site binds copper with higher affinity. We suggest that the histidine-rich N-terminal region constitutes a metal binding domain involved in metal uptake under conditions of metal starvation in vivo. Particular biological importance for this domain is inferred by the observation that its presence enhances the protection offered by periplasmic Cu,Zn-superoxide dismutase toward phagocytic killing.	Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Sch Med, Dept Paediat,Mol Infect Dis Grp, London W2 1PG, England; Univ Naples Federico II, Ist Microbiol 2, I-80138 Naples, Italy	University of Rome Tor Vergata; Imperial College London; University of Naples Federico II	Battistoni, A (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Via Ric Sci, I-00133 Rome, Italy.	andrea.battistoni@uniroma2.it	Battistoni, Andrea/A-4778-2016; Langford, Paul R/B-9092-2008; Langford, Paul/AAU-4189-2020	Battistoni, Andrea/0000-0003-4085-7917; Langford, Paul R/0000-0002-6368-4724; Langford, Paul/0000-0002-6368-4724; DONNARUMMA, Giovanna/0000-0002-3087-1240; VALENTI, Piera/0000-0002-4354-3190; Sansone, Susanna-Assunta/0000-0001-5306-5690				Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; Battistoni A, 1998, BIOCHEM BIOPH RES CO, V243, P804, DOI 10.1006/bbrc.1998.8182; Battistoni A, 1996, BIOCHEM J, V320, P713, DOI 10.1042/bj3200713; Battistoni A, 1998, J BIOL CHEM, V273, P5655, DOI 10.1074/jbc.273.10.5655; Battistoni A, 1999, FEBS LETT, V443, P313, DOI 10.1016/S0014-5793(98)01725-6; Benov L, 1997, ARCH BIOCHEM BIOPHYS, V340, P305, DOI 10.1006/abbi.1997.9940; Bordo D, 1999, J MOL BIOL, V285, P283, DOI 10.1006/jmbi.1998.2267; BORDO D, 1994, J MOL BIOL, V238, P366, DOI 10.1006/jmbi.1994.1298; Bourne Y, 1996, P NATL ACAD SCI USA, V93, P12774, DOI 10.1073/pnas.93.23.12774; Camilli A, 1995, MOL MICROBIOL, V18, P671, DOI 10.1111/j.1365-2958.1995.mmi_18040671.x; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DeGroote MA, 1997, P NATL ACAD SCI USA, V94, P13997, DOI 10.1073/pnas.94.25.13997; Fang FC, 1999, P NATL ACAD SCI USA, V96, P7502, DOI 10.1073/pnas.96.13.7502; Farrant JL, 1997, MOL MICROBIOL, V25, P785, DOI 10.1046/j.1365-2958.1997.5151877.x; Figueroa-Bossi N, 1999, MOL MICROBIOL, V33, P167, DOI 10.1046/j.1365-2958.1999.01461.x; Folcarelli S, 1998, BIOCHEM BIOPH RES CO, V244, P908, DOI 10.1006/bbrc.1998.8364; Fontana A, 1997, FOLD DES, V2, pR17, DOI 10.1016/S1359-0278(97)00010-2; Forest KT, 2000, J MOL BIOL, V296, P145, DOI 10.1006/jmbi.1999.3448; Foti D, 1997, BIOCHEMISTRY-US, V36, P7109, DOI 10.1021/bi963020f; FU CL, 1995, P NATL ACAD SCI USA, V92, P2333, DOI 10.1073/pnas.92.6.2333; Gatti D, 2000, J BIOL CHEM, V275, P34009, DOI 10.1074/jbc.R000012200; Gort AS, 1999, MOL MICROBIOL, V32, P179, DOI 10.1046/j.1365-2958.1999.01343.x; GURUPRASAD K, 1990, PROTEIN ENG, V4, P155, DOI 10.1093/protein/4.2.155; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; HASSAN HM, 1979, J BIOL CHEM, V254, P846; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; KROLL JS, 1991, J BACTERIOL, V173, P7449, DOI 10.1128/jb.173.23.7449-7457.1991; KROLL JS, 1995, MICROBIOL-UK, V141, P2271, DOI 10.1099/13500872-141-9-2271; Kuroda M, 1999, MICROBIOL IMMUNOL, V43, P115, DOI 10.1111/j.1348-0421.1999.tb02382.x; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Langford PR, 1997, FEMS IMMUNOL MED MIC, V17, P235, DOI 10.1016/S0928-8244(97)00011-4; LEE MH, 1993, PROTEIN SCI, V2, P1042, DOI 10.1002/pro.5560020617; Lewis DA, 1999, INFECT IMMUN, V67, P5060, DOI 10.1128/IAI.67.10.5060-5068.1999; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; NAKAYASHIKI T, 1995, MOL GEN GENET, V249, P139, DOI 10.1007/BF00290359; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Pacello F, 2001, J BIOL CHEM, V276, P30326, DOI 10.1074/jbc.M010488200; PANTOLIANO MW, 1982, J AM CHEM SOC, V104, P6043; Pesce A, 1997, J MOL BIOL, V274, P408, DOI 10.1006/jmbi.1997.1400; Pesce A, 2000, J MOL BIOL, V302, P465, DOI 10.1006/jmbi.2000.4074; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; RIGO A, 1977, BIOCHEM J, V161, P27, DOI 10.1042/bj1610027; ROOF WD, 1994, J BIOL CHEM, V269, P2902; ROTILIO G, 1973, J BIOL CHEM, V248, P3855; San Mateo LR, 1999, INFECT IMMUN, V67, P5345, DOI 10.1128/IAI.67.10.5345-5351.1999; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; Sheehan BJ, 2000, INFECT IMMUN, V68, P4778, DOI 10.1128/IAI.68.8.4778-4781.2000; SOLIOZ M, 1995, J BIOL CHEM, V270, P9217, DOI 10.1074/jbc.270.16.9217; Stroppolo ME, 1998, BIOCHEMISTRY-US, V37, P12287, DOI 10.1021/bi980563b; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; Wang JY, 1996, P NATL ACAD SCI USA, V93, P10434, DOI 10.1073/pnas.93.19.10434; Watt RK, 1998, J BIOL CHEM, V273, P10019, DOI 10.1074/jbc.273.16.10019; Wilks KE, 1998, INFECT IMMUN, V66, P213, DOI 10.1128/IAI.66.1.213-217.1998; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; WULFING C, 1994, MOL MICROBIOL, V12, P685, DOI 10.1111/j.1365-2958.1994.tb01056.x	61	53	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30315	30325		10.1074/jbc.M010527200	http://dx.doi.org/10.1074/jbc.M010527200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11369756	hybrid			2022-12-27	WOS:000170558000094
J	Chen, XM; Johns, DC; Geiman, DE; Marban, E; Dang, DT; Hamlin, G; Sun, RG; Yang, VW				Chen, XM; Johns, DC; Geiman, DE; Marban, E; Dang, DT; Hamlin, G; Sun, RG; Yang, VW			Kruppel-like factor 4 (Gut-enriched Kruppel-like factor) inhibits cell proliferation by blocking G(1)/S progression of the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; STRUCTURAL ELEMENTS; ECDYSONE RECEPTOR; NUCLEAR PROTEINS; GENE-EXPRESSION; MAMMALIAN-CELLS; HUMAN KERATIN-4; FINGER; PROMOTER; FAMILY	Kruppel-like factor 4 (KLF4) is an epithelial cell-enriched, zinc finger-containing transcription factor, the expression of which is associated with growth arrest. Previous studies show that constitutive expression of KLF4 inhibits DNA synthesis but the manner by which KLF4 exerts this effect is unclear. In the present study, we developed a system in which expression of KLF4 is controlled by a promoter that is induced upon treatment of cells containing the receptors for the insect hormone, eedysone, with ponasterone A, an eedysone analogue. The rate of proliferation of a stably transfected colon cancer cell line, RKO, was significantly decreased following addition of ponasterone A when compared with untreated cells. Flow cytometric analyses indicated that the inducible expression of KLF4 caused a block in the G(1)/S phase of the cell cycle. A similar block was observed when eedysone receptor-containing RKO cells were infected with a replication-defective recombinant adenovirus containing an inducible KLF4 and treated with ponasterone A. Results of these studies provide evidence that the inhibitory effect of KLF4 on cell proliferation is mainly exerted at the G(1)/S boundary of the cell cycle.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Yang, VW (corresponding author), Emory Univ, Sch Med, Div Digest Dis, Rm 2101 Woodruff Mem Bldg,1639 Pierce Dr, Atlanta, GA 30322 USA.	vyang@emory.edu	Marban, Eduardo/GWC-8514-2022		NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084197, CA84197, R01 CA084197-02] Funding Source: Medline; NIDDK NIH HHS [DK52230, R01 DK052230, R01 DK052230-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Chen ZY, 2000, FEBS LETT, V477, P67, DOI 10.1016/S0014-5793(00)01764-6; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; DANG DT, 2001, IN PRESS ONCOGENE; Dubravka D, 2000, CELL RES, V10, P1, DOI 10.1038/sj.cr.7290031; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Foster KW, 2000, CANCER RES, V60, P6488; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Glynne R, 2000, IMMUNOL REV, V176, P216; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Harper JW, 1997, CANCER SURV, V29, P91; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Johns DC, 1999, J NEUROSCI, V19, P1691; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Okano J, 2000, FEBS LETT, V473, P95, DOI 10.1016/S0014-5793(00)01468-X; Panigada M, 1999, MECH DEVELOP, V81, P103, DOI 10.1016/S0925-4773(98)00237-8; PERKINS AC, 1995, NATURE, V375, P318; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Wani MA, 1998, TRANSGENIC RES, V7, P229, DOI 10.1023/A:1008809809843; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; Zhang GH, 1996, BIOCHEM BIOPH RES CO, V227, P707, DOI 10.1006/bbrc.1996.1573; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	41	198	209	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30423	30428		10.1074/jbc.M101194200	http://dx.doi.org/10.1074/jbc.M101194200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390382	hybrid, Green Accepted			2022-12-27	WOS:000170558000107
J	Gratton, JP; Morales-Ruiz, M; Kureishi, Y; Fulton, D; Walsh, K; Sessa, WC				Gratton, JP; Morales-Ruiz, M; Kureishi, Y; Fulton, D; Walsh, K; Sessa, WC			Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSDUCTION PATHWAY; ACTIN REORGANIZATION; TRANSCRIPTION FACTOR; APOPTOSIS; PHOSPHORYLATION	Vascular endothelial growth factor (VEGF) utilizes a phosphoinositide 3-kinase (PI 3-kinase)/Akt signaling pathway to protect endothelial cells from apoptotic death. Here we show that PI 3-kinase/Akt; signaling promotes endothelial cell survival by inhibiting p38 mitogen-activated protein kinase (MAPK)-dependent apoptosis. Blockade of the PI 3-kinase or Akt pathways in conjunction with serum withdrawal stimulates p38-dependent apoptosis. Blockade of PI 3-kinase/Akt also led to enhanced VEGF activation of p38 and apoptosis. In this context, the pro-apoptotic effect of VEGF is attenuated by the p38 MAPK inhibitor SE203580. VEGF stimulation of endothelial cells or infection with an adenovirus expressing constitutively active Akt; causes MEKK3 phosphorylation, which is associated with decreased MEKK3 kinase activity and down-regulation of MKK3/6 and p38 MAPK activation. Conversely, activation-deficient Akt decreases VEGF-stimulated MEKK3 phosphorylation and increases MKK/p38 activation. Activation of MKK3/6 is not dependent on Rac activation since dominant negative Rac does not decrease p38 activation triggered by inhibition of PI 3-kinase. Thus, cross-talk between the Akt and p38 MAPK pathways may regulate the level of cytoprotection versus apoptosis and is a new mechanism to explain the cytoprotective actions of Akt.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Mol Cardiobiol Program, New Haven, CT 06536 USA; St Elizabeths Med Ctr Boston, Div Cardiovasc Res, Boston, MA USA	Yale University; Yale University; St. Elizabeth's Medical Center	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.		Morales-Ruiz, Manuel/L-1031-2014; Bando, Yasuko K./M-4831-2014; Morales-Ruiz, Manuel/AAM-1487-2020; Morales-Ruiz, Manuel/Z-2332-2019; Sessa, William C/B-6844-2011	Morales-Ruiz, Manuel/0000-0002-9074-2272; Bando, Yasuko K./0000-0003-4166-6784; Morales-Ruiz, Manuel/0000-0002-9074-2272; Sessa, William C/0000-0001-5759-1938; Gratton, Jean-Philippe/0000-0001-9877-8520	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010183, R01HL061371, R01HL050692, R37HL061371, R01HL064793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG015052, R01AG015052] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL10183, HL 61371, HL 64793, HL 50692] Funding Source: Medline; NIAMS NIH HHS [AR 40197] Funding Source: Medline; NIA NIH HHS [AG 15052] Funding Source: Medline; NICHD NIH HHS [HD23681] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Coffer PJ, 1998, BIOCHEM J, V335, P1; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gao ZY, 1996, DIABETES, V45, P854, DOI 10.2337/diabetes.45.7.854; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hashimoto S, 1999, EUR RESPIR J, V13, P1357, DOI 10.1034/j.1399-3003.1999.13f21.x; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kalman D, 1999, MOL BIOL CELL, V10, P1665, DOI 10.1091/mbc.10.5.1665; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Ozes ON, 1999, NATURE, V401, P82; Papapetropoulos A, 1998, P NATL ACAD SCI USA, V95, P4738, DOI 10.1073/pnas.95.8.4738; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Stefanec T, 2000, CHEST, V117, P841, DOI 10.1378/chest.117.3.841; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Yue TL, 1999, J BIOL CHEM, V274, P1479, DOI 10.1074/jbc.274.3.1479; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	46	242	245	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30359	30365		10.1074/jbc.M009698200	http://dx.doi.org/10.1074/jbc.M009698200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11387313	hybrid			2022-12-27	WOS:000170558000099
J	Liang, QR; De Windt, LJ; Witt, SA; Kimball, TR; Markham, BE; Molkentin, JD				Liang, QR; De Windt, LJ; Witt, SA; Kimball, TR; Markham, BE; Molkentin, JD			The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; CARDIAC MYOCYTE HYPERTROPHY; SERUM RESPONSE FACTOR; ALPHA-ACTIN PROMOTER; PROTEIN-KINASE-C; BINDING-PROTEINS; EXPRESSION; PATHWAY; HEART; INDUCTION	The zinc finger-containing transcription factors GATA4 and GATA6 are important regulators of basal and inducible gene expression in cardiac and smooth muscle cell types. Here we demonstrate a direct functional role for GATA4 and GATA6 as regulators of cardiomyocyte hypertrophic growth and gene expression. To model the increase in endogenous GATA4 and GATA6 transcriptional activity that occurs in response to hypertrophic stimulation, each factor was overexpressed in cardiomyocytes using recombinant adenovirus. Overexpression of either GATA4 or GATA6 was sufficient to induce cardiomyocyte hypertrophy characterized by enhanced sarcomeric organization, a greater than 2-fold increase in cell surface area, and a significant increase in total protein accumulation. In vivo, transgenic mice with 2.5-fold overexpression of GATA4 within the adult heart demonstrated a slowly progressing increase in heart to body weight ratio, histological features of cardiomyopathy, and activation of hypertrophy-associated genes, suggesting that GATA factors are sufficient regulators of cardiomyocyte hypertrophy in vitro and in vivo. To evaluate the requirement of GATA factors as downstream transcriptional mediators of hypertrophy, a dominant negative GATA4-engrailed repressor fusion-encoding adenovirus was generated. Expression of GATA4-engrailed blocked GATA4- and GATA6-directed transcriptional responses and agonist-induced cardiomyocyte hypertrophy, demonstrating that cardiac-expressed GATA factors are necessary mediators of this process.	Univ Cincinnati, Childrens Hosp,Med Ctr, Div Mol Cardiovasc Biol, Dept Pediat, Cincinnati, OH 45229 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Dept Cell Biol, Ann Arbor, MI 48105 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Pfizer	Molkentin, JD (corresponding author), Univ Cincinnati, Childrens Hosp,Med Ctr, Div Mol Cardiovasc Biol, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.molkentin@chmcc.org	de Windt, Leon/AAO-6395-2020	de Windt, Leon/0000-0002-7793-2856; Molkentin, Jeffery/0000-0002-3558-6529	NHLBI NIH HHS [HL43662, HL60562] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043662, R37HL060562, R01HL060562] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Babu GJ, 2000, J MOL CELL CARDIOL, V32, P1447, DOI 10.1006/jmcc.2000.1185; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Charron F, 1999, MOL CELL BIOL, V19, P4355; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Fu YC, 1998, DEVELOPMENT, V125, P4439; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Hasegawa K, 1997, CIRCULATION, V96, P3943; Hautala N, 2001, CIRCULATION, V103, P730; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; Huang WY, 2000, NAT MED, V6, P482, DOI 10.1038/74914; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Liang FQ, 1999, J CLIN INVEST, V104, P1603, DOI 10.1172/JCI7362; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Molkentin JD, 1996, J MOL CELL CARDIOL, V28, P1211, DOI 10.1006/jmcc.1996.0112; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Nagata D, 2000, CIRC RES, V87, P699, DOI 10.1161/01.RES.87.8.699; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Saadane N, 2000, AM J PHYSIOL-HEART C, V278, pH796, DOI 10.1152/ajpheart.2000.278.3.H796; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; Steinberg SF, 2000, J MOL CELL CARDIOL, V32, P1381, DOI 10.1006/jmcc.2000.1202; Takemoto Y, 1999, J MOL CELL CARDIOL, V31, P2017, DOI 10.1006/jmcc.1999.1033; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; Wada H, 2000, J BIOL CHEM, V275, P25330, DOI 10.1074/jbc.M000828200; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830	43	276	296	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30245	30253		10.1074/jbc.M102174200	http://dx.doi.org/10.1074/jbc.M102174200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11356841	hybrid			2022-12-27	WOS:000170558000085
J	Martin-Romero, FJ; Kryukov, GV; Lobanov, AV; Carlson, BA; Lee, BJ; Gladyshev, VN; Hatfield, DL				Martin-Romero, FJ; Kryukov, GV; Lobanov, AV; Carlson, BA; Lee, BJ; Gladyshev, VN; Hatfield, DL			Selenium metabolism in Drosophila - Selenoproteins, selenoprotein mRNA expression, fertility, and mortality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOPHOSPHATE SYNTHETASE; SELENOCYSTEINE INSERTION; SELD HOMOLOG; GENE; MELANOGASTER; TRANSLATION; EUKARYOTES; MECHANISM; TISSUES; GENOME	Selenocysteine is a rare amino acid in protein that is encoded by UGA with the requirement of a downstream mRNA stem-loop structure, the selenocysteine insertion sequence element. To detect selenoproteins in Drosophila, the entire genome was analyzed with a novel program that searches for selenocysteine insertion sequence elements, followed by selenoprotein gene signature analyses. This computational screen and subsequent metabolic labeling with (75)Se and characterization of selenoprotein mRNA expression resulted in identification of three selenoproteins: selenophosphate synthetase 2 and novel G-rich and BthD selenoproteins that had no homology to known proteins. To assess a biological role for these proteins, a simple chemically defined medium that supports growth of adult Drosophila and requires selenium supplementation for optimal survival was devised. Flies survived on this medium supplemented with 10(-8) to 10(-6) m selenium or on the commonly used yeast-based complete medium at about twice the rate as those on a medium without selenium or with > 10(-6) M selenium. This effect correlated with changes in selenoprotein mRNA expression. The number of eggs laid by Drosophila was reduced approximately in half in the chemically defined medium compared with the same medium supplemented with selenium. The data provide evidence that dietary selenium deficiency shortens, while supplementation of the diet with selenium normalizes the Drosophila life span by a process that may involve the newly identified selenoproteins.	NCI, Basic Res Lab, Sect Mol Biol Selenium, NIH, Bethesda, MD 20892 USA; Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA; Seoul Natl Univ, Sch Biol Sci, Mol Genet Lab, Seoul 151742, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Nebraska System; University of Nebraska Lincoln; Seoul National University (SNU)	Hatfield, DL (corresponding author), NCI, Basic Res Lab, Sect Mol Biol Selenium, NIH, Bethesda, MD 20892 USA.	hatfield@dc37a.nci.nih.gov	Gladyshev, Vadim N/J-6187-2013; Kryukov, Gregory V/A-9592-2008; Martin-Romero, Francisco Javier/A-7682-2012; Gladyshev, Vadim N/A-9894-2013	Martin-Romero, Francisco Javier/0000-0001-6796-7396; Gladyshev, Vadim/0000-0002-0372-7016; Kryukov, Gregory/0000-0002-6131-9483	NIGMS NIH HHS [GM61603] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061603] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alsina B, 1999, J CELL SCI, V112, P2875; Alsina B, 1998, MOL GEN GENET, V257, P113, DOI 10.1007/s004380050630; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bock A, 2000, Biofactors, V11, P77; Copeland PR, 2000, EMBO J, V19, P306, DOI 10.1093/emboj/19.2.306; Fagegaltier D, 2000, EMBO J, V19, P4796, DOI 10.1093/emboj/19.17.4796; FOSTER HD, 1995, SCI TOTAL ENVIRON, V170, P133, DOI 10.1016/0048-9697(95)04626-C; Gladyshev V. N., 1999, Recent Research Developments in Biochemistry, V1, P145; Guimaraes MJ, 1996, P NATL ACAD SCI USA, V93, P15086, DOI 10.1073/pnas.93.26.15086; Hatfield D, 1999, COMPREHENSIVE NATURA, P353; Hirosawa-Takamori M, 2000, EMBO REP, V1, P441, DOI 10.1093/embo-reports/kvd087; KIM IY, 1995, P NATL ACAD SCI USA, V92, P7710, DOI 10.1073/pnas.92.17.7710; Kryukov GV, 1999, J BIOL CHEM, V274, P33888, DOI 10.1074/jbc.274.48.33888; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; LI FS, 1990, MECH AGEING DEV, V54, P103, DOI 10.1016/0047-6374(90)90059-O; LOW SC, 1995, J BIOL CHEM, V270, P21659, DOI 10.1074/jbc.270.37.21659; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; Persson BC, 1997, J MOL BIOL, V274, P174, DOI 10.1006/jmbi.1997.1371; PHILLIPS JP, 1995, P NATL ACAD SCI USA, V92, P8574, DOI 10.1073/pnas.92.19.8574; Rother M, 2000, J MOL BIOL, V299, P351, DOI 10.1006/jmbi.2000.3756; Tower J, 2000, MECH AGEING DEV, V118, P1, DOI 10.1016/S0047-6374(00)00152-4; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; Vernooy SY, 2000, J CELL BIOL, V150, pF69, DOI 10.1083/jcb.150.2.F69; WIESCHAUS E, 1984, DEV BIOL, V104, P172, DOI 10.1016/0012-1606(84)90046-0; Zhou X, 1999, J BIOL CHEM, V274, P18729, DOI 10.1074/jbc.274.26.18729	26	104	116	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29798	29804		10.1074/jbc.M100422200	http://dx.doi.org/10.1074/jbc.M100422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11389138	hybrid, Green Published			2022-12-27	WOS:000170558000027
J	Sengupta, S; Chen, H; Togawa, T; DiBello, PM; Majors, AK; Budy, B; Ketterer, ME; Jacobsen, DW				Sengupta, S; Chen, H; Togawa, T; DiBello, PM; Majors, AK; Budy, B; Ketterer, ME; Jacobsen, DW			Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONALLY MODIFIED ALBUMINS; HIGH-AFFINITY BINDING; REDOX STATUS; PROTEIN-BINDING; PLASMA HOMOCYSTEINE; SERUM; AMINOTHIOLS; CYSTEINE; ACID; ENDOCYTOSIS	An elevated concentration of plasma total homocysteine is an independent risk factor for cardiovascular disease. Greater than 80% of circulating homocysteine is covalently bound to plasma protein by disulfide bonds. It is known that albumin combines with cysteine in circulation to form albumin-Cys(34)-S-S-Cys. Studies are now presented to show that the formation of albumin-bound homocysteine proceeds through the generation of an albumin thiolate anion. Incubation of human plasma with L-S-35-homocysteine results in the association of > 90% of the protein-bound S-35-homocysteine with albumin as shown by nonreduced SDS-polyacrylamide gel electrophoresis. Treatment of the complex with beta -mercaptoethanol results in near quantitative release of the bound L-S-35-homocysteine, demonstrating that the binding of homocysteine to albumin is through a disulfide bond. Furthermore, using an in vitro model system to study the mechanisms of this disulfide bond formation, we show that homocysteine binds to albumin in two steps. In the first step homocysteine rapidly displaces cysteine from albumin-Cys(34)-S-S-Cys, forming albumin-Cys(34) thiolate anion and homocysteine-cysteine mixed disulfide. In the second step, albumin thiolate anion attacks homocysteine-cysteine mixed disulfide to yield primarily albumin-Cys(34)-S-S-Hcy and to a much lesser extent albumin-Cys(34)-S-S-Cys. The results clearly suggest that when reduced homocysteine enters circulation, it attacks albumin-Cys(34)-S-S-Cys to form albumin-Cys(34) thiolate anion, which in turn, reacts with homocysteine-cysteine mixed disulfide or homocystine to form albumin-bound homocysteine.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; No Arizona Univ, Dept Chem, Flagstaff, AZ 86011 USA	Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Northern Arizona University	Jacobsen, DW (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.	jacobs@ccf.org			NHLBI NIH HHS [R01 HL 52234] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052234] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON A, 1995, CLIN CHEM, V41, P361; BENESCH RE, 1955, J AM CHEM SOC, V77, P5877, DOI 10.1021/ja01627a030; Budy B, 2001, ANAL BIOCHEM, V291, P303, DOI 10.1006/abio.2000.5039; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; CHRISTODOULOU J, 1994, EUR J BIOCHEM, V225, P363, DOI 10.1111/j.1432-1033.1994.00363.x; CHRISTODOULOU J, 1995, FEBS LETT, V376, P1, DOI 10.1016/0014-5793(95)01231-2; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; DUERRE JA, 1966, ANAL BIOCHEM, V17, P310, DOI 10.1016/0003-2697(66)90209-0; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FRIEDMAN M, 1965, J AM CHEM SOC, V87, P3672, DOI 10.1021/ja01094a025; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; HOUK RS, 1994, ACCOUNTS CHEM RES, V27, P333, DOI 10.1021/ar00047a003; Jacobsen DW, 2000, DEV CARDIOVASC MED, V230, P15; Jacobsen DW, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P425; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSOOR MA, 1993, CLIN CHEM, V39, P980; MANSOOR MA, 1993, METABOLISM, V42, P1481, DOI 10.1016/0026-0495(93)90202-Y; MANSOOR MA, 1995, ARTERIOSCL THROM VAS, V15, P232, DOI 10.1161/01.ATV.15.2.232; MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H; McCaddon A, 1998, INT J GERIATR PSYCH, V13, P235, DOI 10.1002/(SICI)1099-1166(199804)13:4<235::AID-GPS761>3.0.CO;2-8; MUDD SH, 1965, J BIOL CHEM, V240, P4382; Narazaki R, 1996, PHARMACEUT RES, V13, P1317, DOI 10.1023/A:1016057513490; Nygard O, 1999, J INTERN MED, V246, P425, DOI 10.1046/j.1365-2796.1999.00512.x; Peters T, 1996, ALL ALBUMIN BIOCH GE, P51; Rasmussen K, 1996, CLIN CHEM, V42, P630; REFSUM H, 1985, CLIN CHEM, V31, P624; ROYER RE, 1983, FEBS LETT, V157, P28, DOI 10.1016/0014-5793(83)81109-0; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SCHNITZER JE, 1992, J BIOL CHEM, V267, P24544; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOGAMI M, 1984, INT J PEPT PROT RES, V24, P96; Tiruppathi C, 1996, P NATL ACAD SCI USA, V93, P250, DOI 10.1073/pnas.93.1.250; Togawa T, 2000, BIOCHEM BIOPH RES CO, V277, P668, DOI 10.1006/bbrc.2000.3723; UBBINK JB, 1995, CLIN CHEM, V41, P1033; Ullrich V, 1996, BIOCHEM PHARMACOL, V52, P15, DOI 10.1016/0006-2952(96)00109-8	42	147	150	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30111	30117		10.1074/jbc.M104324200	http://dx.doi.org/10.1074/jbc.M104324200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11371573	hybrid			2022-12-27	WOS:000170558000069
J	Stebbins, EG; Mochly-Rosen, D				Stebbins, EG; Mochly-Rosen, D			Binding specificity for RACK1 resides in the V5 region of beta II protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTES; ANCHORING PROTEINS; IN-VIVO; HUMAN HEART; RAT; LOCALIZATION; EPSILON; ISOZYME; TRANSLOCATION; DOMAINS	Identification of selective anchoring proteins responsible for specialized localization of specific signaling proteins has led to the identification of new inhibitors of signal transduction, inhibitors of anchoring protein-ligand interactions. RACK1, the first receptor for activated C kinase identified in our lab, is a selective anchoring protein for beta II protein kinase C (beta IIPKC). We previously found that at least part of the RACK1-binding site resides in the C2 domain of beta IIPKC (Ron, D., Luo, J., and Mochly-Rosen, D. (1995) J. Biol. Chem. 270, 24180-24187). Here we show that the V5 domain also contains part of the RACK1-binding site in beta IIPKC. In neonatal rat cardiac myocytes, the beta IIPKC peptide (amino acids 645-650 in beta IIPKC) selectively inhibited phorbol 12-myristate 13-acetate (PMA)-induced translocation of beta IIPKC and not beta IIPKC. In addition, the beta IIV5-3 peptide inhibited cardiac myocyte hypertrophy in PMA-treated cells. Interestingly, beta IV5-3 (646-651 in beta IPKC), a selective translocation inhibitor of beta IPKC, also inhibited PMA-induced cardiac myocyte hypertrophy, demonstrating that both betaI- and beta IIPKC are essential for this cardiac function. Therefore, the beta IIV5 domain contains part of the RACK1-binding site in beta IIPKC; a peptide corresponding to this site is a selective inhibitor of beta IIPKC and, hence, enables the identification of beta IIPKC-selective functions.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Mochly-Rosen, D (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.			Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [HL52141] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Buck E, 1999, SCIENCE, V283, P1332, DOI 10.1126/science.283.5406.1332; CARR DW, 1992, J BIOL CHEM, V267, P16816; Chalfant CE, 1996, MOL ENDOCRINOL, V10, P1273, DOI 10.1210/me.10.10.1273; Chen YB, 1997, P NATL ACAD SCI USA, V94, P2711, DOI 10.1073/pnas.94.6.2711; CHOI KY, 1994, CELL, V78, P499; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Gokmen-Polar Y, 1998, J BIOL CHEM, V273, P20261, DOI 10.1074/jbc.273.32.20261; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; GU X, 1994, CIRC RES, V75, P926, DOI 10.1161/01.RES.75.5.926; Herberg FW, 2000, J MOL BIOL, V298, P329, DOI 10.1006/jmbi.2000.3662; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KARIYA K, 1991, J BIOL CHEM, V266, P10023; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; Luria A, 2000, BIOL REPROD, V62, P1564, DOI 10.1095/biolreprod62.6.1564; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; Simpson PC, 1999, CIRCULATION, V99, P334, DOI 10.1161/01.CIR.99.3.334; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Zhang ZH, 1997, CIRC RES, V80, P720, DOI 10.1161/01.RES.80.5.720	45	144	152	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29644	29650		10.1074/jbc.M101044200	http://dx.doi.org/10.1074/jbc.M101044200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11387319	hybrid			2022-12-27	WOS:000170558000008
J	Stewart, GS; Last, JIK; Stankovic, T; Haites, N; Kidd, AMJ; Byrd, PJ; Taylor, AMR				Stewart, GS; Last, JIK; Stankovic, T; Haites, N; Kidd, AMJ; Byrd, PJ; Taylor, AMR			Residual ataxia telangiectasia mutated protein function in cells from ataxia telangiectasia patients, with 5762ins137 and 7271T -> G mutations, showing a less severe phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN BREAKAGE SYNDROME; DNA-DAMAGE RESPONSE; ATM-DEPENDENT PHOSPHORYLATION; CYCLE CHECKPOINT PATHWAY; CENTRAL-NERVOUS-SYSTEM; ABL TYROSINE KINASE; IONIZING-RADIATION; C-ABL; INDUCED APOPTOSIS; P53	We have assessed several ataxia Telangiectasia mutated (ATM)-dependent functions in cells derived from ataxia telangiectasia patients, carrying either an ATM 5762ins137 splice site or a 7271T -->G missense mutation, with a less severe phenotype compared with the classical disorder. ATM kinase in vitro, from 5762ins137 cells, showed the same specific activity as ATM in normal cells, but the protein was present at low levels. In contrast, mutant ATM kinase activity in the 7271T -->G cells was only about 6% that of the activity in normal cells, although the level of mutant protein expressed was similar to normal cells. Phosphorylation of the DNA double strand break repair proteins Nbs1 and hMre11, following DNA damage, was observed in normal and 7271T -->G cells but was almost absent in both 5762ins137 and classical ataxia telangiectasia cells. The kinetics of p53 response was intermediate between normal and classical ataxia telangiectasia cells in both the 7271T -->G and 5762ins137 cells, but interestingly, c-Jun kinase activation following DNA damage was equally deficient in cell lines derived from all the ataxia telangiectasia patients. Our results indicate that levels of ATM kinase activity, but not induction of p53 or e-Jun kinase activity, in these cells correlate with the degree of neurological disorder in the patients.	Univ Birmingham, Inst Canc Studies, CRC, Birmingham B15 2TT, W Midlands, England; Grampian Univ Hosp, Dept Med Genet, Aberdeen AB25 2ZD, Scotland	University of Birmingham; University of Aberdeen	Taylor, AMR (corresponding author), Univ Birmingham, Inst Canc Studies, CRC, Vincent Dr, Birmingham B15 2TT, W Midlands, England.			Stewart, Grant/0000-0002-0960-3241; Stankovic, Tatjana/0000-0002-3780-274X				ARTUSO M, 1995, ONCOGENE, V11, P1427; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Becker-Catania SG, 2000, MOL GENET METAB, V70, P122, DOI 10.1006/mgme.2000.2998; Borghesani PR, 2000, P NATL ACAD SCI USA, V97, P3336, DOI 10.1073/pnas.050584897; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Gilad S, 1998, AM J HUM GENET, V62, P551, DOI 10.1086/301755; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee Y, 2000, GENE DEV, V14, P2576, DOI 10.1101/gad.837100; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; McConville CM, 1996, AM J HUM GENET, V59, P320; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Vanasse GJ, 1999, BLOOD, V94, P3997, DOI 10.1182/blood.V94.12.3997.424k44_3997_4010; Wang Y, 2000, GENE DEV, V14, P927; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	51	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30133	30141		10.1074/jbc.M103160200	http://dx.doi.org/10.1074/jbc.M103160200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11382771	hybrid			2022-12-27	WOS:000170558000072
J	Allen-Jennings, AE; Hartman, MG; Kociba, GJ; Hai, T				Allen-Jennings, AE; Hartman, MG; Kociba, GJ; Hai, T			The roles of ATF3 in glucose homeostasis - A transgenic mouse model with liver dysfunction and defects in endocrine pancreas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER CELLS; TRANSCRIPTION FACTOR; FREE-RADICALS; N-ACETYLCYSTEINE; OXIDATIVE STRESS; CHOROID-PLEXUS; INSULIN GENE; NEWBORN MICE; BETA-CELLS; S-PHASE	Activating transcription factor 3 (ATF3) is a member of the ATF/cAMP-response element-binding protein family of transcription factors. It is a transcriptional repressor, and the expression of its corresponding gene is induced by stress signals in a variety of tissues, including the liver. In this report, we demonstrate that ATF3 is induced in the pancreas by partial pancreatectomy, streptozotocin treatment, and ischemia coupled with reperfusion. Furthermore, ATF3 is induced in cultured islet cells by oxidative stress. Interestingly, transgenic mice expressing ATF3 in the liver and pancreas under the control of the transthyretin promoter have defects in glucose homeostasis and perinatal lethality. We present evidence that expression of ATF3 in the liver represses the expression of genes encoding gluconeogenic enzymes. Furthermore, expression of ATF3 in the pancreas leads to abnormal endocrine pancreas and reduced numbers of hormone-producing cells. Analyses of embryos indicated that the ATF3 transgene is expressed in the ductal epithelium in the developing pancreas, and the transgenic pancreas has fewer mitotic cells than the non-transgenic counterpart, providing a potential explanation for the reduction of endocrine cells. Because ATF3 is a stress-inducible gene, these mice may represent a model to investigate the molecular mechanisms for some stress-associated diseases.	Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Mol Cellular & Dev Biol Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Hai, T (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, Rm 148,Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.	hai.2@osu.edu	Hai, Tsonwin/H-4480-2011; Hai, Tsonwin/E-3185-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008690] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK064938] Funding Source: Medline; NIEHS NIH HHS [ES08690] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON T, 1974, J CLIN INVEST, V54, P672, DOI 10.1172/JCI107805; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1999, NATURE, V402, pB31, DOI 10.1038/35037026; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Bonner-Weir S, 2000, J MOL ENDOCRINOL, V24, P297, DOI 10.1677/jme.0.0240297; Bouwens L, 1997, DIABETOLOGIA, V40, P398, DOI 10.1007/s001250050693; BOUWENS L, 1994, DIABETES, V43, P1279, DOI 10.2337/diabetes.43.11.1279; Bouwens L, 1996, VIRCHOWS ARCH, V427, P553; BRAGANZA JM, 1989, FREE RADICALS CHEM P, P357; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; BROCKENBROUGH JS, 1988, DIABETES, V37, P232, DOI 10.2337/diabetes.37.2.232; BURGUNDER JM, 1989, EUR J CLIN PHARMACOL, V36, P127, DOI 10.1007/BF00609183; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Drysdale BE, 1996, MOL IMMUNOL, V33, P989, DOI 10.1016/S0161-5890(96)00043-0; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; ELMAGHRABI MR, 1991, J BIOL CHEM, V266, P2115; ERIKSSON U, 1982, BIOL NEONATE, V42, P239; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; FREEMAN BA, 1982, LAB INVEST, V47, P412; GIRARD J, 1992, PHYSIOL REV, V72, P507, DOI 10.1152/physrev.1992.72.2.507; GRANNER D, 1991, RECENT PROG HORM RES, V47, P319; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; GUZ Y, 1995, DEVELOPMENT, V121, P11; Habener JF, 1998, P ASSOC AM PHYSICIAN, V110, P12; Hai T, 1999, GENE EXPRESSION, V7, P321; HAI T, 2001, IN PRESS GENE; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; Ishiguro T, 1996, CANCER RES, V56, P875; JACOBSSON B, 1989, J HISTOCHEM CYTOCHEM, V37, P31, DOI 10.1177/37.1.2642294; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Kakkar R, 1998, CLIN SCI, V94, P623, DOI 10.1042/cs0940623; Kaufman M.H., 1992, ATLAS MOUSE DEV; KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAKE RS, 1972, BIOCHEMISTRY-US, V11, P4817, DOI 10.1021/bi00775a027; Leahy Jack L., 1996, P103; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; Nizielski SE, 1996, J NUTR, V126, P2697; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Oster A, 1998, J HISTOCHEM CYTOCHEM, V46, P707, DOI 10.1177/002215549804600602; PARKS DA, 1983, SURGERY, V94, P428; PICTET R, 1972, HDB PHYSL ENDOCRINOL, V7, P25; PICTET RL, 1972, DEV BIOL, V29, P436, DOI 10.1016/0012-1606(72)90083-8; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; SANFEY H, 1984, ANN SURG, V200, P405, DOI 10.1097/00000658-198410000-00003; SASSONECORSI P, 1994, EMBO J, V13, P4717, DOI 10.1002/j.1460-2075.1994.tb06797.x; SCHMID E, 1987, EUR J BIOCHEM, V165, P499, DOI 10.1111/j.1432-1033.1987.tb11467.x; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SWENNE I, 1982, DIABETOLOGIA, V23, P525; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Weir GC, 1997, ACTA DIABETOL, V34, P177, DOI 10.1007/s005920050071; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Xu B, 1999, FREE RADICAL BIO MED, V27, P830, DOI 10.1016/S0891-5849(99)00130-6; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; Ye HG, 1999, MOL CELL BIOL, V19, P8570; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	61	95	98	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29507	29514		10.1074/jbc.M100986200	http://dx.doi.org/10.1074/jbc.M100986200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11371557	hybrid			2022-12-27	WOS:000170346000114
J	Bagheri-Yarmand, R; Mandal, M; Taludker, AH; Wang, RA; Vadlamudi, RK; Kung, HJ; Kumar, R				Bagheri-Yarmand, R; Mandal, M; Taludker, AH; Wang, RA; Vadlamudi, RK; Kung, HJ; Kumar, R			Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P21-ACTIVATED KINASE; SIGNAL-TRANSDUCTION; FAMILY; DOMAIN; TRANSFORMATION; ORGANIZATION; EXPRESSION; INHIBITION; HOMOLOGY; CDC42	Etk/Bmx, a member of the Tee family of nonreceptor protein-tyrosine kinases, is characterized by an N-terminal pleckstrin homology domain and has been shown to be a downstream effector of phosphatidylinositol 3-kinase. P21-activated kinase 1 (Pak1), another well characterized effector of phosphatidylinositol. 3-kinase, has been implicated in the progression of breast cancer cells. In this study, we characterized the role of Etk in mammary development and tumorigenesis and explored the functional interactions between Etk and Pak1. We report that Etk expression is developmentally regulated in the mammary gland. Using transient transfection, coimmunoprecipitation and glutathione S-transferase-pull down assays, we showed that Etk directly associates with Pak1 via its N-terminal pleckstrin homology domain and also phosphorylates Pak1 on tyrosine residues. The expression of wild-type Etk in a non-invasive human breast cancer MCF-7 cells significantly increased proliferation and anchorage-independent growth of epithelial cancer cells. Conversely, expression of kinase-inactive mutant Etk-KQ suppressed the proliferation, anchorage-independent growth, and tumorigenicity of human breast cancer MDA-MB435 cells. These results indicate that Pak1 is a target of Etk and that Etk controls the proliferation as well as the anchorage-independent and tumorigenic growth of mammary epithelial cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Davis	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Kung, Hsing-Jien/C-7651-2013; Mandal, Mahitosh/GMW-6195-2022; Wang, Brian/HGA-9535-2022	Mandal, Mahitosh/0000-0003-3861-3323; Bagheri-Yarmand, Rozita/0000-0001-5139-6381	NCI NIH HHS [CA80066, CA65746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080066, U01CA065746, R01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Ekman N, 1997, CIRCULATION, V96, P1729, DOI 10.1161/01.CIR.96.6.1729; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hamazaki Y, 1998, ONCOGENE, V16, P2773, DOI 10.1038/sj.onc.1201799; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Mandal M, 2001, J BIOL CHEM, V276, P9699, DOI 10.1074/jbc.M008514200; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Nisitani S, 2000, P NATL ACAD SCI USA, V97, P2737, DOI 10.1073/pnas.050583597; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Satterthwaite AB, 2000, P NATL ACAD SCI USA, V97, P6687, DOI 10.1073/pnas.110146697; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	26	100	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29403	29409		10.1074/jbc.M103129200	http://dx.doi.org/10.1074/jbc.M103129200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382770	hybrid			2022-12-27	WOS:000170346000102
J	Fujiwara, K; Takeuchi, S; Okamura-Ikeda, K; Motokawa, Y				Fujiwara, K; Takeuchi, S; Okamura-Ikeda, K; Motokawa, Y			Purification, characterization, and cDNA cloning of lipoate-activating enzyme from bovine liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE CLEAVAGE SYSTEM; H-PROTEIN; ESCHERICHIA-COLI; ACID; DEHYDROGENASE; LIPOYLATION; LIPOYLTRANSFERASE; IDENTIFICATION; EXPRESSION; COMPLEXES	In mammals, lipoate-activating enzyme (LAE) catalyzes the activation of lipoate to lipoyl-nucleoside monophosphate. The lipoyl moiety is then transferred to the specific lysine residue of lipoate-dependent enzymes by the action of lipoyltransferase. We purified LAE from bovine liver mitochondria to apparent homogeneity. LAE activated lipoate with GTP at a 1000-fold higher rate than with ATP. The reaction absolutely required lipoate, GTP, and Mg2+ ion, and the reaction product was lipoyl-GMP. LAE activated both (R)- and (S)-lipoate to the respective lipoyl-GMP, although a preference for (R)-lipoate was observed. Similarly, lipoyltransferase equally transferred both the (R)- and (S)-lipoyl moieties from the respectively activated lipoates to apoH-protein. Interestingly, however, only H-protein carrying (R)-lipoate was active in the glycine cleavage reaction. cDNA clones encoding a precursor LAE with a mitochondrial presequence were isolated. The predicted amino acid sequence of LAE is identical with that of xenobiotic-metabolizing/medium-chain fatty acid:CoA ligase-Ill, but an amino acid substitution due to a single nucleotide polymorphism was found. These results indicate that the medium-chain acyl-CoA synthetase in mitochondria has a novel function, the activation of lipoate with GTP.	Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan	Tokushima University	Motokawa, Y (corresponding author), Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FUJIWARA K, 1992, J BIOL CHEM, V267, P20011; FUJIWARA K, 1994, J BIOL CHEM, V269, P16605; Fujiwara K, 1997, J BIOL CHEM, V272, P31974, DOI 10.1074/jbc.272.51.31974; Fujiwara K, 1996, J BIOL CHEM, V271, P12932, DOI 10.1074/jbc.271.22.12932; FUJIWARA K, 1986, J BIOL CHEM, V261, P8836; FUJIWARA K, 1990, J BIOL CHEM, V265, P17463; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORRIS TW, 1994, J BIOL CHEM, V269, P16091; Okamura-Ikeda K, 1999, EUR J BIOCHEM, V264, P446, DOI 10.1046/j.1432-1327.1999.00637.x; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1958, J BIOL CHEM, V232, P123; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH CM, 1974, J BIOL CHEM, V249, P1497; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; TSUNODA JN, 1967, ARCH BIOCHEM BIOPHYS, V118, P395, DOI 10.1016/0003-9861(67)90366-9; Vessey D A, 1995, J Biochem Toxicol, V10, P329, DOI 10.1002/jbt.2570100608; Vessey DA, 2000, J BIOCHEM MOL TOXIC, V14, P162, DOI 10.1002/(SICI)1099-0461(2000)14:3<162::AID-JBT6>3.3.CO;2-#; Vessey DA, 2000, J BIOCHEM MOL TOXIC, V14, P11, DOI 10.1002/(SICI)1099-0461(2000)14:1<11::AID-JBT2>3.3.CO;2-5	22	50	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28819	28823		10.1074/jbc.M101748200	http://dx.doi.org/10.1074/jbc.M101748200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382754	hybrid			2022-12-27	WOS:000170346000025
J	Wimmer, C; Hohl, TM; Hughes, CA; Muller, SA; Sollner, TH; Engel, A; Rothman, JE				Wimmer, C; Hohl, TM; Hughes, CA; Muller, SA; Sollner, TH; Engel, A; Rothman, JE			Molecular mass, stoichiometry, and assembly of 20 S particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; NSF-ATTACHMENT PROTEINS; TRANSMISSION ELECTRON-MICROSCOPY; INTEGRAL MEMBRANE-PROTEIN; OLIGOMERIC MATRIX PROTEIN; ALPHA-HELICAL BUNDLE; SNARE COMPLEX; CRYSTAL-STRUCTURE; VESICULAR TRANSPORT; IN-VITRO	N-Ethylmaleimide-sensitive factor (NSF), soluble NSF attachment proteins (SNAPs), and SNAP receptor (neuronal SNARE) complexes form 20 S particles with a mass of 788 +/- 122 kDa as judged by scanning transmission electron microscopy. A single NSF hexamer and three alpha SNAP monomers reside within a 20 S particle as determined by quantitative amino acid analysis. In order to study the binding of aSNAP and NSF in solution, to define their binding domains, and to specify the role of oligomerization in their interaction, we fused domains of aSNAP and NSF to oligomerization modules derived from thrombospondin-1, a trimer, and cartilage oligomeric matrix protein, a pentamer, respectively. Binding studies with these fusion proteins reproduced the interaction of aSNAP and NSF N domains in the absence of the hexamerization domain of NSF (D2). Trimeric aSNAP (or its C-terminal half) is sufficient to recruit NSF even in the absence of SNARE complexes. Furthermore, pentameric NSF N domains are able to bind aSNAP in complex with SNARES, whereas monomeric N domains do not. Our results demonstrate that the oligomerization of both NSF N domains and aSNAP provides a critical driving force for their interaction and the assembly of 20 S particles.	Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Univ Basel, Bioctr, Maurice E Muller Inst High Resolut Electron M, CH-4056 Basel, Switzerland	Memorial Sloan Kettering Cancer Center; University of Basel	Wimmer, C (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.	wimmer@bii.ch		Hohl, Tobias/0000-0002-9097-5412				Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; EFIMOV VP, 1994, FEBS LETT, V341, P54, DOI 10.1016/0014-5793(94)80239-4; Efimov VP, 1996, PROTEINS, V24, P259, DOI 10.1002/(SICI)1097-0134(199602)24:2<259::AID-PROT13>3.0.CO;2-M; ENGEL A, 1978, ULTRAMICROSCOPY, V3, P273, DOI 10.1016/S0304-3991(78)80037-0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fleming KG, 1998, J BIOL CHEM, V273, P15675, DOI 10.1074/jbc.273.25.15675; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Harlow E., 1988, ANTIBODIES LAB MANUA; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; Haynes LP, 1998, FEBS LETT, V436, P1, DOI 10.1016/S0014-5793(98)01088-6; HODGES RS, 1973, COLD SPRING HARB SYM, V37, P299, DOI 10.1101/SQB.1973.037.01.040; Hohl TM, 1998, MOL CELL, V2, P539, DOI 10.1016/S1097-2765(00)80153-7; Katz L, 1998, EMBO J, V17, P6200, DOI 10.1093/emboj/17.21.6200; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; May AP, 1999, NAT CELL BIOL, V1, P175, DOI 10.1038/11097; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Muller JMM, 1999, J BIOL CHEM, V274, P10154, DOI 10.1074/jbc.274.15.10154; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; Rossi G, 1997, J BIOL CHEM, V272, P16610, DOI 10.1074/jbc.272.26.16610; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOTTILE J, 1991, BIOCHEMISTRY-US, V30, P6556, DOI 10.1021/bi00240a028; Stenbeck G, 1998, INT J BIOCHEM CELL B, V30, P573, DOI 10.1016/S1357-2725(97)00064-2; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; Terskikh AV, 1997, P NATL ACAD SCI USA, V94, P1663, DOI 10.1073/pnas.94.5.1663; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; Yu RC, 1999, MOL CELL, V4, P97, DOI 10.1016/S1097-2765(00)80191-4; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843	63	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29091	29097		10.1074/jbc.M011292200	http://dx.doi.org/10.1074/jbc.M011292200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11395481	hybrid			2022-12-27	WOS:000170346000062
J	Coniglio, SJ; Jou, TS; Symons, M				Coniglio, SJ; Jou, TS; Symons, M			Rac1 protects epithelial cells against anoikis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RHO-FAMILY PROTEINS; ANCHORAGE-INDEPENDENT GROWTH; RAS TRANSFORMATION; INDUCED APOPTOSIS; SMALL GTPASES; PHOSPHATIDYLINOSITOL 3-KINASE; ALPHA PROTEOLYSIS; KINASE ACTIVATION; DEPENDENT PATHWAY	Rho family members play a critical role in malignant transformation. Anchorage-independent growth and the ability to avoid apoptosis caused by loss of anchorage (anoikis) are important features of transformed cells. Here we show that constitutive activation of Rac1 inhibits anoikis in Madin-Darby canine kidney (MDCK) epithelial cells. Constitutively active Rac1-V12 decreases DNA fragmentation and caspase activity by 50% in MDCK cells kept in suspension. In addition, expression of Rac1-V12 in MDCK cells in suspension conditions causes an increase in the number of surviving cells. We also investigated the signaling pathways that are activated by Rac1 to stimulate cell survival. We show that expression of Rac1-V12 in MDCK cells in suspension stimulates a number of signaling cascades that have been implicated in the control of cell survival, including the p42/44 ERK, p38, protein kinase B, and nuclear factor kappaB pathways. Using specific chemical or protein inhibitors of these respective pathways, we show that Rac1-mediated cell survival strongly depends on phosphatidylinositol 3-kinase activity and that activation of ERK, p38, and NF-kappaB are largely dispensable for Rac1 survival signaling. In conclusion, these studies demonstrate that Rac1 can suppress apoptosis in epithelial cells in anchorage-independent conditions and suggest a potential role for Rac1-mediated survival signaling in cell transformation.	Picower Inst Med Res, Manhasset, NY 11030 USA; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 100, Taiwan	Northwell Health; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Symons, M (corresponding author), Picower Inst Med Res, 350 Community Dr, Manhasset, NY 11030 USA.	msymons@picower.edu		JOU, TZUU-SHUH/0000-0003-4341-5137				Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Boehm JE, 1999, J BIOL CHEM, V274, P28632, DOI 10.1074/jbc.274.40.28632; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; D'Souza-Schorey C, 1998, MOL CELL BIOL, V18, P3936, DOI 10.1128/MCB.18.7.3936; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Genot EM, 2000, MOL CELL BIOL, V20, P5469, DOI 10.1128/MCB.20.15.5469-5478.2000; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kawazoe N, 1999, ONCOGENE, V18, P2413, DOI 10.1038/sj.onc.1202555; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Lassus P, 2000, ONCOGENE, V19, P2377, DOI 10.1038/sj.onc.1203553; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Leng J, 1999, J BIOL CHEM, V274, P37855, DOI 10.1074/jbc.274.53.37855; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Ruggieri R, 2001, MOL MED, V7, P293, DOI 10.1007/BF03402212; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VAN AL, 1997, GENE DEV, V11, P2295; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	61	63	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28113	28120		10.1074/jbc.M102299200	http://dx.doi.org/10.1074/jbc.M102299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369774	hybrid			2022-12-27	WOS:000170093400050
J	DeLuca, JG; Newton, CN; Himes, RH; Jordan, MA; Wilson, L				DeLuca, JG; Newton, CN; Himes, RH; Jordan, MA; Wilson, L			Purification and characterization of native conventional kinesin, HSET, and CENP-E from mitotic HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE MOTOR PROTEIN; URCHIN EGG KINESIN; CHROMOSOME ALIGNMENT; KINETOCHORE MOTOR; END; MOTILITY; DROSOPHILA; MOVEMENT; SPINDLE; MITOSIS	We have developed a strategy for the purification of native microtubule motor proteins from mitotic HeLa cells and describe here the purification and characterization of human conventional kinesin and two human kinesin-related proteins, HSET and CENP-E. We found that the 120-kDa HeLa cell conventional kinesin is an active motor that induces microtubule gliding at similar to 30 mum/min at room temperature. This active form of HeLa cell kinesin does not contain light chains, although light chains were detected in other fractions. HSET, a member of the C-terminal kinesin subfamily, was also purified in native form for the first time, and the protein migrates as a single band at similar to 75 kDa. The purified HSET is an active motor that induces microtubule gliding at a rate of similar to5 mum/min, and microtubules glide for an average of 3 mum before ceasing movement. Finally, we Purified native CENP-E, a kinesin-related protein that has been implicated in chromosome congression during mitosis, and we found that this form of CENP-E does not induce microtubule gliding but is able to bind to microtubules.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Mat Res Lab, Santa Barbara, CA 93106 USA; Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of Kansas	Wilson, L (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	wilson@lifesci.ucsb.edu			NATIONAL CANCER INSTITUTE [R01CA057291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013560] Funding Source: NIH RePORTER; NCI NIH HHS [CA57291] Funding Source: Medline; NINDS NIH HHS [NS13560] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO A, 1994, IMMUNOGENETICS, V39, P194; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; COHN SA, 1989, J BIOL CHEM, V264, P4290; COLE DG, 1993, NATURE, V366, P268, DOI 10.1038/366268a0; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Endow SA, 1999, EUR J BIOCHEM, V262, P12, DOI 10.1046/j.1432-1327.1999.00339.x; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; GYOEVA FK, 1991, NATURE, V353, P445, DOI 10.1038/353445a0; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HALL DH, 1991, J CELL BIOL, V115, P389; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOWARD J, 1993, METHOD CELL BIOL, V39, P105, DOI 10.1016/S0091-679X(08)60164-8; HUNT AJ, 1993, P NATL ACAD SCI USA, V90, P11653, DOI 10.1073/pnas.90.24.11653; HYMAN AA, 1991, J CELL SCI, P125; JORDAN MA, 1991, CANCER RES, V51, P2212; JORDAN MA, 1992, J CELL SCI, V102, P401; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; KURIYAMA R, 1995, J CELL BIOL, V129, P1049, DOI 10.1083/jcb.129.4.1049; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; LIPPINCOTTSCHWARTZ J, 1995, BIOCHEM SOC T, V23, P544, DOI 10.1042/bst0230544; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; MUROFUSHI H, 1988, J BIOL CHEM, V263, P12744; PORTER ME, 1987, J BIOL CHEM, V262, P2794; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; Schaar BT, 1997, J CELL BIOL, V139, P1373, DOI 10.1083/jcb.139.6.1373; SHIMIZU T, 1991, J CELL BIOL, V112, P1189, DOI 10.1083/jcb.112.6.1189; Song H, 1997, BIOTECHNIQUES, V22, P82, DOI 10.2144/97221bm18; Steinberg G, 1996, J BIOL CHEM, V271, P7516, DOI 10.1074/jbc.271.13.7516; THROWER DA, 1995, EMBO J, V14, P918, DOI 10.1002/j.1460-2075.1995.tb07073.x; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1989, CELL MOVEMENT KINESI, P287; Walczak CE, 1997, J CELL BIOL, V136, P859, DOI 10.1083/jcb.136.4.859; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; WRIGHT BD, 1993, J CELL BIOL, V123, P681, DOI 10.1083/jcb.123.3.681; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	48	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28014	28021		10.1074/jbc.M102801200	http://dx.doi.org/10.1074/jbc.M102801200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382767	hybrid			2022-12-27	WOS:000170093400037
J	Kedei, N; Szabo, T; Lile, JD; Treanor, JJ; Olah, Z; Iadarola, MJ; Blumberg, PM				Kedei, N; Szabo, T; Lile, JD; Treanor, JJ; Olah, Z; Iadarola, MJ; Blumberg, PM			Analysis of the native quaternary structure of vanilloid receptor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; CAPSAICIN-RECEPTOR; OLIGOMERIC STRUCTURE; CHANNELS; PROTEINS; CALCIUM; BINDING; TARGET; HEAT; TRP	Vanilloid receptor subtype I (VRI) is a ligand-gated channel that can be activated by capsaicin and other vanilloids as well as by protons and heat. In the present study, we have analyzed the oligomeric state of VR1. Co-immunoprecipitation of differently tagged VRI molecules indicated that VRI can form oligomers. Using two different heterologous VR1 expression systems as well as endogenous VRI expressed in dorsal root ganglion cells, we analyzed oligomer formation using perfluorooctanoic acid polyacrylamide gel electrophoresis. Results were confirmed both with chemical cross-linking agents as well as through endogenous cross-linking mediated by transglutaminase. Our results clearly show that VRI forms multimers in each of the expression systems with a homotetramer as a predominant form. The oligomeric structure of VR1 may contribute to the complexity of VRI pharmacology. Finally, differences in glycosylation between the systems were observed, indicating the need for caution in the use of the heterologous expression systems for analysis of VRI properties.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; NIDCR, Neuronal Gene Express Unit, Pain & Neurosensory Mech Branch, NIH, Bethesda, MD 20892 USA; Amgen Corp, Thousand Oaks, CA 91320 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Amgen	Blumberg, PM (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bldg 37,Rm 3A01,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000688] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Acs G, 1997, J NEUROSCI, V17, P5622; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; BEVAN S, 1990, TRENDS PHARMACOL SCI, V11, P330; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Debyser Z, 1996, PROTEIN SCI, V5, P278; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; FESUS L, 1993, FEBS LETT, V328, P1, DOI 10.1016/0014-5793(93)80952-Q; Fesus L, 1988, Adv Exp Med Biol, V231, P119; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Guo A, 1999, EUR J NEUROSCI, V11, P946, DOI 10.1046/j.1460-9568.1999.00503.x; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Jerman JC, 2000, BRIT J PHARMACOL, V130, P916, DOI 10.1038/sj.bjp.0703390; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Lagree V, 1998, J BIOL CHEM, V273, P33949, DOI 10.1074/jbc.273.51.33949; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Oh U, 1996, J NEUROSCI, V16, P1659; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; OXFORD GS, 2000, 2000 SOC NEUR ANN M, P1689; PATEL SS, 1993, J BIOL CHEM, V268, P10668; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Ramjeesingh M, 1999, BIOCHEM J, V342, P119, DOI 10.1042/0264-6021:3420119; Rice R H, 1992, Epithelial Cell Biol, V1, P128; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; Szallasi A, 1999, MOL PHARMACOL, V56, P581, DOI 10.1124/mol.56.3.581; SZALLASI A, 1990, BRAIN RES, V524, P106, DOI 10.1016/0006-8993(90)90498-Z; Szallasi A, 1996, PAIN, V68, P195, DOI 10.1016/S0304-3959(96)03202-2; SZALLASI A, 1991, LIFE SCI, V48, P1863, DOI 10.1016/0024-3205(91)90242-4; SZALLASI A, 1993, LIFE SCI, V52, P221; SZOLCSANYI J, 1988, BRAIN RES, V446, P262, DOI 10.1016/0006-8993(88)90885-2; SZOLCSANYI J, 1975, ARZNEIMITTEL-FORSCH, V25, P1877; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Vince JW, 1997, BBA-BIOMEMBRANES, V1326, P295, DOI 10.1016/S0005-2736(97)00033-3; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Zhu X, 1998, NEWS PHYSIOL SCI, V13, P211	44	252	267	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28613	28619		10.1074/jbc.M103272200	http://dx.doi.org/10.1074/jbc.M103272200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11358970	hybrid			2022-12-27	WOS:000170093400115
J	Toonkool, P; Regan, DG; Kuchel, PW; Morris, MB; Weiss, AS				Toonkool, P; Regan, DG; Kuchel, PW; Morris, MB; Weiss, AS			Thermodynamic and hydrodynamic properties of human tropoelastin - Analytical ultracentrifuge and pulsed field-gradient spin-echo NMR studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-ASSOCIATION; COACERVATION; SEDIMENTATION; DIFFUSION; WATER; PROTEINS; SYSTEM	Tropoelastin is the soluble precursor of elastin that bestows tissue elasticity in vertebrates. Tropoelastin is soluble at 20 degreesC in phosphate-buffered saline, pH 7.4, but at 37 degreesC equilibrium is established between soluble protein and insoluble coacervate. Sedimentation equilibrium studies performed before (20 degreesC) and after (37 degreesC) coacervation showed that the soluble component was strictly monomeric. Sedimentation velocity experiments revealed that at both temperatures soluble tropoelastin exists as two independently sedimenting monomeric species present in approximately equal concentrations. Species I had a frictional ratio at both temperatures of similar to2.2, suggesting a very highly expanded or asymmetric protein. Species 2 displayed a frictional ratio at 20 degreesC of 1.4 that increased to 1.7 at 37 degreesC, indicating a compact and symmetrical conformation. that expanded or became asymmetric at the higher temperature. The slow interconversion of the two monomeric species contrasts with the rapid and reversible process of coacervation suggesting both efficiently incorporate into the coacervate. A hydrated protein of equivalent molecular weight modeled as a sphere and a flexible chain was predicted to have a frictional ratio of 1.2 and 1.6, respectively. Tropoelastin appeared as a single species when studied by pulsed field-gradient spin-echo NMR, but computer modeling showed that the method was insensitive to the presence of two species of equal concentration having similar diffusion coefficients. Scintillation proximity assays using radiolabeled tropoelastin and sedimentation analysis showed that the coacervation. at 37 degreesC was a highly cooperative monomer-n-mer self-association. A critical concentration of 3.4 g/liter was obtained when the coacervate was modeled as a helical polymer formed from the monomers via oligomeric intermediates.	Univ Sydney, Dept Biochem G08, Sydney, NSW 2006, Australia; Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Weiss, AS (corresponding author), Univ Sydney, Dept Biochem G08, Sydney, NSW 2006, Australia.	a.weiss@biochem.usyd.edu.au	Weiss, Anthony S/GYV-0157-2022; Weiss, Anthony S/F-8103-2010; Morris, Michael/AAP-6590-2021	Weiss, Anthony S/0000-0002-8106-4836; Kongsaeree, Prachumporn/0000-0003-0273-2638; Morris, Michael/0000-0002-1286-4784; Kuchel, Philip/0000-0003-4100-7332				ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; ATTRI AK, 1991, J BIOL CHEM, V266, P6815; BRESSAN GM, 1986, J ULTRA MOL STRUCT R, V94, P209, DOI 10.1016/0889-1605(86)90068-6; BRESSAN GM, 1983, J ULTRA MOL STRUCT R, V82, P335, DOI 10.1016/S0022-5320(83)80021-5; CALLAGHAN PT, 1983, MACROMOLECULES, V16, P968, DOI 10.1021/ma00240a028; CLAVERIE JM, 1975, BIOPOLYMERS, V14, P1685, DOI 10.1002/bip.1975.360140811; COOKE R, 1974, ANNU REV BIOPHYS BIO, V3, P95, DOI 10.1146/annurev.bb.03.060174.000523; COX BA, 1974, J BIOL CHEM, V249, P997; COX BA, 1973, BIOCHIM BIOPHYS ACTA, V317, P209, DOI 10.1016/0005-2795(73)90215-8; CREETH JM, 1965, BIOCHIM BIOPHYS ACTA, V102, P549, DOI 10.1016/0926-6585(65)90145-7; Harris, 1984, DIFFUSION LIQUIDS TH; JOHNSON ML, 1978, BIOCHEMISTRY-US, V17, P1448, DOI 10.1021/bi00601a014; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kaibara K, 2000, BIOPOLYMERS, V53, P369, DOI 10.1002/(SICI)1097-0282(20000415)53:5<369::AID-BIP2>3.3.CO;2-X; KIRKWOOD JG, 1967, MACROMOLECULES, P67; KUMOSINSKI TF, 1985, METHOD ENZYMOL, V117, P154; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Mecham R.P., 1991, CELL BIOL EXTRACELLU, V2nd, P79; MILLS R, 1973, J PHYS CHEM-US, V77, P685, DOI 10.1021/j100624a025; MILTHORPE BK, 1975, BIOPHYS CHEM, V3, P169, DOI 10.1016/0301-4622(75)80007-X; MORRIS M, 1989, BIOCHEMISTRY-US, V28, P8561, DOI 10.1021/bi00447a044; Morris M B, 1994, Subcell Biochem, V23, P25; NARAYANAN AS, 1978, BIOCHEM J, V173, P857, DOI 10.1042/bj1730857; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; OOSAWA F, 1975, THERMODYNAMICS POLYM, P25; Parkinson EJ, 2000, BIOCHEMISTRY-US, V39, P12345, DOI 10.1021/bi0005658; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; Prosser IW, 1988, SELF ASSEMBLING ARCH, P1; RALSTON GB, 1976, BIOCHIM BIOPHYS ACTA, V455, P163, DOI 10.1016/0005-2736(76)90161-9; RALSTON GB, 1990, J CHEM EDUC, V67, P857, DOI 10.1021/ed067p857; RALSTON GB, 1992, ANAL ULTRACENTRIFUGA, P253; RISEMAN J, 1967, MACROMOLECULES, P96; Schein J, 1977, Adv Exp Med Biol, V79, P727; Sorland GH, 2000, J MAGN RESON, V142, P323, DOI 10.1006/jmre.1999.1941; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; STARCHER BC, 1973, BIOCHIM BIOPHYS ACTA, V310, P481, DOI 10.1016/0005-2795(73)90132-3; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Tanford C, 1961, PHYSICAL CHEM MACROM, P526; Teller D C, 1973, Methods Enzymol, V27, P346; Torres AM, 1999, J MAGN RESON, V138, P135, DOI 10.1006/jmre.1998.1701; URRY D W, 1976, Critical Reviews in Biochemistry, V4, P1, DOI 10.3109/10409237609102557; URRY DW, 1978, PERSPECT BIOL MED, V21, P265; URRY DW, 1969, NATURE, V222, P795, DOI 10.1038/222795a0; URRY DW, 1988, J PROTEIN CHEM, V7, P1, DOI 10.1007/BF01025411; VANHOLDE KE, 1971, PHYSICAL BIOCH, P79; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x; Vrhovski B, 1997, EUR J BIOCHEM, V250, P92, DOI 10.1111/j.1432-1033.1997.00092.x; Wu WJ, 1999, J BIOL CHEM, V274, P21719, DOI 10.1074/jbc.274.31.21719; [No title captured]	50	39	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28042	28050		10.1074/jbc.M103391200	http://dx.doi.org/10.1074/jbc.M103391200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11371569	hybrid			2022-12-27	WOS:000170093400041
J	Burghaus, PA; Lingelbach, K				Burghaus, PA; Lingelbach, K			Luciferase, when fused to an N-terminal signal peptide, is secreted from transfected Plasmodium falciparum and transported to the cytosol of infected erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; RED-BLOOD-CELLS; MALARIA PARASITES; EXPRESSION; TRAFFICKING; GENE; TRANSFORMATION; PYRIMETHAMINE; COMPARTMENT; LEISHMANIA	Plasmodium falciparum, a unicellular parasite that causes human malaria, infects erythrocytes where it develops within a vacuole. The vacuolar membrane separates the parasite from the erythrocyte cytosol, Some secreted parasite proteins remain inside the vacuole, and-others are transported across the vacuolar membrane. To identify the protein sequences responsible for this distribution we investigated the suitability of the green fluorescent protein and luciferase as reporters in transiently transfected parasites. Because of the higher sensitivity of the enzymatic assay, luciferase was quantified 3 days after transfection, whereas reliable detection of green fluorescent protein required prolonged drug selection. Luciferase was confined to the parasite cytosol in subcellular fractions of infected erythrocytes. When parasites were transfected with a hybrid gene coding for the cleavable N-terminal signal peptide of a secreted parasite protein fused to luciferase, the reporter protein was secreted. It was recovered with the vacuolar content and the erythrocyte cytosol. The results suggest that no specific protein sequences are required for translocation across the vacuolar membrane. The high local concentration of luciferase within the vacuole argues against free diffusion, and thus transport into the erythrocyte cytosol must involve a rate-limiting step.	Univ Marburg, FB Biol Zool, Abt Parasitol, D-35032 Marburg, Germany	Philipps University Marburg	Burghaus, PA (corresponding author), Univ Marburg, FB Biol Zool, Abt Parasitol, D-35032 Marburg, Germany.							ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; Ansorge I, 1996, BIOCHEM J, V315, P307, DOI 10.1042/bj3150307; BAUMEISTER S, 1999, NOVART FDN SYMP, V226, P154; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chang HC, 1997, J BIOL CHEM, V272, P30552, DOI 10.1074/jbc.272.48.30552; Colin M, 2000, GENE THER, V7, P1333, DOI 10.1038/sj.gt.3301248; Cooke BM, 2000, PARASITOL TODAY, V16, P416, DOI 10.1016/S0169-4758(00)01753-1; Crabb BS, 1997, MOL BIOCHEM PARASIT, V90, P131, DOI 10.1016/S0166-6851(97)00143-6; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Foley M, 1998, INT J PARASITOL, V28, P1671, DOI 10.1016/S0020-7519(98)00132-5; GUENTHER K, 1991, Molecular and Biochemical Parasitology, V46, P149; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Harlow E., 1988, ANTIBODIES LAB MANUA; KARA U, 1990, MOL BIOCHEM PARASIT, V38, P19, DOI 10.1016/0166-6851(90)90200-6; Kissinger JC, 2001, NUCLEIC ACIDS RES, V29, P66; Lingelbach K, 1998, J CELL SCI, V111, P1467; Lingelbach K, 1997, ANN TROP MED PARASIT, V91, P543, DOI 10.1080/00034989760914; Oduola AMJ, 1997, EXP PARASITOL, V87, P283, DOI 10.1006/expr.1997.4251; PASVOL G, 1978, ANN TROP MED PARASIT, V72, P87, DOI 10.1080/00034983.1978.11719283; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; Saliba KJ, 1999, J BIOL CHEM, V274, P33213, DOI 10.1074/jbc.274.47.33213; Schluter A, 2000, BBA-GENE STRUCT EXPR, V1491, P65, DOI 10.1016/S0167-4781(00)00028-2; SCHRAVENDIJK MR, 1987, J EXP MED, V166, P376; SIMMONS D, 1987, EMBO J, V6, P485, DOI 10.1002/j.1460-2075.1987.tb04779.x; Striepen B, 1998, MOL BIOCHEM PARASIT, V92, P325, DOI 10.1016/S0166-6851(98)00011-5; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Trelka DP, 2000, MOL BIOCHEM PARASIT, V106, P131, DOI 10.1016/S0166-6851(99)00207-8; VanWye JD, 1997, MOL BIOCHEM PARASIT, V87, P225, DOI 10.1016/S0166-6851(97)00059-5; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waters AP, 1997, METHODS, V13, P134, DOI 10.1006/meth.1997.0506; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130	36	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26838	26845		10.1074/jbc.M100111200	http://dx.doi.org/10.1074/jbc.M100111200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375978	hybrid			2022-12-27	WOS:000169966900016
J	Ettenberg, SA; Magnifico, A; Cuello, M; Nau, MM; Rubinstein, YR; Yarden, Y; Weissman, AM; Lipkowitz, S				Ettenberg, SA; Magnifico, A; Cuello, M; Nau, MM; Rubinstein, YR; Yarden, Y; Weissman, AM; Lipkowitz, S			Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASES; PROTOONCOGENE C-CBL; RING FINGER; TYROSINE KINASE; NEGATIVE REGULATOR; HORMONE RECEPTOR; CSF-1 RECEPTOR; EGF RECEPTOR; FAMILY; PHOSPHORYLATION	Cbl proteins function as ubiquitin protein ligases for the activated epidermal growth factor receptor and, thus, negatively regulate its activity. Here we show that Cbl-b is ubiquitinated and degraded upon activation of the receptor. Epidermal growth factor (EGF)-induced Cbl-b degradation requires intact RING finger and tyrosine kinase binding domains and requires binding of the Cbl-b protein to the activated EGF receptor (EGFR), Degradation of both the EGFR and the Cbl-b protein is blocked by lysosomal and proteasomal inhibitors, Other components of the EGFR-signaling complex (i.e. Grb2 and Shc) are also degraded in an EGF-induced Cbl-b-dependent fashion. Our results suggest that the ubiquitin protein ligase function of Cbl-b is regulated by coordinated degradation of the Cbl-b protein along with its substrate. Furthermore, the data demonstrate that Cbl-b mediates degradation of multiple proteins in the EGFR-signaling complex.	NCI, Dept Genet, Med Branch, Natl Naval Med Ctr,NIH, Bethesda, MD 20889 USA; NCI, Lab Immune Cell Biol, Ctr Canc Res, NIH, Bethesda, MD 20889 USA; Uniformed Serv Univ Hlth Sci, Cell & Mol Biol Program, Bethesda, MD 20889 USA; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA; Weizmann Institute of Science	Lipkowitz, S (corresponding author), NCI, Dept Genet, Med Branch, Natl Naval Med Ctr,NIH, Bldg 8,Rm 5101, Bethesda, MD 20889 USA.	lipkowitz@nih.gov	YARDEN, YOSEF/K-1467-2012					Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; BLAKE TJ, 1991, ONCOGENE, V6, P653; Broome MA, 1999, ONCOGENE, V18, P2908, DOI 10.1038/sj.onc.1202873; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HOU D, 1994, J BIOL CHEM, V269, P14244; Hu G, 1999, MOL CELL BIOL, V19, P724; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JONGEWARD GD, 1995, GENETICS, V139, P1553; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Keane MM, 1999, CANCER RES, V59, P734; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Ollendorff V, 1998, INT J ONCOL, V13, P1159; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; SCHINDL L, 1994, LASER THER, V4, P25; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Thien CBF, 1998, IMMUNOL CELL BIOL, V76, P473, DOI 10.1046/j.1440-1711.1998.00768.x; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	60	121	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27677	27684		10.1074/jbc.M102641200	http://dx.doi.org/10.1074/jbc.M102641200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375397	hybrid			2022-12-27	WOS:000169966900124
J	He, JQ; Smith, ER; Xu, XX				He, JQ; Smith, ER; Xu, XX			Disabled-2 exerts its tumor suppressor activity by uncoupling c-Fos expression and MAP kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CARCINOMA-CELLS; DOWN-REGULATION; RAS ACTIVATION; GROWTH-FACTOR; PROTEIN; ELK-1; PATHWAY; DOMAIN; GRB2	Disabled-2 (Dab2) is a putative tumor suppressor in breast and ovarian cancers. Its expression is lost in a majority of tumors, and homozygous deletions have been identified in a small percentage of tumors. Dab2 expression is absent or very low in the majority of breast and ovarian cancer cell Lines, including MCF-7 and SK-Br-3 breast cancer cells. Transfection and expression of Dab2 in MCF-7 and SK-Br-3 cells suppress tumorigenicity. The cells reach a much lower saturation density and have reduced ability to form colonies on agar plates. In examining the signal transduction pathway of Dab2-transfected cells, we found that serum-stimulated c-Fos expression was greatly suppressed; however, the effects of Dab2 on MAPK family kinases were not as consistent. In MCF-2 and SK-Br-3 cells, although c-Fos expression was suppressed, the Erk1/2, JNK, and p38(MAPK) activities were unchanged or even increased. Serum-stimulated c-Fos expression is dependent on MAPK/Erk activity because the MEK inhibitor PD98059 suppresses Erk activity and c-Fos expression. Therefore, Dab2 appears to uncouple MAPK activation and c-fos transcription. Thus, me conclude that Dab2 re-expression suppresses tumorigenicity by reducing c-Fos expression at a site downstream of the activation of MAPK family kinases. Because Dab2 is frequently lost in cancer; the uncoupling of MAPK activation and c-Fos expression may be a favored target for inactivation in tumorigenicity.	Fox Chase Canc Ctr, Ovarian Canc Program, Philadelphia, PA 19111 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	Fox Chase Cancer Center; Emory University; Emory University	Xu, XX (corresponding author), Fox Chase Canc Ctr, Ovarian Canc Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NATIONAL CANCER INSTITUTE [R01CA079716, R01CA075389] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA79716, R01 CA75389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BUDAY L, 1995, ONCOGENE, V11, P1327; CALLAHAN R, 1989, BREAST CANCER RES TR, V13, P191, DOI 10.1007/BF02106570; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; CorbalanGarcia S, 1996, ONCOGENE, V12, P1063; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; Holt J, 1992, Cancer Treat Res, V63, P301; Johnson C. R., 1992, Computers in Physics, V6, P230; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin TH, 1997, J BIOL CHEM, V272, P8849; Marais R, 1996, CANCER SURV, V27, P101; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; PAWSON T, 1993, DEV GENET, V14, P333, DOI 10.1002/dvg.1020140502; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schlaepfer DD, 1996, CELL STRUCT FUNCT, V21, P445, DOI 10.1247/csf.21.445; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Tian JM, 1999, J BIOL CHEM, V274, P15173, DOI 10.1074/jbc.274.21.15173; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; Verheijen MHG, 1999, J BIOL CHEM, V274, P1487, DOI 10.1074/jbc.274.3.1487; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WONG KK, 1993, INT J ONCOL, V3, P13; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	39	35	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26814	26818		10.1074/jbc.M101820200	http://dx.doi.org/10.1074/jbc.M101820200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11359772	hybrid			2022-12-27	WOS:000169966900013
J	Takeuchi, H; Chen, JH; O'Reilly, DR; Turner, PC; Rees, HH				Takeuchi, H; Chen, JH; O'Reilly, DR; Turner, PC; Rees, HH			Regulation of ecdysteroid signaling: Cloning and characterization of ecdysone oxidase - A novel steroid oxidase from the cotton leafworm, Spodoptera littoralis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOLYMPH 3-DEHYDROECDYSONE 3-BETA-REDUCTASE; RECEPTOR-LIKE PROTEIN; MANDUCA-SEXTA; 3-OXOECDYSTEROID REDUCTASES; GMC OXIDOREDUCTASES; PROTHORACIC GLANDS; MOLECULAR-CLONING; INACTIVATION; ENZYMES; BIOSYNTHESIS	One route of inactivation of ecdysteroids in insects involves ecdysone oxidase-catalyzed conversion into 3-dehydroecdysteroid followed by irreversible reduction by 3-dehydroecdysone 3 alpha -reductase to 3-epiecdysone. We have purified from Spodoptera littoralis the first ecdysone oxidase and subjected it to limited amino acid sequencing. A reverse-transcriptase polymerase chain reaction-based approach has been used to clone the cDNA (2.8 kilobases) encoding this 65-kDa protein. Northern blotting showed that the mRNA transcript was expressed in midgut during the prepupal stage of the last larval instar at a time corresponding to an ecdysteroid titer peak. Conceptual translation of the ecdysone oxidase cDNA and data base searching revealed that the enzyme is an FAD flavoprotein that belongs to the glucose-methanol-choline oxidoreductase superfamily. Ecdysone oxidase represents the only oxidase in eukaryotic animals known to catalyze oxygen-dependent oxidation of steroids; by contrast, oxidation of steroids in vertebrates occurs via NAD(P)(+)-linked dehydrogenases. The injection of RH-5992, an ecdysteroid agonist, induced the transcription of ecdysone oxidase, suggesting that ecdysone oxidase is an ecdysteroid-responsive gene. The gene encoding this enzyme, consisting of five exons, has also been isolated. Sequences similar to the binding motifs for Broad-Complex and FTZ-F1 have been found in the 5'-flanking region. Southern blotting indicated that ecdysone oxidase is encoded by a single-copy gene. We have determined the kinetic characteristics of this novel recombinant ecdysone oxidase produced using a baculovirus expression system.	Univ Liverpool, Sch Biol Sci, Cellular Regulat & Signaling Div, Liverpool L69 7ZB, Merseyside, England; Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2AZ, England	University of Liverpool; Imperial College London	Rees, HH (corresponding author), Univ Liverpool, Sch Biol Sci, Cellular Regulat & Signaling Div, Life Sci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.							AYER S, 1992, MOL CELL BIOL, V12, P661, DOI 10.1128/MCB.12.2.661; BLAIS C, 1984, H-S Z PHYSIOL CHEM, V365, P809, DOI 10.1515/bchm2.1984.365.2.809; BLAIS C, 1991, CR ACAD SCI III-VIE, V313, P359; CAVENER DR, 1992, J MOL BIOL, V223, P811, DOI 10.1016/0022-2836(92)90992-S; Chen JH, 1999, J BIOL CHEM, V274, P10551, DOI 10.1074/jbc.274.15.10551; Chen JH, 1996, EUR J BIOCHEM, V242, P394, DOI 10.1111/j.1432-1033.1996.0394r.x; CHEN JH, 1994, BIOCHEM J, V301, P89, DOI 10.1042/bj3010089; Chen JH, 1999, INSECT BIOCHEM MOLEC, V29, P899, DOI 10.1016/S0965-1748(99)00065-X; CHERBAS L, 1991, GENE DEV, V5, P120, DOI 10.1101/gad.5.1.120; CHERBAS L, 1993, INSECT BIOCHEM MOLEC, V23, P81, DOI 10.1016/0965-1748(93)90085-7; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; Kiess M, 1998, EUR J BIOCHEM, V252, P90, DOI 10.1046/j.1432-1327.1998.2520090.x; Kiriishi S, 1990, EXPERIENTIA, V46, P57; KOOLMAN J, 1978, EUR J BIOCHEM, V89, P453, DOI 10.1111/j.1432-1033.1978.tb12548.x; KOOLMAN J, 1978, H-S Z PHYSIOL CHEM, V359, P1315, DOI 10.1515/bchm2.1978.359.2.1315; KOOLMAN J, 1975, H-S Z PHYSIOL CHEM, V356, P1131, DOI 10.1515/bchm2.1975.356.2.1131; Koolman J, 1989, ECDYSONE; Lafont R., 1984, P196; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LUO Y, 1991, MOL CELL BIOL, V11, P3660, DOI 10.1128/MCB.11.7.3660; MILNER NP, 1985, BIOCHEM J, V231, P369, DOI 10.1042/bj2310369; Murata T, 1996, MOL CELL BIOL, V16, P6509; NIGG HN, 1974, LIPIDS, V9, P971, DOI 10.1007/BF02533820; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OHTA T, 1991, GENE, V103, P93, DOI 10.1016/0378-1119(91)90397-T; REES HH, 1995, EUR J ENTOMOL, V92, P9; SAKURAI S, 1989, ARCH INSECT BIOCHEM, V10, P179, DOI 10.1002/arch.940100303; Sambrook J., 2002, MOL CLONING LAB MANU; Schramm G, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.22.e96; SOMMEMARTIN G, 1988, INSECT BIOCHEM, V18, P729, DOI 10.1016/0020-1790(88)90082-0; Steel C.G.H., 1989, P221; SUN GC, 1994, DEV BIOL, V162, P426, DOI 10.1006/dbio.1994.1099; Takeuchi H, 2000, BIOCHEM J, V349, P239, DOI 10.1042/0264-6021:3490239; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VONKALM L, 1994, EMBO J, V13, P3505, DOI 10.1002/j.1460-2075.1994.tb06657.x; WARREN JT, 1988, P NATL ACAD SCI USA, V85, P958, DOI 10.1073/pnas.85.3.958; Watson R.D., 1989, P188; Webb TJ, 1996, INSECT BIOCHEM MOLEC, V26, P809, DOI 10.1016/S0965-1748(96)00030-6; WEBB TJ, 1995, BIOCHEM J, V312, P561, DOI 10.1042/bj3120561; Weirich G.F., 1989, P174; WEIRICH GF, 1989, ARCH INSECT BIOCHEM, V12, P201, DOI 10.1002/arch.940120402; WEIRICH GF, 1993, ARCH INSECT BIOCHEM, V23, P199, DOI 10.1002/arch.940230406; Williams DR, 1997, J BIOL CHEM, V272, P8427, DOI 10.1074/jbc.272.13.8686; WOODARD CT, 1994, CELL, V79, P607, DOI 10.1016/0092-8674(94)90546-0	44	23	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26819	26828		10.1074/jbc.M104291200	http://dx.doi.org/10.1074/jbc.M104291200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11373299	hybrid			2022-12-27	WOS:000169966900014
J	Idrissi, FZ; Garcia-Reyero, N; Fernandez-Larrea, JB; Pina, B				Idrissi, FZ; Garcia-Reyero, N; Fernandez-Larrea, JB; Pina, B			Alternative mechanisms of transcriptional activation by Rap1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-GENOME-DATABASE; TUMOR VIRUS PROMOTER; DNA-BINDING DOMAIN; ASSEMBLY FACTOR-I; NUCLEOSOMAL DNA; TELOMERE LENGTH; GENE-EXPRESSION; PROTEIN RAP1; YEAST RAP1P; CEREVISIAE	Single Rap1p DNA-binding sites are poor activators of transcription of yeast minimal promoters, even when fully occupied in vivo, This low efficiency is due to two independent repression mechanisms as follows: one that requires the presence of histones, and one that requires Hrs1p, a component of the RNA polymerase II mediator complex. Both repression mechanisms were greatly reduced for constructs with tandemly arranged sites. In these constructs, UASrpg sequences (ACACCCATA-CATTT) activated better than telomere-like sequences (ACACCCACACACCC) in an orientation-dependent manner, Both mutations in the SWI/SNF complex and a deletion of amino acids 597-629 of Rap1p (Tox domain) decreased synergistic effects of contiguous telomeric sites. Conversely, deletion of amino acids 700-798 of Rap1p (Sil domain) made UASrpg and telomeric sites functionally indistinguishable. We propose that the Sil domain masks the main transactivation domain of Rap1p in Rap1p-telomere complexes, where the Tox domain behaves as a secondary activation domain, probably by interacting with chromatin-remodeling complexes. Rap1p DNA-binding sites in ribosomal protein gene promoters are mainly UASrpg-like; their replacement by telomeric sequences in one of these promoters (RPS17B) decreased transcription by two-thirds. The functional differences between UASrpgs and telomeric sequences may thus contribute to the differential expression of Rap1p-regulated promoters in vivo.	CSIC, Dept Biol Mol & Cellular, Inst Biol Mol Barcelona, Ctr Invest & Desenvolupament, ES-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Pina, B (corresponding author), CSIC, Dept Biol Mol & Cellular, Inst Biol Mol Barcelona, Ctr Invest & Desenvolupament, Jordi Girona 18, ES-08034 Barcelona, Spain.		Piña, Benjamin/A-1671-2011; Idrissi Azami, Fatima Zohra/P-5627-2015	Piña, Benjamin/0000-0001-9216-2768; Idrissi Azami, Fatima Zohra/0000-0003-3672-7618; Fernandez-Larrea, Juan Bautista/0000-0001-8007-8040				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; Ball CA, 2000, NUCLEIC ACIDS RES, V28, P77, DOI 10.1093/nar/28.1.77; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; Carr MD, 1996, EUR J BIOCHEM, V235, P721, DOI 10.1111/j.1432-1033.1996.00721.x; Chambers A, 1996, MOL MICROBIOL, V22, P449, DOI 10.1046/j.1365-2958.1996.00134.x; CHAVEZ S, 1995, MOL CELL BIOL, V15, P6987; Chavez S, 1997, P NATL ACAD SCI USA, V94, P2885, DOI 10.1073/pnas.94.7.2885; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; DEVLIN C, 1991, MOL CELL BIOL, V11, P3642, DOI 10.1128/MCB.11.7.3642; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; FREEMAN K, 1995, GENETICS, V141, P1253; GARTENBERG MR, 1992, P NATL ACAD SCI USA, V89, P11461, DOI 10.1073/pnas.89.23.11461; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GILSON E, 1995, NUCLEIC ACIDS MOL BI, V9, P308; Goncalves PM, 1996, MOL MICROBIOL, V19, P535, DOI 10.1046/j.1365-2958.1996.404939.x; GRAHAM IR, 1994, NUCLEIC ACIDS RES, V22, P124, DOI 10.1093/nar/22.2.124; Graham IR, 1999, MOL CELL BIOL, V19, P7481; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; Ha N, 1996, NUCLEIC ACIDS RES, V24, P1453, DOI 10.1093/nar/24.8.1453; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HARDY CFJ, 1992, MOL CELL BIOL, V12, P1209, DOI 10.1128/MCB.12.3.1209; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Idrissi FZ, 1999, BIOCHEM J, V341, P477, DOI 10.1042/0264-6021:3410477; Idrissi FZ, 1998, J MOL BIOL, V284, P925, DOI 10.1006/jmbi.1998.2215; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KOENIG P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lascaris RF, 1999, BIOINFORMATICS, V15, P267, DOI 10.1093/bioinformatics/15.4.267; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Liang SD, 1996, MOL CELL BIOL, V16, P3773; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; Lopez MC, 1998, P NATL ACAD SCI USA, V95, P14112, DOI 10.1073/pnas.95.24.14112; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCDONNELL DP, 1991, MOL CELL BIOL, V11, P4350, DOI 10.1128/MCB.11.9.4350; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Morse RH, 2000, TRENDS GENET, V16, P51, DOI 10.1016/S0168-9525(99)01936-8; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Piruat JI, 1997, GENETICS, V147, P1585; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; ROSE M, 1983, J MOL BIOL, V170, P883, DOI 10.1016/S0022-2836(83)80193-4; SCHWABE JWR, 1995, STRUCTURE, V3, P201, DOI 10.1016/S0969-2126(01)00150-2; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Tabtiang RK, 1998, MOL CELL BIOL, V18, P4707, DOI 10.1128/MCB.18.8.4707; Taylor HOB, 2000, J MOL BIOL, V303, P693, DOI 10.1006/jmbi.2000.4161; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; VIGNAIS ML, 1990, J BIOL CHEM, V265, P14669; Wahlin J, 2000, NUCLEIC ACIDS RES, V28, P2292, DOI 10.1093/nar/28.12.2292; Wood JR, 1998, MOL CELL BIOL, V18, P1927, DOI 10.1128/MCB.18.4.1927; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; WOUDT LP, 1987, NUCLEIC ACIDS RES, V15, P6037, DOI 10.1093/nar/15.15.6037; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567; Yu LN, 1999, MOL CELL BIOL, V19, P5279	67	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26090	26098		10.1074/jbc.M101746200	http://dx.doi.org/10.1074/jbc.M101746200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11358963	hybrid			2022-12-27	WOS:000169823300062
